<SEC-DOCUMENT>0001493152-23-010332.txt : 20230331
<SEC-HEADER>0001493152-23-010332.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331163130
ACCESSION NUMBER:		0001493152-23-010332
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RenovoRx, Inc.
		CENTRAL INDEX KEY:			0001574094
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				271448452
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40738
		FILM NUMBER:		23788341

	BUSINESS ADDRESS:	
		STREET 1:		333 W. SANTA CLARA STREET, SUITE 900
		CITY:			SAN JOSE
		STATE:			CA
		ZIP:			95110
		BUSINESS PHONE:		408-800-2649

	MAIL ADDRESS:	
		STREET 1:		333 W. SANTA CLARA STREET, SUITE 900
		CITY:			SAN JOSE
		STATE:			CA
		ZIP:			95110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:RNXT="http://renovorx.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_RNXT_renovorx.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0001574094 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0001574094</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0059" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2022-12-31" id="xdx2ixbrl0067" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0168" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0181" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0195" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0204" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0224" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0289" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0300" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0350" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0361" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:GainOnChangeInFairValueOfDerivativeLiability" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:GainOnLoanExtinguishmentFromPppLoan" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:LossOnLoanExtinguishment" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:PaymentsForLeaseholdImprovements" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:DerivativeLiabilityInFinancingActivities" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:ConversionOfConvertiblePreferredStockUponInitialPublicOffering" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:ConversionOfConvertibleNotesUponInitialPublicOffering" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2022-01-012022-12-31_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0576" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0608" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0618" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0624" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0634" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2021-12-31" id="xdx2ixbrl0648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2022-12-31" id="xdx2ixbrl0660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2021-12-31" id="xdx2ixbrl0661" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0961" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0963" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0965" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0967" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0969" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0971" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1003" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1004" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1006" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1007" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RNXT:DeferredTaxAssetsCapitalizedResearch" contextRef="AsOf2021-12-31" id="xdx2ixbrl1029" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1041" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" contextRef="AsOf2021-12-31" id="xdx2ixbrl1047" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2021-12-31" id="xdx2ixbrl1050" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1052" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1053" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rnxt-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-242021-08-25_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-24</xbrli:startDate>
        <xbrli:endDate>2021-08-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-25_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-25_us-gaap_WarrantMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-292021-08-30_us-gaap_IPOMember_custom_UnderwriterMember_custom_OverAllotmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RNXT:UnderwriterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RNXT:OverAllotmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-29</xbrli:startDate>
        <xbrli:endDate>2021-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-25_us-gaap_IPOMember_custom_UnderwriterMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RNXT:UnderwriterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-042021-08-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-04</xbrli:startDate>
        <xbrli:endDate>2021-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-262022-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-26</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RenovoCathMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RNXT:RenovoCathMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_RenovoCathMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RNXT:RenovoCathMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_NotePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-012020-03-31_custom_NotePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-012020-03-31_custom_TwoThousandAndTwentyConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-292021-08-30_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-29</xbrli:startDate>
        <xbrli:endDate>2021-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-31_custom_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-30_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-19_custom_OmnibusEquityIncentivePlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RNXT:OmnibusEquityIncentivePlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-01_custom_OmnibusEquityIncentivePlan2021Member_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RNXT:OmnibusEquityIncentivePlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_TwoThousandAndTwentyOnePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RNXT:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-31_custom_TwoThousandAndTwentyOnePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RNXT:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UnderwriterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RNXT:UnderwriterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UnderwriterMember_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RNXT:UnderwriterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RNXT:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UnderwriterMember_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RNXT:UnderwriterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RNXT:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ExercisePriceRangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceRangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ExercisePriceRangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceRangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ExercisePriceRangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceRangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ExercisePriceRangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceRangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ExercisePriceRangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceRangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ExercisePriceRangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceRangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ExercisePriceRangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceRangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_FederalAndStateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RNXT:FederalAndStateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CaliforniaTaxCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RNXT:CaliforniaTaxCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-05-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_DrAgahMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_DrAgahMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DrAgahMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_DrAgahMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-01_custom_DrAgahMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012023-02-28_custom_DrAgahMember_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2023-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-30_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-292023-03-30_custom_DefinitiveSecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574094</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:DefinitiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-29</xbrli:startDate>
        <xbrli:endDate>2023-03-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; margin: 0; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90E_edei--DocumentType_c20220101__20221231_zlpLoTQ5Wrof"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
  <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--DocumentAnnualReport_c20220101__20221231_z68RZxIvdvf8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span> &#160;</span></td>
  <td><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual
      report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>
      <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
      <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the
      fiscal year ended <span id="xdx_90C_edei--DocumentPeriodEndDate_c20220101__20221231_zZyVpf8IQbV7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_907_edei--CurrentFiscalYearEndDate_c20220101__20221231_zei0EgncjVEe"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_908_edei--DocumentFiscalYearFocus_c20220101__20221231_zIWuDKooddO7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p></td></tr>
<tr style="vertical-align: top">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top">
  <td><span id="xdx_90B_edei--DocumentTransitionReport_c20220101__20221231_z1w6Fii2pDAf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></td>
  <td><p style="margin: 0"><b>Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act
      of 1934</b></p>
      <p style="margin: 0"><b>&#160;</b></p>
      <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the transition period from
       <span style="text-decoration: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></b></span><b> to <span style="text-decoration: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></b></p></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <span id="xdx_906_edei--EntityFileNumber_c20220101__20221231_zQhPtdCwjuNg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-40738</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_906_edei--EntityRegistrantName_c20220101__20221231_zHEFvo1xOWKg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">RENOVORX,
INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20220101__20221231_zsG9Cz1Knlt8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20220101__20221231_zs4pVaNhaJ7l"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">27-1448452</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
                                                                             <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
                                            incorporation or organization)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin: 0"><span style="font-size: 10pt">(I.R.S.
                                            Employer</span></p>
                                                                             <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
                                            No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20220101__20221231_zEnbiQoPp3l2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">4546
El Camino Real</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20220101__20221231_zvm9n9fYekxb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Suite B1</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressCityOrTown_c20220101__20221231_zpaReXnNhF3h"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Los Altos</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20220101__20221231_zbmJn7QN04Hf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20220101__20221231_zzsdMRt2D769"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">94022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices, including zip code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--CityAreaCode_c20220101__20221231_zI3A7DqZQhJb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">(650)</ix:nonNumeric></span>
<span id="xdx_90B_edei--LocalPhoneNumber_c20220101__20221231_zNdNhsp1nLq9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">284-4433</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each&#160;class </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--Security12bTitle_c20220101__20221231_zmIJ3v8JpOil"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--TradingSymbol_c20220101__20221231_zQaeWGZC5RF2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">RNXT</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--SecurityExchangeName_c20220101__20221231_zUdbAEATyR8c"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant&#160;to Section 12(g) of the Act: None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_902_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_zuIbCPkFYZcl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_908_edei--EntityVoluntaryFilers_c20220101__20221231_zGwLkzWw3Fy3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90E_edei--EntityCurrentReportingStatus_c20220101__20221231_zjCpqUKU1sHe"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_904_edei--EntityInteractiveDataCurrent_c20220101__20221231_zsVS9MajeT72"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityFilerCategory_c20220101__20221231_zZbYTHxXTFwb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_905_edei--EntitySmallBusiness_c20220101__20221231_zRQzmT4sC3J9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20220101__20221231_zAGCRYlcXh9h"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_907_edei--EntityExTransitionPeriod_c20220101__20221231_zj6GR9xFzJ6a"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_908_edei--IcfrAuditorAttestationFlag_c20220101__20221231_zZqLFIJ8Whfk"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect correction of an error to previously issued financial statements. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether any of
those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes &#9744; <span id="xdx_901_edei--EntityShellCompany_c20220101__20221231_zjiPTQvJShzh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">T<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
aggregate market value of registrant&#8217;s common stock held by non-affiliates of the registrant on June 30, 2022, the last business
day of the registrant&#8217;s most recently completed second fiscal quarter, based upon the closing price of the registrant&#8217;s common
stock on such date as reported by Nasdaq Capital Market, was approximately: $<span id="xdx_90B_edei--EntityPublicFloat_iI_pn5n6_c20220630_zsmfd6ZJKJC"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. <span style="background-color: white">Shares
of voting stock held by each officer and director have been excluded in that such persons may be deemed to be affiliates. This assumption
regarding affiliate status is not necessarily a conclusive determination for other purposes.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 24, 2023, the registrant had <span><span style="background-color: white"><span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_c20230324_zZDV2ng7A2Qd"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-24" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,100,448</ix:nonFraction></span> </span></span> shares of common stock, $0.0001 par value
per share, outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentsIncorporatedByReferenceTextBlock_c20220101__20221231_zZUStF5ytoLl" title="Documents Incorporated by Reference"></span>Part III incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2023 Annual
Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant&#8217;s fiscal year
ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; margin: 0; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENOVORX,
INC. FORM 10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="4" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
    OF CONTENTS</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; width: 0.5in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPERTIES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL PROCEEDINGS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY DISCLOSURES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#Na_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS&#160;AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED]</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#Na_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF&#160;OPERATIONS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#Na_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND&#160;FINANCIAL DISCLOSURE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">69</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">69</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE COMPENSATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#Na_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND&#160;RELATED STOCKHOLDER MATTERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    IV</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><a href="#Na_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM 10-K SUMMARY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><a href="#Na_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><a href="#Na_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">POWER OF ATTORNEY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center">73</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for convenience, trademarks and trade names referred to in this Form 10-K may appear without the &#174; or &#8482; symbols.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Special
Note Regarding Forward-Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K, or Form 10-K, and the information incorporated herein by reference, particularly in the sections captioned
&#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
and &#8220;Business,&#8221; contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on our
management&#8217;s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted or quantified. All statements other than present and historical
facts and conditions contained in this Form 10-K, including statements regarding our future results of operations and financial position,
business strategy, plans and our objectives for future operations, are forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221;
&#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221;
&#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221;
&#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these terms or other comparable terminology. Actual events or results
may differ from those expressed in these forward-looking statements, and these differences may be material and adverse. Forward-looking
statements include, but are not limited to, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            sufficiency of our existing cash, cash equivalents, and investments to fund our future operating
                                            expenses and capital expenditure requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            estimates regarding expenses, future revenue, anticipated capital requirements to fund our
                                            future operating expenses, and our need for additional financing;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            financial performance;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            anticipated use of our existing cash, cash equivalents, and investments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability of our clinical trials to demonstrate safety and efficacy of our product candidates,
                                            and other positive results;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            progress and focus of our current and future clinical trials, and the timing of reporting
                                            of data from those trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            continued reliance on third parties to conduct clinical trials of our product candidates,
                                            and for the manufacture of our product&#160;candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to advance product candidates into and successfully complete clinical trials; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to further develop and expand our therapy platform, both to use different chemotherapeutic
                                            agents and to include new indications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expectations
                                            relating to the timing of the provision of updates on, data readouts for, and completion
                                            of our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain regulatory approval of our product candidates and the timing
                                            or likelihood of regulatory filings and approvals, including our expectation to seek special
                                            designations, such as orphan drug designation, for our product candidates for various diseases;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">existing
                                            regulations and regulatory developments in the United States and other jurisdictions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            plans relating to commercializing our product candidates, if approved, including the geographic
                                            areas of focus and our potential and ability to successfully commercialize our product candidates
                                            and generate revenue;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            implementation of our strategic plans for our business and product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            expected potential benefits of strategic collaborations with third parties and our ability
                                            to attract collaborators with relevant and complementary expertise;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            estimates of the number of patients in the United States who suffer from the diseases we
                                            target, and enrollment timing and projections for our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            estimates of potential market opportunities and our ability to successfully realize these
                                            opportunities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            success of competing therapies that are or may become available;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
                                            relating to our competitors and our industry, including competing product candidates and
                                            therapies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            plans relating to the further development and manufacturing of our product candidates, including
                                            for additional indications which we may pursue;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            plans and ability to obtain or protect intellectual property rights, including extensions
                                            of existing patent terms where available;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope of protection we are able to establish and maintain for intellectual property rights,
                                            including our therapy platform and product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to successfully negotiate and enter into agreements with distribution, strategic
                                            and corporate partners;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            potential and ability to successfully manufacture and supply our product candidates for clinical
                                            trials and for commercial use, if approved;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to retain the continued service of our key personnel and to identify, hire, and then
                                            retain additional qualified personnel; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding the impact of the ongoing COVID-19 pandemic and geopolitical events
                                            on our business.</span></td></tr></table>
					    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based the forward-looking statements contained in this Form 10-K primarily on our current expectations and projections about future
events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy and
financial needs. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, assumptions
and other factors described in the section titled &#8220;<i>Risk Factors</i>&#8221; and elsewhere in this Form 10-K. These risks are
not exhaustive. Other sections of this Form 10-K include additional factors that could adversely affect our business and financial performance.
Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time and
it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained
in this Form 10-K. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be
achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation
or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this Form 10-K, and while we believe such information forms a
reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements made in this Form 10-K relate only to events as of the date on which such statements are made. We undertake
no obligation to update any forward-looking statements after the date of this Form 10-K or to conform such statements to actual results
or revised expectations, except as required by law. Unless the context otherwise indicates, &#8220;RenovoRx,&#8221; the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer to RenovoRx, Inc., a Delaware corporation. All information presented
herein is based on our fiscal calendar. Unless otherwise stated, references to particular years, quarters, months or periods refer to
the Company&#8217;s fiscal years ended in December and the associated quarters, months and periods of those fiscal years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Form 10-K contains market data and industry forecasts that were obtained from industry publications. These data and forecasts involve
a number of assumptions and limitations, and you are cautioned not to give undue weight to such information. We have not independently
verified any third-party information. While we believe the market position, market opportunity and market size information included in
this Form 10-K is generally reliable, such information is inherently imprecise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_001"></span>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RenovoRx
is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. Our mission is to
lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy
directly to solid tumors. The proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP&#174;) therapy platform aims to avoid
the harsh side effects typical of the current standard of care, or systemic delivery methods, thus improving patient well-being and,
potentially extension of life, so more time may be enjoyed with loved ones. RenovoTAMP utilizes approved chemotherapeutics with
validated mechanisms of action and well-established safety and clinical use, with the goal of improving their safety, tolerance, and
widening their therapeutic window by providing more targeted delivery at the location of the tumor tissue. RenovoRx&#8217;s lead
product candidate, RenovoGemTM, is a combination of gemcitabine and its patented delivery system, RenovoCath&#174;. The FDA has
determined that RenovoGem will be regulated as, and if approved we expect will be reimbursed as, a new oncology drug product. We
have secured FDA Orphan Drug Designation for RenovoGem in two rare diseases: pancreatic cancer and cholangiocarcinoma (bile duct
cancer, or eCCA). We have completed the first of two planned interim analyses of the ongoing open label Phase III TIGeR-PaC clinical
trial. TIGeR-PaC is a randomized multi-center Phase III open label clinical trial designed to investigate the Company&#8217;s first
product candidate, RenovoGem, which utilizes RenovoRx&#8217;s proprietary therapy platform, RenovoTAMP, to provide targeted
intra-arterial delivery of FDA-approved chemotherapy, gemcitabine, to treat locally advanced pancreatic cancer (&#8220;LAPC&#8221;)
following stereotactic body radiation therapy (&#8220;SBRT&#8221;). The study is comparing treatment with RenovoGem versus standard of care treatment. In this interim analysis, the
control and treatment arms demonstrated divergence in median overall survival for patients. The study is designed to randomize 114
patients (57 in each arm) with all patients receiving upfront induction chemotherapy and SBRT. This first of two planned interim
analysis occurred upon the discovery of the 26th event (death) which equates to 30% of the total events required (96) for the final
analysis. The TIGeR-PaC Data Monitoring Committee (&#8220;DMC&#8221;) met and determined the interim data warrants continuation
of this pivotal trial without modification and no safety concerns were observed. The interim analysis shows a 6-month median overall survival
benefit for patients: approximately a 60% improvement versus the study control arm and current standard of care: intravenous (IV) administration
of gemcitabine and nab-paclitaxel for - LAPC. RenovoGem patients also had greater than 65% reduction in adverse events. These can include
nausea, fatigue, and a decline in white blood cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twenty-three
    patients were randomized to intra-arterial gemcitabine (RenovoGem investigational treatment) arm and 22 to continuation of IV gemcitabine
    and nab-paclitaxel (standard of care control) arm.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    median overall survival in the IV gemcitabine and nab-paclitaxel control arm was 10 months, versus 16 months in the intra-arterial
    RenovoGem arm from time of randomization. (NOTE: Both arms&#8217; median overall survival calculations do not include 4 to 5-months
    of life from diagnosis to randomization during the induction chemotherapy and radiation phase of the trial).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observed a positive trend in median overall survival by 24-weeks (6 months); in this interim analysis, the statistical
significance was not reached to stop the study early (p=0.051).</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observed that patients had greater than 65% reduction in adverse events compared to the control arm: In the IV gemcitabine
and nab-paclitaxel control arm there were 11 reported Serious Adverse Events (out of 22 patients) vs. 4 reported Serious Adverse Events
(out of 23) intra-arterial RenovoGem patients.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="graph_001.jpg" alt="" style="height: 367px; width: 520px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
1: Phase III TIGeR-PaC planned interim analysis demonstrating 6-month median overall survival benefit of RenovoGem (treatment arm) over
current standard of care systemic IV gemcitabine + nab-paclitaxel (control arm).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
second planned interim analysis of this Phase III trial will be performed upon the 52nd event (death) which equates to 60% of the total
events required for the final analysis and is estimated to take place in mid-2024; however, given that it is predicated on the number
of deaths in the study, it is difficult to predict the exact timing. We intend to evaluate RenovoGem in a second indication in a Phase
II/III trial in extrahepatic (or outside the liver) cholangiocarcinoma (or eCCA), cancer that occurs in the bile ducts that lead out
of the liver and join with the gallbladder. We are in the process of incorporating the recently approved and adopted drug, durvalumab,
into the protocol and launching the study mid this year. In addition, we may evaluate RenovoGem in other indications, potentially including
locally advanced lung cancer, locally advanced uterine tumors, and glioblastoma (an aggressive type of cancer that can occur in the brain
or spinal cord). To date, we are focused on developing drug/device candidates with gemcitabine, but we continue to explore the development
of other product candidates with additional therapeutic agents in new clinical indications for intra-arterial delivery via our RenovoTAMP
therapy platform via in-licensing, generic sourcing, and/or strategic partnering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RenovoTAMP therapy platform is focused on optimizing drug concentration in solid tumors using approved small molecule chemotherapeutics.
Our platform enables physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood
vessel wall to bathe these difficult-to-reach solid tumors in chemotherapy. Specifically, our patented approach allows physicians to
combine, on the one hand, pre-treatment of the local blood vessels and tissue with standard-of-care radiation therapy to decrease chemotherapy
washout and, on the other hand, local delivery via our patented RenovoCath delivery system which utilizes pressure to force small molecule
chemotherapy into the tumor tissue. We believe there are many advantages to our RenovoTAMP therapy platform, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Application
    of Approved Small Molecule Chemotherapeutic Agents</i>: We use approved small molecule chemotherapeutic agents, such as gemcitabine,
    with well-known safety and efficacy profiles.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Targeted
    Approach</i>: In a preclinical study using our therapy platform, we demonstrated up to 100 times higher local drug concentration
    compared to systemic chemotherapy. We believe our RenovoTAMP therapy platform allows for a targeted approach that can decrease systemic
    exposure and improve patient outcomes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Delivery
    Method Independent of Tumor Vascularity</i>: Our therapy platform is designed to deliver small molecule chemotherapeutic agents to
    solid tumors resistant to systemic chemotherapy due to lack of tumor feeder blood vessels. If approved, our product candidates have
    the potential to treat tumors that are not directly supported by blood vessels.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Broad
    Application for Solid Tumor Indications</i>: Our therapy platform is not restricted to a single small molecule chemotherapeutic agent
    or solid tumor type. As such, it may be applied for use in additional solid tumor indications, including in solid tumors without
    identifiable tumor feeder blood vessels.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our portfolio of cancer therapies is based on our lead product candidate,
RenovoGem (gemcitabine delivered via our patented delivery system), regulated by the FDA as a novel oncology drug product. RenovoGem utilizes
pressure-mediated delivery of gemcitabine across the arterial wall to bathe tumor tissue in chemotherapy. RenovoGem, via the RenovoTAMP
(RenovoRx Trans-Arterial Micro-Perfusion) therapy platform, is currently being evaluated in a Phase III clinical trial in Locally Advanced
Pancreatic Cancer (LAPC). Our current pipeline is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoGem
Product Pipeline Addresses Multiple Indications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="research_001.jpg" alt="" style="height: 328px; width: 670px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
2: RenovoGem Clinical Pipeline detailing our potential portfolio of cancer therapies based on our RenovoTAMP therapy platform.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemcitabine
has been considered a standard of care drug for several solid tumors, and the drug&#8217;s anti-cancer tumor effects are well
profiled. Our RenovoTAMP platform therapy utilizes pressure mediated delivery of gemcitabine across the arterial wall to bathe the
pancreatic tumor tissue in 120 mL of saline with 1,000 mg/m<sup>2</sup>&#160;of the drug over a 20-minute delivery period
(delivering 1,500-2,000 mg of drug depending upon patient body surface area). Our delivery system, RenovoCath, is a double balloon
catheter designed with the capability to isolate sections of the blood vessel through the adjustment of the distance between the
balloons, thereby excluding any branching blood vessel offshoots in order to create the pressure head needed to push drug across the
blood vessel wall.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to explore applications of our RenovoTAMP platform in additional indications, including bile duct cancer, locally advanced
lung cancer, locally advanced uterine cancer, and glioblastoma. We have completed and presented data on a lung cancer application in
preclinical studies, and additional preclinical experiments in lung cancer may be conducted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using gemcitabine in our initial anti-cancer product candidate, RenovoGem. However, multiple small molecule therapeutics are compatible
with our RenovoTAMP platform. We intend to opportunistically develop additional anti-cancer product candidates using small molecule therapeutics
in combination with our therapy platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the field of oncology has seen progress in treating a handful of deadly cancers over the last few decades, there is a common objective
in chemotherapy: enhanced dosing of the drug to impact the tumor while minimizing systemic toxicity. The characteristics of the blood
vessels, within and surrounding the tumor, can limit or thwart the achievement of this goal. For example, LAPC and eCCA are more difficult
to treat due to the lack of blood vessels that feed these tumors, making it difficult to expose tumors to chemotherapy, which is typically
delivered intravenously. Trans-arterial chemoembolization (TACE) is an established first line therapy for solid tumors. A key component
of this approach is to identify and isolate vessels feeding the tumor, known as tumor feeder blood vessels. However, in patients with
pancreatic cancer, no tumor feeder blood vessels are visible despite attempts to image them using a variety of modalities. In the absence
of visible tumor feeder blood vessels, our therapy platform has the potential to introduce drugs directly across the arterial wall into
the surrounding tissue via pressurized diffusion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>RenovoGem
in Locally Advanced Pancreatic Cancer (LAPC)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2021, we amended the protocol for this
clinical trial to only allow for SBRT during the induction phase of the study (prior to randomization).
We had previously permitted both SBRT and intensity-modulated radiation therapy (&#8220;IMRT&#8221;). Patients receiving IMRT must complete 25 radiation
treatments in combination with oral chemotherapy during the induction phase of the study, which takes between 35 and 56 days to complete.
In comparison, patients receiving SBRT during the induction phase are only required to complete 5 treatments, over 5 consecutive days,
and do not receive oral chemotherapy. The decision to modify the study population was based on the observation in the Phase III TIGeR-PaC
study that IMRT patients had a higher dropout rate during the induction phase of the study due to the high frequency of hospital visits
and side effects from the required concurrent chemotherapy. As part of the pre-randomization, induction phase change made to the protocol,
we initiated a review of the statistical considerations for the study and in June 2022, submitted a modified Statistical Analysis Plan
(the &#8220;Modified SAP&#8221;) to FDA. As part of the Modified SAP, we now plan to (i) analyze only patients receiving SBRT, consistent
with the protocol change made in December 2021, (ii) include a second interim analysis, (iii) change the total number of SBRT patients
randomized in the study to 114 (a reduction from the original 200 patients) with a total of 86 deaths from SBRT patients, including all
deaths from SBRT patients enrolled in the study before the submission of the Modified SAP, and (iv) repower the study from 90% to 80%,
which is commonly used in clinical trials. We believe these changes will shorten the timeframe needed to complete the study and also
significantly decrease our costs. We have not discussed the protocol amendment or the Modified SAP with the FDA, and we cannot provide
any assurance that the FDA will agree with these modifications. The first planned interim analysis was triggered when 30%, or 26 of 86,
of the total number of deaths occurred (and announced in March 2023), and the second interim analysis at 60%, or 52 of 86, of the total
number of deaths have occurred and is estimated to be mid-2024. Given that the timing of the interim analysis is predicated on a specific
number of deaths, it is difficult to predict the exact timing of the interim analysis or when we will be able to complete the study.
As of March 20, 2023, the Phase III TIGeR-PaC trial has randomized 48 SBRT patients out of 114 total needed under the Modified SAP. At
this rate, we anticipate that all patients will be enrolled and randomized in 2024, with the final study readout in 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>RenovoGem
in Extrahepatic Cholangiocarcinoma (eCCA)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are also planning to evaluate RenovoGem in a second indication in a
Phase II/III trial in extrahepatic (or outside the liver) cholangiocarcinoma (or eCCA), cancer that occurs in the bile ducts that lead
out of the liver and join with the gallbladder. After significant input from key opinion leaders across the spectrum of relevant medical
specialties and feedback from the FDA, we submitted the protocol for a Phase II/III eCCA clinical trial to FDA, and after receiving feedback,
we are finalizing the protocol and also including incorporating a recently approved drug, durvalumab into the study protocol with guidance
from the Steering Committee. We anticipate launching this study mid this year. We have also secured FDA Orphan Drug Designation for RenovoGem
for the treatment of cholangiocarcinoma, which would provide us with seven years of orphan exclusivity to market RenovoGem for our eCCA
indication upon NDA approval, provided that we are the first sponsor to obtain FDA approval for intra-arterial gemcitabine for the eCCA
indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Team</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management team, Board of Directors, and Scientific
Advisors provide us with expertise across multiple sectors to drive success through clinical development and subsequent commercialization
of our novel therapy platform. Our Chief Executive Officer, Shaun Bagai, gained extensive experience running clinical trials and launching,
creating, and developing new markets for novel therapies at TransVascular, Medtronic, Ardian, and HeartFlow. Dr. Ramtin Agah, our Co-Founder
and Chief Medical Officer, is a practicing cardiovascular specialist who has 20 years of research experience in vascular biology and
disease in both academia and industry. In 2022, Angela Gill Nelms joined our executive team as our Chief Operating Officer. She has extensive
experience in clinical research, operations, and building world-class organizations. Our Board of Directors includes a wide range of
public and private company management, board and life sciences experience, including drug/device combination and oncology experience.
Clinical advisors include experts across many specialties who treat solid tumors. Dr. Michael Pishvaian, a medical oncologist, has extensive
experience running oncology studies and is an Associate Professor, and Director of the Gastrointestinal, Developmental Therapeutics,
and Clinical Research Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital Johns Hopkins University School of Medicine.
Dr. Pishvaian is the Principal Investigator / Global Study Chair of our TIGeR-PaC Phase III study. Dr. Karyn Goodman serves as the Radiation
Monitor for our TIGeR-PaC Phase III study and Professor and Vice Chair of Clinical Research, Department of Radiation Oncology at the
Icahn School of Medicine at Mount Sinai, and Associate Director of Clinical Research at the Tisch Cancer Institute at Mount Sinai.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current
Treatments and Limitations of Approaches</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
solid tumors are typically treated using one or a combination of treatment modalities: surgery, radiation, and pharmacological therapies
(chemotherapy). For solid tumors, when possible, surgical resection of the tumor is the most frequently employed treatment approach.
If the tumor is detected at an early stage and is localized to the affected organ, surgical removal of the entire tumor may be an effective
and potentially curative treatment. In most cases, surgery is undertaken and / or completed prior to commencing additional treatment
approaches. However, multiple solid tumor types, including LAPC and eCCA are diagnosed at advanced stages, which precludes surgery as
a treatment approach. In many of these circumstances, the tumor has grown into adjacent anatomical structures making surgery difficult
or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intravenous
(IV), or systemic chemotherapy (gemcitabine and nab-paclitaxel), which has a seven-week survival benefit is considered standard of care for most solid tumors, but limitations include less than acceptable
efficacy, systemic toxicities, and other side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the treatment of some localized solid tumors, TACE is an established first line therapy. Many companies have developed therapeutic products
for use in this approach to treat tumors of the liver, uterus, and prostate. Many solid tumors have a dedicated blood supply: small blood
vessels, called tumor feeder blood vessels, that branch off of larger native arteries and terminate in the tumors to provide nutrition
to the tumors. A key aspect of TACE is to identify and isolate these tumor feeder blood vessels during x-ray angiography and then deliver
the desired therapy including chemotherapy and embolic agents. In patients with LAPC, no tumor feeder blood vessels are visible during
angiography due to the avascular (lack of blood vessels) nature of these tumors. This limitation has rendered TACE ineffective in the
treatment of patients with LAPC, eCCA, and a subset of other solid tumors. The limitations of TACE translate to low survival rates in
these tumor subtypes. The use of TACE with or without immuno-oncology treatment approaches, which harness the body&#8217;s immune system
to treat cancer, has not significantly improved survival rates in these subtypes. For example, due to the inability of immune cells to
penetrate the tumor tissue, early studies of targeted immunotherapies in pancreatic cancer have demonstrated limited success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Platform: RenovoTAMP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>RenovoTAMP
may work best with avascular tumors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
tumor types are sufficiently vascularized to enable use of systemic chemotherapy and standard of care local therapy techniques. In Figure
2 below, for example, the panel on the left depicts visualization of an actual tumor, hepatocellular carcinoma (HCC), or primary liver
cancer, under x-ray angiography as dye injected through the arteries reaches the tumor itself. Further, visible tumor feeder blood vessels
can be reached by simple end-hole catheters to deliver targeted therapy to these liver tumors. In contrast, the panel on the right illustrates
the typical lack of tumor feeder blood vessels to a pancreatic tumor. Given the lack of tumor feeder blood vessels, the dye does not
reach the tumor, rendering the tumor &#8220;invisible&#8221; under x-ray angiography. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tumors
in Liver are Different from Hypovascular Tumors in the Pancreas</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="hyper_001.jpg" alt="" style="height: 324px; width: 670px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
3: Showing liver tumors that are highly vascularized, and pancreatic tumors that are avascular. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>RenovoTAMP
has been under development for over 14 years</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2009, our founder Dr. Ramtin Agah, an experienced interventional cardiologist with a degree in biomedical engineering, developed the
concept for RenovoTAMP as a way to deliver chemotherapy locally to treat poorly vascularized tumors. He joined forces with Kamran Najmabadi,
who brought significant medical device engineering experience, to found RenovoRx in 2009. Subsequently, we engaged a contract manufacturer
to prototype and manufacture our RenovoCath delivery devices. We received our first FDA 510(k) clearance for RenovoCath in 2014, a second
clearance to use the RenovoCath for infusion of chemotherapy agents in 2017, a further clearance to use RenovoCath with a power-injector
in 2019, and a fourth clearance in 2021 to expand vessel diameter range to 3-11mm, implement certain changes in the Instructions for
Use, change the recommended saline to contrast solution ratio, among other changes and improvements. RenovoCath is intended for the isolation
of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system.
RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic
drug infusion. RenovoCath is intended for general intravascular use in the peripheral vasculature in arteries 3 mm and larger as well
as for use in arteries from 3 mm in diameter for vessel entry and to occlude vessels ranging between 3 mm to 11 mm in diameter. We are
evaluating our lead product candidate RenovoGem under an IND filed in 2018. FDA has determined that RenovoGem will be regulated as, and
if approved we expect will be reimbursed as, a new oncology drug product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
it works: we developed RenovoTAMP as an attempt to solve the problems of treating avascular tumors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
overcome the limitations resulting from a lack of tumor feeder blood vessels, we explored a different approach to locally deliver anti-cancer
drugs. By isolating a section of the blood vessel and then increasing the intravascular pressure in the isolated segment, we can introduce
chemotherapy directly across the arterial wall into the surrounding tissue via pressurized diffusion, or Trans-Arterial Micro-Perfusion
(RenovoTAMP). To isolate the vessel and create this pressure gradient, we developed RenovoCath, a patented adjustable double balloon
catheter to occlude the proximal and distal part of the vessel. Using the RenovoTAMP technique in explanted (dissected out of the animal
and used separately in a saline water bath) pig aorta and iliac arteries, we were able to validate our hypothesis by demonstrating &gt;99%
gemcitabine pressurized diffusion across the arterial wall in the absence of feeder vessels. This mechanism of action was further supported
by exploratory acute animal studies measuring the pressure gradient within the artery during double balloon occlusion. Figure 3 demonstrates
the change in intra-arterial pressure over time from catheter introduction to balloon inflation, start of infusion, and pressure plateau
when chemotherapy is forced out of vessel. These changes in pressure are a result of pressure declining as the first balloon blocks blood
inflow and then rising as the drug is administered and fills up the space between the balloons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In
procedures developed for the RenovoTAMP platform, interventional radiologists utilize RenovoCath to pressurize an isolated vessel segment.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt="" style="height: 332px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
4: Occluding the vessel with RenovoCath,&#160;while adjusting the balloon-to-balloon distance to exclude all blood vessel branches,
established an intravascular interstitial pressure in the isolated blood vessel segment of approximately 20 mmHg. With subsequent infusion
of fluids between the balloons at 6 mls/minute, the intravascular pressure increases to above 45 mmHg, trans-arterially forcing the small
molecule drug across the arterial wall via diffusion (this patented process of perfusing the vessel wall is Trans Arterial Micro Perfusion,
or RenovoTAMP).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RenovoTAMP platform therapy utilizes pressure mediated delivery of gemcitabine across the arterial wall to bathe the pancreatic tumor
tissue in 120 mL of saline with 1,000 mg/m<sup>2</sup>&#160;of drug over a 20-minute delivery period (delivering 1,500 - 2,000 mg of
drug depending upon patient body surface area. This blanketing approach of large fluid volume delivery over time may enable the drug
to approach these difficult-to-reach tumors. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
advantages of RenovoTAMP include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ideal
                                            for solid tumors where resection is not possible due to proximity/impingement of tumor on
                                            blood vessels, nerves, or other key structures</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            need for identifying tumor feeder blood vessels to deliver the drug. These generally do not
                                            exist in avascular or hypovascular tumors such as LAPC and eCCA</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            solid tumors without identifiable feeder vessels, technically easier than direct cannulation
                                            of small tumor feeder blood vessels</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">High
                                            local concentration of drug into the tumor tissue</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential for decreased systemic exposure of drug due to local metabolism prior to systemic exposure</span></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Developing
a therapeutic platform using an adjustable two-balloon catheter and intra-arterial gemcitabine</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
isolating the vessel adjacent to the tumor and creating a pressure gradient across the arterial wall between the isolated vessel segment
and the surrounding tissue or tumor, we are able to force the small molecule chemotherapy across the vessel directly into surrounding
tissue or tumor. To accomplish this, we needed a minimally invasive technique to isolate the blood vessel next to the tumor, exclude
any branches that can cause washout of chemotherapy away from the target, and then infuse the chemotherapy into the isolated segment
to achieve pressure mediated diffusion through the vessel wall and into the tumor tissue. We accomplished this with our patented RenovoCath
delivery system. RenovoCath is a double balloon catheter designed with the capability to isolate the proximal and distal sections of
the vessel through the adjustment of the distance between the balloons, thereby excluding any branching blood vessel offshoots. Using
standard interventional techniques, an interventional radiologist inserts the RenovoCath delivery system into the body through the femoral
artery and positions it in the artery closest to the tumor. Once the balloons are inflated and the position is confirmed, chemotherapy
is delivered through the handle, exiting the device between the balloons. It is forced through the vessel wall into the tissue over a
20-minute period. The RenovoCath delivery system is depicted below in Figure 4.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoCath
Delivers Chemotherapeutic Agent Between Two Balloons</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt="" style="height: 414px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
5: RenovoCath delivery system illustrating two balloon configuration to isolate the target vessel segment, and chemotherapy delivery port
and exit hole.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the procedure is complete, RenovoCath is discarded, and the patient is generally discharged the same day. On average, the entire procedure
takes approximately 90 minutes. According to the TIGeR-PaC study protocol, intra-arterial treatment is administered through RenovoCath
every other week for a maximum of 8 treatments for approximately 16 weeks. Interventional radiologists using the device are typically
proctored for their first 2-3 cases only. In addition, platform training for our primary indication should transfer to other indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoGem
for LAPC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disease
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic cancer is one of the deadliest cancers in the US with very poor
outcomes. According to American Cancer Society&#8217;s Cancer Facts &amp; Figures 2023, pancreatic cancer has a 5-year combined overall
survival rate of 12% (Stages I-IV) and is on track to be the second leading cause of cancer-related deaths before 2030. LAPC is diagnosed
when the disease has not spread far beyond pancreas, however, has advanced to the point where it cannot be surgically removed. LAPC is
typically associated with patients in stage 3 of the disease as determined by the TNM (tumor, nodes and metastasis) grading system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current
Treatment Landscape and Limitations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic
cancer has limited treatment options including one or a combination of surgery, radiation, chemotherapy, and/or some targeted therapies.
Only a small subset of pancreatic cancer patients is eligible for surgery (&#8220;Resectable&#8221; at the time of presentation (Stage
I-II: 15%); the rest are distributed between having tumors with unresectable LAPC (Stage III: 30%) and metastatic pancreatic cancer (Stage
IV: 50%).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemotherapy
is at the forefront of systemic therapy for cancer. It can be used in the neoadjuvant (before surgery) setting to attempt to decrease
tumor size in resectable or borderline resectable patients, in the adjuvant (after surgery) setting, or first line in the metastatic/advanced
setting. The backbone of our first product candidate, gemcitabine, is a nucleoside metabolic inhibitor that exhibits antitumor activity
by blocking the synthesis of new DNA, which results in cell death. Gemcitabine administered as an intravenous (IV) infusion has an established
role in the treatment of both unresectable LAPC and metastatic pancreatic cancer. Since its introduction in the US as Gemzar&#174; (gemcitabine
for injection) in 1996 with an FDA approved indication as such, it remains in the guidelines as standard of care. It has been demonstrated
to provide clinical benefit for subjects (decreased pain and improved performance status) as well as to improve the time to tumor progression
and survival for subjects with metastatic pancreatic cancer and LAPC. However, major improvement in the survival curve of all pancreatic
cancer subjects has been a clinical challenge, with an average median survival time for LAPC stalled at 12-15 months from time of diagnosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key limitation of conventional chemotherapy in these tumors can be attributed to their avascular nature and desmoplasia (fibrosis or
the growth of scar tissue) that impedes drug delivery. Pancreatic tumor cells have a thick and poorly perfused stroma, or connective
tissue, and high interstitial pressure. This can potentially constrict blood vessels leading to an avascular or hypovascular environment
that impedes chemotherapy from reaching tumor cells in high enough volume, rendering them relatively resistant to chemotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
patients with metastatic disease, two chemotherapy combination regimens have shown superiority to gemcitabine, albeit with increased
toxicity. First, the combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) in a relatively young cohort of
metastatic pancreatic cancer patients appears superior to gemcitabine by improving survival from 6.8 to 11.1 months. Second, in the Metastatic
Pancreatic Adenocarcinoma Clinical Trial (MPACT) trial, the combination of gemcitabine plus nab-paclitaxel (Abraxane) demonstrated an
OS benefit of 9 weeks versus gemcitabine alone at the cost of increased toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
major focus of clinicians is determining the optimal method to treat patients with LAPC, patients with localized disease who are not
surgical candidates, roughly 30% of all pancreatic cancer patients. IV, or systemic, administration of chemotherapy has yielded unsatisfactory
results in these patients. Various localized treatments have included high dose local radiation, direct attempts at local injection of
drugs, and use of adenoviral vectors to deliver toxic agents. These treatment options demonstrated limited success in the treatment of
LAPC. The lack of successful treatment options represents a recognized unmet medical need for these patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standard
of care chemotherapy for the treatment of pancreatic cancer has historically shifted a couple of times with the addition of erlotinib
to gemcitabine 15 years ago resulting in a 14-day survival benefit. In 2013, the addition of Abraxane to gemcitabine was approved, with
immediate deep market penetration based on an 8-week survival benefit despite higher systemic drug toxicities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Solution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our product candidate, RenovoGem, has the potential to address the recognized unmet medical need. Utilizing our patented
RenovoTAMP therapy platform, we believe RenovoGem can enhance local drug concentration, thereby increasing efficacy and decreasing systemic
exposure and toxicity to improve patient outcomes. RenovoGem is a drug/device combination product candidate consisting of intra-arterial
gemcitabine and our proprietary RenovoCath delivery system which forces the anti-cancer drug into the tumor. RenovoGem is regulated by
the FDA as a new oncology drug product. We do not intend to sell RenovoCath alone. Instead, we intend to sell RenovoCath only in combination
with intra-arterial gemcitabine (as RenovoGem) or potentially with other therapeutic agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on primary market research and analysis of the US market sponsored by RenovoRx and conducted by third parties, we believe that over
5,000 patients per year would be excellent candidates and undergo RenovoGem treatment once it is approved in the US. The independent
oncologists interviewed stated their dissatisfaction with current standard of care and the strong desire for a therapy like ours to
extend potential survival while maintaining quality of life. Further, the analysis suggests, based on analogous oncology drugs with
only a&#160;<i>modest</i>&#160;efficacy benefit, a novel drug can expect 50-80%+ penetration in a first line setting. The results of
the Key Opinion Leader, or KOL interviews revealed that a majority of oncologists would refer 90%+ of their LAPC patients who are
eligible for the procedure for RenovoTAMP if the current Phase III trial demonstrates at least a 4-month survival benefit over
systemic chemotherapy. As of March 8, 2023, we announced interim analysis results of the study suggesting a 6-month potential
improvement in median overall survival with RenovoGem, pending ongoing clinical investigation. We believe this first-of-two interim
analyses indicates that the TIGeR-PaC study is on track to demonstrate increased lifespan for patients being treated with RenovoGem
for LAPC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoTAMP
Therapy Platform and First Product Candidate, RenovoGem</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="drug_001.jpg" alt="" style="height: 369px; width: 670px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
6: We invented a new therapy platform, RenovoTAMP, that uses pressure to force small molecule chemotherapeutics across the vessel wall
into the surrounding tissue using our patented RenovoCath delivery system. Our first product candidate, RenovoGem, is a drug/device combination
of intra-arterial gemcitabine and the RenovoCath delivery system, and is under development for LAPC and eCCA. We have secured Orphan
Drug Designations for RenovoGem for the treatment of both pancreatic cancer and cholangiocarcinoma.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Development of RenovoGem in LAPC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preclinical
Studies and Data</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
RenovoCath is introduced via standard interventional technique to the arterial vessel segment next to the targeted tissue, both balloons
are inflated, and the vessel segment is isolated from the rest of the circulatory system. With inflation of balloons, the pressure is
observed to drop within the vessel. However, with
infusion of fluids between the balloons, the intravascular pressure increases beyond 45 mmHg until plateauing, generating a gradient
and trans-arterially forcing the infusate across the arterial wall via diffusion or Trans-Arterial Micro-Perfusion (TAMP). A key aspect
of this approach is to adjust the distance between the balloons to exclude any side blood vessel branches in the isolated segment to
allow the increase in pressure gradient, rather than drug washout via the side branches. Figure 6 shows a comparison, in an animal study,
between proper balloon positioning with no side branches, allowing maximum drug to cross the arterial wall, versus improper balloon positioning
to include side branches, resulting in drug washing out via the side branches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Infusion
Pressure Achieved When Side Blood Vessel Branches Are Excluded</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_006.jpg" alt="" style="height: 379px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
7: Top panel demonstrates proper balloon positioning with no side branch. Pressure increases with infusion and reaches a plateau of
approximately 75 mmHg higher than initial pressure. Bottom panel demonstrates improper balloon positioning with side branch between
the balloons. Pressure increases with infusion and reaches a plateau of approximately only 15mmHg higher than initial
pressure.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
diffusion of fluids across the arterial wall in RenovoTAMP, we expected to be able to deliver small molecules into the surrounding tissue.
We performed the following studies to validate this hypothesis:</span></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            a preclinical study, 99% of the gemcitabine crossed the arterial wall via RenovoTAMP.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
explanted (dissected out of the animal and used separately in a saline water bath) pig iliac and aortic artery, with the introduction
of RenovoCath and infusion of gemcitabine in the isolated vessel segment, we were able to measure (in a time dependent fashion) the amount
of gemcitabine crossing the arterial wall into the surrounding fluid. We isolated the arterial vessel segment using RenovoCath and then
delivered 60 mg/minute of gemcitabine into the isolated area over 20 minutes. By the end of the infusion, we measured 1,188 mg of gemcitabine
in the surrounding fluid around the vessel and 9 mg in the analyzed tissue of the vessel. This demonstrated that 99% of the drug crosses
the arterial wall and only 0.75% is retained in the arterial tissue (Figure 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In
a Preclinical Study - 99% of Chemotherapy Crosses Arterial Wall with RenovoTAMP Delivery</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_007.jpg" alt="" style="height: 355px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
8: RenovoTAMP: delivery of chemotherapy through the RenovoCath and into the tissue to bathe the tumor in chemotherapy. In a preclinical
study using gemcitabine, 99% of the drug crosses the arterial wall and less than 0.75% is retained in the vessel wall tissue.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infusion
                                            of gemcitabine via RenovoTAMP has demonstrated vascular safety with acceptable toxicity in
                                            a pig model and does not cause loss of vessel integrity or inflammation.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
pigs were treated with gemcitabine via RenovoTAMP (6 mL/min for 20 minutes). Target vessels included selection of the superficial femoral
artery (SFA) and splenic arteries from each animal (either test or saline control). A total of 6 vessels (3 SFA and 3 splenic arteries)
were treated with an equal number of control vessels. All animals survived the 7-day in-life period although two of the animals with
gemcitabine treatment in the splenic artery experienced atypical pain during the post-operative phase and required additional pain management
with eventual complete recovery.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analysis
of the vessels demonstrated preserved vessel shape with intact endothelial cells (cells on the inside of the vessels). Minimal to no
inflammation was observed. The only vessel toxicity observed was a reduction of smooth muscles cells in the vessel wall, primarily close
to the inside of the vessel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
  preclinical studies, RenovoTAMP achieved targeted local drug (dye) delivery.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>I.</i></b><b><i>
Targeted small molecule delivery (dye) into pancreatic tissue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further validated our approach for tissue drug delivery using acute animal experiments. Using both dye and gemcitabine infusion via the
RenovoTAMP therapy, we were able to demonstrate that fully isolating a segment of a vessel (by blocking inflow and outflow in the target
vessel as well as side branches with the RenovoCath double balloons) can lead to dye penetration greater than 4.0 cm from the vessel
wall and drug tissue concentration (gemcitabine) up to 100-fold greater than systemic administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an acute pig experiment, RenovoCath was introduced into the gastro-duodenal artery (GDA), a side branch was excluded (using small implants
that block the artery, coils), and then dye was introduced at 6mls/minute over 2 minutes. Analysis demonstrated that the blue dye diffused
covered approximately 10.56 cm<sup>2</sup>&#160;(2.2 cm x 4.8 cm) of the pancreas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dye
Demonstrates RenovoTAMP Delivery of Agent into Pancreatic Tissue</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_008.jpg" alt="" style="height: 213px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
9: RenovoCath was introduced into the GDA and a side branch was excluded by coiling. This test was conducted in an acute porcine model
and demonstrated a dye coverage area of approximately 10.56 cm<sup>2</sup>&#160;for a 2-minute dye infusion. All dimensions in above
figure are in cm.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study was repeated in 6 other vessel targets to validate the impact of vessel isolation on dye penetration into the surrounding tissue
with similar results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>II.</i></b> <b><i>Small
molecule delivery (dye and gemcitabine) locally into lung tissue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
another set of acute animal experiments, the pulmonary artery was isolated via access through the internal jugular vein. Six ml of methylene
blue dye was injected over 1 min and gemcitabine was subsequently delivered locally at rate of 6 mls/minute for 20 minutes to the lung
tissue using the RenovoTAMP procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dense
dye staining localized to the area of the isolated vessel segment was observed. Again, analysis established penetration into surrounding
tissue (4 cm). Furthermore, RenovoTAMP achieved greater than 100-fold tissue concentration of gemcitabine versus the tissue level achieved
by IV (systemic) delivery of gemcitabine at the same infusion rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dye
Staining Demonstrates RenovoTAMP Delivery of Agent to Lung Tissue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="form10-k_009.jpg" alt="" style="height: 373px; width: 430px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
10: Dense dye staining localized to the area of the isolated pulmonary artery segment and penetrating 4 cm into surrounding tissue following
1 minute dye infusion. In addition, gemcitabine was delivered via RenovoTAMP for 20 minutes demonstrating 100-fold increase in tissue
concentration of gemcitabine compared to IV delivery of gemcitabine at the same infusion rate.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
concluded that RenovoTAMP can achieve drug penetration into the surrounding tissue and can achieve high dose concentrations in local
tissue. The tissue concentration with intravenous infusion and/or distant from RenovoTAMP site (likely after recirculation through systemic
system) were two orders of magnitude lower than tissue levels achieved with RenovoTAMP (p&lt;0.02).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoTAMP
Increases Local Tissue Concentration of Gemcitabine Compared to IV Infusion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_010.jpg" alt="" style="height: 382px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
11: Local&#160;tissue concentration of gemcitabine. control (Blue): Intravenous infusion versus RenovoTAMP (Orange): RenovoTAMP: intra-arterial
infusion. The tissue concentration with intravenous infusion and/or distant from RenovoTAMP site (likely after recirculation through
systemic system) are 100-fold lower than tissue levels achieved with RenovoTAMP.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
animal lung study successfully validated the ability of RenovoCath to deliver small molecules locally and effectively to lung tissue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>III. Based on the results of preclinical studies, increase in local tissue delivery of gemcitabine in LAPC may enhance tumor reduction
and therapeutic response</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relevant mouse models of pancreatic tumors, it has been demonstrated that targeted intra-arterial (IA) infusion of gemcitabine into the
pancreas after surgical isolation of arterial blood flow has a superior therapeutic effect with greater reduction in tumor volume compared
to the same concentration administered by conventional systemic (intravenous) injection. To achieve a comparable reduction in tumor growth
as seen with IA treatment, gemcitabine had to be given intravenously at over 300 times the dose which was associated with increased toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>RenovoTAMP
and Radiation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Traditionally
the goal of radiation includes debulking the tumor and/or acting as a chemo-sensitizer. In our RR1 dose escalation safety study and RR2
observational registry study, the benefit of RenovoTAMP appeared to be enhanced in patients with prior radiation. As we were observing
this effect months after radiation and although several randomized studies have not demonstrated a benefit of chemotherapy + radiation
versus chemotherapy alone, we hypothesized that a direct effect of radiation on the vasculature may be enhancing the effect of RenovoTAMP.
One of the side effects of radiation is a decrease in the micro-vasculature in the irradiated tissue including the small blood vessels
that exist in the vessel walls themselves. Therefore, we postulated that by eliminating microvasculature in and around the vessel wall,
radiation may enhance drug penetration into the tissue via RenovoTAMP (Figure 11). As such, a possible enhancing effect of radiation
on RenovoTAMP may involve decreasing washout of the drug as it crosses the arterial wall by preventing draining into the surrounding
microvasculature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed a pig study where we observed the impact of RenovoTAMP in recruiting the vasa vasorum (small blood vessels within the larger
blood vessel walls) around the vessel during drug/dye infusion. It was discovered that the dye drained into the vasa vasorum and other
small vessels in the adjacent tissue (Figure 11); as these vessels can directly connect to the adjacent venous system, the microvascular
networks can serve as an &#8220;escape route&#8221; for drugs. Ultimately this direct washout can reduce the amount of drug concentration
in the tissue. Radiation pretreatment may enhance the impact of RenovoTAMP by attenuating this escape route.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoTAMP
Combined with Radiation Reduces Venous Outflow by Decreasing the Microvasculature</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="form10-k_011.jpg" alt="" style="height: 359px; width: 670px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
12: Mechanism of RenovoTAMP and radiation reduces venous outflow by decreasing the microvasculature networks that could act as an &#8220;escape
route&#8221; for the drugs. The photo on the left illustrates this effect in a dye infusion study in the porcine animal model. The panel
on the right demonstrates venous chemotherapy washout without radiation versus less venous escape routes for chemotherapy following radiation.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further advanced this theory by conducting a pig study to directly test whether radiation can enhance tissue uptake by RenovoTAMP. In
a single-animal study, we examined the use of Stereotactic Body Radiation Therapy (SBRT) pre-treatment on one leg followed by RenovoTAMP
versus RenovoTAMP without prior radiation therapy on the opposite leg. The leg of the animal that was pre-treated with radiation demonstrated
more pronounced tissue staining with methylene blue dye and increased gemcitabine concentration via punch biopsy. Based on these findings,
we believe that the benefit of prior radiation on clinical outcomes with RenovoTAMP may be improved by the effect of radiation on microvasculature
between the vessel wall and the tumor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dye
Test Demonstrates that RenovoTAMP Plus Radiation Increases Concentration of Gemcitabine</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_012.jpg" alt="" style="height: 687px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
13: To demonstrate the effect of radiation pre-treatment, we delivered radiation therapy to the left leg of a pig. After waiting one month
for the therapy to fully affect the vasculature, we performed RenovoTAMP on the left and right leg arteries with blue dye and gemcitabine.
Dissection revealed better dye penetration into the tissue on the left (irradiated) leg, and punch biopsy demonstrated higher gemcitabine
concentration in the left leg.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have demonstrated that the RenovoTAMP therapy allows targeted small molecule drug delivery into the tissue surrounding the vessel wall,
without need to identify tumor feeder blood vessels. The mechanism of action is the exclusion of distal (downstream) and side branch
vessels in the isolated segment and creating a pressure gradient by infusing the drug over time. The pressure gradient results in a diffusion-mediated
delivery of drug into the surrounding tissue. With the use of gemcitabine, the procedure appears safe in terms of local toxicity in the
vasculature. Using this approach, we can achieve increased drug delivery into the surrounding tissue in the range of 4 cm-tissue penetration
as well as concentration orders of magnitude larger than what can be achieved with IV infusion. Lastly, RenovoTAMP appears to be enhanced
by prior radiation of tissue, possibly by decreasing the microvasculature and subsequent potential chemotherapy washout. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LAPC
Clinical Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RenovoTAMP
has been studied in a Phase I/II dose-ranging study of 20 subjects with locally advanced pancreatic cancer (RR1) and in an observational
study that enrolled 25 additional subjects with pancreatic cancer (RR2); two subjects from the RR1 safety study continued to receive
treatment in the RR2 observational registry study. We subsequently launched a Phase III registration trial (TIGeR-PaC). As of March 8, 2023, we announced interim analysis
results of the study suggesting a 6-month potential improvement in median overall survival with RenovoGem, pending ongoing clinical investigation.
We believe this first-of-two interim analyses indicates that the TIGeR-PaC study is on track to demonstrate increased lifespan for patients being
treated with RenovoGem for LAPC. Final analysis will be conducted after 86 protocol-specified events have occurred in the SBRT population
with two planned interim analyses: this first analysis with 30% of the specified events (deaths) reported and the second analysis when
60% of the events have been reported (expected in 2024).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Phase
I/II Dose-Ranging Study: RR1</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Study
Design</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase I/II safety study of our RenovoTAMP therapy has been completed in subjects with LAPC (Phase I/II RenovoCath/Gem RR1). This multicenter,
prospective, open label, interventional, nonrandomized, intra-subject dose escalation study evaluated IA gemcitabine delivered locally
to the pancreas using  RenovoCath in 20 subjects with LAPC. The primary objectives of the study were (1) to establish the maximum
tolerated dose (MTD) and (2) to study the safety and tolerability of intra-arterial (IA) gemcitabine administered by RenovoCath at doses
ranging from 250 mg/m<sup>2&#160;</sup>to 1000 mg/m<sup>2</sup>. Secondary endpoints included overall survival, CA 19-9 marker change,
change in tumor size based on RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) criteria, and pain scores and narcotic use. Adverse
events were collected from the first IA gemcitabine infusion until 3 months following the final IA gemcitabine infusion. Subjects were
followed for survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
constituted introducing RenovoCath to target vessel (adjacent to tumor) via catheterization, occluding the targeted segments via the
RenovoCath balloons, and infusing gemcitabine in the occluded segment. To minimize ischemia (damage due to cessation of blood flow) the
infusion was limited to 20 minutes and an anticoagulant (heparin) was given during the procedure. Tissue markers were followed post procedure
to ensure lack of local tissue damage-toxicity (AST, ALT, Lipase and Amylase).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
was administered in four 28-day cycles, each of which consisted of two IA doses of gemcitabine, one on day 1 and one on day 15, with
a two-week rest period between cycles. The first six subjects received a starting dose of 250 mg/m<sup>2</sup>, and doses increased by
250 mg/m<sup>2</sup>&#160;in each subsequent cycle culminating with the full dose of 1,000 mg/m<sup>2</sup>. After the initial six subjects,
the starting dose increased to 500 mg/m<sup>2</sup>&#160;for one cycle, after which dosing increased to 750 mg/m<sup>2&#160;</sup>for
the second cycle, and then the full 1,000 mg/m<sup>2</sup>&#160;dose for the remaining 2 cycles. Each subject underwent CT scanning prior
to the first procedure for the selection of the optimal target vessel most proximal to the tumor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Study
Subjects and RenovoGem Exposure</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
median age of subjects was 66.7 years with a gender distribution of 9 men and 11 women. Prior treatment included chemotherapy and radiation
therapy in 6 (30%), chemotherapy alone in 5 (25%) and no prior therapy in 9 (45%) subjects. Collectively the 20-subject cohort received
101 IA treatments. It is important to note that 9 of the 20 subjects had a biliary stent or drain in place before the first IA procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Trial
Results</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Safety</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no evidence of local tissue toxicity in any patients post procedure as measured by liver and pancreatic enzymes. Out of 101 procedures,
adverse events were reported in 11 subjects, including catheterization/procedure-related events with arterial dissections at treatment
sites (3), pseudoaneurysm in a visceral artery (1), complications away from the treatment site and site complications (2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious
adverse events were reported in 9 subjects during the study. Overall survival (including deaths that occurred following disease progression)
was followed in all study subjects. The number of subjects with serious adverse events is shown in Table 1 below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
1 Summary of Serious Adverse Events for 9 subjects in RR1 Dose Ranging Study</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 69%; text-align: left">Serious Adverse Event</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 29%">N=20</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cardiac Arrest</td><td>&#160;</td>
    <td>1/20 (5%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Dehydration</td><td>&#160;</td>
    <td>1/20 (5%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Duodenal obstruction</td><td>&#160;</td>
    <td>1/20 (5%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Gastritis</td><td>&#160;</td>
    <td>1/20 (5%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Infection</td><td>&#160;</td>
    <td>1/20 (5%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intraoperative arterial injury-dissection</td><td>&#160;</td>
    <td>3/20 (15%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intraoperative arterial injury-lower extremity</td><td>&#160;</td>
    <td>1/20 (5%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Pain-Abdominal NOS</td><td>&#160;</td>
    <td>1/20 (5%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Respiratory failure</td><td>&#160;</td>
    <td>1/20 (5%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Sepsis</td><td>&#160;</td>
    <td>3/20 (15%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Neutropenia</td><td>&#160;</td>
    <td>4/20 (20%)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
table shows serious adverse events reported in 9 of the 20 subjects during the study. Several subjects had more than one serious adverse
event.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Efficacy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal evaluation of efficacy was survival. All subjects were followed for survival after the end of IA gemcitabine treatment. All
subjects have died, with the longest having an overall survival of 35.9 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subjects
Who Received More Intra-arterial Treatment Cycles Survived Longer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_013.jpg" alt="" style="height: 337px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
14: This chart shows survival as a function of total number of IA treatment cycles received. Subjects receiving all 4 cycles (n=8) had
a median survival time of 21.7 months, compared to a median survival time of 10.9 months for all subjects (n=20).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subjects
Who Received Greater Cumulative Exposure to RenovoGem Survived Longer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_014.jpg" alt="" style="height: 337px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
15: Splitting the entire cohort into equal tertiles based on total dose received, patients receiving the lowest total dose (&lt;2.5g/m2;
n=7) demonstrated the lowest median overall survival (8.1 months) compared to patients in the group receiving the next higher total dose
(&gt;2.5g/m2, but &lt;4g/m2; n=6; median OS=10.9 months), and patients in the group receiving the highest total dose (&gt;4g/m2; n=7;
median OS=27.5 months).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subjects
Who Had Prior Radiation Exposure Survived Longer Than Those Who Did Not</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
shown below in Figure 15, fifteen subjects received more than 1 cycle of intra-arterial gemcitabine treatment. The red line represents
subjects without any prior treatment or received prior chemotherapy only (n=10; median OS=13.6 months). The dark green line depicts subjects
who received prior chemoradiation (n=5; median OS=28.2 months). P &lt; 0.05 for survival between the two subsets. Survival appeared to
be longer in subjects who had prior chemoradiation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_015.jpg" alt="" style="height: 332px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
16: Survival of subjects with or without prior chemoradiation. Subjects with prior chemoradiation (n=5) had a median survival time of
28.2 months, compared with a median survival time of 13.6 months for subjects without prior chemoradiation (n=10).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Disease
Progression Based on RECIST 1.1 Criteria</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RECIST 1.1 criteria was used to compare the baseline and follow up CT images submitted by sites. Follow-up CT scans obtained 5 months
after initiation of IA gemcitabine therapy were submitted for 17 of the 20 subjects and were compared to the baseline images. Six of
the 17 subjects (35.3%) experienced tumor progression, 1 (5.9%) had a partial response, and 10 (58.8%) demonstrated stable disease 5
months post treatment initiation. Two of the 6 subjects with tumor progression received less than 1 cycle (only 1 treatment) of IA gemcitabine.
Among 15 subjects who received more than 1 cycle (2 treatments), 26.7% had disease progression, 6.7% had partial response and 66.7% had
stable disease 5 months post IA therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">CA
19-9 Tumor Marker Change</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA19-9
is a protein that can be detected in serum and is a biomarker of pancreatic cancer; its levels can be used to assess tumor response to
therapy. Twelve of 20 subjects had measurable CA 19-9 tumor markers. The final CA 19-9 tumor marker levels were lower in 7 of 12 (58%)
and greater in 5 of 12 (42%) subjects. It is notable that final tumor marker levels were lower in 4 of 5 subjects with prior chemoradiation
and higher in 5 of 7 subjects without prior chemoradiation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Observational
Registry Study RR2</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
launched the RR2 observational registry study in January 2016 to further explore the clinical utility of the RenovoTAMP procedure. The
key inclusion criteria were patients with locally advanced or borderline resectable pancreatic adenocarcinoma confirmed by histology
or cytology. This was an observational patient registry study with endpoints of safety and survival following intra-arterial gemcitabine
treatment with RenovoCath. The study was conducted at 7 sites in the US and subsequently closed on August 2019 except for one US site
(that did not participate in the Phase III study). This last site in the study was officially closed in September 2020. Over the 3 years
that the trial was open, we enrolled 25 subjects with LAPC. Two of those subjects had participated in our Phase I/II RenovoCath/Gem RR1
trial: each received 8 IA gemcitabine infusions prior to enrollment in the RR2 study. A summary of data updated through January 2021
is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study initially enrolled LAPC subjects without regard to prior radiation or chemotherapy. In April 2017, after the observation of longer
survival of subjects with prior chemoradiation versus subjects who had not had prior radiotherapy, entry into the registry was restricted
to subjects with LAPC who had received prior radiation. Of note, one subject who had prior pancreatic cancer surgery (Whipple procedure)
would not normally have been enrolled in the study but was included for safety observations as her physician had previously planned IA
gemcitabine therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigators
in the study reported all Serious Adverse Events from the first IA gemcitabine infusion to at least 60 days after their last procedure,
but reporting of non-serious adverse events was optional. All subjects received gemcitabine 1000 mg/m<sup>2</sup>&#160;every two weeks,
except one who received 500 mg/m<sup>2</sup>, typically for a total of 8 doses. Subjects were followed post-treatment for survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Study
Subjects and RenovoGem Exposure</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twenty-five
subjects were enrolled at 7 sites. The study enrolled 15 women (60%) and 10 men (40%); with a mean and median age of 73. Of the 25, 10
(40%) had no prior therapy, 8 (32%) had prior radiotherapy and chemotherapy, 6 (24%) had prior chemotherapy alone and 1 (4.5%) had surgery
(Whipple procedure).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
subjects were continuations from the previous Phase I/II RenovoCath/Gem RR1 study, and as a result, received more than eight treatments
(total in both studies). The treatment received summary is shown in Table 2:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
2 Dosing Treatments for RR2 Observational Registry Study, for 25 Subjects Enrolled at 7 Sites</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Dosing Treatments</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">N=25</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: center">1</td><td style="width: 2%">&#160;</td>
    <td style="width: 49%; text-align: center">5/25 (20%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2</td><td>&#160;</td>
    <td style="text-align: center">3/25 (12%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: center">4/25 (16%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">4</td><td>&#160;</td>
    <td style="text-align: center">5/25 (20%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: center">2/25 (8%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">7</td><td>&#160;</td>
    <td style="text-align: center">2/25 (8%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">8</td><td>&#160;</td>
    <td style="text-align: center">2/25 (8%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&gt;8</td><td>&#160;</td>
    <td style="text-align: center">2/25 (8%)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Twenty-five
subjects, 15 women (60%) and 10 men (40%); with a mean and median age of 73 were enrolled at 7 sites. Of 25, 10 (40%) had no prior therapy,
8 (32%) had radiotherapy and chemotherapy, 6 had chemotherapy alone and 1 (4.5%) had surgery (Whipple procedure).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the 25 patients, 109 total IA treatments were administered through one or more of the following arteries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
                                            Hepatic Artery</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Splenic
                                            Artery</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celiac
                                            Axis</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Superior
					Mesenteric Artery</span></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Trial
Results</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Safety</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were a number of adverse events reported. The most common were nausea (36%), vomiting (28%), abdominal pain (32%), followed by
vascular access complications (16%). The less common adverse events reported (&lt; 5%) included rash, allergic reaction,
retroperitoneal hemorrhage, sepsis, ischemic bowel, arterial spasm, atrial fibrillation, chest pain, back pain, hypoglycemia,
pruritis, and other GI issues. No deaths were noted in the immediate post-treatment period. No deaths were considered related to
study treatment. Survival is summarized as an efficacy evaluation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
of Key Safety Observations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
                                            pancreatitis nor local tissue toxicity was reported in LAPC subjects without prior surgery.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            was no instance of arterial dissection in this study.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            incidence of sepsis was lower in this study (1/25 subjects receiving 94 infusions) compared
                                            with the incidence in Phase I/II RenovoCath/Gem RR1 (3/20 subjects receiving 101 infusions).
                                            The subject with sepsis did not have a biliary stent or drain and the source of the sepsis
                                            was not identified. No sepsis events were noted after 51 infusions in 12 subjects with biliary
                                            stents, who received peri-procedure antibiotics. The incidence of sepsis in the RR2 observational
                                            registry is like that of pancreatic cancer subjects receiving myelosuppressive chemotherapeutic
                                            regiment in other studies.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Efficacy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excluding
the subjects with prior or post pancreatic cancer surgery, median survival (n=22) from the time of first IA gemcitabine treatment was
5.43 months, as illustrated in Figure 16 below, whereas median overall survival (from date of diagnosis) was 13.0 months (Figure 17).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Survival
of all Subjects from first IA Gemcitabine Treatment (Median 5.43 Months)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_016.jpg" alt="" style="height: 331px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
17. Overall RR2 observational registry study cohort (N=22) survival from first IA treatment until date of death.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overall
Survival of All Subjects (Median Overall Survival 13 Months)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_017.jpg" alt="" style="height: 334px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
18: Overall RR2 observational registry study cohort (N=22) overall survival from date of diagnosis.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
in Phase I/II RenovoCath/Gem RR1, subjects with prior radiation and chemotherapy demonstrated longer survival than other subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subjects
with Prior Chemoradiation Survived Longer than Subjects with Prior Chemotherapy Only</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_018.jpg" alt="" style="height: 376px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
19: Survival as function of previous treatment received for RR2 registry study subjects. As in RR1 study, subjects with prior radiation
and chemotherapy demonstrated longer survival than other subjects.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, the results of the RR2 observational registry build on the findings of the Phase I/II RenovoCath/Gem RR1 study. The use of RenovoCath
in this patient population can be undertaken with adequate safety, with adequate attention to procedural technique including careful
use/manipulation of a guide catheter to prevent arterial dissection, and with the administration of peri-procedure antibiotics in patients
with prior biliary stent/drain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>RR1
and RR2 Conclusions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients&#160;with
LAPC treated with RenovoTAMP showed efficacy signals:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival
                                            of patients with LAPC following RenovoTAMP was similar to that observed in the previous Phase
                                            I/II RenovoCath/Gem RR1 study.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
                                            with biliary stents or drains who received RenovoTAMP who received prophylactic peri-procedure
                                            antibiotics experienced no episodes of sepsis.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LAPC
                                            patients who received prior radiation and chemotherapy had longer survival than those without
                                            prior radiotherapy.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the RR2 observational registry study, treatment via the Superior Mesenteric Artery (SMA)
                                            showed the greatest survival benefit. It is believed that this is a result of the high contact
                                            area between the SMA and the tumor tissue.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registry study (RR2) results combined with the Phase I dose escalation study (RR1) further
                                            validates prior radiation and treatment location as predictors of overall survival (in combination,
                                            RR1 and RR2 data were statistically significant for these two variables).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the FDA&#8217;s safety review of our Phase I/II study and clinical outcome, the FDA allowed us to proceed to evaluate RenovoGem within
our Phase III registrational clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TIGeR-PaC
Phase III Trial (RR3)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
completion of RR1 and RR2, we obtained FDA approval for Phase III IND study in February 2018 comparing RenovoTAMP with intra-arterial
gemcitabine to standard of care. In the FDA pre-IND meeting, the FDA confirmed the study design and endpoints and indicated that this
Phase III study should result in New Drug Application approval if successful. In April 2018, we obtained Orphan Drug Designation for
the use of RenovoGem in patients with pancreatic cancer. Depending on the progress of the trial and the potential observed benefit of
RenovoGem, we will evaluate submitting a request to the FDA for Breakthrough Therapy Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary endpoint of the study is overall survival, from time of randomization until death. Secondary endpoints include but not limited
to progression free survival and quality of life questionnaire results. The study is a multi-center, open-label, randomized active-controlled
study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable according to NCCN guidelines. The study is currently
enrolling patients in the US.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study design is as follows: all patients receive a four-month induction phase of IV chemotherapy and radiation prior to randomizing to
4 cycles (8 treatments) of RenovoTAMP or 4 cycles of continuation of IV chemotherapy. In December 2021, we amended the protocol for our
Phase III clinical trial to only allow for Stereotactic Body Radiation Therapy (SBRT) radiation during the induction phase of the study.
We had previously permitted both SBRT and intensity-modulated radiation therapy (IMRT). Patients receiving IMRT were required to complete
25 treatments prior to being randomized into our study. In comparison, patients receiving SBRT are only required to complete 5 treatments.
IMRT is generally less tolerable than SBRT, and we had observed a higher drop out for patients on IMRT. While RenovoTAMP data versus
historical controls predicts a much greater survival benefit, the TIGeR-PaC study is powered to detect a 6-month survival benefit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
study flowchart is shown below. Subjects with stable or responding disease after approximately 4 months in induction therapy and who
are not surgical candidates will then be randomized 1:1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TIGeR-PaC
Study Flowchart with Chemoradiation Induction Phase</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;<img src="tiger_001.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
20: TIGeR-PaC Study Flowchart. All subjects undergo a 4-month induction phase that includes IV gemcitabine + Abraxane and radiation therapy.
If the subjects are stable with LAPC post-induction, they are randomized 1:1 into control group (IV gemcitabine + Abraxane) versus treatment
group (intra-arterial gemcitabine via RenovoTAMP therapy). Subjects are then administered continuation therapy until disease progression
and followed through survival.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021 we amended the protocol for this clinical trial to only allow for SBRT during the
induction phase of the study (prior to randomization). We had previously permitted both SBRT and IMRT. Patients receiving IMRT must complete 25 radiation treatments in combination with oral chemotherapy during the induction phase
of the study, which takes between 35 and 56 days to complete. In comparison, patients receiving SBRT during the induction phase are only
required to complete 5 treatments, over 5 consecutive days, and do not receive oral chemotherapy. The decision to modify the study population
was based on the observation in the Phase III TIGeR-PaC study that IMRT patients had a higher dropout rate during the induction phase
of the study due to the high frequency of hospital visits and side effects from the required concurrent chemotherapy. As part of the
pre-randomization, induction phase change made to the protocol, we initiated a review of the statistical considerations for the study
and in June 2022, submitted the Modified SAP to FDA. As part of the Modified SAP,
we now plan to (i) analyze only patients receiving SBRT, consistent with the protocol change made in December 2021, (ii) include a second
interim analysis, (iii) change the total number of SBRT patients randomized in the study to 114 (a reduction from the original 200 patients)
with a total of 86 deaths from SBRT patients, including all deaths from SBRT patients enrolled in the study before the submission of
the Modified SAP, and (iv) repower the study from 90% to 80%, which is commonly used in clinical trials. We believe these changes will
shorten the timeframe needed to complete the study and also significantly decrease our costs. We have not discussed the protocol amendment
or the Modified SAP with the FDA, and we cannot provide any assurance that the FDA will agree with these modifications. As of March 8,
2023, we announced interim analysis results of the study suggesting a 6-month potential improvement in median overall survival with RenovoGem,
pending ongoing clinical investigation. We believe this first-of-two interim analyses indicates that the TIGeR-PaC study is on track to demonstrate
increased lifespan for patients being treated with RenovoGem for LAPC. Final analysis will be conducted after 86 protocol-specified events
have occurred in the SBRT population with two planned interim analyses: this first analysis with 30% of the specified events (deaths)
reported and the second analysis when 60% of the events have been reported (expected in 2024), with the final study readout in 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this interim analysis, the control and treatment arms demonstrated divergence in median overall survival for patients. The study is designed
to randomize 114 patients (57 in each arm) with all patients receiving upfront induction chemotherapy and SBRT. The TIGeR-PaC DMC met and determined the interim data is promising and warrants continuation of this pivotal trial. As of
the date of the analysis, 45 patients from U.S. sites had been randomized in this trial and the survival status of all subjects was used
for the analysis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23
                                            patients were randomized to intra-arterial gemcitabine (RenovoGem investigational treatment)
                                            arm and 22 to continuation of IV gemcitabine and nab-paclitaxel (control or standard of care)
                                            arm. There were an equal number of primary events, 13 in each arm.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            median overall survival in the IV gemcitabine and nab-paclitaxel control arm was 10 months,
                                            versus 16 months in the intra-arterial RenovoGem arm. (NOTE: Both arms&#8217; median overall
                                            survival calculations do not include 4 to 5-months of life since diagnosis during the induction
                                            chemotherapy and radiation phase of the trial).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observed
                                            a positive trend in median overall survival by 24-weeks (6-months); in this interim analysis,
                                            the statistical significance was not reached to stop the study early (p=0.051)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Pharmacokinetic (PK) Data in Patients with LAPC Treated with Gemcitabine via RenovoTAMP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect intra-arterial gemcitabine delivered via the RenovoTAMP technique to have a pharmacokinetic profile that is distinct from intravenous
gemcitabine dosing. Furthermore, with local delivery of gemcitabine into the tissue via RenovoTAMP and drainage into the liver prior
to systemic circulation, we anticipate lower systemic levels of gemcitabine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
presented the initial results of this substudy at ASCO-GI 2023 in San Francisco, CA. At the time of the analysis, 13 samples were collected
across 5 TIGeR-PaC clinical sites. We demonstrated that the cohort had an average greater than 50% reduction in systemic drug exposure
with IA delivery of gemcitabine using RenovoTAMP when compared with IV administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Second
Solid Tumor Indication</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>eCCA
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cholangiocarcinoma
is the second most common primary malignant tumor of the liver with over 7,000 new cases diagnosed annually in the US. Cholangiocarcinoma
(CCA) develops after malignant transformation of the biliary tract mucosa. The global market of CCA was estimated to be $385 million
in 2018 and the US accounted for the largest market size of CCA. Furthermore, the market size for global CCA therapeutics is estimated
to grow by $83 million during 2019-2023 with a compound annual growth rate of 6%. Advanced age, male gender, primary sclerosing cholangitis
(PSC), inflammatory bowel disease, pancreatitis, and cirrhosis are some predisposing factors for development of CCA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the tumor location CCA is defined as intra-hepatic, or within the liver, or extrahepatic, or outside the liver. The eCCA subset of
CCA patients is about 3,000 cases per year. eCCA is a disease with an exceptionally poor prognosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>eCCA
Current Treatment Landscape and Limitations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
patients with eCCA have localized disease with possible extension of the tumor around the bile duct. Based on local extension of the
disease, treatment options include surgery, chemotherapy, and radiation therapy. Surgical resection offers the only chance for curative
therapy for patients with eCCA; however, the surgery is associated with high mortality and morbidity and most patients are not candidates.
Systemic chemotherapy is a primary mode of treatment in these patients as a form of palliation, which is associated with morbidity and
limited improvement in survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
standard chemotherapy treatment in these patients is based on the ABC-2 Trial: a randomized trial of 410 patients with unresectable CCA
(the study included intrahepatic, within the liver, and extrahepatic cholangiocarcinoma patients).&#160;Patients were treated with gemcitabine
plus cisplatin, consisting of a three-week cycle, with treatments on Days 1 and 8 and dosing of&#160;gemcitabine&#160;at 1000 mg/m<sup>2</sup>&#160;and
cisplatin at 25 mg/m<sup>2</sup>. Reported median overall survival for patients on such a regimen (11.7 months) was greater than for
patients receiving gemcitabine alone (8.1 months). With this standard of care treatment, commonly observed Grade 3-4 toxicities include
anemia, leukopenia, neutropenia, thrombocytopenia, lethargy, nausea/vomiting, and anorexia.&#160;In the ABC-02 trial the efficacy of
gemcitabine/cisplatin combination was not significantly different from that of gemcitabine alone in patients with extrahepatic cholangiocarcinoma.
For this reason, a standard of care practice has not been established for extrahepatic cholangiocarcinoma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">More recently, the Phase III TOPAZ-1 study was presented at the 2022 ASCO GI in San Francisco, CA and demonstrated
that the addition of durvalumab to the previously described gemcitabine/cisplatin regimen increased median overall survival from 11.6
months to 12.8 months in this patient population and subsequently received FDA approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoGem
for the Treatment of eCCA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to RenovoGem for LAPC, we believe that RenovoGem may overcome the current treatment limitations of eCCA. In this setting, patients with
eCCA have several tumor characteristics that create the potential for RenovoGem to be more effective than systemic chemotherapy. These
characteristics include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Local
                                            disease with possible extension of disease to local vasculature;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avascular
                                            nature of the tumor lends itself to our RenovoTAMP approach, overcoming the limitations in
                                            drug delivery by targeting the periductal proper hepatic artery or left or right hepatic
                                            artery;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemcitabine,
                                            used as a target molecule for this tumor type, has already been demonstrated to be safe in
                                            terms of local toxicity targeted via our approach to this vasculature and organ; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            bile duct around the hilum is usually within 1-14 mm (mean of 3.8 mm) of the hepatic artery:
                                            a reasonable target for RenovoTAMP therapy given the potential 4 cm tissue penetration of
                                            drug.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Development of RenovoGem in eCCA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rationale</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2020, the FDA granted us Orphan Drug Designation in May 2020 for
RenovoGem for the treatment of CCA. We are planning to evaluate RenovoGem in a second indication in a Phase II/III trial in extrahepatic
(or outside the liver) cholangiocarcinoma (or eCCA), cancer that occurs in the bile ducts that lead out of the liver and join with the
gallbladder. After significant input from key opinion leaders across the spectrum of relevant medical specialties and feedback from the
FDA, we submitted the protocol for a Phase II/III eCCA clinical trial to FDA, and after receiving feedback, we are finalizing the protocol
and also including incorporating a recently approved drug, durvalumab into the study protocol with guidance from the Steering Committee.
We anticipate launching this study mid this year. We have also secured FDA Orphan Drug Designation for RenovoGem for the treatment of
cholangiocarcinoma, which would provide us with seven years of orphan exclusivity to market RenovoGem for our eCCA indication upon NDA
approval, provided that we are the first sponsor to obtain FDA approval for intra-arterial gemcitabine for the eCCA indication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Opportunity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing RenovoGem for LAPC. We also intend to develop it for eCCA, and potentially for locally advanced lung cancer,
locally advanced uterine cancer and glioblastoma. We estimate that the total annualized addressable market opportunity for RenovoGem
for our first market, LAPC, in the United States is approximately $0.5 billion and globally could exceed $1 billion based on a third-party
market research analysis. The total cost of care for a patient on the standard of care treatment of gemcitabine + Abraxane is estimated
at $67,216, which if applied to 60,000 pancreatic cancer cases per year would total $4 billion per year for the total US pancreatic cancer
market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
our initially targeted subset of LAPC patients, we see potential to evaluate RenovoGem in additional settings where it may help to get
more patients to surgery, prolong life, enhance systemic therapy or provide local therapy with fewer side effects than alternative treatments.
These may include patients with stage 1 or stage 2 pancreatic cancer receiving neoadjuvant as well as in subpopulations of patients with
metastases who also have locally advanced disease. Based on third-party market research, several physicians mentioned the role for local
therapy as an adjunct for systemic chemotherapy as well as for patients who decline systemic chemotherapy. Among the locally advanced
(stage 3) patients diagnosed with the cancers shown in Figure 22, we estimate that ~125,000 could be potentially addressable via RenovoGem.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is published epidemiology data showing the 2021 estimated annual incidence of the following tumor types in the United States to be greater
than 350,000 patients in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Opportunity for RenovoTAMP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_021.jpg" alt="" style="height: 460px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
21: <b>US Annual Incidence of Initial RenovoTAMP Target Tumor Types,</b> showing overall incidence in blue, and those treatable via RenovoTAMP
in orange.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
                                            Pancreatic Cancers compared to Locally Advanced Pancreatic Cancers (LAPC)</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
                                            Cholangiocarcinoma (CCA) compared to Extrahepatic CCA</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
                                            Non-Small Cell Lung Cancers (NSCLC) compared to Stage 3 NSCLC</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
                                            Glioma compared to Glioblastoma</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
                                            Uterine cancers versus Transcatheter arterial chemoembolization (TACE) eligible uterine cancers</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe RenovoTAMP is broadly applicable to locally advanced tumors: our platform may be used with multiple small molecule chemotherapeutic
agents in multiple solid tumor indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on our ability to obtain patents and trademarks, maintain trade secret and know-how protection, enforce our proprietary
rights against infringers, and operate without infringing on the proprietary rights of&#160;third&#160;parties. Because of the length
of time and expense associated with developing new products and bringing them through the regulatory approval process, the health care
industry places considerable emphasis on obtaining patent protection and maintaining trade secret protection for new technologies, products,
processes, know-how, and methods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property protection stems from several issued device and method patents on our RenovoCath delivery system that optimizes
delivery of the anti-cancer drug and the RenovoTAMP therapy platform. Our issued patents also&#160;provide&#160;exclusivity as it relates
to utilizing RenovoCath with anti-cancer drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have 8 US patents issued, 1 European patent issued, and 8 additional
patents pending in the US, EU, and Asia. We continue to explore additional opportunities to further bolster our IP position. Table 3 below
describes our issued patents, all of which have been assigned to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
3&#160;RenovoRx has Significant Patent Protection with 8 Issued Patents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family</b></span></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>App. No.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></p></td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 12%; font-weight: bold; text-align: center">Type of Patent Protection</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 24%; font-weight: bold; text-align: center">Patent Focus</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 12%; font-weight: bold; text-align: center">Patent #</td><td style="text-align: center; width: 2%; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration<sup>**</sup></b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Dual Balloon Methods and Apparatuses</td><td>&#160;</td>
    <td style="text-align: center">12/958711<br /> Filed: 12/2/2010</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent</td><td>&#160;</td>
    <td style="text-align: center">Methods: isolating splenic artery with 2 balloons (sliding inner catheter)</td><td>&#160;</td>
    <td style="text-align: center">US8,821,476</td><td>&#160;</td>
    <td style="text-align: center">January 25, 2033</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center">Dual Balloon Methods and Apparatuses</td><td>&#160;</td>
    <td style="text-align: center">14/870833<br /> Filed: 9/30/2015</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent</td><td>&#160;</td>
    <td style="text-align: center">Apparatus: 2 balloons, seal to isolate lumen, and infusion aperture</td><td>&#160;</td>
    <td style="text-align: center">US9,463,304</td><td>&#160;</td>
    <td style="text-align: center">December 2, 2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Dual Balloon Methods and Apparatuses</td><td>&#160;</td>
    <td style="text-align: center">14/293603<br /> Filed: 6/2/2014</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent</td><td>&#160;</td>
    <td style="text-align: center">Apparatus: 2 balloons (sliding inner catheter), 2 ports for fluid handling</td><td>&#160;</td>
    <td style="text-align: center">US9,457,171</td><td>&#160;</td>
    <td style="text-align: center">April 16, 2031</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center">Dual Balloon Methods and Apparatuses</td><td>&#160;</td>
    <td style="text-align: center">15/351922<br /> Filed: 11/15/2016</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent</td><td>&#160;</td>
    <td style="text-align: center">Kits for chemotherapy including catheter with 2 balloons, an infusion aperture and 2 ports</td><td>&#160;</td>
    <td style="text-align: center">US10,512,761</td><td>&#160;</td>
    <td style="text-align: center">April 16, 2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Dual Balloon Methods and Apparatuses</td><td>&#160;</td>
    <td style="text-align: center">108351107<br /> Filed: 12/2/2010</td><td>&#160;</td>
    <td style="text-align: center">E.U. Utility patent, nationalized in BE, CH, DE, ES, FR, GB, IE, IT and NL</td><td>&#160;</td>
    <td style="text-align: center">A two occlusion element, adjustable delivery apparatus having inner and outer catheter, seal to isolate lumen</td><td>&#160;</td>
    <td style="text-align: center">EU 2506913</td><td>&#160;</td>
    <td style="text-align: center">December 2, 2030</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center">Side Branch Isolation Device and Methods</td><td>&#160;</td>
    <td style="text-align: center">14/958428<br /> Filed: 12/3/2015</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent</td><td>&#160;</td>
    <td style="text-align: center">Apparatuses and Methods: 3 balloon catheters for isolating side branches</td><td>&#160;</td>
    <td style="text-align: center">US10,099,040</td><td>&#160;</td>
    <td style="text-align: center">December 3, 2035</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Trans-Arterial Micro-Perfusion (TAMP)</td><td>&#160;</td>
    <td style="text-align: center">15/807011<br /> Filed: 11/8/2017</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent</td><td>&#160;</td>
    <td style="text-align: center">Methods delivering radiation to devascularize then TAMP</td><td>&#160;</td>
    <td style="text-align: center">U.S., 10,695,543</td><td>&#160;</td>
    <td style="text-align: center">August 28, 2038</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center">Dual Balloon Methods and Apparatuses</td><td>&#160;</td>
    <td style="text-align: center">18/149649<br /> Filed: 1/3/2023</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent<br /> (Pending application)</td><td>&#160;</td>
    <td style="text-align: center">Methods of treating bile duct</td><td>&#160;</td>
    <td style="text-align: center">PENDING</td><td>&#160;</td>
    <td style="text-align: center">December 2, 2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Trans-Arterial Micro-Perfusion (TAMP)</td><td>&#160;</td>
    <td style="text-align: center">16/685974<br /> Filed: 11/15/2019</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent<br /> (Pending application)</td><td>&#160;</td>
    <td style="text-align: center">Devascularization in conjunction with TAMP</td><td>&#160;</td>
    <td style="text-align: center">US11,052,224</td><td>&#160;</td>
    <td style="text-align: center">November 8, 2037</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center">Dual Balloon Methods and Apparatuses</td><td>&#160;</td>
    <td style="text-align: center">IN 1632MUMNP2012<br /> Filed: 12/2/2010</td><td>&#160;</td>
    <td style="text-align: center">IN Utility patent<br /> (Pending application)</td><td>&#160;</td>
    <td style="text-align: center">A two occlusion element, adjustable delivery apparatus having inner and outer catheter, seal to isolate lumen</td><td>&#160;</td>
    <td style="text-align: center">PENDING</td><td>&#160;</td>
    <td style="text-align: center">December 2, 2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Trans-Arterial Micro-Perfusion (TAMP)</td><td>&#160;</td>
    <td style="text-align: center">CN 2018800033529<br /> Filed: 5/18/2018</td><td>&#160;</td>
    <td style="text-align: center">CN Utility patent<br /> (Pending application)</td><td>&#160;</td>
    <td style="text-align: center">Devascularization in conjunction with TAMP</td><td>&#160;</td>
    <td style="text-align: center">PENDING</td><td>&#160;</td>
    <td style="text-align: center">November 8, 2037*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center">Trans-Arterial Micro-Perfusion (TAMP)</td><td>&#160;</td>
    <td style="text-align: center">EP 187315908<br /> Filed: 5/18/2018</td><td>&#160;</td>
    <td style="text-align: center">EP Utility patent<br /> (Pending application)</td><td>&#160;</td>
    <td style="text-align: center">Devascularization in conjunction with TAMP</td><td>&#160;</td>
    <td style="text-align: center">PENDING</td><td>&#160;</td>
    <td style="text-align: center">November 8, 2037*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Trans-Arterial Micro-Perfusion (TAMP)</td><td>&#160;</td>
    <td style="text-align: center">JP 2020514151<br /> Filed: 5/18/2018</td><td>&#160;</td>
    <td style="text-align: center">JP Utility patent<br /> (Pending application)</td><td>&#160;</td>
    <td style="text-align: center">Devascularization in conjunction with TAMP</td><td>&#160;</td>
    <td style="text-align: center">PENDING</td><td>&#160;</td>
    <td style="text-align: center">November 8, 2037*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center">Trans-Arterial Micro-Perfusion (TAMP)</td><td>&#160;</td>
    <td style="text-align: center">17/315220 <br />Filed: 5/7/2021</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent<br /> (Pending application)</td><td>&#160;</td>
    <td style="text-align: center">Devascularization in conjunction with TAMP</td><td>&#160;</td>
    <td style="text-align: center">PENDING</td><td>&#160;</td>
    <td style="text-align: center">November 8, 2037*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Trans-Arterial Micro-Perfusion (TAMP)</td><td>&#160;</td>
    <td style="text-align: center">17/367046 <br />Filed: 7/2/21</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent<br /> (Pending application)</td><td>&#160;</td>
    <td style="text-align: center">Devascularization in conjunction with TAMP</td><td>&#160;</td>
    <td style="text-align: center">PENDING</td><td>&#160;</td>
    <td style="text-align: center">November 8, 2037*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center">Dual Balloon Methods and Apparatuses</td><td>&#160;</td>
    <td style="text-align: center">17/558577<br /> Filed: 12/21/2021</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent<br /> (Pending application)</td><td>&#160;</td>
    <td style="text-align: center">Methods of treating bile duct</td><td>&#160;</td>
    <td style="text-align: center">US11,541,211</td><td>&#160;</td>
    <td style="text-align: center">December 2, 2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Improved Dual Balloon Methods and Apparatuses</td><td>&#160;</td>
    <td style="text-align: center">18/184620<br />
Filed: 3/15/2023</td><td>&#160;</td>
    <td style="text-align: center">US Utility patent<br />
(Pending application)</td><td>&#160;</td>
    <td style="text-align: center">Dual occlusion catheter systems</td><td>&#160;</td>
    <td style="text-align: center">PENDING</td><td>&#160;</td>
    <td style="text-align: center">March 15, 2043*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center">Microvascular Delivery of Materials</td><td>&#160;</td>
    <td style="text-align: center">63424842<br />
Filed: 11/11/2022</td><td>&#160;</td>
    <td style="text-align: center">US Provisional patent<br />
(Pending application)</td><td>&#160;</td>
    <td style="text-align: center">Methods and devices for delivering agent through Vasa Vasorum</td><td>&#160;</td>
    <td style="text-align: center">PENDING</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Predicted earliest expiration date. The actual expiration date will depend on factors related to patent prosecution and issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>**&#160;</b>Estimated
expiration dates assume all maintenance fees are paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation provides seven years post-approval market exclusivity protection. Gemcitabine is generic; however, we have exclusivity
for the intra-arterial route of administration. RenovoGem is regulated by the FDA as a new oncology drug product. We intend to make intra-arterial
gemcitabine and RenovoCath available as a combined product and not to make either component available separately. Once approved, we will
have exclusivity over the use of intra-arterial gemcitabine as it will be approved by the FDA in combination with RenovoCath.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
appropriate, we actively pursue protection of our proprietary products, technologies, processes, and methods by filing United States
and international patent and trademark applications. We seek to pursue additional patent protection for technology invented through research
and development, manufacturing, and clinical use of our technology that will enable us to expand our patent portfolio around advances
to our current systems, technology, and methods for our current applications as well as others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the pending patent applications will result in the issuance of patents, that patents issued to or licensed by
us will not be challenged or circumvented by competitors, or that these patents will be found to be valid or sufficiently broad to protect
our technology or provide us with a competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
maintain our proprietary position, we also rely on trade secrets and proprietary technological experience to protect proprietary manufacturing
processes, technology, and know-how relating to our business. We rely, in part, on confidentiality agreements with our marketing partners,
employees, advisors, vendors and consultants to protect our trade secrets and proprietary technological expertise. In addition, we also
seek to maintain our trade secrets through maintenance of the physical security of the premises where our trade secrets are located.
There can be no assurance that these agreements will not be breached, that we will have adequate remedies for any breach, that others
will not independently develop equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets
and proprietary knowledge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain circumstances, United States patent law allows for the extension of a patent&#8217;s duration for a period of up to five years
after FDA approval. We intend to seek extension for one of our patents after FDA approval if it has not expired prior to the date of
approval. In addition to our proprietary protections, the FDA has granted us two orphan drug designations that provide us a seven-year
period of exclusive marketing beginning on the date that our NDA is approved by the FDA for the designated orphan drug. While the exclusivity
only applies to the indication for which the drug has been approved, we believe that this exclusivity will provide us with added protection
once commercialization of an orphan drug designated product begins.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been and continues to be substantial litigation regarding patent and other intellectual property rights in the pharmaceutical and
medical device areas. If a third party asserts a claim against us, we may be forced to expend significant time and money defending such
actions and an adverse determination in any</span> patent
litigation could subject us to significant liabilities to third parties, require us to redesign our product, require us to seek licenses
from third parties, and, if licenses are not available, prevent us from manufacturing, selling or using our system. Additionally, we
plan to enforce our intellectual property rights vigorously and may find it necessary to initiate litigation to enforce our patent rights
or to protect our trade secrets or know-how. Patent litigation can be costly and time consuming and there can be no assurance that the
outcome will be favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
and Supply</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the catheter component (RenovoCath) of the drug/device combination, we currently rely on a single-source contract manufacturer, Medical
Murray, North Barrington, IL. However, we are in early discussions with an additional manufacturer. We are subject to regulatory requirements
of the FDA&#8217;s Quality System Regulation (QSR), for medical devices sold in the United States, and the European Medical Device Directive
93/42/EEC, which was replaced by the EU Medical Device Regulation (MDR) in May 2021, following a four-year transition period for medical
devices marketed in the European Union. We have an agreement in place with Medical Murray to produce the RenovoCath through October 2024
with automatic annual renewal until termination by either party with 12 months&#8217; notice. While we believe Medical Murray has the
capabilities to scale RenovoCath production to peak forecasted commercial volumes, manufacturing can be transferred to additional vendors
if needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA monitors compliance with QSR through periodic inspections of both our facility and the facility of our contact manufacturer. Our
European Union Notified Body, British Standards Institute (BSI), monitors compliance with the MDR requirements through both annual scheduled
audits and periodic unannounced audits of our facilities as well as our contract manufacturer&#8217;s facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure or the failure of our contract manufacturer to maintain acceptable quality requirements could result in the shutdown of our manufacturing
operations or the recall of products which could be detrimental to our company. If our contract manufacturer fails to maintain acceptable
quality requirements, we may have to qualify a new contract manufacturer and could experience a material adverse effect to manufacturing
and manufacturing delays as a result.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate and do not intend to establish our own gemcitabine manufacturing facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
our TIGeR-PaC Phase III trial, hospitals are sourcing generic gemcitabine labeled for IV use from their respective pharmacies to use
in conjunction with the RenovoCath for the RenovoTAMP procedures. In the commercial setting, we expect to rely on contract manufacturing
organizations for gemcitabine production, relabeling and co-packaging with the RenovoCath. The formulation of gemcitabine used in the
TIGeR-PaC Phase III trial and in the commercial setting will be identical, however, the labeling of gemcitabine will be intra-arterial
gemcitabine to be used exclusively in conjunction with RenovoCath.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA. Foreign regulatory agencies,
the FDA and comparable regulatory agencies in state and local jurisdictions impose extensive requirements upon the clinical development,
pre-market clearance and approval, manufacturing, labeling, marketing, advertising and promotion, pricing, storage and distribution of
pharmaceutical and medical device products. Failure to comply with applicable foreign regulatory agency or FDA requirements may result
in Warning Letters, fines, civil or criminal penalties, suspension or delays in clinical development, recall or seizure of products,
partial or total suspension of production or withdrawal of a product from the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>United
States Regulatory Environment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the US, the FDA regulates drug and device products, including combination, under the FDCA, and its implementing regulations. RenovoGem
is subject to regulation as a combination product, which means it is composed of both a drug component and device component. Each component
of a combination product is subject to the requirements established by the FDA for that type of component and if marketed individually,
each component would be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product,
however, is assigned to a center that will have primary jurisdiction over its pre-market review and regulation based on a determination
of its primary mode of action, which is the single mode of action that provides the most important therapeutic action. The center that
regulates the portion of the product that has the primary mode of action becomes the lead evaluator. When evaluating an application,
a lead center may consult other centers but still retain complete reviewing authority, or it may collaborate with another center, by
which the center assigns review of a specific section of the application to another center, delegating its review authority for that
section. Typically, an applicant submits a single marketing application to the center selected to be the lead evaluator, although separate
applications for each constituent part may be submitted to the applicable centers. Combination products where the drug provides the primary
mechanism of action are often referred to as &#8220;drug-led combination&#8221; products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a drug/device combination product, containing two or more separate products packaged together in a single package or as a unit and comprised
of drug and device products, where the primary mode of action is typically a drug mode of action with the Center for Drug Evaluation
and Research, or CDER, as the lead Center, CDER would review the NDA in consultation with the Center for Devices and Radiological Health
on device-specific issues. For co-packaged or single-entity combination products there are two ways to comply with current good manufacturing
practice, or cGMP, requirements. Manufacturers can either (i) demonstrate compliance with all cGMP regulations applicable to each of
the constituent parts in the combination product or (ii) in the case of drug/device combination products, demonstrate compliance with
either the drug cGMP regulations or the device Quality System Regulation, or QSR, and also demonstrate compliance with additional provisions
from the other of these two sets of cGMP requirements, as specified in the combination products regulations. Failure to comply with applicable
regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions: warning or untitled
letters, fines, injunctions, civil or criminal penalties, recall or seizure of current or future products, operating restrictions, partial
suspension or total shutdown of production, refusal or denial of submissions for new products, or withdrawal of clearance, authorization,
or approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of RenovoGem, the primary mode of action is attributable to the drug component of the product, which means that the Center for
Drug Evaluation and Research, has primary jurisdiction over its pre-market development and review.&#160;The underlying RenovoCath drug
delivery device system used in RenovoGem has been separately cleared by the FDA as a Class II medical device (without any prepackaged
drug product) for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites
in the peripheral vascular system. The RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography,
preoperative occlusion, and chemotherapeutic drug infusion. The RenovoCath is intended for general intravascular use in the peripheral
vasculature in arteries 3mm and larger. The RenovoCath is intended for use in arteries from 3mm in diameter for vessel entry and to occlude
vessels ranging between 3mm to 11mm in diameter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before drug product candidates, including drug-led combination products, may be marketed in the United States
generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the FDA of an IND, which must become effective before human clinical trials may begin
                                            and must be updated periodically, but at least annually;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                            of extensive preclinical laboratory tests and preclinical animal studies, all performed in
                                            accordance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
                                            of adequate and well-controlled human clinical trials to establish the safety and efficacy
                                            of the product candidate for each proposed indication;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the FDA of an NDA after completion of all pivotal clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            determination by the FDA within 60 days of its receipt of an NDA to file the NDA for review;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA pre-approval inspection of the manufacturing facilities at which the
                                            product is produced and tested to assess compliance with cGMP regulations; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            review and approval of an NDA prior to any commercial marketing or sale of the drug in the
                                            United States.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals
for our product will be granted on a timely basis, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of preclinical tests (which include laboratory evaluation as well as GLP studies to evaluate toxicity in animals) for a particular
product candidate, together with related manufacturing information and analytical data, are submitted as part of an IND to the FDA. The
IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns
or questions about the conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable
health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.
IND submissions may not result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also
be made for each successive clinical trial conducted during product development. Further, an independent institutional review board,
or IRB, for each medical center proposing to conduct the clinical trial must review and approve the plan for any clinical trial before
it commences at that center and it must monitor the study until completed. The FDA, the IRB or the sponsor may suspend a clinical trial
at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Clinical
testing also must satisfy extensive good clinical practice, or GCP, regulations and regulations for informed consent and privacy of individually
identifiable information. Similar requirements to the United States, IND are required in the EU and other jurisdictions in which we may
conduct clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Trials</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of NDA submission and approval, clinical trials are typically conducted in the following sequential phases, which may overlap:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I Clinical Trials. Studies are initially conducted in a limited population to test the product
                                            candidate for safety, dose tolerance, absorption, distribution, metabolism and excretion,
                                            typically in healthy humans, but in some cases in patients.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            II Clinical Trials. Studies are generally conducted in a limited patient population to identify
                                            possible adverse effects and safety risks, explore the initial efficacy of the product for
                                            specific targeted indications and to determine dose range or pharmacodynamics. Multiple Phase
                                            II clinical trials may be conducted by the sponsor to obtain information prior to beginning
                                            larger and more expensive Phase III clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            III Clinical Trials. These are commonly referred to as pivotal studies. When Phase II evaluations
                                            demonstrate that a dose range of the product is effective and has an acceptable safety profile,
                                            Phase III clinical trials are undertaken in large patient populations to further evaluate
                                            dosage, provide substantial evidence of clinical efficacy and further test for safety in
                                            an expanded and diverse patient population at multiple, geographically dispersed clinical
                                            trial centers.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            IV Clinical Trials. The FDA may approve an NDA for a product candidate, but require that
                                            the sponsor conduct additional clinical trials to further assess the drug after NDA approval
                                            under a post-approval commitment. In addition, a sponsor may decide to conduct additional
                                            clinical trials after the FDA has approved an NDA. Post-approval trials are typically referred
                                            to as Phase IV clinical trials.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsors
of clinical trials may submit proposals for the design, execution, and analysis for their pivotal trials under a Special Protocol Assessment,
or SPA. A SPA is an evaluation by the FDA of a protocol with the goal of reaching an agreement that the Phase III trial protocol design,
clinical endpoints, and statistical analyses are acceptable to support regulatory approval of the drug product candidate with respect
to effectiveness for the indication studied. Under a SPA, the FDA agrees to not later alter its position with respect to adequacy of
the design, execution or analyses of the clinical trial intended to form the primary basis of an effectiveness claim in an NDA, without
the sponsor&#8217;s agreement, unless the FDA identifies a substantial scientific issue essential to determining the safety or efficacy
of the drug after testing begins.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the COVID-19 public health emergency, FDA has
issued various COVID-19 guidance documents, including guidance on conducting clinical trials during the pandemic; resuming normal drug
and biologics manufacturing operations; manufacturing, supply chain, and inspections; and statistical considerations for clinical trials
during the COVID-19 public health emergency, among others. The ultimate impact of the COVID-19 pandemic on our business operations and
clinical development plans is highly uncertain and subject to change and will depend on future developments, including new regulatory
requirements and changes to existing regulations. If new guidance and policies are promulgated by the FDA that require changes in our
clinical protocol or clinical development plans, our anticipated timelines and regulatory approval may be delayed or materially impacted.
President Biden announced that the administration intends to end the COVID-19 national and public health emergencies on May 11, 2023.
The full impact of the termination of the public health emergencies on FDA and other regulatory policies and operations are unclear.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
Drug Applications (NDAs)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of drug development, preclinical studies and clinical trials are submitted to the FDA as part of an NDA. NDAs also must
contain extensive chemistry, manufacturing and control information. An NDA must be accompanied by a significant user fee, which may
be waived in certain circumstances. Once the submission has been accepted for filing, the FDA&#8217;s goal is to review applications
within ten months of submission or, if the application relates to an unmet medical need in a serious or life-threatening indication,
six months from submission. The review process is often significantly extended by FDA requests for additional information or
clarification. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether
the application should be approved. For new oncology products, the FDA will often solicit an opinion from an Oncologic Drugs
Advisory Committee, or ODAC, a panel of expert authorities knowledgeable in the fields of general oncology, pediatric oncology,
hematologic oncology, immunologic <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">oncology,
biostatistics, and other related professions. The ODAC panel reviews and evaluates data concerning the safety and effectiveness of marketed
and investigational human drug products for use in the treatment of cancer, and makes appropriate recommendations to the Commissioner
of Food and Drugs. The FDA is not bound by the recommendation of an advisory committee.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will
generally inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance
with cGMPs is satisfactory, and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication
studied. After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response
letter, or CRL. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing, or information,
in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction
in a resubmission of the NDA, the FDA will issue an approval letter. A CRL may require additional clinical data and/or an additional
pivotal Phase III clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials,
preclinical studies or manufacturing. Data from clinical trials are not always conclusive and the FDA may interpret data differently
than we or our collaborators interpret data. Approval may be contingent on a Risk Evaluation and Mitigation Strategy, or REMS, that limits
the labeling, distribution or promotion of a drug product. Once issued, the FDA may withdraw product approval if ongoing regulatory requirements
are not met or if safety problems occur after the product reaches the market. In addition, the FDA may require testing, including Phase
IV clinical trials, and surveillance programs to monitor the safety effects of approved products which have been commercialized, and
the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs or other
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are three primary regulatory pathways for an NDA under Section 505 of the FDCA: Section 505 (b)(1), Section 505 (b)(2) and Section 505(j).
A Section 505 (b)(1) application is used for approval of a new drug (for clinical use) whose active ingredients have not been previously
approved. A Section 505 (b)(2) application is used for a new drug that relies on data not developed by the applicant. Section 505(b)(2)
of the FDCA was enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman
Act. This statutory provision permits the approval of an NDA where at least some of the information required for approval comes from
studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The Hatch-Waxman Act
permits the applicant to rely in part upon the FDA&#8217;s findings of safety and effectiveness for previously approved products. Section
505(j) application, also known as an abbreviated NDA, is used for a generic version of a drug that has already been approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
approval letter authorizes commercial marketing of the drug product with specific prescribing information for specific indications. As
a condition of NDA approval, the FDA may require a REMS to help ensure that the benefits of the drug outweigh the potential risks. REMS
can include medication guides, communication plans for healthcare professionals, and elements to assure safe use. The requirement for
a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval
testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance
with regulatory standards is not maintained or problems are identified following initial marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes
or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement
for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures
and actions in reviewing NDA supplements as it does in reviewing NDAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NDA review process for drug-led combination includes a review of the device constituent. In this case, the device constituent for RenovoGem
is RenovoCath, which is cleared by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Orphan
Drug Exclusivity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Pursuant to
the Orphan Drug Act, the FDA grants orphan drug designation to drugs intended to treat a rare disease or condition, which is generally
a disease or condition that affects fewer than 200,000 individuals in the United States. The orphan designation is granted for a combination
of a drug entity and an indication and therefore it can be granted for an existing drug with a new (orphan) indication. Applications
are made to the Office of Orphan Products Development at the FDA and a decision or request for more information is rendered in 60 days.
NDAs for designated orphan drugs are exempt from user fees, obtain additional clinical protocol assistance, are eligible for tax credits
up to 50% of research and development costs, and are granted a seven-year period of exclusivity upon approval. The FDA cannot approve
the same drug for the same condition during this period of exclusivity, except in certain circumstances where a new product demonstrates
superiority to the original treatment. Exclusivity begins on the date that the marketing application is approved by the FDA for the designated
orphan drug, and an orphan designation does not limit the use of that drug in other applications outside the approved designation in
either a commercial or investigational setting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received orphan drug designations for RenovoGem for pancreatic cancer and cholangiocarcinoma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
granting of orphan drug designations does not mean that the FDA has approved a new drug. Companies must still pursue the rigorous development
and approval process that requires substantial time, effort and financial resources, and we cannot be certain that any approvals for
our product will be granted at all, or on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in Catalyst Pharms., Inc. v. Becerra, 14
F.4th 1299 (11th Cir. 2021), the court disagreed with the FDA&#8217;s longstanding position that the orphan drug exclusivity only applies
to the approved use or indication within an eligible disease. This decision created uncertainty in the application of the orphan drug
exclusivity. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the
court&#8217;s order in Catalyst, the FDA intends to continue to apply its longstanding interpretation of the regulations to matters outside
of the scope of the Catalyst order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or
indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within
the same orphan designated disease or condition that have not yet been approved. It is unclear how future litigation, legislation, agency
decisions, and administrative actions will impact the scope of the orphan drug exclusivity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDA
Medical Device Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
an exemption applies, each new or significantly modified drug delivery medical device that we develop based on the current 510(k)-cleared
RenovoCath and which we seek to commercially distribute in the United States will require a premarket notification to the FDA requesting
permission for commercial distribution under Section 510(k) of the FDCA, also referred to as a 510(k) clearance, unless addressed as
part of a new drug application for a drug/device combination product. New medical devices without an applicable predicate device as well
as higher-risk medical devices are subject to premarket approval by the FDA under a PMA or a de novo classification from the FDA. The
510(k) clearance, PMA approval, and de novo classification processes can be resource intensive, expensive, and lengthy, and require payment
of significant user fees, unless an exemption is available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA, medical devices are classified into one of three classes &#8211; Class I, Class II or Class III &#8211; depending on the degree
of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by
adherence to a set of FDA regulations, referred to as the general controls for medical devices, which require compliance with the applicable
portions of cGMP regulations known as the Quality System Regulation, or QSR, facility registration and product listing, reporting of
adverse events and malfunctions, and appropriate, truthful, and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-misleading
labeling and promotional materials. Some Class I devices, also called Class I reserved devices, also require premarket clearance by the
FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification
requirements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
II devices are those that are subject to the general controls and special controls, as deemed necessary by the FDA to ensure the safety
and effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents,
and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance
by the FDA for Class II devices is accomplished through the 510(k) premarket notification process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable
devices, or devices that have a new intended use or use advanced technology that are not substantially equivalent to that of a legally
marketed predicate device. The safety and effectiveness of Class III devices cannot be reasonably assured solely by the general controls
and special controls described above. All clinical investigations of devices to determine safety and effectiveness must be conducted
in accordance with the FDA&#8217;s investigational device exemption (IDE), regulations which govern investigational device labeling,
prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of
study sponsors and study investigators. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA,
the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical
trials. If the device under evaluation does not present a significant risk to human health, then the device sponsor is not required to
submit an IDE application to the FDA before initiating human clinical trials, but must still comply with abbreviated IDE requirements
when conducting such trials. Therefore, these devices are subject to the PMA process, which is generally more costly and time consuming
than the 510(k) process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
510(k) Clearance Process</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 510(k) process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially
equivalent,&#8221; as defined in the statute, to a legally marketed predicate device. A predicate device is a legally marketed device
that is not subject to premarket approval, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and
for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously
found substantially equivalent through the 510(k) process. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months,
but may take longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial
equivalence. In addition, FDA collects user fees for certain medical device submissions and annual fees and for medical device establishments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance
to commercially market the device. If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate
device, the device is automatically classified into Class III. The device sponsor must then fulfill the much more rigorous premarketing
requirements of the PMA approval process, or seek risk-based reclassification of the device through the de novo process, which is a route
to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. A manufacturer
can also submit a petition for direct de novo review if the manufacturer is unable to identify an appropriate predicate device and the
new device or new use of the device presents a moderate or low risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device receives 510(k) clearance or de novo classification, any modification that could significantly affect its safety or effectiveness,
or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification,
could require a PMA or de novo classification. The FDA requires each manufacturer to determine whether the proposed change requires submission
of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination.
Many minor modifications are accomplished by a letter-to-file in which the manufacture documents the change in an internal letter-to-file.
The letter-to-file is in lieu of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters
to file in an inspection. If the FDA disagrees with a manufacturer&#8217;s determination regarding whether a new premarket submission
is required for the modification of an existing device, the FDA can require the manufacturer to cease marketing and/or recall the modified
device until marketing authorization is obtained. Also, in these circumstances, the manufacturer may be subject to significant regulatory
fines or penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
FDA Regulatory Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including recordkeeping, annual
product quality review and reporting requirements. Adverse event experiences with the product, including both drug-related and device-related
adverse events (including device malfunctions and medical device reporting), must be reported to the FDA in a timely fashion and pharmacovigilance
programs to proactively look for these adverse events are mandated by the FDA. Drug and device manufacturers and their subcontractors
are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections
by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP and QSR, which impose certain
procedural and documentation requirements upon us and our third-party manufacturers. Following such inspections, the FDA may issue notices
on Form 483, Untitled Letters or Warning Letters that could cause us or our third-party manufacturers to modify certain activities. A
Form 483 Notice, if issued at the conclusion of an FDA inspection, list conditions the FDA investigators believe may have violated cGMP,
QSR or other FDA regulations or guidelines. In addition to Form 483 Notices and Untitled Letters or Warning Letters, failure to comply
with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as suspension
of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future
third-party manufacturers or suppliers will be able to comply with the cGMP regulations, QSR and other ongoing FDA regulatory requirements.
If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may require
us to recall our products from distribution or withdraw any potential approvals of an NDA for that product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA closely regulates the post-approval marketing and promotion of drugs and devices, including standards and regulations for direct-to-consumer
advertising, dissemination of off-label information, industry-sponsored scientific and educational activities and promotional activities
involving the Internet. Drugs and devices may be marketed only for the approved indications and in accordance with the provisions of
the approved label. Further, if there are any modifications to the drug or device, including changes in indications, labeling, or manufacturing
processes or facilities, we may be required to submit and obtain FDA approval of a new or supplemental NDA or clearance or approval of
the modified device, respectively, which may require us to develop additional data or conduct additional preclinical studies and clinical
trials. Failure to comply with these requirements can result in adverse publicity, Warning Letters, corrective advertising and potential
civil and criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physicians
may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested
by us and approved by the FDA. Such off-label uses are common across medical specialties, in particular in oncology. Physicians may believe
that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of
physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers&#8217; communications
regarding off-label use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which
regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation
of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples
and impose requirements to ensure accountability in distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
Regulatory Environment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we seek to market RenovoGem in foreign jurisdictions, we could become subject to a variety of foreign regulations regarding development,
approval, commercial sales, and distribution of our products in addition to regulations in the United States. Whether or not we obtain
FDA approval for a product, we must obtain the necessary approvals by the comparable regulatory authorities of foreign countries before
we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and
can involve additional product testing and additional review periods. The review process may take longer or shorter than that required
to obtain FDA approval. The requirements governing, among other things, the conduct of clinical trials, product licensing, pricing and
reimbursement vary greatly from country to country. Regulatory approval in one country does not ensure regulatory approval in another,
but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others. If we
fail to comply with applicable foreign regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals,
product recalls, seizure of products, operating restrictions, and/or criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
United States Healthcare Laws</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to FDA restrictions on marketing of pharmaceutical and medical device products, including drug/device combination products,
pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities
in the states and foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships
through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws
include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, and transparency
laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers.
If manufacturers&#8217; operations, including activities engaged by their contractors or agents, are found to be in violation of any
of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, administrative,
civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting
obligations, exclusion from participation in federal and state healthcare programs and imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration
to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service
reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. The Affordable Care Act, or ACA, amended the
intent element of the federal statute so that a person or entity no longer needs to have actual knowledge of the statute or specific
intent to violate it in order to commit a violation. This statute has been interpreted to apply to arrangements between pharmaceutical
manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. Although there are a number
of statutory exceptions and regulatory safe harbors protecting certain business activities from prosecution or other regulatory sanctions,
the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases
or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
civil and criminal false claims laws, including the federal civil False Claims Act, prohibit any person or entity from knowingly presenting,
or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false
statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicare
and Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply
Schedule. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating
drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates,
and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product.
In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Additionally, the ACA amended
the federal Anti-Kickback Statute such that a violation of that statute can serve as a basis for liability under the federal False Claims
Act. Most states also have statutes or regulations similar to the federal Anti-Kickback Statute and civil False Claims Act, which apply
to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other
things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payor knows or should know is
likely to influence the beneficiary to order a receive a reimbursable item or service from a particular supplier, and the additional
federal criminal statutes created by the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits,
among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or
obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of
any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective
implementing regulations, impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered
entities, as well as their business associates that perform certain services involving the storage, use or disclosure of individually
identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission
of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain
breaches of security of individually identifiable health information. HITECH increased the civil and criminal penalties that may be imposed
against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil
actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated
with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in certain circumstances,
many of which differ from each other in significant ways and may not have the same effect, and often are not preempted by HIPAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
pursuant to the ACA, the CMS has issued a final rule that requires applicable manufacturers of covered products, including prescription
drugs and certain medical devices, to collect and annually report information on certain payments or transfers of value made in the previous
year to physicians (defined to include doctors of medicine and osteopathy, dentists, podiatrists, optometrists and licensed chiropractors),
certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others) and teaching hospitals,
as well information regarding investment interests held by physicians and their immediate family members. The reported data is made available
in searchable form on a public website on an annual basis. Failure to submit required information may result in civil monetary penalties.
In addition, several states now require prescription drug companies to report certain expenses relating to the marketing and promotion
of drug products and to report gifts and payments to individual healthcare practitioners in these states. Other states prohibit various
marketing-related activities and/or require the posting of information relating to clinical studies and their outcomes. Some states require
the reporting of certain pricing information, including information pertaining to and justifying price increases, or prohibit prescription
drug price gouging. In <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addition,
certain states require pharmaceutical companies to implement a healthcare compliance program or code of conduct. Certain states and local
jurisdictions also require the registration of pharmaceutical sales representatives. Compliance with these federal and state laws is
difficult and time consuming, and companies that do not comply with these state laws are exposed to liabilities and civil penalties.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs.
If a drug company&#8217;s operations are found to be in violation of any such requirements, it may be subject to significant penalties,
including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring
of its operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare
reimbursement or other federal or state government healthcare programs, including Medicare and Medicaid, integrity oversight and reporting
obligations, imprisonment, and reputational harm. Although effective compliance programs can mitigate the risk of investigation and prosecution
for violations of these laws, these risks cannot be entirely eliminated. Any action for an alleged or suspected violation can cause a
drug company to incur significant legal expenses and divert management&#8217;s attention from the operation of the business, even if
such action is successfully defended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Healthcare
Reform</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended,
collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private
insurers, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing
enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. Additionally, the ACA:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
                                            the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1%
                                            to 23.1% of the average manufacturer price;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">required
                                            collection of rebates for drugs paid by Medicaid managed care organizations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">required
                                            manufacturers to participate in a coverage gap discount program, under which they must agree
                                            to offer 70 percent point-of-sale discounts off negotiated prices of applicable brand drugs
                                            to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s
                                            outpatient drugs to be covered under Medicare Part D; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposed
                                            a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded
                                            prescription drugs&#8221; to specified federal government programs.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. For example, in June 2021
the U.S. Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case on procedural
grounds without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. It
is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges
and healthcare measures promulgated by the Biden administration will impact the ACA, our business, financial condition and results of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to
providers of 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031, with the exception of a
temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2022, unless additional
action is taken by Congress. Under current legislation, the actual reduction in Medicare payments can vary from 1% in 2022 to up to
4% in the final fiscal year of this sequester.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products,
which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other
things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform
government program reimbursement methodologies for drug products. For example, under the American Rescue Plan Act of 2021, effective
January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be
eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products,
which could have a material impact on our business. In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions
that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government
to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers
that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs,
with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket
prescription drug costs for beneficiaries, among other changes. The impact of these regulations and any future healthcare measures and agency rules implemented
by the Biden administration on us and the pharmaceutical industry as a whole is currently unknown.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example,
a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially
increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining
regulatory approval for any of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Coverage
and Reimbursement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval. Sales
in the U.S. will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which
include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations
and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge,
reduction or denial by third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting
the reimbursement rate that the payor will pay for the product. A third-party payor&#8217;s decision to provide coverage for a product
does not imply that an adequate reimbursement rate will be available. Additionally, in the U.S. there is no uniform policy among payors
for coverage or reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own
coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for
products can differ significantly from payor to payor. If coverage and adequate reimbursement are not available, or are available only
at limited levels, successful commercialization of, and obtaining a satisfactory financial return on, any product we develop may not
be possible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services,
in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing,
we may need to</span> conduct
expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to
the costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary
or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield
an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment
in drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing a new drug product, RenovoGem, which is intra-arterial gemcitabine delivered via the proprietary RenovoCath delivery system.
If the drug is approved, it is expected to be sold together with the catheter used to administer the drug in the National Drug Code (NDC)
created when the drug receives FDA approval. The reimbursement pathway involves separate payments for the drug product and for the occlusion
procedure to administer it. As to the latter, it is anticipated that the procedure is accurately described by an existing code with existing
payment levels. Given the expectation that the drug will be a novel, non-generic drug, a unique code and payment based on pricing information
for the product should be established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the reasons discussed above, we believe there is a clear path to reimbursement for RenovoGem and its related procedure in both the hospital
outpatient and physician office settings (which may include freestanding entities such as catheterization laboratories). As is typical
for a product still in clinical development, it is difficult to predict whether there would be any Medicare coverage obstacles, which
there usually are not for FDA approved drugs being used for on-label use. We believe the most important step we can take to enhance reimbursement
for our products is the development of published, peer-reviewed clinical literature supporting their clinical benefit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
oncology biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies and strong competition. While
we believe that our knowledge, leadership, experience, scientific resources, intellectual property, regulatory barriers, and the advanced
stage of our clinical development provide us with competitive advantages, we may face competition from major pharmaceutical companies,
specialty pharmaceutical companies, and biotechnology companies, worldwide. Many potential competitors have substantially greater scientific,
research, financial, technical, and/or human resources than we do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies are active in the oncology market both in terms of commercially marketed products and products in development that could potentially
compete with our products and product candidates for the treatment of solid tumors. Any product candidates that we successfully develop
and commercialize may compete directly with approved and/or new therapies that may be approved in the future. Our competitors may also
obtain FDA or foreign regulatory approval for their products more rapidly than we may obtain approval for our product candidates which
could result in our competitors establishing a strong market position prior to us entering the market. Key competitive factors affecting
the success of our product candidates, if approved, are likely to be their safety, efficacy, convenience, price, and the availability
of reimbursement from government and other third-party payors. Many companies are developing new therapeutics and we cannot predict what
the standard of care will be as our product candidate progresses through clinical development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are a number of companies in Phase III clinical trials for the treatment of LAPC including Angiodynamics, Bausch Health, Fibrogen,
NovoCure, and SynCore Biotechnology. We are aware of a number of companies in Phase I and Phase II clinical trials for the treatment
of LAPC including one interventional company, TriSalus Lifesciences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have substantially greater financial, technological, research and development, marketing and personnel resources.
In&#160;addition, some of our competitors have considerable experience in conducting clinical trials, regulatory, manufacturing and commercialization
capabilities. Our competitors may develop alternative treatment methods, or achieve earlier product development, in which case the likelihood
of us achieving meaningful revenues or profitability will be substantially reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees
and Human Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, we had nine employees. <span style="background-color: white">None of our employees are represented
by a labor union or covered by a collective&#160;</span>bargaining&#160;agreement. We focus on employee engagement and believe our relationship
with our employees is good. We have 14 key consultants in the areas of quality, regulatory, finance, legal, clinical, and marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
human capital resources objectives include, as applicable, identifying, recruiting, retaining, and incentivizing our existing employees.
The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based
and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals
to perform to the best of their abilities and achieve our objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
administrative headquarters is located at 4546 El Camino Real, Suite B1, Los Altos, CA 94022. The office space is approximately 1,480
square feet, and we rent on a month-to-month basis. We believe that our facility is adequate for our current operations
and purposes, and that suitable additional or alternative space will be available in the future on commercially reasonable terms, if
required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we are engaged in various legal actions, claims and proceedings arising in the ordinary course of business, none of which
are expected to be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_002"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our securities involves a high degree of risk. You should carefully consider the risks described below, as well as the
other information in this Annual Report on Form 10-K, including our financial statements and the related notes and the section titled
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and in our other public filings
in evaluating our business. The occurrence of any of the events or developments described below could harm our business, financial condition,
results of operations, growth prospects or stock price. In such an event, the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently
known to us or that we currently deem immaterial may also impair our business operations and the market price of our common stock.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Factors Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in shares of our common stock involves a high degree of risk because our business is subject to numerous risks and uncertainties, including
those outside of our control, that could cause our actual results to be harmed. The principal factors and uncertainties that make investing
in shares of our common stock risky and impact our ability to execute on our business strategy include risks regarding the following,
among others:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are a clinical stage biopharmaceutical company, have a limited operating history and have
                                            no drug/device combination products approved for commercial sale, which makes it difficult
                                            to evaluate our current business and predict our future success and viability.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have incurred significant net losses in each period since inception, and we expect to continue
                                            to incur net losses for the foreseeable future.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will need to raise substantial additional capital to develop and commercialize RenovoGem,
                                            and our failure to obtain funding when needed may force us to delay, reduce or eliminate
                                            our product development programs or collaboration efforts. As a result, there is substantial
                                            doubt about our ability to operate as a going concern.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            product candidates&#8217; commercial viability remains subject to current and future preclinical
                                            studies, clinical trials, regulatory approvals, and the risks generally inherent in the development
                                            of a pharmaceutical product candidate. If we are unable to successfully advance or develop
                                            our product candidates, our business will be materially harmed.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we do not achieve our projected development goals in the timeframes we announce and expect,
                                            our stock price may decline.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            product candidates may exhibit undesirable side effects when used alone or in combination
                                            with other approved pharmaceutical products or investigational new drugs, which may delay
                                            or preclude further development or regulatory approval or limit their use if approved.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the results of preclinical studies or clinical trials for our product candidates are negative, we could be delayed or precluded from the further development or commercialization
                                            of our product candidates, which could materially harm our business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we are unable to satisfy regulatory requirements, we may not be able to commercialize our
                                            product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            our product candidates are unable to compete effectively with marketed drugs targeting similar
                                            indications as our product candidates, our commercial opportunity will be reduced or eliminated.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may delay or terminate the development of our product candidates at any time if we believe
                                            the perceived market or commercial opportunity does not justify further investment, which
                                            could materially harm our business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            future success depends on our ability to retain our key personnel and to attract, retain,
                                            and motivate qualified personnel, especially in light of an acute workforce shortage and
                                            hyper-competitive compensation environment.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we are unable to protect our intellectual property effectively, we may be unable to prevent
                                            third parties from using our technologies, which would impair our competitive advantage.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            patents issued to us may not be broad enough to provide any meaningful protection, one or
                                            more of our competitors may develop more effective technologies, designs, or methods without
                                            infringing our intellectual property rights and one or more of our competitors may design
                                            around our proprietary technologies.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            market price of our common stock may be volatile and fluctuate substantially, which could
                                            result in substantial losses for our investors.</span></td></tr>
                                                                                                            </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we face other risks and uncertainties that may materially affect our business prospects, financial condition, and results of
operations. You should consider the risks discussed in &#8220;Risk Factors&#8221; and in our other public filings before investing in
our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business, Financial Condition and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a clinical stage biopharmaceutical company, have a limited operating history and have no drug/device combination products approved
for commercial sale, which makes it difficult to evaluate our current business and predict our future success and viability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects.
While RenovoCath, a drug delivery medical device, has been separately cleared by the FDA for the isolation of blood flow and delivery
of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system, and for temporary vessel
occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion, we are focused on developing
and commercializing drug product candidates in combination with our delivery platform technology. We have no drug/device combination
products approved for commercial sale and have not generated any revenue from product sales. We are developing a novel therapy platform,
which is an unproven and highly uncertain undertaking and involves a substantial degree of risk. <span style="background-color: white">Our
first product candidate, RenovoGem, is a drug/device combination product consisting of intra-arterial gemcitabine and RenovoCath. The
FDA has determined that RenovoGem will be regulated as, and if approved we expect will be reimbursed as, a new oncology drug product.
</span>To date, we have not obtained marketing approval for any drug/device combination product candidates, manufactured a commercial
scale product or arranged for a third-party to do so on our behalf, or conducted sales and marketing activities necessary for successful
product commercialization. Our limited operating history as a company makes any assessment of our future success and viability subject
to significant uncertainty. As a result, it may be more difficult for investors to accurately predict our likelihood of success and viability
than it could be if we had a longer operating history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will encounter expenses, difficulties, complications, delays, and other known and unknown factors and risks frequently experienced by
clinical stage biopharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with a research
and clinical development focus to a company capable of supporting commercial activities. We have not yet demonstrated an ability to successfully
overcome such risks and difficulties, or to make such a transition. If we do not adequately address these risks and difficulties or successfully
make such a transition, our business will suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred significant net losses in each period since inception, and we expect to continue to incur net losses for the foreseeable
future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage company and have incurred significant losses since our formation. As of December 31, 2022, we have an accumulated
total deficit of approximately $31.2 million. For the fiscal years ended December 31, 2022 and 2021, we had net losses of approximately
$9.9 million and $6.3 million, respectively. To date, we have experienced negative cash flow from the development of our product candidate,
RenovoGem, our platform technology, RenovoTAMP, and our RenovoCath delivery system. We have not generated any revenue from operations,
and we expect to incur substantial net losses for the foreseeable future as we seek to further develop and commercialize RenovoGem and
expand our pipeline of product candidates. Because of the numerous risks and uncertainties associated with developing and commercializing
RenovoGem, we are unable to predict the extent of any future losses or when we will attain profitability, if ever. Investors in our common
stock must carefully consider the substantial challenges, risks and uncertainties inherent in the attempted development and commercialization
of RenovoGem. We may never successfully commercialize RenovoGem, and our business may not be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates will require substantial additional development time and resources before we will be able to receive regulatory approvals,
if any, and, if approved, to begin generating revenue from product sales. As a result, we expect that will be several years, if ever,
before we receive approval to commercialize a product and generate revenue from product sales. Even if we succeed in receiving marketing
approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial expenses
and increasing operating losses in the foreseeable future. The amount of our future net losses will depend, in part, on the level of
our future expenditure and revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such
that a period-to-period comparison of our results of operations may not be a good indication of our future performance. If we are unable
to generate significant revenue from RenovoGem or attain profitability, we will not be able to sustain operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our expenses will increase substantially if and as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                            our research and discovery activities; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                            the development of our proprietary technology platform; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">progress
                                            our current and any future product candidates through preclinical and clinical development;
                                            </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
                                            and conduct additional preclinical, clinical, or other studies for our product candidates;
                                            </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">work
                                            with our contract manufacturing organizations to manufacture RenovoCath and our other product
                                            candidates for our clinical trials; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">change
                                            or add additional contract manufacturers or suppliers; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                            regulatory approvals and marketing authorizations for our product candidates; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                            sales, marketing, and distribution infrastructure to commercialize any products for which
                                            we obtain approval; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">take
                                            steps to seek protection of our intellectual property and defend our intellectual property
                                            against challenges from third parties; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain,
                                            expand, maintain, protect, and enforce our intellectual property portfolio; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursue
                                            any licensing or collaboration opportunities; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract,
                                            hire, and retain key and qualified personnel including clinical, scientific, management,
                                            and administrative personnel; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
                                            additional internal infrastructure to support our continued research and development operations
                                            and any planned commercialization efforts in the future; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
                                            any delays or encounter other issues related to our operations; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement
                                            operations, financial, and management information systems; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meet
                                            the requirements and demands of being a public company; and </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">defend
                                            against any product liability claims or other lawsuits related to our products. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
prior operating losses and expected future net losses have had and will continue to have an adverse effect on our stockholders&#8217;
equity, working capital, and our ability to fund our development efforts and achieve and maintain profitability. In any particular period,
our operating results could be below the expectations of securities analysts or investors, or such analysts or investors could perceive
these results to be negative, which could have a substantial adverse effect on the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to raise substantial additional capital to develop and commercialize RenovoGem, and our failure to obtain funding when needed
may force us to delay, reduce or eliminate our product development programs or collaboration efforts. If we do not obtain adequate and
timely funding, we may not be able to continue as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, we had cash, cash equivalents and short-term marketable securities of $6.4 million. Due to our recurring operating
losses and the expectation that we will continue to incur net losses in the future, we will be required to raise additional capital to
complete the development and commercialization of our product candidates. We have historically financed our operations primarily through
private sales of our equity, debt financing and the sale of common stock and warrants in our initial public offering, or IPO. To raise
additional capital, we may seek to sell additional equity and/or debt securities, obtain a credit facility or other loan or enter into
collaborations, licenses or other similar arrangements, which we may not be able to do on favorable terms, or at all. For example, we
have filed an omnibus shelf registration statement on Form S-3 that provides for aggregate offerings of up to $50 million of the Company&#8217;s
securities subject to various limitations, including limited sales in any twelve-month period while we are subject to the &#8220;baby-shelf&#8221;
rules. We also have filed a registration statement on Form S-1 to register the cash exercise of our outstanding warrants, with such cash
exercise only expected to occur when the trading price of our common stock is in excess of the $10.80 per share exercise price of our
outstanding warrants. Our ability to obtain additional financing will be subject to a number of factors, including market conditions,
fluctuations in interest rates, our operating performance and investor sentiment. If we are unable to raise additional capital when required
or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of our
product candidates, restrict or cease our operations or obtain funds by entering into agreements on unfavorable <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">terms.
Failure to obtain additional capital on acceptable terms, or at all, would result in a material and adverse impact on our operations.
As a result, there is substantial doubt about our ability to operate as a going concern.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements as of December 31, 2022 have been prepared on a going concern basis and do not include any adjustments that may
result from the outcome of this uncertainty. If we fail to raise additional working capital, or do so on commercially unfavorable terms,
it would materially and adversely affect our business, prospects, financial condition and results of operations, and we may be unable
to continue as a going concern. As a result, there is substantial doubt about our ability to operate as
a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial
doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding
to us on commercially reasonable terms, if at all. If we are unable to continue as a going concern, we might have to liquidate our assets
and the value we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial
statements, and our shareholders may lose their entire investment in our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Discovery, Development, and Commercialization of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates&#8217; commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory
approvals, and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully
advance or develop our product candidate, our business will be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the near-term, failure to successfully advance the development of any of our product candidates may have a material adverse effect on
us. To date, we have not successfully developed or commercially marketed, distributed, or sold any product candidate. The success of
our business depends primarily upon our ability to successfully advance the development of our current and future product candidates
through preclinical studies and clinical trials, have the product candidates approved for sale by the FDA or regulatory authorities in
other countries, and ultimately have the product candidates successfully commercialized by us or a commercial partner. We cannot assure
you that the results of our ongoing preclinical studies or clinical trials will support or justify the continued development of our product
candidates, or that we will receive regulatory approval from the FDA, or similar regulatory authorities in other countries, to advance
the development of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates must satisfy rigorous regulatory standards of safety and efficacy before we can advance or complete their clinical
development, or before they can be approved for sale. To satisfy these standards, we must engage in expensive and lengthy preclinical
studies and clinical trials, develop acceptable manufacturing processes, and obtain regulatory approval. Despite these efforts, the FDA
could delay, limit or deny approval of a product candidate for many reasons, including because the FDA:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            not deem our product candidate to be safe and effective;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determines
                                            that the product candidate does not have an acceptable benefit-risk profile;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            not agree that the data collected from preclinical studies and clinical trials are acceptable
                                            or sufficient to support the submission of an NDA or other submission or to obtain regulatory
                                            approval, and may impose requirements for additional preclinical studies or clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            determine that adverse events experienced by participants in our clinical trials represent
                                            an unacceptable level of risk;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            determine that population studied in the clinical trial may not be sufficiently broad or
                                            representative to assure safety in the full population for which we seek approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            disagree regarding the formulation, labeling and/or the specifications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            not approve the manufacturing processes associated with our product candidate or may determine
                                            that a manufacturing facility does not have an acceptable compliance status;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            conclude there are CMC issues that preclude approval of the NDA;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            conclude that the drug substance or drug product manufacturing process is not in a state
                                            of control or does not meet cGMP or all the regulatory requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            conclude that the medical device manufacturing process for the drug/device combination product
                                            candidate is not in a state of control or does not meet all the regulatory requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            not be able to timely conduct the necessary pre-approval inspection or devote sufficient
                                            resources to NDA review on a timely basis due to the ongoing COVID-19 pandemic;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            change approval policies or adopt new regulations; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            not file a submission due to, among other reasons, the content or formatting of the submission.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in obtaining approval or if we fail to obtain approval of RenovoGem, our commercial prospects will be harmed and
our ability to generate revenues will be materially impaired which would adversely affect our business, prospects, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that the results of late-stage clinical trials will be favorable enough to support the continued development of our
product candidates. A number of companies in the pharmaceutical and biopharmaceutical industries have experienced significant delays,
setbacks and failures in all stages of development, including late-stage clinical trials, even after achieving promising results in preclinical
testing or early-stage clinical trials. Accordingly, results from completed preclinical studies and early-stage clinical trials of our
product candidates may not be predictive of the results we may obtain in later-stage trials. Furthermore, even if the data collected
from preclinical studies and clinical trials involving our product candidates demonstrate a favorable safety and efficacy profile, such
results may not be sufficient to support the submission of an NDA to obtain regulatory approval from the FDA in the U.S., or other similar
regulatory agencies in other jurisdictions, which is required to market and sell the product. Even if we are successful in obtaining
approval in one jurisdiction, we may not be successful in obtaining approval in any other jurisdictions. If we are unable to obtain approval
for our product candidates in multiple jurisdictions, our business, financial condition, results of operations and our growth prospects
could be negatively affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates will require significant additional research and development efforts, the commitment of substantial financial resources,
and regulatory approvals prior to advancing into further clinical development or being commercialized by us or collaborators. Additionally,
changes in regulations as part of</span> a
response to the COVID-19 pandemic, including the effects of recent variants, may require us to change the ways in which our clinical
trials are conducted, or to discontinue clinical trials altogether, or which may result in unexpected costs. We cannot assure you that
our product candidates will successfully progress through the drug development process or will result in commercially viable products.
We do not expect our product candidates to be commercialized by us or collaborators for at least several years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not achieve our projected development goals in the timeframes we announce and expect, our stock price may decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product
development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific
studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing
of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones
can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as
publicly announced, our stock price may decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates may exhibit undesirable side effects when used alone or in combination with other approved pharmaceutical products
or investigational new drugs, which may delay or preclude further development or regulatory approval or limit their use if approved.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
the drug development process, we must continually demonstrate the efficacy, safety and tolerability of our product candidates to obtain
regulatory approval to further advance clinical development or to market them. Even if our product candidates demonstrate clinical efficacy,
any unacceptable, adverse side effects or toxicities, when administered alone or in the presence of other pharmaceutical products, which
can arise at any stage of development, may outweigh the potential benefits. In preclinical studies and clinical trials we have conducted
to date, each of our product candidate&#8217;s tolerability profile is based on studies and trials that have involved a small number
of subjects or patients over a limited period of time. We may observe adverse or significant adverse events or drug-drug interactions
in future preclinical studies or clinical trial candidates, which could result in the delay or termination of development, prevent regulatory
approval, or limit market acceptance if ultimately approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the results of preclinical studies or clinical trials for our product candidates, including those that are subject to existing or future
license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization
of our product candidates, which could materially harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
further advance the development of, and ultimately receive regulatory approval to sell, our product candidates, we must conduct extensive
preclinical studies and clinical trials to demonstrate their safety and efficacy to the satisfaction of the FDA or similar regulatory
authorities in other countries, as the case may be. Preclinical studies and clinical trials are expensive, complex, can take many years
to complete, and have highly uncertain outcomes. Delays, setbacks, or failures can occur at any time, or in any phase of preclinical
or clinical testing, and can result from concerns about safety or toxicity, a lack of demonstrated efficacy or superior efficacy over
other similar products that have been approved for sale or are in more advanced stages of development, poor study or trial design, and
issues related to the formulation or manufacturing process of the materials used to conduct the trials. The results of prior preclinical
studies or clinical trials are not necessarily predictive of the results we may observe in later stage clinical trials. In many cases,
product candidates in clinical development may fail to show desired safety, efficacy or tolerability characteristics despite having favorably
demonstrated such characteristics in preclinical studies or earlier stage clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may experience numerous unforeseen events during, or as a result of, preclinical studies and the clinical trial process,
which could delay or impede our ability to advance the development of, receive regulatory approval for, or commercialize our product
candidate, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">communications
                                            with the FDA, or similar regulatory authorities in different countries, regarding the scope
                                            or design of a trial or trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            authorities, including an Institutional Review Board (&#8220;IRB&#8221;) or Ethical Committee
                                            (&#8220;EC&#8221;), not authorizing us to commence or conduct a clinical trial at a prospective
                                            trial site;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enrollment
                                            in our clinical trials being delayed, or proceeding at a slower pace than we expected, because
                                            our clinical trial sites have staffing shortages or are unable to recruit/retain qualified
                                            staff, or we have difficulty recruiting patients, including as a result of competing clinical
                                            trials, or participants dropping out of our clinical trials at a higher rate than we anticipated;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            third-party contractors, upon whom we rely for conducting preclinical studies, clinical trials
                                            and manufacturing of our trial materials, may fail to comply with regulatory requirements,
                                            fail to meet their contractual obligations to us in a timely manner, or terminate their relationship
                                            with us;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
                                            to suspend or ultimately terminate our clinical trials if participants are being exposed
                                            to unacceptable health or safety risks;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRBs,
                                            ECs, or regulators requiring that we hold, suspend or terminate our preclinical studies and
                                            clinical trials for various reasons, including non-compliance with regulatory requirements
                                            or due to the effects of the COVID-19 pandemic, including the effects of recent variants;
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            supply or quality of drug material or the supply of our RenovoCath device necessary to conduct
                                            our preclinical studies or clinical trials being insufficient, inadequate, or unavailable,
                                            especially in light of the supply chain issues caused by the effects of the COVID-19 pandemic.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the data collected from preclinical studies or clinical trials involving our product candidates demonstrate a favorable safety and
efficacy profile, such results may not be sufficient to support the submission of an NDA to obtain regulatory approval from the FDA in
the U.S., or other similar foreign regulatory authorities in foreign jurisdictions, which is required to market and sell the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing
testing requirements to maintain regulatory approval. In addition, regulatory authorities may withdraw their approval of a product or
impose restrictions on our distribution, such as in the form of a Risk Evaluation and Mitigation Strategy, or REMS. The failure to obtain
timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would materially and adversely
affect our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interim,
preliminary or topline data from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publish interim, preliminary or topline data from clinical trials. Interim data from clinical trials that we may
complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and
more patient data becomes available. Preliminary or topline data also remain subject to audit and verification procedures that may result
in the final data being materially different from the preliminary or topline data previously published. As a result, interim, preliminary
and topline data should be viewed with caution until the final data are available.
Adverse differences between interim, preliminary or topline data and final data could significantly harm our reputation and business
prospects. Moreover, preliminary, interim and topline data are subject to the risk that one or more of the clinical outcomes may materially
change as more patient data become available when patients mature on study, patient enrollment continues or as other ongoing or future
clinical trials with a product candidate further develop. Past results of clinical trials may not be predictive of future results. In
addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically
more extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information
to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant with respect to future
decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. Similarly, even if we
are able to complete our planned and ongoing preclinical studies and clinical trials of our product candidates according to our current
development timeline, the positive results from such preclinical studies and clinical trials of our product candidates may not be replicated
in subsequent preclinical studies or clinical trial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply
with strict regulations, these studies or trials of our product candidate may be delayed, terminated, or fail, or we could incur significant
additional expenses, which could materially harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited resources dedicated to designing, conducting, and managing preclinical studies and clinical trials. We intend to rely on
third parties, including clinical research organizations, consultants, and principal investigators, to assist us in designing, managing,
monitoring and conducting our preclinical studies and clinical trials. We intend to rely on these vendors and individuals to perform
many facets of the drug development process, including certain preclinical studies, the recruitment of sites and patients for participation
in our clinical trials, maintenance of good relations with the clinical sites, and ensuring that these sites are conducting our trials
in compliance with the trial protocol, including safety monitoring and applicable regulations. If these third parties fail to perform
satisfactorily, or do not adequately fulfill their obligations under the terms of our agreements with them, or terminate their relationship
with us, we may not be able to enter into alternative arrangements without undue delay or additional expenditures, and therefore the
preclinical studies and clinical trials of our product candidate may be delayed or prove unsuccessful. For example, the investigators
we currently use for our clinical trials are not our employees and we cannot control the amount or timing of resources that they devote
to our programs. If these investigators fail to devote sufficient time and resources to our clinical trial, fail to enroll patients as
rapidly as expected, or otherwise do not perform in a satisfactory manner, we may make elect to close such clinical trial site, which
may increase our expenses, require additional attention from our clinical team and delay our clinical trial timeline and regulatory approval.
Further, the FDA, or other similar foreign regulatory authorities, may inspect some of the clinical sites participating in our clinical
trials in the U.S., or our third-party vendors&#8217; sites, to determine if our clinical trials are being conducted according to good
clinical practice, or GCP. If we or the FDA determine that our third-party vendors are not in compliance with, or have not conducted
our clinical trials according to, applicable regulations we may be forced to delay, repeat, or terminate such clinical trials. Additionally,
certain third parties with whom we engage or may engage for preclinical studies or clinical studies may have to adjust their operations
or limit their capacity in light of the effects of the COVID-19 pandemic, including the effects of recent variants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited capacity for recruiting and managing clinical trials, which could impair our timing to initiate or complete clinical trials
of our product candidate and materially harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited capacity to recruit and manage the clinical trials necessary to obtain FDA approval or approval by other regulatory authorities.
By contrast, larger pharmaceutical and biopharmaceutical companies often have substantial staff with extensive experience in conducting
clinical trials with multiple product candidates across multiple indications. In addition, they may have greater financial resources
to compete for the same clinical investigators and patients that we are attempting to recruit for our clinical trials. If potential competitors
are successful in completing drug development for their product candidates and obtain approval from the FDA, they could limit the demand
to participate in clinical trials of our product candidates. As a result, we may be at a competitive disadvantage that could delay the
initiation, recruitment, timing, and completion of our clinical trials, as well as obtaining regulatory approvals, if at all, for our
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We,
and our collaborators, if any, must comply with extensive government regulations in order to advance our product candidates through the
development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
product candidates that we, or our collaborators, are developing or may develop require regulatory approval to advance through clinical
development and to ultimately be marketed and sold and are subject to extensive and rigorous domestic and foreign government regulation.
In the U.S., the FDA regulates, among other things, the development, testing, manufacture, safety, efficacy, record-keeping, labeling,
storage, approval, advertising, promotion, sale, and distribution of pharmaceutical and biopharmaceutical products. Our product candidates
are also subject to similar regulation by foreign governments to the extent we seek to develop or market them in those countries. We,
or our collaborators, must provide the FDA and foreign regulatory authorities, if applicable, with preclinical and clinical data, as
well as data supporting an acceptable manufacturing process, that appropriately demonstrate each of our product candidate&#8217;s safety
and efficacy before it can be approved for the targeted indications. Our product candidates have not been approved for sale in the U.S.
or any foreign market, and we cannot predict whether we or our collaborators will obtain regulatory approval for any product candidates
we are developing or plan to develop. The regulatory review and approval process can take many years, is dependent upon the type, complexity,
novelty of, and medical need for the product candidate, requires the expenditure of substantial resources, and involves post-marketing
surveillance and vigilance and potentially post-marketing studies or Phase IV clinical trials. In addition, we or our collaborators may
encounter delays in, or fail to gain, regulatory approval for any of our product candidates based upon additional governmental regulation
resulting from future legislative, administrative action or changes in FDA&#8217;s or other similar foreign regulatory authorities&#8217;
policy or interpretation during the period of product development. Delays or failures in obtaining regulatory approval to advance any
of our product candidates through clinical development, and ultimately to commercialize them, may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adversely
                                            impact our ability to raise sufficient capital, if at all, to fund the development of our
                                            product candidates; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adversely
                                            affect our ability to further develop or commercialize our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diminish
                                            any competitive advantages that we or our collaborators may have or attain; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adversely
                                            affect the receipt of potential milestone payments and royalties from collaborators, if any,
                                            from the sale of our products or product revenues in the future.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
any regulatory approvals, if granted, may later be withdrawn. If we or our collaborators fail to comply with applicable regulatory requirements
at any time, or if post-approval safety concerns arise, we or our collaborators may be subject to restrictions or a number of actions,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays,
                                            suspension, or termination of clinical trials related to our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            by regulatory authorities to review pending applications or supplements to approved applications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            recalls or seizures;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
                                            of manufacturing;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals
                                            of previously approved marketing applications; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                            civil penalties, and criminal prosecutions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
at any time we or our collaborators may voluntarily suspend or terminate the preclinical or clinical development of a product candidate,
or withdraw any approved product from the market if we believe that it may pose an unacceptable safety risk to patients, or if the product
candidate or approved product no longer meets our business objectives. The ability to develop or market a pharmaceutical product outside
of the U.S. is contingent upon receiving appropriate authorization from the respective foreign regulatory authorities. Foreign regulatory
approval processes typically include many, if not all, of the risks and requirements associated with the FDA regulatory process for drug
development and may include additional risks. Additionally, results acceptable to support approval in one jurisdiction may be deemed
inadequate by another regulatory authority to support regulatory approval in that other jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive
of future trial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates may not prove to be safe and efficacious in clinical trials and may not meet all the applicable regulatory requirements
needed to receive regulatory approval. To receive regulatory approval for the commercialization of our product candidates, we must conduct,
at our own expense, extensive preclinical testing and clinical trials to demonstrate safety and efficacy of our product candidate for
the intended indication of use. Clinical testing is expensive, can take many years to complete, if at all, and its outcome is uncertain.
Failure can occur at any time during the clinical trial process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of preclinical studies and early clinical trials of new drugs do not necessarily predict the results of later-stage clinical
trials. The design of our clinical trials is based on many assumptions about the expected effects of our product candidate, and if those
assumptions are incorrect, they may not produce statistically significant results. Preliminary results may not be confirmed on full analysis
of the detailed results of a clinical trial. Product candidates in later stages of clinical development may fail to show safety and efficacy
sufficient to support intended use claims despite having progressed through earlier clinical testing. The data collected from clinical
trials of our product candidates may not be sufficient to support the filing of an NDA or to obtain regulatory approval in the United
States or elsewhere. Because of the uncertainties associated with drug development and regulatory approvals, we cannot determine if or
when we will have an approved product for commercialization or achieve sales or profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Delays
in clinical testing could result in increased costs to us and delay our ability to generate revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience delays in clinical testing of our product candidates. We do not know whether planned clinical trials will begin on time,
will need to be redesigned or will be completed on schedule, if at all, especially in light of the effects of the COVID-19 pandemic,
including the effects of recent variants. From time to time, based on our experience with a clinical trial, we may amend the clinical
trial protocol to address any issues that we observe as the trial is progressing, including in response to COVID-19 related factors or
other factors impacting safety and the data collected, or we may be required to make certain changes in response to issues raised by
the FDA, IRB, other regulatory authorities, investigators or clinical sites. Protocol amendments are subject to IRB and regulatory approval
before we implement material changes, can result in additional costs, require additional data or participants, and may negatively impact
the timelines for the trial. For example, in December 2021, we amended the protocol for our Phase III clinical trial to only allow SBRT
patients during the induction phase of the study, as we observed a higher drop-out rate for patients on IMRT. As part of this change,
we initiated a review of the statistical considerations for the study and in June 2022, submitted a Modified SAP to FDA. We submitted
a protocol amendment to FDA in the second half of 2022 to reflect the changes in the Modified SAP. Under the modified Phase III clinical
trial protocol and the Modified SAP, we plan to (i) analyze only patients receiving SBRT, consistent with the protocol change made in
December 2021, (ii) include a second interim analysis, (iii) change the total number of SBRT patients randomized in the study to 114
(a reduction from the original 200 patients), with a total of 86 deaths from SBRT patients, including all deaths from SBRT patients enrolled
in the study before the submission of the Modified SAP, and (iv) repower the study from 90% to 80%, which is commonly used in clinical
trials. To date, we have not received any comments or objections from the FDA on the Modified SAP, which we submitted to the FDA in June
2022. We cannot provide assurance that the FDA will not raise any objections or disagree with our Modified SAP or the protocol amendments.
We can provide no assurance on the timing of any of our interim analyses or when we will complete our Phase III study, if at all, or
the outcome of the study. Disclosure of findings from our interim analyses before the completion of the trial may also impact the enrollment
or retention of patients in our ongoing clinical trial. The changes in our study protocol may limit the clinical trial sites that can
participate in our study, impact enrollment, and delay regulatory approval. If the FDA objects to our protocol amendments or Modified
SAP, we may be required to expand the size of our study, increase the power level, or make other changes that can delay our clinical
timelines and delay regulatory approval. <span style="background-color: white">Further, to the extent protocol amendments impact the
data needed to support our proposed indication, the indication that is ultimately approved by the FDA or other regulatory authorities
may be narrower than the indication initially sought. The FDA and other regulatory authorities may also impose other restrictions in
our proposed labeling, which could have a material adverse effect on the prospects of our product candidates, if approved, and our business.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials can be delayed for a variety of reasons, including pandemics, delays in obtaining regulatory approval to commence a clinical trial,
in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining IRB approval to conduct a clinical trial
at a prospective site, in recruiting patients to participate in a clinical trial or in obtaining sufficient supplies of clinical trial
materials, including RenovoCath. Many factors affect patient enrollment, including the size of the patient population, the proximity
of patients to clinical sites, the eligibility criteria for the clinical trial, the existing body of safety and efficacy data with respect
to the study drug, competing clinical trials, new drugs approved for the conditions we are investigating, clinicians&#8217; and patients&#8217;
perceptions of the potential advantages and side effects of the product candidates being studied in relation to other available therapies
and product candidates, and health epidemics such as the COVID-19 pandemic. Clinical investigators will need to decide whether to offer
their patients enrollment in clinical trials of our product candidate versus treating these patients with commercially available drugs
that have established safety and efficacy profiles. Any delays in completing our clinical trials will increase our costs, slow down our
product development, timeliness and approval process, and delay our ability to generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable,
and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but it typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the
regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain
approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have
not obtained regulatory approval for any product candidate and it is possible that any of our existing product candidates, or any
product candidate we may seek to develop in the future, may never obtain regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may disagree with the design or implementation
                                            of our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory
                                            authorities that a product candidate is safe and effective for its proposed indication;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of clinical trials may not meet the level of statistical significance required for
                                            approval by the FDA or comparable foreign regulatory authorities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may disagree with our interpretation of
                                            data from preclinical studies or clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            data collected from clinical trials of our product candidates may not be sufficient to support
                                            the submission of an NDA or other submission or to obtain regulatory approval in the United
                                            States or elsewhere;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes
                                            or facilities of third-party manufacturers with which we contract for clinical and commercial
                                            supplies; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            approval policies or regulations of the FDA or comparable foreign regulatory authorities
                                            may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory
approval to market our product candidates, which would significantly harm our business, results of operations, prospects and our underlying
stock price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we were to obtain approval, regulatory authorities may approve our product candidates for fewer or more limited indications
than we request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product
candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that
product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not previously submitted an NDA to the FDA, nor similar drug approval filings to comparable foreign authorities, for our product
candidates, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval.
Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive
regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory
approvals to market one or more of our product candidates, our revenues will be dependent on many factors including the size of the markets
in the territories for which we gain regulatory approval and have commercial rights. If the markets for patients that we are targeting
for our product candidates are not as significant as we estimate, we may not generate significant revenues from sales of such products,
if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to seek regulatory approval and to commercialize our product candidates, directly or with collaborators in the United States, the
European Union, and other foreign countries which we have not yet identified. While the scope of regulatory approval is similar in other
countries, to obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements
of such countries regarding the safety and efficacy, among other things, of clinical trials and commercial sales, pricing, and distribution
of our product candidates, and we cannot predict success in these jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval
of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trials may be suspended at any time for a number of reasons. For example, we may voluntarily suspend or terminate our clinical
trials if at any time we believe that they present an unacceptable risk to the clinical trial patients. In addition, the FDA or other
regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the
clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety
risk to the clinical trial patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administering
our product candidates to humans may produce undesirable side effects. These adverse side effects could interrupt, delay or halt clinical
trials of our product candidates and could result in the FDA or other regulatory authorities denying further development or approval
of any of our product candidates for any or all targeted indications. Ultimately, our product candidates may prove to be unsafe for human
use. Moreover, we could be subject to significant liability if any volunteer or patient suffers, or appears to suffer, adverse health
effects as a result of participating in our clinical trials. Prosecution, enforcement actions, damages or adverse media coverage related
to such events, if any, will likely result in a materially significant diversion of management&#8217;s attention and resources and significant
defense costs and other professional fees. As a general matter, such events could damage our reputation, brand, international activities,
business, prospects, operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties
and our business, operations and financial condition could be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations and activities may be directly or indirectly subject to various federal and state fraud and abuse laws, including,
without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. The product candidates that we are developing
are highly regulated, and there can be no assurance that the regulatory environment in which we operate will not change significantly
and adversely in the future. If we begin commercializing any products cleared or approved by the FDA in the United States, our exposure
under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. Our
current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose
us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements
and relationships through which we market, sell and distribute our products for which we obtain marketing approval. In addition, we may
be subject to laws of the federal government and state governments in which we conduct our business relating to privacy, data protection
and data security with respect to patient information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a developer of drug/device combination products and a proprietary drug delivery device, certain federal and state healthcare laws and
regulations pertaining to fraud and abuse, false claims, transparency and patients&#8217; privacy rights are and will be applicable to
our business. We could be subject to healthcare fraud and abuse laws, transparency and privacy laws of both the federal government and
the states in which we conduct our business and private &#8220;qui tam&#8221; actions brought by individual whistleblowers on behalf
of the federal or state governments. The scope and enforcement of each of the laws applicable to our business and products are uncertain
and subject to rapid change in the current environment of healthcare reform. The laws include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal healthcare program anti-kickback law, which prohibits, among other things, persons
                                            from soliciting, receiving or providing remuneration, directly or indirectly, to induce either
                                            the referral of an individual, for an item or service or the purchasing or ordering of a
                                            good or service, for which payment may be made under federal healthcare programs such as
                                            the Medicare and Medicaid programs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
                                            false claims laws which prohibit, among other things, individuals, or entities from knowingly
                                            presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other
                                            third-party payors that are false or fraudulent, and which may apply to entities like us
                                            which provide coding and billing information to customers;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Health Insurance Portability and Accountability Act of 1996, which prohibits executing
                                            a scheme to defraud any healthcare benefit program or making false statements relating to
                                            healthcare matters and which also imposes certain requirements relating to the privacy, security
                                            and transmission of individually identifiable health information;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Open Payments program under the Physician Payments Sunshine Act, created under Section
                                            6002 of the ACA and its implementing regulations, which requires certain manufacturers of
                                            covered drugs, devices, biologics and medical supplies for which payment is available under
                                            Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions)
                                            and applicable group purchasing organizations to report annually to CMS information related
                                            to payments or other transfers of value made in the previous year to covered recipients,
                                            including physicians (defined to include doctors, dentists, optometrists, podiatrists and
                                            chiropractors), certain non-physician healthcare professionals (such as physician assistants
                                            and nurse practitioners, among others), and teaching hospitals, and information regarding
                                            ownership and investment interests held by physicians (as defined above) and their immediate
                                            family members;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug manufacturing
                                            and product marketing, prohibits manufacturers from marketing drug products for off-label
                                            use and regulates the distribution of drug samples; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
                                            consumer protection and unfair competition laws, which broadly regulate marketplace activities
                                            and activities that potentially harm consumers;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
                                            government drug price reporting laws, changed by the ACA to, among other things, increase
                                            the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program
                                            and offer such rebates to additional populations, that require us to calculate and report
                                            complex pricing metrics to government programs, where such reported prices may be used in
                                            the calculation of reimbursement or discounts on our marketed drugs (participation in these
                                            programs and compliance with the applicable requirements may subject us to potentially significant
                                            discounts on our product candidates, increased infrastructure costs, and potentially limit
                                            our ability to offer certain marketplace discounts);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Foreign Corrupt Practices Act, a United States law which regulates certain financial relationships
                                            with foreign government officials (which could include, for example, certain medical professionals);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
                                            state and foreign laws and regulations, including: state anti-kickback and false claims laws
                                            which may apply to our business practices, including, but not limited to, research, distribution,
                                            sales and marketing arrangements and claims involving healthcare items or services reimbursed
                                            by state governmental and non-governmental third-party payors, including private insurers;
                                            state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s
                                            voluntary compliance guidelines and the applicable compliance guidance promulgated by the
                                            federal government; state laws that require drug manufacturers to track gifts and other remuneration
                                            and items of value provided to healthcare professionals and entities; state and local laws
                                            that require the registration of pharmaceutical sales representatives; and state laws that
                                            require drug manufacturers to report information relating to pricing and marketing information;
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
                                            and foreign laws governing the privacy and security of health information in certain circumstances,
                                            many of which differ from each other in significant ways and often are not preempted by federal
                                            laws, thus complicating compliance efforts.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws may involve substantial costs.
It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes,
regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation
of any of the laws described above or any governmental regulations that apply to us, we may be subject to greater liabilities, penalties,
including civil and criminal penalties, damages, fines, and the curtailment or restructuring of our operations. Any penalties, damages,
fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results.
Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be
entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to
incur significant legal expenses and divert management&#8217;s attention from the operation of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the physicians or other providers or entities with whom we expect to do business, is found not to be in compliance with applicable
laws, it may be subject to significant criminal, civil or administrative sanctions, including exclusions from participation in government
healthcare programs, which could also materially affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering
laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets.
We can face criminal liability and other serious consequences for violations which can harm our business. Anti-corruption laws are interpreted
broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or
providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may
engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization
phase, or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We may have direct or indirect
interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations.
We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if
we do not explicitly authorize or have actual knowledge of such activities. Any violation of the laws and regulations described above
may result in substantial civil and criminal fines and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">penalties,
imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational
harm, and other consequences.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to satisfy regulatory requirements, we may not be able to commercialize our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
need FDA approval prior to marketing our product candidates in the United States. This approval process is lengthy and subject to extensive
governmental regulations and given the unpredictability of the results of clinical trials, our failure to obtain regulatory approval
from the FDA to market any of our product candidates would significantly harm our business, results of operations and prospects. Any
delay or failure in seeking or obtaining required approvals from the FDA to market any of our product candidates would have a material
and adverse effect on our ability to sell our product candidates in the United States and to generate revenue from any such candidates
we are developing and for which we are seeking approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s review and approval process, including among other things, evaluation of preclinical studies and clinical trials of a product
candidate as well as the manufacturing process and facility, is lengthy, expensive, and uncertain. To receive approval, we must, among
other things, demonstrate with substantial evidence from well-designed and well-controlled preclinical testing and clinical trials that
the product candidates are both safe and effective for each indication for which approval is sought. Satisfaction of these requirements
typically takes several years, and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty
of the pharmaceutical product. We cannot predict if or when we will submit an NDA for approval for any of our product candidates currently
under development. Any approvals we may obtain may not cover all of the clinical indications for which we are seeking approval or may
contain significant limitations on the conditions of use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has substantial discretion in the NDA review process and may either refuse to file our NDA for substantive review or may decide that
our data is insufficient to support approval of our product candidates for the claimed intended uses. Following any regulatory approval
of our product candidates, we will be subject to continuing regulatory obligations such as safety reporting, required and additional
post marketing obligations, and regulatory oversight of promotion and marketing. Even if we receive regulatory approvals for any of our
product candidates, the FDA may subsequently seek to withdraw approval of our NDA if we determine that new data or a reevaluation of
existing data show the product is unsafe for use under the conditions of use upon the basis of which the NDA was approved, or based on
new evidence of adverse effects or adverse clinical experience, or upon other new information. If the FDA does not file or approve our
NDA or withdraws approval of our NDA, the FDA may require that we conduct additional clinical trials, preclinical or manufacturing studies
and submit that data before it reconsiders our application. Depending on the extent of these or any other requested studies, approval
of any applications that we submit may be delayed by several years, may require us to expend more resources than we have available, or
may never be obtained at all. In addition, we have obtained FDA clearance for our RenovoCath delivery system, which is subject to FDA
medical device regulations, including the Quality System Regulation. In the event adverse events arise with respect to the RenovoCath
delivery system, the FDA could revoke its clearance which would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will also be subject to a wide variety of foreign regulations governing the development, manufacture, and marketing of our products to
the extent we seek regulatory approval to develop and market any of our product candidates in a foreign jurisdiction. As of the date
hereof we have not identified any foreign jurisdictions which we intend to seek approval from. Whether or not FDA approval has been obtained,
approval of a product candidate by the comparable regulatory authorities of foreign countries must still be obtained prior to marketing
the product candidate in those countries. The approval process varies, and the time needed to secure approval in any region such as the
European Union or in a country with an independent review procedure may be longer or shorter than that required for FDA approval. We
cannot assure you that clinical trials conducted in one country will be accepted by other countries or that an approval in one country
or region will result in approval elsewhere.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after approval, we are subject to extensive regulations. The regulations to which we are subject are complex and have tended to become
more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher
than anticipated costs or lower than anticipated sales. The FDA and foreign counterparts enforce these regulatory requirements through,
among other means, periodic unannounced inspections and periodic reviews of public marketing and promotion materials. We do not know
whether we will be found compliant in connection with any future FDA or foreign counterparts&#8217; inspections or reviews. Failure to
comply with applicable regulations could jeopardize our ability to sell our products and result in enforcement actions such as: warning
letters; untitled letters; fines; injunctions; civil penalties; termination of distribution; recalls or seizures of products; delays
in the introduction of products into the market; total or partial suspension of production; refusal to grant future clearances, approvals,
or certifications; withdrawals or suspensions of current approvals or certifications, resulting in prohibitions on sales of our products;
and in the most serious cases, criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have received Orphan Drug Designation for RenovoGem for two rare diseases: pancreatic cancer and cholangiocarcinoma. We may seek Orphan
Drug Designation for future product candidates, but we may be unable to obtain such designation or to maintain the benefits associated
with Orphan Drug Designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have secured FDA Orphan Drug Designation for RenovoGem in two rare diseases: pancreatic cancer and cholangiocarcinoma. Although
we may seek Orphan Drug Designation for some or all of our other product candidates, we may never receive such designations. Under the
Orphan Drug Act, the FDA may designate a drug product as an orphan drug if it is intended to treat a rare disease or condition, defined
as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States
where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Orphan
Drug Designation must be requested before submitting an NDA. In the United States, Orphan Drug Designation entitles a party to financial
incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and application fee waivers. After the
FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if a drug product receives the first FDA approval for an indication for which it has orphan designation, the drug product is
entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication
for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan
exclusivity or where the manufacturer is unable to assure sufficient product quantity for the orphan patient population. Exclusive marketing
rights in the United States may also be unavailable if we seek approval for an indication broader than the orphan designation and may
be lost if the FDA later determines that the request for designation was materially defective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain Orphan Drug Designation, we may not be the first to obtain marketing approval for any particular indication within the orphan
designation due to uncertainties associated with developing pharmaceutical products, which would have a material adverse effect on our
operations, regulatory approval and ability to commercialize our product candidate.&#160; Further, even if we obtain orphan drug exclusivity
for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs with different
active moieties can be approved for the same condition.&#160; Even after an orphan drug is approved, the FDA can subsequently approve
the same drug with the same active moiety for the same indication or use if the FDA concludes that the later drug is clinically superior
or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time
of a product candidate nor gives the product candidate any advantage in the regulatory review or approval process or entitles the product
candidate to priority review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in Catalyst Pharms., Inc. v. Becerra, 14
F.4th 1299 (11th Cir. 2021), the court disagreed with the FDA&#8217;s longstanding position that the orphan drug exclusivity only applies
to the approved use or indication within an eligible disease. This decision created uncertainty in the application of the orphan drug
exclusivity. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the
court&#8217;s order in Catalyst, the FDA intends to continue to apply its longstanding interpretation of the regulations to matters outside
of the scope of the Catalyst order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or
indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within
the same orphan designated disease or condition that have not yet been approved. It is unclear how future litigation, legislation, agency
decisions, and administrative actions will impact the scope of the orphan drug exclusivity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our product candidates are unable to compete effectively with marketed drugs targeting similar indications as our product candidates,
our commercial opportunity will be reduced or eliminated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face competition generally from established pharmaceutical and biotechnology companies, as well as from academic institutions, government
agencies and private and public research institutions. Many of our competitors have significantly greater financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved products than we do. Small or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large, established companies. We are aware of a number of companies in Phase III clinical trials for the treatment
of LAPC including Angiodynamics, Bausch Health, FibroGen, Novocure, and SynCore Biotechnology. In addition, we are aware of a number
of companies in Phase I and Phase II clinical trials for the treatment of LAPC including one interventional company, TriSalus Lifesciences.
Our commercial opportunity will be reduced or eliminated if our competitors develop and commercialize any products that are safer, more
effective, have fewer side effects or are less expensive than our product candidates. These potential competitors compete with us in
recruiting and retaining key and qualified scientific and management personnel, establishing clinical trial sites, and patient enrollment
for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved and commercialized, RenovoGem would compete with several currently approved prescription therapies for the treatment of LAPC
and cholangiocarcinoma. To our knowledge, other potential competitors are in earlier stages of development. If potential competitors
are successful in completing drug development for their product candidates and obtain approval from the FDA, they could limit the demand
for RenovoGem.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our ability to compete effectively will depend upon our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            identify and develop key points of product differentiation from currently available therapies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            and timely complete clinical trials and submit for and obtain all requisite regulatory approvals
                                            in a cost-effective manner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
                                            a proprietary position for our products and manufacturing processes and other related product
                                            technology;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
                                            and retain key and qualified personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
                                            relationships with physicians prescribing these products; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">build
                                            an adequate sales and marketing infrastructure for our products, if approved.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we will be competing against significantly larger companies with established track records, we will have to demonstrate that, based on
experience, clinical data, side-effect profiles and other factors, our products, if approved, are competitive with other products. If
we are unable to compete effectively and differentiate our products from other marketed drugs, we may never generate meaningful revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may expend our limited resources to pursue one or more product candidates or indications within our product development strategy, which
has and may continue to change over time, and fail to capitalize on product candidates or indications that may be more profitable or
for which there is a greater likelihood of success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we intend to focus on developing product candidates for specific indications that
we identify as most likely to succeed, in terms of their potential both to gain regulatory approval and to achieve commercialization.
As a result, we may forego or delay the pursuit of opportunities with other product candidates or in other indications with greater commercial
potential. Such resource allocation and strategic decisions may cause us to fail to capitalize on viable commercial products or profitable
market opportunities. Our spending on current and future research and development programs and product candidates for specific indications
may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market
for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or
other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization
rights to the product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the manufacturers upon whom we rely fail to produce our product candidates, in the volumes that we require on a timely basis or fail
to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization
of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently possess internal manufacturing capacity. We plan to utilize the services of cGMP manufacturers, FDA inspected contract
manufacturers to formulate and manufacture our preclinical and clinical supplies. Any curtailment in the availability of gemcitabine,
or RenovoCath, the drug delivery device, however, could result in production or other delays with consequent adverse effects on us. In
addition, because regulatory authorities must generally approve raw material sources for pharmaceutical products, changes in raw material
suppliers may result in production delays or higher raw material costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
obtain our RenovoCath delivery system from a single source, which must be manufactured in accordance with the FDA Quality System Regulation
(QSR). Gemcitabine is supplied from our clinical sites&#8217; pharmacies and used off-label for intra-arterial use within our clinical
study. We continue to pursue supply agreements for gemcitabine and our RenovoCath delivery system. We may be required to agree to minimum
volume requirements, exclusivity arrangements or other restrictions with the contract manufacturers. We may not be able to enter into
long-term agreements on commercially reasonable terms, or at all. If we change or add manufacturers, the FDA and comparable foreign regulators
may require approval of the changes. Approval of these changes could require new testing by the manufacturer and compliance inspections
to ensure the manufacturer is conforming to all applicable laws and regulations and cGMP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture of pharmaceutical products, including drug/device combination products, requires significant expertise and capital investment,
including the development of an acceptable formulation to support later-stage trials for our product candidates, advanced manufacturing
techniques and process controls. Manufacturers of pharmaceutical products may encounter difficulties in production, particularly in scaling
up production and reformulating the form of any of our product candidates. For drug/device combination products, ensuring compliance
with both medical device and drug regulations exposes us to additional risks. These problems include difficulties with production costs
and yields, quality control, including stability of the product and quality assurance testing, shortages of qualified personnel, as well
as compliance with federal, state, and foreign regulations. Our contract manufacturers may also place a priority on the manufacture of
their own products, or other customers&#8217; products. In addition, any delay or interruption in the supply of clinical trial supplies,
due to the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effects
of the COVID-19 pandemic or otherwise, could delay the completion of our clinical trials, increase the costs associated with conducting
our clinical trials and, depending upon the period of delay, require us to commence new clinical trials at significant additional expense
or to terminate a clinical trial.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be responsible for ensuring that our future contract manufacturers comply with the cGMP requirements of the FDA and other regulatory
authorities from which we seek to obtain product approval. These requirements include, among other things, quality control, quality assurance
and the maintenance of records and documentation. The approval process for NDAs includes an inspection of the manufacturer&#8217;s compliance
with cGMP requirements. We will be responsible for regularly assessing a contract manufacturer&#8217;s compliance with cGMP requirements
through record reviews and periodic audits and for ensuring that the contract manufacturer takes responsibility and corrective action
for any identified deviations. Manufacturers of our product candidates may be unable to comply with these cGMP requirements and with
other FDA and foreign regulatory requirements, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we will oversee compliance of our contract manufacturers, ultimately, we will not have control over our manufacturers&#8217; compliance
with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension
of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of
any of our product candidates is compromised due to a manufacturers&#8217; failure to adhere to applicable laws or for other reasons,
we may not be able to obtain regulatory approval for or successfully commercialize any of our product candidates, and we may be held
liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals,
or commercialization of RenovoGem or other product candidates, entail higher costs or result in us being unable to effectively commercialize
any of our product candidates. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis
and at commercially reasonable prices, we may be unable to meet demand for any approved products and would lose potential revenues. There
are also risks of our contract manufacturers failing to perform as agreed, terminating their relationship with us, experiencing the effects
of any strikes or other work stoppages, or not remaining in the contract manufacturing business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
dependence on third-party suppliers subjects us to a number of risks that could negatively impact our ability to manufacture products
and harm our business, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
                                            of supply resulting from modifications to, or discontinuation of, a supplier&#8217;s operations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s
                                            failure to produce components that consistently meet our quality specifications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price
                                            fluctuations due to a lack of long-term supply arrangements with our suppliers for key components;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                            to obtain adequate supply in a timely manner or on commercially reasonable terms;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
                                            identifying and qualifying alternative suppliers for components in a timely manner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                            of suppliers to comply with applicable provisions of the FDA&#8217;s QSR, cGMP regulations
                                            or other applicable laws or regulations enforced by the FDA or state regulatory authorities
                                            and foreign regulatory authorities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                            to ensure the quality of products or components manufactured by third parties;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production
                                            delays related to the evaluation and testing of products and components from alternative
                                            suppliers and corresponding regulatory qualifications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            in delivery by our suppliers due to changes in demand from us or their other customers, or
                                            our suppliers prioritizing their other customers over us; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            outbreak of disease or similar public health threat, such as the existing threat of COVID-19
                                            pandemic, particularly as it may impact our supply chain.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we require that our third-party suppliers provide our manufacturing partners with components that meet our specifications and comply
with applicable provisions of the QSR, cGMP and other applicable legal and regulatory requirements in our agreements and contracts, there
is a risk that our suppliers will not always act with our best interests in mind, and they may not always supply components that meet
our requirements or supply components in a timely manner. Any interruption or delay in the supply of components or materials, or our
inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability
to meet the demand of our customers and cause them to cancel orders or switch to competitive procedures. These events could harm our
business and our operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to manufacture our product candidates in commercial quantities, which would prevent us from commercializing our product
candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, our product candidates have been manufactured in small quantities for preclinical studies and clinical trials. If any of our product
candidates are approved by the FDA or comparable regulatory authorities in other countries for commercial sale, we will need to manufacture
such product candidates in larger quantities. We may not be able to successfully increase the manufacturing capacity for our product
candidates in a timely or economic manner, or at all. A significant scale-up of manufacturing may require additional validation studies,
which the FDA must review and approve. If we are unable to successfully increase the manufacturing capacity for a product candidate,
the clinical trials as well as the regulatory approval or commercial launch of that product candidate may be delayed or there may be
a shortage in supply. Our product candidates require precise, high-quality manufacturing in accordance with cGMP. Our failure to achieve
and maintain these high-quality manufacturing standards in collaboration with our third-party manufacturers, including the incidence
of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing
or delivery, cost overruns or other problems that could harm our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates, if approved for sale, may not gain acceptance among physicians, patients, and the medical community, thereby limiting
our potential to generate revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our product candidates are approved for commercial sale by the FDA or other regulatory authorities, the degree of market acceptance of
any approved product by physicians, healthcare professionals and third-party payors and our profitability and growth will depend on a
number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
                                            of safety and efficacy;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
                                            advantages of our product candidates over alternative treatments; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            indications for which the product candidates are approved and the labeling approved by regulatory
                                            authorities for use with the product candidates, including any warnings, limitations or contraindications
                                            contained in a product&#8217;s approved labeling;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                            of other new therapies for the same indications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            by physicians and patients of the product candidate as a safe and effective treatment;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            cost, safety and efficacy of treatment in relation to alternative treatments, including generic
                                            versions of the product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extent to which our product candidates are included on formularies of hospitals and managed
                                            care organizations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the practice guidelines and the standard of care for the targeted indication;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
                                            convenience and ease of administration;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any adverse side effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">budget
                                            impact of adoption of our product on relevant drug formularies and the availability, cost,
                                            and potential advantages of alternative treatments, including less expensive generic drugs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing,
                                            reimbursement, and cost effectiveness, which may be subject to regulatory control;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectiveness
                                            of our or any of our partners&#8217; sales and marketing strategies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            product labeling or product insert required by the FDA or regulatory authority in other countries;
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of adequate third-party insurance coverage or reimbursement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any product candidate that we develop does not provide a treatment regimen that is as beneficial as, or is perceived as being as beneficial
as, the current standard of care or otherwise does not provide patient benefit, that product candidate, if approved for commercial sale
by the FDA or other regulatory authorities, likely will not achieve market acceptance. Our ability to effectively promote and sell any
approved products will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price
and our ability to obtain sufficient third-party coverage or reimbursement. If any product candidate is approved but does not achieve
an adequate level of acceptance by physicians, patients and third-party payors, our ability to generate revenues from that product would
be substantially reduced. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product
candidates may require significant resources, may be constrained by FDA rules and policies on product promotion, and may never be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Guidelines
and recommendations published by various organizations can impact the use of our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
agencies promulgate regulations and guidelines directly applicable to us and to our product. In addition, professional societies, practice
management groups, private health and science foundations and organizations involved in various diseases from time to time may also publish
guidelines or recommendations to the healthcare and patient communities. Recommendations of government agencies or these other groups
or organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations
or guidelines suggesting the reduced use of our products or the use of competitive or alternative products that are followed by patients
and healthcare providers could result in decreased use of our proposed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market for RenovoGem and our other product candidates may not be as large as we expect.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
estimates of the potential market opportunity for RenovoGem and our other product candidates include several key assumptions based on
our industry knowledge, industry publications, third-party research reports and other surveys, including surveys commissioned by us.
These assumptions include the size of our target populations, the prevalence and incidence of each of our target indications, the number
of patients receiving current treatment, the percentage of patients unsatisfied with the current treatments, the number of diagnosed
but untreated patients, the compliance and adherence of patients in our target populations, the number of treatment centers and prescribing
physicians and the percentage of payer acceptance. While we believe that our internal assumptions are reasonable, if any of these assumptions
proves to be inaccurate, then the actual market for our product candidates could be smaller than our estimates of our potential market
opportunity. If the actual market for any of our product candidates is smaller than we expect, our product revenue may be limited, and
it may be more difficult for us to achieve or maintain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
the event that we need to change our third-party contract manufacturers, our preclinical studies, clinical trials or the commercialization
of our product candidates could be delayed, adversely affected or terminated, or such a change may result in significantly higher costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to regulatory restrictions inherent in an IND or NDA, or for economic reasons, various steps in the manufacture of any of our
product candidates may need to be sole-sourced. We currently obtain our RenovoCath delivery system, subject to requirements under
the QSR, from a single supplier. In accordance with cGMP regulations and QSR, changing manufacturers may require the re-validation
of manufacturing processes and procedures, and may require further preclinical studies or clinical trials to show comparability
between the materials produced by different manufacturers, and further regulatory review and approval. Changing our current or
future contract manufacturers may be difficult for us and could be costly, which could result in our inability to manufacture our
product candidate for an extended period of time and therefore a delay in the development of any of our product candidates. While we
intend to find alternative suppliers to mitigate the risk, our efforts may not be successful. Further, to maintain our development
timelines in the event of a change in our third-party contract manufacturer, we may incur significantly higher costs to manufacture
any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently do not have any internal drug discovery capabilities, and therefore we are dependent on identifying drugs that are off patent
or on in-licensing or acquiring development programs from third parties in order to obtain additional product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
in the future we decide to further expand our pipeline of product candidates, we will be dependent on identifying drugs that are off
patent or on in-licensing or acquiring product candidates as we do not have significant internal discovery capabilities at this time.
We may face substantial competition from other biotechnology and pharmaceutical companies, many of which may have greater resources than
we have, in obtaining in-licensing, sponsored research or acquisition opportunities. In-licensing or acquisition opportunities may not
be available to us on terms we find acceptable, if at all. In-licensed compounds that appear promising in research or in preclinical
studies may fail to progress into further preclinical studies or clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
a product liability claim is successfully brought against us for uninsured liabilities, or such a claim exceeds our insurance coverage,
we could be forced to pay substantial damage awards that could materially harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of any of our existing or future product candidates in clinical trials and the sale of any approved pharmaceutical products may expose
us to significant product liability claims. We have product liability insurance coverage for our proposed clinical trials; however, such
insurance coverage may be inadequate and may not protect us against any or all of the product liability claims that may be brought against
us now or in the future. We may not be able to acquire or maintain adequate product liability insurance coverage at a commercially reasonable
cost or in sufficient amounts or scope to protect us against potential losses. In the event a product liability claim is brought against
us, we may be required to pay legal and other expenses to defend the claim, as well as uncovered damage awards resulting from a claim
brought successfully against us. In the event that any of our product candidates are approved for sale by the FDA and commercialized,
we may need to substantially increase the amount of our product liability coverage. Defending any product liability claim or claims could
require us to expend significant financial and managerial resources, which could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may delay or terminate the development of our product candidates at any time if we believe the perceived market or commercial opportunity
does not justify further investment, which could materially harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
though the results of preclinical studies and clinical trials that have been conducted or may be conducted in the future may support
further development of our product candidates, we may delay, suspend or terminate the future development of a product candidate at any
time for strategic, business, financial or other reasons, including the determination or belief that the emerging profile of the product
candidate is such that it may not receive FDA approval, gain meaningful market acceptance, generate a significant return to stockholders,
or otherwise provide any competitive advantages in its intended indication or market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on the development, regulatory, commercialization, and business development expertise of Shaun Bagai, our Chief
Executive Officer, as well as the other principal members of our management, scientific and clinical teams. Although we have employment
agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating
their services at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be
seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time
because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop
product candidates, gain regulatory approval, and commercialize new products. Competition to hire from this limited pool is intense,
and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among
numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition, including a recent hyper-competitive
compensation environment, for the hiring of scientific and clinical personnel from universities and research institutions. In addition,
we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development
and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under
consulting or advisory contracts with other entities that may limit their availability to us. One such key consultant is Dr. Ramtin Agah,
our Chief Medical Officer. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and
commercialize product candidates will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to increase the size of our organization, and we may experience difficulties in managing growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a small company with less than 10 employees. The future growth of our company will impose significant additional responsibilities
on members of management, including the need to identify, attract, retain, motivate and integrate highly skilled personnel. We may increase
the number of employees in the future depending on the progress of our development and commercialization of our product candidates. Our
future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part,
on our ability to manage any future growth effectively. To that end, we must be able to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
                                            our clinical studies effectively;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">integrate
                                            additional and future management, administrative, manufacturing, sales and marketing, and
                                            regulatory personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
                                            sufficient administrative, accounting and management information systems and controls; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
                                            and train additional qualified personnel.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that we will be able to accomplish these tasks, and our failure to accomplish any of them could materially adversely
affect our business, prospects, and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
disruptions could seriously harm future revenue and financial condition and increase our costs and expenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations, and those of our third-party manufacturers, contract research organizations (&#8220;CROs&#8221;), and other contractors and
consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons,
fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions beyond our control,
for which we are predominantly self-insured. The occurrence of any of these business disruptions could delay our clinical trials, seriously
harm our operations and financial condition and increase our costs and expenses. <span style="background-color: white">In addition, </span>our
ability to obtain clinical supplies for our clinical trials and materials for our product candidates could be disrupted if the operations
of these suppliers are affected by a man-made or natural disaster or other business interruptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located in Silicon Valley, California, an area prone to wildfires and earthquakes. These and other natural
disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial
condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant
portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers,
or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial
period of time. Any disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster
or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity
plans, which could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Catastrophic
events and man-made problems, such as terrorism, war, or climate change may disrupt our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant natural disaster, such as an earthquake, fire, flood, hurricane, or significant power outages, water shortages and the risks
associated with climate change could have an adverse impact on our business, results of operations, and financial condition. Our employees
and executive officers are located in the San Francisco Bay Area, a region known for seismic activity, drought, and wildfires, and the
resultant air quality impacts and power outages associated with such wildfires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, acts of terrorism, pandemics, such as the ongoing COVID-19 pandemic or another public health crisis, protests, riots, and the
increasing frequency and impact of extreme weather events on critical infrastructure in the U.S. and elsewhere have the potential to
disrupt our business and the business of our third-party suppliers, and may cause us to experience higher attrition, losses, and additional
costs to maintain or resume operations. All of the aforementioned risks may be further increased if our course of action in response
to catastrophic events proves to be inadequate. For example, if a catastrophic event occurred that prevented us from using all or a significant
portion of our facility, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers,
or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial
period of time. Any disaster recovery and business continuity plan we have in place may prove inadequate in the event of a serious disaster
or similar event and we may incur substantial expenses as a result of the limited nature of these plans, which could have a material
adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, armed conflict escalated between Russia and Ukraine. The sanctions announced by the U.S. and other countries against Russia,
following Russia&#8217;s invasion of Ukraine, to date include restrictions on selling or importing goods, services, or technology in
or from affected regions, and travel bans and asset freezes impacting connected individuals and political, military, business, and financial
organizations in Russia. The United States and other countries could impose wider sanctions and take other actions should the conflict
further escalate. It is not possible to predict the broader consequences of this conflict, which could include further sanctions, embargoes,
regional instability, prolonged periods of higher inflation, geopolitical shifts, and adverse effects on macroeconomic conditions, currency
exchange rates, and financial markets, all of which could have a material adverse effect on our business, financial condition, and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Security
threats to our information technology infrastructure and/or our physical buildings could expose us to liability and damage our reputation
and business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is essential to our business strategy that our and our vendors, partners, clinical trial sites, and third-party providers&#8217; technology
and network infrastructure and physical buildings remain secure and are perceived by our customers and corporate partners to be secure.
Despite our implementation of security measures, any of the internal computer systems and networks belonging to or used by us or our
employees and our third-party service providers are vulnerable to damage and disruption from computer viruses, ransomware and other malicious
code, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure, as well as security breaches
and incidents from inadvertent or intentional actions, or from cyber-attacks by malicious third parties (including supply chain cyber-attacks,
denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity
and availability of information), which may compromise system infrastructure or lead to the loss, destruction, alteration, prevention
of access to, disclosure, or dissemination of, or damage or unauthorized access to, our data (including trade secrets or other confidential
information, intellectual property, proprietary business information, and personal information) or data that is processed or maintained
on our behalf, or other assets, which could result in financial, legal, business and reputational harm to us. Any system failure, accident
or security breach or incident that causes interruptions in our own or in our third-party service providers&#8217; operations could result
in a material disruption of our development programs or other aspects of our operations. As a result of the ongoing COVID-19 pandemic,
with many of our employees working from home from time to time and accessing our corporate network via remote devices, the potential
for such events to occur is even greater. Despite security measures, we also cannot guarantee the security of our physical buildings.
Physical building penetration or any cyber-attacks could negatively affect our reputation, damage our network infrastructure and our
ability to deploy our products and services, harm our relationship with customers and partners that are affected, and expose us to financial
liability, including the possibility of consequential damages resulting from cyber-attacks and other security threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there are a number of state, federal, and international laws protecting the privacy and security of health information and personal data.
For example, the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes limitations on the use and
disclosure of an individual&#8217;s healthcare information by healthcare providers, healthcare clearinghouses, and health insurance plans,
or, collectively, covered entities, and also grants individuals rights with respect to their health information. HIPAA also imposes compliance
obligations and corresponding penalties for non-compliance on individuals and entities that provide services to healthcare providers
and other covered entities. As part of the American Recovery and Reinvestment Act of 2009 (&#8220;ARRA&#8221;), the privacy and security
provisions of HIPAA were amended. ARRA also made significant increases in the penalties for improper use or disclosure of an individual&#8217;s
health information under HIPAA and extended enforcement authority to state attorneys general. As amended by ARRA and subsequently by
the final omnibus rule adopted in 2013, HIPAA also imposes notification requirements on covered entities in the event that certain health
information has been inappropriately accessed or disclosed, including notification requirements to individuals, federal regulators, and
in some cases, notification to local and national media. Notification is not required under HIPAA if the health information that is improperly
used or disclosed is deemed secured in accordance with encryption or other standards developed by the U.S. Department of Health and Human
Services. Most states have laws requiring notification of affected individuals and/or state regulators in the event of a breach of personal
information, which is a broader class of information than the health information protected by HIPAA. Many state laws impose significant
data security requirements, such as encryption or mandatory contractual terms, to ensure ongoing protection of personal information.
Activities outside of the U.S. implicate local and national data protection standards, impose additional compliance requirements, and
generate additional risks of enforcement for non-compliance. We may be required to expend significant capital and other resources to
ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers or to alleviate
problems caused by such breaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
and our third-party contract manufacturers must comply with environmental, health and safety laws and regulations, and failure to comply
with these laws and regulations could expose us to significant costs or liabilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing
laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous
materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business,
and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment
or disposal of hazardous materials and wastes. In the event of contamination or injury, or failure to comply with environmental, health
and safety laws and regulations, we could be held liable for any resulting damages and any such liability could exceed our assets and
resources. We could also incur significant costs associated with civil or criminal fines and penalties for failure to comply with such
laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological, hazardous or radioactive materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental,
health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with
current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our
research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines,
penalties or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
with respect to the operations of our third-party contract manufacturers, it is possible that if they fail to operate in compliance with
applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could
be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product
candidates or products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
variety of risks associated with operating internationally could materially adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doing
business internationally involves a number of risks, including but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple,
                                            conflicting and changing laws and regulations, such as privacy regulations, tax laws, export
                                            and import restrictions, employment laws, regulatory requirements and other governmental
                                            approvals, permits and licenses;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            by us to obtain and maintain regulatory approvals for the use of our products in various
                                            countries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
                                            potentially relevant third-party patent rights;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
                                            and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
                                            in staffing and managing foreign operations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
                                            associated with managing multiple payor reimbursement regimes, government payors or patient
                                            self-pay systems;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits
                                            in our ability to penetrate international markets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
                                            risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact
                                            of local and regional financial crises on demand and payment for our products, exposure to
                                            foreign currency exchange rate fluctuations and a rising rate of inflation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
                                            disasters, political and economic instability, including wars, terrorism and political unrest,
                                            outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
                                            expenses including, among others, expenses for travel, translation, and insurance; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            and compliance risks that relate to maintaining accurate information and control over sales
                                            and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act,
                                            its books and records provisions, or its anti-bribery provisions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could significantly harm any current or future international operations and, consequently, our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
economic or business conditions may have a negative impact on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Continuing concerns over U.S. healthcare reform legislation
and energy costs, geopolitical issues, fluctuations in inflation rates, market volatility, the availability and cost of credit and government
stimulus programs in the U.S. and other countries, including those related to the COVID-19 pandemic, as well as recent and potential future
disruptions in access to bank deposits or lending commitments due to bank failure, have contributed to increased volatility and could
materially and adversely affect our liquidity, our business and financial condition. The recent closures of Silicon Valley Bank and Signature
Bank and their placement into receivership with the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) created bank-specific and
broader financial institution liquidity risk and concerns. Although the Department of the Treasury, the Federal Reserve, and the FDIC
jointly released a statement that depositors at Silicon Valley Bank and Signature Bank would have access to their funds, even those in
excess of the standard FDIC insurance limits, future adverse developments with respect to specific financial institutions or the broader
financial services industry may lead to market-wide liquidity shortages. The failure of any bank in which we deposit our funds could reduce
the amount of cash we have available for our operations or delay our ability to access such funds. Any such failure may increase the possibility
of a sustained deterioration of financial market liquidity, or illiquidity at clearing, cash management and/or custodial financial institutions.
In the event we have a commercial relationship with a bank that has failed or is otherwise distressed, we may experience delays or other
issues in meeting our financial obligations. If other banks and financial institutions enter receivership or become insolvent in the future
in response to financial conditions affecting the banking system and financial markets, our ability to access our cash and cash equivalents
and investments may be threatened and could have a material adverse effect on our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> If the economic climate deteriorates or is poor, our business, as well as
the financial condition of our suppliers and our third-party payors, could be negatively impacted, which could materially adversely affect
our business, prospects and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operations are subject to the effects of a rising rate of inflation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States has recently experienced historically high levels of inflation. If the inflation rate continues to increase, for example
due to increases in the costs of labor and supplies, it will affect our expenses, such as employee compensation and research and development
charges. Additionally, the United States is experiencing an acute workforce shortage, which in turn, has created a very competitive wage
environment that may increase the Company&#8217;s operating costs. To the extent inflation results in rising interest rates and has other
adverse effects on the market, it may adversely affect our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
reform measures could adversely affect our business. The impact of recent healthcare reform legislation and other changes in the healthcare
industry and in healthcare spending on us is currently unknown and may adversely affect our business model.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained and we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and foreign jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes and
proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue
to be a number of initiatives at the federal and state levels in the United States that seek to reduce healthcare costs. In 2010, the
Patient Protection and Affordable Care Act (the &#8220;PPACA&#8221;) was enacted, which includes measures to significantly change the
way healthcare is financed by both governmental and private insurers. Among the provisions of the PPACA of greatest importance to the
pharmaceutical and biotechnology industry are the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            annual, nondeductible fee on any entity that manufactures or imports certain branded prescription
                                            drugs and biologic agents, apportioned among these entities according to their market share
                                            in certain government healthcare programs; </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementation
                                            of the federal physician payment transparency requirements, sometimes referred to as the
                                            &#8220;Physician Payments Sunshine Act&#8221;;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            licensure framework for follow-on biologic products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and
                                            conduct comparative clinical effectiveness research, along with funding for such research;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
                                            of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services to
                                            test innovative payment and service delivery models to lower Medicare and Medicaid spending,
                                            potentially including prescription drug spending;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug
                                            Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic
                                            drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the
                                            AMP;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
                                            are calculated for certain drugs and biologics, including our product candidates, that are
                                            inhaled, infused, instilled, implanted or injected;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension
                                            of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals
                                            who are enrolled in Medicaid managed care organizations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
                                            of eligibility criteria for Medicaid programs by, among other things, allowing states to
                                            offer Medicaid coverage to additional individuals and by adding new mandatory eligibility
                                            categories for individuals with income at or below 133% of the federal poverty level, thereby
                                            potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer
                                            50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries
                                            during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient
                                            drugs to be covered under Medicare Part D; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
                                            of the entities eligible for discounts under the Public Health program.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its enactment, there remain judicial and Congressional challenges to certain aspects of the PPACA. For example, in June 2021 the U.S.
Supreme Court held that Texas and other challengers had no legal standing to challenge the PPACA, dismissing the case on procedural grounds
without specifically ruling on the constitutionality of the PPACA. Thus, the PPACA will remain in effect in its current form. In addition,
other legislative changes have been proposed and adopted since the PPACA was enacted. These changes include aggregate reductions to Medicare
payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 due to subsequent legislative
amendments will remain in effect through 2031, with the exception of a temporary suspension implemented under various COVID-19 relief
legislation from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. Under current legislation, the
actual reduction in Medicare payments can vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
there has recently been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their marketed
products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for drug products. For example, under the American Rescue Plan
Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state
Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than
it receives on the sale of products, which could have a material impact on our business. In August 2022, Congress passed the
Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the
pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for
certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the
drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions,
if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs
for beneficiaries, among other changes. The impact of these legislative, executive, and administrative actions and any future
healthcare measures and agency rules on us and the pharmaceutical industry as a whole is unclear. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or
commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive
and expensive, resulting in a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost
disclosure and transparency measures, and to encourage importation from other countries and bulk purchasing. Legally mandated price controls
on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and
prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine
what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could
reduce the ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results
of operations, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, given recent federal and state government initiatives directed at lowering the total cost of healthcare, Congress and state
legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics and the reform of the Medicare
and Medicaid programs. While we cannot predict the full outcome of any such legislation, it may result in decreased reimbursement for
drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm our ability
to generate revenue. Further, a number of states are considering or have recently enacted state drug price transparency and reporting
laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin
commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increases
in importation or re-importation of pharmaceutical products from foreign countries into the United States could put competitive pressure
on our ability to profitably price our products, which, in turn, could adversely affect our business, results of operations, financial
condition and prospects. We might elect not to seek approval for or market our products in foreign jurisdictions in order to minimize
the risk of re-importation, which could also reduce the revenue we generate from product sales. It is also possible that other legislative
proposals having similar effects will be adopted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
regulatory authorities&#8217; assessment of the data and results required to demonstrate safety and efficacy can change over time and
can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency
funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable
to our business prospects. For example, average review times at the FDA for marketing approval applications can be affected by a variety
of factors, including budget and funding levels and statutory, regulatory and policy changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reimbursement
for any approved products may be limited or unavailable, which could make it difficult for us to sell our product candidates profitably.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
both domestic and foreign markets, sales of any of our other product candidates, if approved, will depend, in part, on the extent to
which the costs of our product candidates will be covered by third-party payors, such as government health care programs, commercial
insurance and managed health care organizations. These third-party payors decide which drugs will be covered and establish reimbursement
levels for those drugs. The containment of health care costs has become a priority of foreign and domestic governments as well as private
third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to
control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell
our product candidates profitably. Cost-control initiatives could cause us to decrease the price we might establish for product candidates,
which could result in lower than anticipated product revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimbursement
by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product
is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            covered benefit under its health plan;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe,
                                            effective and medically necessary;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
                                            for the specific patient;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective
                                            relative to other alternatives, including generic products; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
                                            experimental nor investigational.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
pricing limitations may hinder our ability to recoup our investment in our existing and any future product candidates, even if such product
candidates obtain marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process
that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our product candidates to
the payor. Further, there is significant uncertainty related to third-party payor coverage and reimbursement of newly approved product
candidates, including our product candidates if they are approved. We may not be able to provide data sufficient to gain acceptance with
respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our product
candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our product candidates.
If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize certain of
our product candidates. In addition, in the United States, third-party payors are increasingly attempting to contain health care costs
by limiting both coverage and the level of reimbursement of new product candidates. As a result, significant uncertainty exists as to
whether and how much third-party payors will reimburse patients for their use of newly approved product candidates, which in turn will
put pressure on pricing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some countries, including member states of the European Union, the pricing of prescription drugs is subject to governmental control.
In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval
for a product. In addition, there can be considerable pressure from governments and other stakeholders on prices and reimbursement levels,
including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations,
and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member
states and other countries and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce
prices. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our
product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts
by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication
and other countries. If reimbursement of our product candidates is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our business could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
outbreak of the novel coronavirus disease, COVID-19, including its most recent variants, could materially adversely impact our business,
results of operations and financial condition, including our clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic, and government responses have created disruption in global supply chains and adversely impacting many industries.
The pandemic could have a continued material adverse impact on economic and market conditions. We continue to monitor the impact of the
COVID-19 pandemic, including its most recent variants, closely. The extent to which the COVID-19 pandemic will impact our operations
or financial results is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce,
as worker shortages have occurred; supply chains have been disrupted; and demand for certain goods and services, such as medical services
and supplies, has spiked, while demand for other goods and services has fallen. While the extent of the impact of the COVID-19 pandemic
on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could
have a material adverse effect on our business, financial condition and results of operations. As a result of the COVID-19 pandemic,
including its most recent variants, we may experience disruptions that could severely impact our business and clinical trials, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            or difficulties in enrolling and retaining patients in our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            or difficulties in clinical site initiation, including difficulties in recruiting clinical
                                            site investigators and clinical site staff;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
                                            of healthcare resources away from the conduct of clinical trials, including the diversion
                                            of hospitals serving as our clinical trial sites and hospital staff supporting the conduct
                                            of our clinical trials;</span></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
                                            of key clinical trial activities, such as clinical trial site data monitoring, due to limitations
                                            on travel imposed or recommended by federal or state governments, employers and others or
                                            interruption of clinical trial subject visits and study procedures, which may impact the
                                            integrity of subject data and clinical study endpoints;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
                                            or delays in the operations of the FDA or other regulatory authorities, which may impact
                                            review and approval timelines;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
                                            of, or delays in receiving, supplies of our product candidates from our contract manufacturing
                                            organizations due to staffing shortages, production slowdowns or stoppages and disruptions
                                            in delivery systems;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            on employee and consulting resources that would otherwise be focused on the conduct of our
                                            clinical trials, including because of sickness of employees, consultants or their families
                                            or the desire of employees or consultants to avoid contact with large groups of people;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
                                            or delays to our outsourced clinical activities; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in clinical site procedures and requirements as well as regulatory requirements for conducting
                                            clinical trials during the pandemic.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since March 2020, the FDA issued various COVID-19
related guidance documents, including guidance on conducting clinical trials during the pandemic and on good manufacturing practice considerations,
among others. President Biden announced that the administration intends to end the COVID-19 national and public health emergencies on
May 11, 2023. The full impact of the termination of the public health emergencies on FDA and other regulatory policies and operations
are unclear.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
legal proceedings or claims against us could be costly and time-consuming to defend and could harm our reputation regardless of the outcome.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future become subject to legal proceedings and claims that arise in the ordinary course of business, including intellectual
property, product liability, employment, wage and hour, class action, derivative, whistleblower and other litigation claims, and governmental
and other regulatory investigations and proceedings. Such matters can be time-consuming, divert management&#8217;s attention and resources,
cause us to incur significant expenses or liability, or require us to change our business practices. In addition, the expense of litigation,
for which we are either not insured or only partially insured depending on the claim, and the timing of this expense from period to period
will be difficult to estimate, subject to change, and could adversely affect our financial condition and results of operations. Because
of the potential risks, expenses, and uncertainties of litigation, we may, from time to time, settle disputes, even where we have meritorious
claims or defenses, by agreeing to settlement agreements. Any of the foregoing could adversely affect our business, financial condition,
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in tax laws or in their implementation or interpretation may adversely affect our business and financial condition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are or may become subject to income and non-income taxes in the United States under federal, state and local jurisdictions and in certain
foreign jurisdictions in which we operate. Tax laws, regulations and administrative practices in these jurisdictions may be subject to
significant change, with or without advance notice. For example, on January 1, 2022, a provision of the Tax Cuts and Jobs Act of 2017
went into effect that eliminates the option to deduct domestic research and development costs in the year incurred and instead requires
taxpayers to amortize such costs over five years. The Company is currently evaluating the potential impact. Also, the Inflation Reduction
Act, which introduced a 15% minimum tax on book income and a 1% excise tax on stock buybacks. Changes in tax laws (including provisions
of the recently enacted federal tax legislation titled the Inflation Reduction Act), regulations, or rulings, changes in interpretations
of existing laws and regulations, or changes in accounting principles could negatively and materially affect our financial position,
effective tax rates, cash flows, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies,
which would impair our competitive advantage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on patent protection as well as a combination of trademark, copyright and trade secret protection, and other contractual restrictions,
to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit
us to gain or keep any competitive advantage. We may not be successful in defending challenges made in connection with our patents and
patent applications. If we fail to protect our intellectual property, we will be unable to prevent third parties from using our technologies
and they will be able to compete more effectively against us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example, others may be able to make
products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents
that we license or may own; we, or our future licensors or <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators,
might not have been the first to file patent applications covering certain of our or their inventions; and issued patents that we hold
rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our patents, we rely on contractual restrictions to protect our proprietary technology. We require our employees and third
parties to sign confidentiality agreements and our employees are also required to sign agreements assigning to us all intellectual property
arising from their work for us. Nevertheless, we cannot guarantee that these measures will be effective in protecting our intellectual
property rights. Should any of these events occur, it or they could have a material adverse effect on our business, financial condition,
results of operations, and growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any of our patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
currently pending or future patent applications may not result in issued patents and any patents issued to us may be challenged, invalidated,
or held unenforceable. Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability
to protect our inventions, obtain, maintain, and enforce our intellectual property rights, and, more generally, could affect the value
of our intellectual property or narrow the scope of our patents with respect to our product candidates. Furthermore, we cannot be certain
that we were the first to make the invention claimed in our issued patents or pending patent applications in the U.S., or that we were
the first to file for protection of the inventions claimed in our foreign issued patents or pending patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are numerous recent changes to the patent laws and proposed changes to the rules of the United States Patent and Trademark Office (&#8220;USPTO&#8221;),
which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example,
in September 2011, the U.S. enacted sweeping changes to the U.S. patent system under the Leahy-Smith America Invents Act, including changes
that transitioned the U.S. from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system and alter the processes
for challenging issued patents. These changes could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents. In addition, we may become subject to interference proceedings conducted in the
patent and trademark offices of various countries to determine our entitlement to patents, and these proceedings may conclude that other
patents or patent applications have priority over our patents or patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that a competitor may successfully challenge our patents through various proceedings and those challenges may result
in the elimination or narrowing of our patents, and therefore reduce our patent protection. The patent prosecution process is expensive,
time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent
applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our
research and development output in time to obtain patent protection. We may not have the right to control the preparation, filing and
prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications
may not be prosecuted and enforced in a manner consistent with the best interests of our business. Any parties who enter into nondisclosure
or confidentiality agreements with us that have access to confidential or patentable aspects of our research and development output may
breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent
protection. In addition, rights under any of our issued patents, patent applications or future patents may not provide us with commercially
meaningful protection for our products or afford us a commercial advantage against our competitors or their competitive products or processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing
on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition
among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar
to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential
trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations
of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade
names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our
business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain
names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources
and could adversely impact our financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
patents issued to us may not be broad enough to provide any meaningful protection, one or more of our competitors may develop more effective
technologies, designs or methods without infringing our intellectual property rights and one or more of our competitors may design around
our proprietary technologies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to protect our proprietary technology, trade secrets and know-how, our competitors may use our inventions to develop
competing products. Our patents may not protect us against our competitors, and patent litigation is very expensive. We may not have
sufficient cash available to pursue any patent litigation to its conclusion because we currently do not generate revenues other than
licensing, milestone and royalty income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot rely solely on our current patents to be successful. The standards that the USPTO and foreign patent office&#8217;s use to grant
patents, and the standards that U.S. and foreign courts use to interpret patents, are not the same, are not always applied predictably
or uniformly and can change, particularly as new technologies develop. As such, the degree of patent protection obtained in the U.S.
may differ substantially from that obtained in various foreign countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain of the level of protection, if any, that will be provided by our patents if they are challenged in court, where our
competitors may raise defenses such as invalidity, unenforceability, or possession of a valid license. In addition, the type and extent
of any patent claims that may be issued to us in the future are uncertain. Any patents that are issued may not contain claims that will
permit us to stop competitors from using similar technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may challenge the validity, inventorship or ownership of our patents and other intellectual property rights, resulting in costly
litigation or other time-consuming and expensive proceedings, which could deprive us of valuable rights. If we become involved in any
intellectual property litigation, interference or other judicial or administrative proceedings, we will incur substantial expenses and
the attention of our technical and management personnel will be diverted. An adverse determination may subject us to significant liabilities
or require us to seek licenses that may not be available from third parties on commercially favorable terms, if at all. Further, if such
claims are proven valid, through litigation or otherwise, we may be required under applicable law to <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay
substantial monetary damages, which can be tripled if the infringement is deemed willful, or be required to discontinue or significantly
delay development, marketing, selling and licensing of the affected products and intellectual property rights.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application
may have priority over our patent applications and could further require us to obtain rights to issued patents covering such technologies.
There may be third-party patents, patent applications and other intellectual property relevant to our potential products that may block
or compete with our potential products or processes. If another party has filed a U.S. patent application on inventions similar to ours,
we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the U.S. The costs
of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our U.S.
patent position with respect to such inventions. In addition, we cannot assure you that we would prevail in any of these suits or that
the damages or other remedies that we are ordered to pay, if any, would not be substantial. Claims of intellectual property infringement,
misappropriation or other violations against us may require us to enter into royalty or license agreements with third parties that may
not be available on acceptable terms, if at all. We may also be subject to injunctions against the further development and use of our
technology, which could materially adversely affect our business, prospects and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially
greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could materially adversely
affect our ability to raise the funds necessary to continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime
of the patent. In the United States, patents have a limited lifespan, and if all maintenance fees are timely paid, the natural expiration
of a patent is generally 20-years from its earliest U.S. non-provisional filing date. The USPTO and various foreign governmental patent
agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application
process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by
other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of
the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance
events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond
to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents.
In certain circumstances, even inadvertent noncompliance events may permanently and irrevocably jeopardize patent rights. In such an
event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such
agreements, our business could be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we
would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license
such technology, on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may
be unable to develop or commercialize the affected product candidates, which could materially harm our business, and the third parties
owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation
on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, agreements we may enter into
in the future, if any, may not provide exclusive rights to use certain intellectual property and technology retained by the collaborator
in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in
the future. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive
products that utilize technology retained by such collaborators to the extent such products are not also covered by our intellectual
property. In such an event, our business, financial condition, results of operations, and growth prospects could be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on confidentiality agreements to protect our trade secrets. If these agreements are breached by our employees or other parties,
our trade secrets may become known to our competitors. We may also be subject to claims that our employees, consultants, or advisors
have wrongfully used or disclosed alleged trade secrets or claims asserting ownership of what we regard as our own intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secrets that we seek to protect through confidentiality agreements with our employees and other parties. If these agreements
are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. We may not have any remedies
against our competitors and any remedies that may be available to us may not be adequate to protect our business or compensate us for
the damaging disclosure. In addition, we may have to expend resources to protect our interests from possible infringement by others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how
of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property,
including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be
necessary to defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>An
active trading market for our common stock may not be sustained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the closing of our IPO in August 2021, there was no public trading market for our common stock. Although our common stock is listed
on the Nasdaq Capital Market, the market for our shares has demonstrated varying levels of trading activity. Our ability to raise capital
to continue to fund operations by selling shares of our common stock and our ability to acquire other companies or technologies by using
shares of our common stock as consideration may be impaired if an active trading market for our common stock is not sustained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock is likely to be highly volatile and may be subject to wide fluctuations in response to a variety of
factors, some of which are beyond our control. These factors include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            delay in the commencement, enrollment and ultimate completion of our clinical trials; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            delay in submitting an NDA and any adverse development or perceived adverse development with
                                            respect to the FDA&#8217;s review of that NDA; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to successfully develop and commercialize RenovoGem; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                            to obtain additional funding; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            or legal developments in the United States and other countries applicable to RenovoGem or
                                            any other product candidate;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
                                            regulatory decisions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the structure of healthcare payment systems;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                            to obtain adequate product supply for RenovoGem, RenovoCath or any other product candidate,
                                            or the inability to do so at acceptable prices; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
                                            of new products, services or technologies by our competitors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to meet or exceed financial projections we provide to the public;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to meet or exceed the estimates and projections of the investment community;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the market valuations of companies similar to ours;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
                                            conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed
                                            securities analysts&#8217; reports or recommendations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            of significant acquisitions, strategic collaborations, joint ventures or capital commitments
                                            by us or our competitors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            lawsuits, including patent or stockholder litigation, and disputes or other developments
                                            relating to our proprietary rights, including patents, litigation matters and our ability
                                            to obtain patent protection for our technologies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
                                            or departures of key scientific or management personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                            of our common stock or other securities by us, our insiders or our other stockholders;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration
                                            of market standoff or lock-up agreements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
                                            volume of our common stock;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
                                            in interest rates and inflation rates; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic, industry and market conditions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">health
                                            epidemics and outbreaks, including the COVID-19 pandemic, or other natural or manmade disasters
                                            which could significantly disrupt our preclinical studies and clinical trials, and therefore
                                            our receipt of necessary regulatory approvals could be delayed or prevented; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market
prices of equity securities of many companies. These fluctuations have often been unrelated or disproportionate to the operating performance
of those companies. Broad market and industry factors, as well as general economic, political, regulatory and market conditions, may
negatively affect the market price of our common stock, regardless of our actual operating performance. In particular, stock markets
have experienced extreme volatility due to the ongoing COVID-19 pandemic, including the emergence of new variants; recent inflationary
concerns; and investor concerns and uncertainty related to the impact of the pandemic on the economies of countries worldwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our
product candidates on unfavorable terms to us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources,
including up-front payments and milestone payments from strategic collaborations. For example, we have filed an omnibus shelf registration
statement on Form S-3 that provides for aggregate offerings of up to $50.0 million of the Company&#8217;s securities subject to various
limitations, including limited sales in any twelve-month period while we are subject to the &#8220;baby-shelf&#8221; rules. We also have
filed a registration statement on Form S-1 to register the cash exercise of our outstanding warrants, with such cash exercise only expected
to occur when the trading price of our common stock is in excess of the $10.80 per share exercise price of our outstanding warrants.
To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest
will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such
financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations or other restrictions
that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations
with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable
to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe
we have sufficient funds for our current or future operating plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Nasdaq Stock Market may delist our securities from its exchange, which could limit investors&#8217; ability to make transactions in our
securities and subject us to additional trading restrictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market. We cannot assure you that, in the future, our securities will meet the continued
listing requirements to be listed on the Nasdaq Capital Market. If the Nasdaq Stock Market delists our common stock, we could face significant
material adverse consequences, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            limited availability of market quotations for our securities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            determination that our common stock is a &#8220;penny stock&#8221; which will require brokers
                                            trading in our common stock to adhere to more stringent rules and possibly resulting in a
                                            reduced level of trading activity in the secondary trading market for our common stock;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            limited amount of news and analyst coverage for our Company; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could be subject to securities class action litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class action and derivative litigation has often been brought against companies following a decline in the market
price of their securities or upon the occurrence of other corporate events. This risk is especially relevant for us because biotechnology
companies have experienced significant share price volatility in recent years. If we face such litigation, it could result in substantial
costs, for which we are not insured, and a diversion of management&#8217;s attention and resources, which could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market
price for the shares and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us
or our business. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may
provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of
our common stock could decline substantially. If one or more of the analysts who cover us downgrades our common stock or publishes inaccurate
or unfavorable research about our business, the market price for our common stock would likely decline. If one or more of these analysts
cease coverage of our Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in
turn, could cause the market price or trading volume for our common stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect to pay dividends in the foreseeable future, and you must rely on price appreciation of your shares for return on your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have paid no cash dividends on any class of our stock to date and we do not anticipate paying cash dividends in the near term. For the
foreseeable future, we intend to retain any earnings to finance the development and expansion of our business, and we do not anticipate
paying any cash dividends on our stock. Accordingly, investors must be prepared to rely on sales of their shares of common stock after
price appreciation to earn an investment return, which may never occur. Investors seeking cash dividends should not purchase our shares
of common stock. Any determination to pay dividends in the future will be made at the discretion of our board of directors and will depend
on our results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors
our board deems relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted
and will continue to devote substantial time to new compliance initiatives and corporate governance practices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we have incurred and particularly after we no longer qualify as an emerging growth company, we will continue to incur
significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;),
the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules
and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective
disclosure and financial controls and corporate governance practices. Our management and other personnel will need to continue to devote
a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial
compliance costs and have made some activities more time-consuming and costly. For example, we expect that these rules and regulations
may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for
us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules and regulations
are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is
provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs
necessitated by ongoing revisions to disclosure and governance practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 404 of SOX (&#8220;Section 404&#8221;), we will be required to furnish a report by our senior management on our internal control
over financial reporting beginning with our second filing of an Annual Report on Form 10-K with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial
reporting issued by our independent registered public accounting firm. To prepare for eventual compliance with Section 404, once we no
longer qualify as an emerging growth company, we will be engaged in a process to document and evaluate our internal control over financial
reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially
engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting,
continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and
implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is
a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting
is effective as required by Section 404.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have identified material weaknesses in our internal control over financial reporting. Failure to maintain effective internal controls
could cause our investors to lose confidence in us and adversely affect the market price of our common stock. If our internal controls
are not effective, we may not be able to accurately report our financial results or prevent fraud.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. In
connection with the audit of our financial statements as of and for the years ended December 31, 2022, 2021, 2020 and 2019, we
identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. Specifically, we
determined that we lacked a sufficient number of qualified accounting and financial reporting personnel with an appropriate level of
knowledge, training and experience to address complex accounting issues, sufficient written policies and procedures for accounting
and financial reporting in <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accordance with U.S. Generally
Accepted Accounting Principles (&#8220;GAAP&#8221;), and adequate management review controls. In addition, we determined that our
financial statement close process includes significant control gaps mainly driven by the small size of our accounting and finance
staff and, as a result, a significant lack of appropriate segregation of duties.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above material weaknesses could result in a misstatement of our account balances or disclosures that would result in a material misstatement
of our annual or interim financial statements that would not be prevented or detected. To address the material weaknesses, we have implemented,
and are continuing to implement, measures designed to improve internal control over financial reporting, including expanding our accounting
and finance team to add additional qualified accounting and finance resources, which may include third party consultants, and new financial
processes. We intend to continue to take steps to remediate the material weaknesses through the hiring or engagement of additional experienced
accounting and financial reporting personnel, formalizing documentation of policies and procedures and further evolving the accounting
processes, including implementing appropriate segregation of duties. We expect to incur additional costs to remediate these weaknesses,
including personnel, consulting and other costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be successful in implementing these changes or in developing other internal controls, which may undermine our ability to provide
accurate, timely and reliable reports on our financial and operating results. Further, we will not be able to fully assess whether the
steps we are taking will remediate the material weakness in our internal control over financial reporting until we have completed our
implementation efforts and sufficient time passes in order to evaluate their effectiveness. In addition, until we remediate these weaknesses,
or if we identify additional material weaknesses in our internal control over financial reporting, we may not detect errors on a timely
basis and our financial statements may be materially misstated. Moreover, in the future we may engage in business transactions, such
as acquisitions, reorganizations or implementation of new information systems that could negatively affect our internal control over
financial reporting and result in material weaknesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we identify new material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements
of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to assert that our internal control over financial reporting
is effective, we may be late with the filing of our periodic reports, investors may lose confidence in the accuracy and completeness
of our financial reports, and the market price of our common stock could be negatively affected. As a result of such failures, we could
also become subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities,
and become subject to litigation from investors and stockholders, which could harm our reputation, financial condition or divert financial
and management resources from our core business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a public company, we maintain disclosure controls and procedures that
are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized,
and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated, communicated
and discussed with our management, including our Chief Executive Officer and Chief Financial Officer or persons performing similar functions,
as appropriate, to allow timely decisions regarding required disclosure. We believe that any disclosure controls and procedures or internal
controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the desired
control objectives will be met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In reaching a reasonable level of assurance, management
has weighed the cost of contemplated controls against their intended benefits. The design of any system of controls is based on management&#8217;s
assumptions about the likelihood of future events. We cannot assure you that our controls will achieve their stated goals under all possible
conditions. Changes in future conditions may render our controls inadequate or may cause our degree of compliance with them to deteriorate.
These inherent limitations include the fact that judgments in decision-making can be faulty and that breakdowns can occur because of simple
error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people
or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements
due to error or fraud may occur and not be detected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Under the supervision and with the participation
of our management, including our Chief Executive Officer and Chief Financial and Accounting Officer, we conducted an evaluation of the
effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the
end of the year ended December 31, 2022. Based on this evaluation, our Chief Executive Officer and Chief Financial and Accounting Officer
have concluded that, during the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were not effective
due to our previously identified material weaknesses in internal control over financial reporting. As a result, we have performed additional
analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. GAAP. Accordingly, notwithstanding
the identified material weaknesses, management, including our Chief Executive Officer and Chief Financial and Accounting Officer, believes
the financial statements included in this Annual Report on Form 10-K are fairly presented, in all material respects, in accordance with
U.S. GAAP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements applicable to emerging growth companies may make
our common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS
Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor
attestation requirements of Section 404; the ability to delay the implementation of new or revised financial accounting standards; reduced
disclosure obligations regarding executive compensation; and exemptions from the requirements of holding a nonbinding advisory vote on
executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information
we provide stockholders will be different than the information that is available with respect to other public companies. We will remain
an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing
of our IPO, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated
filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the end of our prior second
fiscal quarter, or (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards until such time as those
standards apply to private companies. We may elect not to avail ourselves of this exemption from new or revised accounting standards
and, therefore, may be subject to the same new or revised accounting standards as other public companies that are not emerging growth
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find
our common stock less attractive as a result of these exemptions, there may be a less active trading market for our common stock and
our share price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation, bylaws and Delaware law contain provisions that could have the effect of rendering more difficult, delaying
or preventing an acquisition deemed undesirable by our board of directors. Our corporate governance documents include provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing
                                            &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors
                                            without stockholder approval and may contain voting, liquidation, dividend, and other rights
                                            superior to our common stock;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
                                            the liability of, and providing indemnification to, our directors and officers;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
                                            the ability of our stockholders to call and bring business before special meetings; </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
                                            advance notice of stockholder proposals for business to be conducted at meetings of our stockholders
                                            and for nominations of candidates for election to our board of directors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlling
                                            the procedures for the conduct and scheduling of board of directors and stockholder meetings;
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
                                            our board of directors with the express power to postpone previously scheduled annual meetings
                                            and to cancel previously scheduled special meetings.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation
law, which prevents some stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations
without approval of the holders of substantially all of our outstanding common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or deterring a change in control
could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the
price that some investors are willing to pay for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
certificate of incorporation, as amended, designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for
certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability
to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation requires that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery
of the State of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for each of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            derivative action or proceeding brought on our behalf;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            action asserting a claim for breach of any fiduciary duty owed by any director, officer or
                                            other employee of ours to the Company or our stockholders, creditors or other constituents;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            action asserting a claim against us or any director or officer of ours arising pursuant to,
                                            or a claim against us or any of our directors or officers, with respect to the interpretation
                                            or application of any provision of, the DGCL, our certificate of incorporation or bylaws;
                                            or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            action asserting a claim governed by the internal affairs doctrine;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided,
that, if and only if the Court of Chancery of the State of Delaware dismisses any of the foregoing actions for lack of subject matter
jurisdiction, any such action or actions may be brought in another state court sitting in the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exclusive forum provision is limited to the extent permitted by law, and it will not apply to claims arising under the Securities Exchange
Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or for any other federal securities laws which provide for exclusive federal
jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly,
both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions
and the threat of inconsistent or contrary rulings by different courts, among other considerations, our second amended and restated certificate
of incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving
any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice
of forum provisions are facially valid, a stockholder may nevertheless seek to bring such a claim arising under the Securities Act against
us, our directors, officers, or other employees in a venue other than in the federal district courts of the United States of America.
In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our second
amended and restated certificate of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits
to which it applies, this provision may limit or discourage a stockholder&#8217;s ability to bring a claim in a judicial forum that it
finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and
our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate
of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action
in other jurisdictions, which could adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
note that there is uncertainty as to whether a court would enforce the provision and that investors cannot waive compliance with the
federal securities laws and the rules and regulations thereunder. Although we believe this provision benefits us by providing increased
consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging
lawsuits against our directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_003"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_004"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
administrative headquarters is located at 4546 El Camino Real, Suite B1, Los Altos, CA 94022. The office space is approximately 1,480
square feet, and we rent on a month-to-month basis. We believe that our facility is adequate for our current operations
and purposes, and that suitable additional or alternative space will be available in the future on commercially reasonable terms, if
required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_005"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be involved in various legal actions, including claims and proceedings arising in the ordinary course of business.
We are currently not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in
the aggregate, would have a material adverse effect on our results of operations or financial position, and, to the best of management&#8217;s
knowledge, no such litigation is currently pending or threatened.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative
publicity, reputational harm and other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_006"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_007"></span>ITEM
5</b>. <b>MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information for Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is publicly traded on the Nasdaq Capital Market under the symbol &#8220;RNXT.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders
of Record of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 24, 2023, there were approximately 120 holders of record of our common stock. The actual number of stockholders is greater than
this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers
and other nominees. As of such date, there were 9,100,448 shares of our common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not declared or paid any cash dividends on our common stock since our inception. We currently intend to retain all available funds
and any future earnings to support our operations and finance the growth and development of our business, and do not anticipate paying
any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion
of our Board of Directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements,
contractual restrictions, business prospects and other factors our Board of Directors may deem relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding our securities authorized for issuance under equity compensation plans will be included in Item 12, &#8220;Security Ownership
of Certain Beneficial Owners and Management and Related Stockholder Matters,&#8221; of this report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Proceeds from Public Offering of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus
filed with the SEC on August 27, 2021, pursuant to Rule 424(b)(4). We placed the
funds received into a money market account. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to
their associates, or to our affiliates, other than payments in the ordinary course of business to officers for salaries and to non-employee
directors pursuant to our Outside Director Compensation Policy, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_008"></span>ITEM
6. [RESERVED]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_009"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unless
the context otherwise requires, all references in this section to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;
refer to RenovoRx, Inc. You should read the following discussion and analysis of our financial condition and results of operations should
be read in conjunction with the financial statements and related notes thereto included in Part II, Item 8, &#8220;Financial Statements
and Supplementary Data,&#8221; of this Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere
in this Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements
that involves risks and uncertainties. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221;
for a discussion of forward-looking statements and important factors that could cause actual results to differ materially from the results
described in or implied by the forward-looking statements. All information presented herein is based on our fiscal calendar. Unless otherwise
stated, references to particular years, quarters, months or periods refer to our fiscal years ended December 31 and the associated quarters,
months and periods of those fiscal years.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934, as amended, that reflect our plans, estimates, and beliefs that involve risks and uncertainties, including those
described in the section titled &#8220;Forward Looking Statements.&#8221; Our actual results and the timing of selected events could
differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited
to, those identified below and those set forth under the section titled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors. We are currently
conducting a Phase III registrational trial for our lead product candidate RenovoGem&#8482;. Our therapy platform, RenovoRx Trans-Arterial
Micro-Perfusion, or RenovoTAMP&#8482;<sup>&#174;</sup>, utilizes approved chemotherapeutics with validated mechanisms of action and well-established
safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window
by combining such chemotherapeutics with our proprietary drug delivery system. RenovoTAMP combines our patented Food and Drug Administration
(&#8220;FDA&#8221;) cleared delivery system, RenovoCath<sup>&#174;</sup>, with small molecule chemotherapeutic agents that can be forced
across the vessel wall using pressure, targeting these anti-cancer drugs locally to the solid tumors. While we anticipate investigating
other chemotherapeutic agents for intra-arterial delivery via RenovoTAMP, our clinical work to date has focused on gemcitabine, which
is a generic small molecule drug. Our first product candidate, RenovoGem, is a drug /device combination consisting of intra-arterial
gemcitabine and RenovoCath. FDA has determined that RenovoGem will be regulated as, and if approved we expect will be reimbursed as,
a new oncology drug product. We have secured FDA Orphan Drug Designation for RenovoGem in two
indications: pancreatic cancer and cholangiocarcinoma (bile duct cancer, or CCA). We have completed our RR1 Phase I/II and RR2 observational
registry studies, with 20 and 25 patients respectively, in locally advanced pancreatic cancer, or LAPC. These studies demonstrated a
median overall survival of 27.9 months from diagnosis in patients pre-treated with radiation followed by treatment with RenovoGem. Based
on previous large randomized clinical trials, the expected survival of LAPC patients is 12 - 15 months in patients receiving only intravenous
(IV) systemic chemotherapy or IV chemotherapy plus radiation (which are both considered standard of care). Unlike the randomized trials
that established these standard-of-care results, our RR1 and RR2 clinical trials did not prospectively control the standard of care therapy
received prior to administration of RenovoGem. Based on an FDA safety review of our Phase I/II study, FDA allowed us to proceed to evaluate
RenovoGem within our Phase III registrational clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed, in December 2021 we amended the protocol for this clinical trial to only allow for stereotactic body radiation
therapy (SBRT) during the induction phase of the study (prior to randomization). We had previously permitted both SBRT and
intensity-modulated radiation therapy (IMRT). Patients receiving IMRT must complete 25 radiation treatments in combination with oral
chemotherapy during the induction phase of the study, which takes between 35 and 56 days to complete. In comparison, patients
receiving SBRT during the induction phase are only required to complete 5 treatments, over 5 consecutive days, and do not receive
oral chemotherapy. The decision to modify the study population was based on the observation in the Phase III TIGeR-PaC study that
IMRT patients had a higher dropout rate during the induction phase of the study due to the high frequency of hospital visits and
side effects from the required concurrent chemotherapy. As part of the pre-randomization, induction phase change made to the
protocol, we initiated a review of the statistical considerations for the study and in June 2022, submitted a modified Statistical
Analysis Plan (the &#8220;Modified SAP&#8221;) to FDA. As part of the Modified SAP, we now plan to (i) analyze only patients
receiving SBRT, consistent with the protocol change made in December 2021, (ii) include a second interim analysis, (iii) change the
total number of SBRT patients randomized in the study to 114 (a reduction from the original 200 patients) with a total of 86 deaths
from SBRT patients, including all deaths from SBRT patients enrolled in the study before the submission of the Modified SAP, and
(iv) repower the study from 90% to 80%, which is commonly used in clinical trials. We believe these changes will shorten the
timeframe needed to complete the study and also significantly decrease our costs. We have not discussed the protocol amendment or
the Modified SAP with the FDA, and we cannot provide any assurance that the FDA will agree with these modifications. The first
planned interim analysis was triggered when 30%, or 26 of 86, of the total number of deaths occurred (and announced in March 2023),
and the second interim analysis at 60%, or 52 of 86, of the total number of deaths have occurred and is estimated to be mid-2024. Given that the timing of the
interim analysis is predicated on a specific number of deaths, it is difficult to predict the exact timing of the interim analysis
or when we will be able to complete the study. As of March 20, 2023, the Phase III TIGeR-PaC trial has randomized 48 SBRT patients
out of 114 total needed under the Modified SAP. At this rate, we anticipate that all patients will be enrolled and randomized in
2024, with the final study readout in 2025. We submitted a protocol amendment to FDA in the fourth quarter of 2022 to reflect
the changes in the Modified SAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also planning to evaluate RenovoGem in a second indication in a Phase II/III trial in extrahepatic (or outside the liver) cholangiocarcinoma
(or eCCA), cancer that occurs in the bile ducts that lead out of the liver and join with the gallbladder. After significant input from
key opinion leaders across the spectrum of relevant medical specialties and feedback from the FDA, we submitted the protocol for a Phase
II/III eCCA clinical trial to FDA. If FDA does not object to our study protocol, we anticipate launching the eCCA trial and enrolling
the first patient this year. In addition, we may evaluate RenovoGem in other indications, potentially including locally
advanced lung cancer, locally advanced uterine tumors, and glioblastoma (an aggressive type of cancer that can occur in the brain or
spinal cord). To date, we are focused on developing drug/device candidates with gemcitabine, but in the future, we may develop other
product candidates with other chemotherapeutic agents for intra-arterial delivery via our RenovoTAMP therapy platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have devoted substantially all of our efforts to developing our cancer therapy platform and product candidates, raising
capital and organizing and staffing our Company. To date, we have financed our operations primarily through issuance of convertible preferred
stock with net proceeds of $11.8 million, convertible notes with net proceeds of $15.0 million, and a loan of $140,000 pursuant to the
Paycheck Protection Program (&#8220;PPP&#8221;) under the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;),
which was forgiven in February 2021. In August 2021, we completed our IPO with aggregate gross proceeds of $16.7 million. We paid underwriting
discounts and commissions of $1.3 million, and incurred expenses of $0.8 million in <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">connection
with the offering. As a result, the net offering proceeds to us, after deducting underwriting discounts and commissions and offering
expenses were $14.6 million.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred significant operating losses and generated negative cash flows from operations since our inception. As of December 31,
2022, we had cash, cash equivalents and short-term marketable securities of $6.4 million. We had net losses of $9.9 million and $6.3
million for the years ended December 31, 2022, and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $31.2
million. We expect to continue to incur significant expenses, increasing operating losses and negative cash flows for the foreseeable
future. We do not expect to generate revenues from product sales unless and until we successfully complete development and obtain regulatory
approval for one or more product candidates. We expect that our expenses will increase substantially in connection with our ongoing research
and development activities, particularly as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
                                            clinical development of RenovoGem and our platform technology by continuing to enroll patients
                                            in our ongoing Phase III TIGeR-PaC clinical trial, expanding the number of clinical trials
                                            including our planned clinical trial in HCCA, and advancing RenovoGem through preclinical
                                            and clinical development in additional indications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hire
                                            additional research, development, engineering, and general and administrative personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintain,
                                            expand, enforce, defend, and protect our intellectual property portfolio; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expand
                                            our operational, financial and management systems and increase personnel, including personnel
                                            to support our clinical development, manufacturing and commercialization efforts and our
                                            operations as a public company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the variables described above, if and when any of our product candidates successfully complete development, we will incur
substantial additional costs associated with establishing a sales, marketing, medical affairs and distribution infrastructure to commercialize
products for which we may obtain marketing approval, regulatory filings, marketing approval, and post-marketing requirements, in addition
to other commercial costs. We cannot reasonably estimate these costs at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to our recurring operating losses and the expectation that we will continue to incur net losses in the future, we will be required to
raise additional capital to complete the development and commercialization of our product candidates. We have historically financed our
operations primarily through private sales of our equity, debt financing and the sale of common stock and warrants in our initial public
offering, or IPO. To raise additional capital, we may seek to sell additional equity and/or debt securities, obtain a credit facility
or other loan or enter into collaborations, licenses or other similar arrangements, which we may not be able to do on favorable terms,
or at all. For example, we have filed an omnibus shelf registration statement on Form S-3 that provides for aggregate offerings of up
to $50.0 million of the Company&#8217;s securities subject to various limitations, including limited sales in any twelve-month period
while we are subject to the &#8220;baby-shelf&#8221; rules. We also have filed a registration statement on Form S-1 to register the cash
exercise of our outstanding warrants, with such cash exercise only expected to occur when the trading price of our common stock is in
excess of the $10.80 per share exercise price of our outstanding warrants. Our ability to obtain additional financing will be subject
to a number of factors, including market conditions, fluctuations in interest rates, our operating performance and investor sentiment.
If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or
discontinue the development and/or commercialization of our product candidates, restrict or cease our operations or obtain funds by entering
into agreements on unfavorable terms. Failure to obtain additional capital on acceptable terms, or at all, would result in a material
and adverse impact on our operations. As a result, there is substantial doubt about our ability to operate as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements as of December 31, 2022 have been prepared on a going concern basis and do not include any adjustments that may
result from the outcome of this uncertainty. Based on our operating plans, we do not expect that our current cash and cash equivalents
as of December 31, 2022, will be sufficient to fund our operating, investing and financing cash flow needs till at least the third quarter
of fiscal year 2023, assuming our programs advance as currently contemplated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we will require significant additional funding to support our continuing operations. Until such time, if ever, as we can
generate substantial product revenue, we expect to finance our cash needs through private or public equity financings, debt
financings and collaborations, licenses or other similar arrangements. <span>We currently have no credit facility or committed
sources of capital. </span>To the extent that we raise additional capital through the future sale of equity or debt, the ownership
interests of our stockholders will be diluted and the terms of these securities may include liquidation or other preferences that
adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt
securities, these securities could contain covenants that would restrict our operations. We may require additional capital beyond
our currently anticipated amounts and additional capital may not be available on reasonable terms, or at all. If we raise additional
funds through collaboration arrangements or other strategic transactions in the future, we may have to relinquish valuable rights to
our technologies or future revenue streams or grant licenses on terms that may not be favorable to us. If we are unable to raise
additional funds through private or public equity financings or debt financings when needed, we may be required to delay, limit,
reduce or terminate development or future commercialization efforts, and we may be unable to continue as a going concern. If we are
unable to continue as a going concern, we might have to liquidate our assets and the value we receive for our assets in liquidation
or dissolution could be significantly lower than the values reflected in our financial statements, and our shareholders may lose
their entire investment in our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
of COVID-19</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ongoing COVID-19 global and national health emergency has caused significant disruption in the international
and U.S. economies and financial markets. The continued spread of COVID-19, and its variants, has caused illness, quarantines, cancellation
of events and travel, business and school shutdowns, reduction in business activity and financial transactions, labor shortages, supply
chain interruptions and overall economic and financial market instability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to public health directives and orders and to help minimize the risk of the virus to employees, we have taken precautionary
measures, including implementing hybrid work policies for certain employees. The ongoing COVID-19 global pandemic also has negatively
affected, and we expect will continue to negatively affect, our clinical studies. For example, we have faced challenges in conducting
our clinical trials, including recruiting subjects and accommodating patient visits. Additionally, our service providers and their operations
may be disrupted, temporarily closed or experience worker or supply shortages, which could result in additional disruptions or delays
in shipments of purchased materials or the continued development of our product candidates. To date, we have not suffered material supply
chain disruptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not able to estimate the duration of the pandemic and the potential impact on our business. As the COVID-19 global pandemic continues
to evolve, it could result in significant long-term disruption of global financial markets, including a period of a rising rate of inflation,
reducing our ability to raise additional capital when needed and on acceptable terms, if at all, which could negatively affect our liquidity.
The extent to which the COVID-19 pandemic impacts our clinical development and regulatory efforts will depend on future developments
that are highly uncertain and cannot be predicted with confidence, such as the duration of the continued outbreak, new travel restrictions,
quarantines and social distancing requirements in the United States and other countries, business closures or business disruptions and
the effectiveness of actions taken in the United States and other countries to contain and treat the virus. We will continue to monitor
the COVID-19 situation closely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Our Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for several years,
if at all. If our development efforts for our current or future product candidates are successful and result in marketing approval or
collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or
payments from collaboration or license agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist of costs related to the research and development of our platform technology. Clinical trial costs
are a significant component of research and development expenses and include costs associated with third-party contractors and
consultants. We outsource a substantial portion of our clinical trial activities, utilizing the service of third-party clinical
trial sites and contract research organizations to assist us with the execution of our clinical trials. In addition, we have FDA
510(k) clearance for the RenovoCath delivery device, which comprises part of the RenovoGem product. Accordingly, we are able to
charge our clinical trial sites for the RenovoCath delivery device. To date, payments from clinical trial sites in consideration for
RenovoCath delivery devices have been adequate to cover our direct manufacturing costs. Any payments we receive from clinical trial
sites as consideration for use of RenovoCath delivery devices offset our research and development expenses. We expect our research
and development expenses to increase for the foreseeable future as we continue the development of our product candidates and enroll
subjects in our ongoing Phase III clinical trial, initiate new clinical trials and pursue regulatory approval of our product
candidates. It is difficult to predict with any certainty the duration and costs of completing our current or future clinical trials
of our product candidates or if, when or to what extent we will achieve regulatory approval and generate revenue from the
commercialization and sale of our product candidates. The duration, costs and timing of clinical trials and other development of our
product candidates will depend on a variety of factors, including uncertainties in clinical trial enrollment, timing and extent of
future clinical trials, development of new product candidates and significant and changing government regulation. We may never
succeed in achieving regulatory approval for any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
                                            incurred under agreements with clinical trial sites, contract research organizations, and
                                            consultants that are involved in conducting our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            of acquiring and developing clinical trial materials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel
                                            costs, including salaries, benefits, bonuses, and stock-based compensation for employees
                                            engaged in preclinical and clinical research and development;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            related to compliance with regulatory requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
                                            vendor costs related to manufacturing materials and testing;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            related to preclinical studies and pilot testing;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">travel
                                            expenses; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocated
                                            general and administrative expenses which includes facilities and other indirect administrative
                                            expenses to support research and development activities. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials and preclinical studies,
are recognized based on evaluation of progress to completion of specific tasks using data such as subject enrollment, clinical site activations
or information provided to us by third party vendors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the ongoing impact of the COVID-19 pandemic and work-from-home policies and other operational limitations mandated by federal, state,
and local governments as a result of the pandemic, certain of our research and development activities were delayed and may be further
delayed until we and our vendors return to pre-pandemic operations and capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of salaries, benefits, and stock-based compensation for personnel in executive, finance and administrative
functions, professional services and associated costs related to accounting, tax, audit, legal, intellectual property and other matters,
consulting costs, conferences, travel and allocated expenses for rent, insurance and other general overhead costs. We expect to continue
to incur additional expenses as a result of operating as a public company, including costs to comply with the rules and regulations of
the Securities and Exchange Commission, or SEC, and Nasdaq listing standards and increased expenses in the areas of insurance, professional
services and investor relations. As a result, we expect our general and administrative expenses to increase in the foreseeable future.
General and administrative expenses are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Income (Expenses), Net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Income (Expense) Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense consists of charges relating to the amortization of the debt discount and debt issuance costs as well as interest on prior amounts
outstanding on our convertible notes. In March 2020, we completed the offering of $3.0 million of convertible notes, the 2020 Convertible
Notes, that provided for the automatic conversion into shares of our common stock and warrants at the closing of our IPO at a 20% discount
to the public offering price of the units. In April 2021, we completed the offering of $2.0 million of convertible notes, the 2021 Convertible
Notes, that provided for the automatic conversion into shares of our common stock and warrants at the closing of our IPO at a 12.5% discount
to the public offering price of the units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is earned from cash deposited in our short-term marketable securities and money market account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income (Expense), Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income, net primarily represents the mark-to-market adjustment on the derivative liability resulting from the 2020 and 2021 Convertible
Notes. Upon the completion of our IPO in August 2021, the 2020 and 2021 Convertible Notes were converted into units consisting of (a)
one share of common stock and (b) one five-year warrant to purchase one share of common stock at an exercise price equal to $10.80 per
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gain
on Loan Extinguishment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gain on loan extinguishment for the year ended December 31, 2021 represents the loan extinguishment from the forgiveness and cancellation
of our loan pursuant to the Paycheck Protection Program (&#8220;PPP&#8221;) as well as the loss from the conversion and settlement of
our 2020 and 2021 Convertible Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Tax Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are recorded
based on the estimated future tax effects of differences between the financial statement and income tax basis of existing assets and
liabilities. Deferred income tax assets <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
liabilities are recorded net and classified as noncurrent on the balance sheets. A valuation allowance is provided against our deferred
income tax assets when their realization is more likely than not.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to income taxes in the federal and state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation
of the related tax laws and regulations and require significant judgment to apply. In accordance with the authoritative guidance on accounting
for uncertainty in income taxes, we recognize tax liabilities for uncertain tax positions when it is more likely than not that a tax
position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions
are measured based upon the largest amount of benefit that is more-likely-than-not (greater than 50%) of being realized upon settlement.
Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the CARES Act was enacted. The CARES Act includes several significant provisions for corporations, including the usage
of net operating losses, interest deductions and payroll benefits. Corporate taxpayers may carryback net operating losses, or NOLs, originating
during 2018 through 2020 for up to five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the Years Ended December 31, 2022 and 2021</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the significant components of&#160;our results of operations for the periods presented (in thousands, except
percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Increase /<br />
 (Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4,301</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,039</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,262</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">42</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,649</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,632</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,017</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,950</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,671</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,279</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,950</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,671</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,279</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(834</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">891</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(115</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Gain on loan extinguishment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(653</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">714</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,889</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,324</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,565</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(56</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our research and development expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Increase /<br />
 (Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Preclinical research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Clinical development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,548</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Personnel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">690</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Regulatory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">343</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Clinical site payments for RenovoCath devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(141</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(233</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total research and development</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,301</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,039</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,262</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $4.3 million for the year ended December 31, 2022, an increase of $1.3 million compared to $3.0
million for the year ended December 31, 2021. Preclinical research and development expense increased $1.0 million, which was
primarily due to an increase in allocated general and administrative support costs for personnel, facility and office supplies of
$0.4 million, a $0.2 million increase in costs associated with a secondary manufacturer for RenovoCath delivery devices, a $0.2
million increase for contracted research and development costs related to FDA compliance of our ongoing Phase III clinical trial
data, and a $0.2 million increase in the costs of other supplies and marketing expenses. Clinical development expense remained
unchanged from the prior year, including a $0.8 million increase in costs associated with consulting which was offset by a $0.8
million decrease in the Phase III clinical trial costs due to slower patient enrollment in the year, including the unwinding of the
European clinical study. Employee and related benefits expense increased $0.1 million year over year. Cash payments made for use of
RenovoCath delivery devices used in the Phase III clinical trial decreased by $0.1 million for the year ended December 31, 2022
compared to 2021 primarily due to slower enrollment of patients in the study To date, payments received from clinical trial sites
for the devices have been adequate to cover our direct costs of manufacturing the RenovoCath delivery devices and to offset research
and development expenses. We expect the costs of research and development to be higher next year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our general and administrative expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Increase /<br />
 (Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Professional services and other</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,166</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,364</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,802</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Personnel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,916</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">998</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">918</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Legal fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">567</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">270</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">297</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total general and administrative</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,649</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,632</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,017</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $5.6 million for the year ended December 31, 2022, an increase of $3.0 million compared to $2.6
million for the year ended December 31, 2021. The increase was primarily due to an increase in professional services and other
expense which included a $1.1 million increase in continuing post-IPO support from consulting and professional services, a $0.8
million increase in Directors and Officers Liability Insurance, and a $0.2 million increase in franchise tax fees, partially offset
by a $0.4 million increase in the allocation of general and administrative expenses to research and development. Employee and
related benefit expense increased $0.9 million primarily due to costs related to salaries and benefit expenses including the
addition of general and administrative personnel. Legal fees expense increased $0.3 million year over year, primarily due to our
ongoing transition to becoming a publicly traded company including other legal fees and regulatory filings. We expect general and
administrative expenses to be higher in the next fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
(Expense) Income, Net (in thousands)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Increase /<br />
 (Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Interest income (expense), net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">57</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(834</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">891</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income was $0.1 million for the year ended December 31, 2022, an increase of $0.9 million compared to interest (expense) of $0.8 million
for the year ended December 31, 2021. The increase in interest (expense) income, net was primarily due to the conversion of the 2020
and 2021 Convertible Notes upon the closing of the IPO, see &#8220;Note 6. Convertible Notes&#8221; in Notes to Financial Statements
in Item 15 of this Annual Report on Form 10-K. Interest expense includes both the stated interest on the 2020 and 2021 Convertible Notes
of 5% per annum, or $0.1 million, and the amortization of the discount and debt issuance costs associated with the 2020 and 2021 Convertible
Notes of $0.7 million in fiscal year 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income (Expense), Net (in thousands)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Increase /<br />
 (Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Other income (expense), net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">119</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(115</td><td style="width: 1%; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income, net was nil for the year ended December 31, 2022. Other income, net was $0.1 million for the year ended December 31, 2021, and
represents the mark-to-market adjustment on the derivative liabilities resulting from the 2020 and 2021 Convertible Notes. We do not
expect to incur significant income or expense in the next fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gain
on Loan Extinguishment (in thousands)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Increase /<br />
 (Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Gain on loan extinguishment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(62</td><td style="width: 1%; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gain on loan extinguishment was nil for the year ended December 31,2022. The gain on loan extinguishment was $0.1 million for the year ended December 31,
2021 represents a loss of $0.1 million on the automatic conversion of the 2020 and 2021 Convertible Notes upon completion of our
IPO, offset by the forgiveness and cancellation of our PPP loan of $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and December 31, 2021, our net losses were $9.9 million and $6.3 million, respectively. As of December
31, 2022, we had an accumulated deficit of $31.2 million. Our primary requirements for liquidity have been to fund our clinical trial
activity and general corporate and working capital needs. In August 2021, we completed our IPO and received aggregate gross proceeds
of $16.7 million. We paid underwriting discounts and commissions of $1.3 million, and we also incurred expenses of $0.8 million in connection
with the offering. As a result, the net offering proceeds to us, after deducting underwriting discounts and commissions and offering
expenses, were $14.6 million. In February 2021, we received notification and confirmation from Silicon Valley Bank that our PPP loan
of $140,000 was forgiven in its entirety and automatically cancelled by the U.S. Small Business Administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our operating plans, we do not expect that our current cash and cash equivalents as of December 31, 2022, will be sufficient to fund our
operating, investing and financing cash flow needs for at least the next twelve months, assuming our programs advance as currently contemplated.
Based upon this review and the Company&#8217;s current financial condition, the Company has concluded that substantial doubt exists as
to the Company&#8217;s ability to continue as a going concern. We believe we will be able to raise additional capital through debt financing,
private or public equity financings, license agreements, collaborative agreements or other arrangements with other companies, or other
sources of financing. There can be no assurance that such financing will be available or will be at terms acceptable to us. If we are
unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our clinical trials or other
operations. If any of these events occur, our ability to achieve our operational goals would be adversely affected. Our future capital
requirements and the adequacy of available funds will depend on many factors, including those described in the section titled &#8220;Risk
Factors.&#8221; Depending on the severity and direct impact of these factors on us, we may be unable to secure additional financing to
meet our operating requirements on commercially acceptable terms favorable to us, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed an omnibus shelf registration statement on Form S-3 that provides for the aggregate offerings of up to $50.0 million
of the Company&#8217;s securities subject to various limitations, including limited sales in any twelve-month period while the Company
is subject to the &#8220;baby-shelf&#8221; rules. The Company has also filed a registration statement on Form S-1 to register the cash
exercise of the Company&#8217;s outstanding IPO, underwriter and private warrants. Cash exercise of the outstanding warrants is only
expected to occur when the trading price of the Company&#8217;s common stock is in excess of the $10.80 per share exercise price of the
outstanding warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sources
of Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have not generated any revenue from product sales and we have incurred significant operating losses and negative cash
flows from operations. We anticipate that we will continue to incur net losses for the foreseeable future. We do not have any products
that have achieved regulatory marketing approval and we do not expect to generate revenue from sales of any product candidates for several
years, if ever.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have financed our operations primarily through the issuance and sale of convertible preferred stock and convertible debt. Through the
date of this report, we have raised an aggregate of $35.0 million from private placements of our convertible preferred stock, convertible
debt securities, the issuance of securities in our August 2021 IPO, and the exercise of warrants and common stock options. This amount
also includes a loan under the PPP, which was forgiven in February 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 30, 2023, we entered into a definitive securities purchase agreement under our shelf registration statement for the purchase
and sale of our common stock, including the issuance of pre-funded common stock warrants, for aggregate gross proceeds of
approximately $5 million before deducting placement fees and other offering expenses. See &#8220;Note 13. Subsequent Events&#8221;
in Notes to Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary uses of cash are to fund our operations including research and development and general and administrative expenses. We will continue
to incur operating losses in the future and expect that our research and development and general and administrative expenses will continue
to increase as we continue our research and development efforts with respect to clinical development of our product candidates and further
develop our platform. We have used a substantial portion of the net proceeds of the IPO, in combination with our existing cash and cash
equivalents, for these purposes and for the increased expenses associated with being a public company. Cash used to fund operating expenses
is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows for the periods indicated (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in) provided by:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(8,811</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(5,916</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,032</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,328</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,801</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,397</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Used in Operating Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the year ended December 31, 2022 reflected a net loss of $9.9 million adjusted for net change
in our operating assets and liabilities of $0.4 million and net non-cash charges of $0.6 million, consisting primarily of
stock-based compensation expense. Net cash used in operating activities for the year ended December 31, 2021 reflected a net loss of
$6.3 million adjusted for a net change in our operating assets and liabilities of $0.3 million, offset by net non-cash charges of
$0.7 million consisting primarily of amortization of a debt discount, gain/loss on loan/convertible debt extinguishments and
stock-based compensation expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Used in Investing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities for the year ended December 31, 2022 was $2.0 million consisted of purchases and proceeds of U.S. Treasury
bills, which are classified as available-for-sale securities. Net cash used in investing activities for the year ended December 31, 2021
was $15,000 consisted of capital expenditures made for leasehold improvements to our office space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Provided by Financing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing in the year ended December 31, 2022 was $42,000 consisted of exercise of stock options. Net cash provided
by financing in the year ended December 31, 2021 was $19.3 million, consisting of net proceeds of $14.6 million from the issuance of
common stock in our IPO, $2.0 million from the issuance of convertible notes and $2.8 million from the exercise of warrants and stock
options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations and Other Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have no contractual obligations or other commitments. In August 2021, the 2020 and 2021 Convertible Notes,
including accrued interest, of $5.3 million were converted to common shares upon the completion of our IPO. In February 2021, the Company
received notification and confirmation from Silicon Valley Bank that its PPP loan of $0.1 million, had been forgiven in its entirety
and automatically cancelled by the U.S. Small Business Administration. There have been no other significant changes in our contractual
obligations or other commitments as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our financial
statements and the related disclosures, which have been prepared in accordance with accounting principles generally accepted in the United
States, or GAAP. The preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the
reported amounts in our financial statements and accompanying notes. We base our estimates on historical experience and on various other
assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities that are not readily apparent from <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
sources. Actual results may differ from these estimates under different assumptions or conditions. To the extent that there are material
differences between these estimates and actual results, our future financial statement presentation, financial condition, results of
operations and cash flows will be affected. While our significant accounting policies are described in the notes to our financial statements
included elsewhere in this report, we believe that the following critical accounting policies are most important to understanding and
evaluating our reported financial results because they require us to make estimates, assumptions and judgments about matters that are
inherently uncertain.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management
to make difficult, subjective, or complex judgments that could have a material effect on our financial condition and results of operations.
Specifically, critical accounting estimates have the following attributes: (i) we are required to make assumptions about matters that
are highly uncertain at the time of the estimate&#894; and (ii) different estimates we could reasonably have used, or changes in the
estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make payments in connection with our Phase III clinical trial under contracts with clinical trial sites and contract research organizations
that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from
contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed
at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts depends
on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including
actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related
to patient enrollment or treatment are accrued when reasonably estimable. If the amounts we are obligated to pay under clinical trial
agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals
are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give
rise to the revision become reasonably certain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the fair value of stock options using the Black-Scholes option pricing model, which incorporates various assumptions including
those related to the fair value of our common stock, volatility, expected term, and risk-free interest rate. Compensation related to
service-based awards is recognized starting on the grant date on a straight-line basis over the vesting period, which is generally four
years, see &#8220;Note 8. Equity Inventive Plan &#8211; Stock-Based Compensation and Common Stock Warrants&#8221; in Notes to Financial
Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining
the grant date fair value of options using the Black-Scholes option pricing model requires management to make assumptions and judgments.
If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation for future awards may differ
materially compared with the awards granted previously. The assumptions and estimates are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Common Stock</i>&#8212;Given the absence of a public trading market, pre-IPO, our Board considered numerous objective and subjective
factors to determine the fair value of our common stock at each grant date. These factors included but were not limited to: (i) contemporaneous
third-party valuations of common stock; (ii) the prices for preferred stock sold to outside investors; (iii) the rights and preferences
of preferred stock relative to common stock; (iv) the lack of marketability of our common stock; (v) developments in the business; and
(vi) the likelihood of achieving a liquidity event, such as an IPO or sale of the business, given prevailing market conditions. The methodology
to determine the fair value of our common stock included estimating the fair value of the enterprise using the &#8220;backsolve&#8221;
method, which is a market approach that assigns an implied enterprise value by accounting for all share class rights and preferences
based on the latest round of financing. The total equity value implied was then applied in the context of an option pricing model to
determine the value of each class of our shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
grants issued post-IPO, we rely on the closing price of our common stock as reported on the date of grant to determine the fair value
of our common stock, as shares of our common stock are traded in the public market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. We determine the expected
term using the simplified method for pre-IPO and post-IPO awards. The simplified method deems the term to be the average of the time-to-vesting
and the contractual life of the options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>&#8212;Given the absence of a public trading market, pre-IPO and post IPO, the expected volatility was estimated by taking
the average historic price volatility for industry peers, consisting of several public companies in our industry that are either similar
in size, stage, or financial leverage, over a period equivalent to the expected term of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
Interest Rate</i>&#8212;The risk-free interest rate is calculated using the average of the published interest rates of U.S. Treasury
zero-coupon issues with maturities that are commensurate with the expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Rate</i>&#8212;The dividend yield assumption is zero as we have no plans to make dividend payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Instruments and Embedded Derivatives</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate all of our agreements to determine whether such instruments have derivatives or contain features that qualify as embedded derivatives.
We account for certain redemption features that are associated with the terms of convertible notes as liabilities at fair value and adjusts
the instruments to their fair value at the end of each reporting period. For derivative financial instruments that are accounted for
as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with
changes in the fair value reported in other income (expenses), net in the statements of operations. Derivative instrument liabilities
are classified in the balance sheets as current or non-current based on whether or not net-cash settlement of the derivative instrument
could be required within 12 months of the balance sheet date. Our derivative financial instruments were related to the 2020 and 2021
Convertible Notes, which contained certain redemptive features. On August 30, 2021, we completed our IPO which triggered the automatic
conversion of all outstanding Convertible Notes and accrued interest into shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging
Growth Company and Smaller Reporting Company Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act.
Under the JOBS Act, companies have extended transition periods available for complying with new or revised accounting standards. We have
elected this exemption to delay adopting new or revised accounting standards. We will remain an emerging growth company until the earlier
of (1) December 31, 2026, (2) the last day of the fiscal year in which we have total annual gross revenues of at least $1.07 billion,
(3) the date on which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, or
(4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. An
emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements
that are otherwise generally applicable to public companies. As an emerging growth company,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may present only two years of audited financial statements, plus unaudited condensed financial
                                            statements for any interim period, and related Management&#8217;s Discussion and Analysis
                                            of Financial Condition and Results of Operations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may avail ourselves of the exemption from the requirement to obtain an attestation and report
                                            from our auditors on the assessment of our internal control over financial reporting pursuant
                                            to the Sarbanes-Oxley Act;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may provide reduced disclosure about our executive compensation arrangements; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            do not require stockholder non-binding advisory votes on executive compensation or golden
                                            parachute arrangements.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to take advantage of certain of the reduced disclosure obligations in this Annual Report on Form 10-K and may elect to take
advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders
may be different than you might receive from other public reporting companies in which you hold equity interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates plus the proposed
aggregate amount of gross proceeds to us as a result of this offering is less than $700.0 million and our annual revenue is less than
$100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (1) the market
value of our stock held by nonaffiliates is less than $250.0 million or (2) our annual revenue is less than $100.0 million during the
most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million. If we are a
smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present
only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, like emerging growth companies,
smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued and Adopted Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Note 2. Summary of Significant Accounting Policies&#8221; in Notes to Financial Statements, to our audited financial statements
included elsewhere in this Annual Report on Form 10-K for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_010"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disclosures in this section are not required because we qualify as a smaller reporting company under federal securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_011"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements and the report of our independent registered public accounting firm, as listed under Part IV, Item 15. &#8220;Exhibits
and Financial Statement Schedules,&#8221; are included as a separate section of this report beginning on page F-1 and are incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_012"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2021, our Board dismissed Frank, Rimerman + Co. LLP as the Company&#8217;s independent registered public accounting firm.
The report of Frank, Rimerman + Co. LLP on the Company&#8217;s financial statements for each of the fiscal years ended December 31, 2020,
and December 31, 2019, did not contain an adverse or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit
scope, or accounting principles, with the exception that the report dated May 12, 2021, contained an explanatory paragraph relating to
the Company&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the interim period from December 31, 2020 through December 7, 2021, there were
no &#8220;disagreements,&#8221; as that term is defined in Item 304(a)(1)(iv) of Regulation S-K, between the Company and Frank, Rimerman
+ Co. LLP on any matter of accounting principles or practices, financial statement disclosures or auditing scope or procedures, which
disagreements, if not resolved to the satisfaction of Frank, Rimerman + Co. LLP, would have caused Frank, Rimerman + Co. LLP to make
reference to the subject matter of the disagreement in its reports on the financial statements for such time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no &#8220;reportable events,&#8221; as that term is defined in Item 304(a)(1)(v) of Regulation S-K, during the interim period
from December 31, 2020 through December 7, 2021, except
for the existence of material weaknesses identified during Frank, Rimerman + Co. LLP&#8217;s audit of our financial statements for
the fiscal year ended December 31, 2020 related to (i) the Company&#8217;s control environment, in particular
that there was an insufficient number of qualified accounting and financial reporting personnel with an appropriate level of
knowledge, training and experience to address complex accounting issues and a lack of appropriate segregation of duties due to the
small size of the accounting and financing department, and (ii) management review controls, specifically that the Company did not
properly design or maintain effective controls over journal entry review and account reconciliation. These material weaknesses have
not yet been remediated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2021, the Company engaged Baker Tilly US, LLP (&#8220;Baker Tilly&#8221;) to serve as the Company&#8217;s independent registered
public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the interim period from December 31, 2020 through
December 7, 2021, neither the Company nor anyone acting on its behalf has consulted with Baker Tilly regarding (i) the application
of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be
rendered on the Company&#8217;s financial statements, and neither a written report nor oral advice was provided to the Company that
Baker Tilly concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or
financial reporting issue, (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of
Regulation S-K, or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_013"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>(a) Evaluation
of Disclosure Controls and Procedures</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial and Accounting
Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and
15d-15(e) under the Exchange Act) as of the end of the year ended December 31, 2022. Based on this evaluation, our Chief Executive Officer
and Chief Financial and Accounting Officer have concluded that, during the period covered by this Annual Report on Form 10-K, our disclosure
controls and procedures were not effective due to our previously identified material weaknesses in internal control over financial reporting.
As a result, we have performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance
with U.S. GAAP. Accordingly, notwithstanding the identified material weaknesses, management, including our Chief Executive Officer and
Chief Financial and Accounting Officer, believes the financial statements included in this Annual Report on Form 10-K are fairly presented,
in all material respects, in accordance with U.S. GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in our Exchange
Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and
that such information is accumulated, communicated and discussed with our management, including our Chief Executive Officer and Chief
Financial Officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Management
recognizes that controls and procedures, no matter how well designed and operated, can only provide reasonable, not absolute, assurance
the desired control objectives will be met. In reaching a reasonable level of assurance, management has weighed the cost of contemplated
controls against their intended benefits. The design of any system of controls is based on management&#8217;s assumptions about the likelihood
of future events. We cannot assure you that our controls will achieve their stated goals under all possible conditions. Changes in future
conditions may render our controls inadequate or may cause our degree of compliance with them to deteriorate. Because of the inherent
limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Management&#8217;s Report on Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparation for our IPO, we identified a material weakness in our internal control over financial reporting related to our control environment.
Specifically, we have determined that we have not maintained adequate formal accounting policies, processes and controls related to complex
transactions as a result of a lack of finance and accounting staff with the appropriate GAAP technical expertise needed to identify,
evaluate and account for complex and non-routine transactions. We also determined that we have not maintained sufficient staffing or
written policies and procedures for accounting and financial reporting, which contributed to the lack of a formalized process or controls
for management&#8217;s timely review and approval of financial information. More specifically, we have determined that our financial
statement close process includes significant control gaps mainly driven by the small size of our accounting and finance staff and, as
a result, a significant lack of appropriate segregation of duties. A material weakness is a deficiency, or combination of significant
deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the process of implementing a number of measures to address the material weaknesses that has been identified including: (i) engaging
additional accounting and financial reporting personnel with U.S. GAAP, and SEC reporting experience, (ii) developing, communicating
and implementing an accounting policy manual for our accounting and financial reporting personnel for recurring transactions and period-end
closing processes, and (iii) establishing effective monitoring and oversight controls for non-recurring and complex transactions to ensure
the accuracy and completeness of our financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
additional resources and procedures are designed to enable us to broaden the scope and quality of our internal review of underlying information
related to financial reporting and to formalize and enhance our internal control procedures. With the oversight of senior management
and our Audit Committee, we have begun taking steps and plan to take additional measures to remediate the underlying causes of the material
weaknesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to complete the implementation of our remediation plan during 2023. Although we believe that our remediation plan will improve
our internal control over financial reporting, additional time may be required to fully implement it and to make conclusions regarding
the effectiveness of our internal control over financial reporting. Our management will closely monitor and modify, as appropriate, the
remediation plan to eliminate the identified material weakness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or
an attestation report of the Company&#8217;s registered public accounting firm due to a transition period established by SEC rules&#160;for
newly public companies. For as long as we remain an emerging growth company under the JOBS Act, our independent registered public accounting
firm will not be required to attest to the effectiveness of our internal control over financial reporting. When we lose our status as
an emerging growth company and reach an accelerated filer threshold, our independent registered public accounting firm will be required
to attest to the effectiveness of our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
Changes in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
during the last fiscal quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_014"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_015"></span>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_016"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2023 Annual
Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on
Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_017"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2023 Annual
Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on
Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_018"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2023 Annual
Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on
Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_019"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2023 Annual
Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on
Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_020"></span>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2023 Annual Meeting
of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span id="Na_021"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a) The following documents are filed as part of this Annual Report on Form 10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. Financial Statements</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Statements for the Years Ended December 31, 2022 and 2021</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_001">Report
    of Independent Registered Public Accounting Firm</a> Baker Tilly US, LLP (PCAOB Firm ID <span id="xdx_901_edei--AuditorFirmId_c20220101__20221231_z2YUvRPUZQ74"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">23</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#fin_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Sheets</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#fin_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Operations and Comprehensive Loss</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#fin_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
    of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#fin_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Cash Flows</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#fin_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules have been omitted because the required information is not applicable or is not present in amounts sufficient
to require submission of the schedules, or because the information required is included in the financial statements and accompanying
notes included in this Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Exhibit Index&#8221; immediately preceding the signature page of this Form 10-K, which is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_022"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENOVORX,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated
    by Reference</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br />

    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">3.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221021705/ex3-1.htm" style="-sec-extract: exhibit">Sixth Amended and Restated Certificate of Incorporation of RenovoRx, Inc.</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">001-40738</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">3.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    31, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">3.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315222008080/ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of RenovoRx, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">10-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">001-40738</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">3.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    30, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Private Common Stock Warrant (related to the 2020 Convertible Notes and 2021 Convertible Notes)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221018772/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriter&#8217;s Warrant</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-258071</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    25, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221019398/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Agent Agreement (including the terms of the Warrants)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-258071</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    25, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221018772/ex4-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Stock Certificate evidencing the Shares of Common Stock</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-258071</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    25, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221018772/ex4-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Certificate</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-258071</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    25, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315222008080/ex4-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    30, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Investor Rights Agreement, dated as of April 18, 2018</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315222008080/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated 2021 Omnibus Equity Incentive Plan and Forms of Stock Option Grant Notice and Option Agreement</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    30, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-3.htm">Amended and Restated Outside Director Compensation Policy</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Filed herewith</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmatory Offer Letter, by and between RenovoRx, Inc. and Shaun Bagai, dated November 11, 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated January 1, 2018</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated November 11, 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315222008080/ex10-7.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated January 25, 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    30, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-7.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Shaun Bagai, effective as of November 11, 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., effective as of November 11, 2021 </span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221028585/ex10-9.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key Service Provider Incentive Compensation Plan</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221018772/ex10-7.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-258071</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    25, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12<sup>+</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315221017463/ex10-11.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master Supply Agreement, dated October 28, 2019, by and between Medical Murray, Inc. and RenovoRx, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-258071</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    25, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315222019760/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement by and between RenovoRx, Inc. and Danforth Advisors, LLC, dated April 25, 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    19, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315222026179/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Letter between RenovoRx, Inc. and Angela Gill Nelms</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    19, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15<sup>&#8224;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1574094/000149315222026179/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Control and Severance Agreement by and between RenovoRx, Inc. and Angela Gill Nelms, dated August 17, 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    19, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Baker Tilly US, LLP</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#Na_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page of this Form 10-K)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a).</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Principal Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a).</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Instance Document (the instance document does not appear on the Interactive Data File because its XBRL tags
    are embedded within the Inline XBRL document). </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in the Interactive Data Files submitted as Exhibit 101).</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;
Indicates management contract or compensatory plan or arrangement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+
Confidential portions of this Exhibit were redacted pursuant to Item 601(b)(2) of Regulation S-K and &#160;RenovoRx, Inc. agrees to furnish
supplementally to the Securities and Exchange Commission a copy of any redacted information or omitted schedule and/or exhibit upon request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed
with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report,
irrespective of any general incorporation language contained in such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_023"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENOVORX,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Shaun R. Bagai</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shaun
    R. Bagai</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief
    Executive Officer</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    James M. Ahlers</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    M. Ahlers</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief
    Financial Officer</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_024"></span>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Shaun R. Bagai and James M. Ahlers
as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and
in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and
to file the same, with all exhibits thereto and all documents in connection therewith, with the U.S. Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and
thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person,
hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or his or her or their substitute or substitutes,
may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 34.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 34.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer,
    Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shaun R. Bagai</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James M. Ahlers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of
    Directors </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ramtin Agah, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laurence J. Marton, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Una S. Ryan, O.B.E., Ph.D., D.Sc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirsten Angela Macfarlane</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Diamond</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and the Board of Directors of RenovoRx, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying balance sheets of
RenovoRx, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss,
convertible preferred stock and stockholders&#8217; equity, and cash flows for the years then ended, and the related notes to the financial
statements (collectively the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material
respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows
for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Substantial Doubt About
the Company&#8217;s Ability to Continue as a Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred
significant losses and negative cash flows from operations since its inception. The Company incurred a net loss of $9.9 million during
the year ended December 31, 2022, and reported an accumulated deficit of $31.2 million as of December 31, 2022. These matters raise substantial
doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and
management&#8217;s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_90D_edei--AuditorName_c20220101__20221231_zoyHnHEPY8z1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">Baker Tilly US, LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company&#8217;s auditor since
2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--AuditorLocation_c20220101__20221231_zsv0YpAzxNKc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Mountain
View, California</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 76; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_002"></span>RenovoRx,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>in
thousands, except share and per share amounts</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_pn3n3_z1s9DMLhIBs4" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_zw4t3iMw4crl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zrpGiyNPxRWl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of December 31,</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_z2QHCfJEp6he" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzDSp_zTuHptEaZ557" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,391</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,192</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--MarketableSecuritiesCurrent_i02I_maACzDSp_zVtXtRRNmSRd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short-term marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,049</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0059">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzDSp_zakzEulMM6Ka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">825</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,089</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrent_i02TI_mtACzDSp_maAz5Aj_z0tw9uzxV5Ec" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LeaseholdImprovementsGross_i01I_maAz5Aj_zJbTkkRDNiS2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0067">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Assets_i01TI_mtAz5Aj_zajTVaDw5jpd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total assets</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_i02I_maLzkw2_ztekIhtJTojd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">534</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">525</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLzkw2_zBz4THztbUjd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">413</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Liabilities_i01TI_mtLzkw2_maLASEzYb2_zrRJ4aA75Dbd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">938</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzYb2_zcO97j9loNo7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingencies (Note 7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0088">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible preferred stock and stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PreferredStockValue_i02I_maSEz6BG_zHHtlRA7VkPd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible preferred stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zuvAZuwar2Bb" title="Preferred stock, par value, per share"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zv5P1F7fM9Ok" title="Preferred stock, par value, per share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zs49dsrSC4Qi" title="Preferred stock, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zzNcnms5qxOd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized as of December 31, 2022 and 2021, respectively; <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_dc_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zAHcMdp4smU5" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z1wp9fg3wovg" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_dc_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zMrM6mhHAdK3" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zXu9Y8IjfBcl" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at December 31, 2022 and 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0094">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommonStockValue_i02I_maSEz6BG_z3iLPJotdWSf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock, $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zSskqbgYLsc8" title="Common stock, par value, per share"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_zUpGhKk3ldF4" title="Common stock, par value, per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zRmg0ARs0hZ6" title="Common Stock, Shares Authorized"><span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211231_zmgytmOvJIY4" title="Common Stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2022, and 2021, respectively; <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_z6eLMjQzUMe2" title="Common stock, shares, issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zMozHqNKFZE" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,097,701</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zk322vf7JFI3" title="Common stock, shares, issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zV47iEvsDGel" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,933,989</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2022, and 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maSEz6BG_zpjeCRHsPKGb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEz6BG_zjLNJp0la5Dh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0136">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEz6BG_zqYlk2KrPq8a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">31,173</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,284</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i02TI_maLASEzYb2_mtSEz6BG_zmFZlbVxhKd2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total convertible preferred stock and stockholders&#8217; equity</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,349</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzYb2_zvU4mC9ikZag" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total liabilities, convertible preferred stock and stockholders&#8217; equity</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_003"></span>RenovoRx,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations and Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>in
thousands, except share and per share amounts</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_pn3n3_zq6kn6glBJFd" summary="xdx: Statement - Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zLyKg8uFC5y3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zPUvdVVK7ATa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpensesAbstract_iB_zq8sRkVFzUK1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzRU7_zIp5Canbc9Nc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,301</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,039</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzRU7_zN6kYFgm8Zli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,649</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_mtCzRU7_msCzc4T_zfBvqGmz458f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,671</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_mtCzc4T_maCzpIw_zXVu9xasHGA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,950</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,671</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestIncomeExpenseNonoperatingNet_maCzgJG_maNIEzvZO_zVYIyjoT6tt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">834</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingIncomeExpense_maNIEzvZO_z2AhRbyzIss3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GainsLossesOnExtinguishmentOfDebt_maNIEzvZO_zS1GJOSRA1f3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on loan extinguishment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NonoperatingIncomeExpense_iT_mtNIEzvZO_maCzpIw_zW1l4vilW3tl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total other income (expenses), net</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">653</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iT_mtCzpIw_maCINOTzv9i_zJiTrwssRIod" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,889</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,324</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB_zNmenIcBkXS4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax_i01_maCINOTzv9i_zlnm8RZ5W0cj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Unrealized gain on marketable securities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0181">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_mtCINOTzv9i_zH4quhJj0P4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Comprehensive loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,872</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,324</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--EarningsPerShareBasic_pid_zJZAebffp8Lk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss per share, basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.09</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.21</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zVnxYIu2L65d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average shares of common stock outstanding, basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,051,726</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,217,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_004"></span>RenovoRx,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>in
thousands, except share amounts)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_114_pn3n3_zSW6HxGV8833" summary="xdx: Statement - Statements of Convertible Preferred Stock and Stockholders&apos; (Deficit) Equity" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--ConvertiblePreferredStockMember_zCWkHI8SUPRh" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zA3s3p4WX1ff" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zY9tPuxx8swb" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Capital</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z87asSMJLVL3" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Income</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_z49NJbcCtswh" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_z8pNNUhCcnca" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Convertible</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Preferred
                                            Stock</b></span></p></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional<br />
    Paid-In</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated
    Other Comprehensive</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Accumulated</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Stockholders&#8217;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Capital</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Income</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_437_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zkzpVaO0VL88" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance&#8212;December
    31, 2020</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ze04GI4B4Wfa" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,535,469</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,451</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXCOX7zIuQMe" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,233,139</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">303</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0195">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,960</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,656</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_zx5ZsKDcgMed" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion
    of convertible preferred stock to common stock upon initial public offering</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_pid_uShares_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zIHkoX2cdLz1" title="Conversion of convertible preferred stock to common stock upon initial public offering, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="RNXT:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,535,469</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,451</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdj7UjpisQkl" title="Conversion of convertible preferred stock to common stock upon initial public offering, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="RNXT:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,535,469</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0204">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,451</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0206">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0207">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,451</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_z4XQEeWYFJr6" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion
    of convertible notes and accrued interest to units upon initial public offering</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0214">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDsqpVPSVm5c" title="Conversion of convertible notes and accrued interest to common stock upon initial public offering, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">708,820</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0215">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,279</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0217">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,279</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes_zw9MyClBteFa" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Reclassification
    of derivative liability upon conversion of convertible notes</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0223">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0224">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,101</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0226">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0227">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,101</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zShUBgVYVTvh" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Proceeds
    from initial public offering, net of underwriters&#8217; commissions, discounts and issuance costs of $<span id="xdx_902_ecustom--IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet_c20210101__20211231_zGAks7BtbIhg" title="Discount and issuance cost" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDb252ZXJ0aWJsZSBQZXJmZXJyZWQgU3RvY2sgYW5kIFN0b2NraG9sZGVyJ3MgRXF1aXR5IChEZWZpY2l0KSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="RNXT:IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,090</ix:nonFraction></span></span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0230">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDCDH3PB2D1b" title="Proceeds from initial public offering, net of underwriters commissions, discounts and issuance costs of $2,090, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,850,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0231">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,563</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0233">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0234">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,563</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_zWovbkSQlnzh" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock upon exercise of warrants issued upon initial public offering</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0241">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_987_ecustom--StockIssuedDuringPeriodsharesWarrantsExercised_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znotydPtpbu7" title="Issuance of common stock upon exercise of warrants issued upon initial public offering, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="RNXT:StockIssuedDuringPeriodsharesWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">248,200</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0242">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,681</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0244">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="RNXT:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,681</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueReverseStockSplits_i_pn3n3" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Reverse
    stock split adjustment</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0250">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDfYBMXJMK8f" title="Reverse stock split adjustment, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0251">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0252">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0253">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0254">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0255">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zVMjCIKwHbWf" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock upon exercise of stock options</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0259">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuranizwomIi" title="Issuance of common stock upon exercise of stock options, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">358,332</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0262">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0263">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zx4aJ9hiNMQ8" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation expense</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0268">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0269">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0271">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zg5Kk0eoIWx7" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,324</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,324</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_43B_c20220101__20221231_eus-gaap--StockholdersEquity_iS_ziijKuSsa78b" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance&#8212;December
    31, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z8Ox6hrmA95c" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOxssjrVt5oe" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,933,989</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36,632</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,284</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,349</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_432_c20220101__20221231_eus-gaap--StockholdersEquity_iS_z9jNgzVFlpYg" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zVykq2zi2Wbk" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSVJuPUYHcl7" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,933,989</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36,632</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0296">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,284</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,349</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zfqpxJUdxjWk" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock upon exercise of stock options</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFiOgKKQiHGa" title="Issuance of common stock upon exercise of stock options, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,212</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_z65uKteG3Uni" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of restricted stock awards</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeDc2XO7Aglg" title="Issuance of restricted stock awards, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zYAHvYNJet7e" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation expense</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">630</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">630</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zeLI7sjdbZ46" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other
    comprehensive income</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0333">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zMnfC6sfUoWk" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,889</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,889</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_437_c20220101__20221231_eus-gaap--StockholdersEquity_iE_z0cOYp1iVDxb" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance&#8212;December
    31, 2022</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zyrgQO4uEpOc" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxRIJXwXKTR1" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,097,701</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,318</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">31,173</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,163</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_43B_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zXX6XPsT8233" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zK3OHPgiuO6b" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBabsmEmtKWi" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,097,701</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,318</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">31,173</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,163</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_005"></span>RenovoRx,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>in
thousands</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_pn3n3_zvyRRj5fGcia" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zMzqx7lS0xb3" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20211231_zGvnqp5a4Dhe" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zYS6aMUhz9ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities: </td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_i01_maNCPBUzqCn_zwF4smhvt5Wi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,889</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,324</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zhg5cY9enOJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities: </td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_i02_maNCPBUzqCn_zsXFSbZPKwxi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation expense </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">644</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AmortizationOnLeaseholdImprovement_i02_maNCPBUzqCn_zpEh4Eo0dsna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization on leasehold improvements </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RNXT:AmortizationOnLeaseholdImprovement" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RNXT:AmortizationOnLeaseholdImprovement" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--GainOnChangeInFairValueOfDerivativeLiability_i02N_di_msNCPBUzqCn_zt9oxaqIOzHi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain on change in fair value of derivative liability </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="RNXT:GainOnChangeInFairValueOfDerivativeLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--GainOnLoanExtinguishmentFromPppLoan_i02N_di_msNCPBUzqCn_zUTkNbVqTCch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gain on loan extinguishment from PPP loan </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="RNXT:GainOnLoanExtinguishmentFromPppLoan" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--LossOnLoanExtinguishment_i02_maNCPBUzqCn_zg98Ezvg3dl2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Loss on loan extinguishment </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RNXT:LossOnLoanExtinguishment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maNCPBUzqCn_ztM8rymBlced" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount and issuance costs </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Changes in operating assets and liabilities: </td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzqCn_ze8NmGpvp3wj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">970</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzqCn_zXHXJoZI5576" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accounts payable </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">363</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maNCPBUzqCn_z3biaP3E0nqd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Accrued expenses </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">155</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">342</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzqCn_maCCERCz6iR_zbRsaFiuQzya" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt; text-align: left">Net cash used in operating activities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,811</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,916</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z2nwdsCAilk9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities: </td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_di_msNCPBUz1vF_zwZRNjpd5bce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Purchases of marketable securities </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_maNCPBUz1vF_zGqUz15E2oG5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from maturities of marketable securities </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,968</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PaymentsForLeaseholdImprovements_i01N_di_msNCPBUz1vF_zlNIIHX5vhkg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Expenditures for leasehold improvements </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="RNXT:PaymentsForLeaseholdImprovements" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUz1vF_maCCERCz6iR_zGlVUTepbfPg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Net cash used in investing activities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,032</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zNB79FBAnIx5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities: </td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_maNCPBUzCJ7_zXY39Z5PY0Mh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net proceeds from issuance of common stock upon initial public offering </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,563</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUzCJ7_z24osWKyfrr3" style="vertical-align: bottom; background-color: White">
    <td>Proceeds from exercise of warrants </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,681</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzCJ7_zdRKeTWAK5na" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from convertible notes </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,977</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzCJ7_zyKqwVy92rZe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Proceeds from exercise of stock options </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzCJ7_maCCERCz6iR_zKMrT0tkMaej" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Net cash provided by financing activities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,328</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCz6iR_z7QwZxfqSA31" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net (decrease) increase in cash and cash equivalents </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,801</ix:nonFraction></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,397</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAbstract_iB_zqxkJy7ChpIa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash and cash equivalents: </td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_zYiQ2sGNfK4d" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Beginning of year </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,192</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,795</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_zVEXBqCHgAl8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">End of year </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,391</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,192</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zOz81AkkQgb5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental cash flow data: </td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DerivativeLiabilityInFinancingActivities_i01_zFV7ormRfFwf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derivative liability </td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="RNXT:DerivativeLiabilityInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">738</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ConversionOfConvertiblePreferredStockUponInitialPublicOffering_i01_zGGnuzBd0aw7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of convertible preferred stock upon IPO </td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="RNXT:ConversionOfConvertiblePreferredStockUponInitialPublicOffering" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,451</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ConversionOfConvertibleNotesUponInitialPublicOffering_i01_zO2HzhT7iG61" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of convertible notes upon IPO </td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="RNXT:ConversionOfConvertibleNotesUponInitialPublicOffering" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,279</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_006"></span>RenovoRx,
Inc.</b></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zimEgYMKmLl8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zjxzFLXVswV5">1.
Business and Principal Activities</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Description
of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RenovoRx,
Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware in December 2012 and operates from its headquarters in Los
Altos, California. The Company is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment
of solid tumors and conducting a Phase III pancreatic cancer clinical trial for its lead product candidate RenovoGem&#8482;. The Company&#8217;s
therapy platform, RenovoRx Trans-Arterial Micro-Perfusion, or RenovoTAMP&#174; utilizes approved chemotherapeutics with validated mechanisms
of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and
widening their therapeutic window.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Initial
Public Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 25, 2021, the Company&#8217;s Registration Statement on Form S-1 (File No. 333-258071) relating to its initial public offering
(&#8220;IPO&#8221;) was declared effective and its shares of common stock began trading on the Nasdaq Capital Market on August 26, 2021.
In connection with the IPO, the Company issued and sold an aggregate of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-08-242021-08-25_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,850,000</ix:nonFraction></span> units at a price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_c20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-08-25_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.00</ix:nonFraction></span> per unit. Each unit consisted
of (a) one share of common stock and (b) one warrant to purchase one share of common stock at an exercise price equal to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210825__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-08-25_us-gaap_WarrantMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.80</ix:nonFraction></span> per share,
which is exercisable for a period of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210825__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zxaDHLAkknR2" title="Warrants and rights outstanding, term"><ix:nonNumeric contextRef="AsOf2021-08-25_us-gaap_WarrantMember_us-gaap_IPOMember" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> after the issuance date. The underwriters exercised their over-allotment option to purchase
<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210829__20210830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--OverAllotmentOptionsMember_zimZbzJVkkTj" title="Over allotment option to purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-08-292021-08-30_us-gaap_IPOMember_custom_UnderwriterMember_custom_OverAllotmentOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,500</ix:nonFraction></span> common stock warrants on August 30, 2021. In connection with the IPO, the underwriters were issued a five-year warrant, exercisable
on or after February 25, 2022, to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Class of warrant or right, number of securities called by each warrant or right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2021-08-25_us-gaap_IPOMember_custom_UnderwriterMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">198,875</ix:nonFraction></span> shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-08-25_us-gaap_IPOMember_custom_UnderwriterMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.80</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received aggregate gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Aggregate gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-08-242021-08-25_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.7</ix:nonFraction></span> million from the IPO, paid underwriting discounts and commissions of $<span id="xdx_903_ecustom--UnderwritingDiscountsAndCommissions_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Underwriting discounts and commissions"><ix:nonFraction name="RNXT:UnderwritingDiscountsAndCommissions" contextRef="From2021-08-242021-08-25_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million
and incurred other expenses of $<span id="xdx_909_eus-gaap--OtherExpenses_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Other expenses"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2021-08-242021-08-25_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million, resulting in net offering proceeds of $<span id="xdx_909_ecustom--NetProceedsFromIntialPublicOffering_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Net proceeds from intial public offering"><ix:nonFraction name="RNXT:NetProceedsFromIntialPublicOffering" contextRef="From2021-08-242021-08-25_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.6</ix:nonFraction></span> million. Immediately prior to the closing of
the IPO, all shares of convertible preferred stock then outstanding were converted into <span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaTAwRGdGoub" title="Conversion of stock, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2021-08-242021-08-25_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,535,469</ix:nonFraction></span> shares of common stock after giving
effect to the reverse stock split. In addition, all of the outstanding 2020 and 2021 Convertible Notes, representing principal and accrued
but unpaid interest of $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Debt conversion, converted instrument, amount"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-08-242021-08-25_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.3</ix:nonFraction></span> million, <span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember" title="Debt instrument, description"><ix:nonNumeric contextRef="From2021-08-242021-08-25_us-gaap_IPOMember" name="us-gaap:DebtInstrumentDescription">converted at a 20% and 12.5% discount to the IPO price, respectively, into an aggregate of <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zxADBNJ9uCRk" title="Debt conversion, converted instrument, shares"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-08-242021-08-25_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">708,820</ix:nonFraction></span>
units. Each unit consisted of (a) one share of common stock and (b) one five-year warrant to purchase one share of common stock at an
exercise price equal to $10.80 per share</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 5, 2021, the Company effected a <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20210804__20210805_zhSUz5IAsKnf" title="Stockholders equity, reverse stock split"><ix:nonNumeric contextRef="From2021-08-042021-08-05" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-5 reverse stock split</ix:nonNumeric></span> of its issued and outstanding preferred stock and common stock. The
number of authorized shares and the par values of the common stock and convertible preferred stock were not adjusted as a result of the
reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the Company&#8217;s convertible
preferred stock converted into the Company&#8217;s common stock. Accordingly, all share and per share amounts related to the common stock,
stock options, warrants and restricted stock awards for all periods presented in the accompanying financial statements and notes thereto
have been retroactively adjusted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Capital Resources</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
the Company&#8217;s inception through December 31, 2022, it has raised an aggregate of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20211126__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAiGm9BF5Xwa" title="Proceeds from sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-11-262022-12-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">35.0</ix:nonFraction></span> million from private placements of convertible
preferred stock, convertible debt securities, the issuance of securities in the IPO, and the exercise of warrants and common stock options.
As of December 31, 2022, the Company had cash, cash equivalents and short-term marketable securities of $<span id="xdx_90A_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20221231_z3t31gxR1MZ" title="Cash and cash equivalents, and Marketable securities"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.4</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred significant losses and negative cash flows from operations since its inception. For the year ended December 31,
2022, the Company reported a net loss of $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_zw1FpLpXGdOa" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">9.9</ix:nonFraction></span> million and an accumulated deficit of $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_z2gw5NMSSlCb" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">31.2</ix:nonFraction></span> million and does not expect to generate positive
cash flows from operations in the foreseeable future. The Company expects to incur significant and increasing losses until regulatory
approval is granted for its first product candidate, RenovoGem&#8482;. Regulatory approval is not guaranteed and may never be obtained.
The Company believes it will be able to raise additional capital through debt financings, private or public equity financings, license
agreements, collaborative agreements or other arrangements with other companies, or other sources of financing. There can be no assurance
that such financing will be available or will be at terms acceptable to the Company. The inability to raise capital as and when needed
would have a negative impact on the Company&#8217;s liquidity financial condition and its ability to pursue its business strategy. The
Company will need to generate significant revenue to achieve profitability, and it may never do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed an omnibus shelf registration statement on Form S-3 that provides for the aggregate offerings of up to $<span id="xdx_90E_ecustom--MaximumPossibleProceedsFromOfferings_pn6n6_c20220101__20221231_zZEbFt8DlG8i" title="Maximum possible proceeds from offerings"><ix:nonFraction name="RNXT:MaximumPossibleProceedsFromOfferings" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">50.0</ix:nonFraction></span> million
of the Company&#8217;s securities subject to various limitations, including limited sales in any twelve-month period while the Company
is subject to the &#8220;baby-shelf&#8221; rules. The Company has also filed a registration statement on Form S-1 to register the cash
exercise of the Company&#8217;s outstanding IPO, underwriter and private warrants. Cash exercise of the outstanding warrants is only
expected to occur when the trading price of the Company&#8217;s common stock is in excess of the $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zTm5wVmEOUAl" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.80</ix:nonFraction></span> per share exercise price of the
outstanding warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_23A_zYnHTLg1MG1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zuCgwRbRaEjd" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern and has reviewed the
relevant conditions and events surrounding its ability to continue as a going concern including among others: historical losses, projected
future results, negative cash flows from operations, including the effects of the ongoing novel coronavirus (&#8220;COVID-19&#8221;)
pandemic, cash requirements for the upcoming year, funding capacity, net working capital, total stockholders&#8217; equity and future
access to capital. Based upon this review and the Company&#8217;s current financial condition, the Company has concluded that substantial
doubt exists as to the Company&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zPqP6myjMFF7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zwZwvpb7Spsd">2.
Summary of Significant Accounting Policies</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHm1cDSYh01f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zG1ruHCYXIbd">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the SEC for annual reporting. Any reference in these notes to
applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and as amended by Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="RNXT:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_847_ecustom--RisksAndUncertaintiesPolicyTextBlock_zZrgs7WSpMNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z51snjERV0r3">Risks
and Uncertainties</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to a number of risks associated with companies at a similar stage, including the risk associated with the development
of products that must receive regulatory approval before market launch, dependence on key individuals, competition from larger and established
companies, volatility of the industry, ability to obtain adequate financing to support growth, the ability to attract and retain additional
qualified personnel to manage the anticipated growth of the Company and general economic conditions. The Company is subject to a number
of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional
funding, possible failure of current or future preclinical studies or clinical trials, its reliance on third parties to conduct its clinical
trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations,
the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, protection of its proprietary
technology, and the need to secure and maintain adequate manufacturing arrangements with third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic, and government responses have created
disruption in global supply chains and adversely impacting many industries. The pandemic could have a continued material adverse
impact on economic and market conditions. We continue to monitor the impact of the COVID-19 pandemic, including its most recent
variants, closely. The extent to which the COVID-19 pandemic will impact our operations or financial results is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84D_eus-gaap--UseOfEstimates_z3bSwlo5Tfv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zJb5n2pFu3Ze">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, income and expenses as well as the disclosure of contingent assets and liabilities, at the date of
the financial statements during the reporting periods. In preparing these financial statements, management has made its best estimates
and judgments of certain amounts included in the financial statements. Significant estimates and assumptions made in the accompanying
financial statements include, but are not limited to, accruals of certain liabilities, including clinical trial accruals and other contingences,
the valuation of financial instruments, the fair value of the Company&#8217;s common stock and the fair value of options granted under
the Company&#8217;s equity incentive plan. On an ongoing basis, the Company evaluates its estimates, including those related to the fair
values of assets, stock-based compensation, clinical trial accruals and other contingencies. Management bases its estimates on historical
experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially
from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zfVCgmA1nhZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zXBZz0M0lnF3">Concentration
of Credit Risk and Significant Suppliers</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents.
The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits
of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zYUqTu6FA627" title="Cash, FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents
to the extent recorded in the balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relied, and expects to rely, on a small number of third-party manufacturers to manufacture and supply its RenovoCath devices
and its product candidates for clinical trials. These activities could be adversely affected by a significant interruption in supply
of these items. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate
product revenue or achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z7URk1O0oT89" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z2qSqRpAXAn9">Operating
Segment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as one reportable and operating segment, which is the development of a therapy platform to
deliver de-risked small molecules for localized treatment of solid cancer tumors. The Company&#8217;s chief executive officer, who is
the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial
performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_235_zxBSgPeeshH" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zQAnn6TYoh4e" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zNIt6IHC8Ihb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zvaBkezXnvCb">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during
the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average
number of shares of common stock and common stock equivalents of potentially dilutive securities outstanding for the period determined
using the treasury stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of convertible preferred
stock, convertible notes, and warrants including options and restricted stock awards outstanding under the Company&#8217;s Equity Incentive
Plan. For the years ended December 31, 2022 and 2021, there was no difference in the number of shares used to calculate basic and diluted
shares outstanding as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zf3Oqho5xbeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zgthSnXO9tCf">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the
principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement
date. Fair value measurement establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where
available, and minimize the use of unobservable inputs when measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the fair value of financial assets and liabilities using the fair value hierarchy that describes three levels of inputs
that may be used to measure fair value, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Valuations based on unobservable inputs reflecting the Company&#8217;s assumptions, consistent with reasonably available assumptions
made by other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of financial instruments disclosed in the financial statements has been determined by using available market information
and appropriate valuation methodologies. In certain cases where there is limited activity or less transparency around inputs to valuation,
securities are classified as Level 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of current assets, accounts payable and accrued expenses are generally considered to be representative of their respective
fair values because of their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="RNXT:CashCashEquivalentsAndInvestmentsPolicyTextBlock"><p id="xdx_842_ecustom--CashCashEquivalentsAndInvestmentsPolicyTextBlock_zNYL71lzWeP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zMgcde5Caltc">Cash,
Cash Equivalents and Investments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
Available-for-sale securities, comprised of obligations of the U.S. government and its agencies, are carried at fair value, with unrealized
gains and losses recorded within other comprehensive income (loss) as a separate component of stockholders&#8217; equity. Realized gains
and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in earnings.
Purchases and sales of investment securities are recognized on a trade date basis. The cost of investment securities sold is determined
by the specific identification method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="RNXT:LeaseholdImprovementsPolicyTextBlock"><p id="xdx_84D_ecustom--LeaseholdImprovementsPolicyTextBlock_zfbhBvrEoTt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zde547Z2XjD2">Leasehold
Improvements, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are presented at cost, net of accumulated amortization. Amortization expense is recorded using the straight-line method
over the shorter of the remaining lease term or the estimated useful life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8NrWqrEa898" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zQ3RwuZqIjOb">Research
and Development Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses includes personnel costs including salaries,
benefits and stock-based compensation. In addition, it includes expenses for consultants that support clinical trial studies, materials
costs, external clinical drug product manufacturing costs, outside services costs, regulatory activities including filing fees, fees
for maintaining licenses and other amounts due to third-party agreements, laboratory materials, clinical trial, as noted above, and supplies
to support our research activities, including allocated facility and general and administrative indirect overhead related costs. The
Company also receives payments from clinical trial sites for RenovoCath delivery devices used in the Phase III clinical trial. Payments
received from clinical sites cover the direct costs of manufacturing the RenovoCath delivery devices and offset research and development
expenses were $<span id="xdx_90B_ecustom--PaymentsReceivedFromClinicalSites_iN_di_c20220101__20221231__dei--LegalEntityAxis__custom--RenovoCathMember_z4VvX720kpl" title="Payments received from clinical sites"><ix:nonFraction name="RNXT:PaymentsReceivedFromClinicalSites" contextRef="From2022-01-012022-12-31_custom_RenovoCathMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">141,000</ix:nonFraction></span> and $<span id="xdx_906_ecustom--PaymentsReceivedFromClinicalSites_iN_di_c20210101__20211231__dei--LegalEntityAxis__custom--RenovoCathMember_zgJzPsC14hh6" title="Payments received from clinical sites"><ix:nonFraction name="RNXT:PaymentsReceivedFromClinicalSites" contextRef="From2021-01-012021-12-31_custom_RenovoCathMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">233,000</ix:nonFraction></span> for December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="RNXT:ClinicalTrialExpensesPolicyTextBlock"><p id="xdx_84C_ecustom--ClinicalTrialExpensesPolicyTextBlock_zXY6GkKFJes4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zzOdLv079NZ7">Clinical
Trial Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company makes payments in connection with its ongoing Phase III clinical trial under contracts with clinical trial sites and contract
research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation
and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to
be performed at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts
depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including
actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related
to patient enrollment or treatment are accrued when reasonably estimable. If amounts and obligations to pay under clinical trial agreements
are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are
adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give
rise to the revision become reasonably certain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_23D_ziApRC2Li9P9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_236_z2ldXoz20rH3" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_843_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zZL0Ddreuegi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zDAPKDqaalhi">General
and Administrative</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of salaries, benefits, and stock-based compensation for personnel in executive, finance and administrative
functions, professional services and associated costs related to accounting, tax, audit, legal, intellectual property, consulting costs,
conferences and travel, including allocated facility and general and administrative indirect overhead related costs to research and development
expenses. General and administrative expenses are expensed in the period incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="RNXT:ConvertiblePreferredStockPolicyTextBlock"><p id="xdx_84A_ecustom--ConvertiblePreferredStockPolicyTextBlock_z2inqu5ckCW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zXapwkm74uu1">Convertible
Preferred Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records preferred stock at fair value on the date of issuance, net of issuance costs. Preferred stock was previously recorded
outside of stockholders&#8217; equity (deficit) because the shares contained liquidation features that were not solely within the Company&#8217;s
control and was classified as mezzanine equity (temporary equity). The Company completed its IPO on August 30, 2021, which triggered
the automatic conversion of all outstanding convertible preferred stock to common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3EXFdb2Ywf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zhgs7Fwf7Ub">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock options using the Black-Scholes option pricing model, which incorporates various assumptions
including volatility, expected term and risk-free interest rate. Compensation related to service-based awards is recognized starting
on the grant date on a straight-line basis over the vesting period, which is generally four years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
determination of the fair value of each stock award using this option-pricing model is affected by the Company&#8217;s assumptions regarding
a number of complex and subjective variables. These variables include, but are not limited to, the fair value of the common stock at
the date of grant, the expected term of the awards, the expected stock price volatility over the expected term of the awards, the risk-free
interest rate, and the dividend rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Common Stock</i>&#8212;Prior to the IPO, given the absence of a public trading market, the Company&#8217;s Board of Directors
considered numerous objective and subjective factors to determine the fair value of the Company&#8217;s common stock at each grant date.
These factors included, but were not limited to: (i) contemporaneous third-party valuations of common stock; (ii) the prices for preferred
stock sold to outside investors; (iii) the rights and preferences of preferred stock relative to common stock; (iv) the lack of marketability
of the Company&#8217;s common stock; (v) developments in the business; and (vi) the likelihood of achieving a liquidity event, such as
an IPO or sale of the business, given prevailing market conditions. The methodology to determine the fair value of the Company&#8217;s
common stock included estimating the fair value of the enterprise using the &#8220;backsolve&#8221; method, which is a market approach
that assigns an implied enterprise value by accounting for all share class rights and preferences based on the latest round of financing.
The total equity value implied was then applied in the context of an option pricing model to determine the value of each class of the
Company&#8217;s shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
grants issued post-IPO the closing price of the Company&#8217;s common stock as reported on the date of grant will determine the fair
value of the Company&#8217;s common stock, as shares of the Company&#8217;s common stock are traded in the public market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. The Company determines
the expected term using the simplified method for pre-IPO and post-IPO awards. The simplified method deems the term to be the average
of the time-to-vesting and the contractual life of the options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>&#8212;Given the absence of a public trading market, pre-IPO and post IPO, the expected volatility is estimated by taking
the average historic price volatility for industry peers, consisting of several public companies in the Company&#8217;s industry that
are either similar in size, stage, or financial leverage, over a period equivalent to the expected term of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
Interest Rate</i>&#8212;The risk-free interest rate is calculated using the average of the published interest rates of U.S. Treasury
zero-coupon issues with maturities that are commensurate with the expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Rate</i>&#8212;The dividend yield assumption is zero as the Company has no plans to make dividend payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generally granted stock options, pre-IPO, to its employees and consultants for a fixed number of shares with an exercise price
equal to the fair value of the underlying shares at date of grant. For all post-IPO grants issued, the fair value will be the closing
price of the Company&#8217;s common stock on the date of the grant. The Company accounts for all stock option grants using the fair value
method and stock-based compensation is recognized as the underlying options vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zyJ95pZT0R6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z9a65EAP1rof">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities
using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation
allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax
credit carryforwards for all periods presented, as realization of such deferred tax assets cannot be determined to be more likely than
not. Due to losses incurred for all periods presented, the Company does not record tax provision or benefit for income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="RNXT:EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock"><p id="xdx_84B_ecustom--EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_zmoviQgLuoP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zouHFmdnzxFk">Emerging
Growth Company and Smaller Reporting Company Status</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company (&#8220;EGC&#8221;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;) and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of
the JOBS Act exempts emerging growth companies from complying with new or revised financial accounting standards until private companies
are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or
revised accounting standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_236_zdeeFNerM91d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zJkpaGdLscFi" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 of the Exchange Act. If we are a smaller reporting company
at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that
are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most
recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, like emerging growth companies, smaller reporting
companies have reduced disclosure obligations regarding executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of
the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not
have a material impact on the Company&#8217;s financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zvmRGpDTUZLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z7CvUQUNAWec">Recent
Accounting Pronouncement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Adopted Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued Accounting Standards Updates (&#8220;ASU&#8221;) 2016-02, <i>Leases (Topic 842)</i>. The guidance requires
lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expands disclosure requirements regarding
leasing arrangements. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting the new
lease standards, and a package of practical expedients an entity can elect to utilize to reduce the level of effort required for adoption.
Under the transition option, entities can elect to apply the new guidance using a modified retrospective approach at the beginning of
the year in which the new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements.
In November 2019, the FASB issued ASU 2019-10, Leases (Topic 842) (ASU 2019-10), deferring the effective date for the Company for fiscal
years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the
FASB issued ASU 2020-05, Leases (Topic 842) (ASU 2020-05), which further defers the effective date for the Company for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2021. Early adoption is permitted. The
Company adopted ASU 2016-02 on January 1, 2022 and the adoption had no material impact to the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, <i>Income Taxes (Topic 740)</i>: Simplifying the Accounting for Income Taxes (ASU 2019-12),
which simplifies the accounting for income taxes, and is effective on a prospective basis for annual reporting periods beginning after
December 15, 2021, and for interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The
Company adopted ASU 2019-12 on January 1, 2022 and the adoption had no significant impact to the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments&#8212;Credit Losses (Topic 326)</i>. The guidance represents a significant
change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected
credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has
met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU 2019-10, <i>Financial Instruments
&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)</i> &#8212;Effective Dates amended the
effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU 2016-13
effective January 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) </i>(ASU 2020-06): <i>Accounting for Convertible Instruments
and Contracts in an Entity</i>, which simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The updated guidance is effective on a prospective
basis for annual reporting periods beginning after December 15, 2023 and for interim periods within those periods. Early adoption is
permitted. The Company has not yet determined the impact that this new standard will have on its financial position and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"><p id="xdx_807_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_z8vBpTFv7DV4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zqgeMqxRTjkj">3.
Short-Term Marketable Securities</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:MarketableSecuritiesTextBlock"><p id="xdx_89B_eus-gaap--MarketableSecuritiesTextBlock_zpgIdIns1l6j" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tables summarize the Company&#8217;s short-term marketable securities as of December 31, 2022. There were no short-term marketable securities
as of December 31, 2021 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zHj7Nl5NtCgi" style="display: none">Schedule of Short-Term Marketable Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost Basis</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross<br />
 Unrealized <br />
Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">U.S. Treasury bills</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zJ3QUD31T3e6" title="Short-term marketable securities, amortized cost basis" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,032</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zNouzYQi2sFl" title="Short-term marketable securities, unrealized gains" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2022-01-012022-12-31_us-gaap_USTreasurySecuritiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zhJwDgAPBzvl" title="Short-term marketable securities, unrealized losses" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0568">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zJYVlLezGF5b" title="Short-term marketable securities, fair value" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,049</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231_zlY8Ose76Y26" title="Short-term marketable securities, amortized cost basis" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,032</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20220101__20221231_zOSo7eebN7o" title="Short-term marketable securities, unrealized gains" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_pn3n3_c20220101__20221231_z4cvmiBhQxv6" title="Short-term marketable securities, unrealized losses" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20221231_zptcH7QfQkM8" title="Short-term marketable securities, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,049</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z9UB3IRI6xtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_236_zLJIXjnCgHW8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zXx9IRRdacYg" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_80C_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zGLJLz2xf8F7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
<span id="xdx_82B_zWkKc6SS9Tgi">4. Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zaI6UZsjLPUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of accrued expenses as of December 31, 2022 and 2021 are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z5s1YR1nkjRf" style="display: none">Schedule of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_z1q2B2nJ9wWi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_z7AloTSk40u8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccruedClinicalTrialsCurrent_iI_pn3n3_maALCz7Fz_zuCHB2xDe85l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Clinical trial</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="RNXT:AccruedClinicalTrialsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">88</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="RNXT:AccruedClinicalTrialsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCz7Fz_z1ZeFp8Gq2T5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">475</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz7Fz_zfOTfAd00q12" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz7Fz_zyJZo7LN00xi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">568</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">413</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zZfkUUPjSiw6" style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zBHemCjH8by5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_821_zBH5lpKdEqB3">5.
Fair Value Measurements</span></b></span></p>



<p style="margin-top: 0; margin-bottom: 0">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021, the Company held $<span id="xdx_90D_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_c20221231_ziqeCx7PYBTl" title="Money market funds, at carrying value"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.4</ix:nonFraction></span> million and $<span id="xdx_90A_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn6n6_c20211231_zDFWoVubtvT9" title="Money market funds, at carrying value"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15.0</ix:nonFraction></span> million, respectively, in a money market account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zpZmx6gcBMW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables sets summarize the Company&#8217;s financial assets and liabilities, measured at fair value on a recurring basis by
level within the fair value hierarchy, as of December 31, 2022, and 2021, (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zet2hQgJ3eu4" style="display: none">Schedule of Assets Measured at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements at December 31, 2022 using:</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: justify">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzd2NeqEDoIg" title="Fair value of assets" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxuNynEj3Xlg" title="Fair value of assets" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0608">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLQaqRfgJKM9" title="Fair value of assets" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z33j61y5Poo6" title="Fair value of assets" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify">Available-for-sale securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">U.S. Treasury bills</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUSrdJfYPzM6" title="Fair value of assets" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,049</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z89997Oz1RB" title="Fair value of assets" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zumaZefHWfA6" title="Fair value of assets" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zhgBiDaw7oj2" title="Fair value of assets" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,049</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgwbzalb2qXh" title="Fair value of assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,349</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLvimprryWca" title="Fair value of assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0624">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z1odUC8sDVj" title="Fair value of assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0626">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUlmWsAFlscd" title="Fair value of assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,349</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements at December 31, 2021 using:</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1.5pt">Money market funds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" title="Fair value of assets" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,997</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" title="Fair value of assets" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" title="Fair value of assets" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" title="Fair value of assets" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,997</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" title="Fair value of assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,997</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" title="Fair value of assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" title="Fair value of assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zKD4iPGVrgy2" title="Fair value of assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,997</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zMfQZW52q53c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zwMrkrPNNc6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in the fair value of the derivative liability is summarized below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_ztgGfeOkweQ5" style="display: none">Schedule
of Changes in Fair value of Derivative  Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zLhzDhgZ5vY9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_z3ttAK4m1FOj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_zDUxWPk0UNf1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Fair value, beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">856</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_zA2FujfEpSXk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Initial fair value of instruments issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">363</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_iN_pn3n3_di_zvG1x1KBm9S" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in fair value of instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_iN_pn3n3_di_zaATWrAox2L9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Conversion upon IPO</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0657">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,101</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_zYyzo1V7WLia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Fair value, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0661">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zOPuBFNQIZjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between Level 1, Level 2 or Level 3 during the periods presented. The Company had no other financial assets or liabilities
that were required to be measured at fair value on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_802_eus-gaap--LongTermDebtTextBlock_zq8BfDvQc4yc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zEHu9dvm2TD9">6.
Convertible Notes</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the Company entered into a note purchase agreement for the issuance of up to $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zuVuUoo5uITk" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2020-03-31_custom_NotePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million of convertible promissory notes,
which, if not converted, had an initial maturity date of <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20200301__20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zUMHNMoKrlr9" title="Debt instrument, maturity date"><ix:nonNumeric contextRef="From2020-03-012020-03-31_custom_NotePurchaseAgreementMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">March 31, 2021</ix:nonNumeric></span>. The Company entered into a series of convertible note payable
agreements (the &#8220;2020 Convertible Notes&#8221;) for aggregate borrowings of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zeZY9sfaH3o9" title="Debt instrument, face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-03-31_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span> million. The 2020 Convertible Notes bore interest
at the rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pip0_dp_uPure_c20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zq9fmoXfrSNc" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-03-31_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% per annum and could not be prepaid prior to the maturity date unless approved in writing by the Company and requisite
holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the 2020 Convertible Notes provided for automatic conversion into equity shares in the next equity financing round with total
proceeds of not less than $<span id="xdx_909_ecustom--MaximumPossibleTotalProceedsFromConvertibleNotes_pn6n6_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zebk1xbJSxd6" title="Maximum possible total proceeds from convertible notes"><ix:nonFraction name="RNXT:MaximumPossibleTotalProceedsFromConvertibleNotes" contextRef="From2020-03-012020-03-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million (a &#8220;Qualified Financing&#8217;), at a conversion price per share equal to <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_uPure_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zyTO8ZmAcHPi" title="Debt conversion price percentage"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="From2020-03-012020-03-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of the price
per share paid by investors purchasing such equity securities in a Qualified Financing. For purposes of the 2020 Convertible Notes, equity
securities meant the Company&#8217;s common stock, preferred stock or any securities providing for rights to purchase the Company&#8217;s
common stock, preferred stock or securities convertible into or exchangeable for the Company&#8217;s common stock or preferred stock
issued in the Qualified Financing. If the Company consummated a Change of Control prior to a Qualified Financing, the Company would repay
each holder in cash an amount equal to the greater of (a) two times (2x) the entire outstanding principal balance of the 2020 Convertible
Notes or (b) the amount the holder would receive if the 2020 Convertible Notes had been converted into shares of the Company&#8217;s
Series B convertible preferred stock immediately prior to the consummation of the Change in Control, at a conversion price equal to the
Series B convertible preferred stock Original Issue Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_233_zcCiCkcLEZGe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zgQKYeKmRwE1" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 1, 2021, the Company entered into an amendment to the 2020 Convertible Notes which extended the maturity date of the 2020 Convertible
Notes from March 31, 2021 to October 30, 2021 and provided for the conversion of the 2020 Convertible Notes into shares of the Company&#8217;s
common stock upon a Qualified Financing that is an IPO. No other terms of the 2020 Convertible Notes were amended. This amendment was
accounted for as a troubled debt restructuring pursuant to FASB ASC Topic 470-60, &#8220;Troubled Debt Restructurings by Debtors.&#8221;
As the future undiscounted cash flows of the 2020 Convertible Notes were greater than their carrying amount, the carrying amount was
not adjusted and no gain was recognized as a result of the modification of terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that the redemption features contained rights and obligations for conversion were contingent upon a potential
future financing event or a change in control. Thus, the embedded redemption features were bifurcated from the face value of the
notes and accounted for as a derivative liability to be remeasured at the end of each reporting period. The fair value of the
derivative liability including debt issuance costs was $<span id="xdx_907_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zTvlBpYYzQNl" title="Fair value of derivative liability including debt issuance costs"><span id="xdx_900_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zHHSVZ9Ta8J7" title="Fair value of derivative liability including debt issuance costs"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span>
at December 31, 2022 and December 31, 2021, respectively. The derivative liability was subject to fair value remeasurement at the
end of each reporting period. The debt discount and debt issuance costs were being amortized to interest expense using the effective
interest method over the expected term of the 2020 Convertible Notes. For the years ended December 31, 2022 and December 31, 2021,
the Company recognized $<span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zV0pDejhyJW9" title="Amortization of debt discount and debt issuance costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>
and $<span id="xdx_90F_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zjexdVzHMR6d" title="Amortization of debt discount and debt issuance costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">379,000</ix:nonFraction></span>
for amortization of the debt discount and debt issuance costs, respectively. This amortization expense is recognized as interest
expense in the statements of operations. The effective interest rate of the 2020 Convertible Notes was <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zBxpFp7Utg73" title="Debt effective interest rate"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zlalMfUN1xLa" title="Debt effective interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></ix:nonFraction></span></span>%
at December 31, 2022 and December 31, 2021, compared to the stated rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pip0_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zM0SlQUqeOCi" title="Debt stated interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
per annum. The effective interest rate immediately prior to the conversion of the Convertible Notes resulting from the
Company&#8217;s IPO was <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zkwiYeNACb2k"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.6</ix:nonFraction></span>%
per annum. As a result, the Company&#8217;s reported interest expense was significantly higher than the contractual cash interest
payments. During the years ended December 31, 2022 and December 31, 2021, the Company recognized interest expense in the statements
of operations of $<span id="xdx_901_eus-gaap--InterestExpense_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zNm49WmMwT7l" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>
and $<span id="xdx_900_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_z4Ok7kfKKxHk" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></span>,
respectively, related to the 2020 Convertible Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, the Company entered into a note purchase agreement and a series of convertible note payable agreements (the &#8220;2021 Convertible
Notes,&#8221; together with the 2020 Convertible Notes, the &#8220;2020 and 2021 Convertible Notes&#8221;) for aggregate borrowings of
$<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20210430__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember_zFOJAmZ6j7L6" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million. Outstanding borrowings under the 2021 Convertible Notes and accrued interest were due in April 2022, if not previously
converted. The 2021 Notes bore interest at the rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210430__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_z6KdYaW1nwsl" title="Interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%</span> per annum. Pursuant to the 2021 Convertible Notes, the outstanding principal
and accrued interest are automatically convertible into equity shares in a Qualified Financing at a conversion price per share equal
to <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pip0_dp_uPure_c20210401__20210430__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_z3y01Xa4Ib5a" title="Debt conversion price percentage"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="From2021-04-012021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">87.5</ix:nonFraction></span>% of the price per share paid by investors purchasing such equity securities in a Qualified Financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that these redemption features in the 2021 Convertible Notes contained rights and obligations for conversion that
were contingent upon a potential future financing event or a change in control. Thus, the embedded redemption features were bifurcated
from the face value of the note and accounted for as a derivative liability to be remeasured at the end of each reporting period. Upon
issuance of the notes, the Company recorded the fair value of the derivative liability of $<span id="xdx_904_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zgSkFHo3yzgc" title="Fair value of derivative liability"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,000</ix:nonFraction></span> and debt issuance costs of $<span id="xdx_906_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zg0AVIAlZ3De" title="Debt issuance costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,000</ix:nonFraction></span>,
with the offsetting amount being recorded as a debt discount. The discount and debt issuance costs were amortized to interest expense
using the effective interest method over the expected term of the 2021 Convertible Notes. For the year ended December 31, 2022 and December
31, 2021, the Company recognized $<span id="xdx_905_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zfmNzDwMJx22" title="Amortization of debt discount and debt issuance costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCosts_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zG5Pufi16fui" title="Amortization of debt discount and debt issuance costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,000</ix:nonFraction></span>, respectively, for the amortization of the debt discount and debt issuance costs as
interest expense in the statements of operations. The effective interest rate immediately prior to the conversion of the 2021 Convertible
Notes resulting from the Company&#8217;s IPO was <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zmbKZoEB94lk"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">46.5</ix:nonFraction></span>% per annum compared to the stated rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_za4BtWjDDpYl"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% per annum. During the year ended December
31, 2022 and December 31, 2021, the Company recognized interest expense in the statements of operations of $<span id="xdx_90B_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zrug1ggNe9w2" title="Interest expense"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zSESc9ap6jzj" title="Interest expense"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,000</ix:nonFraction></span>, respectively,
relating to the 2021 Convertible Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company completed an IPO on August 30, 2021, which triggered the automatic conversion of the outstanding Convertible Notes plus accrued
interest into an aggregate of <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210829__20210830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNfoDwpEk8Pa" title="Conversion of stock, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2021-08-292021-08-30_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">708,820</ix:nonFraction></span> units (the &#8220;Exchange&#8221;). The 2020 Convertible Notes converted at a 20% discount to the
IPO price and the 2021 Convertible Notes converted at a <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210831__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_zlNZ7KrtnHUe" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-08-31_custom_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% discount to the IPO price. Each unit consisted of (a) one share of common
stock and (b) one five-year warrant to purchase one share of common stock at an exercise price equal to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zWcp3gnBidlj" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-08-30_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.80</ix:nonFraction></span> per share. Upon conversion
of the 2020 and 2021 Convertible Notes, the outstanding principal, including debt discount and debt issuance costs for those Convertible
Notes of $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_zKgen3PS0Vp6" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.3</ix:nonFraction></span> million, was derecognized into stockholders&#8217; equity. The unamortized debt discount totaling $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_zG4xyogqPwa5" title="Unamortized debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,000</ix:nonFraction></span> was recognized
as a loss on extinguishment of debt and is included in loss (gain) on loan extinguishment in the Company&#8217;s statements of operations
for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exchange was made pursuant to an exemption from registration provided by Section 3(a)(9) of the Securities Act. The following facts were
relied upon: (1) no payment was made in connection with the Exchange, (2) the Convertible Notes, the common stock, and the warrants were
issued by the same issuer, (3) the Convertible Note holders were not required to contribute cash or any other property, and (4) the Exchange
was made only to existing note holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zcaiA2icJst3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zTpJGbffe8Q8">7.
Commitments and Contingencies</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company may become involved in legal proceedings arising in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was not subject to any material legal proceedings during the year ended December 31, 2022 and no material legal proceedings are
subsequently outstanding or pending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_233_zbsbPxNShTYh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zCzcYGklJWL7" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Guarantees
and Indemnification</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware
law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the
officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its officers and
directors. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future
payments that the Company could be required to make under these provisions is not determinable. The Company has never incurred material
costs to defend lawsuits or settle claims related to these indemnification provisions. The Company is not currently aware of any indemnification
claims. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of December 31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20221231_zGsBDuUha9h9" title="Lessee, operating lease, description"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="us-gaap:LesseeOperatingLeaseDescription">The
Company leases its headquarters in Los Altos, California under a month-to-month operating lease agreement.</ix:nonNumeric></span> Rent expense was $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20220101__20221231_z0qYZ5NVgOA8" title="Operating lease, rent expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,000</ix:nonFraction></span> and
$<span id="xdx_900_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231_zFN4ticSd897" title="Operating lease, rent expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,000</ix:nonFraction></span> for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80A_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zxRhpnrEKnnc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zWz5XSiJT1ka">8.
Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2021
Omnibus Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 19, 2021, the Company&#8217;s Board of Directors adopted the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the &#8220;2021
Plan&#8221;). The 2021 Plan, which became effective immediately prior to the closing of the IPO, initially reserved <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210719__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member_z15iS7d0Jnk4" title="Number of shares reserved"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-07-19_custom_OmnibusEquityIncentivePlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,185,832</ix:nonFraction></span> shares
of common stock, which included <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210719__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member_pdd" title="Common shares reserved but unissued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-07-19_custom_OmnibusEquityIncentivePlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,832</ix:nonFraction></span> shares of common shares reserved but unissued under the Amended and Restated 2013 Equity Incentive
Plan (the &#8220;2013 Plan&#8221;). The Company&#8217;s 2013 Plan was terminated immediately prior to the closing of the IPO; however,
shares subject to awards granted under the 2013 Plan will continue to be governed by the 2013 Plan. In accordance with the terms of the
2021 Plan, on January 1, 2023, the number of shares reserved and available for issuance increased by <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230101__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztxDbqAbsIhl" title="Number of shares reserved"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-01-01_custom_OmnibusEquityIncentivePlan2021Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">272,391</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPXCuaMrMkbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity for the year ended December 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_z9zGbXyz3wT2" style="display: none">Summary of Stock Option Award Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual Life</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zGSYfJR9fNHk" title="Number of stock options outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">926,379</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zGZdtN3G5Nhk" title="Weighted average exercise price outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zYUIANnIXUlj" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.47</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zx7IgMGZWtMc" title="Aggregate intrinsic value outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,856</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zcqgUOF5Wjz3" title="Number of stock options, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">724,937</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z1Eo5FlUoYVi" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zRH2UD1HMjVj" title="Number of stock options, exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,212</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zJdKL50TwPwh" title="Weighted average exercise price, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zESlJyJBftqb" title="Number of stock options, forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">91,852</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zvdCkn7KclD6" title="Weighted average exercise price, forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.03</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zbTNjo7QEVag" title="Number of stock options outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,399,252</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zra4NJ8fb5rf" title="Weighted average exercise price outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.40</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zVabW1TJeaFj" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.79</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zkbXJYj1UBS9" title="Aggregate intrinsic value outstanding, ending balance" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">928</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231_zOq0XSfUMV05" title="Number of stock options, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">662,909</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zDcWpB1BGtg3" title="Weighted average exercise price, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.79</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zNglQUMFd5T" title="Weighted average remaining contractual life, exercisable"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.87</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zxx9YEqHRkv1" title="Aggregate intrinsic value, exercisable" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">823</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Vested and expected to vest as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20220101__20221231_zn4vll4Yh4C5" title="Number of stock options, vested and expected to vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,399,252</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_z5LizxuZWzwb" title="Weighted average exercise price, vested and expected to vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.40</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zeuKVHvmGwL4" title="Weighted average remaining contractual life, vested and expected"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">7.79</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231_zToJ1H1ieup6" title="Aggregate intrinsic value, vested and expected to vest" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">928</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zDY3hDiNYt04" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there was $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20221231_zNyFeIOSiFSl" title="Unrecognized stock based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million of unrecognized stock-based compensation expense related to options granted but not yet
amortized, which will be recognized over a weighted-average period of approximately <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231_z1XmozeXqgCl" title="Weighted average period"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">3.14</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztcd4lqxqpP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the outstanding and exercisable options as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zFha8OOSuneh" style="display: none">Schedule of Ranges of Stock Options</span></span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    Outstanding</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    Exercisable</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
    of <br />
    Exercise Prices</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br />
 Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br />

    Average<br />
 Remaining<br />
 Contractual Life</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of <br />
Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br />

    Average<br />
 Remaining<br />
 Contractual Life</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z5rNdY6OzZVj" title="Range of Exercise Prices, Lower Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></span> - $ <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zf8czkAbXnK9" title="Range of Exercise Prices, Upper Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYbWOs19alM2" title="Number of Options Outstanding" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">459,080</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zg6ePRyjccT" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">4.51</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zUB3dHBzejib" title="Number of Options Exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">456,179</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zBu7Uv5hRHel" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4.49</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zvN6YN7iB3q6" title="Range of Exercise Prices, Lower Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.01</ix:nonFraction></span> - $ <span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zDTwD7xni7Y4" title="Range of Exercise Prices, Upper Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zVePqkSbGF81" title="Number of Options Outstanding" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">130,510</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zrZyhq50ZDW6" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.91</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z4cMh4UWdgpc" title="Number of Options Exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,909</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zNd8ggKQxyka" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">9.91</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zl8Q0fDKya95" title="Range of Exercise Prices, Lower Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.01</ix:nonFraction></span> - $ <span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zbWTMnWxqDhg" title="Range of Exercise Prices, Upper Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvxs2lgfSeA3" title="Number of Options Outstanding" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">459,786</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z5fpbpYTJkKc" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.65</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zc1lwe7Grcqk" title="Number of Options Exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">41,850</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvlb8PjYAAEl" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">9.09</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zgBxrzN0yOLf" title="Range of Exercise Prices, Lower Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></span> - $ <span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zq6SXywbaQK5" title="Range of Exercise Prices, Upper Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zNPwQ8t24Hv5" title="Number of Options Outstanding" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">110,530</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zTnImbMjTE5k" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFourMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.19</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zezaWnJujP69" title="Number of Options Exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">48,066</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zo1qesulux2h" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFourMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">9.19</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zCxoKiXg2xwg" title="Range of Exercise Prices, Lower Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.01</ix:nonFraction></span> - $ <span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zONVLRvLJ0J2" title="Range of Exercise Prices, Upper Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zjX6Lc3Nmlhf" title="Number of Options Outstanding" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeFiveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">66,924</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_z2l1OVuApgad" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFiveMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.75</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zbYdzUUHS4Qe" title="Number of Options Exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeFiveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">54,530</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zn3KLNahR1if" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFiveMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">8.75</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zKf6UX0UgpQi" title="Range of Exercise Prices, Lower Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.01</ix:nonFraction></span> - $ <span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zqP8Z9cgvhj5" title="Range of Exercise Prices, Upper Range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_z9MOD6y1umgb" title="Number of Options Outstanding" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeSixMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">170,069</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zWpknXv68bai" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSixMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.75</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zgync7dhd7Z5" title="Number of Options Exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeSixMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">56,689</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_z3SHETyQHIM" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSixMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">8.75</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zPhAjbNOaSNa" title="Range of exercise prices, lower range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.01</ix:nonFraction></span> - $ <span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zVtEqkrDcpgl" title="Range of exercise prices, upper range"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zwrIQdMHrlGk" title="Number of Options Outstanding" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeSevenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,353</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zBLpFhGXgv05" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSevenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.86</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_z7e8oc5JHvl7" title="Number of Options Exercisable" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31_custom_ExercisePriceRangeSevenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">686</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_z128nPWWJqo9" title="Weighted-Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSevenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">8.86</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231_zhcALNiEz5M" title="Number of options outstanding" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,399,252</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zOFJi9YrJyah" title="Weighted-average remaining contractual life (years)"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.79</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231_zOf4oIldFVGi" title="Number of options exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">662,909</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5c85f2Fv3Y6" title="Weighted-average remaining contractual life (years)"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.87</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zWr3mP9nzeF9" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_236_zXfBrOAqYZ9d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zrPhAcbEuFRh" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeO0yovDjQS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022, and 2021, the Company utilized the Black-Scholes option-pricing model for estimating the fair value
of the stock option granted. The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option
pricing model with the following weighted-average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zfm8IqfHxek4" style="display: none">Schedule of Estimate Fair Value of Stock Options</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended December 31,</b></span></td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; width: 60%; font-size: 11pt"></td><td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231_z0YfCh9eP8ci" title="Expected volatility rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.48</ix:nonFraction></span>% &#8211; <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231_zW9Fw3q4q5Bh" title="Expected volatility rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">103.20</ix:nonFraction></span> </span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231_z9l5xgHzCn78" title="Expected volatility rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">41.66</ix:nonFraction></span>% &#8211; <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210101__20211231_zxF37h0llfD2" title="Expected volatility rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.12</ix:nonFraction></span> </span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zloucWdbBLFi" title="Expected term (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.27</ix:nonNumeric></span> &#8211; <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zMkXH16V6tVb" title="Expected term (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10.00</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zwQg0SfmN1j7" title="Expected term (years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></span> &#8211; <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zqqypZoGbsvj" title="Expected term (years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.33</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zUk5mmoNcgc4" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.93</ix:nonFraction></span>% &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_zx4JtZqhGoza" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.05</ix:nonFraction></span> </span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zM9r7rsbRMKj" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.62</ix:nonFraction></span>% &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z4IgDTqTMYN7" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.36</ix:nonFraction></span> </span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z55QyJWamnB" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-01to2022-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8211;</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20210101__20211231_zvldb2069aud" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8211;</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A3_zSrmSo2Jlucf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2022, and 2021, the Company recognized $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn3d_c20220101__20221231_zD0tFCpJeAg7" title="Share based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">644,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn3d_c20210101__20211231_zzSnSJJjzYIk" title="Share based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">147,000</ix:nonFraction></span>, respectively, in stock-based compensation
expense from stock option grants and restricted stock awards. The compensation expense is allocated on a departmental basis, based on
the classification of the option holder. No income tax benefits have been recognized in the statements of operations and comprehensive
loss for stock-based compensation arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z0gJ41gFB3ci" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the components of stock-based compensation expense recognized in the Company&#8217;s statements of operations
and comprehensive loss during the years ended December 31, 2022, and 2021 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zFdR7Y9e5dFc" style="display: none">Schedule of Stock Based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231_zkkJutwYNie4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zAqdqlJlNSDb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdq1lcl3QhL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zi7WroVL0aa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">510</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_z9E3W3bLCrpk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zExLIG7lNBui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, the Company granted <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20220131__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOnePlanMember_z4HTlOhmEq6f" title="Restricted common stock granted, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-01-31_custom_TwoThousandAndTwentyOnePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500</ix:nonFraction></span> shares of restricted common stock under the 2021 Plan to a consultant as partial consideration
for services rendered, with a deemed fair value of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220131__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOnePlanMember_zHG8iiAP7ZEb" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-01-31_custom_TwoThousandAndTwentyOnePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">04.03</ix:nonFraction></span> per share or $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20220101__20220131__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOnePlanMember_zfi6pibqmSag" title="Restricted common stock granted"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-01-31_custom_TwoThousandAndTwentyOnePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction></span>. The fair value of this restricted stock award was expensed
as stock-based compensation on the date of grant as they were fully vested on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the IPO, the Company issued warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zqWDMX75FiPf" title="Warrants to purchase common stock, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-31_custom_UnderwriterMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,035,195</ix:nonFraction></span> shares of the Company&#8217;s common stock. Warrants to purchase
<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--WarrantOneMember_z47LQMik2tMf" title="Warrants to purchase common stock, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-31_custom_UnderwriterMember_custom_WarrantOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">198,875</ix:nonFraction></span> shares of the Company&#8217;s common stock expire on <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zTwAhYJwedFh" title="Warrant maturity date"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_UnderwriterMember_custom_WarrantOneMember" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 25, 2026</ix:nonNumeric></span>, and warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_zC3h2nKw8Cl3" title="Warrants to purchase common stock, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-31_custom_UnderwriterMember_custom_WarrantTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,588,120</ix:nonFraction></span> shares of the Company&#8217;s
common stock expire on August 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z6TnvXJOOGx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following is a summary of the common stock warrant activity during the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zkiAwBVDWOAi" style="display: none">Schedule
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares Issuable Upon Exercise of Outstanding Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted- Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_zzHO1g8FChAa" title="Warrants outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,786,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zeHynx49KD99" title="Weighted average exercise price, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.80</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1_dtY_c20220101__20221231_zQpiwlZMU0Gh" title="Weighted average remaining contractual life, beginning"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1">4.67</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pn3n3_c20220101__20221231_zfdPZS9g7Vcd" title="Warrants aggregate intrinsic value, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_z11VanK8BtTh" title="Warrants outstanding, issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zECa7efFD2Jd" title="Weighted average exercise price, issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231_zK3FndpS0ZEh" title="Warrants outstanding, exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zLTehmfOsYV7" title="Weighted average exercise price, execised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Expired</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20221231_zEacbokXdHe2" title="Warrants outstanding, expired" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zS1bumGzNnZk" title="Weighted average exercise price, expired" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0971">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231_zPL10zllLjef" title="Warrants outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,786,995</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20220101__20221231_zhAXrZ4pepPk" title="Weighted average exercise price, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm_dtY_c20220101__20221231_zeHKmgNkZvdb" title="Weighted average remaining contractual life, ending"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm">3.67</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pn3n3_c20220101__20221231_zoYKrBANjfth" title="Warrants aggregate intrinsic value, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zXvPbbOTtLVh" style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zPKLolaUNZtl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_zEH2m7UQ28Kd">9.
Income Taxes</span></b></span></p>



<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, the Company&#8217;s income tax provision is zero due to a full valuation allowance against
the deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zISE6hPrbzg4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
differences between the tax provision (benefit) at the statutory federal tax rate and the tax provision (benefit) are as follows (in
thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zhPAUI2T6rF3" style="display: none">Schedule
of Statutory Tax Expense and Effective Tax Expense Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_znwCkOLBzlk9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zdxYlllhy1dj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzy4e_zjjnu3dFiCb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Statutory federal income tax</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,077</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,321</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Increase (decrease) resulting from:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzy4e_zIvMT4tL1cF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,624</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PermanentItems_pn3n3_maITEBzy4e_zPF9JUW6Ql06" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Permanent items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RNXT:PermanentItems" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RNXT:PermanentItems" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_pn3n3_maITEBzy4e_zDWWnkEvL1N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prior year true ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_pn3n3_di_msITEBzy4e_zui0sQdBQsJj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">421</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">176</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzy4e_zXOuWXnvO8O" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">922</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">331</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maITEBzy4e_zMdEFWMMFb6h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzy4e_zZ4R541HVdwl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zaMLnilyrr7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_23B_zbTis3vAFW46" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zAcYelpTGp2b" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zqnDmx6II5ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zwERnc4H0kBa" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zWExNUiIyr79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231_zTCHjEHErix2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGze5H_zVEDOEaPu4Wd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,492</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,453</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTAGze5H_zZdx0VVhVfk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Tax credits carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">887</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGze5H_zm8ij9uvOk5b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGze5H_zYfhmut5ZGOj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fixed assets/intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">111</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsCharitableContributions_iI_pn3n3_maDTAGze5H_zL7gudQQ4zy6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Charitable contributions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RNXT:DeferredTaxAssetsCharitableContributions" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RNXT:DeferredTaxAssetsCharitableContributions" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsCapitalizedResearch_iI_pn3n3_maDTAGze5H_z4yE61bsHFC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Capitalized research</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RNXT:DeferredTaxAssetsCapitalizedResearch" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">813</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1029">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGze5H_z7WNfzMvUDsb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accruals and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">133</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGze5H_maDTANzECi_z3Z5aAkreLF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gross deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,475</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzECi_z8yavthM81Jj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,475</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzECi_maDTALNzb8Q_zqf9ULAo52re" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zieDzIkSJN95" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_iI_pn3n3_maDTLzAtu_zQXjMLx0M3Mc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Unrealized gain</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilities_iTI_pn3n3_msDTALNzb8Q_mtDTLzAtu_zupbkngAbWp6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzb8Q_z6th2rHVgER8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z4kzzpmdzLrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the Company had  federal and state net operating loss (&#8220;NOL&#8221;) carryforward amounts of $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20221231_zj9d2sRVYeyd" title="Net operating loss carryforward, federal"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">23.8</ix:nonFraction></span> million
and $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20221231_zu4hcbVCHaR7" title="Net operating loss carryforward, state"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.4</ix:nonFraction></span> million, respectively. The federal NOL carryforwards consists of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20171231_zWQDnyrTiUrb" title="Net operating loss carryforward, federal"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.6</ix:nonFraction></span> million generated before January 1, 2018, which will
begin to expire in 2030 but are able to offset 100% of taxable income and $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20180101_zzy0ZlS65DH7"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2018-01-01" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">19.2</ix:nonFraction></span> million generated after December 31, 2017 which can be
carried forward indefinitely and may be able to be used against 100% of taxable income through the tax year ending December 31, 2020,
as updated by the Coronavirus Aid, Relief, and Economic Security Act (P.L. 116-136), otherwise known as the CARES Act. Federal NOLs will
then be subject to 80% limitation for tax years beginning on or after January 1, 2021.The state NOL carryforward will begin to expire
in 2033.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had federal and state tax credit carryforwards of $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalAndStateMember_zVN81BfRFoDa" title="Federal and state tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_FederalAndStateMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million which will begin to expire in 2033,
and California tax credit carryforwards of $<span id="xdx_906_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsForeign_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--CaliforniaTaxCreditMember_zwcdrw2FaHDi" title="Tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" contextRef="AsOf2022-12-31_custom_CaliforniaTaxCreditMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million which do not expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows Financial Accounting Standards Board No. 48, <i>Accounting for Uncertainty in Income Taxes &#8211; an interpretation
of FASB No. 109</i>, as codified in FASB ASC 740-10, <i>Income Taxes</i>. At December 31, 2022, unrecognized tax benefits related to
federal and state tax credits was $<span id="xdx_908_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalAndStateMember_zae44oBzstne" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31_custom_FederalAndStateMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million. The Company did not have tax-related interest and penalties at December 31, 2022. The
Company does not expect significant changes to its unrecognized tax benefits in the next twelve months. If recognized, none of the unrecognized
tax benefits would affect the effective tax rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of
ownership changes that have occurred previously or that may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code
(&#8220;IRC&#8221;) a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change
NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined
as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company
has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. If
an ownership change has occurred, the Company&#8217;s ability to use its NOLs or tax credit carryforwards may be restricted, which could
require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the CARES Act was enacted and signed into law in response to the COVID-19 pandemic. GAAP requires recognition of the
tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax
provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief
measures for businesses include a five-year net operating loss carryback, suspension of the annual deduction limitation of 80% of taxable
income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest,
acceleration of alternative minimum tax credit refunds, payroll tax relief, technical corrections on net operating loss carryforwards
for fiscal year taxpayers and allows accelerated deduction qualified improvement property. The CARES Act also provides other non-tax
benefits to assist those impacted by the pandemic. The Company filed for and received a PPP loan. We evaluated the impact of the CARES
Act and determined that there was no material impact for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2020, California Assembly Bill 85 was signed into law. The legislation suspended the California net operating loss deductions
for 2020 and 2021 for certain taxpayers. <span id="xdx_905_eus-gaap--IncomeTaxHolidayDescription_c20220101__20221231_zdkgTqOjCLbf" title="Income tax, description"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeTaxHolidayDescription">The
legislation disallowed the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted
gross income is greater than $1.0 million. The carryover periods for net operating loss deductions disallowed by this provision will
be extended. The new legislation did not impact the current year provision or our financial statements for the year ended December
31, 2022.</ix:nonNumeric></span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_236_zm0t0AAhxSA7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zqK0SS8jpHYc" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 27, 2020, the Consolidated Appropriations Act, 2021 was enacted and signed into law to further COVID-19 economic relief and
extend certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans
can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion
of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for
food and beverages provided by a restaurant. The provisions did not have a material impact on our financial statements for the year ended
December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Uncertain
Income Tax Positions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total amount of unrecognized tax benefits as of December 31, 2022 is $<span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20221231_zt0zamrvIUq4" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million which relates to federal and state tax credits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zFOzddFMJnag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended December 31, 2021 and
December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_z9nQRS8rmQv2" style="display: none">Schedule
Of Unrecognized Tax Benefits</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20210101__20211231_zlAkIMc3Yvj8" title="Beginning unrecognized tax benefits" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax positions related to the current year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--UnrecognizedTaxBenefitsAdditions_pn3n3_c20210101__20211231_zx5A0gbbRgTh" title="Additions" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="RNXT:UnrecognizedTaxBenefitsAdditions" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20220101__20221231_zZf73DBHBEr8" title="Beginning unrecognized tax benefits" style="text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax positions related to the current year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--UnrecognizedTaxBenefitsAdditions_pn3n3_c20220101__20221231_zaBLvpM0dcOl" title="Additions" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="RNXT:UnrecognizedTaxBenefitsAdditions" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20220101__20221231_zLlD5lPVGDFc" title="Ending unrecognized tax benefits" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">449</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zg9Z8q6uh2c6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy is to account for interest and penalties as income tax expense. As of December 31, 2022, the Company had no interest
related to unrecognized tax benefits. No amounts of penalties related to unrecognized tax benefits were recognized in the provision for
income taxes. We do not anticipate any significant change within twelve months of this reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is subject to U.S. federal
and state income tax examination for calendar tax years beginning in 2010 due to net operating losses that are being carried forward
for tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_z1wm1SAxgZsf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zvfet6qHkRbg">10.
Net Loss per Share</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zWI0aCdsQ6F8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per common share was calculated as follows (in thousands except per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zPUU07vKP2Qd" style="display: none">Schedule of Computation of Basic and Diluted Net Loss Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zeDlRnkl1Gol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231_zGByHEN5YLgh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Numerator:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_z7YdMFcyoHij" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,889</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,324</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zx2FgHMzb9We" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares used in computing net loss per share &#8211; basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9,052</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,217</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_zJdlTwHdUR45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss per share &#8211; basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.09</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.21</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zEuCCVuWbK8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, the Company had a net loss and as such, all outstanding shares of potentially dilutive securities
were excluded from the calculation of diluted net loss per share as the inclusion would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zsI8Bz80kBPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities not included in the computation of diluted net loss per share because to do so would be antidilutive are as follows
(in common stock equivalent shares):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z8zSUZwNfVAc" style="display: none">Schedule of Potentially Anti Dilutive Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zYBSskZsHIbk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_z5oS6p1u9tY7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zwa1JLG0uCUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">730,746</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">684,382</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zLncqyhDISwj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">730,746</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">684,382</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zoSXZcADAMzj" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><p id="xdx_232_zOxaGwPd35Jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RenovoRx,
Inc.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zdLlo0rKsVo" style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zY7ytfdEEJOa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_zC6AkHYgAC2g">11.
Related Party Transactions</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2018, the Company entered into a consulting agreement with one of the Company&#8217;s co-founders, Dr. Ramtin Agah, pursuant
to which Dr. Agah provides consulting services as the Company&#8217;s Chief Medical Officer by overseeing Company-sponsored clinical
trials. The agreement, which was amended on September 1, 2019, and November 11, 2021, respectively, continues in force for as long as
Dr. Agah is providing consulting services and may be terminated by either party on 30 days&#8217; notice. Dr. Agah was awarded (i) options
to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20170531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zQwpfXGjvQ6c" title="Share based compensation arrangement by share based payment award, options, outstanding, number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2017-05-31_custom_DrAgahMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span> shares of the Company&#8217;s common stock in May 2017, which have vested, (ii) options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20180731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zATZqIRKL2Y1" title="Share based compensation arrangement by share based payment award, options, outstanding, number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2018-07-31_custom_DrAgahMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> shares
of the Company&#8217;s common stock in July 2018, which have vested, (iii) options to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zaTLKSU5kFOj" title="Share based compensation arrangement by share based payment award, options, outstanding, number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_custom_DrAgahMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> shares of the Company&#8217;s common
stock in June 2021, which vest ratably over 24 months from the vesting commencement date of May 14, 2021, (iv) options to purchase of
<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zZDysa0R16za" title="Share based compensation arrangement by share based payment award, options, outstanding, number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_DrAgahMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,203</ix:nonFraction></span> shares of the Company&#8217;s common stock in September 2021, which vest ratably over 48 months from the vesting commencement
date of August 26, 2021, and (v) options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zTW61Rdi4YFg"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_custom_DrAgahMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,398</ix:nonFraction></span> shares of the Company&#8217;s common stock in March 2022, which vest ratably
over 48 months from the vesting commencement date of August 26, 2021. In December 2018, Dr. Agah&#8217;s agreement was amended to provide
that he would receive cash compensation of $<span id="xdx_900_ecustom--CashCompensation_iI_pid_c20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_ztn4nE3TB11b" title="Cash compensation per month"><ix:nonFraction name="RNXT:CashCompensation" contextRef="AsOf2018-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span> per month for certain proctoring services, and in September 2019, his compensation
was increased to $<span id="xdx_90E_ecustom--CashCompensation_iI_pid_c20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zz9LA1fO0Uv5" title="Cash compensation per month"><ix:nonFraction name="RNXT:CashCompensation" contextRef="AsOf2019-09-30_custom_DrAgahMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> per month to compensate for additional services he was providing. <span style="background-color: white">In November
2021, we entered into a third amendment to the Consulting Agreement with Dr. Agah which </span>provides for a monthly consulting fee
of $<span id="xdx_903_ecustom--CashCompensation_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember_zY15KEeEQBe5" title="Cash compensation per month"><ix:nonFraction name="RNXT:CashCompensation" contextRef="AsOf2021-11-30_custom_DrAgahMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction></span>, based on Dr. Agah spending no less than 24 hours per week on Company matters. Dr. Agah&#8217;s monthly consulting fee was
increased to $<span id="xdx_90A_ecustom--CashCompensation_iI_c20230101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember_zMEYYCuRR2ji" title="Cash compensation per month"><ix:nonFraction name="RNXT:CashCompensation" contextRef="AsOf2023-01-01_custom_DrAgahMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> effective January 1, 2023. The Company may, in its discretion, proportionally adjust the monthly consulting fee
if Dr. Agah&#8217;s time commitment decreases. The amendment also provides for Dr. Agah&#8217;s eligibility <span style="background-color: white">for
an annual target cash incentive bonus equal to 40% of his annualized base consulting fee. </span>In November 2021, we entered into a
Change in Control and Severance Agreement with Dr. Agah. Consulting fees paid to Dr. Agah for the years ended December 31, 2022 and 2021,
were $<span id="xdx_90B_eus-gaap--ProfessionalFees_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zeUJyoWuALH3" title="Consulting fees"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2022-01-012022-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,000</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ProfessionalFees_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zWgxpYIEO2l5" title="Consulting fees"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2021-01-012021-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,000</ix:nonFraction></span>, respectively. In addition, the Board approved a discretionary bonus of $<span id="xdx_900_ecustom--DiscretionaryBonus_c20230201__20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zf8thLilHH5f" title="Discretionary bonus"><ix:nonFraction name="RNXT:DiscretionaryBonus" contextRef="From2023-02-012023-02-28_custom_DrAgahMember_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,000</ix:nonFraction></span> paid in February 2023 to Dr.
Agah in recognition of Company and individual performance during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock"><p id="xdx_809_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zoBcinCuV7W9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_823_zDW4KbaE84t9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
Employee Benefit Plans</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (the &#8220;401(k)
plan&#8221;). The 401(k) plan covers all employees who meet defined minimum age and service requirements. Employee contributions are
voluntary and are determined on an individual basis, limited to the maximum amount allowable under U.S. federal tax regulations. The
Company makes matching contributions of up to 4% of the eligible employees&#8217; compensation to the 401(k) plan. During the year ended
December 31, 2022, the Company made contributions to the 401(k) plan of $<span id="xdx_908_eus-gaap--DefinedContributionPlanCostRecognized_c20220101__20221231_zI1IIJFbvGPi" title="Defined contribution plan cost"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,200</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zMrrihvOSjJ5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zBNonuzS9HW8">13.
Subsequent Events</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 30, 2023, the Company entered into a
definitive securities purchase agreement with a certain institutional investor under its shelf registration statement for the
purchase and sale of <span id="xdx_903_eus-gaap--SharesIssued_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrZvFV9ZR8Cg"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-03-30_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,557,632</ix:nonFraction></span> shares of the Company&#8217;s common stock (or pre-funded common stock warrants) at a purchase price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWfeMXxHygJg"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-03-30_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.21</ix:nonFraction></span> per share of common stock (or pre-funded common stock warrants) (the &#8220;Registered Direct Offering&#8221;).
Additionally, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlDJzRZJMKm8"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-03-30_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,947,040</ix:nonFraction></span>
shares of its common stock (together with the Registered Direct Offering, the &#8220;March 2023 Offering&#8221;). The aggregate gross
proceeds from the March 2023 Offering are approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfWarrants_c20230329__20230330__us-gaap--TypeOfArrangementAxis__custom--DefinitiveSecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXlwwxjhGKr8" title="Stock warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-03-292023-03-30_custom_DefinitiveSecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></span>
million before deducting placement fees and other offering expenses.</p>

</ix:nonNumeric><p id="xdx_81B_zRGgnkaFOQKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 92; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>ex10-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>RenovoRx,
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INC.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OUTSIDE
DIRECTOR COMPENSATION POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Initially
Adopted and Approved by the Board of Directors on September 30, 2021; most recently amended and restated September 29, 2022 (the &ldquo;<B>Restatement
Date</B>&rdquo;)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RenovoRx,
Inc. (the &ldquo;<B>Company</B>&rdquo;) believes that providing cash and equity compensation to its members of the Board of Directors
(the &ldquo;<B>Board</B>,&rdquo; and members of the Board, the &ldquo;<B>Directors</B>&rdquo;) represents an effective tool to attract,
retain and reward Directors who are not employees of the Company (the &ldquo;<B>Outside Directors</B>&rdquo;). This Outside Director
Compensation Policy as amended and restated (the &ldquo;<B>Policy</B>&rdquo;) is intended to formalize the Company&rsquo;s policy regarding
the compensation to its Outside Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning
given to such terms in the Company&rsquo;s 2021 Omnibus Equity Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;), or if the Plan is no longer
in place, the meaning given to such terms or any similar terms in the equity plan then in place. Each Outside Director will be solely
responsible for any tax obligations incurred by such Outside Director as a result of the equity and cash payments such Outside Director
receives under this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
amended and restated Policy is effective as of the Restatement Date, unless otherwise specified in specific sections of this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>1.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Cash
    Compensation</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Annual
Cash Retainer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Outside Director will be paid an annual cash retainer of $36,000. There are no per-meeting attendance fees for attending Board meetings.
This cash compensation will be paid quarterly in arrears on a prorated basis to each Outside Director who has served in the relevant
capacity at any point during the immediately preceding fiscal quarter, and such payment shall be made no later than forty-five (45) days
following the end of such immediately preceding fiscal quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Committee
Annual Cash Retainer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of April 12, 2022, each Outside Director who serves as the chair or a member of a committee of the Board listed below will be eligible
to earn additional annual cash fees (paid quarterly in arrears on a prorated basis to each Outside Director who has served in the relevant
capacity at any point during the immediately preceding fiscal quarter, and such payment shall be made no later than forty-five (45) days
following the end of such immediately preceding fiscal quarter) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">Chair of Audit Committee:</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">15,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chair of Compensation Committee:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chair of Corporate Governance and Nominating Committee:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-Chair Members of Various Committees:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Lead Independent Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
clarity, each Outside Director who serves as the chair of a committee shall receive only the additional annual cash fee as the chair
of the committee, and not the additional annual cash fee as a member of the committee. For purposes of further clarification, an Outside
Director who has served as an Outside Director, or as a member of an applicable committee (or chair thereof), as applicable, during only
a portion of the relevant Company fiscal quarter will receive a pro-rated payment of the quarterly payment of the applicable annual cash
retainer(s), calculated based on the number of days during such fiscal quarter such Outside Director has served in the relevant capacities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>2.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Equity
    Compensation</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
Directors will be eligible to receive all types of Awards (except Incentive Stock Options) under the Plan (or the applicable equity plan
in place at the time of grant), including discretionary Awards not covered under this Policy. All grants of Awards to Outside Directors
pursuant to Section 2 of this Policy will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in
accordance with the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>No Discretion</U>. No person will have any discretion to select which Outside Directors will be granted any Awards under this Policy
or to determine the number of Shares to be covered by such Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Initial Award</U>. Subject to the following sentence and the terms of this Policy, each individual who first becomes an Outside Director
following the Restatement Date will be granted Options having a Value of $120,000 in the aggregate (an &ldquo;<B>Initial Award</B>&rdquo;),
on the date on which such individual first becomes an Outside Director, whether through election by the stockholders of the Company or
appointment by the Board to fill a vacancy. Notwithstanding the foregoing, no Initial Award granted on or after the Restatement Date
but on or prior to September 30, 2023 will cover more than 43,026 Shares (with such maximum number of Shares to be automatically proportionately
adjusted in the event of a Change in Capitalization, with any fractional Share resulting from such adjustment eliminated). Subject to
Section 11 of the Plan and Section 3 of this Policy, each Initial Award will vest and become exercisable over three years, with 1/36th
of the Initial Award vesting each month on the same day of the month as the commencement of the applicable Outside Director&rsquo;s service
as an Outside Director, subject to the Outside Director continuing to be a Participant (as defined in the Plan) through such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Annual Award</U>. Subject to the following sentence and the terms of this Policy, on October 1 of each year, commencing October 1,
2022, each Outside Director will be automatically granted Options having a Value of $70,000 in the aggregate (an &ldquo;<B>Annual Award</B>&rdquo;).
Notwithstanding the foregoing, no Annual Award granted on or after the Restatement Date but on or prior to September 30, 2023 will cover
more than 25,099 Shares (with such maximum number of Shares to be automatically proportionately adjusted in the event of a Change in
Capitalization, with any fractional Share resulting from such adjustment eliminated). Subject to Section 11 of the Plan and Section 3
of this Policy, 1/12th of each Annual Award will vest monthly after October 1 on the first day of each subsequent month, subject to the
applicable Outside Director continuing to be a Participant through such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Terms</U>. The terms and conditions of each Initial Award or Annual Award will be as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Exercise Price</U>. The per Share exercise price for an Option granted under this Policy will be 100% of the Fair Market Value on
the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Term</U>. The maximum term to expiration of an Option granted under this Policy will be 10 years, subject to earlier termination as
provided in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Value. For purposes of this Policy, &ldquo;<U>Value</U>&rdquo; means the grant date fair value as determined for the Company&rsquo;s
financial reporting purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>3.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Change
    in Control</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a Change in Control, each Outside Director will fully vest in his or her outstanding Company equity Awards, including any
Initial Award or Annual Award, provided that the Outside Director continues to be an Outside Director through such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>4.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Annual
    Compensation Limit</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any fiscal year, other than the fiscal year in which he or she joins the Board, no Outside Director may be paid, issued or granted compensation
(including in the form of cash or equity compensation, with cash compensation measured for this purpose at its value upon payment and
any equity compensation measured for this purpose at its Value) with an aggregate value greater than $250,000 (increased to $300,000
for an Outside Director&rsquo;s first fiscal year of service). Any cash compensation paid or equity compensation award (including any
Awards) granted to an individual for his or her services as an employee, or for his or her services as a consultant (other than as an
Outside Director), will not count for purposes of the limitation under this Section 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>5.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Travel
    Expenses</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Outside Director&rsquo;s reasonable, customary and documented travel expenses to Board or Board committee meetings will be reimbursed
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>6.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Additional
    Provisions</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
provisions of the Plan not inconsistent with this Policy will apply to Awards granted to Outside Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>7.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Adjustments</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that that any extraordinary dividend or other extraordinary distribution (whether in the form of cash, Shares, other securities
or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination,
repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting
the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to
be made available under this Policy, will adjust the number of Shares issuable pursuant to Awards granted under this Policy.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>8.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Section
    409A</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
no event will cash compensation or expense reimbursement payments under this Policy be paid after the later of (i) 15th day of the third
month following the end of the Company&rsquo;s fiscal year in which the compensation is earned or expenses are incurred, as applicable,
or (ii) 15th day of the third month following the end of the calendar year in which the compensation is earned or expenses are incurred,
as applicable, in compliance with the &ldquo;short-term deferral&rdquo; exception under Section 409A of the Internal Revenue Code of
1986, as amended, and the final regulations and guidance thereunder, as may be amended from time to time (together, &ldquo;<B>Section
409A</B>&rdquo;). It is the intent of this Policy that this Policy and all payments hereunder be exempt from or otherwise comply with
the requirements of Section 409A so that none of the compensation to be provided hereunder will be subject to the additional tax imposed
under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or comply. In no event will the
Company reimburse an Outside Director for any taxes imposed or other costs incurred as a result of Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>9.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Revisions</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend, alter, suspend or terminate this Policy at any time and for any reason. No amendment, alteration, suspension or termination
of this Policy will materially impair the rights of an Outside Director with respect to compensation that already has been paid or awarded,
unless otherwise mutually agreed between the Outside Director and the Company. Termination of this Policy will not affect the Board&rsquo;s
or the Compensation Committee&rsquo;s ability to exercise the powers granted to it under the Plan with respect to Awards granted under
the Plan pursuant to this Policy prior to the date of such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR>
Exhibit 23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the registration statements (No. 333-263972 and 333-260573) on Form S-8, registration statement
(No. 333-268302) on Form S-3, and registration statement (No. 333-268316) on Form S-1 of RenovoRx, Inc. of our report dated March 31,
2023, relating to the financial statements of RenovoRx, Inc. (which report expresses an unqualified opinion on the financial statements
for the year ended December 31, 2022 and includes an explanatory paragraph relating to substantial doubt about RenovoRx, Inc.&rsquo;s
ability to continue as a going concern as described in Note 1 to the financial statements), included in this Annual Report on Form 10-K
of RenovoRx, Inc. for the year ended December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    BAKER TILLY US, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mountain
    View, CA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2023</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RULES
13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Shaun R. Bagai, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K of RenovoRx, Inc.;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                            and 15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal control over financial reporting, or caused such internal control over financial
                                            reporting to be designed under our supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Date: March 31, 2023 </FONT></TD>
    <TD STYLE="font-style: italic; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-style: italic; width: 47%"> /s/ Shaun R. Bagai</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RULES
13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</B></FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
James M. Ahlers, certify that:</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K of RenovoRx, Inc.;</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                            and 15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal control over financial reporting, or caused such internal control over financial
                                            reporting to be designed under our supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">Date:
March 31, 2023</TD>
  <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ James M. Ahlers</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>James M. Ahlers</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of RenovoRx, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2022 as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I hereby certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange
                                            Act of 1934; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in the Report fairly presents, in all material respects, the financial
                                            condition and results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">Date:
March 31, 2023</TD>
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%"><I>/s/ Shaun R. Bagai</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Shaun R. Bagai</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD><P STYLE="margin: 0">Chief Executive Officer</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of RenovoRx, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2022 as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I hereby certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange
                                            Act of 1934; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in the Report fairly presents, in all material respects, the financial
                                            condition and results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">Date:
March 31, 2023</TD>
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%"><I>/s/ James M. Ahlers</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>James M. Ahlers</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M^?*V_P"^* UO_P ^5M_WP?\ &CE8'9^='_?7\Q1YT?\ ?7\Q7&;K?_GRMO\
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M8KG/L=I_SY6__?-*+&S/_+E;_P#?/_UZ!'1>='_?7\Q1YT?]]?S%<[]AL_\
MGRM_^^?_ *]'V&S_ .?*W_[Y_P#KT =%YT?]]?S%'G1_WU_,5SOV&S_Y\K?_
M +Y_^O1]AL_^?*W_ .^?_KT#L=%YT?\ ?7\Q1YT?]]?S%<[]AL_^?*W_ .^?
M_KT?8;/_ )\K?_OG_P"O0%CHO.C_ +Z_F*/.C_OK^8KG_P"S[/\ Y\H/^^:/
M[/L_^?*#_OF@1T"R*PR&&/K17*+(FGW%S% K11F0-M4< E5HH Z^BBB@ HHH
MH **** "BBB@ HHHH *:PIU% #=N[K2[1Z4M% !67J7_ "$M*_ZZO_Z U:E9
M>I?\A+2O^NK_ /H#4 >>ZL/^)M=G_IJW\S56K6K?\A6\_P"NK?S-5:[H[')U
M84J_=I*5:; 6BBBF 4J_>I*5?O4F4AU%%%(84444 %.6FTY:0"T444 %%%%
M!1110 JTM(M+0 4Y:;3EH 6BBB@ HHHH&@I5I*5:3!CJ***0@HHHH&@HHHH*
M"BBB@ IU-IU !1110 4Y:;3EH 6BBB@!%^Z*6D6EJ4-A1115"'T444 %<OXD
M@DD\2:.ZQLZ*?F91D#YN]=13>G!J&4.HI%I: '?PT4?PT4$]0HHHH*"BBB@
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M"G4VG4RD%%%%)@PHHHJ215IU-6G5984444F 4445(!1110 4JTE*M #J***
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M4444$%*3_C\NO]\?^@+11)_Q^77^^/\ T!:* .KHHHH **** "BBB@ HHHH
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M1?\ ")'_ )^O_'?_ *]'_")'_GZ_\=_^O1S(=CG:<M=!_P (D?\ GZ_\=_\
MKTG_  B+?\_/_CO_ ->CF06,&BN@_P"$3/\ S\_^.T?\(F?^?G_QVCF06.?H
MKH/^$3/_ #\_^.T?\(F?^?G_ ,=HYD%CGZ*Z#_A$S_S\_P#CM'_"*'_GY_\
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M*3_A'S_SV_\ ':D#*HK5_P"$?/\ SV_\=H_X1\_\]O\ QV@#*HK5_P"$?/\
MSV_\=H_X1\_\]O\ QV@#*HK5_P"$?/\ SV_\=I?^$?/_ #W_ /': ,NBM;^P
M3_SU'_?-)_8!_P">H_*@#*IRUI_V ?\ GJ/RI1H)'_+4?]\TF!F45J?V"?\
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MGT5H?V2?^>GZ4?V0?^>GZ4#N9].6KW]D'_GI^E*NDG_GI^E BC15_P#LD_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K@O!.O7^I>+/$%K<W#2P6[XB0XPO.,"N]K@_!>@W
M^F^+/$%W<VYCM[E\Q/D'=S0!WE%(M+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!RE]_R$[S_KH/_05HHOO^0G>?
M]=!_Z"M% '5T444 %%%% !1110 4444 %%%% !1110 4444 %9FH?\A+2_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M5CNH)I'2.5)'3AE5@2/J*M5YG\//^1X\4?[_ /6@#TRBD6EH **** "BBB@
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M!9/.LVVR%EP.N.* -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%X3_ -__ -FKTRLR\T&QU"^M[RXMTEN;<YBD;JO.>/QH T5IU(HQ2T %%%%
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M\]I/^^J/M$W_ #VD_P"^J7LPYSU3=[BC=[UY7]HF_P">TG_?5+]HF_YZR?\
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MNX>M<=XH\77>C>*M$TV%8S!>MB0L.1SCBLSSI?\ GH__ 'T:Y7Q(LTWB31G
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M>WY<8QC'I5?3]+L]+A,5E:06<1.XQV\:HN3U. .M:-% !67J7_(2TK_KJ_\
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M9=;_ **?X\_\&4?_ ,;I/^&7?^JG^//_  91_P#QNLN2C_/^!5Y/H>E^6_\
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M*3 ****D HHHH *5:2E6@!U%%% !1110 4+UHH7K0 ZBBBEU ****8!1110
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M** 'T444D 4444, HHHJ0,'4-%GNO%%EJ"%?(A7#9//?I6]56;5+:&\CM7E
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M "<I\6/^O+2__0&KW>M\5\?R7Y$4_A&,JR1NC#*."K#V((/Z&O$?ACX)\9?
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M(GQ$T+X7>%[O7_$%XMG90+PO62=S]V.->K.QP  .]>1?!_P_K'B3Q%J_Q/\
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MJ***74 HHHI@%%%% #Z***D HHHIH HHHI@*M.IJTZI **** "BBB@ HHHH
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MRTVG+6 "T444 %%%%!84444 .HHHH(*4G_'Y=?[X_P#0%HHD_P"/RZ_WQ_Z
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MF3_XW7I?/I1^%'M*?\B_'_,.27<\S/Q7^-/_ $272/\ PID_^-T?\+6^-/\
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MY3^=?8FGWB:A8VUU&P>.>)958=/F4'/ZU[^._>8>G4\K?<<E+W9RB6****\
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MZ]Z\*^(C']K+]MS2/"$#F?P7X#'VB^QRDDZD%@?<L OX&OO555<*H"(!A5'
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M5S:6AGM[ZW59)+.\B,4PC8?*X4_PGUKY'T+65UC]G?0XK>"Y@TZQ\71O?^;
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M_P"$;TW_ )]$_7_&C_A&]-_Y]$_7_&CVJ'RGG611D5Z+_P (WIO_ #Z)^O\
MC2?\(WIO_/JOZTO:(.4\[R*,BO1/^$;TW_GU7]:/^$;TW_GU7]:?M4'*>>*:
M=7H/_"-Z;_SZK^M'_"-Z;_SZK^M'M4+E//J<M=__ ,(WIO\ SZK^M+_PCFF_
M\^J_K1[5!RG 45W_ /PCFF_\^J_K1_PCFF_\^J_K1[5!RG 45W__  CFF_\
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M -FVW_/%?UH_LVV_YYK2 P:&ZUO?V;;?\\UI?[/@_P">0H PJ3^*M[^SX/\
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M;5IUF:A_R$M+_P"NK_\ H#4@-.DQ[TM% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!!,HDA93T(KX*_8;9OA[^U1\<_ #GR
MX6N_[0MH>@QO;)'U#K^5?>_^%? OB=F^&/\ P4\T*[_U5KXNTL0G' 9MA&3[
M[H_UKUL!^\IU:7>-_N.6MHXR\S[]YIU,5N*?7DG4%%%% !7 ^,M#O]0\;>'+
MNWMVDMK=LRR#&%YSS7?56DNH8Y$C>1%=ONJS $T 3K3J3BEH **** "BBB@
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M!1110 4444 %%%% !1110 4444 %%%% '*7W_(3O/^N@_P#05HHOO^0G>?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?-&$9<KD[:=ETU,W:^Y]16ZE88PQR0H!/X5/4$,GG0QOC&Y0<?45/7B2WU-
MHHHI %%%% !1110 5F:A_P A+2_^NK_^@-6G69J'_(2TO_KJ_P#Z U &G111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,*\\565CX@M-'E+_:[E=R87([]_PK=KS+Q-_P E;T+_ *Y_XUZ8M "T444
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M_P :H_X;0^&?_/WK7_@BO/\ XU1["I_*PYD>YT5X9_PVA\,_^?O6O_!%>?\
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M )^]:_\ !%>?_&J/^&T/AG_S]ZU_X(KS_P"-4>PJ?RL.9'N=%>%_\-H?#/\
MY^]9_P#!%>?_ !JC_AM#X9_\_>L_^"*\_P#C5'U>I_*PYD>Z5B:3XHL]:U*^
ML;<OY]F<2[EP.O:O)?\ AM#X9_\ /UK7_@BO/_C5<1X/_:P^'NE^*M?NYY]:
M6&X?,9_L.[.><_\ //\ G3^KU.S"Z[GU7SZ4N#Z5X5_PVE\,O^?K6?\ P1WG
M_P :J.;]M+X8PQO))>ZPB(I9F;0KP  <DD^5TQ2^KU.S%S+N>]C%+7.^#?&&
ME^.O#&F>(=%N?MFDZC"MQ;3;2N]&Z'!&:Z'/%8-.+L]RD[BT444QA113=PH
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M%>27\36YA8 9#!@.<$=/6FX58V;3U#FB=G]DA_YXK_WR*/L</_/*/_OFO/\
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M9-MI+[AQIR6Y\U^(K'7]2_;(U>+0-6M]*NE\&0EY;FV$ZD&Y; VY&,'FL?\
M9Q\<0_#WP3\66O1%?ZYI.O7!O-2M6!@U6\D *")<_*<E4V@\&O?]6^!?@+7-
M>NM;O?#-A<:O=#$]XRD2R#T+9J2X^"_@>Z\/6^A2>&M/.CV\XN8[,0@()0<A
M\#JV>]:_6H2@H26EET[$^SGS71\J^$=:U7X,_&[PIXHUK0-7T+3O&47]F^(;
MK4A&L)U%V+0295SZE,D=,5ZYH\BR?ML:T0RG_BCX>A''^D'']:]8\7?"WPE\
M0-/L[#Q'H-EK-G:-N@AO$#K&P& P![X'7K61-^S_ /#R;4I-1D\+:>U_*BQ/
M=8(E95 "KNSG P.*'B*<TY---JWX^HE3E&R7<\T_;%UJQU3X8Z;%:W,=P]MX
MNT>&78<[7%W&2N?4#TKO/VA-0NY/A#XJTG0KDCQ)>:3<?8K>)OWS[4.[:!WQ
MG\2*T[[X"_#_ %31[/2KKPIIMSIUG*T\%M)'E$D)R7 S]XD#DUI^'?A5X3\)
MZL^IZ3HEK97[1>0;B/)?82"5R3T) K#VM.*C:[Y7?\B^63;;ZGDG@_7/!Z_L
M>V<N^T308_#WD31N5XE$6UHV']_?G@\D^]>0_!BUU?P[\1O@0WC@3PVK>$[B
MVT]KXD+'>%P55B?^6AAP!W_45]9R?!OP1)JQU%O#.G&\,GFF3R1@OUW;?NYS
M[5N>(O"NC>+--^P:QIUOJ-ID,(;A P!'0CT-;QQ2BI)+XK_*ZZ$NE)M/L>"?
M%13J7[6'PO30CYFH6-G?2:RT/_+.S:,!!+[%\8SWKD?^$;U'X3QO\6/!D+WN
MGW$US%XLT.URWVJ%9G N8E_YZQXY ZJ"*^FM%^'/A?PS97EIINC6EE;W:[+@
M1+@R*1C#-U(^IJ;PGX!\/>!])ETS0=*M=+L)79WMX%Q&S-U.,]^?SJ8XI1BH
MI76GS_JY3IMLY7]G34K?6O@OX;O[1R]M=6YEB8C!*LS$$CZ&N*_9KU.TM=6^
M*^GSNEO>6OBJZGFBD(4K&ZHRN1_=(!.37N>DZ38Z'I\-CI]M#9V<(Q'#"H5%
M'H!Z9KG?$'PG\'^*-4;4M4T&QO+]@%:X=,.X'0,0>0/>L?;)N2:TD5R/3R/F
M3XO,_P#PS'J%S!)&/M/C$W%M*Y.QU?4MR-G/W2".E>P?#;X-ZS8_%S5_B1XD
MU.RN-5O=,ATNVL]+B>.&*!&+Y<L<NY8]?2N[\6?"GPCXXTNSTS7M L-3T^S(
M-O:SQ@QQ8 QA>G&!73:78VNCV-O9VD:V]I;H(XXEZ*HX 'L*UEB?W7LX[N]_
M1BC2M+F9>(VXQ7EG[3EPMO\ L_\ C]G( ;1KA![LR%1^I%>I,RXZU\\_M1:I
M)XPNO"_PKTMO-U+Q->QS7RH>8-.A=7FD;T!(5!ZDFN6C'FJ1\M?N-*CM$]8^
M$L+6OPT\+0R#$B:7;*P]Q$N:[.J%G'!8VL-O&52.)!&J@C@  8JUYT?]]?SJ
M*CYI.2*BK*Q+13/.C_OK^='G1_WU_.I&/HJ/SH_[Z_F*3[1'_?7\Z ):*B^T
M1_WU_.C[1'_?7\Z /!/VUI&7X(SP@_)<ZKI\$@]5:Y0$?E7NEC&([6%1T"*!
M^ KPK]M216^#*88'_B=Z9T_Z^HZ]XM6'V>/G^$?RKJG_  8^K_0PC_$9D^,H
M=.NO">KPZKG^S'M9%N<$C]V5.[GZ9KY9\/W&K_"75OA[I=Y>V/Q ^'&J7\-K
MX>O@ NH:8S*?+W$'$L87*EL9 ZU];W$,-W;R0S(DT,BE6C< A@>H(]*YC2?A
M3X/T'6(]4L/#]A:7T8Q%-'$ 8^,':.B\>E13K*G%I]2I0<FF>3?&!HX_VEO@
MS&I5/FU'"# _Y8?RK8_:$\0/-::5X,TW2[O6)M:E+ZC9::J&86*G,K$%@,,<
M)U_B-=[X@^$OA#Q3XDL_$&JZ!97^M6N/L]],F98L'(VG/'X5>;X>>')/%Z^*
M6T>U/B%(O(74=O[T1_W<YZ5NL1#W79W2_$AQ>J/GK]DWQ9<>&KKQ?\*M6L[K
M1YM#G>^T6SU#:LQTR8ED& 3PC;EX/H*\(TV:_P!4^%_A+1/%,]IIWPKO?%=Z
MU[K5JK-<6TZ:A(\,<I)Q&KN,>8!QQTSFON;5/@OX*UCQ))XAO?#=A<ZY-"8'
MU!D_?-&1@INZ[<$\9INC_!/P-H?AW4M L?"^F6^BZCS=Z>L ,,QYY9>F>_2N
MF.,IQE*2CJ[??U:,W3DU9LXO]JYK9?V;?&$T#QF%K%2LJL,.NY0#N[Y&.]>F
M^ XU_P"$/T-\ M]AA&[ S]P<9]*R[[X.>"M2\'P>%;KPY8W'AV!MT>FR*6A4
MY)'RY]3WKI_#^@Z=X7T>WTS2K6*PL+==L4$7W4'M7GSJ*5-05][FZB^;F9X-
MILB-^V5XJ7<I(\*V^03_ --G[5YVNBW_ ,"])3XG>%;>2^\+:K#(/%6C6HW'
MJP%["HZ,O\0'45](W'P3\#7'B2\UZ3P[8'6;M6CGOMA$LBL""I;/0@FMGPWX
M#\/^#=!;1=%TJUT_2V+9M(D'EG=][CT/>NOZVDDDKJR37H1[)ZGRIXRFFU+P
M[^S5)I5]%:W%SK*R6]U*@90&MIB"5R,Y!_,UV_[0VCZ[H/[,OBR3Q'?1ZS>)
M=)<O=6\(3_1Q<HRC;VVKGO7KVN?!7P/XF;2WU/PSIUXVE+ML?,C_ ./8 Y 3
MGY?PKKKO3K2^T][*X@CGLW3RG@E4,C*1C!![5$L4KQY5L_UN"INSN>7?$S5K
M/4O!'AB.UNHI9-1OK+[(JN"9N0WR^N ,\>E>;_$+P_JNA^,/&GC#X<ZYIMQ>
MQQK_ ,)+X3UG!@NU2/Y71LYB9DXW'(..17N?A_X3^#_"M\M[I.@6-E=H,))$
MG*9[+SQ^%/\ $7PK\(^*+I[G5= L;VX=MSR21C<_3[Q[C@=:B-91EY!*FY(^
M<M8\36/BKQ5^S5JUA8/H]I=RWDD5A*1N@_T4C8/8$8XKH?V0;A=-M?B38Z[(
M(O%</B>]GU$7##SC"S P.2?X/+QM[<'%>Q:Y\&_!7B36-.U34?#5A>7^G!5L
M[B2,;K<*/E"'^''M5CQ%\+?"GBV^6]U70;*^NPFPSR(-Y4= 2.H'H36LL5"4
M.1)_T[D1IRB[GS'\.=/M]6\-_&Z0PQW'@75/%"KIRR ?9IE)1;@H.FTOGD>^
M*S]2AU+]G_7(/A[=K=7O@;6-:M)/#>HLK/\ 8G\X,UG(W]WJ4.?:OK#7OACX
M4\3>'[;0]2T*SNM'MF#1631XB0CH0H]*U+KPSI-YI]K97%A;W%G;,C0Q2H&5
M&3E6&>XQQ51QBC?2Z[?=9^I7LF;</^K4^U<Q\3KJ.Q^'GB6>5ML<>G7#,?;R
MVKIE957J!7A'[6'B:X;P;9^!M%;S?$GC*Y72[:%#\RP,<W$Q]%2,-D^XK@IQ
MYJB-9?";?[)=G+I_[-OP[@F&V1-&@R/^ Y_K7K_\-8WAG1;/POX?T[2+,!+2
MQMTMXER.%10H_05J^8O]X?G45&G)M;-E07+%(FI&IGG1_P!\?G2-,G0,*10U
ML*I)^M?GQ=,_[7G[>4< ;[5X(^'(W,.L<MP&Z>F2X'X)]:]Y_;(_:@TGX"^
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MTXQ4G+?R_P"")3G=JQ]"[6[&C:?6OGC_ (9'\!?\_/B;_P *"Y_^*I?^&1_
M7_/SXF_\*"Y_^*J/94NDW]W_  1\T^Q]#;3ZT;3ZU\\_\,C^ _\ GY\3?^%!
M<_\ Q5 _9'\!9_X^?$W_ (4-S_\ %4_94OYW]W_!#FGV/H7!]*7:?6OGK_AD
M7P%_S\^)O_"AN?\ XJE_X9%\ YQ]I\3_ /A0W/\ \52]E2_F?W?\$.:?8^A-
MI]:-I]:^>O\ AD7P%_S\^)O_  H+G_XJC_AD7P%_S\^)O_"@N?\ XJG[*E_.
M_N_X(<T^Q]"[6]*ANKJ&SB,MQ-';QJ,EI'"@ =SD]*\ /[(O@+M<^)__  H+
MG_XJI;?]DCX<1R!KFSU?4TS_ *O4-7N)D/L5+=*?LZ6[D_N_X(^:?;\3:\=?
MM.:#IMX= \%Q-X_\8R?)%IFD-OBA8\!KB8?+&@/7G/'2F_!_X5:EX7O=4\5^
M,-0CUOQ_K6#>7D2D0VL(Y2V@':-?U.2:[7POX+T#P/8BR\/Z-9:-;=#'9PJF
M>.YQD_C6W2E4A"+C37J^H*,F^:3$';G]32[?<_G117*MC8-ON?SHV^Y_.BBG
M8!5IU-6G5(!1110!XK^UX/\ BSH[_P#$[TO_ -*DKZ C4LH(';C\JX+XB?#O
M1/BEX5N/#OB*"6YTNX>.1TAF:)]R,&4A@<@@@=#7G*_LA> <?\?/B;_PH+G_
M .*KLC*$J<8RE9J_2YSM24VXH^A-I_R*55(/2OGS_AD/P'_S\^)/_"@N?_BJ
M3_AD/P#_ ,_7B;_P?W7_ ,52]G2_F_#_ ()IS3[(^ASG/_UJ.:^>?^&0O 7_
M #\^)O\ PH+G_P"*H_X9!\ _\_'B;_PH+G_XJCV=+^;\/^"*\^R/H;FCGTKY
MY_X9!\!?\_'B;_PH;G_XJ@?L@^ 3_P O/B;_ ,*&Y_\ BJGV=+^;\/\ @A>?
M9'T-M-'/^17SW_PQ_P" ?^?KQ-_X4-S_ /%4G_#'_@'_ )^O$W_A0W/_ ,51
M[.E_-^'_  0]_LCZ$Y]*7GT-?/7_  R#X"_Y^O$W_A07/_Q5>8K^SMX9_P"&
MEG\(_P!H>)/["'A@:G]G_MRYW>>9RA;=NS]T#BM*="G._++97V_X)$JDHVT/
MM/::-I]*^>_^&/\ P ?^7GQ/_P"%!<__ !5._P"&/_ 7_/QXG_\ "AN?_BJS
M]G2_F_#_ ((^:?8^@MM+M_SFOGW_ (8]\ ?\_'B?_P *&Y_^*I/^&/O &<?:
M/$__ (4-U_\ %4O9TOYOP_X)7-/LCZ#Y_P FEKY['['_ ( S_P ?/B?_ ,*"
MY_\ BJ7_ (8_\ ?\_/B<_P#<P7/_ ,53]G2VYOP_X(<T^R/H3[M86FW36^H:
M@US+Y<*G(\U@%'T)->,?\,?^ .]QXFQ_V,-U_P#%5E:'^QUX,@U:^DU.+5M0
MLV.88KG6;B48ST8;O3UIQI45O)_=_P $GFGV.V^('[37A3PO<?V1H;OXS\62
M?+!H6A$3R[CP#(X^6-0?XF/&*SOA/\+]=3Q-??$'X@W,%_XTOX_)M[:#F#2+
M4\_9XO\ :/\ $W<BN[\'_#KPQ\/[4V_AO0;'1HB,,;6%59OJW4_B:Z.IE4IT
MXN-);[M[E*+;O(93S_GFBALYKD-16KP[]J+]J+0_V<_"^]MNI^*KX;-,TB,Y
M=V/&]@/X 3^/2I/VH/VGM#_9S\*^=(5U'Q1? IIFD1G,DK'C<P[(#CMR>E>.
M?LN_LPZYXP\5'XS_ !DW:GXIOV^T:=I5R,I9H>59E[$ \+CCZU[F&PT*</K&
M(^'HNK?^1RU*CD^2&_Y"_LM_LNZYXF\5-\9?C%NU3Q=J!^T:=IET,K9+_"S+
MV(!X4#@>]?9_XT8/>EKS\1B)XFIS/;HNB-:=-4T%%%%<9J%. %-IRT +1110
M 4444#84Y:;3EH$+1110 4444%A1110 ZBBB@@IOC[9=?[X_] 6BDD_X_+K_
M 'Q_Z M% '5T444 )D4C4OX5C^(/$6G>%='O-6U:\AL-,LXFFGN;A@J1HHR6
M)]!BDDV[)7 \ ^/C0>-OB_X1^'WC#PSH>I?#C5+*XNKK4-3FV2I=)Q''"<@J
MY..AY!;GBK7@_P" _P !_@3J%QXPTG2=(TW4+>-B=0EN3/*@..$WLW)XZ<]J
M\5\0>+/V;?V[OB]HNGR^)[ZXU73K::&#3R);)+L[U965R!O9<,0H/1B>U=YJ
M'_!-/X226^ZRAU:"^B99;::349)%212&5BI/."!UKW)*%&G&$Y.+MJK:&.K>
MB/K:.021HR\AAD?E4U06\?DPHF<[5"U/7B.U]#8**** "BBB@ HHHH *R]2_
MY"6E?]=7_P#0&K4K+U+_ )"6E?\ 75__ $!J //=6_Y"MY_UU;^9JK5K5O\
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M-P]: %HI-P]:-P]: '+2TU6'K2[AZB@!:<M,W#U%.5AZB@!U%-W#U%&X>HH
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MO]GMJ@1-W]G!S)N^[C;M.>F>>M?64/\ P4K^"TG^LOM7@_WK!_Z5Q6O?MS?
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MNR_Y](?^^!5VBB[[BL4?[)L?^?2'_O@4?V39?\^L/_? J]11=]PL4?[(LO\
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M_9=K_P ^\7_?%6Z*+L"I_9EI_P ^\?\ WS2_V;:_\^T?_?(JU12 J_V;:_\
M/M'_ -\BD_LRT_Y]X_\ OFK=% %/^S+7_GWC_P"^17@?[9]G!'\);+9$B?\
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M.5&S%'J=P?+4#H,#D_B:%3P*]YU';M;7[]A\U;:R.8\6?\%'M.U[4GT;X3^
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M:_E4U% $'V6'_GFOY4R..WD8JJQL5X(&"1]:M5YI\.V8^./% +,0). 23WH
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MH B^RQ?\\U_*@V\?]Q?RJ6B@#D[SY=2O .GF#_T%:*6^_P"0G>?]=!_Z"M%
M'5T444 %%%% !1110 4444 %%%% !1110 4444 %9FH?\A+2_P#KJ_\ Z U:
M=9FH?\A+2_\ KJ__ * U &G1110 4444 %%%% !1110 4444 %%%% !1110
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M?M)?RGT7GVI/P_6OGW_A0_Q4'_-<]8_\%-I_\32_\*)^*?\ T7+6/_!3:?\
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M7O\ C765B7GB:PL=<MM)E=Q>7 RBA21^)_"MN@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *Y+PSX/ET'Q!J^HM<K,E\VY4"X*<YY-=;6)I/BBQUK4KRRMF8SVA
MVR@J0!^- &W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!RE]_R$[S_KH/_05HHOO^0G>?]=!_Z"M% '5T444
M%%%% !1110 4444 %%%% !1110 4444 %9FH?\A+2_\ KJ__ * U:=9FH?\
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M=_=8'/MBJY'8GF/:JS-0_P"0EI?_ %U;_P!%M6DOW16;J?\ R$M+_P"NK_\
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M )4?\)!;>C_E19@:=%9G_"06WH_Y4?\ "06WH_\ WS19@:=%9O\ ;UM_M_\
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M2E6FP%HHHI@%*OWJ2E7[U)E(=1114C"BBB@ IRTVG+0 M%%% !1110 4444
M*M+2+2T %.6FTY: %HHHH ****!H*5:2E6DP8ZBBBD(****!H****"@HHHH
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M+10!U=%%% !1110 4444 %%%% !1110 4444 %%%% !67J7_ "$M*_ZZO_Z
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M%%%%22*M.IJTZK+"BBBDP"BBBI **** "E6DI5H =1110 4444 %"]:*%ZT
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M"E)_Q^77^^/_ $!:*)/^/RZ_WQ_Z M% '5T444 %%%% !1110 4444 %%%%
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MO^-+Q_STC_[^+_C2N*PM%)C_ &X_^_BT8_VX_P#OXM%QBT4F/]N/_OXM&/\
M;C_[^+1<!:<M,Q_MQ_\ ?Q:5<?\ /2/_ +^+_C1<!]%&X?\ /2+_ +^#_&C<
M/^>D7_?P?XT7 **-P_YZ1?\ ?P?XT;A_STB_[^#_ !HNNX!11N'_ #TB_P"_
M@_QHW+_STC_[^+_C1==P'T4S<O\ STC_ ._@_P :-R_\](_^_@_QHN@'T4S<
MO_/2/_OX/\:-R_\ /2/_ +^#_&BZ[@/HIFY?^>D?_?P?XTN]?[\?_?Q?\:D"
M-[6*282M&ID7A7*\CZ&IJ9N7_GI'_P!_!_C1N7_GI'_W\'^-5<!].J/>N?\
M61C_ +:+_C3O,0?\M8O^_B_XT77<I#J*3S$_YZQ?]]K_ (T>8G_/6+_OM?\
M&I;!BT4GF)_SUB_[[7_&CS$_YZQ?]]K_ (T$CEIU1K(G_/6/_OM?\:=YL?\
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M?^>\7_?Q:7[5#_SWB_[^+0!8IO\ %47VN'.?/A_[^+_C1]JAW9\^+_OXO^-
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MW#0V>K2V_D/>PC&)"G8Y)'3!QFJ<6E<CFUL>@_8;?_GWB_[X%'V&W_Y]XO\
MO@58HJ2RO]AM_P#GWB_[X%'V&W_Y]XO^^!5BB@"O]AM_^?>+_O@4TV,'_/"+
M_O@?X5:K(\275YI_A_4;C3H!<W\4#O!">CN 2!^= %W[';[O]1%_WP/\*/L-
MO_SPC_[X'^%?+#>.(&A_M-OC)JB>) N\Z)_9ZA?.QS!Y&S.,@K_6OICPO>WN
MI>'=,NM1@^S7TUNCS0_W'*@D?G5./+J1&5R]_9]O_P \(_\ O@?X4?V?;_\
M/"/_ +X'^%6Z*DLK_8;?_GWB_P"^!1]AM_\ GWB_[X%6** *_P!AM_\ GWB_
M[X%-^QVW_/"+_O@?X58_AKSCXQ^(M3\/^%8I["[DTV*2Y2*[U**W,[VD)SND
M"8Y(..<<9IK5V$W8[_[';=H(O^^!_A2_8;?_ )X1?]\"OG#PCXP%CXFTF+PQ
M\2M0^($]W<+%=:7<VX9%B).^7>$'EE0<C)YQBOI=J&K"B[D'V&W_ .?>+_O@
M4?8;?_GWB_[X%6**116_L^W/6"+_ +X%']GV_P#S[Q?]\"K-% %;[#;_ //O
M%_WP*3[%;_\ /O%_WP/\*M5X=\:/$]W8^)K32]1\577@;PY):^8NJ6EN':>;
M<08S(5/EX4 ^]-:NPF[(]G^PV[=((O\ O@?X4G]GV_\ SPC_ .^!_A7CGP7\
M475]XDN]*L/%5SXY\/QV_FG5+J (8)MV/+$@ $@(YZ<8KVU:&K,$[HJ_V?;_
M //"/_O@?X4_[#;_ //O%_WP*L44AE?[#;_\^\7_ 'P*/L-O_P ^\7_? JQ1
M0!4_L^W_ .>$?_? _P */L5O_P ^\7I]P?X59.>*^:?%WB[[9XHU6#Q-\3-0
M\!3VMRT=KIMM;+&C1#[LF\J?,+<]#515R6['T=]AMN?]'B_[X%+_ &?;_P#/
MO%_WP*X/X-^(M2\1>%WFU"YDU&**X:*TU.6W\AKV$8VRE.,=2.G;->BTG=.P
MT[HK?V?;_P#/O%_WP*/[/M_^?>+_ +X%6:*0RM_9]O\ \^\7_? H^P6W_/O%
M_P!\"K-% %7[#;<?Z/%_WP*/L-M_S[Q?]\"LSQ9?7VF^&]4NM+M_MFHPVTCP
M0'^.0*2JX]S7S7_PF\"Q_P!II\9=4?Q(%W_V(;!=IE_YX^1LR!GY>OXU48MZ
MDN5G8^I_L-M_S[Q?]\"E_L^W_P"?>+_O@50\,WEYJ7A_3[K4+?[)>S0))-#_
M '&(R1^=;%245O[/M_\ GWB_[X%']GV__/O%_P!\"K-% %;^S[?_ )]XO^^!
M1_9]O_S[Q?\ ? JS10!5-C;+UMXO^^!1]AMO^?>+_O@5P/QDU[4_#WAF">RO
M)-*@DN%BO-4AM_/>SA.<R!,<G/&<<9KS#P;XN^R^*-*B\.?$K4/'\EU<+'=:
M9<VX94B.=TN\*/+*X[FJ4;K<ARL['T;]AMO^?>+_ +X%+_9]O_S[Q?\ ? J=
M<]Z=4EE;^S[?_GWB_P"^!1_9]O\ \^\7_? JS10!6_L^W_Y]XO\ O@4?V?;_
M //O%_WP*LTC?=- %8V-M_S[Q?\ ? H^PVW_ #[Q?]\"O&/C/XHNK+Q-;:9J
M?BVZ\#>'GMA+'J5K;!C<3;B&C,F#LP,<=\U)\%?%%U?:]>Z;8^*+KQSX>B@$
MO]L75N$:&8M@1!PH$@(R?;%5RNUR>;6Q[)_9]O\ \^\7_? H_L^W_P"?>+_O
M@59HJ2BM_9]O_P ^\7_? H_L^W_Y]XO^^!5FB@"M_9]O_P ^\7_? H^P6W_/
MO%_WP*LTC?=- %;[#;?\^\7_ 'P*/L-M_P ^\7_? KYO\4>,%U#Q)JD7B?XG
M:AX"N[:Y>.VTNWME1/*!^20.5/F%AS_2O5?@[X@U3Q%X3-QJ,\E_''</%;:C
M+!Y#7D(/RRE.Q/TYIN+2W(4KG>?V?;_\^\7_ 'P*/[/M_P#GWB_[X%6:*196
M_L^W_P"?>+_O@4?V?;_\^\7_ 'P*LT4 5O[/M_\ GWB_[X%']GV__/O%_P!\
M"K-8/BZ^OM-\,ZI=:7;_ &G4(8'>"'&=S@$@8[_2@#4^Q6W_ #[Q?]\"@6-L
M?^7>+_O@5\KKXXACC&J0_&35+CQ)M#C0SIXVM+_SQ\C9N )^7K7T[X?NKN^T
M.PN;^W%I>RPH\]N.?+<J"R_@<U4HN/4E.Y<_L^W_ .?>+_O@4?V?;_\ /O%_
MWP*LT5)16_L^W_Y]XO\ O@4?V?;_ //O%_WP*LT4 5OL%M_S[Q?]\"D^PVW_
M #[Q?]\"K+5YK\:O$FJ>'_#MI+8WDFDV<]P(K[5H;<SO90[23($^H R1QFFM
M783=E<] ^QVW3[/%_P!\#_"E^PV__/O%_P!\"OG/P3XO-GXNTBV\._$C4/'_
M -JN!'>:?<VZNL41R6E\P(/+*\'DX/(KZ37WH<>4(NZN0_V?;_\ /O%_WP*/
M[/M_^?>+_O@59HI#*W]GV_\ S[Q?]\"C^S[?_GWB_P"^!5FB@"O]AM_^?>+_
M +X%-^PVW_/O%_WP*LMTKPWXS>*+BS\46^F:IXNNO GAYK;S8]0M;<,;F;<0
M4,A4[,#'&.<TTKB;L>T?8;;_ )]XO^^!3O[/M_\ GWB_[X%>/?!7Q1=ZEK5_
MIMGXGN?&WA^&$2+J]U;^6T4Q;'D[P ) 1SD#BO:J&K G=%;^S[?_ )]XO^^!
M1_9]O_S[Q?\ ? JS12&5O[/M_P#GWB_[X%']GV__ #[Q?]\"K-% %;[#;?\
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MV_\ S[Q?]\"JNAW%Q?:/8W%Y!]FNY(5>6'.=C$ D?G6ED5)17_L^W_Y]XO\
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M32[V]_MOQ!#<.(]1L]":ZALUW JCX&"57/0]Z]?\*Z]8^*M!M-1TZY2\MI$
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M9MM1,HL9;619S"I9]A4[MH]<9Z5TE8WB:\NM-\/ZC=6$'VJ]A@>2&'GYV )
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M;UKZ9T&YN=2T33KJ]MOL=W- DDUOG_5N5!*_@?Y5<KZ&<+:FK1114&@4444
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M**DH**** "N;\<3:K#X1U9]$3S-76W8VRX!._'8>OIGOBNDI&&X8H ^.(?\
MA%X=2_M+1]?\:2_$ ME8I; [GFZ%'4Q[=A/7YNE?7&CM=2:79O>HJ7K0H9U0
M\"3:-P'MG-7?+7=G'/K2JHZU4I<Q$8\HZBBBI+"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M7,:YX)TGQ)XBT+5]
M0MA=W>B22RV0D *Q22)L,@!'W@NY00>-[?AU&T4UN%-";B[H#X._:PB'_#?/
M[-HQQON/_0J^R-5\"Z1JWBC1/$,UNJZOI'G+;7,:*'V2QE'1FQG:?E. 1RJ^
ME?&_[6C*O[?7[-Q+8^:<9/NV!^9K[N7YHQQ7I8J3]G2L^GZD1^)G@_@?]I[P
MWXX^/7BGX<67A_6;'6]!TP7]Y?7]EY!D7='M1$_UC K*K#*COP:Q?#_[:_AW
MQ9XP\>>&-'\*>)[[7_"KPQ?V6+)5N[^1S(&\N,N-D:;%S)*4 \Q?49\_^'*J
MO_!3_P"*@V_\RC:?^VPI_P"R7&C?MF?M3-@9%_I0![_<N,C]*U]A32;:O:*?
MS=A7?XG:_#_]N+P_XX7Q-I;^$?$FG>/- G%M-X+:V274)F()#1!7VE,+R[%5
M7(R<,I;I/@+^U-IOQJ\3>*?"EYX>U3P5XS\-E&OM!UG9YHB< K*C*2&7E?\
MOI>Q!KQSX$PHW_!2K]H3@<:5IF" /^?>VS^M<=XD@N_^'@/QU725*ZE)\++@
MP>6#N,V+0)C'?(7\A2EAZ<I.,5;1/TO8:DSZ+\7?M2/I/A_4?%GAOX?:]XU\
M&:=YAN->TN:V6.5(RPEDMXGE$DR(5;Y@H!Y*EAS7J/PT^)7A_P",'@?2O%OA
MB]&HZ)J49D@FVE3PQ#*RGD,K J01P0:^3_V'?"G@CXR?LP^&TB\2>(I+BRM#
MINK:7:^)+R&.WD7*E#"LH"*ZX8 #!#5]&? /P'X(^&O@FY\.?#Z&2W\/6.HW
M$01IY)U\]7Q,$=V)PKAE(!^\K5RUJ<*2<4GS)V^0XMNS(_VGOC$GP%^!OBKQ
MJ(UGN]/M=MI$W1[AV$<0/^SO8$^P-5?V8?!-QX+^!OAQ=2EDN_$.J6HU;6;V
M8DRW%[<#S9F9NY#-M'H$ KQ[_@JE9W-U^R7J<D&[RK?5;*6X5><Q^9MY]@S*
M?P%?4?A&:*Z\'Z1-"RO!)8PLC*<@J4!!!]#Q5<BCAHS6[D[_ "L*_O'PC^Q3
M\7E^&?P_^+=MI'A?6?&FNCX@ZI.NB:!"CRQP^7 %DD9F"QH2C*,G+%6VAMIQ
M]:? G]H30?V@OAG)XOT.UO[%;>::TO--O(P+JVN(L%XF52<G!4C!R0PZ'BO#
M/^";,:?\(/\ & X&X_$7503C_IE;\?SI?^";[;=/^.$0.(D^(FI%5'09$8X_
M #\JZ\13A4=2I;6+7XDQ;5D>I^ _VKM'\:? G4?BE+X5\3:7I=C)=)+IKV!E
MO"L&2S!%.-N%/)( ((S7&Z7^W=8>*/@[;?$'PS\.O%GB2R(N9;VVL(8R=/AA
ME="TLA8*7*H'\N,L0K G ()]Q^-&QO@_XU*D,/[$O1QC'^H>O _^"<L:R?L+
M^#U(!##5 P(SG_3K@?RKGITZ<J;J./5*U^C*N[V-Y?VUM'\4?#?3_%WP_P#!
M_B;XB)/";BYLM(M55M/VY#QSNS;?-!!_=H68\'&UE)L7G[<'@>']G6W^,-II
MVN:GH,@*RVEE9[YK68.(VCF.X)'AV49+8.<C-</_ ,$M%63]CW22PY.H7^>.
M?]<:^=/ *QK_ ,$N_C*BX"KX@NE51T ^T6O%;_5Z3G*%GI)+Y,7,[7/JOQA^
MW+IWA'P+HWC6/X?>+-9\'W%M;W5_KEC!']EL1*%^0,[@RE&8*60;,\;LY%7?
MB)^VUH_A'PS#XJ\/>"O$_CGP:L*W5YXDT>V5;2WB;!)4R%6D*@G=M&U""&8$
M,!C_ !'B7_AVO>?*"/\ A7L)P?:S6I=#AC;_ ()LQ@KD'X>/D=O^/(TE1HV4
MG'[7+OT'=['J/CS]H31?!_P#D^+&G66H^*=!:S@O;>WTJ',\T<SHJMM8C:%W
MAFS]T*WTJ;6OCUINA_##PIXOFTG51<^*6LX-*T!HDCOI;JY3?';L'8(C !BQ
M9L (QS7/_L1LO_#)?PP+X _L6$Y)X[]Z3]J[X.Z=\=O!>B>&'\2S^%/$0U:/
M4/#^J6X+-%?P12NI !'2,2G[PP1D<BN)TX*HZ;5DF]?(I7M<UO"_QLU#4OBM
M;> M?\#ZMX9U6XTN?58;V6Y@N+*>*&2*-ECDC<L6!F7*LJXX/<55U#]H2ZNK
MSQ,?"O@?5_&.F>&[N2PU"[T^YMHV:YC ,T4$<LBF4IG!SMR<A=Q!KQ+X)_%[
MXJ^ _P!H+0_A3\;]&TW7=7O[2Z/AOQMIL:J;B)$62=&&!C<(UR J$%%R&!#5
MB>-/A/\ %7X.^*/&7Q4_9\\36OB;PWK&K76HZWX)U.(E7NUF9+IH22/F$B29
M"E&PH WX45U?5HJIR2:U6COH_GT)YG;0^L="U+1_C]\&;#4+K2Y/[#\5:0DT
MFG7R@N(9XP2C@<;@&['K7D?[#WQ6U'Q1X9\7?#[Q#>2W_B7X=ZU/H$]W.V7N
MK9)'6WF8]22J,N3R=F3R:]$_9C^*FF?&;X(^%_%>D:1_PC]E>0-$-+4#;:M$
M[1LBX RH93@X'&.!7SQ^QNKM^V5^T_- /]!&I6J,0./-#39'Y[JSITUR5(M6
MY=5]]@;U374^YJ***\\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS&NP*AC\K  $:@;<$ <'K3-#_9?\.Z#\;+_XK1:UKT_BZ_MQ9W4\]S$T,UN
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ .<HHHK]
M7Z(\S45:=2+2TP'+2TBTM "K3EIJTY: 8]:=35IU!(4444 *M24R/[U/J'N
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M + 9 )(YKA_VA/ACX>\)Z+X6UWPW92:9!JD7[RTDF>7!**ZL"Y)!&X@\XX7
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M7C.D>%Y?#^FV\%]X;\6V%W$N)+K0=4202-_>$>"!] >U17J.C3YU%RUZ6O\
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MOHU;Y$NHY/YW/??#OCCPGI?@OQGI$_B6V^T:U<7<ENZVUT559$VJ6_= CU.
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M,<_RH;6OAT_!CMQ[>0W^%'_$0\2G[^75%\O^ 5]24MIH\[COH\GYA4OVR/\
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M UR5ZVMW^-N_^%(U\L:9^S7;#V@;_"K5:G_,OO#DGV+:TM4AJT*KN,%T,_\
M3NV?Y4Q?$5H3@17A]OLS_P"%+VU/^9?>0J<^S-3^&GK6+)XLL(MJO%> ^GV5
M_P#"I;3Q-I]RA93.@!QB2!U_3%'MJ?\ ,OO'[.?\K-A:6LW_ (233D4EIF '
M7]TW^%)'XLTC(!N6&WG_ %3?X4>UI_S+[PY)=C6"G%+M/I7ALWQD^(NL:QJ;
M>&O!'GZ#;W<EM;W%W$ZO(J'!? / )Y'MBLSQ)\>?B;X6TE]0O/"%JL*R+%_J
M9,@G\:Y?K=+9LOV<K;'T)M([4[FO$_AK^T%K?C;1+IKKPU'%JL4Y13O\J'80
M#SG)R#G-=OHOQ-+7+6VO:>; _P#+.XMR94;V(QD'_"M(8JE+J)TY6.UHK!D^
M(WAV($-<S?\  ;9S_2H?^%H>& RC[7.#GO:R8_E6ZK4_YE]YGRR['1LK;O:A
MAN&!UK%D^(GAA%^;55'_ &RD_P *EM_&WAVY)\O5H,#^]E?YBJ]M3_F7WA:7
M8T>=V*?M]*S'\9>'8\YUFU _W_\ ZU+#XT\.W$@2/6K)GZX\S'\Q3]I#^9?>
M&O8T-IH*EJIMXJT$?\QJPSW_ -(6J.L?$+PQH>G37MQK%K+'&/\ 5P.'D<]
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M&O)P*G78LFW>],FO$BR2<5+X:\/:UXWO#;:)9R7/.UYL8C3W+&O1X?A]X/\
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MYKR<E+*,E;>'G"KZD=B:IPQA5P!5:WC$*@ ?C5Q:^QP>"HY;0AAL/&RBK?\
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M%@<,_ABI2^:22.NE[M&<N]E^IY_:KMC'IVJPM0P_=%2K7Z!)W;9R=!U%%%2
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M>-]%3&5%P&/X G^E>'GDE'*\0WLHO\C:BKU(KS1?^(4GG>.M0;.3A%^F%_\
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M7TOJ)?:&W@WQ?KN@29_XE]W)"I/==Q*G_ODBKRG*^U=_^U/X;CTGXA:7XHM
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MU-IZT@8]:DJ-:D7I4LD*D6HZD6CH:1)4Z4[USTIJTV23:I[#U-9N_0EF_P"
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M-36\GV6$W!4L[_)" <=L,W^?6H[6W-Y,(\[4 W.W]U1U/^?6G75U]KF!3B%
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M"U2+'K3UIBT]:9'4>M.6FK3EJ )*<M-7I3EH$Q:***"16I*5J%H18E%%%:(
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M<["BBBK0!112K3+)%I::M.H!A3J;3UH*U%6G+3?>G+0+H.HHHH$1S6Z3*58
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M:F6J-M>1S#Y2#CT-7$<''-?5-7UL<]UT)J>O:H]V:?4 ]B:BBB@A;C?\*/\
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MOLJ=%7VK=]*6NK#X*C0DY-<TGU>K?W[?(X,1F56LN2-HQ[(55VJ !@=!P/\
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ML15HRC"&W+?7R_S-(VDY7Z6_$^:?"O@77/&FL/I>D6:7&I1@L;62XCA?CA@
M[+G&.@R1SFMN^^#OC/2]-U6_N="FBL]+<I=3>;&0I&"2,-\X&>=N[&#Z5ZYX
M6:T_X;&U V6T0^=/N\LC'F>1^\Z=]^[/OFN/^.7Q U_3_B1XVTBUU&:+3+V2
M.WN+7C:R(@X&02N2225ZY-5'%5ZE6,(I:I/6_P#F/EC'FOT.-\/_  O\4>)-
M-MK^QTT-9W4IAMY+BXB@^T/@_+&)'7>>#PN>A':J>D^"-;UCQ$^@V]CMUI2R
M&SN9H[=RR]5'F,!GVSDC)' -?1'Q::W63X*1Z2?^)9]HA^S^7C!&;?;^./ZU
MP_[5<T%K\7H)M/<Q7J6<#S20'#K*&8J<C^+;LQ^%%/&5:DU'17O;RL^H2@HQ
M^XY*X^!_C.SU"73Y]-M8;V*W^TO!)J=JC"')'F%3+]W(()Z=*ZW]GWPS%<2>
M(VO?"4/BT1H+=5CN+1_(<9R</*.&R,2(#]WC->D?%"SU/XB? _\ M*)8T\0Z
M?%$NKV\(4R;5"R20D]5QN20KV*X/2N9_8W4B^\6>OD0$^GWI.E<\\55K4).;
M5T[=?\^HU!1E#U/(/"/PQ\2>/H[N30=/6]6U<+,BW4"/'W&5=P<8X!Q@D'N#
M4]_\%?%]CI=IJUYX;N/LTKJ(6PCR!G.%&P$LI)( R!U ZUZ_^R"Q75_&)'41
M0G_QZ2K_ ,.=6OO^&=/&-X;RX-Y]HNF%P9#YF2%).X\C))/XYIRS"M3;2M96
M_'YFB2O?S9XAXL^&?B?P/:6UUKFE26-O<-LCE\Q'!;&<91CM.,\'!P#Z&D\/
M_#SQ%XDL8+NQT\"VN9?(MY+BXBMUGD_N1&0KO/&/ESTKV7QLQF_91\.._P"\
M998<%CNQAG _(<52\%Z!XAA\!^$+W7=0NKG1#JMJ=)TBUBCW([2$K+))M+;
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M<#C'3-7]<@X\UNQ/(SSRI%KTO5O#?A>'PCI_B%-.N((V(+V<<Y;S2>-I8DX
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MEOI\LF=T_P!@MY9BI"Y7S'C9@,J/E!QP#ZUR=%1.$:D>6:NO,T5T]#I_&7Q
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M5"S%NIJT^P#V;WJ-B.]-:0 =<U&THYJU<5QS.147F'UIC.>U19-:)$GR(O\
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9C:3WQ43.?6BBG<;V(V<#J:C\X4451FS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *P!, # 2(  A$! Q$!_\0
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MZ%?_ ,J'_P!KI?\ AH%L?\BO_P"5#_[77BI<=J8'.:.9C]C#L>V?\-!G./\
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M^&/_ "?_ /M=-_X:!_ZEC_R?_P#M=>+2OO;=4=7S,Y'AZ5]CVW_AH+_J6/\
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M2S_Y/_\ VND_X7^?^A8_\G__ +77C('%(>*.=A]5I=CV?_AH#'_,L_\ D_\
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MIT9VTOJ?_+RG^+_S/H]/BA;LH+::5SZ3YQ_X[5H_$*-ES%IX8^C3X_\ 9:\
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MC_:_2CR/]K]*EHH B\C_ &OTH\C_ &OTJ6B@"+R/]K]*B(P2/2K557^^WUH
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M&P5E.9R1@]?WCUA/"4U2<E>_*G^-BE4?-;S/6J***\PW"BBB@ HHHH ****
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MVNBZ78W'GVFFVD$Q!!DBA56P>O(%7J*.>5K7"R"BBBI&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !55_OM]
M:M55?[[?6@#BOBR-WPRU<?\ 7'_T<E?-$,:JZLZAE!R5SC(]*^H?B197&H^
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M]\5E(Q4Y#0L"1^1S6WUZ@]'-?-K_ (!C[-)^[+4U+SP+IMQDVSRVSGMG>H_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .<UGYO&?AE#RH^U/C_:$8 /Y,?SK
MHF8*I9C@ 9)KG=8_Y'?PU_N7?_H"UT+L%1F8@  DD]JVJ?##T_5DK=F8OB70
MVMX[@:M9^1)+Y*2>:-K/_=!Z9]J;KM_#'87=NFJPV%TD(D\Z3I$,\,1D<9XZ
MUYSX4T_3M:^'=GI.H[3#<ZM.A4MA@3YA4CWZ$4L_]LV/AGQ7HVN9EEL-*\FW
MO#G_ $J)B^P_[W\)]Z[/JL%.R>J?X72O_FC/G=CI=,30++Q#=>(/MVEV\TMC
MM=;9MJ2+N!,K9Z\X&>P/4YI- T&PMM%U+3[W4[6]M/$%S-/&8E*;O,'S*IR<
MX R#5"STB^N_A==N\JWTDNC".R1(]K1 PX:,>I)'X_A4^E7ME=>"_#RK+YJV
MM@6NDA/SQJMNR-QV;)Q]:<D[.TNJ7W7:_$2\T1_V)9:CX?T[P[=Z]:3Z;I["
M9VC&)+B*(_*#S@ <989SCMFM#0K#3K+5]9\4MJNGW%GJ4D9CD10!$4&T /DY
MS[=ZP]"_M#2+E-,EO[36='739GL[Y0%FM(P  KD<8/ '^[[5B:%%.OA[X<WD
M@8Z79W,PN^/EBD+$1L_I@GJ>F?>M73;37-H_QO=_)MK^NJOY'KG]M:8+*:\-
M_;BW@.)I"X C/HWI^-2C4K(BU(NHB+O_ (]R&R)>,_+Z\<UYQJ2?:?&GBF^B
MVG1SI*6]U(?]5+-GA<]"0IP?3.*LZ-I>H^%_&>GZ''F?P]-++=6$I.3;GRWW
M0Y]/FR/_ -=<KPT.6]];7M\KV]5^7F7SN^QZ17,I\GQ,F"?\M=(0R#U*RL%_
M]"-=))(D,3RRNJ1H"S,QP% ZDFN:\,YU;4]1\2LC+#=A+>RW#!:W3)#_ / F
M9B/;%<]/2,I/:UOO+>Z1T]%%%8E!1110 4444 %57^^WUJU55_OM]: .,^*P
M!^&NK@_],?\ T<E?,\S;1@5],?%7_DFVK?\ ;'_T<E?,3YW&L:FYZ6%^!^HS
MK4JXP0:;CB@9J#K0X+D\4<C@BD!YJ0D$4BB(CG-3I+A<4P+FFE3F@JQ)YE1M
MR<TH'%*<8I#2&4H'-."$]*7:1U%!7*+P5IA0TX @U*"-M*X6(.G%&.:>0,TF
M,4A\HW%+BG!2:=C HN'*1<CBC%/Q3P@Q1<.49&[Q.'1F5AT*G!%:T/B75H@
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M_P#K>E7;'3_L97,F\1Q"&/C&%!.,^_3\JO44 5;\D6_!_B%9NYO4_G6E?_\
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M444 %%%% !1110 4444 %%%% !1110 5@>-=)FUOP;JFGV^?/DAW1@?Q,I#
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MJ;#YA^>*4'FF@TO%!5R0&GU'&,MC-6FC4)F@=R+-+3<\THH$QU*#3<$4#)(
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M<R;Q'$(8^,84'C/OT_*KU% %:^)%OD$CYATK-#O_ 'V_.M&__P"/;_@0K,%
M#][_ -]OSHWO_?;\Z;10 _>_]YOSHWO_ 'F_.FT4 .WO_?;\Z/,?^^WYTVE
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MDHH 7<W]X_G1N;^\?SI** %W-_>/YTH9O[Q_.FTHH 7<W]X_G1N;^\?SI**
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MVO8;HD1$GY0P)&-RG(R/;BLY-"(LDMFG!!@$$I"XRH;/'IU(_&K5AIQLRN9
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MZ/RHVK_='Y4 4Z*N;5_NC\J-J_W1^5 %.E%6]J_W1^5&U?[H_*@"I15O:O\
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M6KT++MYJ"< GBBXTBL!4F-J^]/50!S2'DTKCL1\TN#3P*< *+CY2+% 6I2M
M6D.PT+3@,5*,!<8IAZT,:0E. H /I3@.:DM(4+BG4H%2PPM-*D:#+.0!07:Q
MKV ET^UCE0?/<@X/H/\ ]=:'E7%TZ"67"JO.!UJ[K-DEG;6L<*Y:% I^O?\
M6JEFDI!+_>QFG8Y'*^I/#'Y!Q')@^YQ5B[N6=,%VX'][BH(0/Q/6GRVOGD(&
M*CO@4"91WH&&]BS'L.:1_,W91&Q^5;UAI$87< 6./O-_2M2ST'SU(<''?BD+
MG2W.:M0[1[]A J]&\B1DH#P.1TK973A [6X QU (S3[+287<_:)F8=D ZTFA
M\ZZ&,+:]NK=KC&PGH >U)9V""=S*=[8['BNLFL6,)1%:.(C V]?RK)GM9H0L
MB*"R#YCCM2N-2OH95Q"LKY8?*O !IZVV8,@$ =!4T=RLDI,BJ"/2K[!/)WJK
M;<>F*I$R;1AN%8JF=WMFH/[$$Y$F C%LC Z?6BY+"Z8HVWOUZ5:2^1(@QD5B
M!VIV)NUL375M&;54RBLO!Z5!9((!N')]JRM2N5O"#NVLO&1WJ-+YHHE51P.*
MI$JYV0\4/:>6AR,\9J/4KD29G@.=R[P/0]ZX6ZU$-.F2<'WY%6SJTI@*(PSM
MV]>U#?07*DTT;+ZI<3P.5SEE*LA.0RD5P4Z&.1D(P0>E=+9M+YBAI%53BL/5
MN-1F YPU1(ZJ#U:,]JC8FI#UIAZTD=)'C'---.:FF@3&$4E/Q333(8PBD PP
MIQIO6J(.CM,2:>R@'<AS^%<Z5S,WIDUM:=/&HVLX&X8YJM>Z?+!OD5"5//3I
M4K1G=77/"/+T,R5^<"H&J0C)IC"M$>9(C-)3L4TU9D*#2$#K10#ZB@0RG!MO
M0TIQ3,4R66HYE==KU-':QS#Y3S6=@CO4L5PT1X)I6[%<W<6XMFB.,57V'TJ]
M]KWC+C-&^$]J+LGE3V91V-Z4FTU?WPCM1^Y?CH:+BY/,^T****W/)+$7^K%/
MID7^K%/H *X/PY>)/XFVF[$DN^7*'4I)&XSUBQM'X'CM7>5R6B7VJ7.M 3F7
M[,6D _XEWEQ\9QB0MG].: .MHHHH **J76HV]G-'%*6WN,@ 9XR!G\V%/MKV
M&[)$1/W0RDC 922 1[<4 6**** "BBB@ HHHH K:A>1:=IUS?39\JWB:5\#)
MPHR?Y5SGP[L9+?PI%?W*XO-4D:_G//60Y Y)Z+M'X4GQ)N98_!EQ:0%A<:A+
M'8Q8(',C!>3V&,UU%K;16=I#:P($AA18T4=E P!71\-'_$_P7_!9&\O0EHHH
MKG+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *Q/%'AV'Q%I?E%FAO8"9;.Y1MKP2@<,#Z>H[BM
MNBJC)PDI1W$U=69SO@G6Y-;\.1-=$C4;5C:WJ-C<LR<-GZ]?QKHJXKQ%X'-Q
M<7^LZ+J>HZ?J<D?FK';2XBEF485F0\$D#;7/Z5XL\:6E_9ZOX@T^*#0]0FBM
M/*=MKVK'*[\8R S>OM76Z$:MYTFO39WWLN_4SYG'21ZK17!:QJ]SXOUUO#'A
M^^:"T@ ?5-1MI%+(ISB.,Y^\2.3VI-$\7)H6D:W;^(M0EEN='NVA4RJ/.FC;
MF'@?>9A4?5I\M^NFG6SV*YU<[ZBO+;X^*=-T>/QO?ZC=0W22JTFDE<P16S.
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MO_?;\Z7>_P#?;\Z;10 [>_\ ?;\Z7>_]YOSIE+0 [>_]YOSHWO\ WF_.FT4
M.WO_ 'F_.C>_]YOSIM% #M[_ -YOSI=[_P!YOSIE+0 [>_\ >;\Z-[_WF_.F
MT4 /WM_>;\Z-[?WF_.FT4 .WM_>;\Z-[?WF_.FT4 .WM_>;\Z-[?WC^=-I10
M N]O[Q_.C>W]X_G244 +O;^\?SI=S?WC^=-I: %W-_>/YT;F_O'\Z2B@!=S?
MWC^=*&;^\?SIM*.M #MS?WC^=&YO[Q_.DHH 7<W]X_G1N;^\?SI** %W-_>/
MYTNYO[Q_.FTM "[F_O'\Z-S?WC^=)10 NYO[Q_.C<W]X_G244 +N;^\?SI=S
M?WC^=-I10 NX^I_.C<?4_G244"%W'U/YT;CZG\Z2B@!=Q]3^=&X^I_.DHH 7
M<?4_G1N/J?SI** %W'U/YU0UG2+/7]*FTW44:6VFQN 8J00<@@CH015ZBFFX
MNZW#<HZ1HVG:#9"STNU2U@SN*)GD^I)ZFJEWX5T:_P#$,.N7=DDU]#&$1GY7
MCH2O0D9.#VK9HJE4FFY7=V*RV&RQI/"\,R+)$X*NCC*L#U!!ZBKJ *BA0  ,
M #M52K8^Z/I4#%JJ_P!]OK5JJK_?;ZT#./\ BC_R3G5?^V/_ *.2OF_'Y5]*
M?$J)IOA]JD:]3Y6/^_J5\YR0/$<.I%<]5KFL>O@H2=)RMI<CC'-#J0<TX"GC
MD8-97.U(K8YJTH39S4++@T@#=J&%ALB ,:CQ4A!H"$F@=A%4$<T'K3B"!24%
MI#BYQBHS@TXBDQS2*L*@S4@45'4B<M2'88R\TS;@^U6V1<9-1'%(I$0 IZI2
M8&:D' H&+M%&T4 T5):0FVD(I_:D/2@8VE%)VHS5$%JWN9+63S(N'P1GZU8A
ME6#,L@W'KFM?1='@N=(6=TWR32LG7H *R]1MO+G*J&"#C!'2K2LCAJ24INW0
MT(-363&Q#\WJ:O6%Y-;W8W;2I/0BL"R@ D!V.S>E==H6B-?2H6/EQ@]^M)CT
MZG>Z5<Q7EB%PQR.E79+4A J1X4?Q=ZJ6TEII*I$90HZ<UO1NDT'F1L"A'6JM
MS(XIOE>FQC8"$\ 8-9NHRA4+A ?<UI3@2W90L ,=JJZM"7MUC7& ><5ALS6R
MNCEY9[B,%D(P"2.:PY[JZDNU=<J,\FK]V9Q.L2C(#<A?2KW]D331I&B;1G.3
M5&ZDXES2EN)5 N)G9?X03BM67R5*G:Q=>I-0I9RV,<;DAV7' %:"L\JG,?;K
M2>Y'.]SE;\[]0P,C(P-PJ2+3(BZI'G>>=V33KZ%A?J[C"YJ]%M1EEW >E4D.
M4K+0M6>B&>-A*S;1T!JK>:+ I**,#'&#6K:ZPCHZ 9P.3[UF.URUP\A9=O;)
MJY)=#"-2:;N<3J6FO;R_=^4-U]:ISP!P Z_*.02*[>^>WG3RY$!;U%8MY%"J
M#:&8@=JE,TO?4R+<QQP'Y<_2ITV2+OZG'2LRX5U<LIVC/05?LY05+.P4>_>F
M@>B((;>2RNQ*%VJYY!]*WM.GM#<^6XP'(P1V/K67JKM)"JQG.!GI67'KK1H,
M*%9.G'(JD[&<E<3QM$R^(9)=P=)5#*X_B[&N:-=)X@+7=A:7A8#&8RGIWKFF
M/:I>YZ%%W@AIIII:54WG%(U&4G0U/) 4&:@- F(>:%7-%*#Q3($;TJ(]:>33
M213)9&0>HZBM"QD:Z!A8;AC!!JDU6=,8+>+DX!.#3Z%T9-3L5+F$P3-&1T-0
MFM?Q!'Y=]Z@CK6.:I/0QK14:CBA*,T=J2FC!AG!I>#Q3:*9(I IM+WH(Q3)8
MW%(:,$]J,>HH(#<1WXIN:6D(%,1]N4445L>46(O]6*?3(O\ 5BGT %<9HKPQ
M>)%B5-20N\N!+?I)$3R3\@)([D<<5V=<7H:1)XG8A;!)2IPMO -Q4Y.]GV@@
ML1PN>@)YZT =I1110!#+<QQ31PDDR29VJ.N!U/TIMM>PW9(B)/RA@2,;E)(!
M'MQ574-)6^N/-W!2R",MCYDPVX%3V/\ ];TI]AIYLRN9 PCB$,>!CY0>,^_3
M\J );_\ X]O^!"L>6TMKB6.2:WBDDBR8V= 2F>#@GI71$ ]:3:OH/RIIVV Q
M*15"C"@ $YP!WK<VKZ#\J-H]!^5(#%HK:VCT%&T>@H Q:*VL#T%&!Z"@#&%%
M;.T>@HVCT% &-2UL;1Z"C ]!0!CTM:^!Z"C ]!0!D4HZUK8'H*,#T% &516K
M@>@HP/04 9=%:FT>@HVCT% &72UI[1Z"C ]!0!F45IX'H*,#T% &916G@>@H
MP/04 9E+6E@>@HP/04 9M%:6!Z"C ]!0!G45HX'H*,#T% &=16C@>@HP/04
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MB+_5BGTR+_5BGT 5[ZQMM2LY+2[C$L$F-Z$XS@Y_I6?8>%=$TN\2[LK"."=
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M !D^IHR?4T44 &3ZFC)]3110 9/J:MCH*J5;'W1]*!BU5?[[?6K557^^WUH
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JK_?;ZU:JJ_WV^M
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MC&X,2O8\$C]:JZKY2O%))<10$ A6E0.#[!>OXBK.GI$MHIAE25&);>@ 4GV
MZ4 6JS]9N9+.P:XBC9W0C!!'RYXR<D"M"J.J+&8$:65(@KY#R ,H.#V/7^=
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MXYM[?,T:A5S]!T_'FKU %74)&ALVE7C802V,[1W.,C-5='O?MHD:.?[1"/\
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M]%6J,485<SJU+72T_KN?.!^%WC//_('_ /)J'_XND_X5;XS_ .@/_P"34/\
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MRN/[$_\ )J'_ .+KZ6HH]FA_7:G9'S-_PJCQL1SHG/\ U]0__%TS_A4WC?\
MZ G_ )-0_P#Q=?3E%'LT'UVIV1\Q_P#"I_&__0$_\FH?_BZ>OPI\;#_F"_\
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M?_BZ9_PJ/QS_ - /_P FX/\ XNOJ*BGR(Q>*F^B/E\?"/QN!G^Q,G_K[@_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!/&RB, D?G3]Z_WA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_W
MA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\
M>'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_W
MA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\
M>'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_W
MA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\
M>'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_W
MA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\
M>'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_W
MA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\
M>'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_W
MA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\
M>'YU5HH M;U_O#\Z-Z_WA^=5:* +6]?[P_.C>O\ >'YU5HH M;U_O#\Z-Z_W
MA^=5:* +6]?[P_.JS??/UI** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIP^.GB8??L=('_;&3_XY7(^(-.C@=WC7E#Q[URKL36T9MH\:MAH4Y6L>IO\
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MA">3P*7"+[FM*XM(Y 3"6SZ;33(]"U*;B.RG?TVQDY_2ME),\B5"<79*Y0W
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ML[2,L:!068Y9CCN2<DU+292T1YA\:/\ D#6?_ __ $*.O#>]>Y_&?_D#V?\
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M"M2W_A^E<9]A(OQG@9JU')R*IQ__ *ZG0X&?:G<P:)?.!8KGO1))D&L_S_\
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MPV\"<)%"@15^@' J:O.FU*3:-DK(****@84444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFDO-<\&R1 RI9ACR1)9-N_,*?YU*GQ.L=2L'M]4TZ.?*G <!AFN>>RT#4_\
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M=Z %I:2EH$%%%% Q:***0"T444 %%%% "T444 %%%% "U/#]S\:@J>'[GXT
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M#D$'I1S]T)TNS.KNO .I6XWZ=?172@?<E_=.3[<E?S(K#N!J>E2A+^UFMR>
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MC=M^_P#DC\SX@SAXV2I4OX:_\F?^1] 4445YA18B_P!6*?3(O]6*?0 4444
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MZM'5=K=>[LNAGSR.H_X2C1/^@A%^1_PJ6+Q7H2I@ZC%U]#_A7&W_ (DUK3/
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M*E"DL H))X %/DMIHAF2&1!ZLI% B!&:-U=&974Y#*<$&NAL/&^N6! -T+I
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MLW>Z*:2WA4_*L;$$_4BN>#2WEUC>SR.>68Y/U->QE5.MA8SJU9-SGY[?YO\
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MP/"Y\\:IJ"_ZB\O7>%O[Z ! P]B5-++8:MK2^7J3QV-BV-]M;2%Y)1W5I,#
M]0HY]:VXHHX(DBB14C10JHHP% Z "N1VA%QO=LTUD[CZJO\ ?;ZU:JJ_WV^M
M9%B5R7Q#@2Y\/P0L0"]TH7/KL>NMK@OBS<-:^&;&53@C4$_]%R5$_A9U8._U
MB%N_^9XKK6F^4Y##YD)KGI4 /%>DW<<.M6:W0XD  ;W-<%?VWV.[="/ESP:Y
M8OH?1XB#:YS/VTX#-.<@FD'K5'(AP-(Z\TH'/%/89 I%6(.AI<9I2,5)'$9.
ME(I(AQVIP'-/:/:<&D'% 6!N:;3J3% 6 4N,4@%/"[B!1<=A&Y%,P<U8:%E&
M2*CVYI7#E(\4N*=BEVTPL-"TN,4N*4"E<JPF*,4X"G 4#L- IP!]:>H&.:4+
M0,;MIP6EQ3@.:0QN* ,U(V,\"M'0A8IJL,VH[C;1G<R*N=Y'0'VH)<K*YT7A
MGP)=ZM8_;;UVM+0C]V0FYW]P,C ^O6MH?":TN6W6OB C R4EM>1_X]5C4=7C
MU#)@N<08'RJW?VQ5!+Z5>8V<-_>+FJLD<+J5):WL.;X::=9[C=:K.XSP$C"?
MJ<U@ZGX<TJ*\2WLYKHD_>\Q@?RPHK2GU#4I=P>=F'0 YK(662.]$L[,W8=,T
M:,N,IK5LZWPQIUKH\JS6L=FUR/NS3J6<?3G _"NSNXC>P.9([6X##F-U R/Z
MUYEYQ9PZL%&.A.#5N'4KVW*RQ.V,8&<X(JDTM#*<)2?-<N:AX(TW6'F>PBCT
M^=1]U6)C+?0],^U>9W%K+:W$D$JE9(V*L/0BO3QJL\B&1SM90#A1]ZJ]]X:L
M=:NA,EV+::7&&9=R,/?G(-)Q[&E*LXNT]CS/;3N=N*[K7/AAK&E6AN[:6&_A
M RPAR' ]=IZ_@2:XC%0TUN=4*D9J\60[104XS4I6D(XI7+(2M-*U/MII6BXR
M K28J8K3=M,",#% STZYIY%$:%Y44#DL*!I79,\;189NWK4##<<DU<OVY"]@
M-H^E4@:&:U5ROE&E2*;@U,#1@'M086(PIS3I?2I%P!2.H8\&@+%?%(5P*G2+
M<V,TR5=IQ3(:(: 2.E*:2F2T.CE=)%=796!R"#@BMZS\37,/R7@^T1_WNCC\
M>_X_G7/TN\'J*9!V$ES::HHE5MQ' <#YU]CZ_P"<&HH;AHF <@J3]X=ZY9)'
M@<21.5;U%7X]2WC;)\K>HZ&HE&YWX;$^S=F=7'> J,=/YU,FHRV\G[N0C SU
MKF8[PJ,=CP".E2"\#C[W:N>5)25FKH]?ZS"<;2.NB\::A;@#?NY]:)/B%J(7
M"@9]VKBI+D=2:KFY(4\]:Y_[-PK=W!'GU(T;Z(Z#4?&NL7:%3<>6#_<'-<U-
M</-(9)79W/=CDU'))N;)[57>7'UKMI4*=)6IQ2]#EE**V)FFQUXI+'4TAN#O
M&,GAO\:IR,6&*K,*WY4UJ8.O*,DT?;%%%%=9\N6(O]6*Q=8UJ\L;A(8(M/B#
MG:LNH7GD+(>.$ 5B>H'./QK:B_U8KB?%9U'4+];=?#]U/%"YBBN(;F!1(&4%
MEVR*V.G7 /'!YJHJ[$SI-)U=KZYN;*Y2VCO;;'FI;W(F49]\!@?8@>V><:M<
MSX4T8VB2:C.MY#=7#RF2VN)(W\MBP!.449R(T[GI]2>FI/?0$%%%%(85SA^\
M:Z.N</WC5Q)D+1115B"EI*6@ %+2"EI %%%%( I:2EH *6DI: "BBB@8M+24
MM !1112&%%%% "T48XS2X.,XH **0,K,5# LO4 ]*;'+'*&,<B.$8JVU@=I'
M4'W%,!]%5_M]E]A-[]LM_L@&XW'FKY>.F=V<8H>_LH[-;Q[RW6U< K.TJA&!
MZ8;.#FGROL*Z+-%,>:*)HTDE1&D.U S %CZ#U--DNK:&>*"6XA2:;/E1NX#2
M8Z[0>3CVI68R:BH?M-O]J^R^?%]IV>9Y.\;]N<;MO7&>])#>VMQ/-!!=02S0
M$":..0,T9/0,!R/QHLP+':E[U6MK^SO8I)+2\M[B.,X=X95<*1R02#Q2?VG8
M"Q^W_;K7[&.?M'G+Y>,X^]G'7CK1RO:P71:HJI+JNG0627LVH6D=I)C9</.J
MQMGIAB<'-%WJFGZ>81>7UM;F=@L0EE5?,/HN3SU'YT<LNP71<HJN]]9Q7D5G
M)=P)=2J6C@:0"1P.I"YR1P>GI0E_927KV27ENUVB[G@653(HXY*YR!R/SI<K
M[!<L455M=3L+VXN+>UO+>>:V8+-''(&:,^C =.A_(TVVUC3+RVFN;;4;2:"
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M2#T.!@'@'C)KW6BG_:-7JD_E]WW= ]C$\/D^'GB#3KB;PQIA)\.:E)#+<WA
MWQ[%^=<9!^8@''T&>M36WPWUF74U\/7H_P"*1MKR2]A=9 7DW !8R,Y!'.3C
M'+<\BO:J*7]H5K=/^#W]0]C$\0M?AKXAU2V_LSQ 8_L6EV<T.F/')GS9'8E7
M(!R ,+P<<!?>HD\ >*/$6F3ZGK$?V76+.WA@TR+S.?W7)9B"0"QS^))X&,^Z
M44_[1J]+?=]_W]0]C$\4F\%^*W_XK*6WC/BE+];@6:N"@@5=OECDC)X[].^:
MK2>%?&/AF:V\4V,,E]KEZ)EU"$ ,(FD^YC!Y"G!] 5]*]THI+,*FS2M^G;T#
MV*/ YO!/BKPO']BT>*6Z_MRT2WO;A0<V\V_+$D=%VDC/?)-7O^%;ZU9ZI)X;
MM4#>&+Z>&YN+G=\R",?,F"<Y9L>O\)SP:]NHIO,:KZ*_Z]'ZKH'L8GBUE\,=
M6FU<:'J9/_")VD\UU;F.0;I2X 5#SD%1DYQC[W]ZG:;\)]2OXIK?Q/?"6"TM
MC::8(3S&-V0YX'TP<Y!/3 KV>BI>85WL[?UOZOJ'L8GDVG?"VZN=,U!_$5^)
M];N)(W@OK=F+0^6FV,Y(!^H[X'.1FKL7PJLI_",>EZA<ROJ/G/<OJ$7W_-?[
MW7JN  <]<9XKTRBH>-KO[5M;_P!>7EL4J4.QPM]\-O#VHZ)IFEW%M+Y6GKMB
MDC;:Y'5@3CD,<D^YXQ6I>>$=#O\ 5;/4[C2X6O+1@T4J@J<C&W=C[V,#&<XQ
MQ7345BZ]5_:?7KWW^\KDCV,,Z!I9UM-9_L^$:DBE%N0N&P1@Y]3CC)YQQ5Y8
M461I%B4.^-S!>6QTR:O45FY-[L=D4]ISG;R>O%+ACV-6Z*D93P?0UP>I)_97
MQFT:Z4%$U>QEM9-O\;Q_,"?PV#\*](KS[XB(UOXG\$:F.%BU3[.S D'][@8^
MF%.:ZL+K-Q[IK\/^ 14VN=M@^AJ>'A/QJ2BN4L**** "BBB@ JJ_WV^M6JJO
M]]OK0 E>?_%]<^%+,_W;]"?^^)*] KB_B;")_#EL#T6\5OR1ZBI\+.O!*^(@
MO/\ S/!^3*6'7).:>K?.I]_SI9T:(N&ZL<YI(8VFG6/(S)CG^Z/_ -5<!]GH
MBG-<)+<N6['%1272IPM/U:Q,-PYCR=O7%9BJ6/-;*S1Y%:+C-W)WD)^8]Z9G
M/--=@!MIF:=C*Y,*4C IB4\G(XI6*N20LH/S4DNTL2*B YYI7P.E*Q=Q!3FQ
MCBE6/<,YIO0XH&F2+(57%-)R:::0&@=R92,<]:4U$#4I8!<=Z@JXF*!1GBD!
MH'<>.#3RVZHLFC-4!)3A48-.!I!<D%'4T@-6;"T:^O8X%. V2S?W5')/X#-(
MENVK-OPS:JL=S>S*-NWR8\]R>I'T'\Z6VM)$N#N8E0>!Z"JTRSP %)G\L?<0
M= *U=/F695#J=V.IK1:(XI.[;$B_=L0Q  /)-6;6RANY1+@."<9R2!5^]T![
MB%60@!N02,_459TR+[''A8E8]/W?2A]C/FT+EEH:3R*V/DQ]*?-ID<-S)!$!
ML(SA3WK>M'A2WVQNH8###H169+$WG/<QG(Z8]J5T2KDFGZ*(XOD@ ;IYC'<<
M>U5[W22'<;F#,!EO3&>:W-,OU>+"D9[BI(Y&N)Y=Z;%4=2>IJ6T-<UV<*DL@
MG9)!O*G 8\5)J;(EN58#D=NU5-3\^'46,88Q2-][%6<>9*L3.&)';TI)F\J>
MS,&'4HK;[S,<@<=J;+J,&H#9+_"<KGC%;=_H<<\8D#QX'0"N6U&..%L;P#]T
M$=#5)W(Y>I9NKR1,!,,,=*S;75)80_WE;/Y^E6$+" @]#_$:)].$EJTB8W@?
MG5!;0DLKD&19I&DP3EA^M95PP-Q*P/!8D?G4]D&DE6%>#@\'VJ>]TMULH[^'
M+V['9)Q@Q/Z'V/8U,D73:3LS*))Z"FA:FQBIMD9ASWJ#J*+#!I"*D;I4>*!C
M#UJ*4$KD=0<BI332::*+5O)#?Q)"\BQ.O0L>#5:YMY+>0I(I!JM+$2V]#AO3
ML:GBO3*OD3<]AGJ/I56[&JDIZ2W(LT4LJ&-RI[=Z94F;T%S29HI*8FQ2:;VI
M<T[9\N[-!-Q@<J<@XI3*3UYIAIM,ALD\P>E)YH/45$332:=B&R<H&^[1LVCI
M4(:I5<E?6F3<DMFVZA;G_;%==(I(ZY KBA)MN8G/\+ _K7;@AE![<5E4Z'M9
M8[QDBH\6[GTJNT!)K29. .YZTTQ5"9VU(7,\QL@RHJNT3,22*US#QD#BH3#U
MX^M7<XY4S-\CIQ2-#[5I>3WQP*:8>*=R/9'U!1117H'PI8B_U8KG?$%C<WMW
M"9-,O+J&+=Y3V%]Y$BY SN!9/3C#'Z"NBB_U8KE?&VHRV$FE"/48K(R3,V^>
M8Q1$KAOG*L&QP1C!!W<XXJH[B>QK:!!=6UF(9;62V@7/EI<7/GS$EB26;)'?
M@9;ZUKUE>')GN-$AF>_AOF=G8SP$F,_.?E4DDD+]W)/:M6D]P044UW$<;.0Q
M"@G"C)/T ZURO_"5WA^U$66WR6F*J\;J6")&RQ\X^=MY_P"^>AZT)7!NQUG:
MO+[KX6ZIK"7-_P"(?$4NHZM'"ZZ?Y8\B.!\DHQV^^T\ 8Z<X%>H45K2KSI:P
M_K^NHI04MSRF3X6:S+IRZJ?$=V?%OEQ*+EK@K'&%(W+E5W,-OKU(YZFHY_AK
MXAT#4+;4O#.NW,FJWEPRZE=2K&(]C<L_EGKSSCD\\8KUJBNA8^MUM;T7W>GD
M1[*)Y%=^ ?&^F1MI&D^(7O=+U13'?RW6-T!8_.Z@G/(R, Y.3GL1<LO@Q;0/
M)9SZ_J4FB-LD_L^-_+5Y0%W,_)!!V^@(R.>,GU&BD\?6M9.WHEKY^H>RB<7H
M_P *_">CW5U.NGB\-P3A+T+*L(SG" CCZG)XZUN6GA70;'2)=*MM)M4LI5VR
MQ>7GS!_M$\L?<G-;%%83KU9N\I-_,M0BMD9)\,Z(=)M-+;3;=[&S=7@@==RH
MRYP>>IY/7KDYJY<Z;8WEU;75S9P33VI+0221AFB)QDJ3TZ#IZ5:HK/GD^O\
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MGO02V1D\TTG-!ZTW-49MBX.,CI3E?!IOF8&*CS3L2V22D!LBNZA;,"GU4&N
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MP6,$4M;ODQ_\\T_[Y%'DQ_\ /-/^^11S!8PJ*W?)C_YYI_WR*/)C_P">:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!;NVY_V<9SQUK>KFO]":2-Y;:;Y;R0>6B2#S6,Q"MPY5@IR2&S@<@*,"A
MSI:***0RAJU[-9P1^0$,LK[%W#<>A/"9!8\= <]^U&DW<]Y;.UPJ"1'V$JNW
M/ /*DDJ>>A.>_>HM;>""""YN(O-6*7(3RV?)*E?X>GWNX(]LX(-"%O\ 86:!
M)U=GS,9UD#%\#/WR3C& ,$CC&>*?074U****0S!CU:_>_4>5$;9I?+P$XQNV
MY$N[:3WVXSVZUO5RD,M@VL*LL DN#-@QF4;U(D^1A$9#M0?>.!R<-@8KJZ;$
M@K/U:]GM(HA;*AED8@;AO( !)(0$%NG0'WK0K)ULQ,UG!/%*\4TC*YA#;P C
M'@JP(Z=!G/3'-"W!EC2KJXN[9S<HJR(^W*C;NX!R5R2O7H3GOWJ]69HOD>3.
ML,.QEEVRR",HLK[5^9023MZ+UXVX[5IT,:"L%=6OVOP/*B-N9O+ "<8W;<^;
MNVD_[.,]NM;U<I#+82>()H);69V2;:TGD3,A?(9,9)" 9)/&TD!N,#(A,ZNB
MBBD,S=;OY=-L?M$?EJ@8!Y9%W! > =N03DX'![U-IEQ<W-F)+F,(Q/RL!M#K
MCAMN25^A/:JGB VPMH?M@)M_,#-^],0!'*DON4#D#USZ=Z?H!A.FCR$*C<=S
M!MRR,0"64[FX)/J><YYS3Z"ZFI1112&8,.K7TNLO9B.(^6X$D(C.Y%/1C)NP
M>#G&W/:MZN9MUL3=0W;P7!G>X/RXE.9-VP.OSE0  <CTZXZ'IJ;$@K-UJ_FT
MZR$\814W /*Z[@F>!\H()R2!P>]:58WB)H$M;=KE))(A.@\N,2;BQ8!3E",8
M.#SG.,=:%N#+NF7%S<V8DNHPC9^5@-H=<##;<DK]"3T]ZN5FZ$+<:8OV>.6/
M))D65'0[S][AR3C/H2/<]:TJ&-!7/VNLWT^H11^7"8Y22L:K_ #@L)=VU\9'
M '?'%=!7)6KZ?+JD*RVZO/N4>6'_ 'D;!P5(C\PF-,@$J!Z$XQ30F=;1114C
M,[5KVYM%B6U5#)(3R5\P@#T0$%OP/%/TF[FO;%9YE3YC\KITD7LP&3CZ9/2J
MVL^4\UK!-'*T<@DRT(<,N%SU1@V#Z#.?PS4FAI:I:S+:V_DA9=KE8S&DC!57
M<BDG"X  ^A^M/H+J:=%%%(9@V^K7TNI1Q&.(QR,=J!,?*#@L)-VUL9' '?'%
M;U<M:R:?-KDD,EM.TD<@C\PP3% X*2+MR2(USU&,':#GH#U--B05DZ_JITBS
M6<RP0QEL-+-R%_X#N4MGV-:U8^O/!''"UP72+Y@9%G,&WCO('7 ]N<\>F:%N
M#+>DW<M[8)<2A/GY1TX61>S 9./IDU=K/T:2&6PWPQA 6^8IC8[8&67!(P?J
M>^><UH4,85S=AXAGO=9:R5[61T/[VWCP7A'3)?>0V/0*/PKI*YG3'M-MG*8;
M@R3% (V60^6PSADR[*B@9! Z X/I0A,Z:BBBD,**** "JK_?;ZU:JJ_WV^M
M"5YO\;/^1-L_^P@G_HN2O2*\X^-0SX-M/^P@G_HN2IG\+-\/_%B>&6]U);'
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MPJH, #V%.^EA#Z***0SE+:VM1JJ7C^8I:? G6!=S-NP%,F Q4].0/J>M=74
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M +^Q_P#Q%'_"F/#G_/YJG_?V/_XBO1:*.2/8GZS6_F9YY_PIKP[_ ,_FJ?\
M?V/_ .(I#\&?#I_Y?-4_[^Q__$5Z)11R1[!]9K?S,\Y_X4OX<_Y_=5_[^Q__
M !%)_P *6\.?\_NJ_P#?V/\ ^(KT>BCDCV#ZU6_F9YS_ ,*7\.?\_NJ_]_8_
M_B*3_A2WAS_G]U7_ +^Q_P#Q%>CT4<D>P?6:W\S/.1\%_#@_Y?=5_P"_L?\
M\12_\*8\.8Q]LU3_ +^Q_P#Q%>BT4<D>P?6:W\S/.?\ A2WAS_G]U7_O['_\
M12_\*8\.8Q]LU3_O['_\17HM%')'L'UFM_,SSG_A2WAS_G]U7_O['_\ $4?\
M*7\.?\_NJ_\ ?V/_ .(KT:BCV<>P?6JW\S/.O^%,>'/^?S5/^_L?_P 12?\
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M-CS_ .@5W]%')'L-8NNMIL\X_P"%*^&_^?W5?^_L?_Q%)_PI3PW_ ,_NJ_\
M?V/_ .(KTBBCDCV%]:K?S,\V_P"%)>&O^?W5?^_L?_QNC_A27AK_ )_=5_[^
MQ_\ QNO2:*.2/8/K5;^9GFO_  I'PU_S^ZM_W]C_ /C=2Q?!?PY#%+&M[JF)
M!@DRQY'T^2O1:*.2/8:Q59;29YS'\&/#T?W=0U?IC!FCZ?\ ?NF-\$O#+MN^
MV:J/I+'_ /$5Z313Y(]@>+KM6YF>:_\ "D/#7_/]JW_?V/\ ^-TW_A1WAG_G
M^U;_ +_1_P#QNO3**.2/8GZQ5_F/,_\ A1WAG_G^U;_O]'_\;I/^%&>&/^?[
M5_\ O]'_ /&Z]-HHY(]@^L5?YCS'_A1?AC_G^U?_ +_1_P#QNC_A1?AC_G^U
M?_O]'_\ &Z].HHY5V%[>K_,>:I\$/#48P+W5OQEC_P#C=1M\"_##G)OM7_[_
M $?_ ,;KTZBCE0>WJ=SS#_A1/A?'_']J_P#W^C_^-U:L/@QX=TYG:&]U0[Q@
M[Y8S_P"R5Z+10XQ?0J&)K0ES1DTSBA\+]%'_ "]:A_W\3_XBK$/P[TB$#;<7
MIQZNG_Q-=;14^RAV-WF6+?\ R\?]?(PH?"=A /EEN3]67_"K0T*V7_EI-_WT
M/\*TZ*KDBNAC+%UY;R9F_P!B6W_/27\Q_A6'K7P[TC7;J&XNKB]1X5*+Y3H
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A_P#L_K1Y_P#L_K0!+55_OM]:E\__ &?UJ(G))]: /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/'.O#6IFD&G^3=%(X]G0LH&&!/Z5\[>)-0EUSQ-KFI7#%Y[J\ED9FZ_>.!^
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M=0 M%)NHW4 +12;J* (Z3(I-U)0 [(I-U,W4;J '4;O>F;J3=0 _=2;J910
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M.@4DXXK(^&L,WP#_ &N/BNGB=)X= \?2V^L:/K3QLT!E1-LELS ':RGH&QD
M8KZXC585VQHJ+_=48%$BI,NV2-9!Z,,BM?:Z6MI:WZD<FM^I\L_"/P;-;_M"
M?&KXRW\,FE^&-0M+?2]/DDC8->1PKNEN=F-V-V$4XR0IQ7F_P-U)+7_@GUX_
MM+B*Z@O&_MI!:RVLJS$S22&(!"N3N!&,"OO#?\N,<>E)QC&U0/3%'M.;==OP
M#D\SQ_\ 9'OXKS]FOX;QQB17M=#M;2>.6-HWBECB571E8 @A@17L.ZF\+P!@
M>U%9RE=MEQCRQ2["[J4-S3:4<9)Z#FI*/./&36L.M216Z!"%!DQTW&LZSC+
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MCZT =)IY_P!&3Z59JGIK?N0!VJWNK(U%HHHH **** "BBB@ HHHH *7)I**
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M/DA0X+8' &:K:%JESJVFQW-S82:;,W6WF<,R_B.*72XS0HIW!K(75KJ37I+
MZ7,EJJ!A?%UV,?[N.M"5P-6BBFK(DF=KJ^.#M.<4@'44VB@!U%-HH =13:*
M'4VDR*-U "TW=1G\*2@!=U&XTE% "\T;J2DR* %K@_CI\2+GX1_"_5?%5I91
MZC/9O @MY6*JWF3)&<D>@?/X5W>17B_[99_XQS\2?]=K+_TJBH ]0\':])XH
M\(Z-K$L*V\E]:QW#1*<A2R@X!K8!KE?A3_R2_P *?]@V#_T 5U% #Z*9030
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MEKX?:+^T#>6A\H+)D%4('7(J/X-^.M1^*'AW4&UO08;.VA=8[?YO-BN$VY#
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M/F[&Y<>)+BZ8I%B->GR]?SJN&9CEVW'WJE'V"BK2>],6Y:1@:L(PQZFJBN%
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M?80Z7806=LFRWA0(B^@%6**7BLRA,]J3FEH!H ;[UXS^V1\O[.OB3_KM9_\
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M2DTQJ"1K4BOMR:8S4L8\R.4#KC- %Q9L1')[50DX8XZTF]N>3CN*B\WGDYH
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M&;OPK>VEGJ1TR95O)FD0D_,-XP.2T@4'/!-=99WB_P##QZ_NMDPL_P#A"/L
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M;R&;30I:YDB(BDR/X6Q@US5YXX\3_#O2]>UCQ;:+?V"7BQZ?#I<1>7RF. 6
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MWY?O"O%_$WB[2O@'X4M_$/PT\(0ZKI&H?/=RQR["HSP<'FLZ=.51.%M;Z?\
M!93DHZ]#J%\.ZA\/-8F\8:];R:SJDEU]FMH-*4A4A=L LO<C/)K:^,G@F_\
M&C>%-8M]471[/2+H7MWYK%=R8^Z?SKKM+\4'5O ]MKWD_O)K7[0(>O.W./SK
MCYO&6O\ BCPWIUO>>%4F&H3M!?6PFSY,/9_QHYIN2EU6@-1M;N>F6-]:ZE8Q
MW=K.D]JZ;EE0Y4CUS7"R?%33-6\37FD6VE2ZO;V<!N#>QH'AWKG* _WJT9O
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MI!M="% SCNIQUKTOFOD?]BOPCJ__  E&L^));2:TT@VOV:.252HG<MGY0>H
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MG%"_$B!A\NG7)'J,5/)+L5SQ[G8<TVN4_P"%@=UTBZ;\JAD^(<G\&D2CWDD
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M62NWL;'_  J_PW'XDU?7?*>6^OG!E620LI(/]WTKR[QYX?.DV>K>&?A\MO\
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MA=QQN+;<A>*ZKXH>//#?[2WP!\9:1X%TG5_"%O'I2^*9M3^P&"WG*[G>(.N
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M;XI>$[SQXUGILQ6+0\;YI4;$P<=,5>U)O&.BW6DVVBP6][I+>6KR3,JM!&
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MYM?WH99).R=0<GKBO2R^:K)QJ3NY+1-=NMUUL<^(O&SBM$>_7G[2&L7'P_\
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M;4QRTZF[33E4XK(U"BC:<T=.I _&@ HIC31+]Z6-?JPJO-J]A;_ZR]@3_>D
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MN8X+.&,8Z",?SHY8>8<T_(L/\:-)=L65AJ%[Z,L!53[Y-:%K\3;690TMA<0
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M-:.KMHWW/!_"7@L_&;6O$7C/P;I'B_PG:;HHXK70[F./?(3M?:Q'8<FO8_\
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M/QKT>Y\&O!?Z>UE>?9-*MHU8;CNW,#Q@'O7/\+;YNK:2TM?L+VW-HE\V>K^
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MNVWD>!C.)\96ORM1CY*_XLO6_P#PAWA77)]#733JEW$XF2._E WDG!*C[O\
M^JN@T/QLLU]/:Z=#%"(_D5DP@#*,LG'4<UX]I/B:Z\376E76OV8MXHF#6]I@
M*6)'+DMP!@CJ>2:RM>UO5[_1[F:[ME6RM7^SSR0QI$J0OS@$=6-?78?*\+0C
M:%-+Y?J?*ULRQ-=WE4;]3Z5D\::4MS;VNIV.]HG5/.)VQO(5+;<]QQ6#\2OB
M]<6%O;_8H7$<L)=%91M(S@8]>>?RK@_A?XB\-3Z?+::GY,<RS,+6:1PK6JA<
M+RW&><'&>YKRMKH>'_'EY_9>IP7UCN;R)G7:@&0V5#="#GIZ5Z$:48O5'G3K
M.4=&=A9^*+R+QMYB^>NGK;>;*_E[9">"6P.G.?TKKE^*GAZ_TN>>9[O5;2S&
M/)N)&4R,2%Z#H 3CGTKAH]:DO+Z%H8_-GNQR+<[BV>[#MGKS7IGACX=Z7J6E
MI%KMG")&"JZ0KAF"\KN<=>@&.E?.YQG^7Y-!2Q%1)O:-]7Z(WPE&OBFXQC>W
M7H<1XP\076K^/M)73+.V2&^@B$2LP <J!N5O4YQ6):ZAK?A?5M5LH],NKE[I
MBDD*!O)C;<<]>H'&*^@]'^&,$,-L+:V6UBA^:+9_"2<UU-CX%@A^:6/S';JS
M#.?>OS6IQUBL4^7!8=VZ2;T:]#WXY92BKU9Z]D>;:-I>JWWAFVAB9M,NX82&
M/F;DE8Y].1QCZ8K,TOX2Z\UK#%<:OY4D4IDDE1,2/G!!Y[C'7WKW.T\/PV?.
MV-/]XU:\NRA5@\BL3_=%>1+/,XK7E6JQA'7167IJ]3HCA</!^[%R/*+'X.Z9
M#>-)]BDN;@.S"620\D]3P>E=E:^"X88X1;VL=J8UVA?X>G0COS74MKMM;J%4
M;\=*JGQ0B?=11Z<5X=3'48R<L1C)2OJU=M+TMV-HTW]BFD-M=!\ZSBAECC8Q
M]U4@&H9/!\/7'?=\QZ&EF\52MPL0&:I7NL3S2,%<%.QYKQ,9G63J-_>G)65]
MF]--SHITZU][%U?#=M'C>T:X[=:E73["#JZ_\!6N?:ZG;K)4322-U=C7S4N)
M\'%_NZ"OYL[?J]1_%,ZI9K"'LS?D*FCUJQAQMC4?4UQ>T,>>:F6,*N[MTS6U
M'BZNG^YI1BEY7%+!P?Q2;/GOXX>(-.\*_&K4;=KRWM$U73A?K'-A5W*0CG/'
M'3/UKKOV5_BI-JU]J^C3SP7!%NMXD=N0WE9)&UN>#C!_&OF3_@H9HLOB#XU?
M#Z#3IS%JD6CWDZ@H"C1JZF3<V?E.W.#@_A74_P#!/UKJZ\5:Q<'48+JSAL/+
M>:R0^2S%D*JY9599 .JGUK^C*.*JXS(8XINTG&^G=.Q\]**C7]G;2Y]]+KP:
M,N5\L*VWICFLW7KZ:XLV8*IC8-G<V",#K5?^T%\N$J5'S$*K$#\N>M<IXP\2
M7$>ER+!,IF0YDCW D+WR1G KY+"5\9B+*HVXV6RM=GH>RBGHB];SI<:+82,%
ME4$DGIR":UK'5EV[3QQ7G7PG\92>,?!<TI54^SW<\*(N"-JR,%/'J .O/-=(
M9EMRA8X8UY].C66+E&"V;3T*=G$Z^37!%I[G/4[1S40\0"VL48DY8YZUP.J>
M*(5FBLXY Q7[WUK'\0>/+>VD2)9,J@QQ7L5*>)YW[)-\JLOS9FHQLN;J>F-X
MP*] ?SIT?CC;U0G\:\1F^)$*]-Y^BFJC_$Y VT1R$^F*Y8T\RB[QC+[F5RT>
MK7WGT$OCJ#;RC"HI/&T'\,9)]S7@'_"SCT$+'\*5?B8<\V[?A6\I9I:TH/[C
M-1H]&OO/>/\ A+D8_<P/K5F#Q-$>?,*GTS7@R_$RU5?WHDC^JU+!\0M,NV"_
M; C]@<BN&V.4KRB[^AM[.G+8]Z;7!<L1Y@QCUKYP_:&\-)\3/ VJ^2-UQ:RL
M\+#D_*.U=3)XJ-GX8U:[CF\V1(6$>TY)8\ ?G6?\+]-U1?#D=EK5N5>Y61MQ
MY^_G@_G7T60T:E2=2K7;;5DK]V95HJG&RZ_DCLO@KJUMX@^%?AJ\O972Y:S5
M'!&>5RI_E79R:?ID@/[_ /-!7@DEYJG@WP[HNFV\:1QJDFW+8R-YJBWC?6\$
MAHA_P(UX5;A_&U:U1JDG'F=GJM+Z!]:HI?'8]]N-%TW:Q\]&;LI3&:X3QU86
MEG:K/&%#*0>.*\[C\8:U,NXW,*CZG_"J&I>(+V^4)<W2LG=5[UK@^'<RIXJ%
M2*Y5%KKY[[BEC,/R.,I7^1V'VS3TPV('&,XV2-_457F\164<FU$?([0Q(G\P
M:\^O-?*MMW?A5?\ MC=_%7[E3I^[[SN?*^VET21W=QXR2/*QQ-*>WFS-_)<5
MDW7B:XF8,B0P^ZQ@D?B<URSZ@&;.>:C:\;L*KE@MD'M)OJ;\^L7<V?,NI&']
MW<<?E5)K[R@3NK+^T,>6/'M2+,TWW00/7%5ML+?<TX]2+]B*D^U,PXX-9\<;
M=AEO>KT-A/( 2"!^53J/0<)Y,'./J33XYFZ#D_[(JU#I:KC(R:LK;K'QC\J+
M!=%5-[?>;;[5=A;;CC=[TL<*KG"<U/;V\MU.L5NC3S,<".)=Q/Y46'</.=6'
M6@7#\Y?\*[OP_P#!GQ%K3(]U$NE6QZO<GY\>R#G\\5Z5H?P2\/Z3MDNUDU.8
M?\]N$_[Y%9N21K&#?0\+T?2]4UQ]EA9SWAS@F)"0/J>@KN]'^">NWA22]ECL
MD/5-V6KW6"..UA6*"-88E&%1!@ 4[FLG4?0U5-=3A='^$.E::H:9FNG'\3C-
M==9Z7::?&$AA51],5;HJ')LT44M@'R]!@>U+ZTE+_%4C%6EHHH **** '444
M4 %/IE/H **** 'T444 %*M)3J "BBB@ HHHH SOD;H.:8RCH>M1O)MQ4:R
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M(O/"NHZ>Q$UE<0GW0BDJDHZ7+]G&3O8^L(O%TTBC.F9]XKA6'\ZD/BJ55/\
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MI\$UN6!N)%C'7'4BMNR^#N@P1A+I&N_4,=H_(5'M8(OV,WN?.6CVKS6Z2NN
MPST /ZUT%EX)OO$#%8+*XD3IO"D ?C7T7IO@W0=%4+9:3:Q8/79D_K6OQMVJ
MH5>F ,"H=?LC2.'[L^+O$'A74/".K"WU"/'&8WZAE^M;6DZEYEF(@Y8+QCO7
MT-X\\ P^+M'GM6"B8_-#*1RC]C7R]:_:=%\4/IUQ&R3QRF*2-O;C-:PFIHQG
M!P9Z/\&;RVM?&=U;W%K#*TL>]&D0,4*]<9Z9S^E?1/F;E&.G:OF7PZHTSQO8
MW*Y'F-Y9'UXKZ-TN8S6B%A@C@USUEK<Z*#TL703BBBBN<Z1&I**5: $HHHH
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MWO[4WPSMV<66D^*M68CJR11J3CKDOG]*\-TGP??>++P37LAD9ST/2O>/A_\
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M/^0C$ CKDY"N,\XYSBO8X=%CMXY9E&$D)6-5XP/7V'6M*:Q2/2W@<1^7*H#
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MUX-*WF:7_"/Z:T-J'U6:*6)<"7R Q*?W?O=?\:?-X5TJ\NUFFNKN>-E"1-Y
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M2N&2-6YDP3\K')]*]_\ ^"6OQ$U?Q/\ "OQ5HUY<FXM]/U3S[)I9 TNR1<R
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M>=&R]-XX=?KR#_P*L[0=2%]'$\A(*C"KG@5WI\R/-:Y6?5=JWRC!X[58KD_
M?B:+7M)3<P%U  DJ^OHWXUUBG(!K@DK.QZ,7=70VESVH_BI*D84444 %%%%
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MA/\ O<507&*;M ;I7)+&TW\=)/T;1HHSZ2?X&DWAB5ON26\H]G%5V\*W*_\
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MXCN$HHHH **** "BBB@ IO\ %2K2T %%%% !112@T +1110 4^F4^@ HHHH
M<.U+2+2T %%%*M "T444 %.W4BTZ@ HHHH YA<-P32NNU2:@9J5;CC:W(]:U
MU,B.0GI59HV+$]!^M:#1AEW 9%0LM %7RPHZ5$4V_2K#"HG;M0!"RYJO/E>
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MH<1",KS-(2#M([L"![5G^(/AKX9^W-JFG3QFS\0BZM8D^U!K0L$9X9(D'RD
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MO[SUAO$ELV-^K0\?W%)_I2'Q1I$/^MU&20^BIBO)9/VTO@MI_P#JK/5KT_\
M3.Q"@_\ ?3"L>^_;\^'5NK/IO@+4KR7^$70BC!^I!:M:? &%7\6HY>B2)EG5
M5_!!+U;9Z?>>/+W5+AH- T6XOUSM\U^%'O72^(O%4WP#T'3O$'CR]LHK*^A+
MQPV,N9XP5/R[3C)SBOE3Q-^W-X[\40FT\(>%K7PW%)TFV>8P_$@"O+-2\&Z_
MXZNFUGX@>-XTB4%RUS<F:0 ]0B=!]!7T&$X.R_#M3A!NW5NYR5LWKU%RS:7D
MEJ>I>*/VQ/%/Q.O)M/\ !MK-9ZK?7IMK"  /<+&R#,C'!ST<$= #FO=OV7?
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M7<>'-2ELKZ#R[B,X(!X8=B/:KEOIXGMW.3(N/N>GO7L/Q8\"_P#"2:6-0M%
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M[HS4TC!>]0QEKJ816T,EQ*>B1J6/Z4$%1IFY++CZ4S[2J_PY->@:'\$_%/B
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M3Y0YF?*VHZ/K6AY6^T:^M-O!$ENPQ^E9C:I&O#G8?]H8K[NLM>G:%DCO2%<
MA=P*DD=,5#?:3I.J)))+8Z;<;_EWSV,;98=N!UJ=BSX5_M.+LZG\:<U]&R]1
MS7V;-X-\&7$-NMYX5TU?F*RRK;J PX^[C%.NO@Q\.[KYH_"]FRL,85F#$^V&
MI[ ?(G@WQ]K'PY\01ZSH%X;:Z7Y9(SS',O=77N*U_C%I/P^_:>M1<W$:>%/%
MQ7 92/+=_8]P3VZU]*7WP'^%_P"\\SPY,I7E3!<NH*CKD9.*I7W[,OPNO/,(
MTG6K0A ZB&[W9X[^E%];HFR/R\\?? _QS\*9)?MFF2W^EH?DOK4%T(]3CI7
MQZ]#_$Q0]P>*_7^']GW1M/CM+?1_%.K1QW .+6\V7"!1U# ]*X#QI^P?X%\7
M7#S7FIV-K<21^:)(K(Q[CSU*GK[5SNC&6J=OR.F->4=)*_X,_,;^V8F7_6*?
MQIAO().HC;\*^Z]4_P""7^A7DF=.^(%M:JP)'F6LC 8[$D\5R]Q_P2QU%HUF
MMOB/IQMVD$2M)ITO+'L,-63P\NC3-HXB/6Z/C206C98Q1?E4)DL5ZK$/RK[2
MM?\ @E??^<JW?Q/TFU0ACN.F3$\=0/FZUT&@_P#!+_PJS1_VI\1]0NU8'/\
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MJX309]XXI^X+3';95>2ZV\46;V GFN!&N<UGS3-)R =II6DSDGKV%5I)2W?
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M65*-.+DE<[ZW^$OAK09 =:U'SC(N,WDR(&_ GFN\T7PSHFF1@V%A:JIP1(J
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M^Z,@9&#UX_&J>B67A_3=):^G>XN[RY?_ $>!8QMYZDG/'Y5S^G>'[[6+.6X
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M(Q5J3;&NXG\*S[B5Y6QC"^E #9&&[CIZTU5_.CVQ3AG/I]* $9@O7BF-(9%
M"_)ZGO5A5!8\"GI!NY/W::(&0PA5R>35ZW5MP##/]*CAA.X$].@%:-O#R?7I
M6FI)93A54<^]=/X'CVWQ)ZXK"M8EW#UKJ?"J;+X^N*REL:QW.QI5I**YSH%:
MC..*2EVT *#12+2T %%%% !1110 4444 %%%% !12;J-U "T4FZC=0 M%%%
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M!:*** "BBB@ HHHH **** "BBB@!M%.I-M "4ZFT4 .HI%I: "BBB@ HHHH
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M4TFW,6AQM*B.YW#(QA@>HR:UO$GPTLO&FFZ/J_A*UEBGCNU3SO-+C9G._P#
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M7@BXTNVM8+B_A62[W;%F?EF)]:QE;XK&L>QQUY>:;?Z-$D=K<6K--NDWG(!
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M?PE?CPRK7BWT<\3DM)&,'\/I7W5\)?B9IGQ>\%LMG>L-2M4^RW@;Y9%D P7
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M&UB(3Z3=QD9!C->>6"EYH<=V _6KCL9RW/4&I*7N*6H- HHHH *5:-II0,4
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MX/6O>/V)?$FL:OXI\6:!J>E1+H4EM#)]H;J[,"&7\ZPJRFJ<O/<VH_Q$>\^
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ML)5.D3>-+K(KV-C;Z5:QVMI"L$$8PJ(,"IMQI>M)MK Z W4N13:* '-C:22
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MHWMSXBE>ZFNHT_<1$#/S'M5WXS:AXQO+'3?$NA"33-/T^\\N^L[EL&2$/@R
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M))6+NO.T=,UKT45)8444[:* $6G444 %%%% !2[:%I: "BBB@ HHHH ****
M.:9>*C;Y5J4BHV^:M=2-2!N3FC;GG-2;<4X*.]&I)#M]*BDS$N?XC5IAM!)Z
M"J3DNQ8_A1J5J5R#3*L;?:F,M2!7HV^U3;:3;0! 5INVK&VC8* U( ,4;:E*
MTFV@-2+;1MJ78*/+JM22(I\M'E]ZF"4>7@8ZF@"%EVTQL] *L8Q2K'GG% $*
MH<5-'#GD\5*L?K3RH XH 5<%L+^=6(XPHIL,..U6%C+-CM0 V.,S-TP*L[=B
MT^./:.*9.WRX% #]-_X^ YX)-=%7.6LFV1 .2371+]VHD7$6BBBI*"BBB@ H
MHHH **** "BBB@ HYHI-U !S24NZEH ;1110 44O%)0 5C^+Y/+\.W1SC< O
MYFMBN?\ '4FW0_+SS)(H_K51W1,MF>>64>Q2V.]6=)MTU+6+6.1-X,H)XZ 5
M%-NBA4+P#UK;\&A1J4)(QS^N*Z'L<ZWL>B8"X & .@HHHKE.H*;MIU% #**=
MQ2;: $HHHH **** "BBB@ HHHH ;GVHW4O!I-OXT )112YS0 #TI?I3:* 'U
M&W(IVZHI'!8Q*ZB=D)52?UQZ4 5-2L1?6LD&<!AC-?AG^W'X0F\"_M:>-+25
M=L=[-'?18&,I)&IS^8:OVKU#PSXBU2ST'S=82"[L[M9KMK="JSH.J8]Z_+#_
M (*X>&SHO[1&A:T =NIZ+&H]"8793_Z$*_0>#*_LLP=*_P 46ONLSS\9#GI[
M'R+NJM=:A';K\QY["K/A7P[XB^(6J0:;X?TR>]N)I%B#1J=BL>FYNB_C7VY\
M+?V!;+X7^)O"=Y\4[$Z]/?L[7.FJ_P#HL" ?>)'+XZ\X'M7Z]C\WP> 7OR][
MI%;L\"C@Y2?O'RG\-?V??B'\9+66^T+0YH=%BP9-5O 8K=5) R&(^;KT7-?9
MGPM_91T#X*>'M(\2S69U_4[I0+V[U"S$HL^?F,<9/'!Z\FOL?P_X@\*Z7\.[
M6UM]7TNZ\(:?+Y M8[;#>2/]7&%'\0.*EUK4O!^L:3I_B.ZNKVQTO[08HX1"
MVV1\8PZ@?=Y%?DN9<48K&/V<8\D+[*]WZL]F&&A36AYU\;K/3O$V@^'M&T?P
MW=:EIBV(N8=6M9/*2VP1G.>,>V:]-\&VNA>,+339I/$-K>Z':V*P2Z=,00)$
M4!GR>XK%\2>-M4^&O@'43XC6QGT2\F6RL)((@(51P3N*YR0,8Q7,P^$O"^C_
M  CT_4X)WTZ&74/,F>%#(3&QRR #HK"OEY>_#WG;71[[[G3M*Y[3<?#?X?>'
M]%BU*33[5;"R'GB; 8;?4^HKRS]HOPZW]DZ!X_\ "FJ1V(TX)';1PQ9!1R!P
M/I6GX/U:>T\67%SK=K-'X3UQ$M],M7&Z,(HQEA_""/6NDCT6P^(WC*UETV\,
M>A:(3;SZ7)%^YE/8KZXQ7)'FHR4I.Z7S7H:NTHV2(_&6AZEXJ\.V=M'XINM)
MO8[-+Z:Z\@F/9CD9Z9]JO6_B*R^'OP=;Q#YX\3-:Q;OM.W!F_.NG\:76KPVM
MI::+:6MS%)*L5S#,< 0]#C\*QI-1TCQ-:ZIX0TE8=/NK90JQW$/[K)] ?O5G
M%\T4FM+W^0[6>FYA^$OAQI5QXLTSXAV+KI2WEIOFM&. S. <UZ)JGB#3[..%
M;A7FCGE6 83(RW3/M[UY7XF\)Z7K'BC0]+U/Q3=V=[:PKB.QPEL<8X/H?:M_
MQXV@>"=2CGU?6+V/^VD6QMXXQN5& P''H?>E./-)7;?;T!>ZF1?M":38V_PM
MU*=;:,W,/EI!<;06'SKGFOE*ZCM+BW%VZ(;MH]GG8^;(KZ/^(FK36OP^F\*I
M!=:FJ6OF37V0P&U@WS'Z5\K-?+>6[Q0AD*DX^N3750BU&QY^)?OKT.<U33_[
M7:+S';9$Y9H<9#?6N3U1M4N_$\6G+J'V.PEP8H(@0V1Z5T4WARZU#Q%!J?\
M:3000C$EL.CFM*73X9+X7*P[KF)28V(Y%=R=CA-#Q1X.B/AF*Z,4LMU%A@MN
M/G<^I-;NF:IH^BZ1I$NKYCNMF0)OF=/K4_@B[U>X\"M?WA%O>)(Z*T@X [$U
MGZUX%@UJQMYY)'N=2NU+M=1\Q<=O:I5GI)G0D5UUOP[K\TW_  D*R6;1N?)E
MB! 9.W;FK7AJQL%FN[O3U;^RW&%GF;DX[8K/M]6LM4T^WT?6]#DGO+,;%^S8
MW8 ZDUJ1>(]&\N'06T^XTZ*8;8T8<G/>G*Z5D-['/^+O$>LW%\FF:# 8E&&>
MX7N/3/:IH_L]C]IE>Z\BZCMMTD7;)'WOSK16WMO"VHI8P0S,+@\NQR!6'X]\
M'ZDUU'+#;-ADQ+(G0KV%"L[(SZC/#8LK>VBO+W5%$TC%@H!)Q[FMO7[BWL;/
M[9"\<LK?ZO/4Y]*QK'1-'M+"RM)5D&JW"Y19!P.>]3^)M'32[.P1@3(\GU&<
M=J;2<@'1"ZM_#1N%BDDN78XA?J<GM6'H/D6\5[97$6+F0[S&P^O%=;I>DSS6
M]M=SW$PD@8@*W&16)):IKTUS,9EB9)/E*C#X]_6DGN)G,1W%Y;30VCI);VL[
MX\ICQC-=9J&J2>'(XH;:T$ML,#?G@>U2ZA91W2J)!^\5-J-W'O6C:Z7!?:3#
M9-*Q9"&9SU-#DM+DHS;*6ZO]5DN65ELA$,\< ]ZW#>37UO*]O&ZPVJ[T:/\
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M&4;T8=*S/!=\9-/:SF.V>V;:5/7%7NB=F=#11D=C3@*@H3;1MI:* $VTM%%
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MNTE.HVT )^-)1M-% !7(^.I#)-;0@\*-QKKJX7QT675(SV*"KCN1+8P;R/\
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M[=:XZW\3>)/BMK43Z /L.F6Q\WS)!C>1VSZT7&GP^/?!HAU'S8=2D8-)#&V
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M;2;&XO;N>.VM+>-I99I2%5%49+$GH *^95WHCI/,OVCOVA/#O[-/P[NO%?B
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MI&L6:V,\RI\L5Q%G:&/JR'(_W#7Y+PG4IX?-;3W::7K_ ,,>IB4Y4TT>(_\
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M'\1Q];?M7?M#:;^S=\']5\476R?4B/LVF6;'_CXNF!V C^Z/O'V%?FC^PO\
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M[.TL/^XL8<_*B+TSC&6ZDY)K]6/V.?V:?!LW['ND:=K'AVSN9O%&G-<:G--
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MC3X_-'.,U3TGXI*VF@W-G<M-$H#^6O'UJN63 VK#3VT7Q2;>UL]UE,I=KG/
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M'()(U<=",TZOS0] ***IZAJ%MH]C<7MW-';6EO&TLTTC!41%&2Q/8 "FKO1
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M>;]8]D%Q][@=0?4FOERR\ R>-/A3YMQ_I5_ODFE24[2K#UKT*-23@I-Z;?\
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MF?\ =%L=A2LTMQ>9+\-]:M=8\/7^FZK:1PZCIJ&-&5<N2>V<<5S?@N/5-/\
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MC^)C=6,VJW<9TQ[21F:*;/.T\Y/2LJZT6_\ &\6I^)-7BQX9F_U4,<NV-/\
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MYOY-,BU.XTB>5_+*LV&59 ,@@<C(Y(QQUKMOBI\?/^%:_"7P_P")_P"S5O\
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MM9S<P)(5*,PR5/:K%8E"+2T44 %%%*M !MI:** "BBB@ HIRTM #=M*!2T4
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MX\UZ";3)KA+^UPTREL1LJ]<"L8Q;BX]"WNF:/Q!2/1[K0X=/O/L\9N0C6L;
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M1$R@=SW)KV>;XLZ192'^R]/FN;FX?#JJ[3GU-=C&VGR:A!<3I"FH-&&7=CS
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M1R2[*.0, =S5']LKPGXJ^)G@/P-8^&/"^H:I=0>(]/U>ZB5HHS;0PON<-N<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!E%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444[:*
M $VTZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK4
MZD:@!M*M)2K0 ZBBB@ HHHH **** "BBB@ HHHH **** &L*2GTR@!5^[3J1
M:6@ HHHH **** "BBB@ INVG44 ,HIVT4FV@!***7;0 E%%% !1110 4444
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!-HH Q2T4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 3:*6BB@!NVEVTM% #*=^E+10 FVEHHH 3:*-HI:* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTCPY_P" UQ_\?I&_;H\?=M)\.?\ @-<?_'Z871]U45\(?\-W>/\ _H$^&_\
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M&<?]>UQ_\?H ^^**^#5_;N^(&W+:/X;!]K:X_P#C]-7]O3Q[)D+I/ALD=?\
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MVIO^3=?B'_V!Y_\ T&O5*\K_ &IO^3=?B'_V!Y__ $&@#F?V%_\ DU/X=?\
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M_F&!]:'4L*%&4GN_O9Q*_#_3VT>\:9$!\J0G@#^$U]#6.(]#TX#D?98P#_P
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M7]IAD+CIZ4Z21),93)ZUF%CC&[/XU);_ #,<MBE<7-T->-@RG P*9);*QR
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M&??*(V^48K+DG$;8(S5RX)'6L34)=TG'I2OH*]E<T/.&W..*<K[NU9,-UY>
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MC> X]0LV=/+5E4D'%<M\+?$Z>&]2DM[R6.,JNT%N]5%RZGAX[#J*YXH]KO-
MBL]/$H3$BCK52'Q!-8Q?<!%23>)DU6UV02)(&'\-;&C^'UOH1O53QW%:\K9\
MOJ]3FI-6:\N$SQN8<5VVGV]LMN?- W8[UROB#3TT^7,2*'1L]*M6<E[JMN75
ME55J=AV;*UXJM=2"+KGC%7K'3KTVNYA\OUK%AF%GJ2+.V,M@FNBNM>\FVV0,
M'4BA:AK<S&OO[.8NN,T^U\32ZCOBV8&*R</>-O?[I/2N\T>WTRUM$DD5$.WD
MF@T,*WA"ON(YJQJ>I'["R<4FO:A:O>%;)U9<?PUR^I:E*=T3+QZT"Y-;A8PB
M\O"3R-U:VL:;%9PI($"\]:RM+O+>TY+A6SWK6O[]=0A"Y#**!M$^FZQ%;PJ!
M(N163XOU@WBP* #BFVOV'.TLOF9Z5G>(IK>V\H@BG%7=C)R44VS2TQ!-;H">
MHJAK4,=C-YB  @9JKI>JR74B1VY&?7&:Z2W\'W5Y()[F975EX7%)RA3?O,[<
M-@<3C/X5-M=]C"D\6&2U\K9SC%:?@V.*9I)'7G<"<ULQ^"[;@F.,G_=JA?:3
M)HXE,+*J-Q@"CZU2DN6]CM_L',J#52,.:W30ZPWB6[#RB"0>E=EX-DN;ZXB>
M50(]W->.^'=44WR)=2*/G .>]?0WA6]TDV0$4T9?/&#7RV*7-)I/0_HG(:DO
MJD%*/+*VJ[,[G3X[5+8@[17">+#:-P"IZU>U+4'CPL)R6KE[K1[B[8LT@'>N
M*-)GT%:IRQ/*?$EE%'= QH!68_A\7D&Z1%;(KJO&&ARK,A1@<"H;';Y*(WW@
M*ZXS<%H>+6C&O%1DMSRG6/#LUGJ&Z#]VF.<5'=6:F%&.=P8$\UZ/X@M$*LP7
M)Q7D.K:]+'K3V'RJNX 9'/->SAZ[J1Y7T/QO/LKA@ZKJ06DCNK'68[%5(=<_
M6M,:U-K$)PH"CTKF;7PK)(H9G![UH6ZRZ0NP%=F>:[I69\=&/*KDNL>'8[GP
M_J#/&&8V\G_H)KW#P^H7P_I0'W19P@?3RUKPK5O%4,6AWZF5<_9Y./\ @)KW
M/PWG_A&](SU^Q09_[]K7#75DCZ/*)N4I?(T&;:I-1.WG0D#G/I4K ,I!Z4U(
MUC7"C KD/IV5VM!)& =PK-D1D)R"!GBM9FE\PA>G:H;RW,BIM'/?FH:,Y*^Q
MF4-TYX%3_975P"/UHG154J1\U09V*NX9]J7R^,G(S1Y8]*>6+8% []AGDCWI
MK0CWJ;8<9IM.[#F9#L([4+&,U8:,A<D<5'MIW'S#&7:1BF-\U3LNY2>U1_+T
M'6FF5&1&JYHV^E.'RL<]*?ZT[E7(=IHVGTIZCGFGNR@''6BX<W0C!/2E,9]#
M36D6/YFZ57GU>&, !R#_ +M(3;OH65.QJ?),FP_,,_6L:34'F/[I^/I38VN)
M9 "<YH$]6:+W4:Y^=<_6H7U"5<;%5JA%BS,2RY'UJXMNBJ/EIZLK61"UQ/(/
M]6/P!IUOO!7<N*L*H7@4NTU0["4H7=3EC+4]4/I2N#DA8UVBI&5BO R:*?&Q
M4@]JSZF%[NY"NX-AABGT_(:0D]*>JJS 8I#W+&G,!G)Q\U:.>:KPVB+@[<=Z
MLUJC:-TA=W&*KW1(08&:GI&7<I&,TQV.:F8[CFH64.I4]*OW=FZR?= _&EM=
M)GN&7"*0?5J!*R5BI8Z6+B3 WGCM7:Z3IH50"'&%%/T+PS*-C&)>A_C%=M8^
M&9%4$PKRHQ\]008"1;1@ T\0NW12?PKIO^$;D_YYK_WU4T/A^1< QK_WU5EW
M.)NEN!D+$2/H:CM]+GF8L8G'T%>D0^%C,O,*G_@5;6G^"]R_\>Z]/[]03U/)
MYM!FE7Y8I#@=A6/?>%YF4LT4P('3%?02^#Q'G,"C/^W5'4/!S29*0+MQ_?H'
MU/GK_A&VVX9)0?I_]:K%KHYM^BR>G(KU+4_##V\CCRE!'^W6#=:3+$?N #/]
MZ@DY62-XQ]T@>]10R#<"36S>6YVL",\>M84D+QM@#]:+!RFJMXL<8PRU9M[P
M2="O2L!5<G!Z5IV,8CY8=11Y#\F;UK(%8$G%:%Q=HT+@.I.*Q%DQWIYD!7K1
MJA:Q(;HEF;'-4UF.]E('%6V^:H7@'51\QZU99D7T;;3E2*YJZSY@SZ5VFH1Y
MC'';FN1OMN_CKBH>Q$EH5 I/04Y(BQ.0:L6NWC=TQ5J.-'8[12L2HW(;!=N\
M>]:-1V]J%SA>:L&$^E5L:K1693GM5FSDM^%59K>.-0"Q':M0H5Y-026\<OWE
MSWHLF+E3V,EHL9/-1>8W0"MB:U#8VC]:A6S59%RO%39D<K152XDC7.T5?M;Q
MY."J].U5[BWS(54<5:M8/+49'.*:N-)W)O,52,D#-65D#=2*H7$)DV[1TJ90
MR]>M.URFKEV.-7[U#*IW%>P-1-<-&N0<5!'? R'>WZ4K6)MREOR]OK7Z3?"_
M_DFOA+_L$6G_ *)2OS96=6[_ *5^DWPO_P"2:^$O^P1:?^B4HU#7J=11110
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M[&>\_F* /L6BBB@ JI)J5M;R&.2558=C5NN%\2?#^^UO5GNH=6DMHV_Y9J*
M.O\ [5M/^>Z?G1_:MI_SW3\ZX#_A5NH_]!Z;\J/^%6ZC_P!!Z;\J ._CU2UE
M;"S*3]:M=:X/2/AW?:;,7DU>289Z$5W4:^7&JDYP,9H ?1110 4444 %%%%
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M4)+NG^1VV@ZK9W%CN#JW']*Q+Z5[R^$49RI:N-^'%U<7EG+')NC*MC:PP:]
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M9%_%))*I]J]"CBW37++5'Y]FW#<*DG6HMJ3[;7\RK>:8-6\+W]P)V4M;R?\
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M\.FWH>;C*D:=/WNMRQI>K+':(NW/%3/'->.K("$SV-4?LL5E8(T8Y[U>T[5
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M%?>"=,N58N#CZUY;\1/AUH\EFZK%N/F>M>D:QX@%C;L."1[UYCX@\4BZ9P0
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MD\37JPVZ@.,G(ZUYIIN/[5+>9GD\9K&5*3.FGC:<':1ZM-XBN'T]X4ED5&&
M U<KI?P]M=:U-KF[1YFV\%F-=!I>DM>6L95<Y%=9HMC'9_?&SC&:Y*B<-#VZ
M-2-;X3F-0^'>BPZ:X\K#8]:Y5OA;I2_OE@^?KG-=AXPU:.WNFAC=6+>AJYIL
M!F@0RKP141FS#$X>/4\GU#1=0TV63[-;^9&#QS7-ZEX^?0<I?VC0C.W=GBOI
M.'1;&;.^+-<IXT^'_A[4[4K-9I*Q.?FK;F9XL\,XN\6?/>D_$Z*#6H75F*,3
M@!Z])M?B +J%7 <Y_P!JO'_B)\+X]!VSZ?;^3EST8XQ6GX%W^1;QS]0,')IZ
MLZ:-1)6EN>JKXN,L9'E-S[URGB;5IKV.:VM82\[)\HSWK69K:*'[Z@_6NA\/
MZ+I<TBSRJID9!R346+E.[T/'=/\ A'JVIQF75(BVX9 5^!4UCHZ> 9Y/+5D&
MX%ANKVW5M0AL5*QNNP#CFO&_B,XU&WN2K<L>QJE&^IS2E*^K-@>-'\2!8XXF
M**V&);BMV"[^SQ[-N<UYGX'N(=)LVCW N6Z$\UWVG^=?0F0)@"AF<Y:'-^/]
M'-YH=\ZKD_9Y2?\ ODU]+^#9F_X0OP\<_P#,,M?_ $2E?./B76$.AZDI(#+;
M2CK_ +!KZ%\'\>#]  /']G6W_HI:ZZ>JL?#YG!.2EU-U[@GO5:XN3'&3D\4V
M2,N<Y(J)XA&N\G/UK6QXENACZAJDLK%$=D*G-+#I9D7<[*V1FI[)1)J4_ (Q
MZ5I0L68C;M I!8ROL:6X(*@GKQ4?T&*W)!_L_CBJDENJY?>O^[0T1*+,ZF2+
MNJ>=AO( J"H(0Q8^]/9BO.:=L--D0MD=*JY5[O48K?,:&J2.$MP,D_2E:$KU
MS^5&@[K<1E^4U!L]ZM!2RDTW:>W-"=A1E8CC4=*5H\]*D$#R=%;\JDCM7Z8;
M\J8:[E1B%/2C[[#' K0736D8=OPK1MM)(CYY_P" T%& D)+<&IELFD_B%=(E
MJL?& ?PJ008P=GZ47#F,&'16D_C7\JT[7P^-P5MI/TK1C8<+MYK3M5VQC(Y^
ME&XU[QG0Z,ENN2JU=AL8UY*@U8DC\Q<9Q0J[>^:LJPU8(U& @ IRPKNP!BG4
MJMSF@H<JA>#3@H;H,4S=FI47%2S.6@UX^F*1(\U/14W(YG:Q"8R"?2M*UTP*
M Q*G< >E,LE#28/I6W#"6 P">.PJD6GI=D<,"@<#%6X;$S$'( I8[=MP^4_E
M6O9Q[(\$=_2A:L%JS-;2Q$I?Y2:OVJ(0!MY JUC/:G^3QP,?A56L5:PQ5"].
M*DCCWR 4*-K#-6[-1]I3_/:AL;?0DCL0JACBJDFU&P5[UO;21P./I69>6I5L
MX/+>E)B>FI9L I7A<<UJH-JUG:7B.-\^H_E6@L@:DQ,O6T2[0S#-20R+YC@+
MC%4EEPN ?UI8Y-A)QG-(5RQ<7 R  :H7ESY*LZY 4=!4C-ZUEZS/BWD7_9H#
M<5=:W#'S8I'N(YN2F>_-<?'J COF1N !U)XK=M;@%0<@Y'K3V#8BO0)%8*,5
MC'3=T>3C-;5Q(#W'YU7R#TIQU'%'-W-FJR," :HW%B&' '6NFNK7S-S#O[5F
MSV;#L>OI2ZZBZZG-R::>>167J%L(8VS@G%=:\>VLK5H0^>W%(>R.),>Z0^E:
MEC;B-0WJ*G:W"L>!^5/' Q3L"741FZ9&:;Q&V!3MO7FE(S5%@K<9J:W;;)4(
M7!S4L:^])[$RV-TR^9"-O'%9[,%8$C-0[CZFBLV[F+E<EED5X\ <U"N%Z\TG
M\5.I$@<'M2;12TK4 -V\8IWEC:*%4NV!UI2K=-IX]J &O;CC-0M:QM_"*L[O
MF&15T(F\'<M!6K,*338WZ*HJK)I97D,,>E=#>*,E@1^%5EC,G &>_2GU#9ZG
M/S6)7'2OT8^&'R_#7PD/^H1:?^B4KX&DM]O4?I7WW\-?^2=^%O\ L%6O_HE*
MHLZ6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"I<6
MJW$,L3\K(I0_0C%?E;\%=3/[*7[?FO>&M5_T30]:GELXC(VU$AF</!*?P3'_
M  *OU9KX@_X*/_LQW7Q"\*VWQ!\+6SR>)] &;B*W'[RXMQSN ')9"!@#L37T
M&3UX1J3PU9VC45K]GT9PXJ#Y54AO%W_S/M[=3OUKXX_81_;%L?C/X5L_"?B*
M\2#QOIL*Q8E;']H1J,"12>KXQN ^H%?8P/M7DXO"U,'6E2J*S7X^:.BE5C6B
MI1*MYY[6KBV:-+C;\C2@E ?< @XKXC^.7_!/GQ'\=OBA<>.M8\<6-GJ+K#''
M#9V#B-$B^YU8G/K7W-MINWMVHPN-K8*;J479O2]D] J4XU%RRV/E?XH?LS_%
M+XS>&X_#GB7XGV]MH#*L=Y;Z5IYB>[4?WV8G],"N\^ /[)_@C]G/0[RS\.6\
MUUJ%^NV[U2^8-<2KSA<@ !1GH!]<U[9]*7:"O2M9YCB)P]ES6CO9))/UL3&A
M"+YK7?F?"/AG_@FSJ/@_XT77BS0OB1>:)HTT[NL-C#MO!&YRT9D;*D'_ ':O
M6/\ P3EN?#/[0D/C[P[X[N-)TU+HWAM_(\V\#$Y8"5LJ0?=2:^X\&F]ZZI9Q
MC)7O/=<KT6J\^Y'U6GT76Y\M?M=?LAZQ^U)?:*C>)[71M,TE'\F/[*SS2.^W
M<7;=C'RC& .IK=U3]G/Q-J7[+L/PA?Q%IB8L$TAM2%I)S:( %PN__684<].O
M%?1!H]:Y5F%=4X4U+2#NM-GW+]C3YG*VKW/F7]D/]D_5?V9;?7].E\16NO:/
MJVR22(VK1RI(H(&#NQM(9L@C/2L_1?V1=?\ @W\0_$'BCX/^)M-T2VU[+7NB
MZ]9O<VJ-DD&+RF1AMR< D]><U]5# %-VCFB>8XBI4E4G*[GOIH[=T-4*:226
MVQ\\?L]_LCZ;\'_&6O\ CO6]1;Q+X^UZ626[U)D"11[VW.(DZKN.,Y)Z#I3?
MCS^R3:?$[XA:!\1?#6KGPSX_T5U:"^:/S8)PN=HE3J< D#!'!-?1U-_AYJ?K
MU?VGM>;6UO*W:VUO(?L8<O+;0^5-0_8_U;XL?$[1O&7QA\0Z?X@_L50+#1]#
MM'MK/.029!(SL<D G##H*ZS]K3]G/5/VE/!=AX4MM=M-"TJ&Z2]F:2V:25I$
M#! I# !<.V>/2O?=HXS3N.:%CZZG&HI6<-M-%Z(7L8<KC;?<^3_#?[(?BGP[
M^S1K/P@C\6:;+9:@7C&H-92>:D,AS(N-^,Y"X./7.:T/V4?V2=7_ &9[?7].
M/B:UUC3=816=?LK)+'*H8*5.[&W#MD8["OIT]J0R;0?:M'F6)J0G!R7+)W>B
MU?<F.'IQE&26JT1\M_#;]F_XJ?!GP3;>%/#'Q$TO4]'\HQO#X@TZ2;[.6SN^
MS['7"\\*^X"O3OV=_@%HW[/7@MM"TN:2]N;J=KN]OI@H>>5N3P ,*.<#MFO6
M:6L:F,JU8N,FM7=V25V6J48M-= XI::*^=?VP/VJM'_9Q\#SB*:&Z\67\3+I
MVGYR<XQYK@=%'ZUGA\/4Q-2-*FKME5*D:<7*3T1\?_MY>(+CX^_M6>#?ACH<
MHN1I<JVI:,Y"3RLIE#>ZB->O3-?ISH.CV^@Z/9:=:IY=M:PK#&OHJC K\_/^
M";?[/>JZMK&H_&KQHLEQ?Z@6_LM[H?/*7.9+@_7"[3[FOT4KW,XK4Z?L\%2=
MXTU9OO)[G+A8N7-5DM9?ET)*\K_:F_Y-U^(?_8'G_P#0:]4KRO\ :F_Y-U^(
M?_8'G_\ 0:^<.XYG]A?_ )-3^'7_ &#(_P"5>]5X+^PO_P FI_#K_L&1_P J
M]ZH **** "BBB@"&Y_X]9O\ =/\ *OD#_@F7_P DK\9?]C/>?S%?7]S_ ,>L
MW^Z?Y5\@?\$R_P#DE?C+_L9[S^8H ^Q:*** "L/4/!FCZM=-<75FDTK=6:MR
MF+_6@#GO^%>Z!_T#HZ/^%>Z!_P! Z.NDHH YO_A7N@?] Z.C_A7N@?\ 0.CK
MI** .<_X5[H'_0/CK)\2:3X*\)V(N]8%KIUMG'F3-M%=S7C?[3WP);]H+X;W
M?AA;I;1;A61G;/0J1Q^= %*/XH_!-F(7Q1HY(."/M2U1\7?%;X06/A74[B#Q
M-I(DC@9U*W*]0*_%G]IK]COQ1^S'=68U2]AUFSN2R_:;6%D$9']X'. ?7->P
M_"O]B&U\<?LUQ^*?MD"7VH6C78D8'<AY*#KVXX[\^M 'UY^S3^U9\.?'WBJX
ML]8\2Z=$$W".*6<*7P<9 /4=.?>OMW3?#/AC5K:.ZLK>WN89%#+)&<@CUK\+
M_P!F']@_7?VAO$5S:MKMCIMG:']X8=TCO@D$ D +TZ\_05^YGPW\%MX'\+V&
MEO,LS6\"Q%E[X&* .?\ BWX.T6'P#JDBV4:,L>0P%?AA\?M>M=,^-NN6X(CA
M5ERW8-CI^6*_>3XTY_X5OK&/^>=?SQ?M(1O_ ,+P\5Y'+7*X]_W:5T49N&J1
MRUJ,*RY9['>V-]!J5O (G65,C.VM::UMHP!L&:XGX=Z7/INC@R.N_=N ':O0
M= TV75+J.1BI7/2NFI)ZL\?#X7VE=4EM?\#9\#Z+'-J44TB Q8/!%>P1ZC9V
MEFEO$ZB0#A!7*6BV^EV(0A4D XXK2\!Z3->>($O+DI)$5.%Q6>'BVKL^QQ%.
MG1BH+0W[#0I=2832@$$<#%0:OI,5G)Y3(.:]9MX;>*U0B)% 'I7/ZUI"ZM=D
MQA!@>E15ES,Z\)'EBD<MI_AVQ:,-Y*DD57FL;.QN"5C52#D5TJ:!<P<"1:S+
MCPU<75X 9%ZUSN6ECV*=-2W*]K=&XF0#D9Q78Z;HPN8@2!@U+H?A/[)&&?RV
MP<]*ZF$1PQX"J,>U9W.J,816QSZ^'H[=MRHH/K4]K"T<F,UJSN& Q3(H/;FD
MY-/0SG3C-;%RW;RXU.:S=>OO*AD<] *N?,B^U<QXSNFCTV?;UVUM3DV['GUZ
M;C&YYGXUUPR7$BJ_&/6O-]0NVF=AN[YZU>\5:A<+<N2!T%<NM^6F^; YYKUZ
M--[GR5>IJR2[T]KA>O?-9DVE,HQQ6M+JEO& /-7\Z='<02KD.K5VV/';UN8L
M>D]R!5N.U55 P*T-JR8"XJY!I9F48*BF%S+CTT]0!5NWTY=WS*#6O'&EG\LI
M7I4T?ER,2@&*I+4INZ*ZZ?$V!M%2+IHB7Y0!4V=K"K<$BLP'6NF)QU-&16=G
MN'(SS6C'HZ28^45I:?:K(O 4<UJPV! &,?E2D1'L<E>:'N4 !:@L_#I@;=A:
M[I=+:3^[^5:EAX5>X(Y0#'I7G5)I,]G"T%)79SVBZ'N(RH/%=FNFI%"IV#I7
M1Z+H*6JX=(VX]*UVM(V7;Y:_E7%*HSUZ6'46>1ZQ8M)(VT8&:Y'5-%EN<ID$
M$U[9K.EIM8A$S]*P[?0EDD9BJ'GTK'F/3IP49'D?_")O:PL4P.,\5XW\2/%E
MWH*QJ8_,W,5ZFOLBXTV)4*F./ICI7F/C3X:IJT>X10<$GYDS7'*-[GL1K6M9
M'R#I.N:GKS.B,(5]<D5L77@.6ZLUDE<328ZMDUW5U\/;F"\\N%8H.2,A,5[W
M\(_@G/?QQ/<2V\P9!PRU%.FXN[,Z\JM16E+0^<_!/PMDL]TCJIW@'I75S(=!
M<QX P.U?1'C?3=*\#E[.[^SQR*N00 *\ ^(%VNH2M_9X5F8 *P'%=RJ7U9Y\
MJ/+K<Y'7/])625L $YK@%U:*;7DLU4N=V#@<5Z;H_P +?$7B/'FW\44>X?+L
M/2O3/"OP.&DRK),;:9]V2Q3FLTU)Z&JI0FMSS_P;I*P31/'$%D#=<5[)H]O=
M7%J@8@9KH;7PK;V"@^3#D>BTVYQ$P\I F.P%9^Q;9VPM:UB.WT0*H9@&:N@T
MNW2-<;<<5S4FM30J% _2M+3=6? +D#BNF,>4KF:=CIXKM;9CR*AO-81HRNY:
MP[J^:16((K$DU("8JS &LYT];HZJ=21U]G>+R=PK-\3:DL=D6!&<U2L[G<I(
M85E>(9C):D9SS50AJ<.+Q$U%V/(O%'B2XN+UHP#@.>AJAILSP7*RG]36UJ&F
MJMPSD*<FLN:/;7K3IQC3O8^/I8JO+%1YGH>P>$_%EO':PK)(BG;W-/\ %?CG
M[/8SBUVRMLXP:\XT71);\IM? QFNQCT9(+8*ZJQ YXKY6M%2DV?L6!JJ$(W.
M%T6^U#5-7:[O1L'&%R37K5CXD1855BHV@=ZX^XCACDPL:K^%6);$M&I'%<W*
M>M6J>T.OF\7>5'F,*QK*FU_[0S-*0HZUDZ7'YTQA(RQ.*L^+O#LUC8I(&44^
M5WN<E]-3R3XS>*#;Z=$8PK_/C K%\'A[K1[>Y8;2PSBL_P 7R-?-Y4F&VN:Z
MGP>L46FP(P7:!TK5+2YX%27[RR$AM#J%]LW'I7<VNA72P1[9,#:,<UC6<,<N
MJ9B"X KO=WDZ>&_NK65]3T(27+9G(:OHLJV[F1LGZUY1K5X(=0FMF;H>YKU#
MQ)XKC@#QM,@..E?/GC+7&D\0320NK'/:JO;4XZDFWH:^G0QQ^,--:9]L#2<@
MG@U]3:#<>'8=-=6GA#;?4>E?+'A[PGJOC!8KPSI L3Y"[3FNTD\(ZA"OS78/
M&.,TKZCI[>\<]\0KF#S=6^S3!D9)?NGV-?7GA'_D3_#_ /V#;7_T2E?%/B3P
MG>:?9W<JW"LOER%@1VP:^U/!3%O!7APGDG2[7/\ WY2NRF?*YOR\\>4V:KWW
M_'NWX?SJQ39$$BE2,BMCYXS-+CVW<C'NM:M4(R+>XD["I\2M@\8-00F/FFVJ
M<$$XX%9DOG2DY3\A6HT*E@<4[8OI3:N#3D9 M'V@E6IBVYW=#UYK8923@=*1
M88QVY[TN47+V*?V1>-I9A2&QW-G#5HK&%X JQ'9O(H*KQ]:=D/E1FVMF(F)^
M;..]/FL5D7JWX5IM8O'&"R_K5F.S1=I=>#1H&FQST6GMM9=K8)]*>FD@8SO!
MKJ5M(=IVK55H1]H (^6E8EJQFPV0C ^]3_L_/ -;*VD14''ZT\6<0[?K19CU
M,9(=C<@U<A<\)_#ZU8N+3=]Q>WK5;8UO&=W!%+46M]1MQ$ 21R:59C@#CTHA
M?S)/FY%6?L2]0OOUIZ] 2?0KK;D_, 3BK\!8H-PP:(QMX P.]2U5K%I6"BE5
M2W2E\LTRKH;3@M+@4Y,;AZ4$MZ#/N\5(C4K;.]-..,5&Y&Y)N.13U4MT&:8N
M#5NT=,JK5!&I-80_."01Q72:7]YL\<5D0;,@KUK;TZ,MGCL*LTVLC06,<=:E
MVD=N*(T)QCM5M8U\D@CYJN]BKV*B?>YXJW#'YG YP*K,I#D"KUBIR<>E*0I:
ME:2+Y^XJU9QYF0U)=6_S+M'.*=9PNCJ2,#ZU.MQ:W-6%?E%)<0"51G-21?-&
M*FFA:.-6(Z^] =3-M;;:'SD<U,8]O/.:EC_B^M/V[N*JX[V*\>6/(J7<1VIW
MEE>E&VE<3=R.8X7/M7/:I<;LJN#D5T%TW[EOI7+W&)),KTIHI',:I;OYCR!3
MS[5=TS4F5 K[5 '&:L:G"3"V!67!$78J!R.M#T$]#5GO W *FI;-MT?/7-5U
ML1P2H_.KEO#M(P,"A7O=B5]V/J*;<5X&:LF%BQ %-:,KP15;E[F!>6OEX/S<
M^M8FH0ELM@\"NONK?S%8L,XZ<U@W4/RGCC%1;H3;H<M,O)J$?>-7KR,>:P J
MFRE:$$>PE+MIZH#FE:,@<]*=Q\Q&M2%<*#3>.U2*P/!I,EMB[B.U.CRXZ48#
M59L[<[T.WY<\\TC/?09%;[G^?*KZT^6S(4%0S<UHFW1F(QQ4BQJJ@8Z4<I?(
M9T=B&^]N6F363)]U6-:VT&CK3Y2N1&1;J\$@<KCZU-&R^8S%AEJL7<3.A"#F
MJ]O8ON)D7CMS4V(LT[#)+,]0&(JJ59>HQ6]CY<52NH01E1Q3:'*)25&:/@'%
M/ME:.0DC QCFIX(F:+:!5L6ZM&H89-)(48F9<,V1D8]*^\_AN/\ BW7A7_L%
M6O\ Z)6OAV>U611\N<>]?<7PW_Y)WX6'_4*M?_1*T[6'9HZ:BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&2-9%*LH96&"",@CTJ
M:B@#\Z_VM?V"]7L/$TOQ+^#/F66K)*UW=Z3:OL<2?>,MO[DYRG.<C K/^!7_
M  4VO/#,B^%_C-HUU9ZE:$12:M%;LLRXX/GP8W;_ /= [\5^CNWY1VKRKXO?
MLS_#CXT6K_\ "5^&[2YG4$I>Q@Q31G^]N7&3_O9KZ:AFE&O3C0Q\.>*VDOB7
MSZGGSP\J<G4I.S>ZZ%CP7^TO\,/'UI%+I'C?19FDY6WEO8XI_P 8V(8?E77_
M /"P/#/_ $,.F?\ @7'_ /%5^(GQ&^%>A77[1EQX$^$TNI:I;M>+86\UQ*K2
M/."1*59 O[L8)'L.M?7,?_!*+7=HW?$Z3=CG$4N/_0J[\5DV!PZA.I6<5-72
M:N[>=C&GBJM2ZC"]O,_0+_A8?AG_ *&'3/\ P+C_ /BJ/^%A^&?^A@TW_P #
M(_\ XJO@#_AU#KO_ $4Z;_OU)_\ %4?\.H==_P"BG3?]^I/_ (JN#ZAEG_03
M_P"2LW]M6_Y]_B?H!_PL/PS_ -#!IO\ X%Q__%4G_"PO#'_0PZ7_ .!<?_Q5
M? '_  ZAUW_HITW_ 'ZD_P#BJ/\ AU#KO_13IO\ OU)_\51]0RW_ *"?_)6'
MMZO\GXGW]_PL/PS_ -#!IO\ X%Q__%4O_"P_#/\ T,.F?^!<?_Q5? '_  ZA
MUW_HITW_ 'ZD_P#BJ/\ AU#KO_13IO\ OU)_\51]0RS_ *"?_)6'MZO_ #[_
M !/O_P#X6%X:_P"A@TO_ ,"X_P#XJC_A87AK_H8-+_\  N/_ .*KX _X=0Z[
M_P!%.F_[]2?_ !5'_#J'7?\ HITW_?J3_P"*H^HY;_T$_P#DK#VU7_GW^)]_
M_P#"Q/#/_0PZ;_X%Q_\ Q5'_  L3PS_T,.F_^!<?_P 57P!_PZAUW_HITW_?
MJ3_XJC_AU#KO_13IO^_4G_Q5+ZAEG_03_P"2L/:UOY/Q/O\ _P"%A>&?^AAT
MS_P+C_\ BJ/^%A^&?^AATS_P+C_^*KX _P"'4.N_]%.F_P"_4G_Q5'_#J'7?
M^BG3?]^I/_BJ?U#+/^@G_P E8>VJ_P#/O\3[_P#^%A>&?^AATS_P+C_^*H_X
M6%X9_P"AATO_ ,"X_P#XJO@#_AU#KO\ T4Z;_OU)_P#%4G_#I_7/^BG3_P#?
MJ3_XJE]0RW_H)_\ )6'MZO\ S[_$_0'_ (6%X9V_\C#I?_@9'_\ %5SWB;X\
M?#SP?"\FL>--#L@J[O+DOXMY'LN[)_ 5\/'_ ()1:WS_ ,7/E_[]2_\ Q5?(
M'Q1^"Y^"OQZC\&_$2\O[C0XKF/S-0LS^]FLV) ECW[@#['.*]#!Y-E^+FXTZ
M[DTKV2L[>5S&IBJM-7E"WS/N7X[?\%1O#^DPS:/\,-.D\1:Q(3%'J%U$Z6Z/
MT^5.&<^A!Q7!?L]_L8^-_P!H#QXGQ,^.3W@T^1Q/'IMYE+B\.<A73@Q1C^[@
M$Y&*^N?@5^R3\(?AII]CJ_AC1;;5;B:%7CUB[<7#RH1D,/X/Q KW_P"[QT6N
M&MF5#!QE1P$'%O1RE\7R[&D:,ZC4ZLK^2V*NGZ?;Z79PVEI#';6T*".*&-0J
MHH&  !T%7Z**^8;YM6>B%>5_M3?\FZ_$/_L#S_\ H->J5Y7^U-_R;K\0_P#L
M#S_^@T <S^PO_P FI_#K_L&1_P J]ZKP7]A?_DU/X=?]@R/^5>]4 %%%% !1
M110!#<_\>LW^Z?Y5\@?\$R_^25^,O^QGO/YBOK^Y_P"/6;_=/\J^0/\ @F7_
M ,DK\9?]C/>?S% 'V+1110 4BTM)[4 +1110 4444 %%%% '.>*/!.A^,+.6
M#4],M;LNA4--"K%<CKS7P1^TQ^S;\5/A[X%N;/X;^(U739$E8Z>+8-A3D[4(
M'RGGN#7Z-5')&DJX95<?[0S0!^:W_!*GX0^+OAS<:I?>)K&\L)+XLXM[E3E.
MW7)SG&[\:_2VH([6&W_U<21_[J@5/0!PGQD_Y)WK'_7*OPB^."VDWQTUD20J
M[;D;YAFOW>^,W_)-]7_ZYU^ G[0%U);_ !^UDJQYD4'Z;:ZZ,M3AQ$6X63[L
MUUNXT62.+"]L"NU\)S-#IRLHR^<CBO*;>Z:&9'D)V,U>O>"9%FM82O()K6HM
M;,X\KE+VSEUL.:75M:UZ"V2-A"02Q"FO??AYH,L-O:K(C*P3DD55^'N@PS7$
M,Q R0>U>N6=LEJJ  8 ]*ZDXQA9'M5H5*M7GDRO+I#?8R >WI678::\5TV\Y
M&.XKLFO(EMR".<5AS7T7V@XKR:K/H\+#F5BU_9**@;@\>E9[:4OVH$ =?2M*
M&Z\\  G%6XXAN'UKEN>K3IN.I#%9E4QC]*<+'=S6M''\M-\L+4.1Z$8)[F4U
MF%[4^.WV]JO^6#3UAY%9N9TJ@GJ95Q%\I^6N<URQ6[C>(D<CTKL[Q1'&?I7,
M:A 969@2.*=.HU(QK8=3IM(\6\<>%8X1*P()QZ5XSJVES1W+B,-C=Z5])>+-
M&>X60C<3]*\^N/#?F7 0[@6;'2OHZ-5M*Q\1B\*HRU/$=0TZ2!2S%B?0"N9_
MX2S4;&9ECTF]FC4XWK"Q!_2OK_PG^SZGBR^A\V>:.,M@X7BOJ+P'^PGX>O/#
MZ/-J4N6)_A%:_6H4Y>\KGAU,+":WL?F3X?URYU&.-FM+B%F'*O&016CJ'B:^
MTF/]W8W,Q](XR:_2_5/V ?#ULT<T&JS#&?X14^B_L+Z'(P9]3D;'^R*I8NFW
M<YIX9QC:+/RX@\1>(M6)9] OXXO[[1$"NNT>2Z50)X9(CCHRD5^IMW^R/H%K
MHLL,=TQ=4X)05\;_ !X^&D/@OQ4UI;RF1/*!SMKIAB(UG[B.64)4_C/%1&67
MH:GMHO*;D=ZO_9C&^PY_*H9LJVT FNN+1R3\C8TN8*O7O77:/&MTJ+ZUPEG'
M(OK74:#--%)&23MK.;>P0B=K8:0OF#)'Y5I>2+5N!Q5+2[Q6523\U:4EQ'MR
M:\RI'4]7#3Y=C1M[A&C&#SBI&;NIK ;5H+?)R<?2J\GB9 ?E\PCV%<DHL^BI
MVD]&;=Y"9E)-8LD;P,V#WJ-O$R,,'S/RJ*ZU))HODW%OI4JQZ*@UJ21[GDYY
MJ_';QLOS1J?J*XRXO;Z.1BF[&?2G6^MWA^4NV:&D=*A(M>)M-LV0;;:,'!Z*
M*J^'O&4_AM5$# ;1BDO))[I?G8UDM:"-OFJ>0UEK&Q3\;0R_$#6/M=RX "A<
M8J32_"=I:JNZ.-]OJM78K5CG:#4ACFA'&[\J.1+5G"Z4JCN;EDUC;1D>1&I]
ME%-CQ=76(_E4GM65:V5Q=2#._&?2NJT_23 RD;C^%1.48?">IA\')N[$_LQE
M4@_-^%-CT,2-R/TKJK"U,B#<,?A5S["J]#^E8RK-V2/8CAHQCYG&R>&8MA9E
M7CVKD]<C6SFVH ..PKU#4$_<MCTKS#Q#N%\."1BMZ<KG'4II(99QFX09..*H
MZQI:QQO*#S5Z&XVJ,?*:2^;[1:LA/)KI:/*E-Q.$'BYK2[:VW@'..E2ZEK#2
M6^=PKDO%T::7J$D[-MPU86J^,HH[3*R[CC@"MJ<-4>%C,5RQES;&Y?:DK,<M
MT-<?J_B 37*6]HV^0GD 5G6L>OZ_;R7,%I<>3DX(0\BMCP+X;B_M!)IG99.=
MP<=Z]*NHPI.Y\S@Y5,1BH\BT6IZWX)L7CTNVED7YBO/%;UY(D<;YXXJ;2Y(H
MM-CC4@@"LS7%<JQC!;CH!FODJGQ'[#AKJ"3.=O;I&U!%4YY%=]:Z6MS:H>%^
M45Y>UKJ4=^LKV$RPC!,A0XKT_1[L7C6T"$C?@5R2>MD>RY<L>9LET#0<:@7"
M[@KYZ5?^,#16?A^)BH7G%>DZ1X/&FPMAMY8;N:^<_CWXJ:$2V+S-B.0C%5%.
M3L>-4QJU9X-JC)=74FT_QDUHZ3<S*(X(P2?I7):/J/\ :M\PB$A3>07QQ7JO
MAG1UA6*8G<:[W348ZH\%8BI*K<W_  W9_9XUEDY9AS792VYETU^>"M<%J&I&
MSN%C5B,UV\>H)_8H;)SLKSY1U/<A-2CJSYK^,5_/IGB)8(V&UDST]ZXG2]/D
MO]1@:3^*0$Y'7FNK^+F=2\;1J#\NP?SJ"ZM!I\4,ZDC80>*%&^XHS7-9GNW@
MNU@L]-D7RU'T%1ZI#YA..!FN?\ ZXVH:>Q$A89Q72W ^7GFJL=%1V5CSGQE'
MY>CZAGG]Q)_Z":^IO!T17P;X>'8:;:_^B4KY;\<S)_8^H<_\L)?_ $$U]6^#
M;8_\(;X>//.F6IZ?],4K>!\9F<O>B7*=Y9VYJVMKA22:1EQQUJ^8\-R[%)K-
M6^8@9-/6//3M4W)<C:?RJY#8--WQ^%%V*[,UEVTZ./S,#O6NNEGNWZ59AM1#
MC@$_2K+NS&33W?D8JU'I6WE@IK6\OY01Q3".M +4HQV<?38*F^SB->!@5,(\
M=Z=0.Q7:$N@SR/2HI&\PJJ<;3S5QJ-H]*5A<HTI^[(7@XJ.&WQ@ORWK4]+MI
MCT&[0!CM2TOMBA:!B52OT.QN>.*NTC*&&"*!/4R;?$; GD5JJ0RCZ4>6N,8'
MY4H7%):"2:#:*6BBF4/W83CK2A6ZYIBU:C7<O/'%2]#.6A7VG!.:(Q\P/:IB
MN#BEQVJ>8GFT&LN[I33&W'-2T4KD\S$5=M6+6/,JMVJ"M#3X_NM[T+<(ZLT+
M91QQ6YIZL,\\8K+M8MW3TKH(5VQH.G K1;FN[N68<!35B&,R8 /6H%7CK5NQ
M;]\@Z]?Y5.[%NRM<V[0DL2*EM9A&?K5B^^;<,55\EE .#^5-Z!)FFZ&1E8=*
MD7:'"]ZR/M!7CG\Z=#<>7(KG)Q[T[E7.BA(X JW<MF&.L*/40%!V_K4L>H"0
MX_K2L*QH1J-P'J:LR6WS?+@4RQ&_G'>M&;Y5/%%A6*4EOBW!XW54K2W?N\D5
MGR?ZQOK0P9!<+NB;Z5SUQ&H;Y1BMC4I_+3&.H-8*,6Q2#6Q5OX_W)SZUC6+*
MEU+D9_\ UUO7D>Z,_6N<9=MU(,XYJN@]T= N"HI\?# #BJ5FNU6R^?QJ=KA4
M[C\Z?0KH:<+(I!89J&X^9B5X&:I1W@9\?UJ2:^6-1T/XU&Q&PLBX4YY%8&J;
M48@#'%:#WWG9 4_@:KR6)92Q;./:JN-LY_[,LDI) -9EY;[9#C &ZNEDM]K$
M?TJ*2W'<?I4Z"TZ&''9MM)XZ9I([<R],8K9>,=!Q^%$<8C7']*?*'*8LENL0
M*X&14&T=N*V;RWWJ6_I5:WLR[,"<#Z5.I-G<JB$\9-:%JRQ@*>N>*C^QF1CS
MC%3PV9C8$MG%-)W&HZB7#,N2K8IT-SNP"<G'-6< ]12!1Z59=F.H[>]%%!0F
MT&C&*6B@!#GM4<<7RX?FI:* &JBKT&*=110 5]N_#G_DG_AC_L%VO_HI:^(J
M^W?AS_R3_P ,?]@NU_\ 12U+)D='1112("BBB@ HHHH **** "BBB@ HHHH
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M'^SK\;N/)D_]!-?:?@>ZD;P/X:PBG_B56G;_ *8)7PCXPU(-I]T"2=T4@_\
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M4K9]*58]U KC:56Q4T$6[(SCFG26_EL1NS4W)YD5J*<R[6]:;5%A5>ZA,T9
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MRS#IR<'TK[8T_3[72[&.UL[:.UMXQA(84"(H] !P*^-]+_:X^.6L:?;W^G_
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MU5^T!_T0.X_\"/\ [*C_ (:J_: _Z('<?^!'_P!E0!]E45\:_P##57[0'_1
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M_<?]]4-\8KM?^9?N/^^J /4**\\T?XI7.J3;&T6:$9QEC7?Q2>9&K8QN&<4
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M-\FY]2?#OX6V*Z%:R/(V\KR*O^)OAC;-8R/&\A*H3BN=^'?QPT[4+6& 0LI
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M?ZUI'X6923O='4?#W4"T,$.S W $_A7MVD1P*J,6 /UKQCX=VJR6*RJ!P_\
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MW&^-R/0?SI"]29+Q.SJ3]:ZS0?$ L6!#1<J!\Q^E>7?:FC;(//TJS'K#KMY
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M<'ACGJN.X&,'UQ7W?I.EV>AZ;:Z=86\=I8VL2PP01C"QHHP% ] * -&BBB@
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MO7KF5N(QR!FHI+&.08VQG_@(J+$6/"KRS9E;!'0UR&L6KK&P+#.!_.OHR_\
M"Z39(,8X_N"N,\3>$?+L9GRG '\'N*8SP.ZA=0<'!J'=MQN-=9X@TW[/)(F
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M)K[,HH ^,_\ AB3XF_\ 1>O$'_?*_P#Q-'_#$GQ-_P"B]>(/^^5_^)K[,HH
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M&Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;>WA&%C0#  KF_A+\*?#_P %? NF^%/#-JMKIUE&%W8^>9\?-(Y[L3R:[B@
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MO6N3\66<36)=N6)[U[-"BFDY'P6,QDZ<FH,W_"-QJ'C=TN&22*%F^YNKO?\
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M.5=M._8=TMAGEA6&T8%*Z@J1WI]1NIYH6H)W&X"]: %)Z4JKG@T[;57*N-D
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MF1@9^;Z5 9R34R9,I!>)MD3;SQ4:KZU(TADQFFXYP*@AL2IK>X*%NG3'-5Y
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M7&=87VGFDFN%$9QQ72\1)M79Y?\ 9]*BVDB'4FMO)*M&I.>XKS?Q5Y?E2[%
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MRH[_ &\;<L3#\N6X/EJ[,HZBMS35$>$;CZU8M]-M[:'>HP^.>:KK&EQ(RL<
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M_12U\I<M7U9X!_Y$3PY_V#;;_P!%+5(I&]1113&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%</\6/BIH/P7\ ZIXL\1W2VUA8QDX/W
MI7Q\J*.['T'O0!P'[5G[2FG_ +.O@7[3$JZCXJU1OLNC:2O+SS'@,0.=H/4^
MXKDOV.?V:[_X;V>H?$+Q[(=3^*/BC_2+^XF.XV4;'=Y"^AY&['&1Q@5P/[+?
MPMUO]H3XC2_M!_%&T91,2/"F@S#]W9V^?EF([G&,'H<DG)P:^X&H'Y'Y]_\
M!7JZE7X;^#;<.1"^HEV3U8+P?U-?EE7ZR?\ !7#03=? OP]JZQES::W%"S+D
M[5='.3[?)7Y-T%QV"FM]T_2G4UONGZ4#/W!_X)\W1NOV5?!Y:.2/RT:,>9W
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MC*I!)/XT@Z$K+M;%2QP[\?2JRS"3FM"-E\E!WQ46U,[:A)9E=I  KZ?\!_\
M(C^'3_U#K?\ ]%+7S4IRO)S7TIX#/_%#^'O^P=;_ /HI:;*:-^BBBD2%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444A(4$G@4 9^K:M9Z#IMU
MJ%_<1VEE:QM+-/,P544#)))KX-T6TU'_ (*&?&PZO?17%O\  SPA=%;2W;*+
MK%RIQD],KQGCE>AZXK0_:"\=:[^UY\6C\#/AW=-%X5TZ02>+M?MS^["J<& -
MT//&!R>HX!K[*^'_ (#T3X8^$=+\,>';*.PTG3H5AAA1>P&-S'NQZDGDT#V-
MRUM8;&WBM[>)8((E"1Q1J%5% P  .  .U7:**!'BO[87PPD^+G[.OC'0+6'S
MM1-H;BS'I,G(/Y;OSK\%V5D8JRE&4X*L,$'TK^D]E$BE6&5(P17Y"?\ !0#]
MC/5_AGXVU'Q[X5TZ2^\&ZO.T]Q%:QEVT^=B2P90.(SS@]!C!/-!43XJIT;B.
M:-V7<%=6*^N"#C\:C65)/NNK?0YK[4_X)]_L9R?&;7HO'7BVS_XHK39O]'MY
M 1_:,RGI_N+W]<C%!9]*?L:_ +5_B-JVF_&?XEV[.T-K':^$] D'[O3[-!B.
M3;TSMQCOUSDXK[MJI;PQVL*0PQK#%&H5(U "J!P  .@JW09!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %>5_M3?\FZ_$/_ + \_P#Z#7JE>5_M
M3?\ )NOQ#_[ \_\ Z#0!S/["_P#R:G\.O^P9'_*O>J\%_87_ .34_AU_V#(_
MY5[U0 4444 %%%% $-S_ ,>LW^Z?Y5\@?\$R_P#DE?C+_L9[S^8KZ_N?^/6;
M_=/\J^0/^"9?_)*_&7_8SWG\Q0!]BT444 %>?>*?!.M:QK#W-I=Q10GHK9S7
MH-(M 'EJ_#GQ#CF_@_(T-\.?$/:_@S]#7J=% 'F^D^ ]<LKC?->0NN<\9KT2
M)2L2*W) YJ2B@ HHHH **** "BBB@#B/C)C_ (5WK&>GEU_/-^T\R-\</$NS
MM,H/UV"OZ%?C4Q7X;ZP1_P \Z_G?_:08O\</%9[FY7_T6E5'8BVMQOAV258X
M0O3 KMK/39KC;)N KG/#+1);1AE&>*[FQU*UMX0'8*:],^2K2=W8OZ?</:JL
M3D585H[F\7S &&*P]0U 221M;'([FM'2XW;;*QY(J^AYW*UJ;=]!9+ILA6)
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M8ZA%=1@ M+Z5V/A'5)4TY&(R%/I7TV$]ZBKGXAQ4G1S&:CHI),WY-'E7$2L
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M+8C!KFI->\M2\<NS\:RY6=T)<VII>)%99WDBX8MVK%87K+G+8^E-_P"$D#3
MRN&&:U%\4V?EGD=*3.VG?J8&H3)_8.H!A\_V>3_T$U^KGP\C/_"N_";#C.C6
M7_I.E?D#KVO1/'=JDR_,D@QGV-?L%\-A_P 6W\( _P#0%L?_ $GCK@KO:Q]=
ME:E%-M&XD>?O<T_:(^0,&I*0KFN.Y[UQ%;-122!N,U-CBH@NW.>:$-$)RO%)
M3I/O4VM#89)G;Q69-,[,06R :OM=*LA7'3WK/NY%7! '6HEKL92UV(Z8T@4$
MU5N;X1\8SQZU0:Z:Z;8,KGO46,[=S2EO%1>]4I=0VCAC3%LV;[TOYTV[D1$
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M9C ';&*D QP.**M*Q:C8*^M_A_\ \B'X;_[!MM_Z*6ODBOK?X?\ _(A^&_\
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MCW8]23R:X;]FG]GG1_V<?AO;>'[!A>:I-B?5-389>[N",LQ)Y*@DXSSBO8J
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M*** "O*_VIO^3=?B'_V!Y_\ T&O5*\K_ &IO^3=?B'_V!Y__ $&@#F?V%_\
MDU/X=?\ 8,C_ )5[U7@O["__ ":G\.O^P9'_ "KWJ@ HHHH **** (;G_CUF
M_P!T_P J^0/^"9?_ "2OQE_V,]Y_,5]?W/\ QZS?[I_E7R!_P3+_ .25^,O^
MQGO/YB@#[%HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y7XAY_LB''_/
M9:ZJN5^(G_('A_Z[+0!R/C(?N]$_Z^4JI\4/^0]X<_ZZC^56?&6!'H?_ %\I
M5/XH./\ A(/#G/\ RT_I0"T-'4%/_"6:7_NG^55M07_BX^G_ /7-JGU&0?\
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M=:!L7Q("+72O^NZ5O^-L^5IW^^M8'B1A]ETKG_ENE;_C9@(M._WUH$4[[/\
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MY(YQ6@S?*:SKYCY#\9Z?SJUL:1;L8<@7>>*3RQUQ3Y%Y)IADZ#%'H%[[#HU
MS4RQ%EW=J8O3IBI%FVQE:@CJ1DX;%+YA3D&F.WS$U&\GRU5AJ-RIJ$S*,9ZB
MN?OXA)"[$9..M:^H/EEK.FC\R)E]:&-G,3=2!6EH\_S%2>0*J3P_9[IF;YAZ
M4RWF\N9B.,TUV&NQVEI;!OF(K07VK,TJ8R1M]!6DN5Q5(M;%VS8JP)Z8K>M6
M^53[5S4<N*V]/F\Q0/05)*WU.HL[Q6&"3FKM<_$Q7D&KD-\589R::EW!2Z,U
M=Q]:,D5!;W0F8+MJV(ZJZ+NAA)[FG0N5D4@XJ0QY%1,NQA1=,2=S9AG40AFY
M-0"X9IFPWRU7MF,V$SCO4\:_9W.1NSQ4ZDZEOS@R\=<4MK,2HR<G--:W+ $-
MBGQP^7WJM2]1)YF5RQ;BHFF.T'=45Y)N9E%-7+(HQTJ;]"+ZV)))&7'S=:KR
M9?O4[0GC)S3U@P0.M+<5KD%OE),GI5F2[55&,YZ5%,VS*!>1W%0$$<GFC8>L
M46_E;EAFIX?NU';+\IR*GV^E6BTNI%);K(^2 :KS::&7*J!SZU>IR?,<&JU*
ML<[+ T3>E?6/@#_D1/#?_8-MO_12U\V36ZG' KZ4\!C'@?PZ/^H=;_\ HI:S
M9G(WJ***1(4444 %%%% !1110 4444 %%%% !1110!X/^U=^TEI_[.O@'[1"
MBZCXLU1OLNC:2G,D\S<!B!SM!ZGUQ7)_L<_LVW_PVL=0^(7CV0ZE\4?%'^D7
M]Q,=QLHV.[R%].V['&1Q@5[9XJ^$/A#QOXJ\/^)=<T2'4M;T%F;3KJ8L3 6Z
M_+G!_$'I7<4 %%%% !1110!7DF2WC>21E2-069F.  .I)KX+^*7B;6?V\/C
M_P +_"%Y+:?"7P_<!_$6N6I^6^=3CR4;HPSG'8C)["OO.ZM8[JUEMY4#PRH8
MW4]U(P1^5<I\-?A;X5^$.@OHWA#1;?1--:9IVAAR<NQR2222?Q/% &GX0\(Z
M1X#\-Z?H6AV4>G:781+#;V\0X50,#ZGW/)KH:** "BBB@!E?F?\ ';P;HWQ
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MCB<?[34 7+/X<WEK8B)IE+47'@.[DLVC$RY(]*]1I-H]* /+6\ WK6B1F89
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M:-5&\^'MX]K9H)ES&ZD_@:[WPK\WAG3>_P"X7^5:VT>E ''^+/#,^J6]DJ2
M&)E)_"J.O>#[JZ^R2+(O[HY-=_37^ZWTH \AFA-_XOT2W#89)MQ_ @UY!K\?
MDZ_JBL?F6[F4_42-7KVFR;OB=8KVW2?RKR+Q8&_X2K7../[0N?\ T:U T9S2
MXXZTWSCZ5&O)I[1X7.*NR15D-9BQS3:7::-I]*HH2JT\)VDJ235K&:7:?2DQ
M,JK"6B4'.:E2,+4FT^E !/2F%A**D6/UJ7[*7^ZN?QI7"Z*_6I8[=I", U<M
M]-)^\AZ>M:$=JL.,#K[T]1ZE:WL0G))SGTJUM$:U)M/I3'7<I%&H[:%6XNL#
M QQ5-F+8JS/;JN3CFJS$KVXK%F#&M3&XXIU-D4'FF"(^ Q-1L=U*V>E)@BM$
M;:B4444P"BBD;/&* %HHHH **** "JEY(=VP#@CK5MF.":K[1(P+U+[$R[#+
M6$KACZ5;I$ 50!TI::5AI6"H[C/DM@9-24[R]R].*8SGKIRLC9&#4'G&M74+
M$N695)8GUK+:$KU%9V1G9+<ADDVL 352^F'ELH()J>XC#*3W XK$NIF5^:'V
M&^Q%+(68BDCY--P6;.*EC7'44MD3LK$K-NQ4,@.ZIQLP<FH)) . :2)5[C6;
MY<5$W>BD9L*:T-DK&3=.6;FH=IQTI9&9I/QH9RJD'BL^IEU,C5H]JLP&3FL9
ML[AD8YKHKI1,I!YKG-0;[.WI\U,?5'7^&YO,CD!X/'?VK>KB_"=\)3*-PX8"
MNT7YNG-4BT.S\M;&DK@?\!K)6,XSBM/2F;>P[8IA?70V(W.<5<CMVD7(!J"U
MMS(PP,UNV\7EKMQBIM=DV4F+I>FEF4DMG%:,UJT0'!HL79&&WTK8^S^=&I8>
M](.EC+CM2RD\BH982O!!%;?D[>%%0W%J),Y'S?6GR]A\O8QXQY;9!R:UX?WD
M2Y&.,U7CL1YF2O'UJW&NWC' JEYC2?4?39!N0BG[&]*9)(B'KBJ-2M]FQ\Q)
M_&FAEC8\BEDNAN*D\57FCW?,HSDUGZ&'H6[IA\A!S2Q3)M)+#-46E?&#45+F
MU#FUN:GGIG.5-5>))F.0.:CBA$F.,FG,JPX(X-&^HKW-'(51SBG5FSW6X* 1
MQ3EO3L.3S5<Q?,7PW&3Q0K!C@')K->\=N.,5+#<)& =WS$<T<P^<OLQ;K7TC
MX%_Y$?P]_P!@ZW_]%+7S3$Y8$FOI;P'_ ,B/X>_[!UO_ .BEI,F1O4444B0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!E?G7\1O\ E*QX>_Z\;7_T4]?HI7YU_$;_ )2L>'O^O&U_]%/7NY1\=7_!
M+]#AQ.T?5'Z+T44E>$=PRG=*9_#FO%?VLOV@H?V;_A/=^)Q MWJ<LBVFGVTF
M=KSL&(+8YV@*<_A5T*-2O4C2@KR;LB)R5.+D]D>V4S^+/ZU^=.O7?QNO_P!E
MW2/C%I/C76]1\9W$T=\]C9P1- EDP)VK"J?,1\O8]:]HF_:QUOP'^Q_9?$KQ
MIHC6'BJ9!:P6$\;1?:+@@[&*G!4,%+8]J]6IE=2/*J<U)N7+9;W^?3S.:.(B
M]TUI?Y'U=G_@%'KCK7PK\([;XF_&+]GO5_BC??$/5;#Q?<>?=:;;VJ1)9VT<
M?*)L*?,".N<]J[_]B']J2[_:5^'>JV>O%+?Q;HV(;N:V78)D<-LE4=-WRG('
M&<4JN65*<92334':5NC_ %14<1&4E%JUU=%/X8WW[0\G[6/B>'Q-&/\ A6 ,
MWV3<L0@$>X>28ROSEL9ZGZ]J\A_;R_:,^*OP)^,&D:=X2\;S66D:G"LQLI+"
MUD6$[P"%9HRQ!SW-97[/?Q_^)>J?MI:AX"U?QE>:QX<LKVZMEM[B*(;U1@%)
M*J.:Y3_@JI_R6WP?_P!>B_\ HQ:^IPF"4<PA2KPBTX7LEH]-&[]3SZE7]TY0
M;OS=S]0_#=U+>:#I]Q.V^:6!'=L8R2H)-:[=*Q?!W_(KZ7_U[1_^@BMKTKX*
MKI4D>Q'X4+1114%#*^-O^"D_P4B\>?!T^-+"'9X@\)M]K6=.&-MP9%XZG(0C
MTYK[)K#\::':^)/"NJ:7>)YEK=VTD4B^H*FNO 8B6&Q$)]G^'5?<8UH*I!IG
MEG['?Q>D^-GP%\-Z]=2^=J<<?V._D/\ %<1@!S^.:]OKX _X)-ZQ<Q^&_B)X
M:N-P_LC487VYRH:7S<X_[XK]  U;YI1C1Q<X0VO=>CU7YDX>3E338ZO*_P!J
M;_DW7XA_]@>?_P!!KU2O*_VIO^3=?B'_ -@>?_T&O-.@YG]A?_DU/X=?]@R/
M^5>]5X+^PO\ \FI_#K_L&1_RKWJ@ HHHH **** (;G_CUF_W3_*OD#_@F7_R
M2OQE_P!C/>?S%?7]S_QZS?[I_E7R!_P3+_Y)7XR_[&>\_F* /L6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KD?B/_R"K;_KNO\ .NNKD?B/_P @JV_Z
M[K_.@#?T7_CQC^E7ZH:+_P >,?TJ_0 5'-_J7^AJ2HYO]2_T- 'FGA7_ )*/
M=_\ 7&O3Z\N\*L/^%D78_P"F/]:]1H **** .4^(G_(!_P"!?TK-^#?_ "*\
MG_7=_P"=:7Q&_P"0'_P+^E9GP9_Y%>3_ *[O_,T =]1110 5X=\5S_Q6UM]%
M_G7N->&?%B0+XXMAGG"_SH ]JTW_ (\+?_KFO\JLU6TW_CPM_P#KFO\ *K-
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M$3PY_P!@VV_]%+7RW V^OJ7P/_R(_A[_ +!UO_Z*6K+-VBBB@ HHHH ****
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MZ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX ZYZG&* /L_XB_\@$_[W]*SO@W_ ,BO)_UW?^=:WCY?,T%LCO\ TK)^#?\
MR+,O_7=_YT =[1110 4444 %%%>5_&SX\>&O@SX9EU35M8T^S\N18V^U3*@!
M/ !R?6@#U2H;C_CUE_W#_*ORMF_X+':K#\4)='/AC3_^$96^-K_:GV@[M@;;
MYNW&-N>?O=.?:OT(^#_QN\/_ !>\"Q:Y8ZI8SI*IR;>8,O3MS0 WX8_\A&3_
M 'W_ )FO4J\T^'<0CU)R#E69B#^)KTN@ HHHH **** "BJ>I:E;Z5:O<7,J0
MQ("2SG K\XOVFO\ @JM<_"WQ9_8O@W3M,\0R0R.MR[3$+%@X ) /)]/:@#]*
M&&Y2*\NM5*_%8C_IW_K7S9^QW_P4/M?VB-0MM)UV/3M$UME<R6JS?-A3]Y<X
MR,$<X[XKZ<L[NRU3XGM+97$<ZK;X8QG(SF@#TFBBB@ HHHH **** "BL[6M4
M@T/2KJ^N9$BA@C+LTAP!@5\R> _VV=*\>_&BZ\%:7<6-^EO;F:26WE#;3NQM
M.._^(H ],^-*XND/^RO\Z]/T'_D"V7_7%?Y5YA\2KAM4L_M+*H^Z!CZUZAH/
M_(%L?^N2_P J -"BBB@ HHHH ***^/\ ]MK]MY_V66AL[.TM+_4[J#?;VLTF
MUI#D GZ#(R>U 'V!7'_%%2WA*XP,_,/YU^4-O_P6;^(\UQ&B>"M)D9F"B-;A
MRS$GH/DZU]X:#\>-:^(WANP^WZ4M@+J..1UP1@D XH ]Q^'((T7\1_*NMKF/
M JA=)./7^E=/0 4444 %%%% !17*?$'Q]I?P]\-7VJZC>V]JMM$9/W[A1^-?
MF3\0O^"PFM^'_B%=Z=H7AS3-5T&VF5/MWV@YE7C<4 &#CZ\D4 ?J[<?ZE_I7
M$?#/_6:Q_P!?35Q7[./[2FB_'[PC<:Q:W=H4B.UO(DR!QR#[UV_PU:.5M6DB
M</&URQ!7ZT =S1110 4444 %%%<?\5/'0^'?A&YUDJKB'LW2@#L*:W*D>U?E
M3XO_ ."R.K^'?&FIZ7:>"[6^TVTF: 77VDJ[,IP<)MZ9!YS5GPW_ ,%E)M<U
MJTL9_"2V2W#B/SG8%5)Z9P<]<#\: /O*QMVA^)]CD8^:3^5<-XD7=XBU;O\
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M  3+_P"25^,O^QGO/YB@#[%HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y'XC_\ (*MO^NZ_SKKJY'XC_P#(*MO^NZ_SH W]%_X\8_I5^J&B_P#'C']*
MOT %%%% !2>]+10!^?G[9WPQ^*O[1'BC5/!6C:K9Z/X494:61X7:63!SM!#
M8..?4'%?GW\ ?AO??"7]NSP?X3U*5+B[TS65C::-2JOF)F! /L?SK]_?L-NL
MS2B"/S&ZOM&37XP>.KB*3_@K%IZQ!5$6M0H0OKY!/]10/H?L/XZ_Y%V3ZC^1
MK$^#O_(LR_\ 7P_\ZV_''_(OR?4?R-8OP=_Y%J;_ *^'_G0([RBBB@ HHHH
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M.U5;N5RWW)6DV]*;YQJ.BJY4/E0I;)S3E8TRG9XIZC'KZTV1B330Q%!.:5@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>5_M3?\ )NOQ#_[ \_\ Z#7JE>5_M3?\
MFZ_$/_L#S_\ H- ',_L+_P#)J?PZ_P"P9'_*O>J\%_87_P"34_AU_P!@R/\
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MZPQB5'7DG R2?6OJ2/3;2-MR6T*GU""N:^*$WD^$;@]/F6@"UX)F\[2V/O\
MTKI:Y'X;R>9HI/N/Y5UU !1110 4444 ?*/[=?[-,'QB^%^O:C9M.-=M;<2V
M:VX^<3(=R$$<_> KX<\!_MW?M!>!8;+PQKO@S7KJXM8UME:&R?<Y P#C9M_$
M-BOV.90RD, 0>H-8]UX2TR[U!+M[6/S5(/W!0!\(?L5_L]ZQXXG\>?$#Q]9W
M6E>)/$&IFY\B>,!HXU&(U.#R0N,X[FOM'X5VHTW2[RR#[Q!,5W5V3+':PL55
M44#HHQ7&?#6X$\VLG/\ R]-_.@#NJ*** "BBB@ HHHH _+W]MZY\=>/OVCO
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB[_H$_\ DS#_ /%U]-;J-U*X<S/F:/X-^+USG2/_ "9A_P#BZ=_PIWQ?_P!
MC_R9A_\ BZ^F:*1)\QR?!OQ>R\:1S_U\P_\ Q=95]\#_ !O< !=%Z'/_ !]P
M?_%U]8T4 ?(#_ /QUVT//_;W!_\ %UF7W[//Q F8E- W#'_/[;__ !ROM*DR
M* /B,?LX_$16_P"1>_\ )VW_ /CE31_L[?$)>OA[_P G;?\ ^.5]KT4 ?&'_
M  SKX\93G0\'T^UV_P#\<JJW[.?Q!W9_X1__ ,G;?_XY7VS10*Q\5_\ #//Q
M!\H)_P (Z.._VVW_ /CE5I/V<?B&W3P]W_Y_;;_XY7V[10,^(X_V<?B&.OA[
M_P G;?\ ^.5?L_V?_B!"HW>'\<_\_EO_ /'*^S:*/,.MSX^_X4)X[_Z /_DY
M!_\ '*7_ (4)X[_Z 7_DY!_\<K[ HIW*YF?'Z_ 7QW_T O\ R<@_^.5-_P *
M)\<E>=#Y_P"ON#_XNOKJBEN2]3Y#/P'\=XP-#S_V]P?_ !RJUQ\!?'LB_+H.
M3_U^6_\ \<K[%HH ^%=1_9M^)$QS'X<W=?\ E^MO_CE5M/\ V8_B5#(ID\-[
M<'_G^MC_ .U*^\Z* /BJW_9S\?+C?H.W_M\M_P#XY5^']G[QS",?V%GC_G[M
M_P#XNOL:B@%H?'W_  H7QU_T O\ R;M__BZ3_A0?CK_H!_\ DW!_\<K["HIW
M*YCX]_X4+XZ_Z 7_ )-P?_'*B_X9]\<[RW]AX_[>[?\ ^+K[&VBC:*+BN?)E
MG\"_&\3#?HN!_P!?<'_Q=:Z_!GQ?U.DX_P"WF'_XNOIVBD(^;;?X/^*XR-VE
MD<?\_,7_ ,75N/X4^*(_^89G_MXB_P#BJ^AZ3B@:=CYUF^$/B>7G^S,?]O$7
M_P 541^#_BK:0-+_ /)B'_XJOI"B@1\Q2?!CQ=N.W2<C_KYA_P#BZ9_PIGQC
M_P! ?_R:A_\ BZ^H**KF97,SY?\ ^%,^,?\ H#_^34/_ ,71_P *9\8_] ?_
M ,FH?_BZ^H**.9AS,^7_ /A3/C'_ * __DU#_P#%TG_"F/&/_0'_ /)F'_XN
MOJ&BCF8<S/EW_A3/C#_H##_P)A_^+JK<? _QI(IVZ/S_ -?4'_Q=?58QVI:5
M[B;N?(__  HWQS_T!3_X&0?_ !=*GP/\=*V?[$_\G(/_ (NOK>BIL38^6X_@
MSXT*X;1MO'_/U#_\77T+X-L9])\):)972>7<VUC!#*G!VNL:AAD<'D'I6_13
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2,!3T# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>(@V/M*=/[E<A'\H<'J#Q2C)Y-=D97.64;'7_P#"QO$7_/RG_?%'_"QO$/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** $-,?O3S4;]#45/A''<Y^Z.+ES[U 7S4UW_KW^M08KQ*
MNYZM(,TQC3B<5!(QK [(H8Q^:D9@1]*:033<[:!M#'<>E1-@J>*>QR>E-)XQ
MB@EE23I5&49-:4B\54>/)I@F450[LU8!P*?L I& Q5 R(M2 \TC"FL<4$@XR
M*K$<U8#9%1N.:I"%3@59B/2JJU*I(YJX[BEL<KXF7;=;ZY[/RYKK?%$&;82>
MU<=GC%=U,XJ@XF@-30*#6K,T/%.%,W4NZIN,=G%*#FFCFG"BX#L44@/-/!!I
M@-R:D#4F*,8H$/%/'%1@U(IS28T+FG"DI<T(ECTXJ:%L/4"FI(OOU$AH](\*
M39""NZ7D"O.?";'>M>B0G*BN*:*9,@R:N1# JO$.35I*WH/4YICZ6FTZO46Q
MD%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP;@6QS6B*1A/ L<6#4"($!(&:UI+3>F35(QK&V*HUBRA,FX%L=:SY(B6K8E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#9%==&3/+Q$$MB>EI,TO:NT\_J I:!104%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #3][
M%(>%-./6F-]T5,MAK<^9O&L);QAJK#KYQ_E67I%U)IMVI)(!-=3XPA!\5:AQ
MUE-<Q=)Z#D5YU5GLX?8]0L+Q;VT7'4BGO&5KC/"U_)%(%<G'O7<D[E#^O-<+
M=C?J4'#5$0<<U?D (Z52D0YII@5R^VHGEYJP8215.:,@U:1+&N^:KNQS3G!I
MGUII$D$I)%5G0D&KQ7-1/$3TJT(R9$.:J219-;$D!]*J20'TJDRD]#,\@>E*
M$%7/)/I4;1&JN)LAV 4Y5XI=A%/5#BJN):@!4B]:0+2CBD*Q*"*>*C4BG;Q4
MFD62"3"8IZONA*FH>JT(<4+0NQA7R^3<''UIUM=$$<TNM EMX]*R[:3(Z\UJ
MF8SC<Z1B)X2#6$;3=<D 5H6ER NTT)S*6 J6[,=.DV6++3AN&17?:#I@0*=O
M:N6T==\PW=,UW:7T%M$H! .!TJ'(]&GAV:H58ATJ*>["<9K..H)*,AS5:6Y5
MS]ZH2U.A4K;C[N<RG@U1)903FI=ZGO43RKT%:)'3%)#ED!ZFK,04UG DM5V-
MPB\U5A2:->!A$F2:KSW*%N#65<:@V-HZ"LR6[<G :BQA=7.D%Z I -(D@=LF
ML*S6:25<DX-="EO@*3Q4M#;+L 4KFEN"HB-/5%$?!JE.<G&XXII&<F9=P59C
M6;/$>W2M.=0&JI,0%K:*.*<BD%*CFE5Z7K4;G:.E;="+W'B3G%2B,OS52-NY
MJY:RKNP347*4+B&$DU4E4(W-:DK*.E9EP"[\5)5N45)!C I26/2FI$57FAG*
M]J+$\UQQ<X^:HN-V:=YI(P5IZH67.*JQG(AD.X53D@#BK#QL&/)I8(L<$YJD
MC%RL9HB,;<&M2Q=^!@D4V90AZ"EMY=KC%#1FV=!#& H)%:-N.0:R[:7>H%:L
M"Y45SRB:1FD:]J>,5J6<9C??6/:-M8 UT4&#$#6#C8522F;5M*7 ^E6<UCK<
M&(59@OPS8-=-&1YE2#1I44U&W+FG"NY.YSA2TAHI@+124M !1110 444E "T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !13'R/F'7TI"06P20?:@"2B
MHMSAL<;?K3=Q*$OD<]J )Z*** "BBB@ HHHH 0]:8QPHIS<<TR0?*!4SV''<
M^?O%\@_X2O4!_P!-361:V+3R98<5H^)XI9/&FHY4A!,<'UJ]8>4J;3UKR*TM
M3WL+&Z([:Q6W<,HKI;*8.H5NU9>5W>HJ6%]C\&N-NYU\J-B:,=J@:('%6H2)
M(Z0PG-4F8ST,^1".U5GBW9XK4DCR.E5VBZUHI&+1EO;U7:WQ6JR5$\.:JY)E
MF/!I-E7FAJ)HL4[DE1XLBJTD'M6ELQ36AW"JN%S%>+&>*A\JM66#::@:+ JK
ME(SS$*85P<"K4J$5 0:=RDB(BD"DFI0,]J>$Q3N2RN1BFY-3NM0D$4RD2*?E
MI1R*9GBGH<4(TN9>JQLT1]*YZWD$<NUJZZ]020$5Q\D?EW>",\U:':YT,2Q-
M;Y3[U6;:#G)JM80@H#FM+>JKCO2DM3KH**6I<BF6U&X=:2/4&N),$G&:SG+2
M_*#Q5^RLNY&*AH]2+BD;,,X$>,U+'\P)JM#" V*TH80> *21$I(A"L:#&5.X
MUJ):@"H+B/\ A ZU1',55D4<FHI;M!QFJ.H7/V=]E99>:=CMS[51C*9HSW8R
M0#5+SG#[NHIKP.0HR=V.:LP6YQAZUMH8QEJ:%EJR)C<,8K4_MA)<!6%<G=QJ
MF<'&*S(]1-O-RY/-9M'0CTN*]9E"YX-3( S<FN;TK5%N8,8&<=:TX9"7Y<BB
M)$T6+N'TJ@T+=ZTMV3US22A2,#K6J."HC&>$@\"F/%E.:V%MV8'"YJA<J$)'
M0U;>AE&]S+<; <57BE<2<5<>)B#CFF06_P _S<5!TK0M(&<9-.VHO)IRJ0=J
M\TDL)5<DT[$RU&$JQXJ)\#M2K&1SN-2",-UIV%8A4B0[0*O)$ E-A@ DZ5::
M/*<<52,Y&7<1#.:@ Q(*M7*D<9JJ%8-S3,K7$NUW*"*IAB#D5IR8$?(S6<\9
M8DC@4R)1-*PG8D"M^VF8$9KEK%RDH%=);_,!631SR=C?MQD!A6]8L2H!KG+&
M3)"D5TMJ@" J:YZB%&5R25LG&*;%\D@YJ9@N.:J2OAQBLHRL7R<QT5K)F,<U
M:!K&L+G*X(K6!RN:[Z<[HX*L.630_.:*8M/KI3N8L*6DHIB%HHI,XH&+132W
M%!;% FQU%&>,TF:!BT4#D44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME*]S75OEIZTU5PM.48H-1PZ44#I10 4444 %%%% !111F@ HHS1F@ HHS10
M4444 %%%% !11FC- !11FC(H **,T4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 TD9VT'TH/7&/QH ..3F@!N".A'XT#<#EL?A2[!C[M&,C&,4 /HHHH
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M>V##""IXH%R">*L#8AYI)FGLSGKF!HN<<U-::-/J49,2#<*T[WR6';-2:9K
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M6V2?C2\&JWVE!WJ2.='. :.=%RBR;M0*2E%5<@6BBB@ HHHH **** "BBB@
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M<6XG3Y>36<T4D .[.*BTO5?*<+,?SK6FNK>X  (YK)Z&\8W,AG21=IZU3GA
M'3-3:E"89#)&>*SX[\L=KBM(R,*E+J688."<=JKO;2"0MSBKR2!D&VICS&>.
M:UW.-JS,SGIBH9(G8\&I9&99>E3 #9FA1!R*8MR%R:3;@'FIC.,D4U0'!IV(
MYRD\A+8SQ2'@BK#1HC9--RCL%6H<=#I@R_9.VT<UNV5P\>,<5SUF2L@!Z5T,
M6#&"M8214CK-.N%F4#/-:C<1G-<AI\SV[C-=7:SK/$ 36#1QU"@+H0W!#=ZM
M6LPFN,U6U"R/FJZ],4MHC1."*(+4RDKQ.EC/'-25# 24!-35Z5/8X9;A1116
MI(4444 %%%% !S29H!)I2:5PL)FEI,_2@L .HHN%@.1R.:0Y^E1/<Q+]^11^
M-5I=7M(AS*I_&I<AV+K$8^]BD$BGHU8DGBFQ3(W FJR^*H6Z%1]:7,4HG3;L
M#UINX=2<5R\OB>!1DS1C_@0J,>--.BCQ)*I;V(I.>A7L[G6;Q43W2)U.*XJZ
M^(5BJ$1MDUS%U\0&,Q*<CZ5FYFL,/<]5DU&&,9:3 JH^O6?3SAFO)[GQQ<7"
ME1@?A6/)KEV[$AJAU#LCA#VN+7UE/8#US4DFOVD0^>8"O#/[:O1TE_6FMJ%U
M*,O*W_?51[4OZD>R3^,+**3 F!J%_'-FHX=37C@E9SR['\:G20*/F+4>U#ZF
M>FS_ !$@7(15)],UDWGC^23_ %: ?0UPY=&?@&G'!]*ESN:0PECH9?&-^XRK
M,/QK;\%>(+K4/$"P32LR%"2I/>N&P=G %=/X C \3*>_EM5PE=F6)H\J/8@,
MC.>*<*8H(6GCI7:EH>0Q:***8@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!K=:0]*5J1ONUG/8%N53@O4@IH'SU*!7FS6IJ-Q
M32<5(:@F8 5E.R1-KO0AGDZUF7$GR$@]*LS2=:S)7+.%'>N&[<K'HTX\L;A9
MP&XGR>.:Z)( B 53TZV"#=BM/TKNA2T.6I-W*-S:AT-8$\312'TKK64,*RK^
MT&TL!2E2:-:-5WL<^>7-/V!AQ36*B1E)YIT; 'K7.XV/5O>(SR3FH9+8FKR<
MN?0U.8P1TI$*6AAO;,*8+5CTK=> $=*B\@CM0',8[VQQTJG+;LI)KH&BJ":!
M2I&.:J+LQMZ'/J?FQ4@P3C-2SVY1B0*RKNX>,@+US6JD82-,4QUJ"UD=U!(J
MR>E:(G4B883I69=E=IJY-<!.&-9.H/\ NR4:JA"XT86HS$90#BL^VM03O85/
M(Q=B6]:F0KY>!79&%C92&A%["I5;%1[PM*CAC6@^8LJX(QG%13L1R&S4JQC%
M9\V\,?3-%@N0S2RDY5C3H;R5!SGBA'!.#4OE(Q ]:"7IJP;5G4<@U-;W)O/E
M*D U5NK$[,K5K2X_+CR>HJBHM,F>-5X JO,I9=H%32L6DP*3RF'.:B1U11G:
M9.T-TZ2<#=Q7769"IOSD$5RM[9/N$D9YZGFKUG?.D0C;K4W!-(NWNR:4DUES
M*8VXK1VL^&Q52[7 JHBG/0A@/G3I"6P'.,UZ#'\/+>;24G+J24R#BO+F=Q("
MIP0>*]+TW7-2N/#.R,$F)0N<UIRHX*DWT,?2?"E^L\TMG,55,@$#TK=L/&$^
MA-]GOX6=EX+DXJ+PUXB^Q1R03D;BQ)S]:OZS!;:AI[W211MN&036;T,81<GJ
M<AXEUR/6+]9U(D3&-@K&N)(BH*IM]O2J-P6CNG4 +@GI5*XN),J.3SVYI'7&
M*B:*W)"L<\*:U],U98L*SXSQ@US3,)E"JQ4CKGBHIG8MNCS\HZT[#=17.IU&
M[\NYW(WRY[5:MM0DE4;,YKE;:=[N(!S\U=)I,(@B)8UE*)W4))[FPEVSJ$D&
M32-IZSC<A"FJJNK-NS6C9W4:MAC6:NCHG&+*8=[5MC X]:N6]SOZ<U?FAM;J
M/&0#6-):R6TVZ-LK]:WC)GG5:2Z%N9 >2,5#QL*FFO>@J%?K0I63H:VBSSY0
M:*,R,KG'.:?""B?-UJ>8!#1&4<Y--LS2U*T\#2#<M5TB9&_VJWHO+7DCBDDM
MHY&\Q!4-Z'9"UC-1F0 GK6WI5R7(#"LN:!E[58LI/+-8-FL87W.LBC$O*U;M
MKIK>4*<UEZ9<^]7Y8RYWBL78QJTT=&66X@&#S3[:T.1DUG:+<*P:-CSFNA7:
M@R!5P2;N>;4DXZ(>!MP/2GYXZ4S.X9IW:N^-DCC=V 8=^*7</6F,Z*OS$54N
M-2MK=,O(F/K0Y%*+9># G@T$XKF;KQEIELI_>C/TKG+WXE0QY%OM;UW<5/,R
ME!GH_F*.IQ44M[!$"7D4 =2:\6OOB=(Q(W!?H:YB_P#B!-(Q(N7^F:5Y%<A]
M S^(M.@0G[2A]LU@W?CZT@8A4W>X-?/EUXQN9C\K'\ZSIM<NY1PY_.EJ.R/?
M;CXE0@G!V#TS6=<?$V/:0)P#]:\(%[=2'YF/YTA=B>7-)W"R/5K_ .(339Q-
MO]@:P9_&\\A(&[ZYKC%3=C:QJTD(QUYJ;]QV1K2^);PME7:D/B'4GX\YJHQP
M+WJP(!Z5+9I%(E%Y=W)_>2DU*$?;@N3201 &KZQCO42DSJA35RFL+9[U+Y)Q
M[UI10*W:K L01G%82;.^E31CB(]JF2!S6DMIANE3&#:O2IU.V,4C)$*J>:1A
MS@5:EC.[@4Y+<G'%+0W]FR"./!JSY9<<<592V&.:M16OM1H'LS,%NRCFE$9S
MTK9-N"N,4)99[4FRN1%".)F7&*ZKP-%LUY9,=$(K.CLR!]VNB\*6_E:J#C^$
MUM2;N>7C%[K/1E^[3P>*C3[@J0=*]-;'S,MQ<T4E% "T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 AI#]VE--/0U,]@(1UI^:B
M7EB*=NQ7EU'9EK44FL^YFP2,U8FF"#-8]Q/N8UQU9:'70IW8V:7@\TRTC\Z;
M..AJI-+E@*U](C.TDU%"-Y'35]V)L0QA$ J7;0!P*=VKWH021Y+=V(1Q4%S&
M&BQBK%,DY%*I%6*B[,\ZU]I+.X=@"!FJ,&K*R#,@SZ5T7BVT,UL^T<XKQJ_:
M\L+DD,V :\R<-3W:#YHGK=I="55YK71@5%>2:+XI<N$D.,>IKO=/UJ&5%+,*
MRY G%IG1X&*@FPHZBJ=QK$$<)8..!7 :[XX>*8QQ/^1JO9LR6AZ!DL>#F@)D
MX/6O.M/\8SG!9CS[UT-OXHC90TA&X^]#I,IRT-Z:W4@YK$NK%0^[&15U-<M9
MTY89JI<:C#C[PQ51ILR<B!2L8QC%5;F["9YQ4-S?Q[N&%8FH7#2#Y3Q6R@"8
M7]T\K_*U4FFE*[2<TB-N%(6.[%=48%$;1!ADU78F-L"KK<K59D)/%;6'J(.1
MDT^+&[I0D3'M4R(4[4!J3$@+4,B!Q2238XJ+[0#UI%ID?V;#<5+Y!X8=J<KJ
M:GBPW%!=N;0B+9CVFE@RH(QQ4LMHWWA4'G^5(%;I30N7E)Q:/+\R FM+2] G
MOI-IX%4;+4##<J&^X37I.GVT5S8AK*;RY2/X:AA[9Q.)U3PK<V*E_O+6!#%Y
M=T R\9YKU5])U*2)XYYW<>]<G>^&KR-W*1'ZT-!&=R*\%HEI"8W7<1R,UCS1
M"13WK/NDN+.Z9)@0 >]:EFHN8?D/S4D7*[1S]RGERXKV#X?16\V@RH5#,<9'
MX5Y?>VC)(3)VK7\.>)+G1&98T+(QSC-:IG%5BR/Q;9_V5K,D2';D;OSK(_MW
M48;4012#8!CD9JQXHUB76;_SY(O+& ,UDH548!R/6LV=5!(8DL<TI-T&+'N.
M*M:)]BBUU%N(G>%R .>E4)L%LBF6EY]GOHI77='&VY@?2FD:55IH;OQ)L[#3
M6M[C3CM#J2PSGO7.Z?=I=V>S&&'))J_XX\1:;K=G%%90(DJK@E?6N1L9V@<(
M3@FK1YTKIG5VD(W JPSZ5N0[PF"<5R5I>>1<C)XS740W:3*I!YJ9([:$VBVI
M8<$XJ:-'Z@U4:7>V,U*)WB7K6+B>@IW)6FG#8#$8J074Y7!.:CCF5QENM.ZY
MVT]A25QRNN?GZTAE>!LX.*@)PW(K0M6CG3RY0,^]/FL8NDF/1EN4SG)I4MSU
M%126$]JV^'.SVJ>RO4#[)/O4<QC*BB_;VYF7;M/UJ1HOLW'45;@E 0E#3) L
MJ-_>S1<E1L9DLZL=IJ$@)R#4UQ;JAR:J$LW"BH:-?:)&QI]P$(RW-=/93">/
M::X:&"16#%B*UH]9BT^++R\BLW!G-4JHZ>-#9WBXZ-S72QWT B!>15X[FO(-
M0\?0@95QE?>N7O\ XBS2!E1S^=:0@T>;4:;/>[KQ)96O656 ZX-<]J?Q#LX%
M(C//UKY\O/%]],64.P![YK(GU:\G^]*QKH5S*R/9-5^)$TF1%.J_6N*U+QQ/
M*S RNQ[X-<*TCO\ ><TW%.S'=(W[CQ-<R@[68?6LY]2NY?O2C'M5#)I<[::1
M+F3/)*QR7S306;C/-,')J1156(YV+AU/)'Y5/$F[K404LW)JY$JQC)I(LCD8
MH-HQ4: ELDBEG96<X-$2 D<TF4D7H%W' &:T(K?C)%16<2@<-BM14&W[V:Q9
MM&G=%<1>@J4)[4\;AT6I(HY&/2LV;P@A]O&<]*T$MRW:GVMF[ 5JPV,H4?)G
MWK*5['=2C%,KV]IBKOE;5J>*"1>JXJ9X%9,,^WWK%MG9&444-@'.*8S=L5:>
MW /RR$T+92MT4FJ5QNM%%$6X=LD586V QQ6E!I5TY_U)J]'H%VW_ "S-5[-C
M>-B89M^00*FC0CM70Q>'+LC_ %9JW%X6G;[V1^%/V;,)8^)S2Q[NU6X8@.HK
MIXO"9!!9R?;%7XO#42CG^5-4F8RS!=SE%V*.E:^@1D:DK;>-IYK<7P[:CJH_
M*KEMIL=J<J!6].G8\^MB^=%U/NC-24WC%*IKLZ'EN5V+11FC- Q:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(;46KP 7^$"N4T+4=S*A-=4C!AFMX3N>#5CRR%QGN12A<4IQBD S708W#F@
M]Z7%&*!7#'M28Y^Z*=BB@+B8/K1M]Z6C I )C%+BC.*,T#$Q1BEZT8H$)BEQ
M1BEH 3%%+24 %%%%, HHHH **** "BDS[4HYH ***3K0(6BDS1N&,T +0*3/
M&:44#%HHHH **** "BBB@ HHHH **** "BBD)Q0 M%)F@$$9% "T4A;@T9H
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M)TS3+:SW^8(8PN_UQ5I,D;@WR^E #\G)Y%.)XJ-0 QQQG]:<,J>>E #Z***
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M+&(8X%;UG;VZ+OEK,MEV)S4TCDCY7"CWJC-21NIJ\< VPJO'J*JW&H&[4LV
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M.IV)&[?F)H ()S3J0TQ!1110,7-)FBDH&.S1FDHH)%S1FDHI#%S29%(<8YI
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M;;HEEW/DI_*@#2HHHH **** "BBB@ HHHH *2EHH 2EHHH *#110 E%+0>E
M"4C=*7M36'%)[ MSE_$?#*:\WOIM][CT-=_XFF'SKGD5YUC_ $MF//6N.WO'
MI0^$JZVZ221QMTSQ7-:U"P@V(>,5K:N7>X..U9]W*3;*K#G%=45J831R-Q&R
M1%2*PY;?+9KN);=)E.0.E8E[I3H-T0R*ZEL<DD<Z(_FQ4A!1_:G74!1@6R"*
M8L@S\V2*%N0T7X(&F7Y:@NH7B'SYQ3[2]$<N!D#WK5NH!<VP=<$TVB+G,R*.
MHJ2WE$9&34KPB-R#UJ!U7-1L6M38MYVDG#>6"&X!S73:A:W:Z;!)Y*Q#;D.I
MYKA(KF2(!D[5M6GB2X:'R9CE1Q@T[W)L>K_"_P 8BWOS!J$Q5-A49-8GQ1MW
MU;Q&7@P\3/\ *<UPIO?E\R)BKY['%=%X;NK2_O(XM2G8;#U+XH Y6^T>\T]E
M\R-@K#CBLN2"6*<#:1GUKZGL6\)ZU:QV3-#^[ &YB,\>]<+\1?"6F8^TVDL(
MV] K#M1<M'DECH\M].L8SS4>K:9/9'#DX%/?5+K3[@%"G[OC@5TUH]GXHTXI
M-*D<PYY;'2LVQG <9&[K5S8%L6;&3D4NIV9L+YX3AU4\%>:K27#LH7C;[528
M 0!\Q4?-Q2*"N1VI8T9UR*""N0>M:)DM$T5SGY".*GCE6-_E;FJ00CFI(VW'
M%:)F;T-^UNV5@<ULQWX90":YJTA9UP3Q6F\"1VGWSGZU;2:&JC1KW 2>V+@_
M=':MCPM:7D2-/ ' SV%<WH+H)520DQG[V:^BO#5QHKZ7'#$UN&*C.<9Z5RSI
MG1&O8\LNEN+R[!GR6![UV/AO2#&AE<?+[U?U'3+--5++M()[=*=+<);1-'&>
M/:L>6QU0J<YP7C7RVO"(5 (]*X]VD7ADY]:[O4+87$K.1DUSUWISNYXP*ELZ
MXQN<O,H:0;S@5MZ=H,6HPL8F)9!D\5G7MHWG*G;(KL=/>WT721*IW/*-I .:
MAE27*KG%W]L;*<QGL:([HP@$5?O[N.YG9BO4]Q5,NHXPM9M$JLT4;^9[AC+'
M$"3VKT+P8GADZ#.-2BB%T0<97)Z&N%+'<< 8^E1-.D6?WA!] :J)E.M)D=_I
M2'4Y7A?;$K93'UK6:\ADTQ8'0&11C=WK$-_&0 220:2748P 0#Q3L8\S9LQW
M5LJ;40=.3BHQ=#!V"LI-1:=L0H,X[BAOMYZ! #[5:0W)FEYMTX^4\?6EDO&4
M;99-OT-92Z9>SG+2XSZ'%6!X:) >29C_ ,#-#1*=QTNH6L/_ "W+'T(JN=96
M-?E7BK%MH-J+L>8S$9_O5+?6-G A2,<>]7&#9,I6,R35I9Q\B5$+V[499=J^
MH-31HB@[14H7<A##BMU19QRJV-'3]2B,.&B61\=ZI75_=+.?+M$"Y]:B68I\
MI4 #I@57GN)Y#M ^3UQ3=$S=4N(M_<J6CE8_[.>E0-87L[$.,?C4=E=2QN0Q
M(3IQ5B2YDW%!N*'H1UIJFB'-D0T&9@=S8'UJ-M)AA^\W-6[9&N9=LLI15XP6
MP33]02SMDPCN[G_:S2<-2U/0R9+&,_=-0M9JHZU8B?&=V1GIFI&*,,9I\I?,
M4%ME)ZUTVE:99R6^V=%YYR16*BJC9K=M9UDB1=P&!64T7!G:>&=&\.72B&2"
M)G!SRM>K:/X3\.&U4+I\#$#GBO [>\>QG5HVXSV->G^$_%AP-[?=KG9=ST6+
MPSHD1^33X!]!5M-)L$^Y:1CZ"HM.U6&^4$,,UH!AD^E-,5B-+6&/[D*BI0 O
M;%&0U+C%4G<08SSFC'O2T50#2/0T >IS3J*FP#"H_NBC)Z%1BGT4["L-X7MB
MEP.N.:6BG8-AHP3TYI>=WM2T46"XF#ZTA&>]/I* "BEHH&)BBEI#0 "EIM+0
M M%)10 M(:*0TF N:*3%(<4A#J*9D=B/QHR>_P"E.P7'T4Q6YP ?QILLL<7+
ML%]R:=AW):3-9-YK]E:XS<1O[*P)K#N_&F6V65I<,Y[[,BJ2(;.Q) ')%5+K
M4;>SCW2.H4>AKDMGB;6$SOABB;J"-IQ4UOX(B;#WMS.[>BRG'\Z+"N6;KQK8
MH"MN2[^F#5GP]X@&JO*CC:R#.*N6NC6-O%Y:0*1ZNH)KF;=O[*\93Q8"Q7)"
MK@4["N=T&&":"<CCO3$PRE><"G @G@&H9HCR7XA^&O$-YXET_4M'L!<FW)."
MV*O1^(?B.EJL)\)VXP-N[SCD>]>G44#/--'\!W&I:E'KOB"5VGW;A:ORL9]C
M7::UH5KK&D/82@"%AP,=/2M?%% 'DEE9^-_!D\ECI=A_:MB<LDLTFTC/; ]*
MZ'0X?%&L:C#=ZO$VFI <^5&VX2_7-=R:* /-OB9X8U;Q UG_ &?:B7RIXV8Y
MQ@!@37H%K&8K6%&'SHH!'X59%+0!YAI7A'5;;XCRZM)!BU=V8/GIG%:>NIXK
MTK6S?:/ =2A=0OD2/M5??BN\HH \CU:P\8^-IX-/UC2ETVQ)Q(T3[MP]P:[B
M\\)6EWX:313PJ( K8[@<&NDHH \CT^#QUX0D?3--TI=4M$Y6>63:3GV%=-X>
MA\3ZGJ:7^M(VGK#P+:-MRR9]:[7'-.% $2G(*L,-GI7F_C;P7J$VLPZ]HI9K
MV)]_E#@,?3->EGUI: /*ID\=>)[,Z7?Z?_9410DW$,FYF('3GUJW\,O"FI>&
MOM'V]"I(.,GKSUKTD]:7;QTH XOXEZ;#JG@R[#@!PORMZ5Y]\%=!DO+J;6+I
MF<Q%H%+>@X%>D^.M#U/Q!H<NF6$L<:RCYRQP?P-6?"'AY?#6B+9<%L[F*]S0
M!KZEIT&J:=+93*&AE7:P/I7F$.D>,/!6HR1Z'9_VI82DMME?:(_0#%>LJP*C
MM3L4 >?Z='XO\07T<FKVYTB*!@X6%]PD_P!DYKN\[L':!ZGTJ3% XH YOQ58
M:K=V*R:1<2)/&X;8IQNQV/UKDKO6/B/=V,MH/#4,9==HE$QR/>O4LT"@#C?
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MI"<4TR*!DD#ZU3NM4M+9"99E_P" D&G8.9%W.:/E!P3S7*7'C6T0E+5)7?\
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M6EF18\/WJA6($DXP:CDYZ4Z7&[(I@Y%2RK"QL5.0:D?:3EAS4:KEOF.!4DS
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M12[8 "P&[%<*P4R%,DJO3FM33M.N+VUD^S9^0$OCTK(=?)G* 9P:@H&Y(*G
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M8%&*2E<JPZBBBE80HHI*7-%@"BBB@ HHHI@%,D.%)XP.N:?4<H5D*L,@\8H
MY37_  AH7B__ (^'421\%K=@&'U(KRW7-+U/X:^([2YTK4))[65DB,5Q,7/S
M$#@$^]>@:CX)U<ZE+=:!K0TX3-F5-I.:@T_X<7EQJZ7_ (DU1=4,?W%VD8(Z
M&@"I\58Y[SP8ERJ$JJ%G!'(XKIO 4R-X+TU_-CPL R >GUK9U?2H=6TF:QD
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M6.,D@\UG-Z&]&-G<[6Z\>WLVD#39)F,., 9XKAW;9(W&?[M7=)M8[V9DE;!
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MRJL8Q=D:PS3^U-%.KJBCD844451(8HQ110,7%&*** #%&*** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ:NZ("G45=MM5-XNR;]:R(U5 >*?;.JS9/%2F9S@FS2F@0CI5;^S()0=P%:
MD2=/EJ"5'0'%;*9P5L.K&+<Z7#"YP!MJ+SH[6VPF.E1:Q=RPL%.<5D3WA\O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLH)'1Z/&NW)ZUJSSB.(C-8&ESM&AS4>IZF55L&B.IYF*E9&?KMTKY#<UD:3
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M **2C% "T4E% "T4E+0 4444 %%)BC% "T4F*,4 +1110 444F* %HI,48H
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M<_C7&^ 7DTGQY?:5YKB S'RXP>, "@#VA 1WIU,5?FW9_"GT %%%% !1110
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M:?XI?7%NF9G);81ZUV ;<O/% 'B!X^-J8//V@X-7OC.2'TWN?M,/_H0KKCX
MB_X3./Q%]L<E9-_E;>*E\8>!X_%,]L[7;1>3(C[0,YVD'^E '36)(LH<G<-@
MZ?2O(/#Y/_"WI^./,?C\J]CA@\B%8E;HH&:Y*P\!)9>*GUL:A(SLQ;R]HQS0
M!V2DEO;TI]-4?-SUIU !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 AI*4TA.%J6[!88\@4&J=Q<A%)S4-U=;'(S7-ZGJ,N_:I-<E
M2H=U*AS*YMQ7#3OC-740CFL?1]QC#M6U*WEQ[L]LUR\UV3.'+)(P_$6H?9H-
MH.":J:%.S0,YZGO6#XEOS<:@L2GN*WM'3R[(9]*&ST502IIB:IEXRO/)K.\L
MQ6@!K<NX-Q4_2L[5D\N'CM4W-L-))I'-ZC<!8&7CI7#RVCRSLP%=+?B5V/6B
MPLMRDD4'U6'FJ43F]/MVCU2,$=ZW]2L#-M &3BK"::/[2C;'>M2[1(9%+>E-
M$3Q/-(XC43):6XC(J[HUQBT8DU=U2S%\IVCI6?:6$T0*D$"DUJ=$6G'4S;ZX
M;SV8L>/>L34+WS <5T&JZ9(%++7+RVS9PPIQ.:K%O8SY+CY2*H/N9LCI6L;(
M,>:8UH(V %;WLCS9T9-ZE.*!F(R*Z*TL$-OD8S[U6AMMP4=*Z[3-!22TWR.%
M7WI\US>E1L8$:^7D$K212H)2#3M=AALY"L,@)]JRDF. >]92/1BU$UI5$C9'
M2H&VQL,U%]KP*KR2F5NM38B50OR,TI78<"I'>2(*00<5%:;"F&8 TC2(9"OF
M#BJL1*JK&[!XHNH[80+A>.PQ4NG7CW<QWN23ZFN7GD"KF-LM5G3=0$4H!/S&
MM(['EU6I.YUT3+#?@S2D*#TW5NKK44I"1D#:.M>?:I/*<2;CBLM_$HM$&R,[
M\X/-4M3BFXH]2N/$#6\3,<' K.LM3DN7>;<1D]#7GK>,!(422$X)YYK5M_%V
MGH44H%&/6M.2Z.6=5([674[BSRT>&W<<\UCWUY?3Q/(BJ&;T%90\;Z?E@4!
M''-5'\;P2)((H\,/N\TE GVZ:+CZS'IL)>9@9?0\U#;_ !#EC4LJ+@?[-<!J
M=_+>W3.Y.,]*K+</$AX.*WC$XJU4Z?6?&.I:BS;6"*>FWBN6FD9R6E8LQ]3F
MHWF=SG?@'M43D$=<FM&<3&YYIP)[4W:2.14L*?,*$2V/2-V'0T\Q C /-:D,
M:FW88^;%,@L'+9*GFM4C&4^49:6^Y1Z"NW\+6Z._4#%96GZ4=GW>M2D76CLT
MB9 K1:&=^8[MA(Y\L8 ]15BUA2T#2.P)QQS7GT7C*5>"3N^M:EGJUS>C>Y.V
MHE4TL:1H=3I-:N8EM [L!NYQ4]O!;21Q22NH7@D9KF;^-]2$8WX5!S7+ZMXC
MN(IOLT4AV*,'%8N5SKC&R/5+O4=-CFV6VT#VQ4::C$KCISZ5Y/;:J3\_F?-6
MYINJF:0"1JS9K3>IZ&LJB[,RGY6 %7K5I//)QE2?2N7^T$6\+(>-U=-IU\K0
M*3U K+J>@GH02V[R7+8&!C-494FC?':MV1M\)E0XK+\X.Q7.36J9*1EW+\<@
M9JHT^X8P*OS6[/(>.*S9D*/C%-F\'8A?KFF@DBIRN0,TK*JBH9NF53(,[<U"
M\P0X!IDJGS\]J'MRV'K-FL=RW!(6YJZK U3@7"XJ<+@]:R9V1"0\U!(#3I&.
M:KS2,*E&I(J9')J(G:U1).2<$TDCT[";L2LP)&:JO+M?"TR69L8%1),JGYNM
M4D83D60<G)-17,YX45!)= MC.*K27()SGI6L8G'*:"_N-R"+/-:.CQ^3$H8'
MFLJRMVO;T-U KLX[2&&$;P,]JKE,?:*XYKR.WBR.M+:7BW )SBJ5Q$DH('2J
M\2/"VU.]3RG1":L:\J!\X/ZUC7C- V:L SQOR215>\9YA@(2:?L6/ZPD:>E7
M27$"ISN]:34(#D],5EV4MU:_*MN_'>KT*WEY+@Q-S5>Q9A/%HPM0C#0LJ+\P
M'.17*_.)&!4#GTKU$^%-3NWQ#:R'/7 IT?PMU">8>9;. >N16BIV5CRZ]=2E
M<\W:4^6I7 *G/%6Y;Q[VV4"'!]0N*]:MO@\I"[T"GW%;UM\);:, -(A ]JKD
M.7VQX7%I5PT(90<U?BTN_D4( 37T':?#[2H%"R1HV*TX?".C0X9+9:I12*]L
M?.L7AG49.L+GZ*:N6_@"]N)!F"1?J#7TA#IMG#Q' !BK 1%X*@+]*+(EUV>#
M6OPKOKA0.@_VC6W9?".>( R&(CZU[!C^Z1BD=U4?-5)]C-U&S@;/X9V")B3>
M#WP:T[3X?:3:MN +'_:.:Z&75+*(?O+A% ]:HS>)]&B!S>19'O03S,E@T'3[
M4Y^SHQZ<J#5T6-K'C;;1#Z(*YFZ\>:9"I994=1Z&LV3XD JY@T]V!'RL&%%P
MLV=ZL2(<JJC/M0,H#EA^)KR2^^)D\<;%G,4F>%)K)NO'VN3-F*9V3&<"E<:I
M,]N:ZMXU)>5 ?]X56FU6QC7 NHB>N-XKYRO?'^H32R0R*^X<=:U/AU<_\)#X
MM%K>*SJ8V.":=T#@T>US>*].B'+%\?W>:SY/'EGDK':73'U$9-:$'A/2(0"+
M/!^M:-OI=I;9$4:J#UHNC*VIRA\6ZC.V+6T<9Z;XS1]J\5WIVHL"JWJ,5VOE
M1J.$!I0,?P8HN.QQ#:#XBN3^_G11_L/BI8_!#R<W-Y/G_9E-=IG':@@&CF"Q
MR\7@>PCP6FF;_>?-:=OX=T^W Q"C?[R@UJ >U.P/2ES#Y2LMA:ITMH1]$%2K
M#&OW44?05+Q12N'*-"TM+24KA:PM&***+CL+BBBBD,2BBBF N!1110 8I,49
MQ1F@ HQ11F@ Q1BC-&: #%&*,T9H ,48HS2YH 3%&*6B@!,48HS1F@ Q1BC-
M&: #%'X49I<T )2T9I,T +BDQ1FC- !BC%&:,T +129HS0 8HQ1FC- !1FC-
M+F@!,T8I<TF: #%+29I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH :>M-<_)S3CG-1R'Y1436A2.8U&9A<. .AK->W\Y@QK1O)(Q>2!CWK(GU
M)8YMJUYM3<]S"P;B;EI(L$6W-/U*^VV+,#T%9-O*TQ!)XJMKMV([)D![5BA^
MP4JBNCBA=27>N$L. :]"L6Q"$]:X31K0RWQDQWKN[>(@9]*9V5U&,$D:;#<!
M[5C:U*!&V>E;,?,637)^(+@;F0'K3L<V$AS3,5RCDU+ RPJ2#6<TOEJ3FL]]
M1?Y@*#ZM4G)'26MRDUSVRIK.\17WDNH4@GBL/2=2D&J.K$X+4[68I;J?<#P!
M3(CA??-S2I5N8]IQ[U/>-%;BN(L]3GL+C )(Z&MU]2COHPN?FQZTKFKH24_(
M?=W*.A'6N9O!&6.,5<U!WMU/H:PI7=ADFFCJ5&Z(YN&^4U&JF27#4!'9LYJS
M%'\V3UIW)CAKO441R!E '%=5;7RQ:;Y;N1Q6"K8P"*DEP8>O%*YO]626QE7C
MK+=,<EN>]4Y,JW XK3$"!B:@F1<G JT[G%5I-&>9B>,4]6&.M,>,+4?)XJDC
M@E<E:[$.<'G%9TETYD+ FK$D/S<U7*#=@"K21PU9R0HN).N3FI%FD#AQU%0N
M-@Z4Z)\C!J[(XN9MF[%J N(@DI[5BWZ+YI:(;CZ4Y8G#9&<5:M(0UQ\XXQ3B
MD*I3;1S\B,F2PP34;[2O4[JV-62/[5M' S6>(41LGFMT]#RJD'>PD$<8CRY.
M:87&[Y%J?R6F.$!Q4XMA$F"OS4"4&58T4\M3944=#FIVA9N@Q3182-WIW)E2
MN9[+@]!33&7/RBK4L.QB">E,SMY6G<S]FR2/3Y9%''Y59AT^0$ H<_2K6D:B
MMO)F=<K790W>EW4 ; 4@=S33,I4F8.G:279=^0?3%=%%I"8 88QZ51N?$EG9
M(R1KE@."*FTCQ+#.<SG%6IV.2I1;9T%C:0H.>WM5'6DAEW(._7BIGUBU*DQ'
M]:P-4U>,Q2,OWJEU1PIV.6O+!8K\?-\G6M)];CL85AAP?4FN=GO)IY&8MQFJ
MN=_+$YJ=SL6QT\GB5XX66,C+5S3RF21F8DEB33&&#G-#$$<46$V2JS*<CBKE
MK?M!(&S6>H8#DT=ZEQ8XNQZ;HFI_;K*)3M'//-=98'9E2?D[&O'-(O\ [)+M
MW$ ^]>IZ%J44\$:%AG'/-0U8ZX2;-N>X=--=1D')/X5Q<&OR6]^0W(SWKJ?$
MNKVJV:QQ,-V #BN(2U69R^,DTDSJ2.WMM4M[F,,"-WI4<ZPS,OEG+$]*YN*R
MEMXRX8@5I>'V>:_ 7) /.:J[8T[;D]]9W-N5.P;3[U#]CNI+?SUC)C!P37H$
MVEP72*SD;AVS5JS@A%LUF8OW9YSBBS#VJ1Y4;>27)"\#I0OR#:>37<WVG65I
M.45#@'UKE-4M_+N=T/W30X:&D:ZN54;GI4QVD=30AVQ_-C-1Y+M\I%9>QD=<
M<3%$;X!Y)JM.NY<@U9F1F'//TJ*.!W.U$8FJ5%EO%Q*" E\<U)+$P&16O'HE
M\Q!$#MGT6KL?A74KC ^SN!_NU2I6.>>-@<H0S#! JI+%M.<G->E6OPZO9\#&
MQCW8<"M.#X47.X&:>)A["MHTT<-3&7V9XPZ.Y^ZWX"DCL;F7*HA.:^A;3X:6
M$:@3*&/L:UH/ >BVQ!6W8MWYJ^2/0XYXB4NIX)H.ES6Y^>)\_P"Z:Z#[!=S/
MM$+D?[IKW"'P_IL !2W'X@5<6U@482&,?513Y48.M+N>*0>$M3N%'E0#GU.*
MNP?#S5G8&2-%'LU>Q+&%_A0?04K;1S1:/8M8F?<\VM/AIO\ ^/B5U^E:L'PT
MTN!@QGD8^A45US7D,?WYD'U-5Y-<TZ$?-=Q#ZM3;9#J5'U*%OX0TR''[E7QZ
MK5^+1=-C/RV<0/KMK.G\9:7 Q&\/CNK<&LBZ^).GQ$A$8GZBB[9-IO<[*.UM
MXF_=QJN/05)P"20/:O-;KXDAH6,:,GH36#-\2M3,;&-U*I_LTKZZDNG(]E$B
M!B6<#V)IK7MO'N+3)A?]H5X&GQ$O]5>7=,$VJ1TQ7.'Q??W$SVZSL6'7D\TV
MT2J;OJ?2$_B'3H'"O-R1D8YK.G\;Z1 2IE<$?[%>,Z7J$ZCS+R0GTYJ'Q!X@
MAFB*0J0]1SI'0J%]CU2\^)MC #Y15OJ*Y^Z^+\B$A8(R/4YKQB.9Y)LR,W7U
MJW=V\KVV]%)6E[2)HL,SOM1^+$\B91O+)_NFN;N/B3J<C_)<R8/^U7$LB\"0
M'\Z9(B!EV9Z4>TB)X>QTMQX[U6<%&;CUW52'B*^8\G=GU-89/-.)/8U/,QJE
M'L;AOKN;;*20@(R >*V;CQ3.]A'!%$J;>XZFN9LK]85$,@RI.<U=O[BV$ ,/
MWOK4.3-5"*Z"S7;7.'F/S"KEOXB%H0I0-D;<&N:>X)3)ZU)$V^+]Z/H:CF9J
ME&QU.H:9]HT]]4^1-PW84UM?!L_\5ZC _P#+!Q^E>>M=W"0&(39BQ]W-=Y\%
M"3XZ3/\ SQ?^5:Q;,*B1]+I]WDT[ I!TIU:G TKA28YZTM%( HP*** $HI<4
M8H 2EQ1118 I*6C%*P"4HHQ2T6 *9(X0>YZ4^H;N9;>V>5E+!!G I@*)"O\
MK!@GTIVX9P.M<"GQ1TMUU!%@D-S:'"V^1OD^@JO;_%JU:[CBO-%OK%'( EGP
M%R: /1RX H+'' YK/N-3MHM+;4@#)$B[OE-8_A3QE:>+)+HVT,D?V>3RSN-
M'3$@C-9/B;5I=%\/W6H6Z+))"NX*QP#53Q5XHA\+6MO-<(SB678,50\6WT6I
M?#V\O8T8))%D T 2> _%EUXKTN:ZNH8XBDFS"'-=;SD^E>8?!Z2.+PO?2E2
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M6ENK5)I+=5>-F_@.3R*Z/X3G/A34F;.[<XP.G0UC?"X'_A8&NH" WEK^/S4
M=!\9["*X\(R7#@%HF50/8FMOX<:)9:?X7B^SP(HD7+8[Y'-9_P 8,CP1,O?>
MF?SKH/ ^!X8M@O7:.OTH \XMXCIWQFECM6V1S7&' J?XA3S:QXXL-#?+VQ02
MM&>A((YI'9U^,X+;=IN.U.^)ME+IWBNQUR*.5HD"HQ0$XR10!ZM965K:Z?%;
MQ1*D04#:.G2O(Y WAGXMVL=JFR*_9I'4="1@5Z7:>*]'ETF.Z^W6X4(,JTJA
MNGIFO,M+C?Q5\3EU)$E-I:R%5<@X(..E #_C%$MS>Z7#(/DEGB!]\D<5ZGI6
MCV>G:'%IT<"K %QY8Z5YE\6U8:KI"K@J+F(>_45ZW:\6Z*3E@.IH \>^'H6P
M^(6H6D2#8\LC9]/:O1M>NO#VC.-2U<11DG"RMUR*\Z\(;O\ A:=VS8ZR<"J?
MBN:67XIK;ZL673@4*%N(R><]>* -'Q_X_P#"7B#PI<V5KJ"27# "-=O6NA^&
M<[7'@.4DY"[@/IBLGX@W?ANS\,S6MG:6DL\@_=O;HK;?J1TK1^%K*_@*Y(!
MW/Q^= '#>#]%M-4^*NI7%Q&LC6SJRY'2O=+NTBGL)H&0!64@#\*\>^'A"_$7
M6P 2?EY_&O:^ .><T >,>#+R3PSXYN] F8BW(WQY]6)JQX\N#XC\<Z7HD(WQ
MJQ29:K?%BRFT'6K/Q+;+_P M5#X]!_\ KI?ABLWB;Q/J'B.="%,H>+(QP0*
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M%T33([TWB64*W)&#(!SB@":VABM+988H]L:#@583'8=:3&1CM3@,4 +1110
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M7WS2L4V2O-N'-4I%^;-2L<TA(QTH(E(K.N12",U/P3CI2GV%48A$@ YK6C:
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MD@)JS*^^,8JM(P8\4]#QQS3,)QN1^66X-*MN8SNJ8<'D42,2N*+B]E8C>42
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?H6$=J"_KH7DCV'Y5Q3["!M\CMZU<MHFD.=O%6W@$,#MTJ$9NIK8YK6IRBD
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M8@0.G2O=2.1G%:\L:W[A   :S3]RI;J5IKUR_K41^\![T,M%BVM=TF\CBM/
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M+$<<5B^%=+73]#A!'S'FM>0-NR*U6Q#;N.\N,#H*KW"HPP*7:^[VI_DDCFK
MPKN'(-<MJ$3 DXKNY[7=VKG]6L&V' J9 <3,W;%5\9[U?NK9U8\53$#[JS:
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M3X9W&[Q-%&.@B85I X,6]#W!0.E/IBT^NM'@O<****8"T444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ2SM\HS4CQ.;A83P3WK6G:UTO"6T99^Y!S62\LEW.9'.S;ZTKE6-^STS3K.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%8X^M<Y]I)@VG&:FC2L[BE+043PK*^$&":T+1H%&XH,&L4RGH ,_2MG39D"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** (W'S#Z5!<KB(8&34\@R<#K2,#M'&:3"'NRN>*^(M%OIM
M:NI(X7PSY!Q67)HFJ&/;]FD(]EKWA[>-VRT0.>]+]FC' C K)PN>U3S.4(V1
M\YW6B:G;J6CTVX<^RYKG;S0_$5R2%TRY /;97U?Y"*/NBE$2==@I1IV,ZF92
MGN?(H\&:^1EM-N/^^*D'@S7!UTVX_P"^*^N6C4CA:01)C[M5RF'UV1\F)X.U
ML?\ ,,N/^^*E'A#6A_S#+C_OBOJ[RD_NT>4O]VGRA]=9\GOX3UP?\PRX_P"^
M*B/A#7&ZZ9<?]\5]:^4O]T4>4O\ =%+D%]:9\F)X-UH<G3+C_OBI5\):QNYT
MRX_[XKZN\H?W:3R%_NBCD#ZTSY?B\':HP&[3YUQZK6G'X4U!8<?89<_[M?1I
M@4C!44T0*/X12]DF:QQS2L?-2^&=41FQ8S?]\U6E\,:R_'V&;_OFOI[[-'UV
M"E%O&1R@H]BBO[09\TP^#-3,.6LIL_[M1)X.U17_ ./*;_OFOIOR5Z;1B@6Z
M#^$4G10+,9+8^?+?1M5M(L"PE/\ P"DAL=92X+?8)L$8^Y7T)Y"GJ@I#;H,8
MC%3[$K^TZAX2FDZC(I\RQER?]FJ,WAF^$F];&;\J^A&MU.,*!3C!%MY04>Q0
M?VG4/";+P_>S1?O+24'TQ5_3= N(;EM]G(>>,K7L@AC !"@4?9U+AL8H]@A/
M,9,\;ET2^=V(M) ,\?+4$^CZG'$=EG,3]*]L$2'VIYB ' S5>Q1A+&MGS;?:
M-KMSE#IUP5S_ '*I-X=UR-,+I<__ 'Q7T^%SQLQ3MH_NU2A8Q>(;U/E)_"NN
MSM\VF7'_ 'Q3%\*ZTD93^Q[HY[[*^L"@_NT#!7I3Y2'6/DC_ (0S654G^R+K
MG_8JG=^!M>"AXM)NLG_8K["QN7FG <<T^4CVESY!L?!_B"!UE;2;G<#_ '*T
M-3\.Z_>^63I%P-O_ $SKZM*[CG-!4,?IVI\H^8^3K;PAKRD'^RYQ]4K1B\&:
MW-,-]A,/^ 5]/D8_AI'CW$$-BBP<QX%I^@ZC92!3ILYQWVU/J6EZE./ETR?_
M +YKW?R^12;?GZ5ERFGMF?+6J>&=:E8>7I5R<>B5DKX0U_=_R"+K_OBOK[8!
MT'6@#%6HD.JSY$?PCK^/^01=?]\57;P?X@/_ #![K_OBOL,CFC;56%SW/C5O
M!GB$_P#,'N_^^*U=.\):Y%"-VD7>?]VOK7;0!BE8.8^/=1\)>(9)#LTBZ/\
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MN?%@\&>)/^@-=_\ ?%+_ ,(9XD_Z UW_ -\5]I;1Z4;1Z46"Y\6?\(9XD_Z
M]W_WQ2?\(7XE_P"@-=_]\5]J;1Z48'I0%SXK_P"$,\2_] :[_P"^*E3P=XD"
M8.CW?_?NOL_ ]*,>U)H.8^-4\'>(L\Z/=_\ ?%6!X.\18&S2KE3ZE*^P=OM0
M5R.:GE'S'R9'X>\2(FQM+NC[A*N6O@S69SO?3KA3[K7U*01T7-+CCIBCE'S'
MS&/#^L1#":5<\?[%5IO#6OW/ TR=?^ 5]2@?[-&!Z8I<H_:GRJOA'7X5,?\
M9LY!YX2@>"]6ZG3;G/\ NU]58Y]:7:IZBCE#VQ\L1^"M;>0?\2^X ]UHN/#7
MB CRAILY4>B5]3%2>!Q2;0O;)HY1JJ?*/_"+:VJ[/[*NC]%KL_A5I&L6/B]9
M[NPG@C$;+EUP*][*8YV#-)MW?-T/2J427*XGS<$L..<4]"#D@$9INP#.>]2+
MPH%69L6BBB@0M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 (>M)MI3118!NVEP**0BF'*!Q3L"F;:=B@&D+@48%&*,4A608%&!1
MBB@+(*,49HS0.P449HS0%A"*6CK1BDV%A,44N*,4786"D[TN*2BXM@/-%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "&BEHH%83%&*6B@8S::<!Q2
MT4"L)12T4!82BEHH 2BEHI6&)12T46 3%&#2T4Q6$P:,&EHH"PF#1BEHH&)B
MC%+10 F*,4M% "8-&*6B@5A,&C%+10%A,44M% 6$HQ2T4!82EHHH&%%%%*P!
M11118!**6BF E+110 4444K %%%%%@"BBBF E%+10 E%+10 G-&#2T4 )@T<
MTM% "44M% "48-+10 F#1@TM% "44M% "44M% !1112L 44446 *2EHI@)12
MT4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12
MT4 )12T4 )12T4 )2T44K %%%%, HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,44 %%%%
M!128HQ0 M%)2T %%%% !1110 4444 %%%% !1110 44F*,4 +1110 4444 %
M%)1B@!:**3- "T4F:* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BDS1F@!:*2EH **** "BBB@ H
MHI* %HI,TM !12&@&@!:*** "BBB@ HI*,T +129HS0 M%)FB@!:*** "BBB
M@ HHHH **** "BDHQ0 M%)BEZ4 %%)GFEH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ S29I"1NQWK!\1>+M)\+0I+JDS1J[;1M7/- &_F
MC-<!_P +A\)$<3W9^EN:V]"\;Z'XBR+"Y;(SQ*NP_K0!TF:,TQ7#(&S2Y!&1
M0 [- -1EFP"H!^M*6X('WA0 _-&:9GYMIZXHW#G)/% #\T9J,/\ , >_2E!(
M^]0 _-&::3BD+8X'6@!^:,TS=@#/4TUW(&%Y;TH ES2U&C!QD4[<2>!0 ZC-
M-#[@=O:F-)\V!U'6@"3-+FN4\<>*)_#&@RW]K LTB$?*YP*N>%==DU[1([Z:
M-8W;@JIR* -^BHPY/;Z4OF CWH =FC-1[^H_B]*1W*@ #YC0!+FC-1&54 +9
M]*4RA2,]^E $F:,TT<CF@'Y<MQ0 [- IH8'&.]133+;6TL\C82-2S?04 6*2
MN?\ #WB_2O$XE&G3,[1#+@KC%;>\*,]J )<T U&&(^\, ]*=O7GVH ?16-XB
MU:;1])ENX(O-= 2%/?BL'P#XRO\ Q99O+>62VS+V&?7WH [;-&:9DC.[B@L!
MQWH ?FC-,!^4;N":X?Q_XUU#PG%$UG8K<EW53G/ )]J .[S1FLG0-4DU?1X;
MQX_+D<<KZ5IAP3C/S4 /S1FH]X8X7DTXN$!+=* 'YHS48DR0/7FEW'\* 'YH
MS49?&!_$:"Q &: )**YCQMXDG\+^'[G48(4E>)"P5C@&IO".NS^(=%BOIH5B
M9P#M4Y'- '0&C--)P,TA<*H)H ?FC--S^5-9]JEC]T=Z ),T9%1!RR[@.O2@
MO\^Q>2.30!+F@&HS(%4ENU&\!<GOTH ES1FJMS.;>V:0CY@.!7%>#_'=WXDU
MK4+*6UBC2UF,892<F@#OLT9KS[QUX\U#PO?6T%G8+<+(X5B<\ _2NQT>_;4M
M*@NW38TBY*^E &AFC-,W[A\O- <$GVH ?FC-1F10,GI2Y/% #\T9IA;!QZ]*
M') XY- #\T9J.1]D9;VK@?#GQ N]:\77VCR6D21V\QC#J3D\"@#T+- -)WQ3
M"^UL'\* ),T9KG=,\9Z-J^JRZ99SL]U$2&4KC&.M= 3C!% #LT9IF3@G'TH#
MC&3Q0 _-&:;2,2%R.M #\T9IA8@US]MXVT6[UZ31(9W-_&^QD*\9^M '1YHS
M4,\C16\D@ )52<5Y_H/Q%N]7\6WFC/:1(L! 5P3DYH ]&S1FHFD(PN/G/:G!
M]V,4 /S1FF%ASCM020,C\: 'YHS40E!3?_!3E;<N[L>E $F:,U$SJHR3Q2[L
MC([]* 'YHS3>:3=V/6@!^:,TPDX^6D+X)ST H DS1FHQ(&4./NFE#<9/X4 /
MS2YJ(OM W=Z-Q&2WW: )<T9%1;QGBE[?-Q0!)FD-1Y(;C[OK2AMX)7IVS0 _
M-&:C5P00/O#K09!NV]Z ) :,UGZMJD.D:5<:A.<0PKN)KS6P^(/C+7I)9M$T
M*TGLDDV^8\I4X^F* /6LT<50TR>[GL(Y+V%8IS]Y%.0*NY (!/)Z4 .XI<BN
M<U'QEI&DZQ'I5[.R7<@!50N<@]*WP0P!!ZT 29HS7F>H?$B[L_'4&@K9Q&*0
M,3(2<C!'^->CQMOC1O[P!H DS1FF;@20.HI<C..] #LT9I@?GGIVI=V 2W3M
M0 [-&:8Q( (HSD_+T[T /S1FO,[_ .(VI6GC2/15TY6MV&3+SG.:]'1R44MP
M6&: )<TM,IOF?,0* ):*C#\?-U]*5F&* '9%':HMQXXY[UPGB#QY=Z1XOL-&
MAM8I(K@$L['!&#0!Z!FC-00S^9"DAX# &GASN.1\O8T 29HS3-^3@=:@OKV#
M3K*6ZN6*Q1KN8@=J +1-&:Q-!\4Z5XCADETV9I%C.&RN*UC(4Y8<'I0!+FC-
M1[CW SVI=V.#UH ?FC-,W8'/6F^;\V .G6@"7- KC/'OC&Y\*:=#<VELD[/,
ML9$AP ":Z'0-2;5]'AO70(T@Y4=J -.BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :W2O(?C7L,>BC:3
M_I?S?3 KUUF'F!>^,UY)\9PP.C_Q W7(_"@#NO#FG6$F@6;BRMCF/G,2D_RK
MCOB1X$22'^V]'9K:^@PQ"-M0J.?NBN\\-@)X=M-J_P#+,5/K*!M*O,C=F!\C
M\* .1^&/BZ7Q)H,:77-Y$/WI P*V_$_C#3O"MIYEQNEE8C;#&?F;Z"O+_@O(
M8M?UR('9$BC _&LF7Q+HUY\3))O$5R@MK1GC4R=!TQ0!WI^+5MOB6YT+4H(V
M/$KKA1[]*[[3=1M]5L4N+>57C<9RIKS[7_B)X"U?0)[)]5MY#Y96-3V..*R_
M@IJ;7*:G:)(6M+9@L7H1B@#J[WXE:+9^(#H]RDB2JA<2%L X[?6L^\^+%O9%
MRNA:C+"O_+54ROYXKSW4]*M-6^+B6]XBM&%W@'U!KW>73;8Z,]A'$$A9-I4>
ME $>B:]9:_IT=W:2JP906C!^9#Z&JOB#Q5I_AJ)9+G=([G"Q*?F)KS3X6.;#
MQ=K6G1+B,W1Y'L*K?%03Z;XTL=7OD+:8LB!2W0,.IH [73_B=;WVH1P3Z-?V
M<;''FSKA1]37<^>OV;SS(@CQNW'IBN7TOQ%X8\=6DEK!<170QAXO[M9WQ/U8
M>'O!>V!O*&Y8@!_=/&* #4_BCIUGJ4]I:Z==ZCL'S/:C<M6?#WQ"T_6;S[-]
MFGLI2<>7<\,WTKC?AUXT\#^'] 3SKZ"WOGSYWJ16!\0_%GAV\UVPU30;R.2Y
MC^4LG4Y- 'T*O7=V([4I)'*_C5'1YI)M,M99"=S0H<?@*OKW;')[4 ,9DB5B
MQP -Q)K@=4^*6GV.JR6-KIUW?M%RS6PW"M'XDZL^C^%)KF)RC,PCW#WXK(^$
M>A0VOAT:DZ@W5P6$DO=AG- '/?$'QG:^(? =[$B&SEW+^YGX<_2N@\*:W;Z!
MX AO9H)957J$Z].M8OQG\)Z>=&?5EC5)T(^;'/)KH_!]DFH?#YK:2,-OB*KG
MZ4 =#X9\46GBK38[VR!12,E6ZBK&OZ[;>'],?4;H'RD."!W->1_#2]D\-^,;
M_P -W+%06$<2FM'XS:H\YM/#L9PT[H^!W (_QH ]!\,>*+;Q3IG]H6\,D,3$
MJ/,Z\5E^(?B+IFAWD5BEO-?SN#E;;DJ1V-$=FGA'X=S")03% 9,].2!7F/PX
M\7>$[:\O]5UJ[AAO99 Z,_5>.: /0++XI65]?):3:9=V#'&'NA@&N]C>.>-6
M5U=3T(KQ/XE>-/!^N:,CV.HPSWB."N.O%>@?#"[?4/ FGW,S%I&7J: .MP3G
MKD=*P?$GBW3_  W GGAI96; AC/S$_2NAP2#@XKPOXEK<Z3\0;/6+N,G3O,0
M!CT4CJ: .WTSXG0W]ZEO+HM_9(QQYUPF$7ZG%6_&OBA-+T:=%L+JY$L)P\(R
M!D=:LZ=XA\-^.;)[.&>*[CX#K6OJUND/AZ[AC&%2V<*!V 4T >"_"_QHFA/>
M8T>^N3*,?N5SMY[U[GIFO1:AIYOYH)+2->JSC%>:_! @2ZF =WR_UKUN^LK>
M_M3;7,0DC;DH: .-U/XF06=X]O;:/?7B*,^= NY3[9J;PQ\2-.\37SV(ADL[
MJ-MIBN.&8^PKJ;#3[32[86MI L,.<@#U->*>.X;?1_BAI-[:PB*XDD9GD'5C
M0![5JM]#8Z?+<7$7F1HI8KC.<"L7PAXEL/$ME]ITZU%O&,Y&T#/Y4[Q%,S^"
MYI6Y+6Y)_P"^:Y#X)*3X:SGC+9'XT ;^I_$?2-+\1Q:5=1R+(ZDB0G"C%4+W
MXK6MN[[=%O[B%1GSHEROYXKSSQGIL>H?%*SM9QNC<,=A[\BO<K;1[.UT 6-O
M J0F/E!T.1S0!#X:\3V'B72H[NS<!BN6B8_,GL:I>+_$^F^&;>*XU*T^T*[J
M@&T'DG ZUYSX$QI7Q.UJPMU\J*2<#8/PK3^-QVZ1:!N?])B_]"% 'H]IJEO-
MH_\ :$<12#;N" 8-<K8_%31+A[Z,12K+;2;/+8_,_':M?35SX'_[9<>W2O(?
MAMH5EJ?CS4YKR%9C%<$ MVX% '>_\+<LXYXTN-%U"VCD?9YLJX7ZYQ7>VUY;
MZA EQ:RJ\1&5<'(-<_X]TRUO/"MTLL"R+%$VP'^' XKF?@O<RW'A&*UD)V0Q
M@+[4 =/XG\<Z=X;0"6)[BX.,0Q?>/X5RUY\:].L(0U]H.IP*_"EUQGZ<5@:"
M@U;XMO\ V@/.$2R!"W;'2NN^+NG6MWX1:2X12T +19_A.* -;PCXWA\5Q%[?
M3;NWC'"O,."*ZL*-V_GTYKB_A;/-+X-L!*"H6(!3_>KM%+,V2/PH X+XO@_\
M(/>#_ID:N?#(G_A$K9?]A?Y54^+_ !X'O3Z1&I?A\[1> UE Y6'</R- &MXA
M\6Z?X?P"_G7!X\E#EORKEYOB];PQE[CP]JD<0/S.R8 _2N7\"6\?BKXAZAJE
MZ!,(E'EANS FO9]2TZVO].EMKF%9(77YHST- $6D:M8ZY9QW=I,KAE' ;./8
MTS7-?L- T^2ZO)5^5<B//+>PKR/X;73:-XZO=&20FT/F2!>P.34?B^0^(?B?
M9Z3,?,M89\%#TP0: .M'Q:CD :+P]J9B[/LX(]>E=CH^O6NM:6M[ P1,G=N/
M(QZU>MK*&#3H[1$'DJFS9VQ5>ST'3=/MI+:VM4CAESN4=#GK0!SFM_$2TTJ=
M8+;3[K4/[S6PW 5G:7\5=,O]773;FQNK"1AD"Y^7)KM-.T33M),@LK=("YR=
MO>O*?C;86T'V'4U@7[6MQ$@E[XW#B@#UF[<FPF.0R[/EQ7D?PJ_Y&K7">INS
M_*O1]$N9+OP?'-(3N,?6O.?A4,>+=<)X)NSS^% '>^+/%FF>&WM5O[+[0T\H
M12$!P3]16I=:Y'9:"VI16DDJ!=PAB7YORKS;XQ@BZTABW/VM:]0T,9T:V^7!
M9>: .(D^+*HC$>&M64#J3'QC\JT?"/Q'L?%ES/;6UC<Q-" S%Q3?B=XG;P]X
M=/V=MT\[B$(#S\W']:J_"_PV^AZ$=1NAB[N!\X(YQG- '1^)?%NF^&K+S[C,
MLI^[;H?G;Z"N43XN6H*"XT#4X8W./,=<*!Z]*X.Z\3:/=_%%IO$4R16]H[(G
MF<C'%=YKOQ%\!ZEH<UD^K6[_ +LK&#V..* .]TG4[35;*.XLY%>,C/7)%9'B
MKQAIGA.$3W.Z65B (4/S'/M7 ?!+4A<2:G9P3;K6W*B)AT(K-TNW_P"$P^*L
MBZA_I$%MO"AN@*GC^5 '90_%*TO'2*XTN\LHI3CS)UVC\ZY#X<S0S_$K5Y('
M#Q-<DJP.01@5ZMXC\/V&M:2;&[@5P5VH3_#7D'PNTM-(\>:A91'Y(9RJ_D*
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M/TKC/AYXT\$:%X;BBGU"".\(_>D]6KF_'?BCP]=>)+#4/#UY&9@0KO'UR6%
M'T)),L432O(JQJ,L3V%<#=_%?3X=3FMK32[V_6%MK2VXW+5;XD:O<6O@6T,,
MYC>[41L1_'\HXK3^%V@V^E>$+6981'+<QAI3_>- '#?$[Q9:^(O"MJ(O]'D%
MY'F"3B3J*]3\#J!X6M",CY>]>6?&7PII]H;75845)C<1J2!UR17JW@LY\+VA
M(Q\M '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $<FX," ,>]>1?&=0&TA@S$FZZ=NE>O. >HS7#?$
M+P5>^*[:S6PNX[:2"7?N=<]J .C\.9/ARQ(Z^767XW\1VFC>'[EGF7SI4:)8
MP1NR1CI7-V_A'XB6=LD$'BJU$:C 'DFI['X8O?7BWOBN\74KA#E6CRH&.G%
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M&L^_L=-U9&M+H03$#.UB"1^%:6,YS7"^(/!NK3ZN^I:%J26=Q*H1BX+# ]J
M/._'WA"+P1<?VMH]Y+%+*=_DA\*?H*]7M+FXN_ TDUSP[61Z=_DKE3\-=;UC
M4;:;Q5K,.HPP?=CC0KQ7HRV%NNGBSVX@">7M]L8H \D^!<@\W4XCPRKSGZUZ
M!X[UZY\->%Y]2M%5Y58* W/6N3;X;:[I>N75YX9UB"P@GQE'0L<5V+^'9M2\
M./INMSK=.X&648&?6@#SGPUX6N?&MA_;6J:Q>P/*Q41VLQVC'MFN2\3^'H-
M\<:3##J,UYN8Y,TFXK^O%=[IWP\\8Z&CVVC^([:WLRQ81M$21DTMU\([B]U.
MTU.:_C-\AW7$A!Q(WJ!VH ZW6QO\$NJ]?LQZ_P"[7*_!0%?#9#=]W3ZUW>IZ
M1)?>'SIJ2!&\K9O(XZ8K)\!^$)O"6E"TEN4F;G)48[T >9:__P E@L0A_A?.
M[ZBO<QN%FHZKY8Y'TK@M5^'-S?\ C>VUL7<:QQALIM.>2*] 6(QVZQ \@ 4
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M "8&,8XHP,8[4M% !C%(0",&EHH *,"BB@ Q28'I2T4 %)@4M%   !1@444
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M$A()#=!S4BD$ CI0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA^!K&\/?%;4K=I](U>VEN-30L R #/.!Q7K.F1HFB6ZQJ/EBP/I7B\5K;O\
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M>#]=\=6WA>TM]/\ #,$]LB_)*92"U9WBK1_'GBW5+*>Y\/Q6RPLN2DA/ (-
M'K7B3Q%;^']">^<\E,QKGDFO/-(F^(GBFWDU*RU>"RM)/GBCEA)./KFM/XHZ
M?<2>#[-CTMANDR?116_X!U:SN/!5AMD1=D'()QZT >7^'?$_C_5?&#:+<ZK#
M \626>+AE![<]Z].\;:OJ?A[P;=7<,Z_;(XB1)MXS]*\[T.3^V_B]-=6.XQ1
MQE&8#C(/-=S\60Q\$WV!P(CF@#F_#/BSQ9XUT4)I[_9+I<!KF5,IGZ52G\<^
M*?!'B$6WB2==0@DPJ&%-HS^-=E\*((X?"$0C4*7"DX^E<I\8X(GU+2"P^]=
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MI:[:W%GY:XB2(@@8]<UR'Q?+?\)CHFY /W9Y_P"!5[)IP_XEEL#_ ,\5_D*
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M#-FDKLQ,:_>[<5T!],XS0 _-<CX_\1KHFB,D4@%U<9CC7OGM73S2^3 [X!"
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MA/*VG6BP&5B[E>Y/6FZIX7TC6;N"YO[-9IH&WQL?X30!8TYL:3& .-E>.6H
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M$R3E=DKA3^1JU\6M!FUK0XKVQ'FR6V9%"\YXK=F^&/A*XO3>2:3&9R_F%O\
M:SG-=7!:PV\ AC0+&!@"@#@_ /C/2[KPW!;WDZVEU:*(Y$G8(2?8&MR;QGIO
MVJ.U@W7;2,%W0?,%SW.*K7WPU\)ZC>/=76E1R3.<LQ[FM'0_!^A^'68Z78I
M6&#B@#BOC2@3PC)SD+&:ZOP&0WA2S)_YYK_*M76- TW7[,VFHVRSPD8*M5FR
MT^WT^T2VMHQ'"@ 51V H ?=6\=W:R6THRL@VFOE[Q+=7'@W6]4TZ ,D=Y/N3
MZ=*^I]O/O7S]X]AMO$_Q,T_3;>(2R1[@X'J"* /1_A;HS:5X5C,JA997,F?9
MN:[EB<?+5>RM_(L+>$C[D:KCTP*LX% $9;?&3C!%<ZWC/3(M:GTJ[_<-&H/F
M38"MGW-=*0&&#6#KG@S0?$3A]4L$G8=": /+OBO+H^HS6=EI*13WTXW![4 X
MP>Y%;_BKPM>:Q\/K:%<FXMT63!ZG"CCZUU.D?#[PSH5\E[IVF1PW"?=<=JZ;
M ]* /+OAEXQL/^$>32=2D^Q7-JN'$YV9_.NONO&.F031Q6\@O-V!B [R/RJ+
M5/ASX6UN^DO=0TN.:XD.6<]ZGT3P/X?\.W'G:9IZ0/ZB@#DOC&)Y/#=C)%N$
M D+3*.I7 XKS?3T\+S:?$YL/$PRN3Y#N%/TQ7=?&#5+RTGTZ LT5C)/MD)Z,
M,<BO0O#*VO\ PC=B+95\CROW>.XH XOP-XF\-VLHTNULI[.4C(:[7#G\3S6C
M\5P?^$$OL,,>4:XGXI/;7/C*PCT_!U!9(RVWKMR,UZW-I%KK.B+:ZG )XG3#
MHW<4 8'PN!/@VWS@':O\JY/XR#_B8:)_U]C^5>KZ=I5GI5HEM9PB*!1@(.U5
MM6\-:3KCPOJ%HLS0OOC)['UH ET4 :1:CU3FO$]==A\9(,#),0'3MFO>H8(X
M(UCC7:JC %8\_A+1;C6%U62R1KQ1M$G?% '&?%CPW=:KH=K=V*[Y+',NSJ3Q
MCI^-7_ GC73KWP]%;WMS%:7%LHC=)6"'/TKO0H7H*Y&]^&'A'4;R2[NM)B>:
M5MSMZF@"VWC'3EO4LH=UV[$#?!\P&?7%<=\;6QX3D#YR4.W';ZUW.A^$-$\.
M.S:79) 2,$BK6LZ#IFOVK6VIVRSQ,,%6H P_AP ?"5L<_P "_P JXGXS<ZGH
M&/\ GY/\C7K>GZ;::7:+;6<0BA48"BJ>K>&M)UN2"34+19F@;=&3_": &Z8I
M?PQ @[VY_D:\<^'%W%H/C?4[359%M@=[JTAVYRQ]:]VA@BMX4BB4*B# 'H*Y
M[6O 7AOQ#>_:]3TV.><@#<?04 ;EG=P7L(>TF26/LRMD&K'*D'C%4-'T/3]"
MM%M-.MUAA48"BM(J",$4 8GBI)CX:U#[*6\\PG9CUKR;X4RZ3')J9UV6+[6L
MP!%V0>W;=7N913G(Z]:Y*_\ AIX2U*[ENKK2HY)I6W.Q[F@#RGXL:CI=W?V,
M.F6J?+,A\^",!.W&17JED2/AZA8@MY7.*M1> O#<.G)8)IT8MD?S%3T;UK93
M3+2*P%BD0%N!C9[4 >/_  7YU;5?^OEZ]#^() \&:D<?\L6K0TCPOI&A22R:
M=:) TK%G([DU?OK"VU*SDM+J,20R#:RGN* /.?@ZH/A9MN<LHZ].E<Q:>=X$
M^),MQ=)BTN 1OQP"Q]?QKV;2=#T_0[86VGVZPQ#C:*BUKPWI7B*$0ZG:+.@.
M0&H PO$7C.PL]-/]GR+>3R#Y5B(?!]Z\Z^$5Q-=^*[ZYF78YE;Y2,?I7J>D^
M ?#>A7'G:?IT<,GJ*NZ?X7T?2[^2]L[-(KB0EF<=R: -5@!DG.3Q6+XH4#PU
M=A2<E?6MMADCC)K%\3X7P]>XZXYH \*^%OBI-!UJZAN(9# \[CS-O ))[UZ3
M\0/&=A%H%Q9V%PES<W:%$6)@W/X5R?PFTFQUBTU"VOHEGB-Q)E#]37HUC\,O
M">G7D5W:Z3''-&VY&'8T 8OPPT6YLO"EVMU&J277S8*X/((KB_#%P_P]\?7=
MOJ$4BVMQPDQ'RY))ZU[SY*X QTZ5FZWX<TKQ';K;ZK:K<1*<A6[&@"O-XIT:
M&"26+4K:1NH19 2:ET_5H]9TFXN4ADC"JR_.,9XZBL2#X5>#K6998='B5UY!
MS77);Q16H@10(PNW;[4 >%>"LM\5]4],K_.O;-8P-,N/^N;?RJE9>$M%T_4I
M=1MK)$NI?OR#J:UYXDGC:-QE6&"* /&O@V4DN[^-@1B60Y'^\:I>*(+OP=\3
M(?$#P-)82S&1FC7.T>]>OZ1X9TC0FD;3K183(26QWSUJWJ.EV>K6$EE>PK+;
MR##(>XH S8/%VB3V23'4K52Z;MID&1QT^M+H_B*VU>26"TAEQ&,B5A\K?0UC
M?\*E\%!]XT6+=G.<UU>G:=:Z59):6<(B@3[JCM0!X[\8[:>/7=*U#8QMX4Q(
MV. =U>G:%KNE7]G;QV]Y$THA7*"0$]/2M#5](L=<T]['4+=9K=^J'O6-I7P^
M\-:->?:['38XIL8W"@#SCQF3_P +5T7'#>>>M>SVX?[-&1C[M9]YX6T?4-4A
MU*ZLTDNX6W1R'J#6NH"*%7@#@4 >#>._,7XG6CZ@TRV32J!EB(^ASGM7=Z_J
MWA:QT"3[-;V-W($P([>-&<_D*ZC6_#6D>(H4AU2T6X1#E0W8UE:;\-_"ND7J
MWECI<<4Z@@,/>@#SGX&G-U>MC8K2R,%/&,L>*TOC9:7'EZ=>QH6MX2S2\9P*
M]'TKPOI&BRO+86BPN[%F([D\FKNI:9::M92V=[$)8)1AT/<4 8GA77],O="L
M84O8/,$(_=[QN_*O/?BWL;6-$*[@1=CK]*[[3OASX6TJ]6\L]+CBG48#"M35
M?#&D:U)!)J%HLS0-NC)_A- &;J0SX%)[^5_C7!? _B"^/_3S+_Z$:]=DL+:2
MR^QO$#!C&WVJAHWAG2- 5UTVT6 .Q9MO<GK0!A_$\[O NHCCYH3R:ROAFI_X
M0>90?F"<$?[IKN]4TNSU6PDM+R$2V[C#(>XK'OM/B\-^%[F/1K38-I(1.W!H
M \ MUTZ77+Q=9MM5FN QP;(L& R<9QVKIM%U'PGH-_%>RZ7KTA0YW7NYT7_O
MJMWX.WEO?W=Y<74JMJI+"7/WM@)Q79_$*YT^'PE?#447R"O1OXJ -_3KZVU*
MRCN+9T>%@"!&1Q[<5=(R5QVKRSX)_:_["N"R,MN9W*$],9.*]7X;!H J7ENE
MS;202%MCC!VG!KSU?@CX<2>2>*ZU&.1R6)2Y9>O/8UZ:% S@=:0@ 4 >!_$G
MX>:9X>\,W-W!=ZA+)MSB6X9U_(FNE^&G@+3[?3K?54N[TS,@.PSL4Y'IFO1]
M6T73]<LGM-0MUF@<893WJ>PT^UTRV6WM(A'$HP%':@"?;]WGI7->.M';7?"]
MU9I]\X8#UQ73D ]:-H)!QTH \<^%OB6/2;>70=786LT+LP,GR@C/'6N_NO%^
MEB[ALX)A<M*<9@;=C\J36/ ?AO7;TW>HZ='-.0 6/I3M'\!^'-"N//T[3DAD
MSG<* .#^-$AFT*S91A?M,7##G[PKT/PID^'+8$@$K_05/K'AS2]>C2/4;59U
M1@R@]B.E7K>SAM(4BA0*B= .U 'B_C,%?BOHV<$['_F*]E!_XEG_ &R_I5"\
M\*:1?ZI#J5S9J]W""$D/49K6\I?+\O'RXQCVH \)\)8/QCU0_P#3<5[R3Q6'
M:^$=%LM6DU2WLD2\D;<\@ZDUMXXH @OC_H4W^[7C'PQ_Y'_7_P#K[_\ 917M
MCH)$*,,J>"*R=-\*Z/I-[/>V5FD5Q.V^1Q_$: /+/C4"=0TW_KXC_F*]7\/'
M_B26X_V:9K'AC2-=>-]1M%G:-@RD]B.E:5O;QVT2Q1+M1>@H \3\=;6^*6F,
M^01$0/S%>I>)(GN/!]U%$NZ1[?  'L*FO_"NC:EJ<6HW=FDEU$,)(>H%; 10
MNT#C&,>U 'C7P@UFTTR'4K'4IH[:6*0+B0A<\>]==\0M#3Q/X6?[*YD,9\Q=
MK9SCFKNH?#?PIJ=Z]W=Z5').[;F8]S71V5C;:?;+;VL82)1@** /,OA5XK@M
MM$_LC576SEM%_P"6_P F[GMFI/B5XHMKO1_[)TEOMEQ<,IS#\X S@]/K76:S
MX!\-Z]<FYU'38YI2<[C3M$\#>'O#US]HTS3T@E_O"@"K\//#TOA[PM#:3A0Y
M8R''7GFNO'2DIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% #6ZYKD?$G@2Q\2W]M<W%Q*KP2
M!P%Z5UQ&3D=::5QUZ^M $=I;+9VT=NA+*@P":F-)D#!STI6. ,#-  *,49P<
M8HR,T &*,4N:3</6@ Q1BC=@\\4!LD\=* %Q1BC-&X8R>* "DI=PP#V]:0,I
MZ'-  ?>DR*4D>E&1D#'6@!,BBEXH+*.] "4N.*7/M1NXZ4 -Q01Q3N,9[4A(
M Y.* &[:-M&XY(P>* P)QGGTH =D@=*1EWIC- ;.12!L X.?84 <7K7PYL-<
M\10ZO<W4PEBVXC'W>*[(*%C*CY5 P,5)U^E,4*I8$8'O0 J@@#'(]33L4B$8
M/(-+GCUH ,44%@",]Z.,9S0 44#D9H)P* "D/2ESQFDW#OP* %6E-,#9YZ"G
M \\B@!,4N*,C-+G%  .*,TA8#Z>M <$X!H ;,OF0NFXKD8R.HKBM,^'.FZ5X
MF?Q"+J>6X9BV'' S7;LP%-48S@=: $2,*<[F.>QJ0# Q31T^;K3AP,4 &*"*
M-PH)&,GB@!,48HW CCFESB@!.E%(3DC% <'(/% &5KN@V7B"R>UO(PP8$!B,
ME/<5Q/\ PJ)8T2.W\2ZK'$@P%5\ #VYKTO QSWII8JK!0>* .0\/_#_3=$;S
M9)I+Z;.?.N!EOIFNP4[1TPO:D" (< ^M(&)5210 ]>0?2BA<'([4NX9QF@!*
M7%+FDW =>* #%&*-PW8H!!Z&@ (I,&EW>G-*&!&: &T4I:D+@+G]* "BC.0#
MBCZ4 *.M.I@/<\4[<.] "TT]:7<.U&?QH ;2@4M&03@&@!,48HW#./UH+<9'
M/TH &H7K2%@%R?RI'?: 0I.: ''K24H(]: P.>,4 ,<< DD8]*K:A8QZG826
MTA*I(.2.M6R<CI02-G'04 <MX4\#V7A(S&SFDD,CLY#^]=5FFD!<, <TX'+$
M8H ,T4FX9QWI0<B@ ZT#K2 C&1S2^] "&E HSG%&?7B@!**7(S0&!Z4 '-&3
MZ4A;TI"Y# 8/UH <,TI%-#YSSTI<\XH 0T4;AGGBG<4 -HIU-=@/KZ4 %%)G
MG%*.>G2@ IU-)P0,4NX>O-  128I=XXXI-XSR* $<X&.YZ5',@9,.,Y&"O:I
MLY'2FX0=30!P.J_"RPO-3>^L[^YT]Y!AQ;?+FJ\7PHMEG1[K6]0O81]Z*<Y4
M_AFO1L[CPPQVI@4AL@XSUSWH KV5C;:9:);VT2Q1# P@QFKPQCBHL*.>A]ZD
M#<#CK0 ZD;I1N&<9II8$<4 *!2XIN>![TF_VY]* 'T4@8=,\TN: &D<T[M2!
MLCI0QQVH 7-&ZFC!/6DW#&: '[J3-)E<@9Z]*=G!QB@!,T4N12$@<DXH 7%)
M2AAG%)GDT !H%)NR,X[T[TH ;13Z* &8I<4[%% #,<TN*=28H *6DQ2T %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 (3SCO2<8^:APW\./QK \0>*]/\ #D6Z[8O(>!&G+'\*
M -TX Y4;:/NCEN#TKA=*^*6FZG?I:MI]_;;S@23PE4'XD5U.JZS;:3IS7LP+
M1!=PV\T :(/)4G-!&1M'RFL3PSXFM/$^G"]M5=5(S\PQ4?BGQ59^%K);NZ61
M@6"_*,]: .@&2>1Q00IR>XK.L]7M[W3/M\881;=W/6N8C^*6AO\ V@ LN^R;
M:Z8^9_H.] ';@9&#\P]: "#CL.E<EX>\?6GB"Y>*'3[Z!54MNFB*@X_"JS?$
MK1$N]0MG\X/8IO8=WYQ@>M ';L.C%L4A7Y<'YA7'>'/B%:^(]16UM]/OHE8$
MAYHBJ_GBM77_ !7I_ARWW7;[Y">(HSE_RH W!M4XSP>@IH^Z2BC.:\WD^,NF
MQ1%VT?5$5?XGMV 'Z5W.DZO::Q:1WEI*K*R@E0<D?6@#2SCKP32%OF (YKEM
M<\<:9H6K6VGW22M+=/Y:;1P#72(ZRP+(N>F1F@"4?,..#1QSN48'2N6_X3O3
M5\2G0]DOV@(&R!QS5[Q+XHLO"VFM>7BNR 9PHS0!M\@YW<4 8/+9SVKB+CXG
MZ-:V<<\4%S=B10VV!=Y&?I4OAWXD:7K]Z]H(IK28 ;5N5V$_3- ':<=/TJ-L
M,<CG':C@#?GGN<\5Q6N?%#2-&U-K$07%Y(%R?LJ;\?E0!L^+->D\.>'[G5!&
M)/)3=L)P#4/A/Q))XCT<Z@UJL1 SA3GM7#>-/&VF^(O 6I*J2VTHAXBG&QC^
M!K>^%&V+PBK$D@X./PH @M/B1=W?C230?[,5$CP3+D\Y)_PKT12 [':  >M<
M?!XLT&Y\6SZ1%9!;Z)59I/* R#G'.*U/$_BRR\*6'VR^5VA'4*,F@#?R"<=#
M2=05QDBN*U#XG:19013Q6UU=B10V+=-Y&1WQ4WAWXC:5XCN9;>..:UF3&$N%
MV%OH#0!V"@!>% ]J"1G:#@U$\R11EY&VKC<23Q7"ZA\6-(L;Y[>.RO+O9U:W
MC+C]!0!WS  @L:<,8]J\L7XZ:"]T;8:?J'G9QY?DG=^6*]%TO45U*T281/&'
M&X!UP10!=/"_+3)9/*@,C#A1D_2G@8KF/%_B:#P_9R--:74Y:-@/(0MC(]J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>5GGZ5XW\-KR.]^(^KW$)W))."#^5 '5?&M0G@M& &\W,8Z>];7PXB"^"K'
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M" .-E>,:@S#XV/@?(8X_ZT =I\7$0^ K]RH#%*F^%B*?"2%U'4=O:HOB^N?
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M6WGY>M&]CR!QG% '%?#WP9=>$;>:&XN(Y X^7:.G-)X\\!_\)3Y5Y92+!J<
MQ%*WW0,YZ5W&W*\\M2<D8(P?6@#S2+P?XSU"$6NOZO:3V07;LAC*-CIUS4G@
M[X:OX2\0W5W;7"?89'!1#DL!]:]'[9SD=,48"@G&1V% &3XGT"V\2Z/)I]P"
M5/S*0<88=*X+PYX0\<^'O(MK76+)=,1R3&T1+;?KFO5%7YL]..E)RWRE?E-
M&)KWANS\2:/]BU-?,)7[Z\<UP6E^#_B!H*/;:;K=DMKN/EB2(L0.W.:]8.T
M+V% '\)/TH X[PYX6U:&^_M'Q)?)=7B'<A@RJY]QFNU&"*B 96 ;Y@>YJ:@
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/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_=G/XK7U..IQHY+0E0^T_>]3&+YJKN>QZYHMAXBTF\TO4K2'4-.O(F@GM;A
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MEHW Y1\!CC!!V]:^'_\ @E#;PS?M2WS2Q+(\>CW+(S $J=Z D'UP:CFE>/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P 1=>C\Z?1]+G\NTM@JLL5K;"1PJ*@<[GSEB2><+7R)_P $^OV5?B[^SO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -9<TFP>M/HI: -V
M_-FG444P&-&&I/*]ZDHH 9L'K08P:?12L!'Y7O1Y(]34E%,!BQ[3UI=M.HH
M0#%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ-\G_/5_SHHH >&<_P#+1_\ OJEW-_??\S35I: %W-_??\S1N;^^_P"9I**
M'[G_ .>C?]]4FY_^>K?G2T4 )N?_ )ZM^=*&?/\ K'_,T44 .W-_ST;\S1N;
M_GHWYFBB@ W-_P ]&_,TY6;^^WYFFTJT /W-_>/YT;F_O'\Z2B@ RW]]OSI5
MW?WV_.DI5H ?N;^\?SHW-_>/YTE% "[F_O'\Z56;'WF_.FTJT +EO[QHRW]X
MT44 &6_O&G*3ZFFTJT .Y]:.?6BB@ Y]Z5<^II*5: '+G>.:L57_ (A]:L4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >:S?\?5Q_P!=&_G24LW_ !]7'_71OYTE #Z*** "BBB@!U%%% !2
MK24JT .HHHH *5:2E6@!U%%% !2K24JT +1110 4JTE*M #J*** "E6DI5H
M=1110 4JTE*M "T444 %.6FTY: %HHHH *?3*?0 4444 %.IM.H **** '+2
MTBTM !1110 Y:6D6EH **** %6EI%I: "BBB@ I],I] !1110 Y:6D6EH **
M** %6EI%I: "BBB@!RTM(M+0 4444 /HHHH **** '4444 %*M)2K0 ZBBB@
M I5I*5: '4444 %*M)2K0 M%%% !2K24JT .HHHH *5:2E6@!Z_>%3U OWA4
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'FLW_'U<?]=&_G24LW_'U<?]=&_G24 /HHHH **** '4444 %*
MM)2K0 ZBBB@ I5I*5: '4444 %*M)2K0 M%%% !2K24JT .HHHH *5:2E6@!
MU%%% !2K24JT +1110 4Y:;3EH 6BBB@ I],I] !1110 4ZFTZ@ HHHH <M+
M2+2T %%%% #EI:1:6@ HHHH 5:6D6EH **** "GTRGT %%%% #EI:1:6@ HH
MHH 5:6D6EH **** '+2TBTM !1110 ^BBB@ HHHH =1110 4JTE*M #J***
M"E6DI5H =1110 4JTE*M "T444 %*M)2K0 ZBBB@ I5I*5: 'K]X5/4"_>%3
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 >:S?\ 'U<?]=&_G24LW_'U<?\ 71OYTE #Z*** "BBB@!U%%%
M!2K24JT .HHHH *5:2E6@!U%%% !2K24JT +1110 4JTE*M #J*** "E6DI5
MH =1110 4JTE*M "T444 %.6FTY: %HHHH *?3*?0 4444 %.IM.H **** '
M+2TBTM !1110 Y:6D6EH **** %6EI%I: "BBB@ I]-6G4 %%%% #E&[@#-3
M"UD*YV^]11MM;-?&'Q"_9MT33_VD_AUX6M_%_CJ+2?$MKJU[?0+XFN@"\81D
MV_-\H!=N![4 ?9Y4J<$8-%9OAOP];>$?#NG:):375Q;6$*V\<M[,TTS*HP"[
ML<LQ]2:TJ %6EI%I: "BBB@!RTM(M+0 4444 /HHHH **** '4444 %*M)2K
M0 ZBBB@ I5I*5: '4444 %*M)2K0 M%%% !2K24JT .HHHH *5:2E6@!Z_>%
M3U OWA4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CZ_XDTSPE
MH]SJFL:A:Z7IMLADFO+R98HHU R2S' '%6H=0AFLX[N*6.2VDC$R3!AM*$9#
M9]".<UX]^V9H]AK7[+?Q02_LK>\6#P_>7$2W$0<1R)"S(ZY'#*0"".17!?M3
M:Y=:3^R3H6G6K211Z^^BZ#<20DJR6]S)#%+@@]"A9?\ @1H ^B?#OCG0?&'G
M?V)JUGJIA ,@M9E<@'.#P>AP<'H:MP^(M-FURXT9+ZV?5H8$NI;%909DB=F5
M7*=0I96&?4&O _C$J^!OVC/@9?Z+";=KQ-4T&>SM555GM1;+,B$?[#PKMSTW
M&NEMOACJVFPV'C86EL_Q%:[^UW_ED#S+>4JLED).Z)&J;<\;H@>] 'JVO>(]
M-\+V)O-6O[?3K4,%\ZZD$:ECP%!/<^@K0L;R'4+6*YMW$D$JAT<=P:^/K'QQ
MK_BCQU\5/BM-X4G\8Z9X$U*;1="TD7B1"&.W4?;;B!"I#7#,67+$<( IY-?3
MOPW^(&D_%3P%H7BW096FTG6+5+NW9UVL%89VL,\,#P>>HH ZVBBB@ HHHH \
MTD_X^I_^NC?S-%= W@O=-(_VQAN8MCRP>OXT?\(2?^?UO^_8_P : ,*BM[_A
M"S_S^M_WP*/^$+/_ #^M_P!\"@#!H[BM[_A"S_S^M_WP*7_A"S_S^-_WP/\
M&@#"HK>_X0X_\_C?]\#_ !H_X0T]KQO^^!0!@TJ]:W?^$-;_ )_&_P"^/_KT
M?\(>5/\ Q^-_WP/\: ,2BMS_ (1%A_R^-_W['^-'_"(M_P _A_[]_P#UZ ,.
ME6MO_A$6_P"?QO\ OV/\:4>$3_S]M_W['^- &+16W_PB9_Y^V_[XH_X1,_\
M/VW_ 'Q0!B4JUM?\(BW_ #]M_P!\"@>%&[7;?]\#_&@#&HK:_P"$3;_G[/\
MWR*/^$3;_G[/_?(H Q:5:V?^$3;_ )^S_P!\BG#PJW_/VW_?(H QJ*VO^$6;
M_GZ;_O@?XT?\(JW_ #]'_O@4 8M*M;/_  BK?\_1_P"^!0/"Y7_EY8_\ '^-
M &116S_PC)_Y^#_WP*/^$9/_ #\'_O@4 8U*O2MC_A&3_P _!_[X%'_",GM<
MD?\  10!D45L?\(U_P!/1_[Y%'_"-?\ 3T?^^10!CTY:U?\ A&F_Y^C_ -\B
ME'AMA_R\G_OD4 95%:W_  C;?\_+?]\BC_A&V_Y^6_[Y% &33ZT_^$</_/RW
M_?-._P"$=/\ S\D_510!E45J_P#".M_S\?\ CM'_  CK?\_'_CM &53JT_\
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M^WA/\:;_ ,+&\*?]##I__@0G^-?! T.SY_T=<]>@I?[#L_\ GW3_ +Y%</\
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MJ3[.?[U'V<_WJ (Z5:?]G/\ >I5A/K0 U?O"K%1K%M8'.:DH **** "BBB@
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M)C>^T#+M@ 98Y)P.YKM** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU "T4FZC=0 M%)NHW4 +12;J,B@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M111749!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 (U,R*>WW345 #LBC(IM% #LBC(IM% #LBC(IM% #LBC(IM% #LBC(IM
M% #LBC(IM% #LBC(IM% #LBC(IM% #LBC(IM% #LBC(IM% #LBC(IM% #LBC
M(IM% #LBC(IM% #LBC(IM% #LBC(IM% #LBC(IM% #LBE5J92K]XT 2T444
M%%%% 'FOQ^^(VJ_"'X2^)O&.DZ$GB*XT>REO6LY+H6R[(U+,Q<@] .@&3BF>
M-/C!8_#OX,R>/=8MII8X["&Z^PVO,LTTBJ$ACS_$SL%&?4=JS?VOF'_#+OQ5
M'<^&K_\ ]$/7F'[5.FW%]^R/X?U"%G:TT2;0]9OA&I8M:02PR3' [! 6Z8PI
MH ],TGXM:UHOQ(\->"_&NF6&GZEXFTZ>]TZ;3;EIHEF@V&XM7+*OS*LBLK@?
M/A_E7;S:T_XO75U\2&TM](6/PC-,^F6>O";)DU&+F2$ICA""RJV>6B<8Z9X;
MXV*_BW]I#X$:5ILDCM;_ -K:U<7%LP(AM5MDA#$YXWM.NT_[)KUZ;X9Z&_@N
MU\*K!)%I=H(A;^7*PEC:-@Z2!\[MX90VXGDYSG)R <!\2OBMXV3QI+X8^&&A
M^&?%&J:?"LNJPZQKOV.6W\P QJL:QNS J"=Q  XZU[%IK7<EA:M?+''>^4IF
MC@8LBO@;@I.,C/0D5\Y?M,? ?P)XR\*>)?'6F16VD?$7189+BP\5:.VR^AO8
MD_=QNR'+DL%3RV'.0*]Y\ W6L7W@?P_<^(88[77I;"!]0@A.4CN"BF15/H&R
M* .DHHHH **** $R*6N8;QI"LCH;23*MC[P['%'_  FD/_/I)_WT* .GI,BN
M;'C.$?\ +I)_WT*7_A-(?^?23_OH4 ='D49%<Y_PFD/_ #Z2?]]"C_A-(?\
MGTD_,4 ='D49%<Y_PF,1_P"723_OH4?\)A'_ ,^DG_?0H Z/(I:YO_A,(_\
MGTD_[Z% \81'K:2?]]"@#I**YS_A+H?^?63_ +Z%'_"70_\ /K)_WT* .CHK
MG/\ A+H?^?63_OH4J^+HO^?63_OH4 =#D49%8'_"6Q?\^S_]]"C_ (2V+_GV
M?_OH4 ;^11D5@?\ "6Q?\^S_ /?0I%\71'_EU?\ [Z% '09%&16!_P )9'_S
M[/\ ]]"C_A+(_P#GV?\ [Z% &_D49%8'_"61_P#/L_\ WT*7_A+(_P#GU?\
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MBH/M0]*59]W:@"5ONFHJ/,W<8HH **** "BBB@ HHHH **** "BBB@ HHHH
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M^O\ Q9#Z***ZCG"BBB@!U%%% !2K24JT .HHHH *5:2E6@!U%%% !2K24JT
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MX^_W&/K^A^I\ ?[_ #_P_JC!HHHK^>#^@ HHHH **** "BBB@ HHHH ****
M"BBB@ JGJ'WK;_KO'_Z$*N53U#[UM_UWC_\ 0A7?@O\ >(>J.3$?P9>C/T0T
M[_D&VW_7-?Y59JMIW_(-MO\ KFO\JLU_8&&_@Q]$?Q_7_BR'T445TG.%%%%
M#J*** "E6DI5H =1110 4JTE*M #J*** "E6DI5H 6BBB@ I5I*5: '4444
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MDT9-)10 N31DTE% "Y-&3244 +DT9-)10 N31DTE% "Y-&3244 +DT9-)10
MN31DTE% "Y-&3244 +DT9-)10 N31DTE% "Y-&3244 +DT9-)10 N31DTE%
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MKM+7YKI)9V6,R;%.-[# ZXQS7TUX4\-VWA'PWI^CV<UU<6UI$(XY+ZZDN)F
M'5I')9C[DT ;M%%% !1110!YG+O^U3_NW^^W\)]32?O/^>;_ /?)KTS:*-HH
M \V^?_GD_P#WR:7Y_P#GE)_WR:])HH \V^?_ )Y2?]\FDR_'[I_^^37I5)TH
M \Y^?_GF_P#WS1\__/-_^^:]'HH \X^?_GF__?-"E^\;?]\FO1Z* /.]Q_N/
M_P!\FC<?[C_]\FO1** /.]Q_N/\ ]\FA6;_GF_\ WS7HE% 'GN3_ ''_ .^3
M1D_W'_[Y->@[11M% 'GV3_<?_ODTJEO^>;?]\UZ!M%+0!Y_EO^>3?D:,M_SR
M;\C7H%% 'G^6_P">3?D:52W_ #S;\C7?T4 <%N;^XWY&O!OV\P6_9#^()*$8
MAA/((_Y;)STKZT]:^;/^"A_'[(7Q Q_SZQ#_ ,C1UZ>5?[Y2_P 2_,SJ? S\
M,]+T^*:W#.NXD]<U=_LFW_YY_K3-#'^B_C_6M&OZC22C8^,K5)QFTF4_[+M_
M^>7ZT?V7;_\ /(?G5RBC0Y_:S[E/^R[?_GD/SI/[+M_^>7ZFKM%&@_:S[E'^
MR;?_ )Y_K4]C"=+NA<6R1B4# \Q XY]B.M3T5$X1J1<9+0I5JBZEB^UK4-4M
MV@NWAEC9=O\ J$! !R #C^58ZZ3 /X/YU?VTM94:-.BK05EY!+$5);LH_P!D
MP?W/UH_LF#^Y^M7J*WNB?:S[E+^RX/\ GG^II/[)M_\ GG^M7J*/=#VL^Y1_
MLFW_ .>?ZTR32;<+G9^M:-1R9Q^%"2;L5&K.^Y]M?\$?5V_$KXA +G;I4/0?
M]-6_PK]0N=Q^1OR-?F/_ ,$;?^2H?$3_ +!MO_Z-:OUD6OYXXJ?_  J5%Z?D
M?9X;^$CD^?[K?E1S_=;\JZZBOD3I.14M_=;\C2_-_<;\O_K5UM% ')?-_<;\
MO_K4?-_<;\O_ *U=;10!RJ[O[C?D:7YO[K?D:ZFB@#EOF_NM^1H^;^ZWY&NI
MHH YF)6++\K#GT-?#/Q3_P"2N>*_^OH?^@BOT&E_U9K\^?BI_P E@\6C_IY7
M_P! 6ORWCW_<HKS_ $/U+P__ -_G_A_5&'124M?SR?T"%%%% !1110 4444
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M@!:*3=1NH 6BDW4;J %HI-U&Z@!:*3=1NH 6BDW4;J %HI-U&Z@!:*3=1NH
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M44 %1OTJ2HWZ4UNBH_$?<_\ P1K_ .2H_$7_ +!EO_Z-:OUB6OR=_P""-?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4MK_K#]*BJ6U_UA^E %NBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M &_Q5\V_\%$O^30?B#_UZQ?^CHZ^DOXJ^;?^"B7_ ":#\0?^O6+_ -'1UZ.5
M_P"^4?\ $OS,JGPL_#S0_P#CUK1K.T/_ (]:T:_J3[*/A\1_$84444'.%%%%
M !1110 4444 %%%% !1110 5&_2I*C?I36Z*C\1]S_\ !&O_ )*C\1?^P9;_
M /HUJ_6):_)W_@C7_P E1^(O_8,M_P#T:U?K$M?SMQ5_R-:OR_(^YPW\)"T4
M45\D=04444 %%%% !1110 4444 0S_ZL_2OS[^*G_)7O%G_7R/\ T!:_02?_
M %9^E?GW\5/^2O>+/^OD?^@+7Y=QY_N4?4_4O#__ '^?^']48-%%%?SP?T"%
M%%% !1110 4444 %%%% !1110 4444 %4-0^_;?]=X__ $,5=_AJEJ'W[;_K
MO'_Z&*[\%_O$/5'+7_@R]&?I%X>_Y!-I_P!<U_D*TQ_#69X>_P"03:?]<U_D
M*TQ_#7]?X?\ @Q]#^.Z_\67J.HHHKJ,@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ([C_4O]*HJW J[=?ZA_I5!?NB@!^ZC
M=3:* ';J-U-HH =NHW4VB@!VZC=3:* ';J-U-HH =NHW4VB@!VZC=3:* ';J
M-U-HH =NHW4VB@!VZC=3:* ';J-U-HH =NHW4VB@!VZC=3:* ';J-U-HH =N
MHW4VB@!VZC=3:* ';JEM6_>M]*@J:T_US_2@"[1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #>]?-O_  42_P"30?B#_P!>L7_HZ.OI+O7S;_P42_Y-!^(/
M_7K%_P"CHZ]'*_\ ?*/^)?F9S^%GX>:'_P >M:-9VA_\>M:-?U)]E'PV(_B,
M****#G"BBB@ HHHH **** "BBB@ HHHH *C?I4E1OTIK=%1^(^Y_^"-?_)4?
MB+_V#+?_ -&M7ZQ+7Y._\$:_^2H_$7_L&6__ *-:OUB6OYVXJ_Y&M7Y?D?<X
M;^$A:***^2.H**** "BBB@ HHHH **** (9O]6?I7Y]_%3_DKWBS_KY'_H"U
M^@DW^K/TK\^_BI_R5[Q9_P!?(_\ 0%K\MX]_W&'J?J7A_P#[_/\ P_JC!HHH
MK^>3^@0HHHH **** "BBB@ HHHH **** "BBB@!&JCJ'W[;_ *[Q_P#H8J_5
M#4/OVW_7>/\ ]#%=^"_WB'JCEK_P9>C/TB\/?\@FT_ZYK_(5IC^&LSP]_P @
MFT_ZYK_(5IC^&OZ_P_\ !CZ'\=U_XLO4=111749!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 177^H?Z507[HJ_=?ZA_I5!
M6'% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %36G^N?Z5#4UG_ *Q_I0!=HHHH ***
M* "BN$^,?Q,MO@W\.==\87FFW^KV>D6KW4UKIJ!I2J@DGD@ <<DGCK4VO?$[
M1?"?PUD\<ZY<'3=%AL$OYF<;F1652% '5B6  '4D4 =K17FFB?%V.Z\::9X5
MUW2;CP[K>K6,NI:;!<R*XN88B@E7(^[(GF1EDYX<<FK%C\7-/OOB/<>%$M;E
M416CBU4[?LLUT@#2VRG.?,1"K$$?WO[IH ]#HKP[XH?M&3?"G4&NM2\$:Y<>
M#+>XBMK[Q1"T/D6K.X3>8MWF,BL1E@._?%>UQL)(T93D, 0?PH FHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 8WWA7S=_P %$O\ DT'X@?\ 7K'_ .CHZ^D6^\*^;_\ @HC_ ,F@_$#_ *]8
MO_1R5Z66_P"^4?\ $OS,ZGP,_#O0_P#CUK1K.T/_ (]:T:_J/[*/AL1_$844
M44'.%%%% !1110 4444 %%%% !1110 5&_2I*C?I36Z*C\1]S_\ !&O_ )*C
M\1?^P9;_ /HUJ_6):_)W_@C7_P E1^(O_8,M_P#T:U?K$M?SMQ5_R-:OR_(^
MYPW\)"T445\D=04444 %%%% !1110 4444 12_ZLU^?/Q4_Y*]XM_P"O@?\
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M)DU35I[[5]=U73]4N?M4^CZAJ#360;.[:L9'"9Q\N<<#BO2(U\M0HP !V'%
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M:_+N/5;!1]?T/U/P_P#]_G_A_5&!2TE+7\\'] !1110 4444 %%%% !1110
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MJ*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZK%C_KG^E5:L:?\
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MKXI?\E<\5?\ 7S_[*M?<L7WEKX:^*7_)7/%7_7S_ .RK7Y=Q]_N,?7]#]3X
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MM_UWC_\ 0A5RJ>H?>MO^N\?_ *$*[\%_O$/5')B/X,O1GZ(:=_R#;;_KFO\
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M?_GWB_[X'^%']GV__/O%_P!\#_"K5% %?[#;_P#/O'_WP*;_ &?!_P \(_\
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M#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!O>OFW_ (*)?\F@_$'_ *]8
MO_1T=?27>OFW_@HE_P F@_$'_KUB_P#1T=>CE?\ OE'_ !+\S.?PL_#S0_\
MCUK1K.T/_CUK1K^I/LH^&Q'\1A1110<X4444 %%%% !1110 4444 %%%% !4
M;]*DJ-^E-;HJ/Q'W/_P1K_Y*C\1?^P9;_P#HUJ_6):_)W_@C7_R5'XB_]@RW
M_P#1K5^L2U_.W%7_ "-:OR_(^YPW\)"T445\D=04444 %%%% !1110 4444
M0S_ZL_2OS[^*G_)7O%G_ %\C_P! 6OT$G_U9^E?GW\5/^2O>+/\ KY'_ * M
M?EW'G^Y1]3]2\/\ _?Y_X?U1@T445_/!_0(4444 %%%% !1110 4444 %%%%
M !1110 50U#[]M_UWC_]#%7ZH:A]^V_Z[Q_^ABN_!?[Q#U1RU_X,O1GZ1>'O
M^03:?]<U_D*TQ_#69X>_Y!-I_P!<U_D*TQ_#7]?X?^#'T/X[K_Q9>HZBBBNH
MR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0HHHH **** "BBB@ HHHH **** "BBB@ JAJ'W[;_KO'_P"ABK]4-0^_;?\
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MU-HH =NHW4VB@!VZC=3:* %+>U7=&/[^7C'']:HU=T?_ %TOT'\Z -FBBB@
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M )[I^= %BBJ_]H6W_/=/SH_M"V_Y[I^= %BBJ_\ :%M_SW3\Z/M]O_SV3\Z
M+%%5_M]O_P ]D_.C[?;_ //9/SH ?)_JS]*_/GXJ?\E@\6_]?"_^@+7W^UY
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M0, &6)E8C'8UO>"?ASX<^',,J:!IQMY9L":[N)Y+FYEP<@-+(Q8@'L6KI:*
M..\2?"'PCXL\60>*+_23'XCA@-K_ &G93R6T[PYSY;LC#>H.>&Z9JU=?#'PE
M>>!9?!<N@VO_  BTJ-%+ID>Y(I%8DL&VD$[B3G)YR373T4 <+=? WP!??#M/
M =QX8MY?!T84+H[2R>0%5@RKC=T! X)["F>+O@+\/O'G@73O!NN>&K>_\-Z;
M(DME9O))_HS(/E*-NW# XX/K7>T4 >?ZA^S_ /#G5=2\/ZE=>%+62^\/QB/2
MIQ)*K6:CM'A^,G\\FNH\7>#]#\?>&;OP[XDTJVUG1+M0LUG=IYB'!!4_4$ A
M@<C K8HH Y3PG\+O#'@N]MKW3-/<W]K;_9+>\O)Y+F:&$D?NT:1B54X'0\X'
MTJ*X^#_@NZ^($7CF70(G\7QP_9TU<RR><L>2?+'SXV\GC'<UV%% !D]Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J]HO\ Q\3?0?SJC5W0_P#C
MXF^@_G0!MT444 %%%% !1110 4444 %%%% !1110 4444 >:S?\ 'U<?]=&_
MG24LW_'U<?\ 71OYTE #Z*** "BBB@!U%%% !2K24JT .HHHH *5:2E6@!U%
M%% !2K24JT +1110 4JTE*M #J\&_;R_Y-#\?_\ 7"'_ -')7O->#?MY?\FB
M>/\ _KA#_P"CDKU<I_WVE_B7YF57X&?B[HO_ !ZCZUH5GZ+_ ,>H^M:%?U#T
M1\/6_B,****1SA1110 4444 %%%% !1110 4444 %-D^Z?I3J;)]T_2G'<<=
MT?;/_!(#_DIWQ"_[!<'_ *-:OU!_B-?E]_P2 _Y*=\0O^P7!_P"C6K]0?XC7
M\]<6_P#(SJ?+\C[G"_PT%%%%?''6.6EI%I: "BBB@!RTM(M+0 4444 /B^\M
M?#7Q2_Y*YXJ_Z^?_ &5:^Y8OO+7PU\4O^2N>*O\ KY_]E6OR[C[_ '&/K^A^
MI\ ?[_/_  _JC!HHHK^>#^@ HHHH **** "BBB@ HHHH **** "BBB@ JGJ'
MWK;_ *[Q_P#H0JY5/4/O6W_7>/\ ]"%=^"_WB'JCDQ'\&7HS]$-._P"0;;?]
M<U_E5FJVG?\ (-MO^N:_RJS7]@8;^#'T1_']?^+(?11172<X4444 .HHHH *
M5:2E6@!U%%% !2K24JT .HHHH *5:2E6@!:*** "E6DI5H =1110 4JTE*M
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MV[$I"L\"P6T;,.C2;Y3MZ@1DU] S>&=+DT%-#>PMSI"0K;K9B,")8UP%4+T
M7 QCI@4 >)R?$WQ?X\A^*NK>%;B'3X/!=Q-IVF6MS"'CU*Z@A669I6SN$99O
M+ 7!!0MSTKU;X3_$2R^+'PU\,^,=.C>&SUJPAO4AD(+1[T!*$CC*DD'Z5\]>
M$]<3X*^&_C[H6M!XK\:QJ&LZ7;_>EU**]C#Q>2O\;&4M%M'.1S7K_P"RW\.[
MWX4_L\^ ?"NI1^5J6G:3"EU$6#;)BNYUR.N&8C\* /6:*** "BBB@#S.9A]J
MFY_C;^9I&8>M=FWA/3WD9C$<L<GYS1_PB6G?\\6_[[- '(;AZT;AZUV/_"*:
M=_SR;_OLTG_")Z=_SR;_ +[- ''[AZT;AZUV'_")Z=_SR;_OLT?\(IIP_P"6
M3?\ ?9H Y'</6C</6NN_X1;3_P#GDW_?9_QH_P"$6T__ )Y-_P!]G_&@#D=P
M]:56&>M=;_PBVG_\\F_[[/\ C2_\(KIX_P"63?\ ?9H Y/</6C</6NL_X1BQ
M_P">3?\ ?9_QI?\ A%[#_GDW_?9H Y+</6E4BNL_X1;3_P#GFW_?9H_X1>P'
M_+)O^^S_ (T <KD49%=7_P (S8?\\C_WT?\ &C_A&;#_ )Y'_OH_XT <ID4J
ML/6NI_X1FP_YY'_OH_XT#PS8C_EF?^^C0!R^X>M&X>M=7_PC=E_SS/\ WT:/
M^$;LO^>9_P"^C0!RFX>M.!&:Z?\ X1NQ_P">1_[Z-+_PC=@/^6;?]]&@#F-P
M]:\%_;VD'_#(/Q !.,PP_P#HY*^H?^$=LO\ GD?^^C7+_$KX/>&?BQX*U+PI
MXBLGNM%U *)X4F:,MM8,/F!SU45V8.O'#XBG6EM%ID3CS1:1_.WINH10VX5F
MV\YJX=7MN[?SK]GU_P""7OP!7C_A&;PCWU*<G_T*G?\ #K_X _\ 0KWG_@RF
M_P#BJ_8UQQ@NM.7X'BRR_FE<_%[^UK?^\?UI/[6M_P"^:_:+_AU_\ /^A8O/
M_!C-_P#%4?\ #K_]G_\ Z%:[_P#!C-_\53_UZP7_ #[E^!']E^9^+O\ :UO_
M 'S1_:UO_?-?M%_PZ_\ V?\ _H5KO_P8S?\ Q5'_  Z__9__ .A6N_\ P8S?
M_%4_]>L%_P ^Y?@']EKN?B[_ &M;_P!\T?VM;_WS7[1?\.O_ -G_ /Z%:[_\
M&,W_ ,51_P .O_V?_P#H5KO_ ,&,W_Q5'^O6"_Y]R_ /[+7<_%W^UK?^^:/[
M6M_[YK]HO^'7_P"S_P#]"M=_^#&;_P"*H_X=?_L__P#0K7?_ (,9O_BJ/]>L
M%_S[E^ ?V6NY^+O]K6_]\T?VM;_WS7[1?\.O_P!G_P#Z%:[_ /!C-_\ %4?\
M.O\ ]G__ *%:[_\ !C-_\51_KU@O^?<OP#^RUW/Q=_M:W_OFC^UK?^^:_:+_
M (=?_L__ /0K7?\ X,9O_BJ/^'7W[/\ _P!"M=_^#&;_ .*H_P!>L%_S[E^
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M[0G_ #T7\Z/M"?\ /1?SKZ^_X8]^'/\ T"YO_ R7_P"*H_X8]^'/_0+F_P#
MR7_XJI_U"Q7\R%_K_EO\DON7^9\@_:$_YZ+^='VA/^>B_G7U]_PQ[\.?^@7-
M_P"!DO\ \51_PQ[\.?\ H%S?^!DO_P 51_J%BOYD'^O^6_R2^Y?YGR#]H3_G
MHOYT?:$_YZ+^=?7W_#'OPY_Z!<W_ (&2_P#Q5'_#'OPY_P"@7-_X&2__ !5'
M^H6*_F0?Z_Y;_)+[E_F?(/VA/^>B_G1]H3_GHOYU]??\,>_#G_H%S?\ @9+_
M /%4?\,>_#G_ *!<W_@9+_\ %4?ZA8K^9!_K_EO\DON7^9\@_:$_YZ+^='VA
M/^>B_G7U]_PQ[\.?^@7-_P"!DO\ \51_PQ[\.?\ H%S?^!DO_P 51_J%BOYD
M'^O^6_R2^Y?YGR#]H3_GHOYT?:$_YZ+^=?7W_#'OPY_Z!<W_ (&2_P#Q5'_#
M'OPY_P"@7-_X&2__ !5'^H6*_F0?Z_Y;_)+[E_F?(/VA?[Z_G5+4+A-T&9%_
MU\8Z_P"V*^R/^&/?AUN_Y!DVW_K[E_\ BJ8W['/PW:2)VTF9_+8.N;R7[PY'
M\7K75A^!\52J1FY+0RJ\>9=.FX*$M5V/4=-_Y!EL"<?NU_E5K</6K5OIL<,:
M1A<(@"J 3T%3_88?[I_,U^X48N$(Q?1'X+6DI5')=2CN'K1N'K6A]AB_NG\Z
M/L,7]T_G6QB9^X>M&X>M:'V&+^Z?SH^PQ?W?U- %+(HR*O?88O[OZT?88O[O
MZT 4<BE6KOV&+^[^M'V.+^[^M %/(HR*N?8X_3]:/L<?I^M %/(IRU:^QQ^G
MZTOV2/\ N_K0!6HJS]DC_N_K1]DC_N_K0!6I5JQ]DC_N_K2BU0=J *]%6/LR
M>E'V9/2@"O2K4_V9/2C[.M $5%3^2M'DK0!!2K4WDK1Y*T 4]1_X\)^?X:P%
M/'6NHFM5FA>-ONL,'%4AX?MQQN?\Z ,6BMO^P+?^\_YT?V!;_P!Y_P Z ,2B
MMO\ L"W_ +S_ )T?V!;_ -Y_SH Q**V_[ M_[S_G1_8%O_>?\Z ,2BMO^P+?
M^\_YT?V!;_WG_.@#$HK;_L"W_O/^=']@6_\ >?\ .@#$HK;_ + M_P"\_P"=
M']@6_P#>?\Z ,2BMO^P+?^\_YT?V!;_WG_.@#$HK;_L"W_O/^=']@6_]Y_SH
M Q**V_[ M_[S_G1_8%O_ 'G_ #H Q**V_P"P+?\ O/\ G1_8%O\ WG_.@#$H
MK;_L"W_O/^=']@6_]Y_SH Q**V_[ M_[S_G1_8%O_>?\Z ,2BMO^P+?^\_YT
M?V!;_P!Y_P Z ,2BMO\ L"W_ +S_ )T?V!;_ -Y_SH Q**V_[ M_[S_G1_8%
MO_>?\Z ,2BMO^P+?^\_YT?V!;_WG_.@#$W#UK0T'_CXF_P!T5;_L&W_O2?F/
M\*FL]-CLY&:,L2W!W'- %VBBB@ HHHH JW%O%<Q[9HUE7 ;:PR,^M+:V\5O
MB11K%'V1!@#Z"BB@!EOI]O8[EMX8X S[V$:!=S'JQP.I]:M-110!5?3[>XF@
MEEB26:'YHY&4%E)&"0<<9]JMK110 M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_011.jpg
<TEXT>
begin 644 form10-k_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1Z"%L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6D) I-@%%&:3
M(X]Z '"BD%+3 **** "BBB@ HHHH **"<#-&>*5@"BBBF 4444 %%%% !111
M0 4444 %%%% !1110 4E''K12T *6DI:+( HHHI@%%%% !1110 4444K %%)
MD9Q2T %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBC.** "BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#10:
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M/-[H27,4,Q^9D. V.E7M8\(?$6XLI/[2%Y/ @R59@0H'>OHWP]I:Z/H5G9*
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M13K7@>^B5"944.GM@Y/\J[2H+VW%U930'_EHA7\Q7F4I<DU,MZH^2_!WBEM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ P*3 ]*6B@!,"EHHHL 4444 %&!11
M0 8HHHH **** #%%%% !1110 8I*7-(30 48HS1F@ HHS1F@ HHS1F@ HHS1
MF@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS10 4N
M*04M !@48HHH **** "BBB@ P*,444 %&!1118 HHHH **** #%&*** #%%%
M% !1110 4444 %&!110 48HHH *,"BB@ P*,444 %%%% !1110 4444 &!11
M10 48HHH ,48HHH **** "C%%% !@48%%% "8%+110 4444 %%%% !1110 8
MHHHHL 8%%%% !1110 8HQ110 8I,"EHH ,48HHH ,"BBB@ HHHH ,48HHH *
M*** $P/2EHHH ,48HHH ,4444 &*,444 %%%% !@4444 &!1@4446 ,4444
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M9I7 **3-&:+@+11FBF 44F:,T!<6BDS1F@!:*3-&: %HI,TM !1110 4444
M%%&:,T %%&:* "BC-% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 A.#29%>:>.=>U33_$;06E[-#%Y2G:AXSS7-_P#"5Z[_ -!2X_[Z
MJ'*QT1P[DKGM^11FO#F\5:_VU6Y_[ZH3Q;KN[!U2X_[ZHYQ_5I'N.:,UXM_P
MDVNLF1JEQ_WU5*;Q5X@7/_$VN1_P*E[5#6#D>[9%%?/[^+_$(7_D+W7_ 'U5
M9_&GB0=-8NO^^JGVR-8X";ZGT317SI_PFGB7_H,W7_?5'_":>)?^@S=_]]4>
MV1?]G5.Y]%YHS7SN/&7B7'_(9NO^^J#XR\2_]!FZ_P"^J/;(/[.J?S+\3Z(S
M1FOG8>-/$N?^0Q=?]]5*OC+Q'C/]KW7_ 'U1[9%?V;4_F7XGT)FC-?/1\9^)
M/^@Q=?\ ?51GQQXB4\ZQ=?\ ?5+VR#^S*G\R_$^B<T9%?.O_  GVO_\ 07N?
M^^J/^$]U_P#Z#%S_ -]4>V0O[-J?S+\3Z*R*,BOG8>/M>')U>Y/_  *I%\?Z
MV>NJW'_?5'MD']FU/YE^)]"EAWHR#7S\/'NLG&=5N/\ OJNJ\*>)]1U!;DS7
M\LFTKC)Z52J)F<\#..YZMFDS7''5KO'_ !\O^=(-5O/^?E_SJN8YUAV=EFC-
M<<-5N_\ GY?\ZE35+D];A_SIW!T)'69HS7,KJ%R?^6[_ )T];^XZ><WYT[D^
MQ:.CS1FN?%Y<?\]F_.GB[G_YZM1<3@;N:,UB&ZG_ .>K?G3?M5Q_SU;\Z5QJ
MDWJ;F:,US[75UG_7/^=)]LN0?]<_YT7#V+.AH%8*W=QWE;\ZD^V3#_EHU%Q>
MQ9MT9K%%U,?^6K4_[3+_ ,]&HN'LVC7S1FLC[3-_ST:D%U-_ST:G<7(;&:,U
ME?:9?^>AH-Q+C_6&BX_9MFKFC-9!N)C_ ,M6H$\_>5J+C]DS7S1FLO[1+_ST
M:D^T2_\ /1J5P]DS5S1FLDW$O_/1J3[3-_ST:BXG29KYHS61]IF_YZ-3#<3_
M //5J+@J+-DF@GBL4W-Q_P ]6J"[O+E+29EF8$(2#GI2<TBE0;9O@TX-7GO]
MKZB1Q>2_G3#K&IC_ )?9?SJ?:HU^JR/2,T9%>;KK6J=[V7\Z>-:U(G'VR7\Z
M7M43]6D>BY%&1ZUY]_;&HX_X^Y?SH_MK4/\ G[E_.G[5#^K2/0<CUHR/6O.7
MUO4>U[+^=1/K6J8XOIA^-'M4'U61Z62#28%>6G7M64\W\WYTO_"1:GT^W3?G
M2]LD4L'-[,]1XHP*\L.OZLW U"8'ZTR/7-9#_-J,Y'^]355%/!5%U/5\T9KS
M,:[JA_Y?YOSI3KNJ#_E^F_.JYC#ZO(],HKRQM=U@'(U"?'UJ/_A)M43[U_-^
M='.+V+1ZO17E47B352V3?S$?6IW\0ZF%XOI?SI>T0O9,]-HS7EW]O:LRG%_-
M^=9-WXCUZ,G&J7 '^]1[1%QPTI;'L^12;E]:\!N/&'B%<XU>Y'_ JSG\;>)5
M/_(9NO\ OJI]LC>. FSZ0XHXKYE?QYXH'36[O_ONJ[>/O%0'&NWG_?=/VR-/
M[-J=SZAXHR!WKY7?X@^+1TU^\_[[J)OB%XNQ_P A^]_[[I>V1+R^HNI]79'K
M1FOE*#Q]XODD _X2"]Q_OUUVE^+/$DB RZQ=-]6I.NC%X*:/?\T9%>0P>)-9
M8#.HSG_@56AX@U;'_'_-^=0\2B/J\D>J9%&17E)\0:O_ -!";\Z:/$.K_P#0
M0F_.E]90_JTCUC(HR*\J'B'5O^?^;\Z>/$&JX_X_YOSI?64'U:1ZED49%>7K
MKVJG_E^F_.I!KNJ?\_TWYT?6D'U:1Z;D49KS0:[J?_/[+^=2KK>I?\_LOYT?
M6HB^KR/1LTM</I.JW\VJVT<EU(R,X!!/6NXK>E45171E*#B[,****U("BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /'OB.2/%C?]<$_K7)AAZU
MU7Q);'BUA_TP3^M<CFN:6[/5I? B?--V'.<4BM4F<BD:$T+G&"*;/&K#/>A3
M2GFC<%)HSYH5"U09,UK3+FJ?DG-0T;0J=RJ(N.E-*XJX8BHJLXP34G7!I]"/
MFE_&FLV*B:<+UI&R'EL&@W  Y.*KR3"J<UQS0;I%YKH#O566?=WJD\Q/2HO-
M(ZT%61.TI!ZU&9F]:A+YINZG8=D3B=NYI?./K58M29IV%H6O.;KNKO?AW.S1
MWN6Z%?ZUYP2<5W_PX/[F_P _WD_K3BCFQ#7*>A>>?6G+-D]:JDTHY[9]LULC
MQ7W+1E()&>E/6; W$\>M<;%"M[XBN8YWEV+V5R/2I8Y7TW5#9L6EMI5)"ESD
M&M>4RYSL;;4(IP?*E5]IP<'H:T(Y@1UK@;+5(;+3YGA@P1*006//-:L&J7TM
MO(&ME#F/<N'X(HY27*YV&<#)-/5CFN"\(:C?!KD20AH3)\SM*6*\=A6O=^([
MVT5[@Z>GV(G!=I,-]<8IV,I,Z1[ZWCN$MWF19GY5">35GD*2>@[UQ-_<)<>)
MM*E1CAHV/3V%:WBZ8IX=G(9U/R_,I/K3Y$R.=I'1A#G!'.,XJ-D!&1TKS286
M]OH^GW5G>3MJ,A&X+,SD_5<\5V%_XAN+5[2UM[9;B^G0$QL=H'U/:ER JC9L
M'Y>M .\9'-8EMXA#PWB7$ BNK="Q16W#IGK5%?$]])IPU"+3(S; [7<RX(^@
MQ1RE<QU2OSBI V1UKGK_ ,0PVVF6UQ''YLES]Q"<#/UJ*'Q#>6]_;VNHV"0+
M/RI63=^M'*PYCI]U&:Y[3O$7VZ]NX)XDB:#IM?)(QUJE!XL1[*ZNY[<HL<AC
MCVL3O.2/PHLQ<R.O5LGBGE@!R:X__A)]0MXX+B]TR-+68X5DERP]R,<5%JNH
MSZKKUMI4$S); ;I,#!(^M/E%S':#K[4XD 9)P*Y^#2XM#+W%M+<21A23&S%R
M3^-5)?$U_87EM'?6*16]P<(ZOO.2>,C%'*'.=7FH&O;9;I;9IT$[C*QD\D5P
M>H7NJIXWA\J%9,K\L?G84C'6I=5N;B+QM8NEL&N#$-J;N W/&?2CD)]HSNWD
M1(S(S (.I-9R^(=(8L%U&W)7[PW]*I:7KT]]J-QIM]:QPW"?PHV\$5D-II;^
MU?\ 0L,TB["$[8.:.0?.['6MJ-FBQ,UQ&%E^X2?O?2K1KSX6ETT=M'+%+^YE
M0K\IZ$BN_P U+C8N,FP-5KX?Z%/_ +AJQGFH+P?Z'/\ [AJ&C:#]XY3) II;
M-3E,J*KNN#6#.]/04<TH!!SBB+'>IA@FBP-"J"136XXJ< !:@E;!ID-D$BFJ
MQ8]*MLP*U3+#=1<$-<9%4WRK9J^1FJ\J9'%3):E)=2-)@#DFK E5A6=)&0<Y
MJ2)RHIIA+7H::,O>E/)X%5D<-WJ=)5!Q5F$TT2[05YK*O(B&R*U7QLW5GW+A
ME-6HHY)R9#"^$VYYJ;?N'6LZ+<9#5N-3GDU7(C'G+*2;5YK/OW!4XJS+TXK.
MN"<'-0T=-*=C$N1DG%95SQ6Q=<9Q6-<=ZQDCUZ4W8SI&YYJ!CQ4LQYJNQI6.
MG1D3U7D)J9S43$9YIV,)-+8T-*A+R@XKN-/ 5 .E<QHB X.*ZFS0F05E(Y*D
MF;]LGR FK-1PH1$*&;!Q6+.:^HK8J,T,U-+"IL:H<#4H-5@]2*W(I6'<LK4@
MJ!6J0-4V%<F%2(:A5JD5J5B&:^B?\AFT_P"N@KT2O.-#;_B=6G_705Z/7HX3
MX6<5?XD%%%%=ISA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCE(<QXQ2$^E-S3<U=B',?FDS[TS-+FG8CF'9H--S0318.8=FO0OAHW[G4/\
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MS3 **3-&: %HHS1F@ HHS29H 6BBB@ HHHH **** "BDS2YH **,T4 %%%%
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M9>ZSEK;A111728A1110 4AI:0T %%)FDR:GF[ .I*8S[>XQ[TNXD=<?2AR:
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MI9:+&S9564_-5QG4KP:K/'DYK/J58HSE2>14"@=A5N=5)J,(,5HD0RLSA>M
MD0T3154.5--Q'&5BT\*XR.:H3C#8V_I5B.5QQ3WC#C)K"4;G13J69AW5NKH<
M"N>N[([CP:[*2)1FLZY@5@:A0.V-9'$36^UNE4)8B">*ZJZM1S@5D7,'!XIM
M%NHFBIIT[0S#GO7I6C77F6R\YXKRQ\Q-Q77>'-2X$9-92B82=V=7<'.ZL*=L
M2FMQOF3KU%8-\I0L16%@1+%)D8S4<J\DU4MYLL :NR-E#BM$QM$4(W/BM!8
M!65'+Y<F:T8;O)'-6M2&QS+L:K$,A&*@F=6Y!IJ2_+BHD@3.M\)ON\3Z=S_R
MV%>W5X/X.?/BK2Q_TW%>\5K0V9C6>H4445T&(4444 %!HI#0 50U:YEMM-N)
M83AT0L"15^LS7?\ D#7?_7,TX?$@>AX=H?BWXF^*KB]71[FS:."4J1(B CKZ
MUL>'OB3XCTWQ:F@>+(XS*V &C4 <].@KB? 'CIO!USJN-)N+Y99R6,/\/7V-
M;WAFUNOB7\0/^$@N%2VMH"/W98%_EZ?RKUZE**YKQT2W\R>8][EO+6TCWW%Q
M'"IYW2,%'ZU%;:UI=X^RUU&TF?IMCF5C^AKSSXAZ/I-S?17>O:Y):Z:!M-M&
MQ#$COQ_A7DFJ7'A[1_$>GS>"M1N&BW .KE@<_CBN6CA8U%=-[/IH',?4UQ/#
M;1-)/*D2 9+.V /QK@/B7KMI-X'O'TW4X7E1E!-O,"1^1KD/BUK5[=2Z-H$,
MSQK>(I=@V,MTQ].:H>,OAA:>'?!0U#3KR9)2J&X5G)5R1Z?G54L/!).;LWY"
MYCIO#BZAJGP<98KXQW+L0)IIMN.G5B>*W_A1I^HZ9X:EBU34(KN4RDAX[@3
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MZTEIJ5CJ )L[R"X ZF*0-C\J\ :*?XC?%"[TR_N)DTZ!BOE(Y XS_A7I.@>
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M4-EJE$]-'Q,L/^?"Y_[Z6E_X698_\^%S_P!]+7F0I<U#9I[*)Z;_ ,++L?\
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M!UIZR -D]*Q(;\DX-:$4HDQR*R:"YVG@60'QKI '_/P*^D:^9O 9QXYT8?\
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M*3(HR* %HI,BC(H 6BDR*,B@!:*,T9H **,T9H **,T9H **,T9H **,T9H
M**,T9H **,T9H **,T9H **,T9H **,TF: %HINX9I=PH 6BDS1F@!:*3-(7
MP<8- #J*:K@Y[4N1ZT +129'K1D>M "T4F1ZT9'K0 M%)D>M&1ZT +129'K1
MD>M "T4F1ZT9'K0 M%)D>M&1ZT +129'K1D>M "T4F1ZT9% "T4F11D4!<6B
MDR*,B@!:*3(HR* %HI,BC(H 6BDR*,B@!:*3(HR* %HI,BC(H 6BDR*,B@!:
M*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,C
MUHR/6@!:*3(]:,CUH 6BDR*3>*5T ZBFAL]J=3 **** "BDW"C<*!7%HI-PH
MS0%Q:*,T9H&%%&:,T %%&:,T %%&:,T %%&:3- "T4F:,T +129HS0 M%)FE
MS0 449HS0 449I,T +129%&10 M%)D49% "T4F11D4 +129I<T %%&:,T %%
M&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%(6 H
MW"@!:*3-&: %HHHH **** "BBB@#P?XL?\CLW_7O'_6N%)KM_BTV/&[#_IVC
M_K7!EJPEN>M2^!$G% X-1[J7=Q2-!['Y:S[@C!JZ&R"#6?=C!.*M&<C%N"4F
MR*CGNFFCV4MVYW55!YS6B.:8T_(*,TC_ #'FDIF3'9III>M&*5Q)"@4&E%(:
M+EI !2XH%*/>AFB0H%+0**DM!2BDI104+11104.%!H%!H+0"G"FBG"H+3"BE
MI.N:9289Q1UYIO>EI):DRLM11AN#TIC-AMJ<TY5:9MD8.:V+?P_)!!]HFZ=<
M&M.0PE7OH8I0J,D<U$2<^U7;VXC+LB#&#BL\$ELU21SRG8DQ76?#>\M+'QQ8
M37N/)R1STR>E<JH!ZT]"5;*D@CN#5J+,)3/M^.1)(P\3*T1YW UX#\58HO$'
MC>.UT]=SQ1%)2HZMG_"O/[7QIK\%LMI'J$HB VXW'./K7J'PJM[.3==WDF^8
M_,6D;))_&M%39SRD<GJ7@BXTO3EN)5P-N3FN/G";MN.E>T?$[789;;[- ZX'
MI7B%PWSL<UK&!',0NP4\5&MP5--.6[U&$.:U41W-*"5'7YZ#-&C$#I5 -LXI
M?O5HD2V6WE5AP<4D<NT]:K!":D6/:,FID*QIK/&1S2/=HO /%9S-@<56ED.>
M])1$T:_GKUQ4+D.VX506X;;C%.6X/2GRDV-:"0< UIP>5C.!FN?BW$C!K2A4
MA1\U#B1)M&L&3/2IX9=IXK)$SH<#FIQ?^6OS(<_2LG$46SHX+O! W5JPS!ES
MN%< =3=S\BFKUK?W0Y ;'TJ'%&R;.VW!><U:MKE<<FN6M]1DDPK9S6O;12/@
MC.*R<45=FVL@+=>*M*JD9+5G);RA>M*5G3H:S:"[+CL@.!4L(4U5A1F&6&35
MQ %[&I&M2<*HZ4CD"E5ACI39"#VJDQ21$7P %[FK^DVEO>K,94W%2*RS@N,=
MC6[X>0^7/C'+"JN0D6!I%B#_ *@?F:>-)LA_RP'YFKXBQ3B,47-%$S_[)L?^
M>(_,T?V99K_RQ'YFKI%)MHN/E*?]E63=81^9IIT6P)_U _,U>QBC)HN'*4&T
M+3CUMP?Q-1?\(_IN?^/?]36INHZT7#E,T:-8 _Z@?F:G32+#&! ,_4U9V\>]
M6K.V9W&:FY2B5[70+1_^6 Q]36O!H=G#@B%15V&)8TQBG22"-"31S%<ICZGI
M]FR8,8%8ATFQS_J1^=:UW<^:Y /%4<\T7)<2N^DV&.8!^9J!M#TYO^7;]35Y
MG]Z0/[TTR>4SSH&FG_EV'XL:A?P_IO\ S[+_ -]&M8N*B9A1<.4QY/#>EMUM
M%_[Z-4;CPCHKY!LUY_VC71G%5YN0:0TCDYO!FA=[(?\ ?1JH_@K0<'_B7J?J
MY_QKJ)1S4##-!I<\^\7>&=(T[0)KBTMA&ZE1U/<UYGC P:]D\>C/A2Y]V3^=
M>-L#FBPTSJ?AK_R4G0/^OM?ZU]?U\@?#4?\ %Q]!/_3VO]:^O@:3!BT444A!
M1110 4Q^W)_"GTUNU F>5_$'XIWG@WQ FG6^FP7*O )=TDA7J3Z?2N3'[0.J
M#_F!6G_?YO\ "LWX[<>-X/\ KT7^9KS$XKGG4:=D>YA\+3G33:/8/^&@=4S_
M ,@.U_[^M_A2_P##0>J?] *U_P"_K?X5XY2X-1[5FOU.GV/8O^&@]4_Z 5K_
M -_6_P */^&@]4_Z 5K_ -_6_P *\=P:,&CVC#ZG3_E/8O\ AH/5/^@%:_\
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M0F**4TE!+$HHHH *0TM(:8K"9I:**8!1110(**** "BBB@#T_P"!7_(]2_\
M7H_\Q7TI7S7\"O\ D>I?^O1_YBOI2NN'PG@8W^*':@4=J!5+8X^H5YG\<O\
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M7M3P%?AGXB8<VQ7\*<?AEX@7_E@3^%>\MSZU&00>GZTO:,I5&>"/\.O$*?\
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M-C94FIEE<\9KDDSIBBU.(QT-4VN?+/&:L+$"/G-5Y8L'@9%0@;!KHD<4PSR
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ML1\N%%%%,"KJ7_(,N_\ KB_\C7Q1+_KI/]XU]KZE_P @R[_ZXO\ R-?%$O\
MKI/]XUC5/4P'VAO\-(:7^&D-<R/8ZA2TE+3 ****!H!2T"EQ2'84 XV@\'DU
MTO@[PE-XJU$1@E;9#\[>U<T1\O'I7N/PGGMX?#C>6H\P-ASW[U$I61E44DM#
ML]%\,Z=H%HD-K A8=9"H)K6<$>A]Q57[>H_@I/MR?W<5S.I?0XN6;9.<U&^
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M**&""BC.>*4'L*0,****8TPH )HS2KR:!MV'!34@CS2KTJ=*#-S(!!SFI5C
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MN3\06WGV<L(&05/YUT@?*QKGDUEZG%D$>U:)'72T/%X<I,Z?W6(_6M_39/F
MK)U*'[+J\T6,<Y_.KM@VU@<TI(]NA*\3O]-8,F*MRIQ69H\FZMEUR*YVM3FF
M[2,>YC&UO6IM,DX"GJ#3IX\@U7L6V3D5<39^] ["R<$"M-#VK$L7^6MB$G
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M(^UEZ"EI%Z"EKM1\L%%%% %74O\ D&7?_7%_Y&OBB7_72?[QK[7U+_D&7?\
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M8K=:Z7Q#%YEJDPZKQ7-MT%835F?68.7/10VC%%**S.MH;24II*:)#%)BG4E
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M@KOZX'1O^0O:_P"^*[ZO1POPLY*ZLT%%%%=9@%%%% !1110!\V?'C_D>(/\
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M-&;]TOTK*9W8C5&M(,BL^Y7*&M)QQ5"X&0:Q6YST7J1:<?\ 1WSUS7161^4
M=:YJP.Z21#P ,UOV!XZULB,2M+FI/;17<0295/H2.]9B6$R-)$MU*K?PC=Q6
MQ$?DJEJ>\21O Y$HZXK7H>5"5W9E6T6>W81L!+(2<G&#C%<%J+^1KES;!=I#
M<X'/YUZ2!]IVEFVRK_%ZFO/_ !A;P1:W*LNIFWFDY*J?_K5M1L9MJ+=MQ5TR
MZN(@T%Y9S/\ \\Y4)_K6?>Z<(N-0T+([R6Q51_6J_P#PCQ6#[0-;$:>K-_\
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MU2/J<EW/UI#3CPWXTAKA>Y]A3=X"4E+24(84E+24R6(>E?4_P@_Y)OIWU?\
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M IQX(M1[_P!36^ .PX-<\OB/.YGS2! 53!J*?[AJ?J:KS_=-6AQW.>O.&?\
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M7%3W7_'W*?\ :-0>E<,OB/M*?PQ]!#UI>U(>M+VI#&TAI:0T$L!TKZF^$/\
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M%5!Q1FFZDF>S3PT(I/J)D;:7(Q33Q25.YT7:1/!&LC;W^Z*=<732 1QC"K4
M?"[>WI2 \UT>TBH<J1QNBY3O)D@F=>C9J]:W4@MI1(?W9&!6:P]*E>7=:*@X
MYITI<JU(Q,.9I,0W#L0 ?E[5-822?VI;C&X^:N*IGC ':M#01N\06 Z_OE_G
M41=IW*JQ7LFI'OVA,G]BJ@;YQR15:^/+'/6MN6QM[58S$-N8P2!ZXK"OCG/I
M7J3:DE8^(Y%%V.?O"3FLF3K6K>'DUE/UJ+L-">V^^*YOX@G][:?0_P JZ2V_
MU@KE_B V;RW'HH_E655Z'?@/XR9QQZ4AZ4K=:3M7#L?3VW 4AH-)3(O<*0=:
M**!'I_P*_P"1ZE_Z]'_F*^D:^;?@5_R/4O\ UZ/_ #%?25=E/X3YS'_QF-[T
M&CO3JUV.#JA!7F_QQ_Y)Z?\ K[B_K7I->:?'+_DGK?\ 7U%_6IGHC?#Z58GS
M4U HHKB/JA:6DHI%H6@44"D4.%(>M**3O4E"TM)2B@I"BE]/K0,9%&>2!0AR
M>A[WX?CMAX/T\2LRL5.#Z<U:74EMG$)WR+_> )JCIEHQT'3Q,2(Q'D*#UK2^
MT0P! \(P>!@5SR?O')%)7OJ7H;N&=?W;A2.H-1W#J4+!LJOI67?&V8%D22-L
M]5XH336CMP#<28/)&ZJ3'&'4PM9N9'M;HP#Y50Y->70@F9B3DEC7J.M!;?0;
M\+G/E-S7EUI\S@U5ST,/JSJ-*'2NIBXB%<SI2]*Z>/[@KEF]3MEJ(XJE<'"F
MKLG2J,_"MGTJ%N7 U-*YTZ(_[;?SKIK/[M<MITNRRBC5"6W$^U;D5W<0#+0$
MCVKIB>7BE>1L3H63>.B]JJQ7$M[D1_(B\$TAU%! QD<(6'W<<TMA,$MP$ D9
MCGCBK;]T\UJT;CGM)%$LK39 C8X_"OG_ %5S)JMTQ[RM_.OHB4L-.O'=-I6%
MSU]C7SE=N'O)GZ[G)HBO=.C!RNV044M(:#T[B'I24IZ4E42Q#1113)$-'>E%
M(>M!+[B$G;QZU]$?#U2O@*U)[@?RKYX(XQ7T7X$!3P%8@]U'\JZJ'Q'C9H[4
M[$E\>]<[>GK70WQY:N<O#UKM/F68TWWC38J67[U)%UHZB;MJ,\2G'A>Y_P!V
MO+O2O3?%3;?#CCU//Y5YD*XJV]CZ++5:F-HHHK$]1@:2BBFD9O87M5K2/^0S
M8_\ 7Q'_ .A"JG\-6])_Y#5C_P!?$?\ Z$*J&YE4^'Y'VFGW13J:O04ZNU'R
M84444P*FI_\ (,N_^N+_ ,C7Q9+_ *Q_]XU]IZG_ ,@R[_ZXO_(U\5R?ZU_]
MXUSUD>OENT@_A%)1VHKG/:6XHHI*6DRT%.IM.%(H#TH%!HI%(7O0*!2]J"@]
M*]2^$T*26VI%WVC8O/XUY=QD5ZG\+8I#I.H.B@[N#GZU,G[ISXCX6CN3-%IR
M?ZTNM6XKJ*? 1^:HQBWB0AXRY[AN0*E/V250\7[O'=1C-<T='<Y;:%R1CC'%
M8&H,>F?XLUH""5R7\X[!6=> &09I\U]0A+?R1BZH@GFWERJHHZ?6M&U\M)4@
M7)RN:R-0O EX(5BW*7(; [5=LXF6X$@<L3T&>17BU5\3/@,1"\IS]?U.CQA0
M,8J%C@U.X/E\GG%5BV!@UY\-6?-^S7/J02N[-M_AI0JK;S8.?DJ*5]KG;SBF
M0EL29XR.E>CAU::/K,KPZ56%B]8=5^E;2@M%M[GI6'8R;%)*DUJV]T). -I'
MK7N1EH?=U9<SN--U]G;R0A:4TXQ7<F59U&3Q34EC-V9V((''%6HY/-FC!7;S
MWYJ'W.=R239R'BH8U")) &:/CBN5VW!=[BWXA)VX8_G74>,HV'B%]C!<=SW]
MJX\_:HTV@LL0?.TG.>:X9J\CYN45.;D6A=I<2-" N5&":4NS1&V2,LR\YQQ5
M&-%FO7.5BW <=L^M6[629+PQQRK)@<\8J7$56FJ<;H;"3;7,[(X\\_*01QBJ
MT8N4W-+(OE@_,H[T^7=<2M%]PYY?&,T\I:*J0RER^<[@W!/O51*2M%/N,/V3
M"M+O\N3.=N<C'2A6M(\3+EPWR#>?FI+1_)CF26'=&S<,>N/:H+=;22]V/O*
MY#$]*I(?+U'D);N\(0MSVYQ4[0W)9$C=B7&#_LTUKB.WG<QMG+_>89JS;M*U
M])B8%2>PQQBE(RF^QTW@:)(7O(UE<G'*D'!.*GU1OF(/K2>$HUBDO0'R<>N>
MU1ZJ^&->[@_X9F]3EM1**K*,[_6N<O$:0H'88]JZ"_<2EDR 37.7:RANG"=Z
MZ4+8@.W=@BKUEP2!TP:H!&R">:O6AX<^BFJ>QO2UDD<]=?\ 'U+_ +YJ#L*E
MF.9Y#[U$:X9;GV5+6"?80]:7M24E(H*0TM)02P'2OJ;X0_\ ).-.^K_^A&OE
MD]*^IOA#_P DWT[ZO_Z$:Z*.YY>9?PT=R:2E/2FUTH\)$E%%% !1110 4444
M >=>,Q_Q4!_ZY+_6N=(KH_&7_(?/_7)?ZUSQKCG\3.J#T1$U1'I4S5$163-4
MQG.:<*;WIZTAW)5I],45+BF*XW%;'AT8GN/=1_.LG%;/A['G3?054-R)LWJ*
M#1BN@Q%%(12T&@0W%(13J0T"$Q12TE T%(12T$4#&T8I<4I% BGJ-FFHV<EK
M*[A& Z5!8:;%I=HEK"2R*O!-:!%,(HNPLC(UG28=8@$-P2%#9IJ6B1VP@(S&
M%VX-:CCBJSK5J3&TCF)/"&G2S>:7D3U48Q6H^B6LNFK8HS1QCKCO]:N$<TX'
M%7S,BR*%YX;L[NRCM,%%B'RNM0S^&X+AK:1I)0T'3D<UMH^>M2$ BES,+(YV
M30X_[06]5G+JI&#5>324;4DO7)\Q!@5TA '6F^4C=15*8N5'/SZ9#<W\-XSL
M)(^WK5>Z\/65W>&Z)D5R>0I'-='-8EAE*H,DD1PPJN<.5%2TT2TLXIX8MVV8
M<G\*FL+"/3K?R(B2,DU>M8A.< \T^:WD@/(R#3YB>4B4\U(K8-0\MTI<D=:!
M$CO1&_/-1$DT)G-2S1&BK<"I1S5>'!'-6 <"H9JMAP44F"* <TII# M0K<U"
M[&FHYR::1DV6B>*@<CFEWG'6F'D$U:,I'F_C/'_"0/\ ]<U_E7.[L' KH?&1
M'_"02?\ 7-?Y5SR,@.6-;K8Y7N7HON4XD&J3W2JH"FD2Y)'%9S.FGL6MH)SF
MC8 *J^?(3P*>DC,<&LT6VAYRIJW;3D'D\5"D8;J:D\@'@&MD9HUX9E*]JCGD
M&<@\5GQP2 _?XJ9$P<LV:RD43))D=:9L+&K=II4]^V(>!76Z7X*CC4->3@4D
M4D<M;V32*-JDFM6UT:\D( B;![XKMXH=!TZ+&Y6<5'-XPTRT4K%&A(I-FD48
MEMX0NIV!;*CWK6A\$HO^M<8]ZRKOX@.Q(A0+]*R+CQC?S='(_&BQHKG<IX:T
MJTYE>/\ &I/^)!;\'RN*\PFU>^N.6F?'UJ#[3(WWIFS2Y1*YZJ=7T:'[B(::
M?$NGIP$&*\N%RP_C-.%T2/OT.)HHMGIC>*[0#"55D\7J/N@5YX;G'\=->[']
MZH:-%%'>2>,)C]T8]ZJR^,;D#@YKB_MHQ]ZJDMTV>&I<I<819V,OCB\5N/UJ
M!O'5\?X17)"0GJ:7(-2XG1&$3;O?%<MXA1XP,UR]W&;ARV, U9?:3Q5>5B!B
ML>4W56Q1EME5>M9L\>#Q6J[]<U5DV'.::B;*I<Q'0YJM(AK5E52>*JRQC%6D
M#::,X[@:U]*U4VLJAFP*S)(SS4!8A@?2E*-SCJ1NSVK1-4$\:\UU*2!@.:\/
MT'7'@F57? !KU+2M72[1=K#.*PE"QQ3A8WYP"G6N7U8 ,:Z!I/DY-8&K+N!(
MK/8QY3GS(%DJ_:39<<UC3,5E-,BO6B?FJ2%J=S!*#CFKJ'/>N3L=361@-W-=
M!;2;B/FIV):9OZ(O_$[LSG_EH*]'KS;0W_XGEF/^F@KTFNNA\+,Y!111702%
M%%% !2&EI#0)GS=\=O\ D>(?^O1?YFO,%KT_X[?\CQ#_ ->B_P S7F"UQU=S
MZG"?PHBCO10.]%9G3'X4 I:04M)EH!3L\4VEI%"THI**"T.I>@SGO3:7M2'$
MWO!T'G^*+52>^<5[;(BQW$GE(< \D5Y'\-8A<>,8 1]U6/Z5[?)CS'VJ.O-9
M5.AQ3J6D9,4M[)(ZQ@>7V+U$\$LU_&MP(RHY.T=ZT9%DFF*1C9&.2:=#:QP.
M63+'N34H/:&??0QJ#A #CK7GOC]L65B!T+M_(5Z'J!^5L5YIX[EW"SA]"3^E
M7$WI-MHP+!<D5V6F+\BUR6G+R*[+35^0?2LJA[+TB:)J&0]:F[57E-<X0*;!
MFF55&6)X%=#!!-<3;I)I$/HIK#@YU&(?[7]*Z>RYEYK>!EB9*Q8%M>1KO2=I
M$ Y4]:1[QYXT06SA4.3[FM:%1MYZ4Y;<*^]%&T]16J/#E-<Q2BN%>'+S>6Y/
MW37-_$>[0^%DB1]S^=@X^E=9=V4<X!V@,O/%<_XK%O/I<>FRP!9+CA&/K_D4
MUJS-M<R9X>!2'K4L\3P3O"XP4)%0GI3:L>VI7B@-)110@8E ZT44R/,<33.@
M%&:#3U):3=Q3RPK3\,H7\2V  S^^7^=98/(/I6_X+C\WQ79+_P!- ?UIQW,,
M0_<9]$WK8A3.#\@'Z5S%ZPP?6NCU X51Z**YF]/WJ]5?"?$3?OLPKL\FLM_O
M5I71Y-9K]:0BS:_ZP5R'CQLZC"O< 9KL+,9E%<5XV?=KNWT0?RK&KL>CEZO5
M.9:D[4'K1VKB9]*MQIHI3251"V$HHHH$>G? K_D>I?\ KT?^8KZ2KYM^!7_(
M]2_]>C_S%?25=E/X3YS'_P 9C>].IO>G5HS@"O-/CE_R3UO^OJ+^M>EUYI\<
M?^2?/_U]1?UJ)[&]#^*CYJHH[45Q'U0M%%%!8M HH%2-#@:.](*6@H6BDH[T
MBD/&*=$H>= .YI@[U9L$WZA;(!RS@4"J.T3Z'L[1$TZS#@G$0XITD$$!#LI9
MCT4U;Q^X@4?PQK_*D,8=@6[5S/XCAC.Y4D2>X 1HPB$\@T7(VQC)P!5[M5"]
M.4(JTBXRT..\22;=%O@>,QD?C7FEB"6&:] \8S>7H<I_ON%_2N#L%RPJWL>I
MA5U.KTI>!71+]P5AZ6O K<'2N.>YV,CDZ'Z52N3\K$]!UJ[)R#5"Z)*E1_%4
MHN!O6* 1Q#'& :Z.UY3!S^-8-F,)$/1!_*N@MA\HKIB>1BI>\13Z;$\QE6($
MGKFG-IRI"#;L8F R0*T1BD8@ U<G9'G.JVK&#>2W:Z9=Y9F<Q,I4_0UX)+GS
MY 1@AB"*^A=>NDL-"NKIE'RE0?H:\/\ $5L(;P7,:XBG42#'OS5QU@;X2I:=
MC'Q2&G9ZGUIM*QZU[H2BBB@D2DI:2F2Q1TI&I12-UHZD_9'#EU'O7T=X37R_
M!&GKC!\H&OG&+F>(>K ?K7TMHT?D>%K%.F(1770W/#S5Z)%&]/+5SMV>M;]\
MW!KGKL]:[#YUF5+]ZDAZC-$O6B'DBA;DRV*?C!@OA_&?O-@>_%>;^E>@^.7V
MZ1;KZO\ T->?=A7#5^(^GP"M3&GK11WHK(]!B44452(>P?PU:TG_ )#5A_U\
M1_\ H0JK_#5K2?\ D-6'_7Q'_P"A"G'<QJ?#\C[47H*=35Z"G5VH^3"BBBF!
M4U/_ )!EW_UQ?^1KXJD_UK_[QK[5U/\ Y!EW_P!<7_D:^*I/]:_^\:PJGL99
MM(.U%':BN9'LK<*6DI:&6@I124"I&.-%(*6@M"THI*44AK<-M>R_#"W;_A%Y
M74E=\A&1^%>-EL9/H*]V^&\8B\$0MCEY&/\ *HG\+.;$.SL;\EJC1D$G&.3Z
MU#D)&8H+?>HJ[C*8H55C! '-8I&%RNJ%(,, ">WI6-=_\?"(1U:MRXP$Y/6L
M"X!:YP.H&<TTK7"UH2?D8.HRK'J4R(5202'&>]:NFQ-'<)*#N=OO'M6&K1#4
M)GD.YRY-;VD _:=Q^Z>@KQ,1HI'Q&*5D_-FU(I7.X]:J$@YJY,0JG=S5&3"C
M=ZUYM$^?5.]2Q79D1SW)ZBF [EW^^,42$IDY'2B)D>U! ^?=S7KT%[R/L<KI
M-5H&K9#"  5>FM\Q;E'S#L.]5+'H*U$Z8KUTCZBMH48M.4IO4E">JFD\RZM9
M!ND5SGY<]ZTC@#BFI&LMQ&K+G%3)'))>X[GG/BJ=KF]EDEW%RW ';CK6+%/)
M]FDWR"23H<]A70^)8IG:>2V W!MM<KY%W&<,0"1S7'-6/!BE;YC[>&VGWO(^
MY5'&[IFHT:1+A0JXC/3'2DB$LCNG0*I)(^E5[5X9@J2,Y<G(Q22N=+IQ<7<T
M+][EVV/!Y<;#Y6'>F12V^\0RD@#J#U-4KK4YWG$9 3RCG\*L2R/M6=(P),8:
M3M5\I'LI1@D^H7L[32!(F,:)T!ID9A$9!0J>I)[GO4DD.Z)=\ZY(R<'BHUA2
M6V>25L%<;/?FBQ:2C&S+L4]B]NL>U=P;DD42P9N"T4PE+L JGO4)C-W-R1!%
M$>3ZU:A*Q,L?F<*VX+69PSCJ=5X0@DCM[R5XA&>!^E0ZJQY-6?"JR+I]S)(,
M;FX_6J6J-DL#7OX-?NR=CFKWR_(9F4[P>#6 [.["(M@/W-;UU)LRJC<6&.:P
M[D@?NY!SZCM6J(931BAVELG-7K;(CD)&/E-4GB"A6#9J["[&UE)Z!3_*K;]U
MG3A_XD?4YR0YE<^IXJ,TI.32&N*6Y]C25H"4E+24#"DI:2@E@>E?4WPA_P"2
M;Z=]7_\ 0C7RR>E?4WPA_P"2;Z=]7_\ 0C6]'<\O,OX:.Y/2FTX]*;74CPD2
M4444@"BBB@ HHHH \[\9?\A\_P#7)?ZUSQKHO&7_ "'S_P!<E_K7/$5Q3^)G
M3'8B-1MTJ9A41K(T1'CFI$'%-QS4B=*!CP*FIBBI<4 QAK8\/?ZV;Z"LC%;'
MA\?OIO\ =%7 B1O48HHK<Q>@G^>*0]>*YOQ=K-_I,$)L2A9VQ\R^]8TGB#Q1
MIOE75_#$;5L;MJC/-:J#:(YT=[@C!XQ]:3() Z5#:7*7=E%=#"K(NXY/2A;N
MVE.%NHGW=%!&:GE97,B;H>?TI,>F*:\L<)"22HK'H">::MU S;!/"[>BL,T<
MK!21(,;L'.:4\]/UICO'%_KI50>I.*2.>"7/ERI*!_=<5'+(?,AXZX[TOUIJ
M2QN2D<B.<X(# D4++$TIA$J>8O.W(S3:87 KZD?G32N>AR*1[JWC;$L\*,>@
M+#-,N;F*WM7N)& 1!G<.E"N%Q"I*D^G85%)&>WX9KDEU_P 0ZO,SZ3:HL2\;
MG ^:M_1[RYN;$M?J(IHSAB> :IJPKDCQLO)*_@:0=L4]IH)#^[FA<^BL":R-
M1UN+3[R"!@I$AY(8<5:0FS5!!]1CUJ17VY#=>V*Y?Q7=,FF036\[!6?&4;VK
M:L;F,6<2F=/-*C[S DTW$7,6;B[M86Q+<0H<9^9P*A^W6AC,BW4)4=3O%9WB
M>V@.D/,84:7<HW8%9^J6D">&(/+B6-V";B!USBDH7$YG76MW RJRR*\9Z,#Q
M4Y%CJ"L+>9'8<'!'%<%#>-I]A>6 _P!;OQ%].*T/!T:V>I7L>6+*XSD].!5\
MF@E.YLSVLUFVY!@"K$&H1RQ[)@">QS5S5EWZ1<L&PZQ,P_ 5Q&@/YND?:)[E
M5?>PPQZU*3&V=#*(U<[7!J)FRN0"351),KO)&/7-21W$+.H$J$GL&%4DPNK$
MP.#\V13L\CID]LUS>MSS1:K8!)'VNW(!X/-*T\__  E*Q^9^[V#Y?PJ^42D=
M5&^#VQ4^\?6J!FCB.'D1>_S&K$4R2+E'5A_LFLG%FRFBR'R<+^M*3GN/SJJU
MU"G^LGCC]B>:=YT;(65E*_WLTN5E<R)2=S$"DZ56-U  "UQ'@]\BIED#+E2&
M3LPJ[&+8XM@TF_/%1EL=:9DXJD9L\\\9-_Q43C_IFO\ *N;:,L>#70>+^?$;
M_P#7-?Y5CK'CO6B9S-.Y$+;*C)J9("HXJ11ZFG9QTIM7-%*Q)!;.PX%6%LR&
MRW%017#1C@TK7<CGK4<H^8GD14/6G1O&1C=S57<S]32A?3K19E)DYEQG!IJO
M\W6HXXB3S4XMN,YYJ&F:)HO6NLR6@Q&=IITNOZA(V3,<>F:QY(B&.:A)F4TM
MC2*N;$NHRR+\TC9^M5#<ACRQS]:@2.1QR*7[,>O>I;1LDT3B;:<_>J995^\1
M5%E=5Z5&TLBKTHNB[&N+E,8R*8]Q$HY:L(S29Z&JTT\N>AJK@U8W'U&)3C-,
M&H1NW!K!^=^H-+L('I00Y2-R6Z4CAJHR73\X8U1#,.]2 Y%*R)<F3+<S,>M6
M4>1L9-5X4![U: 5!UHL";9;B1F')J?9CO5$7808S41OOFZTK'1$T@HS5:YXS
MBJQOL=ZKSWNX=:RY37F"3[W6HI$&W.ZJSSDMUIDCEA]ZCE-8S%=/>HI%^6HW
MDP.6J)ILCK3L5[09(#FJTD6>U3E^<YI"X-.Q#G<H[7C<%:Z30M<>TD =C^=8
MQYYJ-D.<K6,HW(:YCV+3M<BNXA\XSCUJ:]D66(X/:O)M/U2:SD R<5U5GKPF
M4*[8K'D,G!EF:/$QS2_9492:BEN(V.X-FA;M=O6GRF;@RJY-K)N&:UM,U;<0
M&;'XUCW5S$]9DMQY)W(>]/E#D/9/#-RLNN6/.<R"O5Z^>OA_J_G>)]+A+<M,
M!7T+7115D<U1684445L9A1110 4AI:0T ?-WQWX\<0?]>J_S->8K7IWQW_Y'
M>#_KU7^9KS%>M<53<^GP?\.(44E+4,Z8[ *6D%+2+%HHHI%"T444%H6G=J;1
MVS0-/0[WX40EO%7FXX2-OY&O8>Y]SFO,?A!#NO+Z;'W$ _/->G5A4>J/.E\3
M'8'I37)VGFG"F2GY30MA(QM0/4>M>6^-I,ZY%#V6-3GZUZ=J+9KR?Q3)YWB%
M_P#9C5?RS5(]'#J[$TY>179V Q$/I7):8F2*["S&(A7/4;N>H]BRW2J\HR*L
M-TJM,<"L5N.GN16:[M3C;TYKJ+,9?<*YO2EWW\G^R@KI]/'%=4=CEQ9M0<**
MF9M@]O2H(R0N12&;<<,.*Z(PN?-UJB3T%:53PN?>N!^)UX\%SI<T.=L8!)'0
M'FN_&PC"_P 1P:X#QSKUMINK#3I[19K=1@YQFKC%)D0E*35G<XSQ)9K,D6K6
MP)@F'S8'W3_D5S94@<X]L5Z%I,5C/#)#9SK)9S?>AD/*_3-8.O\ A2[TR4S6
M\9>U;E<<XHG#L>M3KVLINQS0'K00.QH)Z@C##J#2>E96L=JJ)[:ABD-.#8IN
M:+@_43I1FC-&:I7(N@'0_2NI^',)F\:6:],<_J*Y7O7<_"N R^,8Y!T13_2K
MIJ\M3EQ+2I-IGM.I-\Q]N*YJ];K71:DWS-]:YF]/6O26Q\7)K<Q+H\FLYOO5
M?N3DFJ)^]28^A<LO]8*X#QA)NU]SZ*!7H%D/WE>:^))/,UZ?V.*YZST1ZF6K
MWFS*/K29I3TI*Y#Z)Z :2E-)5$,2BBB@D].^!/\ R/4O_7J_\Q7TE7S;\"?^
M1[E_Z]7_ )BOI*NRG\)\[C_XS&]Z=3>].K4X KS3XX_\D]?_ *^HOZUZ77FG
MQQ_Y)Z__ %]1?UJ);&]#^*CYJ[44=J*X3ZH6BBB@I"T"B@4AH6EI.]+2984M
M)2TBD**UO#-O]I\36,6/O2C%9([UU'P]@,_C/3VQQ&X<T&=9^X>[N-K!?10/
MTHH<[I"?>BN9:R.!*R ]*S+TX%:1Z5E7S8%:(UAL>?\ CB3&C)&>IF#?SKE-
M/7)%;_CN7+64(Z."WZUBZ:OSBB3T/:PR]TZS3%P!6OVK.TY<**T:Y);G0R&0
MX!-4I,&>)>Q85<E^Z1ZU55?,O8E'9A1'<TC:USI+4;I OH!6_;+\O-8EH,RY
M'7I6O&Y5L&NI(\+%/WM"_NP.E0O*W0(/SJ(W+Q=5W4>?%(.<J:U=.YX\JW8Y
M[QM+)/X1N((4+REQE5&>*\UM5_MG0FLF!6[MLD CDCT_2O0_B#JKZ-I5H]JJ
M[G;YN,YYKA;75=/U*Z28_P"AWP/!7A7^N*UC!)'13G)1YEJSCV1U^1EVL#@@
M]J;7?ZQX5.IQ->V91I\994/#&N&N+6:VF*3Q,A'J*SE%GJT:T9*W4AHQ1R!Q
MTHW&IMW.B_<0BC%+DT9-.R%\P6D/)HQ2$XH(<K16A+:J7O;=5&3Y@_G7TW&O
MEZ/:)Z1"OF_0H?.UVTC'.9!_.OI6['EPI'_=7%=>'74^?S:6J.>O3P:YZ[[U
MO7IZUS]T>M=9X1FR'YJ=#U&*9)R:EMA^\ I=0,+QZ_\ HMJG_ OYUPN>E=AX
M_D_TJTB_V/ZUQWO7!4?O'U6#5J0AZT445!UB4E+2&F0]A?X:M:3_ ,AJP_Z^
M(_\ T(55_@JUI'_(;L?^OB/_ -"%4M&95/A^1]J)]T4ZFI]VG5VK8^3"BBBF
M!4U+_D&7?_7%_P"1KXJD_P!<_P#O&OM74O\ D&7?_7%_Y&OBJ3_7R?[QK"J>
MOEOV@_AHH_AHKF6Q[/4*6DI:1:"EI*6D4 I:0=:6@I"T445)2%/)KZ#\'P>1
MX.L%Z;OF_,"OGZ-2TB(/XCBOI#1T\GP[IL7]V!?SQ4S^%G'B-9(N8I:.U%90
M,+%:YX4U@.Q\YP6VY4\^G%;EV?E-<UJ'_'O</NP5 Z>].6Q=32C(YE!]EF9I
M#YF6P#ZUUFCF-7W22!>,[3VKD+9UVR9&XJ_>MR"UN[J/B)_G')'85Y%:%[IG
MR6,I7@SJ5FWQ,9"@STP<U1D<*ASSZ52CM[A%2%TDPG\7-6V8(NT#(QWKAC2Y
M7H>#1BW4U148H"Q<Y;' I;<OY:[AM!/2J\P!D+9YQQ5RW8O%'N'S"O4HI731
M]Y@:23C*QM6:XP*U$X%94;E$! JP+IX_F(R*]6*N=V(G9D[W6UL;:2"_BCD9
MW^4J#CWJ-9XKC[PVT\V\"6UQ<2898TRM*43S:M92BT<-:2F[OKE)F 65_E!.
M"#6!+,P>YCFC99$.%4\9%:DNLZ;>7#Q3QF";.$DC/3\JV+C1TU2-!O1V*_)*
MO7\:YI4[GDJ%MSBGN)85?RH5P$&Y0<GD542_CB@,L* .5QAEQ@UJRZ7=V%Y-
M'/"R<?-)NX([5D&5(0T "-\Q(9E[&LTE%VL=E+V<K792<1N4V29+??)/2III
M% C@65]I(R",57N+58+D1K\[2'*;35I&-Q,%N8E&P<%:UT/2JI-*SV+BV3-<
M%E;*[.F>G%)'"H3+,9&R $/ %0P2[)F*R\!3P34L/E21;VE(D/;Z5BTSSJL6
M6KH21IMF4*BG!*G.:8C,Y )Y="<XYQ4$(::*0WDI5"<@^]-N@R8\N0&5>!C^
M[24&VC'E5M3TGPY&(/#)V'(9N23S61J)S(V>E:^CPO:^&H4E.6;YJP=2<L6Q
M7O8=<L;')+<YN]?:^1ZUES84L226;VS5^];!('7N36:TWDG(PR]P:N7D00 H
MT?(((JT&VV$IQP1BJ\KI)( HQ4MRWEZ5(1Z@4?99U8-7JQ]3G1T/L:3.:7HO
MU-(>IKC9]A':P4E+24P84E+24$,0]*^I_A!_R3?3OJ__ *$:^6#TKZG^$'_)
M-].^K_\ H1K>CN>9F7\->IW)Z4VG'I3:ZD>$B2BBBD 4444 %%%% 'GOC'_D
M/'C_ )9+_6N>/T-=UK_AR[U34C<PR1JFP+AB<\5E?\(5J'_/6#\S7-*%VS:,
MK(YD@$=#43+[&NJ_X0G4?^>L/YFFGP1J)_Y:P_F:S]FR^='*X]J>BY[5TW_"
M#ZA_SUA_,TY?!&H#_EI#^9H]FP]HCG5'%2 'TKH?^$+O_P#GI#^9I1X,O_\
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M /PJ'6S_ ,O5I^9_PI1\(=;'_+U:?F?\*KF(46<(BAAFAE"^M=Y_PJ/70?\
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M^OG[MU9#_@3?X5 WP0\0L?\ C[LO^^F_PIFJJ'G#71'>H'NV(KTL_ WQ$?\
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M&@!<48HW+ZT;E]: #%&*-R^M&Y?6@ Q1BN9\3^/=#\)7,$&JS2H\Z%TV1%N
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M7 ]SZ^*LDA**#29H&PHHHH)#^&K6D?\ (<L/^OB/_P!"%5<_+5O2/^0W8?\
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M_P"O1_YBOI,5\U_ K_D>I?\ KT?^8KZ4KLI_"?.8W^*%!HHJSDZB5YK\<?\
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M_P#0C7RP>E?4_P '_P#DG&G?5_\ T(UT4=SR\Q^!'=T445N>*+1113 ****
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MX0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@#YM^/'_(\0?]>B_P S7EXZUZA\>/\
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M .2<:=]7_P#0C7ROVKZH^#__ "3C3OJ__H1K>CNSS,P^!'=T445L>,+1113
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M!1110!Z?\"O^1ZE_Z]'_ )BOI2OFOX%?\CU+_P!>C_S%?2E=</A/ QO\4.U
MH[4"J6QQ]0KS/XY?\D]?_KZB_K7IE>9_'+_DGK_]?47]:3V-:'\1'S1V%%'8
M45QGTR"BBB@ HHHH&%%%% 7%I,T4O% 7 4M)12*0ZBFYI<FBP"T4E%(H,TN:
M2E% PS2TE%(!:*2BF.XM%)10%Q:*2B@+BT4E% 7%HI**!"TF:** #-&:0T46
M$+129I,T["'44W-&:+!<6DS11Q3L(,T44E(E@:3-+13 ****!!1110 O\-7-
M(_Y#=A_U\1_^A"J?\-7-(_Y#=A_U\1_^A"G'<B?P_(^UEZ"EI%Z"EKL1\N%%
M%%,"KJ7_ "#+O_KB_P#(U\42_P"ND_WC7VOJ7_(,N_\ KB_\C7Q1+_KI/]XU
MC5/4P'VAO\-(:7^&D-<R/7ZA1113 *3-+10 "EI** %S1FCBCBD.XM I*44A
MH6BDS132*%KTGX3W8CU"XAZJR_XUYK7IWPQM1!9WVHN.$0X/OS7!F%GAY1?4
MB1#\2O$PN[C^S+=L+"Q#5YUT)^E7-8N#=ZM<SDY+R$YJE6^&HJC14%V1458*
M*":2MRQ:*2B@!:7--HH'<=FDI** N+1244!<6BDHH$&:,T4&@ S1244"%HI*
M3-.PFAQI*3-% K >M)FEHXH%<,4E%%,5PHHHH ****!!1110 =J^J/@__P D
MXT[ZO_Z$:^5^U?5'P?\ ^2<:=]7_ /0C6]'=GFYA\".[HHHK8\86BBBF 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2"EI
M!0!\_P#[0?\ R'M'_P"O9_\ T*O'*]C_ &@_^0]H_P#U[/\ ^A5XY7)4^)GT
M&$_A1"BBE[5!V,**44M(I"4M%% PHHI:120L9PX/IS^5?0WA2]_M#PO92YR=
MH3/N *^>!ZU[+\++[S]!EM<_ZERWYUC67NF<T=]12#VI>@KG2T,BG<CK7(>)
M[<W6G,@'S!U(_ UV4CJZ[O7BN?U*+(([$X-7%:F\&TCSO6QOU2$@?=@7 /XU
MK>'$VWR#L:K>(X?+U>(@?*(P@_"K.B/MNHS[UT58WIF,]3T*&VSQBI+VP#P@
MXY'I5BVP0K>JUH.%,'2O H.U4X(Z3.*N;)H66=,AE/&*OSN"8;G'^L'05=O5
M4QE16>QSIX8?\LWQ^E>ZU>-SU*<KFK:MD"M!!FLBR?(%:R'BLXQ1-9#CP#QT
MXKGO%MH+W0+J C.$W"M^9MB.Q!)49XK)>.;4X\L=D+*2 .IXK.W+(S@CY]6$
ME=I.W9V-*X/E+@# [U=UBS^PZS<6[H_R.<DGM58Q-QN/[NMVS9R6Q7*J1DDT
MBG"=*L^2H^8<I4<@79\K4TQJ2( 6Q[4, J@YJ5E1,9YR*CD !X%.Y8?*1FFJ
MFX$Y%.V.4# ?+3F5 @]:+A<@(/<&I+:3R+F.7^Z<T299>N<4S'%-,4H\UT>V
M6V+BPMI5X!3M44J))N4 !AWJ/P?/]M\+1-_$AVFK-PJ1Y!!R3Q4R<F?GF+C*
M-1Q*2VT17,L:LW84R2W*/A8HXR%ZX!!J2:5!'\V58=Q42.;D*QD 4#&*Y'*5
MSRW.5P#))*> 6'RDK7'^-8#F*X7''RFNDD#1S$)(H+,.!69XFMS+I1!Y*G-=
M5.]M3U\MK2A47F>?=<44N.*2MF??):"4&EI*8-"4AIU(:9#0E%+WI* >QZ%\
M%?\ DI-I_P!<)?\ T&OJ'M7R]\%?^2DVG_7"7_T&OJ'M732^$\''?Q?D+111
M6IPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'S;\>/^1X@_Z]%_F:\O'WJ]0^/'_(\0?]>B_S->7C[U<E3<^BPGP1
M$I*6DJ#H6P4444#"BBB@ HHHH *6DHI#%HI*7-  *6DHH'<6BDHI#N.HIN:7
M- 7%HI**!W%HI** N+1244!<6B@49H"X44E% 7%HI*2@+CJ3-)1307#-&:**
M!7"BBC- KAFDS110%PS1113)"BBB@ HHHH **** "BBB@#T_X%?\CU+_ ->C
M_P Q7TI7S7\"O^1ZE_Z]'_F*^E*ZX?">!C?XH=J!1VH%4MCCZA7F?QR_Y)Z_
M_7U%_6O3*\S^.7_)/7_Z^HOZTGL:T/XB/FCL**.PHKC/ID%%%% !1110 444
M4 %&:** %S29HHH&A:* >**0[AFC-%% [AFG"FT4#N.HIM+2"XM%)10%Q:*!
M1F@+A124"@+BT49I#0%Q:*2B@+BT4E)FF*XI-)FBB@+BTAHHH%<**,TAIH5Q
M:2BBF%PHHHI""BBB@ HHHH **** %_AJYI'_ "&[#_KXC_\ 0A5/^&KFD?\
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M#X$=W1116QXPM%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKWXVY$=])[&I8/P*W(CE:YRQ<JV#UK?MV^6HV.BNM+E/5[LQ&*/S?+5^&/;
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M_P#DG&G?5_\ T(UO1W9YN8? CNZ***V/&%HHHI@%%%% !1110 4444 %%%%
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M5_Y*3:?]<)?_ $&OJ#M752^$\#'?Q?D+1116IPA1110 4444 %%%% !1110
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M4PN&:.:**07#FCFBBD%PYHYHHH"X<T<T44!<.:.:** N%%%%,84444 %%%%
M@HHHH **** "BBB@ HHHH **** "BBB@!?X:N:1_R&[#_KXC_P#0A5/^&KFD
M?\ANP_Z^(_\ T(4X[F<_A^1]K+T%+2*>!2UV(^8"BBBF!5U+_D&7?_7%_P"1
MKXHE_P!=)_O&OM?4C_Q++O\ ZXO_ "-?%$O^ND^IK&J>I@.HW^&D-+_#25SH
M]?J%%%% !1110 4444 %%%% !2BDHH */3VHHI[;@QZR.BE5=@#U -,[YHHH
MT6PD@HHHHMU&&:.:**07#FCFBBD%PYHYHHH"X<T<T44!<.:.:** N'-'-%%
M7"BBB@+A1113 **** "BBB@ HHHH **** "BBB@ HHHH **** #M7U1\'_\
MDG&G?5__ $(U\K]J^I_@_P#\DXT[ZO\ ^A&MZ.[/-S#X$=Y1116QXPM%%%,
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M45!ZS$- H(HH)#O2&E[TE-">QZ!\%?\ DI-I_P!<)?\ T&OJ'M7R_P#!4?\
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M_P#?T?X4?\*(\*_\]K__ +^C_"O3]I]:-I]:.2(?6*W\QYA_PHCPK_SVO_\
MOZ/\*/\ A1'A7_GM?_\ ?T?X5Z?M/K1M/K1R1#ZQ6_F/,/\ A1'A7_GM?_\
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M\+C_ ):W_P#W]'^%2VWP1\,VUS%<)+>^9&X< R#&0<^E>F4GX4U 3K5&MQJ
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M44 %%%% !1110 4444 %%%% !2"EI!0!X!^T%_R'M'_Z]G_]"KQVO8OV@O\
MD/:/_P!>S_\ H5>/ 5R5/B9]%@_X41*6BBL3O%H%% H&D+2TE%(JPM**2EH*
M2%H[4"BDREH>G?!Z;_3=0@)X,((^N17J  _2O&OA;=-;^)&0?\M$V_K7L+9\
MO*\=\5C4T.&<?>8.[1R\],4%UDC.*:Y,\95/E<#O4=JI$3*WWQUJ4[$IV,R_
M4;BQ[&N;UQ!%J$4R*?W@Y]ZZC4%W(?UKG=6N7B2.-QN1X\J0F2.?6L<1?ET.
M',U:BG;K^A3M%D>[E\LYXQM_"MB30;B>-9'.&Q\O-9-C<PVCJ#N+2$9(%=M$
M#Y*E2=N,\FO"KUG3=X['QN*UCS6,NQ@N+:T$5P<N"?RJ211M-6IFR^?;FJTP
M!4A>M7&7,D9X:I=JQ1@)#R(1P:T;!OT.*IHN'5"1FK%B=N5/]ZO8H:Q/T' 5
M.>G9&_$00!FJ^HH)51 3D'J*G@.5 J;:#R0*ZM6BVVGJ9BRQQQ+#,"<'K7">
M.;9_[:2XL[=I@5'RG( Z5Z3+!&_+**X'XCQR1O92QS-$A4[R..]53?0PE=RT
M1SMOK>O6X"QZ<NT?PG)_I5R+5%OF(U/07!_O1*:Y^X\3W,$0@M6X'\97.:K1
M:[K-TVV)R6]%2J;*G1DE?0[BWT/3KHB:WO+JT;^XR\?J:LIX:UY)3+;7L$D7
M;S,<_I7,:?IWB?4=I)\L?WB*V)K.;1U6;4]:+;>?*C;'\C0<4G.]DR])I>NP
MQAFL;6?)Y(/^ K3TOPLNHL/M^E6R#VD-<Y)\3XH8/*MX&.W@%C6<WQ0UG!\I
M%4'I\HJTT4J.(E\)W][\--#,FY;)E)]"3_6LN?X2:>6!5[F-3_<CW?UK@Y?'
MWB*5MQNCGZ55;QOXA/\ R_N/Q-.\36.'Q5[\W]?<=;>_"CRRWV>]8?\ 750M
M=)X1\/7/AJQGCGF257Z;#D5Y:OC36Q\TETS'WYKM_ ?B>]UJ]DLKM@RJN1@8
M[5+\CFQ]&O[)N3T1NWR'Y_[I%<]=*Y5UBVAL8)W5TVH)@D$X'>L.]A0+Y42E
MF7J0:PDSXR<M3#NH?]'9GP&QQ@]ZK!9X!%]HY3KQ5^:)+H9=MH7C JJ+CRH&
M1SO<' R.U3'1D0=M"&Y^>*?'(*Y%<'(")&'O7H$F_:PV=5KA;M=EY,N, -@5
MV6TN?:9++W.4KT&B@TCZ%H2D-+24[$M!WI*6C% GL>@_!;_DI-I_UPE_]!KZ
M?[5\P?!;_DI-I_UPE_\ 0:^G^U==+X3Y['_Q?D+1116IP!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6@C- #:*7 HP*
M8K#:6EVBEI,+6&T4ZBE9#&T4ZBBR ;13J*+(!M%.HHL@&T4ZBBR ;13J*+(!
MM%.HHL@&T4ZBBR ;13J*+(!M%.HHL@&T4ZBBR ;13J*+(!M%.HHL@&T4ZBBR
M ;13J*+(!M%.HHL@&T4ZBBR ;13J*+(!M%.HHL@&T4ZBBR ;13J*+(!M%.HH
ML@&T4ZBG9 )12XHQ0%A**7%)B@044N*3%,:0AHIV**5@&T4ZBE9 -HIU%%D
MVBG4460#:*=119 -HIU%%D VBG4460#:*=119 -HIU%%D VBG4460#:*=119
M -HIU%%D VBG4460#:*=119 -HIU%%D VBG4460#:*=119 -HIU%%D VBG44
M60#:*=119 -HIU%%D VBG4460#:*=119 -I*?2$ TT%A**7:*,"F+E0@ZTZD
MP*6D,**** &GK24[ HP*!6&T4[:*  *860E%.HJ;(8VBG4460#:*=119 -HI
MU%%D VBG4460#:*=119 -HIU%%D VBG4460#:*=119 -HIU%%D VBG4460#:
M*=119 -HIU%%D VBG4460#:*=119 -HIU%%D VBG4460#:*=119 -HIU%%D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!
MZ4 %%)WQCBFDD G'/I0 ^BF]AVS3J "BBB@ HIKC(IA= ^TN S=!0!+13,DG
M&"*0C/(Y(XS0!)149)&>QXYIR'.: '444E "T5&[J@W,VT#C)I000"#GC@T
M/HIJ\$COUIU !1110 4444 %%%(: %HJ-V51EFV@=Z52& (.[N#0 ^C-1G@X
M/4T+U(;'% $E%(O2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I!2T@H \ _:!_Y#VC_ /7L_P#Z%7CU>P_M _\
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M** "BBB@ HHHH **** "BBB@ I!2T@H \ _:!_Y#VC_]>S_^A5X]7L/[0/\
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MOF#X+?\ )2+3_KC+_P"@U]/]JZJ/PGSV/_B_(6BBBMC@"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH/2@!N<'%8W]C/\
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M/[INO3H:M3-*1B,#/O6;J+NNCWWGR841,2GKQ2ZG/>VIX%'(T,IDCF"2!L@
M].:ZVWN;3Q58"WNPL=_$/DD_YZ&JENND:@Y1K*:/_:12<UH?\(I8&,727KVN
MWD!_EY_.M;:'5[>G-7ZHY.]L;NQNFAN(71AZCM5<.@&&^[7JUEI-AJND$:A<
MK.RC DX''X5 GA'PT$"PRI)-G[I?_P"O2Y+F3S&,=]SS6&&6]G(AA+>@Q6U#
MX9U62(,EDV?I7J47A^WMK) L,$*CJQ;FECM/#L0WW&J*N.JA_P#Z]'(83Q[J
M;(\K?P7K;$LMN"WHH-9EYH.JV(/VFRE7W(XKVA?%'A/3&"F<G_:7YOZU4U+X
ME>&6C9(H7N%'7?%BJM$<,;4_D/$"C*<,"#Z5):KF\AY"XD7^=>GP:_X.U60Q
MRVQBD?H=G _6I)?"FCW"B>TEB<!@1M;GK0TNA53'RY7S1L=7G.E6Q50?W8YK
M#NMBDCYL5N28CLHH%7 5 *Q+J1DD"G!!XYK*>Q\+B9>TJ-Q,>>;!(\P[:S[I
MX5:("-I6;/4=*T+AHIRV$)V\^@S64MR IGEBY!8+GC%<YQZI/F&.LB.#(C =
MLCI6#XBP8H,$CG^E;]Q]H<188E&&[)' SVK!\2!1!;[7R<\_E7?#X3Z'*/XT
M3G33:<:;2/N0I#2TAIHAA24M)3)>QZ#\%O\ DI%K_P!<)?\ T&OI_M7S!\%O
M^2D6O_7"7_T&OI_M751^$^>S#^+\A:***V//"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHH/2@!IQM]!2$^G(QT]:.C 8X
MKF]<GNEN )-:BTJ'^$C:Q?\  T =%D9QD XZ=Z7D8R?SKD?#6O3WIU"TDNUN
MGME++<*!\PYQTX[56TJ;7]>@GF_M+[*D+D(416+\=\]*?*+F.VYST.14%S,]
MM:S2 %BBE@6Z5SFE>)+A?#5Y>7P#SV.0Y'1SUJ@1X@OM!FU)=2.'!(M-B[0O
M^]UHL%[G3Z!J<FKZ9]KEC6-M[)A>G%6[Z[CL;-[F4$J@S6+X'W?\(VA? ;S&
MS@Y&<U>\29_X1^\Y_@]/>BP%NQO$U&PBNXP?+E3(%95OXJLKCQ"VCHL@F52=
MYZ'&/\:CTZ]33/ \%T_ C@W?4YKG9[-K'P[8ZLWRW$=R'D=>24))/]* /1N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/K0Y D-Y[],=J>.E(% I:DH**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***#0 4UCC!S2#..N*Y[7_&6D^'94AO
M9':1^<(,D4T)FB^M:>FI#3GNT6[(R(\\UH!ADJ""1^E>36VJVNN?%"TO+-RT
M3Q8P_!'!K9M+[3-*\2:_=I<WLLT:$S1,@V*-P^Z<^M585SK9O$.DPWR64M_&
MMRS;1'GDGTI+GQ#I-I=QVMQ?QPS.?E0GEJ\>TCQ#X>37[S4M6@FF<R;H=@)V
M\=>M3:)JVB:AXK>?4X'E$LBK;=<J>V>:+"N>WJ0PRIR",BG5@:-XEL=5N[JS
MM%E#VGRN&7 /;C\J=8>*+#4=3O-/A659+09E++@#FI:&F;N:"R@X) /UKC)/
MB3H"7HM3-(2&V^:%&W/US5?Q,VG-XFT:6>\NTDD(:)(E!1^1UYHL%SO,T5S^
MN^+-+\/(GVV0EF_@3EORJ'0O&ND^()F@M)664#(CD&"?I18+G39HKD;WQ]I&
MG7UU9SNXG@."N.6/M5SP_P"+=,\1EUL78,O)5A@TFAIG144SCCFGTD,****8
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %(*6D% '@'[0/_(>T?_KV?_T*
MO'J]A_:!_P"0]H__ %[/_P"A5X]7'4^)GT>"_@Q"E%)2BLCN%HZ4"@T-%H6@
M4@I12*%HH[44%(44M(*=2*1TG@*+S?&6G+W\S^AKWJ3_ %C#MG%>)?#*W,WB
M^&3_ )Y?-7MC<MGUYK&J>?5=YD,D'G,-Q(4>AZT\0QQ<HN*D%(_W:(BZF5?G
MY6S7,ZI*PLXXD&&WYS[5T>H-\IKE/$$[(MHJ+C*\G\:RK?#8Y<P7-0Y>Y)9A
M[>%&+!BQP1C%=59*%MA_>;FN1LBQ4#.\]O:NPB(CMXE?[Q%?.XO3W3XC%1FE
M9D,P8M@=!56X)V]>1Z5:GW+*1V-4;AMC87DT4MM#CP=-NJHL9$ ]Q'SSWS5B
MW!^T'M@U1W8N49CSCM6A9?.2S>O%>QA5;4^^RBER.4F;=OTY-3^2FX..&J*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_%".BC)_&N_#+J>_DT.>K<YNDI3UI*Z^I]^]-!,T9HI* 89H)HI#3(84444
MST+X*_\ )2;3_KA+_P"@U]0]J^7O@K_R4FT_ZX2_^@U]0]JZ:7PG@X[^+\A:
M***U.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "D%+2"@#Y_P#V@_\ D/:/_P!>S_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I!2T@H ^?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ'M7R]\%?^2DVG_7"7_T&OJ'M732^$\''?Q?D+1116IPA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-)^%=/\ \*Z\8_\ 0NWW_?NC_A77C'_H7;[_ +]T6EV'[6'\R.8_"C\*Z?\
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M'I1QZ4N*,4 )QZ4<>E+BC% "<>E''I2XHQ0 G'I1QZ4N*,4 )QZ4<>E+BC%
M"<>E''I2XHQ0 G'I1QZ4N*,4 )QZ4<>E+BC% "<>E''I2XHQ0 G'I1QZ4N*,
M4 )QZ4<>E+BC% "<>E%+BC% "44N*,4"$'6G4@%+0,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_012.jpg
<TEXT>
begin 644 form10-k_012.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8721?*DKM<)(!<R?O)&>+9]\8)P7;JIP=1SBHJZ2VL]M_O\ (3?*E=Z'N_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBTK_ *"=G_W_ %_QH TJ*S?^$BTK_H)V?_?]?\:/^$BTK_H)V?\ W_7_ !H
MTJ*SO^$ATK_H)6G_ '_7_&D_X2+2O^@G9_\ ?]?\: -*BLW_ (2+2O\ H)V?
M_?\ 7_&C_A(M*_Z"=G_W_7_&@#2HK-_X2+2O^@G9_P#?]?\ &C_A(M*_Z"=G
M_P!_U_QH TJ*S?\ A(M*_P"@G9_]_P!?\:/^$BTK_H)V?_?]?\: -*BLW_A(
MM*_Z"=G_ -_U_P :=_;VF!0W]HVNT]#YZX_G0!H45F_\)%I7_03L_P#O^O\
MC3KC5K&U53/>6\(897S)5&X>HR: -"BLW_A(M*_Z"=G_ -_U_P :/^$BTK_H
M)V?_ '_7_&@#2HK-_P"$BTK_ *"=G_W_ %_QH_X2+2O^@G9_]_U_QH TJ*S?
M^$BTK_H)V?\ W_7_ !H_X2+2O^@G9_\ ?]?\: -*BLW_ (2+2O\ H)V?_?\
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M_P#O^O\ C0!I45F_\)%I7_03L_\ O^O^-'_"1:5_T$[/_O\ K_C0!I45F_\
M"1:5_P!!.S_[_K_C1_PD6E?]!.S_ ._Z_P"- &E16;_PD6E?]!.S_P"_Z_XT
M?\)%I7_03L_^_P"O^- &E16;_P )%I7_ $$[/_O^O^-69KR"WMS/+/''#U\Q
MG 7\Z +-%9W_  D6E;<_VE:8_P"NZ_XT?\)#I7_02M/^_P"O^- &C16;_P )
M%I7_ $$[/_O^O^-'_"1:5_T$[/\ [_K_ (T :5%9O_"1:5_T$[/_ +_K_C1_
MPD6E?]!.S_[_ *_XT :5%9O_  D6E?\ 03L_^_Z_XT?\)%I7_03L_P#O^O\
MC0!I45F_\)%I7_03L_\ O^O^-'_"1:5_T$[/_O\ K_C0!I45F_\ "1:5_P!!
M.S_[_K_C2_\ "0Z5_P!!*T_[_K_C0!HT5F_\)%I7_03L_P#O^O\ C1_PD6E?
M]!.S_P"_Z_XT :5%9O\ PD6E?]!.S_[_ *_XT?\ "1:5_P!!.S_[_K_C0!I4
M5F_\)%I7_03L_P#O^O\ C1_PD6E?]!.S_P"_Z_XT :5%9O\ PD6E?]!.S_[_
M *_XT?\ "1:5_P!!.S_[_K_C0!I45F_\)%I7_03L_P#O^O\ C1_PD6E?]!.S
M_P"_Z_XT :5%9O\ PD6E?]!.S_[_ *_XT?\ "1:5_P!!.S_[_K_C0!I45F_\
M)%I7_03L_P#O^O\ C2?\)-I ZZI9_P#?]?\ &@#3HK+_ .$FTC_H*V?_ ($)
M_C2_\))I/_04L_\ O^O^- &G16;_ ,)%I7_03L_^_P"O^-+_ ,)#I7_02M/^
M_P"O^- &C16;_P )%I7_ $$[/_O^O^-(WB;2%ZZI9C_MNO\ C0!IT50L=4LM
M25S:W<-T$X;R9 ^/KBB@#P;]ORZGL_V1?B//;326\\=BI62)BK*?,3H17X +
M\0/$\?W?$.J#_M[D_P :_?[_ (*#?\F>_$O_ +!X_P#1B5_/!0!T7_"QO%7_
M $,>J?\ @9)_C3O^%D>*_P#H9-5_\#)/\:YNB@#I/^%D>*_^ADU7_P #)/\
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M<\-:EX=U233[^UDANX^L>,FFI)[,"]_PLCQ7_P!#)JO_ (&2?XT?\+(\5_\
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MF%4+BSFM6Q+&T9_VABH%=,W?^%D>*_\ H9-5_P# R3_&C_A9'BO_ *&35?\
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MP)]Q(&3[5Q_B?0[WPMJ4FFW;@LH#9C;*-D=16>KLD]CKU=DGL?JW_P $2_\
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M%O1]LE #V_I7?^+]7_MFWN?M<'DPJF5D]:XG25S?6PWP%XOT+Q-J%\EWH_\
M:&J71+$!:QM8_9S\(_$:ZNM2OV@MIX24%HW#"J?PDU&/POXRAU$1#R]I 8]Z
ME\8:J;C4[Z\LV:*2:4G>I]:'1MJ8J6IYUX@_9-F^RE_"D+V3V[;S=+R,"N4U
MCX;^+])M8]2O]?.I?9QF.SB4J21V->Y0>*O&&@:1'#IMPU_'+Q/&3C:IZFM:
MU^(&C_V6^ESZ,CWTHP+@CH?6N1MP>AHCYU\/_%OQ)HT+W3:+<:3:Q<2W-R/E
MS6O#\=M,NK9KO4M2M[V3/RV\>-QKVGQ1X=\(77A-[:XU=+N>5?WEB0.OI7)>
M"?V6]&71YM=GT:")22(CUV^AK>%=]2MCS"W^+^G^,[J6QN]$N+"W09W2#:"/
M6JGBSQEH?AG0F/A^6&V8C]]NY+5Z%??LPVOB*&=&\1W5E*N2-BX##^[7D>K?
ML@^+-/DO/LD?]IVSC]QO?!/N:ZH3B]V!R=_XJC\4:&ULEY'$TIY8<'-5X;B/
MPKJ$;7D3S%HO7.1ZU/J'[._C#3(UGO-)%A# /FV,6+$=ZX;6H?$$FL%9XKF6
M>,;$_=G[M=GN-)IW [JSU8:?>?VS:3;K63_EU;DBM6Z^(%U?3(]J553]Z(#F
MO.M-T_4K=4@N;>6 9R'*GGVKK)H[#3[1'W^7(1\\F/NTJE/E=AHFU!HEU2*[
MB<P[ES)O/&:CTOQQ-#?M'#>Q>6*Y;5M;.J6\D-F#<*IPS=,T_0[/2X8=LH57
M[L3SFL^4=CT*'Q'J4EUO@O80#[5!K&HWMQ*OGW"2D]>.*PH%A$;"# 7LP-43
M>>2SQO+N.>*5K:H+%O5-!&I=;@0Y[@5G6K7GA>.4:7)))/C(?<<5H6NM6_F+
M%*/,XIB-+-J!$"GR^ZU$J7MOB)/2OAC\=+/P?H,K^)1]LNW!VJ.M>X?"MO#?
MQ1T.ZUF+5X=*EZI;2L-Q_"OB_7=!DDN3<-;ERO*1]C62VJ:MI2[[99K.3J3&
MQ&WVQ7-.@X-<H'W19^!-3U 7<UI82:E:1$YO(_NC%<O;ZBR27$$!<!<JR\\5
MYS\#?VF/%3-#X2CNS;64RDR2=2?7/YU[[;^.- T?2[O3'T9)KB9#F^QW/>L.
M><79H#R#QGKEPVCO;^<I0 [0>M?*&L0RR:E=OY;8#DG X%?7OB;P;X1;P7JM
MY=^*?(U5E8V]N6 ^;T%>$7'P;\5:;X3G\4V.V^T=1FXDW#Y?P/6NB-6.S95C
MRBBKRVZ2*TTRR6\;?=8(2I_&JDBA7(#;AV8=ZW)&4444 %%%% 'V?^R[#)>?
MLJ_$^WC&2W3\JX#]I*1]-\ ^#K"*4!&M4\Q%]0*]>_8;T]]9^ GQ'LE7=N_P
MKYC^/&N37FO6FG22EA8Q;-OH:TZ$ZW.#TNSO(9$O(H698SN]R*]"C\:1:?HK
M71S%,ZX5&ZDUA>#?%%L)$MKQ53(VANQK1^)4>F_V?:1VF&G9OD"]34]"CV']
MA5GN/B#?W]Q'O#,"7([U]Y:E;6VH:@[22#[IQ7R]^Q[\&]3T'PN-5N-T<EQ^
M\\LCH*^D%OT6X,)@W.."U2!@6MJ\-\Z&3$>[BH]0TRX^V^<MQ\B\J >M;TL=
MM<,^!M8#-5X[JUG A8A9!QS0!#-/)=:8T4B8?'#5BQ^&;N;1Y$BNDVENA'-;
MC:'>^<'$N^#/Z4^2WDCN L0V18Y^M '*:7%JWAYFMW.Z CJ!6S8ZLEXQLS!M
MD/&XUL%HYXQ%*0"O>LZ\\(7$[&>TN-LO4 4 5=2C?3T*AP35&QF%Y^YD4JG6
MFVNN/H]Z]MJ\!EYQO(K8^RVE]:23VLH+GHHH XKQMX(M-6TV>UNXEO;2\4H5
MQG9[U\*?&+X)ZC\,]6=H4DN](DRT<ZKG8,]&K]!&NI9D2V"%2I_>$^E8_B[P
MG!X@LVM#$MS:2#$JD9% 'Y@45[_\8/V;[S1;B74/#=L]Q9#)DA7DI]*\$DC>
M&1D=2CJ<%6&"#0 1W$D3 ANE=3HGBF&QO+=RO.,,:Y*B@#T/5+BTU6VDD*@L
MQR*ADC6UTB+;;LQSQ6+IMPK1IL^;'45V=E8W'BJW>ULQM>-<_+VH Y*\DU!8
MVE1!;QQC^(=:H6.H6)R+V(RL_+..QKN='\&7UOJ$<.LSE[=CC:W2O:M%^ OA
M[Q1IZI;"--V-S"@#Y:AOMDLEP<RQ_<2//:K>GZ>ZA9?LK*LYVG_9%>C?'SX3
MV'PVOK"/3;@2/(0I5?6N6N=%O9&AA2^*F-0TB^U %"X@AM9%LF1E@'W6SPU1
M6[?9K@QAM\79?2M6ZN(1Y<+)]H/17]*SY(8F8L#Y9'!- $MCI*:E=$W+81?F
M'-78[E;ZX>VCB*PQ\#WK+B\BU88O]Y')7U]JGOI)[R!)+']SZL* )KW6+?26
M%N+5GE;CBM+0?!]E<7\=WJ&88WYPYXK0\*:#I]Q8O-J5V'N5&=S=:YWQ+&MU
M>&(:JWDC[J#I0!Z#K"Z+X?L4BL2L\3G!"&LR/P[I6IVKR-BW9!N 8UQ\>H2V
MNBI!:6AN61LER?UJM9V5[X@6>5K]H&Q_J<_I0!LW<ZV!VP$2[>F*8U\^I0M&
MR[3C%2Z1IEOI]ELN9@90.I-8FI1WMO=>9$,P?WJ )G\+VJV@>5\.6J9)M-TV
MU\N&+SYE'1>M9*QZAJUUM7=Y'K6M::*-,E24\NW4F@"G#?W]U(?)MS;C_:%5
M[B)[F81W,!DE]0*V9[XO>!8G!QU%2-9L^HB828&V@#/L]/GDFDA1U@ 7C<*N
MQ^ =7N8_/-T&BZ_*O6F^%V2\\47,5S-A5' -?8OPMM_!?_",K!?-"9]F,-BA
M:@?%%_8:OITQ:"TF>W3AF"D@UK>"8[>YN+FYLX)([A4(92>]?7WB+PWX>GT.
M_CTWRS$<[G7'RU\L:9'#X>\67ULK^7$H,A..HIU-B9:*[.2L=0OX=8EB=&42
M,0<BF7PN5DNP8RJK_%75>(M<L]>MXY;&+R55\/,!T]ZS(;>73[.XGED%Y8R=
M9F(RM;8>G*2ND81G[UC FT6.QLQ++QY@SN-8 :-7/R$CMS5_5M2>ZD\I)FDM
ME^X#Q673JM7LCI'-RQ(&!2<U8L;"XU*Z2WM87GF<X5$&2:]]\,_LTR:;X-G\
M2>) 42/:P@!X ]ZP2;V'J> 0V\EQ(D<:,[N0J@#J37Z%_!L1^#? >EPK$()R
MB[EQSG%9>E_"3P]=Z/H^H6=I""(U<!5%>AKI]NPB"Q?*J@ >AI\HA_EW6K:D
M]Q(K%&J:/3S;W0E<%%![U*8;P*!"^P"K%K:W,UK*;DET'4TN4SE(?=[;A$9'
MS".6:N2\6?$K3M#O(;>UF65\X95/-=3)&MQ9M9V:Y##FLC0/A)I%G>/>:A$L
MLS')W<XK*7N/F1M4O*C>&YYY\:/&T?B3X4ZU#;V4CN(N2*]%_8__ &Q-)^$O
MP?M-!N]'N9;J' W1#.?>J'Q,L]*L? ?B&.SA0;HB.!TXKQ;X7V-N=.A#[>E?
M2Y?PKAN)H^SQ6Q^A\#Y'3S2LX8G8^Y[?_@H-HEBT<DVB7OELW.%Z5^=/[=7Q
M2MOC5\:I_$.F6TD5D8%C56!SQUKVZXL;-H2'52.U>-^(O#]E=>*+EI$483 R
M.M>EB?#; <-TO;X5V9]QQGPM@\KPCK4'9^I\Q1QEVVAL?6MW4=0U5?L?VQ)$
M,<>(=RD;A1XNT4Z+KTR(F(V?*K_2O3->US_A+/ NGQW&B);Q6D:J=2##*$>U
M?$5I<CY7JC^>924DI;HY;0[6YU;3[ZUU R!8X3+'#TY]:Y6X;5?[%2*19AI:
MRDH2GR;OK7;Z?)J-G-!X@N$62PVBV#9^^.G2L[X@Z_!>V,5I9731VX;<VGA?
MEC/KFN2E.T^5+?\  YJ,VI\J6C_ _3;_ ((E_P#)._B%_P!A&#_T T4G_!$O
M_DG?Q"_[",'_ * :*[STCZI_X*"?\F=_$W_L'#_T8E?SO5_1#_P4$/\ QAW\
M3/\ L'#_ -&)7\[WUH **W=/TFW\0:M':V4GV1&3EKEN_?I2:IX3O=/OGMHA
M]M*C.^ 9% &']*=)(9,9I\UO);R&.5&C<=588-14 =;\-=4D\/\ C33-5$<K
M0V<RRRM$I.U>YK1^-7C2U\>>/KW5K-F>"0* S#KBNP_9SU+2[&S\5#45B9GM
M"(_, ZX/2O&;S#74Q7A2[8_.EU KU),WS#'I3%7<V!S3VCVP[CUSBF!'FBBB
MG< KH? NFOJGBK3HE!P)59OH#7/5[E\!?!32L-2FCY<_*2.@I ?4G@_35CVR
M0CD(,UUNH3$V\:D'=CIVK"\+L$C98C\VVM2:\DCC8,0<=:FW0#F-6M9A)YB
M@Y[4J_NXDD5M[L<,/2HM2UBX:3RH5^0GG(J]9O;75N(+6)UO/]OH36D8V%*;
M.1\6;)/-^Z&C&1FL#0OLNI1LM^^1TV]L5OW$EA9^+5M?$UO-]FS\X3C(JCJ4
M>D6FK74UC:326 /[A%&2/K6\3AG69TD/@_4].TN/4?#,QET16S-S^\W>@'I7
M174/ASX@:.8HT^Q>);=<O'C:#Q7+>#_&NI>#Y//.);:0_P#'N1P%/J/6NEU%
M;'Q?<KJFF.EC=V_[UL?+YG^S5RV/+J7<N:)YA:M+#>:AIUU$T<Z\>:1]WZ&K
M7A]I[2Y#QC9?QG]W+_?7ODULZY<2ZU#?75Q&MO(HPZXPS?2L>S@O?L,0NF6V
M1A^ZD;@@>A-8+0].C5A6AR=3H9/$EEJ6N1-=IM=E\I2!_P M/6M/Q1X)FL-%
M$@F5=3^^Y4\,G85S&G201:O"+F R6O&74=3ZBN^UVSAFM[>1;AKG3C_JX5;,
MB'U;VKKC*ZL>?6C*BSA_"NK3WD@#6S_9+;B9]O"T^^L[N34FN+$JUJQSUYQ7
M3Z9-J']GZG8:='";"7B>3;D_@:P_L<:6/E6)>WDC;:1(?O?2N6<;LUP6)7-R
MR,G4+^P;:$0_:U//'&:W+=YM8TZ$><PV?>B_A-9'B!4M)%B2S=@5RQ5>?K3K
M?6I])T.6YAMGE6$;DB4?-GWJ8QL>MBK<EXG1>%9KRQ\30W-Y;1);0C$2^OUJ
MAXTM[R\CU!KB)[=IY"8E88!4]Q5VVTR\OO#=OJ]_)]GDN0)4C/!7VIOBKQIJ
M?CZRM9Y;#RK'3U\@S1I@-CC-6T>;&=DCE/AG\-;;1[V;4[N>1Y&Y3)R,UZ)K
MNK37$-E:7"*(&;!8=Q6?I=]]ETN*!X6>-C\N!SFJFK&[^U*KQLL2\_,.E9GJ
MPJ7B0M;7JWDR6FTPH?DQUJY:K-J%O]F,>)U;)XIWA/3YEU9I%<LK'.">*Z&^
MN(].NI3"G[XJ<G'%5:YS1?O,Y^X5[74HQ#<NJ,-L@!JIK\B:9(MS81^<(^6+
M]?PJ5(Y+B)IT/S[N0:BU[>=.C.S:W;_Z]8RIW.N&FI0U"TT^\@2^TI1)J4HW
M2++P%-:GP\\6:_'J@TF\NGEMLY\K.0#_ (5S5Q=):QQQR.L9D&2R\<UJ_"VX
M6W\42SW&3*R[%SZ>M1]7N.3N?1.J>.%FT%=*_L:V0PC=)=1K\VWZU=U?3O#%
MOX3TF^\.ZK<7.ISX\^&4_*A]JXS0O-LYKG=\]K(#G=R>:O0PJMG,H41H/]7M
MXK!T1&MX[\+G0Y-(>\>*YM[R,,ZYSR>U<5X@\)V#7D:1Z%##)C<6EBVDKZBM
M2+3I]0:%[RXDE$+!T#-D#':M+QEX\F\4^(-.?54BAMK9%B8P#;E!6+;I:@>=
M:]X%\+Z@H$=O&#WPHZUP6N?!/0;Y&BV@!^O'%>Y>)G\-S7%T^A*PM5CR"QS\
MU><WVMVW]GGST8.O\0IT\7?<L\<N?@'X?T.1DWL@?G"&N/UCX&^'[BX9DN9H
M_P#=->]:CK.C00QM,DDK,O!ZUSS2:.TPF>-VCSSCTKJ>*5@/%I/A[IV@V;QV
M]U(W_70UY=JVGQ6.L9:^0\]-]??6C^(O@/:Z7GQ9:RE@/FP:P;CQI^QFL[9T
M6Z=\\MY9(-*GB-=-0/C#0Y+3[9Y+SQN6.=VX9KU_P[I-A]D1X!O4_><BO?M%
M\0?L?WUTKVVA7&5/_/,_X5P7Q@UCP;<^)4B^'-LUMH6SE)!SNHEBXW(.+NK?
M3&9E(&$^Z<<FN,\8+IEGI\US+A0%*@ =21Q72:I>62RPVRHWVR0XSVK@-<B/
MB#Q!!H#[I)6<-\G;%*.(3&CK_@!X%MY+.XU#4H9()I#F!L<[<<5ZOJFJ75CI
MK6*V:NO3SF'S8K0T*WETC0[2...-/)0+R/2L[Q)K4UPH<A O1L"IE/GV*/GS
MXK+;PR013+*S.21(H^[5"QTOXH7'A?\ LVSL-=?0I^?)C@<QN.W;FIOBEXNO
M&U06JQPFVC8.K%<G(.:]S\*_\%,/'_A/P[I^D6_A_098+.(1*TEORP QD\4Z
M<)1CM<@X;5O$7C/5O@_#X%?X9RQ21N&_M)+%A+M'OCK5'QA\)_#MK\&=&O-%
MT?Q&?&L;DZI'<6;K#&G<YQC%>K?\/3/B-N!'AWP[UY_T;_ZU4/%7_!3+Q]XH
M\/ZEI#^'?#]K!?1&)WBM_F /<<545..R_$#QGQY^S3XJ\"^$?#>OS_9[Z+7%
MS;VUFV^4<9Y45Y7>6<VGW$EO<Q/!/&<-'(,,I]"*[CP1\:O$G@?Q9IVO1W']
MI26)8PVM\2\(#=0%/3\*YSQQXNN?'GBK4M>O(HX;J^E,KQPC"*3V K6-^H'/
MT4450'Z%?\$];J/3O@7\2+J4?*HY/X5\.?$C5AK7C;5KI?N-,P7Z U]@_L@Z
MM)I/[*OQ6ECP&5&(_*OB6'&H7VZ=^9'RQ]<FM-TD*Y>;1X/[!AOED(??M;FI
M(?E\0Z:JR&X"R)@-SW'%=UI?A_25TU[=R6"KY@R>]8(T6'^V=&FL&S=R7 RI
MZ<'K1RB4F?IY\+]5/_"':7 D?E-Y0R,8[5TMOXBL+.X:.X@&X\;L<UA_#F)K
M?P;IDMW"6F\H<H..E3:MIMS-<^>(@,\C([5F5=EVYA@GNC-"0L3=N]96H^$Q
MJ$GFV\IC/<YQ22V\WD[A(!(O8&JL&HWX/[YU55]*5V!94:EHZ^4[%XAQN-,7
M66F;RUV@'KFEF\1.L86==\1]N:GM].TC5(3(DOER?W=U,!O]FI,IQ,-_7K5*
M234=+D616+HM37V@O;P"2!I#COFJUOJODQLMTZJH_O4K@3P:YI6K0RQZA$HG
M;@,PKF;:RFT&^EEAD,T>=P13GBMS7O",6M:2;K3KB/SL9&T\UQ&E76L>&;HK
M<P23,QVY89%,#LEUZSU./8D:PW<GRN",55BE;PK<>3L-S%<'YFQG;3[K2;#Q
M!9AK>06VKCYFYP*J:3X@.BLVFZQ 26.!<,./SI7L _6+6&S(DMHO/MI1F0$<
M#UKY]^-W[/.E^.K.;5O#4"VVIH"S1HN%?V-?1VH-)H=J3;A=0TZ?EA'\S+FL
M"YCOM#A%S9F.:*8\Q@9*@T<P'YC:IIMUH]]-97D+07,+%7C<8(-4J^]?B]^S
MKH_Q,T\ZI9LMKKA7+.O0_45\3>+/"NH>#=:N-,U&)HIX6QG'##U'M3 H:9J
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MH9AT5+-;R6\C(Z%64X-14 :/A_3?[6U:WM<X#MR?:ON#X6^%XK#1(81&!\H
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M6V<MC[V*O6'@_53&\K[@C=177:;XNT"QL2(T#72G:4*\UG7GQ)EWM%]B=4/
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M?+T*ISC&'+%7.MO/%5[J^J6\9A"6[QYC;'Y5\]_$SQE:>#?'0CUN2,3W?[M
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M0(]4^$OAG^Q]/%_,O[Z7D?3M7L?A_39;Z1;IR5P>!7,>';.XN)88UB7R8\#
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M<%CR2:Z3X^>)++PWX9NM4ORN8U/[LUD?LNZAH7Q2\(RM!J4T5\CMN0G!7VH
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M!(9E:1@=KC&,U>A1;.%HX>#US6E-]!V3*-U,\<<J2CA>E94UQ)=210JF,X4
MCN:U;IO.A):0*4/.>])<7%I'K&DSQ$21QO&T@4>C FHJ6YA61VNI>,-8\._#
M]/ ^IQ/%!,1,GTZUY=?;/.VH,!1BO:OVDO%VC^,-<T*YT:)56"S5)0OKBO#Y
M&+-D]:*<5R\PAM%*K8I6:KTL VBBBI ^SOV9<_\ #)/Q3'L?Y5\8U]F?LRLO
M_#)?Q2!/.T_RKXSJWT ] ^#/CR?P+XRM7\TI873K#=+G@H3UKT#]I;X:K8Z@
MGB;1]KZ/<*"JJ,\GJ:^?Z^D/@#\0+/QI#!X'\32KL<;+2>7HOL:@#Y]MY'O+
MZ,R#<2<;0*=J%K<M++*T+;%."P7@5[E\1/@G)\)?$EW)<1_;K.=MUM<*O %4
M%DL;W2GMHH!'(1DDCK0+J>L_L9_&"_NF7PY=D-;V^,2-_=K[<O);..QD\^-+
MB"1<*",U^1VC_$+4/ ^N(^F!;<0R_O0O_+0 ]#7Z _"'XG_\)]X1LK\/YFX8
M\D')0^] S(\0WU_\)O%+:K,2NC73Y"K_  9KUOP\8?'6G1W:W0:VD7<%W5#X
MP\")XZT 0W[+)$R\(>U>>:!I=[\-[P6<,C260^ZN>@]* /3;BUL?#.7B4/*W
M'K6=?:UJ.I0^6B,J'^Z*GMY8?$6QU!5_>MB../04:2XG0C' - &?HEO9VD):
M\.),<[JJS/9:U(UI&[)SP0<"HEL6\6Z@RQR>5#G[W:KUYX?@T=4BMP99^A=:
M *ZV#^"YOM4<ZS;_ .'.:7[9JDUQ_:4DFVWZ[2:JVGA&_P!0U:9KJXV6ZC(5
MJ1=/O-:U'^SS?I':1'!7IF@#P/\ ;.TMM:^'IU6.[\M8I5W1[N&]JXO]B?Q#
M)H.D:H\+*DIN.K>FT5[A^U!\/[37/AC>:=:\O"/-$O8,O.:^-_V95UC6/B58
M^'+"Y,<%Y)^]C'\6"!0!^AVEZ7X@^(3/#I(26YF^5F3G%>V_!G]A>/0!)?\
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M,*2'(3Z5W4=$>9BLLG4BYT9GT/XT\!Z%;^ EU"PM(M'GE3]R4P"6QQ6/\*?
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MTL[.9MT+6S]2><'%<[\4++0-'6TC\)F[NHY2%638=OUS560Z.;<^LU8YRWU
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MJ ,-M8@\*VYG\G>M6M-FM_B''OW")5ZKFN&-[>ZIOL)8MR<C=UK@_$FL:_\
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MO'%IX;^$>H6,EU';S72%068#@C%8?_!/'PKIWA'X)V=I9S&>1B7:0G.<G/\
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ME6_B'>LBX\,KI^FR-++B1N<GJ* /B?QGX)\5_LS^*AXCL+I7LYI22L9PN">
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M",'_ * :* /JC_@H)_R9W\3?^P</_1B5_.]7]$/_  4$_P"3._B;_P!@X?\
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MFU'0UDVMA+IZR& [HV]:MV+.-2MPYVN5.TBM%*3*]E3V)VU3R+H6=R=LK#)
MZ9]*U;2:!K;;*YBG7E8@/O5GQQQPVMQ;Q1->7[2;RQ&2HKT*PTS1=/T#3]7/
M^D78D EC/.!6L;]3SZV*IX6]SS:XTG4M0:>^AL?,\CJAXQ7H7AWP3::;KVDC
M4;D/#?VS2NIZ(<=*CU_Q4EU9ZPNF(L:S( O:O+KCQWJ'V&**X9C>0#8A]JZ.
M9'C2=?,':GL=;XF\6^#O _A6^EDCBBN+:^)5<<M@]:X[6/B4/&37&K1S&RM9
M(0FU?3%<'XBT>?Q)'*[)YLWW]C_=S4OANU34M(%@L?E:AG:R,,)4ZW.JCE<,
M.^>KN8&N7TND26;6I^T0W;;?,^M=DOPBC\%^"Y_$&H7327]TXDBT\'*N#47B
M/P/;6.FVZ:7(9]97[\$A^0'_ &:Z2WU6;PG\,9](\07":AXFNOFMU8Y$:>GM
MBCF+Q&(@X^SIJQY]K7CMM*:PL[A/]'C*S+#V#>E8OC/QAJ'BJ:]U.1G6)(L0
MQ#DQ$#J!69XRUS1[[R/#]HYG,;":6X/WU;NOTKT+PAHUMH>GKXDOE2[DC7-E
M8KSYS =&%7S+8\S#X64I<U1Z&#\(?A_>>.%@DE,E[J[C, D!&X>_I71ZUYWA
MF^.BO(T=I%)ONK9<E2X/(S7HN@^/=9L/#]S>:;HMM::AJ S(B@![7V6LY8WD
MT2XL[F&*>_N#Y\ES+U]^:IR5C5T8QDVCYL^-FN6/CCQMI-I: Z%:W#"VFM8^
M/E_O&L3QLVH>&O$%CX.35&U?P]9A94A;G9FIO%VK:%=?$;4KS5Q)#9V\'E6\
MD:G:91Z'UKE/ACI^I>+/'2?9&^T&1R':<Y.W/%<DO>9[U!7BDUH?1?@^PAU?
M[&UM)A(T^YZ5ZK\/+&'5M6NK%<2/&A;%<_H/AIM"MS!!&OVA>'VCI79?#O3%
MT'Q%<W8)WR0G(]\5--7;1CBERRARLQKVZMK>.:.5O*D+E"H^M+H]U!I2R(B
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M4/A9\2+^U=/[0T=/W>Y/O?44 ?N?H_B33=<C5K2[BD; )0,,C\*UZ_'OP?\
MMN:7JVO8T;6&TB\FZ&8D FOJSX=_M@7'A^R5]?U&/5XL<M&PS0!Z1^V]^S?I
M'[07PAU.&>V5M:L(FGLYP/F5@"0,U^)'P'\33_"GXT6=MJ*NB"Z^R7$9) #;
ML9(_SUK]NK?]LCP9XHT>]BMWQ<&%AY;,/2OQ$^.%T-4_:$U6\L(&B6XU%70+
MT)W#)% 'ZIZA<Q:]'I^U,VT@!61.E>A^ OB0?AOKEI:WMSYFFR?*<'[N?6O$
M_AM]ON/ 6E[Y,;(UX/7I6_JVAQ7$43SRYS\Q7- 'WA#-:ZY8QRH5F@E4,K#D
M54\0:.=0\,ZAIUM^[::!HT/N17C_ .SG\2(=2C/AYGW20KE<GFO>J /R<^&>
MMZ_X?^/GBGP;XF@E2'3IBUO/@@.I/%>+_M6?%K5/A?\ &2PN=,1/LI&]PR\N
M,\\U]T?M#>"1HOQH?6)66W2_ "L1C=7YE_MO32-\1H(S<+/&J':!VYH ^NO"
M7Q:T+XB:';7D4RS7+0C<D9Y#8Z&MWP__ *(1/*&5&;A9.]?$'[,Z_P!GZ/J^
MHPWXM[I,[8V;T''%>T_"'XW:OX@M+\>)K-H$LV;RI3P'QW% 'T%XBN([A?-C
MFMH=O/SXS6!IOC+39&>XO-9LUCMSL9%D%?-GBKQ1XB\7ZU=R:>TD6GDX5@>"
M*J>'?@[I4-P]W>7DLK2?O)+5I3AFZYQF@#ZR;6_"VHQ^;'<HG?S-W6J]GK6F
MR7T5O!+]J3=C*'-?)R?&+1X/%1\./I<RHI\M>>IKJM%\075AJ\T5JK:8[#]R
M)#]XT ?4%]HUM9S?:8H'93R36;=:"VJ3+=+&L3H.-PK@/"?Q0UNQ9;'6SYI<
MX QUKTVZ9]7M8C:WRHK#G!^[[4 8ZB=K@L;J-<# C4XKS']KJQ6;X.S27T9<
MHNZ-O1NQKUVX\.P6; .A:Y8<2YKBOB?X9;QUX=ET35[U8[15X!XS0!G_ +/O
MB2PM_@[X=A1<3?9E5F]Z_1S]ENW-O\-8R8C$9)2W(Z^]?FI\'=-@A:W\)6EJ
MWE12JD<_;&:_6_P/H\6@^%=,LXE"B.!<X]<4 ;=Q<);0O+(=J*,DFOEWXQ?$
M*37M2GM5DVV<9PN.]>K?'+QO'X=\/R6L,H%W(,E ><5\E6>J2>(FNO/)C*G*
M[OXJ!HWM'U0VX*2#9$1_K#T%?#/[<GCRQU#5D\->;YY;]Z)%.0F#WKZO\3>(
M[C2-/>*>,M!C'%?GU^T)X;U;6OB-)?Z?ID]S;-#V!/<YK.IL8UMM['O_ /P2
MW\3:)\,_B9JEY?W<)EO8U@ ##*J,G/ZU^FOC+]KCP+X2F>![]9[A1]U6%?@Q
M\,_#_B^U\71/I%M<V<JM^\9E( 7TKK?CH/$MFUM<SR74<B\2R*Q^;WJJ,;_$
M[E8=;\SN?I-\:/\ @H5I^FZ7<06^HV]KO&557^?%?.$_[?6@2:3&MQ>2W,YE
MRRL">*_/:::XU"9I)7DG?NS$L:WK'P#?WUBE^7CALC]Z9^ M5IS#E;F/J+XT
M_M\3^*-$;2/#5F;; VBZ88Q[@4S]EOX%WGQ*U(>,/%\\MTQ.^U6X)/XU\J:'
MX=EU;Q5:Z79XO'>=4#1C(89Y-?K!\+]%A\.^!K*%D$4D42KMZ8XJI-]2C3U#
MP_;W%@+&S98((1SMXZ4S1?LX!MV&9E^56JKJD-TBF. G]Z=VZGZ'I]S!?(S@
MLHZMZ5('QY^WI:_99-*#$F1I#G\J^>O@[-<S>)181/B.=?F7Z5[O^WQXDM[O
MQ-9Z;&=\J$NQ':O*O@7HMHWC.PNX92Z*GSY[-0!](?"O2%T<2_;5V[GPN_O7
M.?M+?$:Y\(Z"-+TJ81-='9A3R,]Z[6Z60RS22.$BB4LIZ=*^,_BMXLO/%WBR
M[N)G9X8',4?IQWH R8O#.KS*V/N3?,YW<'ZUU<FEVVGZ;:64DJLVW+8/>L?P
MGJ5U)"R3S[8%X7=WJ>XBLKB:1VNP9.PW=* ,B\U..QNF/E^9QL /3%>B?LZ_
M#^'XB>,K5);1A9VL@=Y&Y0?6N!MM 3Q%JC0PW )"\*/6OJK2;JV_9_\ @"=1
M6'&I:@AB''S%CT-- <%^V!\1H;S5K;P;IDBM8Z;@.\9X8]A7S15K4+Z;4KR:
MZG=I)IG+LS'))-5:0!1110!^O/\ P1+_ .2<_$+_ +",'_H!HH_X(E_\DY^(
M7_81@_\ 0#10!]4?\%!/^3._B;_V#A_Z,2OYZK/[0MU&]J)#.AWH8P2P(YR/
MI7]"O_!03_DSOXF_]@X?^C$K\#OAG\0KGX:^)/[8MK*VOW\EX3%=+N7##&?K
M0!E>*/%VL^,M06]UO4)M1NU01"6<Y8*.@K$JW?79OKR>Y950S2-(548 R<X%
M5* +-C;FZO(8%&3(X7]:^E?!^B1PW6F6<"9(*[L5X5\.]+;4O$D!QE(?G/\
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M?O ''Y5\:5;Z %%%30VYF5V'\(S4 0T5+Y;;0V."<5M:QX1OM&L8+R5";>4
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M+D,LHQM^E4O!_A/4+G5(](OT6#S&/V<9Y=L]*^L)-#\&WU]]O6!K>Y<?+M7
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M%0;H1:7XCM5P/+QEF X_.OG?Q+\/_$/@W4I;.YLYP1QYD2$JP_"LOPSXFO\
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MGF8 ' J/-+G!.*2@ HHHH **** /UY_X(E_\DY^(7_81@_\ 0#11_P $2_\
MDG/Q"_[",'_H!HH ^J/^"@G_ "9W\3?^P</_ $8E?SO5_1#_ ,% _P#DSOXF
M?]@X?^C$K^=Z@ HHHH **** '*[+G#$?0UU^@?%3Q!X:\-WFA64\2Z==*5D1
MX@QP?>N.HH ]:T7Q=\/+?X.ZCI%[X?FF\82-F'4!C"_C67\/_AKIGB[2[R\O
MM>@TXPQLRQL1DD#I7G-.4MR 3[T =+_PKW7Y-'EU>'3II-+1B!<@?*0#UKF-
MIKJH?B1XAA\-C04OV&E@8\D =/3-==XZ^(WA;Q1X"\.Z'IGAR+3-2M,+<WR@
M9?U- 'D]%>N_&SX>^"_!>D>&[CPMXC_MJZO;</=PX_U38Z5RDWPG\1P^#$\4
M/9XTMC@/N^;\J ..7OQFDI[1O'@LK+GID8IE.X!110?IBD 5UV@ZE81^%=0@
MN8]\W\%<OLC\D,'^?NN*V_".IV^@ZY!=7]I]HMBI'ED<'-6!S[ CJ,4GI6QX
MDA;^V)I3#]GBG8R1KV"GI64L>YF /2H <K+N7:"K9X)-,;.XD\G--["CFK M
M0ZA<VL;1PW$D2-]Y4<@&NU\-?&;7_"OAV;1[,PFVE4J6=,L,UP./EZ\^E)ST
MJ-P/4=!\7>!;?P#J5IJNAR77B.8$Q72@85CWS4NF_!_2[[X1WWB]_$UM%?6Y
MPNFDC<WMZUY33][;=NX[?3/% '4R?"_Q1#X+C\6MH]P/#[OL6^Q\F:?X%D@6
M/5)KJ3E8<@,>M3M\8O%;_#]?!3:FQ\.J^\6NT=?K7IWCSQIX.N/V;?#&D:5X
M?AM/$/F_Z5J"@!Y .N: .;T>1;ZST^YW;H<?<':J/CR222\M=DGD0 @D>M0>
M$+H6NDV7E'[1(QYC_NUH^*[/^TM0LI)?W2(,LGK0!]8?LK_\3"S@#'*J!@&O
MH;Q?XJ6SA%BBX;&*^?\ ]FWRM+T.VO(S^[F;8/:O9_%0M=06>(,!<VZ[C)ZU
MJD!YIXFU*&>&2,-^\_B.:Y*Q4[F#'>IXS6MJEO'=7 8-L;/*_P!ZJ\.DS+JD
M1B&8NI2G+8";1=.N8+J1[8",XRS,.HKUWX6Z/X6UCPKXEG\57$27L"$V<<AQ
MN..U>8ZE>FQO-[MY,0&"H%=!XZ^$]KH7A71/$3ZNSIJYP(]W$->7)W8''/J"
MZJTZ18C,#%8U/I6!K5TEC;LTC MWHENO^$>OI7QYRQ?*K?\ /3WKCO$&K-/'
M+/<KY<,C=?2NJFK%7,O5]7MVMI'5MA[Y->6>']!G^*OC0VZ!OLMF_&.AYJUX
MJO+?6+R+0K2Z*W,[85UY_.O</ASX5A^'.AVT:6ZF[(S+/CEC6@+0[.UM$T'2
M;>TA _=H%8#UK-NKAS;F+D/G=^%-U#599I ZIA6Y-5[RX>0(P'S'B@CJ..'A
MW$9&.*CAD\J-J66X2VA*MZ57M;I)E8F@VU*^XF0G'-5X_P!Y(V:MF1-S#%9T
MDXAD8^U!)R/C.<Q[ES7C6K2"+4@S<@FO1/'6M!9V!X_&O,[H_;KP'M0!5U9A
M-;D=&[5C*&CC&.3GFMC6(2JAEZ+UK'6?R=S,,@\4V05[F;<< 8]37?\ P)\<
M:#\/_'<.J^(M.;4M/6-D,2<D$CK7G4F-V0<YYKZ$^&?[/>C>-/V>?%'CBZU
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MRS'<1(Y(_*LFBC]* "EP?3]*0C%.W-CVH ;12]1GO24 %%%% !1110 4444
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MHH **7C'O24 %+SWH6@F@!****; ****0!1110 4444 %%%% 'Z\_P#!$O\
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M<\BHFDW'U]#WIL#N?@[X@\.>#_B-I>H^,-);6=#MV)N+(8._CBH?B]X@\/\
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M+J6EW&DWDMM<QF*6-MK*>QJCN^;VKTHRYEN>MS<RNG<;1112 **** "BBB@
MHHHH **** "BBB@ JU9WUQIMPD]K.]O,IR'C8@BJM% 'N_@']J[Q!X=M?L&N
M)_;6FXQM; ?\Z]-T^3X5?&K39'E>WT&\/6.7 ;-?'=*K%3D$@^U 'T_XB_8U
MO)=)EO\ PW<-J,8&Y-I!!KP?Q9X5\2^%6%IK5G<6R)P-RY7\ZZ+P7\?O&_@>
M.&"QUF9[*/\ Y=I3E2/3UKW'P[^U!X4^(%J=,\:Z/!:EA@W17<#0!\L1WQL6
MC7S_ +1 1\R 8_"M:;7M+-J$A@:-SP?:OI;5OV8_"/Q!TV:[\%:C&\Q&Y0K
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M-P+QQ895[?6O(.:_=<GIRIX2/-U/Z4R&BZ."@GUU&T445[)]"%%%% !1110
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M4WV&4445ZY[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &WX?\
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M]1_Z*=;_ /@M/_Q='_#D/4?^BG6__@M/_P 77ZQT4 ?DY_PY#U'_ **=;_\
M@M/_ ,71_P .0]1_Z*=;_P#@M/\ \77ZQT4 ?DY_PY#U'_HIUO\ ^"T__%T?
M\.0]1_Z*=;_^"T__ !=?K'10!^3G_#D/4?\ HIUO_P""T_\ Q='_  Y#U'_H
MIUO_ ."T_P#Q=?K'10!^3G_#D/4?^BG6_P#X+3_\71_PY#U'_HIUO_X+3_\
M%U^L=% 'Y.?\.0]1_P"BG6__ (+3_P#%T?\ #D/4?^BG6_\ X+3_ /%U^L=%
M 'Y.?\.0]1_Z*=;_ /@M/_Q='_#D/4?^BG6__@M/_P 77ZQT4 ?DY_PY#U'_
M **=;_\ @M/_ ,71_P .0]1_Z*=;_P#@M/\ \77ZQT4 ?DY_PY#U'_HIUO\
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M*=;_ /@M/_Q=?K'10M%9 ?DY_P .0]1_Z*=;_P#@M/\ \71_PY#U'_HIUO\
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M_HIUO_X+3_\ %U^L=% 'Y.?\.0]1_P"BG6__ (+3_P#%T?\ #D/4?^BG6_\
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M]1_Z*=;_ /@M/_Q=?K'10!^3G_#D/4?^BG6__@M/_P 71_PY#U'_ **=;_\
M@M/_ ,77ZQT4 ?DY_P .0]1_Z*=;_P#@M/\ \71_PY#U'_HIUO\ ^"T__%U^
ML=% 'Y.?\.0]1_Z*=;_^"T__ !='_#D/4?\ HIUO_P""T_\ Q=?K'10!^3G_
M  Y#U'_HIUO_ ."T_P#Q=/C_ ."(=]YB[_B=#LSSMTTYQ_WW7ZP44 ?E-??\
M$2KAILVOQ-40X&/.T_<WYAA5?_AR'J/_ $4ZW_\ !:?_ (NOUAHH ^7/V'?V
M-[G]D/0_$FGS^)$\0?VM/',K);^3Y>U2,=3GK17U'10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )2T44 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 45S?\ ;UY_=C_*C^WKS^['^5 '245S7]O7G]V/\J/[
M?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!T
MM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=
M3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J
M?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_
M;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[
M?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!T
MM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=
M3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J
M?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_
M;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[
M?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!T
MM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=
M3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J
M?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_
M;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[
M?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!T
MM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=
M3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J
M?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_
M;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[
M?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!T
MM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=
M3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J
M?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_
M;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[
M?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!TM%<U_;]Y_=3\J/[?O/[J?E0!T
MM%<U_;]Y_=3\J* &_91ZT?91Z5?:'T&*/)H S_LH]*/L9]*T/)H\F@#/^QGT
MH^QGTK0\FCR: ,_[&?2C[&?2M#R:/)H S_L9]*/L9]*T/)H\F@#/^QGTH^QG
MTK0\FCR: ,_[&?2C[&?2M#R:/)H S_L9]*/L9]*T/)H\F@#/^QGTH^QGTK0\
MFCR: ,_[&?2C[&?2M#R:/)H S_L9]*/L9]*T/)H\F@#/^QGTH^QGTK0\FCR:
M ,_[&?2C[&?2M#R:/)H S_L9]*/L9]*T/)H\F@#/^QGTH^QGTK0\FCR: ,_[
M&?2C[&?2M#R:/)H S_L9]*/L9]*T/)H\F@#/^QGTH^QGTK0\FCR: ,_[&?2C
M[&?2M#R:/)H S_L9]*/L9]*T/)H\F@#/^QGTH^QGTK0\FCR: ,_[&?2C[&?2
MM#R:/)H S_L9]*/L9]*T/)H\F@#/^QGTH^QGTK0\FCR: ,_[&?2C[&?2M#R:
M/)H S_L9]*/L9]*T/)H\F@#/^QGTH^QGTK0\FCR: ,_[&?2C[&?2M#R:/)H
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MM AU%,W#^\*7</[U #J*3</6C</6@!:*3</6C</6@!:3;12T )MI:2DW#UH
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MUKT!8Y?XE8=*PJ4Z\Y7C4:^;.Q8?#4X7E3B_DCJ_!OQ^\81V2MK&MWAD7KN
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M?@;3K/4/(D59/,[/3+C3=(L[J>%UB@-NN0B\9H4JS^V_O9M*CA+WC!/KLO\
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MM-+'%&+BMA\OB?[/%D1&56./+;M31XHMUD1U)6=>=OI6'/XT\.:5=;;^\C4
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M>?:J>O<BN;\2>(U\E_L+F(?PYK.IK%WV-:;::L>D_L=:6=/TOQ"#!Y):X3(
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MJ]X*^&>I^)I";:+RXAUD<<5=\"V>C0^9+J0#;>55J]/3XA6^CZ6'LXEB@48
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M./-<+"-YP5DDOFV=+X?M9+6_D#$LQR2W8FN,\8> ;CQ]YVIWW^CM8NWEHO\
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MW"JW%7"HXJQG4H\WPR.]T#P4DK/))*(T89VUR6OJMKJ3(%*!3C<O&?>I-/\
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M5\X<D&ET-(IF!XGTV:SLP]S(5EFY '6H?"/@^VFFBN+V1C$ISM/>MJQOK?7
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M57&V:G%)OK?;Y'FVF^(-S %=W&,'^=:\<@900<D]!5[Q9\(;KPK$LT):<?Q
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MI\Z8"L3%)C[R]J]*EBO:)4ZBU1^=XC)9X64JV'EI)7L>[> _V@?#%Y;VUAJ
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M3[J\U6Y_=KPDF>U5FTR?1K5[98?M*LOR;.H/O61I*:A9W%S#J=T5M60E(&/
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MO-&"YK>_M"Y\>7$=A81@6 XY[BK.H>%;7QE>7>LWC^1;0KQ;IQYA[5UOPO\
M"2V.EMJ5U']DGDSY<;<86CE;?*MCSJF)A37-]HL>&_ -IHNGO;[EC=E^<K57
M5--TS3;?[/9A$DS^]FZ CZT[Q%KQ68PZ>6O+K[SB+D8%8&K:L=2TL.]I]DB5
ML.KC!<T725D<\?:3ES2D:NJ:HUXNFZ-ICJ3Y@+S+V6O1+7PCIFBVZWKRYD1-
MSLQ]J\=\$Z?-J%XPM-ZW"-D+Z+7?>(+>[OK/[+=3.D:#G8?F;VKLHS[JYQXN
MFKQ4)6[FDWQ8LH=)N(K&*1[TML!V\5P'B[P?)XXT#4)+UV9IH6RDG13BND\
MQVT^O)8W$ AB7HSCK7:WWATZ]>2V&G;3!_RTD_A ]*^TI>RC1BEN? 58UXXJ
M4V_=3/R"T>\O/A_\3);261HFBNC$54\$;N*_2/19)_&GPI6-6WB*/.WOTKX\
M_;L^%8^&_CRQUFSB:.&Z/SR8PN\'BOIK]CWQO;^*/!L-L6$CO!L/UQ7DXJFG
M'1]3OQ%7FDI[Z'BZW3:)X@>VN1B%I._UKTV>UMM0T]+:W(CM)%#.#T->4?M$
M72>"?B3##*3Y=Q-M [ UV.FZY,=+MPL192HQBL\12<::D];F^2X[VE25-:69
M[/X;^'^B>,/#<VG7"J&,>PXZ$5'\+_#5EX4\12>&K7#6MM\VQ>_UKDO!OQ5G
M\.S6]M<VBQ"4E=[=JI^"_$%YIOQ6U+Q*TV[3WPOEYX/TKQE*$)Q=M3[F;K5*
M<X.7NM72\S[ T?3_ #(VG>+R1'T'K7$2:M)XC\=,41DBL_D# <&N:US]H*'0
M]'=Y8B@N!MA]S5_P+X^TN;05FO)4M[AP79F.":]252#M&+U/EXX2O'FJ3C?H
MCU/PS8PWE]-<S#)MQQN[5Y%\7O$WB'QIK4^GZ4"FEVPVR-V9O05S]]\=+B&:
M^LM-B<V3/L:]'3-7K[6C:Z1!<>>(H]FYO5V]:BI63ARQ^8Z. G2KNK55^WD9
M'A?P7=W6I:=I5\6B@9]Y;IBO9;Y;9='?14D-Q'M*;OI7EVG_ !&^SZ?%?W"*
M\A;RT([#UKT>W\::-9Z&UVS1Y,988Z[B*NBXN-F5BE-S4K77;S/#(]4O-2UJ
M?2K>S)6S<@2-TKRGX_>!];\;76BVR6ZH[W2Q/,IY /&:^A_!<:ZDUUJ"P.R2
MRL2RCMGO4?Q)T>/3]0T*>)V2%KA7D;LN#6-2C.II'8^@HXY8?X=[?H=9\%O@
MNWPW\/K8S74MY'Y/RR3G)!(KW;X+K%'H-U A5FAG*MM-<!)XAB\10E+2XV1Q
M1?ZS.-QQ5W]FG6EFAUJ"296=;M@>>OO7NX10IU(PCV9^<YQ[?%8>I6F];IM'
MK/BS5+C0]/\ M5O$9MI^8#M5K0+[^TM)CNNC2+DCTK'^)'B"#0_"MU?2LIAC
M7+<]JP_ACX]L_$7AZ*ZL'$L##(Q7J.I:IR-]#Y".$G4POM5'9VO^AS%Y\.1X
MN^(\]Y+<RH;52!'_  MGUKS:\_9Q@7Q!JWE*+.?S/,A:+C=WKWFWUVY;6+N,
M6ZP2,,QR8^]5+3;6YO+^YO[B?]\JG,8/H*YJF'IU;::GT>&S+%X=-QE:-DK?
MUT/G2-=6N-6DT7487@U"R;_19O[RBO<O L4>H6RK>*L5_LV[B/O5YAXN;4F\
M:6.L74L5MHK,8FNG."C$X&37JVG^%Y+&S2<72S1R#='-&<BN'#TI1G)-77F>
MYF&(A5H0U49-=._5?\ M:3=3:/9WT5O&J3QN<KC 85P/BK5-2TZSNM<^RLOR
ME7C09S[UZ)I-U"NK&SG("S)M$C=S5+6-6&AM)ITEFMU;9^?<,MCVK><.9:.R
M/$H5'3JOW>:3LWYKJ>9>#=-7XC:.FH:9,+:^C)9E'$G'8BNG\&ZUI^J:I>Z4
M[PMK<*E'M[C 8X[@5Y_J37.BZ[-KW@.3?&K?Z5I[<'KS@5VD7P9TSX@7EKX^
MM[JYTG7C&#*L)V\CJ"*YJ--WTU:W]/([L74Y(MS=HRVTU3[/R.(\3_%[5?AW
MXN2QTV+[/)"^9K4]&'M4'BKXLZ%XZ4'5!-HVH<%9(QC)]Z['QUX/M/&EJ]\/
M+.L6@SYJ_>;;V-2_\*QTOXN> 8HI+6.UU.,;)#$,-Q7-45:HW&+TZ&E.6&PZ
MA4FK2V;[?\ X'6)K+QYX0EMFLHYI;5?W6H1\LQ'K7A-K'/8P2)<2%KY92L<?
M0CT(KN_$WA_Q5\'[K[#8K+-I*'YE )-6=&UCPKXNU2U?Q%"VE-%R+A1M&?<U
MX4ZE132GHT?5QC1C2E.&L7KIJSR7XM?&;QKX?\&KIJV;:K%.?*)?.Y%QWKD?
M@;I.N>%;=]3TUS?6]PV^XTV4D[2>N*]8\:_$#PS9_$JVT*22&_TVX^6.ZAPP
MSZ'WK=T.2P\(ZY+)%%# /O(KC"NM92J2JM1INW<Z(TU1IISCI)71S,-TFM:A
M<R2$0OU%K)Q@]Q5W3[RVAN\ Q1,HQACC!KL?%7A73=4TN;Q5:%%C09>*/[V:
M\^_X0VY\2:*^K6D3'R^2F/F'UKNBG%)]3A<>>_8X[QPFLZ]!?6<%_.EU(=L3
MP],&NY^%OAYK#P@--NWG^V0K\T]QP6:M/P+#:-;QK>Q^6RG!8CD&O09-$B\E
MI[*ZCO80,N,\BNO#UZL6[O0QK4:=6"@T<992:Q-82V5OM\V,Y",?E<5GSM=:
M;:RS6S^7(PVO;,< -ZBMR+5!I]\0PVDGY6[?2KVJZ&SZ;]MDC#,QR/0_2O?H
MXI3CRR/D,1@)TJOM(?<</X+L2]U<66O)))%(=Y"C(P:[K4-*\.KI*6L>E#["
MYV_<YKD=375](TV\NHE\X.G&!\RX["N9\ _M 0:E&UIJ.F7EJ()"C?:(\;L'
MJ*RG"48\W0]3#XB;=HZ-&)X\_97O;K6AJVASK80-\R(@YSZUY7XZC\=?#FQG
MT_4XQ=Z?.I5KC9G ]_2ON_0?B-I.I6=JVF1+=2]TD%0^+O MK\1;6YM;ZTCM
MS,N!&R\-["N/V,9)N#LV?78//JU"T:VL5WW/R\VK>+Y2RX63[R9XJM>>%?[/
M;<&4-UZ\UZY\:/V>]0^&NM2W-HC_ -G;LE<<Q_\ UJXS3_#M]J5J]Q'9W-]
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M3J7V#C'K73>.--M=<\+Z=%<Z<MZ&1=VY0V.!4WB75KR32YA<68O HRB]ZW?
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M(/\ EH!Q55<+&I9QT?X'M5L5AW#WI+GMN?.MNQO%"1K\WJ*^AOV>_@F]]/\
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M6W[1"EO@[XFQN_X]OX>OWA7QCX(T;4+FVS"Q3:HZ]:^>SB-\5#3I^I]=P_\
M[K-WZ_HCO5TA+IT69%)'(7'6EU[^SM%@$ERBP_W5'>L2XT_Q)&%>.9,IW(K-
MCT>Z\370DU*X\V:%OEC4_+7,T[(]EV.ET>2UU20-<KY<0Y4GO6OXF6U\1Z%)
MI[LMO;@8WKP35*;2+BWL5=XE;:,*JURMU;ZO>_N8[612QP *3TB3"S:=SSB8
M>&O#MY)'*7E2W;.Y^1UKU7X=^)AXDN$FLT::R4;=J],5%8_"/3]0(35(O*+<
MON'6O5/!_A'P[\.;$W"31P66/NMQFLJ=*5_([JU6GR7U;. F\#73>.!-;;[>
MTNN&4BM6&QT/X?ZY/!:PQR7\OS-,1\U>CMXLT[4+=[RS$<J0C( QDUX-J"W/
MBKQ])J:HUM&IPL+_ ,5:RBD_=,J,I5+\VBL;^HS)I5Y->6LA22\/SENE?)W[
M66F)8Z2/F4F:8,Q'UKZ;^(5[+I.@R7<\8\N/G [5\-_'KXJ6WQ"OK:QT])%@
MMCF1Y.I;T%.GI.[1[F7T95:B<>AZ7X'TRUL?!FGJ@5XI(P-R]J\N^(UG-9^)
MGM9ES$0"C$=C6S\(?B!IVEZ?'H^I2/F1]JLWW5!KU'4O 6F^)-UO,XGFV[X9
MU//L*^@4_K$+1T/OL"GA:C]ILSYUUSPK/H+6UVP66UDPVY.0/8U]Y_!7QEHG
MBSP;I^GV4\:[(U1H\C((ZBOE#4H5\+S3Z/KMI+_9\AV),1D+[UE6L.K_  QU
M"+7/#5X]];9W!H@6 'HP%<LH/#U&X?"_P/0QV%ABJ;L[=4^A]ZZ]:P:#$Z6\
M.9'& P%4[&\T_P "Z'/J^N2Q6^ 6+-@$^U>&^"?VRM!U#19#XFB:UU.W'W5'
MW\>E?/WQF^/FH_%#7#())(=)A.(;7=P?<BK>(C!76I\?1PLZDN2I*T>K_P C
MUGXI?%[7/BUY]H;EM)\,*Q$80X><?X5\WWT<-K=21QM\BD@$]ZAO/%VIWD,2
MR,QB0;4'0"J5UINI;5GFMY41^C;3@UYU>7MF?84ZV&PE-4Z$?PL33:A''QNJ
MK<7DLB@H"J'^(]*U])\!W.I*)IPT$/J:ZRUT32E6*RFE3R(>2WJ:YU3C'7<Y
M*V.JSO%Z+R.1T7P;J&L*L[YCMCR7KIXO#]EHBK+':_;77ICG\ZW=2U2*[T_^
MR-*&'8;%D0<#WJ7PSX''A6U+ZE=RSC[\K%N![5TTIV5SYNM4JR=F9\FM:I>:
M3-Y>G[(X>2R#H*P?#OB2U:\EN-8N&$,2[DCM^7/L:].\<:HVL> GMO"\"S+*
M,,T7W\=ZX_\ 9]M[9=2O-+N[&.YOYGVA95R4%=\*D8Q=T>3]74KRG'8XJ\TC
M7_'&I3R6$-T;.1OW<4AYVUV5C^S/K<UNMU' S$*"\..!ZU]2>&?#.C>$9VNH
M$6>Y'WPP^1?8"J/B;XTKI/B"VT;3M,E9]0.PRA?E6O'K5YNZ3-85HJ2Y(;=S
M%^&?PZ?_ (16X>XF FMEQY7T[5\T?&+1;RRUJ>Z>R\F"5OE95ZXK[JM]*GT7
MPC.)+5HY[CYFE[<UQ/BJS\-Q^"9EU(QR7#*0A8=*Y:45&4;FU/&2O)M7N?.?
M[*NWP]\1-+U&9VAEE==A[8S7W'^V J3V>BZG'\[O;*"WX5^>EOJ$N@_%_P -
MI;RXLQ.N$!X()K]&/VMF-Y\%?#FHV48$RQH')'&,"O=K17LU?8^'Q527UZG-
MK<^+O@E/]C^*EY+-^]5F 917VA'++>6:R11%(0.*^.OAW<06'Q'MIHXP)9\;
MMW2O=O$GQ0/A?Q);V5Q<"X@DQLM;<99LUXKO:S/K>66(=X+2QZU:W$UG9-(E
MR8UQS&AYK#A4:I<2O>2+ C'@L>6JQ)XATJ724FCG6"1E!\J3[W-<CKQBU2$3
M6U\&DA/$,?)-2]-RH1<7M8ZB2^ET2%QI5E')$>3-*.<^U<7=Z?/X@O'N=29K
M%&^\TW"?A4DY\67-G!)%"+:"-@V).^/6HO$2ZAXMCBGU=U2RMOOPVYQNQ6;E
M<VA'6\7H^I)<:!I^C/##IL<EQ),.;@\K^%7-6O+[2=%BAN(X4MF;#.OWL5SF
MK?$"WL]/"V,316,"X\Q_X<5UW@VZ\.6_AD^(=<U9=0BD&4M<YQ2YN9V1K+GH
MTU)IO6WS,KP#X+.OZI(NDK<I%(?WDDG0_2N?^*6C6'@[Q9I6B:K"]GIDTF3.
MW60]<5TFB_M)6]]JDMCX/TE]T;;/,=,*OO3]:T]/$OBB*ZUYY-5O$(()YCA)
MK"I645[KNS2G]8C5O5CRPM\SS[X^>-M%TG1]._X12V:&\M2N+U4Y^F:Y[X*Z
M/XG^.WCRWOKJ7R[2T #KT1SZ&OJKPW\)-$U:^V:Q:0-9X_=1;174#X7:7X&N
MHYO#?EZ>A</(O !%;48S^.>P5,]HX6C+"T8OG:=I/7<[7PQ\/IO#]BB64,%K
M'M^; P6/M6OJ'P__ +>T6>UOH5<7"E?W@R"#7EWB/]I:QT3Q9;>'$@FOM0\O
M>5A4[ !W)KTWPK\8[7Q5I[7$4;%H>&C7^$BO1]M1;<6]3\OQ4,RIR6(:WUO^
M1Y=\)?V1=!\ :YJ5[=6L=U#<.9$C895/89KT;Q5XBTSX;V#+IT*R2]H4&<"N
M<TG7/%?Q-\27")(-+T6%RK.,[FYKLY_AK8V\)D):ZG8<-(<GWK&-N1NFB<1B
MJE6NI8^KS-I7BOPOT/([[4KSXP6=S:"Z:Q382D-MPS$=C7"_#GX2^/(=<\NZ
MDAL['>08).I&>#]:^AXUT_P[82?V9IFW4?NCY>]6/"_A"]M[U=5U.[DN+Z;[
MMN#\J@^U<GU;V\H\VK7R.^.;O"TIQI148O9/5W[HH2:/#X7LXX9/]+O9!MC@
M R,_2DTWX&Z"T<^J:Y:K/>W!W[6&0GL*]'TOP?;6^HMJ%R3-<]@W(7Z5N74D
M$L;(V&XQBO<A@81A>;]$?)U<UJN5H2=WNUI\D<'X;MX]-LWL($"6PR H["LK
M6-<3PC97]S/<0I;HI*G=R.*Z'5-4L? ]C<75Q\\T@)2,'D^U?'FI>"?&/Q.\
M9ZGXDU6]NM(\-R-Y<>E,YVL ?O$>]<U2K[.*25V>UEF#6,J.I4?+#N_M/LBO
M"^K_ !'U]M=UB5TT03%;=,\/SUKOSK5QX5U2PL]-6ZOTE'S+%RJ5K7'@>QOM
M#L+*RO$MK>U^9N<#BNF\':YHTC36EE#&)40C[1)CMW%<M.+YK-GU>*KQE3Y8
M0NH]-DEW$;6##:FZNQ('5<[)*K>$]-U+XE7DT>R2PTU/O3-QN'H*AM8VU[5)
MY;@/+86H+$*/OXKT#X:^-K/Q!I]S'#82::D)*A)!@MCO7ITZ?,^:6Q\YC*_L
M:;5%>]W[&3IOP/\ !>EZ@]X(8VOU'^N?&2:X;Q!XN_X0?5FTG36>\GN7QGJJ
M UW5YH9\6>(FCBOFLK2,Y9\XW>U=BOP]\.6VEO(8HYYU&3,V"W%=7LW4B^5)
M'F_7%1:563G>VG8XVQ6RT?21?73*+IEW.S]^*\2\7^-)/%6H/8)&+>S#<G^]
M75_$*:W\6ZI_9]M=-!#;'!96QG':O*?%T<>CW$4<$F[;U;/6N"=7WN1'TN'H
M^SC[26[_  'ZLW]FV4X(0Q(A;';@5^7GB98?''QPNTDN!!!<7Y E'0 &OOSX
MG>-!HW@?6-0W;42W9<N?XL5^<_@O2E\3>,(I+J8PPO.7=U/)YS@5[&7IVE(\
M/-I<W)36S=_DC]:?V!/!^I:#K6N7%U=QW5A'9'RV7TQ7YK_&2X&H_M9>)I(,
M /K+;?S%?JA^R+'!X9^%OB34XY&\N.P95,AYX6OR@T&0>-OVE+J[/S)-JDDI
M/;AO_K5W49<U*4NNIX#_ -]IQ7='W7H9NM)TVS-LLKRD#*(,Y->N>"?&FNV[
M&*\MW$[+B..4?-CVI/AO#<RVL%O;V4+EL 2R#I7I.LZ&=!M;;4-26%IU^XT?
M&*\3EE=R1^K2Q$.2-)Q5WL8FN1NWA]KAHFFOF.[;W%<G>>,M1TW1TCL1-_:$
M@PY/W57O6_JGQ&^SVD@LK)IWD&&E8?**HZ'KFDK:Q17K*+N0[B#U^E9RT>A,
M8Z/F6A'X)\'VU]I\]U9-]NO9_FN)#U1NXK(^)7PSMI+6UBC39>R=9&ZBNKC\
M16>AM=+H\;)<7 VHL8PK-ZUT7@GX<ZSK5N+W7Y6^V2#]VK= #6;C*HG"*N92
MQ'U9\U1VC^)X)\*?A+IMQXJDBUFZ0^2^560\&OK_ $7X;V-NMO#9XBMBH)D2
MO-)/V9V;5);YM6,>XEF ."*V?A_XCU#PQKCZ#>7ZWUGN*QRL>5]JK"TWAGRU
M(6OLSS,RQ3QT>;"U+\JU5OQ/5;KPOI.EVI,S"8K]T_Q5S/A>:>36+OR+25HD
M;E6'45TEK9S:IJ +L!'_  Y[UIVMG<Z3J68(A(I^_M%>['W[-*Q\;[9THRC*
M5Y-=3R[XR:M?M)##9Z5(W=I".!7FFN>)-3TFS345MA>21?*8!UQ[5] ?&+QE
MI?A/P7=:AJC+;P0C,DA'W1[U\Q^#_&VE_$Y9[SP_=M=V=N^92%(P!7/B/=J)
M1=VS[3(W[;"<TX6C%VOW^9<UK0?#NN:3%XBU"V_LQYL;UN/EW'TKT+P'\8O"
M'@^33M--Q%#YQ"JJL./>O)/CAXJT[QG\/6TH6LRVJML$\:D$,*\6^$/P9\47
MGCJ.[C;^U=$V!99I22RKVQ[BN+VTJ.(481O?J?4?V?1Q^!G/&3<5&]E?IT/U
M$N+/1_%5G'<,(;B,@,LG!K)U#1WNF5+>7;%&,;1WKA/!OB30OAOIL5GJ-W)'
M9-A%DG.0&]*]*ATO[;)%?V4Y:!AN49X85])I+6VI^,5:<L%4<>9\OV6UH9?A
M-6M=4EB.X?6NUFMTNEVNH(]Q6=I=U#=74J_9O*FCX+XZULUI3CRQLSR<16=2
MISVLS*M=%LK*9I885CF;JX'->;?';XE67@?P?>SSS&"\5"8.?OMV%=UXL\3?
M\(Y:_:&CW1*,L?2OA;X_>*C\4/BIH<EOKUI)HT,P#Z.W$LC=Z^?S7'PP])TX
M/WWL?4\/Y;/'8F-6M?DCJWOMT^9L?".3QM\3M8N-3U&%9-(9<KY>=R^]?0'A
M/4_[-CCL-1>-[97Q_I'WASTK>^$FA:;8:;&^FE8HF4"2 C&VMOQ1\+-+\5-_
MI!>+YMP\HXYIY?A*E.A&7-S2W=_,[\TS:A6Q,Z4H\L%M9:JQIZQ;Q#31/;G"
M;> @X(KX[^-7[6.I?"WQ4-#M_#=UJ33$?ZM"5=2>@]37V'I>AWFFZ6;5I%E$
M:[8PWZ5RFG?#F'4M8?4=3L;629'^1I(P<#VKT,1&K4M[-\O<\S+,9A<.YO$1
MYXK;6VO0\Z\&ZY::U9Z?JD]C<Z0M\@>2SN5V[6/M7H6H6>FS:/,T_F*F,)C^
M8K%^.UOJ=OI<0T+3%N).F]>-OO7(?"O4/%VFZ).WBBV%U&KY78#D+7*Y<E3V
M;UTW/4<8XJBL1"7+K\-]?D;G@N\\1Z?J@M9+":^T1CQ),,L%KT.ZNO#RQR,A
M2"=1GRCQDUP_C[]H?PY\*?![:I._V@A<"WC^]],5\]>&_P!J[2OCM'?6D&D7
MFFWR,3'(HX]CFL*V84L-!Q4N9_E<=#*\5C9>V]FX06EUI?Y,F^*WBSQS;^/(
M;G3-#G7P^KXNKJ(<[?:N<\6_L]^#OCC<+JUZT^FW14#S@=OF?6O8?AS\1M6T
M?39].\2V O;!CL%PJYP#ZT[Q1X;BGU*--(<103?/'N^Y]!7APIRK?O7)N_3:
MQ]A3Q=6A+V#BH<JLI+5->?F8?P+\-Z_^SFKZ;I0_MGPO(Q=F7F1*^CK7Q]H7
MC;23!&XD:0;6AD^\IKS31]:C\)Z?':SY:Y;AX^U:5]X$M?$6FIK&B2_8=3B;
MS/D. V.QKW*#E3I^S3OY,^.S"E3K5_;5-&W\2ZONSF/&/AV3P#=37EL&N["3
M+2V\O.![5Y+J%KIFM:@NN>%9Q9ZA;G>]H3@^_%>H:MXPUN..:SUW2Y+R#&V2
M2$<K[UX7XC\,OX;\0-XF\-W!N()SLG@S_JQ[BO!S"I[&*E!75SZO+XMQ<*DO
M>MONFC6N/&4&O.YU.0FZ/R-CH#1_PAU];VZ:A8Q\N<JR]ZZB'X46^J:/%=3L
MI>X^<O#_  D^M6[?Q%)X)4:%JL1GL<8M[J/M]:=#FE'F:,ZU2+:C$=HOQ:DT
M.-+/7+0*5& V.M=#J&F^&]:TV/6;$6LEP_\ K(SC..]<%K'A&YUNX6Z\^.\L
M""2Z=5]JY[4-._L?C3Y)@O\ $N>OTKHYX]-&>=*,XOW6>B/H?A76;%HF06]S
MO^4]*Y1O ]A:W44UF8Y)8YN4/7ZUYWKVO:I;VT:'=I\;O@22_>^N:L^#?B(F
MF:L+>Y+2%>D[<A_QI^VNK7,)4WN9/[0WP5\3>-FM8]&U>XTB*W/G/Y)QSVS[
M9KB_!?CWXVZ+H\^@ZQ80ZY86ORQ741.]P/:OJ[4O$5KJ&FJ+7+7=R K[AD$>
MU+J%CI/A&[LX3,HG50TZ]CFNBCBY4T[ZH\RIAHU))/=GB'A']IQ-!MH+7Q"L
MNDSD[&ANA@"O1++QMH?C"SN%TTP7<;*27CY#5-XB^'/@_P <>(&66QCO!<)D
MJP&0*I7UGH'P?\'W6GZ+8Q0RL^V-B/NBD\P339M'!N+7+<\HM_%E]\,?%AN-
M+L]0NK>ZEV/"HS&I/?Z5[3I.I:9XVTV>9FBL;[9EXSPPKDO"/B:VUZ?[+=)"
MK*.&Q]YJUX=/M674/LT0@O%S@_WJYZ>+;=GJCV94(R2:7+)?B9]GHNG:I)-;
M/=Q2K"?F,G>J6J>$]'O;B.UWQ^43AHP>#0-2T?2;8_:-/GAN\Y=L?*3ZU4U:
M'2?%)C_LFY:"]4?>Z ?6M8U--2^5Q>CL;+>&=%^%K?:U@C:RG7#+%[UJZ-JW
MAR&"-K:T>)I#N5F%8UAI>JR:?%87#)J#@_,2.WM5NRT*WM]4B(9H"G(67E0:
MV<F[(YY335IN[)M2T^[U6[8VMNT)//SC :LR]O-7TB-4GM(VBS@A!R*[1?&>
MH6.J>7,MK+"BX5D6LSQ5JY\27L%O8(%F9<NO2LY2:(IWO9HR=*^'*:E#<:W#
M?_9;ADP(Y6X%-\%Z?XCN/M5IJFFP_P!GQOD7EIR7'O5?Q!X;\0QV8M[>;S+9
MA\Y3JM-L]4UOX?\ AL'3KQM9FD;#6N[I2A)WNSH:<HM1:NQ_Q8^',?C;19FL
M+&._AMX\>5*OSYQ7R+;_ +/NOVZW5U?VDUI&A9HTC7+#GBOOCX?_ &K6=#DO
MKV)].N'ZQYXS72_VE8V;0V^L6,;CH)E4;6'O6DU&6K.S!YI5PEZ<E='Q/^S[
M\1?$=C<7=MJ=W)<V5J?*2"3[P^M>\ZY\)]/^-V@R65W,8[>7Y_W9P5-4/B/X
M"TRW\3W&I^'K985FYD"C@U>\%7U[I$,4EF^Z53\T5<6BT)QF(A4G[6E[M^G8
MW/A[X)'PQT5=!MGDEM+885F/S5TYUBUN&2":W*YZ28Z5--X@74X@SQBWO,?,
MO3)KFM4\106TZI*HBD7JS=#31X4I.HW*6[.J.MO#^XB9)8AUQWJTU]!!8R7$
M*8X^>!N_N*\XNKU5D-W:S;D(Y"GBI[[6'&AI=I+DKUY_2L:DE%-]A1A=JQ[U
M^R?XF&O?\);%',\EO:W,:HLG5<J2116;^QGJ5AJUGXHN;) C-<QB7'=MIHKZ
MK*Y.6%BSX;-H\N+DO0]*_:4O'L?@GXJGC&72UR/^^A7QU\)_&#W%JL979(R\
MLU?7_P"TUJ"Z;\$?%<[P_:%CM,F/^]\PKX)\ :X^J0Q2PV1LT('5J^:SER6,
MA9]/U/L>'Z;E@YNW7]$>T:]XBOC:O;VVQ8FX>3%8NBR6-I((XUEGN3RS;N*Q
MO$33_98HH;L,6Y*#M19VLBV847)6<_W1S^=8ZGK<MM#T/2TN[^Y5%)CC'(W-
M5NZ\9+X:NO):W6XE[,#7E^[4[)L?:) S< !C6W9V,^F1Q7NK1&=#SMW\T+8G
MEMN=#KWQ>BMX<R6V)@,@!,UY!XJ\5ZQX]N5E:XDMK:%ODA7(#?45ZU9^*-!U
M-_LD&G+'.1C<X!J@WA%=+N7NBD;1YW8( %*47)69U4YJ/0\SN+[Q=]BMHX9_
ML2*PYP1D>]=%%XPU.2:"WN'C:51CS(UQ6[KVH6EY&#<W*)$O5$':N&\3>--'
MTNUDO+<1Q6D"_-(S#)IQBH[L[(1=72*-#QUXLA_X1FYMM6F"6L8WLS'D^U?!
M_B62PU+Q)>W6G1&&T9SL4]_>NU^+GQHF\=/]AM%:+3U;D]W_ /K5YW9PSZA-
M'!;1/([''RC-:R=E:)]WE>$AAH\U3?L-A7,@7.WG[U>V:?JT7A/PS!=GQ"IF
MC ?8QW'Z"N5M?@?K6I75O''/%LD +N/X?:O1/#GP'T*PNO+U3?<%%^=I#Q^5
M:T:CI/3J=F*QU.*Y(ZLX7Q=^T-)XNTDV,NG1MQM\YEY^M:OP;^,&H_"NSO;[
M^QEU:UG0JD,J[L9'7%;.L>$_"D6K&VT_38IK9.2P4=17"P_%"Q\+^))K>72]
MMC'F/RSS73[:<F<,L1*K2=-_"]^AY_K$D_CSQE=7,-LMO<W\Y*6T? !)Z5JZ
M3X/;2_$S:1KH:UD7T&1GL,UU_A#0[?Q-XHG\1V-N8;&%\A>A#>M=;X@UB2^O
M[=I+)'"MM^T8!/XFLIZ+4BC#V<ER(EL/ ^D'3X8KB-9T4Y41C!'UK"\=>+D\
M.R)I5I9+.A&0[#.*[I=-33;=;F2X6..5<GG->=^+O&-G:WS06-M'<R ?Z]QW
M]*\V4G>YZ%&G*I/:XR\T?5]9T&.ZL%:* C+R$X _"J7AOPM'J"S0:A<A>P<'
MK71?V7XPU[1+>"T4P6\GWTC7@Y]ZL1_#B]L;5$E@D>6+YF=6SDU//):&LY1B
MG'F2)-/ATOP+>:=IMI_I=Y<-G?C/E^YK=\4W>@1W;C5]6CE?R\F"+@9]"*XZ
M\N->\-QR:K>:4J0,NR/=]_ZUYRRS:IJ!<%IYYR2RJ"3DGI6G,^AI1PL9>])_
M,]!\$VFL>/-<GT?PKG3+-^)9"N>">WI7TS\*_P!FO1OA3=)J6IWIFNY &>21
MLEJ\W_9:\.^);&'52NG?8K=CM$\RX;..U>U:YH=YH.BG4]6OQ(5/WY). /I4
MU:W(K'SF85/WKITVK?F:7B;1+'4M:CCL;9K6W?G?GAO>N=^(?AFR:WM4LX ]
MW"RF.6,<Y%+IOQ4TJ\U*TM9"VH%EQ^[& OXUI7$VI_;I5TS3FNH7^ZW7;FLJ
M<X5(W3N>'RSA-)FK9M>^)+6VAN+I4VQ[6C/&#BN6D\%:7?7UY:ZU'YUG&C /
MT&?:MBQT/4;"Z\S6U:WA)W!%.":H>.IKB6^L88H&ATV1P=PZL/>BW,[,J/NZ
MIGQ9XHTZQ\,_&ZRAM59[1)E\L2'.WFOT$^-6K2:M^S?8)%%@1Q@M,3D)Q7P/
M^U%IX\._%B"YLSL1T21&]P:^VO"=O=^.?V5]3#2>:R6;,_/^SVKU:BE[)11Y
M&81AS0J2W1\(>(O$3--'!8W3_;D.1+#P2/:O<_@VNH3>%5N+^V>[N-Q(FF&Z
M3\Z^?/!MQ;ZA?0VZVVPV4Q61FZD U]_?""SM/^$=M[B&%0".%VYR:Y:D979[
M6#QRHT.1QZ[G-^"_A[K/BR^,UY:2K8YX;.#BO6)OA:GAFUBN=$\N*8GY_/\
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M -$A)AB;Y>._O6"M<^1K:-\NYYYIMGH_AO(UXF\U+J3)SS[5R?QJNIM>\/\
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M<UOJ-_?1_N\;8VDQS6?,Y.\CVZ5"GAX1A&7-S+\3CO&%W'I>K1>:9+I';F-
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MI-I6HR3LFE1*&"YQO.*^CC35.-SP,14E6J<D6=K\']/U;Q%H\4&H#;-<S;5
M')!-?H7X;L;/X3_#V!2%5HXM[]BS8[UX5\!/!^F6:S^)]9V0:?I8.QI/E3CO
M7CWQH_:NO/B/XDO[?PQ<$>&[+,+R8XF;I\M<M7$.E3YDO>EHEV\SKP^7U,;-
MTHO]W'63Z>2]3@OVEOB5_P +$^(#SSOY@B?$,?4+6WX%TNWT'38KF[D7S[H
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M:ZT%YB>(!=U=%.&$IS<5*]NAY&(K9E6IQGRZ/2ZU_P"&/H_4/VROV?\ PO>
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MD?[;7P8NK<7!\2>5<@[C')$2":;=?MO_  6CTF>XM]>,6IC[GEQD9KQC3_\
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M/JZ/&6+IP490C)]V?CZOP'^+JS;S\/\ 4-W8\&H+KX(_&RXF_=>!M1C<<!V
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M4K=1NH\I>FVNNEE-.GJY-OS-:/$%6BU*,%='X:W7[*OQRT/7K?5M%\":K!+
M H50.1Z=:W]0_9U^.6J^(--UFV\#ZQ:7@ %QO VDU^UBKM''%&W/O7;]1IV2
MN]#&IGU:I5=24%KT/R?^'OP;^--QXR2UU_P?>Q::[A5N2HPHSU-?<?Q@T?7?
M!OP';1?"ND7&IZI-;^48[8?,"1S7OG_ ?QIK9;OS6E/!QIQ<5)ZJQQXC-)UZ
MD*G(ERZV74_"Z']DWXT:IXD>XO/A[JPB60R-P/F.<U];?LI_LS^+O#M]/JVM
M:%?:5?,V(XYOX5K]'BH[TBXVG%*&!A3DI+H>I4XDQ5:DZ<TG?=GAGB3PKKNF
MZ4QM(+FYE(P43O7@GC3X<_$*_D>.#0+J1I%)$BC[OM7WAS]:/+7^[6E;"JLK
M-GF4LTG3^RF?EK)\&?BA#)-%<>$-4NA]Y'0<&H_#OP%^*NL7A;_A$KK2T7O<
M@9-?J=Y*_P!T4OEK_='Y5XTLDIR5G-G;_;U1;01^9FF_ CXF66L,JZ!< @_+
M-CY:[3PSI_Q7\(^)(;>\\'7M['_S]0J"@^M??GEI_='Y4H5?[OZ44<FC1E=3
M;+EGTY+^&CY#\4?\+%\3-;PVWAV[M8QS(2,9]JKQ_#/Q_P")+JS01S:1;QG:
M^W@D=Z^Q?+7T%&P>GZ5Z/U&/63,/[:J6LH(^8_'7P?O--TFV$%I=:K-@*P7D
MY]37G=GHGCCPOJ26T7A"\N+6X./-B7(3W-?;Y4'@BC:/[OZ5C4RV%1\RFUZ'
M5A^(J]&'(X)^I\CVO@OQS"LMT;&0(OS+&!\WTK.L?%OQ)T&X'VGP+?ZK;R-L
MR$!91ZU]D[/:F[4_NK1'+8P::DRI\1SJ74Z:=SY1\1:QXWFL1)H_@^ZMYBI)
MC9,<GM6I\(?!WB::U34_$FFS6]_*26AQ]WZU]-+&G913MH]*T_L^/-=R?X&$
ML_FZ7LXTTO/6YY"GA;4X+Z:5(9#&1PK"M'3]'OK>,G[(Z;CRH%>G\>E%=4<+
M&.S.*6;5)*SBCY_U'PSKEOK%U)!:7+6\O.T=*YO3?A_>V/BY-270Y$DDX:55
MY/UKZB\M?2FK&FXG;@U#P<&[W.VGG]6G!P4%JK'GD>AWMU;NES:%EVX7(K \
M'_"W2]!U*]N8M&2&XG8L\FS!:O9:7 ]*T6&C=/JCA6;5HPE".BEV;."N--U%
M+=VLED@,0)1>Q]J^,_VAO&7Q[\;7<FEZ#X:U+2[*UFXNK8_-.!T/TK]!^?3B
MF_9TY^12?I45L+[:/+SM+R.G 9PL%5]K*E&;Z7Z'Y-PWO[3^GWD"MX>U>^MT
M&UHYH RN/>NS\.>)/VDM#O&NK7P?)%!(.;4QX4'UQFOTP\E%_A44W[/&HX1<
M_2N3^S8JSC4:9]#+C&<E)2P\6GTL?FI\2/BE^TCX\\,W?AX_#V\M+2XC,4LD
M<>68'KS76_L(_LFW_@>2X\4^)])N+'7"Y6&&<8V+Z_C7W]"B+T55/>G)$(E.
M !75#!J-13E)RMW/.J<3598>="C2C!2[*SUW,V.6:TLY)/)8RJ.@'6L'PCJF
MI>(+R\;4K"2SBC;$:R#&X>M=K]ZF+CG&*[>7S/E%62C)<NKZ]C.U"UGAC5[0
MG@_=ID>JW"3)'):N=W\2C@5L_6DVBJ2L9J:M:2N07$CQPDQKENPKR3XX>";_
M .+/PY\0>&H!)9:A=6[1VUT!\JMC@U["?N]:3MZUE4I^T5F]!TJSHOFBM>Y^
M/-O^QG^T+\2)-"^&_B?2K&Q\*Z+>"4ZPJJ&= ><'N<5]OP^$?C)H/Q"C\*V$
M&GO\+8])^QPW3#_25E$>T,?;.*^IVHY]:2I1Y>5:&TL54E+GD[L_([QY^RO^
MTSXPMW^&FJ6>GZCX5GU'[0=<5%\Q(RV1S["OT,\%_"<?#'X#Z9\.[=9;^SAT
MXV$DO\7S+@G]:]CVA>O%*5^4U:IJ/PZ$RQ#FUSJZ\S\L/"/[//[4WP;T_7?A
MGX&@TV/PGJ]\]U#K$Q_>0*S9SGL<5M^,/V5_BOX+_:>^&?C7==>-K;34B6_O
M3@^6PP&P/3_"OTUSA::RCKBE*GS:IV?<=/$>SO%QO%]#X/\ @_\ LD^.])^*
MWQS\5ZFEM'8^-+62.PCD&7#,<C<.V*J_LD?LY>./V8/A[XCCUBRDN]4U"[,H
MM;$[EV\[:^^]WK2_49K.I1]I#E;^9KA\9]7J^T44UVZ'R!K7@+Q7XHLTU.ST
MRZT?5>6'&"?9JP&T?QA?0_9-1\%Z@=3C^3[?$G#'US7V[L']VD\M?[OZ5Y<<
MLC'7G9[ZXCK+["/CRW\+^,_[-&F:UX<N+ZVEX61%RR_6N.M_A+XYTO7&GT#2
MM2L)X>563_4N/3%?>NW_ #BDV_[5;++XK[3%_K%5_P"?:_$^!?#?A?XC>)-<
MNX=:\(7VG31,=EXJC9(?:GZA\+?&]YKGF#PW=Q7,(^2Z1>&^M??'E)_=_2CR
MT_NUF\LA+>3%+B&K+["/AW0O"_CC6K>XT[6/"E_#)&?EF*C9(!5&;P+XX\+Z
MU%J&F^%[^> -AX57D?2OO#RQZ#\J/*3T'Y4O[+ATDS)Y]4>\$?#?B[X<^+O$
M:KJUKX=O[:\QGR]N#GWKG[/X?_$>2=%N/#=_NZEB/E/L:_07RT_NK^5+@>E/
M^RXW^-F;SNH_L(_/#3_"?Q&U#5+BVN?!6HVRQ$^5<E1M/TJ:'X:?$?5'D$OA
M^^LI(V^615QN]#7Z#[!Z9I=@]*/[-C_,_P  _MN?\B/@K1]"^),>J#3=>\*:
MA?66,+=(H_6G:IX%\?>'KPW>F^&KZ]LF/-OCYA]*^\]H]*3:/[HIK+8I?$Q?
MVU/^1'Q-I>C^.Y+J*Y'A>_B79M\N1>E30_#?Q3!J#ZDOAZZ$A&3'MX)K[5I=
MO^S3_LV/\[(><5/Y$?%B^#O$FN-([^$[VTN.FYEP/J*AL]#^(.B:@L4WAFZN
M[8'[RKVK[8P/2DV+_=6G_9L?YW^ +.)K["/D+5O .LZI;22OX;N]\B\*%Y4U
MY\O@/XB:"'DTSPS>LX)^0CAA7W_@=A2;1Z?I4RRV,OML2SBHOLH^$[[PMXY\
M0:'$?^$2O[*]3EEV]36GHO@CQKJGAYH=2\.745S&-J[EY85]L[%]*7 ]*3RR
M+=^=_@/^V)VMR(^$X? /C YM9_"EZ8U^[($'%<9XK^&OQ'_U-IX1OYOFRDJJ
M,BOT>V#TI/+3^[6<LJC)6YV..<33OR(_/#PMX9^)V@ZQ';:AX)O[E709N(U!
M0>Q]ZP_%WPS^*S:M=2Z7X2NV/WE)7Y6SVK]*Q&O84OEK_=J)9/"22YV:1SN<
M9<R@CY/_ &$O#_C?0=-\5_\ "9^'Y- N)KJ-H4<<2*%()%%?6&T#@#BBO;P]
M&.'IJG'9'AXJO+$U75LM22BBBMSF"BBB@ HHHH **** "BBB@ HHHH ****
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M?6DKA?BQ\7/#/P9\+'7_ !1>M:VCS):V\,$;37%W</PD$,2@M)(Q'"@=B3@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :U>4?M6_\
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M_@H1XLB\=?L):QKD%I+9VFH75E/:I,"'>W-XODRD$ KYD>R3:1D;\'D5ZO\
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MKS:]C._X)W7&KV?P<^,$VA6%IJ>K+\0]3-O9W]X]I!(?*M,AIEBE*<9Y"-R
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M_$CPE#X3U'Q$C/H6K:9JIU*POF4X,1=H('CDS@8*$99>?F%>)?MC7VB?#/\
M:3^"'B/Q>NIZ7\.?L%]HDNH:+J%UI_\ 9\K!=A\RTDC=%QLRH."BOP=F*[[6
MO O[/VM>,OAWJ5O>7GQ$\6)J]O/X;AD\<:EJTD#"6.66Z1)+N15CB2(2N2-K
M")5.25%+ZO"G&,Y1<HR3=UT=W^5AW=VD]CI;[]KR2S_:"O/A6?AWKPU6WT>3
M587:XMFEO<.JQ)#'&[IM<EOGEDCV!26 &2,G0?VSM4M/BS?_  W\>_##5O"/
MBIK ZEHMG9W\6J'5X\D!$,:JJ.2K=254(Y9E"YKDV95_X*I*. 6^'N![_P"D
MY_I4OQ,(_P"'G7P@+?\ 0I7W\KJNEX>C'ECR;PYKW=[I-]_(SYGO?K8[CP7^
MU9K=Y\>;#X5^/?AM>> =7UFTEO=#N6U:'4(KY8U9W5C$H6-PJ2'&YON=>5)[
M7Q)\<+C_ (69>_#[P1H$?BWQ7I]I'>ZI]JOS96&F1R?ZE9YQ%*PDD&66-(V.
MT%C@<U\]_M*?+_P42_9TP<?Z)??^BYJI? #XE6'PE_;@^//@SQQ>PZ3?^*KN
MUU/1KZ^=88[J)5?9"K,<,=DJA1ZQR#KQ6<L+"4%4@M>6]M=7>S_#4J[O9OK^
MA[S\&?VEG^)OB[QSX,U?PA>>&_&W@]E-]IL5P+J"X1@?+>WG*QA@V!C>J<,#
MZXC^!G[34OQP\??%#PLG@Z^\,7W@::VMY(]6O(FDN)9O/X80[TC \@?,KR A
M\CISZ%HOQ2T;Q1X[O_#.ASPZM)IEH+C4[NSF62*SD=@(8'*Y'F.HE?;G*J@)
M'SK7S;^QS_R=Y^UA_P!A72?_ $&\KFC3A.G4GR\KBDTO5I/\RKM-*YS?P%^(
M7Q=\2?MD?&>WU+2?#>I7VFV^F:?+9_VY<6]MIUF#)(BV[?8G:=CYKLV]8LL3
MC ("^[Z]^T9J-[\9M<^&/@+PO;>)O$7A^RBOM8EU35CIMI:B55:*)76"=Y)&
M5U;A HW#+=<>/?L[ZE::3^W1^U!->W4-G'''I<SO<2!%2-8,LY)/"C(R>@R*
MWO"_Q";XT?M*?%GPKX=FM/AW!X96T@UO6]/M(%UO77PZK^^D0A((@C+N*LV'
M0JR9KLQ%&'M;\JLHI^C:6NA,6[;]6>I_LZ_M%6O[06C^)UDT*Z\,^(?#.J2Z
M-K&D7$RS^1<1G!V2J '7(89P#E3QC!/Q[^QS\;/$7PU^'/Q1L?!WPWUCXDZ\
MWCS5+R6ST^1;6WMX3%;*IDG=2-S%'VQHK,=IR!QGO?\ @G;K&B:?XT_:!L+7
M6H;M+KQU=1Z?--??:);Q,W#HXD9BTQ:.)WWY)8*S9/)K;_X)D3QM\/?BO%N4
MR+\0M39ES\P!AM@"1Z'!_(U<H4\/&K'ENKQ:5VMTWZ]1)N5M==3U3]FO]J_1
M?VDO#>OS6FAZEH'BKP_)Y&K^&;W;]IMY/FVJI;:&#%&7Y@A#*0P'!,OP)_:>
M?XV?$#XH>%_^$-U'PY=>!IK6":.^NH9+BYDE^T979&3&F/(&")7#;^H R?)O
MV9_#_P#;W[;W[0OCS0E'_"(L;31DN8E'DW-]'%#]IVG^(I)')N([R#UJ?]CG
M/_#7G[6/_85TG_T&\K&K0HKVDH*UDFDWJFVKKSM=A%RTOW9OZ)^VY>^)/B-X
M]\#Z9\*/$ESXJ\,^0D.D?:K;S[J20MDR.K&"WB4!&,K3,#Y@ !. >L_9O_:B
MD^-_B/QAX4\0^#KKP!XY\*S1KJ.B7%XEXOER9V.DR*H8<<X&/F4@L#FO+_V9
M?^3[OVG/7_B4_P#HDUA^"]/NM5_;O_:FL-/_ ./ZZ\.:=!;_ #[/WC:?;JOS
M=N2.:VJ8:A>5-1LU%23N]&[7^6K!2>COU:/:[K]I#Q'XB\+ZWXM^'O@&+QCX
M3TN6>-;^ZUH6,NIB LLTEC$()1*BLCJ&D>+>5.W(P3VWP#^.7A_]HCX;Z?XT
M\--,MA=,T4MO=*%FMID.'B< D9'!R#@@@CK7QK^PWK7PE\5?!G3O#/B7Q1XA
M\+>-O#IFL=4T2?QUJ^E!2DK8>*!;R.-5P1N"*-K!@0."?J7]E/PK\-_"?@?6
MH/A/HG]E>#)-:F>WNTO9[J'4Y%BACEN87F=F,>^-HA@[28"RY#9/#B*,*"E!
MQ::=D^C7_!W146Y6=S9^)GQNMO OC#0/!&D:=+XG\=:\DD]GH\4P@2.WC!\R
MYN)B"(H@01D*S,W"J><<A:_M177A/XP:'\.OB=X27P5JOB($:'JUAJ7]HZ7J
M$@(!A$S0PNDF2HVM&,EEY^9<^-ZYJ5Q\._\ @JAIM_XDE\K2?%WA;^RM#N9E
M_=B12C&%6Z!C)$_'7]\H_C&=/_@HQX9N?'6J? C0=#Y\3WGC*-K3RQF6*%$W
M33#_ &(_W;,>@P*Z*>$I<].G+:4;WOL[-^FFPN9V=NC/2OBY^U]#\(?C5X3\
M ZEX'UN5/$!E-OJR21.DRHC'%O#$9))7+A$",(SEP>G7,\,_M@:U_P +TT#X
M=^/?A;JGP\'B:*23P_J-YJ5O=_;-BEBDJ0Y$+8&-N]R"R@@9S7&_M-9_X;N_
M9BW#'_(5_P#1(I_[8TG_ !EY^R=Z_P!JZM_Z#9U<:%'EIQY-91;;N]U>S7W$
MOFU=]FOT/M*OSO\ BIXNT3P+_P %4O"6L^(M:T_0-*A\+,LE]JEU';0(62Z5
M09'(4$D@#)Y)K]#OX5KX%\7;+C_@K;X/0LKK_P (I(K+U_Y97?!_ _K497:]
M:ZTY)%3V7JCF_P!JN\B_;<^,'PO\._"*WD\06GAO4)+G5O&EI$XL+!7:%C&E
MQPKL%CWE5)).P+SNQ]P?%[XL:'\#?AGKWC7Q$9AI&CPJ\JVZ;Y79G6.-%&0,
ML[HHR0!NR2!S7Q=XH6;_ ()U?M*+XAM8)1\"OB!="._@C!:/1K\DDNJCHH&Y
M@ .8RZ@$QK7T3^V-\:_#_P *_P!G'4_%-]X>T_QYIE\UO!;:;=JEQ8W32,&B
M>3(96C&T.#CDA<$$@UIBH.HJ%.DFZ?V>[;=VF_)BB[<S>YB>(OVO/$'PWC\
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MSDVF[)M+NU;1?F7*7*?0_P -_P!J%_$'QJU/X2>-?#?_  A?CNVM/M]I#!J
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MDG//*=:]YI>G>DJ]6[?,[O=W>OJ'*K6L>7?&#]G?P'\>K.TL_'.EWVL6=O\
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M>L4OXU7MZO\ ,_O?7?[PY4<;X%^&?AOX::;<6/AO2ULH;J=KJZD:9YI[J9L
MRS32,TDKD ?,[$\#FO,M6_8:^!6N>-G\5WOPXTV;6))_M$C;YEMY)"VXLUL'
M$+9/)RASDYKWWCM2YJ85ZL;VDTWNTWKZARKL0PPI#&J(H5%&%51@ >@KR#XJ
M?LI_#3XU>(K37O&6D:AK&I695K5O[>U&".U8!?FABBN%2)CM4DHH)(R<GFO9
M:*SC.=.7-%M/NGJ#2>C/%?B)^R3\,/B])HK>+]*U77#HT$=O8FZ\1ZG^Y"
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M+:TM8Q'%#&HPJ(H&%  P *Y[X@?"+P=\5H[2'QCX9T[Q+!:"3R(=3@$\<1<
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M=T+E6UCRKQ1^S7\/?''PSL/A_P"(M DUWPMI[B2UAU/4;JYGA8%L%;EY3."
M[*/GX4[1A0!6%J'[%_P7U30-#T:Z\ :?<:;HMTU[9Q2/*3YS!59I7W[I]P1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1112 ****8!1110 4444 %%%% !1110 4444 %
M%%%( HHHI@%%%% !1110 4444@"BBBF 4444@"BBBF 4444 %%%%( HHHI@%
M%%%( HHHI@%%%%( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%)@%
M%%% !1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2E
MHHH **** "BBB@ HHHI %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_013.jpg
<TEXT>
begin 644 form10-k_013.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLZE_"OC#_A6/[:W_ $5GP)_X*V_^,TJ_#3]M7O\ %CP+_P""MO\ XS1["/\
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MC2L8+M@'_4=J+ ?=-%?$W_"M/VY?^BN> /\ P5?_ '/2?\*R_;F_Z*[X!_\
M!5_]ST6 ^VJ*^)?^%9?MS?\ 17? /_@J_P#N>C_A67[<W_17? /_ (*O_N>B
MP'VO2_=]J^*/^%9_MRK_ ,U<\ ?^"K_[GKPO]ICX^?M8_LLZUX(T_P 4?$+P
MOJG_  E$\T4#Z3H\9,0B>%7W;XEZ^>N,>AJJ=-U)6C:XGHKGZFT5Q]QX)U:9
MLKXVUN+V6.UQ_P"B:A_X0'6O^A]U[_OW:?\ QFH&=M17#_\ " :U_P!#]KW_
M '[M/_C-'_" :U_T/VO?]^[3_P",T =Q17#_ /" :U_T/VO?]^[3_P",T?\
M" :U_P!#]KW_ '[M/_C- '<45P__  @&M?\ 0_:]_P!^[3_XS1_P@&M?]#]K
MW_?NT_\ C- '<45P_P#P@&M?]#]KW_?NT_\ C-'_  @&M?\ 0_:]_P!^[3_X
MS0!W%%</_P (!K7_ $/VO?\ ?NT_^,T?\(!K7_0_:]_W[M/_ (S0!W%%</\
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M /" :U_T/VO?]^[3_P",T?\ " :U_P!#]KW_ '[M/_C- '<45P__  @&M?\
M0_:]_P!^[3_XS1_P@&M?]#]KW_?NT_\ C- '<45P_P#P@&M?]#]KW_?NT_\
MC-'_  @&M?\ 0_:]_P!^[3_XS0!W%%</_P (!K7_ $/VO?\ ?NT_^,T?\(!K
M7_0_:]_W[M/_ (S0!W%%</\ \(!K7_0_:]_W[M/_ (S1_P (!K7_ $/VO?\
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M !BC^U-0_P"AAUW_ +ZM?_C% 6/7LBC(KR'^U-0_Z&'7?^^K7_XQ1_:FH?\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?^!_\
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MBKW/_@'+_P#)%'_#O?QC_P!%7N?_  #E_P#DBG]8Q7_/G\4+^Q\E_P"ABO\
MP"1]M?VI:'!%S%C_ 'Z^<O\ @H:R:I^Q[\0;>VD66=H;7"JW_3U#7F#?\$^?
M&"A3_P +8N?_  $E_P#DBO/_ -H+]CGQ#\+?A#X@\3:C\1[C6K2P6(OI\EO(
MJS;I40 L9V P6!^Z>E=^7U\0\734J5E=:W7<X,=EF48?#3JTL<IR2;4>5J[7
M2[/HS_@FS&T/[&?@"-AAE6]!'_;[/7T]WKY:_85\7>'O#O[+/@VSO=<TVQGC
M^V%X;B\CC==UY,W(+9'!S^->]_\ "U/!O_0U:'_X,H?_ (JO5QD)RQ$VEU?Y
MGQE&K&I",K[I'545RW_"UO!O_0V:'_X,8?\ XJD_X6MX-_Z&O1/_  8P_P#Q
M5<?LY_RLUYUW.KXHXKD_^%J>#?\ H;-#_P#!A#_\52_\+6\&?]#9H?\ X,8?
M_BJ/9S_E8^>/<ZJN)^*G_'OX7_[&&P_]&5<_X6KX-_Z&K1?_  8P_P#Q5<M\
M0/B!X1OK?0-OB?1V\O6[.3C4(>TF?[U'L9]F+GCW/4Z*Y9OBEX.7[WBK1A]=
M0A_^*IO_  M7P7_T->B_^#"'_P"*H]E/LPYUW.KHKEO^%J>#O^ALT7_P80__
M !5'_"U/!W_0VZ+_ .#"'_XJCV<_Y6'.NYU9K\P?^"RG_([?L_\ _7WJ7_HV
MPK]$U^*/@Z3A?%.B,?;48?\ XJOSB_X*[:UIWB+QA\!GTR_M=16&[U#S#9S+
M+LS)8XSM)QG!Q]#75AJ<W46G?\B93C;<_4FBFK]T4ZN(U"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KS_Q=_P E<\ _]<M0_P#1:5Z!7G_B[_DKG@'_
M *Y:A_Z+2@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\_\  _\ R4SXB?\ 7>R_])Q7H%>?^!_^2F?$3_KO9?\ I.*
M/0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!&KQN^_Y#VI_]?4O_H9KV1J\;OO^0]J?_7U+_P"AF@:)%I:1:6@H**** "BB
MB@ HHHH **** "BBEVF@!**4*32^6: &T4$8HQF@ HI2I%)0 4444 %%%% !
M12[324 %%%% !113O+- #:*=Y9I-IH 2BBE"DT )13O+-)M- "4444 %%%%
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MI7H%>?\ B[_DKG@'_KEJ'_HM* /0**** "BBB@ HHHH **** "BBB@ HHHH
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MQCWH&VY[XS4FO:UI7@_P[J.OZY?0Z;I.GP-<7-U<,%2-%&2234?PYA!^&?A
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M=MX$EG^SNLC"*$2 JI(B?YB"<E?3EN#747,CZ=:$KU&*CKY8^&_[0GBGPO\
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MNFVZKY:@](4]ZN_\+,TLKGR;K_OV/\:I0DU=(ER2=F=A17(_\++TS_GE=?\
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M^Y9)%5O]>_4$U[HWCK0/^@O:?]_4_P :^./^& ? OF?\C1KVS_=@_P#B*/\
MA@'P/_T-6N_]\P?_ !%>;2CCJ-.,533LDM^Q]ECZ?#V.Q53%/%RCSMNW*W:[
MO:_6Q]D?\+ \/_\ 06M?^_J_XT?\)]X?_P"@I:_]_5_QKXW_ .& ? W_ $-.
MO?E!_P#$4?\ # /@;_H:=>_*#_XBM;X__GVOO.#ZEP]_T&2_\!_X)]D?\)]H
M'_05M?\ O\O^-'_"?:#_ -!2V_[^K_C7QM_PP#X'_P"AHU[_ +Y@_P#B*/\
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M<DNP<R.CD]:_-S_@K1_R4[]G;_L)WG_HZPK] ?\ A/-/9L"*X_[X'^-? _\
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M:E_5M'MOB)X$NO#_ (UTBSGMM4M3;ZCIT<S3P_,,,%D*H3CJ&VJ00#P:\O\
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M_(W^)_\ ?M__ $54=4!NM&,TGDBI&ZT52 C\D4>2*DHI@1>2,TODBG_Q&EJ
M(_*'I1Y(J1NU%6!'Y(IWDBG4Z@:(_*'I2^2/2GT4F-C/)%'DBGT5)(SR13O)
M%+3ZI%(C\D4JQCTI]%,8S9[4;/:GT5 #-GM1L]J?10 Z&,;JY29?].N/^NC?
MSKK8?O"N4F_X_KC_ *Z-_.IET&AU%%%04%%%% !1110 4444 %%%&51&=V5$
M499F. !ZDT %%2PQK<PI-"ZS1.,J\9#*1Z@BE9%MXY)9F6**-2[NQP%4#))/
MIB@"+::2O&=-_;.^$?B+XK:'\//#NOOXFU_5I6ACETJ+S;6(K&TF7F)"D84_
M<W<XKVN:(HQ%.S6XKW(J*>L1;M3OL[>E(9%14A@8=J58&]* (US0V:Y+XT?%
M*P^!?PYU'QKK&CZMK.E:>R?:H=&BCDGC1CCS"LDB#:#C/.1GIUJ'X(_&#0OV
MAOAO:>-?#5MJ%MI5U++"L.I1)'.K1MM;(1W7&>F&-&MKB\CLJ*D:$KVI8X2[
M8% R/::-IKBM2^-&A6OC;4?"&C6&J>+_ !-IEJ;N_P!/T&%)39C:61)9'=(T
MD?'RHS G(. .:\S^$_[?7PN^+7Q0/P]2S\0>$_$IEDMDA\16L$"/<(Q5H 8Y
MGQ)D'A@,X(SGBGRO<5T?0.TTE>=_%SXY#X1^,/#_ (=F\ >+_$=QKTC0:?=:
M%;VLL$LRHTC1DR7",K*BLQW*!A203@UZ4L+R0H[1-$S*"8WQN7(Z'!(S]#2&
M0T;34ZVS$]*\.^,'[;'P?^"5]+I>M^)/[0UR*412Z5H\7VF>)B<'?@A5QU(+
M ^QXII.3LA;;GM6TTNTU+KEU9^&=%U#6-3F6UTZPMY+JXF?@)&BEF8_0 U\>
M:/\ \%6/A#X@UJPTFP\*^.9[R^N([6!5T^T^=W8*H'^E9Y)';-"3EL&A]>[3
M17+:#\6/#OB'Q]JO@A_M6C>+M/3[0=(U2(12W%OG N(""5EB)XW*3@C!P:Z^
M2W93TI/31AOL0T4NTU(L#-VH&145-]E?^[33 P[4 1T5)Y#>AJ6&U:0\*3[4
M 5]IHVFO&/"G[8'A'Q-^T)<?!B7PYXFT?QC"TB,U_;VWV8[(_,R'CG<X9/F'
MR]^<'BMSP_\ M)>#?%7Q^\1?!ZQ34E\5:' 9YY)K=1:R8"%E1PQ8D"1<Y4#G
M@FC4#TJBIVMF':FBW;/2@"*BI6MV':D6(EL8H CVDTNTUPOQH^/?@?\ 9_TN
MRN/%NI.E]J#&/3M(L8C<7U\^0-L42\GEE&3@9(YYKDO%'[6FB_#FSTK4O'W@
M+QOX$T'4'6)-9UBPMY+:%VSM2;[/<2O&3@_>4=*:3>PKH]FVFEVFLW7/'GA+
MP]\.Y?'M[X@L4\'1VJWO]L1RAX'A;&UD9<[MV0 !DDD =:\NU+]JK1O#_@^'
MQCK?@+QSHO@F5/.7Q%=:9$\ B.-DC11S-.B-N!!>(=><4)-[ VD>Q48)JMH&
ML6OBCP_I>M6._P"Q:E:Q7D'F+M;RY$#KD=C@BN'^+G[1WPU^ ]KO\:^)[73+
MMH_-BTY,RW4J\X*Q*"V#@C)P,]Z6^PST'::7::YWX<_$K0OBA\,=*\?Z:TUC
MX?U&V:[1M158GCC5F#%P"0,;3W->->-/V^OAS\.?%&EZ3XFT#QEHNFZF<VGB
M*]T4Q:?,F<%U+.)&4<=(SP0>AS346[V%='T-14J^5<PPW%NZS03()(Y%Y#*1
MD$?4&LKQEXN\/_#7PO>>(_%6KVNA:): &:\O) B#)P%'JQ. %')) %(9H45Y
M_P#"WXWZ?\8KJ:30?#'B:#P]Y)GM?$FIV"VMC?#< !#N?S6R#N!,84@=>F?0
M_*+=*=GU$G<914WV=O2C[.WI2&0T5)Y+^AI&C*]J &4444 %%%% !1110 44
M44 %0W'W34U0W'W30!L^'?\ D=O#/_8&O?\ T?#7IM>9>'?^1V\,_P#8&O?_
M $?#7IM!+"BBB@04444 %%%% !1110 4444 %9?BG_D6=7_Z\YO_ $ UJ5E^
M*?\ D6=7_P"O.;_T T >?7G_ "3WP7_V#X?_ $2E4(_N_A5^\_Y)[X+_ .P?
M#_Z)2J$?W?PKLI_ CGG\3)*%ZT4+UK0@=11120!1113 ?1114%A1110 4444
M /HHHH **** "BBB@ I5I*5: +-K_K!7Q+X<\2:5X9_;6\6WNLZA;Z9:"21?
M/NI!&F=\)QD^P/Y5]JQMM:O!_B9^R;X)\8^*9_$=]-JT-_JM]']H6"Y41Y;@
ME04)'3UKR<?AZM90=))RB[Z[:'VW"V88' O$4L=)J%2+C=*[3;OLSTZ;XY?#
M=FY\;:)_X&1_XU%_PO#X;?\ 0[:+_P"!D?\ C7EG_#!GPY_Y_P#6O_ B/_XW
M1_PP9\.?^?[6_P#P(C_^(J/:9C?X8_>SJ6$X66GMY_<O\SU/_A>7PX_Z';1/
M_ U/\:/^%Y?#C_H=M$_\#4_QKRS_ (8,^'/_ #^ZW_X$Q_\ Q%)_PP=\./\
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M>9XWCN8(GL(=5M"(X8[CSO->1I%3D*!M5F.6],TY1CI:PH\W4XKQ=^W=\;?
M/@/X-^.];TOPA-X>\:%Q)8VEO-]H9(I55WWE]L9=6^4 -M*Y.<XK]%H[<&1&
MQ@, ?SK\R_C1^R[\;?'7[/\ \!?!FG?#6Z_M/P3!=#5/,U?3E3<\RE A^T?-
ME5)_$5^DFEZM<7VEV%S=6,VEW4D*-+9W#H\D#8Y1F1F4D'C*DCWJ*BBK<I<;
MWU/S%M]:N_B-_P %=K"#Q'9L\&GZQ):VEG>*&$4=O9R/"0".A8"4>[ U]_\
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M]N[_ )2/? K_ *YZ#_Z=YZ_2C6O]<WUKT\7_  :7I^I$=V9-%%%>86.HHHH
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MH *AN/NFIJAN/NF@#9\._P#([>&?^P->_P#H^&O3:\R\._\ ([>&?^P->_\
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MZ+_SY?\ D5__ (JCVL2>1GG_ -J7UI5NE]:[_P#X0?1?^?+_ ,BO_P#%4?\
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M/_(C_P"-)_PB6D?\^G_D1_\ &CVB#E9Q'V@>M.6X7'6NU_X1+2/^?3_R(_\
MC2_\(GI/_/I_Y$?_ !I\Z#E9Q7V@>M)]H7UKMO\ A$])_P"?3_R(_P#C1_PB
M>D_\^G_D1_\ &CG0N5G$_:!ZTOV@>M=K_P (EI/_ #Z?^1'_ ,:/^$2TG_GT
M_P#(C_XU'-$=F<5]H'K1]H7UKM?^$2TG_GT_\B/_ (T?\(EI/_/I_P"1'_QH
MYD%F<9]H7UH^T+ZUVG_"*Z5_SZ_^1'_QH_X172O^?7_R(_\ C1S(.5G%_:!Z
MT?:!ZUVG_"*Z5_SZ_P#D1_\ &C_A%=*_Y]?_ "(_^-',AV9Q?V@>M'V@>M=I
M_P (KI7_ #Z?^1'_ ,:/^$5TK_GT_P#(C_XT<R"QQOG+2^>,=:[#_A$]+_Y]
M?_(C_P"-+_PBNF?\^W_D1_\ &GS(+''?:!ZT?:!ZUV7_  B^E_\ /K_Y$?\
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M;37RI\"?V\O#_P 9/VA/%7AS=>:=X7_T33_#L3:7/)+=7#.ZRRS-&C>0I.T
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M$C>7$ 1\P=QD=1\?_P#!0C1_%'P;_:"^'_QZM/#L>@2M<0131PWZW"2W%OR
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MOC*YO!8ZU=Y2#%X3(!OQMW+,!&5)X# GJ,_I!"L=G;PV\""*"%%CCC7HJ@8
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M0 4444 %%%% !1110 5PWQ4_X]_#'_8PV'_HRNYKAOBI_P >_AC_ +&&P_\
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MR/\ PH_X8C^ O_1)?"?_ (+(_P#"IYJ'9CU/ O\ A\?\"_\ H'>,/_!;#_\
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M/"?_ (+8_P#"C_AB/X"_]$D\)_\ @LC_ ,*ERH7T3#4\"_X?'_ O_H'>,/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;C[IJ:H;C[IH V?#O\
MR.WAG_L#7O\ Z/AKTVO,O#O_ ".WAG_L#7O_ */AKTV@EA1110(**** "BBB
M@ HHK \5>+M#\"Z'<:UXCUBQT+2+?;YU_J5PEO!'N(5=SN0!DD 9/4T ;]%>
M>>"_CU\-OB)K1TKPGX_\,^)=4\IIC9:3JT%S-Y:D!GV(Y.!D9..XK1\._%7P
M7XN\2:GX=T/Q9H>L:_IA87VEV.HQ37-J5;8PDC5BR8;Y3D<'B@#LJQ_%G_(J
MZO\ ]>4W_HMJV*Q_%G_(JZO_ ->4W_HMJ *GPY_Y)[X6_P"P7:_^B5KHZYSX
M<_\ )/?"W_8+M?\ T2M='0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<-\5/\ CW\,?]C#8?\ HRNYKAOBI_Q[^%_^QAL?_1E
M'<T444 %%%% !1110!&:\R_:6_Y(+X]_[ MY_P"B'KTUJ\S_ &EO^2"^/?\
ML"7G_HAZPJ?!+T9WY?\ [W2_Q+\T>$?\$U?^25^(O^PW)_Z3V]?8?\5?'O\
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MBBB@ KS_ ,#_ /)3/B)_UWLO_2<5Z!7G_@?_ )*9\1/^N]E_Z3B@#T"BBB@
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M[_G]M_\ O\O^->5?84]*46*9Z4>R7<.9GJG]N6'_ #_VW_?U?\:/[<L/^?\
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M6"YP?V2^_P"?2;_OV?\ "C[)??\ /I-_W[/^%=YYQH$QIV"YP?V2^_Y])O\
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MOO\ GRN/^_9_PI?L=_\ \^5Q_P!^S_A7H?GMQS3O/;UH"YYU]CO_ /GRN/\
MOV?\*/L=_P#\^5Q_W[/^%>B^>WK1Y[>M 7/.OL=__P ^5Q_W[/\ A1]CO_\
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M_H*UN+6'JW_(W>'O]VX_]!%3+8<=S=:FTY^M-IB"G+3:<M,!R_>%>=?M:?\
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MIEL..YL/UIM3M WI3?(;TICU(J<M#*5H6F2.7[U>=_M9?\FE_%C_ +%R[_\
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MWCUHWBDQL=13=]&^I)'4^HMXI^\52*0ZBF[Q0&%,8ZBF[A2[A4 +12;A1N%
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MN%&X4 +3EIFX4X,,4 .I&I-PI&84 /HI,BDW"I0#J*;N%+D50"T+UI,BC=4
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M*C_A6S?]!0_]^/\ [*NWHH]I+N'*CB/^%;-_T%#_ -^/_LJ/^%;-_P!!0_\
M?C_[*NWHH]I+N'*CB?\ A7+?]!,_]^/_ +*N<\<>#3I]OHF=0+^=J]K#_JL8
MW/C/WJ]8Z=:XCXJ?\>_A?_L8;#_T90ZDNXU%7)6^';-_S$R/^V'_ -E3?^%<
MO_T%#_WX_P#LJ[2EH]I+N+E1Q7_"N7_Z"A_[\?\ V5'_  KE_P#H*'_OQ_\
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MR['*_P#"$'_G_P#_ "%_]E3?^$';_G^_\@__ &5=7M%&T4<S"R.6_P"$(/\
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M_G\_\A?_ %Z/^$1;_G\_\A?_ %ZZ2BB[ YO_ (1%O^?S_P A?_7H_P"$1/\
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M'_OC_P"O1_PC9_Y^O_(?_P!>MNB@#$_X1L_\_1_[X_\ KT?\(V?^?H_]\?\
MUZVZ* ,3_A&S_P _1_[X_P#KTO\ PCI_Y^C_ -\?_7K:HH Q?^$=/_/S_P".
M?_7H_P"$=/\ S\_^.?\ UZVJ* ,;_A'?^GC_ ,<_^O1_PCO_ $\?^.?_ %ZV
M:* ,;_A'?^GC_P <_P#KT?\ "._]/'_CG_UZV:* ,;_A'S_S\_\ CG_UZ/\
MA'S_ ,_/_CG_ ->MFB@#SGXIZ;]F\/Z<?.SG6+!?N^MP@]?>NP;1#(<^?C_@
M'_UZYOXP?\B[I?\ V&]._P#2J.NX6@#)_P"$?/\ S\_^.?\ UZ/^$?(_Y>?_
M !S_ .O6Q10!C_V"?^?G_P <_P#KT?V"?^?G_P <_P#KUL44 8_]@G_GY_\
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M444 %%%% !7#?"/_ ) >L_\ 8=U'_P!*7KN:X;X1_P#(#UG_ +#NH_\ I2]
M'<T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$%-3BXM25TTSX!TG]JSXT>'?BQX8\+>,=-TW3VU"\MHY+?R")#!++Y996$K
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M7#?"/_D!ZS_V'=1_]*7H [FBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M444 %<-\5/\ CW\,?]C#8?\ HRNYKAOBI_Q[^%_^QAL?_1E '<T444 %%%%
M!1110 4444 %%%% "4-]TTM)0!^>G[5G_)ZWP_\ ]W3?_2V:OT"M?^/6'_<%
M?G_^U0N[]M7P /\ 9TT_^3DU??\ 9L/LL'/\(KRL+_%J^J_(^WSS_<<#_@?Y
MENBF[A_>HW#^]7JGQ ZBF[AZT;AZT .HINX>M&X>M #J*;N']ZC</[U "[:\
M_P#%W_)6_ 7_ %RU#_T6E=_YB^M<)XJC\SXJ>!I!T2*_S^,:4#.]HI-P]:3<
M/6@0ZBDI: &K7CW[8'_)K?Q5_P"Q9O\ _P!$/7L*UX[^V!_R:W\5O^Q:O_\
MT0U;X3^-#_$OS%/9GCO_  2E_P"3/-#_ .PE?_\ HXU]B=A7QW_P2E_Y,\T/
M_L)7_P#Z.-?8GI6F._WFIZO\Q1^%#J***Y"@HHHH **** .?^('_ "(/B3_L
M&7/_ **:OSF_X(A_\BC\5O\ K^T__P!%SU^C'Q _Y$'Q)_V#;G_T4U?G1_P1
M%^7PC\5O^O[3_P#T7/7533=&;]/S(>Z/TXHHHKE+"BBB@ HHHH *\_\  _\
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MOPK()(+":SA,4)2&1X2(U('R!HV (&" ",@@U\I^"? ?P9\#^"].D^,/[/\
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MWHO[51U?3C<:U&U[ME^S/FT^4%1OZ1XY&.M?9"W#>M8FK7#?\)=X>Y_AN/\
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M_P"^A1_;X_Y]V_[Z%9VT4;10!H?VZ/\ G@W_ 'U2_P!MC_G@W_?59VT4_:*
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MZ,&%5)*UTR8MWL>XT445)04444 %9?BG_D6=7_Z\YO\ T UJ5E^*?^19U?\
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M^33]4_[&2[_]$V]>Y?MA?\FA_%G_ +%^Z_\ 0:\-_P""0_\ R:?JG_8R7?\
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M%#,>N!@?A74447=K %%%9NK:I9Z'IMWJ&H7,=G86D33SW$S!4CC4$LS$\
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MTCUH%R/6BP&=XZ_Y$?7_ /KRE_\ 036K8_\ (+L_^N"?^@BL/QU<+_P@NO\
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MM'G#UH EHJ+SAZT>;[T%DM%1>;[T>;[T 3T5'YM+YHH(,&X_Y*]H'_8$O/\
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M?^2>^%O^P7:_^B5KHZ (/L<'_/"/_O@4?8X/^>$?_? J>B@"#['!_P \(_\
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M/L\7_/&/_OD4?9XO^>,?_?(J>B@"#[/%_P \8_\ OD4?9XO^>,?_ 'R*GHH
M@^SQ?\\8_P#OD4?9XO\ GC'_ -\BIZ* (/L\7_/&/_OD4?9XO^>,?_?(J>B@
M"#[/%_SQC_[Y%'V>+_GC'_WR*GHH @^SQ?\ /&/_ +Y%'V>+_GC'_P!\BIZ*
M (/L\7_/&/\ [Y%'V>+_ )XQ_P#?(J>B@"#[/%_SQC_[Y%'V>+_GC'_WR*GH
MH A^S0_\\H_^^17">*-J?%3P/&$4!XK_ "-H[1I7H->>>+?^2M^ O^N6H?\
MHM*!H[[[/#_SR3_OD4W[/%_SQC_[Y%3T4"(/L\7_ #QC_P"^13OL\/\ SR3_
M +Y%2T4 5_L\/_/)/^^17E?[44:K\ O'&%4?\2JY[?\ 3-J]9KR?]J3_ )(%
MXX_[!5S_ .BVKGK_ ,*7H_R/4RK_ 'ZC_BC^:/-O^"?*A_@1;9"G_2[CM_TU
M-?3OV>/_ )Y)_P!\BOF/_@GO_P D)M_^ORX_]&FOJ'M7/@?]WAZ'H\2?\C;$
M?XF,^SP_\\D_[Y%'V>'_ )Y)_P!\BI:*] ^:(OL\/_/)/^^11]GA_P">2?\
M?(J6B@"+[/#_ ,\D_P"^11]GA_YY)_WR*EHH Y[QI&J^#]<VJH_T&?H/^F;5
M\(?\$:9#-\)?B#O.?^)]&.?^O=.*^\?&O_(GZW_UXS_^BVKX&_X(X7D%K\(_
M'WFW$<1;7DP'< X^SISS7L8=.6"K)=U^9S2_BQ?D?HG]GB_YY+_WR*/L\7_/
M)?\ OD55_MJQ_P"?R#_OZO\ C2_VU8_\_D'_ ']7_&O)Y9]CHNBS]GB_YY+_
M -\BC[/%_P \E_[Y%5O[:L?^?R#_ +^K_C1_;5C_ ,_D'_?U?\:.6?8+HL_9
MXO\ GDO_ 'R*/L\7_/)?^^15;^VK'_G\@_[^K_C1_;5C_P _D'_?U?\ &CEG
MV"Z+'V>/_GBG_?(KA?!>V3XD?$!"BD+-9XX_Z=Q78?VS9?\ /W;_ /?U?\:X
MSPC?6,/C[QQ+]LM_WLUH?]:O: #UHY*G87,COOL\7_/)?^^11]GB_P">2_\
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M_/Y!_P!_5_QHY9]@NBS]GB_YY+_WR*/L\7_/)?\ OD56_MJQ_P"?R#_OZO\
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M3_@CJ=W[)]^3_P!#->?^B;>O<OVU+ZWNOV3?BM'%/'(S>'KH!4<$GY#7@O\
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MA_Y%O3/^PWIW_I5'7<K7#?&'_D6],_[#>G?^E4==RM #J*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@]2_Y+1H7_8$O/_1T
M%=Y7!ZE_R6C0O^P)>?\ HZ"N\H **** "BBB@ HHHH **** "BBB@ K'\6?\
MBKJ__7E-_P"BVK8K'\6?\BKJ_P#UY3?^BVH J?#G_DGOA;_L%VO_ *)6NCKG
M/AS_ ,D]\+?]@NU_]$K71T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ KS_P/_R4SXB?]=[+_P!)Q7H%>?\ @?\ Y*9\1/\ KO9?^DXH ] HHHH
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MS'W/6/XL_P"15U?_ *\IO_1;5L5D>+/^16UC_KRF_P#0#4E%/X<_\D]\+?\
M8+M?_1*UT=<Y\.N/A_X8'_4+M?\ T4M='0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<-\5/\ CW\,?]C#8?\ HRNYKBOBA'YE
MOX:Q_#K]BW_D2@#M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KS_Q=_P E<\ _]<M0_P#1:5Z!7!>*XRWQ8\"/V6+4/_1:
M4 =[1110 4444 %%%% !1110 4444 %%%% !1110!S?CSYO!^L9X_P!'D_\
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M(CNI;4HWVN( XA .#NJ?;4_YE]Z'_9^+_P"?4ON?^1[3_GI1_GI7!?\ "]/
M/_0V:3_X%Q__ !5)_P +V\ _]#7I/_@9'_\ %57MJ?\ ,OO%_9^+_P"?4ON?
M^1WW^>E'^>E<#_PO;P#_ -#7I/\ X&1__%4?\+V\ _\ 0UZ3_P"!D?\ \51[
M:G_,OO#^S\7_ ,^I?<_\COO\]*/\]*X'_A>W@'_H:])_\#(__BJ/^%[> ?\
MH:])_P# R/\ ^*H]M3_F7WA_9^+_ .?4ON?^1WW^>E'^>E<#_P +V\ _]#7I
M/_@9'_\ %4?\+V\ _P#0UZ3_ .!D?_Q5'MJ?\R^\/[/Q?_/J7W/_ ".^_P ]
M*/\ /2N!_P"%[> ?^AKTG_P,C_\ BJ/^%[> ?^AKTG_P,C_^*H]M3_F7WA_9
M^+_Y]2^Y_P"1WW^>E'^>E<#_ ,+V\ _]#7I/_@9'_P#%4?\ "]O /_0UZ3_X
M&1__ !5'MJ?\R^\/[/Q?_/J7W/\ R.^_STH_STK@?^%[> ?^AKTG_P #(_\
MXJC_ (7MX!_Z&O2?_ R/_P"*H]M3_F7WA_9^+_Y]2^Y_Y'??YZ4?YZ5P/_"]
MO /_ $->D_\ @9'_ /%4?\+V\ _]#7I/_@9'_P#%4>VI_P R^\/[/Q?_ #ZE
M]S_R.^_STH_STK@?^%[> ?\ H:])_P# R/\ ^*H_X7MX!_Z&O2?_  ,C_P#B
MJ/;4_P"9?>']GXO_ )]2^Y_Y'??YZ4?YZ5P/_"]O /\ T->D_P#@9'_\51_P
MO;P#_P!#7I/_ (&1_P#Q5'MJ?\R^\/[/Q?\ SZE]S_R.^_STH_STK@?^%[>
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MUJ&?^/\ NO\ O\W^-34FT5 $?VK4/^?^Z_[_ #?XT?:M0_Y_[K_O\W^-2T4
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M:KZC,AI/,-'U##?R(?\ K1G/_/YGR[_P[I\#_P#0R:]_W\@_^-4?\.Z? _\
MT,FO?]_(/_C5?47F&C>?6CZAAOY$+_6G.?\ G\SY<_X=S^!O^ADUW_OY!_\
M&J/^'<_@;_H9-=_[^0?_ !JOJ/S#ZT>8?6G_ &?A?Y4'^M.<_P#/YGRZO_!.
MGP/_ -#+K_\ W\@_^,TG_#N?P/\ ]#)KW_?<'_QFOJ19#S3O,-)X#"_RH/\
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MVO+\T?:^GO,GA_2]DTB_Z)%]UB/X!3#-<_\ /S-_W\-3:?\ \B_I?_7I%_Z
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M HHHI@/HHHJ"PHHHH **** 'T444 %%%% !1110 4JTE*M "UE^)O^/?3?\
MK_A_]"K4K+\3?\>^F_\ 7_#_ .A4I;,J.YLM3:<U-IDA1110 4444%A3Z93Z
M3)84444@04444%!1110 4444 .HHHH **** %6G4U:=0 JUAZM_R-WA[_=N/
M_016XM8>K?\ (W>'O]VX_P#014RV''<W7ZTVG/UIM,04Y:;3EI@+1110 444
M5!04444 .HHHH)"BBB@H**** "G+3:<M "T444 %%%% #X^U<_H/_(W^)_\
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M%ZU '-_$C_D V'_85LO_ $>M=7)]X_6N4^)'_(!L/^PK9?\ H]:ZN3[Q^M-
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MUAXBU1I&>XUN/4HB]R+ICS+B3#(&X3:-N ,5?*3S'Z&5E^*?^19U?_KSF_\
M0#6I63XJ_P"18UC_ *\YO_0#4%'GU]\OP]\%?]@^'_T2E4(W&VMK3_#=UXF^
M'?A 6TT41BTZW9O,SSF%.F!2K\-]5"X^V6OYM_A77"45!79A)/F9C^8*57&X
M<UM?\*WU3_G\M?\ Q[_"D'PWU8'_ (^[7\V_PI\T>Y/*^QD>8*/,%;/_  KG
M5?\ G[M?S;_"D_X5SJO_ #]6OYM_A0I1[AROL8_F"CS!6Q_PKG5?^?JU_-O\
M*/\ A7.J_P#/U:_FW^%'-'N'*^QD^8*/,%:__"N=5_Y^[;\V_P *!\.]5_Y^
M[7\V_P *.>/<JS[&2&%+N%:X^'>J?\_=K^;?X4O_  KO5/\ GZM?S;_"CFCW
M"S[&/N%)N%;/_"N]4_Y^K7\V_P */^%=ZI_S]6OYM_A1S1[A9]C(:0>M'F"M
M?_A7>J?\_5K^;?X4?\*]U3_GZM?_ ![_  HYX]PL^QD>8*-PW5K_ /"O=4_Y
M^K7\V_PH_P"%>ZI_S]6OYM_A1S1[A9F3N%&X5K?\*_U3_G[M?S;_  I?^%?:
MI_S]VOYM_A1S1[A9]C(W"E$@K6_X5]JG_/W:_FW^%+_P@&J?\_5K^;?X4<T>
MX6?8R?,%97B9AY&F_P#7_#_.NL_X0'5/^?JV_-O\*Y_QIX3O]/M]&\RXMV\W
M5;:$8+=6; [5,I1L]2HIW+S.*;Y@K7;P'J1Z7-M^;?X4W_A =3_Y^;;\V_PJ
MN:/<+,RO,%)Y@K6_X0'4_P#GZMOS;_"C_A -3_Y^K;\V_P *.:/<FS[&5O%&
M\5K?\(#JG_/U;?FW^%'_  @.J?\ /U;?FW^%+FCW*LS)WC<*=Y@K4_X0'5/^
M?JV_-O\ "E_X0'4O^?JV_P#'O\*.:/<+,RO,%'F"M7_A ]1_Y^K;_P >_P *
M3_A =2_Y^K;\V_PI<T>X69F;Q1O%:O\ P@>I?\_-M^;?X4?\('J7_/S;?FW^
M%'-'N%F96\4;Q6K_ ,('J7_/S;?FW^%'_"!ZE_S\VWYM_A1S1[A9F5N%&X5J
M_P#""ZE_S\V_YM_A1_P@>I?\_-M_X]_A2YEW"S,S>*-XK5_X074O^?FW_-O\
M*/\ A!=2_P"?FW_-O\*?-'N%F9>\4F\5J_\ ""ZE_P _-O\ FW^%+_P@NH_\
M_-O^;?X4N:/<JS,I7&:=O%:7_""ZCG_CYM_S;_"G?\(/J/\ S\V_YM_A1S+N
M*S,P,*Q-7;_BKO#W^[<?^@K77?\ "#ZC_P _-O\ FW^%<SKWAN\@\?>%+9IX
M=\Z794@G'RHI/;WJ9-6W&D[FHS#/6F[Q6LW@G4&_Y>;?\V_PIO\ P@^H_P#/
MS;_FW^%5S1[A9F7O%.5QBM+_ (0?4?\ GYM_S;_"E7P1J(_Y>+?\V_PHYEW"
MS,W>*3S!6I_PA.H_\_%O^;?X4?\ "$ZC_P _%O\ FW^%',NY-F9FX4;Q6G_P
MA.H?\_%O_P"/?X4?\(3J'_/Q;_\ CW^%*\>Y6IF;Q1O%:?\ PA.H?\_%O_X]
M_A2?\(3J'_/Q;_\ CW^%%UW'J9^\4;QZ5I?\(3J'_/Q;_FW^%'_"$ZA_S\6_
MYM_A2YEW%9F=NHW5H_\ "%ZA_P _%O\ ^/?X4?\ "%ZA_P _%O\ ^/?X4<R&
M9VX4;A6E_P (7?\ _/>W_-O\*/\ A"[_ /Y[V_YM_A1S(#-W"G!ABM#_ (0O
M4/\ GXM_S;_"E_X0V_\ ^?B#_P >_P *.9 9^X4FZM'_ (0V^_Y[P?\ CW^%
M'_"&WW_/>#_Q[_"CF0&?N%&X5H?\(;??\]X/_'O\*/\ A#;_ /Y^(/\ Q[_"
MCF0%&-ANK T!A_PEWB?_ '[?_P!%UV*^#[Y6S]H@_7_"N5\+Z#=7'CCQE LT
M0:"2U#9SWASZ5+DM"C99A2;A6D?!]]_S\0?K_A2?\(???\_,'Z_X4[KN3J9V
MX4;A6E_PA]]_S\0?K_A1_P (???\_$'Z_P"%',@,W<,T;A6C_P (??\ _/Q!
M^O\ A1_PA]]_S\P?K_A2N@,_(I-PK2_X0^^_Y^(/U_PH_P"$/OO^>\'Z_P"%
M5S(#-W"G[A5[_A#[[_GO!^O^%._X1&^_Y^(?U_PHYD49VZEW"M#_ (0^]_Y^
M(?U_PI?^$1O?^?B']?\ "IN@,[<*-PK1_P"$1OO^>\/Z_P"%'_"(WO\ S\0_
MK_A1=$V,[<*?N%7O^$1OO^>\/Z_X4?\ ")WO_/>'\S_A330T4=PH#5?_ .$3
MOO\ GO#^9_PH7PG?+_RWA_,_X4KH90W"C<*OGPG??\]X?S/^%*/"M[_SWA_,
M_P"%%T!GY%&16A_PBM[_ ,]H?S/^%'_"*WO_ #VA_,_X470%.$_-7/>!6_XE
M-_\ ]A.Z_P#1IKL(_"]XO6:']?\ "N6^'.AW5UH^IE9HAMU:]0YSU69AZ>U*
MZN!LEA2;A6A_PB][_P ]H?S/^%)_PBM[_P ]H?S/^%%T!0W"ER*O?\(K>_\
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MSVC_ %_PH J9%.!&*L_\(_=?\]H_U_PI?[ N?^>L?Z_X4 5LBD9JM?V#=?\
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M'G_OQ_K_ (4X:/./XX_U_P *""OD49%3_P!DS_WH_P!?\*/[)G_O1_K_ (4
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M/_)/?"W_ &"[7_T2M='7.?#G_DGOA;_L%VO_ *)6NCH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N&^*G_ ![^&/\ L8;#_P!&
M5W-<-\5/^/?PQ_V,-A_Z,H [FBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\_\ %W_)7/ /_7+4/_1:5Z!7G_B[_DKG@'_K
MEJ'_ *+2@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *\_P# _P#R4SXB?]=[+_TG%>@5Y_X'_P"2F?$3_KO9?^DXH ]
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M&^$?_(#UG_L.ZC_Z4O7<UPWPC_Y >L_]AW4?_2EZ .YHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ***2@#\L=VW_ (+AD]L?^ZU7ZD[=O09-?DC\4/B%
MI_PI_P""O6K^+=6BGFT[3_*\U;9 TA\S0$C7 ) /S.._3-?6K?\ !1[P(/\
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M -&4 =S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>?^+O^2N> ?^N6H?\ HM*] KS_ ,7?\E<\ _\ 7+4/_1:4 >@4444
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MU6TA%Q8V444NQM^5W*H.#@<>U?4'[+LC-^S;\*C(?F/A;2\_^ D=?G'\<O\
M@HEH/[67@=? <?@NZ\/R37<=VMW<WZ2IF,,=NT(.3GUKT7P__P %0M!^"WP_
M\*^%I_ 5]J#Z/I=KIIFBU"-!(88ECW!2G .W/MFNSZE6EAHTHPUNWTVLCS:N
M,E4Q5ZK;;2U=W?7:_D?I=Q1\M?FM_P /JO#G_1,M4_\ !G%_\13O^'U7AO\
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MP-:_YYVO_?MO_BJ/^%@:U_SSM?\ OVW_ ,51[*0>T1Z717FG_"P-:_YYVO\
MW[/_ ,52_P#"?:U_SSM?^_;?_%4>RD/G1Z517FW_  GVL_W+;_OV?_BJ/^$\
MUK^Y;?\ ?L__ !5+V<@YT>DT5YM_PGFM?W+;_OV?_BJ/^$\UK^Y;?]^S_P#%
M4>SD'.CTFBO-O^$\UG^Y;?\ ?L_XTO\ PG>L_P!RV_[]G_XJG[*0<Z/2**\W
M_P"$[UG^Y;?]^S_\50/'FL_W+;_OV?\ &CV4@YD>D45YU_PG6L?W+;_OV?\
MXJC_ (3K6/[EM_W[/_Q5'LI!SH]%HKSK_A.M8_N6W_?L_P#Q5'_"<:Q_<M_^
M_9_QI>SD'.CT6N)^*2EK?PQCMX@L3_Y$JA_PG.L?W+?_ +X/^-8/C+Q1J-];
MZ/YB0#RM4MI1M0]5;([TO9NPU)7/8Z*\^;QQJW:.V_[X;_XJF_\ "<:O_<M_
M^_9_^*I^SD+F1Z'17GG_  G&K_W+?_OV?_BJ/^$TU?\ N6W_ '[/^-'LY!S(
M]#HKSS_A.-7_ +EO_P!^S_\ %4?\)QJ_]RW_ ._9_P#BJ/9R'S(]#HKSS_A.
M-7_N6_\ W[/_ ,53O^$VU7^Y;_\ ?L_XTO9L7,CT&BO/O^$VU7^Y;_\ ?L_X
MT?\ ";:K_<M_^_9_QH]FPYD>@T5Y]_PFVK?W+?\ [X/^-'_";:M_<M_^^#_C
M2]G(?,CT&BO/O^$VU;^Y;_\ ?!_QH_X3;5O[EO\ ]\'_ !I^SD',CT&BO/\
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M_P"$FO\ ^[#_ -\'_&CE8'6T5R?_  DM_P#W8?\ O@_XT?\ "27WI#_WR?\
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M^6, ]6]J];_9MBBN?@/X!,L,;$:)9J,H/^>"5Y!^W]-/>? U7* H-0AW;%/
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M]O\ ^BJCJ@-]E&:3:*<W6BJ0";12;13J*8#=HS1M%+_$:6H 0J*3:*<W:BK
M;M%/VBDIU T)M%&T4M%)C8FT4;12T5)(FT4_:*;3ZI%(3:*-M+10QB;11M%+
M14@)M%&T4M% $D(^;I7/>!5_XE-__P!A.Z_]&FNBAKGO G_()U#_ +"5U_Z-
M-'4#?(I-M*W6B@!-M&VEHH 3:*-HI:* !0*=M%(M+0P$VT;:6B@!-M&VEHH
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M3*?0 4444#04444#84JTE.6@D6BBB@ HHHH+"BBB@!U%%%!!STW_ "5[0?\
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M!04444 .HHHH)"BBB@H**** "G+3:<M "T444 %%%% #X^U<_H/_ "-_B?\
MW[?_ -%5T$?:N?T'_D;_ !/_ +]O_P"BJCJ@.@;K10W6BJ0!1113 3^(TM)_
M$:6H &[44-VHJP"G4VG4#04444F-A1114DA3Z93ZI%(****&,****D HHHH
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MW_#?'Q@_Z(=)^5W_ /&J/^&^/C!_T0Z3\KO_ .-59_X;J^)O_1+[C_OW-_\
M&Z/^&ZOB9_T2^X_[XF_^-TO[>R__ )]?BR_]0<]_Y^Q_\"C_ )E7_AOKXP_]
M$.D_*[_^-4?\-]_&#_HA<G_DW_\ &:M?\-U?$S_HEMQ_WQ-_\;I/^&Z_B9_T
M2ZX_[]S?_$4?V]@/^?7XL7^H>>_\_8_^!+_,K_\ #?/QB_Z(;)^5Y_\ &:/^
M&^?C%_T0V3\KS_XS5K_ANGXF?]$OG_[]S?\ QNC_ (;I^)G_ $2^?_OW-_\
M&Z/[<P'_ #Z_%C_U#SS_ )^1_P# E_F5?^&_/C%_T0R3\KS_ .,TO_#?WQA_
MZ(9)_P"3?_QFK'_#=7Q-_P"B8S_]^Y?_ (BC_ANKXF_]$QG_ ._<O_Q%']N8
M#_GU^+'_ *B9W_S\C_X%'_,K?\-_?&'_ *(9+_Y-_P#QFD_X;^^,7_1"YO\
MR;_^,U9_X;H^)O\ T3"X_P"_<W_Q%'_#=7Q,_P"B87/_ '[F_P#B*?\ ;N7_
M //G\63_ *A9Y_S]C_X%'_,J_P##P'XQ?]$*D_.[_P#C-'_#P#XQ?]$)E_\
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MR_$W_'OIO_7_  _^A5J5E>)C^XTW_K_A_G2ELRH[FTU-I6--R*9(M%)D4;J
M%HI,BC(H+%I],SR*=D4F2Q:*3(HW4@0M%)D49%!0M%)D49% "T4F11D4 /HH
MR*,B@ HHHR* %6G4Q2,T[(H <M8>K?\ (W>'O]VX_P#016V#6)K'_(W>'O\
M=N/_ $%:F6PX[FZ_6FTK4E,04Y:9D4Y2*8#J*3(HW4 +129%&14%"T4F11D4
M /HHR**"0HHHH*"BBB@ IRTVG+0 M%%% !1110 ^.N?T'_D;_$_^_;_^BJWX
M_O"L#0/^1M\3_P"_;_\ HNHZH#H&ZT4-UI,BJ0"T44F13 /XC2TW^*ER*@!6
M[44$]*3(JP%IU,R*?0-!11128V%%%%22%/IE/JD4@HHHH8PHHHJ0"BBB@"6&
MN>\"?\@G4/\ L)77_HTUT$-<]X&_Y!.H?]A*Z_\ 1IHZ@= W6BANM% !129%
M+0 4444 *M+2+2T, HHHH **** "GTRGTF 4444@"BBBJ *5:2E7O28#J***
M0&/XZ_Y$;7_^O*;_ -!-:EC_ ,@RS_ZX)_Z"*RO'1_XH;7_^O*7_ -!-:MC_
M ,@NS_ZX)_Z"* )*5?O4E*OWJ .%_:D_Y-3^+G_8IZI_Z225\X?\$>MEQ^RW
MKWF(K^7XJNE_\E;0_P!:^C?VH/\ DU/XN_\ 8I:I_P"DDE?-G_!''_DUWQ1_
MV-MU_P"D=E7=3_W.2_O(CF:FK'V[)Y*L?]'C_P"^*C\R'_G@G_?NHIF^8U'7
MG\L;;&O/4_F+/F0_\^\?_?%'F0_\^\?_ 'Q5<&G4N6/8?M*G\Q-YD7_/O'_W
MS3]\/_/O'_WQ5:BCECV%[2I_,6?,B_YXQ?\ ?NCS(O\ GC%_W[JM11RQ["]I
M/^8L;H?^?>+_ +YIVZ';_P >\?\ WQ56G+1RQ[#YZG\Q9W1?\^T?_?%&8O\
MGVC_ ._=5Z1J?*NP^>?\Q/\ N/\ GA%_W[I<P?\ /K%_WQ4&31FI48]@YZO\
MQ-F#_GA%_P!^Z,P?\\(O^_=0YHS1R1[![2I_,6=L'_/%/^^!4ODP?99BL,>[
M8V,+[51S5Z/_ (\Y_P#KFW\C50BKHB4ZG*_>/SV_X)UWC7GAGQ^QY_XF^C_^
MCI*_0:\_US_6OSM_X)MMM\)_$#_L,:/_ .CI*_1*\_US_6O3S'_>7\OR1YV
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M-9O_ (S1_:?Q,_Z%_P ._P#@UF_^,T_;/L'L_,QO[*U;_H'W/_?LT+I>K?\
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M_P#O@U-_:GQ,_P"A>\.?^#6;_P",T?VI\3/^A>\.?^#6;_XS2YPY2+^S[_\
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M;_O@U%_:7Q+_ .A?\.?^#6;_ .,T?VE\2_\ H7_#G_@UF_\ C-'.!,=/OO\
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M^TOB7_T+_AS_ ,&LW_QFCF L?8;W_GTF_P"^#0+&]_Y]9O\ O@U7_M+XE_\
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MCMP[$Y\M5SG'2O6** "BBO(_C1\:)/AOK7@SPOHNF1:YXS\87[V>F6-Q<-!
MD<2&2>XFD5'*I&N. I)+*.F2 #URBO(?@I\;)/B-KWC3PKK.FPZ-XT\'WZV>
MJ:?;7)N(&CD026]Q%(54E)$/0J"&5@>F3Z]0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%>._&+X\?\*Y\1>'_!OAS0)O&/Q#
M\0!I-/T*&801Q6Z</=W4Q!$,"' +89B3A58T >Q45S_A&;79O#]J_B:UL+/6
MF!-Q;Z7.\]NAR<!7=$9N,9)4<UT% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 45PWQD\::I\-_ACXD\4Z1H0\27VCV,U\NF?:?
MLYG6-"[ /M;G /&.:YO3_BWX@\3? /P?X\\.^$6UCQ!XFTO3;ZWT-+ORX89+
MN*-SYMP5^6*,.2S["<+PI)"D ]=HKY^^#?[0WB;Q5\9/%'PM\>^#;;PKXOT?
M3H=8AFTO43?6%[9R,$#H[1QN&#DJ05_A/I7T#0 4444 %%%% !1110 4444
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MGL[R%+B"4='C=0RG\016A2&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M=M;QC:D,*!$4>@ X JY3;N 4444@"BBB@ HHHH **** "BBB@ HHHH ****
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M^$5R>FX $GCZ1UKPKHWB*2)]5TBQU-H@1&;RV28H#U W XS@58NM%T^ZT_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_014.jpg
<TEXT>
begin 644 form10-k_014.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI*6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU\1?^#9O_B:OEAW_  . ^N_^$T\/?]!W3?\ P,C_ /BJ3_A-/#W_ $'=-_\
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M_P"*H_X33P]_T'=,_P# R/\ ^*KY$_X=$_L__P#/KXB_\&S?_$T?\.A_V?\
M_GU\1?\ @V;_ .)K'EAW_ T/KO\ X33P]_T'=-_\#(__ (JD_P"$T\/?]!W3
M?_ R/_XJOD7_ (=#_L__ //IXB_\&S?_ !-'_#H?]G__ )]/$7_@V;_XFBT.
MX'UU_P )IH'_ $'M,_\  R/_ .*H_P"$S\/_ /0=TW_P-C_^*KY$_P"'1'[/
M_P#SZ>(?_!LW_P 36!XZ_P""5/P$\,^&9[Z"RU\2I+"@9M68\-*JGC;Z,:?+
M#O\ @*[['VW_ ,)IX?\ ^@[IO_@9'_\ %4G_  FGA_\ Z#NF?^!D?_Q5?(;?
M\$B?V?VZ67B%/]W5V_JM+_PZ'_9__P"?7Q%_X-V_^)HY8=_P#4^N_P#A-/#W
M_0=TW_P,C_\ BJ/^$T\/?]!W3?\ P,C_ /BJ^1?^'0_[/_\ SZ>(O_!LW_Q-
M'_#H?]G_ /Y]/$7_ (-F_P#B:5H=QGUU_P )GX?_ .@[IG_@9'_\52_\)EH.
M,_VYIO\ X%Q_XU\@K_P2)_9_7DV7B%QZ-J[?T6OD3_@I5^QG\-/V8_ /@[5?
M UC?6EYJ6I2VMP;N^>X#H(MPP&Z$$=O6KITX5)J*E^!-_(_79O'GAJ'A_$.E
M(?\ :O8A_P"S4W_A8GA;_H9=(_\  Z+_ .*JCX9\&Z _A?2 VB:<P%G"!NM(
MS_ /:M+_ (0?PY_T -+_ / ./_"LGH[%$?\ PL3PM_T,ND?^!T7_ ,51_P +
M$\+?]#+I'_@=%_\ %5)_P@_AS_H :7_X!Q_X4?\ "#^'/^@!I?\ X!Q_X4@(
M_P#A8GA;_H9=(_\  Z+_ .*H_P"%B>%O^AETC_P.B_\ BJD_X0?PY_T -+_\
M X_\*/\ A!_#G_0 TO\ \ X_\* (_P#A8GA;_H9=(_\  Z+_ .*H_P"%B>%O
M^AETC_P.B_\ BJD_X0?PY_T -+_\ X_\*/\ A!_#G_0 TO\ \ X_\* (_P#A
M8GA;_H9=(_\  Z+_ .*H_P"%B>%O^AETC_P.B_\ BJD_X0?PY_T -+_\ X_\
M*/\ A!_#G_0 TO\ \ X_\* (_P#A8GA;_H9=(_\  Z+_ .*H_P"%B>%O^AET
MC_P.B_\ BJD_X0?PY_T -+_\ X_\*/\ A!_#G_0 TO\ \ X_\* (_P#A8GA;
M_H9=(_\  Z+_ .*H_P"%B>%O^AETC_P.B_\ BJD_X0?PY_T -+_\ X_\*/\
MA!_#G_0 TO\ \ X_\* (_P#A8GA;_H9=(_\  Z+_ .*H_P"%B>%O^AETC_P.
MB_\ BJD_X0?PY_T -+_\ X_\*/\ A!_#G_0 TO\ \ X_\* (_P#A8GA;_H9=
M(_\  Z+_ .*I?^%@>%_^ADTC_P #HO\ XJG_ /"#^'/^@!I?_@''_A7$>)O"
MNAP_$KP3;IHUBD,RWN^-;9 KXB4C(QSB@#L_^%B>%O\ H9=(_P# Z+_XJC_A
M8GA;_H9=(_\  Z+_ .*J3_A!_#O_ $ -,_\  ./_  H_X0?PY_T -+_\ X_\
M* (_^%B>%O\ H9=(_P# Z+_XJC_A8GA;_H9=(_\  Z+_ .*J3_A!_#G_ $ -
M+_\  ./_  H_X0?PY_T -+_\ X_\* (_^%B>%O\ H9=(_P# Z+_XJC_A8GA;
M_H9=(_\  Z+_ .*J3_A!_#G_ $ -+_\  ./_  H_X0?PY_T -+_\ X_\* (_
M^%B>%O\ H9=(_P# Z+_XJC_A8GA;_H9=(_\  Z+_ .*J3_A!_#G_ $ -+_\
M ./_  H_X0?PY_T -+_\ X_\* (_^%B>%O\ H9=(_P# Z+_XJC_A8GA;_H9=
M(_\  Z+_ .*J3_A!_#G_ $ -+_\  ./_  H_X0?PY_T -+_\ X_\* (_^%B>
M%O\ H9=(_P# Z+_XJC_A8GA;_H9=(_\  Z+_ .*J3_A!_#G_ $ -+_\  ./_
M  H_X0?PY_T -+_\ X_\* (_^%B>%O\ H9=(_P# Z+_XJC_A8GA;_H9=(_\
M Z+_ .*J3_A!_#G_ $ -+_\  ./_  H_X0?PY_T -+_\ X_\* (_^%B>%O\
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M'_PL3PM_T,ND?^!T7_Q5'_"Q/"W_ $,ND?\ @=%_\54G_"#^'/\ H :7_P"
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M;'_\57FFW_IUL?\ P"A_^(HV_P#3K8_^ 4/_ ,11<.4]+_X3CPW_ -#!I?\
MX&Q__%4?\)QX;_Z&#2__  -C_P#BJ\TV_P#3K8_^ 4/_ ,11M_Z=;'_P"A_^
M(HN'*>E_\)QX;_Z&#2__  -C_P#BJ/\ A./#?_0P:7_X&Q__ !5>:;?^G6Q_
M\ H?_B*-O_3K8_\ @%#_ /$47#E/2_\ A./#?_0P:7_X&Q__ !5'_"<>&_\
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MBC;_ -.MC_X!0_\ Q%%PY3TO_A./#?\ T,&E_P#@;'_\51_PG'AO_H8-+_\
M V/_ .*KS3;_ -.MC_X!0_\ Q%&W_IUL?_ *'_XBBX<IZ7_PG'AO_H8-+_\
M V/_ .*H_P"$X\-_]#!I?_@;'_\ %5YIM_Z=;'_P"A_^(HV_].MC_P" 4/\
M\11<.4]+_P"$X\-_]#!I?_@;'_\ %4?\)QX;_P"A@TO_ ,#8_P#XJO--O_3K
M8_\ @%#_ /$4;?\ IUL?_ *'_P"(HN'*>E_\)QX;_P"A@TO_ ,#8_P#XJC_A
M./#?_0P:7_X&Q_\ Q5>:;?\ IUL?_ *'_P"(HV_].MC_ . 4/_Q%%PY3TO\
MX3CPW_T,&E_^!L?_ ,51_P )QX;_ .A@TO\ \#8__BJ\TV_].MC_ . 4/_Q%
M*JC_ )];'_P"A_\ B:8N4]*_X3CPY_T,&E_^!D?_ ,51_P )QX;_ .A@TO\
M\#8__BJ\P^Q0?;#=?9+/S_+\K=]DBQMSG&-N.O?&:E91_P ^MC_X!0__ !-
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MX;_Z&#2__ V/_P"*H_X3CPW_ -#!I?\ X&Q__%5YIM_Z=;'_ , H?_B*-O\
MTZV/_@%#_P#$47#E/2_^$X\-_P#0P:7_ .!L?_Q5'_"<>&_^A@TO_P #8_\
MXJO--O\ TZV/_@%#_P#$4;?^G6Q_\ H?_B*+ARGI?_"<>&_^A@TO_P #8_\
MXJC_ (3CPW_T,&E_^!L?_P 57FFW_IUL?_ *'_XBC;_TZV/_ (!0_P#Q%%PY
M3TO_ (3CPW_T,&E_^!L?_P 53?\ A//#0Z^(=*'_ &^Q?_%5YMM_Z=;'_P
MH?\ XBI--MX;K6+*&6RL7ADF574V4/()Y'W:8K'K%C?6VI6L=S:7$5U!(,I-
M"X=&^A'!JY7$_"&%;?P+;QHJHBW5VJJHP /M$F *[:@D**** "BBB@ HHHH
M**** "BBB@ HHHH X+X+_P#(I7G_ &%]0_\ 2J2N]K@?@O\ \BG>?]A?4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!",U)H_\ R,&G?]=T_F*C:I-'
M_P"0_I__ %\)_,4 =9\)?^1+B_Z^[O\ ]*)*[&N.^$O_ ")<7_7W=_\ I1)7
M8T$!1110 4444 %%%% !1110 4444 %%%% ' _!?_D4[S_L+ZC_Z525WU<#\
M%_\ D4[S_L+ZC_Z525WU WN%%%% @HHHH **** /S^_:4_Y/E^'_ /USL?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!=?\
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M/^$XU[_GM%_WZ%+_ ,)QKV1^^A_[]"J]C(GVB/4>?6CGUKS#_A-M=_Y[1?\
M?H4?\)MKO_/:+_OT*?LI![1'I_2BO,/^$VUW_GM%_P!^A3H_&6N,P!EB(_ZY
M"E[&3#G25SY-_:5^7]N3X?\ _7*Q_P#2J>OO6S_X]X?I_2OSZ_:"O)[K]L_X
M>SR%?/:&Q#$+Q@7,W;\37V--XKUB!@D<D04?],Q7DX.$I5JR[-?D?<<0+V>"
MP+?6'ZL]*HKS'_A-=<_Y[1?]^A1_PFVN?\]8O^_0KU_92/B.='IU%>8_\)MK
MG_/6+_OT*/\ A-M<_P">L7_?H4>RD'.CTNO,?VG5W_LX_%-?7PMJ@_\ )26I
M1XRUO_GM%_WZ%<E\<->U+4O@3\1()7C(E\/7\9P@'#6[@_H:THTY>TCZK\S&
MK44:;?DSR#_@D>NW]D\=O^)]>_RBK[4W"OB;_@G/=7/AW]G&6VLRBQ_VU=,
MRYZI%7TDWC#6E;_6Q8_ZY"M\93;Q$WW;)P]:-2G&2V:N>ET5YI_PF>M_\]HO
M^_0H_P"$SUO_ )[1?]^A7)[*1T<Z/2Z*\T_X3/6_^>T7_?H4+XRUO_GM%_WZ
M%'LI!SH]*:N"^-BEOAW=@?\ /S:?^E$=4_\ A,=;_P">T7_?H5S_ ,0/$&J:
MEX3N()WC9#+"W$8'252/U%1[-I7&I*Y[517G3>+]9[2Q#_MF*9_PF&M?\]HO
M^_8J_92%S(](HKS?_A,-:_Y[1?\ ?L4?\)AK7_/:+_OV*7LV',CT;J:_-_\
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M )ZQ_P#?L4?\)5JW_/6/_OV*.1AS([ZBN!_X2K5O^>L?_?L4?\)5JW_/6/\
M[]BCD8<R.]VBC:*X/_A*M6_YZ1_]^Q2CQ1JS?\M(_P#OV*.1AS'>45P?_"4:
MM_STC_[]BC_A*-6_YZ1_]^Q1R,.9'>45P?\ PE&K?\](_P#OV*7_ (2C5O\
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M))J?_/2/_O@4[_A(M3_YZ)_WP*.5C.SHKC/^$BU/_GHG_? I1XBU+_GHG_?
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MR^YF_M]J-OM6#_PM+P-_T..B?^!T7_Q5)_PM/P-_T.&B_P#@=%_\52^L8?\
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M?]%:\#_^%%9__'*/9U.S^X+H[/9[4FWVKC_^&C?@O_T5OP1_X4-G_P#'*/\
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MBBBDP8;11M%%%22&T4[:*;3ZI%(3;1MI:*&,3BCBEHJ0$VBCBEHH ?C]T_\
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ME:BM#^RY?[IIC:;(O\- %*BK?V&3^[4,ENT?48H BHHHH 1JDT?_ )#^G_\
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M5^)O_K3G/_/YGSQ_PP7\/?\ H*ZY_P!_XO\ XW1_PP7\/?\ H*ZY_P!_XO\
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ME5U;<K#<".X-1^<?6L?KV)_F9T\J['QO_P .B/@U_P!#7XV_\#+/_P"1:/\
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MO&W_ (&6?_R+7V2LQSUIWG'^]2^NXG^=A:/8^-E_X)!_!?\ Z&OQQ_X&6?\
M\BU2O/\ @DM\';;6-,M%\4>-#'="3>3>6>1M4$8_T:OM<3-ZUB:O,W_"6>'N
M>UQ_Z *7U_$I:38*,;['R@W_  2!^#'_ $-?C;_P,L__ )%I?^'0/P8_Z&OQ
MK_X&6?\ \BU]E/,V>M-\X_WJ/KV)_G8<D>Q\;?\ #H'X+_\ 0U>-_P#P-L__
M )%H_P"'0/P7_P"AJ\;_ /@;9_\ R+7V3YQ_O4Y9FQUH^NXC^=A:/8^-?^'0
M/P6_Z&SQM_X&6?\ \BUP_P"T!_P2Y^%GPI^!_C7QII'B/Q==:GH>F2WMO#>W
M5JT+NHX#A;=21]&%?H(LS>M>9?MA,6_9%^*W_8!N/Z5=+&8AUH1<G9M?F#4;
M/0\Q_P""7L8_X8WT1N_]J7__ *-KZ8D^\:^:?^"7G_)F>B?]A2__ /1M?2TG
MWC6&)_WB?JRH;(;1117(4.HHHH)"BBB@H**** "G+3:<M "T444 %%%% #XZ
MP_"W_(0\1_\ 81;_ -%I6Y'6'X6_Y"'B/_L(M_Z+2I8&Y11130!1110P$'>E
MI!WI:D HHHJP"G4VG4%(****3!A1114DA3Z93ZI%(****&,****D HHHH ?_
M ,L7_P!TUQ]OTKL/^6+_ .Z:X^WZ5$^@XEA?FKR/XU?M0:!\"/$&G:3JVC:E
MJ4U[;FX22R,>U0&VX.Y@<UZY5:^T/2-8E274=)L=0E0;5>ZMDD91Z L#BM:$
MJ<:B=6/-'LG;\3*O&I*FU2ERR[M7/G)?^"A/@L_\RMKWYP?_ !=#?\%"?!:C
M_D5M>_.#_P"+KZ+'A7PT/^9=TG_P!B_^)H/A7PT?^9=TG_P!B_\ B:]'ZQ@O
M^?;^\\KZOCO^?J^X\N^"G[4&@?'CQ!J6E:3HVI:;+8VXN'DO3'M8%MN!M8G-
M>NM]ZJMCH>D:/*\NG:58Z?(XVL]K;)&6'H2H&:LGFO.K2IRJ-T8\L>S=SU*$
M:D::567-+NE8=']ZLGXD?$JS^$?@._UZXMY+Z\;%O8:;:J&N-0NW^6*")?XG
M9L?0 D\ UK1MAJ^9?VF/V-?%G[27CK3M;7XQW'A+2M+0?V9I-GI#.;:0C#R^
M:MRA9VYYP,#@=R<5:^IN[]#JOV*_V<1^SSX)OV\0R6:_$'Q;,VKZG#"1NA3.
M5@7NRQF0Y/3<Y_'OOVB/@W<_'SX/ZQX(L_%7_"*1:HT27.I10>>3$KAFC $B
M<-M"GGD$C!S7D7P'_8CG^$=GXZ7Q#\3-6\::AXFTHZ1'J4D#V]QI\)W;O*=I
MI3DEE/4?<%9/A?\ X)YZ)HO[./B'X47WCK5[]-4U1=6CU2*+R1;2I_JP(=[!
MEXRP+?,>1M(&*=KW4B=;6L?,WCS]G7XY?\$Z9K/XC^$O&W_"2>$K>YCCU"*W
M\Q(]C,%"W%LS%2K<+N4Y!88(SFO<?C!XV\6>,O\ @H!\-/!GC*_U'P[\*M0L
MA>65O:WDEE;ZA*;1Y"))48;R)@J;">!MX^;)]I\%_LX^(?\ A6^F> /B3\16
M^(?AC3[B"9(6TD6<]PD+J\45Q*9I#(@95/8G !)'%>&?M.>,/BQJ'[8@TSX:
MZ!X?^*L&D>'$5O">KPI+;Z6TCJ6FD61XU\U@$VL&)VEA@<DVFB=2G^P;I-Y=
M_&[XS^*-3U?Q#J_@3PCJ5Y!H6KWFM7<MHT2RSJR[&<QS 0A&RP.TX/4C'JG[
M._AM_%'[-'Q2^(6KO.FH?$2;5/$"/'-)%-!;*CQVBJX;<NV.-6&",!@.U><^
M"?BU\8OC%KGB?]G'XD>"=)^%UQKGAZ2>VOO#MF&2RMRVURT:S,A#C<@(9<-U
M!S7UUJ?@<6_PAF\!>'+Z/1(ET?\ L>TNIK<W*P1^5Y08IO4MA?\ :'UHYN6U
M_+[AVO>Q^:O[-^A^)/BE^Q;\:_&FK_$CQDFI^%VDNM-2WUJ=$22*V$N6.[<P
M8';M)P.H&<$)XTUKQEKW_!/#PM\5[[XC^+G\666L#2;=H-6D@B%LKL@#JF#(
M_ /F.2W'7KGZ;^%?[".O_"GX%_$/X9:;\5;6;3O&6%GNY?#7SVZE/+E"C[5S
MN0 =1MQGFJ]Y_P $_P#5[K]E^R^"I^*ENND6NM-JPU >'/WC*02(BOVKLY+;
ML],#'<M25G=AROHC?OOACX[_ &KO@S\&?%.F_%:?P1]ET>SU.18=(6YEN+\P
MA6G=S*H.,MM7;P23UQCL--\??\,[^'],\'>([?XA?$S7$C>[N_$FE^&;J^CN
M7DE=N6CW*A P-@/  ]:[3X'_  _OO@W\)?#G@B^UV/Q&^BV_V2+4([+[)OB4
MGRP8_,?D+@$[N<9XKMOM)'>L6]6NA277J>,?\-6Z)_T3KXI_^$-?_P#Q%+_P
MU9HG_1.?BI_X0U__ /$5[1]J;UH^U-ZTOD4?,GQH_;DTCX=_#N]U&T\(^-M!
MU"9X[2VU#Q%X5N[2UMWD8+YK-(H#E%W.(P06VX[U\%_'_P"-7PHU;XW?!O7/
M!&H:EJFC>''MKC7=3O[-H[N[N!>F>>=P<%W8$GCCH!@ "OV4COBIYY'H:^>_
MVA?V08?V@_C5\/\ X@MXO.@-X5,!.GC31<?:A'<></WGFKLSROW6]?:M(R7P
M[$.+W/,_VCO'^O>-/VV/@EX6OM6U71O@_P"(+*&_B6&>73TOYF25BDDB,K$C
M]R-A/&X<<UB_L7^'[C6OVL/C'J$FL^(-7^'_ (2O[F/1]2NM:NY;*&02L#!\
MTFR4+&Q^\&("H<\Y.G^V%XT^*=Y^U]X7T7X<:+HGQ(>Q\,R7O_"'ZQ$LEO;E
MI=CW4BR/&A8@HJ'<2/G&.>:?A'XU?'#QSXHOOV>?B'X!TGX3S>+M"O1I^K>&
M;7Y=.41OOE9$G9&!QLX="&=?457V4D3;6YZM^RSH:_$3X7_%;XF:Q$PN_B)J
M=_<07$;&*8:; &M[-%D3# *L992#_$6!^:OC3]E?3?$WQ6_91^.?B+6_B+XP
M^U^&X/M>G)!K<R*DZ0.X=VW;F' &W=M]L\C],]/\%#PK\);?P-X:O8M*%EI"
MZ597LMJ)EBVQ>6LC1!E#'^(C(R>]?-?PA_8+USX._"'XE> --^*EK/8^-;9;
M>6ZF\-$/:\%9&4?:_FW1DJ 2,'!YP02+5[M_\,-Q=CYYOKKQ?XH_X)KV_P 5
MM4^(WBN7Q/I.HBQT\V^J20)'"+H0D2;"#,Q!SOD+$8&".<_17AWP/X^_:\_9
MC^#'B"U^*MSX-NK.U6\O)H=-%Q+?7D+M$LLA,J@A2A;:5(+$-U Q'#^P?K]O
M^RS<_ [_ (6M:MH4NJ#4%OO^$:Q*J;_,,6/M7.9 &W9X&1BO;_V>_A3<_ 7X
M-Z%X!GUU/$:Z1YJ17Z67V3<CRM( 4\Q^07(SNY]!2DURZ/4:CJ:OP9\"ZU\.
M/!46C^(_&%YXZUDW$UQ<:W?1>4\I=LA0FY@H5<+@''&>,U\D_M$:BWBG_@IQ
M\#?#.I6XN-(TRV6[@ADRT9F832;P#QN#0Q<C^XOI7W"LGS9KY?\ VQOA7KMO
M\0OAQ\=?"%H^I:KX&N5&K:;#'OEN-.+YD:->[(K2\=2'R/NX,1>HY;'M?QZN
M%3Q/\((W4,DGC*)&5AD$?8KO((KX7_:^^ /B/]C'XP6/Q[^$$;6OAQ[G?J.G
MQ@F"SD=OGC=0>;>4G&/X6QC'RX^M_B9X2U_]HQO GC#X??%/2='\.:7=)K6G
MLF@_VB+BX$<D>YI#<1_+LE<;-H(/4Y QZ_J&FVWB;PG/H/B:"UUNTO;7[-J$
M3P;8+G<N'_=DMA3SP2<>IZT^:R2%RWN?*?P[\01?&S]D>S\2P>"?%&NC6O%&
MHZ@=(\*ZV-/NK<O<S$EIO,BW("<8R<Y!QQD<Q'\,SN'_ !8_XU?^' '_ ,F5
M]0? ?X0Z9^S[\.8O!>AWD]WI5O>7-S;&X'SQI+*T@C)_BV[L9ZG%=^+Q\]:I
MU'=ON)4U9(_,7]MR^U+PG\!?!W@V#PEXO\%Z1K_B:2:_B\4ZU_:<\WE11! L
MGFR[4)D)"Y'S0DX[GVKXP?$3QG^RG^U)\#?!WASQ5?:K\/?$T%CI;^']2V2I
M #*EL6C<*&'#HP]P>QQ7T=\?/@;X8_:2^'<OA+Q2)HH5E%S:7UJ0)[2=00LB
M$@CHQ!'<$BN%\-_LDO??$;P1XR^(_C5O'=_X)L8[+0H(=+73X8BARLTP$DAE
MEZ'(*KE0=OJ<R:U8<K3T/)/^"JFI2^"?$WP%\6Z9&W]LZ7KLS0-"/G<9@8I[
MY* 8]SZU[/\ M ?LY^./B=\;/A]XR\/_ !*N/"^A:&T+WVAI+*@N]DPD?"HP
M5MZ_(=X/'J.*\Z^-&@C]L3]J+P)I6DF.\^'_ ,-YWU#6]8C;=#<7S,A6S1L8
M9E\I=V#P'8'! SWWQT_9/MOC-\>O ?Q*?QCJ&C?\(JR,=+MXMPN-DGF+LDWC
MRLGA_E;<O''6IV20]VV>_K&/M&/>OS?UC3=7U[_@J%/\/K?QCXFT3POJ!DDN
M+/3=8GC&'L&DD5/F(3<Q/*@%<Y7! (_1I;C$NZOF2T_8UUG_ (:ZA^/$OQ'M
M3>QW9D&C+X?*I]G,)A\KS?M)^;RS]_;][G;VHIM1=VQR5]CPG]D71_$7Q&_:
M(^-_PEU7XA^+SX-T>2]>&&/5Y#<GR;HPQC[0V9% 4@G8PW%1GO7.?LK?M8>-
MO _[$_QH\27FKW?B#5?#U[9V^E3:G,UP]L]V?+W%F)+*K?,%)QQCO7TQ\&?V
M,_$OP7^,7CKXBZ=\4;&]U3Q9'>+<PS>&L1Q//+YH9<7717QQW''%5_V>?V!]
M/^"_@/X@^"/$'C!/&OA3QG;1PW5H-)^Q2PR)N"R))Y\G(#<<#! .:TDX<S:>
MG;4G7L>4>!]+^*NM?!WX,?$SX:V?C+Q'X]N+\WOB2XU#5 ;#4[21I/.0QR3;
M, A54*J[1D@ UV'@?QCJ7[1'_!1'QGX/\0ZUJEMX0\(Z?(+#0;.]EM(Y)@(E
M:63RV4N078_-D?=KT+X%_LG^)?@?8GPS#\8M8U3X=I<BXM_#_P#9T4,T>'WF
M,W0=FV,?O*BIGGIDYG\=?LA_VI^T%'\8? 7CZ]^'WBJX3R=4$=A'>17D90(P
MVLRA255>3N&54XR*7,G*]PY7;8^>?^"=^A0P_MQ?M":1/-->0*FHVS2SR$RR
M+_: 4EF&#N(ZD=ZV/^"?^M>*=4^.W[1N@1>)=1O$T<7%KHR:YJ$UW#:,MS.D
M1/F.3@;4R>I KV/X$_L6_P#"@_BMXE^(&D_$G5M3U?7%N5GCO[&%HYC*WF S
M8^9R),-\A3.,<5D_ _\ 8CUCX1^+OB)K-[\3H]=A\>65W:ZO;PZ +1P\Y=O-
MBD^T/L*M(YQM(YHO&\G??U'K9:'Q[\;/B5XR\)_ ?2/$,7CN\UWX@Z;XUDM=
M1\9>&]8N9=-D!@:5+4DLL4C+M4[8X]@4#/W_ )OH+_@IMXBUG1_V:?A+XQTS
M6]2T?7[^YMHKBZTZ\EMC(DMD\KAA&P!^=0>G':M#_AV+9R? >;X;3_%74IK9
M-:_MRSF.EQB"WF,?E-F+S-S93C_6  DG')KT/]HC]CG5?V@OA%X"^']W\2OL
M%GX7"-)?3:&D\U[*D1B1B$FC5 %+< '.>O%$G&333%&+M:Q\R>,-:\5_!K]K
M3]G>UTKQUXFU*'Q1HFC7.K1:MJ<EQ%<-.[12CRR=@!51C X(SUYK].WBVM*L
M9VN5(4^^.*^-_'W["?B7QQ\1OAWXUN?BQ8PZGX)L+"PL(X_"Y,<@M6+JSC[7
M_$Q.1VKZX%W("I=@\F/F91@$]SCM45.6]TRXZ'Y?_P#!-NQU#P]^W-\0-+\3
M2;_$L=CJ45Q+(I!EF%W&9&&1T8_-[@YKZN_X*D7$,?[&_B2.5E$DFH6"Q GD
ML+A2<?@#6_\ $W]D_0O&/Q0L?BCX3UJY\ ?$JS(_XG%C"L\%V,%2+FW8@294
M[20RDC'/ Q3\??LLZC\=M:T27XO^.E\4^']'F^TVWAW1-)_LNUDFP 7F)FF>
M3C(P&7&YL=:IR4FI7)Y6KH\6^!OP#\-?';]@GX6_##QM=W/A[Q%JTNHZMX<O
M&3+(5GD=7 )PRM%(#MR,J<C&,UY#JEY^T?\ \$W;S3X=>NXO&_PKFNEA:.4M
M=V3(3S&N_#V\A525'W,_WN17W=\<?V>[7XP7'@2;3?$^H>!9?!LSW&F2Z'%&
M&C<H$0#<"H0 8*XPP)'2LCQQ^S[XC^-&FZ7H?Q3\?6WB;PK8W<=\^F:3H0TU
M[V6,DIY\IFERO/*QK'FA25MPLSVVQU*'6]-L-2MPRP7D$=Q&K<$*ZA@#[X-?
MGS_P69_Y$_X7?]?E[_Z!%7Z"ATA6..)%CBC4(B*,!5'  KYB_:P_8Y\0_M97
MVF)J?Q)L= T/29))+"QM_#C32KO"AO,E-V-Y^7LJCV[UBK7+>QF?\%*K>\N/
MV#=.>SSY$,^DR7>!G]UM"C_R(T=>'_MQ1M=_\$[_ -FZ.!3)-))8HBIR2QL)
M  /?-?=UG\.9M>^#=Q\/?B%J=GXNMKFQ_LZXNK/3S8B2$(%4^699,., [@<9
M ( KR?3_ -C.#4/^%?:/XO\ &<OB?P-X!D\W0O#ZZ>+9F=6S$UW,)&\\H,*
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M%8@G%/E?85T>U4444AGDOAW_ ))CJ/\ V&+S_P!*WJG;_=%6_#O_ "2_4?\
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M?F-:XK^/+U94=D-HI,BES7&,=11102%%%%!04444 %.6FTY: %HHHH ****
M'QUA^%O^0AXC_P"PBW_HM*W(SS6%X5_Y"'B/_L(M_P"BTJ6!NT44F130"T44
MF13 !WI::#R:7(J %HHI,BK 6G4S(I]!2"BBBDP84445)(4^F4^J12"BBBAC
M"BBBI **** '_P#+%_\ =-<?;]*[#_EB_P#NFN/M^E1/H-%BBBBI*"BBB@ H
MHHH *<)"*;10 [S#1YAIM+M- #ED*FN;USX6^"_%7B*+Q!JWANQNM>BB\A-4
M"&.Y$?\ <\Q"&(]LUT.,4JYH R?#?@?PSX-N[R[T/0[/3KV]"BYNXTW3S =
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M""01[T=0/@?X$Z3XL^%_C[X)V?Q)-UXJ\ ZM&Z?#VXDN$:?PY<26TCQ6U\%
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M@?<_]^VI/[-U3_H'W/\ WZ:O4LBC(K/VC[%<IY<--U/'_(/N?^_1H_LW4_\
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M_P"_9I/L.H?\^<__ '[->A44<S"QY[]AU#_GSG_[]FG?8[__ )\Y_P#OV:]
MHHYQGG_V&_\ ^?.?_OV:7[!?_P#/G/\ ]\&N_HHYF!P'V"__ .?.?_O@T?8+
M_P#Y\Y_^^#7?T4<S%8X!;&__ .?.?_O@TOV&_P#^?.?_ +X-=]11S,9P/V&_
M_P"?.?\ [X-/6SOMO-G-_P!\&N[HHYV!PGV&^_Y\YO\ O@TOV*]_Y\YO^^#7
M=44<S X7[#>_\^<W_?!H^PWO_/G-_P!\&NZHHYF!Q'V.\$4F;68#:>J'TKC+
M5MRU[)<?\>LO^X?Y5XMI[?NQ4MW*1?HH7M6/KGC;P[X6N$AUC7=/TNX==ZQ7
MERD3%<XR Q''!J7*,5>3LC6E3J5I<E*+D^R3;^Y&Q17-_P#"V/ ?_0WZ+_X'
M1_\ Q5'_  MCP'_T-^B_^!T?_P 567MJ7\Z^]'9_9N._Y]2^YG245CZ+XV\.
M^*)WBT;7=/U2>-=[1VMRDC*N<9(4GCFMBM8RC)7B[KR.2I3J49<M6+C+LTT_
MN84]8BU)&,M7S%^T-^V%XB^%/CB+P=I7@U=#6X<1)XX\8&2+1(B0#N!B5B_7
M;@LGS$9JDG)V1C=+<^I%MMHRQ"CU8XKP_P",G[;'P?\ @+XL/ACQ1KT[ZY&J
MO<6FFVK7+6VX!E$I7A25(;'7!!QR*S/!O[,P^*UQI7C;XD_%*^^)LZ/%=V=E
MH-U]AT*%D(="D,+?O"" =SM\V.1CBJW[8GPC^%?A']F/XF:AJ'AO31J^I)<7
M%MJ$T'FWL^JS,WD;93ERWF,H"@X"@#&T4[*]KA=VN>Y>"_&&@_$KPCIWB?PQ
MJ,>K:'J";[>ZBR P!((((R""""#W%1>/O&VB?"OP-K'B_P 27#6NB:3#Y]S(
MB;VQD !5[DD@ >IKS+]AGX-ZQ\$_V9_#F@^($:#5[J274KBU?K;&9MPB/N%
MS[DU@_MX:3\6M>\ ^&],^%GA-?$TL>J)J6IK,MO+%Y<'S1QO#,P$@:0JV #_
M *L>M3IS6#I<K^ _^"AGP;^)WC+1O"GAV77KS6M6N%MK:(Z6R@L>Y.[@  DG
ML 37TE):LK$8KX!_91_:^U32_CAH_P .?C'\+-$\+>)]0E6#3M9LM!CTZYAE
M<,%$B!1\K_=#IC&>0021ZA8_M:?$#XP?&+XK>&/AW8^']$T;P!I]Q,]SKUI-
M=SZA/$6&T*DL0B5BC#)W$  X.<"^5MV1/,K79]6K;,3TKDO!?Q*T/X@>(_%N
MBZ*UQ<7'A>\73]0F:+;#]H*!RB-_$5!&?0UX5^R+^UIXG^,'P1\>_$[QR_AV
MSTCPZDJBVTJVGADADBB,K^:TCLK*RM%MV],MFL?0]8\9_LT?L"R_$K38]-;Q
MAJ%RWBK5H=8M7E6<WTX8H=CQE7"R1\G."K#'.1-NX[GUR;9O[M*ENV>E?!GB
M#]NSXU>'OV9? GQIG\,^##H.L:G+IEQ:_P"D^?.RS3C?&-^(EVP,O)<[ANQ@
MXKI?C!^W)\1OA/XH^$^LW_A7PZG@+Q]%'=6UBLTLFI0VY,66>7(C5\3*P4*P
MX(SWI\DMA\R.\_:P^-GQ<^ NDR^,M#\/^&[KP-I]_;6=U;Z@\SZA>)(5!DB*
M,J1C<VP!@YS\V,<5]'0,;NUMY_+:(S1K(8VZKD X/TS7S)^U%J'Q<\0?%;0X
M-!^"-QX\\"^'674+9;K6K6S@O=2Q^ZG9&9F:.(,=J,%RYW?PK7T_X?:_NM'T
MU]6CABU1K>,W<<'^K67:-X7GH&SCFB5K*PE>[.8^('Q'\-_"O2[6]\1W_P!F
M-Y.MK96D,;2W-[.W"Q0Q*"TCG/0#W/%>8?$[]M;X;?!?Q5!X>\;VGB3P[?SJ
MLD+76E$Q21DX\Q75B"H.0<=,&O)_@WXXC^/G_!2#QQ/?^9<Z3\/M-GT_1+68
M?+;3I(D%Q*%Y&]G,PW==NWTKJOVHOV?_  [^T]^T<G@O6RUK=KX FO-,U",G
M=:W*WRJKX_B7YL%3U!/0X-7"FI-KLKB<FE='T#XP^(.D^%_AVGC>UMK_ ,3^
M'WMUO$F\.P"\9[=DWB90&&Y-O.5SP:9\.?'%M\3O"=IXBL-+U;2["\426Z:Q
M:_9YI(R 5<)DG:01C-?G;^SG^T9X@_95N/&W[/?QE=K#3%LKR'2KZ=B8[.5H
MGVJK8^:"7.5;^$G'<A?L#XA?$#Q/X \(?#RV\/>.OAKX3AGT.!Y8?',LJ2S$
M(@#0[)%RH'!SWI.-HW!2U/=UMVSTKQSXZ?M=?#;]FW7M,T;QM=ZA#?ZA;&[A
M2QLFG'E[BN201CD'CVKR]OV@/B0O/_"YOV?/_ JY_P#CU>[^ _AOX3\?6FE>
M._%6E^%/&/BR\T^.";6[&#[39/&I; MO-+;4Y/3J>M9^I7H>=?#G]O;X3_&#
MQ#)H7A&+Q)K.JQVLMX;:WT=RWEQKEB!GD] !W) ')%>Q^!/''A[XI>%[?Q%X
M6U.+5M)G9D$T0(*.IPR.I *LIX*D BO#OV2=!TKQA\>OC)\4M-TJQL-&2^'A
M+06L;5(8FMK8YN)$V* RO+CYN?N8["N%\,^*G^"O_!3;Q#X(M"J^&OB)91ZC
M)9K\L<-[Y#/YH'3<QAD!QU\P$]*NRVZDWZGV*T17M30I->'^#_BM\7=:_:F\
M4>"]=^'JZ5\-[**1K'Q (I,R%50HWFEMC[R6^50"O0_=.?>)K6>:SN5M)(X;
MORF\F29"Z*^#M+*""0#C(R,^HJ'H5N1BW;TH^SMZ5\0? /\ :^^//QR\._%
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M?PW_ &E/B!^U1\.?C/XE\)Z5H.F^ ]%M;K3K"SU*.7[;?G[.S.SS*^V+",K
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M444 %%%% !1110 5Y_XO_P"2J^ O]V__ /12UZ!7G_B__DJO@+_=O_\ T4M
MT>@4444""BBB@!IKP_\ ;=_Y-'^+?_8NW7_H!KW UX?^V[_R:/\ %O\ [%VZ
M_P#0#3I_%'U$]CRO_@DW_P F9^'O^PEJ'_I0U?8BU\=_\$F_^3,_#W_82U#_
M -*&K[$7O55/C8UL.HHHJ "BBB@ HHHH **** "BBB@ HHHH **** "N'^&_
M_(8\=?\ 8=?_ -)X*[BN'^&__(8\=?\ 8=?_ -)X* .XHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+K_CUF_W#_*O%M/\
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M_!0KQE\6-6\ :AI7A#7H;BT@O)KZR=H\QPJLCHD[-M;R3T!(W#(ZX^RA>/\
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M/B92V'4445 PHHHH **** "BBB@ HHHH *\_\7_\E5\!?[M__P"BEKT"O/\
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M+_\ (HW?_87U#_TJDKO:!O<****!!1110 4444 %%%% !1110 4444 %%%%
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MB&O)S2$5A[I=5^:/O.#+O-;/;EE^3/LL>,'T^&.$6/F;5Q_K<?TI?^%A2?\
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M0>/_ )_W_P"_8_QK>9C3@QXH"YS_ /P@T?\ T$'_ ._8_P :/^$&C_Z"#_\
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M_CE='^R-]?P.6/UZ*Z?B3:9^U/\ "77-6L],L?%\$U[>2K#!&;:=-[L< 99
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M*ZJ7P&53XB:BBBMC$=11120!1113 <M+2+2U++"BBBD 4444 /HHHH ****
M"BBB@ I5I*5: %K(\9?\B[-_UTB_]#6M>L?QE_R+LW_72+_T-:/LLJ/Q(W6I
MM.:FT$A1110 Z*OE#]M/_DK/PE_Z^C_Z40U]7Q5\H?MI_P#)6?A+_P!?1_\
M2B&O'S3_ '?YK\T?=<%_\C7_ +=E^3/K6XZ)]*BJ6XZ)]*BKV/LQ/B*W\6?J
M%%%%20+N-20L=XJ*I(?O#ZT%GR3^VV?^+Y?!/_K[7_TJ@K[!U+_7&OCW]MO_
M )+E\$_^OM?_ $J@K["U+_7&O2Q/\&GZ/\SR,)_'J^J_)%"BBBO-/7'4444
M%%%% "K3J:M.H 5:P]8_Y&SP]]+C_P! %;BUAZO_ ,C;X>^EQ_Z *F6PX[FZ
MU-IS4VF(*<M-IRTP%HHHH ****@H**** '4444$A2K24JT%&/\6?^2*?$+_L
M7M0_])I*^2?^"//_ ";GXS_[&B3_ -)+:OK;XL_\D4^(7_8O:A_Z325\D_\
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M0+@4@,?QA_Q^>%_^PM'_ .BY*Z*;[U<OXRG'VSPO_P!A:/\ ]%R5T4MP-QH
M?14'V@>M'V@>M %A?O4M5UN!FE^T"@">BH/M I1./6DP)UIU5Q./6E\\>M"
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M% $7V>/_ )Y)_P!\BC[/'_SR3_OD5+10!%]GC_YY)_WR*/L\?_/)/^^14M%
M$7V>/_GDG_?(H^SQ_P#/)/\ OD5+10!%]GC_ .>2?]\BC[/'_P \D_[Y%2T4
M 1?9X_\ GDG_ 'R*/L\?_/)/^^14M% $7V>/_GDG_?(H^SQ_\\D_[Y%2T4 1
M?9X_^>2?]\BN&^,VRW\ W;JB@_:;4?='>XC%=]7G_P <O^2<WG_7U:?^E,=
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M/]6I]J];%?[M0]'^9A!)3DP^SQ_\\D_[Y%'V>/\ YY)_WR*EHKR3<B^SQ_\
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M^+\J/^1LF[?].=I7V7\<O^2*^/C_ -2_J'_I-)7QK_P1=7;^S7XNSW\6S?\
MI':5UTV_83MM=$?:1]_>5'_SS7\A2^5'_P \U_(4^EKD+(_*C_YYK^0H\J/_
M )YK^0J2B@"/RH_^>:_D*/*C_P">:_D*DHH C\J/_GFOY"N*^'NR35O&P*+\
MNN,!Q_T[PUW-<=X#LS:ZIXP9O^6NM,X_\!X: .M\J/\ YYK^0H\J/_GFOY"I
M** (_*C_ .>:_D*/*C_YYK^0J2B@"/RH_P#GFOY"CRH_^>:_D*DHH C\J/\
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M"/RA_=7\J/*']U?RJ2B@"/RA_=7\J/*']U?RJ2B@!GEK_='Y4>6O]T?E3Z*
M&>6O]T?E1Y:_W1^5/HH 9Y:_W1^5'EK_ '1^5/HH 9Y:_P!T?E1Y:_W1^5/H
MH 9Y:_W1^5'EK_='Y4^B@!GEK_='Y4>6O]T?E3Z* &>6O]T?E2[1Z#\J=10
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M%KB_\*2Z_P#C-'_#(/[=/_1:XO\ PI+K_P",U^H^?>C/O1]8GV7W!RGY<?\
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M)C&DHC?'1MDB-CT85^6'Q._9(_8J^"?BJX\*^,_BCXDTOQ!;HKS6:L]PT08
MKO,-JZJ2"#M)S@@XKZR_X)R>'_A;X;^&?C2W^$/B;4_%'A!O$TC+=:K;&&5)
M?LEL&495"R\ @E%/.,<9-.+2N2I)NQ]<T445)04444 %%%% ' _!?_D4[S_L
M+ZC_ .E4E=]7 _!?_D4[S_L+ZC_Z525WU WN%%%% @HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KS_P"./_).[S_KZM/_ $ICKT"O/_CC
M_P D[O/^OJT_]*8Z!K<[^EI*6@04444 %%%% #!]XUA^,O\ D6=0_P"N+?\
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M **** "BBB@ HHHH ^"?^"RW_)K6A_\ 8TVO_I-<U]0_LJ_\FS_"W_L6M/\
M_2=*^7O^"RW_ ":UH?\ V--K_P"DUS7U#^RO_P FT_"W_L6M/_\ 2=*ZI?P(
M^K)ZGJM%%%<I04444 %%%% !1110!Q7Q(_X_O!7_ &'XO_1$]=K7%?$C_C^\
M%?\ 8?B_]$3UVM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 <2O_):9?\ L7T_]*6KMJXE?^2TR_\ 8OI_Z4M7;4 %%%%
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M_4L1_P ^W]S-/K%/^9?>?2F#1@U\U_\ #Q/]G_\ Z'H_^"J\_P#C-'_#Q/\
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MZ$5T'WJXY)Q;36J-QU%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT5@=)6\N3_GK)_WT:/+D_P">LG_?1JU14W*U*OER?\]9/^^C2^7)_P ])/\
MOHU9HHN*Q!Y<G_/63_OHT>7+_P ]9/\ OHU9HI"*_ER_\]7_ .^C1Y<O_/5_
M^^C5BB@HK^7+_P ]7_[Z-'ER_P#/5_\ OHU8HH @\N3_ )Z/_P!]&E$<F/\
M6O\ ]]&IJ<M %?RY/^>K_P#?1I?+E_YZO_WT:L44 5_+E_YZO_WT:/+D_P">
MK_\ ?1JQ10!'&LF?]8__ 'T:PO"D3KJ'B7#L,ZDQ/S'_ )YI721UA>%?^0AX
MC_["+?\ HM*3 UC')_SU?_OHTGER?\]9/^^C5BBF@U*WER?\]7_[Z-'ER?\
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MX;]#IP?^]4O5?F?,O_!/;_DG_BC_ +"2_P#HE:^H&^]7R_\ \$]O^2?^*/\
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MI!1110QA1114@%%%% #;W_CPNO\ KDW\JRO O_(EZ)_UZ1_^@UJWO_'A=?\
M7)OY5E>!?^1+T3_KTC_]!HZ@;5%%% !1110 4444 *M+2+2T, HHHH *DA^\
M*CJ2'[PH8'QI_P %A/\ DUOPY_V-%O\ ^DUS7TO^S9_R;+\+?^Q:L/\ T0E?
M-'_!83_DUOPY_P!C1;_^DUS7TO\ LV?\FR_"W_L6K#_T0E=]3_<X?XF9KXF=
MHU)3FIM><:!1115 %.6FTY:3 6A>M%"]:0&!XP_X_/"__86C_P#1<E=%-]ZN
M=\8?\?GA?_L+1_\ HN2NBF^]0 RBBB@!5I:1:6@ HHHI,!5IU-6G4( HHHI@
M%%%% !3Z93Z "F_Q4ZF_Q4F ZBBBA %%%%# *<G6FTY.M2!SR_\ )4)/^P*O
M_H]JZ-OO5SB_\E0D_P"P*O\ Z/:NC;[U- ,:EI&I:& 4444@"BBB@!5IU-6G
M4 %%%% T%%%% ,*?3*?0(**** "BBB@L*5:2E6@3%J:U_P"/A/J*AJ:U_P"/
MA/J*"3G?@[_R(L/_ %^7G_I3)7=5POP=_P"1%A_Z_+S_ -*9*[J@;"BBB@04
M45X'^U)I;^*/^%:^&SXOU/P19ZQXH6*[U32-4ET^Y:*.RNIO(21'49D,2KAM
MPP20-P4@ ^<?C9J7[25G\;/'*?#GX >!O$?A8WZ&+6]8TJ/[3?-]GBW2.\ER
MADP?E#!<80#M7M'[!/PO\>_#/X7^)7^(N@Z9X7UOQ!XEN]:30])$8@LHY4B7
M8JHS*H+([!0QP& // ^5_'FL:S^VA^V!I?P8\#^+]8LOA'X$MPVIZKINJS33
M73( )9&NF9FE<LPA5G9NCMSDU]M?LR:7+X/TWQGX+7Q5?^+]+\*Z\VG:??:I
M,9[N*%K6WN#;RS'_ %AB>=U![*%4\K6C;Y;$Z7/<****S*"BBB@ HHHH \E\
M._\ ),=1_P"PQ>?^E;U3M_NBKGAW_DE^H_\ 88O/_2MZIV_W1752^ RJ?$34
M445L8CJ***2 ****8#EI:1:6I984444@"BBB@!]%%% !1110 4444 %*M)2K
M0 M9'C+_ )%V;_KI%_Z&M:]8_C+_ )%V;_KI%_Z&M'V65'XD;K4VG-3:"0HH
MHH ****"PINL?\@'4O\ KVE_] -.I;R-[K2[VWCQYDT#QKGIDJ0/YU-3^'(Z
M,+*,<33E+NOS/F7_ ()YQLWP]\58Z?VHG_HE*^HVMVW'BOAKX>_!W]HGX4V]
MU9>%1!I]O<2^;(OG6TH9P-NX%P2. /RKJFTG]K7S!C5(Q_X _P#Q%?-8/'2P
MU%4ITI-J^RTWN?J&>Y#2S;'SQE+&THQE9I.5GHDM58^N&A9:C/%?&OA3XM?&
MCPC\=O#/@_QSK0FCO98VGM&M[8JT+EE!WQH"#E#W[5]GW"[6KUL+CH8SGY8N
M+C:Z:L]?(^'SG):V2RA&I.,U-73B[IJ]M[>1%1117>?/A1110 ZBBB@ HHHH
M 5:=35IU "K6'K'_ "-GA[Z7'_H K<6L/5_^1M\/?2X_] %3+8<=S?\ XJ\3
M_;F_Y-=\3?\ 7S9?^E4=>V?Q5XG^W-_R:[XF_P"OFR_]*HZ[,+_%CZK]#CQG
M\"7HSH_V5_\ DVKP!_UX'_T8]>D5YO\ LK_\FU> /^O _P#HQZ](K/$?Q)^K
M_,TPO\"'HOR"BBBL3<****@H**** '4444$A11104%%%% !3EIM.6@!:***
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M1\9?M"? /2] \"Z6FLZS::Y!?/:-=16Y:)8ID8AI65<@R+P2.,U\P^%_"?\
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MG)UJ0.>7_DJ$G_8%7_T>U=&WWJYQ?^2H2?\ 8%7_ -'M71M]ZF@&-2TC4M#
M****0!1110 JTZFK3J "BBB@:"BBB@&%/IE/H$%%%% !11106%*M)2K0)BU-
M:_\ 'PGU%0U-:_\ 'PGU%!)SOP=_Y$6'_K\O/_2F2NZKA?@[_P B+#_U^7G_
M *4R5W5 V%%%% @KAOBU\(?"GQP\$W?A3QGI2ZQH=T59X6=D977E71U(96!Z
M$&NYHH \%^'/['W@#X._#G7?"/P^.J^"UUE@;S6M+NP=4?!X GE5]H ) P.
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M?]!0?]^?_LJT]I'N9\LNQSOFKZTGF#UKH_\ A6<W_04'_?G_ .RI?^%9S?\
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M4^OM74OX;=CG[3_XY_\ 7HT RMPHW5I_\(R__/U_XY_]>C_A&7_Y^!_WQ_\
M7H S5;FG;A6@/#+C_EY'_?'_ ->E_P"$;?\ Y^?_ !S_ .O3T SMPHW"M'_A
M&W_Y^?\ QS_Z]+_PC;_\_/\ XY_]>I8&<K"G;A5\>&W_ .?G_P <_P#KT?\
M".O_ ,_/_CO_ ->F!G[J7<*O_P#".O\ \_/_ ([_ /7I?^$=/_/S_P"._P#U
MZ8&?N%&X5?\ ^$=?_GY_\=_^O1_PCK_\_/\ X[_]>@"AN%.W"KW_  C[_P#/
MU_X[_P#7I?\ A'W_ .?G_P =_P#KT 4-PI-PW"M#_A'W_P"?G_QW_P"O2?\
M"//_ ,_'_CO_ ->D!2R*3<*T/^$?/_/Q_P"._P#UZ/\ A'S_ ,_'_CO_ ->D
M@,_<*7(J_P#\(^?^?C_QW_Z]'_"/G_GX_P#'?_KU0%#=3D89J[_PCY_Y^/\
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M)&.%)%?1-%/F8K(:JA0 !@4ZBBD,X+X+_P#(HW?_ &%]0_\ 2J2N]K@?@O\
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M% !1110 4444 4=8_P"07>?]<'_]!-<[\(/^27>%?^P;!_Z *Z'6/^05>_\
M7!__ $$USWP?_P"26^%?^P;!_P"@"@?0["BBB@04444 %%%% !1110 4444
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M&?\ D0K?_K[O/_2F6N]K@_@O_P B#;_]?=Y_Z52UWE V%%%% @HHHH ****
M"BBB@ HHHH **** .!^"_P#R*=Y_V%]1_P#2J2N^K@?@O_R*=Y_V%]1_]*I*
M[Z@;W"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY_\ ''_DG=Y_U]6G_I3'7H%>?_''_DG=Y_U]6G_I3'0-;G?TM)2T""BBB@ H
MHHH **** "BBB@#X&^/G_)]W@/\ ZX6O_HV>OO*W_P!3%_NC^5?!OQ\_Y/N\
M!_\ 7"U_]&SU]Y6_^IB_W1_*O#P7\>MZH^VX@_W3 _X/U)Z***]P^)"BBB@
MHHHH **** "BBB@ KS_Q?_R57P%_NW__ **6O0*\_P#%_P#R57P%_NW_ /Z*
M6@:.\[BOE3_@J%_R97XY_P"NVG?^ET%?5?<5\J?\%0O^3*_'/_7;3O\ TN@K
MLP'^\T_5?F9RV9V'[!O_ "9_\+?^P0O_ *&]>^5X'^P;_P F?_"W_L$+_P"A
MO7OE3BOX]3_$_P QQV0^BBDR*Y2A:*3(HR* %HI,BC(H 6BDR*,B@!:*3(HR
M* %HI,BC(H 6BDR*,B@!:*3(HR* %HI,BC(H 6N'^&__ "&/'7_8=?\ ])X*
M[BN'^&^?[8\<_P#8=?\ ])X* .XHI,BC(H 6BDR*,B@!:*3(HR* %HI,BC(H
M 6BDR*,B@!:*3(HR* %HI,BC(H 6BDR*,B@!:*3(HR* %HI,BC(H 6BDR*,B
M@"CK'_(*O?\ K@__ *":YWX/_P#)+?"G_8,M_P#T 5T>L?\ (+O/^N#_ /H)
MKG?A ,?"[PJ/^H;!_P"@"@?0["BDR*,B@0M%)D49% "T4F11D4 +129%&10
MM%)D49% "T4F11D4 +129%&10 +7Y@?M'?\ *7[X1_\ 7KI_\[FOT_6OR_\
MVD!G_@KY\)/^O73_ .=S6^'W?HR9'Z@T4BTM8%!1110 4444 <5\2/\ C^\%
M?]A^+_T1/7:UQ7Q(_P"/[P5_V'XO_1$]=K0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '$K_R6F7_L7T_]*6KMJXE?^2TR
M_P#8OI_Z4M7;4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!PGP5_Y$&W_Z_+S_ -*I:[NN$^"O_(@V_P#U^7G_ *52UW=
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M*/V=/^BAK_X*;[_XS1_P\H_9T_Z*&O\ X*;[_P",UO?\,#_ #_HF&C?^1?\
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M1V]%</\ \++_ .H:W_?W_P"M1_PLO_J&M_W]_P#K4>SEV#F1VO'I1QZ5Q?\
MPLC_ *AS?]_?_K4?\+*_ZAC_ /?X?X4>SEV%SQ.VVBC:*XC_ (65_P!0U_\
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M_;3_ .M7B8*$OK%9VZH^VXA]S"X&_6'ZG7T5QW_"P/\ J'-_W]'^%'_"PO\
MJ'/_ -_1_A7M<DNQ\3S([&BN._X6(/\ H'/_ -_1_A2?\+"'_0/?_O[_ /6J
M>60<R.RHKCO^%@?]0]O^_O\ ]:C_ (6!_P!0]O\ O[_]:JY9!S([&BN/_P"%
M@#_H'O\ ]_?_ *U'_"P!_P! ]_\ O[_]:CDD.Z.PHKD/^%@#_GQ;_O[_ /6I
M?^$^_P"H>W_?T?X5/+(7,CK:X#Q</^+J> C_ +-__P"BEK2'CS_IP;_O[_\
M6KE?$7BC[1X^\(W7V)A]G6[^7?UW1@>E5RL:DCUBBN2;QYM_Y<6/_;7_ .M2
M?\)\?^?!O^_H_P *.2071UU)7)?\)\?^?!O^_H_PH7QYG_EQ;_OY_P#6HY)!
M='745R7_  GG_3@W_?S_ .M1_P )Y_TX-_W\_P#K4<K%S(ZS(HR*Y3_A.O\
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ML#IZ*YG_ (3/_IR;_OY_]:E_X3+_ *<F_P"_G_UJ.5@=+17-?\)E_P!.3?\
M?S_ZU*OC#=_RYG_OO_ZU'*P.DHKFO^$Q_P"G-O\ OY_]:E_X3#_IS;_OO_ZU
M'*P.DHKF_P#A,/\ IS;_ +[_ /K4?\)A_P!.;?\ ??\ ]:CE8&OJW_()O/\
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MK\X/^"C$;77[4W[/-R$(%O?V[D9ZYU"#C]*_0RXUK[+QY!;_ (%_]:O7Q?\
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MTB_]#6C[+*C\2-QJ;3FIM!(4444 %%%%!84^F4^DR6%%%%(1-;_ZP5\?VO\
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MZQ-8_P"1M\/?2X_] %3+8<=S=:FTYJ;3$%.6FTY:8"T44F10 M%%%04%%%%
M#J***"0HHHH*"BBB@ IRTVG+0 M%%% !1110 ^.L/PM_R$/$?_81;_T6E;D=
M87A;_D(>(_\ L(M_Z+2I8&[11130!1110P$'>EI!WI:D HHHJP"G4VG4%(**
M**3!A1114DA3Z93ZI%(****&,****D HHHH ;>_\>%U_UR;^597@7_D2]$_Z
M](__ $&M6\_Y!]U_UR;^597@;_D2]$_Z](__ $&CJ!M4444 %%%% !1110 J
MTM(M+0P"BBB@ HHHH 5:=35^\*=28!6QI?W&^E8];&E_<;Z4@/S6_P""1?\
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M[1=@Y/,\KM[K=(.#^5?)%K)_QL'G;'\+?^D0K]!Y/N&O@BQS_P /%I_7!_\
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MGPXW_KS+]#[ZI:2EKUCX(**** "BBB@ HHHH **** "O/_%__)5? 7^[?_\
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M9RNSZQQ_G-+Q7R?_ ,/1?V<O^ATNO_!)>_\ QJC_ (>B?LY?]#I=?^"6]_\
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M !1110 4444 %%%% ' _!?\ Y%.\_P"POJ/_ *525WU<#\%_^13O/^POJ/\
MZ525WU WN%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KS_XX_P#).[S_ *^K3_TICKT"O/\ XX_\D[O/^OJT_P#2F.@:W._I:2EH
M$%%%% !1110 4444 %%%)0!!NW!BO2O@JQVK_P %&[CL,_\ MF*^],\X'>OS
M:^+7CJ\^$/[:&M>*H]'FU5;0H!;J2F_?;*N0VUNF<].U>/F,E34)RV4DS]#X
M-I/$3Q="/Q2I245=*[=K*[LC]*OQIWXU\*?\/']2_P"B<W'_ (&G_P"-4?\
M#R'4?^B=W/\ X%G_ .-5K_:.&_F_!_Y''_J;G/\ SZ_\FC_F?=6?>C/O7PK_
M ,/(=1_Z)W<_^!9_^-4?\/(=1_Z)W<_^!9_^-4?VCAOYOP?^0O\ 4W./^?7_
M )-'_,^ZL^]&?>OA7_AY#J/_ $3NY_\  L__ !JC_AY#J/\ T3NY_P# L_\
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M4AP>>1E1^5=!_P ,-? 3_HEOA[_P&/\ C7Q5K'_!8B?5)M*D;X-W<7V2\6X
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M-'_##/P#_P"B7>'_ /P&/^->[;J-U'UJO_/+[V'*NQX3_P ,,_ /_HEWA_\
M\!C_ (T?\,,_ /\ Z)=X?_\  8_XU[MNHW4?6J_\\OO8<J['A/\ PPS\ _\
MHEWA_P#\!C_C1_PPS\ _^B7>'_\ P&/^->[;J-U'UJO_ #R^]ARKL>$?\,,_
M 3_HEGA['_7L?\:^=/V^OV;?A5\(_P!FO6M=\*^!='T+5H[ZRB6ZLX-CA7G5
M6&<]U)%?H#7R%_P50_Y,]\0_]A#3_P#TH2NW XJM+$PC*I)IM=7W,*U.,H-6
M.I_8K4?\*?\ A:0,?\439_\ HPU]*5\U_L4_\D=^%G_8D6?_ *&:^E*X\3_'
MJ?XG^9K'X(^@^BBBN8L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .$^"O_(@V_\ U^7G_I5+7=UPGP5_Y$&W_P"OR\_]*I:[N@;W
M"BBB@04444 %%%% !1110 4444 %%%% ' _!?_D4[S_L+ZC_ .E4E=]7!?!?
M_D4;O_L+ZA_Z525WM WN%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KS_P"./_).[S_KZM/_ $ICKT"N ^.'_).;S_KZM/\ TICH
M&MSOJ6DI:!!1110 4444 %%%% !1110 WJM4I]+MKEMTD$<A_O,H-7<>E H*
MC*4=8LS/[!L?^?2'_OVM']@V/_/I#_W[6M/\:/QJ.6)I[>I_,9G]@V/_ #Z0
M_P#?M:/[!L?^?2'_ +]K6G^-'XT<L0]O4_F,S^P;'_GTA_[]K1_8-C_SZ0_]
M^UK3_&C\:.6(>WJ?S&9_8-C_ ,^D/_?M:/[!L?\ GTA_[]K6G^-'XT<L0]O4
M_F,S^P;'_GTA_P"_:TO_  C]C_S[0_\ ?L5I?C1^-'+$?MZO\QF_\(_8_P#/
MK#_W[%<9XFTVRM_B+X,MQ:P[9EO<_NQVB6O1.?6N#\7?\E4\!?[M_P#^BEI\
ML1>WK=)'5?V#8_\ /I#_ -^UH_L&Q_Y](?\ OVM:?XT?C2Y8A[>K_,9G]@V/
M_/I#_P!^UIW_  C]E_S[0_\ ?L5H_C1^-'+$/;U/YC-.@V'3[+!S_P!,A7E7
M[46BV<7P%\:NEO$A739^5C']PU[(>W>O*/VJ/^2!^-O^P9/_ .@&N?$17L9^
MC_(]7*:U7Z_1][[4?S1PG[ ?_)ONC_\ 7>Z_]'O7TH?O"OFK]@3_ )-]T?\
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M_8?B_P#1$]=I2YI 5/[-M/\ GUA_[]C_  H_L^U_Y]8?^_8_PJW13NP/S_\
M^"S%O%;_ +,/A@QQ1H?^$OM1E5 _Y<KVOJC]E+_DV'X0_P#8GZ1_Z10U\M?\
M%HO^38/#'_8X6O\ Z17U?4W[*?\ R:_\(?\ L4-)_P#2**NB4FZ,;]Q=3U>B
MBBN884444 %%%% !1110 4444 %%%% !1110 4444 -'2OD'_@JA_P F>^(?
M^PAI_P#Z4)7U]_#7R#_P50_Y,]\0_P#80T__ -*$KNP'^]4_5?F95?@9U7[$
M_P#R1OX6_P#8D6?_ *&:^E&ZU\U?L4?\D;^%O_8DV?\ Z,-?2K=:QQ7\>?\
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MLV#&1TG0G^55_LZ^E8_C*W7_ (1V;C_EI%_Z,6E*G%)LJ,G='J/_  G6E?\
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M\FOE7_@IYMO/V1];1,G=J>G#I_T\I7TFD8W5\[?\%'8PW[*6K C_ )B=@?\
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ME20_>%1U)#]X4 ?%'_!9#_DV'PA_V-MO_P"D=Y7U#^S7_P FM_"#_L4-(_\
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MO6BA>M(# \8?\?GA?_L+1_\ HN2NBF^]7.^,/^/SPO\ ]A:/_P!%R5T4WWJ
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MNJ!L****!!1110 4444 %%%% !114'G1^8(RZB0\A,C/Y4 3T444 >2^'?\
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MP/6L36+A?^$L\.\]KC_T 5,MAQW.C:FU$UPN[K3?M(]:8B>G+5;SU]?UIRW
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M?E[G->T[1Z4;1Z4[L-#SMOB1\.N^H6O_ (#R?_$TG_"R/AU_T$+3_P !Y/\
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M[_PM#X>_]!.V_P"_$G_Q-'_"T/A[_P!!.V_[\2?_ !->A;1Z4;1Z478'GO\
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M'I1=@>??\+2^'_\ T%+;_OQ)_P#$T?\ "U/A]_T%+;_OQ)_\37H.T>E&T>E
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M'-,4@D^2,12@L?EZ9*_G72-\5O /?5;?_OQ)_P#$UWVT>E&T>E&H' ?\+6\
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M_P"%N> O^@O;_P#?B3_XFN^VCTHVCTH X'_A;G@+_H+V_P#WXD_^)I?^%N>
M_P#H+V__ 'XD_P#B:[W:/2C:/2@#@O\ A;G@/_H+V_\ WXD_^)I/^%O> O\
MH,6__?B3_P")KOMH]*-H]* ."_X6YX#_ .@O;_\ ?B3_ .)H_P"%N^ _^@Q!
M_P!^9/\ XFN]VCTHVCTH X'_ (6]X#_Z#$'_ 'XD_P#B:/\ A;G@/_H,P_\
M?B7_ .)KOMH]*-H]* ."_P"%O> _^@O;_P#?B3_XFC_A;W@/_H+V_P#WXD_^
M)KO=H]*-H]* .!_X6YX#_P"@S#_WXE_^)H_X6YX#_P"@S#_WXE_^)KOMH]*-
MH]* .!_X6YX#_P"@S#_WXE_^)IW_  M[P'_T&(/^_$G_ ,37>;1Z4;1Z4 <%
M_P +@\"?]!FW_P"_,G_Q-.7XP>!E(*ZU""._DR?_ !-=WM'I1M'I0!P?P9;S
M/ -G* P22YNI$W*5)5KB0J<'U!!KO:** "BBB@ HHHH **** "BBB@ HHHH
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MLYPNYF<EB>,>IT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7E/Q2^!=A\2/%7AWQ7::WK'@_QAH*RPV>NZ&\7FFWE'[RWECF
MCDCDC)"MAD.&4$$<Y]6HHO8#A?A/\*]&^#_A7^P]&>ZN?.NIM0OM0OY?-N;^
M\F;?-<3-@ N[')P !P   !7=444 %%%% !1110 4444 %%%% !1110 4444
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M.6'PMI.LS126VB(XVXAV1J[E4 C4RLY50 "*]YHHYF]0"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR[QU\(]7\6>+%US3_ (D^
M+/"T?V,V4NE:5);-:2*2<R;)H7VR<_?4@C P17J -+26FH'D'BS]FGP=XF^%
MNC>!XO[0T>UT2[BU'2=4LKICJ%C>QN9!=)-)N+2EF<LS[MV]LYS6E\,_@GI_
MPWU[7O$MQJVI>*_%^N"*._\ $&L^5]HDAB&(H56&....-<D[409)).37IM%5
MS/85EN%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5YY\7/A'I7QHT?1--UJXO+6#2=:L]=@:S959IK:3?&K;E/RD]0.?<5Z'10!\
M_P#Q._95E^)GQ,_X31?BIXZ\,:A#:FRM;;0KR"""UA;:76,&$GYV168DDD@#
M.% 'J'PS\$/\.?!UEH,FOZQXHEMVD=]5UZX$]Y.SNSDNX !QNP  ,  5V%%%
MWL 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB,B'Y6VL,C(K?\$_"'P=\.=2O]1\-^&['2=0OXXX;J[@C_>RQQC$:%SD[5'
M7.!7<447>PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10-k_015.jpg
<TEXT>
begin 644 form10-k_015.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@W[=5];Z?\
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M)_$3_H?++_P1K_\ '*/^$3^(G_0^67_@C7_XY7HM% 'G7_")_$3_ *'RR_\
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M#Y9?^"-?_CE>BT4 >=?\(G\1/^A\LO\ P1K_ /'*/^$3^(G_ $/EE_X(U_\
MCE>BT4 >=?\ ")_$3_H?++_P1K_\<H_X1/XB?]#Y9?\ @C7_ ..5Z+10!YU_
MPB?Q$_Z'RR_\$:__ !RC_A$_B)_T/EE_X(U_^.5Z+10!YU_PB?Q$_P"A\LO_
M  1K_P#'*/\ A$_B)_T/EE_X(U_^.5Z+10!YX/"?Q#[^/;,_]P-/_CE<[J&J
M>--'UJYL;SQ5!(L80QR0:0A+9&3D&08_ FO9&KRGQI\WBZZ'^PG_ *"*!HI_
M\)%XF_Z&@_\ @FB_^.TO_"1>)O\ H:&_\$T7_P =IBH,4[RQ04+_ ,)%XG_Z
M&<_^"6+_ ./4?\)%XG_Z&<_^"6+_ ./4GEBCRQ0 O_"1>)_^AG/_ ()8O_CU
M'_"1>)_^AG/_ ()8O_CU)Y8H\L4 +_PD7B?_ *&<_P#@EB_^/4?\)%XG_P"A
MG/\ X)8O_CU)Y8H\L4 +_P )%XG_ .AG/_@EB_\ CU'_  D7B?\ Z&<_^"6+
M_P"/4GEBCRQ0 O\ PD7B?_H9S_X)8O\ X]1_PD7B?_H9S_X)8O\ X]2>6*/+
M% "_\)%XG_Z&<_\ @EB_^/4?\)%XG_Z&<_\ @EB_^/4GEBCRQ0 O_"1>)_\
MH9S_ ."6+_X]1_PD7B?_ *&<_P#@EB_^/4GEBCRQ0 O_  D7B?\ Z&<_^"6+
M_P"/4?\ "1>)_P#H9S_X)8O_ (]2>6*/+% "_P#"1>)_^AG/_@EB_P#CU'_"
M1>)_^AG/_@EB_P#CU)Y8H\L4 +_PD7B?_H9S_P""6+_X]1_PD7B?_H9S_P""
M6+_X]2>6*/+% "_\)%XF_P"AH;_P31?_ !VH;;Q!XM:W4W/B5(YOXEATB-U'
M/8F0?RJ7RQ1Y8H 7_A(O$_\ T,Y_\$L7_P >H_X2+Q/_ -#.?_!+%_\ 'J3R
MQ1Y8H 7_ (2+Q/\ ]#.?_!+%_P#'J/\ A(O$_P#T,Y_\$L7_ ,>I/+%'EB@!
M?^$B\3_]#.?_  2Q?_'J/^$B\3_]#.?_  2Q?_'J3RQ1Y8H 7_A(O$__ $,Y
M_P#!+%_\>H_X2+Q/_P!#.?\ P2Q?_'J3RQ1Y8H 7_A(O$_\ T,Y_\$L7_P >
MH_X2+Q/_ -#.?_!+%_\ 'J3RQ1Y8H 7_ (2+Q/\ ]#.?_!+%_P#'J/\ A(O$
M_P#T,Y_\$L7_ ,>I/+%'EB@!?^$B\3_]#.?_  2Q?_'J/^$B\3_]#.?_  2Q
M?_'J3RQ1Y8H 7_A(O$__ $,Y_P#!+%_\>H_X2+Q/_P!#.?\ P2Q?_'J3RQ1Y
M8H 7_A(O$_\ T,Y_\$L7_P >H_X2+Q/_ -#.?_!+%_\ 'J3RQ1Y8H 7_ (2+
MQ/\ ]#.?_!+%_P#'J/\ A(O$_P#T,Y_\$L7_ ,>I/+%'EB@!?^$B\3?]#0W_
M ()HO_CM-;Q%XH'_ #-!_P#!+%_\=I?+%,D08- "VOB3Q7#>:5<R:_'?64NJ
M6]C/;R:8D+,LA.2&61L8Q7LM>-#_ (\])_[&"Q_FU>RT$L****!!1110 444
M4 %%%% !1110 4444 <A\7O^25^+_P#L$W7_ **:MCPG_P BOH__ %YP_P#H
M K'^+W_)*_%__8)NO_135K^$_P#D5](_Z\X?_0!0/H;%%%% @HHHH **** "
MBBB@ HHHH **** "BBB@#XV_X*6?\DO\/?\ 89C_ /2>>OH']GK_ )(SX0_[
M!=M_Z*2OG[_@I9_R2_P]_P!AF/\ ])YZ^@?V>O\ DC/A#_L%VW_HI*\>G_O\
M_P#"OS/ML5_R3^'_ ,<OT/2****]@^)"BBB@ HHHH X+Q9_R5CP#_P!<]1_]
M%)7>UP7BS_DK'@'_ *YZC_Z*2N]H **** "BBB@ HHHH **** /S \6?\IM?
M"_\ UZ#_ -,TU?I[_#7YA>+/^4VOA?\ Z]!_Z9IJ_3W^&MZWV?1?D)#J***P
M&%%%% !1110 4444 %%%% !1110!P?@O_DI'Q#_Z^++_ -)EKO*X/P7_ ,E(
M^(?_ %\67_I,M=Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<]\0O^1"\3?\ 8,N?_135T-<]\0O^1"\3?]@RY_\ 134 2^!_
M^1*\/_\ 8/M__1:UN5A^!_\ D2O#_P#V#[?_ -%K6Y0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<%\4O^/KP/_P!C';_^BIJ[
MVN ^*/\ Q^>"?^QCM_\ T5+0-'?T444""BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KR?QG_ ,CA=?[D?_H(KUBO)_&?_(X77^Y'
M_P"@B@:*J=*=34Z4Z@H**** "BBB@ HHHH **-IHVF@ HHHH **** "BBB@
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M10 4444 <%XL_P"2L> ?^N>H_P#HI*[VN"\6?\E8\ _]<]1_]%)7>T %%%%
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M K@/BC_Q^>"?^QCM_P#T5+7?UP'Q1_X_/!/_ &,=O_Z*EH&COZ***!!1110
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MW\K-6BLK_A*--_Y_(?\ OXO^-+_PDVF?\_D/_?Q?\:?M(=Q_5ZW\K.8\6?\
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M_A8VC_WYO^_1K@%MEW=*=]E7TJ?9Q'SL[S_A8VC_ -^;_OV:7_A8VC_WYO\
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M_>D_[]FL7QMXDL+KP7X@B5Y"TFGW"#Y#WC85F^2/2J/B2$?\(QJ_'_+I+_Z
M:3BK#3.F\)^)+"U\)Z+&SR92R@4_(>T:UJ?\)?IO]Z3_ +X-<9H4(_X1_3./
M^76+_P! %6O)'I0HH5V=1_PEVF_WI/\ O@TO_"6Z=_>D_P"^#7+>2/2CR1Z4
M^5!=G5?\)=I_]Z3_ +X-'_"7:=_?D_[X-<KY(]*00C XI<J"YU?_  EVG?WY
M/^^#1_PEVG?WI/\ O@URHA'I1Y(]*.5!<ZK_ (2[3O[TG_?!H_X2[3O[TG_?
M!KE?)'I0L(STI\J'<ZK_ (2[3O[\G_?!I?\ A+-/_O2?]\&N6\D>E A7GBER
MH9U/_"6:?_>D_P"^#2?\)=IW]^3_ +X-<OY(]*7R1CI2Y43<ZC_A+-/_ +TG
M_?!I?^$KT_\ OR?]\&N5\D>E*L(]*?*BCJ?^$KT_^_)_WP:/^$KT_P#OR?\
M?!KF/)'I1Y(]*.5 =1_PE5A_>D_[X-)_PE>G_P!^3_O@US/DBD\D>E+E0'4?
M\)58?WI/^^#1_P )58?WI/\ O@US'DBCR13Y4!T__"56']Z3_O@UQ_Q&UBSN
MKGP>59SY>O02'Y3T$<H_K5I8A6#XRB!N/#/_ &%XO_07J7%6 ]&;Q-8J<;G_
M .^#3?\ A*K#^])_WP:YZ2(;NE1^2/2GRH#I?^$JL/[TG_?!H_X2JP_O2?\
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M3*&:1UC<JQ;C< 1M7/!R.W-<7,KV/MEK5E[4GV=O2OD;X<_M(?%#PS^WA??
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MXY^-WA.X^#O_  4&^&?QCNU*^#?$"?V'J-[D;;6Z:WD@B#DX"*VZ$AL_PO[
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M"BBB@04444 %%%% !1110 4444 %%%% ')_%?_DF/BS_ +!5U_Z*:N=\3?\
M( \*?]>G_LD==%\5_P#DF/BS_L%77_HIJYWQ-_R /"G_ %Z?^R1UI3^-$R^$
MRD^[3Z8GW:?78<PJTM(M+4]0"BBBJ *?3*?28T%%%%24%%%% !3Z93Z "BBB
M@ HHHH **** '+TI5I%Z4JT 9.J?\C-H/TG_ /0!6TW:L75/^1FT'Z3_ /H
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M3_KI!_Z+%;+5$2F)1115DCZ*** "BBBI8T%%%%(8JTM(M+02PHHHH*"BBB@
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M 0?\>>E?]C#9?S:O9*\;'_'GI7_8PV7\VKV2@EA1110(**** "BBB@ HHHH
M:!3J\%_;0F\0V/[/?B+4=">8G2WM]1U.VM;]K":[TZ&9)+R".X7YHF>%74,.
M>>.:^>/!/QLM-)^&'QK^+?PIU&\LO FC^'4@M/#.K7<EQ=6^M*&:2X>*9G,"
MA9(EVYQ(49L8 +4HW5R>;6Q^@-%?!-O?77P!L?V9/B!:ZUKVJ:AX\U"PT'Q-
M;W^J2S1:H^I6WF"Y=')59(9@"NP+\I9>A&/O:DU8HY/XK?\ ),/%G_8*NO\
MT4U<[XF_Y 'A3_KT_P#9(ZZ'XL?\DO\ %G_8*NO_ $4U<WXJD$?AWPKG_GT_
M]DCJZ7QHF?P&:GW:?5-+I-O6G_:E]:[#F+*]:=55;I<]:=]J3^_2Z@6**K_:
MD_OT?:D_OTP+%/JI]J3^_2_;$]:+#1:HJM]L7UI?M2^M38HL457^V)ZT?;$]
M:0%BGU4^TIZTOVM?6JL!:HJM]J3^]1]J3^]2L!9HJNMTO/-'VI?6D!8HJO\
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MU1_P\,_9M_Z*3;_^"^Z_^-4_95/Y7]Q5UW/=?+-&PUX9_P /#OV;?^BD6_\
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M11SR[ARHYO\ X5_HG_/JW_?U_P#&C_A7^A_\^K?]_G_QKI**.>7<.5=CG/\
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MX-M5MR(YTO2P\QN=L:D=_>NO_P"$'T<_\NS?]_6_QK \6?\ )5O /_7/4/\
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MF&F0G.]AR5Y[US7[?"C_ (9UUWYL'S[7_P!*(Z[3]E7/_"@/!)')_LV'_P!
M%<=&G"CC)1IQ45RK;3J?38[%XC&\/0J8B;E+VC5VVW:VUV<O\3OV$O@G\9/&
M5WXH\5^$#J&NW21I/>1ZA<PF0(@1,A) "0JJ,XZ 5S'_  Z]_9O_ .A$E_\
M!O>?_':^K-U)7O>WJ_S,_/>5=CY4_P"'7?[-_P#T(DO_ (.+S_X[1_PZ[_9O
M_P"A$E_\'%Y_\=KZMVBC:*/;U/YF%D?*/_#KW]F__H1)?_!Q>?\ QVC_ (=>
M_LW_ /0B2_\ @XO/_CM?5VVC;1[>I_,QV1\H_P##KW]F_P#Z$27_ ,'%Y_\
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M?V</^A$D_P#!O>?_ !VC_AUS^SA_T(DG_@WO/_CM?5WXT?C1[:I_,&A\I?\
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MFT:L+E1^E$VCVMPV7BR?]XU!_P ([8?\\6_[[/\ C6K17,497_".V'_/%O\
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M110 4444 %%%% !1110!R'Q>_P"25^+_ /L$W7_HIJU_"?\ R*^D?]></_H
MK(^+W_)*_%__ &";K_T4U:_A/_D5](_Z\X?_ $ 4#Z&Q1110(**** "BBB@
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M_L'V_P#Z+6MRL/P/_P B5X?_ .P?;_\ HM:W* "BBB@ HHHH **** "BBB@
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M7F7RWL0BL%]"R,/J*Z?_ ((^_$3P_H_P=\4>&+W4H;?7(];N+Z6S?(:*W$$
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M[)2^QF"*ASN9B%&.M=?J'[6O@>3]G#4/C)X<M-6\2Z%;K*@M+2Q<SI,F05G
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M_P!@R'_T 5Q?[?'_ ";SKO\ UVM/_2B.NT_94_Y(%X*_[!D/_H KRE_OTO\
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M (T?\)1I'_04M/\ O\O^-/E?85T:>ZC=69_PE&D?]!2T_P"_R_XT?\)1I/\
MT$[3_O\ +_C1ROL%T:>ZC=69_P )1I/_ $$[3_O\O^-'_"4:3_T$[3_O\O\
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M/^?^V_[^BE_X2+3?^?\ MO\ OZ*+,9I45F_\)%IO_/\ VW_?T4?\)%IO_/\
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M&O7HKEIS:]&10^%]#D1E_LBP0X_AMT_PKY/_ &1;6./X]_%J-$58X[F9550
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MBFL0@S'BLS[./2MG5_\ 7'ZUF5P1V*(?('I1Y ]*FHK0"'R!Z4>0NX<5-10
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MVBBBJ("BBB@:"E6DI5H8V.HHHJ22U:_TKY&_9%_Y.#^+G_7W/_Z5R5]<VO\
M2OD;]D7_ )."^+W_ %]3_P#I5)7DXW^/1]?T/N\A_P"19C_\*_,^LIOO4RGS
M?>IE>OU/A(] HHHI%@O6G4U>M.H **** "G+3:<M "TY.M-IR=: ,31?^1F\
M1_[\'_HL5M-6+HO_ ",WB/\ WX/_ $6*VFJ(E,2BBBK)'T444 %%%%2QH***
M*0Q5I:1:6@EA11104%%%% !1110 ^BBB@ HHHH *H^)/^18U?_KTE_\ 0#5Z
MJ/B3_D6-7_Z])?\ T TGL-;DV@_\@'3?^O6+_P! %6ZJ:#_R =-_Z]8O_0!5
MNDA!1115 %(OW12TB_=%2P%7K10O6BF@"A>M%"]:8#J***3*84O\(I*7^$5)
M(E*M)2K30#J***HL****@ HHHH 5:PO&7_'QX:_["T7_ *"];JUA>,O^/CPU
M_P!A:+_T!Z'L!T3=33*>W4TR@ HHHH **** "G4VG4 %%%%) %%%%,"]IO\
MKEK\[OB]_P IC?A[_P!>=O\ ^DEQ7Z(Z;_KEK\[OB]_RF-^'O_7G;_\ I)<5
MV83XY_X69SV7J?HSJ_\ KC]:S*T]7_UQ^M9E>>MC0****T ****& ^BBBI ?
M'7)^(O\ D.2_[J_R%=9'7)^(O^0Y+_NK_(5,MAQW*ZTM(M+2*"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_),/%G_8*NO_ $4U<WXH<+X?\*?]>G_LD=='\6VV_"WQ<?\ J$W7_HIJK?\
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M.$<72H3Q"K0G&";DHR3=EULCZ.:0>M'F"NE;X?P,<_;IQ^"T?\*^A_Y_)O\
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M<GK76?\ "K;?_H(7'_?*T?\ "K;?_H(7'_?*T:AH<GYR>M'G)ZUUG_"K;?\
MZ"%Q_P!\K1_PJVW_ .@A<?\ ?*T:AH<GYR>M'G)ZUUG_  JVW_Z"%Q_WRM'_
M  JVW_Z"%Q_WRM&H:')^<GK1YR>M=9_PJVW_ .@A<?\ ?*T?\*MM_P#H(7'_
M 'RM&H:')^<GK1YR>M=9_P *MM_^@A<?]\K1_P *MM_^@A<?]\K1J&AR?G)Z
MT><GK76?\*MM_P#H(7'_ 'RM'_"K;?\ Z"%Q_P!\K1J&AR?G)ZT><GK76?\
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M+C_OE:/^%6V__00N/^^5HU#0Y/SD]:/.3UKK/^%6V_\ T$+C_OE:/^%6V_\
MT$+C_OE:-0T.3\Y/6CSD]:ZS_A5MO_T$+C_OE:/^%6V__00N/^^5HU#0Y/SD
M]:/.3UKK/^%6V_\ T$+C_OE:/^%6V_\ T$+C_OE:-0T.3\Y/6CSD]:ZS_A5M
MO_T$+C_OE:/^%6V__00N/^^5HU#0Y/SD]:/.3UKK/^%6V_\ T$+C_OE:/^%6
MV_\ T$+C_OE:-0T.3\Y/6FR3+M/-=?\ \*MM_P#H(7'_ 'RM(?A;;G_F(W'_
M 'RM,6AR<;!K/2L?]#!8_P VKV:O*_%'AN/PO;^'8XIY+CS_ !#9$F0 8P6]
M*]4H$PHHHH$%%%% !17CGQ6^/4?P:\::9#XKT"\M? %_;H&\:0'S;73[LR,I
MBO$ S!$5,9$QRN68-M"Y/P;^V!8W.K?'S7;_ ,2:/\8O$MMJ"P/X7O\ X?7:
M'2A9F)-GE[8V^?S"Y;)Y)!Z$52BV*Y^JM%>=_ FU\26/P?\ !\'BY[QO$<>F
MQ"]_M&1)+H/C@3.@"M(%P&('+ FO1*D9S/CKP/H7Q)\(ZKX7\3Z9#K&A:I U
MO=V5P#MD0^A!!5AU#*05(!!! -8OP[^"?@_X5KJ!\/Z7(ESJ"QQW=[J%Y/?W
M4\:+MCB:>X=Y#&@)VINVKDX R:] HHN]@/+O ?[.OP[^&/B(ZUX;\.K8W_DO
M;6S274\\=C"[EWAM(Y'9+6-F.2D(13@<<"O4:** .0^+W_)*_%__ &";K_T4
MU:_A/_D5](_Z\X?_ $ 5D?%[_DE?B_\ [!-U_P"BFK7\)_\ (KZ1_P!></\
MZ *!]#8HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '!>+#_Q=CP$/^F>H?\ HI*[VN"\6?\ )6/ /_7/4?\ T4E=[0 4444
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MN_K@/BC_ ,?G@G_L8[?_ -%2T#1W]%%% @HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %17'^ID^A_E4M17'^ID^A_E36X'Y;_\
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MT5YW_P +&O\ _GQA_P"^VIW_  L2_P#^?&'_ +[:CV<@YD>A45Y[_P +$O\
M_GQA_P"^VH_X6)?_ //C#_WVU/V<@YD>A45Y[_PL2_\ ^?&'_OMJ3_A8U_\
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MK&=917*?\);=?\^T?_?1H_X2VZ_Y]H_^^C3Y6!U=%<M_PEEU_P ^T?YFF_\
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MC:HK&_MB;_GBOYFE76I6_P"62_F:!&Q16/\ VQ+_ ,\E_,T?VU+_ ,\E_,T
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M 7;1MIU% ";!S2;:=10 W;5+Q(H_X1C5_P#KTE_] -7ZH^)/^18U?_KTE_\
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M>_\ ^@?=?]^&_P */)O_ /GPNO\ OPW^%>OY%&15>V\A\AY MO?_ //A=?\
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MWO\ SXW/_?EO\*=Y-]_SXW/_ 'Y;_"O5>*.*/:>0<IY4(;[/_'C<_P#?EO\
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M\.T_!G_0QZ__ -_8/_C-'_#M3P7_ -#)KW_?V#_XS75]:QG\B^\\K^S^'_\
MH)E_X#_P3VQO'?A9B%7Q)I;,QP%6\B))]/O5K36=XO(M+AAZB)O\*_/S]K']
MF/0OV?=.T.YT?5-1OWU":2-EOFB(4*H(*[$7!R>^:_3+P\SOH5EYG7RD_D*,
M+C:E:I.G4BHRC;9WW1CF^383 X6AB\'5<XU+K56:LTMKLXKR;W_GSN/^_3?X
M4>3>_P#/I<?]^6_PKTW(HR*]/VGD?)<IYDL-Y_SY7'_?IO\ "E\F\_Y\[C_O
MTW^%>F9%&11[3R#E/-/)O/\ GSN/^_3?X4>3>?\ /G<?]^F_PKTRBESCL>9^
M3>?\^=Q_WZ;_  H\F\_Y]+C_ +]-_A7IE%'.%CS/R;S_ )]+C_OTW^%.\J[_
M .?.X_[]-_A7I5%'.%CS?R;O_GTN/^_3?X4GDW?_ #Z7'_?IO\*])HHYPL>;
MB&[Y_P!$N/\ OTW^%'DWG_/I<?\ ?MO\*](HHYPL>;^5=_\ /I<?]^FJCXFC
MN4\*ZPS6TR@6<Q),;?W#7JJU@?$!MO@/Q(1VTVY/_D)J7,%M3C]!CN6\.Z6P
MM9B#:Q$$1G^X/:K?DW?_ #Z3_P#?IJZKP6V[P;H)];"W/_D-:VZ.8+'G7E7?
M_/I/_P!^VH\FZ_Y]9_\ OVW^%>BT4^?R"QYUY-U_SZ3_ /?MJ00W>!_HD_\
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M^#7544 <OY<W_/"3_O@TOES?\\9/^^373T4 <QY<W_/&3_ODT>7-_P \9/\
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M "BBB@ KSWP7_P E8^(?_</_ /1+5Z%7GO@O_DK'Q#_[A_\ Z):@#T*BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CF_U;?0
MUP?P'_Y)1H7^Y)_Z->N\F_U;?0UP?P'_ .24:%_N2?\ HUZ!]#T"BBB@0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <+\5/]7X2_
M[&*R_P#0FKNJX7XJ?ZOPE_V,5E_Z$U=U0 4444 %%%% !1110 4444 %%%%
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MQ^PS_P F@?"7_L7K;_T&O)_^"M/_ "9AKW_83T__ -'BO6/V&?\ DT#X2_\
M8O6W_H-7]E >Z4445 !1110 5Y[X+_Y*Q\0_^X?_ .B6KT*O/?!?_)6/B'_W
M#_\ T2U 'H5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!'-_JV^AK@_@/_R2C0O]R3_T:]=Y-_JV^AK@_@/_ ,DHT+_<D_\
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M%% 'QG_P5J_Y,OU[_L)Z?_Z/%>L?L,_\F@?"7_L7K;_T&O)_^"M7_)E^O?\
M83T__P!'BO6/V&?^30/A+_V+UM_Z#3^R![I1112 **** "O/?!?_ "5CXA_]
MP_\ ]$M7H5>?>"_^2L?$/_N'_P#HEJ /0:*** "BBB@ HHHH **** "BBB@
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M)U:+CRRMO>^B\C]$PN;Y-B,LHX+,(2<J;;3BTD[N_4S_ /AO[X5?]!.Y_P#
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ME7[T9O\ PW]\*?\ H*78_P"W";_XFC_AX!\*?^@K<C_MPF_^)K37]FGX6_\
M0EZ;_P!^A_C7SU^W!\(_!_@'X<Z'J'AO0K/2;J;5$@=[6/:6C,,K%2?3*J?P
MK"M]?P].52HXV7:YWY?1X9S+$QPM&-12D[)MJR]3[OT3Q)I^OZ-9:E;W<1MK
MR%9X79@NY'4,IP?8BKO]J6?_ #]P_P#?Q?\ &O)OAC9H?A=X2P/^87;_ /HM
M*W/LB^E>[2CS4XS>[29^=8B*IUZE..T6U]SL>@_VI:?\_4/_ '\7_&C^U+3_
M )^H?^_B_P"->?\ V-?2C[&OI6G(C"YW_P#:MG_S]P?]_%_QH_M6S_Y^X/\
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M_$/_ '\%<3\3+B&:Z\%E9XSM\06['#CIY<M-6W7TK!\96RFX\,\?\Q>+_P!
M>DX@>K_;K?\ Y^(O^^Q2?VA;_P#/Q#_W\%<7);+N/%,^RKZ4<H';_P!H6_\
MS\0_]_!1_:%O_P _$/\ W\%</]E7TH^RKZ4<H'<?VA;_ //Q#_W\%']H6_\
MS\0_]_!7$BV7'2C[.OI3Y0.V_M"W_P"?B'_OX*/[0M_^?B'_ +^"N)^SKZ4[
M[.*7*!VG]H6__/Q#_P!_!1_:%O\ \_$/_?P5Q?V<4?9Q2Y0.T_M"W_Y^(?\
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M$]K!L>(K+H?]IJ[RO._'BXA\,?\ 8PV7\VKT2@ HHHH **** "BBB@ HHHH
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M6D6EH)84444%#E^]7S-_P4._Y)3X<_[#2_\ HB>OIE?O5\S?\%#O^24^'/\
ML-+_ .B)Z\_,/]UEZ'TW"O\ R.*/J>_?#/\ Y);X2_[!5O\ ^BTK;/WA6)\,
M_P#DEOA+_L%6_P#Z+2ML_>%=>'_A0]%^AXN._P![J_XG^8M%%%:G&%%%% !5
M'Q)_R+&K_P#7I+_Z :O51\2?\BQJ_P#UZ2_^@&D]AK<FT'_D Z;_ ->L7_H
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M5"MPOK2^>OK2 EHJ+SU]://7UH G7I2K4 N!CK2K<#UH S]4_P"1FT'Z3_\
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M%>\;PY<0P2W2#/[F1I(I/W9."0 ,[0"<9!H^!?V?8/"LVJ?VYX[\8_$.RO\
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M/^^U_P#B:Z^BCVDNX<J.0_X5GIO_ #\WG_?:_P#Q-)_PK/3/^?F\_P"_B_\
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M_,_/CPE^W%K'ACPQIFCGX=7%T;&WCA6;[0Z[MB!=V/)XSC.*TO\ AOS5\?\
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M_H7+_P #9\)_\/ ];_Z)I-_X%/\ _&:/^'@>M_\ 1-)O_ I__C-?=G]CV?\
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M7_PC]O\ WY?S'^%'_"/V_P#?E_,?X5J44 9?_"/V_P#STF_[Z'^%'_"/V_\
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M-6OX3_Y%?2/^O.'_ - %9'Q>_P"25^+_ /L$W7_HIJU_"?\ R*^D?]></_H
MH'T-BBBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 <%XL_Y*QX!_ZYZC_Z*2N]K@O%G_)6/ /_ %SU'_T4E=[0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '!^"_^2D?$/\
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MJV^AK@_@/_R2C0O]R3_T:]=Y-_JV^AK@_@/_ ,DHT+_<D_\ 1KT#Z'H%%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X7XJ?Z
MOPE_V,5E_P"A-7=5POQ4_P!7X2_[&*R_]":NZH **** "BBB@ HHHH ****
M"BBB@ HHHH Y#XO?\DK\7_\ 8)NO_135K^$_^17TC_KSA_\ 0!61\7O^25^+
M_P#L$W7_ **:M?PG_P BOI'_ %YP_P#H H'T-BBBB@04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <%XL_P"2L> ?^N>H_P#HI*[V
MN"\6?\E8\ _]<]1_]%)7>T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*** "BBB@ HHHH X7XJ?ZOPE_P!C%9?^A-7=5POQ4_U?A+_L8K+_ -":NZH
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M[VN#^)J&2Z\%G^[XAMS_ .0I:!H[RBBB@04444 %%%% !1110 4444 %%%%
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"_%3_5^$O^QBLO\
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M^M_C2_Z5_P _,_\ W];_ !JSM%+0!5_TK_GYG_[^M_C1_I7_ #\S_P#?UO\
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M+/S_ *1-_P!_#1B?_GXF_P"^S5BB@"#]_P#\]Y?^_AJCXF69O"VL*9Y2#9S
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M7_@/_!/B+R?VO/\ GN_Y67^%'E_M>?\ /=_RLO\ "OMW[6]'VI\]:?\ 9_\
MT]E]X?ZVK_H"I?\ @/\ P3XB\G]K[_GL_P"5E_A2>3^U]_SV?\K+_"ON'[8]
M'VQZ7]GO_G[+[_\ @$_ZV?\ 4%2_\!_X)\/^5^U[_P ]7_*R_P *7;^U[_SV
M?_R2_P *^W_MCT?:V]:/[/?_ #]E]_\ P"O]:U_T!4O_  '_ ()\.^3^U[_S
MV?\ [YLO\*/)_:]_Y[/_ -\V7^%?<7VQZ/M3^M/^S_\ I[+[P_UM7_0%2_\
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MW_[Z-+^\_P">C_F:?10 S]Y_ST?\S1^\_P">C_F:?10 S]Y_ST?\S2KYF/\
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M#:***H@****!H*5:2E6AC8ZBBBI)"BBB@L**** "BBB@ 7K3J:O6G4 %%%%
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M**2 ****8!3EIM.6A@+1114@%%%%4!KZ+]XU^;O_  33_P"3SOVBO^OB\_\
M3B]?I%HOWC7YN_\ !-/_ )/._:*_Z^+S_P!.+UV4?X-3T7YF<MT?HO??ZPU6
MJS??ZPU6K@6QH/CKF/#O_(^>+_I:?^BS73QUS'AW_D?/%_TM/_19I@=*WWJ2
ME;[U)0 4JTE*M "T444 %/IE/J>H!1115 %%%% !2K24JT .HHHH 1:6D6EJ
M4 44450!5BV_U@JO5BV_U@I1W%W/B_XI?\I O!O_ %ZK_P"B[BOK'X>_\B)I
MGTD_]&-7R=\4O^4@7@W_ *]5_P#1=Q7UC\/?^1$TSZ2?^C&KRL#\57_$S[?B
M;^!@/^O:_-FS2?Q4M)_%7JL^)%HHHJ0"BBB@ IRTVG+0 M%%% !11106%*M)
M2K00.HHHH ****"D%%%% QR]**%Z44$',^/O]3X8_P"QALOYM7HE>=^/O]3X
M8_[&&R_FU>B4 %%%% !1110 4444 %%%% !117'?%;XC:=\)/AOXE\9:LKOI
M^AV$M]+'']Y]BY"#W8X ^M '8T5\I>%_VA_'7AVX^#&K_$'_ (1]?#'Q/VVL
M8TV"2&72+Z>(SV4)=I6\]9$'EEMJ$2 '&&P/JV@#D_BQ_P DQ\6?]@JZ_P#1
M35SGBAMOA_PK_P!>G_LD==#\6/\ DE_B[_L$W7_HIJIS>$W\4>'/#C+=BU\B
MS3.8]V[<B>X]*NFTIILF5W&R.320;>M.\T>M=(OPOFQC^U1_X#__ &5+_P *
MOF_Z"H_\!_\ [*NKGAW,.678YM9!NZT_S!71+\,9E_YBH_\  ?\ ^RI?^%9S
M?]!0?]^/_LJ7/#N'++L<YY@H\P5TG_"LYO\ H*_^0/\ [*C_ (5G-_T%?_('
M_P!E3]I'N'++L<WY@I?-'K71_P#"LYO^@K_Y _\ LJ/^%9S?]!7_ ,@?_94N
M:'<?++L<YY@]:7S!71_\*SE_Z"@_[\?_ &5'_"M9?^@J/^_'_P!E1SQ[E<K.
M=\P4>8*Z+_A6LW_04_\ ('_V5'_"M9O^@I_Y _\ LJ7-'N+ED<[Y@I?,'K70
M_P#"M9O^@I_Y _\ LJ7_ (5K+_T%!_WX_P#LJ?/#N'+(Y[S!1Y@KHO\ A7$_
M_04'_?C_ .RH_P"%<3_]!0?]^/\ [*CGCW'RLYT2#GFCS!71?\*WF_Z":_\
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MG_""R?\ 00'_ 'Y_^RI?^$%D_P"?\?\ ?G_[*ES1[CU,-9!3O,%;7_""R?\
M/^/^_/\ ]E1_P@LG_/\ C_OS_P#94<T>XK,Q=XHWBMO_ (0>3_G_ !_WY_\
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M'&!6U_PA;_\ /]_Y"_\ KTG_  A;_P#/]_Y"_P#KU-T!CA^:-XK9_P"$-?\
MY_O_ "%_]>D_X0M_^?W_ ,A?_94U) 8^\4*XS6Q_PA;_ //[_P"0O_LJ=_PA
MC_\ /[_Y"_\ LJ?,@,?>* PK7_X0Q_\ G^_\A?\ UZ=_PAK_ //Y_P"0O_KT
MN9%&-O%+O&T5L?\ "&O_ ,_H_P"_7_UZ3_A#7_Y_?_(7_P!>E=$V,?>*57%;
M'_"&O_S^C_OU_P#7H_X0^3_G]'_?K_Z]%T!D[Q1OK7_X0^3_ )_1_P!^O_KT
M?\(B_P#S^#_OU_\ 7JN9%&3N%)NK9_X1%O\ G\_\A?\ UZ3_ (1%_P#G]_\
M(7_UZBZ R-PHW"MC_A$6_P"?S_R%_P#7H_X1%O\ G\_\A?\ UZ=T!D*PK!\9
M,//\,_\ 86B_]!>NV_X1-O\ G[_\A?\ UZY;Q[X?:VN/"?\ I6[?K<*?<QC*
M2'U]J3:L!JR,-QIFX5L-X49O^7S_ ,A?_7IO_"(O_P _G_D/_P"O3N@,G=1N
MK6_X1%_^?S_R'_\ 7H_X1%_^?S_R'_\ 7I70&5D4;JUO^$3?_G\_\A__ %Z7
M_A$W_P"?S_R'_P#7IW0&1NIVX5J_\(F__/Y_Y#_^O1_PB;?\_?\ Y#_^O1=
M96X4;A6K_P (FW_/W_Y#_P#KT?\ ")M_S]_^0_\ Z]2F@,K<*-PK5_X1-O\
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M (1EO^?K_P A_P#UZY"S/C;YJYCPZW_%?>+_ *6G_HLUW*^&V4Y^U?\ D/\
M^O7'^%]':7XC>-H_/QY8LN=G7,3>] &XS4W<*U3X98_\O7_D/_Z])_PC#?\
M/U_Y#_\ KT] ,O<*<K<5I?\ ",-_S]?^0_\ Z]*OAIE&/M7_ )#_ /KT: 9N
MZC=6G_PC;?\ /U_Y#_\ KT?\(VW_ #]?^0__ *](#-R*=NK0_P"$;;_GZ_\
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M3_X-&_\ B:/^%6K_ -#7XI_\&C?_ !-=QD49% '#_P#"K5_Z&OQ3_P"#1O\
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M_P"AK\4_^#1O_B:/^%6K_P!#7XI_\&C?_$UW-% '#?\ "K5_Z&OQ3_X-&_\
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M_"KQ_P!#7XI_\&C?_$TG_"K5_P"AK\5?^#1O_B:[JB@#A?\ A5J_]#7XJ_\
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MK1_T-?BK_P &K?\ Q-'_  JT?]#7XJ_\&K?_ !-=U10!PO\ PJT?]#7XJ_\
M!JW_ ,31_P *M'_0U^*O_!JW_P 37=44 <+_ ,*M'_0U^*O_  :M_P#$T?\
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M_@U;_P")KNZ* .$_X56O_0V>*O\ P:M_\31_PJM?^AL\5?\ @U;_ .)KNZ*
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M!NS\W:OM%J4K7T'$6BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9=R68] --[ZH6UCZWHHHK,H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$_&#XJ7W[<'Q4^"GC'QNWB+1]/T'^T+&_ATVULYK.1A;']ULCY ^U,!YF_\
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>form10-k_016.jpg
<TEXT>
begin 644 form10-k_016.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M3KPY_P!#!I?_ (&Q?_%4?\)UX<_Z&#2__ V+_P"*H WJ*P?^$Z\.?]#!I?\
MX&Q?_%4?\)UX<_Z&#2__  -B_P#BJ -ZBL'_ (3KPY_T,&E_^!L7_P 51_PG
M7AS_ *&#2_\ P-B_^*H WJ*P?^$Z\.?]#!I?_@;%_P#%4?\ "=>'/^A@TO\
M\#8O_BJ -ZBL'_A.O#G_ $,&E_\ @;%_\52_\)QX</3Q!I9_[?8__BJ -VBL
M/_A-O#W_ $,&E_\ @9'_ /%4W_A.O#G_ $,&E_\ @;%_\50!O45@_P#"=>'/
M^A@TO_P-B_\ BJ/^$Z\.?]#!I?\ X&Q?_%4 ;U%8/_"=>'/^A@TO_P #8O\
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MO#G_ $,&E_\ @;%_\50!O45@_P#"=>'/^A@TO_P-B_\ BJ/^$Z\.?]#!I?\
MX&Q?_%4 ;U%8/_"=>'/^A@TO_P #8O\ XJC_ (3KPY_T,&E_^!L7_P 50!O4
M5@_\)UX<_P"A@TO_ ,#8O_BJ7_A-O#G_ $,&EG_M]C_^*H W:*PO^$V\.?\
M0P:6/^WV/_XJD_X3KPY_T,&E_P#@;%_\50!O45@_\)UX<_Z&#2__  -B_P#B
MJ/\ A.O#G_0P:7_X&Q?_ !5 &]16#_PG7AS_ *&#2_\ P-B_^*H_X3KPY_T,
M&E_^!L7_ ,50!O45@_\ "=>'/^A@TO\ \#8O_BJ/^$Z\.?\ 0P:7_P"!L7_Q
M5 &]16#_ ,)UX<_Z&#2__ V+_P"*H_X3KPY_T,&E_P#@;%_\50!O45@_\)UX
M<_Z&#2__  -B_P#BJ/\ A.O#G_0P:7_X&Q?_ !5 &]16#_PG7AS_ *&#2_\
MP-B_^*H_X3KPY_T,&E_^!L7_ ,50!O45@_\ "=>'/^A@TO\ \#8O_BJ/^$Z\
M.?\ 0P:7_P"!L7_Q5 &]16#_ ,)UX<_Z&#2__ V+_P"*H_X3KPY_T,&E_P#@
M;%_\50!O45@_\)UX<_Z&#2__  -B_P#BJ/\ A.O#G_0P:7_X&Q?_ !5 &]16
M#_PG7AS_ *&#2_\ P-B_^*H_X3KPY_T,&E_^!L7_ ,50!O45@_\ "=>'/^A@
MTO\ \#8O_BJ=_P )MX>_Z&#2_P#P,C_^*H W**PO^$X\-_\ 0P:7_P"!L?\
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M_P#"9:!WUS3?_ N/_&@#:HK/L=8L=7C9K&\M[U5.UFMY5D /H<&M"@ HHHH
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M $ -+_\  ./_ .)H_P"$)\/?] #2_P#P#C_^)K<HH P_^$)\/?\ 0 TO_P
MX_\ XFC_ (0GP]_T -+_ / ./_XFMRB@##_X0GP]_P! #2__  #C_P#B:/\
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M( QQR2?QKL/^$)\/?] #2_\ P#C_ /B:P_ __(\>/O\ K_M__26*NXH P_\
MA"?#W_0 TO\ \ X__B:/^$)\/?\ 0 TO_P  X_\ XFMRB@##_P"$)\/?] #2
M_P#P#C_^)H_X0GP]_P! #2__  #C_P#B:W** ,/_ (0GP]_T -+_ / ./_XF
MC_A"?#W_ $ -+_\  ./_ .)K<HH P_\ A"?#W_0 TO\ \ X__B:/^$)\/?\
M0 TO_P  X_\ XFMRB@##_P"$)\/?] #2_P#P#C_^)H_X0GP]_P! #2__  #C
M_P#B:W** ,/_ (0GP]_T -+_ / ./_XFC_A"?#W_ $ -+_\  ./_ .)K<HH
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M.D.^B::[M9PL6:TC))*#D\5K?\(3X>_Z &E_^ <?_P 33_!O_(I:)_UXP?\
MHM:V: ,/_A"?#W_0 TO_ , X_P#XFC_A"?#W_0 TO_P#C_\ B:W** ,/_A"?
M#W_0 TO_ , X_P#XFC_A"?#W_0 TO_P#C_\ B:W** ,/_A"?#W_0 TO_ , X
M_P#XFC_A"?#W_0 TO_P#C_\ B:W** ,/_A"?#W_0 TO_ , X_P#XFC_A"?#W
M_0 TO_P#C_\ B:W** ,/_A"?#W_0 TO_ , X_P#XFC_A"?#W_0 TO_P#C_\
MB:W** ,/_A"?#W_0 TO_ , X_P#XFC_A"?#W_0 TO_P#C_\ B:W** ,/_A"?
M#W_0 TO_ , X_P#XFC_A"?#W_0 TO_P#C_\ B:W** ,/_A"?#W_0 TO_ , X
M_P#XFC_A"?#W_0 TO_P#C_\ B:W** ,/_A"?#W_0 TO_ , X_P#XFC_A"?#W
M_0 TO_P#C_\ B:W** ,/_A"?#W_0 TO_ , X_P#XFC_A"?#W_0 TO_P#C_\
MB:W** ,/_A"?#W_0 TO_ , X_P#XFN&\7>%]&A^('@:&/2+!(IIKL2(ML@5\
M0$C(QS@UZK7G_C;_ )*5\/O^N]Y_Z3F@:.E_X0OP]WT'3/\ P#C_ /B:3_A"
M?#W_ $ -+_\  ./_ .)K<HH$8?\ PA/A[_H :7_X!Q__ !-'_"$^'O\ H :7
M_P" <?\ \36Y10!A_P#"$^'O^@!I?_@''_\ $T?\(3X>_P"@!I?_ (!Q_P#Q
M-;E% &'_ ,(3X>_Z &E_^ <?_P 31_PA/A[_ * &E_\ @''_ /$UN44 8?\
MPA/A[_H :7_X!Q__ !-'_"$^'O\ H :7_P" <?\ \36Y10!A_P#"$^'O^@!I
M?_@''_\ $T?\(3X>_P"@!I?_ (!Q_P#Q-;E% &'_ ,(3X>_Z &E_^ <?_P 3
M1_PA/A[_ * &E_\ @''_ /$UN44 8?\ PA/A[_H :7_X!Q__ !-'_"$^'O\
MH :7_P" <?\ \36Y10!A_P#"$^'O^@!I?_@''_\ $T?\(3X>_P"@!I?_ (!Q
M_P#Q-;E% &'_ ,(3X>_Z &E_^ <?_P 31_PA/A[_ * &E_\ @''_ /$UN44
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M#=20/):69:%_,3%K&,-@CLO/!/6IN/\ GULO_ .+_P")J:DVB@"+C_GULO\
MP#B_^)HX_P"?6R_\ XO_ (FI=HHVB@"+C_GULO\ P#B_^)HX_P"?6R_\ XO_
M (FI=HHVB@"+C_GULO\ P#B_^)HX_P"?6R_\ XO_ (FI=HHVB@"+C_GULO\
MP#B_^)HX_P"?6R_\ XO_ (FI=HHVB@"+C_GULO\ P#B_^)HX_P"?6R_\ XO_
M (FI=HHVB@"+C_GULO\ P#B_^)HX_P"?6R_\ XO_ (FI=HHVB@"+C_GULO\
MP#B_^)HX_P"?6R_\ XO_ (FI=HHVB@"+C_GULO\ P#B_^)HX_P"?6R_\ XO_
M (FI=HHVB@"+C_GULO\ P#B_^)HX_P"?6R_\ XO_ (FI=HHVB@"+C_GULO\
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MB-_R3_Q+_P!@RY_]%-715SOQ&_Y)_P")?^P9<_\ HIJ +/@W_D4M$_Z\8/\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55N?NU:JK<_=H
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MXC?\D_\ $O\ V#+G_P!%-715SOQ&_P"2?^)?^P9<_P#HIJ +/@W_ )%+1/\
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M_P#D>/'W_7_;_P#I+%7<5Q/@E2OC;QZ?6_M__26*NVH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N>^(G_ "3_ ,3?]@RY_P#1
M35T-<_\ $)=W@'Q*/^H9<_\ HIJ )_!O_(I:)_UXP?\ HM:V:Q_"(V^%=&'_
M $Y0_P#HM:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KS_QM_P E)^'W_7>\_P#2<UZ!7 ^-E+?$CX?'TGO/_2<T#1WU%%%
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M]4_[]BC_ (2K5O\ GJG_ '[%5-HHVBE9=AZES_A)]6_YZI_WP*7_ (2C5?\
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MMIRKQ19 BS_PDFI_\]4_[X%+_P ))J?_ #T3_O@55VTNT4FD-EK_ (234_\
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M/^U9X5^#OQ<TF'Q)J5GI5Q#X?\26YWS0V3(6W&48\V!OL^WYQN5EZU]DZ/\
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MGX>MICEX+%2D9.<YVYP#]*V[S2=-OM:L=8GL;>75;&.2*UO60&6%),>8JMU
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MQ7J.K:;%I-P]S!+I,L:.2ZA6#>8C@C@=L\=:\+_X=&?!]O\ F;/&G_@5:?\
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MCK \*?\ (1\3_P#81/\ Z*CK?CK!\*_\A'Q/_P!A(_\ HJ.CJ!O-VHH;M10
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M)<@DL2S$C!/05^U8U CH /PI3J#;=N!CTQ1[35NVX<FVNQ^;W_!5CQEIFO?
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MGYZ<';GOFOK"LWN6<?K7_)4/#7_8/OO_ $*"N$MSR?K7=:TW_%TO# ]=/O\
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M*T9W;21U0]#TQ70-\M>$?\$\[>[F_8Q\ &&UEE'^FX*(3_R^35[M)INI[O\
MD'77_?IO\*YL1R4ZLX1V3:7I<I;)AD49%-_LW5/^@==?]^6_PH_LW5/^@==?
M]^6_PKGYH@.R*5>M,_LW4_\ H'W7_?EO\*7^S]4_Z!UU_P!^6_PI<P$F12J?
MFJ/^S=4_Z!]U_P!^6_PI\>GZGWT^Z'_;)O\ "CF R]%/_$ZU[_KM'_Z+6M<F
ML30;6_DU[Q$JV5P6CGC# 1G(/E*>?P-;+:?J7_0.NO\ OTU*.Q3W%R*-PIG]
MFZE_T#[C_OTW^%']FZE_T#[C_OTW^%/F)'[J,BF?V?JG_0/NO^_3?X4O]FZG
M_P ^%U_WZ;_"CF+';J>#P*A_LO4_^@?<_P#?IO\ "G?V?J?_ #X77_?HTG(3
M),BC=3?[-U/_ *!]U_WZ-)_9^I?\^%Q_WZ:D2/R*,BD_L_4_^@?=?]^FH_L_
M4_\ H'W7_?IJ7NEBY%&12?V?J?\ T#[K_OTU']GZE_SX77_?IJ/= 7(HR*0:
M;J?_ $#[G_OTU+_9^I_] ^Y_[]&BX#EI::-/U+_H'W/_ 'Z:E^P:E_T#[G_O
MTU%P%HIOV'4O^@?<_P#?IO\ "E^P:E_SXW/_ 'Z;_"BX"Y%.R*C_ +/U+_GP
MN?\ OTU/_L_4?^?"Y_[]-1<!U4?$7_(NZI_UZR?^@FKG]GZC_P ^%S_WZ:J/
MB2SOX_#.K.]E<*JVDI),9  "'FD]AHL:2?\ B36'_7O'_P"@BK%5='LK^31-
M.9;*X93;1D$1G^Z*L_8=2_Y\+C_OT:%L#%H4BD_L_4O^?"X_[]-0NGZC_P ^
M%S_WZ:G<0_(HR*9]@U'_ )\+G_OVU']GZC_SX7/_ '[:BX#\BC(IOV#4/^?"
MX_[]-2_8=1_Y\+C_ +]FD5J+D49%)]AU'_GPN/\ OV:/L.H_\^%Q_P!^S0!)
M2;J;]CU#_GQN/^_34OV'4<_\>-Q_WZ:@D=12?8=1_P"?&X_[]&C[#J/_ #XW
M'_?HT%BT4GV'4?\ GQN/^_1H^P:A_P ^5Q_WZ- A:5:;]AU#_GQN/^_1IPL=
M0_Y\;C_OV:!CJ*;]AU#_ )\KC_OV:/L.H?\ /E<?]^S0(=12?8=0_P"?*X_[
M]FD^PZA_SY7'_?LT .!YK!U\_P#%6>&/^ND__HHUO+8W_P#SY7'_ '[-<[XB
MANX_%_A-&MIE9Y+@*I0Y.(C4/8I'3R?>IF13I+*^SQ9SG_MF:9]AO_\ GRN/
M^_9JB1<BC(I/L-__ ,^=Q_W[-+]AO_\ GSN/^_9IC#/(HR*;]AO^/]"N/^_9
MI?L.H?\ /E<?]^S4"'9I,BC[#?X_X\[C_OV:3[#?_P#/G<?]^S5C%R*<IXIG
MV&__ .?.X_[]&G"SO_\ GSN/^_9H!#J*;]CO_P#GSG_[]FE^QWW_ #YS_P#?
MLU+&Q:*3[#?_ //G/_W[-'V&_P#^?.?_ +]FD(6G;J9]AOO^?.X_[]FG?8[[
M_GTG_P"_9IH$.I-U)]COO^?.?_OV:5;.][V<_P#W[-44+10;.]_Y\Y_^_9H%
MG>_\^D__ '[-0 44?8[W_GTG_P"_9H^QWO\ SZ3_ /?LT /CK \*?\A'Q/\
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MXE6"WA0R22R':J*!DDD] !5R$VVI6=K=6+I-93Q+)!)&<JT; %2/8@BOE/\
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M#+,2> .PKM***0SBM<_Y*QX4'_4.U#_T*WKM:XK7/^2M>%/^P=J'_H5O7:T
M%%%% !1110 4444 %%%% !1110 4444 (:^7_P#@I@Q7]BGXB$?\\[3_ -*X
M:^H&Z5\N_P#!3+_DRGXB?[EI_P"E<-:T;JI%KN)["?\ !,EMW[$OPZ/^S>_^
MEL]?47\-?+O_  3)7;^Q+\.A_LWO_I;/7U%_#2K7]K*^]V"V'4445F,****
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M/W:M55N?NT CLO!?_(]^-_\ KK9_^DZUW%</X+_Y'OQO_P!=;/\ ])UKN*"
MHHHH **** "BBB@ HHHH **** "BBB@#BM<_Y*UX4_[!VH?^A6]=K7%:Y_R5
MKPI_V#M0_P#0K>NUH **** "BBB@ HHHH **** "BBB@ HHHH 2O OVY/AGX
ME^,7[,/C+PEX2T_^U?$&H);_ &:S\Z.'S"EQ&[#?(RJ/E4]2*]^HIQER24ET
M _$W6/%W[9?[#WPCT6QOYV\$^"+>[-A8*T6CW^V:7S9]F0)9#G;*V6X&,9'
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MYWXC?\D_\2_]@RY_]%-715SOQ&_Y)_XE_P"P9<_^BFH L^#?^12T3_KQ@_\
M1:ULUC>#?^12T3_KQ@_]%K6S0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>?>./^2E?#W_ *[WG_I.:]!KS_QM_P E*^'W_7>\
M_P#2<T#1Z!1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N(^'?\ R'?'7_8;/_I-!7;UQ'P[_P"0[XZ_[#9_])H* .WHHHH
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MPI_^@<O_ ']_^M1[.0<R.VHKBO\ A8,W_0/7_O[_ /6H_P"%@S?] ]?^_O\
M]:CDD',CM:*XK_A8,W_0/7_O[_\ 6H_X6#-_T#U_[^__ %J.20<R.UHKBO\
MA8$O_0/7_OY_]:C_ (3^?_H'K_W\/^%')(.9':T5Q?\ PGT__/@O_?P_X4?\
M)]/_ ,^"_P#?P_X4>SD',CM**XS_ (3R;_GR7_OX?\*3_A/IO^? ?]_#_A1[
M.0[H[2BN*_X3^;_GQ7_OX?\ "G_\)U/_ ,^"_P#?S_ZU'LY"YD=C7._$+YO
M/B4?]0RY_P#1350_X3N;_GP7_OY_]:LKQ=XNEO/".M0FR"B6QF0G?TS&1Z>]
M'*QJ2.N\'_\ (IZ+_P!>4'_HM:V:X#P_XREM_#^EQBR4[+6)?O\ H@]JN_\
M"=3?\^*_]_/_ *U')(+H['GTHY]*X[_A.IO^?%?^_G_UJ5?'DQ_Y<5_[^'_"
MCV<A<R.QHKC_ /A.)?\ GQ7_ +^?_6H_X3B7_GQ7_OY_]:CV<@YD=A17'_\
M"<2_\^*_]_/_ *U'_"<2_P#/BO\ W\_^M1[.0<R.PHKC_P#A.)?^?%?^_G_U
MJ/\ A.)?^?%?^_G_ -:CV<AW1V%%<?\ \)U+_P ^(_[^'_"E_P"$XE_Y\U_[
M^'_"CE8N9'7T5R/_  G$W_/BO_?S_P"M1_PG$W_/BO\ W\_^M2Y6.YUU%<C_
M ,)Q-_SXK_W\_P#K4?\ ";R_\^2_]_#_ (4<K"YUU%<E_P )M+_SY+_W\_\
MK4?\)M)_SY#_ +[_ /K4^5A<ZVBN3_X3:7_GR7_OL_X4G_";2?\ /D/^^_\
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MY@H\P5M?\(@G_/XW_?'_ ->E_P"$/3_G\;_OC_Z]%F.Z,3S!1Y@K;_X0]/\
MG\;_ +X_^O1_PAZ?\_C?]\?_ %Z+,+HQ/,%'F"MS_A#D_P"?QO\ O@?XT?\
M"&I_S^O_ -\#_&C46AA^8*/,%;G_  AJ?\_K_P#? _QI?^$+3_G]?_O@?XT:
MA=&%Y@H\P5N?\(:G_/Z__? _QH_X0U/^?U_^^!_C1J&AA^8*-X]:W/\ A#4_
MY_7_ .^!_C2_\(6G_/Z__? _QHU#0PMX]:/,%;W_  A:?\_K_P#? _QI/^$+
M3_G]?_O@?XT#,+S!1O'K6_\ \(1'_P _S?\ ? _QH_X0B/\ Y_F_[X'^- KH
MP-X]:-X]:W_^$(C_ .?YO^^!_C1_PA$?_/\ -_WP/\: NC WCUH\P5O_ /"$
M1_\ /\W_ 'P/\:/^$(C_ .?YO^^!_C0,P=XI/,%7M8T%=)O-&@%RT@U"[^S%
MBN-GR,V>O/W?UK3;P/'_ ,_S?]\#_&@#GMX]:-X]:W_^$)3_ )_7_P"^!_C2
M_P#"$1_\_P"W_? _QH Y_>/6C>/6N@_X0>/_ )_W_P"^!_C1_P (/'_S_O\
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M&[!3]@I*?5(:&^6*%0>E.HH90FT4;12T5(";11M%+10 Z-1FL#PJH_M+Q/\
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M&C<:2BD@%W&C<:2BFP%W&E5C3:5:D#G_ !@Q_M?P?_V%?_:,E=,[&N8\8?\
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M^HJ9;Z%+8X_6C_Q=+PR/^H???^A05YS#>*I//>O0M:;_ (NMX5'_ %#]0_\
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ME6X![UZ!Y*?W5_*CR4_NK^5',!Y^UP*%N!ZUZ!Y*?W5_*CR4_NK^5+F \_\
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M?_TEBKN*X?P/_P CQX^_Z_[?_P!)8J[B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YWXC?\D_\2_]@RY_]%-715SOQ&_Y)_XE
M_P"P9<_^BFH L^#?^12T3_KQ@_\ 1:ULUC>#?^12T3_KQ@_]%K6S0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?\ C;_DI/P^
M_P"N]Y_Z3FO0*\^\<?\ )2OA[_UWO/\ TG- T>@T444""BBB@ HHHH ****
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M?]@[4/\ T*WKM:XK7/\ DK7A3_L':A_Z%;UVM !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $?<5^6Z_\ *<1A_G_D6A7ZD=Q7Y;1_\IQ'
M^O\ [K0KKPG_ "\_PL4NA^IM%%%<@SA_ _\ R/'C[_K_ +?_ -)8J[BN'\#_
M /(\>/O^O^W_ /26*NXH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N=^(W_)/_ !+_ -@RY_\ 135T5<[\1O\ DG_B7_L&7/\
MZ*:@"SX-_P"12T3_ *\8/_1:ULUC>#?^12T3_KQ@_P#1:ULT %%%% !1110
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M ][_ -<)/_037/\ PG_Y)CX5_P"P9;_^BQ0/H==1110(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .'^(G_(?\"?]AK_ -MIZ[BN
M'^(G_(?\"?\ 8:_]MIZ[B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** . \#_\ )2OB)_U\V?\ Z3+7?UP'@?\ Y*5\1/\
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MWO/_ $G- T>@4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:P?A2NWX:^%A_P!0RW_]%K5&^1_[+O/G;_4OW_V365X#C9? N@ .P LHN_\
MLBBP^AZ?17$[7_OM^9I,/_?;_OHT6$=O17$A7R/G;_OJG['_ .>C?F:+ =G1
M7&8;_GJWYT;9/^>C?F:+ =G17&[7W??;\S2[7_OM^=(#L:*X[:_]]OSH"O\
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M17/;6_O-^=.56_O-^= CG_ __)2OB)_U\V?_ *3+7?UP7@<8^(WQ!_Z^+/\
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M4W<*-PJ '44W=1NH ECK \*?\A'Q/_V$3_Z*CK>C89K \*L/[2\3_P#82/\
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M ,E8\*?]@[4/_0K>NTVU49..PI14MS@O^%7R_P#04'_?C_[*E_X5A+_T%/\
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M!?\ Y_\ _P A?_7KL:*.>0<J.,_X0!_^@A_Y"_\ LJ?_ ,("_P#S_C_OS_\
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MNHHHYF,Y;_A"W_Y_?_(?_P!>E_X0U_\ G]'_ '[_ /KUU%%',P.7_P"$-?\
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M+L#!_P"$9;_GY_\ '/\ Z]'_  C3?\_/_CG_ ->MZBBX&%_PC9_Y^1_WQ_\
M7I?^$;;_ )^?_'/_ *];E%(##_X1MO\ GY_\<_\ KT?\(VW_ #\C_OC_ .O6
MY13N!A_\(VW_ #\_^.?_ %Z/^$;;_GY_\<_^O6Y11<##_P"$;;_GY_\ '/\
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M]%-0!9\&_P#(I:)_UXP?^BUK9K&\&_\ (I:)_P!>,'_HM:V: "BBB@ HHHH
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MG_Z3+7?T %%%% !1110 4444 %%%% !1110 4444 <5KG_)6O"G_ &#M0_\
M0K>NUKBM<_Y*UX4_[!VH?^A6]=K0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '#^!_^1X\??\ 7_;_ /I+%7<5P_@?_D>/
M'W_7_;_^DL5=Q0 4444 %%%% !1110!^7O\ P3]_Y2.?M)?]?&L_^G=:_4!:
M_'[]FOX^>!/V>?V\OV@]<\>ZRVAZ;?:GK%E;W"VDUSNE_M3?MVQ(Q'RJ3DC'
M%?:Q_P""HG[-B]?B#)_X(]0_^,5Z%?#U92YHQ;5EK8B,E8^JN/2C ]*^4_\
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MF^)-+T+2KS6=1>[L76ST^W:>9E6X0L0B@DX SP*Z<'&/UB%]KK\PDWRLW?\
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MB,>E'DBERQ'J=!_PGG_3@W_?S_ZU)_PGG_3@W_?S_P"M6!Y(H\D4<L179O\
M_">#_GQ;_OY_]:G?\)T/^?%O^_G_ -:L'RA1Y8]*.5!=F]_PG0_Y\6_[^?\
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MWC#;_P N9_[[_P#K4?\ "7_].9_[[_\ K5C;!1L%*R V?^$P_P"G-O\ OO\
M^M1_PF'_ $YM_P!]_P#UJQMM&T460&XOBW=_RZ-_WW_]:N5\$^(/LNK>,'^R
MD^;JQ?[_ $_<1#T_V:THU&:P/"JC^TO$_P#V$C_Z*CJ;(#M?^$N_Z<V_[^?_
M %J/^$N_Z<V_[^?_ %JR-@I/+%%D!L?\)=_TYM_W\_\ K4?\)=_TYM_W\_\
MK5C^6*/+%%D!L_\ "7?].C?]]_\ UJ/^$N_Z=&_[[_\ K5C[11M%59 ;/_"6
M?].C?]]__6H_X2S_ *=&_P"^_P#ZU8ZJ*7RQ2:0&O_PEH_Y]&_[[_P#K4?\
M"6?].C?]]_\ UJR/+%'EBE9 :_\ PEG_ $Z-_P!]_P#UJ/\ A+/^G1O^^_\
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MMI(#2_X23_IU;_OK_P"M1_PDG_3L?^^__K5F[: HIV T_P#A)!_S[_\ C_\
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M_0H*X2W^\?K6]'=F=3H6Z***Z3 =1114H HHHJ@%6G4U:=4%(****!A1110
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M%%4 4JTE*M)@.HHHI 1WW_(+O/\ KB__ *":RO ?_(CZ#_UY1?\ H(K5OO\
MD%WG_7%__0365X#_ .1'T'_KRB_]!%+J!LT444P"G4VG4 %%%% "K3J:M.I(
M HHHI@%%%% !3Z93Z "D:EI&I,!:***2 ****; *%ZT4+UJ0.?\ &'_(8\'_
M /85_P#:$E=*W\7UKFO&'_(8\'_]A7_VA)72R=Z: 90O2BA>E# ****0!111
M0 4^F4^@ HHHH&@HHHH&PIRTVG+02+1110 4444%A0O6BA>M #J5:2E6@@Y_
MP3_R43X@?]?%G_Z3K7>UP7@G_DHGQ _Z^+/_ -)UKO: "BBB@ HHHH ****
M"BBB@ HHHH **** ./UC_DJ'AK_KPOO_ $*"N$M_O'ZUW>L?\E0\-?\ 7A??
M^A05PEO]X_6MZ.[,ZG0MT445TF ZBBBI0!1115 *M.IJTZI92"BBBD,****
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MBB@!\=8/A7_D(^)_^PD?_14=;T=8'A3_ )"/B?\ [")_]%1T=0-]NU%#=J*
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M"R>U0!B>,/\ D,>#_P#L*_\ M"2NE;^+ZURGC&7&L>#O^PM_[0EKII).>E-
M.H7I4)D/I0LORT,":BHO-H\SZT@):*B\SZT>9]: )O2G5 ).1UIWF_6@"6BH
MO,^M+O/H:!HDHJ/S/8T>8?2@HDIRU#O/H:<LAQTH():*B\SV-+YGL: )**C\
MP^M'F'TH+)*%ZU'YA]*%D.>E $U*M1>8?2G*^3TH(,+P5_R43X@?]?%G_P"D
MZUWM<%X'/_%QOB#_ -?%G_Z3+7>T %%%% !1110 4444 %%%% 'RQ^TU^U%X
M$\,Z]-\)KSQO'X2U/5+1AJNM1^9OTJU=<$1,J,/M+J?D!X0'>>BJ_'>+O$W@
M[3?&G[,?Q-\(M!!\'/#K:QX<EU9H9+>WT^.>"*"VD;>HVP^9:F/S&PN64YYS
M7V1)I=E<2%Y;.WED/5Y(E)/XXJ7[+!]G\DPQ^1C'E[1MQZ8Z57,DDK$<KN?+
MG[(NGMXF^-G[07Q.LTN#X7\4:SI]IH]VVY8;Z.SM?*DN(@>'C9VP)!D':<'@
MU]6 4R*-((PD:JB*,!5& *EI-W99Q>MM_P 78\*C_J':A_Z%;UV>T>E<7KG_
M "5KPI_V#M0_]"MZ[6D FT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10 FT>E
M&T>E+10 FT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10 FT>E
M&T>E+10 FT>E&T>E+10 FT>E&T>E+10!Q?@M]_C+QTI'"WUN!_X"Q5V>T>E<
M1X'_ .1X\??]?]O_ .DL5=Q0 FT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10
M FT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10
M FT>E&T>E+10 FT>E&T>E+10 ROR/_9=^-'@CX-_M7?M.7?C7Q%:^'[;4M0U
M."U>Z#GSG%_,2J[5.3@CBOUQ_"OCWXG?\$V?@7X@N/%OB[4-%U3^U;YKO5+B
M2/59E0S/NE8A<X W$G'2NW"U*<5.%6_+)6TW(DFVK'4V/_!0K]GFST^TBD^)
MNG*RPH"/LUR<?*..(NM6?^'BG[.?_13]-_\  6Y_^-5Y]I/_  2K_9[U#2[*
MY?0M89IH$D)_MB;G*@^OO5K_ (=-_L[_ /0!UC_P<S_XU4EA/LN5OD'O=3N/
M^'BG[.7_ $4[3O\ P%NO_C5'_#Q3]G+_ **=IW_@+=?_ !JN(_X=-_L[?] '
M6/\ P<S_ .-)_P .F_V=_P#H :Q_X.9_\:G_ &;^]^!6IW'_  \4_9R_Z*=I
MW_@+=?\ QJC_ (>*?LY?]%.T[_P%NO\ XU7#_P##IO\ 9W_Z &L?^#F?_&C_
M (=-_L[_ /0 UC_P<S_XT?[-_>_ -3N/^'BG[.7_ $4[3O\ P%NO_C5'_#Q3
M]G+_ **=IW_@+=?_ !JN'_X=-_L[_P#0 UC_ ,',_P#C1_PZ;_9W_P"@!K'_
M (.9_P#&C_9O[WX!J=Q_P\4_9R_Z*=IW_@+=?_&J/^'BG[.7_13M._\  6Z_
M^-5P_P#PZ;_9W_Z &L?^#F?_ !H_X=-_L[_] #6/_!S/_C1_LW][\ U.X_X>
M*?LY?]%.T[_P%NO_ (U1_P /%/V<O^BG:=_X"W7_ ,:KAO\ ATW^SO\ ] #6
M/_!S/_C2_P##IO\ 9W_Z%_6/_!S/_C1_LW][\!:G;?\ #Q7]G3_HINF_^ MS
M_P#&J/\ AXI^SG_T4[3?_ 6Y_P#C5<5_PZ;_ &=^V@:Q_P"#F?\ QKPW]M;_
M ()]_!SX&_LR^,O&WA31]1MM>TS[']GEN-3EF0>9>P0OE&.#\DC5I3IX:I.,
M+R3;MTZDMR2N?HA\/_'GA_XH>$].\4^%M4M]:T'4 SVM];9V2!79&QD @AE9
M2",@@BNGQ[5\L?\ !,/_ ),>^&__ '$O_3G=5]4 UPUH*G4E!;)M?B6M4+M'
MI1M'I2T5 Q-H]*-H]*6B@!-H]*-H]*6B@!-H]*X/QI)M^(W@!?[T]Y_Z3FN]
MKS_QM_R4KX??]=[S_P!)S0-'?[1Z4;1Z4M% A-H]*-H]*6B@!-H]*-H]*6B@
M!-H]*-H]*6B@!-H]*-H]*6B@!-H]*-H]*6B@!-H]*-H]*6B@!-H]*-H]*6B@
M!-H]*-H]*6B@!-H]*-H]*6B@!-H]*-H]*6B@!-H]*XOX?-OUKQP#_#K1'_DM
M!7:UQ'P[_P"0[XZ_[#9_])H* .VVCTHVCTI:* $VCTHVCTI:* $VCTHVCTI:
M* $VCTHVCTI:* $VCTHVCTI:* $VCTHVCTI:* $VCTHVCTI:* $VCTHVCTI:
M* $VCTHVCTI:* $VCTHVCTI:* $VCTHVCTI:* *.L?\ ()O#_P!,'_\ 036%
M\*V\SX;^%F]=,M__ $6M;NM?\@>]_P"N$G_H)KG_ (3_ /),?"O_ &#+?_T6
M*!]#K=H]*-H]*6B@0FT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10 FT>E&T4
MM% !1110 4444 %%%% !1110 4444 %%%% '%?$!MNO>!O?6L?\ DM/7:UQ'
MQ"_Y#W@3_L-_^VT]=O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% ' ^!_^2D?$3_KYL_\ TF6N^K@/ _\ R4KXB?\ 7S9_
M^DRUW] !1110 4444 %%%% !1110 4444 %%%% '%:Y_R5KPI_V#M0_]"MZ[
M6N*US_DK7A3_ +!VH?\ H5O7:T %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!P_@?\ Y'CQ]_U_V_\ Z2Q5W%</X'_Y'CQ]
M_P!?]O\ ^DL5=Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<_\0FV^ ?$I'_0,N?_ $4U=!7/?$3_ ))_XF_[!ES_ .BFH L>
M$?F\*Z,?^G*'_P!%K6S6-X-_Y%+1/^O&#_T6M;- !1110 4444 %%%% !111
M0 4444 -':OEK_@IU_R8[\2?IIO_ *<K6OJ4=J^6?^"GG_)COQ)_[AO_ *<K
M6ML/_%AZK\R9;"?\$P_^3&_AK_W$O_3G=5]4'I7RM_P3#_Y,;^&O_<2_].=U
M7U2W2C$?Q9>K_,<=D%+24M8C"BBB@ HHHH *\^\<?\E*^'O_ %WO/_2<UZ#7
MG_C;_DI7P^_Z[WG_ *3F@:/0****!!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Q'P[_P"0[XZ_[#9_])H*[>N(^'?_ "'?'7_8
M;/\ Z304 =O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 4=:_P"0/>_]<)/_ $$US_PG_P"28^%?^P9;_P#HL5T&M?\ ('O?
M^N$G_H)KG_A/_P DQ\*_]@RW_P#18H'T.NHHHH$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '#_$3_D/^!/^PU_[;3UW%</\1/\
MD/\ @3_L-?\ MM/7<4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!P'@?\ Y*5\1/\ KYL__29:[^N \#_\E*^(G_7S9_\
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MJK#(ITY>SG&?9I_<#U5C\=/V7_\ @IE)^SK\#?#7P^;X97FNMH_VD_V@NHF
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M>?\ I.:^#/\ @DJRM\8/VC-JA%_M"UPJC  ^T7W K[S\;?\ )2/A]_UWO/\
MTG-+$TXTZC4-M!P;:NSOZ***YR@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *XCX=_\ (=\=?]AL_P#I-!7;UQ'P[_Y#OCK_ +#9
M_P#2:"@#MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"CK7_ "![W_KA)_Z":Y_X3_\ ),?"O_8,M_\ T6*Z#6O^0/>_]<)/
M_037/_"?_DF/A7_L&6__ *+% ^AUU%%% @HHHH **** "BBB@ HHHH ****
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MW.GHKF/^%A:1_P ]9?\ ORU'_"PM&_Y[2_\ ?IJ.278.9=SIZ*YC_A86C?\
M/:7_ +]-1_PL+1O^>TO_ 'Z:CDEV#F7<Z>BN8_X6%HW_ #VE_P"_34O_  L#
M1_\ GM+_ -^FHY)=@YEW.ER*,BN:_P"%@:/_ ,]I?^_34?\ "P-'_P">TO\
MWZ:CDEV'='345S/_  L#1_\ GM+_ -^FH_X6!H__ #VE_P"_34<DNPN9=SIJ
M*YG_ (6!H_\ SVE_[]-1_P + T?_ )[2_P#?IJ.278.9=SI-U&ZN<_X3[2/^
M>LO_ 'Z:E7QYI+=)9?\ OTU')+L',C,\$M_Q6WCW_K_M_P#TEBKMLBO-O"?B
MK3;7Q5XQF:20+<7D+K^[/06\:_S!KIO^$\TC_GK+_P!^FHY9=AW1T6ZC=7._
M\)YI'_/67_OTU'_">:1_SUE_[]-1R2[#NCHMU&ZN=_X3S2/^>LO_ 'Z:C_A/
M-(_YZR_]^FHY)=@NCH\BC(KG/^$\TC_GK+_WZ:E_X3K2?^>TG_?IJ.2785T=
M#NHW5SO_  G.E?\ /:3_ +]-1_PG.E?\]I/^_34<LNPN9'1;J-U<_P#\)SI/
M_/67_OTU'_"<Z3_SUE_[]-1RR[%71T&ZC=7/_P#"<Z3_ ,]9?^_34?\ "<Z3
M_P ]9?\ OTU'++L%T=!NHW5@?\)QI/\ STD_[]&E_P"$ZTG_ )ZR?]^S1RR[
M!=&]NHW5@_\ "<:5_P ])/\ OT:/^$XTK_GI)_WZ-'++L%T;VZC=6%_PG&E?
M\])/^_9H_P"$XTK_ )Z2?]^S1RR[!=&[NHW5A?\ "<:5_P ])/\ OV:/^$VT
MO_GI)_W[-+E?8+HW>*Y_XB-_Q;_Q-_V#+G_T4U/_ .$VTO\ YZ2?]^S6+XV\
M5:=>>"]?A1Y-TFGW"#]V>IC8"CE?85T=!X//_%)Z)_UXP?\ HM:U]U<EX;\5
M:;;>&]*C:23*6D*G]V>R"M'_ (333/\ GI)_W[-'*^P71N;J-U8?_"::9_ST
MD_[]FC_A--,_YZ2?]^S1ROL.Z-S=1NK#_P"$TTS_ )Z2?]^S1_PFFF?\])/^
M_9HY7V"Z-S=1NK#_ .$TTS_GI)_W[-'_  FFF?\ /23_ +]FCE?8+HW-U&ZL
M/_A--,_YZ2?]^S1_PFFF?\])/^_9HY7V"Z-S=1NK%_X3+3/^>DG_ '[-'_"9
M:9_STD_[]FCE?8+HVMU&ZL7_ (3+3/\ GI)_W[-'_"9:9_STD_[]FCE?8+HW
M**P_^$RTS_GI)_W[-'_"8:=_ST?_ +]FCE?8#<HK#_X3#3O^>C_]^S1_PF&G
M?\]'_P"_9HY7V VMU&ZL;_A,--_OR?\ ?LT?\)AIO]^3_OV:.5]@NC;HK%_X
M2[3O[\G_ '[-36^O6=YD1NQ/NA%%F!^;_P#P2-_Y*]^T7_V$+7_THOJ^]O&G
M_)1OA]_UWO/_ $G-?!'_  23N(O^%N_M$,N[$E]:R+Q_#]HO?\17WUXLDCD\
M<>#)OFQ!-=$_*>\)%=F,BXU;2WT_(F&QW=%4CJT _O\ _?!I/[7@_P!O_O@U
MQE%ZBJ/]KP?[?_?!H_M:#_II_P!\&@"]15'^UX/]O_O@T?VO!_M_]\&D!>HJ
MC_:T'_33_O@T?VM!_P!-/^^#3 O451_M:#_II_WP:7^UH/\ ;_[X- %VBJ7]
MK0?[?_?!I?[4A_V_^^#0!<HJG_:D/^W_ -\&C^U(?]O_ +X- %RBJ?\ :D/^
MW_WP:/[4A_V_^^#0!<HJG_:D/^W_ -\&C^TH?]O_ +X-("Y15/\ M*'_ &_^
M^#1_:4/^W_WP:8%RBJ?]I0_[?_?!H_M*'_;_ .^#0!<KB/AW_P ASQW_ -AL
M_P#I-!72MKUHAP6<?\ -<?X%UJSM]8\9LS,!)K!<?(>GV>$?S!I68'H5%9/_
M  E%A_??_O@T?\)18?WW_P"^#3LP-:BLG_A*+#^^_P#WP:/^$HL/[[_]\&BS
M UJ*R/\ A)K'^^__ 'P:/^$FL?[[_P#?!HLP->BLC_A)K'^^_P#WP:/^$FL?
M[[_]\&BS UZ*R/\ A)K'^^__ 'P:/^$FL?[[_P#?!HLP->BLC_A)K'^^_P#W
MP:/^$FL?[[_]\&BS UZ*R/\ A)K'^^__ 'P:7_A)+'^^_P#WP:+,#6HK)_X2
M2Q_OO_WP:/\ A)+'^^__ 'P:+,#6HK)_X22Q_OO_ -\&C_A)+'^^_P#WP:+,
M#6HK)_X22Q_OO_WP:</$=DW\;_\ ?!HLP-2BLS_A(K+^^W_?!H_X2*R_OM_W
MP:0$NM?\@>]_ZX2?^@FL#X3_ /),O"G_ &#+?_T6*T-4URTDTN] 9O\ 4O\
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M: -"BL_^VK7^\W_?)H_MJU_O-_WR: -"BL_^VK7^\W_?)IW]L6W]YO\ ODT
M7J*H_P!L6W]YO^^32?VQ;?WF_P"^: +]%4/[8MO[S?\ ?-']L6W]YO\ OF@"
M_15#^V+;^\W_ 'S3O[6M_P"\W_?)H NT52_M:W_O-_WR:/[6M_[S?]\F@"[1
M5+^UK?\ O-_WR:/[6M_[S?\ ?)H NT52_M:W_O-_WR:/[6M_[S?]\F@"[15'
M^U+?_:_[YIXU2 ]V_*@#B_ __)2OB)_U\V?_ *3+7?UP'@;_ )*1\0SZW-G_
M .DRUW] !1110 4444 %%%% !1110!\_?M=KXAN/"_@N+PWX/UGQ?=VOB[1]
M8N(-'6'=%;V=Y%<RDF61!N98]JC/)/. "15^/G@7Q'J'Q0^#'Q0\.:3>:P/"
M-W?0ZGHL/EI<O97UNB/(H<@%XFBC.P')&17T5D4M"E8'J?.G[,_PSU[1?'WQ
M@^)7B726T+4O'6KV\EIIDQ0SP6-K#Y,!F*$@.^68J"<9'?('T7110W?4#C]8
M_P"2H>&O^O"^_P#0H*\^M[=3GCO7H.L?\E0\-?\ 7A??^A05PEO]X_6MZ.[,
MZG0=]E7TI?LJ^E6**Z3 B^RK@<4?9E]*GHI("#[,OI1]F7TJ>BF! MJO]VE^
MRKZ5.M.I7+(!;+GI2_9QZ5-14@0?95_NT?9Q_=J>B@"'[*OI0+5?2K"TM.X%
M?[,OI1]F7TJQ11<"#[.OI1]G7TJ>BD!!]G7TI1;KGI4U"]: (OLXI\=NN>E2
M4Y?O4 8FB6Z_VUKW'_+:/_T6M:S6Z^E9^B_\AK7O^NT?_HM:UVI1V*EN5_('
MI1Y ]*GHIDD'V=?2C[.OI4]%!9!]G7TIPMU]*EIRTF2R#[./2C[.OI5BBD(@
M^SKZ4?9U]*GHH+(/LZ^E'V=?2IZ* (%MUYXI?LZ^E344"L1+;KCI^E+]G7T_
M2I5I:!D/V=?2C[.OI^E344 0_9U]*=]G'^14E/H A\@>E4O$4"_\(YJG'_+K
M)_Z":TZH^(O^1=U3_KUD_P#032>P+<728%_L:PX_Y=X__014_P!G'I2:3_R!
MK#_KWC_]!%3TH[#>Y#Y ]*5;=?2I:5:H1'Y(H\D5-10!#Y(H^SCTJ:BH'8A^
MSCTH\D5-13N%B/[.OI^E'V=?2IJ*0B+[./2C[./2I:*"B+[./2C[./2I:* (
MQ /2E$"^E/IRT 1?9QZ4?9QZ5-10!%Y"^E:>DLL,@-4:<K%>E 'Y=^'?V/\
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MAENO_!QI]'_"K?\ @H5_T,MU_P"#C3Z_2W^T)/[QI5U"3GYJ/[0E_P ^X_\
M@/\ P0Y?-GYJ?\*M_P""A/\ T,MU_P"#?3Z9_P *O_X*%?\ 0R77_@XT_P#Q
MK]+_ .T)/[QI/[0D_O5/]H/_ )]Q^[_@E<OFS\U/^%6_\%"O^ADNO_!OI_\
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MY7-R3[/[BKHW=IHVFL+_ (7-\+O^BC>$_P#P<VO_ ,<H_P"%S?"[_HHWA/\
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MZOA=_P!%$\*_^#JU_P#CE3RS_E?W#NC?VFC::PO^%T?"[_HHWA3_ ,'5K_\
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M/K1YQ]:/KN)_F?X![-=CXAN/^"-_PB@M9I1XQ\:$QHS<W%IV&?\ GWJIX?\
M^"/OPCUC0["^D\7^,%>Y@25@EQ:8!(SQ_H_2ON6_F;^S+SG_ )8O_P"@FLOP
M+,Q\#Z"<_P#+E%_Z"*?U_$[<S_ ?LX]CXY_X<T_"#_H<_&?_ ($6G_R/1_PY
MI^$'_0Y^,_\ P(M/_D>OM[SCZTJS-GK2^NXG^9_@'LUV/SK^.G_!*GX8_"_X
M,^-_&&G>)_%MU?Z%H]UJ-O%=7%J87DCC9U5PL )4D<X(->P_\$F4#?L>Q_\
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MVL0]FS-^U+ZTY+I=W6M#_A8?PW_Y_;7_ ,!I?_B:<OQ$^&^>+ZUS_P!>\O\
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MV_\  >7_ .)HYT+E8GGBCSQ3O^%G?#O_ *"5O_WXE_\ B:/^%G?#O_H)6_\
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M3_A:WP^_Z"EO_P" \O\ \31_PM;X??\ 04M__ >7_P")HYD&I;\X4><*J?\
M"UOA]_T%+?\ \!Y?_B:/^%K?#[_H*6__ (#R_P#Q-',@U+7G"I/.%4?^%K?#
M_P#Z"MO_ . \O_Q-+_PM7X??]!6W_P# >7_XFES(-2[YWO1YWO5'_A:WP^_Z
M"MO_ -^)?_B:/^%K?#[_ *"MO_WXE_\ B:.9!J7O.]Z/.]ZH_P#"UOA]_P!!
M6W_[\2__ !-'_"UOA]_T%;?_ +\2_P#Q-/F0:E[SO>E68<U1_P"%J_#[_H*V
M_P#X#R__ !-'_"V/A^/^8M;_ /@/+_\ $TN9!J7_ #!ZTOG"L_\ X6O\/_\
MH*V__?B7_P")H_X6O\/_ /H*V_\ WXE_^)HY@U+E_(/[,O/^N+_^@FLKP'*/
M^$'T'_KRB_\ 013[SXJ>!9M/N4CU2%BT3*%$$O)(/'W:R_ OQ*\&:;X)T*TO
MM1BANX;*&.:-X),JX0!@?E]<TKH+'5><*591NK/_ .%K_#__ *"UO_X#R_\
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MK#_X6[X$_P"@S#_WXE_^)H_X6[X$_P"@S#_WXE_^)H+-S?3E?BL+_A;W@/\
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M&"BD?2A8448"*!["I** (_*']U?RH\H?W5_*I** (_*']U?RH\H?W5_*I**
M(_*']U?RH\H?W5_*I** (_*']U?RH\H?W5_*I** (_*']U?RH\H?W5_*I**
M(_*']U?RH\H?W5_*I** (_*']U?RH\H?W5_*I** (_*']U?RH\H?W5_*I**
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-C:IB+;LG<N!CG</6IY6G82DFKG<T444%!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>form10-k_017.jpg
<TEXT>
begin 644 form10-k_017.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M(/\ T/-C_P""1?\ XY7H-% 'GW_"*_$'_H>;'_P2+_\ '*/^$5^(/_0\V/\
MX)%_^.5Z#10!Y]_PBOQ!_P"AYL?_  2+_P#'*/\ A%?B#_T/-C_X)%_^.5Z#
M10!Y]_PBOQ!_Z'FQ_P#!(O\ \<H_X17X@_\ 0\V/_@D7_P".5Z#10!Y__P (
MO\0O^AYL?_!(O_QRLSQ)8^/_  [X=U353XRLKC[#:RW/E_V.J[]B%L9\SC.*
M]3KF/B=_R3?Q5_V"[K_T4U '-Z7HWC_5-+L[P>-+*+[1"DNS^QE.W<H.,^9[
MU:_X17X@_P#0\V/_ ()%_P#CE=5X3_Y%;1_^O*'_ - %:] 'GW_"*_$'_H>;
M'_P2+_\ '*/^$5^(/_0\V/\ X)%_^.5Z#10!Y]_PBOQ!_P"AYL?_  2+_P#'
M*/\ A%?B#_T/-C_X)%_^.5Z#10!Y]_PBOQ!_Z'FQ_P#!(O\ \<H_X17X@_\
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M+_\ '*/^$5^(/_0\V/\ X)%_^.5Z#10!Y]_PBOQ!_P"AYL?_  2+_P#'*/\
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M">+_ ..U%#XB\5GS/.\1HOSD)Y>DQME>Q.9!@^W/UIVP>E'EB@!W_"2>)?\
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M))XE_P"AF;_P31?_ !VC_A)/$O\ T,S?^":+_P".TW8/2C8/2@!W_"2>)?\
MH9F_\$T7_P =H_X23Q+_ -#,W_@FB_\ CM-V#THV#TH =_PDGB7_ *&9O_!-
M%_\ ':0^)/$H_P"9F;_P3Q?_ !VDV#TIK1B@"MJ'B;Q;#H^K7EMXEC>33[*6
M\\N;2(U$@09VY$AQGZ5[%I\S7&GVTSX#R1*[8Z9(!->.7BX\->+O^P)=?^@B
MO8](_P"079_]<4_]!%!++E%%% @HHHH **** "BBB@ HHHH **** .*^*O\
MR!=&_P"PYIO_ *51UV:UQGQ5_P"0+HW_ &'--_\ 2J.NS6@!U%%% !1110 4
M444 %%%% !1110 4444 -_AK\O\ _@H5_P I%OV:/^OK1_\ T[FOU 'W37Y<
M_P#!1#4+'1_^"@?[/%_J5W!86%I)I4]Q=74BQQ0Q+JK,[N[$!5 !))X !K2B
MG*=D)GZC[:.*\XF_:,^%%O\ ZWXF^#X_]_7[4?\ M2H?^&F?A!_T57P3_P"%
M%:?_ !RHY9=AGIU%>9?\-,?!_P#Z*IX*_P#"BM/_ (Y39/VG/@_"I>3XJ^"4
M3^\WB*S _P#1E'++L!Z?169I&K67B#3;>_TV\M[^PN$$D%U:RK+%*AZ,KJ2&
M!]0:TZC5.S ****H#@H_^2Y3_P#8NQ_^E+5WM<%'_P ERG_[%V/_ -*6KO:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X
MKX<_\A#QM_V'Y?\ TG@KM:XKX<_\A#QM_P!A^7_TG@KM: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KEOB=_R3?Q5_V"KK_P!%
M-74URWQ._P"2;^*O^P5=?^BFH T?"?\ R*ND?]>4/_HM:V*Q_"?_ "*ND?\
M7E#_ .BUK8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N&^*7_ !Z^&O\ L8+#_P!&BNYKAOBE_P >OAK_ +&"P_\ 1HH&CN:*
M**!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C5Y
ME\1?^1GMO^O5?_0VKTUJ\R^(O_(SVW_7JO\ Z&U T94?W:?3(_NT^@H****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:U.IK4 5+S_D
M6?%O_8$NO_017L.D_P#(+L_^N*?^@BO'[[_D6_%W_8$NO_017L&D_P#(+L_^
MN*?^@B@EERBBB@04444 %%%% !1110 4444 %%%% '%?%7_D"Z-_V'--_P#2
MJ.NS6N,^*O\ R!=&_P"PYIO_ *51UV:T .HHHH **** "BBB@ HHHH ****
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M(>-O^P_+_P"D\%=K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<O\ %#_DF_BG_L%W7_HIJZBN7^*'_)-_%/\ V"[K_P!%-0-;
MFAX3_P"15TC_ *\H?_1:UL5C^$_^15TC_KRA_P#1:UL4""BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KAOBE_P >OAK_ +&"P_\
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M0?BOX+TSQ7X7OEU+1=1C\R&9001V*L#RK @@@]"*VY(2O44AD5%%% !1110
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M?_GO)_WZ;_"C_A/M'_Y[R?\ ?IO\*X+[,/2C[,/2E[.(^9G>CQ[HY_Y;2?\
M?IO\*KWVH^'O%%E)8W\$.HVLF-]M=VWF1M@Y&58$'FN+6W7TK3TB!1,M#IJ.
MJ%S,^!/@BNDZ'_P5S^(,&GVD.G6"V%Q%#!:P".-6^S6Q;"J,#)#'IR3[U^E,
MWC+2[=MK3/GVB;_"OS/^$L8;_@KI\0!Z6]V?_)6&OOS4K=?.-=^,IQ4X><4R
M(R>IV'_">:/_ ,]Y/^_3?X4#QYI#?\MI/^_3?X5PGV4>E*MN/2N#V<2^9EV/
MQ)IG_"VIKSS6\K^PTAW>6W7SV..GH:ZX^.M)'_+:3_OTW^%>7);K_P )K*<?
M\P]?_1AK9:W'I25.)3DSN/\ A.])_P">LG_?IO\ "D_X3S2?^>LG_?IO\*X;
M[./2C[./2G[.(N9G<_\ ">:3_P ]9/\ OTW^%'_"<Z3_ ,]I/^_35PWV=?2E
M^RKZ4>SB',SN/^$YTG_GM)_WZ:E_X3K2?^>TG_?IO\*X7[*OI2K;"CV<1\S.
MY_X3K2?^>TG_ 'Z;_"C_ (3K2?\ GM)_WZ;_  KB/LP]*/LPI>SB+F9VW_"<
M:5_SVD_[]-1_PG&E?\]I/^_35Q/V9?3]*7R%]/TH]G$?,SM?^$XTK_GM)_WZ
M:C_A.-*_Y[2?]^FKBO(7T_2CR%]/TH]G$.9G:_\ "<:5_P ]I/\ OTU+_P )
MQI7_ #UD_P"_35Q'V=<]*=]G'I2Y(AS,[;_A-M*_YZR?]^FI?^$VTO\ YZR?
M]^FKB%MUSTIWV=?2CDB',SM?^$VTO_GK)_WZ:C_A-M+_ .>LG_?IJXK[.OI1
M]G7THY(AS,[7_A-M+_YZR?\ ?IJ/^$VTO_GK)_WZ:N*^SKZ4JVX]*.2(<S.S
M_P"$RTK_ )ZR?]^VIZ^,-+;I+)_WZ;_"N*\@>E21P 'I1R(.9D_@?Q)86M]X
MM9I' EUF21?W9Y'DPC^8-=3_ ,)GI8_Y:2?]^S7FWAF!?M&O<?\ ,1?_ - 2
MM;[./2DHQ&Y,[+_A,]+_ .>LG_?MJ/\ A,]+_P">LG_?MJXW[./2D^SKZ4^2
M(<S.S_X3#2_^>LG_ '[:C_A,-+_YZR?]^VKC_LX]*/LX]*.1"YF=C_PF.E_\
M]I/^_;4?\)CI?_/:3_OVU<=Y ]*7[./2CDB.[.P_X3'2_P#GM)_W[:C_ (3'
M2_\ GM)_W[:N/^SCTH^SKZ4N5!=G8_\ "9:7_P ])/\ OV:3_A,=,_OR?]^S
M7(+;KZ4&W7TI<J#F9V'_  F&F?WY/^^#2_\ "8:9_?D_[]FN/^SKZ4?9QZ4<
MJ'=G8?\ "8Z;_P ])/\ OV:/^$QTW_GI)_W[-<?]G'I1]G'I1RH+G8?\)CIO
M_/23_OV:/^$QTW_GI)_W[-<?]G'I3O)&>E'*@N=?_P )=IO]Z3_OV:/^$NTW
M^])_W[-<C]G'I1]G'I1RH+LZ[_A,--_OR?\ ?LTO_"7:=_ST?_OV:Y#[./2C
M[./2CE07.O\ ^$NT[_GH_P#W[-<_\0/$5A>> _$<*.Y:33KA -AZF-@*H^2*
MS?%D(_X1/6?^O.7_ - -'*AIZG8>&_$FGP^&]*0R-E;2('Y#_<%:'_"5Z=_S
MT?\ [X-<9H\(_L6P_P"O>/\ ]!%3^2/2A10KLZS_ (2S3?\ GJW_ 'P:/^$K
MT[^^_P#W[-<GY(H\D4^5!=G6?\)9IW_/1O\ OV:/^$MT[_GH_P#W[-<GY(H6
M$8%3RH+G6?\ "6:=_P ]&_[]FC_A+-/_ .>C_P#?LURGDBD\D4^5!<ZS_A+-
M/_YZ/_W[-'_"6:?_ ,]'_P"_9KD_)%*L(S3Y4!UG_"5:?_ST?_O@T?\ "5:?
M_P ]'_[X-<KY H$*^E+E11U7_"5:?_ST?_O@T?\ "5:?_P ]'_[X-<KY(]*7
MR1BERHFYU/\ PE6G_P#/1_\ O@T?\)5I_P#??_OV:Y7R12K"*?*AW.I_X2JP
M_OO_ -\&C_A*K#^^_P#WP:YCR12>2*?*AG5?\)18?WW_ .^#2?\ "56']Z3_
M +]FN8\D4GDCTJ>5 =3_ ,)18?WI/^^#1_PE%A_>D_[X-<OY0]*/*'I1RH#J
M?^$HL/[[_P#?!KDOB-K5G=6OA[:[';KEDY^0]!)FI5B'I6'XTA'V?1>/^8K:
M_P#H=#BK >B-XDL5ZR/_ -\&C_A)[#_GHW_?!KG)(1NJ/R1Z4<J Z?\ X2>P
M_P">C?\ ?!H_X2>P_P">C?\ ?!KF/)'I1Y(]*7*!U'_"2V'_ #T?_O@TG_"2
M6/\ ??\ [X-<SY(H\H>E/E0'3?\ "26/]]_^^#2?\)-8_P!]_P#O@US7E#TI
MWDCTHY4!TG_"36']]_\ O@T?\)-8?WW_ .^#7->2/2CR1Z4K(#I?^$FL/[[_
M /?!H_X2:P_OO_WP:YKR1Z4>2/2GRH#I?^$FL/[[_P#?!I5\26+?QO\ ]\&N
M9\D>E.2$<TN4#I/^$CL?[[?]\&C_ (2.Q_OM_P!\&N=\GVH\GVI6 Z+_ (2.
MQ_OM_P!\&C_A(['^^W_?!KG?)]J/)]J?*@.B_P"$CL?[[?\ ?!H_X22Q_P">
MC?\ ?!KG?)]J0Q#N*.5 =)_PD5G_ 'V_[X-'_"16?]]O^^#7/^2*/*'I2L@.
MB7Q!9MT=O^^#7 >/)H[SQ% \9RHMU&2,?Q,?ZUOQQC=7.>*%_P")O'_UQ7^9
MI-:#6Y1C^[3Z:M.I%%'Q!XFT'P7I+:KXDUK3] TM76-KW4[I+>$,WW5+N0,G
ML,US<?[1'P;VC/Q7\$C_ +F"T_\ CE1?'#X*:%^T-\.YO!OB*\O[#39;B*Y,
MVFNBS!HR2 "Z,,<^E?.J?\$D_A"R@GQ7XR_\";3_ .1Z]7"TL'.G>M-QEV2O
MH9R<[^ZCZ1_X:,^#7_15_!/_ (/[3_XY35_:"^$5U/%!;?%'P;<3RL$CCBUZ
MU9G8G   DY)-?.?_  Z1^$'_ $-?C+_P*M/_ )'J?2_^"5?PHT#6+'4K?Q/X
MOEFLYX[A$DN;7:S(P8 XMP<9%=#H9=TF_N)O/LCZ[FB,;$5'4]U-YCDU"OWJ
M\'J;%B&2*UBDN)V$<,*F1W/15 R3^5?F#^VU\+;_ ,7?"O2_VE[:^D_MB\US
MS(X5<[;72BP33R%/0_NTD/3YKELYXK[D_:0\#_$#XG?#^X\*>"-1T32(-41H
M-4N]6:?>UN<;HHQ$.-XW*S9! )QR<A_C;X"Z)XL^">J^%X? '@FQUS4-/>P/
ME1B."V+(4$L<ZV_F;DX8?*#D8R.M:1:2\R9)LZ_X _%BV^/7[/>A>-X?+%QJ
M&F,+R&-MWE7**4F3\'4_ABOSQ_X)\QI_PS3^UN3U.DD'Z?9KW_&OHW]D/]FG
MXP?LL^&?$GAD^(O"?B+P_JBRW$%M))<Q/:WC1A X;RSE&VJ&7';(/4'G?@)^
MQ+\2/@C\,_B_X3&N^%]2_P"$^TW[(ETLEPGV.3;*FXKY9W#;.QQD<JOJ<:0E
M&+OZ$5(N4;&E_P $EU#?LIWG_8Q7?_HN&M#_ (* ?&KQY\#8_A[JNAP:E#X%
MDU%CXCO]'*I<[05\N 2,K",.#(<XY*@;EKKOV*?@'XM_9A^'>J>#O$.I:+J]
ME)?-?VMWIC2B0,ZJKHZNH&/D!!![D8[UUOQ6\">-_%/CK0-9\-ZKHLN@VVGW
M-AJ_ACQ#'+)9ZJDLD1^8+D(RJC8<JQ&<8()K*-N8M['COA/XJ7WCS]F7XZ^-
MO"OQ7U#Q#:Z582ZGH$Y$<.I:28;1I/L]RFP G>I^8@[UYSG->*M^T%\4[K_@
MG+:_%+_A/M8@\7VOBI[$WT?E#SK=B%\MU*8(&<@C!SWKZ,^"/[%=E\.? OQD
MT6]O[2Q/Q'2YM38Z*'-II5K(DB)%$9.7*B0G<0HX   %>+M_P3Y^,<G[/,GP
M@'Q'\)P^&(M7_M:*--/G,MPYZB24_<52 P"J223EL"JNFVQ)-(I?M]:]J7BS
M_@G=\$==UF[>_P!8U)]-N[RZD W2RO8R,[G  R22>*A^*WCSXJ_LB_!?X#^/
M]+^)=_K^@:E;6=IJ'AF]M+?[,L8MUD5(0L88+Y:LI+,6W8;(Z5[1\7OV/_%7
MQB_93^&OPEN_$&C:1J/A66VCGU&%99X9888&A5E4JIWD$$J< <\TNO?L@^,_
MB]I/PB\(_$+7M!C\#^ 4B:6VT59GN-7EB4)&6,BJ(4* !@"QY;!Y!5J4=?45
MG<XC_@I%\;/'GPE\3?">^\$>+=3\/VOB17-W91F-XB%:$J0&4X.)2#@\\5W'
M[2W[1FMV/[7'PZ^"NCZG?^'M&O8!J>N:GI%H]S?3)ME=;>)41V4$0_,RJ3AP
M>-IKY\_X*D?$;PS\1/$'PDF\*ZM:ZM::3JE_I5TUH25@N8GM2\)X^\H9?S%?
M4'[5G[(^L?%KXL>$/BM\/?%=OX2^('AY8X5FOH6EMYXT9F3(7."-\@/!W!L'
M&!4*RM<K5WL><^'_ -ISXE?!_P (_'J\\7Z+X@U?0O"<C7/A+Q!XCT>XLC?1
MRW'DQ1.SQQ[]I>,YX)&?:K'PWTG]H;XI?"/X2_$SP9\1QJ.IZI=27?B/2]5\
MJ.Q:W:8A4B0(=HC52N <DG.1C%>YS?"OQ7\6OA7XH\*?&7Q#INJMKUK]C-OX
M9M6MK6T52&65?,+,\N]5?)P!C &.3Y-^S;^S?\<OV?=&7P5;?$WP[<> EO&G
MCD_LR674((R^YT@#,$C\SG.[>%+$@'O=X]-";.YX7^T1X7U?Q!_P5$\#>''\
M;Z_:QW$4,]E>V\D(FTP.DQ*6X,90#Y.K*Q.>2>,=S^TE^T1XK_9Y_:,TCPEX
MWU[QA8_#!M!AM;'Q-IHA^T7-W@>9>S'R=LSJV0T2@  @[#N /HOQX_9'\6>.
M/VGO"?QD\#>*])TK5-(MXH);;6[:29-R%P'4(1NRLA^4E>5'//'2_%;X&^/?
MB!-XXT_4-2\+>,_"OB*TCBM])\2PS1MIMTMLL1NH9(@2F7!8QH%]0ZDFB+6@
M69VG[+^J:CXF^"'A_5=7\7V?CR]N9+I_^$@L=HCNH_M,GE_* -C*FU63&592
M#R*^9/CI??\ "QO^"GGP7\$7[.VCZ#:-JD5NQRGVI8KBY#@>N;>'G_9KZ1_9
M=^!MO^S7\'=+\$Q:F^L7$,DES=7A!59)I#EMBDG:HX 'MD\DUX?^UUX/U'X;
M_M)?"C]H?3K9KG1]%F32/$31@DVEI(9(S<D ?=5+B7)[87MR%S>\VNI7V4F>
M_P#QXL[/6/'WP=T[4;:.\L+OQ#=P3V\RADD1M*O0RD'J"#7Y_?%KP+XK_P""
M8O[1%E\0O XEU'X::_,8'L7<["A.]K.4XP&4 M&_7 /HV?N7XT>&/B'\0?&?
MP]\0^!;_ ,*KH?AZ^_M97U*:=WOM\+PE%,:%47RY7PV6Y*G&%PWH/C[P9H_Q
M<^'NH^%/&.FP7FG:G;^5=6Z,6$;$?>C<@$,IY5L \ \4N;1)A:[;/G'X;>-+
M'Q9^R7H/BC3]7^('AZRUCQ+K-[#)X%TK[=?[)=2NW"2QB&;:F#R<=0.?7#/B
M!?\ HHG[37_A&'_Y75[[^S3\*9OV?_@KHW@&344U0:7<7C1W:*5WQRW4LJ9'
M]X+( >V0<<5Z7]N?UI2DY2<GU&EH>??LZ_8[SPK<:G<:GXRUR:UO9@FH?$32
MA8:A ICB+)&I@A_<\ [MO+;N>,#P7X#_  C@^-'[97B_]H>.U-IX/M"VG>')
MF78=2G6(6\MVHXS'@2J"?O%\]J]6_:L^'/Q'^-7PY?P?X"\1Z9X7@U E-4OK
MQI1,\/'[J,QJ<!OXCGD<=":\G^$?[+?QZT'QYX)N/'OQAM?$'@?P[=)<_P!A
M6#20!C'&PA7 C4,JOL.UCCY?7%"Y;:[BUN>R_M@:YIOA7]GWQ+X;L='74M<\
M7)+HVCZ)9Q+YE[>W.[+!>GR[FE9CT"D]:N?L:_L[K^S7\"=)\'W;QW.LSN]_
MJ[HVY&N90 RKG^%55$Z<[,]Z\+^,'[-/[1?Q$^-ESX]T'XJ:#X52WB>RTBSM
MTF86EJ6R1AHR/,; +.!D]!P *]4^ ?A/Q%^S3\.?&WB7XQ>/(_%.L7%RVI7F
MLO.YBCMHH5"1JK@;2")/E4 '<.]'V>5,%>]V>%?\$Y;Z^TGXH?M&?#S3I$@T
MG2]9FN=-B"XCMI&FFB&U>@&(X^!_=%>S_LK^!_CGX1M_%(^-'B>S\0F:XC.E
M"W97:-1N\QMRHN%;*84Y(P?6N"_X)^_"77-)T7XD_%'6H9M"U/XBW\MWI]K<
M*?.MK4O*\;N#W+2D@>B@]\#M/V3?@7\1/@;8>*8?'OQ%E\='5+I)K1'>606V
M V]M\IW OE?E'RC9GG)IRLVPC>RN>[OUIM*QR:2H*"BBB@ HHHH **** "FM
M3J:U %6^_P"1;\7?]@2Z_P#017L&D_\ (+L_^N*?^@BO'[[_ )%OQ=_V!+K_
M -!%>P:3_P @NS_ZXI_Z"*"67****!!1110 4444 %%%% !1110 4444 <A\
M2/\ D%:1_P!AO3O_ $ICK!\=?\C*W_7)?ZUO?$C_ )!6D?\ 8;T[_P!*8ZP?
M'7_(RM_UR7^M:T?B,ZFQDKVI]-6G5UF JTM(M+2Z@%%%%, I],I])E(****D
M84444 *M.IJTZ@ HHHH *T])_P!<M9E7]-DVS#/K2EL!\ ?"&,M_P5V^(6.O
MV:[_ /2:"OO_ %)"LQR*_*C]L"W^+W[,/[4OBSXQ>'X'\.Z=KEZ;+3-<9+:Y
M2</;IO01OOP<1MR5'3@U^H/@_6+KQ1\/?"VM7Q4WNI:5:WDY1=JF22%7; [#
M)->QF%+W*56,DXN*6F]UO<B+W19I5H:A:\@LR5_Y'63_ +!Z_P#HPULM6,O_
M ".LG_8/7_T8:VFI1*D-HHHIDA11104@I5[TE*M#!CJ***DD****"PHHHH *
M*** !>M.IJ]:=0 4444 %.6FTY: %IR4VG)0!C^&?^/C7O\ L(O_ .@)6NU9
M'AG_ (^->_["+_\ H"5KM41&Q****L0^BBB@ HHHJ6-!1112&*M+2+2T$L**
M**"@HHHH **** 'T444 %%%% !6=XL_Y%/6?^O27_P! -:-9WBS_ )%/6?\
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M1K*N=K[3P2,G&:V?+62,21.LD9Z,A!!_$5"R[:/0"9ICM"CA1P *B9RU-HH
M**** "BBB@ HHHH **** "FM3J:U %6^_P"1;\7?]@2Z_P#017L&D_\ (+L_
M^N*?^@BO'[[_ )%OQ=_V!+K_ -!%>P:3_P @NS_ZXI_Z"*"67****!!1110
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MHHI#%6EI%I:"6%%%%!04444 %%%% #Z*** "BBB@ K.\6?\ (IZS_P!>DO\
MZ :T:SO%G_(IZS_UZ2_^@&D]AK<N:/\ \@6P_P"O>/\ ]!%6*KZ/_P @6P_Z
M]X__ $$58I(044450!2+]T4M(OW14L!5ZT4+UHIH H7K10O6F ZBBBDRF%+_
M  BDI?X14DB4JTE*M- .HHHJBPHHHJ "BBB@!5K#\9_\>^B_]A6V_P#0ZW%K
M#\9_\>^B_P#85MO_ $.D]@.A;J:93VZFF4P"BBB@ HHHH *=3:=0 4444D 4
M444P"G+3:<M# 6BBBI ****H HHHH8#Z***D!T?WJYGQ5_R%HO\ KBO\S731
M_>KF?%7_ "%HO^N*_P S2>PUN45IU-6G5)04444 %%%% !2I]ZDI5^]0!\_?
M\%$M%L=0_8X\<7=Q;Q2W6GFSN+29E!>"0W<*%D/525=EX[,1WKX>^+'PKT/P
MS_P3O^$OQ'L6U!?&4^I%#J;W\S,D9DG(C12VU%!4$!0.03U))_2OXX_!O3OV
M@OAS=^"-:UK5='T6]ECDN_[(:%9)UC<.J,TD;X7>JMP ?E'.,@^=>(/V%?!?
MBCX'^&OA1J'B_P 62>$] NY+RT19[43%F+$*[_9^54N^!C^+O@8UC*RM>QG*
M+YKV/CG]L308OA/J7[-WCO0[_41XOUNUCO\ 5=:FO))+B]F4VY#N2<='9<
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M:[JKI)=3LS%RH**JHNXD[54#/T%>A2-N-92=Y7'%65AM%%%(H**** "BBB@
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M !K7HHNP,?\ X1FP_P">+?\ ?9_QI?\ A%]/_P">)_[[-:]%%V!D?\(S8?\
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MH?!'P/\ "GP7X>U*3Q"-0TG1;*PN/)TP,GFQ0)&^T[^1E3@UV/\ P^ ^ ?\
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MQ_"?_(JZ1_UY0_\ HM:V*!!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5PWQ2_X]?#7_ &,%A_Z-%=S7#?%+_CU\-?\ 8P6'_HT4
M#1W-%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *\Q^(O_(SVW_7JO_H;5Z=7F/Q%_P"1GMO^O5?_ $-J"H[F5']VGTR/[M/H
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ
M *M]_P BWXN_[ EU_P"@BO8-)_Y!=G_UQ3_T$5X_??\ (M^+O^P)=?\ H(KV
M#2?^079_]<4_]!%!++E%%% @HHHH **** "BBB@ HHHH **** .*^*O_ "!=
M&_[#FF_^E4==FM<9\5?^0+HW_8<TW_TJCKLUH =1110 4444 %%%% !1110
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M^Q@L/_1HH&CN:***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5YC\1?^1GMO\ KU7_ -#:O3J\Q^(O_(SVW_7JO_H;4%1W,J/[
MM/ID?W:?0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *:U.IK4 5;[_D6_%W_ &!+K_T$5[!I/_(+L_\ KBG_ *"*\?O/^1:\6_\
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M^-&H%VBJ7]L6/_/[;_\ ?U?\:7^V+'M>VY_[:K_C1J!RWPY_Y"'C;_L/R_\
MI/!7:UP?@&^M8;[Q@6N80)-<D<9D7D>1 ,]?8UV']KV/_/[;_P#?U?\ &@"Y
M15+^V;'_ )_;?_OZO^-']LV/_/[;_P#?U?\ &BS NT52_MBQ_P"?VW_[^K_C
M1_;%C_S^V_\ W]7_ !HU NT52_MBQ_Y_;?\ [^K_ (TO]KV7_/Y;_P#?U?\
M&C4"Y15/^U[+_G\M_P#OZO\ C1_:]E_S^6__ ']7_&C4"Y15+^V+'_G]M_\
MOZO^-']L6/\ S^V__?U?\:-0+M%4_P"U[+_G\M_^_J_XT?VO9?\ /Y;_ /?U
M?\:-0+E%4_[7LO\ G\M_^_J_XT?VO9?\_EO_ -_5_P : +E%4_[7LO\ G\M_
M^_J_XT?VO9?\_EO_ -_5_P : +E%4_[7LO\ G\M_^_J_XT?VO9?\_EO_ -_5
M_P : +E%4_[7LO\ G\M_^_J_XT?VO9?\_EO_ -_5_P : +E<O\4/^2;^*O\
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MY^X/^_B_XT 6Z*J_VA:_\_4/_?P?XTG]I6G_ #]0_P#?P?XT 6Z*J_VA:_\
M/U#_ -_!_C1_:%K_ ,_4/_?P?XT 6JXCXJ?\>OAG_L8;#_T:*ZW^T+7_ )^H
M?^_@_P :XWXEW5O-:^'-MQ%\NO6+'#CH): .\HJK_:%KWN81_P!M!_C1_:%K
M_P _4/\ W\'^- %JBJO]H6O_ #]0_P#?P?XT?VA:_P#/U#_W\'^- %JBJO\
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M/_/A<_\ ?EO\*/[/U'_GPN?^_+?X4 +D49%)_9^H_P#/A<_]^6_PH_L_4?\
MGPN?^_+?X4 +D49%)_9^H_\ /A<_]^6_PH_L_4?^?"Y_[\M_A0 N136:G?V?
MJ/\ T#[G_ORW^%,;3]1_Z!]U_P!^6_PH K7I_P"*:\6_]@2Z_P#017L.D?\
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M10 4444 %9WBS_D4]9_Z])?_ $ UHUG>+/\ D4]9_P"O27_T TGL-;ES1_\
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M #]-_P!\BC_A%5_Y^F_[Y%+0#)\P4>8*U_\ A%5_Y^6_[Y%'_"*K_P _+?\
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MORH S]XHWBM'_A'%_P">[?E1_P (XO\ SW;\J ,U6'-+O%:/_".K_P _+?\
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M;_XT<D^P'Z1_C^E'X_I7YN?\/M/ 7_1.?$7_ (%6_P#C1_P^T\!?]$Y\1?\
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MR6EI;J2=D:C R3R3W)/4DU?,K6(L[W.D5MR@TZBBH+"BBB@ HHHH XKXJ_\
M(%T;_L.:;_Z51UV:UQGQ5_Y NC?]AS3?_2J.NS6@!U%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!P4?_ "7*?_L78_\ TI:N
M]K@H_P#DN4__ &+L?_I2U=[0 E<=K'PI\%^(M2GO]5\(Z'J=_-CS+J\TV":5
M\# RS*2> !SZ5V5%)-QV8'#?\*/^'/\ T(7AC_P3V_\ \11_PH_X<_\ 0A>&
M/_!/;_\ Q%=QD49%/FEW X?_ (4?\.?^A"\,?^">W_\ B*/^%'_#G_H0O#'_
M ()[?_XBNXR*,BCFEW X?_A1_P .?^A"\,?^">W_ /B*/^%'_#G_ *$+PQ_X
M)[?_ .(KN,BC(HYI=P.'_P"%'_#G_H0O#'_@GM__ (BC_A1_PY_Z$+PQ_P""
M>W_^(KN,BC(HYI=P.'_X4?\ #G_H0O#'_@GM_P#XBC_A1_PY_P"A"\,?^">W
M_P#B*[C(HR*.:7<#A_\ A1_PY_Z$+PQ_X)[?_P"(H_X4?\.?^A"\,?\ @GM_
M_B*[C(HR*.:7<#AO^%&_#G_H0?#'_@GM_P#XBO!?VZ?A7X+\._LC_$R^TSP?
MH.GWD.E9CN+73((I$/FH,AE4$'GM7UE]*^>?^"@O_)F?Q5_[!0_]'1U=.4E.
M.O45E8Y3_@ECS^Q#X!/_ $VU+_TON*^LZ^2_^"5__)CO@'_KMJ7_ *7W%?6E
M34?--L84444@"BBB@#BOAS_R$/&W_8?E_P#2>"NUKBOAS_R$/&W_ &'Y?_2>
M"NUH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M7^*'_)-_%/\ V"[K_P!%-745R_Q0_P"2;^*?^P7=?^BFH&MS0\)_\BKI'_7E
M#_Z+6MBL?PG_ ,BKI'_7E#_Z+6MB@04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<-\4O^/7PU_V,%A_Z-%=S7#?%+_CU\-?]C!8
M?^C10-'<T444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K@K#_ )+AJ_\ V +7_P!'S5WM<%8?\EPU?_L 6O\ Z/FH [VBBB@
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@K#_DN&K_ /8 M?\
MT?-7>UP5A_R7#5_^P!:_^CYJ .]HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N(^%_^L\8_]C#=?^@QUV]<1\+_ /6>,?\
ML8;K_P!!CH [>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^%'_  LN\_Z!L?\ W]/^%'LYBYXGH5%>>_\ "R[S_H&Q_P#?T_X4?\++O/\
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M^_ZX2?\ H)KF?#/_ !]:]_V$7_\ 0$KH8F$D,L+-M65&0D>A&*FGNBC\^?\
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M&4444#%6EI%I:"6%%%%!04444 %%%% #Z*** "BBB@ K.\6?\BGK/_7I+_Z
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M:EK,H**** "BBB@#D/B1_P @K2/^PWIW_I3'6#XZ_P"1E;_KDO\ 6M[XD?\
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M:]_V$7_] 2M=JR/#3?Z1KW_81?\ ] 2M8FHB-CD^]7C'[>D@_P"&,?B8,_\
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M_P!^S_A1Y=U_SZS_ /?H_P"%>MT4>V\BN4\D\NZ_Y]9_^_1_PI56Z_Y]9_\
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MOY\EQX@"P2G;J3@X0\?NXZUV6YS_ ,>TW_?L_P"%;_P]DWZAXSS_  Z[(/\
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MG_?!HQ/_ ,\)/^^#7=T4^9@<)B?_ )X2?]\&G*L_/[F3_ODUW-%+F X?;/\
M\\9/^^#1MG_YX2?]\&NXHI7 X?;-_P \9/\ O@T;9_\ GA)_WP:[BBGS </M
MG_YX2?\ ?!HVS_\ /"3_ +Y-=Q11S <5B;_GC)_WR:,3?\\9/^^37:T4K@<;
M&LV?]3)_WR:YJU,G_"TM13RWW?V1 <;3_P ]9*]7KA+%C_PNS5E[?V#:G_R/
M-1<"PZS9_P!3)_WR:;B;_GC)_P!\FNUHHN!Q6)O^>,G_ 'R:<JS?\\9/^^37
M9T47 XW;-_SQD_[Y-&V;_GC)_P!\FNRHHN!QNV;_ )XR?]\FEQ+_ ,\9/^^3
M78T4@./_ 'O_ #QD_P"^31ME_P">4G_?)KL**=P.0Q+_ ,\I/^^32?O?^>,G
M_?)KL**+@<?^]_YXR?\ ?)I5\W_GE)_WR:Z^BBX'(YE_YY2?]\FC,O\ SRD_
M[Y-==11<#DE$O/[J3_ODTNV7_GE)_P!\FNLHI <GME_YY2?]\FC;+_SRD_[Y
M-=913N!R>V7_ )Y2?]\FC;)_SR?_ +Y-=912 YB$2;O]6_\ WR:YGP&SL?$^
M$8XURY'3V2O3:XGX8MND\7^WB"Z'_CL= %UO,_YY/_WR:;MEW#]T_P#WR:ZN
MBG<#EOWG_/-_^^32?O/^>;?]\FNJHI <K^\_YYM_WR:/WG_/-O\ ODUU5% '
M*_O/^>;?]\FG+YF/]6__ 'R:ZBB@#F,2?\\V_P"^32CS/^>;_P#?)KIJ* .8
MQ)_SS;_ODT8D_P">;?\ ?)KIZ*!W.9_>?W&_[Y-"^9G_ %;?]\FNFHH$<W^\
M_P">;?\ ?)HQ)_SS;_ODUTE% '-@2?\ /-O^^32XE_N-^1KHZ* .<_>?W&_[
MY-'[S^XW_?)KHZ*!W.>7S,?<;\C2_O/[C?D:Z"B@1P'Q(W+\-/%I92!_9-SU
M'^P:['1?^0/8?]>\?_H(KG/B]_R2SQ9_V"[C_P!%M72:)_R!;#_KWC_]!% %
MVBBB@ HHHH **** "BBB@ HHHH **** .*^*O_(%T;_L.:;_ .E4==FM<9\5
M?^0+HW_8<TW_ -*HZ[-: '4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '!1_\ERG_P"Q=C_]*6KO:X*/_DN4_P#V+L?_ *4M
M7>T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!Q7PY_Y"'C;_L/R_\ I/!7:UQ7PY_Y"'C;_L/R_P#I/!7:T %%%% !1110
M WGK7YC?\%%O@_\ %O6OVM_AU\1OAQX'U#Q2OAW2K":*>&W,T"WEO?W$ZQR
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M/_D5]%_Z\H?_ $!:UZR_#<?D^'=+C/5+6)?R05IY%9C%HHHH **** "BBB@
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M+L?_ *4M7>T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_T$5SOQ@_Y);XM_[!5Q_P"BVKHM#_Y UA_U[Q_^@B@"_1110 4444 %%%%
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MRC\J=_9L?]T?E2]DNX_:/L>Q?;K;_GZA_P"_@_QH^W6W_/U#_P!_!_C7CO\
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M_GXC_P"^Q7E7V"/^Z/RI?[/C_NT>S7<7,SU7[=;_ //Q%_WV*/MUO_S\1?\
M?8KRK["F?N_I3OL*?W1^5'LUW#F/4_MUO_S\1?\ ?8H^W6__ #\1?]]BO+/L
M*?W1^5'V%/[H_*CV:[CYCU/[=;_\_$7_ 'V*/MUO_P _$?\ WV*\L^PI_='Y
M4JV*?W1^5+V:[AS'J/VRW_Y[Q?\ ?8I?M5O_ ,]X_P#OH5Y?]A3^Z/RJ2.R3
M/W1^5'LUW#F9N?#^2&'4/&),T8WZ[(P^8?\ /" ?TKL/MMO_ ,]XO^^Q7C7A
MFR3[1K_'_,1?_P! 2M9K%/[H_*DH)]1N1Z?]MM_^>\7_ 'V*/MMO_P ]XO\
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M5/M$?_/5/^^A1]HA_P">J?\ ?0KCFMQGI3?LP]*+ =G]HA_YZI_WT*/M$?\
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M=0 4444 %%%% !1110 ZE6DI5H R$_Y'27_L'K_Z,-;35C+_ ,CK)_V#U_\
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M4$#Z*** "BBB@I!1110,5:6D6EH)9S_Q(_Y)KXL_[!-S_P"@&NPT3_D#V/\
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MQT 8WAG_ (^->_["+_\ H"5KM61X9_X^->_["+_^@)6NU1$;$HHHJQ#Z***
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M?\/KH_\ HC"_^%+_ /<=3_9F)_E_%?YCYUW/T;^RM_=H^RM_=K\Y?^'UT?\
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MRT_Y*=J/_8)@_P#1LE '1OUIM.?K3: "E6DI5H 6BBB@ IRTVG+2Z@+1113
M**** "E6DI5H =1110 @[TM(.]+4H HHHJ@"BBBH DAKFO O_,R_]ANX_DE=
M+#7->!?^9E_[#=Q_)* .D:FG[PIS4T_>%4P%HHHJ0"BBB@ IRTVG+0 M%%%
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M[ARHY#_A6]E_S^77YK_A2_\ "M[+_G\NOS7_  KKJ*/:2[ARHY'_ (5O9?\
M/Y=?FO\ A1_PK>R_Y_+K\U_PKKJ*/:2[ARHY'_A7%G_S^77YK_A2K\.;,?\
M+W<_FO\ A76T4N>7<.5'E4?A&U_X6I-8_:9]G]BI-GY<Y\]E]/:NJ;X>V9_Y
M>[G\U_PK.C_Y+A./^I=C_P#2EJ[K;1SR[ARHY7_A7=G_ ,_=U^:_X4?\*[L_
M^?NZ_-?\*ZRBCGEW#E1R?_"N[3_G\N?_ !W_  I/^%=VG_/W<_\ CO\ A76T
M4<\NX<J.2_X5W:?\_=S_ .._X4H^'=F/^7NY_-?\*ZRBCGEW#E1R?_"O;/\
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M$-MO^>\WZ?X5T5%',P.<_P"$+MO^?B;]/\*7_A#;;_GO-^G^%=%11S,#G?\
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M6\WYC_"F_P#")VW_ #VF_3_"MVBB[ PO^$3MO^>TWZ?X4?\ ")VW_/:;]/\
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M*** "N"L/^2X:O\ ]@"U_P#1\U=[7!6'_)<-7_[ %K_Z/FH [VBBB@ HHHH
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M_P"PYIO_ *51UV:T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ."C_ .2Y3_\ 8NQ_^E+5WM<%'_R7*?\ [%V/_P!*6KO:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'7;UQ/PT4QR>+<_Q:_=-_P".QT =M1110 4444 %%%% !1110 4444 %%%%
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MMHVB@:(OMFH_\_\ =?\ ?UO\:5;S4?\ G_NO^_S?XU)M%*J]:"B/[9J'_/\
MW7_?YO\ &C[9J'_/_=?]_F_QJ;:*-M(@A^V:A_T$+G_OZW^-'VS4/^@A<_\
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MZW^-2;11M%,0W[5??\_US_W];_&C[5??\_US_P!_6_QJ7:*-HH B^U7W_/\
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M-.HH :+B[_Y^IO\ OX?\:P?'$ES):Z)NN)6QJ]JPRYZAZZ"L3QG_ ,>^B_\
M85MO_0Z'L!O27%WN_P"/J;_OLU']HO/^?J;_ +^'_&II/O&FT 1_:+S_ )^I
MO^_A_P :/M%Y_P _4W_?P_XU)10 P7%W_P _4W_?P_XTOGW?_/U-_P!_#_C3
MJ* &^?=_\_4W_?P_XT?:;O\ Y^9O^^S3J=0!']IN_P#GYF_[[-'VF[_Y^9O^
M^S4E%) 1_:;O_GYF_P"^S1]IN_\ GYF_[[-244P(_M-W_P _,W_?9IRSW1SF
MYF_[[-.I5[T -\ZZ_P"?F;_OL_XT^.:ZW#_29?\ OLTM%2!X+_P44D=OV(?B
M5N=V/E60Y))_X_[>ODG]CW_@I)\-_P!GW]G?POX#\0Z1XBN]6TMKLRRZ?!$T
M)$MU+,NTM*IZ2#/'7-?I=J6EZ;XBTFYTK6=/M=5TNZ79/97D2RPRKG.&1@01
MD#KZ5RB_L[_!SO\ "SP?_P""2V_^(KT</B*$*3I5H.6M]';I8S<7S<R9\O-_
MP6,^#W_0O^,O^_$'_P >I/\ A\;\'O\ H7O&7_?B#_X]7U'_ ,,[_!O_ *)9
MX/\ _!);?_$4C?L[_!O_ *)9X/\ _!);?_$4O:83_GW+[P]_N?+_ /P^,^#W
M_0O>,O\ OQ!_\>H_X?&?![_H7O&7_@/!_P#'J^HO^&=?@[_T2SPA_P""2V_^
M(H_X9S^#G_1+_!__ ()+;_XBI]IA/Y']X>_W/EW_ (?&?![_ *%[QE_X#P?_
M !ZLF'_@KI\(H_&%UJI\/>+O)ELH[8?Z/!NW*[M_SVZ?-7UTO[.OP</_ #2W
MP?\ ^"2V_P#B*Y^W_9[^$+>/KRU/PS\)F%=.BD"?V+;X#&1P3C9UXJE4P76F
M_O#W^Y\]_P##XWX._P#0O>,O^_$'_P >I/\ A\9\'O\ H7O&7_@/!_\ 'J^I
M#^SK\'/^B6^#_P#P26W_ ,12?\,Z_!S_ *)=X/\ _!);?_$4O:83^27WA[_<
M^7?^'QGP>_Z%[QE_WX@_^/4G_#X[X._]"]XR_P"_$'_QZOJ3_AG7X.?]$M\'
M_P#@DMO_ (BE7]G7X-G_ )I;X/\ _!);?_$4>TPO\DOO#W^Y\M_\/CO@[_T+
MWC+_ ,!X/_CU'_#X[X._]"]XR_\  >#_ ./5]1_\,Y_!O_HEG@__ ,$EM_\
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M&_\ HEW@_P#\$=M_\11_PS?\&_\ HEW@_P#\$=M_\14>TPG\C^\.67<^6_\
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MTZB@!OF3?\]I/^^C1YTW_/9_^^C3J*"D-\Z;_GM)_P!]&CSIO^>TG_?1IU%
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M6FT +N-.5CMZTRE6@!^XT;C3:* ';C2JQIE.6IZ@.W&C<:2BJ =N-)N-)10
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M1115B'T444 %%%%2QH****0Q5I:1:6@EA11104%%%% !1110 ^BBB@ HHHH
M*SO%G_(IZS_UZ2_^@&M&L[Q9_P BGK/_ %Z2_P#H!I/8:W+FC_\ (%L/^O>/
M_P!!%6*KZ/\ \@6P_P"O>/\ ]!%6*2$%%%%4 4B_=%+2+]T5+ 5>M%"]:*:
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M_"7D_P#BJ_4?^T1Z?I2_VD?04?6H_P#/N(^5]S\M?^&HOV\O^B8W'_A+R?\
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MM;_A![__ )^8/_'O\*5? ]\O_+Q#_P"/?X4<R[E69E>8*?&PS6G_ ,(3??\
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MW?\ SWA_7_"E'A*[_P">\/Z_X470&?N%)NK2_P"$3N_^>\/Z_P"%'_")W?\
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MZQ_F?\*/^$;N?^>L?YG_  J0*&X4;A5__A&[G_GK'^9_PH_X1NY_YZQ_F?\
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M6G_QFNUHH XK_A ]9_Z'K7/^_5I_\9H_X0/6?^AZUS_OU:?_ !FNUHH XO\
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M:[2B@#B_^$#UG_H>M<_[]6G_ ,9H_P"$#UG_ *'K7/\ OU:?_&:[2B@#B_\
MA ]9_P"AZUS_ +]6G_QFC_A ]9_Z'K7/^_5I_P#&:[2B@#B_^$#UG_H>M<_[
M]6G_ ,9H_P"$#UG_ *'K7/\ OU:?_&:[2B@#B_\ A ]9_P"AZUS_ +]6G_QF
MC_A ]9_Z'K7/^_5I_P#&:[2B@#B_^$#UG_H>M<_[]6G_ ,9H_P"$#UG_ *'K
M7/\ OU:?_&:[2B@#B_\ A ]9_P"AZUS_ +]6G_QFC_A ]9_Z'K7/^_5I_P#&
M:[2B@#B_^$#UG_H>M<_[]6G_ ,9H_P"$#UG_ *'K7/\ OU:?_&:[2B@#B_\
MA ]9_P"AZUS_ +]6G_QFC_A ]9_Z'K7/^_5I_P#&:[2B@#B_^$#UG_H>M<_[
M]6G_ ,9H_P"$#UG_ *'O7?\ OU:?_&:[2B@#B_\ A ]9_P"A[UW_ +]6G_QF
ME7P+K _YGK7#_P!LK3_XS79T4 >?6/PWO-.FNWMO&.N1-=S&XG.RU.^0J%+<
MP\<*HXXXJ[_P@>L_]#UKG_?JT_\ C-=I10!Q?_"!ZS_T/>N_]^K3_P",T?\
M"!ZS_P!#WKO_ 'ZM/_C-=I10!Q7_  @>L_\ 0]:Y_P!^K3_XS1_P@>L_]#UK
MG_?JT_\ C-=K10!Q7_"!ZU_T/>N_]^K3_P",T?\ "!:U_P!#WKG_ 'ZM/_C-
M=K10!Q7_  @6M?\ 0]ZY_P!^K3_XS1_P@6M?]#WKG_?JT_\ C-=K10!Q7_"!
M:U_T/>N?]^K3_P",T?\ "!:U_P!#WKG_ 'ZM/_C-=K10!Q7_  @6M?\ 0]ZY
M_P!^K3_XS1_P@6M?]#WKG_?JT_\ C-=K10!Q7_"!:U_T/>N?]^K3_P",T?\
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M:_Z'O7?^_5I_\9H_X0+6O^A[UW_OU:?_ !FNVHH XG_A M:_Z'O7?^_5I_\
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M .,UVU% '$_\(#K/_0^:]_W[M/\ XS1_P@.L_P#0^:]_W[M/_C-=M10!Q/\
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M/"D7G3'+OM4#<Q[DXR:<K:6)5^IHT444B@HHHH **** "BBB@ HHHH ****
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M>"_CAXW\=?MG:7I@D;3_ (7:AX0O-0T:S90)-0:.Y@3[;("NY5;>1&,_<PQ
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M^M_L5U)"CRV^?,\IRH+)NP,X.1GOBBLRS5HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBO OV@_P!L/P-^S/J&GP>.K7Q!:6NH
M BUU*STXSVLC 99 X;[P!!P1],X-))RV ]]HK \&^+-+\=>%](\1:+<+>:/J
MUI%>VEPO22*10RGVX(XKP[P#^W7\-?BA\5[KX>^$5UWQ!K]K/)#</:::WV:%
M8Y!&\K2,P C#'[W?MG(II,#Z0HHHH ***Y^Z\7:9;MK<,5P+Z^T>W6YO+"SQ
M+<1JRLR#8.<N$;:.^* .@HKQG]G/]JCP'^U'I.L:CX(N+Z6'29TM[I;^T,#*
MSJ67&2000#T/:O9J'H 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV#X%_8]LOA[^UGX]^-&EM8LNN:8(K/2]K1^3>.5-Q*S!2 ',8.5!/[Q^.>>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>form10-k_018.jpg
<TEXT>
begin 644 form10-k_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .>!G0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **JC4K(WXL5NHFN]I;R5;+ #J2.U/N[RWL8#/=3)%&"!N8]ST
M'N?:@">BJUG?VM_&SVLRR!#M8#@J?0@\BH9]:TVUNC;37D:2@@,#T7/3<>@S
M[T 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1-!M-/W!FB3YV'=B<G]36G0!!=WEO86S7%U*(XE(!8CIGBLW_A*]#_Z"$?\
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M"+_O@4<N)_FC]S_S#FPW\LOO7^1E_P#"5Z'_ -!"/_OEO\*/^$KT/_H(1_\
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MR* ,[_A)-'_Y_D_(_P"%4]1\=>&=)2-[[5HH5D)"EE8Y(^@K=^SP_P#/&/\
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M]O\ _$T?\+4\$?\ 0P6__?M__B:ZC[!9_P#/I!_W[%'V"S_Y](/^_8HYL/\
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MU/9/.C_OC\Z/.C_OC\Z?@>E&!Z5PFHSSH_[X_.CSH_[Z_G3\#TJ.4?<_WA0
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MYT>='_?'YT_ ]*,#TH 9YT?]\?G1YT?]\?G3\#THP/2@!GG1_P!\?G1YT?\
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M% %KSH_[X_.CSH_[X_.JM% %KSH_[X_.CSH_[X_.JM% %KSH_P"^/SH\Z/\
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M4 %%%% !1110 4444 %%%% !4;_ZV/\ &I*C?_6Q_C0!)1110 4444 %%%%
M!1110 4444 %%%% !1110 V3_5/_ +IKQKX#?Z[Q)_UUC_F]>RR?ZI_]TUXU
M\!O]=XD_ZZQ_S>O1P_\ NM;_ +=_,QG_ !(_,]GHHHKSC8*CE_@_WQ4E1R_P
M?[XH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C
MA_U0^I_G4E1P_P"J'U/\ZDH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH C/\ Q\+_ +I_F*DJ,_\ 'PO^Z?YBI* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** &3?ZE_H:>.@IDW^I?Z&GCH* &O]QO
MI52K;_<;Z54H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CO11WH LP_P"I7Z5)
M4</^I7Z5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %74O^/"3ZK_ #%6JJZE_P >$GU7^8JU0 4444 %%%% !1110 44
M44 %%%% !1110 4R;_4R?[I_E3Z9-_J9/]T_RI/9C6YR'P^_X];[_KHO\C79
M5QOP^_X];[_KHO\ (UV5>=E7^YP_KJST<U_WR?\ 71!1117I'FA4<7\?^\:D
MJ.+^/_>- $E%%% !1110 5R?A;_D-:I_O?\ LQKK*Y/PM_R&M4_WO_9C0!UE
M%%% !1110 4444 %%%% !1110 4444 %1O\ ZV/\:DJ-_P#6Q_C0!)1110 4
M444 %%%% !1110 4444 %%%% !1110 V3_5/_NFO&O@-_KO$G_76/^;U[+)_
MJG_W37C7P&_UWB3_ *ZQ_P WKT</_NM;_MW\S&?\2/S/9Z***\XV"HY?X/\
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M;UZ.'_W6M_V[^9C/^)'YGL]%%%><;!4<O\'^^*DJ.7^#_?% $E%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $</^J'U/\ .I*CA_U0
M^I_G4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $9_X^
M%_W3_,5)49_X^%_W3_,5)0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 R;_4O]#3QT%,F_P!2_P!#3QT% #7^XWTJI5M_N-]*J4 %%%%
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MOI,:R723^6S!0T<1< DX ./6K<4GFQ+($=-PSM=<,/J.U<+I'BE==\."VN7
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M H[T4=Z +,/^I7Z5)4</^I7Z5)0 4444 %%%% !1110 4444 %%%% !1110
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M2T,$<;X>\1?V EQ&]H\ID8'[VW&/PK:_X6"G_0,?_O[_ /6K7(&>@_*C:O\
M='Y5X]+ XFC!4X5K)?W4>O5QV&K3<YT;M_WF9'_"P4_Z!C_]_?\ ZU'_  L%
M/^@8_P#W]_\ K5KA5]!^5)M'H/RK7ZMC/^?W_DJ,_K&#_P"?/_DS*-AXXAO+
MZ&V>Q>(2-MW^9NP?IBNCCN8EW9?JQ/2N$U8 >+K# QPG_H1KJ&[?2G@:E63J
M0JRNXNU[6Z$XZG2BJ<Z4;*2O:]^IK?:H?[_Z&C[5#_?_ $-9(I:](\XU?M4/
M]_\ 0T?:H?[_ .AK*I: -3[5#_?_ $-<MX8E1-8U-F; )X_[Z-:O<5S^@_\
M(2O_ *_^S&@#M/M4/]_]#1]JA_O_ *&LJB@#5^U0_P!_]#1]JA_O_H:RZ* -
M7[3#_?\ T-'VF'^_^AK+HH U/M,/]_\ 0T?:8?[_ .AK+I30!I_:8?[_ .AH
M^TP_W_T-9=+VH T_M,/]_P#0T?:8?[_Z&LNB@#4^TP_W_P!#3&N(C(A#\#.>
M*SJ44 :?VF'^_P#H:/M,/]_]#6;2"@#3^TP_W_T-'VF'^_\ H:S:* -+[3#_
M '_T-'VF'^_^AK-I>U &C]IA_O\ Z&C[3#_?_0UFCK10!I?:8?[_ .AH^TP_
MW_T-9M% &E]IA_O_ *&C[3#_ '_TK.H% &C]IA_O_I1]IA_O_I6?24 7Y+F'
MRG^?^$]J\<^!,J1S>(]S8S+'_-Z]3?\ U;?[IKR7X(_ZWQ#_ -=(_P";5Z&'
M_P!UK?\ ;OYF,_XD?F>V?:8?[_Z4?:8?[_Z50%%>>;%_[3#_ '_TIDEQ$=N'
MZ,#TJB*6@#0^TP_W_P!*/M,/]_\ 2L^E% %_[3#_ '_TH^TP_P!_]#5"B@"_
M]IA_O_H:/M,/]_\ 0U1HH O?:8?[_P"E'VF'^_\ H:I"DH O?:8?[_Z&C[3#
M_?\ TJC0: +WVF'^_P#I1]IA_O\ Z52H- %W[3#_ '_T-'VF'^_^E4:44 7?
MM,/]_P#2C[3#_?\ TJE10!=^TP_W_P!*/M,/]_\ 2J5** +GVF'^_P#I1]IA
M_O\ Z53HH LQ3Q+'@OSD_P Z?]HB_OC\JIKTI: +?VB+^^/RH^T1?WQ^55**
M +?VB+^^/RH^T1?W_P!*J4M %K[3%_?'Y4?:(O[_ .E5#2CI0!:^T1?WQ^5'
MVB+^_P#I53O2F@"U]HB_OC\J/M$7]\?E52E% %K[1%_?_2C[1%_?_2JW:DH
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M<]Q>^>L3'#!=N.GX _C7I?AR6*7PWIQA=&46\:G8<@$*,CZYK2*JWWE!^HH
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MQ31Q2-P)"Q[>HX_6M/X72Q_V'=1!U\T3[BF?FQM'./2NY*@C! QZ8H"JIR%
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MHZTE*.M !WI:3O2T (:6D-+0 "DI124 <SJW_(W6'T3_ -"-=.W;Z5S&K?\
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M*** $_C'TIU-_C'TIU !1110 4444 !Z4#I0>E Z4 +0**!0 4&B@T *.E%
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M(CY+&HM3\,:=K.H+=ZBC3B.,1QQ;BJKR23QR<_TK"T;1-.A\=W3:?:K%;Z?
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MI-\+\<C!4]P1ZU<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** +,/^I7Z5)4</\ J5^E24 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!4U/_D'R?A_,5EGJ:U-3_Y!\GX?S%99
MZF@!*!10* %H%% H 6BBB@!124HI* "BBB@ I1UI*4=: #O2TG>EH 0TM(:6
M@ %)2BDH YG5O^1NL/HG_H1KIV[?2N8U;_D;K#Z)_P"A&NG;M]*\S _Q:_\
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M&/G]YY#_ ,*\^(/_ $-Y_P# J;_"C_A7GQ!_Z&\_^!4W^%>OT4?VC6[1_P#
M4'L8^?WGD'_"O/B#_P!#>?\ P*F_PH_X5Y\0?^AO/_@5-_A7L I*/[1K=H_^
M H/8Q\_O/(/^%>?$'_H;S_X%3?X5D^)?#?CGPQHDNJW7BJ:6&)E4K%=2[CN.
M._UKW6N(^+G_ "3N^_ZZ1?\ H8K?#XZI.K&$DK-K[*(G2BHMJ_WFOX&O;G4?
M!&DW=Y,TUQ)!EY'.2Q!(R??BNA-<O\.?^2>Z+_UP_P#9C74&O.Q"2JR2[O\
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M!QHAOIAB?4)6NG^C'Y1^6*WI8HYX7BFC62-QM9&&0P]"*5$6-%1%"HH 55&
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M4 %%%% !1110 4444 68?]2OTJ2HX?\ 4K]*DH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHJG>ZE!8R0Q.'DGF)$<,2[F;'4X[ >IXH N45
M3L]3M[V::!0\=Q#CS(95VLH/0^X/J*J2^)=/B>7)F:"%_+FN5C)BC;T+>W?L
M* ->BD!# $$$'D$4M %34_\ D'R?A_,5EGJ:U-3_ .0?)^'\Q66>IH 2@44"
M@!:!10* %HHHH 44E**2@ HHHH *4=:2E'6@ [TM)WI: $-+2&EH !24HI*
M.9U;_D;K#Z)_Z$:Z=NWTKF-6_P"1NL/HG_H1KIV[?2O,P/\ %K_XOT1Z>-_A
M4/\ #^K 4M(*6O3/,"EI*6@ [BN?T'_D)7_U_P#9C70=Q7/Z#_R$K_Z_^S&@
M#?HHHH 6BBB@!:*** "E-)2F@!*7M24O:@!**** "E%)2B@!:04M(* %HHHH
M *7M24O:@!!UHH'6B@ HHHH 6@44"@!:2EI* %I>U)2]J  44"B@!HI:04M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGMA;1SVWV8PD@M)SDLV,CI@#DU0M]*UBP\.3^'H(%D0[XH+PR *L3$\L.NX
MG@#F@"_X(GDN?!FF22L6?RBN3W"L0/T KH*J:7I\6E:7;6$.3'!&$!/?'?\
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M7Z&CRO\ :_0UIT4 9GE?[7Z4>5_M?H:TZ* ,WRO]K]#1Y7^U^E:5% &;Y?\
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M-O7]*=M'K^AJU#_JA]3_ #J2@"CM'K^E&T>OZ5>HH H[1_>_2C _O?H:O44
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MP,9/% &]13(I4GACFB8-'(H96'<$9!K@==UJ\UWQ9%X;T^X>WM@^RXEC.&;
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M HHHH ***.] %F#_ %*?2I*CA_U*_2I* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH JZE_QX2?5?YBK55=2_X\)/JO\Q5J
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EK'_($OO\
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MN"^,G_)-+_\ ZZP_^C!75@_]XAZHSJ? S1^&7_)-]#_Z]_\ V8UUE<G\,O\
MDF^A_P#7O_[,:ZRHQ'\:?J_S'#X4%%%%8%A1110 4444 %%%% $</^J'U/\
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MT7=-:O?R(4DO6\[:>JIC"#_OD#\S7)^.-W_"6^'2?N>8.O3.\?\ UJ[X
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M?)V]-N.*LU%;6\5I;16T"!(8E"(H[ 5+0 4444 %%%% !1110 4444 %%%%
M!1WHH[T 68?]2OTJ2HX?]2OTJ2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *NI?\ 'A)]5_F*M55U+_CPD^J_S%6J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6L?\@2^_Z]W_\
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M,D88X7<V,GT'K0!+156#4K&Y@DG@NX98HL^8Z."%QZ^E0+K^CO"\RZI9F)"
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M9XS7!7D>JZ/XXL+/3M5O+U9\/-#/)OV+GYL]@,<]!0!Z)117(:AJ\M[X\L]
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M44 %%%% !1110 4444 4M8_Y E]_U[O_ .@FL3P'_P @&7_KX;_T%:V]8_Y
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M1110 4444 %%%% #)O\ 4O\ 0T\=!3)O]2_T-/'04 -?[C?2JE6W^XWTJI0
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M %%%% !1110 4444 %(S!5+,0 !DD]J6JNI6C7^FW-HDQA,T9C\P#)4'@\4
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M4O:DH **** %HHHH **** $_C'TIU-_C'TIU !1110 4444 !Z4#I0>E Z4
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MW\A70USUM_R-UQ]&_D* .AI124HH 6D%+2"@!:*** "E[4E+VH 0=:*!UHH
M**** %H%% H 6DI:2@!:7M24O:@ %% HH :*6D%+0 4HI*44 %%%% "T444
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M&QD>U %VBJ<6K:=/>FSBOK=[D=8ED!;\JP-4\9V=KXAL],BN(U02'[7,WW4
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MHH **** "BBB@ HHHH LP_ZE?I4E1P_ZE?I4E !1110 4444 %%%% !1110
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M_K^?_P! 2O0I_P"Y3_Q1_4Q?\5>C/2:44E**\\V"BBB@ 7I2TB]*6@ HHHH
M*6DI: $-*.E(:4=* $[TII.]*: $I124HH 7M24O:DH **** %HHHH ****
M$_C'TIU-_C'TIU !1110 4444 !Z4#I0>E Z4 +0**!0 4&B@T *.E% Z44
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M90I NV'A!C/S$<^M6-0 _P"%P6@Q_<_] -='?^$(=1U2VU&?4+G[1;!1'M5
M!M.1D8]:DU7PE9:KJT6IM/<V]U& "\#A2V/PX_"@#>/W3CTK@_A@2UEJCO\
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M>K_]\FM"B@#/^S+ZO_WR:/LR>K_]\FM"B@#/^S+ZO_WR:7[,GJ__ 'R:OT4
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M]O\ [Y-&Q?\ ;_[Y-6Z* *?EK_M_]\FEV+_M_P#?)JW10!4V+_M_]\FC8O\
MM_\ ?)JW10!4\M?]O_ODT;%_V_\ O@U;HH J;%_V_P#ODT;%_P!O_ODU;HH
MJ;%_V_\ ODT;%_V_^^35NB@"KL7_ &_^^31L7_;_ .^35JB@"KL7_;_[Y-&Q
M?]O_ +Y-6J* *>U?,'W^A_A-.VK_ +?_ 'R:F/\ Q\+_ +I_F*DH J[5_P!O
M_ODT;5_V_P#ODU:HH J[5_V_^^31M7_;_P"^35JB@"KM7_;_ .^30%7_ &_^
M^35JB@"KM7_;_P"^31M7_;_[Y-6J* *V%_V_^^300I_O_P#?)JS10!6PO^W_
M -\FC"_[?_?)JS10!6PO^W_WR:,+_M_]\FK-% %;"_[?_?)H^7T?_ODU9HH
MK87_ &_^^31\OH__ 'R:LT4 5)-OEMPW3^Z:<-N.C_\ ?)J:;_4O]#3QT% %
M8[<'A_\ ODU'5M_N-]*J4 %%%% !1110 4444 %%%% !137DCB ,DB(#P"S
M?SI//API\Z/#?=.\?-]/6@!]%-:1%<(SH&/12P!/X4/(D2[I'5!ZLP H =10
M"" 0<@]"*YWQC?36?AVXNK&]:&Y@*_ZI@>I Y'- '145P>CWOB/4HM#NHM4M
MS;D'[6LCJ&8[SU'4\8 Q7=NZHI9V55'=C@4 +13!+$T9D61"@ZL&&!^-(+B
MJ6$\14=2'&!0!)12 A@"""#T([U@^*_$L?AO35E""2YE)6&,]..I/L* -^BN
M6TO3]=U'2H[R\UZXM[F=!(D<,:!(P>0"",G\ZK^&?%-W<:S/H.L!/MT3,J2H
M,"3'4$>N.: .QHKC-*U:Y\3ZOJ$:ZM)8);/LAMX F]P,C<2P.?H*V]*.K1ZG
M=VVHSI/%'&A@E6/9O!)R2/[W':@#8HH) !). .2:\V&JZWKNIS-I?B:RM8Y)
M"(;5WVL%!P.J')/7J>M 'I-%4='M[VUTR&+4;K[5=C)DE[$YZ#@<"LSQ+'K]
MU+:VVA3?9S\SS3-@*!P ,X/N>/2@#H:*\_@3Q;:>)]-T^^UM9EG)ED6+!Q&O
M7.5'7I7H% !114:W$#DA)XFP,G:X.!0!)131+&8_,$B%!_$&&/SI5974,C!E
M/0J<B@!:*8DL4A(CE1R.H5@<4^@ I" P(8 @]012T4 %%%% !1110 4444 %
M(0#C(!P<C(Z&EHH **** "BBB@ HHHH **** "BBB@ HHH[T 68?]2GTJ2HX
M?]2OTJ2@ HHHH **** "BBB@ HHHH **** "HYUD>WD6&01RE2$<C.TXX..]
M24R:5((9)I&VQQJ68^@ R: ,*UU^:SN$L=?A6TN&.V.Y4_N)S['^$^QKE+K3
M?$%A>O:6WAC2;^$NQ2ZD@4LX)SEB3UYJW<>./MTCV][X7O)-*?AI)(R?E_O%
M=N/?K6RMOJ?A]5ETXR:GI)&[[,S9FB'_ $S8_>'^R?PH U]$L9--T:UM)?+\
MR-?F$8PH)))"^PS@?2M"J]C>PZC917=N6,4@R-RE2.Q!!Z'-6* "BBB@ HHH
MH **** *NI?\>$GU7^8JU574O^/"3ZK_ #%6J "BBB@ HHHH **** "BBB@
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MV_!/_09'_?B3_P")HB^%7@IDR=$CSD_\M7]?]ZG_ /"J/!7_ $!(_P#OZ_\
M\51_L/\ >_ /WOD,_P"%M^"?^@R/^_$G_P 31_PMOP3_ -!D?]^)/_B:?_PJ
MCP5_T!(_^_K_ /Q5'_"J/!7_ $!(_P#OZ_\ \51_L/\ >_ /WOD,_P"%M^"?
M^@R/^_$G_P 31_PMOP3_ -!D?]^)/_B:?_PJCP5_T!(_^_K_ /Q5'_"J/!7_
M $!(_P#OZ_\ \51_L/\ >_ /WOD,_P"%M^"?^@R/^_$G_P 31_PMOP3_ -!D
M?]^)/_B:?_PJCP5_T!(_^_K_ /Q5'_"J/!7_ $!(_P#OZ_\ \51_L/\ >_ /
MWOD,_P"%M^"?^@R/^_$G_P 31_PMOP3_ -!D?]^)/_B:?_PJCP5_T!(_^_K_
M /Q5'_"J/!7_ $!(_P#OZ_\ \51_L/\ >_ /WOD,_P"%M^"?^@R/^_$G_P 3
M1_PMOP3_ -!D?]^)/_B:?_PJCP5_T!(_^_K_ /Q5'_"J/!7_ $!(_P#OZ_\
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M%M^"?^@R/^_$G_Q-'_"V_!/_ $&1_P!^)/\ XFG_ /"J/!7_ $!(_P#OZ_\
M\51_PJCP5_T!(_\ OZ__ ,51_L/][\ _>^0S_A;?@G_H,C_OQ)_\31_PMOP3
M_P!!D?\ ?B3_ .)I_P#PJCP5_P! 2/\ [^O_ /%4?\*H\%?] 2/_ +^O_P#%
M4?[#_>_ /WOD,_X6WX)_Z#(_[\2?_$T?\+;\$_\ 09'_ 'XD_P#B:?\ \*H\
M%?\ 0$C_ ._K_P#Q5'_"J/!7_0$C_P"_K_\ Q5'^P_WOP#][Y"P?%7P7<W$<
M$>M)OD8*NZ&11D].2N!795\_?%CPIHGAB^T'^Q[%;7SY6\S#LV[!7'4GU-?0
M"_<'TJ<51I0A"I2O:5]_(=.4FVI=!:***X34**** "BBB@ HHHH 9-_J7^AI
MXZ"F3?ZE_H:>.@H :_W&^E5*MO\ <;Z54H **** "BBB@ HHHH **** .;\>
MHK>#+XLH)7RR,CH=ZUPM_I=JGPVT[4MK&[\X*)"Y^5=S_*!T XS7I7B'29-;
MT>73XYT@$I7<[(6X!!X&1W K%N/!MS<>%;?0FU&$1PR[Q*(#DCD@8W>YH Y7
MQ3910^%-%UC=*VH3;3)<.Y+'Y,@>V,<8K2TS4IM8\=2+=6YNT@M=L4!90!PN
MYL,<$G)_.MC5/!UUJF@Z?I4FHPHEF,"1;<Y? P/XN.*2Z\$227MKJ-GJ9L]0
MBC5'DCBRKX&W.,\9'7DT 9S+KGACP1JJ7)$>) +0K)O,:.<$9'3']:JW=C;C
MX2PW"H!,0)#(/O,2^#D]_P#ZU=I_84<^EW5GJ%Q+>/=#$TK84\=-H'"@=JQO
M^$,N_P#A'WT1M9S9[MT8^SC<.<X)SR/IB@#A(XT%UX48(H9@N2!R?WQKO?%'
ME0>(-*NY+^1F1L1::D8<SL3C/)P.N,G\*I#X?7*S6#C5XRMCCR0UMVW;L'#<
M\UJ:QX2?5->M-7CU%[:X@50=L>[D'.5R>.IZYH Y[P7(X\9ZW921JD,@D+6X
M.44AQQCH>I%8GAG2K2^T/Q%+<(6^SQ;HUW$*&PWS8'4\?SKN=/\ "$FF>(+K
M5;?4V9IU;"21 Y)Y^8YY&>>,57TKP5<Z5I^I6D>I0N+Y-C,UN<IUY'S>YH 7
MX;3R3>%=DC%A%.RID]!@''ZUB?%2"3S].N-I,.QTSZ-D'^7\JZ[PMX?D\.:?
M+9M=)<(TGF*PC*$$C!SR?05HZGIEIK%B]G>Q[XGY]"I[$'L: 'Z<Z2Z9:21D
M%&A0C'IM%>:PQM>?%YFMND=R68CL%7#?K_.NOL] U?3;+[#8ZZ!:J"(_.M0\
MD8] VX#\Q5O0/#5EX?61X2\US*<RW$OWF[_@* .9UGP3%K$G]LZ!="&64F38
M<J"W<@C[IS5CP7KFJR:E=:%K(9KBV3<KO]X8(!!/?J"#6K8^';[2(?+TW6&5
M68N\=Q")$W$Y)4 @K^=6](T)--NKF^FG:ZO[H_O9V4+P.BJ!T% &G/"ES;R0
M2;MDBE&VG!P>.HZ5PFN?#:R%G)/I#RQ3QJ6$3MN5\=@>H-=S=VZW=G-;,[HL
MJ%"R'##(QD'UK$T70=2T:TDLQK GMCGR_,A.^+Z'=_2@!/!FI2WGA*VN+V3#
M1EHS)(<9"G ))_+\*Z%2& *D$'D$'(-86J>%[>^\,+HEO,UM$FTH^-V2/4<9
MSDU?TO3CI6BP:?%.7:&/8LKCOZX]/:@#(T7_ (F7BO5]5ZQ08L8#_N\N?SKI
MJSM#TH:+I4=GYOFN"SR2XQO9CDG%:- !7F&AZ7:ZA\1=9M;B,FW_ 'I:)#M#
M#>O!QV[X]J]/KE]+\*W6F^)+K61?PR/<[]\9@( W$'@[O4"@#D_!FF6^HS:W
M877F/9P?,D&\A-V6 ) ZD 5AVNLW=EX0O+&"614ENE4D'[J[22!Z9(%>B:'X
M2N]#N;^>+48)3>*0P:W(VG)((^;WJK8?#R*#3KVQN[T3Q7)5U=(MCQNN<$<G
MU/% &?XM;^P;7PY>Z<HAFC7:3&,;UPIP?7//YUZ*IW*#TR,USLOA=[^;3CJE
MVL\-@/W<<<6S>>.7))]!P*Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *.]%'>@"S#_J5^E25'#_J5^E24 %%%% !1110 444
M4 %%%% !1110 5'<0I<VTL$@)25"C8]",&I*9+*D$+S2L$C12S,>@ Y)H X?
M_A#O$K7?E/XJN#IY."-S>84]/3/;.:[F.-8HDC085%"@>PK$_P"$S\-_]!FT
M_P"^Z7_A,O#?_09M/^^Z -S&**K:??P:G91WEJVZ"0G8W]X D9_2K- !1110
M 4444 %%%% %74O^/"3ZK_,5:JKJ7_'A)]5_F*M4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %1Q?Q_[QJ2HXOX_]XT <=I'_)0M0^C_
M -*[6N*TC_DH6H?1_P"E=K7F99_#G_BE^9Z>9?Q(?X8_D%%%%>F>8%%%% !1
M110 4444 %%%% !1110 4444 %%%% !4;_ZV/\:DJ-_];'^- $E%%% !1110
M 4444 %%%% !1110 5R7B'_D:M,_X!_Z'76UR7B'_D:M,_X!_P"AT =;1110
M 4444 %%%% !4<O\'^^*DJ.7^#_?% $E%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% $</^J'U/\ZDJ.'_5#ZG^=24 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 1G_CX7_=/\Q4E1G_ (^%_P!T
M_P Q4E !1110 4444 %%%% !1110!XO\=_\ C^\-?]=9/YI7LZ_<'TKQCX[_
M /']X:_ZZR?S2O9U^X/I7HXC_=J/_;WYF,/CE\A:***\XV"BBB@ HHHH ***
M* &3?ZE_H:>.@IDW^I?Z&GCH* &O]QOI52K;_<;Z54H **** "BBB@ HHHH
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M; _KCOC%<9J$$^GZ8FI+X4LY+>_BR\!@^:TDZ<$#.T\$#L?2@#N_"/V8^%;
MV8D%N4)19/O*"Q.#ZXZ9[XK;K*\,O</X:T]KJ 03^2 T87;C'MVR.<>]:M !
M1163K^KMI=M$D#VRWES)Y<'VE]L>>I+'T _I0!K45D:3)K>)9-9;31$%!C-I
MO_$DMVK.C\0ZC=Z/<:Y:6\!T^(L8XF!\R:-3AF#9PO0X&#TH ZBBH+*\AU"Q
M@O+=MT,R!T/L:GH JZE_QX2?5?YBK55=2_X\)/JO\Q5J@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ J.+^/_ 'C4E1Q?Q_[QH X[2/\
MDH6H?1_Z5VM<5I'_ "4+4/H_]*[6O,RS^'/_ !2_,]/,OXD/\,?R"BBBO3/,
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J-_P#6Q_C4E1O_ *V/\: )
M**** "BBB@ HHHH **** "BBB@ KDO$/_(U:9_P#_P!#KK:Y+Q#_ ,C5IG_
M/_0Z .MHHHH **** "BBB@ J.7^#_?%25'+_  ?[XH DHHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU+1M-U= FH6<-P%!"EUY7/H>HJ]65J&EWEU?Q7=KJ]S:;$V-$JJZ/[X/?WH
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MM\GHE+]OD_NI^=4:4=: +OV^3^ZGYT?;Y/[J?G5+O2T 7/M\O]U/SI/M\O\
M=3\ZIFEH M_;Y?[J?G1]OE_NI^=5!24 7?M\O]U/SI!>2+G"KR<]:J4-V^E
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M +HH-X_]T5!0: )_M;_W11]L?^Z*AH- $WVQ_P"Z*/M;_P!T5!2B@";[6_\
M='Y4?:V_NU#10!-]K;^[^E+]K;^[^E04HH F^UM_=_2C[6W]W]*AHH D2Y95
MQM]>U.^UM_=_2H5Z4M $OVMO[OZ4?:V_N_I45% $OVMO[OZ4OVIO[OZ5#2T
M2?:V_N_I1]J;^[^E1&E'2@"3[4W]W]*/M3?W?TJ+O2F@"3[6W]W]*/M3?W?T
MJ*E% $OVIO[OZ4?:F_N_I4?:DH E^U-_=_2C[4W]W]*BHH E^U-_=_2C[4W]
MW]*CHH D^U-_=_2C[4W]W]*CHH <;AO,#;>Q'2G_ &H_W3^50_QCZ4Z@"3[4
MW]W]*/M1_NG\JCHH ?\ :F_NG\J/M3?W3^5,HH D^TG^Z?RH^TM_=/Y5&>E
MZ4 2?:6_NG\J/M+?W3^5,H% 'CWQRE+WWAO(QB1^WNE>QK<D*ORGIZ5XW\<?
M^/WPW_UTD_FE>PC[J_2O0Q'^[4?^WOS,8?'+Y$GVD_W3^5'VD_W3^5-'2BO/
M-AWVD_W3^5'VD_W3^5-%% #OM)_NG\J7[2?[I_*F&@=* '_:3_=/Y4?:3_=/
MY4RE% !).6C8;3R/2G"X./NG\JCD_P!6WTIW:@!3<%@1M//M4=.--H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"S#_J4^E25'#_J5^E24 %%%% !1110
M4444 %%%% !1110 4C*KJ58!E(P01D$4M% '/:KX;TR73K:PB$%C;K=>=M5%
MP[!6XP>#Z\]A7,7&K>$-*O1:7MGIEV,X,]I #M_WEZ?D3]*WO']E!?:#!%<W
ML5E +I&DFD_A&UN@[GGI2^'_  5X?TZ"*Z@B6]=U#I<38?(/0@=!0!MZ,EBF
MDVXTS'V(@M%@$#!)/&>W-7J.E% !1110 4444 %%%% %34_^0?)^'\Q66>IK
M4U/_ )!\GX?S%99ZF@!*!10* %H%% H 6BBB@!124HI* "BBB@ I1UI*4=:
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M/]Y/]Z@!]%%%  :*#10 II*4TE "T444 %%%% !1110 4O:DI>U "4HI*44
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MD_[YKFO$-E=G5+6YM+2618U'1,\@YYQ7844 <9_:6O?] G_R$W^-)_:6O?\
M0)_\A-_C7:44 <9_:6O?] G_ ,A-_C1_:6O?] G_ ,A-_C79T4 <9_:6O?\
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M/RH^7_GG)^56** *_P O_/.3\J/E_P"><GY58HH K_+_ ,\Y/RI?E_YYR?\
M?-3T4 0?+_SSD_*@;<C]V_Y5/10!XE\,,?\ "U_%N58C]]P!_P!-A7LWR_\
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M.3_OFEWC_GF_Y5+10!#O'_/.3_OFEWC_ )YO_P!\U+10!%O'_/.3_OFC>/\
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M('_(+M?^NQ_D:ZZN1^('_(+M?^NQ_D:\[,_]TJ>GZH]'+/\ >Z?K^C.GLO\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CB_C_WC4E1Q?Q_[QH
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M10 5'+_!_OBI*CE_@_WQ0!)1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!'#_JA]3_ #KEM1_Y'JS^B_R-=3#_ *H?4_SKEM1_Y'JS
M^B_R- '6T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!&?\
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M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=J*.U $</\
MJ5^E25'#_J5^E24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M!>6S7=J\"W$UN6&/,A(##Z$@U/69>Z'#>Z@E[]JO8)D39^XG**1[CH>M ',Z
M3::A:Q>(O#C3M=PPP;K>5A\V9%8[2>Y_SWJQX>N(X_A<DC$ 16<JO[$;@174
MV=C!8QLD"$%VW.[$LSMZL3R36?)X9T^1Y01,MO-)YLMLLA$3MW)7W[CH: *_
M@BWDMO!FF1R@J_E;\'L&)8?H1704@ 4    < "EH J:E_P >$G_ ?YBHCJ#
M]%J74_\ D'R?A_,5EGJ: +W]H-Z+1_:#>BU0H% %_P#M!O1:/[0;T'Y51H%
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M>;)ZK^5>,_\ "P/B7_T*0_\  .7_ !H_X6!\2_\ H4A_X!R_XT?V=5[Q_P#
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M@!U%%% !2]J2E[4 )2TE+0 4444 %%%% 'DGQ\_Y &C_ /7V_P#Z!7J.F?\
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M2]J $HHHH *44E** %I!2T@H 6BBB@ I>U)2]J $'6B@=:* "BBB@!:!10*
M%I*6DH 6E[4E+VH !10** &BEI!2T %**2E% !1110 M%%% "BDI124 %!HH
M- "T&B@T )2BDI10 4444 %**2E% !1110 +TKF[[_D<+3Z+_(UTB]*YN^_Y
M'"T^B_R- '2T444 %+24M "&E'2D-*.E "=Z4TG>E- "4HI*44 +VI*7M24
M%%%% "T444 %%%% "?QCZ4ZF_P 8^E.H **** "BBB@ /2@=*#TH'2@!:!10
M* "@T4&@!1THH'2B@ %% HH #0.E!H'2@ I124HH ;)_JV^E.[4V3_5M]*=V
MH 0T4&B@!PI*44E "BDI124  I:04M !1110 4"B@4 !H%!H% "FDI324 +1
M110 4U?O/]:=35^\_P!: '4444 %+VI*7M0 E+24M !1110 4444 >2?'O\
MY &C_P#7V_\ Z!7J.F?\@FR_Z]X__017EWQ[_P"0!H__ %]O_P"@5ZCIG_()
MLO\ KWC_ /017H5O]SI>LOT,8_Q)?(MTE+25YYL**0THI#0 "EI!2T %,?[R
M?[U/IC_>3_>H ?1110 &B@T4 *:2E-)0 M%%% !1110 4444 %+VI*7M0 E*
M*2E% !1110 4444 $/\ J5^E25'#_J5^E24 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 445DZG%K%Y<BWT^Z2PA5-SW!B$C,QZ*H/'&.2?44
M:U%<OX?UC44O=5TO6WCDET\+)]I1=H>,@D$@=#BH;;4]7U'P[/XAM[D1@;Y;
M>TV*4:-2>&.,Y(!Y!&.* .NHJGI6HQ:MI5M?P@B.>,. >H]1^!JY0!4U/_D'
MR?A_,5EGJ:U-3_Y!\GX?S%99ZF@!*!10* %H%% H 6BBB@!124HI* "BBB@
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M)0 "EI!2T %%%% !0**!0 &@4&@4 *:2E-)0 M%%% !35^\_UIU-7[S_ %H
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M4CVA7'S]2!TJ[4<O\'^^* (/L1_YZ?I1]B/]_P#2K=% %3[&?[_Z4?8S_?\
MTJW10!4^QG^^/RH^QG^^/RJW10!5^R'^^/RI/L9_OC\JMT4 5/L9_OC\J/L9
M_P">GZ5;HH J_9&_YZ#\J/LA_OC\JM44 5/L9_YZ?I2_9&_YZ#\JM44 5?LC
M?WQ^5'V1O[X_*K5% %7[(W]\?E1]D;^^/RJU10!5^RM_?'Y4?9&_OC\JM44
M4X[=F3.\#D]JYS6M,U-=:BO+.#S=JC!&."/49KJX?]4/J?YU)0!QWG^*/^?)
M?^^!_C1Y_BC_ )\E_P"^!_C78T4 <=Y_BC_GR7_O@?XT>?XH_P"?)?\ O@?X
MUV-% '&^?XG_ .?)?^^!_C2^?XH_Y\E_[X'^-=C10!QWG^*/^?)?^^!_C1Y_
MBC_GR7_O@?XUV-% ''>?XH_Y\E_[X'^-'G^*/^?)?^^!_C78T4 <=]H\4?\
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M*** "BBB@ HHHH **** "BBB@ J./[\G^]_2I*CC^_)_O?TH DHHHH ****
M"BBB@ HHHH **** /(/C_P#\@'1_^OMO_0*]4TK_ )!%E_UPC_\ 017E?Q__
M .0#H_\ U]M_Z!7JFE?\@BR_ZX1_^@BO1K?[G2]9&,?XDOD6Z***\XV"BBB@
M HHHH *CE^]'_O5)4<OWH_\ >H DHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ H[44=J (X?\ 4K]*DJ.'_4K]*DH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ7_'A)]5_F*M55U+
M_CPD^J_S%6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** (X?\ 5#ZG^=25'#_JA]3_ #J2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@",_\?"_[I_F*DJ,_P#'PO\ NG^8J2@ KDG_ .2A
M#_='_HNNMKDG_P"2A#_='_HN@#K:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!DW^I?Z&GCH*9-_J7^AIXZ"@ HHHH **** "BBB@ HHHH ****
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M*/[1\8_\\U_[X2NDHKG_ +/E_P _I_?_ , Z/[07_/F'W?\ !.;_ +1\8_\
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MGR^H_*CSY?4?E4=% $GGR^H_*CSY?[P_*HZ6@!_VB7U'Y4>?+_>'Y5&:4=*
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MHWR_WQ^5(*6@ WR_WQ^5&^7^^/RHHH -\O\ ?'Y4N^7^^/RI*!0 N^7^^/\
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MT,?O3_PHQI=?5B9E_OC_ +YI<R_WQ_WS2T5YYL)F7^^/^^:,R_WQ_P!\TM%
M"9E_OC_OFC,O]\?]\TM% "9E_OC_ +YHS+_?'_?-+2]J &9E_OC_ +YI?WO]
M\?\ ?-+2B@!O[W_GH/\ OFC][_ST'_?-.HH ;^]_YZ#_ +YH_>_\]!_WS3J*
M "'_ %*?2I*CA_U*_2I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH J:G_ ,@^3\/YBLL]36IJ?_(/D_#^8K+/4T )0**!
M0 M HH% "T444 **2E%)0 4444 %*.M)2CK0 =Z6D[TM "&EI#2T  I*44E
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MM)2T %%%% !1110 4444 +24M)0 HI#2BD-  *6D%+0 4Q_O)_O4^F/]Y/\
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M^'\Q66>IH 2@44"@!:!10* %HHHH 44E**2@ HHHH *4=:2E'6@ [TM)WI:
M$-+2&EH !24HI* %H;M]**&[?2@ %+2"EH *6DI: $-+VI#2]J $HHHH 6BB
MB@!:*** "E-)2F@!*7M24O:@!**** "E%)2B@!:04M(* %HHHH *7M24O:@!
M!UHH'6B@ KE=1_Y'>R^B?UKJJY74?^1WLOHG]:\S,OX</\<?S/3RW^)/_#+\
MCJZ!10*],\P6DI:2@!:7M24O:@ %% HH :*6D%+0 4HI*44 %%%% "T444 *
M*2E%)0 4&B@T +0:*#0 E**2E% !1110 4HI*44 %%%%  O2EI%Z4M !1110
M 4M)2T (:4=*0THZ4 )WI32=Z4T )2BDI10 O:DI>U)0 4444 +1110 4444
M )_&/I3J;_&/I3J "N9;_D>1]!_Z!735S+?\CR/H/_0* .FHHHH #TH'2@]*
M!TH 6@44"@ H-%!H 4=**!THH !10**  T#I0:!TH *44E** &R?ZMOI3NU-
MD_U;?2G=J $-%!HH <*2E%)0 HI*44E  *6D%+0 4444 % HH%  :!0:!0 I
MI*4TE "T444 %-7[S_6G4U?O/]: '4444 %+VI*7M0 E+24M !1110 4444
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MA1_9LO\ S]?^0A6C10!G?V9+_P _7_D(4?V;+_S]?^0A6C10!G?V9+_S]?\
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M]GS?\_?_ )"%7Z* *']GS?\ /W_Y"%']GS?\_?\ Y"%7Z* ,_P#L^;_G[_\
M(0H_L^;_ )^__(0K0HH S_[/F_Y^_P#R$*7^SYO^?O\ \A"K]% %#^SY_P#G
M[_\ (0H^P3_\_?\ Y"%7Z* *'V"?_G[_ /(0H^P3_P#/W_Y"%7Z* *'V"?\
MY^__ "$*/L$__/W_ .0A5^B@"A]@G_Y^_P#R$*/L$_\ S]_^0A5^B@"A]@G_
M .?O_P A"C[!/_S]_P#D(5?HH H?8)_^?O\ \A"C[!/_ ,_?_D(5?HH H?8)
M_P#G[_\ (0H^P3_\_?\ Y"%7Z* *'V"?_G[_ /(0H^PS_P#/W_Y"%7Z* *'V
M&?\ Y^__ "$*/L,__/W_ .0A5^B@"@+"<#_C\_\ (0H^PS_\_G_D(5?HH H?
M89_^?S_R$*7[#/\ \_G_ )"%7J* */V&?_G\_P#(0H^PW'_/Y_Y"%7J* *'V
M&?\ Y_/_ "$*7[#<?\_G_D(5>HH H_8;C_G\_P#(0H^PW'_/Y_Y"%7J* */V
M&?\ Y_/_ "$*/L-Q_P _G_D(5>HH H_8KC_G\_\ (0H^PW'_ #^?^0A5ZB@"
MC]AN/^?S_P A"C[#<?\ /Y_Y"%7J* */V*X_Y_/_ "$*/L5Q_P _G_D(5>HH
M H_8KC_G\_\ (0H^Q7'_ #^?^0A5ZB@"A]AN,Y^V?^0A2_8KC_G\_P#(0J]1
M0!1^Q7'_ #^?^0A6<?#TYUH:A]M&<8QY7/3'KBM^B@"C]BN/^?S_ ,A"C[%<
M?\_G_D(5>HH H_8KC_G\_P#(0H^Q7'_/Y_Y"%7J* */V.Y_Y_/\ R$*/L=S_
M ,_G_D(5>HH I?8[G_G\_P#(0I/L=S_S^?\ D(5>HH I?8[G_G\_\A"C['<_
M\_G_ )"%7:* *7V.Y_Y_/_(0H^QW/_/Y_P"0A5VB@"E]CN?^?S_R$*/L=S_S
M^?\ D(5=HH I?8[G_G\_\A"C['<_\_G_ )"%7:* *)L[D@@WG!_Z9"E^QW/_
M #^?^0A5VB@"E]CN?^?S_P A"C['<_\ /Y_Y"%7:* *7V2Y_Y_/_ "$*/LES
M_P _G_D(5=HH I?9+G_G\_\ (0H^R7/_ #^?^0A5VB@"E]DN?^?S_P A"C[)
M<_\ /Y_Y"%7:* *7V2Y_Y_/_ "$*/LES_P _G_D(5=HH I?9+G_G\_\ (0H^
MR7/_ #^_^0A5VB@"E]DN?^?W_P A"C[)<_\ /[_Y"%7:* *7V2Z_Y_?_ "$*
M/LES_P _G_D(5=HH I_9+K_G]_\ (0H^R77_ #^_^0A5RB@"G]DNO^?W_P A
M"D%G<@D_;.O_ $R%7:* *?V2Z_Y_?_(0H^R77_/[_P"0A5RB@"G]DNO^?W_R
M$*/LMU_S^_\ D(5<HH I_9+K_G]_\A"C[+=?\_O_ )"%7** *?V6Z_Y_?_(0
MH^RW7_/[_P"0A5RB@"G]ENO^?W_R$*/LMU_S^_\ D(5<HH I_9;K_G]_\A"C
M[+=?\_O_ )"%7** *?V6Z_Y_?_(0H^RW7_/[_P"0A5RB@"G]ENO^?W_R$*/L
MMU_S^_\ D(5<HH I_9;K_G]_\A"C[+=?\_O_ )"%7** *?V6Z_Y_?_(0I#:7
M)QF]Z'/^J%7:* *?V6Z_Y_?_ "$*/LMU_P _O_D(5<HH I_9;K_G]_\ (0H^
MRW7_ #^_^0A5RB@#@8OAY=1_$B3Q;_:Z'>"/)^S\\IMZYQ^E=E]ENO\ G]_\
MA"KE%:5*LJEN;HK?(E12V*?V:Z_Y_?\ R$*/LUU_S^_^0A5RBLRBG]FNO^?W
M_P A"C[-=?\ /[_Y"%7** *?V:Z_Y_?_ "$*/LUU_P _O_D(5<HH I_9KK_G
M]_\ (0H^S7?_ #^_^0A5RB@"G]FNO^?W_P A"C[-=_\ /[_Y"%7** *?V:[_
M .?W_P A"C[-=_\ /[_Y"%7** *?V:[_ .?W_P A"C[-=_\ /[_Y"%7** &Q
MILC5<YP,9]:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %:[U"SL IN[F.'><+O;!;Z"IH9H[B%989%DC<95U.01[&N
M5T*5M0\;^(+F;G[)Y=K"#_ O)./J1FE\*S-!XA\1:4O_ ![P7"RQ*.B;QD@>
MV: .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"0H))P!
MR2:S+3Q)HM_=+:VFIVL\[9VQQR DXZT>(+2_O]&GM=.EACGEPI:7.-O<<>HX
M_&L30-0-MK7]D:KI%G8ZEL+036T8"3*.NT]0?:@#KZ*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH @NKVULD#W5Q%"I( ,C 9)["IZX_XAP1
M'2+.8Q(91?0@.5&X#=TS5GQ]>S67A2<6[%'N)$@W#J QP?TH V[?5=/NYS!;
MWD,LHS\J."3CKCUJY7'>-(UTCPQ8W5HHCDTZ>(PE>P^Z1]".M=@C!T5AT(S0
M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C,J*68@*.22>!45M
M=V][$9;6>.:,,5+1L&&1U&13YH8IXC'-&DB'JKC(/X5RWPY 'A0 # %S* /^
M!4 ;VH:SINDF,:A?06QDSL$KA=V.N*GM+RWO[9+FTF2:!_NR(<@_0UR&MV^M
MV&J7>KOIVGZI8X \DKF6.-?[N1CU)KJ=)N[2_P!*MKJQ4+;2H&C4+MVCTP.F
M* +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G1Z]I$M]]BCU*
MU:ZSCRA*"V?3ZU<N8/M-M+ 7=!(I4LAP0#Z5R7C'0M.7P]%!96445YYT:69B
M0*P<L.XYZ9)^F: .MN+F"T@::XE2*)>KN< 4VUO;:^B,EK/',@."4.<'T/I7
M+ZB\MQX\T+39VWQ06[W3#L\@!4$_3&?QI\\QL?B9:QQ'$>H63><HZ,R$[6^N
M.* .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J5_K&FZ64%_?
M6]L7^Z)7"DU=K.?1=.>>YN+FWBGDG^^\RAL*!@*,]!_C0!>AFBN(4FAD62-Q
ME70Y!'L:S9_$NB6MVUI/JEK'<*VTQ-(-P/ICUK(\%V<]KX>O?LAVPRW,SV E
MSA8^BD^Q(S6;9R77AN]M+;Q#I=C+!/)M34H4R1(3G+Y&<D]Z .^HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "HYYXK:%YIY$BB099W. ![FI*K7
MEK;7,:FZC$D<3>9M89!('<=Z &6&JZ?JBNUA>07(0X;RG#8^M.O-3LK J+NZ
MBA+ E0[8) ZGZ5R>A7&DWOCV^N;!UMW2V$1@\LQF8YR7VD#@<#UJSX4D;4=;
M\1WTX#.+K[*F>=L:9&![=Z .K1UD171@R,,AE.013JY/P/.P35].R3%8WTD<
M(/\ "A.0/H.:ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1AN4
MC)&1C(H H'7=*&H?8#J-M]KSM\GS!NSZ8]:O22)#$\LKJD: LS,<  =2:X7Q
MBNA06]GI!1+29IXR+DPD"( Y+%\<D_7J>:Z+Q'9:AJ6DK;Z9+; LZL_GY*R(
M.=O'8\9]J +%CXAT?4[C[/8ZE;7$V"VR-PQQZUI5ROAK4@=3N-+O])M]/U6)
M-Q," )-'G[RGTSVKJJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *AMKRWO$=[:>.94<QL4;(##J/K5#4YY;F=-*M'*RR#=/*O6&+U_P!X]!^)
M[5RVA7+:1X!UV>U&TVUS=>7_ +.#@?E0!V0U;3S>?9!>0_:-VWR]XSN]/K[5
M<KBI+&-/A4 .)%M!<B3^+S?O[L^N>]=+H=X^HZ#87DGWYH$=OJ1S0!H4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4+W=O'=QVCSQBXD4LD1;YF
M ZD"F7U[%86CW$N2!PJ+]YV/ 4>Y/%<A#:SP_$339KMLW=Q9RR2@'(3GA![
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M0J\J%&D9P!@*>0 /7O6[10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!R7C_?-I5K;PP3S2B[BE*Q0L^%4\G@5?\ $VF'Q'X9EAMB1*=L
ML&\%?F4Y (/(STK>HH X_6%G\4Z=8Z8MI<0LTJ27IEB*K$J\L,GAB3P,9]:[
M <#%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1SS);P/+)N
MV*,G:I8_D.37+_#\/!H#6L\$\,RSR.4EA9.">#R.:ZRB@#$C\0F=KB :3J*W
M*,46.2 A9/0[_NX_&K6A::=(T2VL2P9HU)8KTR26./;)-:-% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 175PEI;23NLC*BY*QH78^P Y)KCK
M?Q,KW1U"]T766N%!6");)BL2^Q[L>Y_#Z]M10!RNI6MT-:T;Q&MK(?+B,5U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7G2RG8R0<R)(A0@>N#VH V**Q(_%6ERQ1S(TQMY9O(CG$1*.^<8!^O<\5MT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PM]HW]M^#]7@5<SQ
MWUQ+#_O*YX_$9'XUV\L8EB:-BP##!*,5/X$<BJ6FZ-9:29/L:RH)"696G=P2
M>2<,3S[T <=\-#=7^G1S7/\ J+#?!;9[EB"Q_ 8 ^IK@[!;AHO$0M\Y\@E\=
M=GFKN_2O<(M*LX+%K.WC:"!F9R(G9#DG)Y!SU-9UEX-T/3KCS[.T>&0C!*SR
M?,.X(W<CV- '%:J5_P"%,Z=TY=/SW-6?XACF\_P?'=KF3[-$'##_ &AP?PKT
MQ/"^CIY:BS'E1R>:D)=C&K>H0G:/RI-2\,:3JUZEW>V[RSQ@!&\YUV8YX .!
M0!Q=_P ?&FTQQ\J?^BS3;&1(?C+?O(ZH@5B68X _=K7:R>%M(EU4:H\$IO5(
M(F^T29&.G\73VIUYX8T74-274+JPCDNEQ\Y)YQTR,X/XT <1=;)/C3;'AE*H
MP[_\LC@U'X?*K\2/$0D)$1CGW[>N-PS7<OX6TB35O[4:"3[=NW"83R CMQSC
M&.,4EMX4T>SOY+Z&VD6YE#"20SN2^[KG)YH \S\C5/!=S;E6%]H=W(CICE).
M05/^R_ /OCO7LP.0#65%X;TJ'[.$M3Y=NV^&)I&*(WJ%)QG\*U: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>form10-k_021.jpg
<TEXT>
begin 644 form10-k_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -]!14# 2(  A$! Q$!_\0
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M^@'#_P!]/_\ %5WE% '!_P#"G/ __0#A_P"^G_\ BJ/^%.>!_P#H!P_]]/\
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M3G@?_H!P_P#?3_\ Q5=Y10!P?_"G/ __ $ X?^^G_P#BJ/\ A3G@?_H!P_\
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M0!P?_"G/ _\ T X?^^G_ /BJ/^%.>!_^@'#_ -]/_P#%5WE% '!_\*<\#_\
M0#A_[Z?_ .*H_P"%.>!_^@'#_P!]/_\ %5WE% '!_P#"G/ __0#A_P"^G_\
MBJ/^%.>!_P#H!P_]]/\ _%5WE% '!_\ "G/ _P#T X?^^G_^*H_X4YX'_P"@
M'#_WT_\ \57>44 <'_PISP/_ - .'_OI_P#XJC_A3G@?_H!P_P#?3_\ Q5=Y
M10!P?_"G/ __ $ X?^^G_P#BJ/\ A3G@?_H!P_\ ?3__ !5=Y10!P?\ PISP
M/_T X?\ OI__ (JC_A3G@?\ Z </_?3_ /Q5=Y10!P?_  ISP/\ ] .'_OI_
M_BJ/^%.>!_\ H!P_]]/_ /%5WE% '!_\*<\#_P#0#A_[Z?\ ^*H_X4YX'_Z
M</\ WT__ ,57>44 <'_PISP/_P! .'_OI_\ XJC_ (4YX'_Z </_ 'T__P 5
M7>44 <'_ ,*<\#_] .'_ +Z?_P"*H_X4YX'_ .@'#_WT_P#\57>44 <'_P *
M<\#_ /0#A_[Z?_XJC_A3G@?_ * </_?3_P#Q5=Y10!P?_"G/ _\ T X?^^G_
M /BJ/^%.>!_^@'#_ -]/_P#%5WE% '!_\*<\#_\ 0#A_[Z?_ .*H_P"%.>!_
M^@'#_P!]/_\ %5WE% '!_P#"G/ __0#A_P"^G_\ BJ/^%.>!_P#H!P_]]/\
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M3G@?_H!P_P#?3_\ Q5=Y10!P?_"G/ __ $ X?^^G_P#BJ/\ A3G@?_H!P_\
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M0!P?_"G/ _\ T X?^^G_ /BJ/^%.>!_^@'#_ -]/_P#%5WE% '!_\*<\#_\
M0#A_[Z?_ .*H_P"%.>!_^@'#_P!]/_\ %5WE% '!_P#"G/ __0#A_P"^G_\
MBJ/^%.>!_P#H!P_]]/\ _%5WE% '!_\ "G/ _P#T X?^^G_^*H_X4YX'_P"@
M'#_WT_\ \57>44 <'_PISP/_ - .'_OI_P#XJC_A3G@?_H!P_P#?3_\ Q5=Y
M10!P?_"G/ __ $ X?^^G_P#BJ/\ A3G@?_H!P_\ ?3__ !5=Y10!P?\ PISP
M/_T X?\ OI__ (JC_A3G@?\ Z </_?3_ /Q5=Y10!\F_&SPWI'AGQ)86FCV4
M=K"UL6<(2=S;R,G)/:BM7]HK_D<=/_Z]#_Z&U% 'L'P;_P"28Z/_ -<C_P"A
MM7>UP7P;_P"28Z/_ -<C_P"AM7>T %%%% !1110 4444 %5)].MKJ^M[N>,2
M26X/E;N0I/4X]?>K=<WXN\76OA:UB\R.>6YG;;&D,+2;?5B .@H P]:TM-0^
M+WA^YL8U6>PMY9;Z5./W;#"*WKDYQ]*@\!SOJ/Q$\<WD_P TL-S':QL>JQJ#
M\H_'FI="\<>'HKA+.QBU2[U&]F'F2/8R(9&/<LPP% _("I-/M3X/\>ZY=72,
MNEZULN$N0"P291AD; XSU% &+?:E/H/CCQY%9G:K:,NH #H)@I7=_+\JZ+X;
MV4,GPHTJ)T!6ZM"\V?XR^2Q/US5/2/#LGB#6_%.MWT+P6^J6_P#9]H'!5S %
M(+D=LD\?2F^&M3G\,>!QH-]:3?VOIZ-;06\<9;[1U\MD.,$$$9].: )O@[J$
MU]\/X$G8L;6>6V0G^XK87]*K_&"XD_L71M.!_<ZAJD,,X_O)G./S J[X>M5^
M&OPU1[Z":>:$&>YCMDWL9'.2 /;./PJ/Q=:GQSX%LM5T1&EN;>:._M8G^4LR
M'E".QQD?6@!?BX!:_#NXO(?DEL)H)X&'&QE< 8_ UEV-[+K'QNM3<?-'9Z$D
MT*GHKR8W'Z]JN>,+AO'&@6F@:9#*9;Z:)KS?&5%K$I#/OSWXP!WJ74](?P[\
M0]-\2PPO)ITEE_9]V4!8P@<HY _A[&@"OX@NCI?QL\,M#Q_:-E-;SX_B"D%<
M_0TGPZFDU+QKXXU&X^:5;Y;6,G^&- <*/;O5N*P?Q/\ $ZUUY8F&E:3:M%!,
MRE?.F<\[0>H '7UIFE6W_"&>.=?DND==*UAENX;D*65)0,.C8Z9ZB@"'P]=&
MR^-/BG28R1!<6L%YM'028 )^IR*]&KAO"&DW%SXOU_Q;=P/ E\4M[-)!AS"@
M^^1VW'MZ"NYH *JW>HV=AM^U7"1;AD;CUJU7$>/0#-9Y'\#?TH ZT:C:$ B8
M8/L:/[1M?^>H_(U); ?98>!]Q?Y5+M'H* *W]HVO_/4?D:/[1M?^>H_(U9VC
MT%&T>@H K?VC:_\ /4?D:/[1M?\ GJ/R-6=H]!1M'H* *W]HVO\ SU'Y&C^T
M;7_GJ/R-6=H]!1M'H* *W]HVO_/4?D:/[1M?^>H_(U9VCT%&T>@H K?VC:_\
M]1^1H_M&U_YZC\C5G:/04;1Z"@"M_:-K_P ]1^1H_M&U_P">H_(U9VCT%&T>
M@H K?VC:_P#/4?D:/[1M?^>H_(U9VCT%&T>@H K?VC:_\]1^1H_M&U_YZC\C
M5G:/04;1Z"@"M_:-K_SU'Y&C^T;7_GJ/R-6=H]!1M'H* *W]HVO_ #U'Y&C^
MT;7_ )ZC\C5G:/04;1Z"@"M_:-K_ ,]1^1H_M&U_YZC\C5G:/04;1Z"@"M_:
M-K_SU'Y&C^T;7_GJ/R-6=H]!1M'H* *W]HVO_/4?D:/[1M?^>H_(U9VCT%&T
M>@H K?VC:_\ /4?D:/[1M?\ GJ/R-6=H]!1M'H* *W]HVO\ SU'Y&C^T;7_G
MJ/R-6=H]!1M'H* *W]HVO_/4?D:/[1M?^>H_(U9VCT%&T>@H K?VC:_\]1^1
MH_M&U_YZC\C5G:/04;1Z"@"M_:-K_P ]1^1H_M&U_P">H_(U9VCT%&T>@H K
M?VC:_P#/4?D:/[1M?^>H_(U9VCT%&T>@H K?VC:_\]1^1H_M&U_YZC\C5G:/
M04;1Z"@"M_:-K_SU'Y&C^T;7_GJ/R-6=H]!1M'H* *W]HVO_ #U'Y&C^T;7_
M )ZC\C5G:/04;1Z"@"M_:-K_ ,]1^1H_M&U_YZC\C5G:/04;1Z"@"M_:-K_S
MU'Y&C^T;7_GJ/R-6=H]!1M'H* *W]HVO_/4?D:/[1M?^>H_(U9VCT%&T>@H
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M7_GJ/R-6=H]!1M'H* *W]HVO_/4?D:/[1M?^>H_(U9VCT%&T>@H K?VC:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV#X-_P#),='_ .N1_P#0VKO:X+X-_P#),='_ .N1_P#0VKO: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD?&]A<3Q0742;XH@
MPDQU7/?'I774A (((!!Z@T 8_A_7+?5;147Y)XE >,G]1ZBMFN)UWP_/I=Q_
M:FDEE"'<R+U3W'J/:MO0/$,.L0A'Q'=J/F3LWN* -NBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"CK7_(#O\ _KWD_P#037SI9?\ 'G%_NBOHO6O^0'?_ /7O)_Z"
M:^=++_CSB_W17N97_#EZK\CS<9\<?1EBBF[UW8W#/I3J]4XPHHHS0 4AZ4M(
M>E 'K7PG_P"1(3_KZF_]"KN*X?X3_P#(D)_U]3?^A5W%?,8S_>)^K/8H?PH^
M@4445RFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?,7[17_ "..G_\ 7H?_ $-J*/VBO^1QT_\ Z]#_ .AM10![!\&_
M^28Z/_UR/_H;5WM<%\&_^28Z/_UR/_H;5WM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 '48-<;K_AR2UF_M/2=R.AWO&G
M4>Z_X5V54]2U2UTJW\ZZDV@G"J.2Q]A0!E^'?$D>JQBWN"$O%'(Z!_<?X5T%
M><6]I/XCUMY[*'['$KAFD3^'_P"R->C 8 &<^] "T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!1UK_ ) =_P#]>\G_ *":\"\+^']4\3K##IT16W!"37;_ '(_7'J?85]"
MW=M'>V<UK+N\N9#&VTX.",&N7U?Q!H?P^TFUT^VM\L%VP6<&-V/[Q]!ZDUZ6
M#Q$J<73IQO)O3[CDKTHR:E-V2(;KX9Z$_A\6%O"8[I%REY_RU+^K'N#Z5Y!M
MF@GFM;E=EQ YCD4]B*]#\#>.]0O_ !+/I^M,F+YC):E>D9 _U8]L#/UJ+XJZ
M EFT?B.TAPN=E[L7J.SG'ITKMP\ZM*M[&L[\VJ?G_6GJ<]6,)P]I36VYY_-*
ML,99OH!ZFO2/"_PRBFT]KKQ&KM<3#]W;QR$" =LD=6_2J_P[\&?:F77M9M6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?_KD?_0VKO: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KB/'O^NL_]QOZ5V]<1X]_UUG_N-_2@#LK;_CUA_P!Q?Y5+45M_QZP_
M[B_RJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH HZU_P @._\ ^O>3_P!!-?.E
ME_QYQ?[HKZ+UK_D!W_\ U[R?^@FOG2R_X\XO]T5[F5_!+U7Y'FXSXX^C+%%%
M%>J<84444 %(>E+2'I0!ZU\)_P#D2$_Z^IO_ $*NXKA_A/\ \B0G_7U-_P"A
M5W%?,8S_ 'B?JSV*'\*/H%%%%<IL%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'S%^T5_R..G_P#7H?\ T-J*/VBO^1QT
M_P#Z]#_Z&U% 'L'P;_Y)CH__ %R/_H;5WM<%\&_^28Z/_P!<C_Z&U=[0 444
M4 %%%% !1110 4444 %%%,DFBA ,LB1@]"S 4 /HI 0P!4@@]"*:TT:.J/(B
MLWW5+ $_2@!]%%% !13$FCE+".1'*G!VL#@TXD*"20 .I- "T4V.1)4#QNKJ
M>ZG(I))8X@#)(B G +'% #Z*.M% !7$>/?\ 76?^XW]*[>N(\>_ZZS_W&_I0
M!V5M_P >L/\ N+_*I:BMO^/6'_<7^52T %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZT_YXC\S0!9R/449'J*K?V=:?\\1^9H_LZT_YXC\S0!9R/449'J*K?V=:?\
M/$?F:/[.M/\ GB/S- %G(]11D>HJM_9UI_SQ'YFC^SK3_GB/S- %G(]11D>H
MJM_9UI_SQ'YFC^SK3_GB/S- %G(]11D>HJM_9UI_SQ'YFC^SK3_GB/S- %G(
M]11D>HJM_9UI_P \1^9H_LZT_P">(_,T 6<CU%&1ZBJW]G6G_/$?F:/[.M/^
M>(_,T 6<CU%&1ZBJW]G6G_/$?F:/[.M/^>(_,T 6<CU%&1ZBJW]G6G_/$?F:
M/[.M/^>(_,T 6<CU%&1ZBJW]G6G_ #Q'YFC^SK3_ )XC\S0!9R/449'J*K?V
M=:?\\1^9H_LZT_YXC\S0!9R/449'J*K?V=:?\\1^9H_LZT_YXC\S0!9R/449
M'J*K?V=:?\\1^9H_LZT_YXC\S0!9R/449'J*K?V=:?\ /$?F:/[.M/\ GB/S
M- %G(]11D>HJM_9UI_SQ'YFC^SK3_GB/S- %G(]11D>HJM_9UI_SQ'YFC^SK
M3_GB/S- %G(]11D>HJM_9UI_SQ'YFC^SK3_GB/S- %G(]11D>HJM_9UI_P \
M1^9H_LZT_P">(_,T 6<CU%&1ZBJW]G6G_/$?F:/[.M/^>(_,T 6<CU%&1ZBJ
MW]G6G_/$?F:/[.M/^>(_,T 1:R1_8=_R/^/>3_T$U\ZV7_'G%_NBOH/5[&V3
M1;]EB /V>3N?[IKY\LO^/2+_ '17N97\$O5?D>;C/CCZ,L4445ZIQA1110 4
M'I10>E 'K/PH./!"9_Y^9O\ T*NWR/45P?PMM8)_!:-+&&;[3+S_ ,"KL_[.
MM/\ GB/S-?,8S_>)^K/8H?PH^A9R/449'J*K?V=:?\\1^9K+U+4-!TBXC@OG
M$4DB[U&UCD9QVKCG.,%S2=D=,*<JCY8*[-W(]11D>HKE_P#A)/"O_/P/^^'_
M ,*/^$C\*_\ /P/^^'_PK#ZWA_YU]Z-OJF(_D?W,ZC(]11D>HKE_^$C\*_\
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MD>HJM_9UI_SQ'YFC^SK3_GB/S- %G(]11D>HJM_9UI_SQ'YFC^SK3_GB/S-
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MW]*[>N(\>_ZZS_W&_I0!V5M_QZP_[B_RJ6HK;_CUA_W%_E4M !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+_*I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!FH_X6MX7_Y[7?\ X#-7DF*,4?V=A_/[_P#@!];J>1ZW_P +6\+_ //:[_\
M 9J/^%K>%_\ GM=_^ S5Y)BC%']G8?S^_P#X ?6ZGD>T:/\ $+0-<U:+3+*6
MX-S*K,H>!E& ,GDUU->%^ ?^2AZ=_P!<9O\ T&O=*\O&T(4:BC#:W^9V8>HZ
MD+R"BBBN$Z HHHH **** "BBB@ HHHH **** /F+]HK_ )''3_\ KT/_ *&U
M%'[17_(XZ?\ ]>A_]#:B@#V#X-_\DQT?_KD?_0VKO:X+X-_\DQT?_KD?_0VK
MO: "BBB@ J"YO;6R0-=7$4*L< R.%!/XU/7)^,UTZ.ZTF_UJU\[3+25WD8QE
MQ%(1\CL!VZ_I0!N:CKFEZ1IW]H7]_!;VG:61P%/T]:72=:TW7;/[7I=[#=P9
MP7B;.#Z'TKRB.*+XI^/([V2%QX.T1?D$J%([F7Z'' _D*[#PU>:)=^-=47P^
M(E@@MD2Z,";8WDR=N.Q( (R* .VHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *XCQ[_KK/_<;^E=O7$>/?]=9_P"XW]* .RMO^/6'_<7^52U%;?\ 'K#_
M +B_RJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZU_R [_\ Z]Y/_037SI9?
M\><7^Z*^B]:_Y =__P!>\G_H)KYTLO\ CSB_W17N97\$O5?D>;C/CCZ,L444
M5ZIQA1110 4AZ4M(>E 'K7PG_P"1(3_KZF_]"KN*X?X3_P#(D)_U]3?^A5W%
M?,8S_>)^K/8H?PH^@5YWX^_Y#UE_U[M_Z%7HE>=^/O\ D/67_7NW_H5>'FG^
M[/U7YGM93_O*]'^1S5%%%?,'U04444 %%%% %W0_^1FTS_KN/Y5ZY7D>A_\
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M?_@4U']HZO\ ]!S4_P#P*:MO[+?\Z^YD?7%_+^1]%T5\Z?VCJ_\ T'-3_P#
MIJ/[1U?_ *#FI_\ @4U']EO^=?<P^N+^7\CZ+HKYT_M'5_\ H.:G_P"!35#=
M:IK$<)8:YJ8((_Y>F]?K0LJ;=N=?<P^NQ_E9](T51A2]:WB(N(^47JGM3_+O
MO^?B+_OBO'.XMT54\N^_Y^(O^^*/+OO^?B+_ +XH MT54\N^_P"?B+_OBCR[
M[_GXB_[XH MT54\N^_Y^(O\ OBCR[[_GXB_[XH MT54\N^_Y^(O^^*/+OO\
MGXB_[XH MT54\N^_Y^(O^^*/+OO^?B+_ +XH MT54\N^_P"?B+_OBCR[[_GX
MB_[XH MT54\N^_Y^(O\ OBCR[[_GXB_[XH MT54\N^_Y^(O^^*/+OO\ GXB_
M[XH MT54\N^_Y^(O^^*/+OO^?B+_ +XH MT54\N^_P"?B+_OBCR[[_GXB_[X
MH MT54\N^_Y^(O\ OBCR[[_GXB_[XH MT54\N^_Y^(O^^*/+OO\ GXB_[XH
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M^*\L["W153R[[_GXB_[XH\N^_P"?B+_OB@"W153R[[_GXB_[XH\N^_Y^(O\
MOB@"W153R[[_ )^(O^^*/+OO^?B+_OB@"W153R[[_GXB_P"^*41WNX9GB(SS
M\E %JBBB@#YB_:*_Y''3_P#KT/\ Z&U%'[17_(XZ?_UZ'_T-J* /8/@W_P D
MQT?_ *Y'_P!#:N]K@O@W_P DQT?_ *Y'_P!#:N]H **** "L#Q#>:Q'>:;9:
M*UHL]S(QE:Y!(6-1R0!U/(K?K)UW1/[8@B,5[/8W<#%X;J#&Y"1@@@\$'T-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,W_H->Z5X7X"_P"2B:=_UQF_]!KW2O"S/^+'T_5GI8/^&_4****\L[ HHHH
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MM:\13++KFJ,KSJGW84'W8U^F: .SHHHH **** "BBB@ HHHH **** "BBB@
MHHHH *XCQ[_KK/\ W&_I7;UQ'CW_ %UG_N-_2@#G_BKT\/?[K_\ H(KA:[KX
MJ]/#W^Z__H(KA:^GP7^[Q^?YGCU_XLOZZ!111748A1110 56OO\ CV;ZC^8J
MS5:^_P"/9OJ/YBJC\2$]CZ5MO^/6'_<7^52U%;?\>L/^XO\ *I:^->Y[X444
M4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O /%?\
MR/>N?]=U_P#017O]> >*_P#D>]<_Z[K_ .@BO6ROXY>GZG#C?ACZ_H9M%%%>
MV>>%%%% !1110!N^ O\ DHFG?]<9O_0:]TKPOP%_R433O^N,W_H->Z5X69_Q
M8^GZL]+!_P -^H4445Y9V!1110 4444 %%%% !1110 4444 ?,7[17_(XZ?_
M ->A_P#0VHH_:*_Y''3_ /KT/_H;44 >P?!O_DF.C_\ 7(_^AM7>UP7P;_Y)
MCH__ %R/_H;5WM !1110!%-;Q7&SS8U?RW#KD=&'0UG>(?$FE>%M,.H:O=""
M#<%7C+.Q[*.YK6KD?&SK82:9K4^E3:G:V,CF6&&,.\>X8$@7OC'ZT 8X^-W@
MT]);_P#\!&K3\%^-[#QCJNJ_8+>4QVNP)=/$4\Q3GY>>X-5[OQ)#H\4'B9=,
MO'T74(U-PJVQ\VW<?=<IUP1P?PJ/P#XD/B/Q!KT^GVEQ#H0,9MVFA\O=*0=Y
M /8\4 =_1110 4444 %%%% !1110 4444 %%%% !1110 5Q'CW_76?\ N-_2
MNWKB/'O^NL_]QOZ4 <_\5>GA[_=?_P!!%<+7=?%7IX>_W7_]!%<+7T^"_P!W
MC\_S/'K_ ,67]= HHHKJ,0HHHH *K7W_ ![-]1_,59JM??\ 'LWU'\Q51^)"
M>Q]*VW_'K#_N+_*I:BMO^/6'_<7^52U\:]SWPHHHI %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1UK_D!W_P#U[R?^
M@FOG2R_X\XO]T5]%ZU_R [__ *]Y/_037SI9?\><7^Z*]S*_@EZK\CS<9\<?
M1EBBBBO5.,**** "D/2EI#TH ]:^$_\ R)"?]?4W_H5=Q7#_  G_ .1(3_KZ
MF_\ 0J[BOF,9_O$_5GL4/X4?0*\[\??\AZR_Z]V_]"KT2O._'W_(>LO^O=O_
M $*O#S3_ '9^J_,]K*?]Y7H_R.:HHHKY@^J"BBB@ HHHH NZ'_R,VF?]=Q_*
MO7*\CT/_ )&;3/\ KN/Y5ZY7OY/_  Y^OZ'SF<_Q(>GZA1117M'B!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7@'BO\ Y'O7/^NZ_P#H(KW^O /%?_(]
MZY_UW7_T$5ZV5_'+T_4X<;\,?7]#-HHHKVSSPHHHH **** -WP%_R433O^N,
MW_H->Z5X7X"_Y*)IW_7&;_T&O=*\+,_XL?3]6>E@_P"&_4****\L[ HHHH *
M*** "BBB@ HHHH **** /F+]HK_D<=/_ .O0_P#H;44?M%?\CCI__7H?_0VH
MH ]@^#?_ "3'1_\ KD?_ $-J[VN"^#?_ "3'1_\ KD?_ $-J[V@ HHHH *YS
MQ=XCO_#UM:'3=&FU:YN)2@@A;#  9)^E='7-^,/%4/A2WL[I],NK^6>4PQQV
MJ;G!QD\?A0!SG_"=>,FX/PYO\'UG2M'P+XAU[7+S4_[5T*33+167[*K$'&.&
M4X[YYK+_ .%N/_T)?B/_ ,!&_P *M>!;G7-8\4:UKMWI=QIFE7<<2V]O<\.S
MKD%]O;(H ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCQ[_KK/_<;
M^E=O7$>/?]=9_P"XW]* .?\ BKT\/?[K_P#H(KA:[KXJ]/#W^Z__ *"*X6OI
M\%_N\?G^9X]?^++^N@4445U&(4444 %5K[_CV;ZC^8JS5:^_X]F^H_F*J/Q(
M3V/I6V_X]8?]Q?Y5+45M_P >L/\ N+_*I:^->Y[X4444@"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *[C^5>N5Y'H?_(S:9_UW'\J]<KW\G_AS]?T/G,Y_B0]/U"BBBO:/$"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O /%?_(]ZY_UW7_T$5[_7@'BO_D>]
M<_Z[K_Z"*];*_CEZ?J<.-^&/K^AFT445[9YX4444 %%%% &[X"_Y*)IW_7&;
M_P!!KW2O"_ 7_)1-._ZXS?\ H->Z5X69_P 6/I^K/2P?\-^H4445Y9V!1110
M 4444 %%%% !1110 4444 ?,7[17_(XZ?_UZ'_T-J*/VBO\ D<=/_P"O0_\
MH;44 >P?!O\ Y)CH_P#UR/\ Z&U=[7!?!O\ Y)CH_P#UR/\ Z&U=[0 4444
M%<UXQ\4Z?X3MK2\NK2>[NI9?)M8+==TCN1R!72UPOQ+U.RT2TTG5;FVNI;BU
MO UJ;>/?\^TC:P]&&10!FO\ $KQ+N/E_#O6MG;< #6WX.\5:MXBU/48M2T2X
MTA;>.,QQ7'WGW9R?TK)7XPZ>5!/A[Q""1R/L+5K^$?&D'BW5M16WTZZM$M8X
MP3=Q>6[EL]CV&* .PHHHH *KWU[;Z=8S7EU((X(4+NQ[ 58KEWNHM?O)9C/$
M=,L]ZQJ7!$\HR"3[+T^M %[PMXCM_%>@Q:O:PR102LRJLGWL XS^E5_^$L2X
MEO\ ^S;&:^@L',=Q-&0!O'WE0'[Q'?%<U\.KIK?X3RRQLIGC%TX4'G(9B*M_
M!^/;\,].=FW/,TDKD]2S.2<T =CINI6FKZ;!J%C*);:= Z..X_QIFL:Q9:%I
M<VHW\OEV\0&3C)))P !W)/%<1\(9C_9.N6*Y\FTU:=(N> I.<#VIGQ5DDEU#
MPA89Q;SZLC2>AVC(!H ZF/Q.L5Y8V^I64MC_ &@=MJ\C AFQD(V/NL1VJUK>
MO6NAQVXF#RW%U*(;:WC&7E<]A^')/:N3^,9\KP,MTI(FMKZWEB(X(8..GYFJ
M5]/)?_&_PXDIQ%#I4DZ(>F]N"?K0!VMCX@CGUA]'NX'M-0$7G)&QW"1,X+*P
MZX/!]*9<^(T_MJ71]/MGO;V",2SJK!5B!^Z"Q[GL*Y;QX_V3X@^!KN(D3-=R
M6[;3@LC+R/ITJ+X3N]U>^,;V<YGEUF1&)ZX48 _*@#N-$UNTUVS>XM2RM%(T
M,T3C#Q2+U5AZUI5YQX/E,'Q;\:V4>?)D\BX(!X#D8)^I_I7H] !7$>/?]=9_
M[C?TKMZXCQY_KK/_ '&_I0!S_P 5>GA[_=?_ -!%<+7<?%%_,'A_Y'7"O]X8
M_A%</7TV"_W>/S_,\>O_ !9?UT"BBBNLQ"BBB@ JM??\>S?4?S%6:KWHS;'Z
MC^=5'=">Q]*6W_'K#_N+_*I:HP7FVVA'V><_(O(7VI_VW_IVG_[XKXU[GOEN
MBJGVW_IVG_[XH^V_].T__?%("W153[;_ -.T_P#WQ1]M_P"G:?\ [XH MT54
M^V_].T__ 'Q1]M_Z=I_^^* +=%5/MO\ T[3_ /?%'VW_ *=I_P#OB@"W153[
M;_T[3_\ ?%'VW_IVG_[XH MT54^V_P#3M/\ ]\4?;?\ IVG_ .^* +=%5/MO
M_3M/_P!\4?;?^G:?_OB@"W153[;_ -.T_P#WQ1]M_P"G:?\ [XH MT54^V_]
M.T__ 'Q1]M_Z=I_^^* +=%5/MO\ T[3_ /?%'VW_ *=I_P#OB@"W153[;_T[
M3_\ ?%'VW_IVG_[XH MT54^V_P#3M/\ ]\4?;?\ IVG_ .^* +=%5/MO_3M/
M_P!\4?;?^G:?_OB@"W153[;_ -.T_P#WQ1]M_P"G:?\ [XH MT54^V_].T__
M 'Q1]M_Z=I_^^* +=%5/MO\ T[3_ /?%'VW_ *=I_P#OB@"W153[;_T[3_\
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MI_;3_P ^T_\ WQ7OY/\ PY^OZ'SF<_Q(>GZEJBJGVW_IVG_[XH^V_P#3M/\
M]\5[1XA;HJI]M_Z=I_\ OBC[;_T[3_\ ?% %NBJGVW_IVG_[XH^V_P#3M/\
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MU1110!\Q?M%?\CCI_P#UZ'_T-J*/VBO^1QT__KT/_H;44 >P?!O_ ))CH_\
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M\2Z)XHTRW,\^GEH+B!3AI+=^NWW!P<5V5% '%3Z1<>)O'6F:Q/!-;Z9I$;M
MLHVM-,W&['4!1Z]<TS2]-N?!_BK7)([.:XTG57%VC0+N:*;&&0CT/!!KN**
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MOJ;_ -"KN*^8QG^\3]6>Q0_A1] KSOQ]_P AZR_Z]V_]"KT2O._'W_(>LO\
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M4)5L5N//O3YC%]Y!/->EQ6-M!<M<10HDCH$8J,9 Z"@"Q1110 4444 %%%%
M!1110 4444 %%%% !1110 5Q'CW_ %UG_N-_2NWKB/'O^NL_]QOZ4 <_\5>G
MA[_=?_T$5PM=U\5>GA[_ '7_ /017"U]/@O]WC\_S/'K_P 67]= HHHKJ,0H
MHHH *K7W_'LWU'\Q5FJU]_Q[-]1_,54?B0GL?2MM_P >L/\ N+_*I:BMO^/6
M'_<7^52U\:]SWPHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7OY/_#GZ_H?.9S_$AZ?J%%%%>T>(%%%% !1110 4444 %%%% !1110 4444
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M****]4XPHHHH *0]*6D/2@#UKX3_ /(D)_U]3?\ H5=Q7#_"?_D2$_Z^IO\
MT*NXKYC&?[Q/U9[%#^%'T"O._'W_ "'K+_KW;_T*O1*\[\??\AZR_P"O=O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!1UK_D!W__ %[R?^@FOG2R_P"/.+_=%?1>M?\ (#O_ /KWD_\
M037SI9?\><7^Z*]S*_@EZK\CS<9\<?1EBBBBO5.,**** "D/2EI#TH ]:^$_
M_(D)_P!?4W_H5=Q7#_"?_D2$_P"OJ;_T*NXKYC&?[Q/U9[%#^%'T"O._'W_(
M>LO^O=O_ $*O1*\[\??\AZR_Z]V_]"KP\T_W9^J_,]K*?]Y7H_R.:HHHKY@^
MJ"BBB@ HHHH NZ'_ ,C-IG_7<?RKURO(]#_Y&;3/^NX_E7KE>_D_\.?K^A\Y
MG/\ $AZ?J%%%%>T>(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]8BC;Q3K9**3]MDZBJWD1?\ /-?RKW5EM)I/F?X'FO%SNTDOQ/>?^$S\-?\
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M/#5S874IEETN]ELPQZE%/RY_#^50_%34)ELM&T.%V0:QJ$=O,4."8ARP!]\
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MNOBH01X>P0?E?_T$5PM?3X+_ '>/S_,\>O\ Q9?UT"BBBNHQ"BBB@ JM??\
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M:*_Y''3_ /KT/_H;44?M%?\ (XZ?_P!>A_\ 0VHH ]@^#?\ R3'1_P#KD?\
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M=O\ T*O#S3_=GZK\SVLI_P!Y7H_R.:HHHKY@^J"BBB@ HHHH N:* WB3358
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M"?E5BB@"O]AM?^>"?E1]AM?^>"?E5BB@"O\ 8;7_ )X)^5'V&U_YX)^56**
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MB@ HHHH **** "N(\>_ZZS_W&_I7;UQ'CW_76?\ N-_2@#G_ (J]/#W^Z_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 5X!XK_Y'O7/^NZ_^@BO?Z\
M\5_\CWKG_7=?_017K97\<O3]3AQOPQ]?T,VBBBO;//"BBB@ HHHH W? 7_)1
M-._ZXS?^@U[I7A?@+_DHFG?]<9O_ $&O=*\+,_XL?3]6>E@_X;]0HHHKRSL"
MBBB@ HHHH **** "BBB@ HHHH ^8OVBO^1QT_P#Z]#_Z&U%'[17_ "..G_\
M7H?_ $-J* /8/@W_ ,DQT?\ ZY'_ -#:N]K@O@W_ ,DQT?\ ZY'_ -#:N]H
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M>'I*<&WK;6QN4445ZQXQ\Q?M%?\ (XZ?_P!>A_\ 0VHH_:*_Y''3_P#KT/\
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M_P#KT/\ Z&U% 'L'P;_Y)CH__7(_^AM7>UP7P;_Y)CH__7(_^AM7>T %%%%
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MHKY\]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZU_R
M[_\ Z]Y/_037SI9?\><7^Z*^B]:_Y =__P!>\G_H)KYTLO\ CSB_W17N97\$
MO5?D>;C/CCZ,L4445ZIQA1110 4AZ4M(>E 'K7PG_P"1(3_KZF_]"KN*X?X3
M_P#(D)_U]3?^A5W%?,8S_>)^K/8H?PH^@5YWX^_Y#UE_U[M_Z%7HE>=^/O\
MD/67_7NW_H5>'FG^[/U7YGM93_O*]'^1S5%%%?,'U04444 %%%% %W0_^1FT
MS_KN/Y5ZY7D>A_\ (S:9_P!=Q_*O7*]_)_X<_7]#YS.?XD/3]0HHHKVCQ HH
MHH **** "BBB@ HHHH ^=M7_ .1HUK_K]DJO5C5_^1HUK_K]DJO7V$?A7HOR
M1X3W?J_S"BBBF(**** "NZ^$?_(7UK_KG%_6N%KNOA'_ ,A?6O\ KG%_6N;&
M?[O/^NJ-:/\ %C_70]7HHHKY<]DX3XA_Z_3/^!_TKD:Z[XA_Z_3/^!_TKD:^
M1QW^]3^7Y'V.7_[K#Y_FPHHHKD.T**** "HKC_5?B/YU+45Q_JOQ'\Z3V*CN
MCVN'_41_[H_E3Z9#_J(_]T?RI]?<H^ >X4444Q!1110 4444 %%%% !7@'BO
M_D>]<_Z[K_Z"*]_KP#Q7_P CWKG_ %W7_P!!%>ME?QR]/U.'&_#'U_0S:***
M]L\\**** "BBB@#=\!?\E$T[_KC-_P"@U[I7A?@+_DHFG?\ 7&;_ -!KW2O"
MS/\ BQ]/U9Z6#_AOU"N;\=?\BM-_UT3_ -"%=)7-^.O^16F_ZZ)_Z$*\+%_P
M)^C/7P7^\T_5'G0Z44#I17QZ/LPHHHH **** $?[A^E>G>$/^15L/]P_S->8
MO]P_2O3O"'_(JV'^X?YFO4RK^._3]3R<W_@+U_1FY1117TI\N?,7[17_ "..
MG_\ 7H?_ $-J*/VBO^1QT_\ Z]#_ .AM10![!\&_^28Z/_UR/_H;5WM<%\&_
M^28Z/_UR/_H;5WM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%<-8:K<>+O&NLV,5W+;Z3H^V!E@;:TTYY)+=<+TQZT =S17(^$]=NI==USP
MWJ,IFNM,D5HIF&#+ XRI;_:'0UUU !7$>/?]=9_[C?TKMZXCQ[_KK/\ W&_I
M0!S_ ,5>GA[_ '7_ /017"UW/Q68*/#N2!P__H(KA/,3^\/SKZ?!?[O'Y_F>
M-7_BR_KH.HIOF)_>'YT>8G]X?G778QN.HIOF)_>'YT>8G]X?G18+CJK7W_'L
MWU'\Q4_F)_>'YU6OI$^S'YAU'?W%.*]Y WH?2]M_QZP_[B_RJ6HK;_CTA_W%
M_E4M?&O<]\;)_JV^AKQ2#[A_WF_G7M<G^K;Z&O$H678>1]X_SKP,XWA\_P!#
MZ')?AJ?+]2:BDW+ZBC<OJ*\.Z/>L+12;E]11N7U%%T%A:*3<OJ*-Z^HHN@L=
M;\//^/S4_I'_ .S5WM<%\.R#=ZG@]H__ &:N]KZG+/\ =8_/\V?)9I_O4OE^
M04445Z)YH4444 %%%% !1110 5Q7Q6_Y$.Y_Z[1?^ABNUKB?BN0/ 5R3_P ]
MHO\ T,5U8/\ WB'JC*M_#EZ,\C'2EI@D3'WA^=+YB?WA^=?46/%NAU%-\Q/[
MP_.CS$_O#\Z+!<=13?,3^\/SH\Q/[P_.BP7"3[A^E>T_#?\ Y$'2_P#<;_T(
MUXG)(FQOF'3UKVSX;G/@#2O]QO\ T(UYV9?P%Z_HSJPG\5^GZG54445\\>J>
M6Z]J&HQ^)-0CBU&ZCC63"HLA ''850_M+5/^@I>?]_34WB%@/%.I9/\ RT'\
MJH;E]17Q=:I+VL_>>[ZOOZGW%&G'V4?=6RZ+LO(L_P!I:I_T%+S_ +^FC^TM
M4_Z"EY_W]-5MR^HHW+ZBL_:2_F?WO_,T]G'^5?<O\BS_ &EJG_04O/\ OZ:/
M[2U3_H*7G_?TU6W+ZBC<OJ*/:2_F?WO_ ##V<?Y5]R_R+/\ :6J?]!2\_P"_
MIKH?!%[>W&O7$=S>W$Z"WR%D<D YZURN]?45T?@(@^(;G!_Y=Q_Z%75@JDGB
M(+F>_=]GYG+C(16&F[+;LO+R/1Z***^N/C0HHHH **** "BBB@ HHHH HZU_
MR [_ /Z]Y/\ T$U\Z67_ !YQ?[HKZ+UK_D!W_P#U[R?^@FOG*RD3['%\P^[Z
MU[N5_P .7JOR/-QGQQ]&6J*;YB?WA^='F)_>'YUZMCBN.HIOF)_>'YT>8G]X
M?G18+CJ0]*3S$_O#\Z0R)C[P_.BP71ZY\)_^1(3_ *^IO_0J[BN'^$Q!\#H0
M<_Z5-_Z%7<5\OC/]XGZL]FA_"CZ!7G?C[_D/67_7NW_H5>B5YUX_(&O663_R
M[M_Z%7AYI_NS]5^9[64_[RO1_D<W12;U]11N7U%?+W1]786BDW+ZBC<OJ*+H
M+"T4FY?44;E]11=!8O:'_P C-IG_ %W'\J]<KR+0F!\3Z9@C_7C^1KUVOH,G
M_AS]?T/G,Y_B0]/U"BBBO:/#"BBB@ HHHH **** "BBB@#YVU?\ Y&C6O^OV
M2J]3ZPZCQ3K66'_'[)WJMYB?WA^=?817NKT7Y(\%[OU?YCJ*;YB?WA^='F)_
M>'YU5A7'44WS$_O#\Z/,3^\/SHL%QU=U\(_^0OK7_7.+^M<'YB?WA^==W\(F
M#:OK6"#^[B_K7+C/]WG_ %U1K0?[V/\ 70]8HHHKY<]HX3XA_P"OTS_@?]*Y
M&NM^(A GTS/^W_2N1WKZBOD<>U]:G\OR/L<O_P!UA\_S8M%)N7U%&Y?45QW1
MW6%HI-R^HHW+ZBBZ"PM17'^J_$?SJ3<OJ*BG9?+ZCJ/YTFT.*U/;(?\ 41_[
MH_E3Z9#_ *B/_='\J?7W2/@'N%%%%,04444 %%%% !1110 5X!XK_P"1[US_
M *[K_P"@BO?Z^?\ Q8ZCQYK@+ ?OU_\ 017K97\<O3]3AQOPQ]?T,ZBF^8G]
MX?G1YB?WA^=>Y8\ZXZBF^8G]X?G1YB?WA^=%@N.HIOF)_>'YT>8G]X?G18+F
M_P" O^2B:=_UQF_]!KW2O"O #JWQ$T[!!_<S?^@U[K7@YI_%CZ?JST\'_#?J
M%<WXZ_Y%:;_KHG_H0KI*YOQT<>%IO^NB?^A"O"Q?\"?HSU\%_O-/U1YT.E%-
M#KCJ*7<OJ*^-31]I86BDW+ZBC<OJ*=T%A:*3<OJ*-R^HHN@L#_</TKT[PA_R
M*MA_N'^9KR]V78>1TKU#P?\ \BK8?[A_F:]7*7>O+T_4\C-_X"]?T9N4445]
M*?+GS%^T5_R..G_]>A_]#:BC]HK_ )''3_\ KT/_ *&U% 'L'P;_ .28Z/\
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MJEJUKJ!>ZMV()BEP5)!R*TZ*:;3N@.:_X0'PU_T"K?\ [XH_X0'PU_T"K?\
M[XKI:*T]M4_F?WO_ #,_90_E7W+_ ".:_P"$!\-?] JW_P"^*/\ A ?#7_0*
MM_\ OBNEHH]M4_F?WO\ S#V4/Y5]R.:_X0'PU_T"K?\ [XH_X0'PU_T"K?\
M[XKI:*/;5/YG][_S#V4/Y5]R.:_X0'PU_P! JW_[XK4M-&@T^UCM;)Y+>WC&
M$BC("K]*T:*F52<E:3;^;*4(QV5BI]B?_G[N/^^A_A1]B?\ Y^[C_OH?X5;H
MJ"C&F\+Z7<3O// ))7.6=@,DTS_A$='_ .?1/RK<HK)T:3=W%?<O\C55JJT4
MG][_ ,S#_P"$1T?_ )]$_*C_ (1'1_\ GT3\JW**7L*7\J^Y?Y#]O5_G?WO_
M #,/_A$='_Y]$_*C_A$='_Y]$_*MRBCV%+^5?<O\@]O5_G?WO_,P_P#A$='_
M .?1/RJ:U\.V%C*TMHA@D8;2T> 2/2M:BJ5*G%W44ODO\A.M4:LY/[W_ )E3
M[$__ #]W'_?0_P */L3_ //W<?\ ?0_PJW16AD5/L3_\_=Q_WT/\*/L3_P#/
MW<?]]#_"K=% %3[$_P#S]W'_ 'T/\*/L3_\ /W<?]]#_  JW10!4^Q/_ ,_=
MQ_WT/\*/L3_\_=Q_WT/\*MT4 5/L3_\ /W<?]]#_  H^Q/\ \_=Q_P!]#_"K
M=% %*33Q+&\<MS,\;@JRL1@@]1TK&'@#PRH &E6X _V*Z:BKC.4?A;7S)<8R
MW5SFO^$!\-?] JW_ .^*/^$!\-?] JW_ .^*Z6BJ]M4_F?WO_,GV4/Y5]R.:
M_P"$!\-?] JW_P"^*/\ A ?#7_0*M_\ OBNEHH]M4_F?WO\ S#V4/Y5]R.:_
MX0'PU_T"K?\ [XH_X0'PU_T"K?\ [XKI:*/;5/YG][_S#V4/Y5]R,NPT&TTN
MU%KI^ZUMPQ81Q8 R>IJS]B?_ )^[C_OH?X5;HK-MMW9IL5/L3_\ /W<?]]#_
M  JI=^'K&_E62\4W$BC:K28) ]*UJ*F45)6DKE1E*+O%V,/_ (1'1_\ GT3\
MJ/\ A$='_P"?1/RK<HK+V%+^5?<O\C3V]7^=_>_\S#_X1'1_^?1/RH_X1'1_
M^?1/RK<HH]A2_E7W+_(/;U?YW][_ ,S#_P"$1T?_ )]$_*C_ (1'1_\ GT3\
MJW**/84OY5]R_P @]O5_G?WO_,Q8O"VEP3)-# L<J'*.H&5-7_L3_P#/W<?]
M]#_"K=%:1A&*M%6,Y3E/63OZE3[$_P#S]W'_ 'T/\*/L3_\ /W<?]]#_  JW
M15$E3[$__/W<?]]#_"C[$_\ S]W'_?0_PJW10!4^Q/\ \_=Q_P!]#_"C[$__
M #]W'_?0_P *MT4 5/L3_P#/W<?]]#_"C[$__/W<?]]#_"K=% %3[$__ #]W
M'_?0_P */L;_ //W<?\ ?0_PJW10!SLO@;P]//)/-IT,DTK%Y'91EF/4FF?\
M(#X:_P"@5;_]\5TM%:^VJ?S/[W_F0Z<'NE]R.:_X0'PU_P! JW_[XH_X0'PU
M_P! JW_[XKI:*/;5/YG][_S%[*'\J^Y'-?\ " ^&O^@5;_\ ?%'_  @/AK_H
M%6__ 'Q72T4>VJ?S/[W_ )A[*'\J^Y'-?\(#X:_Z!5O_ -\5<T_POIFD/(^F
MPBT:4 .80!NQTS6S12=6;5G)_>_\QJG!.Z2^XJ?8G_Y^[C_OH?X4?8G_ .?N
MX_[Z'^%6Z*S+,N[T&SU H;S=<%,[?,P<9JO_ ,(CH_\ SZ)^5;E%9RI4Y.\H
MI_)?Y&D:M2*LI-+U?^9A_P#"(Z/_ ,^B?E1_PB.C_P#/HGY5N45/L*7\J^Y?
MY%>WJ_SO[W_F8?\ PB.C_P#/HGY4?\(CH_\ SZ)^5;E%'L*7\J^Y?Y![>K_.
M_O?^9A_\(CH__/HGY4A\(:,1@VB?E6[13]A2_E7W+_(/;U?YW][_ ,RH+)@
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MZ*** "BBB@ HHHH ^8OVBO\ D<=/_P"O0_\ H;44?M%?\CCI_P#UZ'_T-J*
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M==GVFYQ\B_W44<*/IUKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ KG=5\::5H^JVUA<&:0S$J\D$32+"1_?*@[<T>-M8;1/#,URDODM))'
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M[PC&/G([]J[2)UDA21/N,H9?H: 'T444 %%%% !1110 4444 %%%% !1110
M4444 %%5[Z::WL)YK>W-Q-'&62$'!<@<#/O46EWEQ>:9:3WUJ;*ZF0,]L[AB
MA[C/>@!NJZWI>AVXGU2_@M(B<!IG"Y/MZUPFJZ9)XBU+_A+O!?B.*[U&W"J+
M1I UO(@_@('()ZYK4FU?3[;Q_=:9X@2!#<Q(VFRW"C8Z@8= 3QNSSCT(JOJG
MA>T\/>);#Q#X>5+.XN)U@O+6+A+J-NIVCC<.N?K0!&NLZ#\1-*GT'6;%K;68
M_EDL)P1+#)CAT8=L\AA74^&-$DT#0[>RN+Z>^N$0"2XG;<6/^ J['I=E%JDV
MI+;I]LF01M-M^;:.@SZ5<H **** "BBB@ HILCB.-G()"@G &36?8:[INJ"+
M[#=QSF5"Z[#G '!SZ<\<T 4=>\8Z!H)-OJ.L06<[C:N[)*D]"<=/QKB+&[U'
MP /[4CO9?$GA2Z(>6\4AY[4]SQ]Y/ITK:\'ZOI>J6]UH6MPVRZ];RR+>6]PB
M[I<L<.,_>4@BET'P]#X;\87VE:4X_L2]M3/)9YW+;2YQ\H[!@3Q[4 17GA_2
M_%FKV'B3PKJHM;L./M5Y9,,30D<HPZ%NG7D5WT,2PQ+&N2%&,DY)^M4]'T>P
MT+3H[#3K=(+=,D*@QDGJ3[FK] !1110 4444 %%%% !1110 4444 %%%% !1
M110 5%<7,-I"99Y$C0<98X&>PHN;F*SMI+B=PD4:EF8]A7 :EJVD>.M0C\*Z
MOH>MV\<P,\3R1F-'"]'R#D>V: +%SH\GQ'T:&\OX=0T.XMI6>P9)AN4_PRD#
M^1K,&O[ ?!OQ'LDEDN!LM;Q(BT5Z.@QCE9*=:ZUJOPUF@TGQ )M1T!V$5EJ<
M2%I(O[L<JCJ>P(ZUZ"+>VU!K2^FM?WL67A\U?FC)&,X['% &)X+\,W/AS3#;
MW>IW5]AV^SK<-N\B/^%!ZG'>NGHHH **** "BBB@ K)\0:VVC:>\MO:27]YP
M(K.%@)),G'&>WO4NL:S#HUJ)'AGN97.(K>W3?)(?0#^M<#+IUC\2I)=9TXZK
MHVO:7((HI;E"@C8<[2N<,#WH T-:\)ZS]O/BSP]>2VVO,B^=97$FZ"9 /]40
M.A'8BLRYFTSXDP" 0W&C^,-.8$':5EM6SUW=&0\_6MKP[XXNI-3_ .$<\0Z=
M-;>((QTAC+13I_ST5NR_7I780V-M!=SW4<*K<3X\V3'S-CH,^@H 9IMF]C8Q
M0RW,ES,J@23R?>D;N35NBB@ HHHH **** "BBB@#YB_:*_Y''3_^O0_^AM11
M^T5_R..G_P#7H?\ T-J* /8/@W_R3'1_^N1_]#:N]K@O@W_R3'1_^N1_]#:N
M]H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N$^
M(/B^+1_*T8SW=@]\JK_:<4>Y+7+ #<>Q/.#70:[?W*W%II.GW$=M?7HD,<TB
M;@BH 20.YY%5+32[FU\+75IXNO8=95BWFR&W" QGH"H]/6@#,UGPQJRG3M9\
M/Z@EWJ%K"J2QWAS%? #AF(Z.,DAO>J<$'C7Q9K6G-K6G0:)I=A.MR\<<_FR7
M#K]T9'1<U)H7A[Q#X;\1+IFD:@)O"[Q^<!=#>]MSQ'&>X/OT%>@T %%%% !1
M110 4V21(HVDD8*BC+,QP /6G53U+3+75[-K.]0RVS\21;B X]#CM0 W2=5M
MM:L%OK-Q);2$^7(IR' .,BKU>47&D:U\*KB34-!674O"K-ON=,)W26OJT9[C
MVKT'1/$VD^(-$75]/O(Y+0KN9B<&/'4,.Q% &'XJCL](UFP\53J&M;<^1>GJ
M$4GY9"/56_'!KJX9(;^U24(6B?#+O7&1V.#7,^'X[C6[G5KR[A0Z'=3(]E#*
MOS/MZR$>A(! ]LUUM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 9?B/0[?Q)X>O=(N21'<QE-PZJ>Q'T-><:#XZU?P04\/>.K&YVPC9;:K!&9(
MYD' W8Z'%>MTUT21=KJK#T(S0!QS>,H/$I.F^&8YKIY1MEO#$RPVZGJ22.6Q
MT KKK6W6UM8;=,[8D"#/H!BGHB1KM154>BC%.H **** "BBB@ HHK*U;4;V
MFVTJSCN[_P OS=DLGEHJYQR<'DG.!['I0!0\;^'Y_$.@>59R>7?VTBW%L^<?
M.O;/;/-8FA?$JT2/[!XG5],U.$;9#*A"2$=QZ?R]*[339[N?3;>74+=;6[=?
MWD(<,%;T![U+-:6UR09[>*4CH70-C\Z ,)-4C\4R10Z:LC::CK)/=LA59-IR
M$3/WLD#)Z ?6NCI%4*H50 !T I: "BBB@ HHHH **** "BBB@ HHHH ****
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MQY-74@ACD>2.)$=_OLJ@%OJ>]24 %%%% !1110 4444 %%%% !1110 4444
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MD3=<V4,A6*YESP64<8'IWKO:* $50JA5 "@8 '04M%% !1110 4444 %%%%
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MBTS6[N)9M!U?[#= @,)8A)&Z]^#T/O5S2=&ATL22>9)<7<^#/<S'+N?3V [
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M6VU2W+,AW13QG;)$?56ZBL_1_ =OIT\$M]J^IZL;8YMTO9MR1GL=H')'J<T
M;VA_:?[!L/MF[[3Y">9NZYQW]ZOT44 %%%% !1110 4444 %%%% !1110!\Q
M?M%?\CCI_P#UZ'_T-J*/VBO^1QT__KT/_H;44 >P?!O_ ))CH_\ UR/_ *&U
M=[7!?!O_ ))CH_\ UR/_ *&U=[0 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX3OC:ZI;W&HWNG*1):VMS<.T ]"%/4>F: /0[:;[1:0S[=OF(KX/;(S4M
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M)_2@#2\':?J>FZ$(]5F#SR3/,L0Z0(QR(\]\>M=!110 4444 %%%% !1110
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M1%Z 5+0 4444 %%%% !1110 4444 %%%% !1110 4444 ?,7[17_ "..G_\
M7H?_ $-J*/VBO^1QT_\ Z]#_ .AM10![!\&_^28Z/_UR/_H;5WM<%\&_^28Z
M/_UR/_H;5WM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %<AK>G^'_ !7-]DM-1MX=9LR7@FMY
M!YD3#V'49ZBK.NZR]T=2T'24F?5DM?,4[2(^<?+O[$@_K67J?A^#Q#<V<,48
MT?5;.S6X1X,;X78X521U4;6H ;HFJ1B+_A#?%=I%#<B/9&6'[F[3U4_WO;U]
MZO\ A;0M2T6^N;:+46ET",@V<;X9^1R-W]T?S_7-TZVU#QI;167B?28Q%92;
M_MB$8N65L?)W .#GU]J[U$2*-8XU5$4855& !Z"@!U%%% !1110 4444 %%%
M% !1110 4444 %%%% !12!@V<$'!P<'I67X@_MLZ5(F@?91?D?(]SG8OX#K0
M!G:QXPT6SUA/#]Y=R6MQ=H42X*$1ACP%W] WH*Y---U?X5.]SIWVG6?#$AWW
M,#G?<VI[NI_B7N16EIVMZ3XVMKCPIXKTU+368U_?V,PP&_Z:1-W'<$<BHO"5
MKXFL]9N-%-]#J?A> O&EW*VZX4@8\HGOC/6@"9M"T'QQJVF^*=$O98"AS/<V
MA,9N$Q_JV]>>OI6SK?@31?$&I07M^MRWEQB-H$G98YE!R ZC[V/>MZQL;;3;
M.*TLX4AMXEVI&@P *L4 ,AABMX4AAC6.)%"HBC 4#L!3Z** "BBD)"@DG '4
MF@!))$BC:1V"HH+,3T %<@U[XJUJXMM2T5;.VTQ"2L5WDO>(>_'^K]1U/K6A
M9:[IWB>?5M)B<[81Y+A@59PPY90>J\XR*X]=!^*5E;)HVG:SI*Z?"/+AO9(B
M9O+'3(Z9 [T :OCWP?J/B"/3]=T.86/B/3?F@+$8<'K&Q]*H:=\4=0M$2S\3
M>$M8MM2!V?Z);&6.4^JD=*KM\*=1,$M_J/CO6WU-%+K.DVR-"!G[OI7;>#;V
M]U'PAI=WJ)#7DD(\QP,;R.-V/?&?QH @T4ZIK.HC6-2LGT^WC0I9V<A!DYZO
M)C@$XP!VKI*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ****  C((KSCX<^(8+&XO\ P7J3K;ZK87,IB1_E\^)F+*RY
MZ_>KT>N2\7_#O1/&#QW%T);74(O]5>VK;)5_'O0!TEYIUEJ%O-;W=K%-%,NR
M174$,/0UQ?@#PZWA[5];M].O9Y?#P=1:0R-N6.3GS I_NC@4_3?A_J, $.I>
M--;O[,<?9RZQAAZ,P&X_G7:V]O#:6\=O;QK'%&-JHHP * )0,# Z4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5EZK
M=:Q!?::FFV$-S;2S%;R227:84QPRCN<U/=SPW'VC38;V*.^:$D*&!= > VWK
M7G\.I:Y\,YDMM>N)M6\,.=L>IE=TUH3VE ZK[]J /0[IFN;*[ALYT%R$9%(.
M=CD<9].U>:07MIXC\/'PCXE\.75OK 0Q &W/EM(.DB2]!Z]:NWWA>_T^ZD\7
M^!M2:YN;L^?<V<TN^&^4\_*?X6QP"*T++6-&^)VB3Z:Z:A9W,+ 742[HI;:4
M=MX_IU% %:/Q5>SR_P!@>'[!=7BTZ 1:CJ$LVR)2%P44X^9_TKL]&CLX]&M%
ML(%@M?+!CC48"CTKSW2K77IM)3PEI?AZ30K&)C%>:C(R_.F>3$!RS,/XCTS7
MI=M;QVEK%;0KMBB0(@] !@4 2T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'S%^T5_R..G_]>A_]#:BC]HK_ )''3_\ KT/_ *&U% 'L'P;_ .28
MZ/\ ]<C_ .AM7>UP7P;_ .28Z/\ ]<C_ .AM7>T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.Q^*(
M+_6;K0;9'CU*%G5\XQ&FW*R>X.5XZ_E5W7-3EL;"Y^PI'-?1PF41%L80=6(_
MIW-96M^#[/6HDU+3Y?L6K@B:&_BX+-@?>]00!0!BVLVH_#N^:+5))=0T&Y<;
M;\C+V[=,./[OO_\ JK:U7P[9>*+V'5+#6KBVD6/R9);&4?O8SSM)'U_6J=CK
M.KZO_P 4[K.AS1W3!H[JX$8-NT>T_.I/&2<8%=7IFFVFD:=#8640BMX5VJH_
MF?4F@"6TM8;*TAM8%V0PH$1?0 8J:BB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JAK U)M-ECTGR5O'4K')/G9&?4@<GZ5?HH \S\(^,[K1+]?"?C.(66J
M!C]GO2?W5[D]0W][VKTRL?Q)X8TKQ7I;Z?JML)8SRCCAXV_O*>QKA-'/CO0-
M6;P=E-1M6CWVNL2'YK>+IAQW8=AWH W;W3M!\<ZOJ6D:K9&2ZTF5-ES&3&RA
MUW *Z\@]B,UU&D:18Z'IL6GZ= (;:(?*H.23W))Y)/K3='TBVT2P6UM@S$DO
M+*YR\KGJS'N2:T* "BBB@ HHHH *YJY\?^$+:>6VN/$.G))&Q1T:8<'N#70W
M$"7,#PR;MCC#;3@D?6N,UCX;Z([QWVD:1IL5]"NWRI8 8IU[JX['_:ZB@!FL
M:_X)UB.*:/Q1IUI?0\VUW#<('C]O=?53Q5O0?&ECJ5X=#OK^R.I[,H]K."ER
MO]Y,'(/JO450TGPWX&UPR6\_A6PM=1M_]?9RVZJZ>XQ]Y3V8<5J#X;>#1)%+
M%X?LXY(V#(\0*%2.X(- $:^%=5N=4N(M4U^XO-#(!BM-JHQ/=9' RR]/KWKK
M$1(HUCC4*B@!5 P !VI0,  =J6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N:\7>,=/\+0VT
M5Q=01WE[((K=96PH)_B;T45TFX;MN1G&<5G:KX?TK6[.XM=1L8;B*<8D#KR?
M3!ZB@#+&C:7HNGS:U(D%SJ"(9GOI<!I&Q_>[#L!TJWIFMV'B'P^;N>VD@@>/
M]_;WD14H".0P/45YK=66J_#2\MUU$W6L^"8Y-Z#[TEDV?E+C^)1VKOM2\0V>
MKZ*D&ASPWUSJ416WV-N55(P7?'11G\^* ,"#PQKGA'Q#;KX1N(Y-#OY"9[*Z
MRT=GW+QD= ?[M=]:64%FLGDQJC2N9)6 P78]2:@T33GTG0[+3Y+F2Y>VA6-I
MI/O.0.IJ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
MQ?M%?\CCI_\ UZ'_ -#:BC]HK_D<=/\ ^O0_^AM10![!\&_^28Z/_P!<C_Z&
MU=[7!?!O_DF.C_\ 7(_^AM7>T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 4=3U)=.@4B-IKB5MD$"GYI']/8
M=R>PK-M8KG1!)J.L:Q)*L[#SHV4>3"QX&SNJC@9/7J<5E>*_"NKW=['KVCZG
M*-6M,^3 V!$4[H!ZGN3U]NU#2=<'CZ[_ +(U:);(6@#7E@S8>YD!Z>NP8!(Z
MDD=AR ;FI^ M&U>]>_N'O!=R=9X[EE..P],>U8&F^%]<73&&E>*]0BN+>9H&
M@G*R1C:^WC/0;<&NB\0&31](LK31$;[8;E!:VX8X8 Y<'/1 N[V''M6S9Z;;
MV4]U<1)B:[D\R9B<DG  'T % $UI UM:QPR3R3NH^:63[SGN?_K5-110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !30B!V<* S=3CDTZB@ HH
MHH **** "BBB@ HHHH P?$7AF#7WLY/,DMIX)0WVF!BDNSN@(['O6W%$D$21
M1KM1!@#T%/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7[17_(XZ?_UZ'_T-J*/VBO\ D<=/_P"O0_\ H;44 >P?!O\ Y)CH_P#UR/\
MZ&U=[7!?!O\ Y)CH_P#UR/\ Z&U=[0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5QWC7PG#J4!U>P9[76K4;
MH)X!AI".BG'7TS_2NQHH Q=!TN\MXEOM8G6YU:2,+(X&%B']Q!V'J>Y_"MJB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **9++'"A>6140=68X%.!# $$
M$'H10!R>E7L>H_$/6X)VS+IT426\;?PJP)9Q]3QGVKK:\Z\=>%M<CUZV\8^$
MG4ZM;Q^5<6C'"W46>GU%)IWQ:@E5;;4O#FN6FI]&M5LVDRWLPXQ]: .XO/LM
MY,=*N[=)XIX69TD *L,@$$?C7.^#? -AX4DNIXC([RRNT$3R%UM8R>$0'I[F
MM'0H]1O[N36=4MOL;O'Y5M:%LM%'G)+D<;B<<=L5OT %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\Q?M%?\CCI_P#UZ'_T
M-J*/VBO^1QT__KT/_H;44 >P?!O_ ))CH_\ UR/_ *&U=[7!?!O_ ))CH_\
MUR/_ *&U=[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'S%^T5_R..G_ /7H?_0VHH_:*_Y''3_^O0_^AM10![!\&_\ DF.C_P#7(_\
MH;5WM<%\&_\ DF.C_P#7(_\ H;5WM !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 8WBC1I]>T&?3[>\DM7D*DLG\0!R4/L>AJ#7_"&D^)]"
M33=0M518U'DO%P]NP'!0]L5T%% 'EFG>*-9^'E['HWC5S<Z0QV6>M@$C'99?
M0^]>@NFF^)=+"LJW5C(0PR/EDP<CZBG:SHUGKVG&POXQ+;.RL\9&0V#G%7HX
MTBC6.-0B* %51@ >E "@!0   !P *6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YB_:*_Y''3_P#KT/\ Z&U%
M'[17_(XZ?_UZ'_T-J* /8/@W_P DQT?_ *Y'_P!#:N]K@O@W_P DQT?_ *Y'
M_P!#:N]H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#YB_:*_Y''3_^O0_^AM11^T5_R..G_P#7H?\ T-J* /8/
M@W_R3'1_^N1_]#:N]K@O@W_R3'1_^N1_]#:N]H **** "BBB@ HHHH ****
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M1110 4444 %%%% !5.72M.FE:66PM7D;EG:)23]3BKE%--K832>Y1_L72O\
MH&VG_?A?\*L6]K;VD9CMH(H4)R5C0*,^O%344W*3W8));!7)ZQ\/],U[5;;4
MK^\U![JT;=;,L^T1'.<J *ZRBI&16T)MX%C::28C^.0Y)K!\0>#-.U^^M]1,
MEQ9:I;<17MH^R0#^Z3W'L:Z.B@#"L/"]K:ZDFIW5S<:A?QH8XY[I@?*4]0@
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MU@J&-8;AMX53_#TZ<UCV/P]M-)$\&E:MJECITQ+&RAF'EH3UV9&5S[&NQHH
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M_P"&B_$?_0,L/S?_ !H ^G**^8_^&B_$?_0,L/S?_&C_ (:+\1_] RP_-_\
M&@#Z<HKYC_X:+\1_] RP_-_\:/\ AHOQ'_T#+#\W_P : /IRBOF/_AHOQ'_T
M#+#\W_QH_P"&B_$?_0,L/S?_ !H ^G**^8_^&B_$?_0,L/S?_&C_ (:+\1_]
M RP_-_\ &@#Z<HKYC_X:+\1_] RP_-_\:/\ AHOQ'_T#+#\W_P : /IRBOF/
M_AHOQ'_T#+#\W_QH_P"&B_$?_0,L/S?_ !H ^G**^8_^&B_$?_0,L/S?_&C_
M (:+\1_] RP_-_\ &@#Z<HKYC_X:+\1_] RP_-_\:/\ AHOQ'_T#+#\W_P :
M /IRBOF/_AHOQ'_T#+#\W_QH_P"&B_$?_0,L/S?_ !H ^G**^8_^&B_$?_0,
ML/S?_&C_ (:+\1_] RP_-_\ &@#Z<HKYC_X:+\1_] RP_-_\:/\ AHOQ'_T#
M+#\W_P : /IRBOF/_AHOQ'_T#+#\W_QH_P"&B_$?_0,L/S?_ !H ^G**^8_^
M&B_$?_0,L/S?_&C_ (:+\1_] RP_-_\ &@#Z<HKYC_X:+\1_] RP_-_\:/\
MAHOQ'_T#+#\W_P : /IRBOF/_AHOQ'_T#+#\W_QH_P"&B_$?_0,L/S?_ !H
M^G**^8_^&B_$?_0,L/S?_&C_ (:+\1_] RP_-_\ &@#Z<HKYC_X:+\1_] RP
M_-_\:/\ AHOQ'_T#+#\W_P : /IRBOF/_AHOQ'_T#+#\W_QH_P"&B_$?_0,L
M/S?_ !H ^G**^8_^&B_$?_0,L/S?_&C_ (:+\1_] RP_-_\ &@#Z<HKYC_X:
M+\1_] RP_-_\:/\ AHOQ'_T#+#\W_P : /IRBOF/_AHOQ'_T#+#\W_QH_P"&
MB_$?_0,L/S?_ !H ^G**^8_^&B_$?_0,L/S?_&C_ (:+\1_] RP_-_\ &@#Z
M<HKYC_X:+\1_] RP_-_\:/\ AHOQ'_T#+#\W_P : /IRBOF/_AHOQ'_T#+#\
MW_QH_P"&B_$?_0,L/S?_ !H ^G**^8_^&B_$?_0,L/S?_&C_ (:+\1_] RP_
M-_\ &@#Z<HKYC_X:+\1_] RP_-_\:/\ AHOQ'_T#+#\W_P : /IRBOF/_AHO
MQ'_T#+#\W_QH_P"&B_$?_0,L/S?_ !H ^G**^8_^&B_$?_0,L/S?_&C_ (:+
M\1_] RP_-_\ &@#Z<HKYC_X:+\1_] RP_-_\:/\ AHOQ'_T#+#\W_P : /IR
MBOF/_AHOQ'_T#+#\W_QH_P"&B_$?_0,L/S?_ !H ^G**^8_^&B_$?_0,L/S?
M_&C_ (:+\1_] RP_-_\ &@#Z<HKYC_X:+\1_] RP_-_\:/\ AHOQ'_T#+#\W
M_P : /IRBOF/_AHOQ'_T#+#\W_QH_P"&B_$?_0,L/S?_ !H ^G**^8_^&B_$
M?_0,L/S?_&C_ (:+\1_] RP_-_\ &@#Z<HKYC_X:+\1_] RP_-_\:/\ AHOQ
M'_T#+#\W_P : /IRBOF/_AHOQ'_T#+#\W_QH_P"&B_$?_0,L/S?_ !H ^G**
M^8_^&B_$?_0,L/S?_&C_ (:+\1_] RP_-_\ &@#Z<HKYC_X:+\1_] RP_-_\
M:/\ AHOQ'_T#+#\W_P : /IRBOF/_AHOQ'_T#+#\W_QH_P"&B_$?_0,L/S?_
M !H ^G**^8_^&B_$?_0,L/S?_&C_ (:+\1_] RP_-_\ &@#Z<HKYC_X:+\1_
M] RP_-_\:/\ AHOQ'_T#+#\W_P : /IRBOF/_AHOQ'_T#+#\W_QH_P"&B_$?
M_0,L/S?_ !H ^G**^8_^&B_$?_0,L/S?_&C_ (:+\1_] RP_-_\ &@#Z<HKY
MC_X:+\1_] RP_-_\:/\ AHOQ'_T#+#\W_P : /IRBOF/_AHOQ'_T#+#\W_QH
M_P"&B_$?_0,L/S?_ !H ^G**^8_^&B_$?_0,L/S?_&C_ (:+\1_] RP_-_\
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3M8()((O* A)PPR3DY/O10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>graph_001.jpg
<TEXT>
begin 644 graph_001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,&!$D# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP_&G^_X:_P"^7_QKVBB@#Q?[#\:?[_AK_OE_\:/L/QI_O^&O^^7_ ,:]HHH
M\7^P_&G^_P"&O^^7_P :/L/QI_O^&O\ OE_\:]HHH \7^P_&G^_X:_[Y?_&C
M[#\:?[_AK_OE_P#&O:** /%_L/QI_O\ AK_OE_\ &C[#\:?[_AK_ +Y?_&O:
M** /%_L/QI_O^&O^^7_QH^P_&G^_X:_[Y?\ QKVBB@#Q?[#\:?[_ (:_[Y?_
M !H^P_&G^_X:_P"^7_QKVBB@#Q?[#\:?[_AK_OE_\:/L/QI_O^&O^^7_ ,:]
MHHH \7^P_&G^_P"&O^^7_P :/L/QI_O^&O\ OE_\:]HHH \7^P_&G^_X:_[Y
M?_&C[#\:?[_AK_OE_P#&O:** /%_L/QI_O\ AK_OE_\ &C[#\:?[_AK_ +Y?
M_&O:** /%_L/QI_O^&O^^7_QH^P_&G^_X:_[Y?\ QKVBB@#Q?[#\:?[_ (:_
M[Y?_ !H^P_&G^_X:_P"^7_QKVBB@#Q?[#\:?[_AK_OE_\:/L/QI_O^&O^^7_
M ,:]HHH \7^P_&G^_P"&O^^7_P :/L/QI_O^&O\ OE_\:]HHH \7^P_&G^_X
M:_[Y?_&C[#\:?[_AK_OE_P#&O:** /%_L/QI_O\ AK_OE_\ &C[#\:?[_AK_
M +Y?_&O:** /%_L/QI_O^&O^^7_QH^P_&G^_X:_[Y?\ QKVBB@#Q?[#\:?[_
M (:_[Y?_ !H^P_&G^_X:_P"^7_QKVBB@#Q?[#\:?[_AK_OE_\:/L/QI_O^&O
M^^7_ ,:]HHH \7^P_&G^_P"&O^^7_P :/L/QI_O^&O\ OE_\:]HHH \7^P_&
MG^_X:_[Y?_&C[#\:?[_AK_OE_P#&O:** /%_L/QI_O\ AK_OE_\ &C[#\:?[
M_AK_ +Y?_&O:** /%_L/QI_O^&O^^7_QH^P_&G^_X:_[Y?\ QKVBB@#Q?[#\
M:?[_ (:_[Y?_ !JMH/BSQUIOQ,TWPUXH.EM'=VDET/L,;9PIP.2?7->XUXUX
ML_Y.0\-?]@>;_P!#- 'IE+24M !1110 4444 %%%% !1110 4444 %%%% '/
M^/-/\0:IX7NK;POJ<.CZTY7R;RX3>B 'G(P>HKX \3?#+QWX8_:'T_4/B7XG
ML?%WB$V9^S7MC"85CMRWRQE=J@D<\XK]'Z^0/VEO^3A]%_[!B?\ H59T?W>/
MPLX[NK37ROT[7ZVWTOL55]_!8F#Z4YO\.O=>1];Z?_R#[7_KDG_H(KD?C!XQ
M/@KP+J5Y&QCNI+>6.W<8^63RSM.#UYQ77:?_ ,@^U_ZY)_Z"*\>_:NMY)?A[
M;[(V;9<%FP.@V'DUS9C)PH3<7_5T=&"@JE:$9;?\ ^<_@S^QSX4_:.\#P_$+
MXIZ:GB#Q3J<<WG7/G2P$R*2L;%4(7@#TKL?V2[V\^$_Q6UGX,23J^FZ/I_\
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M+]J+_GEXK_\ !8G_ ,11_P +"_:B_P">7BO_ ,%B?_$4?ZHUO^@JE_X%_P
M/[3C_P ^Y?<?I'17YN?\+"_:B_YY>*__  6)_P#$4?\ "POVHO\ GEXK_P#!
M8G_Q%'^J-;_H*I?^!?\  #^TX_\ /N7W'Z1T5^;G_"POVHO^>7BO_P %B?\
MQ%9NO_&;]HSPIIYO];OO$.DV(8(;F\L(XT#'H,E.IJH\'UYM1CB:3;_O/_('
MFD$KNG+[C]-:*\,_8Y\>:_\ $3X/IJWB/4I-4U$WL\9GE50=JM@#Y0!Q7N=?
M&8S"SP6(GAIN[B[.VVAZE*HJL%46S"BBBN,U"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[+7C7BS_ ).0\-?]@>;_ -#- 'IE+24M !1110 4444 %%%% !1110 4444
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MK#:7"/#/<M(FY>.A/K0L0^91E&UQ5>%Z*PU;$X?&1J>S5VDO^"?H51117:?
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M:1;AN =+8R"3GHV^X_\ '10!^B7A/PW9^#?"VCZ!IZ[+#2[.*R@7TCC0(OZ
M5K5Q'QOUZ_\ "_P=\:ZOI=PUIJ-EI%U/;SJ 3'(L3%6&>X/-?GC^R]XQ_:;_
M &UOA7IVFVGC>7P1X4TMY(-3\9N@DU+5YRY8Q18 VJB, 3QVR2: /U%HK\T?
M 'Q"^,?[&?[7_A/X4>/_ !O+X_\  GC$A;'4-2R98MQ*JP)RRLKX5ER0=P-?
M6G[3GQN^)OPDN-"B^'?PDU#XEB\61KN:UEV):[<!5.,G+9)].* />J*^$O\
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M\<?VI\#?&'A.21GET'76EC#$_+#/&"H'_ XI#^-?H50 4444 %%%% !1110
M4444 %>->+/^3D/#7_8'F_\ 0S7LM>->+/\ DY#PU_V!YO\ T,T >F4M)2T
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M;+:3K RNR[3DK'R,=J /U \,_P#(MZ3_ ->D7_H K0FF2WB>61@D:*69F.
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M*)-$O9V!54^9HI&8^OES*1_N4 ?:_P"T=_R0/XA?]@*\_P#135\X_P#!(?\
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MXAZ7X^^+7@!M-CO(Q;7$F_[7 8OO+QC/7I7TE7B7Q%C2/XN?#;8BI_I$WW5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>^_ZX2?^@FDRX?$CX#_81_Y+MK?_ %XS_P#HVOT(K\]_V$?^2[:W_P!>,_\
MZ-K]"*X\)_#/NN-?^1L_\,0HHHKM/@@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KQKQ9_P G(>&O^P/-_P"AFO9:\:\6?\G(>&O^P/-_Z&:
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M#_PO[X;_ /0\:%_X'1_XT?\ "_OAO_T/&A?^!T?^-=G/'N?#_4,7_P ^9?\
M@+_R.^HK@?\ A?WPW_Z'C0O_  .C_P :/^%_?#?_ *'C0O\ P.C_ ,:.>/</
MJ&+_ .?,O_ 7_D=]17)>'_BWX+\5:G'IVC^*=*U._D!9+:UND=V ZD &NMJD
MT]CFJ4JE%\M6+B_-6"BBBF9!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C7BS_DY
M#PU_V!YO_0S7LM>->+/^3D/#7_8'F_\ 0S0!Z92TE+0 4444 %%%% !1110
M4444 %%%% !1110!5U+4(-+LWN;F18H4ZLQP*^&+4?&3]KK7-5USP?\ $O6?
MA)HFEW$VFFSMX_M<=P\1/[W=N3&[CC!QZFOJ[X_7$EK\*]5DA=HY \>&4X/W
MJX#]BZVBM_AOK(BC5!)JLS-M&,D]2:SH056K7E/_ )=QA;UDY)M]_A5KFE6;
MI4Z48_\ +QR3?E%1=EZ\VO7L<I^RA\4O%NF^()OAK\0=2O-<\3(LU\-3U&3;
M*T&0$'EX/'OFOICQ5K(\/^&M4U,KO^QVLMQMW;<[$+8SVZ5\EW9^S_\ !1Q8
MXCY<?_")J=J\#M7U/X_DTY?!>L1ZK=BRL9K*:.6X*EMBF,AFP.N!DT8FI.I@
M:6(;7/*";>BN^KMLK^6A*I*CBY48_"[22U=E*^G=VL?#.A:?\;_VIM2N?&7A
M3XO:Y\._#-W#)/;:=;P_:8D,7!0/N3.XY[<5[9^R!\5O$FJ-/X!\9WEWK'BC
M389;R?5+Z3][*C2?("F. %(P<UX%\,/&/Q-^&=C]C^#O@V7XJ?#E898;/6OM
MJV4;A_\ 62")N04.>W->X_L@PZ!)K]]=W.KBZ^($EK(+ZSDB)FC@WC83)T(Q
MCC-=U",8_NX*U-4KM/X^=.-F[^]HG)2:]R[5];&.+;<Y2;][VONVV]G:7NNV
MG-MH_?T?F?5%%0WEW%I]I/=7#^7!"C22/C[J@9)_*N*_X7EX&_Z#\7_?J3_X
MFN4T,?XD?\E<^&O_ %\3?^@BO:Z^>/$'CC0_&7Q:^'IT:_6^%O<2B7:K+MRO
M'4#T-?0] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %><_M%?\
MD-\;_P#8+F_]!KT:O.?VBO\ DAOC?_L%S?\ H-=V _WNC_BC^:,:W\.7HSYP
M_P"";7_(-\;?]=;;_P!!>OM6OBK_ ()M?\@WQM_UUMO_ $%Z^U:]_BO_ )'-
M?Y?^DHX\M_W6'S_,****^2/2"H+VW^V6<\&[9YL;)NQG&1C-3T4#3L[H^)[G
M_@G//<7$TA\=1XDD9]ITS.,DG'^LJ/\ X=OS?]#U%_X*_P#[97VY17+]5I=C
M['_7#.EI[?\ \EC_ )'Q'_P[?F_Z'J+_ ,%?_P!LH_X=OS?]#U%_X*__ +97
MVY11]5H]A_ZX9W_S_P#_ "6/^1\1_P##M^;_ *'J+_P5_P#VRC_AV_-_T/47
M_@K_ /ME?;E%'U6CV#_7#._^?_\ Y+'_ "/S9_9&TD:'^U!;:?O$IM%NX/,"
M[=VT8SCMTK])J_.G]F?_ ).\N/\ KM??SK]%JSPGP/U/0XVDY8^E)[NG'\V%
M%%%=Q^>!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7C7BS_DY#PU_V!YO_0S7LM>-
M>+/^3D/#7_8'F_\ 0S0!Z92TE+0 4444 %%%% !1110 4444 %%%% !1110!
MC^+/#T/BK0;C3;C_ %4N"> >G/>OA?X+_M3>&?V59/$/@SXL7Y\/W]UJ5S?6
M:K;RW1>!B1$<QA@,XZ5^@%<_JWP]\+:]="YU/PUI&HW &!-=6,<CX],LI-9P
M4Z=2<HO2:2DO2[BUZ7?<N7+.FH26L7>+[7^+[[+[CY5_9TMM1^-'QLN/C(UJ
MHT==/FTF*=&^4E#\ORM\V2/PJY\6OBSXH^)'Q \3?#73=*MQ#I6CG4UFBE*2
M3DH?W;Y.-IZ5]9:9H]AHMK]FTZRM["VSGR;:)8TR>IP!BF)H.F1WTEXNG6JW
MDB>6]P(5$C+_ '2V,D>U.K3IU(1PZO[.,.5)[Z--2;ZM6=]%>X4JDX2E6E;V
MC=[]$M=$NW;5GPI^S[^VY\+O@A\,K'P9\1;VW\)>*K$2BYTNST^>:--Q)4;H
MU93D'G!KIOV85G^*G[1GB3XM>&[98OA[JNDI8V5U;_N4>>)E61?*;##E6Y(Y
MKZNO/AAX-U*X:XN_">B74[?>EFT^)V/U)6MC1]#TWP_9K::7I]KIMJI)6"TA
M6) 2<DA5 ')KL5=RJRQ55?O9)K32/O--Z:O=*VNU]SEE14:3P]%V@W?75V[7
MT^^URW-"EQ$\4J+)&ZE61AD,#U!'I6/_ ,(/X=_Z .F_^ J?X5MT5S&YX_XV
MT33M&^+GPY%A86]D)+B;?]GB";L+QG'6O>*\4^)'_)7/AK_U\3?^@BO:Z "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\Y_:*_Y(;XW_[!<W_H
M->C5YS^T5_R0WQO_ -@N;_T&N[ ?[W1_Q1_-&-;^'+T9\X?\$VO^0;XV_P"N
MMM_Z"]?:M?%7_!-K_D&^-O\ KK;?^@O7VK7O\5_\CFO\O_24<>6_[K#Y_F%%
M%%?)'I!1110 4444 %%%% !1110!^=/[,_\ R=Y<?]=K[^=?HM7YT?LTLJ?M
M=W!9@H\Z^Y8X[U^B/VN#_GM'_P!]"N+"? _4_0>-$_KU+_KW']2:BH?M<'_/
M:/\ [Z%.2XBD;"2(Q]%8&NT_/[,DHHHH$%%%% !1110 4444 %%%% !1110
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M >6?$C_DKGPU_P"OB;_T$5[77BGQ(_Y*Y\-?^OB;_P!!%>UT %%%% !1110
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M <$'OQS6E/+\,L!4JUI\M2,K;-VT>F_6V_03K3]JE%731]ST445\P=H4444
M%%%% !7C7BS_ ).0\-?]@>;_ -#->RUXUXL_Y.0\-?\ 8'F_]#- 'IE+24M
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^4/VJO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK7_(&O_\
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MI]]P=.4L763?_+N7Z'Z)T445W'YZ%%%% !1110 4444 %%%% !1110 4444
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MS_H;M"_\&4/_ ,51_P +1\&?]#=H7_@RA_\ BJ^./^'9D_\ T.]K_P""P_\
MQRC_ (=F3_\ 0[VO_@L/_P <H_LSA_\ Z#W_ . ,/K&-_P"?/XH^Q_\ A:/@
MS_H;M"_\&4/_ ,51_P +1\&?]#=H7_@RA_\ BJ^./^'9D_\ T.]K_P""P_\
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MT/T3HHHKM/@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>->+/\ DY#PU_V!YO\
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M(KVNO%/B1_R5SX:_]?$W_H(KVN@ HHHH **** "BBB@ HHHH **** "BBB@
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M\%?@K\5O"?BE+SQ+\0O$6MV*R1L;>^;*$ Y8??/6@#ZIHHHH **** "BBB@
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M\#AL!BX4\)#EBXIVNWO?O<UR^M4K4FZCNT[!1117R!Z84444 %%%% !1110
M4444 %%%% !1110 4444 ?G3X0_Y/J_[CMQ_Z"]?HM7Y=>*O'C?#3]J77/$T
M5JE_)INL3R"V>38'SN7!.#CK7L/_  \<U'_H2;/_ ,&#?_$5Y=&M"GS*3ZG[
M!G^0YAFOU:KA*?-%4XK=+7?JS[DHKX;_ .'CFH_]"39_^#!O_B*/^'CFH_\
M0DV?_@P;_P"(KI^M4NY\I_J;G7_/G_R:/^9]R45\-_\ #QS4?^A)L_\ P8-_
M\11_P\<U'_H2;/\ \&#?_$4?6J7</]3<Z_Y\_P#DT?\ ,^Y**^&_^'CFH_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?\*H\$_]"AH7_@MA_P#B:ZJBCECV#ZUB/^?C^]G*_P#"J/!/_0H:%_X+8?\
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MY2=W>?YG2T445VGYZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\BS,?\"_]N/(QG^\4/7_ "/T7HHHKX0]<**** "BBB@ HHHH **** "BBB@
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M6/\ QY6__7-?Y"IZ[3X&6["BBB@04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>->+/^3D/#7_8'F_\ 0S7LM>->+/\ DY#P
MU_V!YO\ T,T >F4M)2T %%%% !1110 4444 %%%% !1110 4444 %.61UX#,
M![&FT4 *S%N223[T;CMQDX]*2B@ I68MR22?>DHH **** /+/B1_R5SX:_\
M7Q-_Z"*]KKQ3XD?\E<^&O_7Q-_Z"*]KH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 %%%% 'YY_P#!0C_DLWA[_L')_P"C:^^_#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M91F.6X6AB<5[.5-.ZY6]_P#ACP;8FA7J3IT[J7F?9W_"SO!__0TZ/_X'1?\
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MT7_Q5?&/_#M_7O\ H<['_P !7_QH_P"';^O?]#G8_P#@*_\ C1_960_]!_\
MY(P^L8S_ )\_B?9W_"SO!_\ T-.C_P#@=%_\51_PL[P?_P!#3H__ ('1?_%5
M\8_\.W]>_P"ASL?_  %?_&C_ (=OZ]_T.=C_ . K_P"-']E9#_T'_P#DC#ZQ
MC/\ GS^)]G?\+.\'_P#0TZ/_ .!T7_Q5'_"SO!__ $-.C_\ @=%_\57QC_P[
M?U[_ *'.Q_\  5_\:/\ AV_KW_0YV/\ X"O_ (T?V5D/_0?_ .2,/K&,_P"?
M/XGV=_PL[P?_ -#3H_\ X'1?_%4?\+.\'_\ 0TZ/_P"!T7_Q5?&/_#M_7O\
MH<['_P !7_QH_P"';^O?]#G8_P#@*_\ C1_960_]!_\ Y(P^L8S_ )\_B?9I
M^)_@\#)\4Z,!_P!?\7_Q5='!/'=0I-#(LL4BAD=#E6!Z$'N*_)_]HK]G^]^
M-YIMC>ZO#JS:C;23*\,90)M.,')YK]/?A?\ \DW\+_\ 8-M__1:UQ9QD^&R_
M#4<5A:WM(U&^EMC7"XJI6J2IU(\KB=/1117R)Z84444 %%%% !1110 4444
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M0!Y9\2/^2N?#7_KXF_\ 017M=>*?$C_DKGPU_P"OB;_T$5[70 4444 %%%%
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M;)M2TN\M%F:W:XA>(3)]Y"RD;A[C.:\A'[/.H@?\CYJO_?'_ -G4C-7XD?\
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M]!%>UT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC/\ G_OO_"C;_P"+H_U<P7_0PI_A_F'UZK_SXE_7R/T:HK\Y?^&9/VC/^?\
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M'^KF"_Z&%/\ #_,/KU7_ )\2_KY'Z-45^<O_  S)^T9_S_WW_A1M_P#%T?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>$_MK?\F_:U_UV@_\ 0Z]VKPG]M;_DW[6O^NT'_H=8UOX<O0]O(_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "J6M6MU?:3=V]E=?8KN2,K%<
M9\MNS8J[10!X%?>'?$&@_%KP"->\0MKQDN)/*+)M\O"\_GQ^5?2M>*?$C_DK
MGPU_Z^)O_017M= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B^+O!VC>/-
M#FT?7K"/4M-E(9[>;.TD'(Z5M44M]&7"<J<E.#LULT>2?\,H?"?_ *$O3_R;
M_&C_ (90^$__ $)>G_DW^->MT5'LX?RH]+^ULP_Z")_^!/\ S/)/^&4/A/\
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M9_R<AX:_[ \W_H9KV6O&O%G_ "<AX:_[ \W_ *&: /3*6DI: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSXD?\E<^&O\ U\3?
M^@BO:Z\4^)'_ "5SX:_]?$W_ *"*]KH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KQKQ9_P G(>&O^P/-_P"AFO9:\:\6
M?\G(>&O^P/-_Z&: /3*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **,>X_.B@ HHHH \L^)'_ "5SX:_]?$W_ *"*]KKQ3XD?\E<^&O\
MU\3?^@BO:Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *\:\6?\G(>&O\ L#S?^AFO9:\:\6?\G(>&O^P/-_Z&: /3*6DI
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE/B=XN7P7X-U/41_P ?
M"VTI@##*F0(2H/MG%=77BG[6 8_#VVVAC_I!SCTV&N#'3E3P\I1>NGYHZ\+!
M5*T8RV_X!\O_  __ &49OVL_#Z_$WQKXAUS1]3U..1C:Z'J!AMUDC^5 $(.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>->+/^3D/#7_ &!YO_0S7LM>
M->+/^3D/#7_8'F_]#- 'IE+24M !1110 4444 %%%% !1110 4444 %%%% !
M1110 5R/Q4\+KXM\#:O9! ]Q]DF,&6VCS#&P7/XXKKJ*QK4E6ING+9FE.;IS
M4UT/SH^#O[96C?LP^&4^&?Q!&JG7M-CF5QING&>'S)#F/#CJ.>:]@_9"\*ZQ
MXR\9:E\7=61736+-M/28G9(?*<* 8^PPO6OK%K.W=MS6\3-ZM&"?Y5(J+&N%
M4*/11@5VJM*4W7J:U7'E;V33:<G;75M+6^FN]SFG33O3I^[3<N;E[=DG_*KO
M2W;L.HHHK U/+/B1_P E<^&O_7Q-_P"@BO:Z\4^)'_)7/AK_ -?$W_H(KVN@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO&O%G_)R'AK_ + \W_H9KV6O&O%G_)R'AK_L#S?^AF@#TREI*6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \Z^*'@77_$^N>']
M5\/WUI8WFE&1E>Z!/S-C!  /OUKF?%E_\6O!_AZ[UB[\1:5-;VH!=(8/F.2!
MQE?>O:ZX/XZ?\DJU[_<3_P!#6@#G=+@^+^K:;:WL7B71UBN(EE57@.0",\_+
M5K^R?C%_T,^B_P#?@_\ Q%=WX+_Y%'1?^O.+_P!!%;- 'E?]D_&+_H9]%_[\
M'_XBC^R?C%_T,^B_]^#_ /$5ZI10!Y7_ &3\8O\ H9]%_P"_!_\ B*/[)^,7
M_0SZ+_WX/_Q%>J44 >5_V3\8O^AGT7_OP?\ XBC^R?C%_P!#/HO_ 'X/_P 1
M7JE% 'E?]D_&+_H9]%_[\'_XBC^R?C%_T,^B_P#?@_\ Q%>J44 >5_V3\8O^
MAGT7_OP?_B*/[)^,7_0SZ+_WX/\ \17JE% 'E?\ 9/QB_P"AGT7_ +\'_P"(
MH_LGXQ?]#/HO_?@__$5ZI10!Y/<:?\8;:WEF;Q-HQ6-&<@0'. ,_W:Q_!>L?
M%?QSX?AU>R\0Z7!;RNZ!)[?Y@58@]%]J]JO(3=6=Q"#M,D;(">V017-_#/P?
M-X#\(V^CSW"74D4DCF2,$ [F)[_6@#E?[)^,7_0SZ+_WX/\ \11_9/QB_P"A
MGT7_ +\'_P"(KU2B@#RO^R?C%_T,^B_]^#_\11_9/QB_Z&?1?^_!_P#B*]4H
MH \K_LGXQ?\ 0SZ+_P!^#_\ $4?V3\8O^AGT7_OP?_B*]4HH \K_ +)^,7_0
MSZ+_ -^#_P#$4?V3\8O^AGT7_OP?_B*]4HH \K_LGXQ?]#/HO_?@_P#Q%']D
M_&+_ *&?1?\ OP?_ (BO5** /*_[)^,7_0SZ+_WX/_Q%']D_&+_H9]%_[\'_
M .(KU2B@#RO^R?C%_P!#/HO_ 'X/_P 10-'^,1X_X2?1?^_!_P#B*]4I5^\/
MK0!X3X-\0?%;QM#?R6?B#3(197#6TGG6_5AW&%Z5T/\ 9/QB_P"AGT7_ +\'
M_P"(IG[/_P#QX^*/^PM)7J] 'E?]D_&+_H9]%_[\'_XBC^R?C%_T,^B_]^#_
M /$5ZI10!Y7_ &3\8O\ H9]%_P"_!_\ B*/[)^,7_0SZ+_WX/_Q%>J44 >5_
MV3\8O^AGT7_OP?\ XBC^R?C%_P!#/HO_ 'X/_P 17JE% 'E?]D_&+_H9]%_[
M\'_XBC^R?C%_T,^B_P#?@_\ Q%>J44 >5_V3\8O^AGT7_OP?_B*/[)^,7_0S
MZ+_WX/\ \17JE% 'E?\ 9/QB_P"AGT7_ +\'_P"(H_LGXQ?]#/HO_?@__$5Z
MI10!Y7_9/QB_Z&?1?^_!_P#B*Y[3]?\ BMJ7C+4O#<?B#3%O+"%)I)6M_P!V
MP;H!\N<U[K7'Z1X'GTWXD:UXE:YC>"_MXX5@ .Y"O<F@#F_[)^,7_0SZ+_WX
M/_Q%']D_&+_H9]%_[\'_ .(KU2B@#RO^R?C%_P!#/HO_ 'X/_P 11_9/QB_Z
M&?1?^_!_^(KU2B@#RO\ LGXQ?]#/HO\ WX/_ ,11_9/QB_Z&?1?^_!_^(KU2
MB@#RO^R?C%_T,^B_]^#_ /$4?V3\8O\ H9]%_P"_!_\ B*]4HH \K_LGXQ?]
M#/HO_?@__$4?V3\8O^AGT7_OP?\ XBO5** /*_[)^,7_ $,^B_\ ?@__ !%'
M]D_&+_H9]%_[\'_XBO5** /*_P"R?C%_T,^B_P#?@_\ Q%']D_&+_H9]%_[\
M'_XBO5** /"M8U_XK:+XKT;0)O$.EO=ZHK-#(EO\B[>N[Y<]NU=#_9/QB_Z&
M?1?^_!_^(I/'O_)</A]_USF_F:]5H \K_LGXQ?\ 0SZ+_P!^#_\ $4?V3\8O
M^AGT7_OP?_B*]4HH \K_ +)^,7_0SZ+_ -^#_P#$4?V3\8O^AGT7_OP?_B*]
M4HH \K_LGXQ?]#/HO_?@_P#Q%']D_&+_ *&?1?\ OP?_ (BO5** /*_[)^,7
M_0SZ+_WX/_Q%']D_&+_H9]%_[\'_ .(KU2B@#RO^R?C%_P!#/HO_ 'X/_P 1
M1_9/QB_Z&?1?^_!_^(KU2B@#RO\ LGXQ?]#/HO\ WX/_ ,11_9/QB_Z&?1?^
M_!_^(KU2B@#RO^R?C%_T,^B_]^#_ /$5SWB[Q!\5O!LFDI=^(-,F.I7(M8O)
MM_NL>[97I7NM<=\0_ \_C2;0'@N8[8:;>BZ<2 G> .@]Z .<_LCXQ?\ 0SZ+
M_P!^#_\ $4?V3\8O^AGT7_OP?_B*]4-% 'E?]D_&+_H9]%_[\'_XBC^R?C%_
MT,^B_P#?@_\ Q%>J44 >5_V3\8O^AGT7_OP?_B*/[)^,7_0SZ+_WX/\ \17J
ME% 'E?\ 9/QB_P"AGT7_ +\'_P"(H_LGXQ?]#/HO_?@__$5ZI10!Y7_9/QB_
MZ&?1?^_!_P#B*/[)^,7_ $,^B_\ ?@__ !%>J44 >5_V3\8O^AGT7_OP?_B*
M/[)^,7_0SZ+_ -^#_P#$5ZI10!Y7_9/QB_Z&?1?^_!_^(H_LGXQ?]#/HO_?@
M_P#Q%>J44 >)^,-2^+/@OP[=ZS>>(M*FMK;;O2&W^<Y..,K6AIMM\7]3T^UO
M(_$NCK'<1+*JM <@, 1GY?>MSX]?\DFUWZ1_^A"NJ\)_\BKHW_7G#_Z * .!
M_LGXQ?\ 0SZ+_P!^#_\ $4?V3\8O^AGT7_OP?_B*]4HH \K_ +)^,7_0SZ+_
M -^#_P#$4?V3\8O^AGT7_OP?_B*]4HH \K_LGXQ?]#/HO_?@_P#Q%']D_&+_
M *&?1?\ OP?_ (BO5** /*_[)^,7_0SZ+_WX/_Q%']D_&+_H9]%_[\'_ .(K
MU2B@#RO^R?C%_P!#/HO_ 'X/_P 11_9/QB_Z&?1?^_!_^(KU2B@#RO\ LGXQ
M?]#/HO\ WX/_ ,11_9/QB_Z&?1?^_!_^(KU2B@#RO^R?C%_T,^B_]^#_ /$5
M%=6/Q@L[6:=_$VC%(D9R! <X S_=KUFJ^H6YO+"YMP=IEB:,,>V1B@#Q?P7K
M'Q8\<^';;6++Q#I<%O.6"I/;_.,''.%K<_LGXQ?]#/HO_?@__$5U7PS\'S>!
M/!]EHL]PEU+;ER98P0#DY[UU5 'E?]D_&+_H9]%_[\'_ .(H_LGXQ?\ 0SZ+
M_P!^#_\ $5ZI10!Y7_9/QB_Z&?1?^_!_^(H_LGXQ?]#/HO\ WX/_ ,17JE%
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M!/\ =M*>C?<[&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-?9"?<7Z5ST[RP6&D]^1?/<ZJT8PQ<U#9J,G_B=[_DM!U%%%0 4444 %%%%
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M]+N7WW9\(VW@_P"//[,/B[58/AEX _X6-H.K7,FI33:G>BW$,KL1Y:JK#(
M(/O7H_[.OP9\9:UXU?XC_$[3IO#_ (FM[F1[32C(MQ$D<J'<JN22 K.P ]J^
MIZ*WI3E3LY/FFDTI/=)Z/:RU6FJV(K6K2D]E)IM+9M;?E?3YB4M%%0,****
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M(Q)G. 21CVKZ:I:*J4DU&$5:,59);)=M=?O)C%IN4G>3=V^["BBBLRPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH;R[CL;6
M2>7B.,9;%3*2BG*6R&DY.R'37,-LI::>*!?[TL@0?J:KKK6FL0%U*R)/0"YC
M_P :^)?$TVN?MH?%+5_""2_9_ 6@7SZ=K>TFUNG7)9/)=>O*KD^F:UM8_P""
M7_PVTO1[FZ\,WGB-?$<*;K)KS6I#"),\;AW'6A<T8*K65HO5=96[VTU>Z5]5
M;74=3E51T8.\EOT2?:_S5]-->Q]G*RR*&1E=3R&4Y!^AJ&?4K.U8+/>VL#'H
MLLZ*?R)KY:_9N^,VO:39>*/ _B>2"6]\*7$6D:?]FBR76,%6+$\R'Y1S7E'@
M#X#Z)^V=XP\::O\ $W4KI;O1-9N-,TVWT743:-]F#%AOC4_,V3R:OEE*HXTM
M8J*E?R;:5O.Z::Z=V3=0IN5725^6WGH_NLT[]4S[^M[RWNEW07,-P,XS#*K_
M ,C4U>#_  1_9FMOV>_$"V7A*XN9/",H>XN%U.\:XN/M#+M^4MT7"KQ]:]PU
M"Z%E8W%PW2*-G_($_P!*=1PA!33T:OKI;R9,.:3:DNI(US"LGEF>(2==AD4-
M^6<TUKRW23RVN8%D_P">;2J&_+.:^2O@UI-M\?OBOJ/Q&N)+Q--EM!;PHDK0
M_O(G Y0<8KYZ_:SU#Q+IO[8TE_H<[""PO;.YNXV9F40JBDX4<5G&24L/"K[K
MJ:O^ZGM?S>S73S-I4W_M')K[)?>TTI+T71]>R/U J.:XAMQF::*$>LL@7^9K
MG/AGXRC^('@K3->C8%+Q2PX Z,1T'TKXA_X*$>-]1\5#^R]%O%C@T19TU$(^
MUU!P1@J?YTZW-1Q$,*U[TI<O^?W*_KL10Y:])U[VBE?[]OQ:7D?H&DBR*&1U
M=3R&4@@_B*=7EG[,[?\ %C?!):1G_P")1!EY&R3QU)-=W=>,O#UC.\-SX@TF
MWFC.UXYK^)&4^A!;(-;5H*E4E3O>QA1J.K#G:L;%%06=_:ZC");2Z@NXB,B2
MWE613GIR":SKKQEX>L9#'<^(-)MY!U26_B4C\"U9;.S-M]4:DEQ#$VV2>*-O
M[KR!3^1-25\M?ML^#Y-0\#IXW\,W;3>(+6>VM(VCN2]N82Q+91203CO7NWPK
M\96_CGP;9:A;OO"*('/'WU #=/>BE^\A.6TH.S7D_A?_ &][WW!4_=NGU4T[
M>JM=?*ZL^OE8Z^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*H()!ZBN&^$_[!GP]^/G@?2?B'\2+:]U7Q3XEMDU"\N++4);>,S,2&(13@#
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M_?H>[4445QG6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 *&*]#BE\QS_$:;10 4X2,O1B*;10
M %BW4YIK*'5E/((P:=10!X%-\"/%^E_'*_\ %_A[6[+2] N;2*V^Q MYO# O
MGC&#BO?<G&***(^Y2A16T=O3MZ+HN@2]ZI*H]W:_^?J^KZADT D=*** "G"1
MAP&.*;10 9)IWFO_ 'C3:* /!?VD/@/XH^.%U:Z?!J]E'X458Y)]-O"V'F1B
M0_ ]Z]OTG3TTO3;6TC55$,2QX7IPH']*MT40_=TW2CLY.7S=D_R"?OR4I=%9
M?UW?5];+L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>hyper_001.jpg
<TEXT>
begin 644 hyper_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /S""L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM8_] J^_)?\ &O.?Q/Y49]S^5+E%S'HW_"UK'_H%7_Y+_C1_PM:P_P"@5?\
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MFPPBFD4_%(:+B:(Z81U^E2D4W''U%5N@MJF9FIL42$CKFDB&\*00"22>*EU
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M$<G_ !\6/_7Y#_Z&*^B?2OG:3_CXL?\ K\A_]#%?17I6<S1(6BBBH+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS6;=Z3=62K+*OR,,@BO1A64CQ9T)0*@/-2K4((/MZ5(M;IF-B513@*:,T\4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUJ-V:2W*4L1:!W#!4/<GFJ+2,\BPA R#DMZU?E*DLK\H!G%1J0]L\B[-J#
M&#6D9'#4;Z&<UND\H@$C +\P<#C/I4+QO&QE=$+_ '0=W/IDBGRRO':G8X!!
MR!C^M,N;B&6VC0O^^QE\?XULF<,KW-.QM(4LW\QE\UCG.?Y5-IRE7E0D';_$
M.]4+6Y=DC C4[/SQ6I9.K-,X3"DX%=>"_B<QA5TH,M4445[YXK=PI:2B@0M)
M110(BD_X^+'_ *_(?_0Q7T6.U?.DG_'Q8_\ 7Y#_ .ABOHL=JSF;1%HHHJ"@
MHHHH **** "C(I#TIG!&?2DY).S DR*,CUJ(XR!_6E')/8YHN!)D4F1ZU'U.
M"?EI1[&C4"3-%-Q2T7[#%HI**+ZB%HI*2DW8!U%,/6EHNUN.PZBD'2BGJ(6B
MFTM "T4VEI@+124G?-*]MP'44WJ:.E2IJUQV'44E%5<0M%)0::U 6BFB@5-W
M:XQU%-[TM.^MA"T9'K36/%(>/>CK8!^129![UGW&JV%LYCFOK>*0?PO( ?R)
MJTC+*H92"AY#*>M#=MT!/1312]Z+@+12447 6BDHHUZ +132,B@'M0VD ZBF
MBCO2N ZBDHIW 6BDHI@+12447 6BDHI +129HS1<!:*;D44_4!U%)12 6BDI
M* '44VEHN,6BDHS2YEU$+129%%',@%HI*.E- +12447[@+124M).X!12$X%%
M/F5[ +124F0*3DEN ZBDI" 15 +D9QFER*J7%Y!:)ON9HH%S@-(X'\Z2VO+:
M[RUM<13 =3&X8?I1:6X%S-%,SP?Y4M #J*;2TE<!:*2BF M%)B@4@%HI*#UI
M7MN M%)G%(#FAR5[ .S133C-%%P'9HIG%+BCF3V =124=*=P%HS25#<7$-M'
MYD\B1QCJSL *%KH!/D452MM0LKLD6UU#,5Z^7(&_E5L=*;TW =1244FP%HHH
MHN 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO0&N=OK[S7$*\LIYJ8IW)560FGSB.4B2/@\ 5(]C%'>"XS@,>A]:BQF5)",
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M<A;G()_*N58&HXWNB^9'TOGMWI"U<WX+\50>+M CU&# DQME0=%;TKS7Q_\
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M>B6/@ZSTJZN/+N(21@]\DFF_'>#[7X8L[R-69%8'('8D5O3C..+7-W)6Q9^
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M+_*NK'I+#0E <7J?.'Q'58OB5K>U0JBZZ*.!P*^K-&L[>+3+.1+>,-Y"'<$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M#2TAH .U?/MU_P AG5_^OZ7^=?07:OGVZ_Y#.K?]?TO\ZJ.Y,MB,]:*7KS28
MK4R"D(R,4N** ('7;TJ)G.1GI5L@$5#+%QQ4.(TR,$'Z5!>VPN[62''.,C^E
M!+*<'I4B-T).#GGW%9M*QI%V9DZ$##!);2G'.#6I<M#!$@#\8JG>V\B7)GM%
MSW*GN:2>62YMD62U*N!RQZ5Y52#3NSU:<TQ]C?!@_EJ2Z'@CTK7;45EC4/&
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MFND(Q@=,#I7.QA&> _/YA/OBNA;.[D]J]? _"SAS!Z1"BBBO06S/)ZL****
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M0#6%+3(V#J&4@@]".]/H6J ****8!1110 4444 %%%% !1110 4444 %%%%
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MI]&!10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6DH #
MTKY\NO\ D,ZM_P!?TO\ .OH(]*^?;I@VM:MC[PO9?YU47J3)70RBD!R.12UL
MS*/F%%%% WH+2&BBD 48HHH>H@&>E(5#*0PI:<*'J"T(T@5&R?\ 5XYJMY.U
MG('RGI5X#/':AE!0LG!%>?B:,HQ<XLWIRU2,UD95RN1]:<KO@9[59@E-VS).
MOW3@&I39@@A>!6>$4I1YI%U)6E8JI,.=S?I4Z3,1U&*:UBZ].:C^S.#TKKL9
MMW+0;/6I$;FJH5U'W:E0-QS340N7E/%2H:IH3QS5@'BJL(M YJ1:KHU2C)/%
M4A6)UJ85$@.!FIU6@0H%2**0"G@47&. IX%- J0#BBX(4"G@4@%/ I#%45(!
M30*>!2&. IX%- IX%(88I0*4"G 4 )BE IP IP% #0*4"G8I<4#&D4F*?BDQ
M0 W;2%*?BC%(",BFXJ8TQA0!%WI"*DQ32*!$1%,(^6IZ8PI@]3 \4+_Q*&<\
M ,":Y#45@EL8W1CE=IKN?$$7G:)<I_L&N!(4Z9M0 G!'Y5Y6,5JD6>Y@-:;.
M_P!/D$NFVSCO&O\ *IB.:R_#,PGT*#^]&=N/IBM4\EF]:].'?N>/6CRU'$B(
MIA%2FF&M#"Q$149%28II% $1%1$$H<5.141'+4]T/S,/Q"?W,<8X)(JG"NR,
M9ZYJ;Q(W[^ 8S[4V&3<ZB1.,<5X6/E[]CZ?"*V'7F:43E0,'I5V&4CD=:RXE
M:24CISP?:M!54#:/O^M>=>R-)JZ+0E!/'6F3N"IYYJ)2V]L<8%-9@R8Q\_K0
MW8<4HE2<ABJ9-9UZI+@1GIP<U?F8K+@G8/451DD =B7Z=/>E%ZG=2?40DQA5
M(7/TJK+#B?=(V1VQ4Q)<>8>0>*K7 ,0\MN-W*D=J:=F9U-&0N_[TE2P"\ XJ
MLUSNM7# G<^ V[&#BKN\0!4W^;GU]:HRP&9V=K8A%.2!T-6CBJ.Q4 C=I0CM
MDKA2>QJ)0_G*DPRJ#&1[U>NKA#"R6]D#R,D8XJIY7E6ZR.[&5L@@'IZ5LC@;
MNRS&$_M&&-93A>.5-="WWB>N3UK"LU$MY "X)4=_I6X<X P,"O:P*_=\QQ8]
M[(****[]D>:]&%% ZT4 %+BDI:8B*7_CXL?^OR'_ -#%?10[5\ZR_P#'Q8_]
M?D/_ *&*^BAVK*9K$6BBBH+"BBB@ HHHH #TJ,G QTI[?=-9FM3SV^CWDUL
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MZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI6 ****8!1110 4444
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M\-"4,+-O0EO4[[]H'(M=.R3CT]>:=\"_#%A-I$FLSQ+)<.[*A89V $CBF?M
MG-IIWX_SK>^!'_(BK_UVD_\ 0C4RGRX"+7];CWD=+X^M88/!&I>5&J KD[1C
M/-?/OPHT"U\0^+TBO%W0P*)#'V;G'-?0_P 1/^1(U'_<_K7A_P "/^1SN/\
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M2I0?D9K=GC'QPQ_PFAP. F#^0KV3X;>&]-T[PC:2PVT9EGC#.[#DY ->-?'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?:Q6MM&L<4:A0H%6,>WXTO'4552O4J?&[BL@&*6@45B,**** "BBB@ HHHH
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M-:#Q4@I@IXJ0'BGBF"G"FAD@ZU*M1#K4BFDP)!3Q3%YIXH*)%Z5(*C7I4@H
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MFC5MA!)[U\_COB/M*6F'CZ&H &P%X#')J4#$+*IY89J, !&=>1TX]:D&$12
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OGV[_ .0UJO\
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M*D6@9(*>*CIX- QXIXIJT\4 /6GBF+3Q2&.%/%1@U(.E)@.%+249J1BT444
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M2R^5"\F-VT$D#VH EHK"T/Q(FM3W$20-'Y)ZDYSS5K6-5;2K,SBW><_W4ZT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&,U(* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9KFUDA63864KN'N*@T;2TTBP2V1MYSEF/<T"-&BBC- !11FB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T4&@ [5\^W7_(:U;_K
M]E_G7T%VKY]NO^0UJW_7[+_.JCN1(B["BCL**U,Q:*3-+0 E-=@BL['"J,YI
MW89[U4U!#,HME<+OX.:QJSY%<UHT_:3L4S8OK-W\LA* 9Q6K/9BUM1'($^4
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MA,DG3H!ZF@"Q17./XJ,$B_:]+NK:!F"B>0KM/IT.:OZGK<&EV0O)@6A8\%:
M-2BN<F\6"']Z=-N3:?\ /QE=N/SS6O)J5M%8_;'E58=N=QH GFE6&)Y7/R*"
M34-I>0WMNLT!W(:YZ]\2&73[D3:7=0P/&P2=RNUN.#P<U;\(D?\ "/0;1C/<
M=^E &ZV0>F1WIRGC&,8KF?%^IW>GZ8YMK>=MP!,L1  Y]ZN:7K-S-:%KG3KF
M%43/FR%</],&@#<HKFK7Q<M\P6TTZYF;>58*1\O/4\UH:AKD=@L6(7EEDZ1)
MC=0!JT5B:=XA6]NS:SVLMG/C*QS8RWTQ4E]K;VUQY%O8S7CK]\18^7\Z -5C
M@@TU1CL,UE6&O)J$=Q_HTL-Q!PT+D;LUS]EX@U+_ (2*Z0Z;>3+A1Y2E<K[]
M: .X'04M9-]KD=C!"QA=Y9.!"N-V?2HM/\1+>7GV6XM)K*8C*I,1E_IB@#:J
MI<ZA;VMS#!*V'E!V_A5/4M>CL)DMX8)+NZ;GR8<;L>O-<W?ZHFH^)-+#P/!-
M&&#Q2=5R1Z4 =V#WSQ2CI4;'8I.,X["L_3]:BU":YB2-E:W8JP/>@#4IAX.[
ML!S679:_!>ZO/IRQNLD(R2>AIQUB,ZP--\IC)L+'TH FL]1M;R>6*"0M)$?F
M'I5H$[B2.V*YZTU.S$U__9^FN;B(XD*8RQYJAX>U[499;A)=-O)1Y[#)*_(/
M?F@#J%O[=[Y[-6_?*NXBK8SZ]ZXQ[Z*R\;W#B,R2M;X2)?O.=W;M6QI_B)+F
M^%G<VDUG.02BS$?,/;% &[1302?3%8M[XB%M=_9;6QGO9A]Y82/E^N: -RBL
MB+7-]A/<RVDL#PC+1/C=^E6=-U--3TV.]B1E209 /6@"]163I^MIJ$$\D<3
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M=+=VZS1_=8<9J<'- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2(E?QEJ,A0;U1<-W7K6Y8:9-;W'VB[NWNIP-H8C8,?0<4EGHPL]7NKX39\\
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M*#3PU1 T[-("8,*<*B!IX/% (E!IP:H@:<#3&2@T\&H0:>#0!(#3@:C!I0:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_ =O\*!V+!-&>*K_:A_SQN?_ =O\*0W0_YXW/\ X#M_A0%B?-<Q+.'UNXB
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MHRSR7-D([2Y)^UPDYA88&\9[5]$J1COCWK.6IK$?12 Y&:6H*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%%*P
M!1113 **** $Q1BEHH 3%+BBB@!,48I:* "BBB@ HHHH 3%+BBB@ Q1110 4
M444 %%%% !1110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ
M110 8HQ110 8HQ110 8HQ110 8HQ110 8I,4M% "8HQ2T4 )CFEQ110 8HQ1
M10 8HQ110 8HHHH **** "DQ2T4 )BC%+10 4444 &*3%+10 8HQ110 8HQ1
M10 8HQ110 F*,4M% !BBBB@ HHHH **** "C%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!3U49TB\]1"Y'_ 'R:\"^U7 8$SREFXP'/%>_:J,Z1>_\
M7!__ $$U\^+P!BFB63?:+A>/M$O'^V:/M5Q_S\2_]]FH?YT58B;[5<?\_$O_
M 'V:/M5Q_P _$O\ WV:AHH F^TW'_/Q+_P!]FC[5<?\ /Q+_ -]FH:* )OM5
MQ_S\2_\ ?9H^U7'_ #\2_P#?9J&B@";[5<?\_$O_ 'V:/M5Q_P _$O\ WV:A
MHH F^TW'_/Q+_P!]FC[3<?\ /Q+_ -]FH:* )OM5Q_S\2_\ ?9H^U7'_ #\2
M_P#?9J&B@";[3<_\]Y?^^S1]IN?^>\O_ 'V:AS2T 2_:;G_GO+_WV:/M-Q_S
M\2_]]FH<T9I,";[3<?\ /Q+_ -]FD^US_P#/Q+_WV:BS24A$WVJX_P"?B7_O
MLT?:;C_GXE_[[-0T4RDR;[5/_P _$O\ WV:/M4__ #\2_P#?9J&BBP7)OM4_
M_/>7_OLT?:I_^>\O_?9J&DS0%R?[5/\ \]Y?^^S2?:9_^?B7_OLU#FC- ,F^
MTS_\_$O_ 'V:/M,__/Q+_P!]FH<T9IB)OM4__/Q+_P!]FC[5/C_CXE_[[-0Y
MHS0!+]JN/^?B7_OLT?:KG_GXE_[[-19HS0!+]JN?^?B7_OLTHNKG_GXE_P"^
MS4.:,T 3?:;C_GXE_P"^S1]IN/\ GXE_[[-04M $WVFX_P"?B7_OLTOVFY_Y
M^)?^^S4%+GVH F^TW/\ S\2_]]FC[3<?\_$O_?9J'.:* )OM-Q_S\2_]]FC[
M3<?\_$O_ 'V:AQ1B@";[3<?\_$O_ 'V:475Q_P ]Y?\ OLU!10!/]JN?^>\O
M_?9H^U7/_/>7_OLU!FES28$WVJY_Y[R_]]FC[3<?\_$O_?9J'-+2 E^U7'_/
M>7_OLT?:KC_GO+_WV:BI*- >PPS74VJ6Z)-+DGGYS6KKTL\>GR[9W4Q^C&LN
MWA:75HBG!49ZX[5/KDTBZ:TC!55S@X.:\+%SJ*NK'T^#HITBEI5S<?8U<W$S
M'W<U=^U7.<_:)?IO-4K%2EB@'2K'4Y[U[<=CYZM\1-]JN/\ GO+_ -]FC[3<
M'_EO+_WV:AS15]3)DWVFX_Y^)?\ OLT?:[C_ )[R_P#?9J&ES3$2_:KC_GO+
M_P!]FC[5/_S\2_\ ?9J+.:*3V%+8D-U.2 9Y?^^S6?J%Y<"=5$\N/]\U;/ &
M.N:I7*J]\B.VT'O6%=VB>MEM-2KHM6&^:7]_/*-PPK;SQ6W']H0"."9Y?+'S
M-O-84*0AF68N44@K(./TK2MG:&0X5QG# G/(-?.5ZTG(^EJ4:+?PEZWNIFG8
M6LC@?QAV-:=M/,BE!(RENN6-47MTF=9OE23NJMBM!2%C0 ;O]HBH]K-Z&4X4
MMN465V4!AO?;UPQIOVF1E;,C ,.!N/%/E<J<(?O#IBHYQ*P 55SCM6\G)(7L
MJ?8HR2R1@)(9'QU 8Y-1)?W4.T":5$/.":C>%Q(PD<B4=/0TV)BC8F!,@& ,
M9%8SJU.AT^QI./PBLMQ<1MY=Q,HZL6-*8MR+MOI%* [OFZYH-X\<31L5Q(<!
M0.:KF)I'96?$@4D#'' K)UJA+I4E'X3.O;^XC5T$KNIX'SFJZ0WS0LT=PZ1E
M<D>8<XI\\S31;+IA&5YR$JJQF,8<-M5E 4DXYKIC5DT<E2C#E%OKJXT]XI9I
MI5C^\2'/2LZ1[J5Y+A;B7R'Y5O,/Y58GC1[J2TN\[O+/.[(K/C#>4J1*RB)B
M22<AN?2MX2?+=GGNE!)LMW6H7D$]M()988D4'F0_.<5874;NZ?[26E17/ WF
MJC.VJ%(3(O[LDDL ,>U2QHD2>5*7$@?@ 9!%:1J>\@P\(G0)=7&Q0+B7I_?-
M.^TW'_/Q+_WV:@7   R 1Z4M>W'5(\*:2EH:.EW,YU:T#3RE3,H(W'U%>\@%
M5P!@5\_Z9SJMF/\ ING_ *$*^@MO)/K1(0X=****0PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF?NU7%>_8*4>179;S@*I;(QG-%+P%QGIVI*]^.R/!E\3+6E_\A:S_P"NZ?\
MH0KZ#[5\^Z7_ ,A:S_Z[I_Z$*^@NU$@%HHHI#"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *;3J;1U$RCJV/[+NL]/*;/Y&OGK4M%>V<2PG][*=T>.A
M'6OH76,_V1>%1D^2^!_P$UX0DTGE@7$@\PGY1Z>PKR\95<)*QZN!Y7>+,^"Z
M$KF.3Y9E.&4]<U9.,#WZ4EQIUO/(9,/%*.F!W]ZIPW30RFVN.).@<CBM\/C(
MRLF3B\+RR;6Q=Q12'Y1US2CGFO1NGJ>5:P4M)10 M)110 4444 %%%% !124
M4 %%%% !29H)HS0 9HS124 %%%+F@!**,TAZ4 +FDS244 +FBDHH 6DS110
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MEL6]*_Y"UG_UW3_T(5]!=J^?=*_Y"UG_ -=T_P#0A7T%VJ64A:***0PHHHH
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M3Z8.U/KP[W- HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME.()'7M7#6JNM4<WHRK:'/:]X.T7Q)-')J-N96C!4<XZUD?\*D\(_P#/@_\
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M3R[X*>";JWO#K]]"T1VE84?@D'J>:QOCY_R,MN>1^[4=,]J^BE@1$"( J@8
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M129HS0.PM%)10*PZBDS1FF M*#3<T9H =FC-)FC-(8X&C--!I<T .HIN:7-
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M+ENDK)E\2Z-"[(^I6H(_Z:K_ (U9M;^TO<FUN8I0.<I(&_E3<))7L%R[D>M
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MW'OMIXY5/=&!Q^5237$5O'OFD2-?[S' H]Z]K!<GHX]:QQXDT<S>5_:5KO\
M^NRX_G6@DT4JAXW5PW0J<C\Z<HSBM4%R>C-5Y)HX4+2R*@'4L<#\ZSQXGT;[
M0T1U*UW@]/-4?KFFHSDKI!<V :,@]*@BFCN$$D<J21G^)&!!_*HKF]M;-?\
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M7HWE+N'XXK4(XP!QZT5\4I0]G!60HQ/GGX[Z%<KK\.KK$Q@EC6,LHSMVCO\
MG4'@3XL:G81:=X?2PAEB5A&)3(0VW'IBOH6YL8+R)HKJ".9#_#(@8?K5"V\*
M:+9R++!IELKKT;RER/TK18NFZ*I26P*.IY!\?F+KIK8/S)GG@+R:[#X)@#P!
M;YX^9OYFN_NM.L[U5^UV=O.%Z"6(/C\Q3[:SM[2/R[:".&,=$C0*OY"LI8I.
MC[%CMJ>#_M!\7NF8Z'=D_@*[CX40"X^'*0D?*^Y<_@*[RZTNQOB/M=E;W!7I
MYT0?'YBI;>UAM(O*MX8X8AT2- H_(4I8GFI1IKH.Q\K:]H>L?#KQC_:$$!\F
M*7?#)SM(]S7<P?'_ !9KYNEKYP'9CM/XU[7<6-M>QE+NVAN%':2,,/UK''@?
MP]]H,PTN#=Z;!M_+%;RQ<*R7M([$V.0^'GQ%U7QEK4R3Z>EO:*IP58GM[BN$
M^/HSXBMBO_/,#]*^@;;3K2S7;:6<$(QC]W&$_E3+K2[&]93=V-M.PZ&6)7/Y
MD5E2Q,*=?GA'H5:Z.8^%?/P]TOCI"HQ7F/QVT&]_M>TU..)GMA$0[CG:<]*]
M\AM(;6".&&)8HTX"QC 'X"F7EG#>P-#<01SQ,,;'4$?K44<5*.(=1K0.7W3P
M#PU\9I-(\/1Z<-.62XC&V, GD]JX+47U&X\8PW&IPF&XN+B.4*?1F!%?5-OX
M1T*UG\Z/2[82>\2G!_*KTVCZ;/(LDVGVLDJXP[0*2,=.U=L<?2A-RA%IO?4A
M1N8'BY3_ ,*\OL<_N!W]Q7R[X?NM7LM3-]HZN;BV^<E!GC-?5GCM<>"-25<+
MB+L/<5X1\$@DOC:=712CPD%6&0?F':ML!44</4<OZV%..I!XA^,&MZYHK:3)
M;);!AMDD5B6;U&,5TWP0\(74>I-X@NH#'&JLL);J<@@\5ZZ?!VA?:_M)TNV:
M3WB7'Y8K:A@C@B$<42)&.BHH4#\JYJF.I^S=.DK7W*2U,SQ)I4>L^'[NSD3<
M)(S@'U[5\=7]G/IFH75E+N22-BCCUK[5O;E;2TEFD( 1&;)Z<"OD2_E?QG\0
M9&MX]OVVZ^50/\^E;955]ES<VPIH]V^"F@_V9X0%ZPVO?'S,$<C'']*].7D5
M1TJR33M+M[2)0JQ1@ 5<7/.:\FO5]K.53S-$M!]>7_&W1+C5_"44MM'YC6DI
MD8#KC&*]/'2HY(UE4HZ*R'[RLN0111J\DXU+ U<^3?!'Q$O_  (ES;P6:7"R
MON9)&*X.,5['XVU2;6OA U_/&(I)B&*+R.]=O)X1T&28RG2[7>3D_N5Y_2M(
MV%LUL+9K:)H!_P LV0%?RZ5VUL93E5C54=;DQ6AX+^S\,ZIJ38P-J]/QKWN\
MMQ<6LT!X65"N?K4=MIMCIY+6EC;P%OO&&)4S^0JV!Q7/B<0ZM5U$@2LCY2US
M0M7^'GC W\,#_9X9=\$@&5(]Z[>#X_E;53+ID?G@8X<X/XU[==6-K>(4NK6&
M:/TD0-_.L9?!6@+<>=_9=L7]#"N/RQ73]:I54G4CJ*QR/P]^(FJ^,]8G2>PC
MMK15^4JQ/./<5YO\8]$OK+QG_:S0.;5U3;)C(!'-?1MMI]G8@_9;2&'/7RX@
MO\A1>6%IJ$/EW=NDR?W9$##]:SI8J%.K>,=!VN>$Z?\ &J6+P_!IEMIBR7HC
M\I=I/)]:X#0UNT^)-E]N0I=?:U:16XVFOJ6S\*Z)9RF>#3+82,<AC"O'TXXJ
MX='TV2Y^TMIUJ9]V[S/(7=GZXS6\,?2I*2IPLF+D(]6M3?\ AJZM$&YI[9D'
MU*XKY*LKW4/ OB[[0(=MQ;.RA7X!'2OL;&!TX'I67>^'-)U%\W.GVTA/)9H5
M+'\<5AAL7["Z>S"43C_A]X]O/&NG:@]U91VPB0[2CEL_G7A^D#'Q:ML=/MO&
M.U?5-CI-EIL9BM+2*&,]D0#/UQ3%T32UN!.NFVBR@Y#K H;/UQ5T\;"#FH+1
MC:(]8 /AVY_ZX'^5?,GP['_%STR.!+)G'UKZL*!EVL@*D8(/(JG%HNF03B>'
M3K6.49.](%4\^X%8X?%*BI0MN.2T*'C #_A%;_IS$>]?//P8_P"1Z3(8$ =O
M>OJ&2))HF21%=#P59<@U2M]%TZU(>VT^VA;'WXXE5OS S3I8GDIRI=Q<NIYI
M\:/!EQKUC!J=E$TMQ;+M,:C)*]:X'P;\6-0\(V(TF]LA+%$QVAB0R\U]+,"5
M(P&]B.M8]]X3T34.;C3+8D\DK$H)/UQ6E'&0]DZ5170I1U/(KCX[WU].EMIF
MDH79U!;<<\GZ5Z3XDGEN_AQ=SSH5FDM@60\<Y%:MGX7T6P"BWTNV7!^\8ES^
M>*U'A26,QM$K)T*L,@_A6$ZU*+A*$-G^I2CH?-7P1'_%=N#P?*/_ *$*]Q^(
M?_(C:H<'(A;'OP:WK?2=.LY#)::?:PR8QNCA53^8%6)K>*XC:.:-9(V&&5QD
M'\*UKXI5JRJ6M87+96/F_P"!&?\ A,']XVS^1KT/XWZ)<:OX7MIK:(R-:R,[
M#V( KT2VTFPLI/,L[&V@D/&Z.%5./J!5F6)9HS'(@9#U##(-.IC.>LJW8$CY
M0\$?$>_\#VT]K;VD=PLTF[8[D8-?4'AW49M6T.UOIXUCDE3<54YQ5?\ X1+0
MVF,O]EV@8G/^H7_"MB*%(45(T"(HP%48%1B\13K+F2U"(_MQS7C_ (H^*FI>
M$O&$MC=6 EL2@*.<CGGI7K_49'K5'4=$T[5%Q>V4$WH7C!/YXK&G.$7[ZNBF
MKGSE\0?B-#XUM+:PM-."/NSO(^;I7IWP6\.7>@>%YY+U"DEY()54_P (QCG\
MJ["R\':%8REX=-MRV<@O&#C]*V%4;=H7:$[ <"NG$8M2I*E17ND<NI\M?$_0
M[OP_XUGNU1Q!(X>*;'&?_P!=:<?Q9\3:UI<.AV%FOG%?*,JL2Q&,=,5]&7NG
M6=_%LN[2&<'IYD8;'YCBJEAX:TC36W6NFV\;YR6$2Y_ XK?^T(RIQC*.J!Q/
ME'2;&[T[QQ:VUXO^DB8%QGO7T+\4/"LOBCP=MM@6N+;][$JC.XXQC]:[)M'T
MUIS<MIUJ9LY\PPJ6_/&:M>7PHP<+TP<5A7QKG4C-+8:B?)OA7QGK/P[O9X1;
M9!;]Y;2Y7+=C78V7Q5\3>+_$5A:6=I]FA\Y#*D&7XR,Y)'UKV^]\-Z/?N6N=
M-MI'/)<Q+G\\5+9:'IVG*/LEA;Q-@Y=(E4_F!6M;%T:J<G3]X21XS\;?!5U<
MW<>OV44DQ*B.5$7. O?]:Y;PO\8M7\+:0FF?8HKN.(;8S*Y4J/3@5].&)'CV
M2(&1AC##(-9$OA+0IIA(VE6F?00K_A6=+&0=+V=6%[#<>J/./AKXM\0>,?$U
MQ<ZBCI8+$0B!?D#<=^]>=^-_"VI^"O%[ZE:02-;>=YR2A> <Y_G7TY:V-M8Q
ME+6UB@'I&H _2G36L%W"8KBVCF7NLJAA^M*&,<*DFHVB^@^6Z/#[+X_NMF!=
MZ:GGJH (8X<]R?2MSP/\3]6\7^)C;G34ALO[Z,3_ $KNV\$^'WG$QTNVWCMY
M2X_+%:EII5E9J5MK."'WBB"']!2G7PW+[D'=^8EIH>;^./B7J7@_Q1%;M8^;
M8.N2S9&#FN!\=?%.V\5:,NFP:<!)(P/F,.1]*^A;[2;'4XBEY:0S#MYD88_F
M:S+7P7H%I.9(],@+'D;XP<?I54,12I)3Y/?02C<\\^"?AW4-&T>_U"ZA,37*
MYB1N"=N>U5#\:;O2-7O+'5]-P(Y"$9<DD9]*]K2%$5510JKT '2LS4?#&C:H
M2UWIT#,>K! "?QQ4?683J2G6C=L3B?,OC/Q-)\0M?@;3].",!L4(.6]S7T9\
M/=(FT+P5I^GW Q-$GS#ZDG^M7;#PUH^F;&L]-MT9?NMY:[A^.*V4&,\8S3Q&
M*52$:<59(I*PZBBBN(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@!U%-#<XY_*@DCWYH =13 Q).>*7+=#^= #J*;DGI0&/![&@!U%(#S4$UU%
M 9YHXLGC<P&: +%%1"4-\P;*D @@4\MC [F@!U%-SCC]:=0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!VKHK'4(3Y9W[B1]WTKBJX?6Z/2I8NZU.M$G,<Y'[J/@!FSS4HOFN(S*\B*
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M=02JT2C<2!T%>9O-_:,ER=+T*">*-B))74$@_G5_P*\@TW6(W*KM4_*!TX-
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M+>+YC="HR/SKC_$NA:?9^&;.6"!5D;&7 Y/2I-0T#3X/ ZWBVJ"X\K/F <T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M70T4".'TWPAJDFKPZCK-^)9(ONA.?PZ5-X@\(7EYJ2:AI5T+:<<DD]37944
M<$G@K4QJUKJ4U\)YD8&3>>WMQ5#Q9:-=>,;>W$K(SJ"K#J#BO3#TK,FT2QN;
MY;V2/,Z=#F@=SDE\%ZM>:@LFJWHEMXVR@!R?Y5#X\@635=/MPY0$!<KVZUZ%
MLX^[^M4+S1;*_N8[BYCS)'TYH"YQ[>"M8U"6&.^U$26*8(7/)'Y5M^(_#=QJ
M>G6MI9O&BPE>7/88_P *Z9%"H% P!P*<>E 7,J2S6/0OLUP1M6':Y[<"O/\
MP)I0N=>EGW!XK<?(>V<UZ;-;I/"T4BYC88;FJ^EZ19Z3&R6<016Y)SUH$7L'
M&#2@8&*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M17  _.@#H02>OY4M5K*Z6\MQ,$*$]5;J*LT %%%% !1110 4444 %)@"EHH
M3%&!2T4 %%%% "8%+BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5-5Y/#)2Y>?3KZ6P,G^L$:A@Q]>: *^EZ7?6,FHW%W);DS#.V'..G?-1>"4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSCMZTNXXH ?13-Q]*"Q'O[4 /HIA<[L8XQUI<GG _&@!U%,#\9_#I1N/'\J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1(I^=3CL:/"R01ZWJ1M8##"P.W/\7-0:%K%MINIZLMXQB@:<$RMP@.!P3ZT
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MV\3-UW% 34CPAX]A564\;2.*EHH KQV=O$08X(E/JJ &I=A!R.>.*?10!%'
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M0RD,O]X'@UQOAO2(M4M;I[UVGC$[K'&_2,YZCWJWX<#6VHZCIZR.88G.P'^
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MI</N:VE\L$_3- &IK$$]S8[+>Z%M)N!#G^56;?=#:HLL@=@OS/GBL/QDS?V
MY#%6WC&._6J6L7+M9Z381NR+<(GF,.X &10!I>)+PIH5Q);3 R#;MV-SU%:&
MENSZ9;R2$[C&,DGFN8\2>'K.RT:2>Q#6[H5W"/\ CY'7-/U?47L?#MBBR^3]
MH(C:7O'QGB@#K!=1,=J2H6_NAAFGM*$^\0,]LUY[?R^'K33TN=,O85OHAOS&
M3ES5_P 2SS76E:6RR/&\TD8++U!)'- '8&ZB!"B5"[=%SS5/5M7CTFQ>XE3>
M5Z*& )Y]ZP=<T2WL-)^V6^1>1,"9S]YN><U'XCM[;4/"D5]/;J\YC4AG[<T
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M(QAPZE>Y##BN1\6:99/J.FF2!299P&/KUJQX@T^VT_PQ/]C@$.<$D=^#0!U
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M+UK]3-%;L5B@;[H.<9_&H8]/&G>-;>..5C#Y0(C/2,9/ ]J .S:41D;V5?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^\.W-H+*ZBE$)&'C(R?:F6=I<)X)EMS$XF,;C:1SSFNI\L#D YQCK2[?;\*
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M#J#B@#B;31;^.VCN8M%M&(&X%KI__0>E;%P1XG\-@6T6V2.0$HPP,J>14_\
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MP>] 4]SF@#.TN62=6D^R""(_=!7:WXBM <CU.>]((_FR<Y'O3L$]: '4444
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M&2.E _6G>F:=KV\A;7*=T)01Y8W,>H%6(26C!(P1QBGQVXN;E8?-$6[^(4"
MVKM 7#E6/([UQ0DE5:.Z;O25AV* *=_.C!KL.02GA<AO3%)2C(&*F23B+JBK
M;33;FMY%_=@D@U;(!7D9 [U1NKEX+E$"@JW4FKPP%XSMK*FK/0WJ2ES*70R[
MP/#=0Q+U=@<UIQ,2F".:K7JY$<Q4ED;(JQ'(TARZ[21T%9)N,K'0VITR44O>
MC% KK]3SXZ*PH%%%%,84X4E**0+<.]!&:*,T-7&M'<+)W*A=QV(^=OKS6D+F
M6SNG?R_W<P 4'M6/ [QZB<,-P&=IZ5JK.;P!9')"MGGM]*^6Q<4IW/NL.[TU
M+H:]A%))-MDD5\<@CM6WLWPD-@OZBN=@Q#('1E5&XQW-;EJ22J,2#VQ6"3NF
MA58=2PJM%&O/-2;W# GFH6=B-I7+ X&:>@?<,]CU[5I):'$UJ/D8^1D#YB>:
MS+U T80<LG))K08.)"R$@GUZ52DD.QU9=WKGJ:PBVMC2G)IG/!?,O]\Q B'S
M;1WQ4IEMU:0D<$?*E27,(" F/RSN&-WI501Q-<,@RWRDAO3BB=GN>B[26IDS
M,89'6X9DMY. %]:BCMHHK9YF#ND X4?Q5<DB=$C2\9O*WE@3T-1S7SK*WD':
M'^0HO3'K5IWV.2O&ZT,<;19,\P*(>B#KBL["F/[1N9%Z8S\QJ_?.29T4/YX'
MWCT_"JEG91S%9)[MHYD^\&/05V0LXGF5*;L[B3$VMPDBL7MW0;CW'%2VD99I
M6AD)@?Y5&>U-N8&E@FDMI.G&!W [FJFD,8& AV2LPQM/05K%K=$4+--(ZFU(
M-NBC)*#!.:EJG8+Y495\ ^WK5RO:I_"CQ\1%J9;TO_D+6?\ UW3_ -"%?0?:
MOGS2O^0M9_\ 7=/_ $(5]!=JMF"%HHHI#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$_YZW7_?8_PH_P"%8:)_SUNO^^Q_A1<+'CI%-(->R?\ "K]$_P">MU_WV/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>drug_001.jpg
<TEXT>
begin 644 drug_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2G"',# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M M%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'GNK=M\:1KECVXKHA7IQA",DGNW]XK$7@'POIWA'PW-JRW2SRW,?F/<=@/\
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MO9M M?L.@V-LVT-%"JL!TR!7F7@WX<:G<:__ ,)%XHD,MQG*1OV]/RKV +M
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MRW+'THI*45(!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 8I,#T%+10 48'I110 F!Z"C ]!2T4 )@>E+@>E%% !BBB
MB@!,#T%&!C&!BEHH 3 ]!2X'I110 8'I1@>E%% !@>E)@>@I:* #%%%% !@4
M8'I110 8'I28'H*6B@ Q1@444 )@>E+BBB@!,#THP/2EHH *,#THHH 3 ]*7
M ]*** $P/2EP/2BB@ P*3 ]*6B@ HQ110 F!Z"EQ110 8%&!Z444 &!Z48HH
MH 3 ]*7 HHH 3 ]*,#T%+10 F!Z"C ]*6B@!,#TI<"BB@ P/2C ]*** # ]*
M3 ]!2T4 (0#U -+@>E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"C'_  K;1<<_N3S_ ,"-8YDXSHPJVLV.&CL=K1117@&H4444 %%%% !1110
M4$XZT5',K-$0C8/K4R?*FP0_</6C</6LG[)J&XD7.!2?8]1[W5<OUF7\C_ O
ME1K[AZT9%9'V/4/^?JE^QZC_ ,_5+ZS/I!_@-17<ULBC(K)^QZC_ ,_5'V/4
M?^?JCZS/_GV_P_S'R+N:V11D5D_8]1_Y^J/L>H_\_5'UF?\ S[?X?YAR+N:V
M11D5D_8]1_Y^J/L>H_\ /U1]9G_S[?X?YAR+N:V11D5D_8]1_P"?JC['J/\
MS]4?69_\^W^'^8<B[FMD49%9/V/4?^?JC['J/_/U1]9G_P ^W^'^8<B[FMD4
M9%9/V/4?^?JC['J/_/U1]9G_ ,^W^'^8<B[FMN [T;AZUD&TU#O=<4TW%_;'
M:\?F)_>H6*M\2L2XHVLBDW#-4+;48I?D;Y&]#5P8R,5TQGSJ\2;$E&1245IT
M$+FBF]J<.E) %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1WHH[T %13?ZM_H:EJ*;_ %;_ $-8U?A8UN9^A_ZA_P#>K5K*T/\
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MTH9[-]L>#D,G7.?QK2HN:#\@/5<CUI,@KP:Y_6?$\>C7"0OIFIW3,,YM;?S
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MFH_ C_;?AUIJVLWD.;8*)$ )0Y]#73'2',,<WP\T*WECFTRW_LRXC8-YUO\
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M>"_#NC7(N=.TJ"WFQRZYR?UKEOB/,=7U"P\+1,2UWEY IY4*,BO17E$<9=N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :U4=4_P"0=)^%7FJCJG_(
M.D_"N?%?P9%T_B)+#_CP@_W!5KO56P_X\(/]P5:[U5'^''T1,OB'4445L(**
M** "BBB@ HHHH **** "BBB@ H[T4=Z "HIO]6_T-2U%-_JW^AK&K\+&MS/T
M/_4/_O5JUE:'_J'_ -ZM6L\+_#^\<MPH-%!KJ)"BBB@ HHHH **** "BBB@
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M!N4'.#]:<.G0_G3\<=:S;3 ,]*6D[BEI %%%% !1110 4444 %%%% !1110
M4444 %%%% &7K/\ QZC_ 'JOV_\ J$_W15#6?^/4?[U7[?\ U"?[HK@I_P"\
M3]%^I;^$DI:2EKO,T%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@ Q28'I2T4 &!2%0>HI:* $P,YQS1M&,8I:*
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MVGW=NUGJ<'^M@8=?<9[4.%]@.KR!WY-(3CKC)[U!>74.GVLEU<N(XHU+N[=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHS1< HI,T9H 6BDS1F@!:**,T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 449I,T +11FDS0 M%)FC- "T4F:,T +129
MHS0 M%)FC- "T4F:7- !111F@ HI,TN:5P"BC-)FF M%)FEHN 44F:,T +12
M9HS2N M%)FC-.X"T4F:,T +129HS2N M%&:*8!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #6JCJG_ "#I/PJ\U4=4_P"0=)^%<^*_@R+I_$26'_'A!_N"
MK7>JMA_QX0?[@JUWJJ/\./HB9?$.HHHK804444 %%%% !1110 4444 %%%%
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M)Q[#'4#K10!S7,MQBT4450@HHHS0 449I,T +129HS0 M%)FC- "T49HS2N
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 UJHZI_R#I/PJ\U4=4_Y!TGX5SXK^#(NG\1)8?\>$'^X*M=ZJV'_'A!
M_N"K7>JH_P ./HB9?$.HHHK804444 %%%% !1110 4444 %%%% !1WHH[T %
M13?ZM_H:EJ*;_5O]#6-7X6-;F?H?^H?_ 'JU:RM#_P!0_P#O5JUGA?X?WCEN
M%!HH-=1(4444 %%%% !1110 4444 %%%% !1110 4AI::>M'H 4F#1S2T78<
MP#-+2<T9]Z35PN*:3)H/M2?6GH@NA]%%% !1110 4444 %%%%(!CY)'7UI,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.,7(^.++4;W3)?,LYY;=TZ-&VT_C7MWPR^+,M[<Q:3KC!I&&$G)Z_6L;XQ>
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M]O\ ZA/]T5P4_P#>)^B_4M_"24M)2UWF:"BBB@84444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYQQ_.OH,PC&MAW**NS*.DCZ=U$XTZ[/;R6_D:^)+X8OIA_MFOMO42#IMT/\
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M=GTHJ-)5= P.0>AIV[':O-ZV/23OJAU%)GVI: "BBB@ HHHH **** "BBB@
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MB>%IO.LXMT^,;V'-=?@48&:U>)JN')<5D(.O3FGTW IU9*_484444P"BBB@
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M99,;4(K8@AC&,1K^56T4=%0#\*+@00-/#&<\58M<W((>GK"[ C'%6+*#RPV
M2:+,I6*4,!2<A..:T[2W=F*A<D]ZO6FB/)\S9R>:VK/3_LJDGK6\$839B/;L
MJX855=,&NEGMU<'-9%S:E3E1Q77&QRR1E,E0,E7GC_"H'B-:I7,6[%)A49&*
MLNM0LM-Q)4M1BMM.:MJZR)SUJHPQ3%DVG@UG?E-&N8N44Q7W@8IXKTJ,[Q//
MJPM(44N=I#=A24O:JM=6(;MJ=CX;UXDK;7!X_A)KL 01G->0H[1N'4X8=#7<
M>'=>%VJVLS?O@.#ZUY.-PO)[T3U,-B?LLZCO2TP')%/KS3TM.@4444 %%%%
M!1110 4444 %%%% !1110 4444 %(:6D:@ J&9D0&1FVA1DMZ"G%S@GT[5PW
MB[Q/M/V&S;<W\;#M[5<*;F[(B<U%79G^*O$5QJCM:6I,=JA^9N[G_"N.(QE.
MF.];)*20B7<%Q]_-8^J:A"D!2!]SMT(%=E.LJ%XG+.'M-2K<W4=M@NGT-48S
M'JDX7<5K4T[PY=7J"X=RY(Z8Z5M6WAX0#S @#*:BK7E/8JG12,FXM$TBP222
M3Y#G'K7,ZCJ,NI6_D6\3!"<;O45Z7?V>E-9&ZOP3L7&W-<1<W:(K)!"$B/W3
MCH*CVTG'E-/9)2N9L5NEF]O#@?..3Z5T+SAXDP?E08XKG+.S>\NU$DAP.YK;
MO--\B *DN1WP:BG4<7<NI!,S;J 7-_YH<J%'>NAL([FXLE>V+,%R'8="*R98
M88X'0E@S+P?PKHO#TUM9>'TA,Y\QG8MD=15IN<MA:*)E2;$D=MO/<&HH;BY2
MX$ID"(.U6;[RVN2T3?+58UZ5/#.5FS@G4Y6R2[O&N7&&!6JIJ0C/M33C'3\:
M[5'D1SN\F1L0JEF'%4XXI+V8[D(C'>DO%>Z988'/7DBM2.(0PI"#CCFN64W.
M5C>,%&)!)%@<=JBZBKKK\F/UJF4P>O%=,975C"2L,(IA&34G/89IH&7([XXJ
MKI(F[9M:+:1O:O=MC<KXQ^%0:T&D"[1FKNDH\6G.&').1]:N+;I(H9\-BO$J
M5FJET>I&FG3.:M;#<V^?Y4'/-0ZCJ>^,PP_+$O!Q5G7+E8V,:''L*Y2ZN\$X
MZUW1?M8\TMSG2L-N[D*"%.:SHHFG?)SBGJC3OD]*U+:WVC&*N-Y$M]1L$ 0=
M*LA:D5 .U!&#73&-C&4KC"*8:D(IN*L0PBF$4\TT^U%[!KT&'-7-)TYM3OO(
M'RJ.IK.EE" CJ:?9ZI)9S;ED\O=U-<U>K:&AO2I]SUK1_#EF]JT:% Z+SGO6
M)J,J:=*0<!1D9%06'B2"PMED^UY9EYKD_$6M-JLABM\A3U:O&C*<WJ=GNI%C
M4O%H@F!M&)G4X&#TQ7K_ ,-_'1\06@LM18"^C7J3RX]:\ M[=+91QEAU)YJ[
MI^HW6G:A%>VDICFB;<I%=7U6\;F7MK,^H]:_X]5(_O"KT!_<I_NBN)T+Q=;^
M*O#Z2 ;+J)@LL?OZBNUMO]2G?Y1S7@>SE'$3OV7ZG<I)Q)>U.'2DI:[!!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX/R%OF^E>DVTZW,"2(<AAFOG\12<)>1[N&JJ:LRS131WHQQ7,=?4=12#I2T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK#YL]ZD%>#8]-:H44M(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKTU-@N,9+#%,%Q"&_P!;'G_>KYEUOXG>*O%NJ&#13+#&WW8H!DD>^:KGPO\
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M[1117.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_R+%_\ ]<C7R[\-/^2E:3_U]#^M1E\W&A4DASU9]&>$?!.F^$=)CBBB1YR
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M4-N+1+S[XYKQ,="TKG?AGH75P<FG4U>.*=7G(ZPHHHI@%%%% !1110 4444
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M:9-<ZA''&P8A%CSTS[URU,-4C"\D7S(Z;Q7_ ,BQ?_\ 7(U\N_#3_DI.D_\
M7R/ZU]/^*@?^$:O^G^I-?+_PT*GXCZ3R/^/D#^=>A@Y)8::?4F6Y]=#[M)2+
MNV\XS2MGMCWKQMM"UL?)'Q(_Y*'??]=/_9C7TOX&_P"1*TG/> 5\S_$C'_"P
M;P9 (ES^IKZ7\"8/@G2"#_R[K7LX]IT*<4]C..C/-/V@;(M86%]MX0^63]23
M4/P!U>%8+[37;YRP9 3]<UZ?XV\-1^*_#,^GN!YI^:(GLW:OER&36? 7B8L%
M>WN8&Y#<!AG^HJ\-*%;#.C?4'HS[(R,4TL-I)X KQC2_C[IKVZ+J%E<),%^8
MQXVD_B:R?$_QT-[8R6VBVLT#MD>8^/\ &N!8"NYVMH5S'(_%[6(]7\;3);G<
M+7,0Q^?]:]_^&VGMIO@:PMV7!VY(^IS7@GP[\&WGBSQ(E_>I(;)9-\TC#AO:
MOJ.WA$,*QJ,(H"K]!77CZBC3C1CK8B*UN%Q"EQ;RQ./D="A^A&#7R'XJT^7P
MMXYG1,QJD_F1XXPF>*^PR.*\"^/N@%+FSUR--VX>5)QP !Q_.L\LJ*-1QD]&
M5/:YJ?$OQBES\,;%H)/FU),. >=N/_K5D? 7P\)+JZUN1<B/]TF1ZC.?TKR"
M?4KJ]M[:REE+Q0 )$G;_ #S7UC\.M$_L'P;96Q7$A4,_X\_UKMQ:AAZ#IP?Q
M$ZLZM3QS7SW\?K)H]9L[T+Q,NS/T'_UZ^@V)"?6N*^)/A#_A+?#C0Q8%U "T
M3'L>X'UQ7DX.K&G5394E='-_ G5XI_#$FGLW[Z&0G&>V!7K6[@'UKX\T76=8
M\!>(-RK+;RQ-LEA;C>!V->P6/QZT>2#;>V5PDRKDE<8;V'-=N-PE2<G4IJ]Q
M0ET/8)I$BB=V("JI)-?(GC?4!X@\>W,D&6#2B'\CBNS\8?&N?6;%['1H'MDD
MX:1OO8]*K_"3P)<:SK*ZQJ$3K:Q,6RXXD;V^AK7"TGA82J5-&#U/>_"=I_9_
MA33;8C!CMU4_E7G_ ,?/^1/M/^OC_P!E->K@ )C;P. *\I^/GR^#[4X_Y>>O
M_ 37F8>:EB%+S*:]TX[X ?\ (?N_^N9_I7T.!G()&>]?//P"&/$%V ,_NSD_
M@*^B .M;YE;V^G4(['F?QF\-C5?"IOH5S<6GS @<D' KRKX,^)#H_BQ=/E;$
M-[^[QG@-US^E?3-_:K>Z?/;.,B1"OYBOCW7M.G\(^+Y[4%D>UF_=OZ@=ZZ\N
MY:U*5"1,E9W/LD$%<CJ15'6-4@T?3)[ZX8*D*%CD]>*H>%-93Q!X8L=2C/\
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MKPUL>@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9+0'Y)(7<CW&*Y<:KP-Z#U/?U.12TB^E+7SR/3"BBBF 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %&*** $P!2T44 %)BEHI6 3 HP*6BF]0$Q2XHHH 3 HP*6BE8 Q
M1BBBF 8HQ110 8HQ110 8HQ110 F*,"EHH:N 8HQ110 8I,4M% !BC%%% !B
MC%%% !BDQ2T4K(!,4N***8"8H"@4M% !BBBB@ I-HI:*32>X"8I<444UH 8H
MQ110 F*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\ :EIUSXG6.UB59#"YR/;%8UZLY4W=%TXI2T/6$)QS3J8G>GUX^O4] ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVKF(G\J57'45T<$JS0AU//>OSSB/+W3J>UIK1GU.68E27(R2BCZ45\F>T%'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%$<MU<X?X$:\;G2+G2)FY@8&,'T.2:]ESZ5\D_#76I/#OCJW+MA'<P/D\9)
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ML<F!B@KTI8.E12]H_>9FI297\>?%+PIX@\'W^F6%S.]S.@$8>!@ <@]37*?
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MN%YCGB# 'T8?_7K@K[X(^%-0OI[R4W@DF<NP6; R?3BN"BJ*;5:]QO78RO\
MA?FB?\^TOY'_  KH/"'Q4TOQ;JW]G6T;I-L+X8$# K-_X4+X0_O7W_?_ /\
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M#1)_*O /6NOS\P]ZEC)!]WKDT$<@@D4@IU38HL1'< & /U%71;P3*%>%"/\
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M\Y^,?A-K;^)[FYTN+=!*_F CL2<U[& KQBI0F]&B9+L?0UM,EQ;QR1MN5U#
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M[?\  *BK#ATHHHKD&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG$Z:-%\W,:8&V,!5  &,>E2+C:,=*:5XZFG#I7C1V/2%HHHI@%%%% !1110
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MQHDCUI,\9K'L?$>CZHX6TO[>=AS\K5KX!]Z37+K)#3'CI2TB]*6A:@%%%%,
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MYZU92";=_K:(CQ5F,UBZC1?(1FU>0$-)4J6B^2(VYJ9>E.%1[9LJQ7:Q5G#
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MS->WLTSO*8\("Q.3SVI(-)\6_$*]DO(4E='8G>Y(0>V:R?"'AY_$WB.UTY2
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M$\94J0<)K4M)"DDD=QTKY.^)-U<#Q_=@3R *R[0&/%?6?'I7R-\2O^2@WO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"9 -9&,'*G!J]9:I/9G'537GU:-];&\:BN=)ITS:9.'4X [5WND^*(KF,(7
M?TS7F"ZG#,I\T')J@VL36<DGV52,=&;WKP\5AY*+:/2I54]&=[X]NF:Q5@3@
MG!KS?3=*O-9N_LME"9)">3V'N:]%\*Z;J'B/2BE_&1"P^^XZCU%=]HGAW3]"
MM]EG"!GEF/+'\:O+<5.G3:>YGB*<92T1C>#/ =KH*"ZN0)KXC[Q'">PKM0@
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M@8SUI<,>W [43QSFK-?@-(BNO^/&;/\ SS;^5?%[VZW7B%[8G[]P1^M?9]X
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M1&4=S2U?2;76=-EL+R/?#(.:^??%GP6U72YWN]$;[1!DL$Z,H^M?1Q=0P!8
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M\(/]P5:[U5'^''T1,OB'4445L(**** "BBB@ HHHH **** "BBB@ H[T4=Z
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M7FL9+S:H)CB!YQP36H%(&,#VIV#^51>X7L0V]I!:Q[(8U4=\#K4_&,4=J.]
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M\Z;3H]_^S\H_(4J->BH6G&XWN>(^)_C/JFNV4EA96JP)+\N\$[F]JU?@_P"
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M5_!D73^(DL/^/"#_ '!5KO56P_X\(/\ <%6N]51_AQ]$3+XAU%%%;""BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M-:J.J?\ (.D_"KS51U3_ )!TGX5SXK^#(NG\1)8?\>$'^X*M=ZJV'_'A!_N"
MK7>JH_PX^B)E\0ZBBBMA!1110 4444 %%%% !1110 4444 %'>BCO0 5%-_J
MW^AJ6HIO]6_T-8U?A8UN9^A_ZA_]ZM6LK0_]0_\ O5JUGA?X?WCEN%!HH-=1
M(4444 %)2T4 )12T8H&)12XHH$(312T4@&$9]3^-&T]:?@44]0*\MI;W Q-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K51U3_ )!T
MGX5>:J.J?\@Z3\*Y\5_!D73^(DL/^/"#_<%6N]5;#_CP@_W!5KO54?X<?1$R
M^(=1116P@HHHH **** "BBB@ HHHH **** "CO11WH *BF_U;_0U+44W^K?Z
M&L:OPL:W,_0_]0_^]6K65H?^H?\ WJU:SPO\/[QRW"@T4&NHD**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH :U4=4_Y!TGX5>:J.J?\@Z3\*Y\5_!D73^(DL/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]O\ ZA/]T5P4_P#>)^B_4M_"24M)2UWF:"BBB@84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #6JCJG_ "#I/PJ\U4=4_P"0=)^%<^*_@R+I_$26'_'A!_N"
MK7>JMA_QX0?[@JUWJJ/\./HB9?$.HHHK804444 %%%% !1110 4444 %%%%
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M G@BN!PD;J29IQ7$J@?-6C!J%PN,/63'GU!J[",]OUJ'&1:Y3934[@C[U/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'8_SKL=*_P!0OTH&:-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9>L_P#'J/\ >J_;_P"H3_=%4-9_X]1_O5?M_P#4
M)_NBN"G_ +Q/T7ZEOX22EI*6N\S04444#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/PJ?^VB!]ZKNH_"_7+:4_8IXYD[  Y K+'P]\5.^TP8'J?\ ]=;1JP!Q"76
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ML@XQP*ZN&TAB "(H ]!7/1KPJQ;B74I^S=CGX["]N>3^[%7K?0HP09CO-;.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)=D87T%9,&;S4VE/,:<#ZUK@_G7)AUS2<BV^@ZG#I3:=77'8@****H HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_9,G_/T]:V*,4?58]PYC)_LF3_GZ>C^R9/\ GZ>M;%&*/JL>X<QD_P!DR?\
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MZ>M;%&*/JL>X<QD_V3)_S]/1_9,G_/T]:V*,4?58]PYC)_LF3_GZ>C^R9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** *[IDU"T56VZ\"DVGTH I&*F&*KI4>E-,8H I^52>3GFKFP4
M;!0!2:'=Q5&;1P\N]6VD\DUM^6* F/>@#%AT2(.6D^<^M:$-G'$/E6K>WT&*
M>%% $ C([4X+4H6EQ0 P+2[:?BEH :!2XI:7K0 @%+BBES0 E+2YI* "DQ2T
MN:  =**,T9H **,T9H *ANO]0W%39J&X&8B,]: ,>:UCF7#)U%9-QX<ADYB.
M#70@< 4;?:BX')'0;J+[C;AZ4@T^^CZ1 UV C4=:/+%%P.52VU#_ )]P/PJS
M'9:B_8+72".EV 47 Q4T:>0?O[@_2KUMIL%M@JHW?WJO\#L#]::0,Y_2BX#(
MQ^^&*O55B \S-6J "BBC.* .3\5?\A*Q_P!QOYBMS2_]0OTK#\5?\A*Q_P!Q
MOYBMO2CF!?I0!I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 5[BYCMEW2;L>PS66_B?3D8J?.S_N5JW,
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M F_X2S3?6?\ []TV3Q5IK)UG_P"_=1_\(^GH*/\ A'T]!0!'_P )+IP[S_\
M?NE'B73O6;_OW3_[ 3T%)_PC\?I0 G_"2Z=ZS_\ ?NE'B?3?6?\ []TO_"/I
MZ"C^P$]!1H H\4:;ZS?]^Z7_ (2C3?6;_OW3?^$?3T%'_"/IZ"C0!W_"4:;Z
MS?\ ?ND/BC3?6;_OW2?\(^GH*/\ A'T]!0 +XHTT'K/_ -^ZF_X2S3?6?_OW
M4'_"/Q^@I?\ A'T]!0!-_P )9IOK/_W[II\6:8!R9_\ OW4?_"/IZ"D'A^,
MC% &9K&H0:I?VSVYD.Q2/F3 ZUTVE BW7/I5&'0TC;IQ6S!"(D H FHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH #2=:6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH
M3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#T
MHP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]
M*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#TH_"EHH 3IVI:** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN67WQM-<^7XB7ME3Z,J2TN=)\(/%4OB/PPT5P?\ 2+1A$23UXS_6KOQ;'_%
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MZ2V2(MJ?9-OG[.F?2O!?V@O^0CIW^[_C7O=ODVZ$_P!T5X)^T%_R$=._W?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EI#0 57>VADD+/$KD]R
MH.*L4E*+8%<6=LHP((OKM%*L$2G*QJ#Z@5/2T[R[B:&*".,Y]Z?112UZC13N
M=.M;MMT\".1W*U,D21QB.)0B#H *FI/PH?-)6N!!-%',FR11(I_A(R#4,&G6
M=J_F0VR(Q[@=*N_A2TTY15KZ ,7(P.H]::Z*V5(R#V(J;%)2N^@&1<>']*NY
MO,GT^"0COMYJW;V%I:C;!;I&!Z+5RC%4YU&K-DV&@8.!3J*6IV*1&0=U0/96
MTR$301-G_9JUWI*2=M4PL9"^&M'6?SO[/BW^NVM%;>-%VQHB#MM&*GI,5HZC
MENPM8Y/XB:T-!\%WUT/O.OE*?]H@XKP3X1:&==\<)<S()(H=TKG_ &CR/UKZ
M@N[."\B\JXB62/\ NL,BH;+2K+3\_9;>.+/78@%=5'%JC2E!+5DM79:48^4?
M4U)3<'-.KA6URADL:R(589'IC-0BSMC@FWC&.Q059I*I-VT"Q7^RP#I#&/\
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M$5$5>@6IJ*+R>@AC#)Y!QWJI)IME)())+:)F'0E:NT8I7E'X0L,5 J@ *!V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 )BC%+122L F#FBEHHL 4E+13 2C!I:* $P:*6B@!**6B@!.:,4M%*P"4M
M%%%@$HP:6BG8!,&CFEHI60#<'UHP:=10E8!I!-+BEHHL F#1@TM% "#-+111
M8!**6BG8!**6B@!.:,4M%*P"48-+13 3%%+10 E'-+12L 4G-+13 3!HQ2T4
M -P:4 TM%*PK"8-&*6BF,3FBEHI) )1S2T4 )S1BEHHL F*,4M%,5A,&CFEH
MI6&'-%%%%@$YHYI:*+:6 3FC%+118!.:6BBA*P"<T4M%,!*,&EHI-7 2BEHH
ML E&*6BF F#1@TM% "8-&*6B@!,&C!I:*5@$HI:*8"8H&:6BA@%)2T4 (0:,
M&EHI6 3%&#2T46 2CFEHIV 3!HI:*5D 4E+118!#THQ2T4P$P:*6B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>research_001.jpg
<TEXT>
begin 644 research_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0:"%X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%I#129'/M3]0%I:;N''O2YI)KH 4E&:0L!WIV?0+#ATI:13D4M, I#2TAHW
M*.]&:,U-[@+129I:8!1113 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/$H(W;!_*NS'8>-%1MU(3N3TM,#@G@@XZXIP.:X&7>XM,.<GK3Z:PR,5.[U
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M=*87Z#Z*9O\ :ER<4 *>G%-Z _PBESD=.*JWMW'8VDEU-E885WM1UL Z:>*
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M,P_E7"?'T_\ %<6WH;-?YFN.T2;Q/'ILK:0;L6R_>\@MU^@KZ14'6P-.*?\
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M%%\G0B*;.2U;XD:EX?\ AWH=\T8FOKV,#>?7&:\[E\8?$771OC%Y)&>5$4'
M'U KZ*U+0M#DM[07]O;K;V3;H@^T*.,=#Q7/W/Q%\%Z$6B^TQIY9PWD0Y'X8
MKSJ5>+5X4[O4NQXG:?$[QAH5\@O9)&V=8)TV9_'&:]]T;Q6GB/P5+J]B")A
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MG+?+"'R?RKZ)\+ZEJ6J_#Z&ZU,-]L>#+%EV\YKD_@/9VT_A*=IH(I&%PPRR
MGH*]3U&-(M(N$C144(<!1@"N3%UJ?M53Y=;E1^$^.;:\73_%"7C_ #+!=%R!
M[-7:ZU\6?$VKS%-,)M[5%QMC7<>/4XXKB+:S74/$XLW)$<UWL)'NU?6&@>#M
M&TC1HK2.Q@<; 6=XP6.1ZUZ.*JTJ48N<;DQ3/"/"WQA\0:=J4,.HSBYM&8*R
MLH&WWS7TII]U!?6<5U;MNBD7*-V(KY*^(^F0Z1XUOH+= B$[U4< 9)KZ2^&,
MC/\ #K1-QR?LRUQ9C3IN$:L(VN.#.NI#TI:0]*\5&C/B_P 4?\CMJG_7\_\
MZ'7U?X*_Y$[2AU MU&:^3O%N?^$PU?&<_;),8_WC6C:6OC1K2$VDNJBW*@H$
MDD Q7U6-PCQ%.%G:UOR1C&5CZ^P"H!YK-UO6K/0-+GO[Q]L42]^Y[ 5X5\,8
M?&$?C*V;4'U!K;H_GNY7&?>MK]H#598;;3M+0D).#*W/]T__ %Z\98-*NJ4F
M:.:2.7U[XR^(]5OVCT8_9X"=J*J!F/YBLC_A.?'FD,9Y);B'<<[YHL _F*Z_
MX%>';2\EN]3NHDD*85 ZY ZBO8O$>@6.JZ'=6T]O%AHSM.P<8&>*[9UJ%&?L
M'"]M+DJ[5SS_ .&_Q6;Q#<)I>J;4O6^6-A_&:Z_XE?\ (A:H1_SQ;/Y5\LZ=
M+)HOBB"0.5:VGX(.#7T_X]D,WPSO)#U:US_X[66(P\:>(@XK=DI^ZSP3X0_\
ME#M/^N;_ ,J]I^-O_(@3_P"\O\Q7BWPA_P"2AVG_ %S?^5>T_&W_ )$"?_>7
M^8KIQ/\ O=,K[)YC\!?^1ONO^N _]"KWOQ)KMOX<TB?4+Q_W2#(7UKP3X"_\
MC?=?]<!_Z%6_^T'JLR2:?IB.1')$9F /H2*RQ=%5<;ROL"=HG-ZQ\8O$^KW[
M1Z0YMH#D+&B!RWYBLL^.O'FCL)I9KB#)S^]AP&_,5W'P(\.6=Q;W>J74*22*
MP6/>,@#!S7JGBKP]8ZOX=O()H(LB)F5M@R,#/!HGB,/3DJ7)Y KM'&?#;XJ_
M\)3<+IFHHL5[CY6'\=0?&7Q%X@\/?8I]+N?)M7&&^4'+<_TKPS0;J31/%=K,
MC,K0S@ @\^G]:^C/BUI/]K?#Z:;;E[9?/7USC_Z].OAZ=#%0?1@F[&;\'?&M
M_P")[6\M]5N/,N(G&SY0/EQS6M\6/%=UX7\+^9I\OE7DCJ$8@'C//%>+_!W5
MQI7CN%9&(693%MSP22*Z+X^ZK]IUBPTU&YA4LRCONP142PB6,4?LCOH'PT^)
M>N:AXK@L-5O/,AG)YV@<X->ZZWJ"Z7HMW>LVT0QEBV*^/;/[5H&OV,L@*."D
MOI\K&OH/XL>)8H_AN3"W&HIY:8/X_P!*K&X>'MX\FS(4F>:^&_B+XMU?QE9V
MBWW[J6?:P" _+GZ5],1[O*3<<MM&3[U\U? W1C?>*Y+]US'!&>2.C<$5ZUXU
M^)MGX,N[>VFMGG:52< XZ?A7/C*2=54Z2V-(L[PD@5%(RQAF8XP,EO:O'1^T
M%IW?2Y1CMO\ _K5T6J^.8M4^%^H:]9AHBL> I['(_P :Y982HI)307.2\??&
M6:QO)=-T!5WQG:T_4@^PKA&\8^/[H+?>==-&.2ZP\?RK,\!Z2-?\=6,%Q\R/
M,&DSSD5]90Z78PVH@2UA\K 7;Y8Q7I5'0PJC#EN*/4\"\*_&C5[:_6UUQQ<P
MLP7>5"E?RKZ MKR.\T^.\@.Z.1-ZG\*^7/BYH=OHGC>>.U4)%(JR *, $C)K
MVGX0ZE)J'P[B>0EFC=XN3T  K+&TJ4X1JPC9"C)W/,]<^)GB/3_B!<P?;@EE
M;SE1'M'W:7Q'\8]>U2X-OHA:" +@E4R6]^G%<1XW4-X[U89X-R<_I7T;X!\$
MZ/I'AN _9(II)E#,TJ!C^&:ZJRH4J,9N&HHW;/#-%^+'BG2+Y3/=&6 -F2)U
M'/X]J^E_#FN0>(M$MM2@( D4%E!S@XY%?/'QKT6TTGQ3'+:QK&LZ?<08' ':
MO3?@5*TG@%0V3BYD'/X5SXVE3E0C4@K%)^\SU 9R>>_%8OBZWFO/"NHP6^3+
M) RJ!ZUM]Z:>0.!CN#7CJ2BTRV?%%A=G2/$4%W(I+VUR'=2/1J^J?#/Q T/Q
M':QF"[CCG('[J0A23WP*X;Q_\&CJ=U+J>ANJSN<O W 8^Q[5XGJ&D:SX;O62
MY@GM)8SPZY _ U]%*-#&17O6D96LS[-\N/?YHC7<1]XCG%?-WQ5\2^)9->U;
M2IC)_9*2E8LQ8!7 [UM?"OXH79OX-#U>4RQR<12L<G/N?PKL_C+;P'P1/,(D
MW'D/M&>GK7!1I/#XE1GJ-NZ/GGPYK.K:+J7VO12PN]I7Y4W<'K7O7PD\3^)]
M?GOEU]W94QY9:()CK[<UYC\%(8Y_'R)*BNOV=SAAD=17U!#:06^?)ACCSUV*
M!FNO-*T.?DMK;<F%['S[\2OB'XDTCQE+96%[Y4,:@CY <]:]@^'^KW6M^#=.
MOKV3S+B6(,[8QDU\[?%WCX@W8_Z9K_,U[U\*?^2?:4#_ ,\%K+%4H1P<&EJ5
M&6MC!^,GBO5_#=C:'2KGR3+PWR YY/K3/@MXJU?Q+::F=5N?.,#H%X Z@UD_
MM @FRL,>O]34?[._S6NN9P/WD8_0U$Z,5@U/N.^IZ)X\\:6_@[1OM#?-<2Y$
M*>IKY]N_BAXQU>[W073+SD11H#C]*V_CMJ$D_C!-/9CL@B5P,\<C_P"M79_!
M/PQ8+X;;4YX(Y9II"!YBAL+QCK6U*%*AAU5G&]Q-MNQYIJOQ*UC5_#EQHVM#
MS)&&%?;@CCTJ]\#%Q\10>XM).?RKN_C1X2TM= .K0VZ0SQ<?NE"[N_.*X/X%
MG/Q&4=OLDO'Y5M.K3JX&3A&W_#DV:9[#\5O$6H>'O",EYILOE3^8B[BN>"<&
MN/\ @]XUUWQ#K=[9ZG=_:(5C5URH&"2?2MWX[?\ (B-_UU3_ -"%<#\ 2!XF
MU#/_ #Q3^9KFHTHO 2GU7_ *;?,>Z>)O$-KX:TB34+M@ @^1?[QKY_O_ (F^
M,O$VI2P:1YBPL<K##'N('UQFM[]H'4Y/[0T_3 S!/+\X@'@]163\+?&_AKPC
MI\YU!6-Y*X.\1DD#'3-5AL/R8?VO+S-B<M2@/'_CWPO<1B_:9(V.2DT6W=]"
M17N?@+QK;>,=)\\ )=1_ZV,=O>O+/B1\0_#/B[PR]K;!OM:R*R,8R" #ZXK/
M^!%Y)%XIN+96(25.1U'>E7HQGAN9QLT--GIOQ-^(8\(6*0VHW7TW"Y_@7L:\
M=M_$OQ"\0J;FV>YEC!SOCBX_05T?Q[TF[&M6>IK%(T!A$65!(4C)YJO\./BK
M8>&M/72M3M\0H>)XU_F .:O#TN7#*<(IL3>IN?#3QEXMG\4KHVO++Y;1LRB6
M+8>,>WO7MZ\]!S6%HNL:)XA"7^FFWEEQC=M&\#^=;W&..F:\?$/FE\-F:H?1
M1160!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4'I10>E 'S1\?,?\)S: =[1>/Q-=S\!\-X5N^ 2LX'3_9K
MF_C5X9UO5O%MO<:;IUQ<0I:JFZ, C.379_!C1[_1O#=Q'J-I);RM*&PXP<8K
MV:U6,L'&%]496UN<%\;_  C'IM_#K-E B0S\3X7HW;^M7_@5XJ=9)] GDRGW
MX%)[\DUZGXZT!?$?A6[LF7=)M,D?^\ <5\[^'/#?BW0/$MK>V^E7.8Y0A<+P
M5)P?TJJ$U6PKA-ZH+-.YN_'JS9/&$%WC"O;JN<=2,\5?^%_@CPOXKT)WO#)]
MLC?!57 .,?2O2_'G@Q?&_AZ./:(;N,;XRW4&O!/^$;\<^#-0E>R@O+9AP)XA
M\K#U%70J<^']E&=I"MK<]K?X,>$_O>7. /5Q_A6[X7\%:%X:N'GTQ<RL-K,6
M!Q7@W_"3_$C5HQ'#<:@Z@;2%QAOK7J_PCT?7],L+Z?7O.$DY!19>HZUSXNG7
MITFJE6^VA:[G"_'37S=:W#H81=ENHD#XY!;@_P JQM(^$U[J>D6E_;:U9*EQ
M$&*'(*^QYJ[\<)])G\3QBT8M?A%$S+TQS@?7K6-H?P_\7:CID=[9))%:R+O0
M'/SCUKOIRC'"TW!\K\R7N>A^#?@U::;J$=[JU_#>M&P9$CZ9]Z]F0)&BHO"J
M  *^2[Z]\:^";Q(KFXO+1NL>X\,/45[Q\+_&DWB_0G:Z7_2[8A9".^>A_2O-
MQM&IRJLY)HI,\/\ C#_R4.Y_ZYI_6O?/ACQ\/]+)Z>2O/IQ7COQ3\*:]J'CF
MXN;+3+B6%HU^8+QWKV+P5I]W:_#NSL9HVBN/LVW:_KBM<54A+#Q46)73)_$/
M@OP_XO0_;(U=SQYT+#=GZUX%\1OATW@F2*XAN%EMI3@?WE.>*E*_$/P7=3P6
MWVZ*W#%LK]UA5.]M_'/C>YA%W;WMSCA=P&U?>M\)2JTTFZEX^8/4]+^ NNWE
M_I]_I]S(SQVI4H6.?O9K"_: 1AJ=BV#M(QG\*]&^&?@EO!VC,+AU^V7'S2A.
MGL/UJA\7?!USXHT.":Q1C=6SEPH'+ @"N2G54<8ZD7H-J\3"^ %S"F@W\+2*
M)//W;2>V!7KM](DFG3,K @H>17R/8Z7XOT2YD%E;7EO*>#L'6OHSP-!JR> X
M(]5$AO&C.5?[Q.33Q]%<_M8RU8H7V/FFU/\ Q6L7;&H=/7]Y7V-9_P#'I$?5
M!_*OE2V\%^)4\8I,^CW*PB^WERO&-^:^K+4%+6)2O(4#%7FE53<;/^M @F>#
M?'7Q'>Q:Q#HT,K);B$2R;3C=G(JO\-_A3IOB71!J>IW+E9&RJ1-@@>A]ZZ;X
MQ> ;WQ \>K:<CS3Q)L:,#L/_ -=>8Z#?^._#8:PTZ*\3S/NQ*._M6V'?-A>2
MG*TNXG=.Y<^+GA32/"FI:=;Z5NQ)$YDW,"<@C%>A_ ([?#ESQQYA_F:\ZU;P
M)XRU/2SKFI0W,]Z[A?*89=5[_P J]3^"FCW^DZ#<+?6K0,[G 88/6JQ$[8.T
MYW?_  P13N<E^T$A_M#3Y,?*> ??%:O[/]U"FBZA"TBK)Y^[:3VP*Z'XN^#K
MKQ5H<4EBK/<VK%A&.K<8KP:STKQ=H<\BVMG>V\K'!" <FIH<E?"\CE8K5,^N
M+UU?3IBI!!0\BOCF(_\ %;K_ -A'_P!J5]+^!(-97P)#'JPG:[9#D/UZFO!H
MO!?B,>+UF_LJY$/V[?OV\8WYK+ 6I\ZYA2NSW+XG6;7?PPNHT4LVQ#@?45X7
M\*M4BTKQU9&<A8Y6V,QZ#J:^I39K<Z8+6X!VO%L<>@QWKYP\9?"?6=&OVN-'
M@:ZLWD+1>2.4'O2P=:+A.E*5FPDNI],":/R!)YB[>N<\5\K_ !9U6#5O'-RU
MJP>.,!<CUP,U VJ_$!83I[7&HB/;@0\5T7@GX2:OJU]'?:S&]O;JX=DD'+]Z
MWH8>.%O5G(3;EH>J?"FP;3?AM!$ZE2S228/HW-?.OB0?\5]?9'_+Z?\ T*OK
MZ*VCM=/6U@3:BQ[$'L!BOEWQ!X,\22>-KV:/2;AH&N]XE"\$;NM9X+$1]K.<
MNH-'T]HY_P")-:Y/_+,5\\_'?/\ PEEOSTB;'YBOH?3(FBTN"-EVL$ (->'?
M&?PQK6J^*+:?3M-GN(Q$0609'45S9?45/$MW&U=6.Q^!_P#R3J'."!-*?_'C
M7C/Q!U_4-<\8W=K<7#>3'<&"-0< 8..E>Y?![2KS2? L5M?6S03>;(2".1EJ
M\P^)OPWU:VU^?5=-MY+B&=S(2H^Z2<UOAJD(XF3?4'>UCKO#OP4T%])MKK4)
MYI970,?+?"Y_*O&/'.FV>C^+]2L=/YM8I J<YXP*Z?3M:^)$FG#1[$7S*GR_
M*!E5JEK_ ,-_$]A)"_V2XNY+A-\KH,X;/0UW4)5(UFYU-[V1+39]!^"CGP!;
M?]<3_*OEV]Y\;R^VH?\ L]?5'A&RN;;P9:VUQ"8YEB(*-UZ5\[WO@KQ(_C.6
M9-(N6@^W;]X7C&_-<V#J*%2JV]RG=GU-IQ_XE\'^Z*M@U4L%9+&)9%*,%&0>
MU61TXKP9?&TBT5[_ %"VTVRDN[N41P1C+.>PJM8:UINK6Z36=Y'+&W(*M_2J
MOBO1Y=<\-7UA"P666)E7/3.*^9I/#'C;PG=O]GM[N%5_Y;0]#^==N'PT*T6E
M*TN@2;6Q]%>.+32;SPW>?VIY)01DJ6QD'M7RCHD,D^OV<< )E>4 #UK=G3QM
MXA017'VZ\7/"O7J'PU^$\VF7L>K:U&/,4!HX2/NFO5488*A*-25VS)ILZOXG
M*Q^&DRXRPB&?^^:\0^#T\=O\0[5I7"*8G4$^I%?2WB/2%UOP[>Z7C!GA**WI
MQ7RQJ'@OQ-H.ID)8W.8V_=RQCT/%88"K"=&5)NPY*VI]>B2-SL5U)'7!KY@^
M-T)C\=.2,9B!'TR:[OX.#Q5+J5[<:V;IH"BB/SO7)J_\7?A_<>)(XM4TQ%:\
M@&UTQRZ^@_.N?"26'Q'*WN4[M%_X-:I;2^"+: 3)OB&UU)P0>:Y#X[:[87<4
M&GV]PDD\3 NJ]N:\UL=)\7Z5=-;65I>032'YHT')KHIOA5XBE\-2:O>132:@
M7 %N1\^#G-=\:%*&*51S$VVK'3_L\$+<ZYG^Y'_6L/X\6;Q>,HKK!"20*H/J
M>>*ZSX&>']5T>?5WU*QEM?,6,()!C.,UUGQ.\#_\)AHX$&U;RW)>(GO[&L)5
MN3'NI?1AK:Q@_ W6+:?PS-8M(JS028"D\D8'-:'QBURQM/",MH]Q&;B8@+&#
MDD<UX5'H7BWPWJ.ZVM+NVG)VAT'6NDT[X;^*O$JW.I:V+N,I&2@D^_)].U:5
M,-35?VSGI>X)NUBO\#\CXF6Y'0V\W_H-?35[;K>V4]M(NX.C+@^XKY^^$OAC
M6M)^(L4]YIMS!;K#*H=@,=.*^BL=<],=ZX<RG&5=2@RH['QMK5C-X1\9S01[
MD:UG_=MZ@=ZD\7:]/XO\0FX7)R D:_@/ZUZ)\>O#IAU*UUJ,!4D7RVQW;DUQ
M?PPT3^V_&]E$R92W82R#U /_ ->O;A5C.A[?JD9[2L?27@C15T+PO86B#&(P
MQ'J6YKI1TID:!$"#HH %/%?*S?-/F9L))_JV^AKXX\=_\CYJP'_/Q_05]CN,
MHP]0:^5?&G@WQ'<^--6GMM*N9('GW*R*,8P*]/+:BA*5W8B2/HS11GP?;#./
MW _E7R<2/^$UP/\ H)?^U*^M=)MYHO"]O \;K(( "K=<XKYF_P"$*\2_\)?Y
M_P#8]WY']H;_ #-HQCS,UT8"M&$JMWO_ ,$EW9]4V618Q=SL&17S-\:_^1[?
M'01_UKZ<M5*6<2/P=HR#UKY[^+OA;7-3\8F>PTR>>$I]Y!QUKERVHJ=64FRI
M?">H?"'GX;Z5G_GF?_0C7=]#[5QWPQL;K3? NG6U["8IT4@J1R.378@8)->?
MB$G5<D5'8"<*:^._'N#\1-<R,_Z8_'XU]A-]W!YS7RUXV\&^([SQUJUS;:5/
M+#)=,R.J\8S7H9;45.HY/L3/70]>\#>!O#=YX1TV\N-)MIIIH<N9(P>YKNK#
M1=/TT8LK*& ?],UQ6=X)MIK'P=IEM<1F*:.'#*W4<FNAKAQ-64JDFV4EH9^K
MW#6&D7MTOWHX7<'W"DU\D))<^-O%L:7MQ\]R_P!\]A7U]?VZWFGSVS#(EC9#
M^(Q7RSXC\ Z_X8UR22RM9F@5]T<\8Z#M7?E<HQ4K[L4CU:'X*^%;"P:2XDGD
M<)\S&0;<_E7@FE1K'XJMXT^X+K:#Z<\5W$%Y\2/%=M'IP-XMM(-KRG[NWWK.
MB^'OB+3?%L,0TV>:..9=TJ+\I[Y%>CA).ES\\[F;5SZ#\4G_ (M_<\_\N>/_
M !ROFWX7_P#(_P"G<9^9OY5]+^(K.>Y\$W%K%&7F-J5"#KG;BO!?ASX0\06'
MCBQGN]*N(X4+$R%>!Q7+@JBC3JIO=,K5M'TU)S$W; .*^./&^?\ A,]4&?\
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MYB$$*[CJ/PKQV'Q1\1]/ L1<WYXPJMC*5L^%=,\?:YXGLKK5&O#!#(KL\W3
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MRM('<]0\4_";PQX>\(ZE?0-/]HAMV>,R2 @L/3BO+_A><^/+$>Y_F*Z(:?\
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MN'(<<R<YKZ,L[**RT];6WC$<<:;55:PQM:G&E&C3E>P)/<^1?&P \?:N,?\
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M=!CZ5)2 42][J(0KR3FD\I"<E5_*GXHJT^PQ,< 4QHE;J!GUQ3S29J92Y=4
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MH'AV^U5TW_9(]^&[\@?UKPB3X^:W]J9TTVV:,'Y5+-S7KWQ2'_%L]=_Z]_\
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M7TZWUNVU'3+AK=8G#F$C.>?4FLG7PM2#2C9E*]SU0'!'!.>AI],&% ':N?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS#"BR)SD\G']*VOCSC_A#XSC_EJO\Q7'?L]C_BHM4_Z]T_F:ER=; RG/=?\
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M"^(G@>7P/J\1MF=K60YAE)Y!'.,U[+5)XK^\97=CL/@]X!N_[5CU[486BBA
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,V\TX#BDI14I)
M:( Q2;>1S3J3%/R 3;0%Z\TM%*P#2,XYXI<4M%/3<!A7/KBEQS2T4G)]@#%(
M5]A^5.HHN^P#<=*7;UHI133 3'.>U&WTIU%*P#-N.2<F@#BG44]!B8I,=<TH
MI:2E?= )MXQVI-O-.HHYGV$)C\Z:4Y//7K3J4<T7ON@&;!G/-*1GK3J2G?L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 48HHH **** "BBB@ HHHH **** #%%%% !BBBB@ HHHH *
M,444 &**** "BBB@ HHHH ,48HHH **** "BBB@ Q1BBB@ Q1@444 %&***
M$"@=J7 HHH , 4444 %%%% !1110 4444 %%%% !1110 8HQ110 4444 %%%
M%%@"BBB@ HQ110 8HHHH **** "BBB@ HQ110 4444 %%%% !1110 48HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBBBP!BBBB@ HHHH *,444
M %%%% !1@4446 ,48HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C
M%%% !BBBB@ Q1110 8HHHH **** "C%%% !BBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "C--[T8YJ;ZH!U%-]*6FG=@+1244P%HI*7B@ HHXHXI:@%%%%
M%P"BBD-,!:*2BIN M%)13N M%)13 6BDI>*6H!11Q11J 444W/>C4!V:3(]:
M:3QD4T':O/8<\4;;@2Y%)D8SFHSR1UP.] QDX[]J+Z: 2T4W-+FB^M@%HIN:
M6BZ 7-%-Q2T7[@+1FDHQ1?6P"T9IM&*2=[@.HH'2BJ **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSNHT8SJ1UN&I5^%?B<W_ ( F:>4M/9J^[<>< <?RKC?AI/<:[X]U;69WD-M
M#* 7.!S7&6.MW'@[^W](^=))F\I<C' )Y_&O8?A)X>^R> I;B0?O[T,P./X2
M.*WKT(TE.6EG:WW KG'7>J:U\4/'$^DV=_+;:7"2V4.,+TS^M-\6>#-7^'%M
M%K&E:Y=7"*X5_-/<_P#ZJJ_#N_A\'_$B_M-4/DK)F)6?@9)!Z^E==\8_%6F7
M7A==,LKJ*YGFE5@(6#X SGI]:AJ?MH145R^@R/Q+XRFUWX*_VE$YCG:18GSQ
MG!PU7?@=8PP>#;B_1 UQ)*X(]<8(%0^'_!DUY\&7TZ>(K,Y:=$/7(^85SGPH
M\8)X4NYO#NM*UL&<E&<8 ;OU[<4ZL(.G.--ZJ3T\@N;VN_%7Q=HLUR9O"*K:
MPL1YSEPI'UKJ_"_CR76_!UUK]W:Q0>0I;;&Q(Q^-8?Q9U_2;KP/<0V^HVL\K
M\;8Y%)_0UD^!K*:_^#VJ6L W2/"P51U)P:Y?9Q=+G:L.YRMMJ:_$'6+R77?%
M']EVT;$1() I(I=,\02^!O&UM9Z9KAU;2Y"H8EP<EN.WI6?\/=&\*7^H7FG^
M*8S%<JV(G:8QCC.<UZ(/!_PPL-5M(X',MPS@QB&Z,GS#GG!KJKM1FXJ.ENQ.
MI0^.MW/ ^E/;S2(S2Y4*Q Z&J[^ O$/B;PE_;.HZ[.+KRMT%O&0%Q[D<YIWQ
MW4(^D%>!Y@'/.!BO4=#VGP/:[3D+!QQUK/FY:5.R6_ZAJ>(^!9_%GB=Y_#4>
MK30VD;'?+P64#J!D4FMV&L?#+Q?8BVU.XN(9Y%W;VSG)&?YUL_!+_D:M8 Y!
ME<_J:F^.G_(=T(]#YO/YBNAV>)4.56M_F&I[;I]Q]LLH;C'^L0,:ME0<<=*S
M/#__ " K'GGR5_E6I7ARW:9:$V@=J-HSTI:*FUAF)XHY\.W_  /]2^,_0UX+
M\$=;TS1M0OWU*_M[5'B 4ROMR<BO>O%&?^$=O\]!"W\C7SO\(O!^C^++^]BU
M6!Y!%$&4K(5[@=J]3#./U2I?N0[W+7Q/U:'QQXTL[#1,7)C3R@R<AB3FNP^,
M%L]G\,;&W<?/&T(;V->@>'_ V@>'3G3[$(V?E=SN8?B:XWX\ #P4GIYZ?SHI
M5N>I",>@=#?^$H#> +(GKN;^E<K\>[&!]#L;P@"9)C@CJ1BM;X7Z]I%AX#M4
MN-2M8I%9LH\R@_D37#_%'Q2/&.JVV@Z,C7"129D:,;LYXXQ50C)8SF6UW^0&
MY//)/^S[OD)8BT/)^M4/@OXDT;1M!O8=1U*WMG>52HE< G@UTWBK1_[!^"\V
MF_Q06NT^YKAOA+X!T#Q;I%Y<ZK;R22PR*J,DA7'!["KYH/#S;_F_03W,W5YC
MX]^+4,VEH6A22,[P.#Y9&3^E?3$*E(54_> P:Q]#\*:3X?3R]/LT08^^>6_.
MML+@8->=BJZFXJ*T12)%&% I:**P*"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%D1QJ$7)R<"K-,5=IXQBG9K--VO(0M%(6QBD+X/2J JW]I%?6LEK/N\J4%6
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M[Q0%QU%)N%&10 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
MM%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T
M +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%(6
MI-XQD<T .HI V11FBX"T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYSWX7_"DN/\ DE%H?^HNX_\ (=<F22![5ST<)1E.=UL_\BN9G6_\+/\ &O\
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MZ_)?\*/^%G^-?^AANOR7_"N1YHYH^HX;^4.=G7?\+/\ &O\ T,-U^2_X4?\
M"S_&O_0PW7Y+_A7(\T<T?4<-_*'.SKO^%G^-?^AANOR7_"C_ (6?XU_Z&&Z_
M)?\ "N1YHYH^HX;^4.=G7?\ "S_&O_0PW7Y+_A1_PL_QK_T,-U^2_P"%<CS1
MS1]1PW\H<[.N_P"%G^-?^AANOR7_  H_X6?XU_Z&&Z_)?\*Y'FCFCZCAOY0Y
MV==_PL_QK_T,-U^2_P"%'_"S_&O_ $,-U^2_X5R/-'-'U'#?RASLZ[_A9_C7
M_H8;K\E_PH_X6?XU_P"AANOR7_"N1YHYH^HX;^4.=G7?\+/\:_\ 0PW7Y+_A
M1_PM#QKW\0W7Y+_A7(\T4OJ.&[!SL](\(_$#Q?J7BS2K&Y\07)AN;A4887[I
M/TK-U'XE>,K;4[N&+7[D)',Z#A>@8CTK,\ G=\0-#SWO$_G63K/_ "&[_P#Z
M^9/_ $(UR0PE%UI1MT7ZE.;.@_X6AXV_Z&"Y_)?\*7_A9_C7_H8;G\E_PKD*
M7FNM8##I:HGG9UW_  L_QK_T,-U^2_X4?\+/\:_]##=?DO\ A7(\T<T_J.&_
ME#G9UW_"S_&O_0PW7Y+_ (4?\+/\:_\ 0PW7Y+_A7(\T<T?4<-_*'.SKO^%G
M^-?^AANOR7_"C_A9_C7_ *&&Z_)?\*Y'FCFCZCAOY0YV==_PL_QK_P!##=?D
MO^%'_"S_ !K_ -##=?DO^%<CS1S1]1PW\H<[.N_X6?XU_P"AANOR7_"C_A9_
MC7_H8;K\E_PKD>:.:/J.&_E#G9UW_"S_ !K_ -##=?DO^%'_  L_QK_T,-U^
M2_X5R/-'-'U'#?RASLZ[_A9_C7_H8;K\E_PH_P"%G^-?^AANOR7_  KD>:.:
M/J.&_E#G9UW_  L_QK_T,-U^2_X4?\+/\:_]##=?DO\ A7(\T<T?4<-_*'.S
MKO\ A9_C7_H8;K\E_P */^%G^-?^AANOR7_"N1YHYH^HX;^4.=G7?\+/\:_]
M##=?DO\ A1_PL_QK_P!##=?DO^%<CS1S1]1PW\H<[.N_X6?XU_Z&&Z_)?\*/
M^%G^-?\ H8;K\E_PKD>:.:/J.&_E#G9UW_"S_&O_ $,-U^2_X4?\+/\ &O\
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MO_0PW7Y+_A7(\T<T?4<-_*'.SKO^%G^-?^AANOR7_"C_ (6AXU_Z&&Y_)?\
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MZ_)?\*/^%G^-?^AANOR7_"N1YHYH^HX;^4.=G7?\+/\ &O\ T,-U^2_X4?\
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M^%G^-?\ H8;K\E_PKD>:.:/J.&_E#G9UW_"S_&O_ $,-U^2_X4?\+/\ &O\
MT,-U^2_X5R/-'-'U'#?RASLZ[_A9_C7_ *&&Z_)?\*/^%G^-?^AANOR7_"N1
MYHYH^HX;^4.=G7?\+/\ &O\ T,-U^2_X4?\ "S_&O_0PW7Y+_A7(\T<T?4<-
M_*'.SKO^%G^-?^AANOR7_"C_ (6?XU_Z&&Z_)?\ "N1YHYH^HX;^4.=G7?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!#TI!3J0TNH"5YM\<_^2:7'_7S#_Z%7I7>O-?CG_R32Y_Z^8?_
M $*NG!ZUX/S)DSY;HHHK[Q)',%%%%.R ****+( HHHHL@"BBBBR ****+( H
MHHHL@"BBBBR ****+( HHHHL@"BBBBR ****+( HHHHL@"BBBBR ****+( H
MHHHZ ==<?\DGM/\ L+O_ .BZY/\ AKK+C_DD]I_V%W_]%UR1Z5Q872=1>?\
MD4Q****[;(D****+( HHHHL@"BBBBR ****+( HHHHL@"BBBBR ****+( HH
MHHL@"BBBBR ****+( HHHHL@"BBBBR ****+( I1UI**$D!TO@#_ )*!H7_7
MXG\ZR-9_Y#FH?]?,G_H1K7^'_P#R/^A?]?B?SK(UG_D.7_\ U\R?^A&N"'^]
M3]%^H[:%&B@45WV)"BBBBR&%%%%%D 444460!11119 %%%%%D 444460!111
M19 %%%%%D 444460!11119 %%%%%D 444460!11119 %%%%%D 4O:DH%+2S
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M+!? _5_F4P[44=J*[B0HHHH **** "BBB@ HI,T9I7 6BDS1FBX"T4F:,T7
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M5D25B*BBBO43N0%%%% !1110!TOP_P#^1_T+_K\3^=9&L_\ (<O_ /KYD_\
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MO!29Z/?^,-)G^$=IX=CFD-]%,&8&,@8RQ//XU8\5>.M*U'1-!AL)93<6(3S
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M;6%GX1N%2"&$))YUN.2% [TQOB?:>(_ E[IGB:4OJ,A/EM%!@8R,=*\C.,G
MQZYHS\PX[=JI9;AMUN+F9[1HWC3P)+X#L?#VOS7C>3& ZQPL.?J*\Z\8#PJV
MHP?\(N)UM2IWB7<23GWKG-Q)..K>M(/8@>]52PBI2;A)Z@W<,<9Q3:?D9/>F
M5Z"5D2%%%% !1110 4444 %%%% !1110 "MKPE_R.&C_ /7Y%_Z$*Q16UX2_
MY'#1_P#K\B_]"%95_@?H_P AK<^U!10**_/CI0M%%%,84444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .NN/^23VG_87?\ ]%UR1Z5UMQ_R2>T_["[_ /HNN2/2N+#?'4]?\BA*
M***[20HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .E^'_P#R/^A?]?B?SK(UG_D.7_\ U\R?^A&M?X?_
M /(_Z%_U^)_.LC6?^0Y?_P#7S)_Z$:X(?[S/T7YLKH4110**[R0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "@44"D]@.ONO^23:?\ ]A:7_P!%BN0KK[K_ ))-I_\ V%I?_18KD*XL
M%\#]7^93#M11VHKN)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH8"5V'Q(_Y'&7_ *]H/_1:UQ]=A\2/
M^1QE_P"O:#_T6M<4O]ZCZ/\ ,I;'(4=J*.U=O<D**** "BBB@ HHHH ****
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MK:.%A!TWVO\ D+F$HHHKM)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZBC(]11S1[A82BEX]11QZTN9"$HI?QH_&GS1 2BE_&C\:.:("44OXT?C1S1
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M_P! @?\ ?UO\:ZW^V--_Z"%I_P!_E_QH_MC3?^@A:?\ ?Y?\:/:XG^9_B'-
MY+_A3_@G_H$#_OZW^-'_  I_P3_T"!_W];_&NM_MC3?^@A:?]_E_QH_MC3?^
M@A:?]_E_QH]KB?YG^(<T#DO^%/\ @G_H$#_OZW^-'_"G_!'_ $"!_P!_6_QK
MK?[8TW_H(6G_ '^7_&D_MG3?^@A:?]_E_P :/:XG^9_B'- Y/_A3_@G_ *!
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M:L7WPQ\+:I<-=7NFAYRH7/F-T P._I72_P!L:;_T$+3_ +_+_C1_;.F_\_\
M:?\ ?Y?\:GVF)OS7?XCYH'(CX/\ @G_H#C_OZW^-+_PI_P $_P#0('_?QO\
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M?\$_] <?]_6_QH_X4_X)_P"@./\ OZW^-=U11]:K_P [^\.5'"_\*?\ !/\
MT!Q_W];_ !H_X4_X)_Z X_[^M_C7=44?6J_\[^\.5'"_\*?\$_\ 0''_ '];
M_&C_ (4_X)_Z X_[^M_C7=44?6J_\[^\.5'"_P#"G_!/_0''_?UO\:/^%/\
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M_P $_P#0''_?UO\ &C_A3_@G_H#C_OZW^-=U11]:K_SO[PY4<+_PI_P3_P!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$%%&:,CIGFDVD 44=\9HIIWV **,'.*/J0* "BCO]*.X]QG-3S+N 44#D9%
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M ) 5_P#]>[_^@FG'<F7PGS/1117WM/X5Z'C/<****U)84444""BBB@ HHHH
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MLE8\_P!.T._U4.;:($1]68[5S]33[[0K[2IH!=Q 1RD<HP93[9'%>AQ-I_\
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M03H/AG_A%O[9%A>;<9\K[3S^>*I:9H.B:OH&KZE';W,36W,:-+NP<9ZXYK0
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M,%%%%=)F%%%% !1110 4444 %%%&<4:=1H*0CD8I>>HZ5+;6\MW.L,*%Y&.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!:0F.WACB7.2J*%&?H*GI%Z4M<1UA1110 4444 %%%% !1110 4444 %%%%
M!2&EIK4 )QFDXII;FDS0 _BCCTIF:-U $F11D5'NHW4 /W4N:CW4FZ@"3<*-
MU1;J-U $NZC-1;J7=0!)NI,U'NHW4 29HW5&6I-U $NZDW5'NI-U $N:,U'N
MH+4 2!L'FI0:J[N15E>M #J*3O2T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M * ]S^0_QH_X0GQ+_P! >Y_(?XU]$8'K1@>M']L5NR_$/JD3YW_X0GQ+_P!
M>Y_(?XT?\(3XE_Z ]S^0_P :^B,#UHP/6C^V*W9?B'U2)\[_ /"$^)?^@/<_
MD/\ &C_A"?$O_0'N?R'^-?1&!ZT8'K1_;%;LOQ#ZI$^=_P#A"?$O_0'N?R'^
M-'_"$^)?^@/<_D/\:^B,#UHP/6C^V*W9?B'U2)\[_P#"$^)?^@/<_D/\:/\
MA"?$O_0'N?R'^-?1&!ZT8'K1_;%;LOQ#ZI$^=_\ A"?$O_0'N?R'^-'_  A/
MB7_H#W/Y#_&OHC ]:,#UH_MBMV7XA]4B?.__  A/B7_H#W/Y#_&C_A"?$O\
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M^=O^$)\2_P#0'N?R%'_"$^)?^@/<_D*^B<"C H_MBMV7XA]51\[?\(3XE_Z
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MPI+IT4>%B3>H ZLHS_.L3X;Z%)!93W]TA624F(HPZ ?_ *Z]!(R.>>QIH55
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M_P#/S'_WZ%'_  L#Q#_S\Q_]^A7+T4?4,+_('MI]SJ/^%@>(?^?F/_OT*/\
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M_0H_X6!XA_Y^8_\ OT*Y>BCZAA?Y ]M/N=1_PL#Q#_S\Q_\ ?H4?\+ \0_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%(3BDWCU'O0 ZBBDSS0 M%%% !1110 4444 %%
M%% !1110 4AI:0C)H Q;D[9B*@W5-J0VW##Z51WT 3[J-]0;Z-] $Q;-&ZH"
M]&Z@"?=2;J@WT;Z )]](7J'?07H FWT;Z@WT;Z )]]&ZH-])OH G+8HWU!OH
MWT 3;Z-]0;Z-] $^^DWU#OH+\4 3E^16UIQS$U<]OR16[I;9B:@#1[TM(.E+
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\BE+_P!=4_G76#I7)_$7_D4I?^NJ?SKHPG\:'JC&K_#9XU1117W2/%"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUH W:6D'2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?S'^%'_"K])_Y^;G\Q_A1_:N'[O[@^K5#R7\:/QKUK_A5^D_\_-S^8_PI/\
MA5^E?\_%S^8_PH_M6AW?W#^K3ZGDWXT'ID#!'4$UZS_PK#2O^?BY_,?X4G_"
MK]*!!$T^>^2.:)9MA[=06%=SS_P_X?N->NUC1&6'J['TKV?2=*MM)M$@MT50
MH^9L<FG:7I,&D6P@ME.T>O>KY';;G->%B\8Z\O=T1VTZ*@A1ZTA'.:4 @<TO
M->?\)ON+1115 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@_[ZH_X271_^@C!_WU7C.:,T?V+_ '@^ML]F_P"$ET?_ *",'_?5'_"2Z/\
M]!&#_OJO&<T9H_L7^\'UMGLW_"2Z/_T$8/\ OJC_ (271_\ H(P?]]5XSFC-
M']B_W@^ML]F_X271_P#H(P?]]4?\)+H__01@_P"^J\9S1FC^Q?[P?6V>S?\
M"2Z/_P!!&#_OJC_A)='_ .@C!_WU7C.:,T?V+_>#ZVSV;_A)='_Z",'_ 'U1
M_P )+H__ $$8/^^J\9S1FC^Q?[P?6V>S?\)+H_\ T$8/^^J/^$ET?_H(P?\
M?5>,YHS1_8O]X/K;/9O^$ET?_H(P?]]4A\2:/_T$(/\ OJO&LTG7&>U']B_W
M@^ML]D'B+2@\<:7T#%C_ 'JUU(8 C&T\@UX(I*'<IPP.0?2N^\)^*]^+.];Y
M^@8FN7%97*C'FB[FM/$\SLSO<CI2C%,#!U!4Y!IV<5XN_J=NEKCEQCBEIJ]*
M=35[:@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD>FE96%HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J-AG-24A% %*2/K6?
M<0YSQ6RRYJI-$,&@#FKFWZ\5B7=MUXKKKB$&LBZM^M ''SQR0SK+$=KH<Y]:
M[SP_K(U>U /RW$8P5/>N9NK8$G(XK/M[B?2[U;J$\@Y91W% 'I]Y:0:M9/;3
M("",?0UX[KFA7&BZ@T3@F)B2I]J]9TZ_CO;:.>!@1_&/0U)JVE0:S9E'4>8!
MPWI711J^S=C*I3Y]3Q!EQR>E2P2^7<1DGY,\UHZUI,]A<F%D("GAL=:SA:M)
MQM(YKV+^UIM)G&FXR.XM94G6,*X"XXYJIKVDVDMOYBS*LH[ ]:Q88KJ.+",>
M!QS4?V6ZE??*S,>W->)AL!*C4<[G?5Q+G'E,[R"O#<#UK8T&?[+>'<Q4'I[U
M*FEW5WA8X68CKQBMFS\'7#LLDSK$@Z@C)KUJE2/+9O4XXT[2N0:OH3:Q:-?6
M" 7<?^L"_P 1KE9+[5;.3RWLI\@8^52:]>TV*UTBW,<9+D]3GK1)<I(>((MV
M>K*#7G>W2>AU6T/*[6R\0:L1Y=N50_Q.=M;MIX")(DU&\+?["]J[(NWLH]%&
M*;C)SU^M3.M+0.30R&T/3[&Q9;6#<V.K5SWV=68JZ8YKM+D$PL6/Y&L$I'*Q
M X/J:\O%8Z5.KJ=]+#<T2I#I=LXZ'-7ET.S2/<5R:15>$_*ZM^%3&>4+@D"E
M_:]D'U#41((8E'EQX/O6SI=I//"2, 5AJ[N2&8$=L#%=7X?YLV&>AQ6$,Q=>
MKREU,*J5/F)X]*4$-*Y)]*NQV\48^2-:EQ2[0:]7H<"=V %.HHI#"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0T +12<T<TDP%HI.U'
M-%P%HI,T9I@+1112N 4444P"BDHI7 4]*:>E+2&A[ Q#U%,=U5<E@!TR:D-<
M_P",25T"3:2/G7I]:J$'4G&*)F[1-L3Q <NN?K2^?%_?7\Z\=\Q_[[?G1YC_
M -]OSKUO[+E_,<OUE=CV+SXO[Z_G1Y\7]]?SKQWS'_OM^='F/_?;\Z/[+E_,
M+ZRNQ[%Y\7]]?S%'GQ?WU_,5X[YC_P!]OSH\Q_[[?G1_9<OY@^LKL>Q>?%_?
M7\Q1Y\7]]?S%>.^8_P#?;\Z/,?\ OM^=']ER_F#ZRNQ[%Y\7]]?S%'GQ?WU_
M,5X[YC_WV_.CS'_OM^=']ER_F#ZRNQ[%Y\7]]?S%'GQ?WU_,5X[YC_WV_.CS
M'_OM^=']ER_F#ZRNQ[%Y\7]]?S%'GQ?WU_,5X[YC_P!]OSH\Q_[[?G1_9<OY
M@^LKL>Q>?%_?7\Q1Y\7]]?S%>.^8_P#?;\Z/,?\ OM^=']ER_F#ZRNQ[%Y\7
M]]?S%'GQ?WU_.O'?,?\ OM^='F/_ 'V_.C^RY?S!]978]B\^+^^OYT>?%_?7
M\Z\=\Q_[[?G1YC_WV_.C^RY?S#^LKL>Q>?%_?7\Z//B_OK^=>.^8_P#?;\Z/
M,?\ OM^=']ER_F#ZRNQ[%Y\7]]?SH\^+^^OYUX[YC_WV_.CS'_OM^=']ER_F
M#ZRNQ[%Y\7]]?SH\^+^^O_?5>.^8_P#?;\Z/,?\ OM^=']ER_F#ZRNQ[%Y\7
M]]?SI^<C(YKQM99%8%78$'(YKMO#GB3S@+6[?#CHQ[USUL#4I*Z=RX5U(Z['
MM2\>E(#D#'3UHY]*\^[O8Z-!?PH_"E XI<4]1C?PH_"G8HQ2U ;^%'X4[%&*
M-0&_A1^%.Q1BC4!OX4?A3L48HU ;^%'X4[%&*-0&_A1^%.Q1BGJ W ]*.G7I
M3J,4!88>1Q@T[M1@9I:5@$HI:*+  HHHI@%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 TBHI$R*GI& (H S)HN.E9MQ!QTK=E3BJ,T610!S
M-S;]>*R;BUY/%=7<0>U95Q;9R,4 9.CWSZ/>A>3;R'##TKOX)EP'C?<K8.17
M#36>X$;<UIZ)J!M7^R3DA#]S/:@#=US1X]6M=R@>8.E<E#X8N1(0\6/>NT:Y
M:WCW ;@>AJK)>3/_ !8]JTC4E$AP3,>#PRJC,KA5[^U7XM/T^V&1&)CZFE9F
M8Y9C28SVS]:)U&]F-P70L"YVKMBC5!["H6F=C@N3[4QB% W,!]*16+G;&I8U
MFVV.R'[::S*H.XXJQ%IUS)RY* U9_LB,#+_.WO0DAF.;GG$:%JD3[1+]["K5
MF>/R/NQX%4);DC.#S0VW833Z%MX(! Q+Y;%<_+&WF-C &:NR7#>1(0>BYK&6
M])D(/->-F.%J57S1/2PE>,=)%GE>N:>JJ>I--25G'%2@';E^*\.6'K;6/55:
ME:]PP!T&*ZKP]_QZ2?[W]*YJ./.#U%=+H Q;R#/&[^E>GEV#G3ESS//QE>,X
M\L38)Q2YH SUI<5]$>2]K"T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4AI:8Y.>,#% "YXI<UP^G^/#?>.+WPX;$H;;_EMOSGIV_&
MIO$_C<>&M?TK2VLC.=08(L@DQMY Z?C5RIRT27F*YV61ZTF1ZU@7OBK3-.U>
MVTNZF87=P,HH0X_.MP\<@C;42BUNAW),C&<T5%@],BD# +GD9]34Z!<FSSBD
MR/6N4\3^++C0=2TVUATN:[2\D"M+'G$0R!D\>]=-O!![9]JM)@349 ZFHP,#
M'YT,>.#R>F:A\W09)D>M%1@Y(.:DH3?404E+246L &N>\9_\B_)_UT3^==">
MHKGO&?\ R )/^NB?SKHPW\:)G5^$\XHHHK[!(\H****+ %%%%%@"BBBBP!11
M118 HHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHHL 44446 *<CLK[\
MX8=,4VBDXJ2LP3:U.W\-^)1(JVMVV&'1C77J0>0<@UXT&9"&0X8=#7:^&_$N
M]5M;LX;H&->!C,$XOFB=U*MT9V:]*6HPP900<@]Q3N!]*\FUCK'4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQG_R )/^NB?SK?#?QHF=7X3SBBBBOL$>4%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%*VMPN%*&(8,#C'3%)13
MDN968+38[3PUXEZ6MVW/\+&NR# H"N"#R*\9&[<"O!'(-=CX;\3886EVW(X#
M&O QF":;G!'=2K=)';[Q2YYQ3%?(R,$'TIP'/6O(LUN=5[[#J***!A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% "8HVBEHH ;L%(8Q3Z* &;/RI=F.
MF*=10 FT48I:* $Q2T44 %%%% !1110 R3A#5, $U=?E#53RQGWI,:%"\\4\
M)["H]C#H32X8]Z5V,>P 4YQ^%/A(*?+4'EDGDYJQ$H1::6@B0=*6D'2EIV$%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,8 L/;FG
MTU_89I-7 ;C(!YI, CG/7->9>+/BCJGAG59K5?#4]Q;Q=9QN"8]<XQ53P]\7
MM4U_4K6"/PO.MM,X4W(+%0,XSG&*Z?JE24>:RMZHGF/61@GI3MH]*8G!Y[TX
MFN5WZ%7%P.F*7 INX>M&1ZT:A<7 '.*, T9&.M("/6BS0"X!-&T>E(#S3LCU
MHC>P";1Z4ZDR/6EIV 2DI:2A@!ZBN>\9_P#( D_ZZ)_.NA/45SWC/_D 2?\
M71/YUOAOXT3.K\)YQ1117V"/*"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0FG*2@#=#GBDZ_ATKI/#
MOAV2]D%S<@B(<@$5SUZ\80=S2G!R9T'A2XO9K/%RI\L#Y6/>NC7.XYY]Z9'$
MD481% 4= *D'WOPKY*4^>39Z<%RJPZBBBD4%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EHI,!HH-+BEQ
M2MH VBEP*7%.P#<GTHIV*3%*S[@)0.E.Q1BBVH#>]**,"EQ1RC$HI<44["$I
M*4TE%F# ]17/>,_^0!)_UT3^== :Y_QE_P @!^OWUZ#WK?#.U6+,ZNL3SBBE
MX/:CBOKE)6/+:?82BEXHXIW06?82BEXHXHN@L^PE%+Q1Q1=!9]A**7BCBBZ"
MS["44O%'%%T%GV$HI>*0T706?8****86?8***7CTI7"S["44O'I1QZ47%9]A
M**7CTHX]*+A9]A**7CTHX]*+A9]A**7CTHX]*7,@L^PE+VX&?048R< 9-=5X
M<\-F=UNKI?D'(4USXC$1IQU+A!R8GASPTUPRW5T"$'(4UW<<:HH1!A1Z4L:*
MB ( %'  I]?,5:\JDM3TH044%% I<5C9(O42@4N**8PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4W)QGI[4ZFGCW)H "6XXINXCN?RK USQIH
M/AQBNIWZ1,.H')_(5%H?CC0/$LGEZ5?B:0 G9@@G'UI\C>H'2[S@>] 8YP>N
M*X[0O']MK>NZOIIM'B_LP$RR,P(QDCI^%;6B>)=,\1VS7&DW'VB)&VL0",'\
M:3@T!LTA.!2YXK"\6^(H_"^@3:I);O.J$+L1@#SWH2N!MY_SBC=SC/(YK/T3
M4QJ^D6]\L;1B:-7"L<]1FL;QIXT@\&V]G-/9R7(NI?* 1PNT^O-/EN[ =3D]
M>N>E/JO#*)88Y-OW\$ ]JGS2:L M%%1O<01,JR31HS= S $T("2BBB@ HHHH
M **,T9H **,T4 %-IU-I, ;J*Q?%/_(&?_?7^=;3=16+XI_Y S_[Z_SK:A_%
MB14^$X:BBBOISS@HHHH **** "BBB@ HHHH **** "BBB@ H[@^E%%&Z!%JQ
MOY;"X$J'C.2/6N\T_48[^ .A&[N/2O.:M:??2Z?.)(F.W/S"O/Q.&4US(WIU
M.70]*%%4M.OXK^ 21L,XY&:NUXCCRNS.R]T*.E%%%(84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG@S5;CX;ZSI%S!-97-Q*6B61<9Z?X5F^5[@-?XH>.);1M5M/#<;:-RWGLO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML4H^[$Z*=-O42TM8[2$1(H  ZU9H'(HQ7BMR;N=:20HXHHHIC"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3%+10 A!)JCJ>G_V
MC:& G + U?HIIM-27035U9G+_P#"'1]KIQ_P$4?\(='_ ,_;_P#?(KJ**V^L
M5.Y'LXG+_P#"'1_\_;_]\BC_ (0Z/_G[?_OD5U%%'UBIW#V<3E_^$.C_ .?M
M_P#OD4?\(='_ ,_;_P#?(KJ**/K%3N'LXG+_ /"'1_\ /V__ 'R*/^$.C_Y^
MW_[Y%=111]8J=P]G$Y?_ (0Z/_G[?_OD4?\ "'1_\_;_ /?(KJ**/K%3N'LX
MG+_\(='_ ,_;_P#?(H_X0Z/_ )^W_P"^17444?6*G</9Q.7_ .$.C_Y^W_[Y
M%'_"'19YN&8?3%=111]8J=P]G$IV=@EC L40''>K>*6BL6V]66E83O2T44AA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tiger_001.jpg
<TEXT>
begin 644 tiger_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #S IX# 2(  A$! Q$!_\0
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M^*-.EGN->T/6%\6>,-"U.UET'P]%%XENKV.QELKNQN4M;"6XU**6T')^!?\
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M1OC[XDZJFGOX+3P7K.JOI2:;IT-MJ+^(+GQ!!<*J+:-I4<-[/-#;6,]Q=2"
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MZ].@\5A\*L5F,Z,Z.$K898C#87!+%*MB</\ 6Y_S=>$/V&/VJ_$OPU_X)L_
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M3G[6_P 6/A%^RQK?[2G@O]M33_AYX^T)-%^(_P ,O!_B7X0?%S0?"%[X7N_
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M5Q#AA<3B,+AJE&FZ;H_C#_P2N_9:_:N_9T^+?[;^K?M2O%XGO?B!XP^">F^
M_BW'J.BW#?%[PO\ "OP-K7@33/&5]I>FZE>W^CZW/X;M/"R^(8M9L]-O;G6Y
M+N5DO&6:[K]HZC$8&,\]#D]20V1GMQV&, \@ U)7QW%O%&.XSS_%\19EAL!A
M,;C,/E>'K4,KPOU+ 1CE64X#**,J&$]K6CA_:T<OA7JT:4HX:GB,17CA*&%P
MBP^%H?3<.Y#A.&<IH9-@:N+KX7#5<95I5,=B)8K%-XW&XG'555Q$E&=;EJXF
M4(5*G-6E3ITW6J5:O/5F4445\V>V%%%% !1110 4444 %%%% !1110 4444
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M_AVW/AOQ%I,:^%5T9I;^VM%N-06"?1/V!_CKX@^$OP+^'OQ!_9TU'7M MO\
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M 6<R9)YV[<'.0P\NG8[;(]1^8HROJ/S%?-O_  T#;_\ 0"?_ +Z7_P"/4?\
M#0-O_P! )_\ OI?_ (]0%EV7W+_(^DLKZC\Q1E?4?F*^;?\ AH&W_P"@$_\
MWTO_ ,>H_P"&@;?_ * 3_P#?2_\ QZ@++LON7^1])94="H_*C*\\KSUZ<_7U
MKYM_X:!M_P#H!/\ ]]+_ /'J/^&@;?\ Z 3_ /?2_P#QZC?<#Z1^3.?ESZ\9
M_.CY/]G]*^;O^&@;?_H!/_WTO_QZC_AH&W_Z 3_]]+_\>I679?<O\@/I'Y/]
MG]*7*CH0/Q%?-O\ PT#;_P#0"?\ [Z7_ ./4?\- V_\ T G_ .^E_P#CU.[[
ML-]]?77\SZ2ROJ/S%)\O^S^E?-W_  T#;_\ 0"?_ +Z7_P"/4?\ #0-O_P!
M)_\ OI?_ (]19=EJK/1:KL]-5Y/3R ^DLJ.A _$49'8CGZ?A7S;_ ,- VW_0
M"?\ [Z7Z_P#/;_/3K7?^ _B1%XVN+N&.P:S%G&\CEL8;8+?&"'<$DW' ^7 3
M.6WX0"QZIUHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ,#T%(54D$@$CH2 2/I2T4)6VT]-/RL FU?[H_(4M%%'_#?(!"JDY*J2#D
M$@9R>I^IP/RI-J_W5_(>WM[#\AZ4ZBE9=ETZ+IMTZ=.W2P?I>WE?>WK=W[W=
M[W8F!Z#\J6BBG9=E]R_R#RZ=A,#.<#/K@9_.C X.!D=#@<?3TI:*++LON0?\
M-\NWIY!1110 4444 %,<D*<'!RO(]V I],D^X?JO_H0H @B'[UAZ;L>WR0#^
M1K/\0^(=%\*Z-J?B'Q%JMEH>A:-93:CJ^L:G/':Z?IFGVRF2XO;RXE*QP6T"
M*7GGE=(H8\N[!16A%_KG_P"!?^@P5POQ:BU&X^&7Q#L](TG4-=U2^\#^*+#3
MM&TI+1]2U.^O]'N[*SL[(7][I]D9Y+BXC4"[O+6##[GG0(: +7AOXC>!?%ZV
MS^%?&?AOQ MUX;T_QE;C2]6L[QI_"6JW>HV&F>)85BF:230M1O-&U:UL]41'
ML[BXL;I(YW,+@33_ ! \$6W@Y/B)<^,?#5KX"ETNVUJ+QG<ZWI\'AB72K]H?
ML&HIK,TZ:>]G?&:!+&>.X>*\:XA6V:1IHP_P9XJ^$?Q>OOA%^SY=^ /#.J^'
M_B#-\&K']F#XJ6%]<Z)IFL^#_ ?C30_#>FZ[XW::#5KNQO;OX::_X:76=%M]
M)OM1N)[;6]0-BK>?<J?H?XR?#B_M/#WP5D\">$8?%7A[X'^/_#?B6Y^%UI+8
M6DOB'PIH7A#Q!X0LK;0+?5;K3_#]WXA\&W.M:5XS\+Z9K%WI^FW&J^&K86][
M8:T-*O(0#WGPIXO\.>.-&M_$7A+6;+Q#H=U+<00:IILGFVDDUG</;7<:L51M
M]O,DD4H(^62-D."N*Z8,&Y!!'J.1^8X_S[5^7GCS1/VJ/'WA?0+C7(_B'#X2
ML?B9\1(KJQT7PWH>C?$W4O!5]X+T"#X<^(=9\(>$/B9X&MI6T/QA-XS*16_B
MN*^M9CX4U[4O#5X+*ZDM-#Q%\"_C'JZ^+;N[UCXQ^(=8TO3?V/\ 1O!7B3_A
M9&L>$=6U:UT34M*TWX_:Y+H'AOQI::!I'B'6_#TNL_\ ";2(@DOC<RVNF7=W
M'%;RL ?ID6Z@$;]N0#[YP2,$XR#V/0\5S-MXN\.3:A>Z4=<T]-0T_6+;P[=6
M=S.MK,NO7NE1ZY:Z/!]I,2WNH3:0_P!OCM[%KEGMDFE 40RA?@.\^&?Q0T"*
MTTG6_#GQ6\8?!7P[\;_B_=2^ ?"/CV_D\8:KX"UG1-(D^%MU%>W'C'3-=U[P
M3H7B6?Q*3X8G\4V=W8W%]HE\=-N-&T%K=(OB9\)_B'XGUUO$NN>"?B#XN\(^
M$OVJOAU\1?#/AFT\5W)\16OPSC_9ZT_P9K+>&;/_ (3+3!;3:=XZOI'U?2O[
M4LYFE3Q%J4$-ZUW<G40#]$=;UO3/#NDZMX@US4;;2=#T/3K[5M8U6^E$%EIN
MF:;;/=W][=SN#'!:V=M#+<7$\@81I')NVJC$9]]XKT"PT.T\27>KVT>@WYT<
MV>J()9[6Z&OW%K::*;=[:*21XM1N;ZS6"4*8R9U!<1DL/S;\6> _VA_%_P 1
M?B]=V7@3Q+H&C^*/ '[37@K4-/C\0W]WX1\5QZIX=BT[X)ZG]HU_XIZSIFIZ
MOK(@%Y''HWP_\&V'@J74]6T2YNYHC-=7>KX5^'/QKL/"GBG3_!7ASXM>"-$2
M+]E#3[7PYXG\=RS:Y<^,_!OQ*TVZ^-_B'PO.?&VO/IGA+4? L.G:;KR#6;?3
M_&,MAJ<MOI5U;-/=:V ?IHK'&7^7G'(Q^?)'KR.#C(XP2I=5ZL 3T!X)QZ#N
M/<<5^;DGPB^/]CJ-_P"*/"%]XVTWQ[XC\7?MHV$NL^(/B#J.J^&M.\+>);GQ
M_>?L[2SZ%?\ B#4=(L-"T[5AX(O/#EOI&BF\T&V:ZCGM[2WN+^.3U?\ 9%\%
M^/?"FD^++CQSJGQ-$^JGPK"?"_Q#L%L[31-;TG1[B#Q'JWAJ]F^)/Q.O]6;Q
M)>3Q3^(]5&KV.CZAJ-I'J.DZ9;O<W\D@!]F;EX^8<C(YZ@$#(]1EEYZ<CUKE
M/$9PUL00N1][.WD7EN!\W!Z.P'/\1]:\L^&/PL\>>#_'_P 4/%?B;XL>)?&N
MB>,=5TF[T#PWK%MX=6TTF&S\*^'-'GF>/2_#ND_8+F*]TS4(+:VTB:&PNK24
M:AJT-[KEQ=WK^G>)Q@6@]-H_*^M*3^ZRF_\ P&G-CBKM?XH_^W'S(?\ D]O0
M#@<_LQ:D20 ,D_$6,GH!W.?J3[Y^QD[?6+_T 5\<G_D]KP__ -FQ:E_ZL6*O
ML9.WUB_] %?-Y%=U>)V^O%><_P#J/DO]>?4\O+=\R7;-<2ONAER)Z***^E/3
M"BBB@ HHHH ****  G )/0<FD!!S@YQU_P _UKSKXK^/?^%:^ /$/C)=,;6+
MK2UTZTTS2A=K8Q:AK&N:QI^@:);7FH/%.FFZ9-J^J62:IJ1@N/[/T_[5=BWN
M'@$+^<Z[\:[CX66L6F_$S2Y?$GBZ+PQXG\?Z[!\*='N)]*\/?#SPK=6,&I>)
M=2C\4ZY9W<D6GOJ<%L]OILVHZUK#037&EZ$8X9H+8 ^BR0 23@#J?2@,"< Y
MZ_H<'\CQ7S)JO[4'A:"?Q18:7X3\9ZE+H@^(&G:1JKVNA6OAKQ3XF^'_ (%3
MX@7_ (>TN_?7I-2B?4-!=I;#4]1T2STF22UO;>6]BN84AFI:7^U-X:AT/0M4
M\5^#_&?AN6Z^"&C?'/Q3BWT/5=+\(^&-8>\M+&TN+O3M>FNM6U;4M2L)K72-
M-T73=1U&YMY;2:^@T^47EO: 'U1N4'!8 ^A(!I:^:X/CQ+K'Q!\!>"].\,:I
MX?OM6\:Z]X3\=Z)XSM((/$7AX6GPHU/XD^'[O3Y?#^M:UH%W!JT5O8*;B+4;
M^!(GU"QF%IJUM)!']*4 %%%% !7AWQT_Y%#ZWD /T6_L OY D ]:]QKP[XZ?
M\B@/^OV+_P!.&GT ?'^![_F?\:I:E?VFDZ=?ZI?RO!8Z=9W5]>SI!<W;06MI
M \\\ZVUK%<7,YAC1I/+B@E9PI#1LA85>K*UMKO\ L76UL+*74;Y]&U6*RL(;
MBUM9;V[GT^X@M[9+F]GM;2W,DTJ*TMU<P01IN>6:- 6 !B>'/'?@[Q>VE+X;
MUZWU-M=\/_\ "6Z-'Y%_:2ZGX7;46TI==LX=0M;"6;2UOO*@:Y2$$H\=TT8L
M[J)Y'KXY\'GPE#X^;Q'I<?@JYL8M1M?$=Q/)#IUS9W<B6]A+:NZ)/='49YH(
MM/@MH7NM1N)X(+"">6>!'^=M3^&7Q-NOA#\';+PY;V_AKXG>$/!(^%/B/[7K
M=DJV?A#QAX:M/!GC35++6=->YMK^[\/W%AHGC;PW:QN//O='6"YBM[B>:"'V
M'QUX*GET#P#!X#TNQD7X5^,? _BOP[X1OKR/3-,UK2?!EO<:3!X<-\T#PV5Y
M#IUZ;KP_>WUO+:6FOZ1IB2M%!"MV@!W7A_7M,\3Z<-6T9[Z:Q,LL&;W2-9T2
MZ26#R_-$NG:YI^EZA"O[Z/9(]J(7)/ERN<@;HAE)($,Q(8H0%8L'4X*8SG>"
M""F-P(((X-?('BCP)\8O'&E1-XC/BS4/#MC\4]0UFU\&ZIJ/PNU7QE>> 9_A
M_;:9I]MJ*.C_  VUF?P_X]FUV]TW2]5OI94TR33-16_.IV2N*/B#X":]JNA^
M*X!;7^N:S%\,?@%X8^'NM^+O%=O)XLT[5_"'B;59_'D]]JFE7,%C8:S)H=[:
MV%YKVGK%'K\4$EC!=2B4&@#[+V,"04DRJ^8PYSL.0K9R0JL^%W\#)(!SD5B2
MZ]H]O<M:7E[_ &=*-9TOP[;OJ5O<Z;:ZGKNM6PNM*TG1+R[@AL];N[Z+>L<>
MF7$[)-'+;R213Q/$GSIJOPGUBQN]3M=/\'6NN_#"P^.7B+QG8_">QURSL+'7
M? NM?#G2-*TR"QT_4;^RT-O^$?\ 'RZMKZ^$-5N['2;ZYGFU$R?;H;824_&G
MPFUWQ'<:GJMSX&L?$6E6'Q6^!WCC0_!-_J^BRS-X7\&^!$\,^,/#NGO?7B:)
MIU[;2R"VAAEO+>SUA;%O]/=9(YF /HUO%6A)K.G^'IKNYM]8U?4];TC2;.YT
MW5+<:G>^&M%AU_6QIUQ/8I9WEI:Z1*MPNII.VFW,RW%M;7=Q<V]P(]A;N-M4
M;1O*O3?)8KJ#(NG7PM'MWNI;,1QZFT!L6OC)#+)_9L=T-2B@:"Y:W2R_>M\M
MZ_\ ##Q%?>*[;7]>\ 0?$3PK9_%GXF^+)_!<_B32!/=>%_%?PG\+>%/#]M:)
MK%]::;"T'B*TU(7.FS:A#%86T#:I;K+(T1N<J\^#WQ2N_"=GH6IW?]K7K?!W
MX:^"]3FD\7WBI/KVC?&O2_%WB.U%Y)/:W]X++P!#/I+^(I)!>:Q'9R6GVAHK
MTA@#[&$;]-DA(7>>"!LROS<$*%_>1CK@%U ))%)C!*D,K D$,6!!!P01G((/
M4'D'CJ#CX[\7?!7Q5+)K.G:)IMPOPXC^,'B[Q39> O#-YX7E-SX7\0?#GPYH
MVC7>G:)XV8>%XSHGC>T\3:F="O;BQ>RN=4G\4Z)-'JPM /J+PAI,V@>%?#6A
M7%_K6J3Z+H.DZ5+J/B2_M=4\07CZ?8P6OGZWJ5DB6E_JA6)5O;RW!ANKA99T
M9M[.X!T6![_F?\:^A_V?Q_IVM^ODL,]_^8?_ )YKYYKZ'_9__P"/[6_^N3?^
MX^@#ZG3[B_[H/YC-.IJ?<7_=7^0IU !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R3[
MA^J_^A"GTR3[A^J_^A"@""+_ %S_ / O_08*L%%8@D9(S@Y(QD8/0]<$@'J
M6 P&.:\7^N?_ (%_Z#!5J@!AC0Y!4'((.<]#N!'7N';\_88/+3KMYY&<G.#C
M(SGOM'Y4^B@#Y^^(_P <]*^'GQ+^&7PZF\/:AJ__  GMZT6N^(;.Z@CL/AY8
MZGJ=AX5\&:GK=I+&US?P>,OB!JVD^#=,AL65[:\GGU&\:.PL9)#E>'?VDO!F
MH_$OQM\+?$$=QX6UWPY\38?AIX=N[FSUZ^T/Q7J%WX$\+>.;$-XEB\/V_A;0
M=>OTU^^LM-\+WNN7&JWJZ/YULDC:A;VIR_B3^RKX.^*>N?$WQ+XG\0>*AXB\
M<:-X6T#PSJ6EZSJNC0_#NW\$QS:GX5NM,TG3-3LM)\27NC^.[S4/'D,WBFRU
M*,ZE/#IXC_L^UB1V']F2YG\<WOB&_P#B1J%UX4UCXP^&/CKKO@^/PQH]K/J'
MC_P=X2\)^&]!\OQ*DTE[:>'4U#P?I7B6]TI+.2\GOX(]/AU:VT=KFRN0#?'[
M4/P4/AF]\;P>(M=OO!^EZIK&D:IXGTOX;_$O4]$T^Y\.27J>()[S4[+P?/;1
M:+H$FGWT.M>()&71--NK26"YOTN$EAC[%?C/\,7\56_@A?%UI+XMO-8TG1;'
M0HK/5;J]OKG7O#5YXQTF^L8H+&1;G0;CP]I]]?\ _"21._AVU>TN+&ZU6#4(
MGMY/GKQ3^Q;;>(OASX/^&L/Q/UJVT3PUI?Q>T>^BU'0-/UJPUF/XMZQ<ZQ-K
MHT2:\M=+M?%_@]KN[L/"6N746JP:?8ZEJX;3'N;]9[?O(OV94@^(OA_XFVOQ
M$\167B/PUX%LOA)I36-AIEK#;_"8:$EOK7A=-J.PUC5_&=MI7Q C\68_M+2M
M3T'2-%L84T'^U+34P#HY?VEO@W:Z=XHU;4_$^I:';^#-0\):;XAM]?\ !/CG
M1-7MYO'VN-X;\$W%GX?U3PU9Z]JFG^*]<$NDZ)JFEZ=?Z?=7MM<0Q3XAF8)+
M^TM\%8/#UMXF?Q9?BPNM6\3^'_[.3P9XWD\56>I^"U67QE;ZKX*3PX_B[2H_
M"MJ4O/$%[JFBVMGI5E-:7L]PMMJ-I)/XQX5_8IL/#UMJ,>H?$;4=5U'47^ X
MN]7MO"^EZ;>WZ? ;XE-\1])U'7+J2\U&\UWQ+XQOWFMO&.NWE\)9Y)C?:;:Z
M=M6UEU?&_P"Q?X;\7:Q<^)F\0:?=Z^WQ ^)?C:RA\:^"=%\<>%8+/XIZ/X+T
MKQ#X>N_#=Y<Z:;Q;:7P'H.H:1J\>IVE]9.EU93+>6%W- P!]@Z/J6F:]I>FZ
MWI-[::KI6K65GJNE:I83QW%CJ.G:A;0WMA?V-S"3'/:7=M-%<6TR,ZR0R*ZN
MR,"=(1QC.% SC/IQTXZ=S^))[UF:!H]KX?T/1]!L8+.TL=%TO3])LK73K.'3
MM/MK/3;2&SMK>PTZW_T?3[*&&!$M;&W_ '%G J6\)\N-:UJ $50O08_$D_F<
MG_ZY)ZDUQ_BC_EU^H_\ 2ZTKL:X[Q1_RZ_4?^EUI2?\ [;5_]-3*C\2_Q1_]
MN/F,_P#)[7A__LV+4O\ U8L5?8R=OK%_Z *^.3_R>UX?_P"S8M2_]6+%7V,G
M;ZQ?^@"OF\A_B\3_ /959Q_ZCY*>5EV^9?\ 8UQ/_I.7$]%%%?2GIA1110 4
M444 %%%% '#^)QX/\0Z7K?A3Q5)H.HZ/K%G=Z3K6C:K=6;0W=E=@P7%K=6TK
MAE22)@@?*R1N5DC*3 /7E6I?"+X&:S866FZU"NM6]A::MI<4VK?$OQEJ>HS:
M)KHL%UGPQJ>M7GBN?5M9\):HFEZ<M]X1U:]OO#,PLH ^E,% KG-1\,W=Y\.?
MB[JW@_PEX-UGXA_\)?\ %"+PQ<>(=)T*=?[8?Q-?6EE-=W.M*EI.MKO\Z&VO
MKN"SN'ACM9G2.9F7Q#Q'?L_PG\4:EX7N8=.^)O@WQW<?"E/#VN?"?X-7.H>)
MOB7XCE\/0^#-!E&B6FJ>';C1K4^(=-UK4M2\-7HGM]#;6[C5TM+K1+V&S^&R
MO,N+LXR_"YEAJ/"U&ACO;5:%/%5N*)XBGAX8G,,.E5EA:$:$:KE@82DE&I#E
MJR4)KE3?M8K"9/@L35PE6OG$ZV']C&I.G0RCV4I/#X>LU3YZSG9O%2BN?WY*
MBG/WM%]9?\(/\'#=R7ITSPT]S-X@\1>*9-^N3O#-KWBWPRW@WQ#>R6KWYM77
M4_#+MI$EFT)L(;<[[6U@N )AGZ=\,_@?I>FR:3#I>@WNF7'@*#X7S6VM^*-2
M\0Q3?#ZVO-0OK/PI,VOZQJ;RZ79SZK>K9*[M-9VSQ6-K-#8VEG;6_ ?%#7/#
M_P +9_!F@0?"?X?>--9UGP=X_P#$^J7]T/#_ (+TR&V^&6C^'=0UYH#-X>UJ
M$7>LQZL?[*L9'M+.W:!#?ZA!91SW</F&J?'CX=7FKQZ1X.^#WA35XM9\#^(]
M6T#7;O18K>VTGQWI/PE_X6XG@GQC;_\ ")_V=97B>&[G3/[2BT3Q'KFH:?<W
M=O;WMA"TC/;]]N-_Y.$+=_K/%7WV^K7_ ,SGODG\V>?^$^2__+_G]_H?2V@_
M#WX-^&K[2=4TJVTT:MHVNW_B:RUK4_&&M:]K;ZYJ/AB3P5<:CJ&LZ[KFI:GK
M,R>$Y/\ A'[-=9NM0ATW2UBM=-BM%@A\OU+_ (2C0_\ H-:1Z_\ (2M.G//W
M_8_D:^!1\8_#WA_POX8U_P 5?!SPMJWB/7O@Q\(?&9\.^#+#0-2\,WGB'XK?
M$*'P)I"V,S>$?^$@@1Y[^TU#5)F;4K:ST]#I6E:?K&JPQW>J[%_\:=#TL6+:
MS^S-H^@S67AC2/&7C+3]=;0M.UO0M'U/XL7GPLBET+3G\*/)KMU=26B>*M(A
MU6;PI-=Z)/#;WJZ7J[K946XW?V.$/_"GBI?^ZWZ^0G_8O\^=OTH9+_\ +S[C
M_P"$FT7_ *#.D],_\A&TZ>OW^GO2?\)1HG_0:TC_ ,&5I_\ %U\.6?Q'ET[P
MQ\0/$WB'X'?"Z]TSPI\=?B-\/(M6TN,1Z-X7\">"+C6V/C/X@_9/ ^NZSI4%
MO;Z7#9W%UH^C:O9)-JD.H:M-X?TF.:]3[!L? _P_U&TL[VV\'^"+JUO[2WO;
M:YMM"T6YM;B"XB6:">VNHK$17-O)%)&T$\8V/$4<'YURG'C9?8X0?IB>*_\
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M8QOG<N2R[MRYR"N.2K< ?,,@J H.S * 8SU).3DDD\]>OKU)ZD\G)YII;)R
M I/*Y!X&-@4EB>.^3R ,DFEW#_)7_P"*H 3U)Y!Y //)!QQGIDC_  '%>^?
MO4;"PO-9-Y?6-MOARJW5Y;V[%&%IM94ED#LK&,@. 5)5@#D<^!@D9P<=<890
M5X(X+9 (X(X/(^7!P1[A\%/#OA_6[_5GUG0-%UB2" I#-JFE6&H20Q?Z'MCC
MGNH)Y54LQ8J)<.22%XXX\=_:'U>7]F_47BM.2./EBX8=KF7/[26!A/%)J',Z
M?LTTZG*JEJ?,S;#_ %=3?UOV_LK/7"QH2JIV7+R1Q$H47K;FYVK1YG&\K7^G
MU\3Z(%4?VUI'  _Y"5IZ?[YI?^$HT3_H-:1_X,K3_P"+K)'PX\"X&? _@PG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDGW#]5_\
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MS-VUNO\ ;:V]TA:***^K/*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *0C((/<$?G2TA(49/3CWZG% &1>1S@-Y&[?M&X*
M"QR2"<!022< D;3QZ#)'-2PZV68AKC )  MI^>>Q\L9'IZC&,]3VL>'+9 /S
M29'T9,#/?&/;GL*E\M/[HH \\^S^(#R'N,'I_HTW3MU0?R%'V?Q#_?N/_ :;
M_P")KT/RT_NBCRT_NB@#SS[/XA_OW'_@--_\31]G\0_W[C_P&F_^)KT/RT_N
MBCRT_NB@#SS[/XA_OW'_ (#3?_$T?9_$/]^X_P# :;_XFO0_+3^Z*/+3^Z*
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M]EUS?B+PGX=\6V<=CXET33M<LX91/%:ZE;QW,$<V ?,5'."00,$\@JI P :
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MS/:*ORK^M/\ X>W_ +!&,_\ "[_;_D1_'1Y^@T3/KU_/CEA_X*W_ +!6<?\
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M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :_W&_P!UOY&JH_X^(O\
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MC]F'4A_YD2-?0]B?J?T^PPFX*"00&0\CD952,8(QCGKD9YQUKX\/_)[6@?\
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MOA[3$SR.3G!([ Y)XY\\C_9P^#FX9^#GPF !ZI\,_ JXSC/RIX>VGH"<Y)
MX!!KW;2]+2SCCCCCVQQ(D<4:@*L<<:)%&B(,!$CCCCC157"(BJ. ,_COC!XN
M8/Q0IY#2PN18[)GDM;-*M66,Q>&Q<<2\PA@8Q]D\/"'*H2PDVKI)*27+&*B?
M=\"<#5N#IYI4KYEA\<\PA@XTU1HUZ4J2H2J2DIJLY2N_:SO>4FN9:[*/01_=
M(]&/Z_-_7%24BJ%&!^)Z9/<_C2U^)'Z(%%%% !1136.%8],*<?7'% &7>1S,
MC1QD;MJ \ KC.<G<"ISZ,!CJ,D URTNF:GO)7H>1B.#&,GIP/\]_3MHOF)#<
MX:0 'G@;,9]<9.,Y_05*R0Y&Y(\GIN5<GD#C(SU('U(]: //#I6K$D[\>WD6
MQ_7&3]3R>II/[)U;^_\ ^0+;_"O0_+AX_=Q<D@?(G)&<@<<D8.1U&#Z&@QP#
MDI$!R<E4' &2>1V )/L,T >>?V3JW]__ ,@6W^%']DZM_?\ _(%M_A7H?EP9
M(V19'!&U,@@!B#QQA2#]"#T-'EP<_NXN,Y^5.,=<\<8[T >>?V3JW]__ ,@6
MW^%']DZM_?\ _(%M_A7H?E0YQY<6>#C8F<'.#C'?!QZX/H:#' , QQ G. 53
MG')QQS@ D^F* ///[)U;^_\ ^0+;_"C^R=6_O_\ D"V_PKT/RH>GEQ9_W$]<
M>GKQ]:/*A_YYQ?\ ?">F?3TY^G- 'GG]DZM_?_\ (%M_A1_9.K?W_P#R!;?X
M5Z'Y4)Z1Q'_@"?X>Q_*CRX?^><7/(^1.G7/3T(/XT >?KIFJ@8)).?\ GE;K
MQ^ Y/N?:K,&GSHZ-=X(0MM&R-"0=K\F-?F/F*,%CP 3R<5W BA/2.(_1%],^
MGH0?H:PM6N%M0BA0-Y4#"@#:;B-?3H%8@^F[.1P0GL^ONU?_ $U/]"H?$O5?
MJ?+-RH3]N'1%'1?V9-34<8Z?$6(=*^P$[?6+_P! %?'LS^9^V]H3_P![]F34
MB>G7_A8L63QQR?2OL).WUB_] %?-Y#_$XF[_ .M.;W]?JV2W_&YY66[YE_V-
M<3_Z1EQ/1117TIZ84444 %(0#P1GO^/K2T4 5)K1)0> ,CCCG(P!]1@8P>H)
M!^4XK!DL9[5@]HQ0!B3%AO*W<!F5!S$V"6W1E6&X*?EXKJ:0J#U&?_KXS_(4
M >3Z1K>K^)K+5B5BMQI_B[Q?X=+6[.6>U\/ZU<Z9:S,78@7%PD2M<8 7(*Q@
M9%;VFZ D3;W!:3:JER"S,<DY+D%CGL#P,G&<DUB_#.-#IOBPE02/B=\1_P!?
M%M^3^9%>GPJJKP,<+_6OG^%L9B<?P]D^+QE5U\1B,-B*E2LX1ISE*.8YK32D
MH*THQAAJ,%?7W$]VST<WI4Z&9XRA1@J=*C.,81CVE1P->-[W>DJV);UWJ*W6
MT$%G'$J    '(Q@D%<8Z<<<'&.!C/6KBJ%&!TY_6EHKZ \X**** "BBB@ K\
MSO\ @KZ^I6__  3U^/<FD:EJ>D:AN^&_DZAHVI7NDZC 7^*O@E)C;7^GS6]W
M;^9"7C?RI5\R)Y(9-T;LI_3&OSM_X*M6OVW]@_XVVV-WF/\ #WC&<A/B=X.<
MCGCHI_I@X(^N\/N5\><&*45*/^M&1.491C*,H_VE1O%QFI0DFEJI1<6M&FCP
M.*INGPQQ%4BW&4,DS2:E%VDG'!U6FG=6:M=.ZL^I_#=>:O\ $<%R/B+\2EYZ
M+\0O&@4=5[:YD?((P1@_,"<X( Y>]UCXDY('Q*^)JD$ X^(GC95;.#G_ )#@
M(&??MW(-?2UYX67YB8<]2.,?PDY.!Z\CC.?6N7O/"0PQ$8R>>%_W<#D\$+D#
MCL#Z"O\ 4:-'!VM]4P;Y4HOFP>!WLGI_LOWMG\94LWKJZ^L8EOF?Q57;_P!/
M/74^9Y=:^((GC6^^+'Q.TZP,T2WNHMX]^(-ZFG69=!<W\EG9:Y)>W*6D!DN#
M:V,4M[<"+R;:&25T4?0'CS]E7]JO2_B[\2/A#\,?'/Q>^.^H?"RZ\*:3XS\4
M_#SQ9\5]/\,:/J_C33HM0T#3;^7Q=J.B7FG?VBTW]GZ9=:A'!#K&J(]AIAN;
MG,1S9_!UA/-#'JMK=3:7)/$FIQ6,D%OJ$NGM(@OH[&YN+2^M[>[>T\];2>>S
MN(8[DQ&6*=&:WG^H/BW\?/#/C77_ (^ZCH/PT\0Z5I_QT^(W[/'Q'FT_Q%XO
MTK7K[P[J/P'FU2:^T];JQ\+:9;ZA:^)EOHUMV>VMIM'^RLTPU&)H8*\'-UF5
M'&X2>4X#!5**P.(525;!Y4L)1Q-7,<NHP<Y570KJ=/+EF6*C1PT52Q-1TJ>(
M:FJ:G]3E&8X"MAL0LSQE6E/ZRH4W#$5(U:F&^H3DY651TTHXOE6NFFS=XOXI
MO_V8/VU?^%>>"/B5;3_&V^TKX@_%KQ)\#_#WAVS^(WCP^.A\2_#>IZ/H,WAS
M4O"$NO0:K9ZAJOB+5_\ A'=%L_+DOIM;T[4K*^M=/*6LEYYAXC^ _P"VCHVB
M>-O$6K6?[16GZ1\-F5?']P_Q \9O<^$%6STN^O)=:TJW\72ZO;6FD6^O:%_P
MD%XEC):>&Y-7LTUV;32)VB_2>Y_:D\-W'Q#\-_$W5/A3KDGB/P)^V_\ $#]L
M/P?#IGC?2[33C9_%/Q+X*UWQ5\/_ !0)_"MY>WE[81^ +"T\/>*-+O=.6.*_
MF.HZ+<&SML>6?#O]H'P5\-OA+XM\%:=\%3%X[\9^"OV@? GB/QMI6H^";9/%
M]G\=+6YAT_7_ !A=:CX U?Q_=ZO\.[1Y=*T#0?#?C[PUX1U"RDFO=5TF?5)Y
M4N/$HXSC*E37-PIDM;%5:E.,:%'"Y?R1I8C,:'(O;59RA4AA,NK8M>U25:>)
MC1YHNC11]*L9D-24FL\Q,5[%S_?XA58U*D*+:A&-J=IU,7)RBW)KE>J3NU\&
M?L\_!']H7]J+XD3_  V\%_&[QAX6O;?PSJGB6\\2>-_C!\2M+\+V"VU[I.@Z
M!I%[?V>KWLMOJOC?QUXD\+?#[PO&UN8+KQ5XETRVGEA@,L\?F'ASX0_MB>//
M#^J^+?"4G[1E_P"%O#_C&T^'?B/Q.?B'\0=/\/\ AWQY?7NC6%OX.UC6+_Q7
M:6=GXBDO-?TR--&8_P!IM%/+<I9M;6EW-!]G_"7XR:E\"?A_\1M \$>!?!>K
M>-_B1XF^'.HZCXR\>^&]%\;Z+I7@WX9WNK>+-*\,Z5X0UG3GM4U2;XC3:!XR
MG\1_VAO@7P?HEK#:I-+)/;5OCW\;],^+?AOQEH6C_#&W\$GQE^UCJ_[7%_!'
MK46IZ)IWC'Q=\-_#WA;Q=X=TO2HM)T[[+H=[XULM>\4Z*/M4LVC^'_$<'AGR
M&-O+J4_N5)\04LYQ;P>493_8CGEM' 8VI3RZ+PE*EB7#,\9BHX2-/$5J>.I^
MTEA8S591CA*O-2I0DE)X;,<H>!H_6,?4^NQYI5XJ;O/FE[E**C5</:4HJU35
M1O)6E*Q\N>//V-_^"@OA#XT?$KX"1P_M">,/B%\*[Z.S\4P> ?BA\1?$FD.E
M]>7UAX>NM(U:/Q1:PWS^,KG2]1A\%Z),EIXI\426<]MH_A^ZO8+FU@\N\&_L
MZ?MD^-M.\)^*;[6?VK/#_P .O'5A\19_!WCNWU7XP^)K7Q1J/PW\*^/O$>OZ
M7X<T33O%MEK.M)I-S\.?$NF>+;^PMY;7P+#IVHZOXE6WBL)+.7]5(_VW_#FF
M>//VB?%'A_X=_$WP-I?[17Q@\!?M):O=^$?&?PFU;QSX#^-_@:?QS)<R>"]6
M\??!#Q?X=D^'VH_\)M?'2H]1\.6_CKP??Z=INO:7XOO))[V*3YWT;]JF^T?Q
M?\ ?&6L>"M5\3:W\$_@M^U9\*M4U&_\ %-LNJ>.-9_:>U/X\ZMJGCB>=M %O
MIE]I.H_&\7NJZ?\ 9I?[?N]"F4S6$.JQ"V\RGBN-JF'E3K<.Y+"M++\*JE>=
M'#T\1B\6LHPF,Q4E2]I5PM"K1S><\)["E)5J.$C0Q4XSPM>G.E]!',LCC*,X
M9KCG>MB(-^WBJ<:*JNE1O[.,*MVH^TC]ETY*3UT7P9X$_9G_ &TO'^L?LZ?;
M_%GQ^\#?#[]IKXI_"?X4>!/B[JOQ-^(>J^![36?C'K-EIWA&]UB31/%]W?6$
M%_87%[K^DV>HP:9>^)M'T?5+OP\E]:6TEXOR?XUU/XV^$_%'BKPM)\</B]?3
M^%?$_B/PS->0_%7XDQ0WD_AW6]0T22[MXKGQ$MQ%;WCV)O+>.=5G6WGA$R"0
M$']S= _;9^'W@+P%\'O!?@/]G!?"MO\ #GXM?L0?&;Q-IFB>(_ FD>&-:\5_
ML=C5#K=QHD^C?"_3_B!?ZI\<]2UK4?%OB3Q1\5?&7C[6?#VNZE<6NDQMI,$%
MO-^4_CW2/^$H\8>+_% L#8?\)1XL\4>)A9.ZW#6?_"0ZYJ&L"S:Y*1FX:V^V
M?9S.88?/$:N(D4A5]G(Y9SC,;C:F=Y!@<KR]1J_4J/U?+\14K2EF5>O&I5J1
MHUJD*ZP$)86K"DY8?GA1G0E*E5E)=>)SG!T:5/ZGCZ^(G*;YG];K72LM/>=[
M+>_1M[GR)>^/?C<A*M\9/C(  <_\75\?N& (Y._Q"1R!T///R\CC]>/^#>[Q
MK\5-4_X+&_L;:7XB^)WQ(U_1+S4OB]]MT;7?'OB[6-*O!;_ _P"(<\*WFG:C
MK$]I=I%<)%<1I<0RQI/%#-Y?FQ1.GYW7W@S@_N#CDY !ZGN'7!'J 0.XP,5^
MJ?\ P0/\+"P_X+ _L:W>Q1Y6I_&+.$"G#_ KXB)VSG)/J.!U.":P\0LOP$>!
M>-9+ 8*,Z?"W$$X26#P2E&=/+,5*+3^J*46G'22M.#M*+4E==^49U*KF&!I>
MTK)SQ5&%WB)S7O5(IWC)I.]VKO:]TFS_ $YI-&MY"6V+]\X'EKGT P$ '( &
MT* .A!J-M!MSC=&@'^T N?IO#9QWP!C(YYKHT[<],8Y]2!G\14Q /4 _6O\
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M'D1?W:FHH B$*#H/Y?X4]45>@_SZ>PSS[GFG44 %%%% !1110 4R3[A^J_\
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M_P!&6U>HKT'T'\J\N^'7W/'7_92/%O\ Z,MJ]17H/H/Y5\WPE_R3^7>F,_\
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M^QKB?_2<N)Z***^E/3"BBB@ HHHH **** /$_">OZ?X8\*>.M=U1-2DL-/\
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MI*O1E1J.BJ>#492ISC&4;U*;2;BN:%I6M),L4445].>H%%%% !1110 4444
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MEBE4E]?BJ?FXR2P&,J818F&(=&W-4A=*\[U.5ZOWE"4&^W,CY=U#P^V"&C+
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MIC';TI:* $(!Z@'Z@'KU_.C ]!UST'7U^M+10 A /4 X.1D9P1T/U'K2T44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/#_CWQGK/@.]\'/JU]<67B&YN/#.K^'1=6FB*UG^UIC<C&_(]P>1G)!YP0<
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M_P 0ZX'_ .B9RS_P#$?_ #<?D7)_P1F_9AD)+>,_C5R"#CQ)X7Z9R,[O!9!
MP.#Z#IBJ4G_!%C]ER7&[QI\;<?W?^$D\+8_(>"O\_I7[ T4_^(M^)O\ T7/$
M*],50_\ G</_ (AWP/\ ]$SE?_@&)_\ FX_&Z3_@B/\ LKR<'QQ\<0,'@>)?
M"??/3/@8XP#Z=>:SI?\ @AK^RC*"&\=?'< Y^[XG\)#KSU_X08?Y_"OVBHJE
MXN>)J=_]>.(?_"NA_P#.X?\ Q#W@KIPWEJ_[<Q#_ #QK_(_$N7_@A%^R3*<M
MX[^/8XQ\OBGPB.H]_ I'YCCM6=+_ ,$$OV0YLAO'G[0?)."OBWP8,9/8MX#R
MN>A'3%?N+15?\1>\3O\ HN.(?_"RC_\ .X:\/^#(NZX=RU?]PZ__ ,UGX52?
M\&_W['<W+_$#]H<9SPOB_P &C&>W_(@E3^.17KG[.?\ P1H_9F_9B^-_@7X]
M> ?&/QJU3Q=\/YM<N-&T_P 5^)?"]_H%Q)KWA[4O#5X+^TT_P;I=Y*$L-6NI
M;<0ZA;;;M()'+HC(WZ\T5RX_Q2\1LRP.+R[&\9Y[B<'C</5PN)P];$T9TJU"
MM'DJ4ZD%@:7-"4;IQ]I%-:-VT?5AN#.%L)6I8C#Y'@*5:A4C5HU84ZJG3J0:
ME"4&\1-)Q:33<7\ND4:L N2<CJ3P3T[9Z'GU].:EHHKX%*U_-W]+I)_E?U;/
MI^K??<****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>29
<FILENAME>rnxt-20221231.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSJqbP9z5Z8aekhvWB+bYm67yIrx7BAXCebRC5mcW8N -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:RNXT="http://renovorx.com/20221231" elementFormDefault="qualified" targetNamespace="http://renovorx.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://renovorx.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" id="StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity">
	  <link:definition>00000005 - Statement - Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical" id="StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical">
	  <link:definition>00000006 - Statement - Statements of Convertible Perferred Stock and Stockholder's Equity (Deficit) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/BusinessAndPrincipalActivities" id="BusinessAndPrincipalActivities">
	  <link:definition>00000008 - Disclosure - 1. Business and Principal Activities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - 2. Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/Short-termMarketableSecurities" id="Short-termMarketableSecurities">
	  <link:definition>00000010 - Disclosure - 3. Short-Term Marketable Securities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/AccruedExpenses" id="AccruedExpenses">
	  <link:definition>00000011 - Disclosure - 4. Accrued Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000012 - Disclosure - 5. Fair Value Measurements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ConvertibleNotes" id="ConvertibleNotes">
	  <link:definition>00000013 - Disclosure - 6. Convertible Notes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000014 - Disclosure - 7. Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants" id="EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants">
	  <link:definition>00000015 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000016 - Disclosure - 9. Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/NetLossPerShare" id="NetLossPerShare">
	  <link:definition>00000017 - Disclosure - 10. Net Loss per Share</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000018 - Disclosure - 11. Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/EmployeeBenefitPlans" id="EmployeeBenefitPlans">
	  <link:definition>00000019 - Disclosure - 12. Employee Benefit Plans</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000020 - Disclosure - 13. Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000021 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/Short-termMarketableSecuritiesTables" id="Short-termMarketableSecuritiesTables">
	  <link:definition>00000022 - Disclosure - 3. Short-Term Marketable Securities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
	  <link:definition>00000023 - Disclosure - 4. Accrued Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>00000024 - Disclosure - 5. Fair Value Measurements (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables" id="EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables">
	  <link:definition>00000025 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000026 - Disclosure - 9. Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
	  <link:definition>00000027 - Disclosure - 10. Net Loss per Share (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative" id="BusinessAndPrincipalActivitiesDetailsNarrative">
	  <link:definition>00000028 - Disclosure - 1. Business and Principal Activities (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000029 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails" id="ScheduleOfShort-termMarketableSecuritiesDetails">
	  <link:definition>00000030 - Disclosure - Schedule of Short-Term Marketable Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfAccruedExpensesDetails" id="ScheduleOfAccruedExpensesDetails">
	  <link:definition>00000031 - Disclosure - Schedule of Accrued Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
	  <link:definition>00000032 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails" id="ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails">
	  <link:definition>00000033 - Disclosure - Schedule of Changes in Fair value of Derivative Liability (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/FairValueMeasurementsDetailsNarrative" id="FairValueMeasurementsDetailsNarrative">
	  <link:definition>00000034 - Disclosure - 5. Fair Value Measurements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ConvertibleNotesDetailsNarrative" id="ConvertibleNotesDetailsNarrative">
	  <link:definition>00000035 - Disclosure - 6. Convertible Notes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000036 - Disclosure - 7. Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails" id="SummaryOfStockOptionAwardActivityDetails">
	  <link:definition>00000037 - Disclosure - Summary of Stock Option Award Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails" id="ScheduleOfRangesOfStockOptionsDetails">
	  <link:definition>00000038 - Disclosure - Schedule of Ranges of Stock Options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails" id="ScheduleOfEstimateFairValueOfStockOptionsDetails">
	  <link:definition>00000039 - Disclosure - Schedule of Estimate Fair Value of Stock Options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails" id="ScheduleOfStockBasedCompensationExpenseDetails">
	  <link:definition>00000040 - Disclosure - Schedule of Stock Based Compensation Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
	  <link:definition>00000041 - Disclosure - Schedule of Warrant Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative" id="EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative">
	  <link:definition>00000042 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails" id="ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails">
	  <link:definition>00000043 - Disclosure - Schedule of Statutory Tax Expense and Effective Tax Expense Benefit (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
	  <link:definition>00000044 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" id="ScheduleOfUnrecognizedTaxBenefitsDetails">
	  <link:definition>00000045 - Disclosure - Schedule Of Unrecognized Tax Benefits (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000046 - Disclosure - 9. Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails">
	  <link:definition>00000047 - Disclosure - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails" id="ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails">
	  <link:definition>00000048 - Disclosure - Schedule of Potentially Anti Dilutive Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000049 - Disclosure - 11. Related Party Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/EmployeeBenefitPlansDetailsNarrative" id="EmployeeBenefitPlansDetailsNarrative">
	  <link:definition>00000050 - Disclosure - 12. Employee Benefit Plans (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://renovorx.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000051 - Disclosure - 13. Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="rnxt-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="rnxt-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="rnxt-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="rnxt-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="RNXT_UnderwriterMember" name="UnderwriterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_OverAllotmentOptionsMember" name="OverAllotmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_RenovoCathMember" name="RenovoCathMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_NotePurchaseAgreementMember" name="NotePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_TwoThousandAndTwentyConvertibleNotesMember" name="TwoThousandAndTwentyConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" name="TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_TwoThousandAndTwentyOneConvertibleNotesMember" name="TwoThousandAndTwentyOneConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" name="TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_OmnibusEquityIncentivePlan2021Member" name="OmnibusEquityIncentivePlan2021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_TwoThousandAndTwentyOnePlanMember" name="TwoThousandAndTwentyOnePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_WarrantTwoMember" name="WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ExercisePriceRangeFourMember" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ExercisePriceRangeFiveMember" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ExercisePriceRangeSixMember" name="ExercisePriceRangeSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ExercisePriceRangeSevenMember" name="ExercisePriceRangeSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_FederalAndStateMember" name="FederalAndStateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_CaliforniaTaxCreditMember" name="CaliforniaTaxCreditMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_DrAgahMember" name="DrAgahMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_DefinitiveSecuritiesPurchaseAgreementMember" name="DefinitiveSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" name="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" name="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_StockIssuedDuringPeriodsharesWarrantsExercised" name="StockIssuedDuringPeriodsharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_StockIssuedDuringPeriodValueReverseStockSplits" name="StockIssuedDuringPeriodValueReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet" name="IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_AmortizationOnLeaseholdImprovement" name="AmortizationOnLeaseholdImprovement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_GainOnChangeInFairValueOfDerivativeLiability" name="GainOnChangeInFairValueOfDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_GainOnLoanExtinguishmentFromPppLoan" name="GainOnLoanExtinguishmentFromPppLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_LossOnLoanExtinguishment" name="LossOnLoanExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_PaymentsForLeaseholdImprovements" name="PaymentsForLeaseholdImprovements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_DerivativeLiabilityInFinancingActivities" name="DerivativeLiabilityInFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering" name="ConversionOfConvertiblePreferredStockUponInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering" name="ConversionOfConvertibleNotesUponInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock" name="CashCashEquivalentsAndInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_LeaseholdImprovementsPolicyTextBlock" name="LeaseholdImprovementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ClinicalTrialExpensesPolicyTextBlock" name="ClinicalTrialExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ConvertiblePreferredStockPolicyTextBlock" name="ConvertiblePreferredStockPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_NetProceedsFromIntialPublicOffering" name="NetProceedsFromIntialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_MaximumPossibleProceedsFromOfferings" name="MaximumPossibleProceedsFromOfferings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_PaymentsReceivedFromClinicalSites" name="PaymentsReceivedFromClinicalSites" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_AccruedClinicalTrialsCurrent" name="AccruedClinicalTrialsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes" name="MaximumPossibleTotalProceedsFromConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_PermanentItems" name="PermanentItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_DeferredTaxAssetsCharitableContributions" name="DeferredTaxAssetsCharitableContributions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_DeferredTaxAssetsCapitalizedResearch" name="DeferredTaxAssetsCapitalizedResearch" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_UnrecognizedTaxBenefitsAdditions" name="UnrecognizedTaxBenefitsAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_CashCompensation" name="CashCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_DiscretionaryBonus" name="DiscretionaryBonus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_DeferredCompensationArrangementWithIndividualCashAwardGrantedPerMonthAmount" name="DeferredCompensationArrangementWithIndividualCashAwardGrantedPerMonthAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_EstimatedOfferingCostsAfterDeductingUnderwritingDiscountsAndCommissions" name="EstimatedOfferingCostsAfterDeductingUnderwritingDiscountsAndCommissions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RNXT_AggregateNetProceedsFromOfferingCosts" name="AggregateNetProceedsFromOfferingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>30
<FILENAME>rnxt-20221231_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://renovorx.com/role/Cover" xlink:href="rnxt-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BalanceSheets" xlink:href="rnxt-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BalanceSheetsParenthetical" xlink:href="rnxt-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="rnxt-20221231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:href="rnxt-20221231.xsd#StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="rnxt-20221231.xsd#StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfCashFlows" xlink:href="rnxt-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BusinessAndPrincipalActivities" xlink:href="rnxt-20221231.xsd#BusinessAndPrincipalActivities" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="rnxt-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/Short-termMarketableSecurities" xlink:href="rnxt-20221231.xsd#Short-termMarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/AccruedExpenses" xlink:href="rnxt-20221231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/FairValueMeasurements" xlink:href="rnxt-20221231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ConvertibleNotes" xlink:href="rnxt-20221231.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/CommitmentsAndContingencies" xlink:href="rnxt-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants" xlink:href="rnxt-20221231.xsd#EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/IncomeTaxes" xlink:href="rnxt-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/NetLossPerShare" xlink:href="rnxt-20221231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/RelatedPartyTransactions" xlink:href="rnxt-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EmployeeBenefitPlans" xlink:href="rnxt-20221231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SubsequentEvents" xlink:href="rnxt-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rnxt-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/Short-termMarketableSecuritiesTables" xlink:href="rnxt-20221231.xsd#Short-termMarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/AccruedExpensesTables" xlink:href="rnxt-20221231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/FairValueMeasurementsTables" xlink:href="rnxt-20221231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables" xlink:href="rnxt-20221231.xsd#EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/IncomeTaxesTables" xlink:href="rnxt-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/NetLossPerShareTables" xlink:href="rnxt-20221231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative" xlink:href="rnxt-20221231.xsd#BusinessAndPrincipalActivitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="rnxt-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfShort-termMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="rnxt-20221231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ConvertibleNotesDetailsNarrative" xlink:href="rnxt-20221231.xsd#ConvertibleNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="rnxt-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails" xlink:href="rnxt-20221231.xsd#SummaryOfStockOptionAwardActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfRangesOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfEstimateFairValueOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfWarrantActivityDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative" xlink:href="rnxt-20221231.xsd#EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/IncomeTaxesDetailsNarrative" xlink:href="rnxt-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="rnxt-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:href="rnxt-20221231.xsd#EmployeeBenefitPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SubsequentEventsDetailsNarrative" xlink:href="rnxt-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:title="00000005 - Statement - Statements of Convertible Preferred Stock and Stockholders&apos; (Deficit) Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="00000006 - Statement - Statements of Convertible Perferred Stock and Stockholder&apos;s Equity (Deficit) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_AmortizationOnLeaseholdImprovement" xlink:label="loc_RNXTAmortizationOnLeaseholdImprovement" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RNXTAmortizationOnLeaseholdImprovement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_GainOnChangeInFairValueOfDerivativeLiability" xlink:label="loc_RNXTGainOnChangeInFairValueOfDerivativeLiability" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RNXTGainOnChangeInFairValueOfDerivativeLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_GainOnLoanExtinguishmentFromPppLoan" xlink:label="loc_RNXTGainOnLoanExtinguishmentFromPppLoan" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RNXTGainOnLoanExtinguishmentFromPppLoan" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_LossOnLoanExtinguishment" xlink:label="loc_RNXTLossOnLoanExtinguishment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RNXTLossOnLoanExtinguishment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_PaymentsForLeaseholdImprovements" xlink:label="loc_RNXTPaymentsForLeaseholdImprovements" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_RNXTPaymentsForLeaseholdImprovements" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/BusinessAndPrincipalActivities" xlink:title="00000008 - Disclosure - 1. Business and Principal Activities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - 2. Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/Short-termMarketableSecurities" xlink:title="00000010 - Disclosure - 3. Short-Term Marketable Securities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - 4. Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/FairValueMeasurements" xlink:title="00000012 - Disclosure - 5. Fair Value Measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ConvertibleNotes" xlink:title="00000013 - Disclosure - 6. Convertible Notes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - 7. Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants" xlink:title="00000015 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - 9. Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/NetLossPerShare" xlink:title="00000017 - Disclosure - 10. Net Loss per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - 11. Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/EmployeeBenefitPlans" xlink:title="00000019 - Disclosure - 12. Employee Benefit Plans" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - 13. Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/Short-termMarketableSecuritiesTables" xlink:title="00000022 - Disclosure - 3. Short-Term Marketable Securities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/AccruedExpensesTables" xlink:title="00000023 - Disclosure - 4. Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/FairValueMeasurementsTables" xlink:title="00000024 - Disclosure - 5. Fair Value Measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables" xlink:title="00000025 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - 9. Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/NetLossPerShareTables" xlink:title="00000027 - Disclosure - 10. Net Loss per Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative" xlink:title="00000028 - Disclosure - 1. Business and Principal Activities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails" xlink:title="00000030 - Disclosure - Schedule of Short-Term Marketable Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000031 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_AccruedClinicalTrialsCurrent" xlink:label="loc_RNXTAccruedClinicalTrialsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_RNXTAccruedClinicalTrialsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000032 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails" xlink:title="00000033 - Disclosure - Schedule of Changes in Fair value of Derivative Liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="00000034 - Disclosure - 5. Fair Value Measurements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ConvertibleNotesDetailsNarrative" xlink:title="00000035 - Disclosure - 6. Convertible Notes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - 7. Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails" xlink:title="00000037 - Disclosure - Summary of Stock Option Award Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails" xlink:title="00000038 - Disclosure - Schedule of Ranges of Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails" xlink:title="00000039 - Disclosure - Schedule of Estimate Fair Value of Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="00000040 - Disclosure - Schedule of Stock Based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000041 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative" xlink:title="00000042 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails" xlink:title="00000043 - Disclosure - Schedule of Statutory Tax Expense and Effective Tax Expense Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_PermanentItems" xlink:label="loc_RNXTPermanentItems" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_RNXTPermanentItems" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCredits" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCredits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000044 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DeferredTaxAssetsCharitableContributions" xlink:label="loc_RNXTDeferredTaxAssetsCharitableContributions" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_RNXTDeferredTaxAssetsCharitableContributions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DeferredTaxAssetsCapitalizedResearch" xlink:label="loc_RNXTDeferredTaxAssetsCapitalizedResearch" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_RNXTDeferredTaxAssetsCapitalizedResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:label="loc_us-gaapDeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="00000045 - Disclosure - Schedule Of Unrecognized Tax Benefits (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000046 - Disclosure - 9. Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="00000047 - Disclosure - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails" xlink:title="00000048 - Disclosure - Schedule of Potentially Anti Dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000049 - Disclosure - 11. Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="00000050 - Disclosure - 12. Employee Benefit Plans (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000051 - Disclosure - 13. Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>31
<FILENAME>rnxt-20221231_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://renovorx.com/role/Cover" xlink:href="rnxt-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BalanceSheets" xlink:href="rnxt-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BalanceSheetsParenthetical" xlink:href="rnxt-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="rnxt-20221231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:href="rnxt-20221231.xsd#StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="rnxt-20221231.xsd#StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfCashFlows" xlink:href="rnxt-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BusinessAndPrincipalActivities" xlink:href="rnxt-20221231.xsd#BusinessAndPrincipalActivities" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="rnxt-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/Short-termMarketableSecurities" xlink:href="rnxt-20221231.xsd#Short-termMarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/AccruedExpenses" xlink:href="rnxt-20221231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/FairValueMeasurements" xlink:href="rnxt-20221231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ConvertibleNotes" xlink:href="rnxt-20221231.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/CommitmentsAndContingencies" xlink:href="rnxt-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants" xlink:href="rnxt-20221231.xsd#EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/IncomeTaxes" xlink:href="rnxt-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/NetLossPerShare" xlink:href="rnxt-20221231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/RelatedPartyTransactions" xlink:href="rnxt-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EmployeeBenefitPlans" xlink:href="rnxt-20221231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SubsequentEvents" xlink:href="rnxt-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rnxt-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/Short-termMarketableSecuritiesTables" xlink:href="rnxt-20221231.xsd#Short-termMarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/AccruedExpensesTables" xlink:href="rnxt-20221231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/FairValueMeasurementsTables" xlink:href="rnxt-20221231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables" xlink:href="rnxt-20221231.xsd#EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/IncomeTaxesTables" xlink:href="rnxt-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/NetLossPerShareTables" xlink:href="rnxt-20221231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative" xlink:href="rnxt-20221231.xsd#BusinessAndPrincipalActivitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="rnxt-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfShort-termMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="rnxt-20221231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ConvertibleNotesDetailsNarrative" xlink:href="rnxt-20221231.xsd#ConvertibleNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="rnxt-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails" xlink:href="rnxt-20221231.xsd#SummaryOfStockOptionAwardActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfRangesOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfEstimateFairValueOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfWarrantActivityDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative" xlink:href="rnxt-20221231.xsd#EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/IncomeTaxesDetailsNarrative" xlink:href="rnxt-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="rnxt-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:href="rnxt-20221231.xsd#EmployeeBenefitPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SubsequentEventsDetailsNarrative" xlink:href="rnxt-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:title="00000005 - Statement - Statements of Convertible Preferred Stock and Stockholders&apos; (Deficit) Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:label="loc_RNXTStockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTStockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:label="loc_RNXTStockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTStockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" xlink:label="loc_RNXTAdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTAdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_RNXTStockIssuedDuringPeriodValueWarrantsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTStockIssuedDuringPeriodValueWarrantsExercised_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodsharesWarrantsExercised" xlink:label="loc_RNXTStockIssuedDuringPeriodsharesWarrantsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTStockIssuedDuringPeriodsharesWarrantsExercised_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_RNXTStockIssuedDuringPeriodValueReverseStockSplits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTStockIssuedDuringPeriodValueReverseStockSplits_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_70" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="00000006 - Statement - Statements of Convertible Perferred Stock and Stockholder&apos;s Equity (Deficit) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/BusinessAndPrincipalActivities" xlink:title="00000008 - Disclosure - 1. Business and Principal Activities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - 2. Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/Short-termMarketableSecurities" xlink:title="00000010 - Disclosure - 3. Short-Term Marketable Securities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - 4. Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/FairValueMeasurements" xlink:title="00000012 - Disclosure - 5. Fair Value Measurements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ConvertibleNotes" xlink:title="00000013 - Disclosure - 6. Convertible Notes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - 7. Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants" xlink:title="00000015 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - 9. Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/NetLossPerShare" xlink:title="00000017 - Disclosure - 10. Net Loss per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - 11. Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/EmployeeBenefitPlans" xlink:title="00000019 - Disclosure - 12. Employee Benefit Plans" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - 13. Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/Short-termMarketableSecuritiesTables" xlink:title="00000022 - Disclosure - 3. Short-Term Marketable Securities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/AccruedExpensesTables" xlink:title="00000023 - Disclosure - 4. Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/FairValueMeasurementsTables" xlink:title="00000024 - Disclosure - 5. Fair Value Measurements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables" xlink:title="00000025 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - 9. Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/NetLossPerShareTables" xlink:title="00000027 - Disclosure - 10. Net Loss per Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative" xlink:title="00000028 - Disclosure - 1. Business and Principal Activities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_UnderwriterMember" xlink:label="loc_RNXTUnderwriterMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_RNXTUnderwriterMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_OverAllotmentOptionsMember" xlink:label="loc_RNXTOverAllotmentOptionsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RNXTOverAllotmentOptionsMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_UnderwritingDiscountsAndCommissions" xlink:label="loc_RNXTUnderwritingDiscountsAndCommissions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RNXTUnderwritingDiscountsAndCommissions_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOtherExpenses_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_NetProceedsFromIntialPublicOffering" xlink:label="loc_RNXTNetProceedsFromIntialPublicOffering_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RNXTNetProceedsFromIntialPublicOffering_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_MaximumPossibleProceedsFromOfferings" xlink:label="loc_RNXTMaximumPossibleProceedsFromOfferings_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RNXTMaximumPossibleProceedsFromOfferings_100" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_RenovoCathMember" xlink:label="loc_RNXTRenovoCathMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_RNXTRenovoCathMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_PaymentsReceivedFromClinicalSites" xlink:label="loc_RNXTPaymentsReceivedFromClinicalSites_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTPaymentsReceivedFromClinicalSites_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails" xlink:title="00000030 - Disclosure - Schedule of Short-Term Marketable Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapMarketableSecuritiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000031 - Disclosure - Schedule of Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000032 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure_210" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails" xlink:title="00000033 - Disclosure - Schedule of Changes in Fair value of Derivative Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="00000034 - Disclosure - 5. Fair Value Measurements (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ConvertibleNotesDetailsNarrative" xlink:title="00000035 - Disclosure - 6. Convertible Notes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_NotePurchaseAgreementMember" xlink:label="loc_RNXTNotePurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RNXTNotePurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyConvertibleNotesMember" xlink:label="loc_RNXTTwoThousandAndTwentyConvertibleNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RNXTTwoThousandAndTwentyConvertibleNotesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" xlink:label="loc_RNXTTwoThousandAndTwentyAndTwentyOneConvertibleNotesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RNXTTwoThousandAndTwentyAndTwentyOneConvertibleNotesMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyOneConvertibleNotesMember" xlink:label="loc_RNXTTwoThousandAndTwentyOneConvertibleNotesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RNXTTwoThousandAndTwentyOneConvertibleNotesMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" xlink:label="loc_RNXTTwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RNXTTwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes" xlink:label="loc_RNXTMaximumPossibleTotalProceedsFromConvertibleNotes_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_RNXTMaximumPossibleTotalProceedsFromConvertibleNotes_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseNet_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_200" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - 7. Commitments and Contingencies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails" xlink:title="00000037 - Disclosure - Summary of Stock Option Award Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails" xlink:title="00000038 - Disclosure - Schedule of Ranges of Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeOneMember" xlink:label="loc_RNXTExercisePriceRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeTwoMember" xlink:label="loc_RNXTExercisePriceRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeThreeMember" xlink:label="loc_RNXTExercisePriceRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeFourMember" xlink:label="loc_RNXTExercisePriceRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeFiveMember" xlink:label="loc_RNXTExercisePriceRangeFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeSixMember" xlink:label="loc_RNXTExercisePriceRangeSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeSevenMember" xlink:label="loc_RNXTExercisePriceRangeSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_170" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails" xlink:title="00000039 - Disclosure - Schedule of Estimate Fair Value of Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="00000040 - Disclosure - Schedule of Stock Based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000041 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative" xlink:title="00000042 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_OmnibusEquityIncentivePlan2021Member" xlink:label="loc_RNXTOmnibusEquityIncentivePlan2021Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RNXTOmnibusEquityIncentivePlan2021Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyOnePlanMember" xlink:label="loc_RNXTTwoThousandAndTwentyOnePlanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RNXTTwoThousandAndTwentyOnePlanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_UnderwriterMember" xlink:label="loc_RNXTUnderwriterMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_RNXTUnderwriterMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_WarrantOneMember" xlink:label="loc_RNXTWarrantOneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RNXTWarrantOneMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_WarrantTwoMember" xlink:label="loc_RNXTWarrantTwoMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RNXTWarrantTwoMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_110" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails" xlink:title="00000043 - Disclosure - Schedule of Statutory Tax Expense and Effective Tax Expense Benefit (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000044 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="00000045 - Disclosure - Schedule Of Unrecognized Tax Benefits (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000046 - Disclosure - 9. Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_FederalAndStateMember" xlink:label="loc_RNXTFederalAndStateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_RNXTFederalAndStateMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_CaliforniaTaxCreditMember" xlink:label="loc_RNXTCaliforniaTaxCreditMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_RNXTCaliforniaTaxCreditMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsForeign_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsForeign_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayDescription" xlink:label="loc_us-gaapIncomeTaxHolidayDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxHolidayDescription_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="00000047 - Disclosure - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails" xlink:title="00000048 - Disclosure - Schedule of Potentially Anti Dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000049 - Disclosure - 11. Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DrAgahMember" xlink:label="loc_RNXTDrAgahMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RNXTDrAgahMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ConsultingAgreementMember" xlink:label="loc_RNXTConsultingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RNXTConsultingAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_CashCompensation" xlink:label="loc_RNXTCashCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RNXTCashCompensation_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProfessionalFees_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DiscretionaryBonus" xlink:label="loc_RNXTDiscretionaryBonus_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RNXTDiscretionaryBonus_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="00000050 - Disclosure - 12. Employee Benefit Plans (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovorx.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000051 - Disclosure - 13. Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DefinitiveSecuritiesPurchaseAgreementMember" xlink:label="loc_RNXTDefinitiveSecuritiesPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RNXTDefinitiveSecuritiesPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssued_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_30" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>32
<FILENAME>rnxt-20221231_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_UnderwriterMember" xlink:label="RNXT_UnderwriterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_UnderwriterMember" xlink:to="RNXT_UnderwriterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_UnderwriterMember_lbl" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_OverAllotmentOptionsMember" xlink:label="RNXT_OverAllotmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_OverAllotmentOptionsMember" xlink:to="RNXT_OverAllotmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_OverAllotmentOptionsMember_lbl" xml:lang="en-US">Over Allotment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_RenovoCathMember" xlink:label="RNXT_RenovoCathMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_RenovoCathMember" xlink:to="RNXT_RenovoCathMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_RenovoCathMember_lbl" xml:lang="en-US">RenovoCath [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_NotePurchaseAgreementMember" xlink:label="RNXT_NotePurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_NotePurchaseAgreementMember" xlink:to="RNXT_NotePurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_NotePurchaseAgreementMember_lbl" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyConvertibleNotesMember" xlink:label="RNXT_TwoThousandAndTwentyConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyConvertibleNotesMember" xlink:to="RNXT_TwoThousandAndTwentyConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_TwoThousandAndTwentyConvertibleNotesMember_lbl" xml:lang="en-US">2020 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" xlink:label="RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" xlink:to="RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember_lbl" xml:lang="en-US">2020 and 2021 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyOneConvertibleNotesMember" xlink:label="RNXT_TwoThousandAndTwentyOneConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyOneConvertibleNotesMember" xlink:to="RNXT_TwoThousandAndTwentyOneConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_TwoThousandAndTwentyOneConvertibleNotesMember_lbl" xml:lang="en-US">2021 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" xlink:label="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" xlink:to="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_lbl" xml:lang="en-US">2020 and 2021 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_OmnibusEquityIncentivePlan2021Member" xlink:label="RNXT_OmnibusEquityIncentivePlan2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_OmnibusEquityIncentivePlan2021Member" xlink:to="RNXT_OmnibusEquityIncentivePlan2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_OmnibusEquityIncentivePlan2021Member_lbl" xml:lang="en-US">2021 Omnibus Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyOnePlanMember" xlink:label="RNXT_TwoThousandAndTwentyOnePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyOnePlanMember" xlink:to="RNXT_TwoThousandAndTwentyOnePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_TwoThousandAndTwentyOnePlanMember_lbl" xml:lang="en-US">2021 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_WarrantOneMember" xlink:label="RNXT_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_WarrantOneMember" xlink:to="RNXT_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_WarrantOneMember_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_WarrantTwoMember" xlink:label="RNXT_WarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_WarrantTwoMember" xlink:to="RNXT_WarrantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_WarrantTwoMember_lbl" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeOneMember" xlink:label="RNXT_ExercisePriceRangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeOneMember" xlink:to="RNXT_ExercisePriceRangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeTwoMember" xlink:label="RNXT_ExercisePriceRangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeTwoMember" xlink:to="RNXT_ExercisePriceRangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeThreeMember" xlink:label="RNXT_ExercisePriceRangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeThreeMember" xlink:to="RNXT_ExercisePriceRangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeFourMember" xlink:label="RNXT_ExercisePriceRangeFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeFourMember" xlink:to="RNXT_ExercisePriceRangeFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ExercisePriceRangeFourMember_lbl" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeFiveMember" xlink:label="RNXT_ExercisePriceRangeFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeFiveMember" xlink:to="RNXT_ExercisePriceRangeFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ExercisePriceRangeFiveMember_lbl" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeSixMember" xlink:label="RNXT_ExercisePriceRangeSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeSixMember" xlink:to="RNXT_ExercisePriceRangeSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ExercisePriceRangeSixMember_lbl" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeSevenMember" xlink:label="RNXT_ExercisePriceRangeSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeSevenMember" xlink:to="RNXT_ExercisePriceRangeSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ExercisePriceRangeSevenMember_lbl" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_FederalAndStateMember" xlink:label="RNXT_FederalAndStateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_FederalAndStateMember" xlink:to="RNXT_FederalAndStateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_FederalAndStateMember_lbl" xml:lang="en-US">Federal and state [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_CaliforniaTaxCreditMember" xlink:label="RNXT_CaliforniaTaxCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_CaliforniaTaxCreditMember" xlink:to="RNXT_CaliforniaTaxCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_CaliforniaTaxCreditMember_lbl" xml:lang="en-US">California [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DrAgahMember" xlink:label="RNXT_DrAgahMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DrAgahMember" xlink:to="RNXT_DrAgahMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_DrAgahMember_lbl" xml:lang="en-US">Dr.Agah [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ConsultingAgreementMember" xlink:label="RNXT_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ConsultingAgreementMember" xlink:to="RNXT_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DefinitiveSecuritiesPurchaseAgreementMember" xlink:label="RNXT_DefinitiveSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DefinitiveSecuritiesPurchaseAgreementMember" xlink:to="RNXT_DefinitiveSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_DefinitiveSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Definitive Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Short-term marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Convertible preferred stock and stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible preferred stock, $0.0001 par value; 15,000,000 shares authorized as of December 31, 2022 and 2021, respectively; zero shares issued and outstanding at December 31, 2022 and 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2022, and 2021, respectively; 9,097,701 and 8,933,989 shares issued and outstanding as of December 31, 2022, and 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total convertible preferred stock and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on loan extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax_lbl" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average shares of common stock outstanding, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:label="RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:to="RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:label="RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:to="RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible notes and accrued interest to units upon initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible notes and accrued interest to common stock upon initial public offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" xlink:label="RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" xlink:to="RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes_lbl" xml:lang="en-US">Reclassification of derivative liability upon conversion of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Proceeds from initial public offering, net of underwriters&#8217; commissions, discounts and issuance costs of $2,090</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Proceeds from initial public offering, net of underwriters commissions, discounts and issuance costs of $2,090, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="RNXT_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="RNXT_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants issued upon initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodsharesWarrantsExercised" xlink:label="RNXT_StockIssuedDuringPeriodsharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_StockIssuedDuringPeriodsharesWarrantsExercised" xlink:to="RNXT_StockIssuedDuringPeriodsharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_StockIssuedDuringPeriodsharesWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants issued upon initial public offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="RNXT_StockIssuedDuringPeriodValueReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="RNXT_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US">Reverse stock split adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Reverse stock split adjustment, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock awards, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet" xlink:label="RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet" xlink:to="RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet_lbl" xml:lang="en-US">Discount and issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_AmortizationOnLeaseholdImprovement" xlink:label="RNXT_AmortizationOnLeaseholdImprovement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_AmortizationOnLeaseholdImprovement" xlink:to="RNXT_AmortizationOnLeaseholdImprovement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_AmortizationOnLeaseholdImprovement_lbl" xml:lang="en-US">Amortization on leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_GainOnChangeInFairValueOfDerivativeLiability" xlink:label="RNXT_GainOnChangeInFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_GainOnChangeInFairValueOfDerivativeLiability" xlink:to="RNXT_GainOnChangeInFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RNXT_GainOnChangeInFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Gain on change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_GainOnLoanExtinguishmentFromPppLoan" xlink:label="RNXT_GainOnLoanExtinguishmentFromPppLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_GainOnLoanExtinguishmentFromPppLoan" xlink:to="RNXT_GainOnLoanExtinguishmentFromPppLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RNXT_GainOnLoanExtinguishmentFromPppLoan_lbl" xml:lang="en-US">Gain on loan extinguishment from PPP loan</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_LossOnLoanExtinguishment" xlink:label="RNXT_LossOnLoanExtinguishment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_LossOnLoanExtinguishment" xlink:to="RNXT_LossOnLoanExtinguishment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_LossOnLoanExtinguishment_lbl" xml:lang="en-US">Loss on loan extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchases of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_PaymentsForLeaseholdImprovements" xlink:label="RNXT_PaymentsForLeaseholdImprovements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_PaymentsForLeaseholdImprovements" xlink:to="RNXT_PaymentsForLeaseholdImprovements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RNXT_PaymentsForLeaseholdImprovements_lbl" xml:lang="en-US">Expenditures for leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds from issuance of common stock upon initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and cash equivalents:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">End of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental cash flow data:</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DerivativeLiabilityInFinancingActivities" xlink:label="RNXT_DerivativeLiabilityInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DerivativeLiabilityInFinancingActivities" xlink:to="RNXT_DerivativeLiabilityInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_DerivativeLiabilityInFinancingActivities_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:label="RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:to="RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering_lbl" xml:lang="en-US">Conversion of convertible preferred stock upon IPO</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering" xlink:label="RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering" xlink:to="RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering_lbl" xml:lang="en-US">Conversion of convertible notes upon IPO</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">1. Business and Principal Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">2. Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">3. Short-Term Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">4. Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">5. Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">6. Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">7. Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">9. Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">10. Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">11. Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">12. Employee Benefit Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">13. Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_RisksAndUncertaintiesPolicyTextBlock" xlink:label="RNXT_RisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_RisksAndUncertaintiesPolicyTextBlock" xlink:to="RNXT_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk and Significant Suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Operating Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:label="RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:to="RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_LeaseholdImprovementsPolicyTextBlock" xlink:label="RNXT_LeaseholdImprovementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_LeaseholdImprovementsPolicyTextBlock" xlink:to="RNXT_LeaseholdImprovementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_LeaseholdImprovementsPolicyTextBlock_lbl" xml:lang="en-US">Leasehold Improvements, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ClinicalTrialExpensesPolicyTextBlock" xlink:label="RNXT_ClinicalTrialExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ClinicalTrialExpensesPolicyTextBlock" xlink:to="RNXT_ClinicalTrialExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ClinicalTrialExpensesPolicyTextBlock_lbl" xml:lang="en-US">Clinical Trial Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ConvertiblePreferredStockPolicyTextBlock" xlink:label="RNXT_ConvertiblePreferredStockPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ConvertiblePreferredStockPolicyTextBlock" xlink:to="RNXT_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US">Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" xlink:label="RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" xlink:to="RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_lbl" xml:lang="en-US">Emerging Growth Company and Smaller Reporting Company Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of Short-Term Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Fair value of Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Award Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Ranges of Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimate Fair Value of Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Schedule of Stock Based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Statutory Tax Expense and Effective Tax Expense Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Anti Dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and rights outstanding, term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Over allotment option to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of warrant or right, number of securities called by each warrant or right</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Aggregate gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_UnderwritingDiscountsAndCommissions" xlink:label="RNXT_UnderwritingDiscountsAndCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_UnderwritingDiscountsAndCommissions" xlink:to="RNXT_UnderwritingDiscountsAndCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_UnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US">Underwriting discounts and commissions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_NetProceedsFromIntialPublicOffering" xlink:label="RNXT_NetProceedsFromIntialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_NetProceedsFromIntialPublicOffering" xlink:to="RNXT_NetProceedsFromIntialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_NetProceedsFromIntialPublicOffering_lbl" xml:lang="en-US">Net proceeds from intial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Debt instrument, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt conversion, converted instrument, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders equity, reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from sale of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash and cash equivalents, and Marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_MaximumPossibleProceedsFromOfferings" xlink:label="RNXT_MaximumPossibleProceedsFromOfferings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_MaximumPossibleProceedsFromOfferings" xlink:to="RNXT_MaximumPossibleProceedsFromOfferings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_MaximumPossibleProceedsFromOfferings_lbl" xml:lang="en-US">Maximum possible proceeds from offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_PaymentsReceivedFromClinicalSites" xlink:label="RNXT_PaymentsReceivedFromClinicalSites" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_PaymentsReceivedFromClinicalSites" xlink:to="RNXT_PaymentsReceivedFromClinicalSites_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RNXT_PaymentsReceivedFromClinicalSites_lbl" xml:lang="en-US">Payments received from clinical sites</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Short-term marketable securities, amortized cost basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Short-term marketable securities, unrealized gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Short-term marketable securities, unrealized losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Short-term marketable securities, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_AccruedClinicalTrialsCurrent" xlink:label="RNXT_AccruedClinicalTrialsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_AccruedClinicalTrialsCurrent" xlink:to="RNXT_AccruedClinicalTrialsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_AccruedClinicalTrialsCurrent_lbl" xml:lang="en-US">Clinical trial</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Employee benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Fair value of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xml:lang="en-US">Fair value, beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_lbl" xml:lang="en-US">Initial fair value of instruments issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value of instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_lbl" xml:lang="en-US">Conversion upon IPO</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2_lbl" xml:lang="en-US">Fair value, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market funds, at carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt instrument, maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes" xlink:label="RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes" xlink:to="RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes_lbl" xml:lang="en-US">Maximum possible total proceeds from convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Debt conversion price percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt effective interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of stock, shares converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lessee, operating lease, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease, rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of stock options outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of stock options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Number of stock options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of stock options, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of stock options outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of stock options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of stock options, vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, vested and expected</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, lower range</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, upper range</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average remaining contractual life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average remaining contractual life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1" xlink:to="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Warrants aggregate intrinsic value, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants outstanding, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants outstanding, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, execised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants outstanding, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4_lbl" xml:lang="en-US">Weighted average exercise price, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm" xlink:to="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual life, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Warrants aggregate intrinsic value, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of shares reserved</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Common shares reserved but unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Restricted common stock granted, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Restricted common stock granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xml:lang="en-US">Warrants to purchase common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrant maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory federal income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_PermanentItems" xlink:label="RNXT_PermanentItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_PermanentItems" xlink:to="RNXT_PermanentItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_PermanentItems_lbl" xml:lang="en-US">Permanent items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior year true ups</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credits carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Fixed assets/intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DeferredTaxAssetsCharitableContributions" xlink:label="RNXT_DeferredTaxAssetsCharitableContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DeferredTaxAssetsCharitableContributions" xlink:to="RNXT_DeferredTaxAssetsCharitableContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_DeferredTaxAssetsCharitableContributions_lbl" xml:lang="en-US">Charitable contributions</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DeferredTaxAssetsCapitalizedResearch" xlink:label="RNXT_DeferredTaxAssetsCapitalizedResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DeferredTaxAssetsCapitalizedResearch" xlink:to="RNXT_DeferredTaxAssetsCapitalizedResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_DeferredTaxAssetsCapitalizedResearch_lbl" xml:lang="en-US">Capitalized research</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl" xml:lang="en-US">Accruals and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_lbl" xml:lang="en-US">Unrealized gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Beginning unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_UnrecognizedTaxBenefitsAdditions" xlink:label="RNXT_UnrecognizedTaxBenefitsAdditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_UnrecognizedTaxBenefitsAdditions" xlink:to="RNXT_UnrecognizedTaxBenefitsAdditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_UnrecognizedTaxBenefitsAdditions_lbl" xml:lang="en-US">Additions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_2_lbl" xml:lang="en-US">Ending unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Net operating loss carryforward, federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Net operating loss carryforward, state</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xml:lang="en-US">Federal and state tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl" xml:lang="en-US">Tax credit carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_3_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayDescription" xlink:label="us-gaap_IncomeTaxHolidayDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayDescription" xlink:to="us-gaap_IncomeTaxHolidayDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayDescription_lbl" xml:lang="en-US">Income tax, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average shares used in computing net loss per share &#8211; basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Net loss per share &#8211; basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award, options, outstanding, number</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_CashCompensation" xlink:label="RNXT_CashCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_CashCompensation" xlink:to="RNXT_CashCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_CashCompensation_lbl" xml:lang="en-US">Cash compensation per month</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Consulting fees</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DiscretionaryBonus" xlink:label="RNXT_DiscretionaryBonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DiscretionaryBonus" xlink:to="RNXT_DiscretionaryBonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_DiscretionaryBonus_lbl" xml:lang="en-US">Discretionary bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Defined contribution plan cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Stock warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" xlink:to="RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes_doc" xml:lang="en-US">Reclassification of derivative liability upon conversion of convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet" xlink:to="RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet_doc" xml:lang="en-US">Issuance of initial public offering of underwriter, commissions and discounts,net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="RNXT_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Issuance of common stock upon exercise of warrants issued upon initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_StockIssuedDuringPeriodsharesWarrantsExercised" xlink:to="RNXT_StockIssuedDuringPeriodsharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_StockIssuedDuringPeriodsharesWarrantsExercised_doc" xml:lang="en-US">Issuance of common stock upon exercise of stock options, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="RNXT_StockIssuedDuringPeriodValueReverseStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_StockIssuedDuringPeriodValueReverseStockSplits_doc" xml:lang="en-US">Issuance of common stock upon exercise of stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:to="RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_doc" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_AmortizationOnLeaseholdImprovement" xlink:to="RNXT_AmortizationOnLeaseholdImprovement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_AmortizationOnLeaseholdImprovement_doc" xml:lang="en-US">Amortization on leasehold improvement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_GainOnLoanExtinguishmentFromPppLoan" xlink:to="RNXT_GainOnLoanExtinguishmentFromPppLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_GainOnLoanExtinguishmentFromPppLoan_doc" xml:lang="en-US">Gain on loan extinguishment from PPP loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_GainOnChangeInFairValueOfDerivativeLiability" xlink:to="RNXT_GainOnChangeInFairValueOfDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_GainOnChangeInFairValueOfDerivativeLiability_doc" xml:lang="en-US">Gain on change in fair value of derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_LossOnLoanExtinguishment" xlink:to="RNXT_LossOnLoanExtinguishment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_LossOnLoanExtinguishment_doc" xml:lang="en-US">Loss on loan extinguishment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_PaymentsForLeaseholdImprovements" xlink:to="RNXT_PaymentsForLeaseholdImprovements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_PaymentsForLeaseholdImprovements_doc" xml:lang="en-US">Payments for lease hold improvements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DerivativeLiabilityInFinancingActivities" xlink:to="RNXT_DerivativeLiabilityInFinancingActivities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_DerivativeLiabilityInFinancingActivities_doc" xml:lang="en-US">Derivative liability in financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:to="RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering_doc" xml:lang="en-US">Conversion of convertible preferred stock upon initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering" xlink:to="RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering_doc" xml:lang="en-US">Conversion of convertible notes upon initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_UnderwriterMember" xlink:to="RNXT_UnderwriterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_UnderwriterMember_doc" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_OverAllotmentOptionsMember" xlink:to="RNXT_OverAllotmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_OverAllotmentOptionsMember_doc" xml:lang="en-US">Over Allotment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_NetProceedsFromIntialPublicOffering" xlink:to="RNXT_NetProceedsFromIntialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_NetProceedsFromIntialPublicOffering_doc" xml:lang="en-US">Net proceeds from intial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_UnderwritingDiscountsAndCommissions" xlink:to="RNXT_UnderwritingDiscountsAndCommissions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_UnderwritingDiscountsAndCommissions_doc" xml:lang="en-US">Underwriting discounts and commissions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_RisksAndUncertaintiesPolicyTextBlock" xlink:to="RNXT_RisksAndUncertaintiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_RisksAndUncertaintiesPolicyTextBlock_doc" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_LeaseholdImprovementsPolicyTextBlock" xlink:to="RNXT_LeaseholdImprovementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_LeaseholdImprovementsPolicyTextBlock_doc" xml:lang="en-US">Leasehold Improvements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ClinicalTrialExpensesPolicyTextBlock" xlink:to="RNXT_ClinicalTrialExpensesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ClinicalTrialExpensesPolicyTextBlock_doc" xml:lang="en-US">Clinical Trial Expenses [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ConvertiblePreferredStockPolicyTextBlock" xlink:to="RNXT_ConvertiblePreferredStockPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ConvertiblePreferredStockPolicyTextBlock_doc" xml:lang="en-US">Convertible Preferred Stock [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_AccruedClinicalTrialsCurrent" xlink:to="RNXT_AccruedClinicalTrialsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_AccruedClinicalTrialsCurrent_doc" xml:lang="en-US">Accrued clinical trials current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_RenovoCathMember" xlink:to="RNXT_RenovoCathMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_RenovoCathMember_doc" xml:lang="en-US">RenovoCath [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_NotePurchaseAgreementMember" xlink:to="RNXT_NotePurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_NotePurchaseAgreementMember_doc" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyConvertibleNotesMember" xlink:to="RNXT_TwoThousandAndTwentyConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_TwoThousandAndTwentyConvertibleNotesMember_doc" xml:lang="en-US">2020 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" xlink:to="RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember_doc" xml:lang="en-US">2020 and 2021 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyOneConvertibleNotesMember" xlink:to="RNXT_TwoThousandAndTwentyOneConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_TwoThousandAndTwentyOneConvertibleNotesMember_doc" xml:lang="en-US">2021 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" xlink:to="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_doc" xml:lang="en-US">2020 and 2021 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_OmnibusEquityIncentivePlan2021Member" xlink:to="RNXT_OmnibusEquityIncentivePlan2021Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_OmnibusEquityIncentivePlan2021Member_doc" xml:lang="en-US">2021 Omnibus Equity Incentive Plan [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeOneMember" xlink:to="RNXT_ExercisePriceRangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ExercisePriceRangeOneMember_doc" xml:lang="en-US">Type of estimate of range of exercise prices, one including, but not limited to, upper and lower bound amounts, maximum and minimum amounts, and point estimates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeTwoMember" xlink:to="RNXT_ExercisePriceRangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ExercisePriceRangeTwoMember_doc" xml:lang="en-US">Type of estimate of range of exercise prices, one including, but not limited to, upper and lower bound amounts, maximum and minimum amounts, and point estimates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeThreeMember" xlink:to="RNXT_ExercisePriceRangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ExercisePriceRangeThreeMember_doc" xml:lang="en-US">Type of estimate of range of exercise prices, one including, but not limited to, upper and lower bound amounts, maximum and minimum amounts, and point estimates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeFourMember" xlink:to="RNXT_ExercisePriceRangeFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ExercisePriceRangeFourMember_doc" xml:lang="en-US">Type of estimate of range of exercise prices, one including, but not limited to, upper and lower bound amounts, maximum and minimum amounts, and point estimates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeFiveMember" xlink:to="RNXT_ExercisePriceRangeFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ExercisePriceRangeFiveMember_doc" xml:lang="en-US">Type of estimate of range of exercise prices, one including, but not limited to, upper and lower bound amounts, maximum and minimum amounts, and point estimates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeSixMember" xlink:to="RNXT_ExercisePriceRangeSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ExercisePriceRangeSixMember_doc" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ExercisePriceRangeSevenMember" xlink:to="RNXT_ExercisePriceRangeSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ExercisePriceRangeSevenMember_doc" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyOnePlanMember" xlink:to="RNXT_TwoThousandAndTwentyOnePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_TwoThousandAndTwentyOnePlanMember_doc" xml:lang="en-US">2021 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_WarrantOneMember" xlink:to="RNXT_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_WarrantOneMember_doc" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_WarrantTwoMember" xlink:to="RNXT_WarrantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_WarrantTwoMember_doc" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options expired in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm" xlink:to="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options grants in period weighted average contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1" xlink:to="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options grants in period weighted average contractual term 1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_PermanentItems" xlink:to="RNXT_PermanentItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_PermanentItems_doc" xml:lang="en-US">Permanent Items.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DeferredTaxAssetsCharitableContributions" xlink:to="RNXT_DeferredTaxAssetsCharitableContributions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_DeferredTaxAssetsCharitableContributions_doc" xml:lang="en-US">Deferred tax assets charitable contributions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_FederalAndStateMember" xlink:to="RNXT_FederalAndStateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_FederalAndStateMember_doc" xml:lang="en-US">Federal and state [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_CaliforniaTaxCreditMember" xlink:to="RNXT_CaliforniaTaxCreditMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_CaliforniaTaxCreditMember_doc" xml:lang="en-US">California [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_UnrecognizedTaxBenefitsAdditions" xlink:to="RNXT_UnrecognizedTaxBenefitsAdditions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_UnrecognizedTaxBenefitsAdditions_doc" xml:lang="en-US">Unrecognized tax benefits additions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DrAgahMember" xlink:to="RNXT_DrAgahMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_DrAgahMember_doc" xml:lang="en-US">DrAgah [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_ConsultingAgreementMember" xlink:to="RNXT_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DeferredCompensationArrangementWithIndividualCashAwardGrantedPerMonthAmount" xlink:label="RNXT_DeferredCompensationArrangementWithIndividualCashAwardGrantedPerMonthAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DeferredCompensationArrangementWithIndividualCashAwardGrantedPerMonthAmount" xlink:to="RNXT_DeferredCompensationArrangementWithIndividualCashAwardGrantedPerMonthAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_DeferredCompensationArrangementWithIndividualCashAwardGrantedPerMonthAmount_doc" xml:lang="en-US">Deferred compensation arrangement with individual cash award granted per month amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" xlink:to="RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_doc" xml:lang="en-US">Emerging Growth Company and Smaller Reporting Company Status [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_EstimatedOfferingCostsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:label="RNXT_EstimatedOfferingCostsAfterDeductingUnderwritingDiscountsAndCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_EstimatedOfferingCostsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:to="RNXT_EstimatedOfferingCostsAfterDeductingUnderwritingDiscountsAndCommissions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_EstimatedOfferingCostsAfterDeductingUnderwritingDiscountsAndCommissions_doc" xml:lang="en-US">Estimate offering costs after deducting underwriting discounts and commissions.</link:label>
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_AggregateNetProceedsFromOfferingCosts" xlink:label="RNXT_AggregateNetProceedsFromOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_AggregateNetProceedsFromOfferingCosts" xlink:to="RNXT_AggregateNetProceedsFromOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_AggregateNetProceedsFromOfferingCosts_doc" xml:lang="en-US">Aggregate net proceeds from offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DeferredTaxAssetsCapitalizedResearch" xlink:to="RNXT_DeferredTaxAssetsCapitalizedResearch_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_DeferredTaxAssetsCapitalizedResearch_doc" xml:lang="en-US">Deferred tax assets capitalized research.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:to="RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_doc" xml:lang="en-US">Stock issued during period value conversion of convertible preferred stock to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:to="RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock_doc" xml:lang="en-US">Cash, Cash Equivalents and Investments [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_PaymentsReceivedFromClinicalSites" xlink:to="RNXT_PaymentsReceivedFromClinicalSites_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_PaymentsReceivedFromClinicalSites_doc" xml:lang="en-US">Payments received from clinical sites.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes" xlink:to="RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes_doc" xml:lang="en-US">Maximum possible total proceeds from convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_CashCompensation" xlink:to="RNXT_CashCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_CashCompensation_doc" xml:lang="en-US">Cash compensation per month.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DiscretionaryBonus" xlink:to="RNXT_DiscretionaryBonus_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_DiscretionaryBonus_doc" xml:lang="en-US">Discretionary bonus.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_MaximumPossibleProceedsFromOfferings" xlink:to="RNXT_MaximumPossibleProceedsFromOfferings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_MaximumPossibleProceedsFromOfferings_doc" xml:lang="en-US">Maximum possible proceeds from offerings.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_DefinitiveSecuritiesPurchaseAgreementMember" xlink:to="RNXT_DefinitiveSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RNXT_DefinitiveSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Definitive Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" xlink:to="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_3_lbl" xml:lang="en-US">2020 and 2021 Convertible Notes [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_GainOnChangeInFairValueOfDerivativeLiability" xlink:to="RNXT_GainOnChangeInFairValueOfDerivativeLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_GainOnChangeInFairValueOfDerivativeLiability_3_lbl" xml:lang="en-US">GainOnChangeInFairValueOfDerivativeLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_GainOnLoanExtinguishmentFromPppLoan" xlink:to="RNXT_GainOnLoanExtinguishmentFromPppLoan_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_GainOnLoanExtinguishmentFromPppLoan_3_lbl" xml:lang="en-US">GainOnLoanExtinguishmentFromPppLoan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_PaymentsForLeaseholdImprovements" xlink:to="RNXT_PaymentsForLeaseholdImprovements_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_PaymentsForLeaseholdImprovements_3_lbl" xml:lang="en-US">PaymentsForLeaseholdImprovements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RNXT_PaymentsReceivedFromClinicalSites" xlink:to="RNXT_PaymentsReceivedFromClinicalSites_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RNXT_PaymentsReceivedFromClinicalSites_3_lbl" xml:lang="en-US">PaymentsReceivedFromClinicalSites</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3_lbl" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_2_lbl" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Interest Income (Expense), Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>33
<FILENAME>rnxt-20221231_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://renovorx.com/role/Cover" xlink:href="rnxt-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BalanceSheets" xlink:href="rnxt-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BalanceSheetsParenthetical" xlink:href="rnxt-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="rnxt-20221231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:href="rnxt-20221231.xsd#StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="rnxt-20221231.xsd#StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/StatementsOfCashFlows" xlink:href="rnxt-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BusinessAndPrincipalActivities" xlink:href="rnxt-20221231.xsd#BusinessAndPrincipalActivities" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="rnxt-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/Short-termMarketableSecurities" xlink:href="rnxt-20221231.xsd#Short-termMarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/AccruedExpenses" xlink:href="rnxt-20221231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/FairValueMeasurements" xlink:href="rnxt-20221231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ConvertibleNotes" xlink:href="rnxt-20221231.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/CommitmentsAndContingencies" xlink:href="rnxt-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants" xlink:href="rnxt-20221231.xsd#EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/IncomeTaxes" xlink:href="rnxt-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/NetLossPerShare" xlink:href="rnxt-20221231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/RelatedPartyTransactions" xlink:href="rnxt-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EmployeeBenefitPlans" xlink:href="rnxt-20221231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SubsequentEvents" xlink:href="rnxt-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rnxt-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/Short-termMarketableSecuritiesTables" xlink:href="rnxt-20221231.xsd#Short-termMarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/AccruedExpensesTables" xlink:href="rnxt-20221231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/FairValueMeasurementsTables" xlink:href="rnxt-20221231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables" xlink:href="rnxt-20221231.xsd#EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/IncomeTaxesTables" xlink:href="rnxt-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/NetLossPerShareTables" xlink:href="rnxt-20221231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative" xlink:href="rnxt-20221231.xsd#BusinessAndPrincipalActivitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="rnxt-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfShort-termMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="rnxt-20221231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ConvertibleNotesDetailsNarrative" xlink:href="rnxt-20221231.xsd#ConvertibleNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="rnxt-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails" xlink:href="rnxt-20221231.xsd#SummaryOfStockOptionAwardActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfRangesOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfEstimateFairValueOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfWarrantActivityDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative" xlink:href="rnxt-20221231.xsd#EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/IncomeTaxesDetailsNarrative" xlink:href="rnxt-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails" xlink:href="rnxt-20221231.xsd#ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="rnxt-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:href="rnxt-20221231.xsd#EmployeeBenefitPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovorx.com/role/SubsequentEventsDetailsNarrative" xlink:href="rnxt-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:title="00000005 - Statement - Statements of Convertible Preferred Stock and Stockholders&apos; (Deficit) Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:label="loc_RNXTStockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTStockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:label="loc_RNXTStockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTStockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" xlink:label="loc_RNXTAdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTAdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_RNXTStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodsharesWarrantsExercised" xlink:label="loc_RNXTStockIssuedDuringPeriodsharesWarrantsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTStockIssuedDuringPeriodsharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_RNXTStockIssuedDuringPeriodValueReverseStockSplits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTStockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="00000006 - Statement - Statements of Convertible Perferred Stock and Stockholder&apos;s Equity (Deficit) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet" xlink:label="loc_RNXTIssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_RNXTIssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_AmortizationOnLeaseholdImprovement" xlink:label="loc_RNXTAmortizationOnLeaseholdImprovement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RNXTAmortizationOnLeaseholdImprovement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_GainOnChangeInFairValueOfDerivativeLiability" xlink:label="loc_RNXTGainOnChangeInFairValueOfDerivativeLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RNXTGainOnChangeInFairValueOfDerivativeLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_GainOnLoanExtinguishmentFromPppLoan" xlink:label="loc_RNXTGainOnLoanExtinguishmentFromPppLoan" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RNXTGainOnLoanExtinguishmentFromPppLoan" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_LossOnLoanExtinguishment" xlink:label="loc_RNXTLossOnLoanExtinguishment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RNXTLossOnLoanExtinguishment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_PaymentsForLeaseholdImprovements" xlink:label="loc_RNXTPaymentsForLeaseholdImprovements" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_RNXTPaymentsForLeaseholdImprovements" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DerivativeLiabilityInFinancingActivities" xlink:label="loc_RNXTDerivativeLiabilityInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_RNXTDerivativeLiabilityInFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:label="loc_RNXTConversionOfConvertiblePreferredStockUponInitialPublicOffering" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_RNXTConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering" xlink:label="loc_RNXTConversionOfConvertibleNotesUponInitialPublicOffering" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_RNXTConversionOfConvertibleNotesUponInitialPublicOffering" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/BusinessAndPrincipalActivities" xlink:title="00000008 - Disclosure - 1. Business and Principal Activities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - 2. Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/Short-termMarketableSecurities" xlink:title="00000010 - Disclosure - 3. Short-Term Marketable Securities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - 4. Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/FairValueMeasurements" xlink:title="00000012 - Disclosure - 5. Fair Value Measurements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ConvertibleNotes" xlink:title="00000013 - Disclosure - 6. Convertible Notes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - 7. Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants" xlink:title="00000015 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - 9. Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/NetLossPerShare" xlink:title="00000017 - Disclosure - 10. Net Loss per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - 11. Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/EmployeeBenefitPlans" xlink:title="00000019 - Disclosure - 12. Employee Benefit Plans">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - 13. Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_RNXTRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RNXTRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:label="loc_RNXTCashCashEquivalentsAndInvestmentsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RNXTCashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_LeaseholdImprovementsPolicyTextBlock" xlink:label="loc_RNXTLeaseholdImprovementsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RNXTLeaseholdImprovementsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ClinicalTrialExpensesPolicyTextBlock" xlink:label="loc_RNXTClinicalTrialExpensesPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RNXTClinicalTrialExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ConvertiblePreferredStockPolicyTextBlock" xlink:label="loc_RNXTConvertiblePreferredStockPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RNXTConvertiblePreferredStockPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" xlink:label="loc_RNXTEmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RNXTEmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/Short-termMarketableSecuritiesTables" xlink:title="00000022 - Disclosure - 3. Short-Term Marketable Securities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaapMarketableSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/AccruedExpensesTables" xlink:title="00000023 - Disclosure - 4. Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/FairValueMeasurementsTables" xlink:title="00000024 - Disclosure - 5. Fair Value Measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables" xlink:title="00000025 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - 9. Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/NetLossPerShareTables" xlink:title="00000027 - Disclosure - 10. Net Loss per Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative" xlink:title="00000028 - Disclosure - 1. Business and Principal Activities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_UnderwriterMember" xlink:label="loc_RNXTUnderwriterMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_RNXTUnderwriterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_OverAllotmentOptionsMember" xlink:label="loc_RNXTOverAllotmentOptionsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RNXTOverAllotmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_UnderwritingDiscountsAndCommissions" xlink:label="loc_RNXTUnderwritingDiscountsAndCommissions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RNXTUnderwritingDiscountsAndCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_NetProceedsFromIntialPublicOffering" xlink:label="loc_RNXTNetProceedsFromIntialPublicOffering" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RNXTNetProceedsFromIntialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_MaximumPossibleProceedsFromOfferings" xlink:label="loc_RNXTMaximumPossibleProceedsFromOfferings" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RNXTMaximumPossibleProceedsFromOfferings" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_RenovoCathMember" xlink:label="loc_RNXTRenovoCathMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_RNXTRenovoCathMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_PaymentsReceivedFromClinicalSites" xlink:label="loc_RNXTPaymentsReceivedFromClinicalSites" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RNXTPaymentsReceivedFromClinicalSites" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails" xlink:title="00000030 - Disclosure - Schedule of Short-Term Marketable Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapMarketableSecuritiesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000031 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_AccruedClinicalTrialsCurrent" xlink:label="loc_RNXTAccruedClinicalTrialsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_RNXTAccruedClinicalTrialsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000032 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails" xlink:title="00000033 - Disclosure - Schedule of Changes in Fair value of Derivative Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="00000034 - Disclosure - 5. Fair Value Measurements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ConvertibleNotesDetailsNarrative" xlink:title="00000035 - Disclosure - 6. Convertible Notes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_NotePurchaseAgreementMember" xlink:label="loc_RNXTNotePurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RNXTNotePurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyConvertibleNotesMember" xlink:label="loc_RNXTTwoThousandAndTwentyConvertibleNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RNXTTwoThousandAndTwentyConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" xlink:label="loc_RNXTTwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RNXTTwoThousandAndTwentyAndTwentyOneConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyOneConvertibleNotesMember" xlink:label="loc_RNXTTwoThousandAndTwentyOneConvertibleNotesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RNXTTwoThousandAndTwentyOneConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" xlink:label="loc_RNXTTwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RNXTTwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes" xlink:label="loc_RNXTMaximumPossibleTotalProceedsFromConvertibleNotes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_RNXTMaximumPossibleTotalProceedsFromConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - 7. Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails" xlink:title="00000037 - Disclosure - Summary of Stock Option Award Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails" xlink:title="00000038 - Disclosure - Schedule of Ranges of Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeOneMember" xlink:label="loc_RNXTExercisePriceRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeTwoMember" xlink:label="loc_RNXTExercisePriceRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeThreeMember" xlink:label="loc_RNXTExercisePriceRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeFourMember" xlink:label="loc_RNXTExercisePriceRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeFiveMember" xlink:label="loc_RNXTExercisePriceRangeFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeSixMember" xlink:label="loc_RNXTExercisePriceRangeSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ExercisePriceRangeSevenMember" xlink:label="loc_RNXTExercisePriceRangeSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RNXTExercisePriceRangeSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails" xlink:title="00000039 - Disclosure - Schedule of Estimate Fair Value of Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="00000040 - Disclosure - Schedule of Stock Based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000041 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1" xlink:label="loc_RNXTShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_RNXTShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_RNXTShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_RNXTShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_RNXTShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_RNXTShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_RNXTShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_RNXTShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm" xlink:label="loc_RNXTShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_RNXTShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative" xlink:title="00000042 - Disclosure - 8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_OmnibusEquityIncentivePlan2021Member" xlink:label="loc_RNXTOmnibusEquityIncentivePlan2021Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RNXTOmnibusEquityIncentivePlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_TwoThousandAndTwentyOnePlanMember" xlink:label="loc_RNXTTwoThousandAndTwentyOnePlanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RNXTTwoThousandAndTwentyOnePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_UnderwriterMember" xlink:label="loc_RNXTUnderwriterMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_RNXTUnderwriterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_WarrantOneMember" xlink:label="loc_RNXTWarrantOneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RNXTWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_WarrantTwoMember" xlink:label="loc_RNXTWarrantTwoMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RNXTWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails" xlink:title="00000043 - Disclosure - Schedule of Statutory Tax Expense and Effective Tax Expense Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_PermanentItems" xlink:label="loc_RNXTPermanentItems" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RNXTPermanentItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCredits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCredits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000044 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DeferredTaxAssetsCharitableContributions" xlink:label="loc_RNXTDeferredTaxAssetsCharitableContributions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RNXTDeferredTaxAssetsCharitableContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DeferredTaxAssetsCapitalizedResearch" xlink:label="loc_RNXTDeferredTaxAssetsCapitalizedResearch" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RNXTDeferredTaxAssetsCapitalizedResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:label="loc_us-gaapDeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="00000045 - Disclosure - Schedule Of Unrecognized Tax Benefits (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_UnrecognizedTaxBenefitsAdditions" xlink:label="loc_RNXTUnrecognizedTaxBenefitsAdditions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RNXTUnrecognizedTaxBenefitsAdditions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000046 - Disclosure - 9. Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_FederalAndStateMember" xlink:label="loc_RNXTFederalAndStateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_RNXTFederalAndStateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_CaliforniaTaxCreditMember" xlink:label="loc_RNXTCaliforniaTaxCreditMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_RNXTCaliforniaTaxCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsForeign" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayDescription" xlink:label="loc_us-gaapIncomeTaxHolidayDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxHolidayDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="00000047 - Disclosure - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails" xlink:title="00000048 - Disclosure - Schedule of Potentially Anti Dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000049 - Disclosure - 11. Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DrAgahMember" xlink:label="loc_RNXTDrAgahMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RNXTDrAgahMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_ConsultingAgreementMember" xlink:label="loc_RNXTConsultingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RNXTConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_CashCompensation" xlink:label="loc_RNXTCashCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RNXTCashCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DiscretionaryBonus" xlink:label="loc_RNXTDiscretionaryBonus" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RNXTDiscretionaryBonus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="00000050 - Disclosure - 12. Employee Benefit Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaapDefinedContributionPlanCostRecognized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanCostRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovorx.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000051 - Disclosure - 13. Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="rnxt-20221231.xsd#RNXT_DefinitiveSecuritiesPurchaseAgreementMember" xlink:label="loc_RNXTDefinitiveSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RNXTDefinitiveSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531248160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RENOVORX,
INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001574094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-1448452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4546
El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite B1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Altos<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">284-4433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RNXT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Baker Tilly US, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Mountain
View, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531265920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,391<span></span>
</td>
<td class="nump">$ 15,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">2,049<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,265<span></span>
</td>
<td class="nump">16,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,265<span></span>
</td>
<td class="nump">16,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Convertible preferred stock and stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.0001 par value; 15,000,000 shares authorized as of December 31, 2022 and 2021, respectively; zero shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2022, and 2021, respectively; 9,097,701 and 8,933,989 shares issued and outstanding as of December 31, 2022, and 2021, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">37,318<span></span>
</td>
<td class="nump">36,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(31,173)<span></span>
</td>
<td class="num">(21,284)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total convertible preferred stock and stockholders&#8217; equity</a></td>
<td class="nump">6,163<span></span>
</td>
<td class="nump">15,349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity</a></td>
<td class="nump">$ 7,265<span></span>
</td>
<td class="nump">$ 16,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423530526976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value, per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">9,097,701<span></span>
</td>
<td class="nump">8,933,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">9,097,701<span></span>
</td>
<td class="nump">8,933,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value, per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423528836112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4,301<span></span>
</td>
<td class="nump">$ 3,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,649<span></span>
</td>
<td class="nump">2,632<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,950<span></span>
</td>
<td class="nump">5,671<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,950)<span></span>
</td>
<td class="num">(5,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">57<span></span>
</td>
<td class="num">(834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on loan extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses), net</a></td>
<td class="nump">61<span></span>
</td>
<td class="num">(653)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,889)<span></span>
</td>
<td class="num">(6,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (9,872)<span></span>
</td>
<td class="num">$ (6,324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic and diluted</a></td>
<td class="nump">9,051,726<span></span>
</td>
<td class="nump">5,217,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423528371168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 12,451<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (14,960)<span></span>
</td>
<td class="num">$ (14,656)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">3,535,469<span></span>
</td>
<td class="nump">2,233,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock', window );">Conversion of convertible preferred stock to common stock upon initial public offering</a></td>
<td class="num">$ (12,451)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,451<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock', window );">Conversion of convertible preferred stock to common stock upon initial public offering, shares</a></td>
<td class="num">(3,535,469)<span></span>
</td>
<td class="nump">3,535,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes and accrued interest to units upon initial public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,279<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes and accrued interest to common stock upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">708,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes', window );">Reclassification of derivative liability upon conversion of convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from initial public offering, net of underwriters&#8217; commissions, discounts and issuance costs of $2,090</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,563<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from initial public offering, net of underwriters commissions, discounts and issuance costs of $2,090, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants issued upon initial public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,681<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_StockIssuedDuringPeriodsharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants issued upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_StockIssuedDuringPeriodValueReverseStockSplits', window );">Reverse stock split adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split adjustment, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,324)<span></span>
</td>
<td class="num">(6,324)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">36,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,284)<span></span>
</td>
<td class="nump">15,349<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,933,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,889)<span></span>
</td>
<td class="num">(9,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock awards, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 37,318<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="num">$ (31,173)<span></span>
</td>
<td class="nump">$ 6,163<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,097,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability upon conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock to common stock upon initial public offering, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of warrants issued upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_StockIssuedDuringPeriodsharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of stock options, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_StockIssuedDuringPeriodsharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534581776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Convertible Perferred Stock and Stockholder's Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet', window );">Discount and issuance cost</a></td>
<td class="nump">$ 2,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of initial public offering of underwriter, commissions and discounts,net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423529593968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,889)<span></span>
</td>
<td class="num">$ (6,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_AmortizationOnLeaseholdImprovement', window );">Amortization on leasehold improvements</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_GainOnChangeInFairValueOfDerivativeLiability', window );">Gain on change in fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_GainOnLoanExtinguishmentFromPppLoan', window );">Gain on loan extinguishment from PPP loan</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_LossOnLoanExtinguishment', window );">Loss on loan extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">264<span></span>
</td>
<td class="num">(970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,811)<span></span>
</td>
<td class="num">(5,916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">5,968<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_PaymentsForLeaseholdImprovements', window );">Expenditures for leasehold improvements</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,032)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance of common stock upon initial public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">19,328<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(10,801)<span></span>
</td>
<td class="nump">13,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Beginning of year</a></td>
<td class="nump">15,192<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">End of year</a></td>
<td class="nump">4,391<span></span>
</td>
<td class="nump">15,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow data:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_DerivativeLiabilityInFinancingActivities', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering', window );">Conversion of convertible preferred stock upon IPO</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering', window );">Conversion of convertible notes upon IPO</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_AmortizationOnLeaseholdImprovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization on leasehold improvement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_AmortizationOnLeaseholdImprovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible notes upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_DerivativeLiabilityInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability in financing activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_DerivativeLiabilityInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_GainOnChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on change in fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_GainOnChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_GainOnLoanExtinguishmentFromPppLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on loan extinguishment from PPP loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_GainOnLoanExtinguishmentFromPppLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_LossOnLoanExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on loan extinguishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_LossOnLoanExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_PaymentsForLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for lease hold improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_PaymentsForLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423530520128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. Business and Principal Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">1. Business and Principal Activities</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zimEgYMKmLl8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zjxzFLXVswV5">1.
Business and Principal Activities</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Description
of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RenovoRx,
Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware in December 2012 and operates from its headquarters in Los
Altos, California. The Company is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment
of solid tumors and conducting a Phase III pancreatic cancer clinical trial for its lead product candidate RenovoGem&#8482;. The Company&#8217;s
therapy platform, RenovoRx Trans-Arterial Micro-Perfusion, or RenovoTAMP&#174; utilizes approved chemotherapeutics with validated mechanisms
of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and
widening their therapeutic window.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Initial
Public Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 25, 2021, the Company&#8217;s Registration Statement on Form S-1 (File No. 333-258071) relating to its initial public offering
(&#8220;IPO&#8221;) was declared effective and its shares of common stock began trading on the Nasdaq Capital Market on August 26, 2021.
In connection with the IPO, the Company issued and sold an aggregate of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of stock, number of shares issued in transaction">1,850,000</span> units at a price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_c20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of stock, price per share">9.00</span> per unit. Each unit consisted
of (a) one share of common stock and (b) one warrant to purchase one share of common stock at an exercise price equal to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210825__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Class of warrant or right, exercise price of warrants or rights">10.80</span> per share,
which is exercisable for a period of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210825__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zxaDHLAkknR2" title="Warrants and rights outstanding, term">five years</span> after the issuance date. The underwriters exercised their over-allotment option to purchase
<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210829__20210830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--OverAllotmentOptionsMember_zimZbzJVkkTj" title="Over allotment option to purchase">277,500</span> common stock warrants on August 30, 2021. In connection with the IPO, the underwriters were issued a five-year warrant, exercisable
on or after February 25, 2022, to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Class of warrant or right, number of securities called by each warrant or right">198,875</span> shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Class of warrant or right, exercise price of warrants or rights">10.80</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received aggregate gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Aggregate gross proceeds">16.7</span> million from the IPO, paid underwriting discounts and commissions of $<span id="xdx_903_ecustom--UnderwritingDiscountsAndCommissions_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Underwriting discounts and commissions">1.3</span> million
and incurred other expenses of $<span id="xdx_909_eus-gaap--OtherExpenses_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Other expenses">0.8</span> million, resulting in net offering proceeds of $<span id="xdx_909_ecustom--NetProceedsFromIntialPublicOffering_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Net proceeds from intial public offering">14.6</span> million. Immediately prior to the closing of
the IPO, all shares of convertible preferred stock then outstanding were converted into <span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaTAwRGdGoub" title="Conversion of stock, shares issued">3,535,469</span> shares of common stock after giving
effect to the reverse stock split. In addition, all of the outstanding 2020 and 2021 Convertible Notes, representing principal and accrued
but unpaid interest of $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Debt conversion, converted instrument, amount">5.3</span> million, <span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember" title="Debt instrument, description">converted at a 20% and 12.5% discount to the IPO price, respectively, into an aggregate of <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zxADBNJ9uCRk" title="Debt conversion, converted instrument, shares">708,820</span>
units. Each unit consisted of (a) one share of common stock and (b) one five-year warrant to purchase one share of common stock at an
exercise price equal to $10.80 per share</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 5, 2021, the Company effected a <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20210804__20210805_zhSUz5IAsKnf" title="Stockholders equity, reverse stock split">1-for-5 reverse stock split</span> of its issued and outstanding preferred stock and common stock. The
number of authorized shares and the par values of the common stock and convertible preferred stock were not adjusted as a result of the
reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the Company&#8217;s convertible
preferred stock converted into the Company&#8217;s common stock. Accordingly, all share and per share amounts related to the common stock,
stock options, warrants and restricted stock awards for all periods presented in the accompanying financial statements and notes thereto
have been retroactively adjusted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Capital Resources</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
the Company&#8217;s inception through December 31, 2022, it has raised an aggregate of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20211126__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAiGm9BF5Xwa" title="Proceeds from sale of equity">35.0</span> million from private placements of convertible
preferred stock, convertible debt securities, the issuance of securities in the IPO, and the exercise of warrants and common stock options.
As of December 31, 2022, the Company had cash, cash equivalents and short-term marketable securities of $<span id="xdx_90A_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20221231_z3t31gxR1MZ" title="Cash and cash equivalents, and Marketable securities">6.4</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred significant losses and negative cash flows from operations since its inception. For the year ended December 31,
2022, the Company reported a net loss of $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_zw1FpLpXGdOa" title="Net loss">9.9</span> million and an accumulated deficit of $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_z2gw5NMSSlCb" title="Accumulated deficit">31.2</span> million and does not expect to generate positive
cash flows from operations in the foreseeable future. The Company expects to incur significant and increasing losses until regulatory
approval is granted for its first product candidate, RenovoGem&#8482;. Regulatory approval is not guaranteed and may never be obtained.
The Company believes it will be able to raise additional capital through debt financings, private or public equity financings, license
agreements, collaborative agreements or other arrangements with other companies, or other sources of financing. There can be no assurance
that such financing will be available or will be at terms acceptable to the Company. The inability to raise capital as and when needed
would have a negative impact on the Company&#8217;s liquidity financial condition and its ability to pursue its business strategy. The
Company will need to generate significant revenue to achieve profitability, and it may never do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed an omnibus shelf registration statement on Form S-3 that provides for the aggregate offerings of up to $<span id="xdx_90E_ecustom--MaximumPossibleProceedsFromOfferings_pn6n6_c20220101__20221231_zZEbFt8DlG8i" title="Maximum possible proceeds from offerings">50.0</span> million
of the Company&#8217;s securities subject to various limitations, including limited sales in any twelve-month period while the Company
is subject to the &#8220;baby-shelf&#8221; rules. The Company has also filed a registration statement on Form S-1 to register the cash
exercise of the Company&#8217;s outstanding IPO, underwriter and private warrants. Cash exercise of the outstanding warrants is only
expected to occur when the trading price of the Company&#8217;s common stock is in excess of the $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zTm5wVmEOUAl" title="Class of warrant or right, exercise price of warrants or rights">10.80</span> per share exercise price of the
outstanding warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern and has reviewed the
relevant conditions and events surrounding its ability to continue as a going concern including among others: historical losses, projected
future results, negative cash flows from operations, including the effects of the ongoing novel coronavirus (&#8220;COVID-19&#8221;)
pandemic, cash requirements for the upcoming year, funding capacity, net working capital, total stockholders&#8217; equity and future
access to capital. Based upon this review and the Company&#8217;s current financial condition, the Company has concluded that substantial
doubt exists as to the Company&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423533261776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">2. Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zPqP6myjMFF7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zwZwvpb7Spsd">2.
Summary of Significant Accounting Policies</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHm1cDSYh01f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zG1ruHCYXIbd">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the SEC for annual reporting. Any reference in these notes to
applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and as amended by Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_ecustom--RisksAndUncertaintiesPolicyTextBlock_zZrgs7WSpMNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z51snjERV0r3">Risks
and Uncertainties</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to a number of risks associated with companies at a similar stage, including the risk associated with the development
of products that must receive regulatory approval before market launch, dependence on key individuals, competition from larger and established
companies, volatility of the industry, ability to obtain adequate financing to support growth, the ability to attract and retain additional
qualified personnel to manage the anticipated growth of the Company and general economic conditions. The Company is subject to a number
of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional
funding, possible failure of current or future preclinical studies or clinical trials, its reliance on third parties to conduct its clinical
trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations,
the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, protection of its proprietary
technology, and the need to secure and maintain adequate manufacturing arrangements with third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic, and government responses have created
disruption in global supply chains and adversely impacting many industries. The pandemic could have a continued material adverse
impact on economic and market conditions. We continue to monitor the impact of the COVID-19 pandemic, including its most recent
variants, closely. The extent to which the COVID-19 pandemic will impact our operations or financial results is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--UseOfEstimates_z3bSwlo5Tfv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zJb5n2pFu3Ze">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, income and expenses as well as the disclosure of contingent assets and liabilities, at the date of
the financial statements during the reporting periods. In preparing these financial statements, management has made its best estimates
and judgments of certain amounts included in the financial statements. Significant estimates and assumptions made in the accompanying
financial statements include, but are not limited to, accruals of certain liabilities, including clinical trial accruals and other contingences,
the valuation of financial instruments, the fair value of the Company&#8217;s common stock and the fair value of options granted under
the Company&#8217;s equity incentive plan. On an ongoing basis, the Company evaluates its estimates, including those related to the fair
values of assets, stock-based compensation, clinical trial accruals and other contingencies. Management bases its estimates on historical
experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially
from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zfVCgmA1nhZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zXBZz0M0lnF3">Concentration
of Credit Risk and Significant Suppliers</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents.
The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits
of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zYUqTu6FA627" title="Cash, FDIC insured amount">250,000</span>. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents
to the extent recorded in the balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relied, and expects to rely, on a small number of third-party manufacturers to manufacture and supply its RenovoCath devices
and its product candidates for clinical trials. These activities could be adversely affected by a significant interruption in supply
of these items. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate
product revenue or achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z7URk1O0oT89" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z2qSqRpAXAn9">Operating
Segment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as one reportable and operating segment, which is the development of a therapy platform to
deliver de-risked small molecules for localized treatment of solid cancer tumors. The Company&#8217;s chief executive officer, who is
the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial
performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zNIt6IHC8Ihb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zvaBkezXnvCb">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during
the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average
number of shares of common stock and common stock equivalents of potentially dilutive securities outstanding for the period determined
using the treasury stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of convertible preferred
stock, convertible notes, and warrants including options and restricted stock awards outstanding under the Company&#8217;s Equity Incentive
Plan. For the years ended December 31, 2022 and 2021, there was no difference in the number of shares used to calculate basic and diluted
shares outstanding as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zf3Oqho5xbeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zgthSnXO9tCf">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the
principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement
date. Fair value measurement establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where
available, and minimize the use of unobservable inputs when measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the fair value of financial assets and liabilities using the fair value hierarchy that describes three levels of inputs
that may be used to measure fair value, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Valuations based on unobservable inputs reflecting the Company&#8217;s assumptions, consistent with reasonably available assumptions
made by other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of financial instruments disclosed in the financial statements has been determined by using available market information
and appropriate valuation methodologies. In certain cases where there is limited activity or less transparency around inputs to valuation,
securities are classified as Level 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of current assets, accounts payable and accrued expenses are generally considered to be representative of their respective
fair values because of their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_ecustom--CashCashEquivalentsAndInvestmentsPolicyTextBlock_zNYL71lzWeP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zMgcde5Caltc">Cash,
Cash Equivalents and Investments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
Available-for-sale securities, comprised of obligations of the U.S. government and its agencies, are carried at fair value, with unrealized
gains and losses recorded within other comprehensive income (loss) as a separate component of stockholders&#8217; equity. Realized gains
and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in earnings.
Purchases and sales of investment securities are recognized on a trade date basis. The cost of investment securities sold is determined
by the specific identification method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_ecustom--LeaseholdImprovementsPolicyTextBlock_zfbhBvrEoTt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zde547Z2XjD2">Leasehold
Improvements, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are presented at cost, net of accumulated amortization. Amortization expense is recorded using the straight-line method
over the shorter of the remaining lease term or the estimated useful life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8NrWqrEa898" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zQ3RwuZqIjOb">Research
and Development Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses includes personnel costs including salaries,
benefits and stock-based compensation. In addition, it includes expenses for consultants that support clinical trial studies, materials
costs, external clinical drug product manufacturing costs, outside services costs, regulatory activities including filing fees, fees
for maintaining licenses and other amounts due to third-party agreements, laboratory materials, clinical trial, as noted above, and supplies
to support our research activities, including allocated facility and general and administrative indirect overhead related costs. The
Company also receives payments from clinical trial sites for RenovoCath delivery devices used in the Phase III clinical trial. Payments
received from clinical sites cover the direct costs of manufacturing the RenovoCath delivery devices and offset research and development
expenses were $<span id="xdx_90B_ecustom--PaymentsReceivedFromClinicalSites_iN_di_c20220101__20221231__dei--LegalEntityAxis__custom--RenovoCathMember_z4VvX720kpl" title="Payments received from clinical sites">141,000</span> and $<span id="xdx_906_ecustom--PaymentsReceivedFromClinicalSites_iN_di_c20210101__20211231__dei--LegalEntityAxis__custom--RenovoCathMember_zgJzPsC14hh6" title="Payments received from clinical sites">233,000</span> for December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--ClinicalTrialExpensesPolicyTextBlock_zXY6GkKFJes4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zzOdLv079NZ7">Clinical
Trial Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company makes payments in connection with its ongoing Phase III clinical trial under contracts with clinical trial sites and contract
research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation
and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to
be performed at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts
depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including
actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related
to patient enrollment or treatment are accrued when reasonably estimable. If amounts and obligations to pay under clinical trial agreements
are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are
adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give
rise to the revision become reasonably certain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_843_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zZL0Ddreuegi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zDAPKDqaalhi">General
and Administrative</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of salaries, benefits, and stock-based compensation for personnel in executive, finance and administrative
functions, professional services and associated costs related to accounting, tax, audit, legal, intellectual property, consulting costs,
conferences and travel, including allocated facility and general and administrative indirect overhead related costs to research and development
expenses. General and administrative expenses are expensed in the period incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--ConvertiblePreferredStockPolicyTextBlock_z2inqu5ckCW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zXapwkm74uu1">Convertible
Preferred Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records preferred stock at fair value on the date of issuance, net of issuance costs. Preferred stock was previously recorded
outside of stockholders&#8217; equity (deficit) because the shares contained liquidation features that were not solely within the Company&#8217;s
control and was classified as mezzanine equity (temporary equity). The Company completed its IPO on August 30, 2021, which triggered
the automatic conversion of all outstanding convertible preferred stock to common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3EXFdb2Ywf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zhgs7Fwf7Ub">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock options using the Black-Scholes option pricing model, which incorporates various assumptions
including volatility, expected term and risk-free interest rate. Compensation related to service-based awards is recognized starting
on the grant date on a straight-line basis over the vesting period, which is generally four years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
determination of the fair value of each stock award using this option-pricing model is affected by the Company&#8217;s assumptions regarding
a number of complex and subjective variables. These variables include, but are not limited to, the fair value of the common stock at
the date of grant, the expected term of the awards, the expected stock price volatility over the expected term of the awards, the risk-free
interest rate, and the dividend rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Common Stock</i>&#8212;Prior to the IPO, given the absence of a public trading market, the Company&#8217;s Board of Directors
considered numerous objective and subjective factors to determine the fair value of the Company&#8217;s common stock at each grant date.
These factors included, but were not limited to: (i) contemporaneous third-party valuations of common stock; (ii) the prices for preferred
stock sold to outside investors; (iii) the rights and preferences of preferred stock relative to common stock; (iv) the lack of marketability
of the Company&#8217;s common stock; (v) developments in the business; and (vi) the likelihood of achieving a liquidity event, such as
an IPO or sale of the business, given prevailing market conditions. The methodology to determine the fair value of the Company&#8217;s
common stock included estimating the fair value of the enterprise using the &#8220;backsolve&#8221; method, which is a market approach
that assigns an implied enterprise value by accounting for all share class rights and preferences based on the latest round of financing.
The total equity value implied was then applied in the context of an option pricing model to determine the value of each class of the
Company&#8217;s shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
grants issued post-IPO the closing price of the Company&#8217;s common stock as reported on the date of grant will determine the fair
value of the Company&#8217;s common stock, as shares of the Company&#8217;s common stock are traded in the public market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. The Company determines
the expected term using the simplified method for pre-IPO and post-IPO awards. The simplified method deems the term to be the average
of the time-to-vesting and the contractual life of the options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>&#8212;Given the absence of a public trading market, pre-IPO and post IPO, the expected volatility is estimated by taking
the average historic price volatility for industry peers, consisting of several public companies in the Company&#8217;s industry that
are either similar in size, stage, or financial leverage, over a period equivalent to the expected term of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
Interest Rate</i>&#8212;The risk-free interest rate is calculated using the average of the published interest rates of U.S. Treasury
zero-coupon issues with maturities that are commensurate with the expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Rate</i>&#8212;The dividend yield assumption is zero as the Company has no plans to make dividend payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generally granted stock options, pre-IPO, to its employees and consultants for a fixed number of shares with an exercise price
equal to the fair value of the underlying shares at date of grant. For all post-IPO grants issued, the fair value will be the closing
price of the Company&#8217;s common stock on the date of the grant. The Company accounts for all stock option grants using the fair value
method and stock-based compensation is recognized as the underlying options vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zyJ95pZT0R6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z9a65EAP1rof">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities
using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation
allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax
credit carryforwards for all periods presented, as realization of such deferred tax assets cannot be determined to be more likely than
not. Due to losses incurred for all periods presented, the Company does not record tax provision or benefit for income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_zmoviQgLuoP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zouHFmdnzxFk">Emerging
Growth Company and Smaller Reporting Company Status</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company (&#8220;EGC&#8221;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;) and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of
the JOBS Act exempts emerging growth companies from complying with new or revised financial accounting standards until private companies
are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or
revised accounting standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 of the Exchange Act. If we are a smaller reporting company
at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that
are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most
recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, like emerging growth companies, smaller reporting
companies have reduced disclosure obligations regarding executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of
the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not
have a material impact on the Company&#8217;s financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zvmRGpDTUZLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z7CvUQUNAWec">Recent
Accounting Pronouncement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Adopted Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued Accounting Standards Updates (&#8220;ASU&#8221;) 2016-02, <i>Leases (Topic 842)</i>. The guidance requires
lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expands disclosure requirements regarding
leasing arrangements. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting the new
lease standards, and a package of practical expedients an entity can elect to utilize to reduce the level of effort required for adoption.
Under the transition option, entities can elect to apply the new guidance using a modified retrospective approach at the beginning of
the year in which the new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements.
In November 2019, the FASB issued ASU 2019-10, Leases (Topic 842) (ASU 2019-10), deferring the effective date for the Company for fiscal
years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the
FASB issued ASU 2020-05, Leases (Topic 842) (ASU 2020-05), which further defers the effective date for the Company for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2021. Early adoption is permitted. The
Company adopted ASU 2016-02 on January 1, 2022 and the adoption had no material impact to the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, <i>Income Taxes (Topic 740)</i>: Simplifying the Accounting for Income Taxes (ASU 2019-12),
which simplifies the accounting for income taxes, and is effective on a prospective basis for annual reporting periods beginning after
December 15, 2021, and for interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The
Company adopted ASU 2019-12 on January 1, 2022 and the adoption had no significant impact to the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments&#8212;Credit Losses (Topic 326)</i>. The guidance represents a significant
change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected
credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has
met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU 2019-10, <i>Financial Instruments
&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)</i> &#8212;Effective Dates amended the
effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU 2016-13
effective January 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) </i>(ASU 2020-06): <i>Accounting for Convertible Instruments
and Contracts in an Entity</i>, which simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The updated guidance is effective on a prospective
basis for annual reporting periods beginning after December 15, 2023 and for interim periods within those periods. Early adoption is
permitted. The Company has not yet determined the impact that this new standard will have on its financial position and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534601344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Short-Term Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">3. Short-Term Marketable Securities</a></td>
<td class="text"><p id="xdx_807_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_z8vBpTFv7DV4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zqgeMqxRTjkj">3.
Short-Term Marketable Securities</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89B_eus-gaap--MarketableSecuritiesTextBlock_zpgIdIns1l6j" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tables summarize the Company&#8217;s short-term marketable securities as of December 31, 2022. There were no short-term marketable securities
as of December 31, 2021 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zHj7Nl5NtCgi" style="display: none">Schedule of Short-Term Marketable Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost Basis</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross<br/>
 Unrealized <br/>
Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">U.S. Treasury bills</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zJ3QUD31T3e6" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, amortized cost basis">2,032</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zNouzYQi2sFl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, unrealized gains">17</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zhJwDgAPBzvl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, unrealized losses">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0568">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zJYVlLezGF5b" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, fair value">2,049</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231_zlY8Ose76Y26" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, amortized cost basis">2,032</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20220101__20221231_zOSo7eebN7o" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, unrealized gains">17</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_pn3n3_c20220101__20221231_z4cvmiBhQxv6" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, unrealized losses"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20221231_zptcH7QfQkM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, fair value">2,049</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z9UB3IRI6xtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534528144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">4. Accrued Expenses</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zGLJLz2xf8F7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
<span id="xdx_82B_zWkKc6SS9Tgi">4. Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zaI6UZsjLPUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of accrued expenses as of December 31, 2022 and 2021 are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z5s1YR1nkjRf" style="display: none">Schedule of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_z1q2B2nJ9wWi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_z7AloTSk40u8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccruedClinicalTrialsCurrent_iI_pn3n3_maALCz7Fz_zuCHB2xDe85l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Clinical trial</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCz7Fz_z1ZeFp8Gq2T5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz7Fz_zfOTfAd00q12" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz7Fz_zyJZo7LN00xi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">568</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">413</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zZfkUUPjSiw6" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423535666400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">5. Fair Value Measurements</a></td>
<td class="text"><p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zBHemCjH8by5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_821_zBH5lpKdEqB3">5.
Fair Value Measurements</span></b></span></p>



<p style="margin-top: 0; margin-bottom: 0">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021, the Company held $<span id="xdx_90D_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_c20221231_ziqeCx7PYBTl" title="Money market funds, at carrying value">4.4</span> million and $<span id="xdx_90A_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn6n6_c20211231_zDFWoVubtvT9" title="Money market funds, at carrying value">15.0</span> million, respectively, in a money market account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zpZmx6gcBMW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables sets summarize the Company&#8217;s financial assets and liabilities, measured at fair value on a recurring basis by
level within the fair value hierarchy, as of December 31, 2022, and 2021, (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zet2hQgJ3eu4" style="display: none">Schedule of Assets Measured at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements at December 31, 2022 using:</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: justify">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzd2NeqEDoIg" style="width: 11%; text-align: right" title="Fair value of assets">4,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxuNynEj3Xlg" style="width: 11%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0608">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLQaqRfgJKM9" style="width: 11%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z33j61y5Poo6" style="width: 11%; text-align: right" title="Fair value of assets">4,300</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify">Available-for-sale securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">U.S. Treasury bills</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUSrdJfYPzM6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets">2,049</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z89997Oz1RB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zumaZefHWfA6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0618">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zhgBiDaw7oj2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets">2,049</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgwbzalb2qXh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets">6,349</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLvimprryWca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0624">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z1odUC8sDVj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0626">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUlmWsAFlscd" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets">6,349</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements at December 31, 2021 using:</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1.5pt">Money market funds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets">14,997</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets">14,997</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets">14,997</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zKD4iPGVrgy2" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets">14,997</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zMfQZW52q53c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zwMrkrPNNc6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in the fair value of the derivative liability is summarized below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_ztgGfeOkweQ5" style="display: none">Schedule
of Changes in Fair value of Derivative  Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zLhzDhgZ5vY9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_z3ttAK4m1FOj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_zDUxWPk0UNf1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Fair value, beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">856</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_zA2FujfEpSXk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Initial fair value of instruments issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_iN_pn3n3_di_zvG1x1KBm9S" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in fair value of instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(118</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_iN_pn3n3_di_zaATWrAox2L9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Conversion upon IPO</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0657">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,101</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_zYyzo1V7WLia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Fair value, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0661">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zOPuBFNQIZjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between Level 1, Level 2 or Level 3 during the periods presented. The Company had no other financial assets or liabilities
that were required to be measured at fair value on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534598912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">6. Convertible Notes</a></td>
<td class="text"><p id="xdx_802_eus-gaap--LongTermDebtTextBlock_zq8BfDvQc4yc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zEHu9dvm2TD9">6.
Convertible Notes</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the Company entered into a note purchase agreement for the issuance of up to $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zuVuUoo5uITk" title="Convertible notes payable">4.0</span> million of convertible promissory notes,
which, if not converted, had an initial maturity date of <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20200301__20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zUMHNMoKrlr9" title="Debt instrument, maturity date">March 31, 2021</span>. The Company entered into a series of convertible note payable
agreements (the &#8220;2020 Convertible Notes&#8221;) for aggregate borrowings of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zeZY9sfaH3o9" title="Debt instrument, face amount">3.0</span> million. The 2020 Convertible Notes bore interest
at the rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pip0_dp_uPure_c20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zq9fmoXfrSNc" title="Debt interest rate">5</span>% per annum and could not be prepaid prior to the maturity date unless approved in writing by the Company and requisite
holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the 2020 Convertible Notes provided for automatic conversion into equity shares in the next equity financing round with total
proceeds of not less than $<span id="xdx_909_ecustom--MaximumPossibleTotalProceedsFromConvertibleNotes_pn6n6_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zebk1xbJSxd6" title="Maximum possible total proceeds from convertible notes">10.0</span> million (a &#8220;Qualified Financing&#8217;), at a conversion price per share equal to <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_uPure_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zyTO8ZmAcHPi" title="Debt conversion price percentage">80</span>% of the price
per share paid by investors purchasing such equity securities in a Qualified Financing. For purposes of the 2020 Convertible Notes, equity
securities meant the Company&#8217;s common stock, preferred stock or any securities providing for rights to purchase the Company&#8217;s
common stock, preferred stock or securities convertible into or exchangeable for the Company&#8217;s common stock or preferred stock
issued in the Qualified Financing. If the Company consummated a Change of Control prior to a Qualified Financing, the Company would repay
each holder in cash an amount equal to the greater of (a) two times (2x) the entire outstanding principal balance of the 2020 Convertible
Notes or (b) the amount the holder would receive if the 2020 Convertible Notes had been converted into shares of the Company&#8217;s
Series B convertible preferred stock immediately prior to the consummation of the Change in Control, at a conversion price equal to the
Series B convertible preferred stock Original Issue Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 1, 2021, the Company entered into an amendment to the 2020 Convertible Notes which extended the maturity date of the 2020 Convertible
Notes from March 31, 2021 to October 30, 2021 and provided for the conversion of the 2020 Convertible Notes into shares of the Company&#8217;s
common stock upon a Qualified Financing that is an IPO. No other terms of the 2020 Convertible Notes were amended. This amendment was
accounted for as a troubled debt restructuring pursuant to FASB ASC Topic 470-60, &#8220;Troubled Debt Restructurings by Debtors.&#8221;
As the future undiscounted cash flows of the 2020 Convertible Notes were greater than their carrying amount, the carrying amount was
not adjusted and no gain was recognized as a result of the modification of terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that the redemption features contained rights and obligations for conversion were contingent upon a potential
future financing event or a change in control. Thus, the embedded redemption features were bifurcated from the face value of the
notes and accounted for as a derivative liability to be remeasured at the end of each reporting period. The fair value of the
derivative liability including debt issuance costs was $<span id="xdx_907_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zTvlBpYYzQNl" title="Fair value of derivative liability including debt issuance costs"><span id="xdx_900_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zHHSVZ9Ta8J7" title="Fair value of derivative liability including debt issuance costs">0</span></span>
at December 31, 2022 and December 31, 2021, respectively. The derivative liability was subject to fair value remeasurement at the
end of each reporting period. The debt discount and debt issuance costs were being amortized to interest expense using the effective
interest method over the expected term of the 2020 Convertible Notes. For the years ended December 31, 2022 and December 31, 2021,
the Company recognized $<span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zV0pDejhyJW9" title="Amortization of debt discount and debt issuance costs">0</span>
and $<span id="xdx_90F_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zjexdVzHMR6d" title="Amortization of debt discount and debt issuance costs">379,000</span>
for amortization of the debt discount and debt issuance costs, respectively. This amortization expense is recognized as interest
expense in the statements of operations. The effective interest rate of the 2020 Convertible Notes was <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zBxpFp7Utg73" title="Debt effective interest rate"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zlalMfUN1xLa" title="Debt effective interest rate">0</span></span>%
at December 31, 2022 and December 31, 2021, compared to the stated rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pip0_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zM0SlQUqeOCi" title="Debt stated interest rate">5</span>%
per annum. The effective interest rate immediately prior to the conversion of the Convertible Notes resulting from the
Company&#8217;s IPO was <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zkwiYeNACb2k">8.6</span>%
per annum. As a result, the Company&#8217;s reported interest expense was significantly higher than the contractual cash interest
payments. During the years ended December 31, 2022 and December 31, 2021, the Company recognized interest expense in the statements
of operations of $<span id="xdx_901_eus-gaap--InterestExpense_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zNm49WmMwT7l" title="Interest expense">0</span>
and $<span id="xdx_900_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_z4Ok7kfKKxHk" title="Interest expense">101,000</span>,
respectively, related to the 2020 Convertible Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, the Company entered into a note purchase agreement and a series of convertible note payable agreements (the &#8220;2021 Convertible
Notes,&#8221; together with the 2020 Convertible Notes, the &#8220;2020 and 2021 Convertible Notes&#8221;) for aggregate borrowings of
$<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20210430__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember_zFOJAmZ6j7L6" title="Debt face amount">2.0</span> million. Outstanding borrowings under the 2021 Convertible Notes and accrued interest were due in April 2022, if not previously
converted. The 2021 Notes bore interest at the rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210430__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_z6KdYaW1nwsl" title="Interest rate percentage">5%</span> per annum. Pursuant to the 2021 Convertible Notes, the outstanding principal
and accrued interest are automatically convertible into equity shares in a Qualified Financing at a conversion price per share equal
to <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pip0_dp_uPure_c20210401__20210430__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_z3y01Xa4Ib5a" title="Debt conversion price percentage">87.5</span>% of the price per share paid by investors purchasing such equity securities in a Qualified Financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that these redemption features in the 2021 Convertible Notes contained rights and obligations for conversion that
were contingent upon a potential future financing event or a change in control. Thus, the embedded redemption features were bifurcated
from the face value of the note and accounted for as a derivative liability to be remeasured at the end of each reporting period. Upon
issuance of the notes, the Company recorded the fair value of the derivative liability of $<span id="xdx_904_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zgSkFHo3yzgc" title="Fair value of derivative liability">363,000</span> and debt issuance costs of $<span id="xdx_906_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zg0AVIAlZ3De" title="Debt issuance costs">23,000</span>,
with the offsetting amount being recorded as a debt discount. The discount and debt issuance costs were amortized to interest expense
using the effective interest method over the expected term of the 2021 Convertible Notes. For the year ended December 31, 2022 and December
31, 2021, the Company recognized $<span id="xdx_905_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zfmNzDwMJx22" title="Amortization of debt discount and debt issuance costs">0</span> and $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCosts_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zG5Pufi16fui" title="Amortization of debt discount and debt issuance costs">386,000</span>, respectively, for the amortization of the debt discount and debt issuance costs as
interest expense in the statements of operations. The effective interest rate immediately prior to the conversion of the 2021 Convertible
Notes resulting from the Company&#8217;s IPO was <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zmbKZoEB94lk">46.5</span>% per annum compared to the stated rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_za4BtWjDDpYl">5</span>% per annum. During the year ended December
31, 2022 and December 31, 2021, the Company recognized interest expense in the statements of operations of $<span id="xdx_90B_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zrug1ggNe9w2" title="Interest expense">0</span> and $<span id="xdx_902_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zSESc9ap6jzj" title="Interest expense">38,000</span>, respectively,
relating to the 2021 Convertible Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company completed an IPO on August 30, 2021, which triggered the automatic conversion of the outstanding Convertible Notes plus accrued
interest into an aggregate of <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210829__20210830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNfoDwpEk8Pa" title="Conversion of stock, shares converted">708,820</span> units (the &#8220;Exchange&#8221;). The 2020 Convertible Notes converted at a 20% discount to the
IPO price and the 2021 Convertible Notes converted at a <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210831__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_zlNZ7KrtnHUe" title="Debt interest rate">12.5</span>% discount to the IPO price. Each unit consisted of (a) one share of common
stock and (b) one five-year warrant to purchase one share of common stock at an exercise price equal to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zWcp3gnBidlj" title="Warrant exercise price per share">10.80</span> per share. Upon conversion
of the 2020 and 2021 Convertible Notes, the outstanding principal, including debt discount and debt issuance costs for those Convertible
Notes of $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_zKgen3PS0Vp6" title="Convertible notes payable">5.3</span> million, was derecognized into stockholders&#8217; equity. The unamortized debt discount totaling $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_zG4xyogqPwa5" title="Unamortized debt discount">78,000</span> was recognized
as a loss on extinguishment of debt and is included in loss (gain) on loan extinguishment in the Company&#8217;s statements of operations
for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exchange was made pursuant to an exemption from registration provided by Section 3(a)(9) of the Securities Act. The following facts were
relied upon: (1) no payment was made in connection with the Exchange, (2) the Convertible Notes, the common stock, and the warrants were
issued by the same issuer, (3) the Convertible Note holders were not required to contribute cash or any other property, and (4) the Exchange
was made only to existing note holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423527659040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">7. Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zcaiA2icJst3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zTpJGbffe8Q8">7.
Commitments and Contingencies</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company may become involved in legal proceedings arising in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was not subject to any material legal proceedings during the year ended December 31, 2022 and no material legal proceedings are
subsequently outstanding or pending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Guarantees
and Indemnification</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware
law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the
officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its officers and
directors. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future
payments that the Company could be required to make under these provisions is not determinable. The Company has never incurred material
costs to defend lawsuits or settle claims related to these indemnification provisions. The Company is not currently aware of any indemnification
claims. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of December 31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20221231_zGsBDuUha9h9" title="Lessee, operating lease, description">The
Company leases its headquarters in Los Altos, California under a month-to-month operating lease agreement.</span> Rent expense was $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20220101__20221231_z0qYZ5NVgOA8" title="Operating lease, rent expense">72,000</span> and
$<span id="xdx_900_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231_zFN4ticSd897" title="Operating lease, rent expense">60,000</span> for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534571456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zxRhpnrEKnnc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zWz5XSiJT1ka">8.
Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2021
Omnibus Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 19, 2021, the Company&#8217;s Board of Directors adopted the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the &#8220;2021
Plan&#8221;). The 2021 Plan, which became effective immediately prior to the closing of the IPO, initially reserved <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210719__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member_z15iS7d0Jnk4" title="Number of shares reserved">2,185,832</span> shares
of common stock, which included <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210719__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member_pdd" title="Common shares reserved but unissued">10,832</span> shares of common shares reserved but unissued under the Amended and Restated 2013 Equity Incentive
Plan (the &#8220;2013 Plan&#8221;). The Company&#8217;s 2013 Plan was terminated immediately prior to the closing of the IPO; however,
shares subject to awards granted under the 2013 Plan will continue to be governed by the 2013 Plan. In accordance with the terms of the
2021 Plan, on January 1, 2023, the number of shares reserved and available for issuance increased by <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230101__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztxDbqAbsIhl" title="Number of shares reserved">272,391</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPXCuaMrMkbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity for the year ended December 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_z9zGbXyz3wT2" style="display: none">Summary of Stock Option Award Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual Life</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zGSYfJR9fNHk" style="width: 11%; text-align: right" title="Number of stock options outstanding, beginning balance">926,379</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zGZdtN3G5Nhk" style="width: 11%; text-align: right" title="Weighted average exercise price outstanding, beginning balance">2.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zYUIANnIXUlj" title="Weighted average remaining contractual life">6.47</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zx7IgMGZWtMc" style="width: 11%; text-align: right" title="Aggregate intrinsic value outstanding, beginning balance">2,856</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zcqgUOF5Wjz3" style="text-align: right" title="Number of stock options, granted">724,937</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z1Eo5FlUoYVi" style="text-align: right" title="Weighted average exercise price, granted">2.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zRH2UD1HMjVj" style="text-align: right" title="Number of stock options, exercised">(160,212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zJdKL50TwPwh" style="text-align: right" title="Weighted average exercise price, exercised">0.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zESlJyJBftqb" style="text-align: right" title="Number of stock options, forfeited">(91,852</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zvdCkn7KclD6" style="text-align: right" title="Weighted average exercise price, forfeited">3.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zbTNjo7QEVag" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, ending balance">1,399,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zra4NJ8fb5rf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, ending balance">2.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zVabW1TJeaFj" title="Weighted average remaining contractual life">7.79</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zkbXJYj1UBS9" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value outstanding, ending balance">928</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231_zOq0XSfUMV05" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options, exercisable">662,909</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zDcWpB1BGtg3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">1.79</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zNglQUMFd5T" title="Weighted average remaining contractual life, exercisable">5.87</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zxx9YEqHRkv1" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, exercisable">823</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Vested and expected to vest as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20220101__20221231_zn4vll4Yh4C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options, vested and expected to vest">1,399,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_z5LizxuZWzwb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest">2.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zeuKVHvmGwL4" title="Weighted average remaining contractual life, vested and expected">7.79</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231_zToJ1H1ieup6" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, vested and expected to vest">928</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zDY3hDiNYt04" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there was $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20221231_zNyFeIOSiFSl" title="Unrecognized stock based compensation expense">0.7</span> million of unrecognized stock-based compensation expense related to options granted but not yet
amortized, which will be recognized over a weighted-average period of approximately <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231_z1XmozeXqgCl" title="Weighted average period">3.14</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztcd4lqxqpP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the outstanding and exercisable options as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zFha8OOSuneh" style="display: none">Schedule of Ranges of Stock Options</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    Outstanding</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    Exercisable</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
    of <br/>
    Exercise Prices</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
 Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>

    Average<br/>
 Remaining<br/>
 Contractual Life</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of <br/>
Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>

    Average<br/>
 Remaining<br/>
 Contractual Life</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z5rNdY6OzZVj" title="Range of Exercise Prices, Lower Range">0.00</span> - $ <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zf8czkAbXnK9" title="Range of Exercise Prices, Upper Range">1.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYbWOs19alM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">459,080</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zg6ePRyjccT" title="Weighted-Average Remaining Contractual Life (years)">4.51</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zUB3dHBzejib" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">456,179</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zBu7Uv5hRHel" title="Weighted-Average Remaining Contractual Life (years)">4.49</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zvN6YN7iB3q6" title="Range of Exercise Prices, Lower Range">1.01</span> - $ <span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zDTwD7xni7Y4" title="Range of Exercise Prices, Upper Range">2.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zVePqkSbGF81" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130,510</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zrZyhq50ZDW6" title="Weighted-Average Remaining Contractual Life (years)">9.91</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z4cMh4UWdgpc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,909</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zNd8ggKQxyka" title="Weighted-Average Remaining Contractual Life (years)">9.91</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zl8Q0fDKya95" title="Range of Exercise Prices, Lower Range">2.01</span> - $ <span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zbWTMnWxqDhg" title="Range of Exercise Prices, Upper Range">3.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvxs2lgfSeA3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">459,786</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z5fpbpYTJkKc" title="Weighted-Average Remaining Contractual Life (years)">9.65</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zc1lwe7Grcqk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,850</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvlb8PjYAAEl" title="Weighted-Average Remaining Contractual Life (years)">9.09</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zgBxrzN0yOLf" title="Range of Exercise Prices, Lower Range">3.01</span> - $ <span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zq6SXywbaQK5" title="Range of Exercise Prices, Upper Range">4.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zNPwQ8t24Hv5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,530</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zTnImbMjTE5k" title="Weighted-Average Remaining Contractual Life (years)">9.19</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zezaWnJujP69" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,066</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zo1qesulux2h" title="Weighted-Average Remaining Contractual Life (years)">9.19</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zCxoKiXg2xwg" title="Range of Exercise Prices, Lower Range">5.01</span> - $ <span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zONVLRvLJ0J2" title="Range of Exercise Prices, Upper Range">6.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zjX6Lc3Nmlhf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,924</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_z2l1OVuApgad" title="Weighted-Average Remaining Contractual Life (years)">8.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zbYdzUUHS4Qe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,530</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zn3KLNahR1if" title="Weighted-Average Remaining Contractual Life (years)">8.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zKf6UX0UgpQi" title="Range of Exercise Prices, Lower Range">6.01</span> - $ <span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zqP8Z9cgvhj5" title="Range of Exercise Prices, Upper Range">7.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_z9MOD6y1umgb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170,069</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zWpknXv68bai" title="Weighted-Average Remaining Contractual Life (years)">8.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zgync7dhd7Z5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,689</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_z3SHETyQHIM" title="Weighted-Average Remaining Contractual Life (years)">8.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zPhAjbNOaSNa" title="Range of exercise prices, lower range">8.01</span> - $ <span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zVtEqkrDcpgl" title="Range of exercise prices, upper range">9.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zwrIQdMHrlGk" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,353</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zBLpFhGXgv05" title="Weighted-Average Remaining Contractual Life (years)">8.86</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_z7e8oc5JHvl7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">686</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_z128nPWWJqo9" title="Weighted-Average Remaining Contractual Life (years)">8.86</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231_zhcALNiEz5M" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,399,252</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zOFJi9YrJyah" title="Weighted-average remaining contractual life (years)">7.79</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231_zOf4oIldFVGi" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">662,909</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5c85f2Fv3Y6" title="Weighted-average remaining contractual life (years)">5.87</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zWr3mP9nzeF9" style="margin-top: 0; margin-bottom: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeO0yovDjQS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022, and 2021, the Company utilized the Black-Scholes option-pricing model for estimating the fair value
of the stock option granted. The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option
pricing model with the following weighted-average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zfm8IqfHxek4" style="display: none">Schedule of Estimate Fair Value of Stock Options</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended December 31,</b></span></td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; width: 60%; font-size: 11pt"/><td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231_z0YfCh9eP8ci" title="Expected volatility rate, minimum">100.48</span>% &#8211; <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231_zW9Fw3q4q5Bh" title="Expected volatility rate, maximum">103.20</span> </span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231_z9l5xgHzCn78" title="Expected volatility rate, minimum">41.66</span>% &#8211; <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210101__20211231_zxF37h0llfD2" title="Expected volatility rate, maximum">82.12</span> </span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zloucWdbBLFi" title="Expected term (years)">5.27</span> &#8211; <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zMkXH16V6tVb" title="Expected term (years)">10.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zwQg0SfmN1j7" title="Expected term (years)">5.00</span> &#8211; <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zqqypZoGbsvj" title="Expected term (years)">6.33</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zUk5mmoNcgc4" title="Risk-free interest rate, minimum">1.93</span>% &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_zx4JtZqhGoza" title="Risk-free interest rate, maximum">4.05</span> </span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zM9r7rsbRMKj" title="Risk-free interest rate, minimum">0.62</span>% &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z4IgDTqTMYN7" title="Risk-free interest rate, maximum">1.36</span> </span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z55QyJWamnB" title="Dividend rate">&#8211;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20210101__20211231_zvldb2069aud" title="Dividend rate">&#8211;</span></td><td style="text-align: left">%</td></tr>
  </table>


<p id="xdx_8A3_zSrmSo2Jlucf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2022, and 2021, the Company recognized $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn3d_c20220101__20221231_zD0tFCpJeAg7" title="Share based compensation expense">644,000</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn3d_c20210101__20211231_zzSnSJJjzYIk" title="Share based compensation expense">147,000</span>, respectively, in stock-based compensation
expense from stock option grants and restricted stock awards. The compensation expense is allocated on a departmental basis, based on
the classification of the option holder. No income tax benefits have been recognized in the statements of operations and comprehensive
loss for stock-based compensation arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z0gJ41gFB3ci" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the components of stock-based compensation expense recognized in the Company&#8217;s statements of operations
and comprehensive loss during the years ended December 31, 2022, and 2021 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zFdR7Y9e5dFc" style="display: none">Schedule of Stock Based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231_zkkJutwYNie4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zAqdqlJlNSDb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdq1lcl3QhL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">134</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">26</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zi7WroVL0aa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">121</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_z9E3W3bLCrpk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">147</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zExLIG7lNBui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, the Company granted <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20220131__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOnePlanMember_z4HTlOhmEq6f" title="Restricted common stock granted, shares">3,500</span> shares of restricted common stock under the 2021 Plan to a consultant as partial consideration
for services rendered, with a deemed fair value of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220131__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOnePlanMember_zHG8iiAP7ZEb" title="Shares issued price per share">04.03</span> per share or $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20220101__20220131__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOnePlanMember_zfi6pibqmSag" title="Restricted common stock granted">14,000</span>. The fair value of this restricted stock award was expensed
as stock-based compensation on the date of grant as they were fully vested on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the IPO, the Company issued warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zqWDMX75FiPf" title="Warrants to purchase common stock, shares">3,035,195</span> shares of the Company&#8217;s common stock. Warrants to purchase
<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--WarrantOneMember_z47LQMik2tMf" title="Warrants to purchase common stock, shares">198,875</span> shares of the Company&#8217;s common stock expire on <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zTwAhYJwedFh" title="Warrant maturity date">August 25, 2026</span>, and warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_zC3h2nKw8Cl3" title="Warrants to purchase common stock, shares">2,588,120</span> shares of the Company&#8217;s
common stock expire on August 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z6TnvXJOOGx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following is a summary of the common stock warrant activity during the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zkiAwBVDWOAi" style="display: none">Schedule
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares Issuable Upon Exercise of Outstanding Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted- Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_zzHO1g8FChAa" style="width: 11%; text-align: right" title="Warrants outstanding, beginning balance">2,786,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zeHynx49KD99" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning balance">10.80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1_dtY_c20220101__20221231_zQpiwlZMU0Gh" title="Weighted average remaining contractual life, beginning">4.67</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pn3n3_c20220101__20221231_zfdPZS9g7Vcd" style="width: 11%; text-align: right" title="Warrants aggregate intrinsic value, beginning balance">30,100</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_z11VanK8BtTh" style="text-align: right" title="Warrants outstanding, issued"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zECa7efFD2Jd" style="text-align: right" title="Weighted average exercise price, issued"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231_zK3FndpS0ZEh" style="text-align: right" title="Warrants outstanding, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zLTehmfOsYV7" style="text-align: right" title="Weighted average exercise price, execised"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Expired</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20221231_zEacbokXdHe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, expired"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zS1bumGzNnZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl0971">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231_zPL10zllLjef" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">2,786,995</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20220101__20221231_zhAXrZ4pepPk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">10.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm_dtY_c20220101__20221231_zeHKmgNkZvdb" title="Weighted average remaining contractual life, ending">3.67</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pn3n3_c20220101__20221231_zoYKrBANjfth" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants aggregate intrinsic value, ending balance">30,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zXvPbbOTtLVh" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534569456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">9. Income Taxes</a></td>
<td class="text"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zPKLolaUNZtl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_zEH2m7UQ28Kd">9.
Income Taxes</span></b></span></p>



<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, the Company&#8217;s income tax provision is zero due to a full valuation allowance against
the deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zISE6hPrbzg4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
differences between the tax provision (benefit) at the statutory federal tax rate and the tax provision (benefit) are as follows (in
thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zhPAUI2T6rF3" style="display: none">Schedule
of Statutory Tax Expense and Effective Tax Expense Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_znwCkOLBzlk9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zdxYlllhy1dj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzy4e_zjjnu3dFiCb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Statutory federal income tax</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,077</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,321</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Increase (decrease) resulting from:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzy4e_zIvMT4tL1cF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,624</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PermanentItems_pn3n3_maITEBzy4e_zPF9JUW6Ql06" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Permanent items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_pn3n3_maITEBzy4e_zDWWnkEvL1N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prior year true ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_pn3n3_di_msITEBzy4e_zui0sQdBQsJj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(421</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(176</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzy4e_zXOuWXnvO8O" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(922</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(331</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maITEBzy4e_zMdEFWMMFb6h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzy4e_zZ4R541HVdwl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zaMLnilyrr7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zqnDmx6II5ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zwERnc4H0kBa" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zWExNUiIyr79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231_zTCHjEHErix2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGze5H_zVEDOEaPu4Wd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,492</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,453</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTAGze5H_zZdx0VVhVfk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Tax credits carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">887</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGze5H_zm8ij9uvOk5b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGze5H_zYfhmut5ZGOj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fixed assets/intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsCharitableContributions_iI_pn3n3_maDTAGze5H_zL7gudQQ4zy6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Charitable contributions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsCapitalizedResearch_iI_pn3n3_maDTAGze5H_z4yE61bsHFC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Capitalized research</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1029">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGze5H_z7WNfzMvUDsb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accruals and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGze5H_maDTANzECi_z3Z5aAkreLF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gross deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,475</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzECi_z8yavthM81Jj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,475</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzECi_maDTALNzb8Q_zqf9ULAo52re" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zieDzIkSJN95" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_iI_pn3n3_maDTLzAtu_zQXjMLx0M3Mc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Unrealized gain</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilities_iTI_pn3n3_msDTALNzb8Q_mtDTLzAtu_zupbkngAbWp6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzb8Q_z6th2rHVgER8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_z4kzzpmdzLrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the Company had  federal and state net operating loss (&#8220;NOL&#8221;) carryforward amounts of $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20221231_zj9d2sRVYeyd" title="Net operating loss carryforward, federal">23.8</span> million
and $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20221231_zu4hcbVCHaR7" title="Net operating loss carryforward, state">17.4</span> million, respectively. The federal NOL carryforwards consists of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20171231_zWQDnyrTiUrb" title="Net operating loss carryforward, federal">4.6</span> million generated before January 1, 2018, which will
begin to expire in 2030 but are able to offset 100% of taxable income and $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20180101_zzy0ZlS65DH7">19.2</span> million generated after December 31, 2017 which can be
carried forward indefinitely and may be able to be used against 100% of taxable income through the tax year ending December 31, 2020,
as updated by the Coronavirus Aid, Relief, and Economic Security Act (P.L. 116-136), otherwise known as the CARES Act. Federal NOLs will
then be subject to 80% limitation for tax years beginning on or after January 1, 2021.The state NOL carryforward will begin to expire
in 2033.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had federal and state tax credit carryforwards of $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalAndStateMember_zVN81BfRFoDa" title="Federal and state tax credit carryforwards">1.5</span> million which will begin to expire in 2033,
and California tax credit carryforwards of $<span id="xdx_906_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsForeign_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--CaliforniaTaxCreditMember_zwcdrw2FaHDi" title="Tax credit carryforwards">0.3</span> million which do not expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows Financial Accounting Standards Board No. 48, <i>Accounting for Uncertainty in Income Taxes &#8211; an interpretation
of FASB No. 109</i>, as codified in FASB ASC 740-10, <i>Income Taxes</i>. At December 31, 2022, unrecognized tax benefits related to
federal and state tax credits was $<span id="xdx_908_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalAndStateMember_zae44oBzstne" title="Unrecognized tax benefits">0.4</span> million. The Company did not have tax-related interest and penalties at December 31, 2022. The
Company does not expect significant changes to its unrecognized tax benefits in the next twelve months. If recognized, none of the unrecognized
tax benefits would affect the effective tax rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of
ownership changes that have occurred previously or that may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code
(&#8220;IRC&#8221;) a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change
NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined
as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company
has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. If
an ownership change has occurred, the Company&#8217;s ability to use its NOLs or tax credit carryforwards may be restricted, which could
require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the CARES Act was enacted and signed into law in response to the COVID-19 pandemic. GAAP requires recognition of the
tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax
provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief
measures for businesses include a five-year net operating loss carryback, suspension of the annual deduction limitation of 80% of taxable
income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest,
acceleration of alternative minimum tax credit refunds, payroll tax relief, technical corrections on net operating loss carryforwards
for fiscal year taxpayers and allows accelerated deduction qualified improvement property. The CARES Act also provides other non-tax
benefits to assist those impacted by the pandemic. The Company filed for and received a PPP loan. We evaluated the impact of the CARES
Act and determined that there was no material impact for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2020, California Assembly Bill 85 was signed into law. The legislation suspended the California net operating loss deductions
for 2020 and 2021 for certain taxpayers. <span id="xdx_905_eus-gaap--IncomeTaxHolidayDescription_c20220101__20221231_zdkgTqOjCLbf" title="Income tax, description">The
legislation disallowed the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted
gross income is greater than $1.0 million. The carryover periods for net operating loss deductions disallowed by this provision will
be extended. The new legislation did not impact the current year provision or our financial statements for the year ended December
31, 2022.</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 27, 2020, the Consolidated Appropriations Act, 2021 was enacted and signed into law to further COVID-19 economic relief and
extend certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans
can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion
of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for
food and beverages provided by a restaurant. The provisions did not have a material impact on our financial statements for the year ended
December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Uncertain
Income Tax Positions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total amount of unrecognized tax benefits as of December 31, 2022 is $<span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20221231_zt0zamrvIUq4" title="Unrecognized tax benefits">0.4</span> million which relates to federal and state tax credits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zFOzddFMJnag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended December 31, 2021 and
December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_z9nQRS8rmQv2" style="display: none">Schedule
Of Unrecognized Tax Benefits</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20210101__20211231_zlAkIMc3Yvj8" style="width: 16%; text-align: right" title="Beginning unrecognized tax benefits">212</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax positions related to the current year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--UnrecognizedTaxBenefitsAdditions_pn3n3_c20210101__20211231_zx5A0gbbRgTh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions">97</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20220101__20221231_zZf73DBHBEr8" style="text-align: right" title="Beginning unrecognized tax benefits">309</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax positions related to the current year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--UnrecognizedTaxBenefitsAdditions_pn3n3_c20220101__20221231_zaBLvpM0dcOl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions">140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20220101__20221231_zLlD5lPVGDFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending unrecognized tax benefits">449</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zg9Z8q6uh2c6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy is to account for interest and penalties as income tax expense. As of December 31, 2022, the Company had no interest
related to unrecognized tax benefits. No amounts of penalties related to unrecognized tax benefits were recognized in the provision for
income taxes. We do not anticipate any significant change within twelve months of this reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is subject to U.S. federal
and state income tax examination for calendar tax years beginning in 2010 due to net operating losses that are being carried forward
for tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534687408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">10. Net Loss per Share</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_z1wm1SAxgZsf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zvfet6qHkRbg">10.
Net Loss per Share</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zWI0aCdsQ6F8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per common share was calculated as follows (in thousands except per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zPUU07vKP2Qd" style="display: none">Schedule of Computation of Basic and Diluted Net Loss Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zeDlRnkl1Gol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231_zGByHEN5YLgh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Numerator:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_z7YdMFcyoHij" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(9,889</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(6,324</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zx2FgHMzb9We" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares used in computing net loss per share &#8211; basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,052</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,217</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_zJdlTwHdUR45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss per share &#8211; basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.09</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.21</td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8A0_zEuCCVuWbK8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, the Company had a net loss and as such, all outstanding shares of potentially dilutive securities
were excluded from the calculation of diluted net loss per share as the inclusion would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zsI8Bz80kBPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities not included in the computation of diluted net loss per share because to do so would be antidilutive are as follows
(in common stock equivalent shares):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z8zSUZwNfVAc" style="display: none">Schedule of Potentially Anti Dilutive Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zYBSskZsHIbk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_z5oS6p1u9tY7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zwa1JLG0uCUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">730,746</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">684,382</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zLncqyhDISwj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">730,746</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">684,382</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zoSXZcADAMzj" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534633728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">11. Related Party Transactions</a></td>
<td class="text"><p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zY7ytfdEEJOa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_zC6AkHYgAC2g">11.
Related Party Transactions</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2018, the Company entered into a consulting agreement with one of the Company&#8217;s co-founders, Dr. Ramtin Agah, pursuant
to which Dr. Agah provides consulting services as the Company&#8217;s Chief Medical Officer by overseeing Company-sponsored clinical
trials. The agreement, which was amended on September 1, 2019, and November 11, 2021, respectively, continues in force for as long as
Dr. Agah is providing consulting services and may be terminated by either party on 30 days&#8217; notice. Dr. Agah was awarded (i) options
to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20170531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zQwpfXGjvQ6c" title="Share based compensation arrangement by share based payment award, options, outstanding, number">60,000</span> shares of the Company&#8217;s common stock in May 2017, which have vested, (ii) options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20180731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zATZqIRKL2Y1" title="Share based compensation arrangement by share based payment award, options, outstanding, number">40,000</span> shares
of the Company&#8217;s common stock in July 2018, which have vested, (iii) options to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zaTLKSU5kFOj" title="Share based compensation arrangement by share based payment award, options, outstanding, number">20,000</span> shares of the Company&#8217;s common
stock in June 2021, which vest ratably over 24 months from the vesting commencement date of May 14, 2021, (iv) options to purchase of
<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zZDysa0R16za" title="Share based compensation arrangement by share based payment award, options, outstanding, number">52,203</span> shares of the Company&#8217;s common stock in September 2021, which vest ratably over 48 months from the vesting commencement
date of August 26, 2021, and (v) options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zTW61Rdi4YFg">21,398</span> shares of the Company&#8217;s common stock in March 2022, which vest ratably
over 48 months from the vesting commencement date of August 26, 2021. In December 2018, Dr. Agah&#8217;s agreement was amended to provide
that he would receive cash compensation of $<span id="xdx_900_ecustom--CashCompensation_iI_pid_c20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_ztn4nE3TB11b" title="Cash compensation per month">4,000</span> per month for certain proctoring services, and in September 2019, his compensation
was increased to $<span id="xdx_90E_ecustom--CashCompensation_iI_pid_c20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zz9LA1fO0Uv5" title="Cash compensation per month">10,000</span> per month to compensate for additional services he was providing. <span style="background-color: white">In November
2021, we entered into a third amendment to the Consulting Agreement with Dr. Agah which </span>provides for a monthly consulting fee
of $<span id="xdx_903_ecustom--CashCompensation_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember_zY15KEeEQBe5" title="Cash compensation per month">22,000</span>, based on Dr. Agah spending no less than 24 hours per week on Company matters. Dr. Agah&#8217;s monthly consulting fee was
increased to $<span id="xdx_90A_ecustom--CashCompensation_iI_c20230101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember_zMEYYCuRR2ji" title="Cash compensation per month">25,000</span> effective January 1, 2023. The Company may, in its discretion, proportionally adjust the monthly consulting fee
if Dr. Agah&#8217;s time commitment decreases. The amendment also provides for Dr. Agah&#8217;s eligibility <span style="background-color: white">for
an annual target cash incentive bonus equal to 40% of his annualized base consulting fee. </span>In November 2021, we entered into a
Change in Control and Severance Agreement with Dr. Agah. Consulting fees paid to Dr. Agah for the years ended December 31, 2022 and 2021,
were $<span id="xdx_90B_eus-gaap--ProfessionalFees_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zeUJyoWuALH3" title="Consulting fees">289,000</span> and $<span id="xdx_90F_eus-gaap--ProfessionalFees_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zWgxpYIEO2l5" title="Consulting fees">227,000</span>, respectively. In addition, the Board approved a discretionary bonus of $<span id="xdx_900_ecustom--DiscretionaryBonus_c20230201__20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zf8thLilHH5f" title="Discretionary bonus">91,000</span> paid in February 2023 to Dr.
Agah in recognition of Company and individual performance during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534571456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">12. Employee Benefit Plans</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zoBcinCuV7W9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_823_zDW4KbaE84t9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
Employee Benefit Plans</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (the &#8220;401(k)
plan&#8221;). The 401(k) plan covers all employees who meet defined minimum age and service requirements. Employee contributions are
voluntary and are determined on an individual basis, limited to the maximum amount allowable under U.S. federal tax regulations. The
Company makes matching contributions of up to 4% of the eligible employees&#8217; compensation to the 401(k) plan. During the year ended
December 31, 2022, the Company made contributions to the 401(k) plan of $<span id="xdx_908_eus-gaap--DefinedContributionPlanCostRecognized_c20220101__20221231_zI1IIJFbvGPi" title="Defined contribution plan cost">10,200</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534493104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">13. Subsequent Events</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zMrrihvOSjJ5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zBNonuzS9HW8">13.
Subsequent Events</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 30, 2023, the Company entered into a
definitive securities purchase agreement with a certain institutional investor under its shelf registration statement for the
purchase and sale of <span id="xdx_903_eus-gaap--SharesIssued_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrZvFV9ZR8Cg">1,557,632</span> shares of the Company&#8217;s common stock (or pre-funded common stock warrants) at a purchase price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWfeMXxHygJg">3.21</span> per share of common stock (or pre-funded common stock warrants) (the &#8220;Registered Direct Offering&#8221;).
Additionally, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlDJzRZJMKm8">1,947,040</span>
shares of its common stock (together with the Registered Direct Offering, the &#8220;March 2023 Offering&#8221;). The aggregate gross
proceeds from the March 2023 Offering are approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfWarrants_c20230329__20230330__us-gaap--TypeOfArrangementAxis__custom--DefinitiveSecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXlwwxjhGKr8" title="Stock warrants">5</span>
million before deducting placement fees and other offering expenses.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423528836032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHm1cDSYh01f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zG1ruHCYXIbd">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the SEC for annual reporting. Any reference in these notes to
applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and as amended by Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_847_ecustom--RisksAndUncertaintiesPolicyTextBlock_zZrgs7WSpMNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z51snjERV0r3">Risks
and Uncertainties</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to a number of risks associated with companies at a similar stage, including the risk associated with the development
of products that must receive regulatory approval before market launch, dependence on key individuals, competition from larger and established
companies, volatility of the industry, ability to obtain adequate financing to support growth, the ability to attract and retain additional
qualified personnel to manage the anticipated growth of the Company and general economic conditions. The Company is subject to a number
of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional
funding, possible failure of current or future preclinical studies or clinical trials, its reliance on third parties to conduct its clinical
trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations,
the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, protection of its proprietary
technology, and the need to secure and maintain adequate manufacturing arrangements with third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic, and government responses have created
disruption in global supply chains and adversely impacting many industries. The pandemic could have a continued material adverse
impact on economic and market conditions. We continue to monitor the impact of the COVID-19 pandemic, including its most recent
variants, closely. The extent to which the COVID-19 pandemic will impact our operations or financial results is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--UseOfEstimates_z3bSwlo5Tfv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zJb5n2pFu3Ze">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, income and expenses as well as the disclosure of contingent assets and liabilities, at the date of
the financial statements during the reporting periods. In preparing these financial statements, management has made its best estimates
and judgments of certain amounts included in the financial statements. Significant estimates and assumptions made in the accompanying
financial statements include, but are not limited to, accruals of certain liabilities, including clinical trial accruals and other contingences,
the valuation of financial instruments, the fair value of the Company&#8217;s common stock and the fair value of options granted under
the Company&#8217;s equity incentive plan. On an ongoing basis, the Company evaluates its estimates, including those related to the fair
values of assets, stock-based compensation, clinical trial accruals and other contingencies. Management bases its estimates on historical
experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially
from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Significant Suppliers</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zfVCgmA1nhZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zXBZz0M0lnF3">Concentration
of Credit Risk and Significant Suppliers</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents.
The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits
of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zYUqTu6FA627" title="Cash, FDIC insured amount">250,000</span>. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents
to the extent recorded in the balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relied, and expects to rely, on a small number of third-party manufacturers to manufacture and supply its RenovoCath devices
and its product candidates for clinical trials. These activities could be adversely affected by a significant interruption in supply
of these items. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate
product revenue or achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segment</a></td>
<td class="text"><p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z7URk1O0oT89" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z2qSqRpAXAn9">Operating
Segment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as one reportable and operating segment, which is the development of a therapy platform to
deliver de-risked small molecules for localized treatment of solid cancer tumors. The Company&#8217;s chief executive officer, who is
the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial
performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zNIt6IHC8Ihb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zvaBkezXnvCb">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during
the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average
number of shares of common stock and common stock equivalents of potentially dilutive securities outstanding for the period determined
using the treasury stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of convertible preferred
stock, convertible notes, and warrants including options and restricted stock awards outstanding under the Company&#8217;s Equity Incentive
Plan. For the years ended December 31, 2022 and 2021, there was no difference in the number of shares used to calculate basic and diluted
shares outstanding as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zf3Oqho5xbeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zgthSnXO9tCf">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the
principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement
date. Fair value measurement establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where
available, and minimize the use of unobservable inputs when measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the fair value of financial assets and liabilities using the fair value hierarchy that describes three levels of inputs
that may be used to measure fair value, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Valuations based on unobservable inputs reflecting the Company&#8217;s assumptions, consistent with reasonably available assumptions
made by other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of financial instruments disclosed in the financial statements has been determined by using available market information
and appropriate valuation methodologies. In certain cases where there is limited activity or less transparency around inputs to valuation,
securities are classified as Level 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of current assets, accounts payable and accrued expenses are generally considered to be representative of their respective
fair values because of their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text"><p id="xdx_842_ecustom--CashCashEquivalentsAndInvestmentsPolicyTextBlock_zNYL71lzWeP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zMgcde5Caltc">Cash,
Cash Equivalents and Investments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
Available-for-sale securities, comprised of obligations of the U.S. government and its agencies, are carried at fair value, with unrealized
gains and losses recorded within other comprehensive income (loss) as a separate component of stockholders&#8217; equity. Realized gains
and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in earnings.
Purchases and sales of investment securities are recognized on a trade date basis. The cost of investment securities sold is determined
by the specific identification method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_LeaseholdImprovementsPolicyTextBlock', window );">Leasehold Improvements, Net</a></td>
<td class="text"><p id="xdx_84D_ecustom--LeaseholdImprovementsPolicyTextBlock_zfbhBvrEoTt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zde547Z2XjD2">Leasehold
Improvements, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are presented at cost, net of accumulated amortization. Amortization expense is recorded using the straight-line method
over the shorter of the remaining lease term or the estimated useful life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8NrWqrEa898" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zQ3RwuZqIjOb">Research
and Development Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses includes personnel costs including salaries,
benefits and stock-based compensation. In addition, it includes expenses for consultants that support clinical trial studies, materials
costs, external clinical drug product manufacturing costs, outside services costs, regulatory activities including filing fees, fees
for maintaining licenses and other amounts due to third-party agreements, laboratory materials, clinical trial, as noted above, and supplies
to support our research activities, including allocated facility and general and administrative indirect overhead related costs. The
Company also receives payments from clinical trial sites for RenovoCath delivery devices used in the Phase III clinical trial. Payments
received from clinical sites cover the direct costs of manufacturing the RenovoCath delivery devices and offset research and development
expenses were $<span id="xdx_90B_ecustom--PaymentsReceivedFromClinicalSites_iN_di_c20220101__20221231__dei--LegalEntityAxis__custom--RenovoCathMember_z4VvX720kpl" title="Payments received from clinical sites">141,000</span> and $<span id="xdx_906_ecustom--PaymentsReceivedFromClinicalSites_iN_di_c20210101__20211231__dei--LegalEntityAxis__custom--RenovoCathMember_zgJzPsC14hh6" title="Payments received from clinical sites">233,000</span> for December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_ClinicalTrialExpensesPolicyTextBlock', window );">Clinical Trial Expenses</a></td>
<td class="text"><p id="xdx_84C_ecustom--ClinicalTrialExpensesPolicyTextBlock_zXY6GkKFJes4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zzOdLv079NZ7">Clinical
Trial Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company makes payments in connection with its ongoing Phase III clinical trial under contracts with clinical trial sites and contract
research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation
and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to
be performed at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts
depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including
actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related
to patient enrollment or treatment are accrued when reasonably estimable. If amounts and obligations to pay under clinical trial agreements
are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are
adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give
rise to the revision become reasonably certain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text"><p id="xdx_843_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zZL0Ddreuegi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zDAPKDqaalhi">General
and Administrative</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of salaries, benefits, and stock-based compensation for personnel in executive, finance and administrative
functions, professional services and associated costs related to accounting, tax, audit, legal, intellectual property, consulting costs,
conferences and travel, including allocated facility and general and administrative indirect overhead related costs to research and development
expenses. General and administrative expenses are expensed in the period incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_ConvertiblePreferredStockPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p id="xdx_84A_ecustom--ConvertiblePreferredStockPolicyTextBlock_z2inqu5ckCW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zXapwkm74uu1">Convertible
Preferred Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records preferred stock at fair value on the date of issuance, net of issuance costs. Preferred stock was previously recorded
outside of stockholders&#8217; equity (deficit) because the shares contained liquidation features that were not solely within the Company&#8217;s
control and was classified as mezzanine equity (temporary equity). The Company completed its IPO on August 30, 2021, which triggered
the automatic conversion of all outstanding convertible preferred stock to common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3EXFdb2Ywf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zhgs7Fwf7Ub">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock options using the Black-Scholes option pricing model, which incorporates various assumptions
including volatility, expected term and risk-free interest rate. Compensation related to service-based awards is recognized starting
on the grant date on a straight-line basis over the vesting period, which is generally four years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
determination of the fair value of each stock award using this option-pricing model is affected by the Company&#8217;s assumptions regarding
a number of complex and subjective variables. These variables include, but are not limited to, the fair value of the common stock at
the date of grant, the expected term of the awards, the expected stock price volatility over the expected term of the awards, the risk-free
interest rate, and the dividend rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Common Stock</i>&#8212;Prior to the IPO, given the absence of a public trading market, the Company&#8217;s Board of Directors
considered numerous objective and subjective factors to determine the fair value of the Company&#8217;s common stock at each grant date.
These factors included, but were not limited to: (i) contemporaneous third-party valuations of common stock; (ii) the prices for preferred
stock sold to outside investors; (iii) the rights and preferences of preferred stock relative to common stock; (iv) the lack of marketability
of the Company&#8217;s common stock; (v) developments in the business; and (vi) the likelihood of achieving a liquidity event, such as
an IPO or sale of the business, given prevailing market conditions. The methodology to determine the fair value of the Company&#8217;s
common stock included estimating the fair value of the enterprise using the &#8220;backsolve&#8221; method, which is a market approach
that assigns an implied enterprise value by accounting for all share class rights and preferences based on the latest round of financing.
The total equity value implied was then applied in the context of an option pricing model to determine the value of each class of the
Company&#8217;s shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
grants issued post-IPO the closing price of the Company&#8217;s common stock as reported on the date of grant will determine the fair
value of the Company&#8217;s common stock, as shares of the Company&#8217;s common stock are traded in the public market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. The Company determines
the expected term using the simplified method for pre-IPO and post-IPO awards. The simplified method deems the term to be the average
of the time-to-vesting and the contractual life of the options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>&#8212;Given the absence of a public trading market, pre-IPO and post IPO, the expected volatility is estimated by taking
the average historic price volatility for industry peers, consisting of several public companies in the Company&#8217;s industry that
are either similar in size, stage, or financial leverage, over a period equivalent to the expected term of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
Interest Rate</i>&#8212;The risk-free interest rate is calculated using the average of the published interest rates of U.S. Treasury
zero-coupon issues with maturities that are commensurate with the expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Rate</i>&#8212;The dividend yield assumption is zero as the Company has no plans to make dividend payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generally granted stock options, pre-IPO, to its employees and consultants for a fixed number of shares with an exercise price
equal to the fair value of the underlying shares at date of grant. For all post-IPO grants issued, the fair value will be the closing
price of the Company&#8217;s common stock on the date of the grant. The Company accounts for all stock option grants using the fair value
method and stock-based compensation is recognized as the underlying options vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zyJ95pZT0R6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z9a65EAP1rof">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities
using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation
allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax
credit carryforwards for all periods presented, as realization of such deferred tax assets cannot be determined to be more likely than
not. Due to losses incurred for all periods presented, the Company does not record tax provision or benefit for income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock', window );">Emerging Growth Company and Smaller Reporting Company Status</a></td>
<td class="text"><p id="xdx_84B_ecustom--EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_zmoviQgLuoP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zouHFmdnzxFk">Emerging
Growth Company and Smaller Reporting Company Status</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company (&#8220;EGC&#8221;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;) and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of
the JOBS Act exempts emerging growth companies from complying with new or revised financial accounting standards until private companies
are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or
revised accounting standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 of the Exchange Act. If we are a smaller reporting company
at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that
are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most
recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, like emerging growth companies, smaller reporting
companies have reduced disclosure obligations regarding executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of
the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not
have a material impact on the Company&#8217;s financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncement</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zvmRGpDTUZLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z7CvUQUNAWec">Recent
Accounting Pronouncement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Adopted Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued Accounting Standards Updates (&#8220;ASU&#8221;) 2016-02, <i>Leases (Topic 842)</i>. The guidance requires
lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expands disclosure requirements regarding
leasing arrangements. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting the new
lease standards, and a package of practical expedients an entity can elect to utilize to reduce the level of effort required for adoption.
Under the transition option, entities can elect to apply the new guidance using a modified retrospective approach at the beginning of
the year in which the new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements.
In November 2019, the FASB issued ASU 2019-10, Leases (Topic 842) (ASU 2019-10), deferring the effective date for the Company for fiscal
years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the
FASB issued ASU 2020-05, Leases (Topic 842) (ASU 2020-05), which further defers the effective date for the Company for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2021. Early adoption is permitted. The
Company adopted ASU 2016-02 on January 1, 2022 and the adoption had no material impact to the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, <i>Income Taxes (Topic 740)</i>: Simplifying the Accounting for Income Taxes (ASU 2019-12),
which simplifies the accounting for income taxes, and is effective on a prospective basis for annual reporting periods beginning after
December 15, 2021, and for interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The
Company adopted ASU 2019-12 on January 1, 2022 and the adoption had no significant impact to the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments&#8212;Credit Losses (Topic 326)</i>. The guidance represents a significant
change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected
credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has
met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU 2019-10, <i>Financial Instruments
&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)</i> &#8212;Effective Dates amended the
effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU 2016-13
effective January 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) </i>(ASU 2020-06): <i>Accounting for Convertible Instruments
and Contracts in an Entity</i>, which simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The updated guidance is effective on a prospective
basis for annual reporting periods beginning after December 15, 2023 and for interim periods within those periods. Early adoption is
permitted. The Company has not yet determined the impact that this new standard will have on its financial position and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents and Investments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_ClinicalTrialExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Expenses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_ClinicalTrialExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_ConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_ConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company and Smaller Reporting Company Status [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_LeaseholdImprovementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Improvements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_LeaseholdImprovementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534516576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Short-Term Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Short-Term Marketable Securities</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--MarketableSecuritiesTextBlock_zpgIdIns1l6j" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tables summarize the Company&#8217;s short-term marketable securities as of December 31, 2022. There were no short-term marketable securities
as of December 31, 2021 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zHj7Nl5NtCgi" style="display: none">Schedule of Short-Term Marketable Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost Basis</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross<br/>
 Unrealized <br/>
Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">U.S. Treasury bills</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zJ3QUD31T3e6" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, amortized cost basis">2,032</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zNouzYQi2sFl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, unrealized gains">17</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zhJwDgAPBzvl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, unrealized losses">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0568">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zJYVlLezGF5b" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, fair value">2,049</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231_zlY8Ose76Y26" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, amortized cost basis">2,032</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20220101__20221231_zOSo7eebN7o" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, unrealized gains">17</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_pn3n3_c20220101__20221231_z4cvmiBhQxv6" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, unrealized losses"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20221231_zptcH7QfQkM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, fair value">2,049</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423534577632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zaI6UZsjLPUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of accrued expenses as of December 31, 2022 and 2021 are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z5s1YR1nkjRf" style="display: none">Schedule of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_z1q2B2nJ9wWi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_z7AloTSk40u8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccruedClinicalTrialsCurrent_iI_pn3n3_maALCz7Fz_zuCHB2xDe85l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Clinical trial</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCz7Fz_z1ZeFp8Gq2T5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz7Fz_zfOTfAd00q12" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz7Fz_zyJZo7LN00xi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">568</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">413</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423533264416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zpZmx6gcBMW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables sets summarize the Company&#8217;s financial assets and liabilities, measured at fair value on a recurring basis by
level within the fair value hierarchy, as of December 31, 2022, and 2021, (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zet2hQgJ3eu4" style="display: none">Schedule of Assets Measured at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements at December 31, 2022 using:</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: justify">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzd2NeqEDoIg" style="width: 11%; text-align: right" title="Fair value of assets">4,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxuNynEj3Xlg" style="width: 11%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0608">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLQaqRfgJKM9" style="width: 11%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z33j61y5Poo6" style="width: 11%; text-align: right" title="Fair value of assets">4,300</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify">Available-for-sale securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">U.S. Treasury bills</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUSrdJfYPzM6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets">2,049</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z89997Oz1RB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zumaZefHWfA6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0618">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zhgBiDaw7oj2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets">2,049</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgwbzalb2qXh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets">6,349</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLvimprryWca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0624">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z1odUC8sDVj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0626">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUlmWsAFlscd" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets">6,349</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements at December 31, 2021 using:</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1.5pt">Money market funds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets">14,997</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets">14,997</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets">14,997</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zKD4iPGVrgy2" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets">14,997</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Changes in Fair value of Derivative Liability</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zwMrkrPNNc6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in the fair value of the derivative liability is summarized below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_ztgGfeOkweQ5" style="display: none">Schedule
of Changes in Fair value of Derivative  Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zLhzDhgZ5vY9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_z3ttAK4m1FOj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_zDUxWPk0UNf1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Fair value, beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">856</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_zA2FujfEpSXk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Initial fair value of instruments issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_iN_pn3n3_di_zvG1x1KBm9S" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in fair value of instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(118</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_iN_pn3n3_di_zaATWrAox2L9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Conversion upon IPO</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0657">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,101</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_zYyzo1V7WLia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Fair value, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0661">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423530509264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Award Activity</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPXCuaMrMkbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity for the year ended December 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_z9zGbXyz3wT2" style="display: none">Summary of Stock Option Award Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual Life</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zGSYfJR9fNHk" style="width: 11%; text-align: right" title="Number of stock options outstanding, beginning balance">926,379</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zGZdtN3G5Nhk" style="width: 11%; text-align: right" title="Weighted average exercise price outstanding, beginning balance">2.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zYUIANnIXUlj" title="Weighted average remaining contractual life">6.47</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zx7IgMGZWtMc" style="width: 11%; text-align: right" title="Aggregate intrinsic value outstanding, beginning balance">2,856</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zcqgUOF5Wjz3" style="text-align: right" title="Number of stock options, granted">724,937</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z1Eo5FlUoYVi" style="text-align: right" title="Weighted average exercise price, granted">2.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zRH2UD1HMjVj" style="text-align: right" title="Number of stock options, exercised">(160,212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zJdKL50TwPwh" style="text-align: right" title="Weighted average exercise price, exercised">0.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zESlJyJBftqb" style="text-align: right" title="Number of stock options, forfeited">(91,852</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zvdCkn7KclD6" style="text-align: right" title="Weighted average exercise price, forfeited">3.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zbTNjo7QEVag" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, ending balance">1,399,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zra4NJ8fb5rf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, ending balance">2.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zVabW1TJeaFj" title="Weighted average remaining contractual life">7.79</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zkbXJYj1UBS9" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value outstanding, ending balance">928</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231_zOq0XSfUMV05" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options, exercisable">662,909</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zDcWpB1BGtg3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">1.79</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zNglQUMFd5T" title="Weighted average remaining contractual life, exercisable">5.87</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zxx9YEqHRkv1" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, exercisable">823</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Vested and expected to vest as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20220101__20221231_zn4vll4Yh4C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options, vested and expected to vest">1,399,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_z5LizxuZWzwb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest">2.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zeuKVHvmGwL4" title="Weighted average remaining contractual life, vested and expected">7.79</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231_zToJ1H1ieup6" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, vested and expected to vest">928</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Ranges of Stock Options</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztcd4lqxqpP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the outstanding and exercisable options as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zFha8OOSuneh" style="display: none">Schedule of Ranges of Stock Options</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    Outstanding</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    Exercisable</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
    of <br/>
    Exercise Prices</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
 Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>

    Average<br/>
 Remaining<br/>
 Contractual Life</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of <br/>
Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>

    Average<br/>
 Remaining<br/>
 Contractual Life</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z5rNdY6OzZVj" title="Range of Exercise Prices, Lower Range">0.00</span> - $ <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zf8czkAbXnK9" title="Range of Exercise Prices, Upper Range">1.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYbWOs19alM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">459,080</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zg6ePRyjccT" title="Weighted-Average Remaining Contractual Life (years)">4.51</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zUB3dHBzejib" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">456,179</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zBu7Uv5hRHel" title="Weighted-Average Remaining Contractual Life (years)">4.49</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zvN6YN7iB3q6" title="Range of Exercise Prices, Lower Range">1.01</span> - $ <span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zDTwD7xni7Y4" title="Range of Exercise Prices, Upper Range">2.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zVePqkSbGF81" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130,510</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zrZyhq50ZDW6" title="Weighted-Average Remaining Contractual Life (years)">9.91</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z4cMh4UWdgpc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,909</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zNd8ggKQxyka" title="Weighted-Average Remaining Contractual Life (years)">9.91</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zl8Q0fDKya95" title="Range of Exercise Prices, Lower Range">2.01</span> - $ <span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zbWTMnWxqDhg" title="Range of Exercise Prices, Upper Range">3.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvxs2lgfSeA3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">459,786</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z5fpbpYTJkKc" title="Weighted-Average Remaining Contractual Life (years)">9.65</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zc1lwe7Grcqk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,850</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvlb8PjYAAEl" title="Weighted-Average Remaining Contractual Life (years)">9.09</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zgBxrzN0yOLf" title="Range of Exercise Prices, Lower Range">3.01</span> - $ <span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zq6SXywbaQK5" title="Range of Exercise Prices, Upper Range">4.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zNPwQ8t24Hv5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,530</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zTnImbMjTE5k" title="Weighted-Average Remaining Contractual Life (years)">9.19</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zezaWnJujP69" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,066</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zo1qesulux2h" title="Weighted-Average Remaining Contractual Life (years)">9.19</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zCxoKiXg2xwg" title="Range of Exercise Prices, Lower Range">5.01</span> - $ <span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zONVLRvLJ0J2" title="Range of Exercise Prices, Upper Range">6.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zjX6Lc3Nmlhf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,924</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_z2l1OVuApgad" title="Weighted-Average Remaining Contractual Life (years)">8.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zbYdzUUHS4Qe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,530</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zn3KLNahR1if" title="Weighted-Average Remaining Contractual Life (years)">8.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zKf6UX0UgpQi" title="Range of Exercise Prices, Lower Range">6.01</span> - $ <span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zqP8Z9cgvhj5" title="Range of Exercise Prices, Upper Range">7.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_z9MOD6y1umgb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170,069</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zWpknXv68bai" title="Weighted-Average Remaining Contractual Life (years)">8.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zgync7dhd7Z5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,689</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_z3SHETyQHIM" title="Weighted-Average Remaining Contractual Life (years)">8.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    <span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zPhAjbNOaSNa" title="Range of exercise prices, lower range">8.01</span> - $ <span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zVtEqkrDcpgl" title="Range of exercise prices, upper range">9.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zwrIQdMHrlGk" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,353</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zBLpFhGXgv05" title="Weighted-Average Remaining Contractual Life (years)">8.86</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_z7e8oc5JHvl7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">686</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_z128nPWWJqo9" title="Weighted-Average Remaining Contractual Life (years)">8.86</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231_zhcALNiEz5M" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,399,252</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zOFJi9YrJyah" title="Weighted-average remaining contractual life (years)">7.79</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231_zOf4oIldFVGi" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">662,909</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5c85f2Fv3Y6" title="Weighted-average remaining contractual life (years)">5.87</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimate Fair Value of Stock Options</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeO0yovDjQS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022, and 2021, the Company utilized the Black-Scholes option-pricing model for estimating the fair value
of the stock option granted. The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option
pricing model with the following weighted-average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zfm8IqfHxek4" style="display: none">Schedule of Estimate Fair Value of Stock Options</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended December 31,</b></span></td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; width: 60%; font-size: 11pt"/><td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231_z0YfCh9eP8ci" title="Expected volatility rate, minimum">100.48</span>% &#8211; <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231_zW9Fw3q4q5Bh" title="Expected volatility rate, maximum">103.20</span> </span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231_z9l5xgHzCn78" title="Expected volatility rate, minimum">41.66</span>% &#8211; <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210101__20211231_zxF37h0llfD2" title="Expected volatility rate, maximum">82.12</span> </span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zloucWdbBLFi" title="Expected term (years)">5.27</span> &#8211; <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zMkXH16V6tVb" title="Expected term (years)">10.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zwQg0SfmN1j7" title="Expected term (years)">5.00</span> &#8211; <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zqqypZoGbsvj" title="Expected term (years)">6.33</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zUk5mmoNcgc4" title="Risk-free interest rate, minimum">1.93</span>% &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_zx4JtZqhGoza" title="Risk-free interest rate, maximum">4.05</span> </span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zM9r7rsbRMKj" title="Risk-free interest rate, minimum">0.62</span>% &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z4IgDTqTMYN7" title="Risk-free interest rate, maximum">1.36</span> </span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z55QyJWamnB" title="Dividend rate">&#8211;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20210101__20211231_zvldb2069aud" title="Dividend rate">&#8211;</span></td><td style="text-align: left">%</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Stock Based Compensation Expense</a></td>
<td class="text"><p id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z0gJ41gFB3ci" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the components of stock-based compensation expense recognized in the Company&#8217;s statements of operations
and comprehensive loss during the years ended December 31, 2022, and 2021 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zFdR7Y9e5dFc" style="display: none">Schedule of Stock Based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231_zkkJutwYNie4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zAqdqlJlNSDb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdq1lcl3QhL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">134</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">26</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zi7WroVL0aa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">121</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_z9E3W3bLCrpk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">147</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z6TnvXJOOGx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following is a summary of the common stock warrant activity during the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zkiAwBVDWOAi" style="display: none">Schedule
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares Issuable Upon Exercise of Outstanding Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted- Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_zzHO1g8FChAa" style="width: 11%; text-align: right" title="Warrants outstanding, beginning balance">2,786,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zeHynx49KD99" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning balance">10.80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1_dtY_c20220101__20221231_zQpiwlZMU0Gh" title="Weighted average remaining contractual life, beginning">4.67</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pn3n3_c20220101__20221231_zfdPZS9g7Vcd" style="width: 11%; text-align: right" title="Warrants aggregate intrinsic value, beginning balance">30,100</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_z11VanK8BtTh" style="text-align: right" title="Warrants outstanding, issued"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zECa7efFD2Jd" style="text-align: right" title="Weighted average exercise price, issued"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231_zK3FndpS0ZEh" style="text-align: right" title="Warrants outstanding, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zLTehmfOsYV7" style="text-align: right" title="Weighted average exercise price, execised"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Expired</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20221231_zEacbokXdHe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, expired"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zS1bumGzNnZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl0971">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231_zPL10zllLjef" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">2,786,995</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20220101__20221231_zhAXrZ4pepPk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">10.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm_dtY_c20220101__20221231_zeHKmgNkZvdb" title="Weighted average remaining contractual life, ending">3.67</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pn3n3_c20220101__20221231_zoYKrBANjfth" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants aggregate intrinsic value, ending balance">30,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531134848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Statutory Tax Expense and Effective Tax Expense Benefit</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zISE6hPrbzg4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
differences between the tax provision (benefit) at the statutory federal tax rate and the tax provision (benefit) are as follows (in
thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zhPAUI2T6rF3" style="display: none">Schedule
of Statutory Tax Expense and Effective Tax Expense Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_znwCkOLBzlk9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zdxYlllhy1dj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzy4e_zjjnu3dFiCb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Statutory federal income tax</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,077</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,321</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Increase (decrease) resulting from:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzy4e_zIvMT4tL1cF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,624</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PermanentItems_pn3n3_maITEBzy4e_zPF9JUW6Ql06" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Permanent items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_pn3n3_maITEBzy4e_zDWWnkEvL1N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prior year true ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_pn3n3_di_msITEBzy4e_zui0sQdBQsJj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(421</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(176</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzy4e_zXOuWXnvO8O" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(922</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(331</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maITEBzy4e_zMdEFWMMFb6h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzy4e_zZ4R541HVdwl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zqnDmx6II5ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zwERnc4H0kBa" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zWExNUiIyr79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231_zTCHjEHErix2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGze5H_zVEDOEaPu4Wd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,492</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,453</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTAGze5H_zZdx0VVhVfk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Tax credits carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">887</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGze5H_zm8ij9uvOk5b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGze5H_zYfhmut5ZGOj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fixed assets/intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsCharitableContributions_iI_pn3n3_maDTAGze5H_zL7gudQQ4zy6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Charitable contributions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsCapitalizedResearch_iI_pn3n3_maDTAGze5H_z4yE61bsHFC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Capitalized research</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1029">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGze5H_z7WNfzMvUDsb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accruals and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGze5H_maDTANzECi_z3Z5aAkreLF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gross deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,475</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzECi_z8yavthM81Jj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,475</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzECi_maDTALNzb8Q_zqf9ULAo52re" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zieDzIkSJN95" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_iI_pn3n3_maDTLzAtu_zQXjMLx0M3Mc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Unrealized gain</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilities_iTI_pn3n3_msDTALNzb8Q_mtDTLzAtu_zupbkngAbWp6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzb8Q_z6th2rHVgER8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule Of Unrecognized Tax Benefits</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zFOzddFMJnag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended December 31, 2021 and
December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_z9nQRS8rmQv2" style="display: none">Schedule
Of Unrecognized Tax Benefits</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20210101__20211231_zlAkIMc3Yvj8" style="width: 16%; text-align: right" title="Beginning unrecognized tax benefits">212</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax positions related to the current year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--UnrecognizedTaxBenefitsAdditions_pn3n3_c20210101__20211231_zx5A0gbbRgTh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions">97</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20220101__20221231_zZf73DBHBEr8" style="text-align: right" title="Beginning unrecognized tax benefits">309</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax positions related to the current year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--UnrecognizedTaxBenefitsAdditions_pn3n3_c20220101__20221231_zaBLvpM0dcOl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions">140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20220101__20221231_zLlD5lPVGDFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending unrecognized tax benefits">449</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423535639904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zWI0aCdsQ6F8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per common share was calculated as follows (in thousands except per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zPUU07vKP2Qd" style="display: none">Schedule of Computation of Basic and Diluted Net Loss Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zeDlRnkl1Gol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231_zGByHEN5YLgh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Numerator:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_z7YdMFcyoHij" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(9,889</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(6,324</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zx2FgHMzb9We" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares used in computing net loss per share &#8211; basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,052</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,217</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_zJdlTwHdUR45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss per share &#8211; basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.09</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.21</td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Anti Dilutive Securities</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zsI8Bz80kBPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities not included in the computation of diluted net loss per share because to do so would be antidilutive are as follows
(in common stock equivalent shares):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z8zSUZwNfVAc" style="display: none">Schedule of Potentially Anti Dilutive Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zYBSskZsHIbk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_z5oS6p1u9tY7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zwa1JLG0uCUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">730,746</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">684,382</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zLncqyhDISwj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">730,746</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">684,382</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423528964384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. Business and Principal Activities (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2021</div></th>
<th class="th"><div>Aug. 25, 2021</div></th>
<th class="th"><div>Aug. 05, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Over allotment option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders equity, reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-5 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents, and Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,889<span></span>
</td>
<td class="nump">6,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,173<span></span>
</td>
<td class="nump">$ 21,284<span></span>
</td>
<td class="nump">$ 31,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_MaximumPossibleProceedsFromOfferings', window );">Maximum possible proceeds from offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=RNXT_UnderwriterMember', window );">Underwriter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,035,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,035,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights</a></td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_UnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_NetProceedsFromIntialPublicOffering', window );">Net proceeds from intial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,535,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">converted at a 20% and 12.5% discount to the IPO price, respectively, into an aggregate of 708,820
units. Each unit consisted of (a) one share of common stock and (b) one five-year warrant to purchase one share of common stock at an
exercise price equal to $10.80 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">708,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Underwriter [Member] | Over Allotment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Over allotment option to purchase</a></td>
<td class="nump">277,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Underwriter [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_MaximumPossibleProceedsFromOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum possible proceeds from offerings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_MaximumPossibleProceedsFromOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_NetProceedsFromIntialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from intial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_NetProceedsFromIntialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_UnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_UnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=RNXT_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=RNXT_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RNXT_OverAllotmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RNXT_OverAllotmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423530524592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=RNXT_RenovoCathMember', window );">RenovoCath [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_PaymentsReceivedFromClinicalSites', window );">Payments received from clinical sites</a></td>
<td class="nump">$ 141,000<span></span>
</td>
<td class="nump">$ 233,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_PaymentsReceivedFromClinicalSites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments received from clinical sites.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_PaymentsReceivedFromClinicalSites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=RNXT_RenovoCathMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=RNXT_RenovoCathMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531141664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Short-Term Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term marketable securities, amortized cost basis</a></td>
<td class="nump">$ 2,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Short-term marketable securities, unrealized gains</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Short-term marketable securities, unrealized losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities, fair value</a></td>
<td class="nump">2,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term marketable securities, amortized cost basis</a></td>
<td class="nump">2,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Short-term marketable securities, unrealized gains</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Short-term marketable securities, unrealized losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities, fair value</a></td>
<td class="nump">$ 2,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423530511456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_AccruedClinicalTrialsCurrent', window );">Clinical trial</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee benefits</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 568<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_AccruedClinicalTrialsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_AccruedClinicalTrialsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423528912528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">$ 6,349<span></span>
</td>
<td class="nump">$ 14,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">14,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">2,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">6,349<span></span>
</td>
<td class="nump">14,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">14,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">2,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531060688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Fair value of Derivative Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value, beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Initial fair value of instruments issued</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease', window );">Change in fair value of instruments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet', window );">Conversion upon IPO</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value, end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423533492944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>5. Fair Value Measurements (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds, at carrying value</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423528613952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Convertible Notes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="nump">708,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyConvertibleNotesMember', window );">2020 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes', window );">Maximum possible total proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyConvertibleNotesMember', window );">2020 Convertible Notes [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyOneConvertibleNotesMember', window );">2021 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 363,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 386,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember', window );">2020 and 2021 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=RNXT_NotePurchaseAgreementMember', window );">Note Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=RNXT_NotePurchaseAgreementMember', window );">Note Purchase Agreement [Member] | 2020 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=RNXT_NotePurchaseAgreementMember', window );">Note Purchase Agreement [Member] | 2020 and 2021 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=RNXT_NotePurchaseAgreementMember', window );">Note Purchase Agreement [Member] | 2021 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum possible total proceeds from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyOneConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyOneConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RNXT_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RNXT_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423527657616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lessee, operating lease, description</a></td>
<td class="text">The
Company leases its headquarters in Los Altos, California under a month-to-month operating lease agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, rent expense</a></td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531453200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Award Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding, beginning balance</a></td>
<td class="nump">926,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning balance</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 9 months 14 days<span></span>
</td>
<td class="text">6 years 5 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value outstanding, beginning balance</a></td>
<td class="nump">$ 2,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options, granted</a></td>
<td class="nump">724,937,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of stock options, exercised</a></td>
<td class="num">(160,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock options, forfeited</a></td>
<td class="num">(91,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options outstanding, ending balance</a></td>
<td class="nump">1,399,252<span></span>
</td>
<td class="nump">926,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending balance</a></td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value outstanding, ending balance</a></td>
<td class="nump">$ 928<span></span>
</td>
<td class="nump">$ 2,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options, exercisable</a></td>
<td class="nump">662,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">5 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of stock options, vested and expected to vest</a></td>
<td class="nump">1,399,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest</a></td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, vested and expected</a></td>
<td class="text">7 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423529521280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Ranges of Stock Options (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding</a></td>
<td class="nump">1,399,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">7 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">662,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">5 years 10 months 13 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeOneMember', window );">Exercise Price Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding</a></td>
<td class="nump">459,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">4 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">456,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">4 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeTwoMember', window );">Exercise Price Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range | $ / shares</a></td>
<td class="nump">$ 1.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding</a></td>
<td class="nump">130,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">9 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">4,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">9 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeThreeMember', window );">Exercise Price Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range | $ / shares</a></td>
<td class="nump">$ 2.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding</a></td>
<td class="nump">459,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">9 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">41,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">9 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeFourMember', window );">Exercise Price Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range | $ / shares</a></td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding</a></td>
<td class="nump">110,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">9 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">48,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">9 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeFiveMember', window );">Exercise Price Range Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range | $ / shares</a></td>
<td class="nump">$ 5.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range | $ / shares</a></td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding</a></td>
<td class="nump">66,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">8 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">54,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">8 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeSixMember', window );">Exercise Price Range Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range | $ / shares</a></td>
<td class="nump">$ 6.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range | $ / shares</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding</a></td>
<td class="nump">170,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">8 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">56,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">8 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeSevenMember', window );">Exercise Price Range Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range | $ / shares</a></td>
<td class="nump">$ 8.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range | $ / shares</a></td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding</a></td>
<td class="nump">2,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RNXT_ExercisePriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423532631344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Estimate Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="nump">100.48%<span></span>
</td>
<td class="nump">41.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="nump">103.20%<span></span>
</td>
<td class="nump">82.12%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.93%<span></span>
</td>
<td class="nump">0.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">6 years 3 months 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531143360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 644<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 510<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423528465888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, beginning balance | shares</a></td>
<td class="nump">2,786,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 10.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1', window );">Weighted average remaining contractual life, beginning</a></td>
<td class="text">4 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Warrants aggregate intrinsic value, beginning balance | $</a></td>
<td class="nump">$ 30,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants outstanding, issued | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, issued | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants outstanding, exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, execised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants outstanding, expired | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, ending balance | shares</a></td>
<td class="nump">2,786,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price, ending balance | $ / shares</a></td>
<td class="nump">$ 10.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm', window );">Weighted average remaining contractual life, ending</a></td>
<td class="text">3 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Warrants aggregate intrinsic value, ending balance | $</a></td>
<td class="nump">$ 30,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options grants in period weighted average contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options grants in period weighted average contractual term 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531536752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Equity Incentive Plan &#8211; Stock-Based Compensation Expense and Common Stock Warrants (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jul. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 644,000<span></span>
</td>
<td class="nump">$ 147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=RNXT_UnderwriterMember', window );">Underwriter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,035,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=RNXT_UnderwriterMember', window );">Underwriter [Member] | Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 25,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=RNXT_UnderwriterMember', window );">Underwriter [Member] | Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,588,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=RNXT_OmnibusEquityIncentivePlan2021Member', window );">2021 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares reserved but unissued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=RNXT_OmnibusEquityIncentivePlan2021Member', window );">2021 Omnibus Equity Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=RNXT_TwoThousandAndTwentyOnePlanMember', window );">2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock granted, shares</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted common stock granted</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=RNXT_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=RNXT_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RNXT_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RNXT_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RNXT_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RNXT_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=RNXT_OmnibusEquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=RNXT_OmnibusEquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=RNXT_TwoThousandAndTwentyOnePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=RNXT_TwoThousandAndTwentyOnePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531201648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Statutory Tax Expense and Effective Tax Expense Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax</a></td>
<td class="num">$ (2,077)<span></span>
</td>
<td class="num">$ (1,321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">3,411<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_PermanentItems', window );">Permanent items</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior year true ups</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(421)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State</a></td>
<td class="num">(922)<span></span>
</td>
<td class="num">(331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_PermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Permanent Items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_PermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423528742160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 6,492<span></span>
</td>
<td class="nump">$ 4,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits carryforwards</a></td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Fixed assets/intangible assets</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_DeferredTaxAssetsCharitableContributions', window );">Charitable contributions</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_DeferredTaxAssetsCapitalizedResearch', window );">Capitalized research</a></td>
<td class="nump">813<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther', window );">Accruals and other</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">8,904<span></span>
</td>
<td class="nump">5,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(8,886)<span></span>
</td>
<td class="num">(5,475)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains', window );">Unrealized gain</a></td>
<td class="nump">18<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">18<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_DeferredTaxAssetsCapitalizedResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_DeferredTaxAssetsCapitalizedResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_DeferredTaxAssetsCharitableContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets charitable contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_DeferredTaxAssetsCharitableContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423530418544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule Of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning unrecognized tax benefits</a></td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_UnrecognizedTaxBenefitsAdditions', window );">Additions</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending unrecognized tax benefits</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_UnrecognizedTaxBenefitsAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits additions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_UnrecognizedTaxBenefitsAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423529416976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Income Taxes (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss carryforward, federal</a></td>
<td class="nump">$ 23,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,200<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforward, state</a></td>
<td class="nump">17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state tax credit carryforwards</a></td>
<td class="nump">6,492<span></span>
</td>
<td class="nump">$ 4,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayDescription', window );">Income tax, description</a></td>
<td class="text">The
legislation disallowed the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted
gross income is greater than $1.0 million. The carryover periods for net operating loss deductions disallowed by this provision will
be extended. The new legislation did not impact the current year provision or our financial statements for the year ended December
31, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=RNXT_FederalAndStateMember', window );">Federal and state [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state tax credit carryforwards</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=RNXT_CaliforniaTaxCreditMember', window );">California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the factual circumstances giving rise to an income tax exemption or special reduction received from a taxing jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=RNXT_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=RNXT_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=RNXT_CaliforniaTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=RNXT_CaliforniaTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531332544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,889)<span></span>
</td>
<td class="num">$ (6,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing net loss per share &#8211; basic and diluted</a></td>
<td class="nump">9,051,726<span></span>
</td>
<td class="nump">5,217,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share &#8211; basic and diluted</a></td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423531475936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Potentially Anti Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">730,746<span></span>
</td>
<td class="nump">684,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">730,746<span></span>
</td>
<td class="nump">684,382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423528714560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>May 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation arrangement by share based payment award, options, outstanding, number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399,252<span></span>
</td>
<td class="nump">926,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RNXT_DrAgahMember', window );">Dr.Agah [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_CashCompensation', window );">Cash compensation per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RNXT_DrAgahMember', window );">Dr.Agah [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation arrangement by share based payment award, options, outstanding, number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,203<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_CashCompensation', window );">Cash compensation per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,000<span></span>
</td>
<td class="nump">$ 227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RNXT_DrAgahMember', window );">Dr.Agah [Member] | Consulting Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RNXT_DiscretionaryBonus', window );">Discretionary bonus</a></td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_CashCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash compensation per month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_CashCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RNXT_DiscretionaryBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discretionary bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RNXT_DiscretionaryBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RNXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RNXT_DrAgahMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RNXT_DrAgahMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RNXT_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RNXT_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423533252624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Employee Benefit Plans (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan cost</a></td>
<td class="nump">$ 10,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140423532726832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>13. Subsequent Events (Details Narrative) - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued</a></td>
<td class="nump">1,557,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 3.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">1,947,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Definitive Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Stock warrants | $</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RNXT_DefinitiveSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RNXT_DefinitiveSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:RNXT="http://renovorx.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rnxt-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
        </entity>
        <period>
            <instant>2023-03-24</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-08-242021-08-25_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-24</startDate>
            <endDate>2021-08-25</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-25_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="AsOf2021-08-25_us-gaap_WarrantMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="From2021-08-292021-08-30_us-gaap_IPOMember_custom_UnderwriterMember_custom_OverAllotmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RNXT:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RNXT:OverAllotmentOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-29</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-25_us-gaap_IPOMember_custom_UnderwriterMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RNXT:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="From2021-08-042021-08-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="From2021-11-262022-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-26</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RenovoCathMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RNXT:RenovoCathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_RenovoCathMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RNXT:RenovoCathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_NotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-03-012020-03-31_custom_NotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-03-012020-03-31_custom_TwoThousandAndTwentyConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="AsOf2021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-08-292021-08-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-29</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-31_custom_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="AsOf2021-08-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RNXT:TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-19_custom_OmnibusEquityIncentivePlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RNXT:OmnibusEquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-19</instant>
        </period>
    </context>
    <context id="AsOf2023-01-01_custom_OmnibusEquityIncentivePlan2021Member_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RNXT:OmnibusEquityIncentivePlan2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_TwoThousandAndTwentyOnePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RNXT:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-31_custom_TwoThousandAndTwentyOnePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RNXT:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UnderwriterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RNXT:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UnderwriterMember_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RNXT:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RNXT:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UnderwriterMember_custom_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RNXT:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RNXT:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ExercisePriceRangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceRangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ExercisePriceRangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceRangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ExercisePriceRangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceRangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RNXT:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_FederalAndStateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RNXT:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CaliforniaTaxCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RNXT:CaliforniaTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-05-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="AsOf2018-07-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_DrAgahMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_DrAgahMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DrAgahMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_DrAgahMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="AsOf2023-01-01_custom_DrAgahMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012023-02-28_custom_DrAgahMember_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RNXT:DrAgahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-30_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-30</instant>
        </period>
    </context>
    <context id="From2023-03-292023-03-30_custom_DefinitiveSecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001574094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RNXT:DefinitiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001574094</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0067"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0168"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0195"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0204"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0224"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0289"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0300"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0350"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0361"
      unitRef="Shares"
      xsi:nil="true"/>
    <RNXT:GainOnChangeInFairValueOfDerivativeLiability
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:GainOnLoanExtinguishmentFromPppLoan
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:LossOnLoanExtinguishment
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:PaymentsForLeaseholdImprovements
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:DerivativeLiabilityInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:ConversionOfConvertiblePreferredStockUponInitialPublicOffering
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:ConversionOfConvertibleNotesUponInitialPublicOffering
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2022-01-012022-12-31_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0608"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0618"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0624"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0961"
      unitRef="Shares"
      xsi:nil="true"/>
    <RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0963"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0965"
      unitRef="Shares"
      xsi:nil="true"/>
    <RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0967"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0969"
      unitRef="Shares"
      xsi:nil="true"/>
    <RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0971"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1003"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1004"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1006"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1007"
      unitRef="USD"
      xsi:nil="true"/>
    <RNXT:DeferredTaxAssetsCapitalizedResearch
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1029"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1041"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1047"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1050"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1052"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1053"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-40738</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">RENOVORX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">27-1448452</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">4546 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Suite B1</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Los Altos</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">94022</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">284-4433</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common     Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">RNXT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-01-01to2022-12-31">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="-5" unitRef="USD">15500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-24" decimals="INF" unitRef="Shares">9100448</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">23</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Mountain View, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">4391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">15192000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2049000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">825000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1089000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">7265000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">16281000</us-gaap:AssetsCurrent>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">7265000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">16287000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">534000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">525000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">568000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">413000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1102000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">938000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">9097701</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">9097701</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">8933989</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">8933989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">37318000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">36632000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">17000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-31173000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-21284000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">6163000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">15349000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">7265000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">16287000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">4301000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">3039000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">5649000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">2632000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">9950000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">5671000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-9950000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-5671000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">57000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-834000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">119000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">62000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">61000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-653000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-9889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-6324000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-9872000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-6324000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">9051726</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">5217000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">3535469</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">12451000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2233139</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-14960000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-14656000</us-gaap:StockholdersEquity>
    <RNXT:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">-3535469</RNXT:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock>
    <RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">-12451000</RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock>
    <RNXT:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3535469</RNXT:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock>
    <RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">12451000</RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock>
    <RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">12451000</RNXT:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">708820</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">5279000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">5279000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1101000</RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes>
    <RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1101000</RNXT:AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes>
    <RNXT:IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">2090000</RNXT:IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1850000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">14563000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">14563000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <RNXT:StockIssuedDuringPeriodsharesWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">248200</RNXT:StockIssuedDuringPeriodsharesWarrantsExercised>
    <RNXT:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">2681000</RNXT:StockIssuedDuringPeriodValueWarrantsExercised>
    <RNXT:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">2681000</RNXT:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">29</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">358332</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">107000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">107000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">147000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">147000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-6324000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-6324000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8933989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">36632000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-21284000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">15349000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8933989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">36632000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-21284000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">15349000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">160212</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">42000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">42000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">14000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">14000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">630000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">630000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-9889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-9889000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9097701</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">37318000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-31173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">6163000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9097701</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">37318000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-31173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">6163000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-9889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-6324000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">644000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">147000</us-gaap:ShareBasedCompensation>
    <RNXT:AmortizationOnLeaseholdImprovement
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">6000</RNXT:AmortizationOnLeaseholdImprovement>
    <RNXT:AmortizationOnLeaseholdImprovement
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">9000</RNXT:AmortizationOnLeaseholdImprovement>
    <RNXT:GainOnChangeInFairValueOfDerivativeLiability
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">118000</RNXT:GainOnChangeInFairValueOfDerivativeLiability>
    <RNXT:GainOnLoanExtinguishmentFromPppLoan
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">140000</RNXT:GainOnLoanExtinguishmentFromPppLoan>
    <RNXT:LossOnLoanExtinguishment
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">78000</RNXT:LossOnLoanExtinguishment>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">697000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-264000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">970000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">9000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">363000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">155000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">342000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-8811000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-5916000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">8000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">5968000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <RNXT:PaymentsForLeaseholdImprovements
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">15000</RNXT:PaymentsForLeaseholdImprovements>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-2032000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-15000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">14563000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">2681000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1977000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">42000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">107000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">42000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">19328000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10801000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">13397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">15192000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">4391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">15192000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <RNXT:DerivativeLiabilityInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">738000</RNXT:DerivativeLiabilityInFinancingActivities>
    <RNXT:ConversionOfConvertiblePreferredStockUponInitialPublicOffering
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">12451000</RNXT:ConversionOfConvertiblePreferredStockUponInitialPublicOffering>
    <RNXT:ConversionOfConvertibleNotesUponInitialPublicOffering
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">5279000</RNXT:ConversionOfConvertibleNotesUponInitialPublicOffering>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zimEgYMKmLl8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82A_zjxzFLXVswV5"&gt;1.
Business and Principal Activities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Description
of Business&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;RenovoRx,
Inc. (the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in December 2012 and operates from its headquarters in Los
Altos, California. The Company is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment
of solid tumors and conducting a Phase III pancreatic cancer clinical trial for its lead product candidate RenovoGem&#x2122;. The Company&#x2019;s
therapy platform, RenovoRx Trans-Arterial Micro-Perfusion, or RenovoTAMP&#xae; utilizes approved chemotherapeutics with validated mechanisms
of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and
widening their therapeutic window.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Initial
Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 25, 2021, the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-258071) relating to its initial public offering
(&#x201c;IPO&#x201d;) was declared effective and its shares of common stock began trading on the Nasdaq Capital Market on August 26, 2021.
In connection with the IPO, the Company issued and sold an aggregate of &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of stock, number of shares issued in transaction"&gt;1,850,000&lt;/span&gt; units at a price of $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_c20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of stock, price per share"&gt;9.00&lt;/span&gt; per unit. Each unit consisted
of (a) one share of common stock and (b) one warrant to purchase one share of common stock at an exercise price equal to $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210825__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Class of warrant or right, exercise price of warrants or rights"&gt;10.80&lt;/span&gt; per share,
which is exercisable for a period of &lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210825__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zxaDHLAkknR2" title="Warrants and rights outstanding, term"&gt;five years&lt;/span&gt; after the issuance date. The underwriters exercised their over-allotment option to purchase
&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210829__20210830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--OverAllotmentOptionsMember_zimZbzJVkkTj" title="Over allotment option to purchase"&gt;277,500&lt;/span&gt; common stock warrants on August 30, 2021. In connection with the IPO, the underwriters were issued a five-year warrant, exercisable
on or after February 25, 2022, to purchase up to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Class of warrant or right, number of securities called by each warrant or right"&gt;198,875&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Class of warrant or right, exercise price of warrants or rights"&gt;10.80&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company received aggregate gross proceeds of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Aggregate gross proceeds"&gt;16.7&lt;/span&gt; million from the IPO, paid underwriting discounts and commissions of $&lt;span id="xdx_903_ecustom--UnderwritingDiscountsAndCommissions_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Underwriting discounts and commissions"&gt;1.3&lt;/span&gt; million
and incurred other expenses of $&lt;span id="xdx_909_eus-gaap--OtherExpenses_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Other expenses"&gt;0.8&lt;/span&gt; million, resulting in net offering proceeds of $&lt;span id="xdx_909_ecustom--NetProceedsFromIntialPublicOffering_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Net proceeds from intial public offering"&gt;14.6&lt;/span&gt; million. Immediately prior to the closing of
the IPO, all shares of convertible preferred stock then outstanding were converted into &lt;span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaTAwRGdGoub" title="Conversion of stock, shares issued"&gt;3,535,469&lt;/span&gt; shares of common stock after giving
effect to the reverse stock split. In addition, all of the outstanding 2020 and 2021 Convertible Notes, representing principal and accrued
but unpaid interest of $&lt;span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Debt conversion, converted instrument, amount"&gt;5.3&lt;/span&gt; million, &lt;span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember" title="Debt instrument, description"&gt;converted at a 20% and 12.5% discount to the IPO price, respectively, into an aggregate of &lt;span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210824__20210825__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zxADBNJ9uCRk" title="Debt conversion, converted instrument, shares"&gt;708,820&lt;/span&gt;
units. Each unit consisted of (a) one share of common stock and (b) one five-year warrant to purchase one share of common stock at an
exercise price equal to $10.80 per share&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 5, 2021, the Company effected a &lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20210804__20210805_zhSUz5IAsKnf" title="Stockholders equity, reverse stock split"&gt;1-for-5 reverse stock split&lt;/span&gt; of its issued and outstanding preferred stock and common stock. The
number of authorized shares and the par values of the common stock and convertible preferred stock were not adjusted as a result of the
reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the Company&#x2019;s convertible
preferred stock converted into the Company&#x2019;s common stock. Accordingly, all share and per share amounts related to the common stock,
stock options, warrants and restricted stock awards for all periods presented in the accompanying financial statements and notes thereto
have been retroactively adjusted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Capital Resources&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
the Company&#x2019;s inception through December 31, 2022, it has raised an aggregate of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20211126__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAiGm9BF5Xwa" title="Proceeds from sale of equity"&gt;35.0&lt;/span&gt; million from private placements of convertible
preferred stock, convertible debt securities, the issuance of securities in the IPO, and the exercise of warrants and common stock options.
As of December 31, 2022, the Company had cash, cash equivalents and short-term marketable securities of $&lt;span id="xdx_90A_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20221231_z3t31gxR1MZ" title="Cash and cash equivalents, and Marketable securities"&gt;6.4&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has incurred significant losses and negative cash flows from operations since its inception. For the year ended December 31,
2022, the Company reported a net loss of $&lt;span id="xdx_905_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_zw1FpLpXGdOa" title="Net loss"&gt;9.9&lt;/span&gt; million and an accumulated deficit of $&lt;span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_z2gw5NMSSlCb" title="Accumulated deficit"&gt;31.2&lt;/span&gt; million and does not expect to generate positive
cash flows from operations in the foreseeable future. The Company expects to incur significant and increasing losses until regulatory
approval is granted for its first product candidate, RenovoGem&#x2122;. Regulatory approval is not guaranteed and may never be obtained.
The Company believes it will be able to raise additional capital through debt financings, private or public equity financings, license
agreements, collaborative agreements or other arrangements with other companies, or other sources of financing. There can be no assurance
that such financing will be available or will be at terms acceptable to the Company. The inability to raise capital as and when needed
would have a negative impact on the Company&#x2019;s liquidity financial condition and its ability to pursue its business strategy. The
Company will need to generate significant revenue to achieve profitability, and it may never do so.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has filed an omnibus shelf registration statement on Form S-3 that provides for the aggregate offerings of up to $&lt;span id="xdx_90E_ecustom--MaximumPossibleProceedsFromOfferings_pn6n6_c20220101__20221231_zZEbFt8DlG8i" title="Maximum possible proceeds from offerings"&gt;50.0&lt;/span&gt; million
of the Company&#x2019;s securities subject to various limitations, including limited sales in any twelve-month period while the Company
is subject to the &#x201c;baby-shelf&#x201d; rules. The Company has also filed a registration statement on Form S-1 to register the cash
exercise of the Company&#x2019;s outstanding IPO, underwriter and private warrants. Cash exercise of the outstanding warrants is only
expected to occur when the trading price of the Company&#x2019;s common stock is in excess of the $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zTm5wVmEOUAl" title="Class of warrant or right, exercise price of warrants or rights"&gt;10.80&lt;/span&gt; per share exercise price of the
outstanding warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern and has reviewed the
relevant conditions and events surrounding its ability to continue as a going concern including among others: historical losses, projected
future results, negative cash flows from operations, including the effects of the ongoing novel coronavirus (&#x201c;COVID-19&#x201d;)
pandemic, cash requirements for the upcoming year, funding capacity, net working capital, total stockholders&#x2019; equity and future
access to capital. Based upon this review and the Company&#x2019;s current financial condition, the Company has concluded that substantial
doubt exists as to the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-08-242021-08-25_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">1850000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-08-25_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">9.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-08-25_us-gaap_WarrantMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">10.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-08-25_us-gaap_WarrantMember_us-gaap_IPOMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-08-292021-08-30_us-gaap_IPOMember_custom_UnderwriterMember_custom_OverAllotmentOptionsMember"
      decimals="INF"
      unitRef="Shares">277500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2021-08-25_us-gaap_IPOMember_custom_UnderwriterMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">198875</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-08-25_us-gaap_IPOMember_custom_UnderwriterMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">10.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-08-242021-08-25_us-gaap_IPOMember"
      decimals="-5"
      unitRef="USD">16700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <RNXT:UnderwritingDiscountsAndCommissions
      contextRef="From2021-08-242021-08-25_us-gaap_IPOMember"
      decimals="-5"
      unitRef="USD">1300000</RNXT:UnderwritingDiscountsAndCommissions>
    <us-gaap:OtherExpenses
      contextRef="From2021-08-242021-08-25_us-gaap_IPOMember"
      decimals="-5"
      unitRef="USD">800000</us-gaap:OtherExpenses>
    <RNXT:NetProceedsFromIntialPublicOffering
      contextRef="From2021-08-242021-08-25_us-gaap_IPOMember"
      decimals="-5"
      unitRef="USD">14600000</RNXT:NetProceedsFromIntialPublicOffering>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2021-08-242021-08-25_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">3535469</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-08-242021-08-25_us-gaap_IPOMember"
      decimals="-5"
      unitRef="USD">5300000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentDescription contextRef="From2021-08-242021-08-25_us-gaap_IPOMember">converted at a 20% and 12.5% discount to the IPO price, respectively, into an aggregate of 708,820
units. Each unit consisted of (a) one share of common stock and (b) one five-year warrant to purchase one share of common stock at an
exercise price equal to $10.80 per share</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-08-242021-08-25_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">708820</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2021-08-042021-08-05">1-for-5 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-11-262022-12-31_us-gaap_IPOMember"
      decimals="-6"
      unitRef="USD">35000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">6400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">-9900000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">-31200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <RNXT:MaximumPossibleProceedsFromOfferings
      contextRef="From2022-01-01to2022-12-31"
      decimals="-6"
      unitRef="USD">50000000.0</RNXT:MaximumPossibleProceedsFromOfferings>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">10.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zPqP6myjMFF7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82F_zwZwvpb7Spsd"&gt;2.
Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHm1cDSYh01f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zG1ruHCYXIbd"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the SEC for annual reporting. Any reference in these notes to
applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;)
and as amended by Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--RisksAndUncertaintiesPolicyTextBlock_zZrgs7WSpMNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z51snjERV0r3"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to a number of risks associated with companies at a similar stage, including the risk associated with the development
of products that must receive regulatory approval before market launch, dependence on key individuals, competition from larger and established
companies, volatility of the industry, ability to obtain adequate financing to support growth, the ability to attract and retain additional
qualified personnel to manage the anticipated growth of the Company and general economic conditions. The Company is subject to a number
of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional
funding, possible failure of current or future preclinical studies or clinical trials, its reliance on third parties to conduct its clinical
trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations,
the need to successfully commercialize and gain market acceptance of the Company&#x2019;s product candidates, protection of its proprietary
technology, and the need to secure and maintain adequate manufacturing arrangements with third parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic, and government responses have created
disruption in global supply chains and adversely impacting many industries. The pandemic could have a continued material adverse
impact on economic and market conditions. We continue to monitor the impact of the COVID-19 pandemic, including its most recent
variants, closely. The extent to which the COVID-19 pandemic will impact our operations or financial results is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_z3bSwlo5Tfv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zJb5n2pFu3Ze"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, income and expenses as well as the disclosure of contingent assets and liabilities, at the date of
the financial statements during the reporting periods. In preparing these financial statements, management has made its best estimates
and judgments of certain amounts included in the financial statements. Significant estimates and assumptions made in the accompanying
financial statements include, but are not limited to, accruals of certain liabilities, including clinical trial accruals and other contingences,
the valuation of financial instruments, the fair value of the Company&#x2019;s common stock and the fair value of options granted under
the Company&#x2019;s equity incentive plan. On an ongoing basis, the Company evaluates its estimates, including those related to the fair
values of assets, stock-based compensation, clinical trial accruals and other contingencies. Management bases its estimates on historical
experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially
from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zfVCgmA1nhZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zXBZz0M0lnF3"&gt;Concentration
of Credit Risk and Significant Suppliers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents.
The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits
of $&lt;span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zYUqTu6FA627" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents
to the extent recorded in the balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relied, and expects to rely, on a small number of third-party manufacturers to manufacture and supply its RenovoCath devices
and its product candidates for clinical trials. These activities could be adversely affected by a significant interruption in supply
of these items. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate
product revenue or achieve profitability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z7URk1O0oT89" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_z2qSqRpAXAn9"&gt;Operating
Segment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and manages its business as one reportable and operating segment, which is the development of a therapy platform to
deliver de-risked small molecules for localized treatment of solid cancer tumors. The Company&#x2019;s chief executive officer, who is
the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial
performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zNIt6IHC8Ihb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zvaBkezXnvCb"&gt;Net
Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during
the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average
number of shares of common stock and common stock equivalents of potentially dilutive securities outstanding for the period determined
using the treasury stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of convertible preferred
stock, convertible notes, and warrants including options and restricted stock awards outstanding under the Company&#x2019;s Equity Incentive
Plan. For the years ended December 31, 2022 and 2021, there was no difference in the number of shares used to calculate basic and diluted
shares outstanding as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zf3Oqho5xbeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zgthSnXO9tCf"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the
principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement
date. Fair value measurement establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where
available, and minimize the use of unobservable inputs when measuring fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined the fair value of financial assets and liabilities using the fair value hierarchy that describes three levels of inputs
that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 &#x2013; Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 &#x2013; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 &#x2013; Valuations based on unobservable inputs reflecting the Company&#x2019;s assumptions, consistent with reasonably available assumptions
made by other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value of financial instruments disclosed in the financial statements has been determined by using available market information
and appropriate valuation methodologies. In certain cases where there is limited activity or less transparency around inputs to valuation,
securities are classified as Level 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of current assets, accounts payable and accrued expenses are generally considered to be representative of their respective
fair values because of their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--CashCashEquivalentsAndInvestmentsPolicyTextBlock_zNYL71lzWeP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zMgcde5Caltc"&gt;Cash,
Cash Equivalents and Investments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
Available-for-sale securities, comprised of obligations of the U.S. government and its agencies, are carried at fair value, with unrealized
gains and losses recorded within other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. Realized gains
and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in earnings.
Purchases and sales of investment securities are recognized on a trade date basis. The cost of investment securities sold is determined
by the specific identification method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--LeaseholdImprovementsPolicyTextBlock_zfbhBvrEoTt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zde547Z2XjD2"&gt;Leasehold
Improvements, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are presented at cost, net of accumulated amortization. Amortization expense is recorded using the straight-line method
over the shorter of the remaining lease term or the estimated useful life.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8NrWqrEa898" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zQ3RwuZqIjOb"&gt;Research
and Development Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to expense as incurred. Research and development expenses includes personnel costs including salaries,
benefits and stock-based compensation. In addition, it includes expenses for consultants that support clinical trial studies, materials
costs, external clinical drug product manufacturing costs, outside services costs, regulatory activities including filing fees, fees
for maintaining licenses and other amounts due to third-party agreements, laboratory materials, clinical trial, as noted above, and supplies
to support our research activities, including allocated facility and general and administrative indirect overhead related costs. The
Company also receives payments from clinical trial sites for RenovoCath delivery devices used in the Phase III clinical trial. Payments
received from clinical sites cover the direct costs of manufacturing the RenovoCath delivery devices and offset research and development
expenses were $&lt;span id="xdx_90B_ecustom--PaymentsReceivedFromClinicalSites_iN_di_c20220101__20221231__dei--LegalEntityAxis__custom--RenovoCathMember_z4VvX720kpl" title="Payments received from clinical sites"&gt;141,000&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--PaymentsReceivedFromClinicalSites_iN_di_c20210101__20211231__dei--LegalEntityAxis__custom--RenovoCathMember_zgJzPsC14hh6" title="Payments received from clinical sites"&gt;233,000&lt;/span&gt; for December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--ClinicalTrialExpensesPolicyTextBlock_zXY6GkKFJes4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zzOdLv079NZ7"&gt;Clinical
Trial Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company makes payments in connection with its ongoing Phase III clinical trial under contracts with clinical trial sites and contract
research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation
and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to
be performed at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts
depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses
related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including
actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related
to patient enrollment or treatment are accrued when reasonably estimable. If amounts and obligations to pay under clinical trial agreements
are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are
adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give
rise to the revision become reasonably certain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_843_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zZL0Ddreuegi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zDAPKDqaalhi"&gt;General
and Administrative&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist of salaries, benefits, and stock-based compensation for personnel in executive, finance and administrative
functions, professional services and associated costs related to accounting, tax, audit, legal, intellectual property, consulting costs,
conferences and travel, including allocated facility and general and administrative indirect overhead related costs to research and development
expenses. General and administrative expenses are expensed in the period incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--ConvertiblePreferredStockPolicyTextBlock_z2inqu5ckCW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zXapwkm74uu1"&gt;Convertible
Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records preferred stock at fair value on the date of issuance, net of issuance costs. Preferred stock was previously recorded
outside of stockholders&#x2019; equity (deficit) because the shares contained liquidation features that were not solely within the Company&#x2019;s
control and was classified as mezzanine equity (temporary equity). The Company completed its IPO on August 30, 2021, which triggered
the automatic conversion of all outstanding convertible preferred stock to common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3EXFdb2Ywf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zhgs7Fwf7Ub"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of stock options using the Black-Scholes option pricing model, which incorporates various assumptions
including volatility, expected term and risk-free interest rate. Compensation related to service-based awards is recognized starting
on the grant date on a straight-line basis over the vesting period, which is generally four years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
determination of the fair value of each stock award using this option-pricing model is affected by the Company&#x2019;s assumptions regarding
a number of complex and subjective variables. These variables include, but are not limited to, the fair value of the common stock at
the date of grant, the expected term of the awards, the expected stock price volatility over the expected term of the awards, the risk-free
interest rate, and the dividend rate as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value of Common Stock&lt;/i&gt;&#x2014;Prior to the IPO, given the absence of a public trading market, the Company&#x2019;s Board of Directors
considered numerous objective and subjective factors to determine the fair value of the Company&#x2019;s common stock at each grant date.
These factors included, but were not limited to: (i) contemporaneous third-party valuations of common stock; (ii) the prices for preferred
stock sold to outside investors; (iii) the rights and preferences of preferred stock relative to common stock; (iv) the lack of marketability
of the Company&#x2019;s common stock; (v) developments in the business; and (vi) the likelihood of achieving a liquidity event, such as
an IPO or sale of the business, given prevailing market conditions. The methodology to determine the fair value of the Company&#x2019;s
common stock included estimating the fair value of the enterprise using the &#x201c;backsolve&#x201d; method, which is a market approach
that assigns an implied enterprise value by accounting for all share class rights and preferences based on the latest round of financing.
The total equity value implied was then applied in the context of an option pricing model to determine the value of each class of the
Company&#x2019;s shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
grants issued post-IPO the closing price of the Company&#x2019;s common stock as reported on the date of grant will determine the fair
value of the Company&#x2019;s common stock, as shares of the Company&#x2019;s common stock are traded in the public market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Term&lt;/i&gt;&#x2014;The expected term represents the period that the stock-based awards are expected to be outstanding. The Company determines
the expected term using the simplified method for pre-IPO and post-IPO awards. The simplified method deems the term to be the average
of the time-to-vesting and the contractual life of the options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Volatility&lt;/i&gt;&#x2014;Given the absence of a public trading market, pre-IPO and post IPO, the expected volatility is estimated by taking
the average historic price volatility for industry peers, consisting of several public companies in the Company&#x2019;s industry that
are either similar in size, stage, or financial leverage, over a period equivalent to the expected term of the awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-Free
Interest Rate&lt;/i&gt;&#x2014;The risk-free interest rate is calculated using the average of the published interest rates of U.S. Treasury
zero-coupon issues with maturities that are commensurate with the expected term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividend
Rate&lt;/i&gt;&#x2014;The dividend yield assumption is zero as the Company has no plans to make dividend payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generally granted stock options, pre-IPO, to its employees and consultants for a fixed number of shares with an exercise price
equal to the fair value of the underlying shares at date of grant. For all post-IPO grants issued, the fair value will be the closing
price of the Company&#x2019;s common stock on the date of the grant. The Company accounts for all stock option grants using the fair value
method and stock-based compensation is recognized as the underlying options vest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zyJ95pZT0R6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z9a65EAP1rof"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities
using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation
allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax
credit carryforwards for all periods presented, as realization of such deferred tax assets cannot be determined to be more likely than
not. Due to losses incurred for all periods presented, the Company does not record tax provision or benefit for income taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_zmoviQgLuoP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zouHFmdnzxFk"&gt;Emerging
Growth Company and Smaller Reporting Company Status&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an emerging growth company (&#x201c;EGC&#x201d;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS
Act&#x201d;) and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of
the JOBS Act exempts emerging growth companies from complying with new or revised financial accounting standards until private companies
are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or
revised accounting standards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are also a &#x201c;smaller reporting company,&#x201d; as defined in Rule 12b-2 of the Exchange Act. If we are a smaller reporting company
at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that
are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most
recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, like emerging growth companies, smaller reporting
companies have reduced disclosure obligations regarding executive compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of
the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not
have a material impact on the Company&#x2019;s financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zvmRGpDTUZLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_z7CvUQUNAWec"&gt;Recent
Accounting Pronouncement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2016, the FASB issued Accounting Standards Updates (&#x201c;ASU&#x201d;) 2016-02, &lt;i&gt;Leases (Topic 842)&lt;/i&gt;. The guidance requires
lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expands disclosure requirements regarding
leasing arrangements. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting the new
lease standards, and a package of practical expedients an entity can elect to utilize to reduce the level of effort required for adoption.
Under the transition option, entities can elect to apply the new guidance using a modified retrospective approach at the beginning of
the year in which the new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements.
In November 2019, the FASB issued ASU 2019-10, Leases (Topic 842) (ASU 2019-10), deferring the effective date for the Company for fiscal
years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the
FASB issued ASU 2020-05, Leases (Topic 842) (ASU 2020-05), which further defers the effective date for the Company for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2021. Early adoption is permitted. The
Company adopted ASU 2016-02 on January 1, 2022 and the adoption had no material impact to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2019, the FASB issued ASU 2019-12, &lt;i&gt;Income Taxes (Topic 740)&lt;/i&gt;: Simplifying the Accounting for Income Taxes (ASU 2019-12),
which simplifies the accounting for income taxes, and is effective on a prospective basis for annual reporting periods beginning after
December 15, 2021, and for interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The
Company adopted ASU 2019-12 on January 1, 2022 and the adoption had no significant impact to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments&#x2014;Credit Losses (Topic 326)&lt;/i&gt;. The guidance represents a significant
change in the accounting for credit losses model by requiring immediate recognition of management&#x2019;s estimates of current expected
credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has
met the criteria of a smaller reporting company (&#x201c;SRC&#x201d;) as of November 15, 2019. As such, ASU 2019-10, &lt;i&gt;Financial Instruments
&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&lt;/i&gt; &#x2014;Effective Dates amended the
effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU 2016-13
effective January 1, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, &lt;i&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) &lt;/i&gt;(ASU 2020-06): &lt;i&gt;Accounting for Convertible Instruments
and Contracts in an Entity&lt;/i&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The updated guidance is effective on a prospective
basis for annual reporting periods beginning after December 15, 2023 and for interim periods within those periods. Early adoption is
permitted. The Company has not yet determined the impact that this new standard will have on its financial position and results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHm1cDSYh01f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zG1ruHCYXIbd"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the SEC for annual reporting. Any reference in these notes to
applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;)
and as amended by Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <RNXT:RisksAndUncertaintiesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_ecustom--RisksAndUncertaintiesPolicyTextBlock_zZrgs7WSpMNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z51snjERV0r3"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to a number of risks associated with companies at a similar stage, including the risk associated with the development
of products that must receive regulatory approval before market launch, dependence on key individuals, competition from larger and established
companies, volatility of the industry, ability to obtain adequate financing to support growth, the ability to attract and retain additional
qualified personnel to manage the anticipated growth of the Company and general economic conditions. The Company is subject to a number
of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional
funding, possible failure of current or future preclinical studies or clinical trials, its reliance on third parties to conduct its clinical
trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations,
the need to successfully commercialize and gain market acceptance of the Company&#x2019;s product candidates, protection of its proprietary
technology, and the need to secure and maintain adequate manufacturing arrangements with third parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic, and government responses have created
disruption in global supply chains and adversely impacting many industries. The pandemic could have a continued material adverse
impact on economic and market conditions. We continue to monitor the impact of the COVID-19 pandemic, including its most recent
variants, closely. The extent to which the COVID-19 pandemic will impact our operations or financial results is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</RNXT:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_z3bSwlo5Tfv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zJb5n2pFu3Ze"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, income and expenses as well as the disclosure of contingent assets and liabilities, at the date of
the financial statements during the reporting periods. In preparing these financial statements, management has made its best estimates
and judgments of certain amounts included in the financial statements. Significant estimates and assumptions made in the accompanying
financial statements include, but are not limited to, accruals of certain liabilities, including clinical trial accruals and other contingences,
the valuation of financial instruments, the fair value of the Company&#x2019;s common stock and the fair value of options granted under
the Company&#x2019;s equity incentive plan. On an ongoing basis, the Company evaluates its estimates, including those related to the fair
values of assets, stock-based compensation, clinical trial accruals and other contingencies. Management bases its estimates on historical
experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially
from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zfVCgmA1nhZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zXBZz0M0lnF3"&gt;Concentration
of Credit Risk and Significant Suppliers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents.
The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits
of $&lt;span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zYUqTu6FA627" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents
to the extent recorded in the balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relied, and expects to rely, on a small number of third-party manufacturers to manufacture and supply its RenovoCath devices
and its product candidates for clinical trials. These activities could be adversely affected by a significant interruption in supply
of these items. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate
product revenue or achieve profitability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z7URk1O0oT89" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_z2qSqRpAXAn9"&gt;Operating
Segment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and manages its business as one reportable and operating segment, which is the development of a therapy platform to
deliver de-risked small molecules for localized treatment of solid cancer tumors. The Company&#x2019;s chief executive officer, who is
the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial
performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zNIt6IHC8Ihb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zvaBkezXnvCb"&gt;Net
Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during
the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average
number of shares of common stock and common stock equivalents of potentially dilutive securities outstanding for the period determined
using the treasury stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of convertible preferred
stock, convertible notes, and warrants including options and restricted stock awards outstanding under the Company&#x2019;s Equity Incentive
Plan. For the years ended December 31, 2022 and 2021, there was no difference in the number of shares used to calculate basic and diluted
shares outstanding as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zf3Oqho5xbeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zgthSnXO9tCf"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the
principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement
date. Fair value measurement establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where
available, and minimize the use of unobservable inputs when measuring fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined the fair value of financial assets and liabilities using the fair value hierarchy that describes three levels of inputs
that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 &#x2013; Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 &#x2013; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets
and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 &#x2013; Valuations based on unobservable inputs reflecting the Company&#x2019;s assumptions, consistent with reasonably available assumptions
made by other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value of financial instruments disclosed in the financial statements has been determined by using available market information
and appropriate valuation methodologies. In certain cases where there is limited activity or less transparency around inputs to valuation,
securities are classified as Level 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of current assets, accounts payable and accrued expenses are generally considered to be representative of their respective
fair values because of their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <RNXT:CashCashEquivalentsAndInvestmentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_ecustom--CashCashEquivalentsAndInvestmentsPolicyTextBlock_zNYL71lzWeP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zMgcde5Caltc"&gt;Cash,
Cash Equivalents and Investments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
Available-for-sale securities, comprised of obligations of the U.S. government and its agencies, are carried at fair value, with unrealized
gains and losses recorded within other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. Realized gains
and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in earnings.
Purchases and sales of investment securities are recognized on a trade date basis. The cost of investment securities sold is determined
by the specific identification method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</RNXT:CashCashEquivalentsAndInvestmentsPolicyTextBlock>
    <RNXT:LeaseholdImprovementsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_ecustom--LeaseholdImprovementsPolicyTextBlock_zfbhBvrEoTt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zde547Z2XjD2"&gt;Leasehold
Improvements, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are presented at cost, net of accumulated amortization. Amortization expense is recorded using the straight-line method
over the shorter of the remaining lease term or the estimated useful life.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</RNXT:LeaseholdImprovementsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8NrWqrEa898" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zQ3RwuZqIjOb"&gt;Research
and Development Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to expense as incurred. Research and development expenses includes personnel costs including salaries,
benefits and stock-based compensation. In addition, it includes expenses for consultants that support clinical trial studies, materials
costs, external clinical drug product manufacturing costs, outside services costs, regulatory activities including filing fees, fees
for maintaining licenses and other amounts due to third-party agreements, laboratory materials, clinical trial, as noted above, and supplies
to support our research activities, including allocated facility and general and administrative indirect overhead related costs. The
Company also receives payments from clinical trial sites for RenovoCath delivery devices used in the Phase III clinical trial. Payments
received from clinical sites cover the direct costs of manufacturing the RenovoCath delivery devices and offset research and development
expenses were $&lt;span id="xdx_90B_ecustom--PaymentsReceivedFromClinicalSites_iN_di_c20220101__20221231__dei--LegalEntityAxis__custom--RenovoCathMember_z4VvX720kpl" title="Payments received from clinical sites"&gt;141,000&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--PaymentsReceivedFromClinicalSites_iN_di_c20210101__20211231__dei--LegalEntityAxis__custom--RenovoCathMember_zgJzPsC14hh6" title="Payments received from clinical sites"&gt;233,000&lt;/span&gt; for December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <RNXT:PaymentsReceivedFromClinicalSites
      contextRef="From2022-01-012022-12-31_custom_RenovoCathMember"
      decimals="0"
      unitRef="USD">-141000</RNXT:PaymentsReceivedFromClinicalSites>
    <RNXT:PaymentsReceivedFromClinicalSites
      contextRef="From2021-01-012021-12-31_custom_RenovoCathMember"
      decimals="0"
      unitRef="USD">-233000</RNXT:PaymentsReceivedFromClinicalSites>
    <RNXT:ClinicalTrialExpensesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_ecustom--ClinicalTrialExpensesPolicyTextBlock_zXY6GkKFJes4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zzOdLv079NZ7"&gt;Clinical
Trial Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company makes payments in connection with its ongoing Phase III clinical trial under contracts with clinical trial sites and contract
research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation
and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to
be performed at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts
depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses
related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including
actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related
to patient enrollment or treatment are accrued when reasonably estimable. If amounts and obligations to pay under clinical trial agreements
are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are
adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give
rise to the revision become reasonably certain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</RNXT:ClinicalTrialExpensesPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_843_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zZL0Ddreuegi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zDAPKDqaalhi"&gt;General
and Administrative&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist of salaries, benefits, and stock-based compensation for personnel in executive, finance and administrative
functions, professional services and associated costs related to accounting, tax, audit, legal, intellectual property, consulting costs,
conferences and travel, including allocated facility and general and administrative indirect overhead related costs to research and development
expenses. General and administrative expenses are expensed in the period incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <RNXT:ConvertiblePreferredStockPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_ecustom--ConvertiblePreferredStockPolicyTextBlock_z2inqu5ckCW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zXapwkm74uu1"&gt;Convertible
Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records preferred stock at fair value on the date of issuance, net of issuance costs. Preferred stock was previously recorded
outside of stockholders&#x2019; equity (deficit) because the shares contained liquidation features that were not solely within the Company&#x2019;s
control and was classified as mezzanine equity (temporary equity). The Company completed its IPO on August 30, 2021, which triggered
the automatic conversion of all outstanding convertible preferred stock to common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</RNXT:ConvertiblePreferredStockPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3EXFdb2Ywf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zhgs7Fwf7Ub"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of stock options using the Black-Scholes option pricing model, which incorporates various assumptions
including volatility, expected term and risk-free interest rate. Compensation related to service-based awards is recognized starting
on the grant date on a straight-line basis over the vesting period, which is generally four years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
determination of the fair value of each stock award using this option-pricing model is affected by the Company&#x2019;s assumptions regarding
a number of complex and subjective variables. These variables include, but are not limited to, the fair value of the common stock at
the date of grant, the expected term of the awards, the expected stock price volatility over the expected term of the awards, the risk-free
interest rate, and the dividend rate as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value of Common Stock&lt;/i&gt;&#x2014;Prior to the IPO, given the absence of a public trading market, the Company&#x2019;s Board of Directors
considered numerous objective and subjective factors to determine the fair value of the Company&#x2019;s common stock at each grant date.
These factors included, but were not limited to: (i) contemporaneous third-party valuations of common stock; (ii) the prices for preferred
stock sold to outside investors; (iii) the rights and preferences of preferred stock relative to common stock; (iv) the lack of marketability
of the Company&#x2019;s common stock; (v) developments in the business; and (vi) the likelihood of achieving a liquidity event, such as
an IPO or sale of the business, given prevailing market conditions. The methodology to determine the fair value of the Company&#x2019;s
common stock included estimating the fair value of the enterprise using the &#x201c;backsolve&#x201d; method, which is a market approach
that assigns an implied enterprise value by accounting for all share class rights and preferences based on the latest round of financing.
The total equity value implied was then applied in the context of an option pricing model to determine the value of each class of the
Company&#x2019;s shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
grants issued post-IPO the closing price of the Company&#x2019;s common stock as reported on the date of grant will determine the fair
value of the Company&#x2019;s common stock, as shares of the Company&#x2019;s common stock are traded in the public market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Term&lt;/i&gt;&#x2014;The expected term represents the period that the stock-based awards are expected to be outstanding. The Company determines
the expected term using the simplified method for pre-IPO and post-IPO awards. The simplified method deems the term to be the average
of the time-to-vesting and the contractual life of the options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Volatility&lt;/i&gt;&#x2014;Given the absence of a public trading market, pre-IPO and post IPO, the expected volatility is estimated by taking
the average historic price volatility for industry peers, consisting of several public companies in the Company&#x2019;s industry that
are either similar in size, stage, or financial leverage, over a period equivalent to the expected term of the awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-Free
Interest Rate&lt;/i&gt;&#x2014;The risk-free interest rate is calculated using the average of the published interest rates of U.S. Treasury
zero-coupon issues with maturities that are commensurate with the expected term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividend
Rate&lt;/i&gt;&#x2014;The dividend yield assumption is zero as the Company has no plans to make dividend payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generally granted stock options, pre-IPO, to its employees and consultants for a fixed number of shares with an exercise price
equal to the fair value of the underlying shares at date of grant. For all post-IPO grants issued, the fair value will be the closing
price of the Company&#x2019;s common stock on the date of the grant. The Company accounts for all stock option grants using the fair value
method and stock-based compensation is recognized as the underlying options vest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zyJ95pZT0R6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z9a65EAP1rof"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities
using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation
allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax
credit carryforwards for all periods presented, as realization of such deferred tax assets cannot be determined to be more likely than
not. Due to losses incurred for all periods presented, the Company does not record tax provision or benefit for income taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <RNXT:EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_ecustom--EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_zmoviQgLuoP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zouHFmdnzxFk"&gt;Emerging
Growth Company and Smaller Reporting Company Status&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an emerging growth company (&#x201c;EGC&#x201d;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS
Act&#x201d;) and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of
the JOBS Act exempts emerging growth companies from complying with new or revised financial accounting standards until private companies
are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or
revised accounting standards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are also a &#x201c;smaller reporting company,&#x201d; as defined in Rule 12b-2 of the Exchange Act. If we are a smaller reporting company
at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that
are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most
recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, like emerging growth companies, smaller reporting
companies have reduced disclosure obligations regarding executive compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of
the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not
have a material impact on the Company&#x2019;s financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</RNXT:EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zvmRGpDTUZLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_z7CvUQUNAWec"&gt;Recent
Accounting Pronouncement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2016, the FASB issued Accounting Standards Updates (&#x201c;ASU&#x201d;) 2016-02, &lt;i&gt;Leases (Topic 842)&lt;/i&gt;. The guidance requires
lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expands disclosure requirements regarding
leasing arrangements. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting the new
lease standards, and a package of practical expedients an entity can elect to utilize to reduce the level of effort required for adoption.
Under the transition option, entities can elect to apply the new guidance using a modified retrospective approach at the beginning of
the year in which the new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements.
In November 2019, the FASB issued ASU 2019-10, Leases (Topic 842) (ASU 2019-10), deferring the effective date for the Company for fiscal
years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the
FASB issued ASU 2020-05, Leases (Topic 842) (ASU 2020-05), which further defers the effective date for the Company for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2021. Early adoption is permitted. The
Company adopted ASU 2016-02 on January 1, 2022 and the adoption had no material impact to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2019, the FASB issued ASU 2019-12, &lt;i&gt;Income Taxes (Topic 740)&lt;/i&gt;: Simplifying the Accounting for Income Taxes (ASU 2019-12),
which simplifies the accounting for income taxes, and is effective on a prospective basis for annual reporting periods beginning after
December 15, 2021, and for interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The
Company adopted ASU 2019-12 on January 1, 2022 and the adoption had no significant impact to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments&#x2014;Credit Losses (Topic 326)&lt;/i&gt;. The guidance represents a significant
change in the accounting for credit losses model by requiring immediate recognition of management&#x2019;s estimates of current expected
credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has
met the criteria of a smaller reporting company (&#x201c;SRC&#x201d;) as of November 15, 2019. As such, ASU 2019-10, &lt;i&gt;Financial Instruments
&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&lt;/i&gt; &#x2014;Effective Dates amended the
effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU 2016-13
effective January 1, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, &lt;i&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) &lt;/i&gt;(ASU 2020-06): &lt;i&gt;Accounting for Convertible Instruments
and Contracts in an Entity&lt;/i&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The updated guidance is effective on a prospective
basis for annual reporting periods beginning after December 15, 2023 and for interim periods within those periods. Early adoption is
permitted. The Company has not yet determined the impact that this new standard will have on its financial position and results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_z8vBpTFv7DV4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_827_zqgeMqxRTjkj"&gt;3.
Short-Term Marketable Securities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--MarketableSecuritiesTextBlock_zpgIdIns1l6j" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tables summarize the Company&#x2019;s short-term marketable securities as of December 31, 2022. There were no short-term marketable securities
as of December 31, 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zHj7Nl5NtCgi" style="display: none"&gt;Schedule of Short-Term Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cost Basis&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross&lt;br/&gt;
 Unrealized &lt;br/&gt;
Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify; padding-bottom: 1.5pt"&gt;U.S. Treasury bills&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zJ3QUD31T3e6" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, amortized cost basis"&gt;2,032&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zNouzYQi2sFl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, unrealized gains"&gt;17&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zhJwDgAPBzvl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, unrealized losses"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0568"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zJYVlLezGF5b" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, fair value"&gt;2,049&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231_zlY8Ose76Y26" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, amortized cost basis"&gt;2,032&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20220101__20221231_zOSo7eebN7o" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, unrealized gains"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_pn3n3_c20220101__20221231_z4cvmiBhQxv6" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, unrealized losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0576"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20221231_zptcH7QfQkM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, fair value"&gt;2,049&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z9UB3IRI6xtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--MarketableSecuritiesTextBlock_zpgIdIns1l6j" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tables summarize the Company&#x2019;s short-term marketable securities as of December 31, 2022. There were no short-term marketable securities
as of December 31, 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zHj7Nl5NtCgi" style="display: none"&gt;Schedule of Short-Term Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cost Basis&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross&lt;br/&gt;
 Unrealized &lt;br/&gt;
Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify; padding-bottom: 1.5pt"&gt;U.S. Treasury bills&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zJ3QUD31T3e6" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, amortized cost basis"&gt;2,032&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zNouzYQi2sFl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, unrealized gains"&gt;17&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zhJwDgAPBzvl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, unrealized losses"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0568"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zJYVlLezGF5b" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Short-term marketable securities, fair value"&gt;2,049&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231_zlY8Ose76Y26" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, amortized cost basis"&gt;2,032&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20220101__20221231_zOSo7eebN7o" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, unrealized gains"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_pn3n3_c20220101__20221231_z4cvmiBhQxv6" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, unrealized losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0576"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20221231_zptcH7QfQkM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term marketable securities, fair value"&gt;2,049&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      unitRef="USD">2032000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2022-01-012022-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      unitRef="USD">17000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      unitRef="USD">2049000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2032000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">17000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2049000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80C_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zGLJLz2xf8F7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;
&lt;span id="xdx_82B_zWkKc6SS9Tgi"&gt;4. Accrued Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zaI6UZsjLPUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of accrued expenses as of December 31, 2022 and 2021 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z5s1YR1nkjRf" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231_z1q2B2nJ9wWi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_z7AloTSk40u8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedClinicalTrialsCurrent_iI_pn3n3_maALCz7Fz_zuCHB2xDe85l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Clinical trial&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCz7Fz_z1ZeFp8Gq2T5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Employee benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz7Fz_zfOTfAd00q12" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz7Fz_zyJZo7LN00xi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;568&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;413&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zZfkUUPjSiw6" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zaI6UZsjLPUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of accrued expenses as of December 31, 2022 and 2021 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z5s1YR1nkjRf" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231_z1q2B2nJ9wWi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_z7AloTSk40u8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedClinicalTrialsCurrent_iI_pn3n3_maALCz7Fz_zuCHB2xDe85l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Clinical trial&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCz7Fz_z1ZeFp8Gq2T5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Employee benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz7Fz_zfOTfAd00q12" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz7Fz_zyJZo7LN00xi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;568&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;413&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <RNXT:AccruedClinicalTrialsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">88000</RNXT:AccruedClinicalTrialsCurrent>
    <RNXT:AccruedClinicalTrialsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">358000</RNXT:AccruedClinicalTrialsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">475000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">33000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">5000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">22000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">568000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">413000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zBHemCjH8by5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_821_zBH5lpKdEqB3"&gt;5.
Fair Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, and 2021, the Company held $&lt;span id="xdx_90D_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_c20221231_ziqeCx7PYBTl" title="Money market funds, at carrying value"&gt;4.4&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn6n6_c20211231_zDFWoVubtvT9" title="Money market funds, at carrying value"&gt;15.0&lt;/span&gt; million, respectively, in a money market account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zpZmx6gcBMW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables sets summarize the Company&#x2019;s financial assets and liabilities, measured at fair value on a recurring basis by
level within the fair value hierarchy, as of December 31, 2022, and 2021, (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zet2hQgJ3eu4" style="display: none"&gt;Schedule of Assets Measured at Fair Value on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at December 31, 2022 using:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Cash equivalents:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzd2NeqEDoIg" style="width: 11%; text-align: right" title="Fair value of assets"&gt;4,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxuNynEj3Xlg" style="width: 11%; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0608"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLQaqRfgJKM9" style="width: 11%; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0610"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z33j61y5Poo6" style="width: 11%; text-align: right" title="Fair value of assets"&gt;4,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: justify"&gt;Available-for-sale securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;U.S. Treasury bills&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUSrdJfYPzM6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"&gt;2,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z89997Oz1RB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0616"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zumaZefHWfA6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0618"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zhgBiDaw7oj2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"&gt;2,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgwbzalb2qXh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;6,349&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLvimprryWca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0624"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z1odUC8sDVj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUlmWsAFlscd" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;6,349&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at December 31, 2021 using:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Cash equivalents:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"&gt;14,997&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"&gt;14,997&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;14,997&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zKD4iPGVrgy2" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;14,997&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zMfQZW52q53c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zwMrkrPNNc6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
change in the fair value of the derivative liability is summarized below (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_ztgGfeOkweQ5" style="display: none"&gt;Schedule
of Changes in Fair value of Derivative  Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zLhzDhgZ5vY9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_z3ttAK4m1FOj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_zDUxWPk0UNf1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Fair value, beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0648"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;856&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_zA2FujfEpSXk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Initial fair value of instruments issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_iN_pn3n3_di_zvG1x1KBm9S" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Change in fair value of instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(118&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_iN_pn3n3_di_zaATWrAox2L9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Conversion upon IPO&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,101&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_zYyzo1V7WLia" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Fair value, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0660"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0661"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zOPuBFNQIZjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between Level 1, Level 2 or Level 3 during the periods presented. The Company had no other financial assets or liabilities
that were required to be measured at fair value on a recurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">4400000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-6" unitRef="USD">15000000.0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zpZmx6gcBMW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables sets summarize the Company&#x2019;s financial assets and liabilities, measured at fair value on a recurring basis by
level within the fair value hierarchy, as of December 31, 2022, and 2021, (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zet2hQgJ3eu4" style="display: none"&gt;Schedule of Assets Measured at Fair Value on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at December 31, 2022 using:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Cash equivalents:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzd2NeqEDoIg" style="width: 11%; text-align: right" title="Fair value of assets"&gt;4,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxuNynEj3Xlg" style="width: 11%; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0608"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLQaqRfgJKM9" style="width: 11%; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0610"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z33j61y5Poo6" style="width: 11%; text-align: right" title="Fair value of assets"&gt;4,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: justify"&gt;Available-for-sale securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;U.S. Treasury bills&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUSrdJfYPzM6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"&gt;2,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z89997Oz1RB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0616"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zumaZefHWfA6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0618"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zhgBiDaw7oj2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of assets"&gt;2,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgwbzalb2qXh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;6,349&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLvimprryWca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0624"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z1odUC8sDVj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUlmWsAFlscd" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;6,349&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at December 31, 2021 using:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Cash equivalents:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"&gt;14,997&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value of assets"&gt;14,997&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;14,997&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zKD4iPGVrgy2" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of assets"&gt;14,997&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">4300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">4300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">2049000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">2049000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">6349000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">6349000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">14997000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">14997000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">14997000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">14997000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zwMrkrPNNc6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
change in the fair value of the derivative liability is summarized below (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_ztgGfeOkweQ5" style="display: none"&gt;Schedule
of Changes in Fair value of Derivative  Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zLhzDhgZ5vY9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_z3ttAK4m1FOj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_zDUxWPk0UNf1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Fair value, beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0648"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;856&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_zA2FujfEpSXk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Initial fair value of instruments issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_iN_pn3n3_di_zvG1x1KBm9S" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Change in fair value of instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(118&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_iN_pn3n3_di_zaATWrAox2L9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Conversion upon IPO&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,101&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_zYyzo1V7WLia" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Fair value, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0660"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0661"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">856000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">363000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">118000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1101000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet>
    <us-gaap:LongTermDebtTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_802_eus-gaap--LongTermDebtTextBlock_zq8BfDvQc4yc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_820_zEHu9dvm2TD9"&gt;6.
Convertible Notes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2020, the Company entered into a note purchase agreement for the issuance of up to $&lt;span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zuVuUoo5uITk" title="Convertible notes payable"&gt;4.0&lt;/span&gt; million of convertible promissory notes,
which, if not converted, had an initial maturity date of &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20200301__20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zUMHNMoKrlr9" title="Debt instrument, maturity date"&gt;March 31, 2021&lt;/span&gt;. The Company entered into a series of convertible note payable
agreements (the &#x201c;2020 Convertible Notes&#x201d;) for aggregate borrowings of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zeZY9sfaH3o9" title="Debt instrument, face amount"&gt;3.0&lt;/span&gt; million. The 2020 Convertible Notes bore interest
at the rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pip0_dp_uPure_c20200331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zq9fmoXfrSNc" title="Debt interest rate"&gt;5&lt;/span&gt;% per annum and could not be prepaid prior to the maturity date unless approved in writing by the Company and requisite
holders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
terms of the 2020 Convertible Notes provided for automatic conversion into equity shares in the next equity financing round with total
proceeds of not less than $&lt;span id="xdx_909_ecustom--MaximumPossibleTotalProceedsFromConvertibleNotes_pn6n6_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zebk1xbJSxd6" title="Maximum possible total proceeds from convertible notes"&gt;10.0&lt;/span&gt; million (a &#x201c;Qualified Financing&#x2019;), at a conversion price per share equal to &lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_uPure_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zyTO8ZmAcHPi" title="Debt conversion price percentage"&gt;80&lt;/span&gt;% of the price
per share paid by investors purchasing such equity securities in a Qualified Financing. For purposes of the 2020 Convertible Notes, equity
securities meant the Company&#x2019;s common stock, preferred stock or any securities providing for rights to purchase the Company&#x2019;s
common stock, preferred stock or securities convertible into or exchangeable for the Company&#x2019;s common stock or preferred stock
issued in the Qualified Financing. If the Company consummated a Change of Control prior to a Qualified Financing, the Company would repay
each holder in cash an amount equal to the greater of (a) two times (2x) the entire outstanding principal balance of the 2020 Convertible
Notes or (b) the amount the holder would receive if the 2020 Convertible Notes had been converted into shares of the Company&#x2019;s
Series B convertible preferred stock immediately prior to the consummation of the Change in Control, at a conversion price equal to the
Series B convertible preferred stock Original Issue Price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 1, 2021, the Company entered into an amendment to the 2020 Convertible Notes which extended the maturity date of the 2020 Convertible
Notes from March 31, 2021 to October 30, 2021 and provided for the conversion of the 2020 Convertible Notes into shares of the Company&#x2019;s
common stock upon a Qualified Financing that is an IPO. No other terms of the 2020 Convertible Notes were amended. This amendment was
accounted for as a troubled debt restructuring pursuant to FASB ASC Topic 470-60, &#x201c;Troubled Debt Restructurings by Debtors.&#x201d;
As the future undiscounted cash flows of the 2020 Convertible Notes were greater than their carrying amount, the carrying amount was
not adjusted and no gain was recognized as a result of the modification of terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that the redemption features contained rights and obligations for conversion were contingent upon a potential
future financing event or a change in control. Thus, the embedded redemption features were bifurcated from the face value of the
notes and accounted for as a derivative liability to be remeasured at the end of each reporting period. The fair value of the
derivative liability including debt issuance costs was $&lt;span id="xdx_907_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zTvlBpYYzQNl" title="Fair value of derivative liability including debt issuance costs"&gt;&lt;span id="xdx_900_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zHHSVZ9Ta8J7" title="Fair value of derivative liability including debt issuance costs"&gt;0&lt;/span&gt;&lt;/span&gt;
at December 31, 2022 and December 31, 2021, respectively. The derivative liability was subject to fair value remeasurement at the
end of each reporting period. The debt discount and debt issuance costs were being amortized to interest expense using the effective
interest method over the expected term of the 2020 Convertible Notes. For the years ended December 31, 2022 and December 31, 2021,
the Company recognized $&lt;span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zV0pDejhyJW9" title="Amortization of debt discount and debt issuance costs"&gt;0&lt;/span&gt;
and $&lt;span id="xdx_90F_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zjexdVzHMR6d" title="Amortization of debt discount and debt issuance costs"&gt;379,000&lt;/span&gt;
for amortization of the debt discount and debt issuance costs, respectively. This amortization expense is recognized as interest
expense in the statements of operations. The effective interest rate of the 2020 Convertible Notes was &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zBxpFp7Utg73" title="Debt effective interest rate"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zlalMfUN1xLa" title="Debt effective interest rate"&gt;0&lt;/span&gt;&lt;/span&gt;%
at December 31, 2022 and December 31, 2021, compared to the stated rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pip0_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zM0SlQUqeOCi" title="Debt stated interest rate"&gt;5&lt;/span&gt;%
per annum. The effective interest rate immediately prior to the conversion of the Convertible Notes resulting from the
Company&#x2019;s IPO was &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zkwiYeNACb2k"&gt;8.6&lt;/span&gt;%
per annum. As a result, the Company&#x2019;s reported interest expense was significantly higher than the contractual cash interest
payments. During the years ended December 31, 2022 and December 31, 2021, the Company recognized interest expense in the statements
of operations of $&lt;span id="xdx_901_eus-gaap--InterestExpense_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_zNm49WmMwT7l" title="Interest expense"&gt;0&lt;/span&gt;
and $&lt;span id="xdx_900_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyConvertibleNotesMember_z4Ok7kfKKxHk" title="Interest expense"&gt;101,000&lt;/span&gt;,
respectively, related to the 2020 Convertible Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2021, the Company entered into a note purchase agreement and a series of convertible note payable agreements (the &#x201c;2021 Convertible
Notes,&#x201d; together with the 2020 Convertible Notes, the &#x201c;2020 and 2021 Convertible Notes&#x201d;) for aggregate borrowings of
$&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20210430__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember_zFOJAmZ6j7L6" title="Debt face amount"&gt;2.0&lt;/span&gt; million. Outstanding borrowings under the 2021 Convertible Notes and accrued interest were due in April 2022, if not previously
converted. The 2021 Notes bore interest at the rate of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210430__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_z6KdYaW1nwsl" title="Interest rate percentage"&gt;5%&lt;/span&gt; per annum. Pursuant to the 2021 Convertible Notes, the outstanding principal
and accrued interest are automatically convertible into equity shares in a Qualified Financing at a conversion price per share equal
to &lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pip0_dp_uPure_c20210401__20210430__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_z3y01Xa4Ib5a" title="Debt conversion price percentage"&gt;87.5&lt;/span&gt;% of the price per share paid by investors purchasing such equity securities in a Qualified Financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that these redemption features in the 2021 Convertible Notes contained rights and obligations for conversion that
were contingent upon a potential future financing event or a change in control. Thus, the embedded redemption features were bifurcated
from the face value of the note and accounted for as a derivative liability to be remeasured at the end of each reporting period. Upon
issuance of the notes, the Company recorded the fair value of the derivative liability of $&lt;span id="xdx_904_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zgSkFHo3yzgc" title="Fair value of derivative liability"&gt;363,000&lt;/span&gt; and debt issuance costs of $&lt;span id="xdx_906_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zg0AVIAlZ3De" title="Debt issuance costs"&gt;23,000&lt;/span&gt;,
with the offsetting amount being recorded as a debt discount. The discount and debt issuance costs were amortized to interest expense
using the effective interest method over the expected term of the 2021 Convertible Notes. For the year ended December 31, 2022 and December
31, 2021, the Company recognized $&lt;span id="xdx_905_eus-gaap--AmortizationOfFinancingCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zfmNzDwMJx22" title="Amortization of debt discount and debt issuance costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--AmortizationOfFinancingCosts_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zG5Pufi16fui" title="Amortization of debt discount and debt issuance costs"&gt;386,000&lt;/span&gt;, respectively, for the amortization of the debt discount and debt issuance costs as
interest expense in the statements of operations. The effective interest rate immediately prior to the conversion of the 2021 Convertible
Notes resulting from the Company&#x2019;s IPO was &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zmbKZoEB94lk"&gt;46.5&lt;/span&gt;% per annum compared to the stated rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_za4BtWjDDpYl"&gt;5&lt;/span&gt;% per annum. During the year ended December
31, 2022 and December 31, 2021, the Company recognized interest expense in the statements of operations of $&lt;span id="xdx_90B_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zrug1ggNe9w2" title="Interest expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneConvertibleNotesMember_zSESc9ap6jzj" title="Interest expense"&gt;38,000&lt;/span&gt;, respectively,
relating to the 2021 Convertible Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company completed an IPO on August 30, 2021, which triggered the automatic conversion of the outstanding Convertible Notes plus accrued
interest into an aggregate of &lt;span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210829__20210830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNfoDwpEk8Pa" title="Conversion of stock, shares converted"&gt;708,820&lt;/span&gt; units (the &#x201c;Exchange&#x201d;). The 2020 Convertible Notes converted at a 20% discount to the
IPO price and the 2021 Convertible Notes converted at a &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210831__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_zlNZ7KrtnHUe" title="Debt interest rate"&gt;12.5&lt;/span&gt;% discount to the IPO price. Each unit consisted of (a) one share of common
stock and (b) one five-year warrant to purchase one share of common stock at an exercise price equal to $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zWcp3gnBidlj" title="Warrant exercise price per share"&gt;10.80&lt;/span&gt; per share. Upon conversion
of the 2020 and 2021 Convertible Notes, the outstanding principal, including debt discount and debt issuance costs for those Convertible
Notes of $&lt;span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_zKgen3PS0Vp6" title="Convertible notes payable"&gt;5.3&lt;/span&gt; million, was derecognized into stockholders&#x2019; equity. The unamortized debt discount totaling $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember_zG4xyogqPwa5" title="Unamortized debt discount"&gt;78,000&lt;/span&gt; was recognized
as a loss on extinguishment of debt and is included in loss (gain) on loan extinguishment in the Company&#x2019;s statements of operations
for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Exchange was made pursuant to an exemption from registration provided by Section 3(a)(9) of the Securities Act. The following facts were
relied upon: (1) no payment was made in connection with the Exchange, (2) the Convertible Notes, the common stock, and the warrants were
issued by the same issuer, (3) the Convertible Note holders were not required to contribute cash or any other property, and (4) the Exchange
was made only to existing note holders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2020-03-31_custom_NotePurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">4000000.0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-03-012020-03-31_custom_NotePurchaseAgreementMember">2021-03-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-03-31_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="-5"
      unitRef="USD">3000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-03-31_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <RNXT:MaximumPossibleTotalProceedsFromConvertibleNotes
      contextRef="From2020-03-012020-03-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="-6"
      unitRef="USD">10000000.0</RNXT:MaximumPossibleTotalProceedsFromConvertibleNotes>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2020-03-012020-03-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="INF"
      unitRef="Pure">0.80</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="0"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="0"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="0"
      unitRef="USD">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="0"
      unitRef="USD">379000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Pure">0.086</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="0"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyConvertibleNotesMember"
      decimals="0"
      unitRef="USD">101000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember"
      decimals="-6"
      unitRef="USD">2000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2021-04-012021-04-30_custom_NotePurchaseAgreementMember_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="INF"
      unitRef="Pure">0.875</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="0"
      unitRef="USD">363000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="0"
      unitRef="USD">23000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="0"
      unitRef="USD">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="0"
      unitRef="USD">386000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="INF"
      unitRef="Pure">0.465</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="0"
      unitRef="USD">0</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="0"
      unitRef="USD">38000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2021-08-292021-08-30_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">708820</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-08-31_custom_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="INF"
      unitRef="Pure">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-08-30_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">10.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="-5"
      unitRef="USD">5300000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember"
      decimals="0"
      unitRef="USD">78000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zcaiA2icJst3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82B_zTpJGbffe8Q8"&gt;7.
Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal
Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company may become involved in legal proceedings arising in the ordinary course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was not subject to any material legal proceedings during the year ended December 31, 2022 and no material legal proceedings are
subsequently outstanding or pending.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Guarantees
and Indemnification&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware
law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the
officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its officers and
directors. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future
payments that the Company could be required to make under these provisions is not determinable. The Company has never incurred material
costs to defend lawsuits or settle claims related to these indemnification provisions. The Company is not currently aware of any indemnification
claims. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of December 31,
2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Operating
Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20221231_zGsBDuUha9h9" title="Lessee, operating lease, description"&gt;The
Company leases its headquarters in Los Altos, California under a month-to-month operating lease agreement.&lt;/span&gt; Rent expense was $&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20220101__20221231_z0qYZ5NVgOA8" title="Operating lease, rent expense"&gt;72,000&lt;/span&gt; and
$&lt;span id="xdx_900_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231_zFN4ticSd897" title="Operating lease, rent expense"&gt;60,000&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2022-01-01to2022-12-31">The
Company leases its headquarters in Los Altos, California under a month-to-month operating lease agreement.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">72000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">60000</us-gaap:OperatingLeaseExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zxRhpnrEKnnc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82C_zWz5XSiJT1ka"&gt;8.
Equity Incentive Plan &#x2013; Stock-Based Compensation Expense and Common Stock Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2021
Omnibus Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 19, 2021, the Company&#x2019;s Board of Directors adopted the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the &#x201c;2021
Plan&#x201d;). The 2021 Plan, which became effective immediately prior to the closing of the IPO, initially reserved &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210719__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member_z15iS7d0Jnk4" title="Number of shares reserved"&gt;2,185,832&lt;/span&gt; shares
of common stock, which included &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210719__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member_pdd" title="Common shares reserved but unissued"&gt;10,832&lt;/span&gt; shares of common shares reserved but unissued under the Amended and Restated 2013 Equity Incentive
Plan (the &#x201c;2013 Plan&#x201d;). The Company&#x2019;s 2013 Plan was terminated immediately prior to the closing of the IPO; however,
shares subject to awards granted under the 2013 Plan will continue to be governed by the 2013 Plan. In accordance with the terms of the
2021 Plan, on January 1, 2023, the number of shares reserved and available for issuance increased by &lt;span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230101__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztxDbqAbsIhl" title="Number of shares reserved"&gt;272,391&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPXCuaMrMkbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity for the year ended December 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_z9zGbXyz3wT2" style="display: none"&gt;Summary of Stock Option Award Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zGSYfJR9fNHk" style="width: 11%; text-align: right" title="Number of stock options outstanding, beginning balance"&gt;926,379&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zGZdtN3G5Nhk" style="width: 11%; text-align: right" title="Weighted average exercise price outstanding, beginning balance"&gt;2.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zYUIANnIXUlj" title="Weighted average remaining contractual life"&gt;6.47&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zx7IgMGZWtMc" style="width: 11%; text-align: right" title="Aggregate intrinsic value outstanding, beginning balance"&gt;2,856&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zcqgUOF5Wjz3" style="text-align: right" title="Number of stock options, granted"&gt;724,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z1Eo5FlUoYVi" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zRH2UD1HMjVj" style="text-align: right" title="Number of stock options, exercised"&gt;(160,212&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zJdKL50TwPwh" style="text-align: right" title="Weighted average exercise price, exercised"&gt;0.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zESlJyJBftqb" style="text-align: right" title="Number of stock options, forfeited"&gt;(91,852&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zvdCkn7KclD6" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;3.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zbTNjo7QEVag" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, ending balance"&gt;1,399,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zra4NJ8fb5rf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, ending balance"&gt;2.40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zVabW1TJeaFj" title="Weighted average remaining contractual life"&gt;7.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zkbXJYj1UBS9" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value outstanding, ending balance"&gt;928&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231_zOq0XSfUMV05" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options, exercisable"&gt;662,909&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zDcWpB1BGtg3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;1.79&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zNglQUMFd5T" title="Weighted average remaining contractual life, exercisable"&gt;5.87&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zxx9YEqHRkv1" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, exercisable"&gt;823&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Vested and expected to vest as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20220101__20221231_zn4vll4Yh4C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options, vested and expected to vest"&gt;1,399,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_z5LizxuZWzwb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest"&gt;2.40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zeuKVHvmGwL4" title="Weighted average remaining contractual life, vested and expected"&gt;7.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231_zToJ1H1ieup6" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, vested and expected to vest"&gt;928&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zDY3hDiNYt04" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, there was $&lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20221231_zNyFeIOSiFSl" title="Unrecognized stock based compensation expense"&gt;0.7&lt;/span&gt; million of unrecognized stock-based compensation expense related to options granted but not yet
amortized, which will be recognized over a weighted-average period of approximately &lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231_z1XmozeXqgCl" title="Weighted average period"&gt;3.14&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztcd4lqxqpP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the outstanding and exercisable options as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zFha8OOSuneh" style="display: none"&gt;Schedule of Ranges of Stock Options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
    Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
    Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
    of &lt;br/&gt;
    Exercise Prices&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of&lt;br/&gt;
 Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;

    Average&lt;br/&gt;
 Remaining&lt;br/&gt;
 Contractual Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of &lt;br/&gt;
Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;

    Average&lt;br/&gt;
 Remaining&lt;br/&gt;
 Contractual Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z5rNdY6OzZVj" title="Range of Exercise Prices, Lower Range"&gt;0.00&lt;/span&gt; - $ &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zf8czkAbXnK9" title="Range of Exercise Prices, Upper Range"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYbWOs19alM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;459,080&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zg6ePRyjccT" title="Weighted-Average Remaining Contractual Life (years)"&gt;4.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zUB3dHBzejib" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;456,179&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zBu7Uv5hRHel" title="Weighted-Average Remaining Contractual Life (years)"&gt;4.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zvN6YN7iB3q6" title="Range of Exercise Prices, Lower Range"&gt;1.01&lt;/span&gt; - $ &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zDTwD7xni7Y4" title="Range of Exercise Prices, Upper Range"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zVePqkSbGF81" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130,510&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zrZyhq50ZDW6" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z4cMh4UWdgpc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,909&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zNd8ggKQxyka" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zl8Q0fDKya95" title="Range of Exercise Prices, Lower Range"&gt;2.01&lt;/span&gt; - $ &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zbWTMnWxqDhg" title="Range of Exercise Prices, Upper Range"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvxs2lgfSeA3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;459,786&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z5fpbpYTJkKc" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zc1lwe7Grcqk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;41,850&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvlb8PjYAAEl" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zgBxrzN0yOLf" title="Range of Exercise Prices, Lower Range"&gt;3.01&lt;/span&gt; - $ &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zq6SXywbaQK5" title="Range of Exercise Prices, Upper Range"&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zNPwQ8t24Hv5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110,530&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zTnImbMjTE5k" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.19&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zezaWnJujP69" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;48,066&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zo1qesulux2h" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.19&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zCxoKiXg2xwg" title="Range of Exercise Prices, Lower Range"&gt;5.01&lt;/span&gt; - $ &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zONVLRvLJ0J2" title="Range of Exercise Prices, Upper Range"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zjX6Lc3Nmlhf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;66,924&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_z2l1OVuApgad" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zbYdzUUHS4Qe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;54,530&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zn3KLNahR1if" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zKf6UX0UgpQi" title="Range of Exercise Prices, Lower Range"&gt;6.01&lt;/span&gt; - $ &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zqP8Z9cgvhj5" title="Range of Exercise Prices, Upper Range"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_z9MOD6y1umgb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;170,069&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zWpknXv68bai" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zgync7dhd7Z5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;56,689&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_z3SHETyQHIM" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zPhAjbNOaSNa" title="Range of exercise prices, lower range"&gt;8.01&lt;/span&gt; - $ &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zVtEqkrDcpgl" title="Range of exercise prices, upper range"&gt;9.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zwrIQdMHrlGk" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,353&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zBLpFhGXgv05" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.86&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_z7e8oc5JHvl7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;686&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_z128nPWWJqo9" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.86&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231_zhcALNiEz5M" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,399,252&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zOFJi9YrJyah" title="Weighted-average remaining contractual life (years)"&gt;7.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231_zOf4oIldFVGi" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;662,909&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5c85f2Fv3Y6" title="Weighted-average remaining contractual life (years)"&gt;5.87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zWr3mP9nzeF9" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeO0yovDjQS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2022, and 2021, the Company utilized the Black-Scholes option-pricing model for estimating the fair value
of the stock option granted. The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option
pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zfm8IqfHxek4" style="display: none"&gt;Schedule of Estimate Fair Value of Stock Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 60%; font-size: 11pt"/&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231_z0YfCh9eP8ci" title="Expected volatility rate, minimum"&gt;100.48&lt;/span&gt;% &#x2013; &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231_zW9Fw3q4q5Bh" title="Expected volatility rate, maximum"&gt;103.20&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231_z9l5xgHzCn78" title="Expected volatility rate, minimum"&gt;41.66&lt;/span&gt;% &#x2013; &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210101__20211231_zxF37h0llfD2" title="Expected volatility rate, maximum"&gt;82.12&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zloucWdbBLFi" title="Expected term (years)"&gt;5.27&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zMkXH16V6tVb" title="Expected term (years)"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zwQg0SfmN1j7" title="Expected term (years)"&gt;5.00&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zqqypZoGbsvj" title="Expected term (years)"&gt;6.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zUk5mmoNcgc4" title="Risk-free interest rate, minimum"&gt;1.93&lt;/span&gt;% &#x2013; &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_zx4JtZqhGoza" title="Risk-free interest rate, maximum"&gt;4.05&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zM9r7rsbRMKj" title="Risk-free interest rate, minimum"&gt;0.62&lt;/span&gt;% &#x2013; &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z4IgDTqTMYN7" title="Risk-free interest rate, maximum"&gt;1.36&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z55QyJWamnB" title="Dividend rate"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20210101__20211231_zvldb2069aud" title="Dividend rate"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A3_zSrmSo2Jlucf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2022, and 2021, the Company recognized $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn3d_c20220101__20221231_zD0tFCpJeAg7" title="Share based compensation expense"&gt;644,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pn3d_c20210101__20211231_zzSnSJJjzYIk" title="Share based compensation expense"&gt;147,000&lt;/span&gt;, respectively, in stock-based compensation
expense from stock option grants and restricted stock awards. The compensation expense is allocated on a departmental basis, based on
the classification of the option holder. No income tax benefits have been recognized in the statements of operations and comprehensive
loss for stock-based compensation arrangements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z0gJ41gFB3ci" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the components of stock-based compensation expense recognized in the Company&#x2019;s statements of operations
and comprehensive loss during the years ended December 31, 2022, and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zFdR7Y9e5dFc" style="display: none"&gt;Schedule of Stock Based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20221231_zkkJutwYNie4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_zAqdqlJlNSDb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdq1lcl3QhL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zi7WroVL0aa4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;121&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_z9E3W3bLCrpk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;147&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zExLIG7lNBui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2022, the Company granted &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20220131__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOnePlanMember_z4HTlOhmEq6f" title="Restricted common stock granted, shares"&gt;3,500&lt;/span&gt; shares of restricted common stock under the 2021 Plan to a consultant as partial consideration
for services rendered, with a deemed fair value of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220131__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOnePlanMember_zHG8iiAP7ZEb" title="Shares issued price per share"&gt;04.03&lt;/span&gt; per share or $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20220101__20220131__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOnePlanMember_zfi6pibqmSag" title="Restricted common stock granted"&gt;14,000&lt;/span&gt;. The fair value of this restricted stock award was expensed
as stock-based compensation on the date of grant as they were fully vested on that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the IPO, the Company issued warrants to purchase &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zqWDMX75FiPf" title="Warrants to purchase common stock, shares"&gt;3,035,195&lt;/span&gt; shares of the Company&#x2019;s common stock. Warrants to purchase
&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--WarrantOneMember_z47LQMik2tMf" title="Warrants to purchase common stock, shares"&gt;198,875&lt;/span&gt; shares of the Company&#x2019;s common stock expire on &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zTwAhYJwedFh" title="Warrant maturity date"&gt;August 25, 2026&lt;/span&gt;, and warrants to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_zC3h2nKw8Cl3" title="Warrants to purchase common stock, shares"&gt;2,588,120&lt;/span&gt; shares of the Company&#x2019;s
common stock expire on August 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z6TnvXJOOGx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following is a summary of the common stock warrant activity during the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zkiAwBVDWOAi" style="display: none"&gt;Schedule
of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares Issuable Upon Exercise of Outstanding Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted- Average Remaining Contractual Life (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_zzHO1g8FChAa" style="width: 11%; text-align: right" title="Warrants outstanding, beginning balance"&gt;2,786,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zeHynx49KD99" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;10.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1_dtY_c20220101__20221231_zQpiwlZMU0Gh" title="Weighted average remaining contractual life, beginning"&gt;4.67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pn3n3_c20220101__20221231_zfdPZS9g7Vcd" style="width: 11%; text-align: right" title="Warrants aggregate intrinsic value, beginning balance"&gt;30,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_z11VanK8BtTh" style="text-align: right" title="Warrants outstanding, issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zECa7efFD2Jd" style="text-align: right" title="Weighted average exercise price, issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231_zK3FndpS0ZEh" style="text-align: right" title="Warrants outstanding, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zLTehmfOsYV7" style="text-align: right" title="Weighted average exercise price, execised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0967"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20221231_zEacbokXdHe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zS1bumGzNnZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0971"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231_zPL10zllLjef" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;2,786,995&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20220101__20221231_zhAXrZ4pepPk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"&gt;10.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm_dtY_c20220101__20221231_zeHKmgNkZvdb" title="Weighted average remaining contractual life, ending"&gt;3.67&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pn3n3_c20220101__20221231_zoYKrBANjfth" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants aggregate intrinsic value, ending balance"&gt;30,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zXvPbbOTtLVh" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-07-19_custom_OmnibusEquityIncentivePlan2021Member"
      decimals="INF"
      unitRef="Shares">2185832</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-07-19_custom_OmnibusEquityIncentivePlan2021Member"
      decimals="INF"
      unitRef="Shares">10832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-01-01_custom_OmnibusEquityIncentivePlan2021Member_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">272391</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPXCuaMrMkbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity for the year ended December 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_z9zGbXyz3wT2" style="display: none"&gt;Summary of Stock Option Award Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zGSYfJR9fNHk" style="width: 11%; text-align: right" title="Number of stock options outstanding, beginning balance"&gt;926,379&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zGZdtN3G5Nhk" style="width: 11%; text-align: right" title="Weighted average exercise price outstanding, beginning balance"&gt;2.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zYUIANnIXUlj" title="Weighted average remaining contractual life"&gt;6.47&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zx7IgMGZWtMc" style="width: 11%; text-align: right" title="Aggregate intrinsic value outstanding, beginning balance"&gt;2,856&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zcqgUOF5Wjz3" style="text-align: right" title="Number of stock options, granted"&gt;724,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z1Eo5FlUoYVi" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zRH2UD1HMjVj" style="text-align: right" title="Number of stock options, exercised"&gt;(160,212&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zJdKL50TwPwh" style="text-align: right" title="Weighted average exercise price, exercised"&gt;0.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zESlJyJBftqb" style="text-align: right" title="Number of stock options, forfeited"&gt;(91,852&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zvdCkn7KclD6" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;3.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zbTNjo7QEVag" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, ending balance"&gt;1,399,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zra4NJ8fb5rf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, ending balance"&gt;2.40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zVabW1TJeaFj" title="Weighted average remaining contractual life"&gt;7.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zkbXJYj1UBS9" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value outstanding, ending balance"&gt;928&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231_zOq0XSfUMV05" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options, exercisable"&gt;662,909&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zDcWpB1BGtg3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;1.79&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zNglQUMFd5T" title="Weighted average remaining contractual life, exercisable"&gt;5.87&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zxx9YEqHRkv1" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, exercisable"&gt;823&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Vested and expected to vest as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20220101__20221231_zn4vll4Yh4C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options, vested and expected to vest"&gt;1,399,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_z5LizxuZWzwb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest"&gt;2.40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zeuKVHvmGwL4" title="Weighted average remaining contractual life, vested and expected"&gt;7.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231_zToJ1H1ieup6" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, vested and expected to vest"&gt;928&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">926379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">2.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31">P6Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2856000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="Shares">724937000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">160212</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">91852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">3.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1399252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-12-31">P7Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">928000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">662909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-01to2022-12-31">P5Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">823000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1399252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-01to2022-12-31">P7Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">928000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-01-01to2022-12-31">P3Y1M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztcd4lqxqpP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the outstanding and exercisable options as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zFha8OOSuneh" style="display: none"&gt;Schedule of Ranges of Stock Options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
    Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
    Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
    of &lt;br/&gt;
    Exercise Prices&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of&lt;br/&gt;
 Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;

    Average&lt;br/&gt;
 Remaining&lt;br/&gt;
 Contractual Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of &lt;br/&gt;
Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;

    Average&lt;br/&gt;
 Remaining&lt;br/&gt;
 Contractual Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z5rNdY6OzZVj" title="Range of Exercise Prices, Lower Range"&gt;0.00&lt;/span&gt; - $ &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zf8czkAbXnK9" title="Range of Exercise Prices, Upper Range"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYbWOs19alM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;459,080&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zg6ePRyjccT" title="Weighted-Average Remaining Contractual Life (years)"&gt;4.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zUB3dHBzejib" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;456,179&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zBu7Uv5hRHel" title="Weighted-Average Remaining Contractual Life (years)"&gt;4.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zvN6YN7iB3q6" title="Range of Exercise Prices, Lower Range"&gt;1.01&lt;/span&gt; - $ &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zDTwD7xni7Y4" title="Range of Exercise Prices, Upper Range"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zVePqkSbGF81" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130,510&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zrZyhq50ZDW6" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z4cMh4UWdgpc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,909&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zNd8ggKQxyka" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zl8Q0fDKya95" title="Range of Exercise Prices, Lower Range"&gt;2.01&lt;/span&gt; - $ &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zbWTMnWxqDhg" title="Range of Exercise Prices, Upper Range"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvxs2lgfSeA3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;459,786&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z5fpbpYTJkKc" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zc1lwe7Grcqk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;41,850&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvlb8PjYAAEl" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zgBxrzN0yOLf" title="Range of Exercise Prices, Lower Range"&gt;3.01&lt;/span&gt; - $ &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zq6SXywbaQK5" title="Range of Exercise Prices, Upper Range"&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zNPwQ8t24Hv5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110,530&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zTnImbMjTE5k" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.19&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zezaWnJujP69" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;48,066&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zo1qesulux2h" title="Weighted-Average Remaining Contractual Life (years)"&gt;9.19&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zCxoKiXg2xwg" title="Range of Exercise Prices, Lower Range"&gt;5.01&lt;/span&gt; - $ &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zONVLRvLJ0J2" title="Range of Exercise Prices, Upper Range"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zjX6Lc3Nmlhf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;66,924&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_z2l1OVuApgad" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zbYdzUUHS4Qe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;54,530&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember_zn3KLNahR1if" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zKf6UX0UgpQi" title="Range of Exercise Prices, Lower Range"&gt;6.01&lt;/span&gt; - $ &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zqP8Z9cgvhj5" title="Range of Exercise Prices, Upper Range"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_z9MOD6y1umgb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;170,069&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zWpknXv68bai" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_zgync7dhd7Z5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;56,689&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember_z3SHETyQHIM" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
    &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zPhAjbNOaSNa" title="Range of exercise prices, lower range"&gt;8.01&lt;/span&gt; - $ &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zVtEqkrDcpgl" title="Range of exercise prices, upper range"&gt;9.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zwrIQdMHrlGk" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,353&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_zBLpFhGXgv05" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.86&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_z7e8oc5JHvl7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;686&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSevenMember_z128nPWWJqo9" title="Weighted-Average Remaining Contractual Life (years)"&gt;8.86&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20221231_zhcALNiEz5M" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,399,252&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zOFJi9YrJyah" title="Weighted-average remaining contractual life (years)"&gt;7.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20221231_zOf4oIldFVGi" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;662,909&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5c85f2Fv3Y6" title="Weighted-average remaining contractual life (years)"&gt;5.87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeOneMember"
      decimals="INF"
      unitRef="USDPShares">0.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeOneMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeOneMember"
      decimals="-3"
      unitRef="Shares">459080000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeOneMember">P4Y6M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeOneMember"
      decimals="-3"
      unitRef="Shares">456179000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeOneMember">P4Y5M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">1.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">2.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeTwoMember"
      decimals="-3"
      unitRef="Shares">130510000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeTwoMember">P9Y10M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeTwoMember"
      decimals="-3"
      unitRef="Shares">4909000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeTwoMember">P9Y10M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeThreeMember"
      decimals="INF"
      unitRef="USDPShares">2.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeThreeMember"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeThreeMember"
      decimals="-3"
      unitRef="Shares">459786000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeThreeMember">P9Y7M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeThreeMember"
      decimals="-3"
      unitRef="Shares">41850000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeThreeMember">P9Y1M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFourMember"
      decimals="INF"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFourMember"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeFourMember"
      decimals="-3"
      unitRef="Shares">110530000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFourMember">P9Y2M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeFourMember"
      decimals="-3"
      unitRef="Shares">48066000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFourMember">P9Y2M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFiveMember"
      decimals="INF"
      unitRef="USDPShares">5.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFiveMember"
      decimals="INF"
      unitRef="USDPShares">6.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeFiveMember"
      decimals="-3"
      unitRef="Shares">66924000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFiveMember">P8Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeFiveMember"
      decimals="-3"
      unitRef="Shares">54530000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeFiveMember">P8Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSixMember"
      decimals="INF"
      unitRef="USDPShares">6.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSixMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeSixMember"
      decimals="-3"
      unitRef="Shares">170069000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSixMember">P8Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeSixMember"
      decimals="-3"
      unitRef="Shares">56689000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSixMember">P8Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSevenMember"
      decimals="INF"
      unitRef="USDPShares">8.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSevenMember"
      decimals="INF"
      unitRef="USDPShares">9.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeSevenMember"
      decimals="-3"
      unitRef="Shares">2353000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSevenMember">P8Y10M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-12-31_custom_ExercisePriceRangeSevenMember"
      decimals="-3"
      unitRef="Shares">686000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_ExercisePriceRangeSevenMember">P8Y10M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">1399252000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-12-31">P7Y9M14D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">662909000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-12-31">P5Y10M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeO0yovDjQS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2022, and 2021, the Company utilized the Black-Scholes option-pricing model for estimating the fair value
of the stock option granted. The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option
pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zfm8IqfHxek4" style="display: none"&gt;Schedule of Estimate Fair Value of Stock Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 60%; font-size: 11pt"/&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231_z0YfCh9eP8ci" title="Expected volatility rate, minimum"&gt;100.48&lt;/span&gt;% &#x2013; &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231_zW9Fw3q4q5Bh" title="Expected volatility rate, maximum"&gt;103.20&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231_z9l5xgHzCn78" title="Expected volatility rate, minimum"&gt;41.66&lt;/span&gt;% &#x2013; &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210101__20211231_zxF37h0llfD2" title="Expected volatility rate, maximum"&gt;82.12&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zloucWdbBLFi" title="Expected term (years)"&gt;5.27&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zMkXH16V6tVb" title="Expected term (years)"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zwQg0SfmN1j7" title="Expected term (years)"&gt;5.00&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zqqypZoGbsvj" title="Expected term (years)"&gt;6.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zUk5mmoNcgc4" title="Risk-free interest rate, minimum"&gt;1.93&lt;/span&gt;% &#x2013; &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_zx4JtZqhGoza" title="Risk-free interest rate, maximum"&gt;4.05&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zM9r7rsbRMKj" title="Risk-free interest rate, minimum"&gt;0.62&lt;/span&gt;% &#x2013; &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z4IgDTqTMYN7" title="Risk-free interest rate, maximum"&gt;1.36&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z55QyJWamnB" title="Dividend rate"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20210101__20211231_zvldb2069aud" title="Dividend rate"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">1.0048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">1.0320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.4166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.8212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31_srt_MinimumMember">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_srt_MaximumMember">P6Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">644000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">147000</us-gaap:ShareBasedCompensation>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z0gJ41gFB3ci" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the components of stock-based compensation expense recognized in the Company&#x2019;s statements of operations
and comprehensive loss during the years ended December 31, 2022, and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zFdR7Y9e5dFc" style="display: none"&gt;Schedule of Stock Based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20221231_zkkJutwYNie4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_zAqdqlJlNSDb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdq1lcl3QhL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zi7WroVL0aa4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;121&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_z9E3W3bLCrpk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;147&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">134000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">26000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">510000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">121000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">644000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">147000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-01-31_custom_TwoThousandAndTwentyOnePlanMember"
      decimals="INF"
      unitRef="Shares">3500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-01-31_custom_TwoThousandAndTwentyOnePlanMember"
      decimals="INF"
      unitRef="USDPShares">4.03</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-01-31_custom_TwoThousandAndTwentyOnePlanMember"
      decimals="0"
      unitRef="USD">14000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-12-31_custom_UnderwriterMember"
      decimals="INF"
      unitRef="Shares">3035195</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-12-31_custom_UnderwriterMember_custom_WarrantOneMember"
      decimals="INF"
      unitRef="Shares">198875</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-12-31_custom_UnderwriterMember_custom_WarrantOneMember">2026-08-25</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-12-31_custom_UnderwriterMember_custom_WarrantTwoMember"
      decimals="INF"
      unitRef="Shares">2588120</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z6TnvXJOOGx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following is a summary of the common stock warrant activity during the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zkiAwBVDWOAi" style="display: none"&gt;Schedule
of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares Issuable Upon Exercise of Outstanding Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted- Average Remaining Contractual Life (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_zzHO1g8FChAa" style="width: 11%; text-align: right" title="Warrants outstanding, beginning balance"&gt;2,786,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zeHynx49KD99" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;10.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1_dtY_c20220101__20221231_zQpiwlZMU0Gh" title="Weighted average remaining contractual life, beginning"&gt;4.67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pn3n3_c20220101__20221231_zfdPZS9g7Vcd" style="width: 11%; text-align: right" title="Warrants aggregate intrinsic value, beginning balance"&gt;30,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_z11VanK8BtTh" style="text-align: right" title="Warrants outstanding, issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zECa7efFD2Jd" style="text-align: right" title="Weighted average exercise price, issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231_zK3FndpS0ZEh" style="text-align: right" title="Warrants outstanding, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zLTehmfOsYV7" style="text-align: right" title="Weighted average exercise price, execised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0967"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20221231_zEacbokXdHe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zS1bumGzNnZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0971"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231_zPL10zllLjef" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;2,786,995&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20220101__20221231_zhAXrZ4pepPk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"&gt;10.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm_dtY_c20220101__20221231_zeHKmgNkZvdb" title="Weighted average remaining contractual life, ending"&gt;3.67&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pn3n3_c20220101__20221231_zoYKrBANjfth" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants aggregate intrinsic value, ending balance"&gt;30,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">2786995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">10.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1 contextRef="From2022-01-01to2022-12-31">P4Y8M1D</RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">30100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">2786995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">10.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm contextRef="From2022-01-01to2022-12-31">P3Y8M1D</RNXT:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">30100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zPKLolaUNZtl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_829_zEH2m7UQ28Kd"&gt;9.
Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2022 and 2021, the Company&#x2019;s income tax provision is zero due to a full valuation allowance against
the deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zISE6hPrbzg4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
differences between the tax provision (benefit) at the statutory federal tax rate and the tax provision (benefit) are as follows (in
thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zhPAUI2T6rF3" style="display: none"&gt;Schedule
of Statutory Tax Expense and Effective Tax Expense Benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_znwCkOLBzlk9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231_zdxYlllhy1dj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzy4e_zjjnu3dFiCb5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Statutory federal income tax&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(2,077&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(1,321&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Increase (decrease) resulting from:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzy4e_zIvMT4tL1cF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PermanentItems_pn3n3_maITEBzy4e_zPF9JUW6Ql06" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Permanent items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_pn3n3_maITEBzy4e_zDWWnkEvL1N" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Prior year true ups&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_pn3n3_di_msITEBzy4e_zui0sQdBQsJj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(421&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(176&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzy4e_zXOuWXnvO8O" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(922&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(331&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maITEBzy4e_zMdEFWMMFb6h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzy4e_zZ4R541HVdwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax provision&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1006"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zaMLnilyrr7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zqnDmx6II5ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zwERnc4H0kBa" style="display: none"&gt;Schedule
of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zWExNUiIyr79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20211231_zTCHjEHErix2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGze5H_zVEDOEaPu4Wd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTAGze5H_zZdx0VVhVfk2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Tax credits carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGze5H_zm8ij9uvOk5b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGze5H_zYfhmut5ZGOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Fixed assets/intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsCharitableContributions_iI_pn3n3_maDTAGze5H_zL7gudQQ4zy6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Charitable contributions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsCapitalizedResearch_iI_pn3n3_maDTAGze5H_z4yE61bsHFC6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Capitalized research&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1029"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGze5H_z7WNfzMvUDsb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Accruals and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGze5H_maDTANzECi_z3Z5aAkreLF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzECi_z8yavthM81Jj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzECi_maDTALNzb8Q_zqf9ULAo52re" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1041"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zieDzIkSJN95" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_iI_pn3n3_maDTLzAtu_zQXjMLx0M3Mc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Unrealized gain&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxLiabilities_iTI_pn3n3_msDTALNzb8Q_mtDTLzAtu_zupbkngAbWp6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzb8Q_z6th2rHVgER8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1053"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z4kzzpmdzLrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022, the Company had  federal and state net operating loss (&#x201c;NOL&#x201d;) carryforward amounts of $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20221231_zj9d2sRVYeyd" title="Net operating loss carryforward, federal"&gt;23.8&lt;/span&gt; million
and $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20221231_zu4hcbVCHaR7" title="Net operating loss carryforward, state"&gt;17.4&lt;/span&gt; million, respectively. The federal NOL carryforwards consists of $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20171231_zWQDnyrTiUrb" title="Net operating loss carryforward, federal"&gt;4.6&lt;/span&gt; million generated before January 1, 2018, which will
begin to expire in 2030 but are able to offset 100% of taxable income and $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20180101_zzy0ZlS65DH7"&gt;19.2&lt;/span&gt; million generated after December 31, 2017 which can be
carried forward indefinitely and may be able to be used against 100% of taxable income through the tax year ending December 31, 2020,
as updated by the Coronavirus Aid, Relief, and Economic Security Act (P.L. 116-136), otherwise known as the CARES Act. Federal NOLs will
then be subject to 80% limitation for tax years beginning on or after January 1, 2021.The state NOL carryforward will begin to expire
in 2033.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company had federal and state tax credit carryforwards of $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalAndStateMember_zVN81BfRFoDa" title="Federal and state tax credit carryforwards"&gt;1.5&lt;/span&gt; million which will begin to expire in 2033,
and California tax credit carryforwards of $&lt;span id="xdx_906_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsForeign_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--CaliforniaTaxCreditMember_zwcdrw2FaHDi" title="Tax credit carryforwards"&gt;0.3&lt;/span&gt; million which do not expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows Financial Accounting Standards Board No. 48, &lt;i&gt;Accounting for Uncertainty in Income Taxes &#x2013; an interpretation
of FASB No. 109&lt;/i&gt;, as codified in FASB ASC 740-10, &lt;i&gt;Income Taxes&lt;/i&gt;. At December 31, 2022, unrecognized tax benefits related to
federal and state tax credits was $&lt;span id="xdx_908_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalAndStateMember_zae44oBzstne" title="Unrecognized tax benefits"&gt;0.4&lt;/span&gt; million. The Company did not have tax-related interest and penalties at December 31, 2022. The
Company does not expect significant changes to its unrecognized tax benefits in the next twelve months. If recognized, none of the unrecognized
tax benefits would affect the effective tax rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of
ownership changes that have occurred previously or that may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code
(&#x201c;IRC&#x201d;) a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change
NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined
as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company
has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. If
an ownership change has occurred, the Company&#x2019;s ability to use its NOLs or tax credit carryforwards may be restricted, which could
require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 27, 2020, the CARES Act was enacted and signed into law in response to the COVID-19 pandemic. GAAP requires recognition of the
tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax
provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief
measures for businesses include a five-year net operating loss carryback, suspension of the annual deduction limitation of 80% of taxable
income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest,
acceleration of alternative minimum tax credit refunds, payroll tax relief, technical corrections on net operating loss carryforwards
for fiscal year taxpayers and allows accelerated deduction qualified improvement property. The CARES Act also provides other non-tax
benefits to assist those impacted by the pandemic. The Company filed for and received a PPP loan. We evaluated the impact of the CARES
Act and determined that there was no material impact for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 29, 2020, California Assembly Bill 85 was signed into law. The legislation suspended the California net operating loss deductions
for 2020 and 2021 for certain taxpayers. &lt;span id="xdx_905_eus-gaap--IncomeTaxHolidayDescription_c20220101__20221231_zdkgTqOjCLbf" title="Income tax, description"&gt;The
legislation disallowed the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted
gross income is greater than $1.0 million. The carryover periods for net operating loss deductions disallowed by this provision will
be extended. The new legislation did not impact the current year provision or our financial statements for the year ended December
31, 2022.&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 27, 2020, the Consolidated Appropriations Act, 2021 was enacted and signed into law to further COVID-19 economic relief and
extend certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans
can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion
of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for
food and beverages provided by a restaurant. The provisions did not have a material impact on our financial statements for the year ended
December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Uncertain
Income Tax Positions&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total amount of unrecognized tax benefits as of December 31, 2022 is $&lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20221231_zt0zamrvIUq4" title="Unrecognized tax benefits"&gt;0.4&lt;/span&gt; million which relates to federal and state tax credits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zFOzddFMJnag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the activity related to the Company&#x2019;s unrecognized tax benefits for the years ended December 31, 2021 and
December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_z9nQRS8rmQv2" style="display: none"&gt;Schedule
Of Unrecognized Tax Benefits&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20210101__20211231_zlAkIMc3Yvj8" style="width: 16%; text-align: right" title="Beginning unrecognized tax benefits"&gt;212&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax positions related to the current year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--UnrecognizedTaxBenefitsAdditions_pn3n3_c20210101__20211231_zx5A0gbbRgTh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions"&gt;97&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20220101__20221231_zZf73DBHBEr8" style="text-align: right" title="Beginning unrecognized tax benefits"&gt;309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax positions related to the current year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--UnrecognizedTaxBenefitsAdditions_pn3n3_c20220101__20221231_zaBLvpM0dcOl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions"&gt;140&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20220101__20221231_zLlD5lPVGDFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending unrecognized tax benefits"&gt;449&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zg9Z8q6uh2c6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy is to account for interest and penalties as income tax expense. As of December 31, 2022, the Company had no interest
related to unrecognized tax benefits. No amounts of penalties related to unrecognized tax benefits were recognized in the provision for
income taxes. We do not anticipate any significant change within twelve months of this reporting date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is subject to U.S. federal
and state income tax examination for calendar tax years beginning in 2010 due to net operating losses that are being carried forward
for tax purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zISE6hPrbzg4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
differences between the tax provision (benefit) at the statutory federal tax rate and the tax provision (benefit) are as follows (in
thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zhPAUI2T6rF3" style="display: none"&gt;Schedule
of Statutory Tax Expense and Effective Tax Expense Benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_znwCkOLBzlk9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231_zdxYlllhy1dj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzy4e_zjjnu3dFiCb5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Statutory federal income tax&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(2,077&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(1,321&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Increase (decrease) resulting from:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzy4e_zIvMT4tL1cF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PermanentItems_pn3n3_maITEBzy4e_zPF9JUW6Ql06" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Permanent items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_pn3n3_maITEBzy4e_zDWWnkEvL1N" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Prior year true ups&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_pn3n3_di_msITEBzy4e_zui0sQdBQsJj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(421&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(176&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzy4e_zXOuWXnvO8O" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(922&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(331&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maITEBzy4e_zMdEFWMMFb6h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzy4e_zZ4R541HVdwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax provision&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1006"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-2077000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-1321000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3411000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1624000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <RNXT:PermanentItems
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">26000</RNXT:PermanentItems>
    <RNXT:PermanentItems
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">134000</RNXT:PermanentItems>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-17000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">70000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">421000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">176000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-922000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-331000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zqnDmx6II5ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zwERnc4H0kBa" style="display: none"&gt;Schedule
of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zWExNUiIyr79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20211231_zTCHjEHErix2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGze5H_zVEDOEaPu4Wd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTAGze5H_zZdx0VVhVfk2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Tax credits carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGze5H_zm8ij9uvOk5b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGze5H_zYfhmut5ZGOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Fixed assets/intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsCharitableContributions_iI_pn3n3_maDTAGze5H_zL7gudQQ4zy6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Charitable contributions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsCapitalizedResearch_iI_pn3n3_maDTAGze5H_z4yE61bsHFC6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Capitalized research&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1029"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGze5H_z7WNfzMvUDsb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Accruals and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGze5H_maDTANzECi_z3Z5aAkreLF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzECi_z8yavthM81Jj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzECi_maDTALNzb8Q_zqf9ULAo52re" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1041"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zieDzIkSJN95" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_iI_pn3n3_maDTLzAtu_zQXjMLx0M3Mc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Unrealized gain&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxLiabilities_iTI_pn3n3_msDTALNzb8Q_mtDTLzAtu_zupbkngAbWp6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzb8Q_z6th2rHVgER8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1053"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">6492000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">4453000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1297000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">887000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">56000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">29000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">111000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">99000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <RNXT:DeferredTaxAssetsCharitableContributions contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2000</RNXT:DeferredTaxAssetsCharitableContributions>
    <RNXT:DeferredTaxAssetsCharitableContributions contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1000</RNXT:DeferredTaxAssetsCharitableContributions>
    <RNXT:DeferredTaxAssetsCapitalizedResearch contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">813000</RNXT:DeferredTaxAssetsCapitalizedResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">133000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">8904000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5475000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">8886000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5475000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">18000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">18000</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">18000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">23800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">17400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2017-12-31" decimals="-5" unitRef="USD">4600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2018-01-01" decimals="-5" unitRef="USD">19200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_FederalAndStateMember"
      decimals="-5"
      unitRef="USD">1500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign
      contextRef="AsOf2022-12-31_custom_CaliforniaTaxCreditMember"
      decimals="-5"
      unitRef="USD">300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2022-12-31_custom_FederalAndStateMember"
      decimals="-5"
      unitRef="USD">400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxHolidayDescription contextRef="From2022-01-01to2022-12-31">The
legislation disallowed the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted
gross income is greater than $1.0 million. The carryover periods for net operating loss deductions disallowed by this provision will
be extended. The new legislation did not impact the current year provision or our financial statements for the year ended December
31, 2022.</us-gaap:IncomeTaxHolidayDescription>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zFOzddFMJnag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the activity related to the Company&#x2019;s unrecognized tax benefits for the years ended December 31, 2021 and
December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_z9nQRS8rmQv2" style="display: none"&gt;Schedule
Of Unrecognized Tax Benefits&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20210101__20211231_zlAkIMc3Yvj8" style="width: 16%; text-align: right" title="Beginning unrecognized tax benefits"&gt;212&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax positions related to the current year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--UnrecognizedTaxBenefitsAdditions_pn3n3_c20210101__20211231_zx5A0gbbRgTh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions"&gt;97&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20220101__20221231_zZf73DBHBEr8" style="text-align: right" title="Beginning unrecognized tax benefits"&gt;309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax positions related to the current year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--UnrecognizedTaxBenefitsAdditions_pn3n3_c20220101__20221231_zaBLvpM0dcOl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions"&gt;140&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20220101__20221231_zLlD5lPVGDFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending unrecognized tax benefits"&gt;449&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">212000</us-gaap:UnrecognizedTaxBenefits>
    <RNXT:UnrecognizedTaxBenefitsAdditions
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">97000</RNXT:UnrecognizedTaxBenefitsAdditions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">309000</us-gaap:UnrecognizedTaxBenefits>
    <RNXT:UnrecognizedTaxBenefitsAdditions
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">140000</RNXT:UnrecognizedTaxBenefitsAdditions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">449000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_z1wm1SAxgZsf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_820_zvfet6qHkRbg"&gt;10.
Net Loss per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zWI0aCdsQ6F8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per common share was calculated as follows (in thousands except per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zPUU07vKP2Qd" style="display: none"&gt;Schedule of Computation of Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_zeDlRnkl1Gol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20211231_zGByHEN5YLgh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_z7YdMFcyoHij" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;(9,889&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;(6,324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zx2FgHMzb9We" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares used in computing net loss per share &#x2013; basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_zJdlTwHdUR45" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss per share &#x2013; basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.09&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.21&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zEuCCVuWbK8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2022 and 2021, the Company had a net loss and as such, all outstanding shares of potentially dilutive securities
were excluded from the calculation of diluted net loss per share as the inclusion would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zsI8Bz80kBPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities not included in the computation of diluted net loss per share because to do so would be antidilutive are as follows
(in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z8zSUZwNfVAc" style="display: none"&gt;Schedule of Potentially Anti Dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zYBSskZsHIbk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_z5oS6p1u9tY7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zwa1JLG0uCUf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify; padding-bottom: 1.5pt"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;730,746&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;684,382&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zLncqyhDISwj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;730,746&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;684,382&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zoSXZcADAMzj" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zWI0aCdsQ6F8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per common share was calculated as follows (in thousands except per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zPUU07vKP2Qd" style="display: none"&gt;Schedule of Computation of Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_zeDlRnkl1Gol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20211231_zGByHEN5YLgh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_z7YdMFcyoHij" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;(9,889&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;(6,324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zx2FgHMzb9We" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares used in computing net loss per share &#x2013; basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_zJdlTwHdUR45" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss per share &#x2013; basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.09&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.21&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-9889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-6324000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="Shares">9052000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="Shares">5217000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zsI8Bz80kBPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities not included in the computation of diluted net loss per share because to do so would be antidilutive are as follows
(in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z8zSUZwNfVAc" style="display: none"&gt;Schedule of Potentially Anti Dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zYBSskZsHIbk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_z5oS6p1u9tY7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zwa1JLG0uCUf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify; padding-bottom: 1.5pt"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;730,746&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;684,382&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zLncqyhDISwj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;730,746&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;684,382&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">730746</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">684382</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">730746</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">684382</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zY7ytfdEEJOa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_823_zC6AkHYgAC2g"&gt;11.
Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2018, the Company entered into a consulting agreement with one of the Company&#x2019;s co-founders, Dr. Ramtin Agah, pursuant
to which Dr. Agah provides consulting services as the Company&#x2019;s Chief Medical Officer by overseeing Company-sponsored clinical
trials. The agreement, which was amended on September 1, 2019, and November 11, 2021, respectively, continues in force for as long as
Dr. Agah is providing consulting services and may be terminated by either party on 30 days&#x2019; notice. Dr. Agah was awarded (i) options
to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20170531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zQwpfXGjvQ6c" title="Share based compensation arrangement by share based payment award, options, outstanding, number"&gt;60,000&lt;/span&gt; shares of the Company&#x2019;s common stock in May 2017, which have vested, (ii) options to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20180731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zATZqIRKL2Y1" title="Share based compensation arrangement by share based payment award, options, outstanding, number"&gt;40,000&lt;/span&gt; shares
of the Company&#x2019;s common stock in July 2018, which have vested, (iii) options to purchase &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zaTLKSU5kFOj" title="Share based compensation arrangement by share based payment award, options, outstanding, number"&gt;20,000&lt;/span&gt; shares of the Company&#x2019;s common
stock in June 2021, which vest ratably over 24 months from the vesting commencement date of May 14, 2021, (iv) options to purchase of
&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zZDysa0R16za" title="Share based compensation arrangement by share based payment award, options, outstanding, number"&gt;52,203&lt;/span&gt; shares of the Company&#x2019;s common stock in September 2021, which vest ratably over 48 months from the vesting commencement
date of August 26, 2021, and (v) options to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zTW61Rdi4YFg"&gt;21,398&lt;/span&gt; shares of the Company&#x2019;s common stock in March 2022, which vest ratably
over 48 months from the vesting commencement date of August 26, 2021. In December 2018, Dr. Agah&#x2019;s agreement was amended to provide
that he would receive cash compensation of $&lt;span id="xdx_900_ecustom--CashCompensation_iI_pid_c20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_ztn4nE3TB11b" title="Cash compensation per month"&gt;4,000&lt;/span&gt; per month for certain proctoring services, and in September 2019, his compensation
was increased to $&lt;span id="xdx_90E_ecustom--CashCompensation_iI_pid_c20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zz9LA1fO0Uv5" title="Cash compensation per month"&gt;10,000&lt;/span&gt; per month to compensate for additional services he was providing. &lt;span style="background-color: white"&gt;In November
2021, we entered into a third amendment to the Consulting Agreement with Dr. Agah which &lt;/span&gt;provides for a monthly consulting fee
of $&lt;span id="xdx_903_ecustom--CashCompensation_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember_zY15KEeEQBe5" title="Cash compensation per month"&gt;22,000&lt;/span&gt;, based on Dr. Agah spending no less than 24 hours per week on Company matters. Dr. Agah&#x2019;s monthly consulting fee was
increased to $&lt;span id="xdx_90A_ecustom--CashCompensation_iI_c20230101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember_zMEYYCuRR2ji" title="Cash compensation per month"&gt;25,000&lt;/span&gt; effective January 1, 2023. The Company may, in its discretion, proportionally adjust the monthly consulting fee
if Dr. Agah&#x2019;s time commitment decreases. The amendment also provides for Dr. Agah&#x2019;s eligibility &lt;span style="background-color: white"&gt;for
an annual target cash incentive bonus equal to 40% of his annualized base consulting fee. &lt;/span&gt;In November 2021, we entered into a
Change in Control and Severance Agreement with Dr. Agah. Consulting fees paid to Dr. Agah for the years ended December 31, 2022 and 2021,
were $&lt;span id="xdx_90B_eus-gaap--ProfessionalFees_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zeUJyoWuALH3" title="Consulting fees"&gt;289,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ProfessionalFees_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zWgxpYIEO2l5" title="Consulting fees"&gt;227,000&lt;/span&gt;, respectively. In addition, the Board approved a discretionary bonus of $&lt;span id="xdx_900_ecustom--DiscretionaryBonus_c20230201__20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAgahMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zf8thLilHH5f" title="Discretionary bonus"&gt;91,000&lt;/span&gt; paid in February 2023 to Dr.
Agah in recognition of Company and individual performance during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2017-05-31_custom_DrAgahMember_custom_ConsultingAgreementMember"
      decimals="INF"
      unitRef="Shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2018-07-31_custom_DrAgahMember_custom_ConsultingAgreementMember"
      decimals="INF"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-06-30_custom_DrAgahMember_custom_ConsultingAgreementMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_DrAgahMember_custom_ConsultingAgreementMember"
      decimals="INF"
      unitRef="Shares">52203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_DrAgahMember_custom_ConsultingAgreementMember"
      decimals="INF"
      unitRef="Shares">21398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <RNXT:CashCompensation
      contextRef="AsOf2018-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember"
      decimals="0"
      unitRef="USD">4000</RNXT:CashCompensation>
    <RNXT:CashCompensation
      contextRef="AsOf2019-09-30_custom_DrAgahMember_custom_ConsultingAgreementMember"
      decimals="0"
      unitRef="USD">10000</RNXT:CashCompensation>
    <RNXT:CashCompensation
      contextRef="AsOf2021-11-30_custom_DrAgahMember"
      decimals="0"
      unitRef="USD">22000</RNXT:CashCompensation>
    <RNXT:CashCompensation
      contextRef="AsOf2023-01-01_custom_DrAgahMember"
      decimals="0"
      unitRef="USD">25000</RNXT:CashCompensation>
    <us-gaap:ProfessionalFees
      contextRef="From2022-01-012022-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember"
      decimals="0"
      unitRef="USD">289000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2021-01-012021-12-31_custom_DrAgahMember_custom_ConsultingAgreementMember"
      decimals="0"
      unitRef="USD">227000</us-gaap:ProfessionalFees>
    <RNXT:DiscretionaryBonus
      contextRef="From2023-02-012023-02-28_custom_DrAgahMember_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">91000</RNXT:DiscretionaryBonus>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_809_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zoBcinCuV7W9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_823_zDW4KbaE84t9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
Employee Benefit Plans&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2022, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k)
plan&#x201d;). The 401(k) plan covers all employees who meet defined minimum age and service requirements. Employee contributions are
voluntary and are determined on an individual basis, limited to the maximum amount allowable under U.S. federal tax regulations. The
Company makes matching contributions of up to 4% of the eligible employees&#x2019; compensation to the 401(k) plan. During the year ended
December 31, 2022, the Company made contributions to the 401(k) plan of $&lt;span id="xdx_908_eus-gaap--DefinedContributionPlanCostRecognized_c20220101__20221231_zI1IIJFbvGPi" title="Defined contribution plan cost"&gt;10,200&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">10200</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zMrrihvOSjJ5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_827_zBNonuzS9HW8"&gt;13.
Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 30, 2023, the Company entered into a
definitive securities purchase agreement with a certain institutional investor under its shelf registration statement for the
purchase and sale of &lt;span id="xdx_903_eus-gaap--SharesIssued_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrZvFV9ZR8Cg"&gt;1,557,632&lt;/span&gt; shares of the Company&#x2019;s common stock (or pre-funded common stock warrants) at a purchase price of $&lt;span id="xdx_905_eus-gaap--SharePrice_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWfeMXxHygJg"&gt;3.21&lt;/span&gt; per share of common stock (or pre-funded common stock warrants) (the &#x201c;Registered Direct Offering&#x201d;).
Additionally, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlDJzRZJMKm8"&gt;1,947,040&lt;/span&gt;
shares of its common stock (together with the Registered Direct Offering, the &#x201c;March 2023 Offering&#x201d;). The aggregate gross
proceeds from the March 2023 Offering are approximately $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfWarrants_c20230329__20230330__us-gaap--TypeOfArrangementAxis__custom--DefinitiveSecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXlwwxjhGKr8" title="Stock warrants"&gt;5&lt;/span&gt;
million before deducting placement fees and other offering expenses.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-03-30_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">1557632</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2023-03-30_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">3.21</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-03-30_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">1947040</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-03-292023-03-30_custom_DefinitiveSecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">5</us-gaap:ProceedsFromIssuanceOfWarrants>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M+Z31_?DGO:/](J.C4JRO2*Q SMJ3LR#U;I\ZL3C?<#1[6Q,9-KA<UYI?97S
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M '!5;6JG2 !FG@#,HQ+ ,.2$;2?;)/?"\0ZC="("K%A"#:ZJ/>7@% ' S .
M>50 2(<CLD5F6E(F=1P5.B,:-K'C$"$C1-RMH)2>TAB@2JU(+X\!YE%/$Z8!
M]GUT&T?BZT@Z/BMTRIZXPV6U89TB#)@',X..>I9P%Q"V3,YFOPH%OA(!*ECC
M4-[G8,%2:FKG!)TB%)AY*# KGB0D$PC%@!I1CF84/44$\141=HV39 +:X12&
M[3-F*4AX'Z5S&."ZVB1/$0C,/!"81SU=F*Z$=P-[W?^<1P37U89UBEQ@YKG
M/.IAPCB>^YZ#!C[%\BNH2F]O*U7K9VKM5"V9'OS2U=OG[>O6BXQ,G@#,HQ+
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M(_TE$'9382>*%^6ZO.1*K_+E,-4;,1 F0%]?<:X>)V:IK[=VT3]02P,$%
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MC4'1$E"T% JMS;0C]=*U,NW+&R>JF:6[8J'?*,^8J+[=$<Z)II*FD5KK7+K
MM0=R0<6! HIJH);L$LRZLQ*4NP0**#T5=YL*C7CHVM7#[T,%:W&Y0ABT%!?<
M[Q9?+6][M072:PR*EH"BI5!H;4(U@JEK5TP?J%ZVTII%8J-6M(@L_[L54O]>
M8B3$%<J?N48  4500#$44 (%E ( M8G12*RN76.U$\-:,:[0%2T5HZ\NXJ[0
M!NHQ!D5+0-%2*+0V*1I-UK6+LN=//_O+Y48_.9M9<H5L:"XC0$"1V]=U72?L
MKC2 O"500.F)L-N9;G15URZL7IEI:UVX0D&TU(6^CNA-9YZ'N[4!TFL,BI:
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MN1D(%5,.6D?JP!MD7@,*1E3^B>:,?@K-J4+<FEB:ORE7J,^HIE9[$8>RGSC
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M=V]R:W-H965T<R]S:&5E=#DN>&ULM5QK;]S(E?W.7T$H03 &NF6I[?%,YF%
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M@MK+R920. KQL=2?VZ9#HKSUDSB36O4.6VJ%T7?!H'VU#81Y_#35%B2,"&V
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M5[7!PK<%!,C47J< "#ED;+$M:5V^V=U ]KM6.^AA0"8M9XY&.,Y4S_ST!-T
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MYU [ =I?*64/$V>@>2#._@%02P,$%     @ YX-_5I]5AVE[!@  EQ   !D
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MQZY/AR">\?4-N:I '-5*ZF'0VTRHPSON@(K=#D@.'=#.=E6[MX'!A&2Y5V5
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MR:_1O]G];_?<WWGD=L^4CM^?B>>CWO#L3+R@R[@W'L7B!44:#(T-GZ<J7+T
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M=[J$!LK<8LH]SB,(?S]^]\?K_G9N[!QKBINV+R?N\<;3@,L3,S%-5;:4$8;
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M<VAE971S+W-H965T,3<N>&ULE59M;]LV$/ZN7W%0AR(!/.O%CN.XMH&\M-B
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MZZL0=#-$FXU5E1]<*V5I#/IE0;\[4#L#^KY6%+EVXR[H?LG,_P-02P,$%
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MRY*+YOS D\)*>G$XA"^TWX*"BUROT5A@0@"VD5C8E!JD[VB=-"H<+FL)U&:
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M"CC=DJ3.*4_4[*V16]E Q]UA0#(-;MFZ9%FOI'L$KU!+@GHP'C:.U-'+.:H
M*VH$74(\FDY/1L=I NDXB=D]FYR,HDD$T[>N/MS31H-FY2> A5QWBGJ9#*O#
MD+GHM?42WD\HOK85UP4UEIP:C4^F 9A>];U#NO5*6VIBW7JSXD&)Q@7P?JDU
M[1QWP#!ZLS]02P,$%     @ YX-_5MLOX)U5&P  8%(  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&ULM5Q;C]M&LG[GKR"\BT4,2&-)=NQ<#8S'=G;V
M).N!)\[BX. \M,B6Q#7%5GB9\>37G_JJJIM-B:*S!LZ+/9+8U=5UOS5_N'?U
MQV9G;9M^VI=5\^.C7=L>OGORI,EV=F^:"W>P%?VR<?7>M/2QWCYI#K4U.2_:
MET]6B\7S)WM35(]>_L#?W=0O?W!=6Q:5O:G3IMOO3?WPRI;N_L='RT?^B_?%
M=M?BBR<O?SB8K;VU[8?#34V?G@0H>;&W55.X*JWMYL='E\OO7JT66,!/_%;8
M^R;Z.\51ULY]Q(?K_,='"V!D2YNU &'HOSM[9<L2D B/WQ7HH[ G%L9_>^AO
M^?!TF+5I[)4K_U7D[>['1]\\2G.[,5W9OG?W?[=ZH*\!+W-EP_^F]_+L<]HQ
MZYK6[74Q?=X7E?QO/BDAH@7?+,XL6.F"%>,M&S&6KTUK7OY0N_NTQM,$#7_P
M47DU(5=4X,IM6].O!:UK7ZXNTEMA2.HVZ6VQK8I-D9FJ32^SS'556U3;],:5
M15;8)OW*__7XAR<M[0X83S+=Z97LM#JSTW*5_N*J=M>D;ZK<YD, 3PCM@/O*
MX_YJ-0GQM<TNTJ?+6;I:K%83\)X&6CQE>$_/P!L[\?]<KINV)MGYW[$3"[QG
MX_"@4-\U!Y/9'Q^1QC2VOK./7O[M+\OGB^\GL'T6L'TV!?WE*],4#9AV ]A5
M:R#E8TA.@AE'DF$G1[#37W<V,42C_<%4#Z#2IJA,E16F3!MZQ)*RMDVZ,W<V
M75M;I03O8&J;IP6T+W-U3D];$O!VQY^5UH>Z(""'DJB]M96M35D^X'=[:&5M
MN[/IAZK IUOLPYA=[FU-@II^];>_?+-:+;[_Z?+RAO]<?O\X-56>FL.!>&C6
MI4WK#L#Q96VW7<FG8=(!\NV;JY2L&_U<=702PMG5P.LBO:P>8'AL;8&V(-+8
MM'*$0MJZ)-IAVQ5R.&+)WD)]6B=K\0>V,5V[<W4!4A)]@&UJ&MJXJ\(9(_FC
M<U:YJ?,FO7(Y:R1SP!_V\O;*GS7AL]+IB/JD5NGZ81S.AT-.I(L@? C44D*\
M#=P<!?#*T7]A_=O+VU<>P$4Z(<Y?!W'^>E*<WQ?-1^'1!Z)CW9)#:4D!QP1Z
M$M"X0#/TY 0ZB_25"#18UW3K?Y.[ ,],6G7[-?&/J%,+;DWCB#P00Q9A401
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M]URJCDG0QW/'%N&-1,W7/FI.;CAJ?JLT>["&O*<4U5]3;L]L\]TFWI[^6')
M34>]-_!'&@]&_8)3L>T:":2#'K"AD"I%+@*7>-&(SJ$Y)A.B4<EEUGY&'.Z#
M,Z:GYOZ)2<.R7/3-P\6D:7F+A.4WG[#T#83K/MH;;11.0ATW-M@JF=XJ?1OR
M$NAG;C<0=4\Y"L9VJ*$A2,RL!*&!.%IDS[43)"F-1!"%I#TDAPU"?1/R281B
M_+#]5+0"=:9<3[2G1?C1(UP>HEB(.$ 6 (F)5J-$/4W;;Q=@<\^,F%R3]!)G
M>7LC5<:U;>_17E,@7 +$7FP?1.CVK-*</R6(<2Z8-)I:1C]&]7[2J#C_)$]8
MHY[X( B&>@N.2X(D-?N]^42![!]2@.^D=.368!A'"$5%]K&!AR652,R=*4I\
M+ZI-9NAD;5>=K,;B2E%FBQ90O!A$,+UI&\FD>W\]7HE)>VMXG@2Y;;*Z6"-G
MW-76IB5B&[;(@FDB+1L*^]<V*+G2.@([D[8?103WS7?ISP"2+%,V2LOO69<T
MQ9$\FACZ>^=@X5C M%J>@P?9^?,4?MQ!A82LM^RTFMSIE/J20=/)CM&(:T ,
M.B532,'X#L<[Q=BW2P3?Y+/XSB9/?0)PC  *215,:T6R"RLN'RW1<X:'(A(@
MUS%0-_).=>W6KO9!2_20*B$IF?$T?CI)XS$9)V_(4RHJ@\>.*BI@S'RJ"^7E
M<F@H75!BY34L7I%PA0U(,RM'C(;/X.YZ;%7=!XF:+PF*WOG:1GY6U>*,7RNC
MTR5#+DKRX$"DS(2X*&=_.#U"%'HGVN_GO@L\:E^GD^B%VT32)@EEP8SK2FR;
MU(>3S_"U1,UF']@F(_]A XQIABHC0M?:MA?9<?U^LR1RO1P"E<0+Z5S2Z413
MG@H),PIN>(Q"ZJIQX\Y7U'1*@@)/\Q"2+JZ>V;@,3?OTDQ,^OA4#Q+[M$*8X
M[GQ!DGB&#HYE?4AZ'H(#F5%[+,\U.TKYYN!(6AG4$*:#AVCR:#E=T#+-;I;B
M7P[%0N!(1[RF:+!IS\</DX#/5+"P6_*YW08^Q5.R00)'[F"[(_*6!:T&[_LU
MK(>N+K8DU"5J@2$4WZBOV,O@DQ<F]FD'2@-WI@EL.JU277J1GY.DSQOZ.@KL
M9L/HVI$7WPX'6SY<W%[$'3M?US%:99V)@)(4LG2V R?%9^HJLBZ<="?;T+I#
M=F-A(C#0HZ,,I$Z^C$LXV1VF]NZL[YE\A26/>4B%#L ]'\D-7.6S>$3O.U>"
MV&KVM*A]D;Y7%+A5JZY#4."(F?O:8O'%",%.!:)&_HNLS(%,.$86B@TJ0E))
MFZ(Q$RCV=)025*2QQ)L;Y9Y@@74:"GBQ. 8#>I$Q_4.\@(%!R;7UPX4"J5ID
M"!7/PFF(0A+9ACQ.TTQH,@RU.LDP,"3F;UIA5[W"KB85]F=R-19<2J_W:-[[
MOM(_[6B5:AK:N):&+9*3+=+^MR+ZC8FK!D[$&#2<<2*.DE.6=7LM-Y"=):\G
M/?"+]#+ZY&TIB!L$NP\*,0&(-'Z.,RA-$RB6_ K[Z*NP8#0JREA: N&4#:?F
ME+W7) N[Z4JR)IO/F--^>'$Y.6WX\CV1@"< ()"OH\+;%=%CW(Q^P?BBWR49
MW24=_!Q7_P;.BC2G5AWUA#<<4L+]Y1?IX"BC4%0IFV@<*&,$^D(!Z:3!',$L
M69-OW!1J[,\UJ3@V\ ,V7!(.>X1=N?Q-%K8K6Q,:&7ZNZ:C'I5,VL] ;:A+&
M<,:C #4\15B1U]TV%*:'@Q^Z!I4 4NT47." 6+^/QVOZ GQ/A T%Q/C/ A/\
MF^ ,ON7!0DK@*F_'M&&F?=Y<!B/BUH+9DCM3G22SB9 8>X<S'K?Z.-NI.)*G
MI^\T]VND040I4S\6AG&'.O ]G"7N16H9E6/.3++D>*9+YDJ05S;<)V('E%,8
MBV$*4M:=-7GH9#+]ABDDH>]\(8 C+K$OW- [9F[ANR&#_@G7L1]\(T620 UX
M;^ LTNOKZR-0%^F-;I3T-8C!CK)7%LR-GDC$G6S.4%[PQ!1.S.7-!N6&^HR6
M)4'>[Q$5_S5=/EMRAVKU]"G_/V6N^NGEY?3X\I4_WZ],T3>ZYZB=^H()9@\^
M&8(?,!Q5_8C1,FM2Z2P7!T %EU2D?WZ.@UIA1 ,; XP:#HX*C)1VY;DDD-]%
MHUG'-D6F[5CX?6?F='9!8X<^IX++\6$@;&M06K:^T5QC9;>N+?H<Z@[W $3\
M%$V=^>MG,U'@D!XX"-95:(IY&J8;5#4NTI]\,C([Q:"1NI>.OS:9.W"J@;L;
M: :MN5B-S$Z<N:%C?>(>*MF.KO*%-FWT4QA5[/T$G9H@'TY=ICPITU=*^Q Y
MC H%WH<J<6-[3B8R2,M5-6@8AA!]B8.1#[W'U%:U*\N]#ET..E0'VE)J]SI6
M0-)76H^8ALU#:=D7%$ZV%!W3,;SD)M$,QA'[F:L^*PR%AL',S1-7#_) 2!KS
M61T*O,^=Y#KH7M5L;YDG@1N1)4Z,S$)P"2PZ8T2&V=$Y_1-^^!0LHSU)+IJ0
ML)Q(]3LF#BJIB&J-]_%*"7B/TXV'](\IPUE75"X1 E'HS]UE[_380$;)%&_R
MX)7\:(XEB'6"C?8\JD\[?<7EJDI&1V:2^*C.(,GG,G3C/<,13(R3.MP#0I'K
M2#O26#L>S_S0E,[2H,::_[MKI'Z!()9857(&=<=MS"969O#/JVU\WC/QF2*K
MC23ZU(\Q;DP86-^BF("<U$\*U;HUJ@I(!2/R_YFQQ65_>V Y?7W@IR@(N!P$
M :,>Y0NN$.@.R>D.:?S34002?*D?44&VZR/3U$>FL\G0E .-/M!%'NK;V#.U
M^G8D^L&,>*950PPJD*;Q['@?1.HPGK^4,- N'GL/]T!(ULPGPI*4EU2[)!-1
MSGATHT3ALA.Y)131%-$(N8]>$XQP2E=,1V5J0X;C_S6TDW&9SP0XP5.-;3#(
M6/1#?J('/F69$N)^^'8Y/7U[%75!;WR+-+V%6(Q*\1=,XD9;)$=;'$T@P8 T
M?:?6=UC;0<&WB@=8*7MN.C%YFGW[+WRX?7,$#5W3 VR$ZYKR(:3>B4]W)DM#
MZ5?H\&5%^SC4+"4=Y]XI[)SA$K)4[%23+%<PU5QQ?,M31*[$E)*6LD9J\ F;
M35=J5[HYJNON[1]_4 Q7V8!:J#;I-X^'UTO4.5JIR%W?O ,I+[LM+OP\7<RT
MM:PVMBZV6]1S$[U'YE#USK1G[GO!*%'&_>+1=KN2G=U W[>?EMY^/G$Y/:#(
M0C1_Q>;K*C)?HZ+[!3.($?PDAC^0VS[J.6T#ZIB(#A#TY9U7I2' MQE)&:IX
M,HJ&,)-O);@<IDK'FBH2T(.362D_91HW6WJ+UE^9FND('VPJ:D$\N5 T'^<;
ME(9Y_@T#V#7W:0<'BTRQVFSU#CKGH-4J+2L2ZWDR/%&MY+EAU4T>&1Q4L60Z
M*625*#?V4^71&%??6-@@1>>I",F;?172Q$'VD.+6$)!H-",0O?!TG@_HC WC
M4<'/=,/Z6#6)K^N)<GW24@,G.S#H?#.#U"%J>.D7GY\K'Q_J'L[MM$EL"YGZ
M,YT\B-FO:X6%1P\(),EPXCMWGDN?A13D*AG(57_WB >5+"20+Y1%K>CA@,65
M'$T<PUM7)UL=Q"'JHRU+]GP.LR41K&OT(N_YJU-#6C7A[L6Q#Q&IY7',4.8^
M&CK_,UMPU-U/6'T>(W0!49+O77Q'47&FW4;)PT#ZY%>0/GSZK><29J'G;T'[
M:T_[]SC4:R5YPI]B8]7KEI_Q'Y@HA&T65)[! O $/ FV>[!]*2&4(GEN17/E
MDY$CN7'-86.=(3IG3B6X:5;&,_U#Z>:4I^0.I<(Q[9!-,BP%SQ/D82 F)WKC
MIVPCJ4G^O-0<24JP<4/7&GJF.GDYH*G';VS@(Y'"_G0H/C2Y6@B(*.6]"^SI
MM%_M)X*7TR/!U])%^]5\.E,>^X)Q8(&9,,STM1_&HQC_W$ %Y[<RS!+5&/IQ
MMR:,)0W;^_U]);9 M,':O[=@?">=3+2584/7CR67YCZ:T^@M(6?%R(GD7A=G
M^6+I>MR.5V"4NV[L4'!\R&OZ=GZ"O.2>(U@_2HE)\ZACG_O(RK?LQ7'*8!D7
M=^ZA<#)B)GTEA@1"^+8$NWF])=T/'_,4J1(MT<L./#) Z\7]>P'7FV!]%VPF
M!A9]T^"<N7 5L(TXG9D*WFYM!S-43-4]+I>7Q4?$QNBA)O3@1?I:V@+:A/4I
MT!0VHY/[0@_&A(M/$LC6GBPR\B.BWT),I[6I'X9>3D]#O]G;FFNH/\DE\?AV
M^"WFSBV*^EYH_:]X[T0WKGU?,#CM<4B^ (?C5Q; K/LCZ;UWO447WM7PYJ>K
M_LT8_5RD^KE_4#3%H6/ZCN*[5W[@_Q9?=8<&]YX@/ZO%<D5I#2U0J/]X]^HV
MH1\'+]U =;A%936,._+[$VS>95#F<"8=,(KN _'P5="7Z-4:*,")*PZ7Z"_2
M6ZW2+Q<O_,U)X,/(DI>C^+ Y0Q88,ZUPDS-EF\WN$5?*N4AZQR,5T<A@_S*,
M)KP, U^@YE'<^5D&AIQ(IY_/EFN:==#$4J_2!1A#XX/9)WY5D:SSR2Q?&\[Y
MTH.I&GEG@]8>I!DY<H;$GV$,<UQ[9BRYVV4\,QN5NIY#*D0S9>^1X+SOB#/+
MU7J^\I[XC1^O)19P0?7>2O4U/0L[T?NO7,.GQS/IESN95CXGUC,\"CF++V_C
M9A07O9GW?7G;#WM%5W-/1$_($<;+D&R=P5A$3T<MI+\A0RWG3AA0W3DG1U.K
M2+B6DMZT]XX'A!.Y/TZ"UZ 8+-/G\)(HN0T$<G@]&DG9I;RZ1DP&R( 75I%N
MS/\+2CEC$WY>'6:G^/?O_I ;]UZ!XQO.4<VX;QGT]VN&O?6WQ(R$^8QPD_Z?
ML; .W@+D*H?+['VC2G,-S0/QQIDPMQD$&OTD7K]VH:]@<G<X32#Y"I.8"IV6
MP0P=!PW 5\:D/U0\H-4;(IRX(T>G7JQ_,8"P"[?H!,O>-@P&3A]L&VW"\2]]
MG>A[#,+;"_JW%HQ%P3WO^7*A.DI_$]5MXO<$= <D^[G$H9,^<]6/^:^FQ_S?
MBVC&[\>*N37F%J<AGILMX3<HG-LF?:\D3RZ5P>>>;/ ZC+=V77<HP)'G>C[K
M14CY-?&2I&;T+4D ,U^L9C*'1,_\Z@[DE+YYMGJ,[<(5$7KNVY'M;C_P+_,E
M08@C>@_GQ;/%X_0S%&C2?Y)(_3>)E*< ;?R/CA+D,V>439_/ET]GXU<F6,16
MW^MMWI\EI%.,GJZ>/QY?E7QNV8QR"O:-/$H!G?R[S=GX>*HMOWXL18EQ:FHI
MM'^9R>FQ5HOYXCDV6K=AX)H_L"N\ZHNCV$4ZB>_4-7QUVZU;WN_9B\5\M7BL
M,U,#E!./L@=^%3K\9';?\"6(H*'O[BM_GZ@'3H><@ZL1.^&TXRI_3%3@,-C#
M^&U&M?A)]-(_F'9^M2%?OJU:>?]?^#:\/O%27AK8/R[O7OS%P#,T:6DWM'1Q
M\>+K1VDMKS.4#W0>?H7@VK6MV_.?:+G8&@_0[QOG6O\!&X272K[\/U!+ P04
M    " #G@W]6U#V7#,$"  !8!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6R554M/XS 0OO=7C,(*@03-H^6QI8W4\EH.2(@">UCMP4FFC45B%]NA
M='_]CITV=*6V:"^VY_7--W9FTI]+]:IS1 ,?92'TP,N-F?5\7Z<YEDRWY0P%
M6292E<R0J*:^GBEDF0LJ"S\*@E._9%QX<=_I'E3<EY4IN, '!;HJ2Z86(RSD
M?."%WDKQR*>YL0H_[L_8%,=HGF</BB2_0<EXB4)S*4#A9. -P]ZH:_V=PPO'
MN5X[@ZTDD?+5"G?9P LL(2PP-1:!T?:.EU@4%HAHO"TQO2:E#5P_K]!O7.U4
M2\(T7LKB)\],/O#./<APPJK"/,KY#US6<V+Q4EEHM\*\]CVAC&FEC2R7P227
M7-0[^UC>PUK >; E(%H&1(YWG<BQO&*&Q7TEYZ"L-Z'9@RO511,Y+NRCC(TB
M*Z<X$W?:,,ZE,L=/J$JX9^H5#4L*A#&FE>*&HX:#)ZO1AWW?4$8;YZ=+]%&-
M'FU!#R.XE\+D&JY%AMF_ #Y1;?A&*[ZC:"?B%:9MZ(1'$ 51M .OT]3?<7B=
M+7AWXAVUH:_,Z".XPL0 $QE<OU7<+-;OX-<PT4;1-_1[TRW4.;J;<]B^ZND9
M2W'@4>-H5._HQ?M[X6EPL:.";E-!=Q=Z/*8^S2IZ,3GY\BDW<=^)OIG[4XXM
M!ZV7S<S_()@<X5*6,R86^WOG47AV05;'QU@^Y2<?_7FM3%O:]*A8)JB:AVT#
MI5 (<[L(^25.:S-." =<$#%9:7I5?=B#_[FLUK D!RHMH[JT@1'37,.MDEK#
MLZ )6#C;+4V^E?J&<04OK*BP]=P>4Q7DI2NU@(07A89O$!T%G8CV\(R6XUK1
M_=[:9H!-WX>_UNTEJJF;:1I260E3-WZC;<;FL)X6G^[US*6ZIY9]@1,*#=IG
M)QZH>H[5@I$S-SL2:6@2N6-.HQ^5=2#[1$JS$FR"YF<2_P502P,$%     @
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MC.%8S<*#_BI1;_P4,9"J6MJFU;K3;E MFO[\[]Y,N5NF-UP:$)A3Z*!_.0Y
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M@*[G8+VQJO2S9Z,L33*_S.G3 ;4SH.=;195K-BY ^S&R^ ]02P,$%     @
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M[$Y?*]&!^L%0F@>E^5!: *6%*)HNG]8U=E]XH\$K)#I08[FAO93H0 UC*"V
MTD(43==+ZRN[9E_YZ[,$U.ICK0%2E((+^3W)ER=$3MBS7E5 ?>,76CDF:BVT
M3YT>M!T^E!9 :2&*5BMEN/7RR(RR9?5>4)G(JC7P^N6(FZ.;=X]>5F_<[!SW
M[0]!_0;1%E._T/13Q)9)SDE*[R72.IW*C(S5[PBMOXAB7;VB\JX0HLBJCRL:
M+2A3)\B_WQ>%>/ZB*MB\J?7B?U!+ P04    " #G@W]6)D#>3)8"  "3!@
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MH# .^CSG7.T,$Z#_#L5_ 5!+ P04    " #G@W]6(8QB./4"  #'"@  &0
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M    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*U576^;,!3]*Q:KIE;:2H!
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M""(2\X#&@)'EV/GBGUV@?CHA&_$M(#M>.09I*C-*'].3Z\78\=*(2$CF(I7
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M5Z5^H-)M=5N/AU2I-*Y^W<A@);-R@>+OZ[28_C0/R@;V=[>9_PE02P,$%
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M0@0^)G&V3L';>,$7/QIP9/Q5)]"A$[?(:O$-GU\"#"\ <A$"/P/G$&CQ9?&
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MJRBVO!8G6;+)MYD^)%F61/GAFOL++M0-\O=EDF2'$^6@VG@\^Q=02P,$%
M  @ YX-_5GEH6G28 P  E0X  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&ULQ5=MC]HX$/XK5BI5/:DE<0(!]B#2PFYUE6YUJUVU_5#U@TD&L#:.4]O
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M'Q5/G]!_I0F[1.]N0!&:R[\FOM+V#8J?UK9FE:VPQ18.T1TOU%JBVR*#[!3
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MZ:;$#M>Z;P1A!/3W)>?J96(,-)UH\C]02P,$%     @ YX-_5JQ>)K<P P
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MM$ZZ> ?SO&O,)Y)ENO&:,8EMG!Z&V&D#5P;X?<Z8W$S4!F7O[OT'4$L#!!0
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MIEL;:C>!OJ^4LL>."]#< ^?_ 5!+ P04    " #G@W]6JIBOJ8(&  #L.
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M)[I^B:Y!Z@:*-[;'>.!*=RSVLM1-)0@3H)\7G*NG@9F@;U/3GU!+ P04
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MDQ2>E*0NQ3]7+SRH3!#L5^\PIE_A1JK=ZR<5\-RT68$25E/97,=NM>OD$]/
M]M:GJL,W#?D/3?,\W&&N#HA )62*TKD<J0KRIN4V$\E6IFLMF50]T P+]4H!
MUP%J/V-,[B8Z0??NQ;\!4$L#!!0    ( .>#?U9!C$,+&P4  *\=   9
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M4%\_HFLG$*BF0S4#JIFY=OS'!DUM#P?E1?X$VJE5T6E7GEJTRYW:56-33DY
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M8+T#G9?&X''C+^C^5-E?4$L#!!0    ( .>#?U9^DSYAL@(  %X'   9
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MH4S"#1&"F/]V A]>Q,'W:\R7*'Y$KM)6#*&;[&0O:UG_%=EK(GH0>*?@>WX
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M">Z[U%^,+#<O0FQ>XOC\'5!+ P04    " #G@W]6H9?JE,D!  "@'@  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=FY;L) %(7A5T%^ (:[F"R"
M5&G21KR 189%++8\$P7>/@@*<JP4::(YE36V?/W+Q2=K/'N/^R9OVV/:;+LT
M.AWVQS2O-CEWSR&DY28>FC1NNWB\7%FU_:')EV6_#EVSW#7K&'0RF8;^YXSJ
M9?9SYFAQ[N)?)K:KU7897]OEYR$>\R^#PU?;[](FQER-%DV_CGE>A=/^?CJ%
MZT'&E\G5Z.UC7O5O'U*%TD$*05H^R"#(R@<Y!'GYH!J"ZO)!4PB:E@]Z@*"'
M\D&/$/18/N@)@I[*!\D$99P0) VP)M!:D&LA\%H0;"$06Y!L(3!;$&TA4%N0
M;2%P6Q!N(9!;D&XAL%L0;R'06U%O)=!;46\ET%L'']L$>BOJK01Z*^JM!'HK
MZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01ZVV"SA$!O
M0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U ;T>]G4!O
M1[V=0&\?;'83Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^A=H]XU@=XUZEW_
MI]XIG_<QW7MN:WS^?U*=+_?&^^.OR]O)P4NXXAS@A_3+-U!+ P04    " #G
M@W]6*+1H$\,!  ")'@  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4
M!=!?0=E6Q'B #@(V;;<MB_Z FSP@(HDMVU#X^SIAD%K1J(A*O9M$B>UW7VSI
M;#)^VUGRO6U5UGZ2+$.P#XSY;$F5]JFQ5,>1N7&5#O'1+9C5V4HOB(G!8,0R
M4P>J0S\T-9+I^(GF>EV&WO,VOO:%J2>)H](GO<?]Q"9KDFAKRR+3(8ZS39U_
M2^D?$M*XLIWCEX7U-W%"PLXF-",_!QS6O6[(N2*GWDR[\**K.(MM2^;#KB2?
M=I<XTZ.9SXN,<I.MJ[@D]=:1SOV2*%1ENB]ZTYT<X@[3_LJOSF_+= 7&F3-G
MK(\GYNCRN..1-*O[-A8B%XKN3SPEQM)7?Q\UIYU3_LOLN+T?QJW:\_"LO5V_
MQU_/^%3_PCX$2!\2I \%TL<0I(\12!^W('W<@?1Q#](''Z T@B(J1R&5HYC*
M45#E**IR%%8YBJL<!5:.(JM D56@R"I09!4HL@H4606*K )%5H$BJT"15:#(
M*E%DE2BR2A19)8JL$D56B2*K1)%5HL@J4625*+(J%%D5BJP*15:%(JM"D56A
MR*I09%4HLBH4616*K$,468?_*>N[,:N__CG:W--*%_4QG[5_H*>?4$L! A0#
M%     @ YX-_5@=!36*!    L0   !               ( !     &1O8U!R
M;W!S+V%P<"YX;6Q02P$"% ,4    " #G@W]6GV0+:.T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #G@W]6
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( .>#?U8Q.9K;P0<  "0S   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #G@W]6
M-_Q:X_H$   \%   &               @($#$   >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ YX-_5J]=+9_2 @  Y@D  !@
M     ("!,Q4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M .>#?U:<6AG4/@0   L/   8              " @3L8  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #G@W]6PH) >^T'  !O/   &
M            @(&O'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ YX-_5FL'4#9: @  ^P0  !@              ("!TB0  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .>#?U:>RD%]J 8  #D?
M   8              " @6(G  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #G@W]6-:7HY3,'  "4#P  &               @(% +@
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ YX-_5MZ.D$[C
M&0  #4@  !@              ("!J34  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( .>#?U8:I-%^OP(  &L&   9              "
M@<)/  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ YX-_
M5J;A7F"1 @  S 4  !D              ("!N%(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #G@W]6<%7!:"T$   L"@  &0
M        @(& 50  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( .>#?U:?58=I>P8  )<0   9              " @>19  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ YX-_5OCC?.N(!   IPH
M !D              ("!EF   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #G@W]6#YYUF%X'  "F$@  &0              @(%590
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .>#?U:J]U^O
MUPL  "T>   9              " @>IL  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ YX-_5@7^!AC% P  U0@  !D
M ("!^'@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #G
M@W]6'(A2L:P#   E"   &0              @('T?   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .>#?U:,XU*M0 ,  #\'   9
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M970R,RYX;6Q02P$"% ,4    " #G@W]66%OQK>0#  #G"0  &0
M    @(%9J   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M .>#?U:1!L<BD 8  $H2   9              " @72L  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ YX-_5BV7=,S?!   EPP  !D
M             ("!.[,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #G@W]6.&ZF;80#  "8"   &0              @(%1N   >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .>#?U;GU+6CD0D
M +55   9              " @0R\  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ YX-_5B9 WDR6 @  DP8  !D              ("!
MU,4  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #G@W]6
M(8QB./4"  #'"@  &0              @(&AR   >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( .>#?U;[,Z::A@(  ,H&   9
M      " @<W+  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ YX-_5@[]^:+A!   $2@  !D              ("!BLX  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #G@W]6F39PF/8"  !4"0
M&0              @(&BTP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( .>#?U9R<4N?/@(  " %   9              " @<_6  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ YX-_5B61QV43
M"0  Z68  !D              ("!1-D  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #G@W]681Y$O,D"   @!P  &0
M@(&.X@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( .>#
M?U9(VRJNU 0  $$8   9              " @8[E  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ YX-_5DV".@Q5!@  A"P  !D
M         ("!F>H  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " #G@W]6>6A:=)@#  "5#@  &0              @($E\0  >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .>#?U:L7B:W, ,  ,<+
M   9              " @?3T  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ YX-_5MG\Q,:3 P  $PX  !D              ("!6_@
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #G@W]6JIBO
MJ8(&  #L.   &0              @($E_   >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( .>#?U9;=E ]5 ,  +(*   9
M  " @=X" 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MYX-_5B)-IDW= P  G X  !D              ("!:08! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " #G@W]68]?JS*<"   #!P  &0
M            @(%]"@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( .>#?U9!C$,+&P4  *\=   9              " @5L- 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ YX-_5ED'KO_E @
M?@<  !D              ("!K1(! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " #G@W]6M7U>4<\"  "P"   &0              @(')
M%0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( .>#?U9X
MO;M?\P4  'D[   9              " @<\8 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ YX-_5JS"(^XU @  M00  !D
M     ("!^1X! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .>#?U:AE^J4R0$  * >   :
M          "  8<M 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( .>#?U8HM&@3PP$  (D>   3              "  8@O 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     [ #L %!   'PQ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>133</ContextCount>
  <ElementCount>291</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Convertible Perferred Stock and Stockholder's Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Convertible Perferred Stock and Stockholder's Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - 1. Business and Principal Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/BusinessAndPrincipalActivities</Role>
      <ShortName>1. Business and Principal Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - 2. Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>2. Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - 3. Short-Term Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/Short-termMarketableSecurities</Role>
      <ShortName>3. Short-Term Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - 4. Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/AccruedExpenses</Role>
      <ShortName>4. Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - 5. Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/FairValueMeasurements</Role>
      <ShortName>5. Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - 6. Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://renovorx.com/role/ConvertibleNotes</Role>
      <ShortName>6. Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - 7. Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>7. Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 8. Equity Incentive Plan ??? Stock-Based Compensation Expense and Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants</Role>
      <ShortName>8. Equity Incentive Plan ??? Stock-Based Compensation Expense and Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 9. Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/IncomeTaxes</Role>
      <ShortName>9. Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - 10. Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/NetLossPerShare</Role>
      <ShortName>10. Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - 11. Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/RelatedPartyTransactions</Role>
      <ShortName>11. Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - 12. Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/EmployeeBenefitPlans</Role>
      <ShortName>12. Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - 13. Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/SubsequentEvents</Role>
      <ShortName>13. Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>2. Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://renovorx.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - 3. Short-Term Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/Short-termMarketableSecuritiesTables</Role>
      <ShortName>3. Short-Term Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovorx.com/role/Short-termMarketableSecurities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - 4. Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/AccruedExpensesTables</Role>
      <ShortName>4. Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovorx.com/role/AccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - 5. Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>5. Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovorx.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - 8. Equity Incentive Plan ??? Stock-Based Compensation Expense and Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables</Role>
      <ShortName>8. Equity Incentive Plan ??? Stock-Based Compensation Expense and Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - 9. Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/IncomeTaxesTables</Role>
      <ShortName>9. Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovorx.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - 10. Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/NetLossPerShareTables</Role>
      <ShortName>10. Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovorx.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - 1. Business and Principal Activities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative</Role>
      <ShortName>1. Business and Principal Activities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovorx.com/role/BusinessAndPrincipalActivities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>2. Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Short-Term Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails</Role>
      <ShortName>Schedule of Short-Term Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of Changes in Fair value of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails</Role>
      <ShortName>Schedule of Changes in Fair value of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - 5. Fair Value Measurements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/FairValueMeasurementsDetailsNarrative</Role>
      <ShortName>5. Fair Value Measurements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovorx.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - 6. Convertible Notes (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://renovorx.com/role/ConvertibleNotesDetailsNarrative</Role>
      <ShortName>6. Convertible Notes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovorx.com/role/ConvertibleNotes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - 7. Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>7. Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovorx.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Summary of Stock Option Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails</Role>
      <ShortName>Summary of Stock Option Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Ranges of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails</Role>
      <ShortName>Schedule of Ranges of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Estimate Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails</Role>
      <ShortName>Schedule of Estimate Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - 8. Equity Incentive Plan ??? Stock-Based Compensation Expense and Common Stock Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative</Role>
      <ShortName>8. Equity Incentive Plan ??? Stock-Based Compensation Expense and Common Stock Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Statutory Tax Expense and Effective Tax Expense Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails</Role>
      <ShortName>Schedule of Statutory Tax Expense and Effective Tax Expense Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule Of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Schedule Of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - 9. Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>9. Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovorx.com/role/IncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Schedule of Potentially Anti Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Schedule of Potentially Anti Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - 11. Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>11. Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovorx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - 12. Employee Benefit Plans (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/EmployeeBenefitPlansDetailsNarrative</Role>
      <ShortName>12. Employee Benefit Plans (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovorx.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - 13. Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovorx.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>13. Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovorx.com/role/SubsequentEvents</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>ex10-3.htm</File>
    <File>ex23-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>rnxt-20221231.xsd</File>
    <File>rnxt-20221231_cal.xml</File>
    <File>rnxt-20221231_def.xml</File>
    <File>rnxt-20221231_lab.xml</File>
    <File>rnxt-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>drug_001.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
    <File>form10-k_011.jpg</File>
    <File>form10-k_012.jpg</File>
    <File>form10-k_013.jpg</File>
    <File>form10-k_014.jpg</File>
    <File>form10-k_015.jpg</File>
    <File>form10-k_016.jpg</File>
    <File>form10-k_017.jpg</File>
    <File>form10-k_018.jpg</File>
    <File>form10-k_021.jpg</File>
    <File>graph_001.jpg</File>
    <File>hyper_001.jpg</File>
    <File>research_001.jpg</File>
    <File>tiger_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="536">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 536,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 133,
   "dts": {
    "calculationLink": {
     "local": [
      "rnxt-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rnxt-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rnxt-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rnxt-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rnxt-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 456,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 95,
    "http://renovorx.com/20221231": 28,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 126
   },
   "keyCustom": 38,
   "keyStandard": 253,
   "memberCustom": 24,
   "memberStandard": 20,
   "nsprefix": "RNXT",
   "nsuri": "http://renovorx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://renovorx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - 3. Short-Term Marketable Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://renovorx.com/role/Short-termMarketableSecurities",
     "shortName": "3. Short-Term Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - 4. Accrued Expenses",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://renovorx.com/role/AccruedExpenses",
     "shortName": "4. Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - 5. Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://renovorx.com/role/FairValueMeasurements",
     "shortName": "5. Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - 6. Convertible Notes",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://renovorx.com/role/ConvertibleNotes",
     "shortName": "6. Convertible Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - 7. Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://renovorx.com/role/CommitmentsAndContingencies",
     "shortName": "7. Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - 8. Equity Incentive Plan \u2013 Stock-Based Compensation Expense and Common Stock Warrants",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants",
     "shortName": "8. Equity Incentive Plan \u2013 Stock-Based Compensation Expense and Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - 9. Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://renovorx.com/role/IncomeTaxes",
     "shortName": "9. Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - 10. Net Loss per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://renovorx.com/role/NetLossPerShare",
     "shortName": "10. Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - 11. Related Party Transactions",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://renovorx.com/role/RelatedPartyTransactions",
     "shortName": "11. Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - 12. Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://renovorx.com/role/EmployeeBenefitPlans",
     "shortName": "12. Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://renovorx.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - 13. Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://renovorx.com/role/SubsequentEvents",
     "shortName": "13. Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "2. Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - 3. Short-Term Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://renovorx.com/role/Short-termMarketableSecuritiesTables",
     "shortName": "3. Short-Term Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - 4. Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://renovorx.com/role/AccruedExpensesTables",
     "shortName": "4. Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - 5. Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://renovorx.com/role/FairValueMeasurementsTables",
     "shortName": "5. Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - 8. Equity Incentive Plan \u2013 Stock-Based Compensation Expense and Common Stock Warrants (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables",
     "shortName": "8. Equity Incentive Plan \u2013 Stock-Based Compensation Expense and Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - 9. Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://renovorx.com/role/IncomeTaxesTables",
     "shortName": "9. Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - 10. Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://renovorx.com/role/NetLossPerShareTables",
     "shortName": "10. Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - 1. Business and Principal Activities (Details Narrative)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
     "shortName": "1. Business and Principal Activities (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-08-042021-08-05",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "2. Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://renovorx.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of Short-Term Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails",
     "shortName": "Schedule of Short-Term Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "RNXT:AccruedClinicalTrialsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://renovorx.com/role/ScheduleOfAccruedExpensesDetails",
     "shortName": "Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "RNXT:AccruedClinicalTrialsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Schedule of Assets Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Schedule of Changes in Fair value of Derivative Liability (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails",
     "shortName": "Schedule of Changes in Fair value of Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - 5. Fair Value Measurements (Details Narrative)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://renovorx.com/role/FairValueMeasurementsDetailsNarrative",
     "shortName": "5. Fair Value Measurements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - 6. Convertible Notes (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://renovorx.com/role/ConvertibleNotesDetailsNarrative",
     "shortName": "6. Convertible Notes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-08-292021-08-30_us-gaap_IPOMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - 7. Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "7. Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Summary of Stock Option Award Activity (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails",
     "shortName": "Summary of Stock Option Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Schedule of Ranges of Stock Options (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails",
     "shortName": "Schedule of Ranges of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Schedule of Estimate Fair Value of Stock Options (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails",
     "shortName": "Schedule of Estimate Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Schedule of Stock Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails",
     "shortName": "Schedule of Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Schedule of Warrant Activity (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://renovorx.com/role/ScheduleOfWarrantActivityDetails",
     "shortName": "Schedule of Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - 8. Equity Incentive Plan \u2013 Stock-Based Compensation Expense and Common Stock Warrants (Details Narrative)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative",
     "shortName": "8. Equity Incentive Plan \u2013 Stock-Based Compensation Expense and Common Stock Warrants (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Schedule of Statutory Tax Expense and Effective Tax Expense Benefit (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails",
     "shortName": "Schedule of Statutory Tax Expense and Effective Tax Expense Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Schedule Of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Schedule Of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "RNXT:UnrecognizedTaxBenefitsAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - 9. Income Taxes (Details Narrative)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://renovorx.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "9. Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Schedule of Potentially Anti Dilutive Securities (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails",
     "shortName": "Schedule of Potentially Anti Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - 11. Related Party Transactions (Details Narrative)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "11. Related Party Transactions (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-01-01_custom_DrAgahMember",
      "decimals": "0",
      "lang": null,
      "name": "RNXT:CashCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - 12. Employee Benefit Plans (Details Narrative)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://renovorx.com/role/EmployeeBenefitPlansDetailsNarrative",
     "shortName": "12. Employee Benefit Plans (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-03-30_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - 13. Subsequent Events (Details Narrative)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://renovorx.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "13. Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-03-30_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "RNXT:IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Statements of Convertible Perferred Stock and Stockholder's Equity (Deficit) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://renovorx.com/role/StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Convertible Perferred Stock and Stockholder's Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "RNXT:IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://renovorx.com/role/StatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "RNXT:AmortizationOnLeaseholdImprovement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - 1. Business and Principal Activities",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://renovorx.com/role/BusinessAndPrincipalActivities",
     "shortName": "1. Business and Principal Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - 2. Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://renovorx.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "2. Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "RNXT_AccruedClinicalTrialsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trials current.",
        "label": "Clinical trial"
       }
      }
     },
     "localname": "AccruedClinicalTrialsCurrent",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of derivative liability upon conversion of convertible notes.",
        "label": "Reclassification of derivative liability upon conversion of convertible notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityUponConversionOfConvertibleNotes",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_AmortizationOnLeaseholdImprovement": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization on leasehold improvement",
        "label": "Amortization on leasehold improvements"
       }
      }
     },
     "localname": "AmortizationOnLeaseholdImprovement",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_CaliforniaTaxCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California [Member]",
        "label": "California [Member]"
       }
      }
     },
     "localname": "CaliforniaTaxCreditMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_CashCashEquivalentsAndInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents and Investments [Policy Text Block]",
        "label": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsPolicyTextBlock",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "RNXT_CashCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash compensation per month.",
        "label": "Cash compensation per month"
       }
      }
     },
     "localname": "CashCompensation",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_ClinicalTrialExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trial Expenses [Policy Text Block]",
        "label": "Clinical Trial Expenses"
       }
      }
     },
     "localname": "ClinicalTrialExpensesPolicyTextBlock",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "RNXT_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreement [Member]",
        "label": "Consulting Agreement [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_ConversionOfConvertibleNotesUponInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible notes upon initial public offering.",
        "label": "Conversion of convertible notes upon IPO"
       }
      }
     },
     "localname": "ConversionOfConvertibleNotesUponInitialPublicOffering",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_ConversionOfConvertiblePreferredStockUponInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock upon initial public offering.",
        "label": "Conversion of convertible preferred stock upon IPO"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredStockUponInitialPublicOffering",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_ConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Preferred Stock [Policy Text Block]",
        "label": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "RNXT_DeferredTaxAssetsCapitalizedResearch": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized research.",
        "label": "Capitalized research"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearch",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_DeferredTaxAssetsCharitableContributions": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets charitable contributions.",
        "label": "Charitable contributions"
       }
      }
     },
     "localname": "DeferredTaxAssetsCharitableContributions",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_DefinitiveSecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Definitive Securities Purchase Agreement [Member]",
        "label": "Definitive Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "DefinitiveSecuritiesPurchaseAgreementMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_DerivativeLiabilityInFinancingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability in financing activities",
        "label": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilityInFinancingActivities",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_DiscretionaryBonus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discretionary bonus.",
        "label": "Discretionary bonus"
       }
      }
     },
     "localname": "DiscretionaryBonus",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_DrAgahMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DrAgah [Member]",
        "label": "Dr.Agah [Member]"
       }
      }
     },
     "localname": "DrAgahMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging Growth Company and Smaller Reporting Company Status [Policy Text Block]",
        "label": "Emerging Growth Company and Smaller Reporting Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "RNXT_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of estimate of range of exercise prices, one including, but not limited to, upper and lower bound amounts, maximum and minimum amounts, and point estimates.",
        "label": "Exercise Price Range Five [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of estimate of range of exercise prices, one including, but not limited to, upper and lower bound amounts, maximum and minimum amounts, and point estimates.",
        "label": "Exercise Price Range Four [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of estimate of range of exercise prices, one including, but not limited to, upper and lower bound amounts, maximum and minimum amounts, and point estimates.",
        "label": "Exercise Price Range One [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_ExercisePriceRangeSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Seven [Member]",
        "label": "Exercise Price Range Seven [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeSevenMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_ExercisePriceRangeSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Six [Member]",
        "label": "Exercise Price Range Six [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeSixMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of estimate of range of exercise prices, one including, but not limited to, upper and lower bound amounts, maximum and minimum amounts, and point estimates.",
        "label": "Exercise Price Range Three [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of estimate of range of exercise prices, one including, but not limited to, upper and lower bound amounts, maximum and minimum amounts, and point estimates.",
        "label": "Exercise Price Range Two [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_FederalAndStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal and state [Member]",
        "label": "Federal and state [Member]"
       }
      }
     },
     "localname": "FederalAndStateMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_GainOnChangeInFairValueOfDerivativeLiability": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on change in fair value of derivative liability.",
        "label": "GainOnChangeInFairValueOfDerivativeLiability",
        "negatedLabel": "Gain on change in fair value of derivative liability"
       }
      }
     },
     "localname": "GainOnChangeInFairValueOfDerivativeLiability",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_GainOnLoanExtinguishmentFromPppLoan": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on loan extinguishment from PPP loan.",
        "label": "GainOnLoanExtinguishmentFromPppLoan",
        "negatedLabel": "Gain on loan extinguishment from PPP loan"
       }
      }
     },
     "localname": "GainOnLoanExtinguishmentFromPppLoan",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of initial public offering of underwriter, commissions and discounts,net.",
        "label": "Discount and issuance cost"
       }
      }
     },
     "localname": "IssuanceOfinitialPublicofferingOfUnderwritersCommissionsDiscountsNet",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePerferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_LeaseholdImprovementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasehold Improvements [Policy Text Block]",
        "label": "Leasehold Improvements, Net"
       }
      }
     },
     "localname": "LeaseholdImprovementsPolicyTextBlock",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "RNXT_LossOnLoanExtinguishment": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss on loan extinguishment.",
        "label": "Loss on loan extinguishment"
       }
      }
     },
     "localname": "LossOnLoanExtinguishment",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_MaximumPossibleProceedsFromOfferings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum possible proceeds from offerings.",
        "label": "Maximum possible proceeds from offerings"
       }
      }
     },
     "localname": "MaximumPossibleProceedsFromOfferings",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_MaximumPossibleTotalProceedsFromConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum possible total proceeds from convertible notes.",
        "label": "Maximum possible total proceeds from convertible notes"
       }
      }
     },
     "localname": "MaximumPossibleTotalProceedsFromConvertibleNotes",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_NetProceedsFromIntialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from intial public offering.",
        "label": "Net proceeds from intial public offering"
       }
      }
     },
     "localname": "NetProceedsFromIntialPublicOffering",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_NotePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Purchase Agreement [Member]",
        "label": "Note Purchase Agreement [Member]"
       }
      }
     },
     "localname": "NotePurchaseAgreementMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_OmnibusEquityIncentivePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Omnibus Equity Incentive Plan [Member].",
        "label": "2021 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "OmnibusEquityIncentivePlan2021Member",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_OverAllotmentOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over Allotment Options [Member]",
        "label": "Over Allotment Options [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionsMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_PaymentsForLeaseholdImprovements": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for lease hold improvements.",
        "label": "PaymentsForLeaseholdImprovements",
        "negatedLabel": "Expenditures for leasehold improvements"
       }
      }
     },
     "localname": "PaymentsForLeaseholdImprovements",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_PaymentsReceivedFromClinicalSites": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments received from clinical sites.",
        "label": "PaymentsReceivedFromClinicalSites",
        "negatedLabel": "Payments received from clinical sites"
       }
      }
     },
     "localname": "PaymentsReceivedFromClinicalSites",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_PermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Permanent Items.",
        "label": "Permanent items"
       }
      }
     },
     "localname": "PermanentItems",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_RenovoCathMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RenovoCath [Member]",
        "label": "RenovoCath [Member]"
       }
      }
     },
     "localname": "RenovoCathMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and Uncertainties [Policy Text Block]",
        "label": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options exercised in period weighted average exercise price.",
        "label": "Weighted average exercise price, execised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options expired in period weighted average exercise price.",
        "label": "Weighted average exercise price, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options grants in period weighted average contractual term.",
        "label": "Weighted average remaining contractual life, ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options grants in period weighted average contractual term 1.",
        "label": "Weighted average remaining contractual life, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageContractualTerm1",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "RNXT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.",
        "label": "Weighted average exercise price, issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "RNXT_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock to common stock upon initial public offering, shares",
        "label": "Conversion of convertible preferred stock to common stock upon initial public offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "RNXT_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value conversion of convertible preferred stock to common stock.",
        "label": "Conversion of convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_StockIssuedDuringPeriodValueReverseStockSplits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock upon exercise of stock options.",
        "label": "Reverse stock split adjustment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueReverseStockSplits",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock upon exercise of warrants issued upon initial public offering.",
        "label": "Issuance of common stock upon exercise of warrants issued upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_StockIssuedDuringPeriodsharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock upon exercise of stock options, shares",
        "label": "Issuance of common stock upon exercise of warrants issued upon initial public offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodsharesWarrantsExercised",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "RNXT_TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 and 2021 Convertible Notes [Member]",
        "label": "2020 and 2021 Convertible Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyAndTwentyOneConvertibleNotesMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 and 2021 Convertible Notes [Member]",
        "label": "2020 and 2021 Convertible Notes [Member] [Default Label]",
        "verboseLabel": "2020 and 2021 Convertible Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyAndTwoThousandAndTwentyOneConvertibleNotesMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_TwoThousandAndTwentyConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Convertible Notes [Member]",
        "label": "2020 Convertible Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyConvertibleNotesMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_TwoThousandAndTwentyOneConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Convertible Notes [Member]",
        "label": "2021 Convertible Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneConvertibleNotesMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_TwoThousandAndTwentyOnePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Plan [Member]",
        "label": "2021 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOnePlanMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_UnderwriterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriter [Member]",
        "label": "Underwriter [Member]"
       }
      }
     },
     "localname": "UnderwriterMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_UnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions.",
        "label": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "UnderwritingDiscountsAndCommissions",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_UnrecognizedTaxBenefitsAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits additions.",
        "label": "Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsAdditions",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "RNXT_WarrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant One [Member]",
        "label": "Warrant One [Member]"
       }
      }
     },
     "localname": "WarrantOneMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "RNXT_WarrantTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Two [Member]",
        "label": "Warrant Two [Member]"
       }
      }
     },
     "localname": "WarrantTwoMember",
     "nsuri": "http://renovorx.com/20221231",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r491",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r491",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r491",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r491",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r491",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://renovorx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r294",
      "r424",
      "r447",
      "r455",
      "r456",
      "r471",
      "r475",
      "r479",
      "r525",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r294",
      "r424",
      "r447",
      "r455",
      "r456",
      "r471",
      "r475",
      "r479",
      "r525",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r285",
      "r294",
      "r321",
      "r322",
      "r323",
      "r400",
      "r424",
      "r447",
      "r455",
      "r456",
      "r471",
      "r475",
      "r479",
      "r521",
      "r525",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r285",
      "r294",
      "r321",
      "r322",
      "r323",
      "r400",
      "r424",
      "r447",
      "r455",
      "r456",
      "r471",
      "r475",
      "r479",
      "r521",
      "r525",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r516",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "4. Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r478"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://renovorx.com/role/ScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets",
      "http://renovorx.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r156",
      "r442",
      "r452",
      "r453"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r23",
      "r26",
      "r107",
      "r384",
      "r448",
      "r449",
      "r503",
      "r504",
      "r505",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r511",
      "r512",
      "r513",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r95",
      "r96",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r31",
      "r274",
      "r381",
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r274",
      "r381",
      "r469",
      "r470",
      "r507"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative",
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r124",
      "r136",
      "r152",
      "r175",
      "r214",
      "r222",
      "r224",
      "r231",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r356",
      "r358",
      "r371",
      "r478",
      "r523",
      "r524",
      "r566"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r150",
      "r157",
      "r175",
      "r231",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r356",
      "r358",
      "r371",
      "r478",
      "r523",
      "r524",
      "r566"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r228",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Short-term marketable securities, amortized cost basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Short-term marketable securities, unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Short-term marketable securities, unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r56",
      "r227",
      "r238",
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Short-term marketable securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r43",
      "r151",
      "r459"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash and cash equivalents, and Marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r38",
      "r43",
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r38",
      "r115"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC insured amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r175",
      "r193",
      "r194",
      "r196",
      "r198",
      "r205",
      "r206",
      "r231",
      "r250",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r371",
      "r457",
      "r500",
      "r508",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of warrant or right, exercise price of warrants or rights",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "verboseLabel": "Warrant exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative",
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of warrant or right, number of securities called by each warrant or right",
        "verboseLabel": "Warrants to purchase common stock, shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r128",
      "r140"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r244",
      "r245",
      "r454",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "7. Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Number of shares reserved"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r511",
      "r512",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value, per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r478"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2022, and 2021, respectively; 9,097,701 and 8,933,989 shares issued and outstanding as of December 31, 2022, and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "12. Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r27",
      "r162",
      "r164",
      "r171",
      "r440",
      "r444"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r134",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk and Significant Suppliers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of stock, shares converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of stock, shares issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r3",
      "r126",
      "r137",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r277",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r44",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r44",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt conversion, converted instrument, shares"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r125",
      "r126",
      "r135",
      "r178",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r382",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt conversion price percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r1",
      "r3",
      "r66",
      "r125",
      "r126",
      "r133",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt instrument, description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r117",
      "r119",
      "r259",
      "r382",
      "r467",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r16",
      "r117",
      "r276",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r16",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r158",
      "r466",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r17",
      "r178",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r382",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r116",
      "r119",
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r118",
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Fixed assets/intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r105",
      "r557"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards",
        "verboseLabel": "Federal and state tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative",
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r105",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Net operating loss carryforward, federal"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r105",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Net operating loss carryforward, state"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r103",
      "r105",
      "r557"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Tax credits carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": {
     "auth_ref": [
      "r103",
      "r105",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.",
        "label": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": {
     "auth_ref": [
      "r105",
      "r557"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.",
        "label": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r105",
      "r557"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r100",
      "r556"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains": {
     "auth_ref": [
      "r105",
      "r557"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.",
        "label": "Unrealized gain"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined contribution plan cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r22",
      "r109",
      "r122",
      "r159",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r298",
      "r325",
      "r326",
      "r328",
      "r332",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "8. Equity Incentive Plan \u2013 Stock-Based Compensation Expense and Common Stock Warrants"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r74",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Schedule of Stock Based Compensation Expense"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r172",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r196",
      "r197",
      "r198",
      "r202",
      "r362",
      "r363",
      "r441",
      "r445",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share, basic and diluted",
        "verboseLabel": "Net loss per share \u2013 basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "10. Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r65",
      "r148",
      "r166",
      "r167",
      "r168",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r204",
      "r232",
      "r284",
      "r329",
      "r330",
      "r331",
      "r347",
      "r348",
      "r361",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r384",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r364",
      "r365",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r267",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r365",
      "r397",
      "r398",
      "r399",
      "r467",
      "r468",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r367",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "5. Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r267",
      "r286",
      "r291",
      "r365",
      "r397",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r267",
      "r286",
      "r291",
      "r365",
      "r398",
      "r467",
      "r468",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r267",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r365",
      "r399",
      "r467",
      "r468",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r267",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r397",
      "r398",
      "r399",
      "r467",
      "r468",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r368",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": {
     "auth_ref": [
      "r113",
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Initial fair value of instruments issued"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease": {
     "auth_ref": [
      "r112",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)",
        "negatedLabel": "Change in fair value of instruments"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet": {
     "auth_ref": [
      "r561"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net",
        "negatedLabel": "Conversion upon IPO"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "auth_ref": [
      "r110",
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfChangesInFairValueOfDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r275",
      "r281",
      "r360",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r465",
      "r517",
      "r518",
      "r519",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r41",
      "r62",
      "r63"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain on loan extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r176",
      "r338",
      "r340",
      "r345",
      "r349",
      "r351",
      "r353",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "9. Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r177",
      "r190",
      "r191",
      "r213",
      "r336",
      "r350",
      "r352",
      "r446"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxHolidayDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the factual circumstances giving rise to an income tax exemption or special reduction received from a taxing jurisdiction.",
        "label": "Income tax, description"
       }
      }
     },
     "localname": "IncomeTaxHolidayDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r165",
      "r334",
      "r335",
      "r340",
      "r341",
      "r344",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Statutory federal income tax"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).",
        "label": "Prior year true ups"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStatutoryTaxExpenseAndEffectiveTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r118",
      "r131",
      "r169",
      "r212",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Fair value of assets"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r123",
      "r132",
      "r146",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "3. Short-Term Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/Short-termMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements, net"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r175",
      "r231",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r357",
      "r358",
      "r359",
      "r371",
      "r463",
      "r523",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r127",
      "r139",
      "r478",
      "r510",
      "r520",
      "r562"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Convertible Preferred Stock and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "6. Convertible Notes"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Schedule of Short-Term Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/Short-termMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money market funds, at carrying value"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r38",
      "r39",
      "r42"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r42",
      "r129",
      "r141",
      "r149",
      "r160",
      "r163",
      "r168",
      "r175",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r195",
      "r214",
      "r221",
      "r223",
      "r225",
      "r231",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r363",
      "r371",
      "r464",
      "r523"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://renovorx.com/role/StatementsOfCashFlows",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow data:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expenses), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r214",
      "r221",
      "r223",
      "r225",
      "r464"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease, rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "1. Business and Principal Activities"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://renovorx.com/role/ScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r65",
      "r161",
      "r164",
      "r170",
      "r372",
      "r377",
      "r378",
      "r439",
      "r443",
      "r503",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Unrealized gain on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r33",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value, per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r478"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Convertible preferred stock, $0.0001 par value; 15,000,000 shares authorized as of December 31, 2022 and 2021, respectively; zero shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r501"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Net proceeds from issuance of common stock upon initial public offering",
        "verboseLabel": "Aggregate gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Stock warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from sale of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r93"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Consulting fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r292",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r292",
      "r387",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r385",
      "r386",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "11. Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r99",
      "r147",
      "r574"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r67",
      "r138",
      "r451",
      "r453",
      "r478"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets",
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r148",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r232",
      "r329",
      "r330",
      "r331",
      "r347",
      "r348",
      "r361",
      "r448",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of stock, number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfPotentiallyAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Potentially Anti Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Statutory Tax Expense and Effective Tax Expense Benefit"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Changes in Fair value of Derivative Liability"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r91",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r295",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative",
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule of Ranges of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r76",
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Summary of Stock Option Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Estimate Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r69",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r477",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Operating Segment"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://renovorx.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Total stock-based compensation expense",
        "terseLabel": "Share based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative",
      "http://renovorx.com/role/ScheduleOfStockBasedCompensationExpenseDetails",
      "http://renovorx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative",
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Warrants outstanding, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Warrants outstanding, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Warrants outstanding, issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "periodStartLabel": "Warrants outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Common shares reserved but unissued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of stock options, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of stock options, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of stock options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value outstanding, ending balance",
        "periodStartLabel": "Aggregate intrinsic value outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share based compensation arrangement by share based payment award, options, outstanding, number",
        "periodEndLabel": "Number of stock options outstanding, ending balance",
        "periodStartLabel": "Number of stock options outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price outstanding, ending balance",
        "periodStartLabel": "Weighted average exercise price outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Number of stock options, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, lower range"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Number of options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Number of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, upper range"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Warrants aggregate intrinsic value, ending balance",
        "periodStartLabel": "Warrants aggregate intrinsic value, beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average remaining contractual life, vested and expected"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-average remaining contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfRangesOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r48",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "2. Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r175",
      "r193",
      "r194",
      "r196",
      "r198",
      "r205",
      "r206",
      "r231",
      "r250",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r371",
      "r457",
      "r500",
      "r508",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r65",
      "r148",
      "r166",
      "r167",
      "r168",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r204",
      "r232",
      "r284",
      "r329",
      "r330",
      "r331",
      "r347",
      "r348",
      "r361",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r384",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r204",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheetsParenthetical",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r20",
      "r65",
      "r66",
      "r67",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Conversion of convertible notes and accrued interest to common stock upon initial public offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Proceeds from initial public offering, net of underwriters commissions, discounts and issuance costs of $2,090, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r65",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Issuance of restricted stock awards, shares",
        "verboseLabel": "Restricted common stock granted, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Reverse stock split adjustment, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r67",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Issuance of common stock upon exercise of stock options, shares",
        "negatedLabel": "Number of stock options, exercised",
        "verboseLabel": "Over allotment option to purchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://renovorx.com/role/SummaryOfStockOptionAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r21",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Conversion of convertible notes and accrued interest to units upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Proceeds from initial public offering, net of underwriters\u2019 commissions, discounts and issuance costs of $2,090"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Issuance of restricted stock awards",
        "verboseLabel": "Restricted common stock granted"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r54",
      "r478",
      "r510",
      "r520",
      "r562"
     ],
     "calculation": {
      "http://renovorx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total convertible preferred stock and stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets",
      "http://renovorx.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible preferred stock and stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders equity, reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r379",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative",
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r379",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r379",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative",
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r379",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative",
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r391",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "13. Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative",
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r229",
      "r230",
      "r275",
      "r281",
      "r360",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r517",
      "r518",
      "r519",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ConvertibleNotesDetailsNarrative",
      "http://renovorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://renovorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r461",
      "r472",
      "r474",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://renovorx.com/role/ScheduleOfShort-termMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r333",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized tax benefits",
        "periodEndLabel": "Ending unrecognized tax benefits",
        "periodStartLabel": "Beginning unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/IncomeTaxesDetailsNarrative",
      "http://renovorx.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r207",
      "r208",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrant maturity date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/EquityIncentivePlanStock-basedCompensationExpenseAndCommonStockWarrantsDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and rights outstanding, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/BusinessAndPrincipalActivitiesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r192",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted-average shares of common stock outstanding, basic and diluted",
        "verboseLabel": "Weighted average shares used in computing net loss per share \u2013 basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://renovorx.com/role/ScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://renovorx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r481": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r485": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r486": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r487": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r488": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r489": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r491": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r492": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r493": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r494": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r495": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r496": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r497": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r498": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r499": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001493152-23-010332-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-010332-xbrl.zip
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M1U NNYD-^Y(_.LT+K I7N<IOF$G:"P!G-E+SK7FVZZYB,ZL;TU]E9B.^52O
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MA7[TJ&F-+Q:.-Q2NKK0V-<$S$;./,'\HR)-C!V/ TP=V#Z>)A34%LK?4QG&
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M7'>'>T,(F=XK86^0-FTNMA*%GU^<F^+6-X =WS5G/^[G+@\%WX_QJ*Y)?^'
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M.!3TG!;F!>,3*3]E_]M!\G="S9\]/NX?FJ:YK^;4<TRL0LH\$. 5D;*QAAR
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MMAC'C[<%".C6S5;*#:;T*4>VU8@4[8V+-0B:Y>6SX)\,6N^G;T7$$UX??-K
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M]%MRU*2<7H"]QIJ0V&YS]2R=ZQ]2O?ZJL0PG(M/_7H@8NB)_02W^?I.Y9"R
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M1OJ\-(#7_UN@[G=2!HCOGJ-ES.^$A?Q_R]3X=^*?A(8"1O/I25]-^^=\;'<
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M0/P<E0PEO(ALE+!S>YQ$Z4$4J2F.MVN*\EAF6U-F&ME+DG])(!!WA:0X4EB
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M,M)2(]=EYG.\9&(O:K5+^(X6/K!UGH0D,QQZBN[.2+"9(9F86(BJZ*;!@MM
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M3<=![D%C8,G0<<I]/'AF1YB?G,ZO9CX-;O.1?6JC)+'6SF?[IB^\B<X:'(Z
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M54!5>9#Z(G>R?25%+86XBG4J(YPG;/2_K11@MA:'G$H "$FO13MIFPFF*B(
M&%E9ISD(<K1,KUQ]&T)\8P-YL5=M<<DNP7H+Y%8#;VF5NL?'&1*? Q#=5AOO
M+*>MG]!H"[H_B9TM+O<@*>779)[DEFN7!$[:JP_>)4(EVE8'XL73]/9'%/CD
M)3_@B$&78@A^&RHZV67_5A2TY-BAPJ29KJT,VO^]M_],_YU390Y!$ =21KD'
M06G+!:ZNJ*FH,?"QFF(#A[RB0B^R$<7^4JQ,MOA;SO&(+D>IKJU$!2](ABE?
MA2P>G3S*5+KHFRX!@",O)W?KJA'X88+[:5U80;1\;PG=:P#=Z_2 C3UQDN5B
MVH^UU:-<WQ*)WHPQXMUR9LEW*SOT(Y2CV84"7N"0OQ3.(FQE]-$S-P:.+4TR
M3V2/[TV=RR6EL0[YYU45OB"&&.Y985K2.LY?TYAUT(V*\[-Y_G9L/64\+SQD
M5PF>T&D*6$]ME23#&1 E#$5;NQ3?J%FJ#!U;$/,TU85+DNB^8SPO]B1/E7Z)
M42+\'-- ER[2[&I*Z-LR/89>/31U[]G8RM+J18)B[4I-N7*EM^[)B_+T?*N9
M#U$X<?EO.^QHZ78_.3XZ0X0IC:],(%I"AT -3F%?>0?\*B!45%N*& BZP9"
M:S<*66Z@1O!KGS^VRZIU_C??_$TEJ[ZEJ.%YA\"%Z^6C<YCMO* $=SKVD?6;
MUF<4GK<+(H@N*H3'!![EE5YF$57SK#7YQO-%X->ZF87LDH]XZ,&13H%CB-;L
MU'<?VK*WII#'QAW6>$:J%PC\$V!WV:J$E^3IKI9R-9H\-SDCWE_3C86;.A==
M2V:KZ[E7'OJ8DY++0D)![RV' \FT&UM>Z!FF=G#"GD+0$[B <H+&+@\W^<<K
M!FL!E%8!47:*,GFE(1<;(I?Z0%7M?RWA*< J.SX6UR78V.,HV]KN#JAV6/>
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MZ(=5%K@9K:!]_ ,O]R2-9M5!R@I]V[\KW\[6Z8%PG$5Y.<!]S8H\JR_M08\
MN+A*XV+:C88,^CHSA<KZ-'7%=)>]U%+>3<AS_W+/H7Q_2GR.[WX2C^X!-$>#
ME*^:D55LWVV_>3'(#>%0[4-WI#!1]E+XGLZ$+P$GTO-,W@E3#16^:A2LRO:O
MGN2_ZL&0T/ LXT!].5+V%1G.VV)6]E8<6EM3-#J 5WT>$0?Y%#9+.9&(W$J5
M^#H5+*H6+ Y[B#U)4F3Y>E$FP-5^K7\R;*;<\.3,Y+'-S-S !?+G8./F>U9@
M0)'LT.JO.>YUO@LQ(LX)21)/O,5.%^5"&ZW]ZL"PI*_+,9<4!SD=,[*S?IF[
MC[^67P@A\TU>($(SF9^ZB'3UHE;ZM9K&64ZX-I/FQW,49C57C></^U<&:FKX
MK$57L>-"29V];Z&TJY0!WT_?1+P9?WH\!I:T06LM>QJJ&.2:PE6<8Z&T"]77
M1D3F#).(=64Z?T^-?4$/[6]^.3\'04FHD5+UJV3%(0M*>]IH*J#^I#^:'!JW
M@E$/*#4<=0I;B=&\VFZY>ER6V='&)1NQ;^='G,D-$JMUX%ZGU [ZB=[CT>1=
M$W'W8LXOB%#XU==+>*I%G82+L: FQ1A*N"TE)J)*QL&FM)Q](/Y<RT0+WK&\
M:MW_+6KV _WD?-?-@MW$ 5=^L=+O C-KIH3!J%_UP$9BE2OMV:6P,-)6&4X5
MBQY^IWAHUXW?4ITO]7<N:FX[(36+AI6?W^#MDU\J M:?5(D1A\!(#TI ;UW]
M(!XI,_:DBK:)4B:_FC]AVAGZ4QS."5#QF"5K$-C3D6P307<=L+:YOWO*J;9\
MWM!_IV?J!^T;_%&>=YDS46^[8(FF+-6!!*UDDMSQ-GT^MO;&QV 3L;X*$(LI
M<3>A:%1;H#_TZ_F\SL,3"'^NT\OL=LNY+NR>I.#1Y^S<4Y?#U5;4?'I._MOE
M]92;A+&"<,W/N?V7G9$:DLE%5&UM>UW>EAW T)V5^9F0<[TV(G*89W35WNN;
M%X>^CKC1(7:\=D-IM]"13C/'4R"S7G:D@>3KH)657VJS T=]=WUEFH>478.*
M*HWP?LCGN1DQK(7YU][Q-CU=O*$O_CPI*=Y2*;8E8HY2G*=84W-6XDPJ_2I'
M')$],Y=:.5S[?3^[J3IZ!8>8'$ZM<@4>@%%V?WN_FCQ9RGQL1/$%,W#(LTP1
M1;FB[,:-O:J:W@]*]<W-R%I;/7P 6@RN)"XYLS:CK,,8)$_/1= ;Z;C>T(&9
M!XW+ZU9HA!K\$-O52+ZY7^(U6 'VN&7EE<6=$Z[]T()>\Z07K5?(SG=G9Z S
MG#8[EVO-MA^_!3ZH N=O?>X!D(/!PU_LNI\>>T@PKKEL&0L</4R&:7V(=75%
MI1U?_V<1D25DA22 ^12]60-54@*S\UQ83JP@9U3(F7.$#O:S7:OT\6\,R3C8
M#X11DCHP$^R7E333R3D1!U8.5RGM"<CBVXO#+QW:(7([_JSE/V5BC]$7PZ3&
MFG\BJZC$^98-4L?0>Z!$LM%WD[,ILAPJGY7"7&)1,4>B0'P%6UNA_@*1I3/\
ML[*,*AC%#F3N^P5RK#XAOB$:VR:CL%"]V,9EP5!)?\U91B+$51)PJ-LL,/5*
M['Q6<2#*:.+'PT=W[?FL)4MT+EGTJJ B4_ORJG/)!(4(Z,SM2WL9[DPKTQ>%
MFCHW*EZ.M90U?T;?9^/8"3S?LF9+*G^4W@,X^ (4$68$W1\1?7;82V-UFPPD
MJ,Q23^<M/9]/]B4"";1"FDN:*E?0CIG;S/#*KV[XPEATOAWBP5LFE"]^)]IG
M+=U"D7=8J""HD;L=D>+MQ,X&CR9^X.Q)CD";SKGQ6*RLXBA5C]Q45.T?:WEN
MW_I9,Y=!?U"D)\4]8/$N\?C$+'(-.2%%V[+V*N'V'K!EPL, W?D9X6=BI_;!
M#_]:ZA[02WIZ#ZBY5?>1E(!VPRSO 9=H"_> EH<?)'S/7]X#*C7^U.X*4X$2
M5B2T!&'$"R8M2F8\V$YI>G5KX#A?-V173-C*6(ZOJN-L.#TR%LK%PFNMQR>O
M^LKWHM"HZ@[AXO&4!?&Y6O.=N@^PU8'XLF)A>ZP;;^\1&<EB+"S=,UO!J+U@
M[NT2L39TIRQTAN./,6YY,)4E Y38';TY1K!PU]J9*4.T8G,Q@H9J],;%K=(N
M>CTR*["U3]P_L=_*.RU%J,ZR(,]#AM$1QQ=<?^-U>%D_NN>FE+ 9TAO7\KL'
ME7*Y63"<3S$:6'@6*9'Y+KY"<F[,04=K;,\^+IBK/#AN!]Z82]+E%=:F[FKC
M3_Q$\_F'"KM\R4O0UO8+SK6=\7,W0_7L??C,EYM@GI:=!!C'WYGJ8$;@H%]-
M(:R7?^>N3NJX+/R@9?4*=C'H0\U_D:=N%*."HL7T8."I#96?B['9;KV@ ].O
MTM.?2I$OZM>VGN!'$CAJ2)?.+@G?1%? D TPE2G4159XV1[HZ_AZG(J*8D$K
M!9)F[NLFY42JE3/P4=7!KA1-*_6O-I=C*0GOU8?9]Y9Y=5P<V5$]#FH:$'AZ
MF>/8>OLW([@CU\E 7MXRA]]'=2*14B< IZNBT-6E;G[+-FQS*;"2U'3;L"H6
MQ#Q/V-)'=7IV*^]'NWKK<HW13HF$7UN0)$;<[D\>W50(GB@+'(_QF?KGIWA)
M$$$G8(P%0\AER<#;NE6?]\_L@PAZ-^G0L16/<U:F>V)*6Y=@9X/>F:WI 'V4
MMYV>[C.#/#:!:?;52V22KP' \VK7F\ _KX$->?ZUS\O*TL&UZU#J)D94ZM:7
MVR^!\NKS/< 5W+V <P^(VU2\!Y2%E/TTO0=H9^[#EX?N >'6A-$8JXHW"<5E
M5SO D[+$.BF-R3/-[IA+5K#)V934I@EG=+)$ ]A8]8::3,?59W/W!K9B5.!V
M?0]8-IYV]+J%=OJCJ<1M(7>8X=]-1%CIG(P;_$JV4GP55%/_Y+RA7B_N[>EV
M[A1,[(\86?$'?0WKZ)N12=CLQJEYWFRTFN8*VLY\<L?8M6*MHSZ>.V]!TA_K
MZ;X+PSL>H O!D$P\6*^TT"0^\/C@XF%9=S>\8)E<$'B!CI'9":Y39TTDL4?K
M]BH#H5BSJA.7I:J&$!;U=JW _31PSORKYS56T?@D;:"3Z=_=GLFJB,%GE9)O
MCC0['4AL1.='JR?VN;\IXW'(KGO3P52V_"E\I2=G.V.WZA/7:EX,$"'C/C$B
MTU#!RLUC50T%/-SS="H#N;R89"G;_F16E"F9D7O[VL*/V_$%?JR"]B8186_M
M+>K2YX>+9+8T"UK1_"H&E4UX)W[_C_I0L:O^09S!*?\X[5_J"SXT-Y(*C^^X
M$V>\!SB^*3W3^Z])75@8\)5:\],)+7E;QO_@7 X@IXG<(PO][]Q9]>]G_<N+
M#\M+!F[_J?9)_'8/*(!=%.M5M-\#B _H:O (R6FVF?\6ABLWP"M?UUDTBR4<
M0*2<8QS0-:0@#UI7&JGX&;BMP9DR>?/>\AV-B%*\S):A$&*%]E9M0Y_:[&X[
M,ZF^\-VZA'Z_#@75'X_Z+Y%<7,YPM9^N,Z&-Q=UW$E.;.H2YBY9AD]BT)_F;
M4ORGY]]O(1U[[GLAM $E?)[">.# = )5E_)!ZV:6QA1'7DLO8-X&:++-G44K
MN,MK;:J;_;=3*/WV;70.J!SMT[-F5LK0S4E[/WF:0D6=$9*31?3<83JGMT]2
M&IT#D]"KF.JT^6F?-3X:2?-0_$93^$78:?$HYV5!DOS[J?24KO-RL%T@P^E'
MG1#>YXF_?@P&I9'K1E!+5.@]JXH;GE_YG/^NXL\;^4%($*M[>R'(?U%-^W=<
M $5!_-OI4G]M**^UQ[>TN=@4^\\#<DHJ@>#]@Z6?D5U/\+VG0 MU3$&Q-]D5
MG2&9OC'#SM W//TN.!K:O@=FSFW-X\Z6B3\BAJ "QA,A9ZW10BQ,5(-FQCO&
MMBUF%<Z4J/"\@[>M.LBZL[*FY0'1[+HB[N',09N76Z2GE,@G^2\&=O92_E0N
M4AG*A=2;\'D[=3G;;'O3P("0:U:%=/EO)[]*E"0TM<N/L!+_&)62Q#ST]ILX
M0_1\IJE&:^J$?(J&?,_L_6&;7]U6/6838$)#,I-'LYI4U7%;!H4"*;WC;CNJ
MI[3F: V%VYQOZ8Z)*3952",JQ')$^JPDX6RY;___!GW[&*@<:R72-RCCXD:8
MJZ"\]G;"0U"_7-C45+I(-+K,,J_=>,5-4R8#"D=*,A9)Q2&RXFI<F/Q&3\ND
MFEKJ)YZ?V&]:F]SFC#44++-(&/=PJ\E7BY5 5Y2'O^3)5?5@*Z[1+%<10JYU
MF>?GQ"/20EC7<;;>U+LRZC@=I)QN+7\CU.KB&$M:Q65V"?(3TV; P<C8R'C@
MO]OJMJ8C V8A6XOBXTJG^2NQ<%H_+'.%ASNQ<&MR<@7YI^3'[+FO,0B?YL>I
M/PN,%!QC7],FD29X]E5>Z:$0(#R(4# &\5>2;*K-7,$?W",&@TAK'"L(N^>;
MI:7$SXRIU@5E,3*<@>BT!946#P\B;F3RY[CT:M0%WV&Q"[TE1GB7)A\!51+'
M%NXT*^88ZM;(;CE[2O.#7X7]JGDW_F(]S&8-1"B3_#OB9K/P[+R,IX1JV*R4
MS.H:F[; _AEIQ[/>CY8<K1.!/_DYUS4?H8:-#W=BGJ\/8-P9?;W)!^UG4**B
M$#N]L1H[=N[2 _;>&:A2]N5U>O75-P*U."\1!:/![X)PARE87$ ?[&JSX5A_
M#PGVOQZ#_J]Y6ZDCIFW6\N-ID;O$FEP46!^Y[%4YRYJLN[2'N?*CK>^&\X])
M@+XDL($[FEFB;L_D?52G2B)M#F[W9IB--W9QC@A->DA7P:ZYVH<"A1VZ(GVY
MO"65*^3O^GM V.[9K214K%:K@X<\<<T?=*P(KZ1N!)7-;56PTP(Y>FK/2WVQ
MI69[?C>U:Y4?+#ZJ:B&R<<?'3K4@1.R:$5.M9>H,@[9%<)A=RR)N^$H-43"3
MZJ; 7X"=%GJD^%WB.4\"C"$?,;O0+J,<*\6PTJC63\RATUA5ETN]F4E71C/>
M]NFQ0]**'"VQ5B1R()AI&CEZ#P R6?NRF"H>SI'"#E(N6^-%D56?"[A$G4^>
MY5S$J!V"N]P/_4-3G*U'58.4G34TU%TS#T=T+L:>#E\/&FX&2Y+41%12N0E.
M1++TT0IA1-)Y(Q\,/L$U'XYHV^I=<LQ1J?<]X/5Y3,8%ED=YR"IQ1,S*()ZZ
MJ#H_V\7INQ[X\3'?1-I%E\^[VTS+WNXB:> N\5$^Z^ZEP#NA'[]*D"3!MU"5
MMXTLN,[CM!';[BU8F];B&-8,SN5K_N93ECV9EV3C=_5E)Q0+*,V.6)2);)A:
MR,TPV[LZJGE#8,^W&)S\6S>3#<Z>'!9Q<_/JNAR49BJAG_*AW@S5#3Y!!$V8
M2Y+])OS2]K2LJ)D UAML=W:7N&<);!/(K_LC(RW!V=EB)1([;7UL1]O&".P$
MUWB4D=]FM:Q1O[^[.*-8MMCBDBUWF;X\+6>,1")-\&%KF=8F9VVP1-]/.R;&
MOMP/PPF&@"&Q[M[L67)>:)T]2]YHJ:1?IH2X)>T3**BW?*)87CH;AIR;S) R
MW;;DJ8CZ?2Z[$X=V:VH9>4%5"0E%8<G\DYGO?$7'$S0.U3\J!6)DQ0;._<"N
M_R%"5>K1>L'ILG0+"L3$?>-YKF7TQ F.NIHZCW>H:]0+98WDRID0YRPP4 H,
M[O0$'>5NDWH]=JH*OX7N$9,9XIL0F0PHT3YC34&UK^W7)88=B0&GFH-9HN,%
MTF-T482N?2N_[6H>,SRW]5X"UZ,ZE&,,#IOV$@K$<KC0SNB0P3=8-?R>?9MM
M[;*K4EHFROQALE3N74X?G-<[Y[THZ$U]7XH30QT/5?B8[2J#C8L/62'7E)]8
MQ\U]6=K7%8L=.=-0Q=GIM#W@?/N).C-!LQ&RMY)/)@U>'4F$W.WB/M>S]X9?
MV/!^?T]JD+P[7-JH6LB3N#R[TVU70L<%WH&CAL[7#QSRZQV:N"+O <F#?OA'
M^9U08)!=B6D"F;%M[&/O,MBFB2@6E[1Q?J"AESHEU4NEY_L^Q*UV^'N0P:D2
M+B^EU[A]N[\W3T'SOH[-4$W,\(ZX3>7U3'].S66%4$$'S!G2VO@UKY*X84:P
MU-'5LSOB"B8IEB'-VV/H8"%X9A5<M@898QW"R!,#/TP=--?3B'9GXUVTS=B@
MA5IF\!#FS719GB26(2<*V(OYX:7!F9EQLTW+[\GPZ,V"/?+^C_J,<6_1\1[+
M*V=,]"F1\ T?IER*5 V:NTK$1/J"/Z3 X&?X5DB;'O;6TP.(%-'^8'ZTX":!
MC"4NC)0C,\J24I)O8H,N]$O-R)N8L/.-S>X9F\CTGZ$BY\^:QXKO 68ODS:G
M@[/R=11E-/9,R%T9H$<-=Z]>2OU%)=?]%/\]XZYY0]S8;CFR6'$/$*4_>(#<
M$\@*<.3=\.(Q>M,] ':5<FYS.>=P/; /)0P,Q]5$^.8<.9B((J,LHPQ<]5H:
MY+9&D&,97%-DLH?=WPKJ@'7A/QBJCA!SQX;S@X)A+-/E4E'>U!(X["<)0O:>
M0+4[Y)%?5!WCL]JX3ULAC'$F1AU>9IBJ-)J/Y0$ 8A54!O5ZC=](0]=SR>-R
M' KA<\0Y$>_^3]A6,2S*^^LN?J>Z3[=38DSIC0%64MURQ Y.LI0?-49FSQ6X
MY^)Q)5D?+6'#6_C7;>_ >\"7G7B7>X!$ZHU-!6E7#5W:24+*.%J0*T_J(Y7-
M'-\GR*&$58K*>-GJ"Q7=,M,;-)/73R^]D9VB=B?6*>E5NUZ+!(&H,^SFH1'>
M<9V1W?W18*\?.7PXXK'\G%V#!063]8+!(^7_((["QZ CEHL;F.;=95GU&>\E
MMA$,^?Q.H9FY^1X0L]6R""I5/E+CV/6&M9I<TEL\D"/WN\3=3-)3%J0OA1^V
ML+CJ)C&*2-US\=]NGT8><8V(VZ.!L=YZ!QM.;]6:[H<!/Z+,@W)#J9@*+LI\
M43@K0-&I$X6X.W-)&XP_CGS&FJM[U*=2U"8S>[.T+^.PQ4B=5)<T'PN'B8.A
M/@TD]IW!$@K$9V4N))H[(G8$29&G+3$93T]8*T>?^A8PF'^5P&4V.RNC'K==
M?#VQ9\>$XSJ&V_WP" @#YU1JIR1+TX0J?8*D+L.<:0-QT )0M"8B9/=3_<($
M*6QA6RJ1P^FM&D-#C!=0P=-#59U)NN*G+O[ZJV_E\S\$3/A\_PMW;QD45[2M
MBS82(&B0)D"0X!82W"60X-ZX!Y?&70.!8$WC%CI( MTX- 0:AP37QB6X!H?@
M$$+@D7WV.77NN>_=5Z_.KE>W[H^Y:M:J4:OGZKG6&M\WQQS?,!4[/E^]D=&Q
M,'SSSH+]QO2>(M[N7]\!8I'LG*YZ&[-Z@@HO[N=K(^#^+=I;!>]_^#I9]#N_
M3?A_XI=Z]J%=M,*B)/\Y0'KPTT+WQO'^^^KC<P<PL[[U.:D"K.>"D6RW%*W*
M):/)[#"^F,UDKWZ\+E#KXJ#[)5E]C1A2\TI[18JY^T($M,NU;^U,5*Y8A @T
MM<"69(-25R#<RBMNA5#!/EPZ-<:QLC6;2E.+8Q0" NY_*XMW+D>*1U4'T!V6
M8;7;P'F-%*B_DJA<_&'^1D\[-FL\H:'>/]I_>O\>[>BSRN.7 H, ?.:N[,)I
MZX,/K*8DB%"UX<-+HD^A+-KQI055);Z)*CYT>UV!NVA2C765JF:QAEK(JUU=
MG8-]'A<#E]86C\0+ Z ]4ZH[EAC0] 35A-^'MZ,!1Y2\PO]O;B;\_RUJ.L?^
M;U'3('W]N'_3=3"?RGB\\KN7YYZR'I@9L'787, ' \<%'JA5 X@+&V4>^;=)
ML/+.5@5XA7<F<:MX([2W[<6KPR?GIH2:S3@?PBSR:)_N@D>$D)1+3BR]3SY,
MB,Y)<5,>GJQ=K"(:DNHT32>I1E3.MU=UA>RS])LSAO19$]ES-U,2U#F0L@I]
M/SS;UD85SM^()RL":,]*#416B;__NM;7*Z+7 .UP>IG1OH47SIV\3@N&;_GH
M/[Q1/64LNQY\.%6?I(GR&I2<1H=YYJ8??R\7$422[W#H.SJ!%:@#="!?W8($
M;8*[(/WA%YP-PQ,_#72P@Z.%UG41[$U25'HB3Z?YPJ8^$Q?'0V&;@',@%UDK
MD?L($7FI$'&'1-K;> -FCB#(NE5.^^_E"H=N7X]+M+MNIW14:?442W+QL+R:
M$+9LF)=I_B+MGW5]T I&RG)6I:.E46EIN>M@<0V4.%UW8"B 9=IDN2O'D'R;
MJ_%K8_8:WORNO/?8X.[@J@*HJ]W56=F/%L]8 4!BW-,\9=>B#_D.A)X[6>S/
MLDL<PF4.(0:O(WT_8<B'4))P:/EE%&69T,S5RK533CV\99X<YYF@-O'H&\%,
M[@PP DQR-;0+G?&9QJ73FV0*3,Y$7D(_=YLH2X@8]]5;Q6<?&U<G\^(B?,8K
M.,[%2L>@390"2ZE2Q=K?)R"DP]R3B!C06*ZMFD0"/&GHJ,K&"N[-U.3"WNW5
M,4BT/)2W+#0 W1)LP8*F:#HU-?@KDVK4YN\'+E;L&WC@1KT<W.4:UJ2=2=N9
MJ^B!_4Z.I?[AU>W7)-V,@R#;B$QM8 >N3W<,Y!:5*)(A"H3?">:GBE$CC#<D
M1":-_[^5<W%5K. .:RS<.!L13.@K:_P $$\!AQ\KQ@='@Z5$HU(_O^VH+5+0
MHTO.48'@;]XVKY5)41L9=2Y8OV>8;OEJ?$QT6\,H0O:E.R^#\3)4?+@!9A)K
M;&3:$G\9NUFPW7"P8SY%R/(&M7#J9"561R7/)E6RF=+L.T:[@(8RP?[![WRK
MS#=L0%:Y\M@@3'X<3KC.#MXG:SR*#JY7TQ\A;_[2Q "*]UK8-CI*)7B%R2][
M2-6?3J %89@S5+*%R9J"47$4?7V;'V1QYQ#,L-SA#M4>J20?URF!E,+*<([P
MN0&3?CD%/-G+7.32DFS1_)_<^2?'IZ*(EJ\)/0MSQNLR71V-W//++10_FC<;
M%A85_3Z/5UAF7D9O=I+UE)B\/!7>I-@+\LNZ_,J$6HMA@N(WO,I:?-C,6$+9
MC0E7<#ABMFH0(YK R8'"Y'!5=GZH&Q40VWNU'"5V#1[0K=1,FAQ0JI[\>G\2
M,==:H#2]CVJ6]; 6[VO])EER)G32OW7EKM@*=J!GFY04";J(HR8>AL:/14]<
MS^3$='B!R0O3P:XA<N_SC#TJ-=N7A*J/I3[/K4G O_D;KOQ1+*ZL>J1H?,**
MBVL7B*^BLFW,R4'GY"H@\$^-98OZ>]:1=PCY_%\S#-TG_D-VF96'E<<OZU,^
MA(/J7Z$W#P*-@P _S=WN<9;ROX5BD8KLU.R(@*\]FPQ'2+:M6W/F6U0;PU7R
M.?GW7ZYMT5<8=X"GW%^OMT,1P2>*/RQ>!0/N $E$JW> PO>A7-?0<=7OM;;J
MN6ASZN.]SJ#Q>9-(Z:W##>:%\S_<"WL$W4W\X*4GK1.SLH[6C%ZSU>W(C X]
M[U).FGXS!JK47J$S^W82BC]?.T\<R:7WXG0:O18UL7X9C/A-)]J'2)6'Q3+Y
MRI$$T]HU6433_/;WZQ%.S9RGZ%)\>DZ'>XHL&WI:-@KB38!>/UZK3)BK?_<3
M6[G-T"#8>AGR2Q!*!O=L>2MTR1)'>S&<&/&$D'9F*(_L[9.EJR#=E.N.1415
M<MSS]DMIU(\?'SYT_^:$:8A,+EUQKIN \3;'A!Z^E_U.97@D=0?0,?]-D3SP
MJ:#@N4#ZT\TVNH4Q);R!ILM#(E<3_^6N.H]RW[FI#0X<@#*?F6%VI9[MB(8J
MR)K;-221I9\L?+A4(N.I_O."M0,2U3?/7ZPM:  ,</,ZVD!-Q\A8)+G+='T
M4RZ:#<S&<8@B0'%\T92@Q]N8>?8E%F10(B@=E.<FSS5(UA?-,4!%<Y*7*'/"
M_F],<;S6QZ$V2'0^X]$GZ07\4XM$=FD234VA@!OY@"MU/CYSNY1["JFI<EVV
MTGL3([QLL6/!3=HCBP[1/K)9_^;;68\K$QG4V*R1$*5[*476HG,1<3^A9M&_
MER<-4'8M!A?OME2K5U9$_I+'@Q!+&DWKK1'CZ]-5^YO4/R]N&UZ<()/QOK&<
M(2O;*+/]L509SN[)9)!1I_D ]]!P5M]-P!ALZV7=I+5:[0M4WRUP8V:X<1N
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MMW2MCWTSLM)HRT@OU7T-O_6$TOAR>JAXI:O;4%*)T0E -H3N -'BN#%(Z:D
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MT,K+\>K$O[9_/7EP;L9&T.R+(R+[:SW9@H-$B[\HG"A0IF/Y<?SS&T>1TSM
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M3,K+7$^@9;SV"YE9TTQ!^.>A7[F]Q,]1F5S<R0EA-NX""H =3:94X#ZWXNL
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M=ZS%P#4RV:4R,9V3N2APO4<'%(G>1A>&/*6"N0N1":^42SM?ECSP%Y82*J4
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MOG+RKE1]RJM@DWD$9/OH)G3S$3[P= <6$=("@\5N,"H>Y9[7%UM\2U:H^P0
M#',/ZYFVL?F6!A<W3#P)\JQ;3^(UKF)M?C:D:;X)_VBHE2N7J[19#4\?BF+!
MSLC'']YGY2YC=-U:R3Z\+/]>K\D)Q?0S,"KR%]&:E&OI_R$7\*L)ABHS=%RB
MJY_CM=V7V*ST"624>U&RY>(T?:E)3DC:5_&$'[$."F#?O-:3:$Z5FE#IPA'"
M2%XX@-+F:=2VEJJZ;S2/T7]$[%UKQ'I1>"BPXOYL.#"OL1?**"I\%AOQA#C]
M5#TROM_=72.('K7\_:K<WTO>P2[SLBN^E,CC5 ,DG/:TH)3''V(S[B/VYAEF
MKB+*(S"]8[D_4JQT+O=SZ!J/;"5O.[&8D*!^^!)?:L9/\W/J_IZA7_XKS+2O
M2FNIZ9H46D!U@?@AC.L(;Y9$E4OFOW)*CE&E&[%J@M>.<*T!*"0)9OD)#RTX
M@>8=Y8M78X)+3BA]LK'1(;HW"V-V<I&*Y ^C<;1.SD^V,3<R!%X(ZJAL)+@+
M1$!HU 5[<K+.&2+./2K\G7K.5I19WO3A6D\ 1PT2;X#3>@6MXW"[ )& XB"N
M,!P9\?,_G=-M=K4!-F.[H/0U#@3<W!%,X42A+<_[W_FB8BFK.'*9;UO1G";&
M;S&0L,J<_2/E5&B+X<D=8"-7]9_U0+8[__K2XHS@/RL_*1>N7NF)U(VR5 XH
M$%BC_#2/+XT<!BIS\!NW_;:N]=D[>(A[S8XE3"PZ-Q4>9;_%::W7OE)=5=VS
M@\ZVN$!Q%.=D;[B7>J8Z>T+;#)*S7UBW^\B0^V>NT1< (Y23T"??6C#.F5I3
M5Y&=V$?5-%&?]-5E9R)Q&151_KW0%NZ28)F9KUX2,1\WHVQ8:$/ 2V\?^X_<
MDHV0E&IT'DROV\1#[9>J>]J,.4>O#!77)G]JTFXEJOR:7\^,96LZQG1(KOXM
MB4<7<]A;OV/Q6@!HT='V^BK:AW4DT6TQ=J ?I2#UL-O3UGNR[/1+J7.07_L]
MXC3>,:>LG_P12[]YC-W(S*I[@51G$58  $_9<M828S+F7%J$M?)JF##H>7[K
M?;U2>\MN_>=5Z I?:454]JZ*J^K OO*VCPR=)!_X3R)],]DSSVZFGM\*(JXR
M?YQ*CK ,TN\ M8*-AK\\PH[#@U*\3*-095>_+29@G=JH%"7J=UP\,1M!,SI'
M!IU-=5E(TQ$_, O?EW>G]["ZT#2Y7718>7!FU+@NB %R/U<&7^\ E0IM+\?.
MLLX7WQ()SV.:Q/IRLF.V?3NVN(E[? <X[YL9_$HDLX%PE#D_DZE0L!"A ;)$
M2QF=V;\/)B^\4E1.X,A7S ZS24\CZYVK%Y+BFM&KSEC:9/5.Q@\S2$XV?B)K
M+O\<A[O'QQX]-*OL$.Q8/IM'<C4-]O]0.K\8_-X7HVPO'O,<18??LW^>\;2G
MS>@J"?-&[NNW.T!&XQV@-SZ$;P6D&5Z;>'UI?%[S(C!=[ Y@]O#=X(W],39,
M)L(8CZJ\WGY0=*]V2VAC&>_FR>-8H9G&5@O^N9D,W&9ZQ9/*LHOP9DOA+&?I
M'6CC=51%8ICO=BY]:QJ]3?+;%KO*CQ?^[$+-!.:*Y<:SLO;XW=A@FN)O #UU
ML'S-]'[N] EVLI)DLC%8]1WD&*B\J$QC>+7<U>1\2W*<,_0H0P'UD4^F^!Q9
MTO*X(M3-W[CG#M 26YOGT>UOT1NC_^*Q,46/.28ZX0X@%!C=_F;Y"%GQ</BA
MZU<=\VDAK]55O<.AS*Z WMYXP-R>.QBO(>&'G#2NW"?\ VD<<,=IIV;A(-N.
MRT(Z[N\6##/<;AGB.T"'[,I\\3I@Y-&I;FY[@,PG),F51&4.0\]8QY:-@?6@
MRV)UJ@;# 94(?35M;?I(J==2F^75?&6.00\FFAC4K_8&:S*;YEK"8#)_W#NH
M[)<&<SA_3YOF&,_FL5\7WE1[TH+I8=(=H"9;7\R&1T3?[-%F".Y1WLO;CB/U
MAO27#7G\8A>2B:,S L?S7?S?':9AMLTNOU5)&7&S 7A(T]HZ$[#2&[4'\9AO
M7P%/\WK+,MPHY9UEYY*Y2;IT+8TKXC8S3:HRDEFO^%:"7#PW70RTHX?"L>HD
M<PD2;ZN1GRWKE9CQD^'!UG@2!GDWP$BK(Q;;T/C+M^&MM*%<O73ZH"X5ND>O
M5GE;5%<_,I Z>LXMRI4/P[D/-NBG3G)=;QC7,1^E@\%03'_65Z&1(2D+ZPL&
M S*/5PRE&1>YK'$$K1,]S )L%I55XKZ#I//&A$A+MZ?K]Z":9&W2J,U[^"^S
MH87:0_?>#H#+KYRH_$E4%G/?@ 3.*C779[E7"32OK^X L^I>VO'5P64%3ZXT
M*8\LH(?!U'X\W:U-:N.<M'7<-:GKF[7'!R94VHFOOA;M_-W_0>,7(Q2[,OF&
M+)_Q:=!,I=-7O!N>XGE^UK)7;,33^KU">U9EED 37>,DI'7'\_-$LAN%J744
MOYN=Y%,9CNN9QF"A*P_<B!41D6>LDZPO:<\?[LOTM#!T!=*7_-58[Q$M3,9,
M&A,GPZ!//]/L3*0LBFL1H#WA_6WSAN5J??.\%V&9Z*(=ASA*D-CUE?=*3?"
M;+QE]-<@ ?I[!ED5'/!57IG0'M*^NYJQ2'RE#*T66M5)^URZ^$3(.SAVE2[P
MM)V>1S&3^XLFUYK *'1=)EIH-Y2RC:G[3R1.#ER##JDET90;$QC*M7DKYO^V
M5W/:Y9S _C5L)8^?<3+H5@PI,LZHKFKRI;:Y@9M U&S_[?;9M<&DPGON=JL\
MS;TSL9^CYXGA;_' <<@KI1<%;()B8;R[(:$Y0=?>9Q?E!US#,QH3+@<5%#PM
M#I@K^BEGR-PN Q\G873*J#%'?M6_1"[A?X],1%9&:BH$W#6M O'>W8+T'#MA
M_ GO=U^7K9WQEIE0H=;U/YH';QE3,&4FPR,8<KSH78-F6B,AD0*#71)]#?2Y
M-"6Q4KOR:0:@9+35=]$B'*"1+6ZKJ&AI(P^E+!H(2,D,>2QK%3S*]?3LX(R-
MK99K=UV84-&IIPHF\:%#9AG8["LRV_3;@#)5"#'[QB,5<L+G--ZXLYJ;(6[[
M'NN=IB&$)GS\V+8'K[_"?XVXL=*_)H )>UA \T#3085VPK^L,2=J+?L!&^>@
M[@<8/84N))VF!*W12'&H] /X?W'WED%Q!5V[Z) $"!X()+@')^A T E)<'<;
M(%AP=\LD0(!,<&>"P^## &%P=PDZN#O!);A>\GWGG#IU?]P_[ZE;=>^/KMVU
M5_?JM6OV[O4\/:M7TY..J-*PD9^2<9P6Q(\53T3W3N1)J3W>TF3(Q,/1(2G*
MH4RC_0'MK'3DZ'#22E1(L,C%/(V#BN_E U4'NWW-YS[2>N=VV;Z:$G\NS]Q.
MP5*>N$,P";6H)NES)L1\\=$D<8>B=4#S]6!'G/HC;'"<J@AC9;C[(W9%^>.U
M4=MGS 8NY%0]^7%E6$\L-.;?.3G,_XK(?"9AS<X4E?#T?3H**W6J0?U MQ2+
MK%AT:+WQ_<&')K;O-_A;?I^"9#/WH,:HG9PVOW),MAUIMCP&/_0W08]\=?=H
M[LZM 4;:M# 14G,)7_5%UL/<Y7P!TZ+$T%SKER8VHUDB_1Q[((-&KBW*V%T
MC5W,X?IEY:\8"A7YOC'T7+^SHLBVGV[[QIL+];BU\;FKDE?L*AP;\(E?48ED
M0XU6\GXNK+J=NG#L1TW&39)P7<]=W[(<\BS%\O5DF W]N4A.(T7I2_7J>LY8
MQE#3D0A5LM,.V77_*%^DM!UE161Y])MW79U5J+\.*2Y_[ Q$<A+><^*N2<L_
M&;*_3HC:-*YZ*9CJGIC/=7A^H1*J52LT8W]<B)& 0V=P?/[)RRJN4.1FIWS2
MZ0Z=O0<^6!" K@ZQ EPE[ Y<BZ(+"=U/)=UX-54Z2!Y#AVJX@Z#CG#':N6'/
MO)$&ZC9&M.Z$G_[T2*U-O.KK<>LM+=U_1;%2[LA$?03^53N)%>FHIW<U;HJ'
M#41QN'H7K?#\_ JN"++_HZG#5!FV&6/H.;)$R %O8)7@-"#O>0R=(?ZD$<OU
M(?E122"@()I:HQPX0I4<Z5/&D5I->[(E;%94%Z>B82YG'S?N&1^GZ@$D-NCM
MA3$+5HL@9,=?K P^A0)&(FI+<CK?CIK^TAO3%?I1W@Q<CT=C'9_U9>)&7AU]
MK/Y+EA0S6I;?X$/G,IMA"BT6')5OIX9N:HT/1MIE6=0["2K6,U-GP.V085PM
M\MH@WT;O$F*JY^C'$TE]TDL 5009I4*/NLJF ZC##VU&7Q'.HHLE0UXJN7UF
MURL^G1LKCR/""A=ZDZZ+6V2X-9KG'C+\6,#1=$2G]J7 U*+BLT[[OS<M_CF%
M@N>U@>@'$A![=:7E .Q<M5>-!9W)<-R6Q@.>((%HE:#$#?ZBG/)W3\98:TF8
MP]/'483QO[<D_J:0>PX8A6"&X1/:@F$'D61,B1ZS+WT_"'5D$BE\^\'7K[%*
M(5D9"ML-)Y$%[O<</= )6],B\O\*:.8=?D1IDT]IDVG^-(_2)X_RW]K\ ]<@
MQ8^$V5SDP0"F!0/_33ELME1M3;?>=@UW?.NA(2 -+;5^7'+A5-B;YSW8R=BB
MF$\L(O$5>!)]6;XSIMN36,T_8R3K@D<6*S27/SPY(:H5&/!Z0FWVQX>&ZU78
M$=]P9:G7<OJW\=;>?$W=2/;Q3:82MO\PF@HK-DB:I>Y+2,/J*N1_+L<;1_I&
M]37,KKK@'1Z#JPW#CJXFIB KG9>95LDW.'1'^LVW;J">R=&2Q\Z^N@.@1V'W
M@.">;ZV2AA9W6$V)V");1BG(H_WO(=T9-_J'HSM-A#6)@E@;PQ3F %<_\U,D
MR87Z"O:PN"4I?ZV>HVK\ZEPTYW;*LOZ2A6-DO;)_T*H$HPG>Q>#^#._(I=.&
MS&(IQ.!/BPJ0O2^^_CDWS5 9!F&1+'TX]%)XQ2-NZS.H7G>.8DH)YX09=L73
M0GEQQ!ILC\2X74$F+A[2@L"Z=$<_6F+M)NR*MX937B^!Y9[Y_\Z$J-AE8*NK
ME8Y54:-D30[WKVAD6RG!!7V_Z;7]/8'C>[2!3:J'K!T.LJT"5)]4A893Q5G+
M3\EV7MP#:!M$=U(<]ID<+[LO1J!M6INN(87?!7UK 9ZYY+LB2(H)24F]#]_<
M=W",CMJ5(YJS2I'+&>% HI<V<>!MXFXJ+(87XB=#C:YC[5KA/,PF_*).9/>
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M(]8>%>""!C6Z>QX]9=!&I@\)8(?FY= ,J;YNN]:9G?+EZ,ID6]*LW58FU=U
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M:%1<EBBI8$:6G:XSG&ZT[KDT<5S01N2J>"SDRPQU13UB;:3PSU<L[!W=RN;
M=/+R&.,5H3K.Z8L[F4;^\&N=(3*CVRS7!*[*62-1S)!14BC?#0=''_N36-\3
MVO@KSK3>Z@(]3M8.6MJR(Q;8OW0JC$ZCJ(*\GS_J*#8F0)@W0$O?)%KU@% &
MJOR_R ]0LN]";&U+^+Y:E=HJ)=N.+>_X:_)\/C^@>=]8Z("LX2G!H(G)(4O0
MREOE6RB%RW%/PS.['Y O,"J168AHX1U-T(W=)+O GA%QAPZT(D8\/\T&A-7
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M0ME5>0^(RKV:U&EVUAVQ=&<?^U';&?:S*114J ^O8U<80 S8W6K<VA$V[ 8
M5> QJ!=S'KALV0U_G7,*LZ&Z=O.&D4*^ G2&0>>?;2/])B5])TU]GL(FI"53
M2I7-Z:-]@Z"W5*'E*BA:V>%+\4%H\'[8. Z0OY2]+X'>X"HXBG&53Q'JB<E0
MA/'@GKNB(]D)\"4X&G(82V+413>*.L$#*2H<P2/EJV35S&\+'F7&DAGKA4\H
MO\XK<\KZ,C$X7W-:5#&#J?%;AE/F0.U#]'O;$)LA*BUG#KR?H%=/ZH*3S7N^
M$UWH$MB.1(;MPQ4TQE-L\%0Z/X*_CD<IN$J3BF,**-X#(J.Z\M(]8[EX7QP2
M?@E8U?X013_M^-1$@S,077 J)M'#C2V6*^N^5WO->%(T=/9S$W!$9TFM R^-
M!8<XRY\"RPG"7=@N9>Q*$ZEJAS2?A8LI4UGCOT5X.Y#PM?069Y$28K)(%(]$
ML.6Z*.38AP.P%?@Z);X)HVQC97S+\Y+G;39@ON@'4)*7;A,2_-@F)&T!-M;!
MBZ;,%6QC(V]7$ORK)(C_7EEP55G"FARM'J-!:9KY-.Q?+G#TVYX!0:A+[@/0
M48=%GQ8, 'C1RB*%E?BFN8)YL7$8^7 _UI9+P*]Q\YZYT:SN8<JCNA/5(-U8
MGA\6E=AKL2]=);HXDRB1CWV)-!?'UC1&>>#<_L<2O-E0]B__,5?[%[G50EKY
M;ULANS7\X_-'X;@&[(UOE316'J8^7K86>';"%SX9MNQD++9.4C4,*-]#)[-P
M]7]'<C_(0DK_QYTXTLK_74C^#Q"5?/FGA?U+<B;;?TG_14@H9R="E5EK<*!@
M=6E@YG_I?&26^!\@K_^#Y?]H,B"5\0Y_-;HCA>J)^L\/5?5[0(QV$\K]CI_U
M,!UO+OTD.R6=:"(-=AJSR7>2G<S>@JX)A3H#:6W<M))+E"CAN@\,-$BSEOOE
MDP1Z%RB\*6W#1=N5"TRD?=#DS1ZH0%,M(VVIJP?3T(GY1L^HVH7BCGJO/TFM
M>#'QK5K*6,'X:+LY>(O+<-T@5&L(1JYIOPC0JKX'")H69V-Q4UR<#$G8>63;
M#6 ]KGF43P<W=74)@LY6Q<Z?6%63F$DC+()_)/)RIZ=O>6YKA_;8X9O_CN91
M.CK0W5V+/)M'O(X:N@=P#0BH_N(LEG5RK9?QO1J%EED#W^/3A&.J)/=L5#J^
M"J&1RH[& +P9$-)!+S=A 9B_EST]1ZPRZC]Z-D=(5%@H^P3_#EA<U&IGQ:42
MQMN;AN)*%#JGI)L=MK>\HRSU>VY.)PX3"'1#H^RW8.\&X/T%BB.@T(D":3>B
M&;4&\WYNJ$2VJ5D9_AP;5\ W!F8/<J8"QCK%@J3WC8'KY@1.;'-:9[D3)T,B
MJPV_.$SC_3L@!+0CF.$NI@Q?/^$_=?OV&*',W>#KK2KAU2?C,J69W:AH]&Y>
ME8^!HM#C!+IR:Q5HDO@62X*MWM3N!6-9]9B[B"-#E,7PZ0D"C[->0K6]JTW_
MD5RS%S#LO-D,O3"XH+H@O-AIZ?Z'2*)3,6\-R S.4'E1*MX;TPIJW]) 3#N4
MR3C_T"]Y2\XE1ULYUA1AT>:!$.%"D>V?B&*ZD*_=5?:6>OD7O2FJRME[[(^H
MDMPH57[B8I ;4[6D;)DM:&SY?E!"69JM!_AQZ7DWD'4JI63!?":M9?U ]\FM
M+>GW#A\/>D])U"_S//G"A9*WGP\\Y1$@LFE9<])G,ID.^V*3$K:P*1<#B@E9
MH<SS8J.BM*^_R8OS&A4(3X9>U%6> -BEZ>&(<&QWTHO0 V(_1]+!\5?-PFR@
M&;(AJ&<6IR<PN_'$'<J;Z8MK(/I92W<59;CAA!BJAYZ;M4'92E:+R_-FXV3M
M! OCP^\\&-"ED,TT6^MV7NJ-R@MD5KNE<R'AIT'<A#D+MZHS8;XY)O*+ 7?%
MMI6D1Y$).Z9E:NV[@[8)U"@!E)T/RW=/_-0)V;. H9N_I3D%&Q$YHV6()$WD
MZT\##$9=0B*0W>N8<5Z.<DSY)ZZ<2&<AV/IKOK,4++_)[Y&M;8$C::3%(A)R
M!=G08\V*#='THI4WF$2CM<5A@48*V,KC:'.$FQ>:8Z'OZ1V3B6Z[AR5E[+IX
M^&@J6+O'\WIT)64S'\XZ0]*T.JMUI]FBQ7X/X#W&Y-T<C=LC'G8DB7+2O%2X
MJJ3]_?XD=W,T:8^-77*<!N2D>_EX^\A()F9(P89VG'4F^R3O9T$C)NT"I(\P
MV/>7T+4:M(OQMR+(0CU./T;?5K3P6AE]"_OMZL='F]!DC'8VI3R@C=]R1&RJ
MO5)N\2P5K4!RDXC:R 1[-.4+N'A0<Z_9>%X_"]A*<^T^*NE=<^VV;:B !-26
M+@[\P@FBY+@R2T::A3)BD@7FO"J)0>]ICE!;-J5)M,[SETN>5COD,YL<#U9U
MCA>E/\-5]W.ZG5D04)]K4]N8CG]BZHTK#?QW@,]$U"SWKW/K:\OJ<TX/J%SO
M<+,F;S'=<FZ[KT[^+'=S[96F\CKRYN\MV]4*T<?P*IT3P3;$+=K@'N#X@$'2
MW3,<*NE:.)HJ06;F"4[[,!N=NRU$',3J=D3^-LL"](7R!7MC-F&\.E2[N<X&
M3G>=5PVJY&K>3,Z]&RY_Z&Z&,*/3J_!AO\TWQS;?W(?9R2S. X<AUGI1EY_8
M097VJC>_2/UL$/:T@S040V20_8R^9.U[0(U=CFA$Z,U?THR9%W1_>S2O.F4K
ML0JZ_5)'9.^6;PKSA.]6=55OX?GW@"$&^8<K9(A!MKKP)L<]II\4LB^\KLQV
M>1UQJ:OE(2%\YX.KNO?OPDV[D'\<6F$TJ)9S#W!IYK")>!AG?()&5>G!3$7Y
MVT+X@[97.;-C=VIGBK4]E4[W /'9XSSRM0>QPZ6N^7\W(,L5S4MXD.C\>UED
M=Y/<PJWG(/U"-X7?Z.Y\JM>-D&>E\:#UL!MV0L2_YAS&_V-0YFZ&.ZR;PA!V
M4,UB@A=HEE+WYNA.*U1OM'GS&^A_J KF YU3'>==:D >S#L 5;E'73X\+.&O
M7*)+TYN"LU-0/#AL2>F?]"!.?EW^MNL>T*3LU3PK*GMS>*?5/&L@"1J#<)CH
M%33UN#(-_=;X&D-EM66TV?9TWM\SMZLO>T8J5NQ(170BZL%^SL)#+'@^^"+-
M'/5=YSU>:I2]#G![4&M^Q'TEOE+"%*=;<-O,*W\R"JDY_)\'G^<( M25%]@6
M)&R, -ML RPV7RHU/L5Y;\Y\H9%F69:QQK#.$4S)Q,P.'X$!V'('7C\T>P L
M+0_]U#"D*?YI&*!X('L",M8UF*2?_J?CC1,$5&J\>!31EC#1PDWZ*1P->+CU
MZ<N+?^W^52W4'HW(Q\B\?5 <QYCT8(*,]7\I^:==3H[4D7Q :*\&3YKA(]L<
M&X9UW@'82EQCGZ(3P$V: A\ D*K_MY9O8_@;#V8*OI&LK(5[^ $J_\.@T?^W
M0_7WP+*=U) VKNG3TH6:Q>_1*>*OQ#Q55+=T55<9(3A+^!C8M)65R2V"M2N-
M%CZ_V:7RXF2VS>BD>5$LVZ_57^^JUV7Q#% 5U JQS,M<A7JP7.G2L9M#&CEZ
M9XJ=,M_@"RBH_+'1CS$*N!F??1]?-/F6%"NOPK2BH3LW2LKNN>W8(8>RC,X+
M"R@"@Q$!)N+OC?= L#?*Q\21+=%C%]LQEET:DD7+$!*IJ^A8_E'VTA<TLP]<
M#O[:9*IK/I9GCT5!OU%[6N^QHY/=" X_M%ZO 6_I;'.>/5I=[R188_XBVQ=(
M:,?(F9Q*Z%-<WO^"+V8 B(>[J5P\A#FG)A<+Z$ON-$8[.H1\?54R^IAA"YQK
MGTQNOXH$FNK[41,A)!6_#=SR:$=.3#A(KB;G#A(=EYQ45\M/OL8WK<:%U[CO
MG.;^)79+O+4=9S0$ I654=ARO;=CYA_S#&RK7WB.SB+Y>%>!:1N=D89D>,8=
M&1WR)X^B+#@K>AF^F_F(CTQ>% 79,D02RTNV%0_X"2F0S>IDF<[#HKCD^X6!
M.@Y2VI^E8%D5-N!2'*91Q-36\_G>6-SL5,I2Z\QRO3EE%WH-%]C4\,G&R\4M
M)HHGX5<Z#J<5>MNXQ-]G)TKE"\3/R^5QZ(L<NE7&2;PP<T3%DC_:D)D[$\O^
MYA 04(J9[1ZFUL9S3U\/VA,1)S8D[CP3C)B6D05/<#,9]3KLAKNF,(.+3O/D
M*DSF+E^$>=+6%&J!MR=IM9O>I>>C/*Z,$UZD.,0%WO:6ZH^59TM+@.1#E:JT
MU83+UJXG!5:U0/4#'M$+ 47R:N%DKABE;EU\CH'".^"(JGT# ^J\C'-E(QK;
MM"2*XH3]Y:;'K1TWYO5JE6J<N1LT"QDX'7\60E+FU C'A[)*BCH54I-BW.=S
M(S-I^HC*X$5GL3C<\5?:D=/([G)UEZ+)E',MJX&GE:3JTFZ-^Q$+>=\2L[FC
M U%VURZ@>KV<)NN]<%T/+@\#NP0!'--5%B?I$JZ*8+P)%.FZ5*G*))VM*GA2
MJW:V,P!+_WNQD:0;M$&+)L;X^,@!P&P%5+QVAK@F/7@XK49.HJ-2?$]1E&A#
M^:>Q0AGU>B%# QUR=FAOHA3S[K(OF@WYNHH?H6U#PYN74_;P@76C-54K"-J>
M;PVX"MO3;LN<VF[S6!(;UC__HONHYGBV0GX3>$XM(&6L*3OT:=S)^JO@A. +
M@!5C,IV+F!1(X5I>7MI8I3N4?-%"#"5XR"]?R(BJ2[W;?WDC;135?HZF2PTV
M<3,. $]BJ\HKF_3\"7F!4/TF($!_K"*)HG"9@FX];Z^*#A]R):JR6?NC8TZA
M:WI@;&G, *?[*N3YGB=IQHKW2:0S5'6T1#;?N']T/FK9X-@[2KE*S*SJ260P
M_KB\OY'(RE->,7]4NZ98E]8=-4WDM\"\)G:&PN4!J0OK-NW<PY*O$!])3D:3
M9W;/4SF^T1F4_K7]ZSK)A0UWN_8?S!NM/OUC  _Y.@)I$_F4L>,$N"F@5(EZ
M;KGO95[3Z;IGY<5SU9]_\X?2T'PS;>@&%[Y\]/=B$[(SW&PC[2Y:X2]!WBZ?
MJB5SW5Z([@-%N+$JA-8_8(2O&O< 2T.B%<%$?0,3FZ".42/"T&N3]IT11E $
MW6PZ'=WQ(,]@[<'NK+J<^ZP!*G[\SI,'H7&GY6XRNT [B._RV3U'__ O!-\D
MS0TR794>"'/O-U!E*[[9A1C I[8Q[P&A&45=(,IH4*C%*IMD2,U?N"'MM^:#
M(M.199#''-UYA.J9I?=V;ON.5GJB&+O@ .'F+;BF8+;MRCW#=8<NP:5;,>;S
M>GO4!7'>;9):V-W^WH/[' \PH2,*A$S. 45YLB:K@\AJH6LQ%]HX-W3^*>PA
M9"'5,VOBW*V,)=(KC;:+!]TU1+ZV50Z*NLSW *14S?+Z$:-\)<T[?C<,9E_<
MG%<-(R2T+)HGB%D('7\XV##:+ZVV^-#[EVS]BMX8WTZMB^%[\2[T*$+H3H:_
M52.C;==%B=='_'IDLOC!NU]++5^?7AK0=X\4Y2X05:5X&:J&3SJ\9LKQTU*F
M_MN?B_I1VY%Z)C@JX3MQ._G-:>E)-M;CX8D/$\)J<1MMJS1'G7Z";EPT3B&^
MJ4-$!A(46FAEL71O030:^(<U(.7'#\/RD&AT81Y,>9>Z@B1Z="-ZY)-*8X?@
MX,F*36U^/R/B]0JE3?YS9<&2MJ&:]G_K(8+ZD;OOY:5R!X#NE-\7ZA>#$W_?
ML0O3^Q?B%=ZX@(G%=4O\*;XJ^0;G^O=L@WCMXLAG\O:=Y(UE2Q"BL,KMRW4_
M6]^O_VFB7P+2O-BX1^DY$*P42^!ZOT/@*ZY-BA:D)"0BG3121E,\63.2";1L
MM% ++T5E+]@,=FJL\ <'#1+X//?'0)FMF93ANP5"KL8G0[4,;I<B?]R]C J^
M!VQ6-I^WW@-P0<O>%YIWOOWW '^ZPU+CG:57*%3)+XCU\W(\\_3V+6.>LV<>
M&678]X#$!>.#;K+MX;:/.ZQ6Y025 73W +SN-LC?&9/KI7O -Q%)86_U-:WG
M\D,E5C><,),O+TJSNC*UB%.I_PDA5CO@\&VNSRD/0ZZ[M.KG=I7Z2<!_>U65
M@SLZNAE#3+(H"K?3,ZRY!"^X,7I"@$H9IE!4@V[LZ(]*124/;F'Q42= Z@G-
MEH0PQD7VS]03P?IF49WM+^S2 BYG^5@;:<-@CU<LW@,,S,_\O#*QU946+]$5
M @.X0Q])-=!N Q2;I"R/SK-_UF=L20D*3V%KH%VMN94PX7F/Y 9$5*3%_J$@
M -9/!5]-_3*</8WQEM8CV1_NS3@S\*Y\/FDW%  <:Y<^<L=]864PEEU6G39A
M8VCK^+X7R7ZQB$Q3[53?BA'Z@Y"A@,RNZ:;+TYR'>NA9.IO7A'UG8IUHO*)P
M9Y6%&?YB%8JJDNH+VF:WHVJ[ZO!=#"U!FMN'AC\*:&E%A*>N-+!SB@FHV_ I
MB*+E1:A==A3F 1ZO&.QQ,08Y-)0PF1AA3_$AA3G>O8]C.5OOV&ZD)@5!+ZCP
M*";>:+L-7TW*T 8A)>7*ZF0;D H&F^($16 [6D(T"B^10/!HWTS4@[&..D-=
MKV9&Y;\>'D.B>U4QPWYTW:C;=$S3RVU,O3X]WHB%,S(;1D[]5V9WE73_BR<[
MGWRZQ-83:,L>D!^%PM [N[43 (\O#5>FG%)%FG]WE4786*7J"$,%!8]HO[KD
M57[%SPF5B+ AH_48* ,O^8L<U;4;33*@"6%G*SHSL2][0"&<XS'57WR#!KR3
M0CYC+UC?,:#&>(!O7D5BSY$ /_KZ359E/GT4A/YJ]"9!&KB;UAOV]]V1\F!
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MPLF%DB='FJ0"[^+5KO?IEF;\);S<D8>P%7>_+ODS5GZD,FTG#I5>E#'JRSW
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MQ\A(RO,SIV_9Z%5_1<\.:MJWY$ $.4>".;'\-*U UGOA"$FFCF/_19N:A7N
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M6PWAV2OO,SH1FR'Z=I&^%3D5(:IIGW1!FXQ\EDIG_6]0-OF\J7 )M-PLE 8
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M+4-ZF#N:9&G5]8O!C3)FU1%HBU*&-:SC!CE>6G:%';O)%,.IJ]AELQM6V+D
MOCZ%;2Y1QL)NS]K;2FY7B&5=30+1*S:S3^=J]:-<>9AELZM)!,&0WPC]6_C8
M56@7_#.ZW!C9)8ERULYTT*=,7S*6*HH-ZZ,R7DV&'2V"Z ";&9B\\Q\[?5U#
MZ3?+6@%B5V:60BYC[4O-8X><(X<, N= \8BWW*X[:K-[C5/P+DZ]=Z&;M0S'
M;Q,+D,D%^MCK8B>3TC[5%5<P?1W(F2!+2#Y7>D2G+ KN<PXL!\TICNIW'E..
MX6P6?(!>ZGP-^\$P.ETH1:N0EURU/[&13BYEZ5*XMK2C#&KSC)V"*WL6'[BV
M= MK$"M \S)_*#,BG?_AIE*R!?'UX\K,:="\+]^4WR:@U!CI<Q&@E*P?A"3C
M"E!67/Q'8@O%%]$O-W18)<2*5OCXW<F%39D;OEDLK:R7HSM4JDQ-:]@P5I;X
M]6M'AHS=6#JGL&:>0V<2!N#R:7/BC7VOQ)Z^$$W5VWB?B#(EO0V.M2KA2BVF
M_4('GWH_A:0XRJ(=S1U(*29,,BBFK[[4&'V[;<Z(I4[G6TLS_N;/3)6@\S+4
M >X;$IN-A*?QY#K4D8Y^@D=5-OH?JPSI;M_O#X@MK-&6>II4Z>D@_B".&=CK
M#533/WIB_Q 'N"W[LYV-"E+A_86>B0R59CW3EU 4[_R7-,<P>YB?0FVR,-MS
MT)-@G.@FZC C&X3#9Y(TC5CY(#D,! M-0I-\#I2:C3F.)M#DF1'KG"(,RECR
MF4?^LP]J; B<_5Q#8WGLO<$NNED$H:T^C\)"NX2<;,V[IU%0_5L;#"<L4,-%
M#HG)>*.^K@V;-!D(K8?T>;6Z-.CQ35\DALA #FB//YJ,8S*1D52[:L2C\<B,
M0KUSGD::G0$0N8C\370*)<UH!24-C]W'9]D:XKDA-B,TJM!XQ,D0'3EPC]8L
MYB?,/"H]9#VD]3BH>- J/C/K>!&9B54RB5E29#<9R7=$=JHX/P;(+((*;J@U
M4QI"\ITFP541YO,#6SR'I#[G::J$*8_,D]?X9*"2.G$Z-2&-,1CKDAHIC+7H
M_U/"/?\8>\MDHV$7H\9K]8E"FJQ)F.GPO9!&R]>QD\LH/S&6T#MY9S1#R2T_
MZPJLM$_ G_'&[_VTCBJF03R>#BF-M3_Q/(T> %G(].] L]SGLNH?)C;<7%7H
MX9+0AGZLJ1AXK20U7 EE#5.0HE)FAN+D#F&0P%4F0F!*@&FI'V_W](@%>USS
MZH3?]F18EFQ5.,TO1A^4JB12O":Q;I'C2/_CH-#FI;W2#E0AX>R*2O3;G^69
MK7>>F*YJ& ].;I9PY7C_N6!(B"-!0,.IVRI/6B:!,],C+U4^K"^5$MWY,Y^1
MI8A.Z,>OL,WW?<DL/_?@DT$ZC88NV,#/4Q$QWR=JH>6(/UYJ.,!<K:E?J3W;
M8W,=J^0)$06E L+247H<7VOA&WRMHHDN(^J\_>JK)M**B983MB1+4BW1W85U
M?]4+0\-B",^UV]/EUQKZDGIYIDKPM1I)Y;Y_F4JN1LXC+64K9NK"=#,3>=3E
M5W'F@GOMXI1-9\7#<;BB%?SJ7@H0Q*9E3!*XWT;/C'T@"+2WVH*>,L[BJV=<
M%=]?F,?Q/O69DOEY6XX97FVA?=OR8G7_U?<T3("S>O_B28/RN#'>1]X/&C/$
MS$I-;D!EAS)])R !3T>IG2I>%\L0N_^B!#-2VAR3]EU]^[9(T:2 ] <N^:W$
M2\$U4W<OK.];&.7@?/-L\=J982?O(<.X^]EYP<[//E13'S86.N<"<ESK-ZNV
MBGWY+32;WB9M3O5(]H28"&EK-R5M;H1T9E>6<%G#+3)TZ*(FQV30,P(;J5:>
MV.Q:#KS2#3MI%Y$6C?5Q0Y34<<G^BE))3'<2U2D5%-+Q6PO2VW\UU0>RG/,8
M5/5Q"S^UGBKZ4/OSX@+\L=Q2<]_8.*DE.O47:80E%SD)I#EEI4*B8^C-+4N^
MX;C/9+B7\J_"9Q%) B %'?TPF3]+1[49#J^5?Q+&"D$<!(8T4'^"$[/?YU"Y
M0LJ=8=>[YX*;_D^P7=J=EM7%LROX__? /.(6$G48H&_Z;&,"-,- ZRUA>3,=
MWX_"XF!EW^LP5K@8)Z?;:O'NBP3I5+?>?H1^VQ3.]#GH&&)SJ0H%8MGE)+*
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M_''5RA8_#VP7Z*R^<F*2>@"@DRQW50P1[,RVRTO+Z!(MH2=0;:%"LPBSXV
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M6,*L!Y\K' IF' .I5E\4*'NPN&;HO\.@, 6M*8-U*$<EH:,2X,E."4?R.(B
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M/.W']"R@;PA9X>^@<W\ 6$RD]Y4J;0SNFS0P0]&&K =*=&7=+ZR:PJQ'YD?
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M&D(T2CL"BFJ@D(C->' A_2-<SAL%0/DD\C*J0UY#67.9OS^ASP$1RV&"QB5
M"0!-93;0N!(F**%Z:D])DE@9E(LB%A\-B1E]A,]/I=GC!("J9 YVXB?L)15;
M"(XYE^PA+BK9+9,CKQ[HK@ZL7T40/&3P:TR)+(UHMI&QY:7:OFMH'[ G/#!N
MC" -X<JO.G$ *DX+?>=J%)WM%?>N_O-K'!%I;\2\F)?66_[XWTKD\KUV&U54
M6,)OJ$<\\3_HHT1D#8ZZ]0MNI8N^L&0=ZGG</T_4Y/PJL&_02C3U9%VAS/NR
M;*E?5KE#5J$/S:B4<44TJ%2%=Y*&;16?:-^4]R,=;)VRK<97+-+L&_2P'0NX
M>G)T&)6"1'9H7\0VK*W20_$WXS%C (P9G[7*N[BZ!_!8C60%M*CU6QP[C DT
M)G/:)F.$E[SI33O_^O= C5]DE2@+J2B5+M.&MI?XU);2DN'CX=^-U/A4EJ'0
MEY^IH7_F@1FZ&N$KQ*4VB0A(2)/#1^Y\HB^+_K;=?/TG#0??^EY$]G;RT])?
MR8!&CJ'\^V,QZ9M4L:]Q27%)3;]&U:5)\/X-*0TV-B@;P!/)?[7P & \<;RY
MBKZ9SOU?[_^IT"T[H6K^L_7)Y_LW3C(!'A*7RU../:4XU;240\+L?JF!3)H1
MII7RZ-7WF,YK6-2_[.\B?5AZ1P@";+VT'5<-1ZP4,YV\D#X(;45JA\B E#A]
MRC;<YO>M=$?VN<&70]A$BO>7^OM2[N? TX#V-B+_H _)LHD5U&/7:&)]?6?
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MA"=GFHU"EI,0\NR?_0@(7#48$]-+^+(KWJVLQ0E-QLGPJ5T9:=D-O'*.6>!
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MZ-'T!CTK5"SM(J91^ND.$^P)H/-II)-229*LXKQD%[H !;L4@V719.X;W7M
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M,5E4Q%<TM2NE4-]2P5;>YM/8)S+]SG9'*%LZL.B:HL=QFS\HGF@<I]5,A>J
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MSUFF*O" Y?& )NW=>\ XW75.[0-+:U0>\<]O^6?7COY/D'_BK^;_$,$1:6\
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M2.US2"NR!655OFIK HVK[R\K=T<,GSON.CM79WX()LD%R\G7T'&N$]JI<-9
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MYM[<R\>?'8M+&)1XD$?-\" _5ERY)<VUNOR!==B//2EK2:CM\[Z <3N*T0:
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MQFW^7P)F.A,7.O U_[_X!_K^S5N[&/#Y/%HO!!7TPNW5/Z(AT/(I%M1&S;@
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M 7Y]ET'UO?36O .\84'YT+'"-2YI]=L$2+=>P>7P;R>!/S%_^RB5^3Z ^;>
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M)A$6F.^W+&I?+2J'IU._3K011Q6[74"*/"1^N2-LY^FB2N]/0CW_%="WNO+
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MMVL=)T_)'DOB'.F5L![-6A'NM#-,=I/=L4YC<@+Z5GP[#-P5@IQI7:2V7,E
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M=KN=_'P'Z*C;]7F1O\T53S^793Z_]7,[2^G > [W]IF8QU7'FM&98X+#GP_
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MNA_43 'WVC7&?"&K0RQJH=VCL$?]C1I5C>5^PJMAT1L3>V9QGU_GHYTQF%'
M]!]H[AUQ>$<HOO63PGHX,NE# ?8A9X*T(D-!2:K>.LF3&3&$:Q"@ZX#5R)[0
M_;B&Q"M]C.SU:8(#K=ZGEVH1<U\VWLN_XR?/6OV!O6O\PJY90FP_QKG  *W:
MG)WJJNYP*ZH5J^Q<6>OH,8OG<\=87<1+G8;@4IQ/'L\<1[XIC36=Q//&W:.V
M*B!P!,?LTP5.FJ<*<3IAB&!.?R4%$5V;F%C3$7VEH\;^H!LGR?&\)]ZSH]^?
MK;:I25AK7I9[K27$N, NT\LG<C-!^P0H]O;RN7:@HV!I"Z25YCX<RK4/E$,J
MJ=%G3$TS-='PVOU<1R2BK6%@ZH1<:YT;>CE#GC;D=C/*;^JJNYR4?*TB#$H2
M2^--;?IY*95SKS ?_+V'S@G)MGQ&]SJMM*BLW#S3$I>2S;1W>J!9./I::\7"
MSD<G7:Z0BE$KP-;0&+'(A124&]K\5'JB$ @83S9DXB@HWV&2"B&@LC7KE1)I
M:PSBEQ=<EXW=-58[QU#VH^H2,XS.>RQ/-G0R )IJ]5@)ZY[?/J'R,]..&@@E
M/6*(02S= 43A.:^PU &=&.B99N#'&H7X0='>F5Q7,A!$2-CTY7@[X"C?^#W_
M@]L"*+1*F2L$^I%*!#LC3W+[#@!8C9=D/F_F?]_S/M]#D(TI:(.DKFD+0EJK
ME7.^KSBJE+^N>G\[7O$V*6%UB6QX]9-K$>Q[FJ>[R,G;3+O9=E%/KSH> MFB
MSI34T2BI>XI& ?YU:T88!\?-TU$_WZ227?$F4N"R7=7],"D=2R(1_?48["$5
M?NZ6G8'1.770#'VJ</;9SP_TW%@0?@U=N^W.NM)N[ST,UG[&!&0O&(5*<ZP3
MVKS+E$(KW\"T];HJ+$R;:N1U<]A1<M1^#:U<O@- 72]Q#M3F"&Z?@?]DT2=H
M4IJ 0BJ9(4\=Q+S-5EME/&NF+ :V;<*NKL6A>J_A14QIGO'RZZ3RX5#N.1_K
M?!->H%C07'T[NZ>+?%JW,!F!(YZ [!>%$K1AF"<T5,)Q50U'3[(@R\%=W$%\
MU5167 ?)$^UKF?O-(KU_D.]Q,2"KOZ7PF6U'[=;8S8"/+J1;O#1<BFZ6$:^W
M\LW7F6B=R?@/IZA<V7'#2.8@;:5\,<*U>:H4^/$=<3"T>5T'KJHVNXX&";@#
ML"\C7H4HG05JC.J>3X/O !^J?]VVI%X!E>X <2I9-\YJ-Y@ZB+D^V/AY_;;F
MG.:B/U_MD;'QMI<A^PA_$CTQ)O!,UO'3D.*S+A*SK2RH\>%3V3N  >*09#?K
M89[>+>U,_Q<<01D%J4\DZW< FNQ48Y)GH]V';-$$28I;Z&V.*_$2_O?&)R?R
M@BFT:;LS]/I6GI TDV0,8YQGK.A)\*T.F(<H@0V$4PB!W9(@I4XD:;/;>F6\
MYLN1;LUG/D>(;6-E7]6#.*1\J(6N>MTZA:?SPJ4?QT94C-C^G.5[?1N,/)/V
MYT:AV(0/QE75%G4Z?K!QJ97>DA\M*^-=4NN D"W&MU\/ JKEYKG6]L@E GCM
M8.=NF%.9.)6QKGP9^7'>R\?P1^?#Q88[[?Q7Q,X*!]U1-3@*"YY"&V/!5E$.
M^H:)B\DB,?>.],99A)M?$M5^0GR*JUF^)>GP6H52VS[5 ALPK2<?<B/N85/<
M:UM:D0MU-<8$<X:/?G7"C*6JHF\)E:D+HZ!OMMU,+G;#W+MQ?QPEW^=MN#['
MW6+CJ9$7_^!Y,__R,O7T+*70H:VW9/G.HQ>CI0?>YI;MSN>C*Q=EK6_.*I_U
M<^0/?VG% SSTAG2I6-HMW8_B"#'A:DDGQ?1M6KO0'+25:Q/2X^"-C0Y;0UQ'
M/H),:UV'.(-JSJZC/]X!3G[= 6IP]FY%Y3D7"</SWZZ8B^+P^^A0'. \,$-B
M'4.IZ#_Q)6N*?BY;T?!3GCVY [P7M_7#YX@Z+T8%-DR_5@P_L8PU+D7>/SRG
M/6' R@H*$#"R *[29R*"?"GN /$Q9L>.-YC3XZE##?.N^HWWAU,(28Z$N^:]
MULZ#+!BZZ-E#\?14I;;AQ6$+@*.Y-KPO^1:O%=WI6<^;^W_\,&*+W)=]4NX@
M'">?LVUL8GUV8 LVK)O KZCN+U/*#"-9[2#V)S4:+E(ILQYYH*F6JO#H'4?
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M_(V_\3?^QM_X&W_C;_R-O_$W_@-WL_\#4$L#!!0    ( .>#?U;!Z+E0*1,
M #>+   *    97@Q,"TS+FAT;>T]:U-C-[+?7>7_H$O-IDR5S<,,LQE@J6*
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M"%_?V* ZUJ]%U>78XAF8)G R J<[Q17@0,&S2.+E^#T;U%T*UL6N?D"ZV)&
M#QX$(#G("78GS91P4ESFT!@:$;V\US+O<"$=O@Z ?SV\2("B/"$@S]Q@%Q3>
MH7U,!D5=HSY9$ S%,X/Z%1C0@V6#NE8<4B)E"BS-#\ <T8."KW#(D<!0:% E
M:QKCS90K08=@*/*CXT.7[:#+J_F]PX5TAI:V7":2W2)+6S?9\'<D&]C+*IO
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MS^^)=):5*]49SP>VP3IGOA ,R#2M,T'2RUOMY:HQ[5:G$'K._,9BEBAY*0D
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MDI<N*<IQC8MWNAT"ED-5>.- U\%]I-S&3JG<QCG79E5>8Q'E-7;^<GF-5RF
M\6KG9//+Y<EOJ!!L_CSXY?SPOU!+ P04    " #G@W]6J@9%\, #  "K$
M"@   &5X,C,M,2YH=&WE6&V/VC@0_H[$?YA#NJJ5"&]1MRVD2$!"BYH%!-F>
M]J.3&/!=L+..TUWZZV],DB[+OO3V-NCN= @!&7MFGN>9B6UB??;.W7ZU8GUV
M!C9^@WY9WL1SG;[5S+YQM)D/6\.9?0E+[])U/M96@JLNM%NQ H]M:0)3>@T+
ML26\GAGJL*22K6KHB*[SY_KU8$ODFO$NX-1:WQK/IMYA#&-%MBS:=7\693\W
M8=]IEK36?\7]).Y931T06<[+P-<#16^402*V1H-DZTVID*TAOA<(U+G9,)\I
MZ)B-MM5$ZPE9!)0K*F_U>FD*0XDX3Y,;?*&4V#Z1NE0%1[/ITIEZU<IL#).I
M[<P=_)AZI<KX3W-<.)\F2\]9.':U,K\8NI,1#$:CV<74FTP_P7BR.#]UU_R>
M)HJM=N6US5,YRM/N-UJM!((G6!10 M2& N.!D+&01#'!P=^!I"LJ*0_TT'Z&
MI&N6J'Q"HHBB6_1/X/54-, T3:-S9GYXUP'"P_RR]?:=^09P]EC(+2R-]_5'
M@E0K!T'>FZW.H9=9WX=\V!/N.+;/#AW;(%:PH%Q\$XN;.DQXT- 6D4H,AE05
MA!@EA',B@PV8[7JUTFEU3 TRPC1\76BS8ISP@)'HD/;]V*^O-PP#Y;'I32QI
MDF!="(>47Z58SA7#=")F7',0_-'@U<I*R/WHCA()E(?H9]. ;GTJ-5) H)G2
M6+<H#;,LF#(BG"@A=Q 32=:2Q)L[;)+4QRQ<Z72A2'T%Q!>I.F+R2B97J>@A
M#.*SB*F==L5^P2@I!8*Y8"UT1+0%5')M0@B!9#[5B& J%(7V4_*]J1?(PZR_
M6 (#SE$DQ++7KZACNV5\J5;NJ_U7%&J4>^^??E_V!D/7@9'CNLOY8(2KV,=:
MJ[:_G@]LN[A^-H=K%JJ-GMKZM0<^"?Y82Y'RT A$)&07L&\5Q0$A0RJU,2)Q
M@DB+7[7]8<GR%L_/_(U*Q0(2%8L9[ABU_.AE>?:+F)19C6;2S$ -!U^<!7@3
MU[V$BV4=4/@?-?)L_;'XNV*\@/<)&^^%I,JN<)E,S[''%6$\ _.5T>LZC ;_
M"^9Z1\N0Y$NA^3#MYG[!Z?_[3RRG_QMS M#'<'\Q#!@S&H5=F),UKKA+>I7J
M(Q8Z]& 6ZZ--T@67) H,HV@E>_*U0'-TRC[3'/)5N[ -(US>H=UXBU(D(F(A
MPKC=50YWD>-=)L_QZ"YPM(W<9WM[#SUP9]P5.Z*KO<>/N^3.NEX4NVC5HDVM
M)FI1R'(@9E.KF2GVGVF*HS\,3?VP(7OZH!]2_ E02P,$%     @ YX-_5GN(
M&>-K"    $(   H   !E>#,Q+3$N:'1M[9SO;^(X&L??5^K_X$/:52N% NUT
M5T?92E#2'71LJ2 ][;PTB0.^&IN)$RCWU]_SV %2AFX;AIER.ZG4'R2._?BQ
MGT^^CYVT\='[HWM]?-3XZ#;;\)O@5\/K>%WWNE&QO^%L)3W=:/7:G\C ^]1U
M?RN%2L9U4JM.8^+Q"=/DCLU)7TVH=.P!APQ8Q,,27 B7WN>][HI,:#3BLDZP
MZ.J[=-VX[=UYV=K*(9UPL:B_5I\IJ_E_F6V^=/VS'.KI5:."%4)_[_=KZ16)
MV5-<IH*/X%3$1^-XG\8W6M?NTY@/>7Q\=%$[JS4JK>OOTY7_)#KFX>* 1Z(<
MJZGIPNK 4,6QFJ3'LIWQF8Q9M.>!N7'[7N>V<]/T.KV[XZ/[A_[@H0G5>[V]
MCM)[=[/_T'4'QT>U"UJN?3BAIZ1YUR:URR#]]'#7=OO$^^B2@7OST.]X'7=
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M$=E&_<:$K.!_<+#_T@'_\\/_ %!+ P04    " #G@W]6_R>R5TT(  !-0P
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MI!$("F (AEPQ0UQ\5@!67(D9&0,"D(O(2R&6+,O(H%_8"6R-.%I1P1*I@ (
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MT)O.8]_A[3$?;7:3U/#C,-SG8^#':/P%4$L#!!0    ( .>#?U84L$1:7P0
M /$7   *    97@S,BTQ+FAT;>U8;6_:2!#^CL1_F")=E$B\T_1:<)$,F,8J
M!82=JOFXV&O8.[-VUTL2[M??K-\""5*/!JI+%80PWI?99V;G>3Q>[<K^,NH6
M"]J5H0_P"NJCV:8],KI:+;EB;RWMUGJ3P0U8]LW(^%CR B[;T*B'$FRVHA&,
MZ1W,@A7AY:2A#!85S"OA1)PZ/71>!U9$+!AO@QI:[X"D][)"?+; )L$62UGJ
M:L/)V-XV7/'(BOF;]H],QV,C]@]-D*"E7O>,SZ.PH]5ZZ+JRBY?I2\%NW"_9
MG,EBH=6L-D[OPE_K2#)O<TPGLNB?$K9#N:3BR*'O&S/;')I]W38GXV)A,H3I
MS!SWS:D^ N.;T;^VS:\&3(8XQ)C!]'IF7>NXNCTY_3:=Q-_&^V+ANFI5^U6P
MC+YR&AJMRWKYA;JC6\6"/IA,;6.PO3FY;Q_J[W#SP+XRP-)G/7UL6)7)MY%Q
M WK?5CW->KWY(AF7 LZ(]US8%1F$,?2\81Y(&:QVVWSJR;1ECWMI(^,N58O7
MJY>,']-EDQ<+3L Y=20+.-PQN02YI*!SOB8^S&@8" F!A_]X<!O,[LM@<J<*
MYVK0F>]^7P>=?K *"=^<B?CN M#.,! K7*'R&5<4L<$-)0(HNN'"@#IT-:<"
M6HTR)DNS"20J%CSF8U\.P*+.6C#)T!O"73#NG27A"PJXV(I%D0*+7S72)9+"
MD@J**+=A)=@S5(@['C3?(&N$"FT9PK6(UH1+D $TWD/"X6+!2H,1DQBQ 7&#
M4"*X[?'9(,4&7#B&3,2<<!I5)O<^W8#NQ(%3;"AC/Y'M%T>(_8\@6^^-#.@;
MH]%4'PS,\:>/I7HIOK>F>C^[/]BU.^;*I1I:_^,1@Y[R!YVT9X<O<:MVWB%^
M%C(TKXHQS1[\--R,D35[T#V&G:/MW7GC(M^XG\5VXO2RES2ML/_C)Y4C;^W[
M2&.4'5_I0ZX9@GY?,T%7*)61HEZ4$_F<H"P):%R>NQ<Y71\4)E.7P]"D!&]\
M:+WM*)':"7?-GJD?1957LK^2_=1D;_Y^9&<<:X<5B1F,)8HDC.,SF"4/_4P)
M"!,H!:&@D2)]6743W\<4PKJ880&#'2&J0%2.9WF,$^Y@^V%(<'67Q3A4*8(F
MUWXB,$%(10PPRD0EK86JOZ46_.]A/TN\YH%PJ:@X@>^3,$*;V;]DH8-U+1&;
M7+CVR-%N/-2+0"D^<MJB;VKO4ID;8%*WBX4O1#C+K'9NQ1FV?U(+Y_0V[7TC
M4E\SB>WYQ/D;&M5+=# *?.;FCKS]$XUH9K<6U<!:DC6'615Z9$&85C.WTOL9
MKN;)]@!S7]/CU7_=R@]YGV=SJ=M?,NIAX8!%A&2W%":>Q_#%0J7>#K97VO]Z
MVK^I5&#(J.^V84H6R%\+"T/*'36A Y,P5NPVC$@DH5))3WFU@?EU=Y]S>KQ3
M+^<_HHRJ4HXD-SO%T5-O#T[WI]*0Z--6KN\\H[0:QB(+RU8P:RJ:2<1>4%H\
M.LZIJ2/[Y Q?'?7_"U!+ P04    " #G@W]6%VD.H$P$   K%@  "@   &5X
M,S(M,BYH=&WM6&UOXD80_H[$?Y@B-4HDC'FY7._ AV3 -&X)1M@Y73XN]CIL
M:]:^]7()_?6=]0L'3:0K*5QU45 48%]FGIF=Y_&PQI5W/>E7*\:598[P'=3+
M\&QO8O4-/7_'6;V8-@;.Z!9<[W9B?:B%,9==:#43"1Y;T12F]![F\8KP>CY0
M!Y<*%M9P(VZ=';JO!RLB[ACO@EK:K/6-L3/U=JUH(5FQ:-/]EIUL;<K^HKG;
M6O^,+]*D9^C*(,8Y.P["'DCZ(#42L3L<$NQN*8\)VACTK8<E6S!9K73:C;:A
M#_JG#>&/=2I9N/G1,N]3+JDX<NJ'UMRSQ_;0]&QG6JTX8YC-[>G0GID3L#Y9
MPQO/_FB!,\8EUAQF-W/WQD3OGG/Z8SI)O*UWU<I-PVT,&^!:0Q4TM#J7S?H/
M&H[I5BOFR)EYUFCW<+:QO6^^Q<,#[\H"UYP/S*GE:LZGB74+YM!3,^UF\Y5Q
M"%N3<9)!WPXL8BGCU?Y81$-9C#P17C'(>$"5\V;CDO%CAFSS:L6/.:>^9#&'
M>R:7()<43,[7)((Y36(A(0[Q$X^_Q/.'.MC<;\"Y6G06!9_7<6\8KQ+"-V<B
M^W8!:&<<BQ5ZT'Y'CR(SN*%$ ,4P AA1GZX65$"G5<=B:;>!I-5*R"*<VP)P
MJ;\63#*,AO  K =_2?@=!72V8FFJP.*?6AD026%)!464N[!R["4JQ)TM6FR0
M-4*EM@[)6J1KPB7(&%KO(.=PM>(6R<A(C-B !'$B$=SN^G*18@,ZSB 3L2"<
MIIKS$-$-F'Z6.,6&.LX3V7TAA/#,P<2"H369S,S1R)[^^J'6K&7?W9DY++\7
M_N]9()?*7O/GW,$S&/28/QBD-S\\>U_4R?LD*E.&YE7+97BCPVT5@96,U+U1
M_QAVCG9VYZV+[<$]%]N)R\M;TJ*/_I>O0H["=10AC5%V(J4/6\T0]/.:";I"
MJ4P5]=(MD<\)RI* UN5Y<+&EZU>%*=7E,#0%P5OO.V]Z2J3VTJU[<_5/4>65
M[*]D/S79VR^/[(QC[[ B&8.Q19&$<7P&L_RA7RH!80*E(!$T5:2OJVD215A"
MV!<S;&!P(D$52.O9KI!QPGT</PP)>@]8AD.U(FAR'>4"$R=49 #34E2*7JCQ
MOVA!R> 3MQ?/DH9%+ (J-#^.(I*D6!7EIT.$8D=?<BIO9>$)LN_#5VUV+;NV
MV2%'8>]2F1MAR72KE6LB_&79F7:R\WMZ4P?W##;=IU84L98"-HB(_R>T&I<8
M8!I'+-@&\N87-&+8?3W5X3>B0K]N@+F,J$@-W=ZIGO\0Z[8JON)\:NB1^^_G
M>KAD-(1QR4UPPI!AC[X'X>6QYR=-PYAI%'1A1NZ0!BYV+Y3[2C![X"29K'1A
M0E()FE9<.!HC^V.)ZQ^/R;?J%^2W*D\]2H_$VD?/^OU[A(-KYC'#<IKO%,R>
MD!HZYJ),RTXR=97-/&/?K59T==F;W_ZJ2^*_ 5!+ P04    " #G@W]62PYD
M%A5F P"Q-QT #    &9O<FTQ,"UK+FAT;>R]^5/;V+8H_/.CBO]!E_OZ%M1G
M$]L,"22=5PZ8Q-T)<,!)GSZO7J5D:]M61Y;<VA+@_NN_M=8>M"4/V$0&&]3W
MU@FVI3VN>7SW?^X&GG7#0NX&_J];U=W*EL7\3N"X?N_7K3CJEM]L_9_WFQOO
M^A$\!\_Z_->M?A0-CU^]NKV]W;W=VPW"WJOJT='1JSM\9DL\='PW\;E:I5)]
M]>\OGZ\[?3:PRZ[/(]OO,/V2Y_H_IH^/O^I'VZ'GIA[%;]0D>Z_&AH9?G>0%
M\^'#5^+'U*/1Q$</Q*.1>M3EP7ZM^GK6.L03^H6[:<]6<<VP0_;O#U>?D\>C
MR<\GC[Z*0MOGW2 <V!'<(8YT4*[4RK5#8Y R9YW40/!YMQ?<W#O.F_)>58TS
M=CGIG>+/;9OK$W=8YKC5G/ #O%&KJ0=#UITZ[.$K^%4]&/-RS[:'^N&NS=OT
MH/PA-:K\KLSCX=!C ^9'4]_#9^C=O_?4VSR,9KXI?\^\!>.%@<?XQ)GHE]02
MG2@L1Z,AXY.W#S^_PI_QG4JY4BW7]%5T@MB/PM'D\Y4_IJ:"]4[<1.JAJ_-_
MM_13(?.#FR"\V^T$ WJJ6@-0(%+ ; ?^M?"_=Y$;>>S]NU?B7_AUP"+;PC'*
M[._8O?EUZR3P(SC#<@NVLF5UQ*=?MR)V%[T2%.,5OO=*#OONO\IEZ\QEGG-L
M7;/HK75N#]BQ=>?<O;6:I_3']TKMP_>OU[_43C_6ZY?P#R[/*I?G?7OO\#MN
M];NYQ>]JBPN,L_^&WJI4*]6'O'YP]IT!+L#ZX?\;/IS@Z 2.)K2]IN^PN]_9
MZ'L%Z.7!Z_W*T?XBXQX9X]8!?AV$X3//[GWOVAYGBPQ5-X8Z#3HQC>3RCNU=
MLM -G#/XCG\_^W.!,0_Q[DZ_5[]+TB@&AZ\6&:/V_;IOAXQ_KWTG3B &X?3=
M(N.<XEHNY5A[8TOZN<&/OE_&(?N^;XXRA&_D&.W &>&_CGMC\6CDL5^W')</
M/7MT;/F!SPC9W+MC1 P6(L;1)]=QF$_XAQ_AP7.XE=#M"-2ZBZZ0G)Z%P0!!
M$LE&I1H%]'>U1M3<A[7"5,P]G@AT6^\3J'OW*C5%/K.F0'+K/<'D4B::"K!;
M[\_^G#'C66AWD ?*H227./YBAS^ N+4]=LTZ<>A&+N,G<0A4)-I*K:[.+[JP
MHJI:D>O\N@4047,1#D"(.-JR8M\5SP*0 ?GEQ[[K 4T,8[AUM3*UC#F6]ID!
MX^T'GM,<#,/@AI@6_Q@&G$]<66W*R@Y?Y[ZRDV P<"-:3]UWD!> 9 D2)IS=
M0DM[\R;WI5V":,'@^ISK*.C\^&9[,5MH24?[3[:D::!U=)#[DNH=0*+8LR/F
M7$1]%L*%#D/69SYW;U@35(4!^PQP=LZBBV[+OEMDN=6]P]R7^]$&R1\7Q/B%
MW[A#:(M=WD< O.B>LG8&56<1DLQB#_.'P%D'VB)Q'!0S7.(GX#2MX(L=(=D9
MM8+ZC>UZ2(G.@O#:-@G2Y'N0VZR*;<ZXD3?5W#=)H(RT"?;2 )$P&DV$D8I8
MT7?YVO<K(+6@FC@-._3A$OD7-FBS<&S!.4(\RH1BM4W.8^:<PI'Z/<$V"!6!
M>DE-^:(K_HY<N(,TTK8")'F!3Q_FNP6]9^/-R=NM5?*C.4^_W?FNN%;)CTH\
M_9[G(*?3CB%_YOR DT@HS8(;3Q^AV*,!^%..>LI95/-GO8]Y%O?C>35_1OZ8
M&YP3LZOK#=(/Q^5J?K($D;2Z\U?,A90-PH'CN/@ J#RVZS3]$WOH1K9WQ3J>
MS;G;=3MDX4-Q*'1OX.\;]MFUVZX'K/GK,/"G'--Y$#TMTM?V7L:AW4\=:CE+
M :MZ$G.2D5K. L*J'L?#Z4WM<0GM.;NE7YZ47.Q5UF+/]V/[WI)TLIPW,B>R
M[N5'Q9>YFX?CVMXCJFA_V&%H YEJW+&PXW+F/"7"[><'ITO?^/U8MU];G]W,
MB7K[:P29#\>__4>T"%TQY.V,'KD> LM_4HYWD!_'6_[.[\? @T>D)S^]G2EB
MXK2M/2)Q^>FMS4E=#G)6SY9[70\F+P>/2$0?NLWQ13^N.8E^NQCB6ZLAFBS!
MY;KL_=]/'P\?5\')8U-SDI+#_,CC8^WLX03E,'^%:!X#!L6\8+R>@TN%=9(9
MXPJ#MK@;L6L6WK@=)D[IBG6"GD^C3/!)/RXJ+\$-NV+'-0?FYT_.5NP,YB04
MK_,WC:S803R<KKS.GXB>LR@)4'A*(O Z?WGF9_9V/\:^SC_2Y6<6O)BV\CI_
MZ_'/+'Y>VI _HY@SE&6IH/]F2;+1XMN:\Q[>+$'WH%#<BSC"' ],57F":S!9
ML%C/,P&PHR49Z)<&8$?YT]:G!["]2F5I /;3:E!-T^;:4H_@<:-\\MC_O9+
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MN;:O_SK0$-.\O'@F$!&WN>NX=CC")AP3I4:]UZ?VG+PQRG[,ZSFA:UNJ,E2
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MKVX5^+B^^)A5N0I\7'^UJ\#']<#' M<*D'YF(#V/"O828'IE]:L"P)>OTQ0
M_H0*2P'@RU<2"@!_0@V@ /"< /QE &\!(P]H %($:ZVWE%MX]-:LP<H">%@$
M:ZV/,%[@X?/%PR)8:WUTA@(/GP<>%CA6@/(S >7"4[#B.E0!X,O770H +SP%
MSPK "T_!"DG]!8#G!. O W@+&)D#1BKERIY1-N0\B-AE#(AN<U;OA8R.Y'E
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MA9Q9Y#U]Q![KTAO9,I,"PK(%Y)6K5#4-&SN6D-D_RFT&E I6,Z2S-*UPAUF
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M(67_ ED +)VJKF?\  O2@M#RW!_,<_M!X @7@IZZ"VOT>S(K2"Z#FVDO(N!
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MF R5/1\$"=MQ>P/*8$6[78C&>CL2MM0+$,4'+N>2C:.D[*%ZCP8Q$))B*2.
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MLTKRR8]LT/I2L@36!H.VZ^O!>VS0 ?T!OA+H@!@BTCO,50DH4<.=V%%?@*B
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M.<!%>1)1 :0VT('&)19$V$CF7M&ZRID &=O2./6Y?GDBS5,[:'OTO.!66/1
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M6HUCZP.V*D551^JA4W<",-S1G7^<0+I+17CJ/I+M R'+RH!V:0X32X 1>W[
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MMDH117912!!ZVW<FAI^H6).2CIS#4R"_M=ZB#E&1^0D4/@?C2Q>O')^._J\
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M1W<W-S"L6$_-*$,9^$8?F%#'Q4QX=.;"%$A'..N)C$I)+F]L+M+[@&L!AH\
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M]5ZQR"^4V0MT61=U07&V14KL-VG.<*.1H-X7D_KX9'*VI%H]IS!+1@9<1\J
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M)*U[LV4#M<G93I+/D_T+9+-^BT$T!GI1PS2LMD1)6Q:]Q_PO8[RZJEUQZ=F
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M&.!)!8RJ!1C!J @7 P6%A3TF35J:24PL8'3SVPXYUB97D]J>W7ET1X%#G_+
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M7AS3N/5]K.PL=@7V=3=ZA]F.YS*N"NWJP@A?KX4I1[(]C-<-X@@S@;/$LCZ
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M'8\%U*-%Q0QT8.*^VZ;^B>3?8W?TD5--$>EPQ48,;C2BX@B4BJ\3W$:^K.X
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M13?HC.,94@)C$11$?ZE-A+FNLRT9B%V2 'P SK^0*,BC\&$4/\(TV@1%#/9
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M)2M>OH]VB/-KE\4/HP7 #6;DS2PU=R&L.!+"VWI0DO_[>@9OXXWT[\(&V2O
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M31(A;KFBI37/8O8#?&;D&]?'93HMR/NO<' RP2_R6DAA+:(\@?/*(4>A.M=
M;KL9K]U'%Z9<F,Z_\N:XAOYNHK*>X8SR7Z?$"I!<U['Q*N*P:<;U-F&:_418
M@9!_0:=PXM(&\651&A;V[T'X><^M'71$@[ :$WVV)*^JY3]?G:Y?"E:L31R\
MP!44.BYCOV7B9GA\C]3B>AE^-J6:[:3E;M(EY&W3*\B2[8KVST@(=$MZ,YZ5
M0/GFE5CRS8U7=(683,'KHB2?]&E<X@TN</G3E[WH'UZY!Y:(3"KJGM<0/Q\M
MJTJ3?TR?[">@_9MQM(,O&T/+UM*2D:N)Y"!>^,_%H[>AUO\N)9%R)OS2[^2K
MC*_[W[-W6UUVTL.3J8(7.6Z4#C9JFXDC+-:Y,&W3SV@T7 ?8W#C:>;0[?/3\
M^4E7HX"K&'4JYD2WT<?S7^M7\(?XZMF[+0SD%9E)0*RZGLQQC(1DR8$1+%TN
M*3 33'J/!9YB>2X)E1+[;/8AZ"%143,DS7@=)C?"Z2D,6=Z4&:R\>;6X=%PE
M'@LWE\=,DN?-:%$PM*D_W$5"!&]["7T=","IF#.MPN0*!0%R0[+(/X5IEK1N
M)LX!?W\PQ,&^N*CT+>.(H^<S89H74-5&"T>(;?0HG@>'<T4?"D:O9[">.C1'
M'S"CR2BN,'TNRHHN"[065;5"ASDB^+U,DE+EA;PUKJFYS0TZKO.$CO^V/KWJ
MO&YN(#BG=\WY>;9TY%7E9BW2!K;+3)8]+2GR%>>:@8 -I!!0LJ;T;@0"9G:P
M_86F2F#KZJ:.J>,W-\)]0M:.GC6E5_JT&)/Q>UK22ZTN8"+R,3G-571*_FJZ
M0-FZ\_3LE(S,VD? 0&B3!W;,/A./7;=(A8SD,@/Z(5Z.4Y.G-4^]S.ESQ9*%
M7?3O^ECZF&D2%K+T@5>,NS6<[GOMPFS01YB00PU^'$T<V1\GZZ<VR(HC4SN7
MC,2_](@*UH!$%V%1K+I8+L;%E2TGU\H1HC(B"[]4U8Z1DM!;F0\YB>3JYQSS
ME"GN*.V2,O89S=0U1V;KGP4/7*UYHLV-ID>RT1L?,?1-_M#D6B$:S;>1B!6#
M]:HS<313E*"-W9+)1)V#V:HS&9KF<9+%UY6 -F1^VP6^*BTU+J2^<,4E""-@
MP^7]0BL:)@.=<)\N+""6"[[A8T_"R6^MRMI)I^,@S:5B_/[T1?)N^VU\$KTE
MER6)3D]/R96@]=Z-+HIJ3E.;26S/;CKF52%6P<Q3P)_0@<&NX.EOC+;0I$&2
MEECZ<_%43;)&?2'Z' O&K_1;U!P\DS/WE%>X(#JFC5MQH8##%.<J5<EBP3F&
MJX1WLW'F)?1HV/]BU<IIG&LR6^HK_C,Z/ZW+I58X?AJKCXKM>3SZ$+.@4<,#
M"-02E3;C;I.=]*_-(FAB>C<WUKX2I7Y<\[ V"R!%W9&\0@V+6+K)#+EV<_N]
M&P!IDL#C8=IR2';=V"O38KENR#^\ )0NGW&"ST5?;?*AV?-QBF%A5*XUR$LY
M)4K-\T53.[DF;M>X#O$44IZ^M!B9,39#QD<G][\7_;+^@UW)A7!=D[<\I%S9
MJ6JZ:HI9,,<8ZR'2))5I!4PV6Y=T-B^JQ'N2P"5;SK6L: %L/M(-$Y-L*S!V
ME%%4SEX^YYBU>KJ"AC.;O^N*F%UQ:2B@,':,OCLKQ,+-R<1+EI8>#!43/H\!
MB4W/EVK":!PKN?=:@L-Z@S2WZK?2^^/01"-L3SIRW6MB,!,F/I@C^'?B5/$9
M\GM<<CWV)5E#5L.; /S2C4;I)07Z@&.1]YDRZ#"A_Y4L=K6LYJ9X7AIW#4:M
M:=JMCUN2R4W_K3ZXK_Z&Y'C,'U@4<'/]RT_\0+\03LQQ&2,7(75[K8^:<U/?
M4VM#5VRHI,DV-Q09\<ZMEN?Y95H6; %:D]J(-3'Z9<:4&2Q[Y23N:ANWZQ.Z
M^EG=93Y65/@OSTZ.E9=ZP99-F'68>L[:X<I#T=.&K1JRK-Q#X@#NMD5 2E02
M3LZ2.&>(>2H9C@(NB4F^Q/(4'N[=/8_]92]Z'G-<JC]S+K?QGE$X2@ES/0MD
MHY$FA =J-*H:$HXGG?C)T3&9I_&2JUR;&TDPL.C*A,[>(,8IA9^E=\1AW<_)
MV;KB2!/'(3UO<B5#<I^6$K_DP-6%Y!/ON'&R-S>LYYA6@8Q<K%?RL-,<9--Y
M,4,]S3_EI&\ :\([KV1X.E)W2,?\'E$6"&JC_'+D"G+]63&6#@WUQ&55I)5D
M+;BB4/M,@/.1S\T***?.@.KF&J[3%M;OB,/N/>GFAMLI7'2FKZI95TU57C!\
M*TW]KADRO4_4["I54XW)H:;S>HD7B:QRDIN?Y5#VX<OT6F+YBHX,1Z""+;5@
M;EXSG=%D,P3L+. R'+D)HPDQ_WSQY>*B /"1T<CI0B^7D:M06 U9&H)_Y2[#
MGAW22 <B*Z0R+Y<W%&(^%*A1%?7GRGL@7E"UZ],AG$SEZ?'>S7(Q8[6["_!/
M\ZZNY^E("L5NPH#%7Y[/.'UI%X;%;]4&X3U*E:">G!CT]>I;@MHBM'6G%[:9
MAE%K#F2.(>I6ENPLHRZA&JR( AF8WL2;$P$-\1OL12>K^]) 4BW&*UC5NMZ
M?AA=4"!;S;Q5%[.W0LXFS:A7):@B9&&'_2>XW'8F!0=S6_[3X(GSX=H#=>5
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MMQUU=]%1=]AVU+5G1GMF?(TS0VLBMSXSN"?<X#8H<+"'@%9."J:RJ"S!A?M
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M9W%8!,\<=+U J1XTFJ)/(B0Q?D;#6[]^<N$7SXXXOPO6I2BU6WZNFM@!#8O
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M1+5N&P)U28PF6#+1$6#JV'(]$),=\:"(H,[5*DZ&;&)XFE+9[H[<DL9T38#
MJ&2S98-Q4&0J; OI:I*3FBID:>K.($)Z ,EU@X=+%7#:Z_LX.I[@DK+,C; 6
MV=U'%\VH-;H B:9$,>1,,$U\>->D9"2><9WZ.?+:4O;0C@I1FNI+)N,?O[$>
M@/U_ML#^/P3L_]D"^_\EV?-7Q(^<R!JDT<-6+3SC4R7M5 R]DH:QA>="?P+)
M\U]#+NFUN</@M0M6ZLW7KQ54"3OA/.GQ*)S#3-?J<N(K[315L!4ZD(I\% :;
M%F%4Q-.P&W;.H5;_<M)C%KULA,#<;ZYC0!KA8+$YV>&O&O$\Z1E6*A9,2-S[
MSO%HO<=DZK.)0AK;X,0/B@T3Y H/M9$A!S/O;[CX+E/FAF!1PN6I_=_B_&_J
MN[)M:IK;I10PB_)QM A2G8LT8R5@$S2IJQ&+YGTA64.!2CL#D;-WP_S=^G4?
MZ$:GP8NE1BKWS-,D='FE7%;C_98D1\HT>>?O-T]7^8/4)H%:X5S5-2=TDW",
MN1$L-T8A'67T)7*CZ\:^IYAT$8,"&=46WH+/T#G)23=%V.W4L"3@;+P:"HL$
M<UY,=(::D8J+\[/YH9&GULNR*SAA&</+DN02?_; X1K_DS7'42"FX+](XT"^
MER=6=W]6OF&D\KM9\=,1$!$Q[RW5281]U%.@;5"RG@F9)PSTG714<)$I2K%3
M'J^^Z92:B^-::F\>@]YC4_*:4J=TF7WPC>49Z3@K=]=#"%#AX=_1NT<K$"4Y
MYN?QRA<HH]!1#?8!_;CY_7("S*F1HUJ/IQ$L9V[I9B0T*JA*R32-JAS'[DMO
MH2ZH=P0U)<=SY)5I5*^V-EU[9$TO+^C^XPC?D8&,3,"TW!+3),Z*H/Z=N>RU
M3W9RFF3FR5B]2W6>*(7:S>6X"1C'RN7<XF*!CXF+Q61!"!Z+]7+DGBS IX0Y
M?XI2$G\.'M-R[IYTS+7 /HV_G64?>9,S->>XLEVY^C2C#S9+>N&UL5>.ZK'.
MK#NE$%?P1TJ9,M!K$2,X),X[&^2=LF9<)Z<@VNNB ZZ([:G?D0"Q#F;".?UQ
M/71ES70Y+,JXYOX)PYPI128UP8739F>,$LSN'3Y]6^XA=L<(6*.-4OKC3'F,
M4%<KB [3:9<X'BFD>WR"S"XEQ]<1;)'DLBC.H#E!*VIF'$N(/"2_+V5NFBB9
M84+-/GE7KM]=Y^MW63B'\H'A#?DU<(;;8!W!;U/NPB)!=C><:7?Y^B QU7IH
MD6A%0B[,4%CM+7/D(>X9ERN<@J*(Z=@!J=1&G:O#X8I;E,RV*^J&BXS;+I<5
M/Y_JT9#R:"N%NMG$E)CS$<.[JVL4]4U^8XG#LETY7 ,RZ3=\&-$-N5TCC.P:
MZ#BN*5NI^L",3?JB\.7POGG8<9W# 7*TD,B.$JEDQHMW>N197MH]POS;3UD*
ML]-9;GK9N_!X5)CF0S6LU)NFY1T@SM! 9=MJ)V5/V*)!14O(U4ZFMR]N0(/=
M0,"*1+P2J$Z8G^M*NV\SI414(B[.MY9[ =/5;@%KG)V^>\:]2+P<C %'<\MA
M/%.\U*E\0;;@/\06X%@> %?G[N%NWBDF3I_P+^FBI+K[=H >+J7EV0?.#PP:
M:%"4D=YV!F*S)[4;:EDH<-:I"DE%*-" AC^'!86(,B-XV?HV9]>:1.JDM+8I
M6KDJ&VGH_DI:1[Y2\!>X6@_J5-Z5?M64Q$.$UH>6V]'488=#RBVY3/%(':C\
MKW*31:2(3"3Y\S@V@N&8690<>+P@&N8-KOR2_JH)L!>@[=N)7@.]'@"_>Q73
MTHA-7YHTY879%6-!D5/'CJ^((]2-!DK$^H5D$?,"A*T:KD!OL"HV-]9IH)=T
MRF4VBO!= <M 35EUB*75!KT39O@2)<(BMLD9&ZZP48$SE_[A3]CKHK^'VF/B
M:B3HP]9(\BDLN>4.KDVL/U&Y3U]_:_[!CHHV &0$Z]:FJYH\?+DB_4A 73*C
MW->BY>%5/>RNR7\E>VZX')8*L**TU^DBR;/P%-=T9I"F0L&MS0IZB1Y(/'?8
MYL4@(JZQY,+*9\55W-$0DOM"[0.J8G68YO#"Y<C>TV$6VVTT7/=[,I$/X;WI
MU>[B'+,\%:$U*?.PD2-L!KR\;L-#A;W'97>*8!&_ LBY/41I#GD<+,3X,(L-
M3VVX$%_/'N?>?8/?,5:R43/"W_T6'W_)'X=%,NX(.*=CRX)E&D\ @4 QZP2%
MP_F XCK[1/)7[I]U Q-9 OA^6BJ8!@ PCO%6N_R=XBK2NY![:#<@THE@JO3*
MPH;B[[T/%ESLE)'YR729HZG.!*M]'(E/++G311"='A:<MX\'AHL''G=QM,Y)
M&YI9M'@?D":4\4_D+4LSAESK.X*$!!?TN_5ML1FJXHHIZM/8<.)"Q[@NZDBK
M40+1NPC-=U+DP!D]YR00:UUPHZ&ZNJUR=O?,_^?ZSD%<09YRC@KD)(XMA,$X
MDS-P7P"#$BOZ;J[(P(382N=^Y:=^E:;@H-$BA$XP.C9,#A[@1[#DLJ0LPS$7
M-G"S8XRAU'L(1[[N76<8^\;V.<YX$R)17ZV]=?-2!%L70A7?TFQ]RTX[6^RU
MW\BQBFX8+!:E0E.CGM<36T!X>(W/)< @]T.]#SY43CN'3,_!?D<2\##>03X%
M7"H1%3+],-0?\.A5J74J6TMV0V^+1-@8U%H:[=.C85G*73J':,7!DR@-/O0@
ML)I';*!0 ? .HC.P+R2TT/49U]4F\1/+C=M8'*7HJ\_0GD?0<T)6B".'F@7<
M(:YV5([D+%C(Y>P;GWV221PYP]!STDPVI'+-I(T2',;<A2V+]Q_,5]&3AVBA
M<"2^$'V#V8@(V&2K$R#\6;F##9EGYU2AY&6KI(F1A6CXKDL:0Y3SH.LU>D4Y
M"CNI?)!]H9_#.7%Y497O"O:GR=8RU(*!0.ZRC?CMN3;$XE\NVAG%0GS2YQ[V
MI #FJ-(9LWWQC9@G8J]&94)&J3Y._ZY>40V#"63"6:#6@>[P(BULFRSZ%[^#
M%_"G5V]>O)B^H6#<SPA:BQ_A;TLLV??@X.(UQ'^B>>K"&;HK&/^HRRF)(T6$
M6;<Z-#0D@W=]@"H05_!@: C\21<9T+".J*CN6-I5'*;8=D#6O01H#!#5NCC(
M;VFYAW_?UR:S'NVI,CZ#%_?T0$M0+]7")V_GFY'L0S/$5O1(_UFEIS.QCW'Q
M+(C)DP@;6;ET-$K8+UO#MD24 /P^\O31]'\37E=8$@S-?JGU2/F>9A3^].K[
M;U[^R;9IV3IT;XCK5>4W;<7K#.OGLG(4'*M+,I=IS>2W+!#.=_3N)&&0PVV"
MP<(*-SKH-7EOY' @K$#RT;G(XSR]<J)+R"J,GK&52\_D%'<>O+$V!/R9TA]N
MRHX ^U+ABSJ5=,:K6C8LH3S2$3(;[I,S9G5)J5!?<\=)6)UL^*4AB+T9!,7
M;A]2Z=E<'MVWQ/OAK1X<G9<+&*M-,$&!H.A5F7.4L!@A#:QEC3!XP?;AESK@
M\>0]-+HK68XTA43KR$FNU:E,-+]F22/PHJ1VRYN<F !T[:SBTIE;*4+92KU(
MFG/G8%96Z8TZD@69_:8-IM7(X@"KUSDYK+0!'D,.XUB[/@S.F'/B\F_6Z^FR
MU="7$K@6JE[I&4B68&5U$P!L=#@&@39V(JAH.HD :1=#"RXBER2TEW&..),
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M$6K12@K#2M=/E_*Z'A0@M52L*"JLK1[<>+6RT2@01,JR3&V 9%KX(2YX-+N
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MLQ_?ODS+'#MEKQH@/"0=<3D2[,KD)P$15_J)F,$FC9XT4_,5QL5)&QF\M/.
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M/0J6CW2W5H@6!15=4;#X/"-.EQV][.AE1T_^0SE,FME7;4[$FU[XV%73%(Z
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M0\$,)=NR<(03V:H0PD^44E<5E!_0S;;*@4Z_;]IWC#+I;HF3F%4DS@3,'?9
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M# AC../;%2WU<,C;!'^>CWR3AFP!SC[!!H$^1;X6]72(+1SC1YU2(B2"#E[
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M9&4'M<3.QZ[L=A&F]'#D#I>)29"&%]SX77M@M;W5IEF/QZC _F01_B*H:,
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ME1/!5@VVI/#. *9N#6TQTMDXOK:/?P/Q9&+DFZ$L*X&#=3RZ<&CJ][[OEDB
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MM?E[KKV- Z"(.1& Y>_NR64R.GF;6K!V[:6D;$JY6&IS*@?,0&\9P>LK_]W
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M:OI;O01]-H 3AX[D/"0$I<<^T"W!N!$0S!S(O_<-P92@T-1V@0\&&^?H5@"
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MAO]$9]GR*GLLK.<%]32D?=(.[2=3.2E]DZ9-?!HFW"FHQYE>_8UB!KAI>%F
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M$(B";C>;;D_$H#)S,I\GRD^_+L>&W@7NQB):HHZ6P)0*^ZN Q,K/KZ_*B.X
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M 8TMZYO-:]L=0?H6#X/90?8C;L>R,HHXK5-3(5E4524LZ_7)FERF(9?8<I=
M/.1@U0M74>VAS$/QD!-Y$56+##="<W4N.B!9T<7)$-DU'0]/I5V"0797/OD?
M#,_.7\8+W%>\=8OLH[Q\BE3O+#_)V/9Y M.%.B[CM_E&SJF0#5#+RI]SRR6)
MH+>3:%I?1@P*OX;I7O/7WF=( +X,3H=FR[#[9Y7T#)?YZ1U;5?D96/:D'7<M
M;@"PO4LC$&!/%NV?NZI'WO\$-&:(167J)5UJA7B6^@7N0)-QY:(U,Z5%VCU<
M>EPB8:6NFA<4C7%#IQ3QRRUK+7S4"0@=\%U7'F(.WS'QX:8Q%EK&B1TAK!>O
MQFKMSU0059Q5V:)HR&$GM(UJ<'+G(TAJ=80:< 1N&<"0P:K?7G1!2-'BAFS>
M=T&61DZ1K/$7VU=.T@5?O-M<,*.KU4-Y4PRO4.ZD<++Z4$H$\DPKWT=)$=Q6
M%%%M[YNV;N^D_G-D-&GZ]#A8<8BVKI+"C2BOU&^)Q=XA/NY2B0=!% A;^/<%
M[CJNN&"$IYTA)^9(;D;+_2XQC6&[U<M:4WR'/.F;I8U=^E.S%2B4:34_)L^Y
MH,4$\KSO8I B\8>$O8I$'[\M*+\?.5=V[L=C**'$#U6OX.?^'1#;1=_E^LJ<
M%SF<JM;J)VU>S]K W=4/<WE^>EOQ'BS2_[MBD7X*+-)_6;%(?T[V1U,4W,>2
MVOLJ<\BW=5D=D%[R'!*W'3-:<2V*=&(O?##L^3?H)V)4N<JY+BY!@*>%'[<4
M1O;J^D\;D KHW1@]*+TWZYKRE-F#77G@8RP?0:C@R 0L3F)/=LHKL'HAR[<
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MG!^)[R][5?-]&P5MD$$DQ,\YDG?'GJ,OE;L/0OV@UTXBX[BELGI:EQ&V&B_
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M.VEB*]V@;S^ OFL?=LQ55\3YX:XQ55F7C[U!D<9C9,)039Y[(=%4O(]F,G/
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M=E!#!]87T#ME?Q_I1U0[Z8S7A%V79V@C-:^KXNAA( ^-[U,06?Q;UZK3G,+
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M8IGDD"F2\1& !6EC3H[:]=7VGDX!>+@>[ED"IFS#&!7=MDE:,LGJ4  "N!;
M*D:W*\)ATHN-75-@L\T++S= U\42&9R5S,PC?88Q$^.\?DJ492[0:_H,.7 1
M7#E-8F/OR-E38?EQ$%,<ST9S)6R-17:0;2%#*,&G BCVYD(LL"G)P#U;WTB3
MMQA&+2GF,M$<K>F:]ZO#/\1\ R.#(.%@@/L&(_;D7#U\_L3)J3'JDUD,GQ=
M T24RGNWF!B!B"/E']D?-7YG'&4(BV;X:(UC(PRSTL3\'E2 S:$EC_9_5WKI
M$^+H_$C:&?  ;N*0<TU;3J^#; 7'-V4J]0VL4R":6X8*@=^CP-"X8LJR4DBT
MFT*YA4E'H2Y+'3F;A+@AT'<"4.CIY>KJ7:BK>[ S:\0.$S%H!F%QN4DKEMP?
M)!B&!K/C,W)L/7:'JJG *E4A_)=*8JB47W5!P?.G$'_#N#T*UG]?MX]*%J-$
M1^6N/,(M<8(2]%BRB6VE'54T;W50&SKJ'*R[B^<GH6G\:MXS^]*E0=-4X(EA
M80VHX.:DFAIF*AX2=D__$-&-C.]HU/.8$+S*[7T5'G B&F+SR>XKZ]!8M?:<
MC'-^G1 !: F+(=?Z79SY'Q*_,:.L%['4!O)8$(05&;I'O-T/P:,6X!;H+40Z
MCX>K@%!N/U7OV2MJ":N=I'OC+<*T;*L9L1-\55OZ[F[V%ME+@)/X-J?*('D<
M*KP#<GB(XC0M"%]/0+[%UUP44*RY#^'=!EE2SDUE?!'B [T!9OYGA7!6?U>B
M1W_S73Z@]HK!M':0KM?\6:8V^"5_H^9/O_ONU>M$AO$( /$L-%2RRSY9YAQR
MN+:3D64\EAGA!9E'\9,$COJ6+&^&ZB#9=$:A0$VV!S@4N:CHFQ"2!4^GP#_!
MBJ$ZX6>29R=P$X85B&4<N?Y6;L.86K!NJS8C3#0+WXG+&7E=?WKT&$4-73%D
M5@R93S-)?F'G$GDM(P.G-2WS># *']+< 0PM;&1!KG$RKR1BD?6)MKB/*,ZW
M70DV$'*"^FU7'<51N60YNVZ\ZS/\Z$UYI\#_1R5<9UMN.H+#-V/_$&X*98"4
M HCFQ?O[\E(@#(=-[=RTG( &A<<O-__371-/(0Y_OB(.?PK$X=^NB,,KZ-EJ
ML/X1!BNG [YXPL8[V,*\2,%BG*)!@RVY\QA[F7#FM >*'7FM7=B'3EE@REY\
MR$M68=YT_/;OY-O[S=N1ZZ -/&_UL]<V^K6I]SF(=7F9# DX'X?E>W*J EA,
MP?F R.P%DRF:/V@3<:LDK9*T2M+L_SCWJOF@%Z_A )-E^W8<N(.E1VL:2H1O
MM.L%:9,6I8I0;(3F>\]-X17S/PH$DI*N7;(*+HLA2<[%/$U/;^NJ049&"F[T
M(QLR4UCXDF=UI6F(&Z84!48*G_97J]2O4O\<I#[PJ&A=]?>'B\%7T#TBH@_Y
M^2-7I#AE\:9IV@>MA$IJ6OZJS__L_RT/%&7+/ZL=K] (>"];A^1G]3L?0G3*
MRT0SSN6V"IT"*(CV0GWZ&-QJ^*_C6JP >^%@C(=)3&W@/DN%Q%-\_*ID5B7S
M')3,I<GBV*>CE2NN9HTHT'$=^C >R$S?2ETPH_P0XDS&@Q*"8OYLE.FO2?(N
M6\;W^!*N=G$&%NRI+[^X^?P7T!6??_$+RPN42LF4+84\&R5:.O"(B:6L,6#"
M R[5]B,RUH5UP4N+I33F'H]!VO^'=D!G-%:M+>:@]!;=R%T'DO8>D-W2Y5^V
MC%=__&[56JO6>A9:Z_* Z!"&^W8GU=_;DU:W35>1OX$"]2'C?CVCJ2;*Y\)B
M&Q?PRYI;"[CB#T([+3+-"U_9R-IRXU$A9;F/*&[=E[50VN]'Y;:G8ZKE9X=C
M73:#CF@T?P59^:I;5MWR''0+FO/ZCRE$9-K#6"VCZE#CG]@<C=B2Y[H@^DQ#
MQIW>.NJYJQZJW5C6%T(1/-ZWT#*AZ1C5# VL<1$R\L6N"3H1[\JF^ENY@ONL
MXOV,Q)N>]%'B'6A-E1%B=Q6&I5S:I-JE2?3;4P;^PX-9#8<(I3:921/@Y?F4
M%AR"\?LBXRS:=6,/M%,=XDZ<-E*@%T>(AWT1L;D7NC"U2XN_:SMCY?;?A]0M
M.2T\+%D.,CG)K<6??Y&"LEBLY>4S/V,0*"3NL[R]<"F3O(X2IUZHBE?=M^J^
MYZ#[/B)LBDG8[\INV'R=5,Y=>62'!>@:IOB*-&V?1U)(_I1W79!:$VNQRY;R
MF\]^0:)>T?NT^Q>,SQ2_FQN#>=S@KAT$]AS9'1F@3!RQR/&HFT4K$,W'/P]-
MV'/+1G<QTOIN['24N^KR;>'A.1[X*'L,QMMTF-%D^:U)(V[C\%$PZ_&5;D/T
M)B5NG9S<"B>WZKGGHN<^WL?#5*EU$T<MP9*;]$U*"WTWWI*"V<@<HRG!%4+M
MJ:-Y2TX:3U@..FERP.R=C-AT@<>_Z%MW%09K666_)B>:,4'$L]W>DZ,7;.+'
M$F>E8A'X"1' ZMDL-NS2OX]-V+S\[.7G$23J^NKM>.1N0/J6L1N$R1OIM!_H
M@WT^*RK?V_% ^6[3M#RJQ* U#)VC_>;QC](J&&2\/U1];Z ?6RZ=M)@SVX8=
M(PQO[KJ6H6&$7)W,0(30@4_;C;5.F\KH>$(J*1&(Y._\P_TH8U<Z)H-1<MU6
M'M^3"2C^QQ '5_EV'S!.9"%$<7TEK^W'L6S2*LU!Q2$L&<%LCVQ]^PIS.&D%
M::0(\[I]</.$&"TBOX!.^(X=\D[&#WC:A_;3#-CUU=&Z*9D9@2>"=GP0].KC
M$96?7[#)W>Q)0FD_3Z'L&&>Q'\&$)X-A7XV[NS#P;0+,XRN9&'[YV>>?VZ#3
M+2T!FT0__,(0N?KQ5M'X_%Y<7Y6TG)T!("UM\7#? 3/JY6=?\#<8N!7C+L41
MR9)DC:<GRHXA@9#Z >F[=<-&2ZX$F@F?K"/-%/;75WZP&4.B?RQ/&_H^NN6?
MQ27\$<T^7\B/7Q;TS!I +BE>S&5,1DAY=&LHWX7F9O-G+,)NB_M.'3TKA? L
M'EY*.'6QXM]SRII?Y"0+_?P7LM4O7_(VRS'^^A<15*<2F/QTGKCFM"2<!D-L
MK[.9N5[]8]L%=O\*C&AB7M'A7D!>R5&]NQ?XGVP&K]]VI%":DR !JH?:R/2P
MR 8Z(W*/O@^#>=KJU\99FR #FLI9($^0U?"TI20D^_" %$!^]:J&V[,QR(.Y
M0*=?;')[:9(R"<$N\&@B$J@%2^D\ W,+I_W0\MB?[PP7S8+B"K\60+*Z *S6
MX3[DF%:W87@4!5AM'6F9*S";)V\)H4*G60%'X#F6Y/<3-J94JK(,"P[ ]G1B
MVI([\NK M6NZ4-^'?DL*[+N:J_M1U[TD%1#[[C;_3@MF<12]\.MB4LW?4AS3
M-D\6OF+U;#H81M>#"_VL/_F$KJ_F"3)H31[(YZG[IH1U^)W^MZI'R#LOXU#&
MQOW-9+ S_U(^P_(DAXL1\KB\ACT.P_2*,!^((^F;II=U&1CK##XH&\Y7XQT'
MN*)?[4K36OI>RO^,FF80)=]'-9D.YN5LVG;>F.0F815'C9;G!G%A-^B_Q'RJ
M3,XF83-DBZBDLRC8UQQCOM*G[=S]I1V/D3?VZD>T@.S+RG597%^9H\8H.R_P
M<S@*=[3]/6WF-J2E:"\%CQ7":2*K6 H/)[3 CUL&1&"*>K1OY,?/V\+0<E)9
MH>TX1<M[?:6;R&NR)0MBC)\(D7\);DS"E)%KQ%](^S&)J[_"NC0YHHO'EP).
M(NR2R>])(U5[U91I-7UJJ=F#/ +W-7V_J0Y1;;RT:4HF#8F3]\CYD6.[?0?U
M/+U#F!R_OMHC*YL=N5>5ZI]-X55DU-*Y08QH'[:C_*?X@ M8%$HH0^;%H/+<
M!&4<*L??W,F,SEB+B(Y]1,\\>XLYP_)XW]88-1\; !S&A;NA(N YTMO376P!
M,*&*5K_>0 7GX#$"':(@(;PDN"^W =*AH!5H&A+_E?YJY-T8YF@2C'K!7V\X
MB62\S]3T&1M#X"Q8+;[&3:ZL+9IWDA-S4U";!:B$"/TVD._P@I&0R,.$^PI1
M.LH_"S7,<NL_' IP]<"FZ!A6!6%L8L4>0ZRDR)%6G.#NL#OQ>AY@J-A0\.Y/
MCS1>84%<26@VSLV)R/43$=%;Q2Z(>C.^ZY6U8")VG+@?"#([!F+IBY3V*#(J
M&+X,IM7M @LV9:'ND.&RB-3Q8P0[6&3:NUXFA0J6VY*O1U^);*I".Z0 9P+I
M+.6ML7[' 1]=>][&F\U_<&A>G[3292EAVRG&JTGC@=*+QQ6[!?3$I!>R=S?_
M@'RY'!9Q$4^D. <5!O=04A=Y^)V8PIPZ*D=R"G4>0V"I[+IM[NDII&9J 13,
M+MJ(BW5;[?3@)>L@Z1,@4I+&9M@.-IW+-TB^3=R3A#AI_ILZ+#N-W&#VIU8G
MI5$69N=965>]X5>K'6.5SQI)@3,/"C&3L:'A_HYBY7"O5#W-O'COTSD,S 5(
MKGB  O3T_A-,.)BK,IQ#!:7[?,>#/H;/-H_@G$/IL7-VY)<AYJ.[B8D <T2E
MF=;@X=.E<KYW?'A*DN#:X]X"E.N4 1'MV^T(I39S (J(V2BAPN1V3QKVHL>B
ML9ZFYU(J*YME2$+PE_N*?(G'10RQ_4AK;F5\RZ"M,1"5I6(4JU!N,(OC+AA6
M?*[>X9$O]AI:Y8Y=M0X"2T$F:?E;0><1GTL@N*/4)>=S*61A_]9+>%*:I?4=
M+/A/%.#*]^?@4&I4!0*)7)>=W C2 ["S">134P5RN9S?GUD=\9F )\(P<W7Y
MV'NP*,[\#>6DLT <-D<X0[NZ"XW%)IRM8!>17PG@1)WK]I(P'>>F>0O^1D:9
MYV._I:-L<N^P7'%TE_2*@JD"<=N[!^"T?I']9'_6I FBGI%B1F\"M 1S/"X%
M"AR'#,S41 #NQ)2^5QW_^F3.5L;C"4$K$FSJ!X!=OM^Y0&BS:)L8F_# N;]-
M8)938-]Q<H81Q@PV3^QKA,O)+&W5+ .\@;>X0_:IE?$/.BF!B ./ C Y_9'D
MQI@<EJ@\1&5"^ED<HD; 09E)!R\3N4H#!WOXM&#E<Q3&DCLK6AA0'+M&I"/0
M>$6+K,LN(KZ:(Z/UBY]>WMZ#WO-R1>_Y!.@]O_EL1>_Y.:EYM?^<R2TR"%@7
M!5E7'V=9^]Y3LE#05V98S)KDVTG4<Y#X=N $\#XH@4Y@+NAR>T*=2A$-I1Y2
M'8)$:_P;UA30''%>Y&0\8 F>&Y4^LN-WN&,*ANH8Y[*ICD;55K(.^':$:X9W
MF[)CUU<Z%E^P%T%KUO(#TZ0(685'HKUE>'EREQ[O [Y#82\GH)EN>STTMVG&
M??G0=M ;@(>-_X3KEB$:.XN352AL",_J*;@,.G[\S=>O-)4[!7*U]BV-N>>;
M7Z(P&I0F)9Y"VMM;*?HB>E0P 87=M/  M8XBP_I5YMUM3*.M+M@2=O?W/J:0
ME#++@J4MD_.@R,N6#A>(82/3F1)0O L<QT1B=MP,<:C[@"!H,5V:O*T53OM\
M. [PU1U#@ S"BA6=ND@V P?+0DS%NLZT4S9XYK+4A6B+7>#I^4)RFMU06*%-
M\:ZYVUW..Z-!.'.JIG^LJW$Q0Y>4[@RB<9/EF0K'4,2Q@W%<:>T60S'^<]EL
MC'6N+&0(*<KF>#C5R><+AWDQ+(<\&.?L!!22U.LX?L0SI(3A2Q4QT;%)&,"H
MJFMZN32\%AR<G2R:7NW(TP[UGM=.X7?9;Y^^G2PC-=3*^SDD9,V;(/G'O!&,
M-CS<;'[OO\DA_"[LGU19!^Z$$8X[J=!P1EO>D8X=ND-RR6I)+,N2R+IF.0X'
MX;PY(.&B 5,6@J1 RT5OK&N$\>9I9;-Y32M\8<OUJ2MY^K8<8T+ LC&*:EQ)
MV*]16;P<6/=<U$QLC*W,4CR"DX%Z(:<JMM51T]WR! VH5@LVT883VP578G8U
M8;A$H6W&(\?4+A6UX&P@,3E]2&SOMEQ[F?#]^6Z@"RR6:JK^IP>?7E$\#7QS
M!?'\*6=+HE5''\*@Z5%N2U4SQQ/HZUS6.J_P'&2'\Q 7XEFE1CYXL'!PN%+1
M!"["E]TZT[C*SK.0'82@Y% CA+E$@FP<+S(6:S?,*CBKX#P'P>'P^D4T(Y?)
MCK3#/\@T+Q)$Y+-1R"_AKP^+%% M03:O8ZBKA#T3"6N$A>]"QP[<JSJ:TP!=
M@XF\E<F\K-?QTJ>V_)7T4,2V5\D=EHD$\KY"H#G)^'5AVXY'_#3QIJ.] ?R[
M2GJ8-[(OYL0YX\:)<62E8V+'I0^%BW"AW+4FZ?*3_!8;A=ZL+.V;)WJS]I68
M2I.VD=+7!&(G[SS1Q\TDTB+/;67CP8Z:#20:>%H.J917TE*P,HXT^I%4M,=*
M/]FFWU: 4:^V10(]MX>^R-'/4:XV;U2S@F>2SYP>1P*9%^[:Y&3DC^<CW4#0
MV&B']G 2@RT%\/D&/+&_4KRNYX4]?ZG?CU*XD<$7H=M+HPU_25R<7-O5<0K;
M3NQ+/W(ML-)AHSN,>V]YH@;5&YZ(X/X E)TCH-KBJRS5Q?5$]2-@4Z6#E4Y$
MOPNQ2<CJEANK=^9'Y3?E9O.J[MO"]71FWSJYQMJ%CB_BOW5M4:G_&;RIJ7[0
M[HMS;+375V^F)1&Z'. \C:^@-S_]NZFA"ZU2*Y6IPA.FND,B!<=2P;VIITT^
MU&)S >W^7!%ETNZ^1()9+!6+9NWM6CBR 7RIE\T+9<CQQRH2"J&S4A)>=UY)
MTNZ-I7=XQ7I#BC'%6<&#\4"]3:J?TH@!&O+V<7,840R=O:@.E>M"+#+UH[:J
M)Y:%,S-)&44[GDS6<=(XK]9RM4'SLCF31*464:_J#@'E(&U+UMZCWXU=>PST
M_72;=4(^S@DO]X^SUAYO_ZH*+)O,UM(BBW.C\W=N)?98-\ZH^&LYQ:H;'.$N
M&I[JCPW4(LX5%Y#W ^9<MH%6)VB6<VKES,I.I%ALD/;I9,^/-PUF^6Y2'!:S
MW/.R[MM:D!T:*SK/+9*J):[AQRG5'L5>F_';+(WXW6R^:\G;8SM,7AK]17O0
M+@C7_+/C9[='69OO@Y>6;X:]6]SU0OKZ%P\$7.4V:6";[%](BOCD-AI-]<WF
M>Z8C0_.8/9(A>KD4;E 0^373JQCGSAQP238IQ3PL=4UJ;L=3FM7M*"?'A]K=
M5@/TH0VW,^>2CNI"6[G1W>SB%SARVRBQ6^)^JYZ?"I#:D]N0M>496TR9W*4!
M0XC1<>L'.NT0F_295";$1I*)2R5F.<(0Y"Z492RBY>-_ED=I $\-S>JIHQ(<
M2<DST] E! !SXA42J+0&]#@^!Q.T/&'F!13DYJ'$EMB>>D4]N'Z,Z4725A+6
M )7!Q?"NPTLYIG7)99W<#W#!STS?.6^N]TU<O!)S&AC:84LW$^\%I\;(WFVK
M*L&.*,E9&IN>%M1+,?T4'8ZLIS#.L$Z[X_\G>K7_N:V5-.;]P,/N[3B@6]FL
M4M.R<[-MNY:.K>I&8 US.TH1066\9>,R+*@1=&2+M4Z)&5!KU),)83Z,>"PV
M*>Z'%N";SZ<6I/ML/E,W#21R5="OW7W+!X\CC^! 1V:S.'#@"4*+% )SF$2;
M;W/)6XPH[?@F=./1@'ONZO:6,6%XTA,ML)5-\$\.6E%6(Y5ZA; #_6*Z@!Q'
MPVQ@NCUQOCPA:V2&64=1XNV0018_M7=H*630F"@#*EC<C@^ZWW7+[RB-;[%M
M<9.Z%F?/%5_=7?YTS4D..W?-310$J4 BA%6'+5SEN+63"QSA&@!,)1 O<J7U
MDO%($,.SE5-@%#J;0N(^&2J-$]3\#[2IFLI23TDC6J[*<ZMD2S>1/)!['F2*
M(&CM%IA8NR\GTI+Z(U6T^$_0B9DFF1.Q>+OK/1V6ZVC5HG[\C=AMG<&FOV/'
ML3]6[]!^B_E1/RH-\SY_/#ZU!U"=39VZ#ETU%YDLS:]\G'B+5CK7YTL7O<A4
M@,ZG,=D?1ZT"HVAA>U?UB(G2,,5<Z'1>?(K1\S1BQ?DY[D4KE47X9S<CBT3.
M*Q;U>B6[#]<^Z=U\\)21L<[84[F:N5%T>FWM'OR?ZQY<.<#_OF7N0EV>+D1@
M!BJKCHIH]":D%Y;![X+6$%(&36LZ$R%:>S[6BO0J91\L95%Z^@K($)5FN[R/
M/?T,6<1NU#$._?AEZ]#OLF(XZ@'>'.+W&(I<I7F5YF<AS<R;^U$PYQG*C4 P
MDC0]EHK.JU#32/MQ4OVLQRD%RH]?1@2N0G@BJ?RY>89H]UHTDT^(H/N*NUOS
MQ>OX((_ M]G\)+[U4[ 07ZRP$)\"%N+S%19B#>C6@.X?89P8;K33!,?%"OE=
M.$UM *><'U D2QFR!3,A74.:& 9.AD+YNT; "Y?3,' 8UT\ 2BP8!MPP>& 2
M "G+&J9=JU517^0N-N%PK-M3Z%QAM@<8["7+\/LY-\JQA8 QH@<#N!AW)X?Y
MZ '>-+ET,<<TK^+.ILSM.R/>2O+%\=6T/>!L6L/KU2%?==[32H:";,3FU@SG
MBJ6:>6:D'(='NP2)-)?P2\<Z -"#<I\UUG)S4,W9YU6(5R%>A?A)(=X7N2 +
MX82@=6G9[HFN&@&X!L!H0Q['UG-JH _^,H7B\&LBG9%!AL5*9F$+8:^BK]O'
M7?O8].+'M,<CBITH7:9BU:4. ^\'9PA.F_[4#^&P*I)5D3P+1?+W1!P:,@1M
M1FB,H"%EZU R?D3)&"[!(Q.C,%P?(S)QD-),TWCHB+QD'4_D_6Z#@!MQ%%!M
MWUG3I2T;G6)8=-D(5+MTK6,K+V9:U0X?9CWH0O8U&TROI"]B'NR'%LS8S< :
M5*A8RHZ96;MV/&*5Q] >Z["JH54-/0<U]"F"$D7Z;,=!U(\+]5->YDOZP"I3
MJTP] YE2:-B+7>&\6.WH6*1;)5&1>8!&%^MG?[(7XP?O_=+P8&+:'9EY;&Q;
M!\V?;+;_Q[?:@2I9Z5N9T;6(::"J[[F+<LH+R]WV,N9[-U),B29#\@8U"^TP
M.>RW3.(4+]"'W E)8$O;:AZ=TF5F2[!UHU]Q-"IQR_$8%EUW^G4S;+[B_]GP
M;"QWB2KS,E ]'8\<NM*'T.QZ88;:Y5V83:D<MN@HS?I(#8$;03=9/G#C"MOE
M%]+?#6*5O-?5HS3JCYYZ*DXC3=,X2<VPNWU+.-?<C:A.;L^SO^@_*[G'D,VK
MY@1B(>$4V8; <B712%U6!SIUGE3O01@8)Y@43P #QU6&-@!\V'UH=AKN94PY
M73B.RFC"--G=KM9@"VEBH05:)V.63^LOX?H*R7#EE1;@#H5,=E.W\Z.4<A;.
M$GJ)5&T?8G*^HS]B\ESFJ9,H./68NVYP4EPU,ZZ $Y!ARLA;.\646R('LA(A
M:^IB\VACZ??T=!Y)*;GS>RL-=DQZ]% *Y^;C/2G).MP*#'!20SSG*G Q^@K3
M42!>SJ+6RK!F(@NS;<K-YNV(ZL(P< 531WWSNUQ(.]"@H-K\;1$$ES_7^)Y[
M2644#)N0D))I_^C6^P$.H:J4:-_M&<JP'H?#:!MR3@(Q2U/, 1EZP'/Y^-*6
M%3+E+(64QP#, <'Q 00"D,.E!@S !*!,E\(1);\1S&#E=D *AL^@B$ #0W70
M87#!S-9%"-,-G6Z+X4_YK^LK@YY(F/AL!NF,>.:A\'=8WKYP*F214.C"$8BO
M)-$#B@58PQ9GR%,>5?^.B]MZ./+%"?I <]UN8W4&HM >,[HV@".A_RUX)'2H
M,1-!RHX?!B"=1XR4/^IX#[-;<U&?7!ZZ,2*;"%'WN@ &<K[K0E"5*L\4? W^
M,?R@F\TK@>V /FCI[K>"+/X!#$Q+$XLB2,N;MRKC!=/YVD(GUJ7ECTJ#UB4"
MR2EQ;R>M#T=NYL=/6*$_>5+GQDM7(WG62 KE@0[F3ZTC:>162'!(!38O])]T
M>"&6JW/"- %SUJ:80EMB0%/3<GR1DXC)*)Y-Q$'[+E.-194L(A;(B=?[$QE<
M$M]T3D4=K8"NE_1M_GA%)$@O?7WE+9#I5J23V3K0_Y+KQ=<0@119!GKZA/:&
MKNJ_4XC$?H*$'2\+ <\0'G=30OP2KT?MV?GW]K9/Q/"?_RL9 $$B8ZTO-QWN
M2.#B0J/T]KPC@BO/?B1<BTCZ0)HI((*4 <2(;Z'L"GI\)_H;,;Q&6,'>*^,0
MJ(5E^*ORQV.)+B;.LA^X[?9O05JQE,J#Z9+VO-W\."6/8/9J3 F3O\!/%X;&
MA[(>R]BVFVR*!&,&G<2_>Q-YV+\/6J>\OGK%0YN&:S/ F^)E;S[_S2^$AVX\
M0+?P7&?;OO,7F/[H%YY&GLN>0[M]1\KC=%MNW]&R54-MO(+ZI6=/U@/LHU&<
M44]:/Q@^[UB=AXHLTN[<B_'!_RJ[R^+DC#S0U!>1MZEJ)BI15A)QZK!B!VT2
MG^0>4&X!_:!TT*0HCTS],F?);?)I_R4_XMCV9@L3*C6_>6?X(,QL04YJ7SSA
M::Q*>6HLOV<'Z_KJ^P3=]L8%%)OO-)Y8+=H93^/-GK7G1A(N#EQNL"OLX[.-
MA6<)6;T^>; :_PAV3@=!<Y$ P+HWA&Z;GTU?<M^ 63<D_A8IU[*2J[I()6M\
MHK EW)2Q!O/G_11,1H.^'?/J>IJ(85+"G"?-#[<^C=>5/!K?O>.R]/'4@76G
M%!YZQFUD;A[_L")#4))FG%$&VR,+? '^.W^=!(><5#(9_.SX-Z0[>1ER"0S>
MT"!S_#M VPK6GD$1"@)E_!*L7<C/.57)*#I]1$:DG[X+X0ADPN6K-8%<3"A^
MTJBSU\B5# 4C!+"M./ .54@4-[I,\8+XC7$*O9+9RY%XUCZ "CTRA6!5?Y#P
M0> LY/T[)$ZB,B!.1NQ&?9;L"^U"VP4OZRYEM]JB!5".7> 8&N1'$?XVWEOF
M_=)6^/.*5:^N1X6(?21/?@+1?]9-\P&"$H/!*"J:)8IH7N<5\,2/EX9]M0-V
MCYBL, *,Q21AB 3#6C)?Z/-C3L.A E1F_&.[N_05XY >QN^7\=\%2TI:.D8D
M4,%I'WF;MI+3DF"N?6R^I!_#^X/7)F<G?Z7X8Y\24KZNR]NVPW0N*4BA-^.7
M2)@HR+M478_(<L_X(PN*0UX:FBB"B4H'@G42<:82N41!E+>2F&DDVPY&%"2K
M(?<(IX9#O ]LAQL*0RJEI Q,S[H-0DJ900MZ!!#)$SOMJ!?>KI'NJ$,:-FV5
M=,H_%[_TK]=!PD\Q2/AR'23\.5DT!G:U6D#4U*(ZX(*8FWG.^9LZ,XNNWPG>
MEI4H@"0?^Q;%/2']P'Z3N#.<L>:\%WWG'@5RAE,>3BYW+5YI_IQ.8:\\EB8>
MXS_6(Y<E67$R@NR.+AI<S@-6<*AL#)PT+8-?*1'O#6TQ2QRI3R3$$[;UW5AV
M9#Q#B%7\/B2\+O/!4GJ &6+5?U#W;;E8IB[ S>;MO63H8_*>49X>\'K X2J8
M.%BLPRD'GOM[P*'. 1AJ0:UK'X=[1WN]^HUGPG /E;Y@[7>MU-;8A@N:[V!@
M/?Q)GZH]AT=N;KWSZ-<X>OE8ON4^\)2,C=7*Z!TN'9%M>2*?G7A<1HX1STY^
M+1I'W:[H.($C&MX7I[8* "7")\L<L2P5JS78Y/3&RI$YA%F1R.H2-V]O%N&0
MP>Y:H4AP[]E 9E%]<C0+A00N8@@A:D!7_-[(!W]=2. )6B1.J1JD:FG)_;#A
MY+@47,\_D5Z[*3O2/T)A)I"[^RPH1Y3NJ!'.0?$KB00O:\)6$$LRYDT_!H5<
MC@X\*-L!&6C;) &*0 %C_?DU030F%V[IFKEC4[:#],U"?9''#DJ8;(&HX1?&
M,YNNQHI+%ZUJU>NS?$"G-<-F/(2.>Q 5\- J#. 9R255FTEDA'[R=]VHQ//S
M6N)W>A[TZ1\LC;?YEILAPN:7W%KR\K,O__SVNQ^^Q7]__N6O8K85=#_B \SA
M0,W\.Q(@+_4N(+]$Q//, 6K<;\-Q$+STEY]Q^V'42E8KZA]#.&K2S>\)_D@W
M4";GM*[*O_R/4-Z?7KP]L(R_XL:(;;EYTX@_A.I8"F%CK[)X9N2F2;E&ZU#X
M&N7+T>V$B%',\4+D2#?6%L'5O]E?LC!._@X&@5GA%+0<+#J\CKU4HF )!!'<
MRR+*AGV(NR'J45D_1-?D32;&JL.0H:01QR8"$[%C%K:C:88SWD?,%=HI&[B[
M-I;81Z?+S-J)8IU@7CNG'4AH_JG!3!MO134- GL;;WI,6-.7[P7M?1_;?9,1
M0[U76E8UP&A083PH;'$,:?0-^WP)2DW %T7]=EA)6XFHQ04E#:&B>*<5((@'
MY=-Z^E.K$IV$H"!\E^"-=&)?"1-!.4CY0M-).*.<:\=\J&S/AWNZ^7?W\8Y,
M6QF'^[8/>5K_I+Z<=.+P]=>> NVZ$?]"6]6R %EO4X=,A5$5.>E*!EEZ -*/
MHSBJ.MC$!CAN:"05->DE5"AF4J8_RC^6G7_6/D5\?O .FLIT(;V#DAOE^#?R
M)(ND]Y52E6"II!+\?<>9L/III2(!DA%I61+B,#H6.G+RZ$@K@&EIX52ML&&U
M$ GQ]^8PX\&EQ)%Q6/-L\T8[#DSAPP>G;73*5K%P J[B \&%O45B5BF3NK96
M=1F8($04&FVIHJ@B&/=Z=$&XQ5=SN?7X);W30W8 B88L9D<W/]A]*DQ1^;@B
M4]?N L0CWWDSO9.3D2.1>81^$!ZO05#<;T,_B&H.?=SOF J0'D'+RSS>\]P!
MVS%TX32<&^@9)WYD)TAF<,XE;/"%HZ:CQ1>!*.O6QX\EG;EP#\[W\.@UH VY
MON+L(?V)0"/E*2-=KS;KZ(<DS\@-2;/CY!O,(K534I];"L%#2_NQJ_YFZ1KG
M-_4AO(N"XV]>9B'U-H@+X_(!N5DM%@W.-#1-X:@54T?=Z\1$5M.>'$+):2\N
M;[H@8:^UD%B[8:X25+"0''//2"6A6!U<R/9+_.DK2?[)T?%9#>"Y[! <;O-X
M>E>8;\J#YCB7"WUZ0YLS9N%VK+B;B1X"O*Z[IK+4 '^CT$M R$P3:%>\KQY:
MU6^)?6;-+IW++HU-QUUO PJ7[FC;+CO9Q;30GNM^_)_;JMN.!XY ^%\PTQ3-
M\Q.-5!H_4_\71N4VV ,P$<GV"GD??/L3?)/3]@H)P3C<.'LMB]2/V@3]]L7[
M9@-PJ<LQ*Y.B+X^.@>*&KG_B;I)1&F#M@:V0%)!T0[?'(=O9-I,H+3,CM\43
M*TFO4S <=@LZ75[EMD-I%49JD$A8G1IAJ=*20B)JV8_]7/,/0@QG8U!Q'V@Y
M<<79@N,ED$95*7C?PL$=4'%];("@MT\#+$_<-?D7+##W@79'WO@@U RI>9+?
M_\-N[<WFVP<-:IF_ B.#!3-<S7K-,K_='KTYI^VNKU3=L2/3LR/ J<F9]KHM
M%=WC::WYI&)<2)875EPB3^+]NF_S+0>;;#,'G<O4_$B729,OBZED>2+:N/@B
M:\2B?^[: Q*/^BJQ:<M5UY?3,+ID6G\L-:5YF)2[I@"]9\00D<8^^DD*9"PT
MH#J>)$9A.B#BV#F6)FHPF[2VN7Z@$_!#2G\L% [T\I("*-G%1YSK:(+9EUQT
M]+@#7QIAVBYF<::J4]WI23L8J::L@8\#Q#MQ1 ^!8NE='T< DKUY?^N33$]_
MP)JD@HMD5N307>PM7+V0,]F5U/L+UW'!U"_7[">J"$?VKFD?7]RWC\7B:0$&
M*2L425X.]XK)R_'G,CB J$"TYT(D@Z6-_;E8HU .3TFIIQE/BM8 KQ83*;.8
M__K*T6BC'=^17]*ND$LP!E>]\T_G5,70:YX0RM%Z]KA6%*N(6L*5NA8(M&DW
M1O9$M&Q7DCJ7^!^9'3I6,G(L#!@):$]E/9QT4&-5DO/&9ZW*H3&E;VOM3\$-
MD3-(J< V[^R5'!R;NQU%\'V"64#59*.$8:B*Z>E+SCF.[?)9<X<Q-WA$-9WF
M62=/CA57>RC/2 _Q*;%,Z]*)*J1X6,G3H%%LZT=&'T(N )W2S(C&GM$)B9>Q
MJ>A+#CJFPN/(-J>%W,UV))^7?]F#PMNK31-/4'QQ5J10A#'K<9WWEQL[KR]1
M2BZ*1W.9'2[Y%'7D4>"<NON@I6?=WBC]ZGKESUWY5(BV F&D:O>VGAQP4F"%
M)ENUX4A]A-B8''V,O30*@2$^1I_2YDZWM=#)8[C#4WW?E3P[9E/'$8M<^QDP
MF>ZZ&-*L.D=.))'J7I8;:3[5E.C"=/IP.HIR%&X^1"E.17MP O-ZO>>40QXH
MZHB23FI^T[7*\N_UXV8XE$4[^R)EC_?MU(P3FME$UY8_;V]>[_F2_YM@*@!]
M, ].)EW(R3K'<,@7?!!C:6SNBHI/Q4U:OEZ]R3,-#UFG)NJFL0RG+3LJ^N(%
MDAS<5T><#G(5^$?>GO-A)U+HL0N<B$+(L",UOP%Y[4PUAWJ$_GI8XDHBVET@
M)_@!"724F.L17J&U,\C\CI:UZ=W:^D'+*XR L[QR#_F0E;_C4O\ZDAW7LL=L
M4MLO5&MF<[F(D" H4 $T*H*+Z$9#Z0A$(:9%#(Z$IT%Z'F:J-PE<@[M:.:_Q
MJHEMHI99+"/H@)7UQ]BL:STEADJ"T:,9+@D*)*KHG<:VI$QTQ=5G\#-.Z$%.
M)8W-OGQHI5+)B^O%[+&C5,=&+OR,K5($R2AE6H<1-7!1BU@N7KA'C"/KYQYC
M8[%6;J0NPRNHRT=^NT\G9D>N8_E3/E!\@/AL5QX$K5JOKB+/=#RUO%-KGF<-
M*_;Q G=^\2&3&PP;[-^'@[2JCW32;88YPT(&[$M?;RLTTRF WB'Q3,:XQCP4
M2Y2E2I#,U#^I>O\IYT-^L\Z'?(KYD"_6^9"?D\'_=LGQ1_U>Z^(V@)A[V=J'
M\M0\FVLLS"<%M>L X<3\">(?/MEXE7]AREGOQ2Q,;)+VBZ1ZUZ0C-BX8"\I2
MCM=7:-8P P&#]8(-UNGI*OY[/9Y @5W9I&;E6##+IRSQO76[?:?=%U++2$/)
M\X]E97CV:<I&O6:L&I3H?*[D9?NN2]\2@;IQ3/!-CJY LC&>$-QNUCL5/TB\
MI7.-@*FHJ?.=DI7).OO2B>]=G[7O</_A7KJ2(B1)/VTVU.*;LZYRB2N8RKQ5
M"4=NU9U'^^C8I)S2Q"TM-W7;QW85R8Q8!D7!06;MZ/B2M*7S?DH-_\N>&VTV
MIW9,?518$@^%<R^5#HG$]^['RB#GRT%\0W4?/'T.>0952'.B@G^T"^H8'!FF
MS#(*\G5Q8CYNX,WF=9S%7;[1WB/!.&P/6IVC5A[3>AZJ-J(7)>1(Z='S4NOZ
MD"QEZOO:)HU'N2MILG-]-7,\6^#!A.-PQK/4=#*ZVFXG[:U_'9MMOG)1B*)T
M?+<2\.%B/ZTKL9SRD,3CS3P-R!8GK\XA?JWIAMRNO:4P+I:[I_;-%8A[^FIK
MXU-PI[TU8B[4"&98"ISN5QF.Y0(DW* ?LTSI]17=6C[Q5'&=Z *6[KSE.RF?
M2%>;2*B-,H/=^M("0GZ&A\4\>]&NK]Q-<PT1DO63J\U@Q*E_5+LH)8C@$?6U
MV/MDLNM;>![HSQ$O2EI&W>R-R[H+F*;%P62. ;<&[9:U.N]&(,T9W#5?,=*V
MO;2R!NX;/!WR/)B'4K^^,FI',L(>)C5Z @KY'+LD%I8:;:PT1 -7(,*TH1P"
M]+SI:XC1\JM9LW#+U^<[0*)66_:%@0F.3=P'29,(R)SS86'3E?B*2P%EM8NC
M-><J7W;.Z!'A46=AFH;O$)M^JGW@7%N"1,5GH;1FXTM%=*AU$LE0?_@IO#/J
MA>W1E#Y[+WX%;3#G]4MA@.X3WW;.@56=1@>H*.A+D#\7QPLW+S][ 30^T93L
M&=&_F()'*W5\)2.B'3U4^[YW@J^8[=6T>+4@*"32MH/FN$SO>\DS8SP.)?6;
MF>B22CTGL@EY+\>FGP=+-EX@1US7,L< .T%71+#OTXZ1@W//PX3PTF$)=&KM
MV(L)JSC_QYA*)2?P;E'W%F5AB\33N+,)2^=,$Y<HI?<PE$V$W.MVF>3[=!IF
MX*Q;3I!DAC&-18J'1,?E-I37EIJ:REMZW;:Q\259?KL7%]A*NTO1XL2;5TCC
MC097-4=7YM_KAPW*1QO]+7#S@]HWFS_YM5Y?Z;0^W-#_G[TW[8WC2M:$OQ/@
M?TCTN <2D&23E"A+[3L-T!+EYKVVQ"'E[KD8O'B1576*3"LKLSH74M6_?N*)
MB+/D4B1+IC8S/9C;-JLJ\VP1)Y8GGNCBL=8,W9_IP7%KD1NYW"#-L4EC*V%U
M$7.Q!;P'7. D;@4'BPM)<-NFPEA?[ =3$IAJ6J83(PSM\BC:$Q82O]-SR^ 0
M/%YL?L9%7B3,[<,M>'$-U9"8!;W--6,@]^C$,9XJSA46T=0Q'X?GL+WGNHPP
MV)"'2W+!7[ 6*<DE*G": L"^:>\9JRG)6>:Z)P.P%BX/">Q!\3NPUQ(!=>#7
MCR!:&*VB.Y,5:I#&I0[ND" (RI38C^/:"2TYXE.T\I&28I(YJG>)[DO:P/N1
M<1L,[TP<-"<8(? WE?:I0^7=!&%0D>2\"2XN,12'P6A*$A\Z\46PW1#NL) E
M]O<$;BIRP.A,>:O4YSWT7"4N<F#=J,ITZ[).!G#-]E?MT*"@'#P.6DNQ_/>1
MV^G^(*?']G):PV<N\-;T^ T.SLW-+[V^WV:UMK=:Y((6 2K77;"T0XF<@#EA
M;=#"=>[P@0K'_1\N+AD(U[D+L=X(')5W<!Y1>3#8*K&Q%WS_,IVDCDRG2MB6
M*,IXD 9"/T[R0 5(M40C,5&-@6F02:NL_^+"5;C/7$B EC:1"_^8;RZW)[T=
M<?L0!JHDM.0#6ZX<56+J/@S7+?DR'QB0>!46&D*T[+4ZO*"\$U[ P!?"X"S+
MKA>49O!(8)8[^V:.5 E/'"]2XG)\ QWVN#>!:3.58\S7@/'?=,X&^ 9<Y%K8
M-^QB,%S-(D'6,>%8LLS;.>E$['5<-I<9CDTZ([BZMB[=H64Q7+.>2@T>UKJH
M_R6()LUUN RI _U514AZN)X<*K1EHL"4N9G2:1B8/\SH=)/V&2^]-4BF@#QM
M75ULEVTCA%RS6I>[**QC1=\>+G'UIZ+5!M8G=(1QN??<D* !B&Y'_!8(RDVA
M[A 'UWI[J]=M+)@6\E/I<=M;;!I?EP77)F0,%N?[WI;D@B*#/ 9;;^3&&G22
MJBKDL*'80RC1M28NI"44$&)LT5VOT7NCJ78[IW1[!VQFB"_=X+Q:Z,QM5=]]
MOK_6"1T\Y<*I8X_Y<+F!O4UM,J5WS"T9=!*J[J"2F0-93=4G!D"$PR;&X 0,
M%SQ;GJ]V"LWF#\*R@G;YCJW>[<I^R-/KS G.=\UQ!;OT'4>E7.'],/V*S;XR
M.BSH,#7$/2V5_])UR68_6P@B*)F:>Q:.,K.6/!/<YJB#NF!SIY9TB.%.6+=K
M2FG4(JK2%I XYRAPB-*< R@V96K+<221Q5ODNP<%;)4ABFV-'K\V6L#/%-2S
ME S+!JTO^2#U=?4P9SGL1$NVU-/B+G(Y-)O8IJ;4 [ #<*47MK:C$)O;N+4L
M=Z.?@_P;3W)[JY64LAT%?5:VLNS1XXF^0[,-%&F])&.8UO<<'6+&VW.-S7<$
M?:!=7THI"M>*<,NT,95EE$8[K?8#E;@+HWFR)N4%Y ^'K-DY)2T4\#&=G+Z%
MWCMJ+NC%Z"^U;[,'URAY*FSGVCML"CHNJ1KO[5<*WIZ*A((C!!C'FZ2:)?^*
M7B;+%*F?7S0D[,/#[AT5^4JF8H#5S- C&>8MG8M7W*D(OF=E6W2P"RKMY%=2
M)-E+P$_EG;PD+NL.!JBFU6:7W4\%Z.H8/.C!3\TF<X/7)%.E:ZZ%+Q3=JU(E
M5 @+R"8KJ7'9WKKI^56[&[(KU.$.,()<3O)H ^%)*Y:=4' ^M\#<A!9^-J*%
M[P,M_'1$"W]+6CH@,5#9)6-O:@95@FJ *\;[91)$G&<-3,JZ@XQJ!YB'R2LR
M+BID72&]>XMRQ(_<U,;FU@WBZ^X]@]@X G297ES2?[0VK.]47",B;??1INPE
MY2QUSPG#)PR#>+>WYJ3RN:*_0C3*M89B[]^L"KV6E)S/,J+JCVS66X+D%MSP
MUR]0.,+OV4A)WWTL=U/G+>U]]X</Z/D__0USF6W^+!W-WN[!89K_217T?3SH
MWL[]__P?+YY]_^('=T ^=H"?6#RYHC#:X!^ISW(HU<4"EZ34:9F<Y";SJ..L
MYG[9%L\25 E.R4;D(L$:T?WJAZBU3+AH<2Z^Z!GS@O=Q._=[?W^+-OB*UNGC
M5VB4MCM+FV"::LD71F]>';F0L*^<#2A*N?O:U*2H&Q[Z H+EFXTD2&9#\E^_
M.G+QLM)<I;0$#)M(:@QN%.A1H!^$0"L6<3-1ZI(46HQ"%PA@HC.3%U?%3V8Q
M"M0H4 ]"H-+<M03:4*1LBE9S9$#52U>*479&V7D0LE.:BR8#Y&M#X0'VGUNL
M!A:B;PK5Z@LTU-0KJ*8@,7175H0<RB;#X'IBF[AMPSY_&"5XE. '(,'JJFWJ
MF5FQ!ZV!E&J- C,*S$,0&-=F;1.!T9NMJDMD#H01^M( 4C5ETBZM.9..:J,H
MC:+T($3I'CPOQ9I:\ZUJEJA\0YK4686Q_NO+!&C=\B:C+][8BA5*B@!7,BNB
MJF!"%4^TPDG(,>4PBO5#$>M:!(NKS382J#DS>/LZQ\J45](6LP_+Z@#6QTMS
ME*Z'(%T?&_]?&,-9.O,!;'%!Q1Q)VV_&\B,X*G77V9FQI:-PC<(U"M>=A8MK
M7VEP"Q?!#(4L:%Y?U0LMX5TT.5F0HYR-<O80Y.SW!%$4V<D4]DZ@/("_0]DZ
M2M0H40]!HD0J-A,HQY7@4F]+<!XD4]/4KJ'")"U"+FLS]2W*NCQK\-U0W<O"
M/=ML+&CO7:9*09)DJZJN%.T5E6;)#,7<;T'PGS.1_%&X1^%^",(-ANQ&0<\;
M7IHDEF$#$RY[$Z9NA%>X3.\BG0;T+?+);T5*WP;52E-*^$4K\MA63>N/& E7
MTD6^V&T,W(Q"_)"$.!##S00G2ZZ9ZSZ.//^ I\OD:J;+(@.M7]B121H=5\NF
M-@%!08BWV33G[YN-#?=\[H^/_A2RAZ-UDS*+!-6X'YO\Z3,SVTK:,%(\:I=1
MNSP$[6)!J)N:!U )H"IJM+;]O2$CGQL(0U=Q!^N!CFJC5(U2]1"DB@DT-S:X
M>[7&[OH-O%PVAV.EJ6+J"&<<ZW?]Q3[>8J.\/0AY"UL=;"AT&A;F+N7%?,X0
M<Q*@G689$.^-<C3*T4.0(Z48VDR(KHJL60R298QB,XK-0Q";D-AEX]RD)1N-
M2I?U3_.YM/N3OXT(T%&.'H0<:5NJS43(3(N\6*13A!%G-*9RI1Q,;-?Y7.5X
M&8U"]!"$2.J#-I2A93HS)$,VR%XS.V K,H^D_<NW_SAYM;/_(J*Q\O=C'Z+(
MM>N<1/X6H#F>I552(72_V6!"5KL@^0'ZB;0JFV6M>03CN)FJNIEI$Y(N89-#
M')3,=+BA>]@P=,"DRUIP"I8^.2ADY(Z]5R"%=KT@F K']NWAOA-F]@/&,6J@
M40,]  U47VXJ9](U2/D+9Z[)'J.+TBH"HN=@[P=P<$>OY5O\I_T?&%C4:N1L
MC\Q_*/_IR&S99>27BE(A&X6-I'3V:(I0IN#(FZ$!#_HW* TF-_<4)[]%8<D<
M6M(:PK;!"GHK"ZVEM/CS^$MTYY'*G'F$CF/U*@QN<SP.C30M+--Q6X;OY5<6
M\]J@>;1!B[!2:=F%C1\IYJ)D:I7:%20H^3-RS*9DAGWN.LF@ZJ(RX2M_+(O$
M&9#BCZEAZ7@Y$]0\9!G^5XW6P Y=%LA>3]&U-+PHAHS26#NN&^2ZKX)&Y@%B
M=2T7::S=73)3.7[I1)H/#,Z6FV)P?Y$I#:J,VZ= F]$,'0,E-\5F:<-<7M'\
MHL ;!JR"MME CR@O3 #V ]4I6CS\P+<K6M):AS<!(P@MS]249+'KX@MO;63_
M+)2-KN'W*BH]*3]#"VDCI[6%R]M!14I.KMMD%/YKJ4&NBS*;@:5U['TP1%Y\
MEJ3"9AZ0%EED%]ANI87[+,T:#ELHUL-\2"L^A&%.BAMLT:)KKY6 E+UP7;>U
M$R)M;)H#>'89]'"C'[E&8T&[O<%>@=)F9B0\'M[:?QKI0\DMC 8VUK8R"KF)
MI5UQ6\+E6]I-@(W>] J:5_1[3!?ZI+:%8_E%@"K2]CNM#BG-<F=>%@ -"+F!
MB#M-$$H@-_[/W)IG'1)Q-WK-934)^%RYT0LKMSD]9L9]#1=Y.J%#5EV:; XU
MFO*3.(%4@4!(R"ES/&81G>\\D<M.B]R$4#NYN(#^K:'6YJ:4J<UI CAUWQWN
M[>YAV)F2R;+_Q'?,RM%1!C=?P!6M?;2WM[B]<*+WA%\AV\"8D\S<89!NS)JN
MHRNS0W<#^M,9=$*'(Y49VVTQ> &&HB;5))FL=G@1K$'%;::Y^1/W.,.R;6_I
MNK46*AI:IWT16WQ+&P)/$Y)>\P%,@96[Q<C#Y(0;IG.=E*7T^^&^6-(5L/VC
MG.Y%W$M3[C(!'3"EA:/Y&='IMC/"C:S=M% HLZI<(=5W^WN[S_>P6-(#PK^P
M]9RAL>YN;[UKM2JTW8*D"\4-LL3&%VU<8/_(U<:^"A072PL.;]<ZBJ.5]G#3
M-F\V<KR]=4WGC#U/*&!T!G,-15D++IB955C!LY2>*SCXL/^0H1.,*UJM.J7W
M\?8(OUJ5<((FDX%*WXW.N2^P$W%^H2>D#Z^%]DU 5W4AJ&*L!\\<G1US.0\T
M9+0KYJK3#^BQ:EML!WV)W13LI2(Q>-=T3(??:C"M?6%[>P46OLKM5%\1(;31
MUT/+ID0I0RVS&U9'V"'NZ!YTU^QU)0MN.RY2XJ;OX;4WT&068[K D?1-H+'.
M<O?Q1FK73'<QLOPTU7"#M'4W@5I]_G;M&;("*?6S#[J:5-JRG!=]0I,T4"E6
M)5<--UO'OLKZN[XF06^K1LAOO%&;T27T!['4[M(WY?NQ;\I]]$TY'/NF?$OV
M:= WY8VTE.)&:]I0BA76S*#WE/22\L84FX8IZ4VZ\+FHK-TJA0THWP_%UHL%
M;#R+Y#U;%7F53%VA&SL>K7JSF;.JQ%\)-*<U2<)K:?1#AO?Y+19VN*=8=%-+
M,;92IRARJM$&%U<$F2E\[\51ITMXYX2PP<35]](<0B)6,]C<XK&J(^K:$4_,
MW48D75NCH?,J9[4:".-<&SV9\X344:O@P_:5=MSXN%I5<85>P=C?Y8OD!<;^
M+O=7B;!A=9-ZP=I26%2WQW/^JRG4=?;-!IWXCU" ,1$WBE3OGYF!XTA.O#CK
MMCUS]V9.;/!H:7+T)L;?;?1(S"R^76TH=U(6[S?& %CS2<RN]A#8T.(^IK#4
MBI+Y4=&6FYQ%CEX)<XXT[;9Q"'W8ABM2&O*W2<EP']*A-J2.H15IA1EW5KZ]
M2^>H?D;U,ZJ?WC_N1E\@*Z>YPDJ[1S&U!P<'2WC(5JPTHCZB:T:I&J5J\)^9
ML4'T(+X!]IU6Z#O$8)1##6I<:+_E5X^PF]OC5\BR.FA@D(4+EGR:)5452:@I
M8#X8XT7KX4P"[:CJ>.TZ,I&%X50TNJ<'A!)H-Q_ AR:<[ZFCY((./5\REA/.
M=<\EFW?&<%/39I-3-)-F%-.R(T?-4H-%G*\L+03&MJ4IE\@/&4Z/U QU(NNZ
M!,B-_I>;&'*?9R2&S!5R/+CUFHI&+7"+%L461]!TW#T@3TCE([E.&7< [.%^
MQ S&69FD=$DRB4@A)QN2A*3U35VG,90*"3R,5ST"XS)1M,:D.31'2>N:(JZE
M&<"%XPQP.7*0?^1N0^E]BAEH171!/];.\8TB,Z"*3N:M #8W!7<E$T*>!B)Z
M[!*C.8"[,14=ARDSX-N_T5V \\S(A[(%NG'?3B9%T\ZZQ@-B,U<F?#Z28NE9
M]TGQAK*]*GNC/AS>7,Z0W,'O!&6'08HU%1B@#67[76,)$]8\=O]O.RSV1,AV
M [.BKVWEV@5&3TJNX0/CT[BB/4C/)@Q?(%VKF I /6R"?^Y?%W:QQW_(3P!_
M039NFN [DLEFA%C(1RW+PO4*Z5Q;HP<_&?RV]EO?:%ARS.VM0.O1W8/6B0ZU
M9K:2Q<IYD3BNH4 5]Z+KRT)<(-P"L^(ZOZ!--_V,0B"LC!"RXLK;\Q'R&GEQ
M[;WJ6E-J[PWW!Q5!'9Y(Y:="5P2,4N_0*=A&_3E.^B=IAOWPFDCI''/,7H"U
M9;8*LB<9<+Q7:95.W)7&&^THRQ7IJG<'LB<D-TU)$B8/D&NU#[TMNVII<"70
MQ<,IJE%!#1K">KN(*/'N(HF;0O94,5G1K(SA(VH3>-!-R.XM&I3*XK#1PBL^
M?8EBH#2Q."+&*NF=,F=0*389WU\);8HET!XOE/7 4+8AETDZHPT3/)[?ID(P
MAV)NJ^1Z&8!=@-TBN=3MAH*;IDONN).L($>=!^J^YP8$S*9<"'R3ZTB&SL*U
M8>Q;/A/8E#BK-"#Z><XP3&"56.I%FL-^XA@9';\DMS9G6^FM&SA=*#)RGGAO
M.=P*[$9'4[+LH2R@F_QUQ>=V@JL!O%E&AR['6)"<WHF0HROTU%Z_).2RE-9T
M:IUY>A2F#F!KP XOQ]X:RD!+Y 9W!SLCP'_9H0'U-; IU24K1;$&Z9* OO:2
MQ:43X?AHYOFJFT-8)^ "Z+*P1:X63"07/TNK*8T\W)PB*6>,#TQ+H1&67<*/
MQ:*AL>1J98A!@5\Z7'D<W  .L!9STK_4<HD0I1&W_DL@BK1=DU78/C1+KH,.
MHUH6(K>]#'=FS*)RGMMX(:R[$%C-I#F[QS._KV$-$7\:@$'9N100JKJ??KLA
MH/A P>CB$J]BQQWI'4R. I!B*!A3//AB^32TT:*:YH6/4,6"AV<I*YDTIT/%
M<08M0G6^_04,'-%$2YPVU#Z-U\[PJ3@B">IOG06*M@Z)KV)BB#+ YM<(+Y -
MF%_0?_R+I)I&QX<AEP(DG(V+LKBN+UO/'CYNY"<'(1/N.1RC-1LR$W(+6-F'
M*<.X6PL!GZ4SC7/@V,IIU(((?2\7M47G23E)Z-+9>?LA,RNZ-O@<'^SM'42/
M-,%Z_O;_:&+U<2PAKU?%;+;SNDSR]]$_X32=UR5 3&> (RYX5"]):9&)6D:G
MGN"4GBWF_""ZB=XJ<*4XF%:@ZP(GD-.K(BU:V1;H2%NXT'EZ'OVZ>[ZKYCN#
M=\,-3ELH)ML!)6&3W]W7BX2O>\L7;QC3G0)%C-N"S'Y<)OAB2]'799'=21RC
MMVW-X%?!$5?*,<F-W-M])8&#&^H)G\.R&D/\GV&=L1O]0E8.AA;K]WP>.UQG
M*P>J"*'0I!UV:^X2"=2WJ++,9_)COFFK@H:D&6SL*KMH&.?.E ^//>#X+;S2
M;BF-M=XOY<I>-UPI+F(H95K+2T18$([54*:GY;67NZP^,.%,3)PX7XXV&3.R
M]@PL"5CUXKFUWC)+\7-<#'-T]E9L9LVWO0Z27RE*(D5\U.3I&LI2]F'-8@*>
M1>OV]2V2#IS^QE5)2EN]VB[Z64EZA739$@-48X1^'H>77:Q&H@HHRS?B.7J:
MV<ZC(YFA1!;6'I\_^CUNK M4?O#9JUR A"V;3IFJ2 F&,REF6H6;6H(#'_)5
M,>"JK58Y)HI2V:#TYS D<;Y,+R0 SH$ 855 H9.,Q9:5EN9*.D2SE+7E?,VM
M.MZFP6UZJG4I7/!QKC?!T[VG.+=TL?A+QG_D+AMW,4Z,U>:L^.8D<1SO4W5N
M^RGVY4<-<C[.N=?'9"+C4'H][:^%B:&%X4/'M3**V"M8LV7X,X?<R,G(8;&?
MR?MMY=G^WLY_15IC0U?K\<OQ-+1/P]^+:SA_9$:XJD"ZH<5QOMT^@CW3.0JV
MGHQ^#M&N1&'9<U'DO:V/VCN_O>6WGM/1,WN8TER\.O%AI900U5]B-@1&V#Q%
MI.!=87UJUL^<3&NDX815/GPP@G,>1P7_&1;C]M;'F8RT'":_H./.-!6P\0HN
M+N1>OM/&QQJDX909%(?U:^*NN8IT,+\?=[%<RY=D^=&[Z5M\[3!%ABC=8,<&
M3949;@SCAQ&DTY8%Y]D0A][>DIEQZ2.BXFP69+!M%(XS*^AL(R=**A^5H==%
M^9Z+LOBFK2HL!.=?[4IP&)N[+D\9I7O+0GBU$#,=@$R!#L*2%YCL3;J\C/NQ
MKKT1KW I+0;0EQF%=%PHY^LOC5C ;+QX(Q&'A^XP'!#U(>W0Q>'8WDIA_LBN
MVD456]<>8N8JD($MM,$ 'XAY<>N^^Z?L1J],M4SUN)"ABY!W+/Q%?&LGDB"V
MSD8HG5+VSEO.HBD%M;9#4^E856 1S,MDP8%ME AF6>S1GG<>*BU)Y4UQ+)E3
M#R3(@;2-JOCFX,=,2/,-K%@M]K@VR?M<3G0Z?)'><()>2S-*J6.BWT')^WWJ
M/JBRZ!1)?O@ .>)L=2%)%?KN'.-DMP5VNVB!3HWP73A+7$)P8!P6(> &Z^I2
M.R?<YK,8&R'W3=-># T#.@*NB Y\,QL#+\,G\M@[U'<^9[B9/"&:=^=L)A75
MS!*T[_Q6* M8"V5P#\G)XF@T*_I<U88SY6C7TMH>)/\HQSW *I\MPYF#$S"
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M%#"",5RVV]=I7Y"CPN#*[T'B"&E^B%_EZ'Z#QA[NB-MR;"XOYX2>^Q&P[ZY
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MR,(_L?4OE8]N,=KA&6O=LWL:P^H@Y<?OL4WCVJ:]7Y*UD7=7"JQO\[-T#L.
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M:QJC/KQW$[<8G#3]Q03+T(<LK)*F [Y"+E;KH-AH7Q 7OSD#HNPOK(N'XOL
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M&5[#A?:"SPZ9GCTLU@ O>TA]="Y:V?X-Z"FQ/5S-&!L4.RT;#3=1:Z^XM6H
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MN7J,07':''1'L"\[A\&3+O)PLS<U-+5#V[:?G6F[DM-3:,V*-ITT!3.N+:G
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MQ;R-(72Q/5K=RK!+&:H/V4YE=Q"2X#,'R2[T86Z&S)(W0UU[?O',>6"Y+:L
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M5#48X=B9JXLRK!CAV'F>1G0CNA'=B&Z,<*QH=OIMGH\@H#L2X<AMMY##$^+
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M"E!#"-Z+%0KMHZR;E*L =JT;1O)65J'PY*.0R9YDF"K89P&[,/.R9(K%S:%
M?J5-B&JE42RA:V5/NII"_P6TQXG4 )%B)5CXRPX//+D:($"KV-N57>RW7%RP
M(@(0([SB*Y"TR[;))1H9EG5\UEE%H6\SD"S ,X'G,%JV?6 ==2)_\8:TBW51
M#JX8EE8IFG5.G=YT;FG+MYP-]L#TEF]D4R$!WJT?\#/NV[G#V?YUQ.[VK0&#
M^;2<#?IN(?@69-IQ]^(=\>HJP&:-#:%U.P(I8-:,9A!];ZEL.RU!+ ([G06T
MZE+.J2?3H5XM7L>&KH/EP#C4?HFP'5#.D_49>T=8X1+0NX8NJQUY*"K33/T>
ML;TKNALU\\YP+*)UMU@3S>I(P[I)L]JGI@'QOSD[>E=-Z*G:LKTCJHW9T%,<
MC#;TSBAJ5,,[P[&(UMUB3;2A(PWKIFQH4=8',%V(5]&<::(NT7^,AZ8- 2\$
MC>JW'ZXI#DQ9%4H]L9^@MO7Y/@Z[1"6-2CK:7(HTA*R)K(GV<[RH;#OFFFTA
MHX&,!G( A[L21WP\XM<3:-4VH;$*[614QJB,(\BL2$/(FLB::"?'B\JV:R<C
MPM%,?OOA;E51:)T(S1?X;/WD[*1RDA :?6HH)X3SDU8'[654RJB4H\:U2$/(
MFLB::"_'B\K07MX+A.^TO?Q-U@V3J$))[1%%%*[%3E?4%5$E>TA>J(Q1&4>;
M6Y&&D#61-=%.CA>5H9V\%PC?:3OY7'R4)>%<%@>:*NTA2:$"WA,%'.HB\L '
MN<=C2NTZ6U%SN!75X:=PMJ)F<"MJV#L*[..T0^37D)<K=&7U/IE,.1*G66G4
MFS=LO4*U=EYI5.A_U6Z$9N6RVKJI-"OG0N/V[*I:%DKE<OVV=E.M70H7U>9U
MN$C [>@ \HT&$^R)T#*USD-?4V#5*1NW[>U?]+0NTG\TB:H]:LWGA%!5.SNP
M:SO:(%/.J@]E5=94MIX6KL4=\= R19,/;D=>F07R=R+TQ4<BB"-)-@DG;+'3
MT0;TQ6Q%0EM41-!B1I\0-@$?!M)[25QX!]_YW_\4T^GDIS+_(OM7ZM-[V,H
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MO62I:23[O_*3]]_B]\\?(I3F.,SYU5]OD=^@]V(.ZH]?JS^GR*^UIG,[!X#
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MYTY-3D.P)R&,U2[5J!E1[9P]_&AE0XW'UF=.D<#"I2#"[W,F8-SHHFITB6X
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M),34QI>&C(8:S-.G?@R,TQ^U%;E#'T&_0B_G;2084:FXQ9AT:B$C\ CG&IP
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M@CY"Y&)5OM02 SV"5+Y'5+ZT_1E@E4G$&".@? ,RSEXQ#JH'I/+=I_*EU4.
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M7"]@(J,NH"&PM)&T>MR_(\@#EPN3BUPME?K!E6('N'B]T09:8L7+/O]@AL]
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MFW&[]\V%LLL;FQ5/4HWX&U63O(E6&_.-5=V _]5=[;_P064CQ.^8Z^4OVA%
M6-408'4VBX::B8F8+>7==,XM!&@$_NVX_VINJ_XIG]W.Y L[F7RQ^%EAR&(P
MSM6WH<@D5A])V-@(M(Y&#6MKZ)3YT/E_ICN=B4]$"*2!F;-JE__(V0CA7-G9
M5A2[JLA+/G3<*]TB8 <I1H]@P<#2D*/5S*-:UR[8A5H#U)T<%!C4Y&C2#1GZ
M.JHO]*7PB9LKL5GA5TY1\ZGUCPL_;_8+N>L"*6UHONG#\J_&Z$\9*"MG<\2^
M&RS -@4]B]T;W#X$ ]T0INXAYH=0*SVJ3D^[>QL1);[JG3=#Q5WL42UYBS;
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M2OC+2^7NX/'[Y<-3;KP2'L]\9ZIUSV7U<U:[=_+C8XR+5[NG]('_(I[/D;
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M*UF?8@N<MYJTV"V!'/C<=E*O,NP*]1':/+T#)#5K4!#X;<>%W;\!H'NE\!(
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M[K\J)J5PE>W&:7O[YM9H=1N+BTFMN(8WJSC4C#6\[82V 2MT.=?3^CCZW7A
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M+-+0S-%6]CWWHO!8;-PTS'AXR&U,0>VVT+2-K[RM7:CMD;)W6;@VE%H.D&K
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M;^.-G\PL7P)@,%E,^B6+?87BX:V;7X%,4[#8R"R./[)$J!726OVK(=/]QKM
M)H&[QO7L2?V?("V^GZ@Y7-MR4>K<ULQ'B9I%=8C7!Y,2,0I_GCIWU.;=BAI?
MXO05-3MSS.X"F9NB9C9;3;MRIJ_.1U=#YMV)FM!K('!)27/[2%M-4,<O X7C
M, '&%#E50\;R]Q5\AVN6S[3D(:32 % Y"TZGQ=J:X^!D(I>8(4.M9_!YP_YK
M?-0]U[MQJ.4UZCM2RM]%C=P4[4<'V9947NO.^(QLT$>@_0O\TSW7NRW:J5<\
M^%O'UV)W(;AV0BS%J!)6U'ZM^#[Z-037E>(K^&O(-[QR[V)K!^E4;IALS!K%
M3BG\:XBM*R&=> WXAE/O-::6%.8"RTGL#>V\/:ND+AUGM6\'"<(B=-RGH2)8
M7>7;]$2*.R2^ 9HO"1.[CW^>_C4X169IE3^!BBWAM+<QZQZT[I[8V\W(:$=4
MSD6V3^*A**VSWXF.#@C$+Z0BK\Z7 [TO@9Y15R9UF<R+.C/X7'7O5C_,9\I'
M-^MJ1KJJ"8/5)4W(I*X(TO 3)<0*Q\A#"141_^OTX?F]J13PGGMO)'$MG9CF
MN=AP;4"@AV HS (H<OT8C%O"?Y_)*!?V4EX"FS/@?_P3HJAGW'_^.X+L#O .
MZ[DU\'9$BE&7ZOG\R.CDQE\!O'-MI5W0$51X'^B> ?VI4%X)<TY</0.[TJP^
M?]F]YN.#=4]L  [I4:2N(CQ 4Q!(!QAR-+]"0T&IFO7K7F##!/!#49095,\.
M_DZ#"TUI18-2EA8AP 7 @.:!X#$@]S BK:K" !AFZ%%6X;QU&EX664YYQ4HR
MN ]X)8=I]!+K<Q(W$, I>7H.T,AQDIOW!,DJO;<[5,SF=DZAS?YV>#5X>H7C
MP:$!M!X?1%E5446_'\0P>JU!U-=+5L5?7:SYMF]=N)4E*:@,@"/07NX>$Q\M
MK/JI8;]>%K<(N/";>@8^S%/$,!T/P-*]3W596_B[4M<#X+O'AW7GAMF! *P5
M\#+P+161/:1:6;+)WI>>;8[=Y1M+FR$#)/RWZLM'CP\[C(0A/F*1'L5.4*/8
M3_1N65?!7]2_OEG72;1GI-E:N!/E@FR:.:;KQ&PO012)N<D62YE8^18=)QOW
M\QM!Z#-I\(AJ;&]OQN/'GB7:/K7I3E,(,+AM!%)1JN=E=(W'>5U;=$H"1UV^
M@^2$^O[]=??7ADVPYV53Q6;L3,R+I7JR?Q78'%N'?P V1\> [I5,0Y>'KG^[
MT1^(F\3_F_'Z]V!?1R+AA^?]0V=0"O1XYVLYY#HX+>L%V?0US/(+YULU3@6\
MP? QB4URP(>2I_#+EDJV"S/8&2$R8J#*%\(_]E/XF44%[DXY3\_ /B:RGMCU
M0;=A[K1N[>_3<K4R[0:1_N7S4-16Y159O'#(P54=9SVD=P26/C=@R_2U Y2'
MG^T-"T_(>;/MM\;);AG1;7%">B6'SD2)MV@YG#\\4[1D. FX32* 3XR%65U5
M@T[4G-L2+D*XK<BM D[3U!G"Y=BDE:^JL$Z)! N]<<ZCY/E^FCZL7R[7_/DU
MDNDH)%^ #X*$5PSP*(7[J6[@WP.__E+N5O@E2*^]O!? K[?0.]R)9@D](YH*
MM /]0D*9CJ]C^QPMJ=#F@(/!K2^BZAT%?1<"Z\SLC1^1AJC#!M+W$$)WAJ[/
MY(M\)0H5OK)$.7:N8J1GI):%7"8LEN+Z.<'VV^5-_MMWKMK?"<7>=<8G)ST^
MY&E)IY65%6AW9ZFM*50[Q7,;T\*@9,VIJLZQ9E:\ EXEL^;@T9J3%D1?0\F4
MC"*KZG;R&B<V]BW!L:1P8./FHJ3&0FY8D7^@61L+8$2ORA('OVR;Q52V(9;Y
M26H6&JSKY]:Y22#Z)[*5[+1O]XRIUISD XQYUD4/&H;@7^L]2P=O>-9&=7L.
M=. YN">=;D(!YAP4'X#I<'@L(A"4B8&GPC09H^$555W4X* Q6L5@%A?._8-_
M%5@K!P2340JF<LH<+KL'KX#/@L!'8\9@\A<X1>S64+.=[/[.GEG51 B:7 OP
M@?[F3#*_%%%E,Q%!B%7"W51_LRQ Q03T>@Q.3N.P*8 .@N)1,M[KZ#ZSP&]
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MCO6&C#>7?D&B$!5[>Y+=@*UTZ]%AN,6PN]J5MI\.)]I9QB&J,[FNKOTB2%U
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M07#"--%VY<:WWHH:[!E1J5JK1Y1)=;Y>SN.[%;4\P#;D&%1_-DU]BUVH%^U
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M6G:":E>FEE"$>@Y$3IIB\.DVM[5&2%U%(Q@%B9FM^&2NOKADH<91 M?JC6O
MD5)?U4=WNR31U:7FN;']LZ7B62UP?U!\$5%W$T%VLQY'N?[196+)6-%8"Z&#
M(V2W>FFF1__PY*G:Q)^IVI>9JAWZ=:=JW]<L8-^1SV3/*"_IS*+"!H)Y\>R
M_*\P_3K:,]B"*./*N]J2_PR__C8DX#?\^OK-E#6SL;I"*]JJH="2:NI--2FH
MC"C#X<I^[97NG2TG/*5G=,(K;<"F4ODR_2T;+H%R3X1BXVQG&$N0L.&2>'U\
ML"" (1!@;AA<L?'RN([<N\XYY^#Z(EK2X3QM$B<BF^E_Q&CV/'2X7E."JT#1
M)K*APIE[M]#H<-<^V>VI!XS\,I#1'DYPC*3RBM7H"7@$%AO2_#.,AZDZ+6E(
MVIA#:>%WX(?KI5VN]ZJ<,A<8<SB"U]L2/)Q-7N18M)6L/!B +RMPQC?<JJ-R
MJ&W;^LT+6K8GP_LQHH#6F(%3P-G>5M^Y<T=[E2/LBP3<BP+^P%*O<U/-#/J;
M>]BBYHCR$MQ(AOYJ#0)[1HO]S,6YXNH9R0U!TLUU;<#F .8*6B&F8J(,00M$
MKP,#>YL/JK#PA /:G8=V3YJKPVAK:QDGH+'U4\00<%,FCK'T2K4@!?/1X/>O
M:VBCR\$V=O#SG\)?F#RUMDJYHY;;4Y;=,\GL>B6.A0#F  /"!\04!0YO@&",
MK]9?J= K^*<8?*$5'G55-9KECF@^L\#"N3)$& ]N[++VDWCQE?N3S?W6205>
MU(H6KQ\%#<SRP'7.S5\E'*#';'JP \[5Q73PD1G-JZ'U;)NZF:^'=T3Y?1L.
M&+U^ 42/ZOK>U 2&"?YG&_+/[NJ:9TQ",#GD+UX<"5YS<8CP"QYT;>;> *SU
M-U^P?<[-Q)]QW&L4E#G=>EV"Y"V)7)40@/6*],I:GVBR-YKP/^=4M+SUI[#F
M >PN6"""A^^/!6*-[BQ7>R^0'>+W8H'("Q[^$A:@CF$!9_?&(1[(ZZ*M^+V9
MX$@N"-Z("T@"#P7P>^,"NE%XKS>#XW1Y]%MQ 0PBAEX /F[.!>3G%<'C@XL+
MX )/9*J97  9 %-H&#8R34>,I.R)4TZY*OR2:99-)C#HY.Q)AN^%RH6@; /P
MIS#WYB-Y #R$+5X*WXZ7HO?'2]WD2J7Q&A$RZ-^.EZ)?PDM!\IG$ Q<RJM9.
MT7Y^HB)'\=/C@\U0,7T(@("1(9NGH.?STX>MMEDJ?BN6 H"\/R.MT0X1-5:@
M.NGA?9 Z^8('OL1X G03B$8NYC\ :K-F+^Z2.3#!3J!SS(?,7[&<M"XN- TU
MVV5W#N8*QK@B%)JS]ASV?] :!EYMEHU;B\HQAE;Y37D*#K"S20E?SS!.@!^X
MZ6+#/4&UJW=&^9I$2:E (TX0?4>9)'9N#>OL$9+VCD/>OKR/6V"6C5R1LO&=
MV;)[32'G<AO+P.&*/TU6W*$D4Z)NB7 8U(+C-=WP>GQ8F*-)%0YI6D!H.T23
M.HYHHO=H@1C10HP8E/'F/'@;HHE>7_/O$ VQWX!>4PW KG-O*U"Y7@KIA"%Y
M<VJ<$ZNT=\S;&=:=,I^%6>8#I)L=+WU\L"P&;CONK/&"PIIR#4DY9TN4$PZ-
M;8:CUT%-)):M2SGQ9'0)\WK ''%%50<<ASSG'7(.["=G9$P3Q&5)V>@0P?<4
MEZK&N=O0(2P$(7SH\%PR [IQ#YD]6[8Z.*N#,A6<$46[)1D3X2I/H+LDZ'[Q
MLJZ8/5$+CAO#W]AI"G N0"_JZZYF],8Q)%4TB'B/ (L=QGC [-NX(,:+J4XG
MH==JY$BX#<8#9K[RHA@/[A4LW&!@9D(P.^UD9DD"F[-^)_3J&>HB.%>:%52
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MB7EDD"L*G8_A__YGFM#_'U!+ P04    " #G@W]64AOB6K$2 0!Z5 $ $
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MI+M1%\ !BILFW&&PP W,IK>]B7EEBRX.5_:.G@M!,_$MIH7462/FD9:H&52
M\Y+RO?^K&B#F>//T&Q/[=/9V+6SENS>D  64#H>78]S,NPKM&*A07?\08H4*
M+5O%G/$7@+O&>\S:"8E6$"@YB:#RW %U1@#Z+ZC<?T];.+:L?WU0"1<]0+53
M,YB"%,8,(%8WM?X5C2,XPWO"+WO]H8FQWU3_QT-01!/4E5#01-PT!/V35<?O
M'5(*?8OSWUU09X8>Y7Q!]%(GYLV[O'[N0-5!>,E2N0=6L)/,6L2.5VDKJ:(O
M0$U/,/K5QD&]@I&XE:H!5I+J7'_SPR$52:'+JI%W-3IL+_0$?9A_+Q_2VJI[
M-?6XYM6'.7LN76K$*VG.M51G?=71#=.:&_[FUC)X)?NVY]:MEC9T<FHK%Q'5
MC'+6DXA'R/VE0KB2*OM)'HZ.W3\@^5:+GUNGOU*A;5E+[-^:[-@[1!7$E64U
M!70"%5C26=65O-"Z!/JAE:DW65YRN"/1NWP8^S\G6)_Z$#YY3K%:BE?Z$*-]
MRXI:%OOLISPN+W<KSYS9@8Z1D1 YDP_+6\0G"-AE%W*6N.&S-E##S@QM00[N
MQ?67N(M9NMXX=V;'5K3</&N]]9B!M^"G:J-W1MCZUM)C29E^0D(2'NUIK[X(
M-*@D"T$;.XPOFAE'C[?=J@4.>T1;]N'(OZJ6P8V4U7E$:8W."_/S8>RC0J:]
MR:0C\N)%=#9.>H9O7A7TB]ZZRQHS6OP>KQN2%,_NP'>Z7;]Q$>V/V"LK-N=8
M)3I9+M 1_S['@!<M'7K[T_FXE6/E<M<IQWR^AW]Q60"=9^!W_?MUH8OT5 C]
MDNF+9Q>P9*#'O,:02U:#M=HPL%M4G_/4T3#?*O; H\W79+ C^B8C7*M1G<LV
M ;[E$>8,B0F[^G0KXT['^IZ/$SYU#_K!HI,]H='0+73FDO>JR(4WBLYY'KRO
M\29SR57(+;)BC+Z#WI)GMIW^=.,CHW($5TZ!@_=D)A7:KRM8E:KMG-@BY=*<
MDLANBGZ&L3T:7('BDF?&+Q_*/N,Y:&+/1^0Q?K&5"CE'E;=KLXC*\"@-B9&M
M1UKP_!@_U32B7*3ND7[[N GME4NHXD3_X%7_%;6'E&,\XO@;@W)W)1>\DZH$
MI=+NT*%'MWN>1@_<&A3N-DQMVG[\$A\(2IV62&,AH<-M';'OP?[CD3Q<X7-F
M<ST]B0W6J=O<0TF9.YCT%W39@U,G_50[IC)DP:[7<MC'/M"^+?:5E9#,_Z9O
MXER1D2C[E,% G%D8Y-#G0>[294>[9QTPW*EG6:Y*A:0=1VW'NTF"QJG_=^W=
MF!O:O9#6B1/[7._.+M@&FG[KX7;\F''%W+^R55:%_"'-2M) *619\1.YI[]9
MQN4=O8O__]&F:;/5 A7R-V03\MD_ODQG8]HID:%I;YTT_N&]=M2%SPV(XG?2
M1Q:SSF4QX;L'-0?82IF&FLY7WM2I*G;XIOO] I<-7T^O0N65:\[J;GP\(1K*
M):*FO;H'H@[C0S))2+S/:LL3'97RSID9WKSW.>V7MSS/CDQY_O/MCR6C^]JE
MO#A6';^AS>7;<']IFVA[[DKI_79=\(2F4HEU$D=PD9K70CCN3?F^2=>H[3@&
M"MK,S<D3N:<JPZ)8G_@PK]34_3Y[$7/M$8'%K+^^W#''86O=9,ULK.WM8L<]
M3GWPMWX2SBL^+S]*=[&9C<7A5'@!NXGX2.R,8=6-XM^N>6B'=]G&PE=$1"C%
M!91G5G5?%YI^*\U?O[L=S<Q,BIAV6^#*E\1RIH -(AUR 8^:]1_7VGT1.^(=
M>"G$.IT*/6+ 8&>I$%<B_-&/5$:%AO,,VN1J&GB#XXHQ^+,M)#(X]0HS=[]@
M[9/G1;\3)5R1VU;2X-G;_YZ]A0JU8"G22KE/.DP=<G6TJ- 6D,+1+:2[8'6I
MW(*B$;*5)2C5-VOZ3\#Z4*%D# F^<*A$.FA. 1M37+U<PH60MXG2UJF (0M@
M.$"1O@P8<=(8.: M=\WGA,851\-Z45##KU"5C"@LB *N^*A#]<VZX7F@;ZYD
M'E@@4*% 350E,PH+NA8NQ+!2+OKNB'D#)E=G*F*0"@5\B32H !IPX<JR9W*[
MA'Q4&J4WG95Y'ACST\<9.Y"#F9;(P)O7J,Q%#W/8B-5HIQ_ZT&FKNAOG./_X
MCC-OO&N3=RU02@ HE45R!?H;G"$J^=3V[JMMV1;AF4JI&MJF;JC:.8S>??Z'
M*>/!GZER.0;?#R!4$^0"^:XO>FLT'!=]-GJ_7Z2A(EGGLV'.2FV ZZ!=X)X?
MW9]Z#ESING68F[=ZSP+[3_=*1A_",(N:%X^]X9W:'P/2%S)&1W@/^M8A,^X.
MI9(-7/KEHA4M50U:W=_V2ULG\3 98W"@E0A$+8T/S#T"[F(E#A5ZQ\W8U3<;
M^X]C!AF1"TM@&+Z;"M#E .AV4\[ 5YZG#W.ECUID1E!VFE AI"$>.,H@C++3
M1<X6N*2%4L;3!L U#K&&O<R-H>&=C*K<N08SD.986TBXT:1Q4XIT2 @P 'N2
M>_ JN9<*+<#ZM&%OUM!4 (AO_>5S%<#L!)K@085J4:N+C@=SI-\%6K[D,%#F
M- F4.#$SM>E=H#)?$I12SFO]G0NO,1B!V>D6;^!WJ5WHDZ[RV0:NN^_.!'^E
M"\>'#E_'1Q)]K+OW2SW2Q%88;KT5=F>UM%Y;[^..+77(4[R1,3_,@PU"]VV?
M#DZ5:F H0<4&*/,3TQQ=A_=-NV;@9ZN;YK _M"*L5TD)-<Z9<3,/.I5[&Q^M
M.BY$5Y9@>EJ6Y5LIN]1 OR[R-!,Y> *W5+%PK&/FJ=-]]!'% ^7*A !/NXJL
M'G0EAMY+-%SI<:R>PUDIJ9?\EC,'2L0\S NL%I'X\U1H' Y#*C39K7"G,O*T
MYPG)H(G5[$.**@MJ5U\3FX*[$C*#*3N# 78H/!:^+X _KT8BHX9#AHAJ8FDA
M;_O9VU"5N]>".9ZR,Y[FI1&NR4*'G$\8"S7FK "?+?@^1<$R;/M1M^[.ULL@
MW<OO98E1H0<^^!2WX&7K5J&&V0CE<+U]/*^-ZY&S+Y$RJTG$BL-#S6ZZ/T4O
M'U"L,E<_5S=IR(ZJD'4*'AS@]#+".Y^@7!C?WQ+!8NIP+4?@].IQBO/LX(1B
MTJ8$D71=5&S#T08M>6SW*QU%V?T#M,!J!3EAC8*#RH!)5C53V]'Z\LW]>/&U
M.(.SV)*6,"YAXDJW'9UTE/\^@\9?H-F;2^BV=\B)BBM&XB_T47PPN%[D(*L=
M >P6:BVP3Z::'8K4]J#JFN*\4<M6BZT_0" BD;1HC0NN4.85E*V_X3,N4+=Z
MK>A@SLF43%\O'A06P,D-W]("\;CV#79#^^B%#RVM-_>1#BO!4@8H98BYIPB:
M'#@6_XH0BXPK%L'_A8:5PI ]D(.[?^7.N./A=,=<'06@?="O J#T-R>N.A?I
M7H?N<W^,P[8^0[6TT/(M_@W#\_V",2#^KP!LP#DP&Y0_%*Y7^L5U[%CF0\HN
M,9IETT"K: (!MG[TG$ET7#$K_J\6$@E4X5Q4)?_?MH%!IL//_0< QVN 8RV-
M8S+%!PDX/OC$J,#)C@'R04F-1L-8*ZB12 !K1X;G+/ZB@BC*KJM &@*6YA]-
M /N%6LN;#&B)+N1/'X#:-]"Q30I:EO)D''Q1EW2NU9^%XLRWP=TRUNI6>YHC
M99<BX!U-<HD$8DI0L )J;]ANM>H-S#U;XV@!5-,'JJ':PD3WG+3(F,4KM)!6
MR/R_3H=\23<2DBE #NY#+N!6-0"?HC5UHT7YJ^+6SZ_'V/I(H"DC-WO1W]_1
M,$_8L,Q[_V+&LYB3X]KYH K]-E2Q,73*@;\N X-71--XH"K%4=AA@&_<&,L5
M@)(=95?\!DH!B#6;BNGW' Y1D\@#7%HW5%",0((DA>-@WUF35CW#N4 $8?KO
MHGL7&&M'BXA+/XS_W;#JOQ]6^%@7EX\<!-Y/&H!50D?3Z#KNHQ7NH"KE4=@"
M. 9XL11/8,L,HQS[!Z D"*2HWZG;B^D/67:FR\HHD0K( LA!!'(!;#JX4^F/
M^X-E])$731JP2:F%M S;^Y^=#Z/L GDI!T#HA1KB\C#OU4A+B)4FOF6PW$?%
MS\>PO'/HBE[_DKA_*V*^ S4@_IKSE7;R\E98P43$5SZ*I\^KCV R$DQ>)O-3
M*H!FBS$LQ8)7B9MA*6WHJ3U !N82U)Q$A=BM4$9K%K6AC*+*74&Q.2NV-U(7
M^=7F+:%J/I%2@USH7DQ@=" /ZDL]4"-I11VB0JC5[D24<0%--P6$GTE SXNX
M,]Y#J0]\\LYJZ.JVK4V*)[(!>89M"2R]VAF(*9 H<JA+R ]Z-%SIHI5)6HED
M?Q0V:UQI&70#41C\M"2C,WO\'^<2#XJE_#87P$'FIY=YFX=:YQU)#H2ISW(N
M:OLM@[(1%9V(Z&&B>/B\HHM6L$"91A/&5S7(+U#8Y/&S,^;MH5DH4P0XI9GY
MDG;*7QQT6E-@[9!#7D)FJY$6R?R;?-E1Q". N1H :FV$R>'O<\'K?^\5J?J7
MD4-A+DK+-VB"-YT"0^B&K)5:RKW<JR)B/+$N)<6GJ= 7;7]H,N6?7#H08'YX
M60&2LEB,MT@&7?YM*\3\;E U)M.HT-AV7><W*:BZRZ#T9V:!EEX"LFRS8<M5
MWV3#]K_]TZ51(^\/X41Z+R];SG5/'_K1W;;D5MZ0VO=@U2=U/V6Y]\I=QWYO
M4 1E"&G+GN1$V:O$,VY#R(<(+NZXO^P$%7#BU82K2F\/ET2]4SQ9FWS!$%50
MYLXZO8LHC3=9?CYW996GQ):W5%VW0?,YJTR7:F-R^^FZ68.D?>Q,"*,G.@^)
MW>'2[ZZZ8A]CWU6)NZJG!Q6Z?674WKQ32=TGY#9&7IZ!Y(4SGTH;3I%G];)Z
MJ=3ZIK2,M7I^=RO'Y\HTY(J',[&,E7UE.J-#YT6MN'!VS>''.A=>?)S?(A_2
MY%_9P"J/\Y0/8%>->[D@W*K2KYIYX2Y\C5_27Y<_AO&'34R;MDM&^@T+#Z^5
M7M]&;9>[ N[F;RKC^#F/1'6\M$D(Z6,5G3S59RA#:4/EZSRB0N9]AE.=+_!^
M-0O;\WNY@QF#[8E)YYGJQ?#1EW"H9X;YKL_D)=SB4'Z&.:,1PHENC<:E.&FU
M;WJI/[)WGX0H..0Y@TBB.*6JF*GRP/TA-+L^@M.-\H,0;!76$V3D^'G7X]GH
M(5FR8$^R;Z*??YK_0(('QJ#NI_/:E484Z+&G,+A]RYDXK62TC^S-IN2Q+=]M
M_!X9'3NY#\GOW%)_4M'Q<U:IUYG!?K%*#X7\D(3K%<GC776\C[_W;SK,_P."
M,HPXM&JVS>J[/=?';>=+T/Y\)\"R74-G FF1&.<_++EQ9?"PV;?*<J8Y81^P
M0ZA0*=5(#OIY Y^F(K4+>V\Z3P^-WRWA/3?@*3&G-/VA9'!@VGY.JC9(N"[I
M[7B8Z"+=E?MPJUH_$.+18U<FT$8Q[9YPZ.H5G6HI/W<Z$;IV4G*L\WZ=++H^
M72?8VL)Y:ZYFZ_K-V @%(39(AWY8R($*J>"2_6R$,O<+6C^N_G#OY+?A\-FT
M![C AZA4M_:J[OPOG$(9$2O9]/<P$I"KM6I2EH?SKQNZ_]UQ5V:Y!&6-XU5J
MCRLTS7DC=N0ZAQRJLF3BQ](T(V5R2#(HI<;6H)FM^J7I+6>P3,_^ZUN>_W\=
MF=LJ9)8HB4,M.W6_?1-_KU=^^,)SD=,?,Y<+D0QC4JMVSV3/N3K:FA04>543
MF%S%Z;YK7,S-_76-Y#\\Z.H-476J"Y1B5C*#11R1<MXU>ND+:DQ0 7)V^C?H
ML?]9?"R[;F_LES&4>QUTR?#UR?_@V.31;KFHSA3JY8)G'43W,E6X\O#@N./J
MM@A9N\6XY[>9^%WH&__2#6\(*:?=JI:%<5-(9HKP9:'9!S.(VWY#+BP-^\V9
MTP?ZZ3DWDS"7R#NS9/ ]<TI52![9/>Z#F-T]0C6E[ZY(,3-%V!T[[61;K1/_
MN$;QU+)$R \JQ"KNV)$TV[*]>4"M0RCO\FGA:5O>POS(S4$-!QAUKM8=7-VE
MXZJ#1512(?_OI\B/? Y>F!L8NA,\@=DA8O8I8$@HT;<X^",?,?YYIMO$Z:PO
M37S:N=WB1,])P2<ST\([E=E:3YHY\QY\.*9@_K2R_J&FZIRG_'"RAII24:J"
MA,\TBX?.KL)75X\$F6A>]X5,@]O*9<EQ2-L&.Y9)P[D'7B?>RTOAR%4<6C;7
M/MM9$2I.*'TW&MO!Y*@W.+=T:G?N/H+(59D07I6;48.X[F7_.?,IXF!!IY=&
MZA'-]\C;[4.WNO>=.'.8"NGBA[JK,!R8'S&]U:ZK"_HD.?S9E[://XOF&!YS
M0TZ;HG81E.YT>\Y)+7-V>"D,F>+1N&Y-N[WX_-L+L6VWO9>[WDA#@8\"3]/3
M?R_OR,Y[\*G_X /QQUL^:@6>A-1/0W0&;],T/F;J&BRIDO<E$U[S-^=GM[J<
MQCQ",7KQS:E5SHT9[&TS;L_8Z343+]HX\-UE0GDEZZQA:-B$Q7+6_D3ECN!7
M_7TR\>SLIC+^_ DG?W]KXGD>SH[$OJ=JVGU.2@7'PJ_RZ6%:Q=UTID/*Q]T7
MFP6GC^-0O<0*S%R43[./3%OE3#!1YO(CCL_]' N,<A3#KI*[8M=P.WU0;WPM
M%LY%ME2B]O ]+^=RL],[SV'X]0(2,7V0;ZG)A2=O 4G:TU(S,!=*:?#9\YTX
MVMYUF5/4X5Q '2))<#S@6Y?;.Y_FTN&>[-3+X5L#X_P%7W=L+,['T\/4]1J#
M/A\_@JY,.[F9S*";)0;Z7M(K$694&17*46=*S! ZN)CXKV]'_L/!G.&\62Q!
M2/1$QHK)"3KD.>VT1B^PCS_J"-J63-2P0?B?#ZS\GSC8M<^D' MJD]944N74
MNL\[<;S3/;JJA< CJT$!77,,ZY4X^#;[_["NT;\JIT(O(K%D)\0J<ZO""NG1
M+'(R9JT-^O=W4L34X3LI81MW4MK3FRY0SNL:KM])4?T/<:8=+U+$<]69Z'#6
M@ZR/*9)NDBM5!GSM;<N?!E6[>+&^1!FIVTQMY;QS2'2I.17:O();E-^*^Q:V
M?Z52Y;QQL78AVX?LSX-J,=S=..[)1:V2;EZ<V&"R'T7(#>S5JJ*.M@]WB/?E
M'O]\<.1 CL#4Q^'-.O&^-?Q\BMFE/),%X=(3FJ,K\?%2XG(>5=6]*OFIB?U5
MWD9.#Z[;'KQ;-Z&T>7\=;J7:;@=)9*Z_N6CHIN; I7:;"J$3,XQJ9AK?HL\9
M1N'PP4-^I#W1U=T&W#+>W8'E^R?,FOT5A[Y<\9DP97V%Y30@*WE,D.B)PJ0+
MY'19%9OA%K14^W@OXZQD5>7)4V?W/:#/FJ,?0)Y:8N^=7[TVD!>I,+4J43)?
MX"BAJ]9_^;N 6_ PL@;5%Z]?.%=;F6:=M<7KM-+\K)?RW?W2?/KS=*LHYK>K
MX:MARR[D5U[[B-)C<=Q[&PTF';)6#7*<2C+Y[CBVS#T<$^ST$AN4XZOP$,H,
MCOVJ-^YA\V[+8'[^V2?^9^CTO%:[>7@YFQ!F"@Y5!3H3#<F76L(]/F@I"BQV
M<K!-+*B^^&=O4@6TLT<,;9>3L-F[6J_%REW-ND=@AO-BC97IU2.$5_[VMJ(J
M6R?2O<"^8'-=>7!5&N[RQWTL7OVL^K>U[&;RKZ&;D+K$[')ZO&3M8!:)S7,(
MX?=Y?KI4P=3.V,!?;]LQG]*"24-O*K1OTB#)C'WZ55>;,H5) N%;^^$HFX:!
M1L>OI&AT>P@VMGT^!]N<D;D$0Z,[!$_'DK=+F5'OG>WVWACKK7D<<3IX>E_R
M+G;]P,*?7QB'L&P35NN/F/PG^1'64<I-CAWJVVXW?73[N^GY?*RK 14*<&9_
MZ#[4< :Q4]=B_D2T9=&!%^]&/)>0OG;_T4K[_^FA7^OGA2 _S+0*]^N5'<C/
MGXZP+WC;K79=%_E,2")#<[62(;@YQR9[K_Z.PJ%[4A;_)J?_U3$B@OG)!S]_
MP41YD*L!O'+H3,OJ&'*1/>Z>3/%O-Z__R]'8@?QY-)$*K3W5D3OY#S4#:O]?
M=&+T3>4R7N=:R_=ZB77+WL@XXJ W_H)S*%!K>[E1M571S/7 D/E9TIZ(Y7<=
M/B(B3TE"0R4+CED*CL<2+=H*&KOF)2^QFO(AS@M.&CXUW$82PYE49<7ATY2?
MW6C?JQ QE1.<XX&U/,AS\?/D)-A@5*,V>6U-&-,Q$,J>6\K#/,F0*-.L/[!X
MXLAUS<'6JUG]S-!/ERPKWRLR%1T!%PO.I,G7LG60<_6=E+KKW9*O"BP-1<;^
M*Z^IV)6H)A7TQ[#>1UE%X_,Q!7P569PB,[<ZZ=IO&WTTUL_B&S],T5K)M2D^
M:F>%CZ P!\26HEB\^(:(1OG8JM5OHH1[#N]J2>>[NPWH<)L-CLT9^*6==V1?
M>J7#C/I^=J"K[+GA[,G<=\XZABZU0DB7A#BG7$TA(3>L^D:[J?,&3Z1<V@?V
M3P-4J">M75!TX=R'#I&,66&A-KT(Q]<)MFG-;B0+>@7+#O]3E\_^_C#2OSMX
MS(?L"(+A3&1'T*<OYJ7W!3!^FKSV4#VTQV!^UZ/72X:)EE_^CZ>(@?G<+$4I
MBVV!"@DA,SS,;E\?DY2Q&:GIS\NNL;_K*)BEO?J%\65;Z_]\478(&YC? S^!
M^Y *G=/E_WTQ/<M]\Y_@LW5:W[5:A)N5;LS2F3MY.3#6_GA?S]>G+_?8\_*P
MB7&QT'V6^-K]AF30[L.#]Y=#7L U],Q$.X4J.Q\*>$CWH*[GQWU5R?(X3PO$
M7-Y,+L)OA><HSN6^E-\QY;].60Y87'YZS/CN_4OVH7SLKI6(/<@"667'P28]
ME>"_N@?S]3IS7YX[^)+Q]#<.#YXMTP9;L]S,=?/P8A;3SN[I%@8(W!4=EV!]
MLZ1@%65&CI5##G?5C Q\DR]&B9*3,B0R#I]S3+241UC8"L>-[%<V90F:F3D_
M\D'7X5,W[YNHA=_OV FE*?B,I?=?I$+5#>N;DKC>;''Q4Y0O\8AIYGFR[I!9
MI^W'\+.R71#C06?Y);WIJZ@62^1L#D6B.-'9\XWG7QXM/!WVTP8JRT\QV-SH
ME1X02UJ%$8C)!"I4CL:W3I56]?)VG5Y.&"9VCB M(BB>RE3(6V.=NI.GME$N
M3L[0E7@^H*JK-'YZ#XW[.PU[*=)R, 5^-3![@=7RIT<!3ZZI:]9QXE\#"]_5
MB&.@K(OTWJ9"46VH 262Q;*!"5;N*EKW]%*6($S2JT:<0.>")E .UB+5\R08
M=2V,=RUS-^P]MC;K&@;HXO$9Z *_L.F'#)J(\,L0'IPTT,+"\PPI1'%W$(,M
MYNMFU#:BKWXKCPM#Z\YCY%&$*2JTT@I,==W@!VMAC)530EL9R%DW^+32]%_]
M99!!T\H.QP[,_M/+I,E?H\CAR]@-)9MTLKUK&ST"!R<5@1+ZPK_86C;8;U K
MY2SL,.F08M55J>KP<1XUM I;0Q-8,*T)= 6"XBGB9:\=>0+N5C7X*%T@I54B
M3;A0E1F=8$EX$P9*>UM!YJ<S3TMKR%-^T;,(7-8^<C VR(?3RLCT+G+P<.=I
M%A1V9#(S<M^46=8UTY'9^$G#:LT9GKQ1!(P6+ LX-PPY:0HT#K G'K-I]'!9
MT]AR^0T*]B@,BGR[R"^-=YBT9>>:63?)CJ.PZ6 X82$)6):-&E!$FX]RU2;-
M\.3: OX&3@,+7<"QK31 :.QY6AKU_YMQ:;3*-SE+*<_N\(QJS$(G%9J-OXR]
M3'/?*@V'H-H\+D^="$(;0$>'-LEIG4ZMAX!^O1CY?2@(79@EM0!6OJ@LV#R'
M%A'2(@H(FB+5--H;YJ\\1 V>)K\AV1L_X;&XT_3-?<KXT *!7@MYBPIQH"HM
MB2?=CHTD+O#EY4LZ[';O/\!>^Y/!F7+DO<R*WY**I+FK_WS714[7/2_JSW&0
MK'_.XH\MY]F;_!C@<I-WO\'WQ3EYDURUC?81)RKDKN+YRM+SSN9AE&_RRIC#
MY_E.M:+5G3O.M,VLL(].RA:"32D<<\GN\QNVN!FT-$X5C?65U1PHJW%OB18A
M+<&*8QO6 2"_+D(K]L_P]\\(-I,(*&P:6#\4T?*&A F8$0CZ4V,E?AGVW_EQ
MSM\#AC+VJ/B:G#3(/W)"FFO8OY&&"!I&9,3K8H[*D KGQZ!*'KV7^T:7$NO.
M1/6FRUE\D[-NIK2N25W]6ZR#NV_+A>'>0+FT%DHK/V(2/L<Y4KM:"^O,%3<J
MQ^2:R@8$N\]&\*UKK+SNTY2?"]PMY[_16+=XC2/AB.GD<8J&73\1J':R:$S/
M+^, /#423 41EG@C85U-D /!C<(>.VC1J,\$QA=_L4; 6ODV4Z&[2_%WES+I
MFX,I'DCRHL7"QN3]TN>QJ$*/UD*/;KI?,]S;4"U*:]E?O^\,N:H+5*A"$1E#
MPM@ K!1FH14S^TX_UK%L3=\'-,0"X.)&"\$#E-5D,*^_JBL8R&1M#J-X2)&7
ME")!>-D1Q]I&%K:%+MGM[?^*G[S2.GR]*:_>UEBI"<_5;<SAT?UL8E(0/ZGR
M:BOS.T>^(SM8/2;A](D'21.H7O1]+24J8/T484S/P/9(D1<MYY_/K+#J@OHP
M* NP@\G#UL5>?K5C<LWX?7\J,A&HH3^3S0_T][V1.,L+ID1O !#_RMQN#9-=
M&Z<2%HZLYXE&/9/]VB#K*&SM$=A["T?!Z$M06QWN?[.E*5E%> FB51D40-G/
M*&P"\"97C.L!F@_O4DPQ"VW KR&F0'T,T(B?NWS->SIO@&YP]6P,6RLZ0)KU
MFC3V?RJM=PV2&O<-:9O1T4OH/R;N&T6"B&AL7?]3SV3Y'YUO+ZVE$.&\"50_
M([06 H-'H@< <&&-P<1I0G@$W=<U4VL)+U'>&#&E-WPK?0OB#O?_V6D)_1@7
M3C93G8/9R)4^$&+E=V!68QU?=Y0<?N[_TZL'63X ,K,)<(:C\@33S2!%!0?Y
M-:K6T<_D9=C?>^DSZ^(/%R$DU68+@->]/J_Y^AE=UT^-(/VD%0H1? N8W2!.
M@XE5UK_RNTY-XS\D,&G!C/M^4H@^3G:P'>WON545.-D;:%]:RP%GK,*]"0?^
MNDP]+R"]^3XO=K9@U&*-JG'&#HPKC\K/E@]$[J5/A@7X!LW[N)":A$=AEO?&
MLP71<]'/A)>R=EM+[DDW%I2L9.>0LV_2NX&X2^C+2LWDJWC?Q.J?M^+DI'@G
M;>?=@5.SJA\]1HXI.![J6[-=2@K@E<"D O1T/!,!E&H+\R*/DIH@IR( H/0H
M8E9JU++<Q);81 B'QF%%'1N1W^V (^$1"_IX6*F6DZ"N O!?HTH'WL3L0 .0
ML;)5,)OC=0/?[9KOR9SP%Q6,^N:MMQ#?:#<KA3W+O0/8UV(KGT%H+:-"I0.1
M]!^^_-3L/E.X6H ]GT.%W"A.6\: M/3M+>1A0FL1H$')0 -U(+7^.,5D@@+"
M/GZC0M^1D0>B2Q#-]SY@@"U&CD#ZV)UE$T+X9LW?6]#+QWQZ_GXP%KZK=<4Q
M7-7201"-]QU.D:6/R9O4U9\(:S_YN.%*CDI[?Z-COCCB_I$H:'/XX;>1+[B=
MCPU^]2=(52-VH"SM_ M4W)'5W+R#/F\.1PLJMV:HC#1:V5?G2#'XO?NA[1)!
ME*2T\FPS+?Q"D0\P_LMFM*5Z_W6W(\O&6V^Q?F#_^KZ#8#L:/)TJY8W^4!@_
ME\6'-\)MJR[H5JKRD6N-;96]NGN?OZ? E5"9YR:/7S+R\FY^'L_R/+!SHEY)
M=_B5_LW'D;6M"FPL@E+JK>)DDP:B=T#>;*A#M(6OH>42)]?^MKA[@MY18K9&
M_$E")5<\??1-.&H3==H72^2$]["').RUWU-8:[<_[N?2:?H,B]:S#&83AO.[
MVS#K-^]"PE)1=9<O_;IYYSZ3 ?:X>BVK$P.-G;IY::@Z[05*,?S"74G\ASK:
MRQQ?MRFP7842#<N4+V$\@@7@%[P4:7N"D23GX519G5"WX&'&Q#2WE\.5T=MS
MM7!V3X0"&R;'C_0D6S[W5.%SH4)F[AFIK0ZN5.CQ84T-I;0?RTQSB?-]Q R"
M3EB?%P/^X= NK%O:4-GB;BE2L=OM'B$C-77.AZ=("F#!?JQGN"KP798*5;Q"
MD6R+Y2+A=P#I^/B^+-H)4:'B@1 >/2KDC#F^$(TWPZRFTBC#4;AB-;Q9'NC%
M(X8'2)S)5.A XA3H>:5^(#T_C%'69L@64"9]M+#(N083BC\*C9R['4VR1>/-
M/E A!61M-%Y,C2*EE!-+HD+W/,EHQ6M>Y"Y2*N4&F*18.D#A=&(E_"T-.1B&
M)K/-<J-^?$;B^W769I$IM?$$.WA6PX% ?Q2O@3458L%0(2VQ6A1>%%37@/;N
MY9M\%"L4FHE<'4^%AIUYFOT6*'2S+G*\#:B9Z'HT;"+J^ (*;P;:0H4+0"O:
M//"%I1@YEN*V0H48-:@0KMBK$(4E<9!G:A..9[\_JM=]S_H>GF]N11UO-WB@
M25#]I30V0JNT7-OOJ(N*F,S#6O4M['H43D?*.S]@MQD"Q@= ?7.6"FU#UF+P
MHL!TW9K6YUQLBSY_$;O+T$KS \!;FNEVY';"?EB=+H!M]' +B1,L\)_&@?FH
MB63\PH8V#2_1"Q0& [78<1^ M1/EFCL\42<<525,A3K5<%@*2_"Z&24 #QAM
M6.3E4#!MTTH)3]@()I:40I.I$TZ%JH31J\=Y-F(@C,+INJ:X*7!8V#$$ 4.7
M+%R;0(/Z]TE99#8JQ$.%?C0!GR#F&M+0A.,\<H#+6\ %;>Y'07V4FZE-=/_'
M>4"8O/P_"$.MHS3UG@HUX4]]OXE69NX!,ZXN%ZRHC1A8H<Q:^X9@,EBG0M9G
MAMN=U1[FN/'JM,L?<BO0D/(YFM..S>O(TKYHZJ]TZ%7*N0ZZ[V\M6U,()D+>
M6QU>:?7*^\6%E.,^)F3RQ7](67LKP'"('6<.]DG1?J@"J1J1;8C^OLE3WOEL
M8QP_3Y]>%=/I=<:9UXK@"U %?E7(/:S]?=:A0_7FXZ$CIU:SL ;+>K,"[10+
MBA*WC;193[2EL$M;:SM25["B)]=E J3O)MJ[92I#D?J8I\=>(G=9U&>+\B+>
M:#UA&IU57^2?X/_?O+]*I^ 0GMLF$BA>UZ6X*]NKCN.>QQ)[9^<Q^%6WU%</
M &F%+R"[F 8_BIS^'GXBFID_+H%V93S$4D";]@(H[3+&^:4XWTGX53 !9_BA
MYWOK3U_#I$FPN%NTAZA3_[A,V[%6E-I#DU- R=+Z^ZEM.]S55$R-\CTAF?#<
MB9MG!4I1EQPRK^NP_YA\FHA3+$<+UCW!:]T^PAKQ_AU]7ER0I=7__ 76!+!<
M/JA9UV(S6\+?#UQH\)%\;J+*D8L,&Y<0XR7>ZNQ6.A)T(F!7XYWZK9KG-@>>
M/GTZK=- >=/[ELUSR!/#B_$&][Q&B(I>MCAL%0KAIG-Q;I^O<*FCJ[.=O=QR
ML-6FS?HI@<K'#A*LMMX2E:[-<\3L0EJC=X\A<U!/9$'*;4FL?53JF-3?-YYC
MT5LY>_UVZ%\*01=Y&Y\_/K%E$IWA.L M;NC?*YRQ[RF%32G>RG5>+R,S/GX2
MBHG4>AIX\2?3B)DP@>EA^-S DX&<V=HL_ZAM!7[5Q=&^29C.O,MG^E7[]UXT
M:1>:_E:L<,!Q=)-CX5NN#Y^4U&X_%U#=Y9A=$)75R?FYW*\,OZ\FO N-HU>=
MTPFP.T$ZE]IO.9TV[E$M^<S6Y_R')DZ56A;9FBJ!GZ<XAJ.M#9;F!^XM8KB]
M_B*G\.)$GLKR.@ZJT%?N%^]U?AO<&"B2>=MYX,B=Y-'GAW<4_GQ^OZT\27\X
M2;"Y1O%4>(%6QK/ JK$X?RS'ALO_NQ?+?WN7/$VW@.1KAYQ,0XEI61>?X8JL
MA",Q O;R+;8TVCMTFF:'@%<O5@:E6NY_S6.$RZG97VH=YR98.?^Z5&,H-2!=
M9]OGG#R--S/R[\KDZK*T\=9SV+_P.H-GU%@M)"NWG68T#2IZ.71>M.WB0/64
M\L_559U7;L>^60_D^3W-'"5C2;RKV\LR"N5V-M>\1CM [(N,O6/5RNW/+6L[
MW[3K>#6>FK"H+9-4O#[LZNBK<*+VZR9EDJ^;7^7 /K>LX;RHY*$(;C>\=96A
M37B[<EY>@3*/64 ^9])M;L[[!!VN'46C1:D5'<]"IH)*DQM,/='RN6\D*L9]
MCG25(N8JAZ_A<M^W9%Q/C[MA$VRLVE?W) Y[[V,69Z;K,@J?F.%U>2XPQWR(
MPZ1=UC+NYF>S%#T&@HGQMK\&O9F#EBK>+>^V=]0[+)=@&]=B^%.CQ8J -2C%
M+?OAGE7X;$?Q?&^PR[C>_ZU?-?_NIFQ%.O5H/GJ^V'?RQW%8?Q\NTITY-3^2
M,F[KX2]YVV6&)E:5,XR?FKT\1G?VCMD%^F:YTQGQCX/S$O)T6.^$CJVJ[T?N
M)[0/KJ#S9I\8\LAZQUCZR'D.;!L/-Y625+-D.6$2?I/ L#R_AQZB2#1['< 7
MI;E-?EQU*BZHN< 4(.RL/+5'Y?)UR:+ D6'UUJF6QF?!#[_[^;[4*>^:[;B4
M[<V:5L3VSGORHX^DE8','%<41U$>+J/11!^G4/ZJ"Z=;-5)A+;C+MSZXE&[E
MZ3L4M\3L :^C7TA2;CX'+X6&11TM:,\43LI]Q);SZL?,&?NBB\B3W*SB\8]'
M-7+#RE;I4\O]6CU32-95P[BCHXFQ;FVS59C=R=U&;8OMAQN%!DWL[/,B+]ZZ
M?YV=_KB23]XHA14_,GQZ&(]T*3^*K@DK/V&*UO[B]814M^M5:.'YAS^O\4;V
M6]9N%5#(!;L1/[Z^HZ8MF<C]8DT. ^Q\'7?@ZZ@+2AV&ESM.3"45/9@0USD4
MM TZQW$PR%!.)+!<J(_$CW<=OLEG:+=[0N;1X<FK7\QSG^Z=.9G8?]@,2O/E
M<CF=GOHE1*$Q_'N-ZKN'.4J=WUKQW?ZZI+\*\;$97K)=LD>'/ .09[MDE\K>
M7S>YS;K[\:FB@]GR#AF+6<:=$MN\$2HEF!)[]KQT%?',VGOOMO+-LXO&\^?Q
MI!<V*>OG-,_D^D@,42&((F8UL$LB:Y^%P='LFR)Z[9E[9YI9;$0M%U@JCLF=
MK9-?&EU=J6'=9T$Y@J^P058KM+57Q@DXO9X5^B$H**M *K@9&WUB4T "CY)N
M[VGE>ENAB>?DW#MOED*D7&.S3LR589]1CGA)SX4].=J1*7O U3'9.TW]0\']
M_8I!P<>1;CLZ-YLG>_R4WSS!(X\/F2M0PFFM! IK#DW;[1YES_&S^#H3E(L2
M89$,+'.PTN;N*3@:_\&@_</B/G%S?X+.CY::#)W:J*USY.9XW)7:X6W3YR^K
M3>7EWXM_/6K6JW[L![.(R;=KE&/XIT,9?$-AU>3]PT,BR\<B!\G'!C3:PR>V
M,#\]PG+IM&"8^EEH$ZL$ZEK8&=_EI:-=VBK1&JDKJ8+89^C=7EKX$*+XV'>A
MN9HO<]V!V[-Z?[ZWUC(K8U95%T2_R YH:/'(BR&=[Z2(6LHSHRMXCA>WSVAM
MIAR,TKO^TRU$L?NQ N_(JT+>^Y^VIJR6OK0E6I#\IK6?\@ZP$;M]*5W1\_1X
M;RID$AI)A6+#5TY_ZM ZH9_%$"A=RXG4G</TME/.HE@Q4P[MF$6QR]M)UT.$
MT*IVI3Y@%?L.F@=IKRM&\!IHI2CDY4R%&+C:S=IEI7X@./NR5A7]TF._G3YT
M_?'DDH:A<;>O3Y\!.Q5ZE+-LC?-BCAC->6IGPO&Y7E*9E&.0I'>4ZXK>9/)W
MQRZT^(VIWAV)/#FQX[V/E+QTM%N;,R8XZ5HF=2;KD*;1@$.E"5$&?YP<[?6A
M9]L-Z98F1 .ZCGEI=:3FJM-D,W>$Q*.BN-<:"NSUUVEOIU9T.5DN;3=7+7Z>
M%6+KT%>\U,)>IF4K(>BI]R0F].S+AA6V%2P[2UPG_)XY93\_^.5+ 0L&&]M&
M[_#K[>!-:Z^JL\%O.ET _<7QLQ4=XC=F2C7,4@X9'F:O,ET82+33NI%WV<*.
M-\_];.$+LZM%:5JZ_W>][$77L7_4Z\P@,5)$O]/NJ.FIFY(_>QT\L.'C[R*3
MLBR]'>5*]Z2__&A_>$=:\_%[14!?2#/OJ*#ZIC84NQ ?[NHM(3:-BYO^?A>N
M34)(P=F1/3(]IWF(W_CJD<!O#.I;CT2?>TBXJIS_<F)??O)C2MM 7JT?ZG91
MKIZ<TB4,CC$CS=;BCOA02:4([FW4(URM!\X.[SZ2@WJ'OSQ4 +9)&::4YOQL
MGP[#O-IGY4)6N\CQE11.DV2+U(/U=L1W2H50P9#@+"*[4GIG,GD>65GN?WG;
MPY%D3:ZVO._Y.5/V-9VI[@H]B-VL> &SZNB)<E:W&"I4RH2_VDUA/I>.7,UZ
M0#F*RD3APXG64SB7 ";29DVA4L.%SZC9( I[=/=)PP4LSHQX/+K12XT*L>[&
M70,\F-R"RL3 SN0I:"+\'KC-JRT9TI'.4B%-*D12\,[[F;RB,\\V*X0JS"TO
M>C2NX#T5;::3WO*$"@V6R1_[7&V8,U-(A:[R@0U#,JK*P<L@^#7&W,;2C]@.
MMHK$._ST'/'RV*64U=$#%*^L,K_L5%)M<W3.[/0!W+ZA@N?);5Y:<VC-.?G7
MH=.B$ZXGB-OH*W?6E4:/&RIDB)QQ%]>),$@X?CE\U\C-H,XMA6G*WT LZ%<)
M_/9B7=QO_X'*VM-T4GCW+%9RRATO]U0WJ?,/!S.^[>41DJDI*B@JN?GEB(GK
M:U,.I,"5.4;WH;(J7-81<FRYM.5 SL##J5*-] KQ7J6^H=QBHNQM90W3^L<:
M44WH*HD,'EOG^DSBUBFOD>&TK%[B1P\;W^F5YU[TXJ[A 9GASQB>]^Q6.UZ=
M[E!&?[(EWTJ-VTUIN<20^7M^\E +P_?Q6P*E!6T99I??'/PF^]&WFU,P"M/\
MP4<,57%.?B_^_V'N/<.:;+J%T2@JTD2:( A105$0$*0(0J(B74"*!&E1D1H!
M:=*)BH @141 :A2DE] [1#H*THOT)KTEU$ *YP[J4]YW?^]^OGW.OJ[S(S"9
M>V;U6;-FYIZ5J1N=0N)]?0EJQA[JF'#O:('GK%(7>=\H+[""OU8PP,FT%E@,
M05*YT'7S=;#)PUR#!ON4YK!H#E_CUB>2+Y2\&ZM6MWS91,S 92<))47M>9=Z
MLK,@%>QHDQ?90O)V_/%V+ E9'U#U=P-WOL"CBZW_]M[1WW='K/\61O8<F"W_
M,U2T[OOKQLE*2!/_$\JPWK\<^?ZP &E!]2ZA)UH94([V96 @/Y_9 ]$@?TQ#
M!%&[#EV4/!!H5_11O-H>B/\BSI1<68@A'<@<6?2$-:W!PUC)3$&9?+9!8B&T
MN5NG?78Y<6 _" TNZO/W349Z*P/UD@#/\]L%QO,E9Y?O)WPS>_B--6/,]0A_
MQ++)E()#8U(J.W>WN+U&>]X4DJF2:W*5Q]J$K<.9"PZM>SB[7-ZPA7+-E5%.
M%57B1+U/C&/VF"RK$ID !WISDCL9)S5I]=LS\8;W\@R]'-25M/6BIW76E)^M
M1U"="B'".EGU.NM51:?5U SJ"7PC[<RXDI?$!^G>G2:,. 4_'[9^_T(/M=?W
M<A@6^'+,0+:Z_(E355<:31APYMD$1;QF@^0HSXO5.O>[+[=8AE6<.9Y>8;O6
M2S/WR4EBA?7NI5L1A0:"5)]0)JDO7.UJO26PJTWM/*Y5GA?IYF**(QCB8YJ\
MF"M4CDW2T6-/Y>ZZ9,%?0H[A?;"K$[=YN$JQW+ZC96R;#3^D5I$T+\Y'3D_K
MD<EW+L])-W@)*C"RG(]!>'@?U.WZCH,/,M9"+N-\,<]/=XB_<G;IDJ@P?KAE
M9?L6Y/G6(9 1)ZG9S;HZR%M;?0DWC7KQL,/I*+HQ/GMP$=8B-VS_6#_@_)GP
M==%VDSA8H4[D.\17V6*U$<&!5,<FYV9/1,X]?)B0+ /B4X-;RA>[:5(Y6'+A
MZ6$=QXN#:<\2*OLC7=G'&8/)W'AD3<)Y[(Q_RGRU3*=-E&J?>$FI9H'U5O07
M^].$MU3-?%Z(16N!I,!W#\<C<O@5Q5RNHGB$*]">@KW+2TYW!F>2'IS+[1Z=
M!@6,T,9]B?]T47:RLNDSY"1NVU>6"]MRJPP;)R+\3#9S!Z;UVK8CV>5TFZ96
MS8;$QCFV=XBK31%"PE+J4D_;68OPU")^WG)6Y"O8S<D!O.V<D6;&'(EE.20P
MT_[XDC+U$YZ($MQ0'9D7%QF0ZNJBU!TSJ]HC_ ;!SF0B5)DW)'CP[I7>6*K4
M*G=?5IFU&>W1FJ7>K-!83W4LK'[T*+YW0H33]=CHHF$(%RRW3T>WIW^[^%/P
MJVBPFW)S%K?\UM-^"*\K85)H#_1*G$/<<O.+#5I<SOK:^Y32[A6A_J/W%+WU
M3I^B#RE#9UW(G@I.F$<@C*(413K6[:@6X,<Q$_"1ADD,XST4B\'UCJ8MKL(U
MYR-TS\;W0"VRFS7;.1Y;WEC,:S(GD5Z3<9&3'CY4CARDE\2.\I[K#!MH!$.%
MZ4Q1JEL9@HR/-_5&AHL.Q5A\0QTE@G%4$ZNU58*UZ_@3C5ZV?0OWIGH^5?M^
M"/@4C6JENA9PU[8N-PMUW+M=IJF^_37/M2H<U/]#<:=S%:2O7Z./MRQ@Y?&*
MS9K>DZKKYC4@;SG$0HS@W==QCZ;9,GD'SK^U2"""2W'+:'\-U%2V<(=UC/N.
MEO4)EDRE-($XP:4]4.3CZR>IJQ'AI'A/EDG4H4432#@<2ZH.L\M!B%D7YQN.
M* DS/3LH24>4/[DQ4U4>KT\P[XFH%FK1[4NX*>0JLLP@@X^=5*I%4]>L#TMF
M#/8L2 \PE,_:\RQ=)R)ZO<]ZWNJH9G<U687C#D\.#%RO%+G'[[AM&NQ>D/<9
M=&SS!YR:",UR#:\WP-3O@=@&BR*+<A1SK<H?HSS4<W7>!>V!BH>OF/;HX5U+
M^;4-A2J_9T 0"CPEV_F6'^BUC))_7@-_V,<?O"&.D_)Q_G;V-FMU?LSP+.G3
M U2=1,G-*5F28&+0L("B<<#;<LL=+C)-!5H614.4GXC^<F^#^Z$^,=_MKFD<
M^7Y_OP3.8BD/Y0]@I&X4.2(ZP+9#<!+L. 69>+Z![*KN1BN)O[@[W#^H0IKA
M<'$=R@4"OREN7LK+FX+A."EBT"!__Q[(/">_P*Y0WVXU.^>3.;-A7!IU2-G,
MQW>6V4*L=Z@P?H%0OT :RA;8X7^_P[Z_C[2AI<!'V>[Y#$1:;Z2Y3<E*WT1(
MPTB9Q4S)6?D7BS ?+8=:2T56JJ9)0=7_OV5F8_->(R'\L'!B\/Y]*(HP)O.=
M,,>&Y@U\IW_<GE%+BJ;BD9D-_" !^Y"<&/B?\Y)  ZL?D##5HNK8L?'6F&-O
M?^"C&K21Y@8*)W>V1'E,#VR<1G[.G.][T(,;&UI C*/HTDC9&%O$B*V"%(0.
M[UY]M]@M4*4WI$NNY>"8 MOB=(];JD OA"-S#Q36;J#QE6D$I>'=@J1^@ =C
M->M&N=8B)!CYC!:.)1W..67[F'0EM+;*(;:=;Y,_QMEM,T,U^YZ&84&BZ)U
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M<@<L_&>U6O2!+YW&%EMRJ40LX$>6/#1WQC'9IYJ/:3QSRRGXW??7XY#[TD:
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M*T[-=+DK-2"['LY-QLD<@0ZG!57NZ*QSWU@;$@,%Q6HKVYN ,-+7=T)#>8<
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M,#]DG:7GE3T0J@I8EQZ"H8C6H7@;1C_D^G8V<CQP'5@_:BT)( 6//?*(9YM
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M$;21TU[C+=/A?=8R/0/OH>.CFRO<&?W =*WTZJ/[;O2,#R]^9;N/YNNXJ&C
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MM'N@6H7#G>IG3-UX$"\M*XMNKPYGB8GZ]'>EW,E4Y^?;Y'QGTKC]_2-@("H
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M,H]-U;NHVE8[\_KIM=#]\:^S[WG!^XX1?3Y\*P%[2G+WT+*;)V]_?/CM/5"
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ML';8V.%-N':8LAI'@(&HUA\'W+ NZARV-7O"@PO2NO9-]CU:ZY+;%)HH>3!
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M9&-ME\&[XNM=RB/EF5:^)8G%><_EW985[6NJKDQ>=K?OG?LVE6)PHF,",L"
MS'\<K5_>CJ]TRS"=%!=\'+]/?U^M;WZ*L6PT(0\OGM>RZ\:KZVJQ6VYW$S+M
MDO[M;&$*YY9+Z4 8.(@A[Y?"4/G%>B7 =C4:D>8V".:/4<*AY38=Z.A,H@/C
M1(LQ9UJQU@HNTZV=MET)C'\"/JJ!@NRGFQR2)B(6>?":)^KRSP./['"Z#T@F
M&QC!<B,#\_+9KRL OI_)P.P\[T%>>WGS[Y'9HM/B,&[^+IH.7(.&RX2NH2/7
MS-I)GIC:UF5HGGO_-+ %#'JM21.]R C4.I,;C'D, QT67U]8GC_"][WX9G'!
M,;E&3JR1)_(QEU&;Y'3D'NX\A^3'7V>=0_6V-$T$S2.[SBV'$.:FIP8ZI34U
M_4>S;VWW= SGWF+Z<NN'3[19SU>ZD-\V=HE5XG)Q#_H-VJYS>69^F%^<.2SS
MI?"$*Z^U/S/W34-HPY +3D\-23ZQ.('@*9<Z4MKJN#5&^9OPIEI[?I<GGSPM
M<S"I6%.V@(=79Z8F.%M*Y$3UW+^'8.</4R%I;]"!G=XZQ&<D/#&9;3;?]?R:
MDO\MI+LMOTO()]]9I+^7FP*^*W/%7S96T;;!S./51>*>DB;Q*"A<Z^I]FUS'
MFQZ^D="DS''O?RIL<\38VL1MF4GN_B>0-?]/!B_4 5HWF!M[?WCK,+$O,752
M,G5_-YNXN!\VE/>$^JX"M Z+'!:;7H.S%Z0#>[/Z:97%*-KS3$\/GI9$DQ-O
MIK_8G3T9K"./?8!C=FV\7\[.S]V$G7/*ZQBU3>#ZPIW8^UE?Z6762L&1AI48
MRG)2EDF;D$Y2RF$S';5#>7(8?HHLH;&:;8>F8+6\8@'V6B5K;MS1V,G>,_PU
MY6"+$E,#^<2XDIA6(%Z6I[IW9<TW_$W?8.G+4.<1IMASUVGZ2]+GA$IU5,,4
MU.>%>V\ H8OI*<&O+.N%/?JORCL[O73TQA&<EF>@C6F0-"<!7R6NA (\BF7F
M8\7:K I#:YFWJ]2I+6'?9LX*%OL+!9R/9N8V%KQ25]GAUSA@_]7WN&^C$C-I
MY$T9[O&B37+)MD?Y(H#&B[*MCJ1%.6Q4E@(3$;\L]W*6PN<C7 4&9O,U)O>,
MO+DO3R@[PSN?/TE%L3TQ3)0P7O9"7KB]T)J2%(&_/?LU(;)T_P X\W1 Z^E&
M105SQ Z/%]LU$B>MZQPJ@8>6*T44G_0^^5OVGS+]T\^:Y1K("_[1</@%9'07
M'O]_#T4>08B=\*8#6VGY>+T3)A4++-%2)["LW[>CDS7U[L%.<.(9M(I_ ;F4
MJ!KCOR[ZD9!7'(9#)R/[(;QM^,;\R!>/F=>"CX=;WH#B6V*UUVO\6B?8A_Q:
M>I(1#'W^#(8]64C\9QHQJZO_8V#CXC%T316T2'K4 P6[RV4V,+RL1!S4 1Q2
M[R%^=/(-&FT7-YNX2=NV'?AU],C_Q,UM78+SXL6Q$J7I0/@7D+P;V@*I1Y?E
ME&J"WQ<0M"IH$]3\)FL:V;UX0V=BTLL*VG >3OR)X@MLN_2VZWR 3)B*T;"%
M<>^#MVL86ME=1!6ZJWY0JR(_U*V?RWA_'H(X<:W?Y@7YJI;96GLK84GLU%GQ
MT",U8GW6T,C=B7U=+N;M^PUG;7ZJJIB6Q3,Z?_>BO&/LO=GB& 7V%97;%H9I
MX,<SI1K#4S4MY3LIXFW>Y\3XLOM1%^H1>, 2H2/:_Q'5:5I#!W8I"2"K0/0)
M%?>[VQ,<3E4ZO[?WP.3F^-V_QUP_T^"Y^.YX'#7K2*=DKH]Q@VA?BZI X/08
M6=$#/1SU-)'40GS-,S1Z3:C)E:5V=@ M=^'Z-/.F(XN?L>\Y[Q".);[9<GR1
M(RA>#P#V??CP@<*<+(I_'52ML>M4ID"!^:XR4?7H!3[UUN>99EL2_HM$2S^0
MF=C\&7YU]C]#NO\'-!K]V<,A?8KSJMDI=^Y\H$S>R>(:8JXL8Z_=F4AZF?R^
M><;26J;<2WGO[&RUJC!3W.$P_)F3^<:<SXY=N7#RF<=:Z^4>9=>2A%"AB\,N
MQZ[6VJV:3 Y7\6\F<:5,L/AX1$;W/^;2RHYU/VSC.B%4D35;)+I#\86A6WR:
M!]-R8!ZA((R?CUW_6_2HAF95QNWSY/-^L=LD419B*.NV75^\VG[/3FR_HGS#
M#O47%E%!1@.[8AONNQC\HM%T-3K=P"T T85_10?J#6CYNK>6LD9RY.1#DDT<
MYYS5,XZWO[5\F\3()F^SP=9P3M>=W43_ZM3I]N'Q-[/\"5&WEM[NRUL/M,T!
M_-"4?T26D>T=,/F'"Y?F%OW 3(G!29$-MO47>Q25Y8P\X0U:;V6K]ON_KF3/
MG?XVJ?]F!'XCJG]U4F2+4I LN_:%P4G1\QQP/<>YY;<\?,JR[F0]1SI@]R!0
M6[.7UK8?UQ7'K)L:$YAYZM82%#2>,O*BPUOV'PSO2 B'D\W/*@/;-%0S8'GL
M+G?D#R/R4RAAZ5KD';:8-9W\Z>[ 3(_&F>N5-$Y-''*!OP6YF&Q?R$XY;R7I
M']O1[T'CZ.(KMVQ<K3X\.&6D1WJI:C+F-J,SVFC6/#,4?E.75WX8^T=6(*3"
MVU5[3_9,K>DUG6_D,"L)\1N=,U)\NN.IS<C=+>&"[9#6TM E:4P5OG_XUM"8
M2&WET)8]I=+W,$+*I.9%/.+6=R[MCV/$%>R.?"*^=JYS[Z 4M!&9T/6^3)#'
M2/1?SN]9J$F,.[I%I2EP&.7Z0%%Y?\#6QDU70FK*[+B?))2]OIZ,0"[(62G+
M-O!QST<%@ -)B.UN+'O9=QI/67 5"6^7R-1XB]3NGK)H&* #72<'H] <X#52
MMVJ1R\F1LHJJX8Z .7/FQTK[2.=J=A7;6W WNQVKW-1HXU^T4@.:$#%[P8](
M&IO'ZUA5*>X\L8#O:F_,<@"?.Z]H9XOE<M:Z4[A6XGW7E*R;#%9V65PX5!A]
MZJ'@P?A;PPO,R6K3]D/=Z [FJM@]+QH'V(/7VI_5UYGVYCJL69FF#&H71)&O
M4*0/F$Z:(-'3B<,KR=L?>FZHO!'5:J/7'G&>ZLKN\ =%6ZD]1=Q;#U<(34,;
M/QTD^1&L=?)JV9RO(9CZ-UDN9?57@ 1MR8?R"T=-(D:3!TO":Z/>=KUB-WM'
MRV_0%<=RNA9%129GG.=>I')6D72'K>^5.N_S8:_NNA!?,IMF?L#I4_2,Y571
MV0N[)5<2#P:.BCU(9LWK3=F_/_6"R1MQCL"6Y/V!;RE3&X*5#RN+7*V5 M9^
MN+?JYG4'6WJSL4FS1]'V[A7GQM5)6Y&BF\RG4NVB9&@2[W+5CCN)/I@**?.B
M<7ZC VP>C=7H$(M-)-10_:G^7:3(NJ8#:/'M+BQ6 YCG @NQ]M5N6,A&Q*6%
M"11S.>^DA<![RWRW;>,=YY%=7<Q:J9P3VO53;?C(^I*F?75Y@O'+ 7=2;QS<
MZ6+\"/"Q_ZPD[-N.VN:[^[%@.T7?7GPRY*CK,M>>/1/^$Z3HU67)3OSR0])2
M >HQ9B<XN*?Y^O?Q-8VK#Y8^LIZ>F%3#FI.LR=LIATEV1+/7>VB[%?7OVO=:
ME0Z9M@KWCO7PS*Z5[V&G&"\HU5.^M*8U#AHH)$PMMY->$CV'--C],-L=1Y^\
MDLA,B^_ S5CZU[:VX :305MV_TGDX!\D]>B9-!]RK\BQQF_Q5U&VQIW=$\L3
M#K;;#=K'C[VKN+_3\AOKNWW8"[6.;.=J!X=G+X2-+/3/L5OJN@M^1['1@8_J
M2HB>BY&TH]_R^[>:C;$O!UL*'($B-NZX!7Z@O\MRT*EJ\YD$4K]:[ 7N^1LO
MS@YWI//CGKKU"1#8 [S-68)-";27:8*W?-OLGMQ=J?; /$%>0?KQ'SVA@0B\
M_BW+%".K_MZ& +DRN@XC@S(=>I) R3]CE]W9LR;0/+F_HRJR1>4V-W<O4R#"
M@DVSN%RDB X\ $F)'W/WHP-17$N9O*EUIA:G'):Y#2:6./<CNMD'O>]Q-2L)
M&*FT4@(N,!7\X=2,:;5II7&JXH03>3)%(&_N22@7@1&%[GE@/^9N<WK4OW7I
MZ4$\U:KZV;7$UJ>5:_AD$I+&NH%@61TC$%5U8ISKJ%R@?J%- 7GOA%G;B9[S
MG*V.I?E2(0+L&I@+VF8K@;X'/5#5WPYU23[*:[@DP[UE6Q(RY*1IPN3>"><-
M:^HI:WB,*.>UZ:&;*5R9GT7>W'WDJ<%-!^ZGTO*(TQ^H6S.HS]LGT-&*%1$V
M7=0(]#>=5<>BND+J@HK@M(1E)6C_.9S&20<" E_<HP,5QDEALNRKL_+XH@8!
M-<'G;L[OYY-X*/"+D0AO0?Q,J5H<J?YL+$V#3\=HVO'FT,MEH0YD\:VB 4R*
M-NJJ[U=P^VSY'LK!;WD:Y)C@F2O5RT_/#HU>N&/;O3E 36&'W[A]5]75@[Q"
M\MD1W4[GPEZKJ6>$F_#'*&]0F]8:U Q3?KCGZ..=O)CC#^C 28L3#Y,35*R^
M37)ENJSU5TLR>[C(^FA5RRN_0)4>*CT-'L5'D_R6>TA'!LOZ;8AMK^NQFX_J
MIR O;C"M93;Q.D.MDG\6,KVB+O;=P9[&:DFH:0NR*39\I'!&6%EFN82#YG8/
M=,+RD>)+<5N]=[4[UOM\EE@96./=3,MOX\W=)7X]<W+Z.I&C:;F:MQ#8[9,^
M=(,43T:16FAGD.R+F.TUO3PD"</^,4></_, =L9JV(H./!ZKWL^WD9G\S=A2
M#*.9WCUEFE&D8MP:M-J#R0"/&B^//:<#O4[DT9B1PA73>6FB**T*R35,G?3V
M;5-8'KEOJ]I8V-!"2 $K#].^18-[0;XWWJX+&LU&HNPTE&118$$L):7;#'M9
MI3T<HTYZ#5KCN@HJ:8I*TB:JS%K0.K=#"JS 4K./@FT4M69)(I4 P^!$("\G
MT7BR*>>Z-3*,EQLXB6(VN(((]%J9926>1*,#48WS;T![WVX#T$N=4-;!'W 4
M0_%-)TN[IG(M<+6?JL8X-J%V2U8Y=?/74L%[BQHXE)@3,KP%/XR?,;>$]I@(
MYDS';#J@4 B>4UDV*]9#]P4N^;<?)5O9MA%5*%)C,W+[ZBDLC2U?8/#DP72D
M#;04:_=F#B?L-@ [W?B;T7U!:U5>)V<\Q89 DCVV:PMR";,AA:+02( 6PI56
MWLYH):</]HTD]I<T#CJ08^^.\N1J%^S$.&BC=D,5'+VOH*E.'UZ?!HNOTX$A
M6_:93N)9B,3&?%3E%[@ O-X^3VZRZ!+N=C6LPA#Z,3NOT@%3@I@Q93N&HBD"
MN76@1[G"7=S&_%GY&6M&"RO\=/DBP@A]>Z9.;.@,'=A\H&T86CFB'\0*!N,W
MHVGUZCB"SG@B7.2O=#@8OU5K,9D:]0AJ).G$-)/F@J\.AAK)$2;I0&UM)8Y#
M>?$13R22),IUWY#J[D?1Y\+.[LZ]:R'D@ZG>F+ECK'/1L/86% 0O*^U[3QT-
M'+(!^_)T*4_-@VFL#H20BW>?V4/32MEU3<GI'G7R4=\^OL8,2?&NR:\>.M:%
M=W>%WD!O>/;L]-59]GEL7;K/N>%<6@>&X(_@GL00PC)PG3-IFS3[.S]^B2F?
ME9F1FXCUQ+=?AB,N;9L:+8=LZ$>=8J9%5-OW%\I^>(JLJ:V5YX])\T#7Z!B#
MUB*%.38=M25_'$);T-JFKJ0.'>LAOE9RM+)RO6JBG5K7FFDY4^*A65:J+84]
M_G2C5([+U]- ]C!NZ2TV_Y2Y:$\/RJS2VC%17+SJ/@>[63AJI^P,,_DBQ755
MB9^B&/RQ6"^02;=-Y0O'RF;"R45.N]IE9B*V*CT91\(14;KMYB%C+8MC DCG
ML+,T#3.,=HKFPC51D55QU(#M3 Q)\#:^_)!O+X:9MC^O8,$CU*U7^8^])B>X
M.S":'V:8)^UK1JFYY2>\KX7.^.ZB'"E^T!O2UN;FYI!.PQ\0H6AZK52B.E8&
MA2L^\D8C'V;,2G+14-*[EA]KE9NB/QGFF%;RY=ER:&=H2V[C$=%'^ L_^MA$
MXY7#N--4S2*LB>I]@96W:)] WG*I8^])6.(E!XFF50<QE6L?V&>)_I0%"QRA
M?YF%A"3,)+R79_((UC[+4MJ.^BI4=I;:_[4\<+A,SC[RC95%PHC?B'FD?\T3
M7;S.FZBDCO&"5-N4SH^6-Q.WL>5I\*!O;C#BYVK'2DONG))IJ2_??Z?*_M[Q
MKV+IFZX;'AQ4E)ELK(KN6>@N=;ZX^K3CBJQB^M?GR<)W9EW%I52GQI,^)0KD
M[,O+U/R4?$UD0RNF6D,-$\U(U'[ZY_]/[N^;.KU-&5KQ7AC\Y:(C;^2-(W_>
MB,!]:&4M\"0(6N>?$($V"4<9Z_T3\%X]]/=D*[HWX&L,= T?9S;]9YLJ"V>B
M1H62.-&Z(YZP7'(UR;BF>_9J:?Y)ED_C*:'SB]@+6T)34ZY*W_X\6\XQY2M!
M$!]].D3UW#9SND?%V<KMJMT!C0M/_+CU&R^K2"</(@(*(Y6DBH@W<&^KT^RQ
M-XJ]#V\-4MY^8/8/[LF&SUCE9#XVWJ\?ZPHY[67AEXVQ47]] /@K?F-K@/J:
M^:LGQC.)-RS#U(-0TR62JXN!-!+GG2 )<E U8CH&P;CG *]W@HT9R)4/Z:W:
M[CU'M6F?8.Q^(W#NOLJR<A1EK9(.>+.6*9]ZEZU!YJ^E^1RD ^6;$9U[D0M3
M7-1YT1F.+/*39&HH%"J5LL%^ ?2T%V)U*9BVRNCH_GJ;:S!D J)C^<\VLQ\2
MJ:%P3H!W=*"?B7($S)[&C74AR:-93>IS[SG6;R7)WW5Q.7!:@'9)\H!^W9'>
M^UKDPXWKY#;+D@7J:3Z),&6+A.!W4*"[;@PVYL%P0;\_.0)>-Z8#C1FHE0_0
MDY_-S1.B3LYNEIP.1L+<DCAPG3+@PA0"XFZ$PWQE8\JR>0J%K S+CLR90<+,
M#.@70QSHPB#Z/@GK2KB#69CAHA)$>SG,_ZL'61]2J5&VD*1-8/]&]'2)UNHR
MU!VG8Y#$?_S _8H>K3X/,HX-;NZ^!C7&?EWE&S.UU:=9<9T%.%B[A"/(7 <D
MK,OO^L4B)9 @#I @#'@@+9C6"DS+!:*ENT[+@T$+3A>@1 3[?W3_$NZ>")E&
MBD%V!E9+&\>]]/4^FV"$C7#R"4A<:-HHM^OEV*!%/H%?OU/V0,Q@K#>!+#<+
MSC^&MG\S)Q/NTP%)-=19_#U:ER8=V!M93ZOLLJ9%"#F=P=D\BJTMJGW3?=?.
M^]'"?8I $JTA'Q80AB+1/4?+5(H0NGIXUMB0+(/_8=$+[06B=5@.T9F5,TS"
M$X;I7RB>#71@V[:*>R<!TV<LM!7GT_S^O_")GNY&K2ZC(7^T+DJ.@]2TC%N8
M@R$P:(T%L/AP3P9OX0<%_0L5D-:TJ3!THH(@W)E)PNL.3A!. / 0\JND]:P&
MNV"RF4VJVR>D2DX]^N)BJB(:FS:^E?+T5OE1:JPOG\>0L*;3QR[%63I0.F,3
MU+_RC9MJW[2:8MF>]]3NG?N3Z(,U)WH1!SUP-):G!"\+ZQC5_-;2DRZ^4Q-X
MAWRMMP:-"UBD$TD8787:^@4<9"'U9AAW8WL?K-SE[ZRT7,3B;MG*T(%7AFX*
M]7O8>+%3J<&).QZ1.,NWTSHLV%&D2&_E)LJYW3X=68G<2///5#LAXMA,Q*#"
M:ZT/)LR/$E"KBYWO(0'$6ZEB<S/EK5<\6;O):I^]%H=HY\G;O$]8?\ 1NC#<
M"J)%1*UI.N#[5FG!.(!26V<W@J9P+%3>.23\J)R;%'7!]R'UI1'[".J.U/%"
M?>;)D\8KL;PMTD)B[BDF/7ZM&JR%"QP^M[<)S3618Q"Y;PM"Y[/@)8,(B2_U
M)I=[H<G%IS7=]<S[**<%RO:<H^8H,7OX/S/QF#J_6U9U%!3''=Y8XF,_P%Z)
MW;51&K'9)NI4<:Y1+::1<[1K97H; 6EA;>N]R\%)$.3+0',C3K,OIHW6CQ4_
M]QT5,S"5\LQ"$\4^1,\+VO8=:')B\ND7'17$5$J_'FY\@F'WY9H87:DJ/]B\
M^#[[V:$(C4)RFISPN-A8KRF-Q8D0-NP=?7-M^>GQ\?:5JOLDR[46RAXZL*F6
M9!TWB7$D\HUF#LMIYW)XOOXXW[K#CRF<%,VIP+KR6L6Q'3_7X=U6D".'W@M^
M5,F;\=+QV3^(O+>$Y+.[>4?%>?F.JBQ_X+Y>=.8UL"*1F@K:5#<&4]3L"8V5
M"[QTP'JB<H^#PL",W%=%4P+VO;<P8:4REKEE..>;E"F?0.=I;;[7Q2E:9CM
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M3O;W#$_%MZ@/NR 96(6'4JA<BM!V8/->S*")%P_X]?%R&$UW7%1L;(ZDC>2
M1"ZV1Y!$H,4G*W+P/$67#B1,9( #"2V4(^1]H#Q%>4:(DO)-RK"QGY#@>X0.
M-+FV(PG:MC0.L.(Q*06*RBU&T/Y>.86D/7V5,D5DMY4<4;J?4.Y+!_PYB;JT
MX*QL.O @6(N02.,PK-9:DXBNI;&*(RNBL@,7L%6*2;CG:UN"5LDT#JU?'H;_
MN/5<O\7\51?:LV^@YKTG:5QCIC+G-5)%U:TI(F!0#.X[+,412(HA^V@B?CJ1
MR%[;)6];C*DI,YCL=+Q:O*L^J7M#L>R.%-$-GP[XZF?RN Y*"TM;31Y1=S$8
M44HJI ,Z.'5?GZFQ?-(NHC8X6O23G.VO<NM"*_&J]DM/)(G8*M]F5)T/4_1(
MZ9E!;NG&W39K"3T9&M<Z;>J^X^0&\,]A]:1"ZL'#ZM&$%+5'W]&7C7(Q__V#
M/BTTSZ=(IV)D]@P[K5Z%(1V#&A?&3JMR"8L!!\]1]! +9DO0*J\+)$KA?K#@
M\I.%)DC7XXJ)TSZ;E;VI/ZVL^</**A013!!FT5P::FT"^O/7(;[B=GFI@4<6
MV3@75N"'X)\/$7\SJA=L\G-=&JM:<>Z2F?L#,[W)/\F;_XV\VP_R-1#YG<MA
MTSY,)?F(NG(D:600$8S<2N/R\*M^YVW=)LWB^C[2JB!*(U\_?(S)]J#G%7R[
MO'AEKZV,KFIW4AC'':6DM\)+&9.ZEX/"PFPC6(IDHJ7&$X*J6O\9;O_W)2UF
MC;<>]5KMU76U?&DSQR(.%5K0@:=N$8_O#MEOXW/I5HOHL3#;GN!_R%>8D%G\
M;R<$^)_ZB841&OU&OGF?29\4=\D56G#4V_;@U5BXN<,U6R61[/9\L7JQ&Y:*
M\=TBHJ<13P&'_T9L^;]ER/@O?IR_A[6__7MB0\J_F3SE7_V8Q)Z04HFLE8.H
M>TOH/7:'RLHQ+&Z/?1=S7%5;W6]<8QXV?^U-)FM:6Q"C*I!;ZQ>,)OL.DI6_
MF"=I>'R)URH80(H6.^M$:SG-GTP5WM=30F >U&S+:*&<(T8']S_B/W#F:.,!
M(5<2^_&N*O9>UB1KODMJV-OZBU(='_3-MNL]3U/[:A)R?$15H7@?N_H=NY"D
MW,^6HMWJ[WI.("0NF'\TY=U]XJ1._C?<B?[!M6;W"=01BBPI']HC\]IV%79Y
MWQZLY[N!-XU1+<CV.4F#%J+W,7VSFP,\6<=-:S$[9Y64/%(^$NV+S<O1*>.?
MTTR/MVBH\YRMVX5^^8 CZW;(;7.,?G1XL-WXV'*3W5@3B,*:(%E)>&5J<OE!
M6R0;!1+=@JR"%\2[131GY9W2.,E6PW/GH8)FZ?>LWJI=%JE$P>$MF8D4BV8*
MIU/:1-_>H+E+9*N"^/33YI)O^@RGQ]U%4X'KW\=&]W&>J&A]4F0Z1V(S"#94
M["90;4%6HD;FN2%__(,K;2CM9F^DE[6#NQ %=<T^]&2\DC9:XIC_&>2C-%PN
M-DCI .4L 1.@8)IE+V_^-2;-1*IPK\SR%J['GT^IER^$?IP\U2I_XHE94:2?
M_IZPIVA7RA$.LF$C@I-VR*.R$N13D!XT1>ZVE;_@GVEL9O88FW&N5'PG*LHY
M] S;^R6^=/L!1'6F=6U7[1-7'[U.NU"2+U%\$)^7+V;O5>2^<\LE/GD9EN]!
MV'2])W?GW.S171*.NCU'D*R$7L3R0P>-Y7M%!*EE^RV!SG;#ZJVKU;T]1Y6_
MG*8#.5LGQNUP54Z\'F,:U+A2KD%S88.63 HRZZ/"?'+UXS /RK/D!P7$E?NS
M?Z2NE:YF+$(3^8'ET/RF.3-)NTN*8I] VSD>#\Q@8P6?957YWM+<@E:I#SG/
MRPM.'DHS.H(J/7:WX0[__G8GJ?[ ]NC"1T[Q1>]#ZF?<W2]7CAR6F;O&)0RP
M>S9V:D2H*?8&C1IFXWTYO]ICYH]-H'0ME <P?-[G264#>"(V4$*J;+]Z\<*A
M9M?Z>H.7L]<,#IJHR;+%$#R9GH3D!R-F%!$A"HH#DB25O+>U3Q74[BH^O!-U
M\Z(!^P:!497:/KW:?5.AS05K>=TY$[BH5*4FA*9CM7!\M8?*(R4A#^R@5G"I
M9#(I:ZW6L)FB=LMURD&]N?7#<I2_VE-SV9V?JG:]6N(,'$"$T$2::$?L?#>1
M FX^ZS53L$ 0-[_:LM_^C?[F.+>CSB+";^[6<AP]VF,:K)4JD:"E.W'IR!]3
M?FOXE][<[0KZF2I#*)*:M*FB<L:2W-',\MH;5[H>,8LO\(:'3C07X0*4CA%'
MBXB5M>6(=FD?F>%*&D*&=O[.\F&YI(6FU^>.WUXYN\S;[EMGL9Q^MBRA1;/1
MY=-79XT:3\,O?7^0'A,E*Y4X29F9E4-L F<&7[*\\\_+71!1#M^-.)F%<.)_
MF>*!& X,%O<5\4!4]!TH:J&<<1K*Y,X_%'.I\-AG2P&!DRQ<M]F>E@!A<EOR
MUC)Z[K88H C?R49]M2VGE/=OWG8IR_)V)=+!:54&P0_BH=W%>!76G#!'N>?:
MO[:,I@-G.+^C"@H1N0CT23J@!&U.$G>7>56^IP,/04TZ@+6A XN[S'5HFWQ0
MWY_@:^QTFG7P1^+^6>P=A8]'A.7'@7@D$7LQ(QC+-K$275V>*K4?>V6?FBP_
MDK7]]T,B_SN)HY"!X+P"*856#)HLUM6V>,NF3,A&N1>\N^O.I7*B7*V7=..>
M='ODOY<_[[=<>L]_74<K_XHK"DR._ZMI\.1E^.A-U,^C-RV_XEJ^9;KT/Y!.
M;XOA/0JTMPE_2.*D ZBN*%H8S\HD03($,7\+LQ&<(NO0@>9SYAQ*R'#*D[2;
M7D/4)AT]>QU#6=W+:5QX=B=KA<<<43L>&5]#[W]U?^6"ENZ<X<36WO9HIE&P
M,V7P:<,3WT-1U>5;:9_:$*CW;3>=)$JCGM4*SEZ4WWV&26&/=GG,4#>BZV0-
MOQ _6^M8DX3KOL5N^Q>C@2?J]Y_B/>)]SQTXB=+4O8-6GUK[4M33U3.VK/X9
MP>HM1V(:1FWQ4*DH/]9<RM]>KDCH;:AR]Y2(=]Y?F=K5</+DOFYGO0B])[)\
M6^6PMXA+6?%$UMI/T.B1<\/N,#<Z:,K-O^>NK7M1)7O9_?GI2C$WSKF,1 [G
MB4M&17I14I%QJ8<R;W^D\9.0U2AV.F!MVL"E75"*E[[/UFQBY!-O%?M'TM&#
M_DF6 2+)9RPG3*#P6AZ<23(<0 <L2NZT:1DOSGK)W#GRP%IETX-+>JD*MRT^
MYEF'SEQHFC"JRWUN8N_N,JRI_,:[D>A7*?^UB'S.0\O,:6.O1V!EL=)KMTT+
M[ <COC\_8OYVYNNQNP+O*'L&^OF\3[4J'2'E5O;M#-?,:4L(4-SVD6AV8>O[
MR^=ZWO5FR^YF 18*V\MSNT18E?)SJM6/7RZ(+!QVX>,8\<+LIYRGQE*,$RBG
M" 8E@[9+,^XUOGRM@JTS4B6IXJ&;LM3>&SHD!FP.[%-4=HL]IG2R7>FDMQS1
MCK3-P)X-<:F(*RWWM(G<#>4-'$YCF_A](Q;GLCE*?-+*"X4=/5+L:0>G#2]X
MMQ&'M'@I.J230S,(+8(TQ9"K3S\S(B/WK-#-$[E?QGR_E5IR"P=-9;JA=Y)R
M+[10!)%^TN*26L4Y,L4!\3Z'S@B@Z[H^GBT2>OP'[[6RJ""9D,J@VBG6.E$Q
M36V+1O/&5^7[C$D+ ]C*]Y0MY1SA53H39S5\Q/0*8J4+HW=755GU=#][>X"7
MJ25H:(#ZBG*&4-,X6)"9D%^>.=2[A;9PN54\>-6Y+[A 7$$[_%LJ4L)GLX]?
MWAW.KU.AX4-\8JSJ#UQ.#V?:\NH-=6OX4*JG(R(ZA_LD"-C'2K*DEH_ADSQL
MC0'><H,EQ/3ZY4Y!62[#K4DJ/*+'*QZH'=54Q^VX3JJ.(S6>)2(#L'E;W[1I
MSD:!1T-?[OJ DK"I.RY:5Q\+9GJMO9UJ?L5Q)X.6?2A*-+\ D:MU^S-HC6(A
MI7]48BG))KZN,HP>MMNC)O3]CVZ7I'LY ZY'@6&\= ,=N$)*&<35-'*1(EO.
M8*J@B4@Z/U6@0K7=WG;0X.*)$@G]YTO,^5Z3;Q<3;9)GDK]\;R>C.Y/"S-EC
MH.D.61U=^Q'UZ#%SX.$B(G,P-^7U899$\8TOVKB^N)P=VQ;^9"EK> !5Z2-<
MJ;2GR:G1/_PT$=%QL*#TY.:['Y59#3V$1SXILB=[MC>U\&J3="+NJO,&:YY/
M318Z6*]1'%/2E[ND:8)7;IF5=,JRS,LK/'<H]^)';8[M86K38OMEII]B;E<C
M;VH\+"<9LOL_GRLG7DBQ3>I6H0XMB,D.[#*B<<[R.+S/SRX(I-VM25UE7<4/
M3H?1FOKWBI<?K-_T>$"+[?$!0M>E9)/EB7)C)QG,P+8(K53IQ;!,U]:5@SP^
M!MA1*S;34&D.;;.:^'^6FE PW:-X6(M8\#KQD C!7&+T6?A[MXE50W,+^R%5
M\_*C-I=V!3TB&$DR83T7T_[W]S;/"+C@%+RW<H;M?"6O<Z=,FY6P>(/;TBB.
MW3(,N=\C_N6^+>$'<IZQ*[YE:GZ;9&+R'_<P\BM:M;8/M$$YU;@VCESD3+@G
M7_Q/9KX]#C(7JL4,8RFNI:UYC?Y* KCF?.[%]"F-"]&G'@'BS^1=D!$LYAU:
MEM_<$>KF?6U#F-U*@G:Q7"3DH%?P_@?2#<X9&9;%5UA47AJZ8BZS2-&!'5-=
M40]\I94'@I]>FC)LR1<_-+EWOJ]\U3):IFO8?<6(EWPM/;0CUK(K_:\9SI3Q
MOE>RES,&VO#_N<=*Z$K*U;!)M,GR':[A\2FK"E6]WK^?\Z:$"O,4M.9X.':1
M#KS!K50K&;..CQ<$760=0P[*M"#+9*D$L.:5@L.;M7KX#,729)'1;8FQ<Z$3
M%U22;_<38FS[%_'P]\53372 I> U'= $Y]"T,MX,LT_C'LE=8E#)PVY-VB)N
MI98.6*!)FGG]QCBXAI;8M))5SWB.R*<LD+9'4[;=B3P&K7U.$V-?>7V&NJ(#
M2Q/S]>_,^=@X&^E A54*Z*E%AO9'6!7*81/W%3A5!7)M22%G6V)<0A$=(%V$
M"(-S&%H9@A!MVY<#]G.X?)((>1 $$1V4:BF[#K^0@'AIN;043EM-C#SCZLIA
MB(1XCL5 /"/GHE$0!3JP3H(7HNH;] &J7J^U%$5;_2%>)&9*DKI !_!P<Z<F
M,SH L>*4@5MI9(AV,6]N3HVAI/&19^9\F__&M\8_4C!"$E[8TF!>P8JK*6NP
MV-KU!XIEWV8@2!<AZQLCYX*0@\=:J##W(A#1_:T&[)3#/& &9J4:08BR'8L/
M7^=NO94D22,#.9%"75"A"'7!E6#&0HPW-Q6%7E"^"E:87_&\NUX81=O=C8#(
M0\(:BFU+M"OWH29*@7M5B-L&P2#ODX.F:$Z5N#X+-7=[!V?>$Z+U&YZJ2IPF
MU[:7)=)VU_/3G!A"O('D,[S*,#E$1][%=<3+[*6).EXAF,:54H59$Y"?HVV?
MAFPS(DF1='J,6CSOUDCA-@&)=4N-)/4,'U@J<&T11WAN!"L)-K\Y?S/R$VZW
M'&J!_QP=V-8]I$7=Q7:;#FPQP%!<T"2+_MW@^"-[#.E$'OQQUQ2.$&[D^7D5
M04P!*[0MN[^L$Z0F(<>Z*. 7F,J9'U1VSKA#5.Z %)<H&E<MQ-S!KI_,>4)V
M%#) +;8P5-D,5NA;30E3B9" R8V([ZA'JZC;G\!!;V_(M@E\671@X"NDP1!M
MB/#P;X3+O&B[TV&E0MXM21&*5((,BZ!Z6C0C/N%VCO@T'J #_D2B,.W1G1(Z
MX'<*29-3H4BB'R,7S^7W4[@[Z0"D%X@?C:,,Q2#7%L$*8\L?G"1VG5OE&N+%
M%D&>1"@K%Z(#33OQ2(*U-1VH%8'HSA E:8\"BG[0M?@(^9I^%%5J71^P;B Z
M#+_KJERG\QU!*%<Z!)'9@0?_(O,[>Q8XF R&08;!CK858ZQ QE;RH ,"E',1
M*PH@C:NP"KLFP/-3G0B8/Q!B[P==L0YP4"07BBX81@B /,]+$E)2-,:6'5*N
M2_D8&JP@D<+IP/E3YG3@XVMH//)"H]M_@BCH1P=83YE]H@-O(^!2[#5H1";4
M4W'DT?<@ET<\OH8?09;^TM2UE[IH>4"VH><&)B]P7K)*#G4[\J=.?'_J1..G
M(U!_M5<P<LUV?<C"I!MIT0R3*28A0WT/UI%C81_L'U+YI5$X+"YF7=P9)&G$
MBYURJ-V(#D1B5CY#8\,>%BU<?^8@M*_#]U5"^O'Z6P/&4$ LGI?^:?-E=I):
M!B,^:2((X<:><!2(AIVF?)DW9]:C%,-5?LRN[EIS^8[/5L<'K=JE7^P^..M=
M5HLXHV])VC/,'H3_UD<Q)VZ7E=>[R*<@&+\E6,M%CDK&1#MZ\;*N(&#BAW[Z
M@:;M>K##V QE[DL>:Y63+!&W7?,IB+#>G)QTO-OD0S#OY:IX?8Y; %.!**W?
M$U+]PTB&5K9 =@O68B@+KYC4VYF:K7P=ID?KIRY  X-%*.5'N D^)B.2 9+4
M')#=/T)N9 MLL1"#+=6<T-Z713R%#*XT2$)JP\S 'Y&XO),>ST###=8CUZ$"
M##P4$[ZP>8H)TG:;:JG\2:<)3H%T] ,^(0<Y*)3'<*D&2&<F8(L6>33XF+3,
M$[_[&+/;6MAC> 5-48IR\VZQQV%?4N8$-MV[':N:U4_;K;$N C2YC.<R70N"
M'/)A&!YB#XX]EQ@W4!^B1S^T)^2 @X?^["+,Q!-'75!^P=-JH$4Y%!D+S:?>
M30RITV$1C.]G*EN!%6H,;4 2&.!^2& B)D;;+89B] G7Y\0R!I--+I-!4!W4
M71 >UJT46*%LOVZ8HQ_:$G)P@P+Y/WL.A79%/Z2SR<"25#/!'UKZI0])VNYM
MJ&5(-^%0^5X<K-7#4'V1#!Q)51SL7O>L9Q"A0MBUCGYH3<B!)L4#4!].M%6H
M\S,.W2!#NN<&UA"!/O0/;C<7)M+TC.^G*-^ ZT C) (B8^J)'(&JNOZHNJJ]
M7G%=#5!5B*@I"'?41"US@/6ARB8J)DOV[(:= #TSY00S&@TT)^2"A9DXAH_0
M^@H8K,1!-4^17;K;X!K(0O'UITP7@K[2>M9K)$)/83KWI&PRYF;JUVG]%S4=
M^W_6I ,SZ> R3A19D$D'NBAOF<X&-=*Z(![MYQ/)=OU4;-T]*9'_?JU$:B8S
M&16!Z-[INHH3!<J4+],Z_."^H\@6[,MPR<5MC:>1K_5H[7X0E?=:FZ9:&H8:
M=PI55^5\0#\:MGQ6NLRQ84)*?T/&&?00)16$ 4[LY^.VM>HC9CR079149'[<
M>LDB5&*S/K!H[8$P2Y+:>KCUIXED$T9O)<HZZQVAH:H0AQMG.#76'Z%F5$&X
M8 0J,$!<@'LZN$[WN;[DC)'/?H@&7+[>A'%%:PUN8M#47;]"Y@LL.M7=D]#6
MHP.,2_2,:ME^!@4DXRJ1K(. N2A2UJ,U,UKD76/TL</WEW<#0LUWB_V[/3^M
M+Z7K_LE2FJ?MH[=-TQ)Z-T4:+^7#^O54K\KE0GM7XS>[$F8'LH7?+6>17FGG
M\>S)W=-F1.S?Y7VRK=2! )YO=AP(UB#R/W/($J^-/O1$:\NQ;1M6C#;*NZ<K
M[2%(%+ZE7 JO53J4'ZA5Y*?)X_#ZR>['=QYT)X7&M,8"?.GM=]#JFG'ZM\O\
MZP)_._?;EFKL&45YF(==3W>M]_SN[)]'?[^FM67^ N/2RQ=R^O^C4\#*'/I;
M?> WR%?LHQ4;EO/?F%5Q5#-+AOOA%5C[TQ8LSCA).:L))*%7]$+#%]]:[:$#
MNY*3]LUHG-Y!XQ&!_H3?_HD.\QLO\(^Y29GCV68.[7, ?.)];(F/?W2JVD!V
MG&N:*+$O<@SG5%/,BA5:W-DK5**>X#YR.59KT$#TV6;YF$MO="#^P[= 9-4$
M& ?D<RJ"1)(8AUT9MM9/2C991S2!?]O:@[@RX:.+R:WPD7K&:YSQ]:K1,"3*
M/<89_Z1?__'&_"<<3FR<.(>VWI^O?WX>)ST,P! JJ6Z Q3Z>$8IT7)]M]#+6
M7?YMP$0N?_OGJ5AE-TZ#[LL%);%&\2\/12++T\Z(WO[6ML$N2.0MD.Q4IJ;>
M"N3!WQ!3]#JV*7/H /]@1::K\!%_FYT_;C?#!WUA2)<#R<(4WQ_82(^1P_-3
M\%(.XG%#V[]ZS_:O/.\R<^QD_SPGG$<VD]*@GV[RUVET^^)3O*\K8+@#QI?.
M5SC25U*/&,[I6!ULU596K?B'(Z.,7[J&:E[>[UA"]^-@]TWZ& )I>RMDI2UP
MAEM&NKL47=M6X'?LH5TPYE R&R2PWL%%^*U>G4<,[8(#!QE#92TN_M(JI;K$
M=K9YXKN5EZ^^X3Z%L>B&].>V3:JGFELV]%<J(RJ5-RU!73YX\,^Y6Q-)"(.U
M?052JBIOR#OD4'DS'>BE SQ3Z1)39T.F3 I;351VGSV6=CR$ZK&2J9[?NO&U
M9LKE_]]XW ;#.<GV]TZ;)2GZL5"D!>G C:RA[$7,CG-)D^Z%V?6"9=U6$=GW
MOWJD,9G;VB3$;8Q(/6)R;V\X*=46&?3[!^M_#<>;# B$C3]OW\%GR"$3__99
MNO9?CO?/_U/Q_S9$%12#'BK!\N?D\SE+4<\V-R58RRJ(,7T8XTPWPSS.AI8D
M,H\4&VG^QCB!D!S(JDRX@"!D0!#+Y%_HI__Z'/X)QZ7O^>TSB\/[N5Y<_T.!
MM7T=,XH,[2)<09.IM"C3>[JI>9-6!V"P$2CRZH6)MJ2F7TH_"C6^")DEE4$6
M'DGKW@+_+I?9Q'M^@_$IS&',$-BK :6@_PSJZ>><H11#T9MT(NI<V09[9]1E
MUIIF!37^S#14YR'Q_5TRW"\(=VLY<W >ANP#&3"$DR2TM2)+7^:KY@C6N+P!
M/E-^>AL4T*"XI@D#DQSX7<__$N]-!ZP=P</_T3AM(A).0TK@^A%K&_]O'S7]
M?GP[XG>0#>"7Z?1+FTE^.OC)8(%67+@@;5"2F/VYAS$7OML+CTYUG&<8Y&F'
M=?@@G3_YYV@RK'EYP1I_LS /8]1?W =)\ R.-C904U:&T&XRKT__[A$;]D:&
MVMI=[M!6YCR+@,6_K&:[O3DI[#Q6P*?=ZC/BG"X>F66W(B/?]])AS]N@VX\W
M7-8RN^4;P?;<E4-G^TIR'#/(Q@'][6G]LY/?-/LSQ,#G^./O0;T<.+M\Z_.M
M\#Q5*XL0PU&(OJ%BJCW7_VGO/8.B:KI%X4$0E""B()E1HF3)2AH022)1<E0!
M"2,@DN,0)&<44+($R9DA!\E)1#(.&10DSQ"& 0:X,V!XSCWO6W5.U5??O;?J
M_-A5W;N[5Z_4JU?OW:M;^X2KM"SBK<'G6G/8Y:V9.IK_^GDW]+][NK_WZW@Q
M=J<S6_;+JF*K?L0>I_+D3&OS_OF/#6M+SBU.3BX&8ZV_UM@.\3BON4/1AQMK
M4XVD.!J$A9';/5QJ772QKS[GX]CE%1#UX1B6!#JM]2NUTS06;A9=K']VA_S"
MO2[6W"OY9[.I]4/M](M9)QSZJ@MG#E+T?QZ+M.?,"OB5Y?HU"J0OLO]C!OW'
M\2[I5XK_W5^Y-R[4)=RHZ<5^F98ZE2C3+/Z.?##LK;YYPS:@E?Z "[5YWW\<
MEHL"=B2FAB$<M.$WLG.5"V094ACR+-Q>$B155G7)W70([ 319-/SJ/(W1CTM
M;,3>?J=S?AN>1IE36/#&5F4/2XRI-*?Y.Y][<O36#^]*_,-@.FB$?!PI-J*F
MIY'C:!DG8-X9*_!*.=8Y.3)!%(^,QN=PI\SXLVNG(%WV3(XV()W8A.I98MS^
M&Y):%M3SYCCJ"-6\*/^&[0BXC\ 6O*Q8Y\<, +'?10]O>6+:8!*RXR\5D=="
M(;$G>9B9AA)MN6URA(UQ )\(B1CU8EIABDX!,U'8SC-[(%N85;57"6JH;O.&
M5^#C^(2_;X)-1D%;"Z> "$JCUH'2MQH'=FO 8S2F41\$8P+_0XEJY",(%JV$
M'KM?K0>=IKB.2#)2OE?O8P,RQC%H&/Q"0]#(A4BRE9N;Z+K%%AL68(Z;S?'/
M?T*$O1K\426Y>P;RK1RD\:S;C+4:/20A^XS>R7E!%-<IP!WTB^**=>%0E_A?
M-3/[0!CR3GBQ2%A)MEEI)_Q^,<1E<80-6&G!(D&?]G1$XP"R(?^+39AEW'FE
MX5IAK]<9"58G:,@^'!+!8'*$6=O.=F#<#<%-C?OJ2C\P2YY?'9T"K,]0D$OI
M>GH[^P^(P;]55.:?LH\DJ7BCSQE$<,:$<UB<=S+"@5N_NF_Y15:$6, [S(3I
M_X<C=WF/!<^!YKRLN!$J? H85OA5Q#I[:'762QY&>D\J*T.;=X?.T%&J/DD\
MAVO%&CI>JB[WNV(F<*/K[+WU[J;RNT/V!HCW60.5 \ARUJ_^(UO4>^S((R-_
M%J_MZX;'[ JQ8<B48#H%-(>="-8'H7<QV) B<NLV^6YG8NA,C?E%D JH^;>@
M2$]HV&N!.[^0Z3IK@F%L32$W^;M3@"WF=:7I<0V6BD'[,%E6T"2FG)OJ5XGA
MQ1QN@7,\;\39_^W:D&!0;AZ39<1D_=&64Z#E+!.L?"@!&1%M)^ZRF/H$J,$:
MR(!"\Q9FX4S#4^^C_A\:-/]""*,O0%F!5Z>  2PCL55%>']1E?&38/#1KXJ@
MSHC?A&-:UVWB_OQH:W*P@J$1N*C4"#DG-N^""#14\741S7O*@%<-41_R\I(2
M3MSESW&I/6,J!D6M3UZBF3.UIP ]#)%5&%JV^ C0T+!?.HKQE%3Y0,N%)OLP
MC% 9GD$&=)NWH!BTXEO"9-G>I>V,\6*-0=3?.GB1^DYRY6SHO;-1G..&<72P
M;<I.A'2XG,@'^'G/T,2(NU_U8(T2F\KZY$4^>PX \0<4)A5])2-I"0/H')<_
MJ:^X>=KO_^:8'YT"BLZ3>)6/Q4<P4B^#G G]GVF %_F T)\N_J1\@/?W/KIA
MC)'$LW-!<@WNQ_-B!2%U;5#].(/W#$5RK]\):[RWFA#L#808F)"+P#\I@**L
M/#*X&0L5KOX[@;UD%'OGH8?LN;I[#U+^0GK$EX4">'9]XB_T)/\4#4O]!85%
MM5+V+W*?XJQ&":=D9RR;SX88T.I7]Y@A(X6]69/O3#K_6Y'E!6N.\PLC?T'!
MW@YYSOBSNSN'?_<\A"5WXU?!S]RF85+T?M 9ZY'O(,L-H#-^L>1P2__-QMG.
M;PF>I;)])2A()S'KA]2O6!LF_S>IB;WY$1QTXG&.CI7D. 8NID/NLPM0:S"@
M,(1:>8_^?JN+79S((FL<TB2!9_,*[,-TFN0OF12)IE.J[1RA(&=4\D[>/ 6D
M!9]G5-58<Y]6!EYF4%AXX'+T.9_?^V-4E?0I '3UEPW WOV*ECEGEP^67=&0
M@?8SY/]C/1_6;&O__U#8=?C@G'HN#0@&M6[0\L(9:LI'9K3-XVUG VKXB6Y&
M!F6T"+HZZ)R9Y:0'6Z1GZHW5&>Q=LVWG\L!>-SL#/*?G<?R'?V0;JO^2 U"5
ME47V00Y0&'"$=I/<^Y"N<WQ\V#(RCLR;STFYR#;)?0HXDX8E+2M6-K^;W$#.
M A&(,P3294,Y2*'8Z"4,!,R(!X)_]8,U+V?WQ3J? G:P=8$8;F]@X&') W7Z
M]?S,E1RW^\4:S+R49EO=A?;$DG'#AUM=:^QPXA30]_F<2]63.&F5ORB\&?J/
MX^RTK6(75G\LQAB)^%#KFFX6D>/ _MTNW24030.NQZ(RFUS]4&M3V8=5/FOG
MLF[GPNPKU (3Y6\T&XCFIA^KH;(+43LZY:(&_4\9WEL\92KHCBFXX?+L[D$2
M/:GU7GRFO];GC6=N3C6KH6#'=\\>Z-#[$\:'QH;./JW^%2QZ0I[V#0X9N'1V
M6SR%=2B@"$D+.9C'1IXVFYY%@T%F+^2[^JVN=LF,\'#=I*0LD]H@ED<E7Y!"
M(TSX2R)OQ?+E#2 2-*L0MVF3'IP,&!7PHA';PA8EU/T:47>2BS[L@29L4*<
M^; 3%'!>"0O]+&@U;E[B_I$V?.:]2YZ!5^2)AV.LY1VYKIO7.)VSS"&E6 $U
M8$-\US'SZ,X6-OBV@QS'Y$_N]A%),_JH QO06R8+T/F;L_N&U8'7F*;%I(O
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MX'XBI![F'OO#PG05\AM:]LG ;V74%!=P<\MSA:C6C7"?]'@(7F;&N"_VP3W
ME!>:;[7_UI-'>C7_Q?#?%F@)"_>-_=(ONW/]^H0V&\?HM^OSR^LES$/IL?//
M&D9O5>_,?+F>W'V=+AF1;)^X0XJ/JE]ONCV4 5]N+Y+IVC8RY'+1-^^O,5>(
M=%%JN+W=NUB;KUXW%<0I!I0[#IS\Q4/>OUVG.,RD:.@9_.7O_Z;'_[J R6M8
MBB(BHOJ/^MC\4I\&TT50*$]A@[+-1VMO[CJX2%#JA!)#-O@%U91R36!XCW\%
M+IU+OR)<IX-2![:WF62Z$%9"AW*_C=<\2:D]3T,=]N0!W>UK%_B]?IOG];2_
MLO[+.VW+O-OGL==GO4:M'_T:DW]BLL_?EQJ<RZU ,&)?&:"-48__A'&3'4(^
MG%(-P9I'&7+"9LUPH;ZJUG6CLM[#_,&V[P'S%<V#@"#04*/.W%:PD"J9ZZ,I
M:X$>")T+*455)A>#C/%]TCYVE?;C>Q\7AJ8".%.6_W+V?!2=S0V)[#?^NQJA
M*\G3U#3L*9!O9(7QMJQ&;OG.7+)/^8)ST[1YR$=(LN,W^KZF+\ZG1IW>M<5@
MTW#K:+39*(^X8N7=KU]2A2N;=[JZO]5<\#:&[FX%;19O58H1)1W96WEPW=Z9
MC/2LYB#BG7/0NEVSQR*6\!=?];\<+!S44/_WRK%^8_:7C?O#SD*H6TEGR37K
M5"!\(ZM*)-9*V&'J4@G4TN;SEOF5H4>^DNG$,9U614:OI^,&I##V7!4;@>I)
M"L_^:XP.!EHD>86]>8:X&\003&J(4P"L&,\ET:N_KJZ#K,?*\Y-_'V?+][EM
MSA6A_0]=;QDWBV7^M2K(_#L+\D^G0V1=^)P(CC['$A)4_T)8&(C<8"4Q)ZRX
MX?+\4M6.Z0BW31OM^^JK:MV:ZY^ZJ)8%AVJ2RC: 3ZM^B4WEKP2-);":[1X/
MA7S\ADI=[IP!!I(QKNYKGQC(\KUP$_MT04K^'FXH,I^FE,WQWVG$K;CF?RT)
M*8JF/VQ.0G*:G+F@',->PR9\J+!.7#4$_L=4-M2'7%?"$]B2PMR0S8;6U0=4
MKU]VD";5 %PE5C,I&0W*=M-+J_YSK_,G9& 8QO-@0A;)631\$^NP@3#CX]>_
M?EG^M@OO^%Z'RYIB 8G8JO1_F\]>?K]MC@"6SZV\1]^U3<*%2&24X%\*7+(G
MCPO4 J>_^]%=K_7I7FR6*%C:0U0RZ(W8>/.M)C0Q=LY_J$JM-TNBWGY$RX\#
MXM7/IF0T+/1211*=FTCRO_WFU]%W=""C3.W="+X5?P\PUG5("9?"^![9,1KJ
M)O]=ZZ9VT>ZWQ<_\K1Z< Y*"KF&/X:> H'78T(DR3:]'%,>13N#D@,?=8-#=
M1RYW:<LZP5\\B19Q+18V.,;;TLCL3FZQ?&\5ZZ/-Q>7BHWLC\H[\!6<7WDYB
M]HW13:6XE*B,IA:;_\1.T6.8DZ*LW>_\/T@L$,3@]>>]UQ]KKO<1BG7O?YNV
MBQ&8*2WA3!O9$&$=E-K>'%%*HPTF+G-&N.MK7")C\?,1(Z]3NLTYG&T +PGN
M%33CH=5=\JP3(Y/ "P9I-#^OWB^7+YPV"/[&PN5P]66Z M\7^QBMONSNI;&N
MTG\I:%U]_=A_SLG_M-/IA/^ZP*H<.X7 6B=_GR#T9SB9"+KZ=RIY+9#(GURS
M"Q4-\G6B!2=$<C/"OIG*A@-C_,E9C=H([FT9=\#?&(^*R\^ABO?NT6R\+HXV
M4<3Q+;E%0,0>A5*Z,I%O;V48QUE/7_VO+3+&O_^W2ONW(.LO6RMB#+<BA;CE
MY>&111Y9TL@4.2)G5T:8@0-.%_TQA%#D*TE4*0Q[X@?6(OQM=F#>8$-,=)SS
M%!&E.8)6C.C[(.07%V]RL/#T6ZV<ZUI7D9=$YI2AL97S8R-9I,?[6_*)P,U[
M:GH0W!@MEMY'YI]U__),\<_HPWJ2%"P48U^FY?#X<G=AMPO^:]&C^,]+AW@2
M7+].L22'7:>HB38WO0E\%R5]S-G&C!J='VT<A RE*B6Y15O33'PU*MK4O$"5
ME>0MI8H@Q$CPJN[DJK[$<=':BXI$@DCM+U/L!&R2K4W&P&M;ZQ.NSK-=7SSO
M-/\LR(.TWF.B"*+J2HK(P465Z4L;?C$B+>"VS6CP8Y^+,0^4)8Z]U<WAA@=T
MK]4UIAA:WS4A6:D2=4SUBFBX3,=O2U(K175OGZ)>+_'WGR\ZDW8;5Q3D?IC:
M&ZT@>6C@#Y*V?H+DYU')[073254"AO*^)]RN+MJ(^>I*?DMDPLO@C2([0>=*
M_D=7%*_%47>?7%\Q$NE4DA!6O9R]E%U(3V@D.<]39!?/QZX8>-_GW<%.+%_D
MWG=C$D3V>'O4=2N82:BGOG</1>N G=5Q$$MP7<P536K@;.E:N':9C@Z_W4S9
M'N'QH))")30F]\]G").K:/L<5U[=:M'IN8;A8NYNY6M$UQWLF7V#M@" E'3[
M@2*!N=E(P5D*W5E]@VE2:)M8-]>LJK J.3/:YP/=XL=YP_W.#0T0_IJV/O+]
M@O @6H8+?W8]4Q4\[W!ESDV6UH< %2 /E]<UH77U6S8<];SO9.0.(ZTH>C^<
MV+6.*,.+#A<15J![8V P79MRO,:P)LLX-,;JBY6YLIV^DU#CH1I!@.OP0F#<
MAREPHG:FHU._^?-H6)]%!G3(:E7J=NS5.PKW)!SZW2$^:.6G"R7$$S,3QBRK
M;D_IAP1NT.'4D(OG#9@:4RR64!MZBB">YYG.VU'$D'3T31E-G *>]7AR/W=(
MN/" OH?-2EPG#TT-+;4C&LC76V,SKAU9!A?TC87U</,!*+81VT^(GX2/E>L;
M]G+/=&6KRU*<LU!;!<H<LR)2<G'$6:.02WO)_"+C33H!4NGQM(=CA2;DNM^L
MC8$CW$+4>,("]P?[;SVI5\O#6X8"7"O3:,5%CK,SXFKL61IZA4C 1Q<_4]XD
MYE,41OM47=F4XYS>L&5LJ YUI3?#:AU[MSG33?^5H0:/DZL@($^R8,SB]!T4
MN'?[=9>J26685TWG^L:7&52)%GSSC<T'2U'OM.<=&S;SNHO/7NE)S2W/'H[V
MC@E$'":1J\M*G\4MQG6@Y<:# G==>9='/PP5,=:J5AY\=>M<D'2XQJO1WR5M
ME/-PH8G9U19TW:KJCGQ^!*UFX ^+X4UX4<A;.I*<0#R+4/M9=8E(WD_-% UB
M1:XK&^L-_0RPS8M*'DJ-]$4TBM+//K-TTC(!V7=+K$IHH7!@V%Z1$G8_YW"'
MN\WF>ZM7"61Z$_J7]-VB?XCP2>!0MXZ7%5M]@>F^F\U=O9V1A=U# 2CA1@4L
M1HBUU.V:&M53'CIU5#$.VNPB:U.R2#[7 - 8U<QVCW-SB6A@REUEX#@9A^<$
M;SA"R(KR6^SM7 C[Z4HW691X7-@)Q$-S88=ON -08HM%(AVB7AM9E _'2Q\-
MT>H,]X=UD8%N\L4,T-G2@T<X/S<0S1T;#[0/K7G?'M^ ICBLSSQ0^W;_5BB5
MDEFT0*PB[IL5X_<K#PK?R2%']#%H8G?AX!09DR[RAM(8A[%69YO,0&S60@22
MP&$29,6Q+0JT&H^(K]W;FFF<+^A\#E<-K3R644]J8> ;MJDLJ$](55):DTWK
M>9M\5QO/A9ZF^,;J@Y*ONR!\U]"!#F/:BN;AXJ%M?%FY&"8^]*>GOO?Y<R2B
M'JZ PU!N\^KS1JP;ST=. 55"M 7Q-4T-6IJD?("KY"_3 7?1:Y5Y'F^K"&]G
M1&,W&1%#R!3Y+5VV[%QNI(FV_N#Y",B2)[CR"4D/[@#-.[G:'1G(FM7$, >:
MTP26'A(=4(+8\0KKO:4,")S<E]O9ABE;1.?']!:'O'MNUL7><>$R5W@F\:GD
M=I(T(A\EFRTI49K4DF;>4Q>FA+^VWB%/[[QLYZE="H4*Q&U]V'3>)YN^']MQ
M,Y:=G+\N6IH@6GY>>XVTU7GLAC?M\,UAEIU=U,:B@9N(A:.'W'":O4'<FVW!
MWSM3[C8'P[9=+>3]U=(T@QZ5A\XK?XW%%3"4<W@7(R_V;K?3G6:A"8C6AB/+
M%D,V;$16M,=?YNOK3?_<>#YPD[GLVE41,],?&T:DG9?6>;@=[[*-70G([_%N
M_I;0I!NC/<?^R5S\2?A>\7,[4E3"D8.T:C #=WGM\ DLPLHN9^* 4ZAUVW<J
M50PN.I;'25T_A>P07'V&S!F3\_T=AA7O*8<82YH;N"I7-STQ(G@4]D+VPZ35
MTM)<-^U[%9P#^RZF(F6X71>-2VAE?1+8HW3?>4>,5J<48S5??),RE?2/:"OF
MY.V,%]%/:'?3:35F\7^ >*;;A4PR6%,7%)B,MWGMTBW6M++5KPN7C'(!+X;E
MH95+.@I0Y6(L#_Q@X^OP#MO^6#4+[GA<YE1.Y7N/H$L2ST-O%_;?/_O1SDZ[
MF0B FU![:@Q50C8B. [7CL!&D587&W^D!HZKZ^;=S =1L<@Y^.^5Z,#M0K@\
MM>8G)>15ZPTFZ"^\)R/T;,/QU<#1N.(JP=DG*,'6[A[062+25D*E*YTE@3X%
M6):/O/ <KZZ9\?Q4>(GY1L]2O>KK0Z^XJ" [_4E-FV>'!M_T3Y84T)G(\/GQ
M)T?I]I\V]!]B3,]6WD]'==GG9]=2,3D6VEU3%A1E2$?NQU@-<W'UN-PECJ'S
M0E+_Y#2OTQ% X!X)H@3T:-HC;L3;F&Q<N\D29S_B\;7ZO@>#0C,-6O"P,W!%
M/(8J2ZMY#'C?_N*,SL5XH^:;W%^V'NZ_8U4*UE#H=IW"UWX<+;U\<SR@.A"-
M<5,OG0*^\:"]GHCSLJ0_F_WF8T)K"'@EX.,<+1"YM]Y$6U$Q[ G*T;?:6M*5
ML0W!W9RNNY/./E#3805B-/7^V$&NKA=_=D1&.UH!<<'51*E\A,=)U[%?4BSN
M2/.5P?O$5?XKSV3I-L4="1J=1Y>:;Q3:"%V$[X)@L9:':]:X1ZP_;EW'L2\K
MI_;(,_HV\-!^2M44=WZK@QM7'P'M2,GLR9J<OA]F9>&6)90I[L\2'!V5A#&<
M]^;&*TJF2ZY#X5O!Q=!CL@:'11+)[:&9 _VQ8=4*LLL\6BX<W0=SOFBF(H]G
M7K!7TX1B5S)".1YB!P]9TTH)#RID<4.@I8E1=V^R>8.6*,QDVC(>9E^;]IGD
M<PY@WKY+:)5D']PM;O5QUAIXE8<%GA;\81"M2.)'.V%GX[GF4CWU,!82X+LK
MI [=8S6@:<9'V^2@"F13840MW!N5A6;5PJS]"W+/U*@&JB2?&K\WUIFCQ]^>
M[1C7#PKVE,6O7M"NT%38X&Z_*F]K<$\ZN89[5FC5I.-!]:5U[':TLYVS<D<?
M&T@[9BD$&UF<O'B0NVO>-T/=\$20[M>-9,UJ:4T]B6\8._@G[G=BZM$J#J(?
M].>JSH&H=/5^7K>^SF2P.D8;[H)_GUEWDNDE;RK4GE'GIWO7:T]ITX4HTF^K
M-$XP8X,ZG"7&MP=!:CH1.:!6=YW[T%9/CL$-00CI5%'31R=P;?'W^,.5Z%M@
MOY>+&%U]\D3'36.?_05&U+>P.T:I4EGC#;P(U.)GD-S\F@'O;9?5!MNECCY+
M7'3M];2&][GZR\;>RZI6^#[IE=^37M?F%%/]JJ_Z.VWM]%!C6GL=176HH-@Q
MQWKYY'3KH,"M%FH\,X]0^,"5KH596J'E((+((KDH\EC=FB1%,J-^&OIPLHK2
M0]L+E:&#[WOWY;]&=R=<S8HI;W@APLG>?7,GVKK?PDKTA;YP@I6I[26_&980
M$;ID'-\W^D+O?Y]#@-.&,4J,KCK*95CMK-R0%(OF^>!A*C;]@6!?(=W"7M*_
MK%AI?K9#E71M1K"ALG+V8YO3M3 QVD:6PNEW%F[7R':6HQ*@CD JP=<-\&9D
MK_4U*YTZ:O":1\W\=9M;"C<_S/L"CZU_>))^0 4ML'0FY*.B.H3=XP)>Y[E<
M23-_BG39L8_CWV0)Q/G)J9G _7GZH-#C%68YR(CQ./5HSAQBH8I0)R8U@CC/
M^PADPMPI@*Q!?V\<&9>,['TR:..XZ"!:8VM^E^ '4Z07QVQ+,ZVN:X%,_"4[
M;8-)*]T^.^1U,T3>/:EG3,/A40^73WAE(/.@:WK@0X;:XYC<U0[!@V?Q71MJ
MO5<%.._@\<_=6#$X!9"@.?-D<I47;!Q,JL?W#.J=JB*5[N+=D;]D,ZEIP?QF
M;46_LO;1R6B4$G:_=F'$V1:E)+9IP56P%PP YZ7 &-#==WO*/,C]([OVJU-W
MH]0KOB:NT@I-$6;./8DSW)58&T=SENBB"J0K1QS7WC94Q0"N=1*&1Z;G_91>
M!W<Z74)+SVW1&:,LVB1YH<-<'T\!*MM.RB+]2@Z<:7'F!+4#,WLE>G"@?Y>_
MHTZ51]>('0^K1T%!EUK3B^)7G\E?$J139%6&O+5S**33&)1];GUF@@(6:G.J
MX3.9W(UH4<T5(OZ9J=MF0>&;3]Q]#: ]:(4HI:1/=2/NWS=LLJ 51"%O6&*\
MI+K8[GZP+2:(ET$4M/&[OGD02VU6&<$\Z977_T&TS?'AXKG2]NR5. 7*)@HZ
MWHKQN?7V^U7,*N<AW,A4"6'4E)9C1;/?;L,QWE97<^.KP$HK9]XB>\I[-LMG
M3:V-PXIE_LK#7!LVD39S 8QAR>C\]"O>/MIOJI;LFQ_?Q\Y*_]4#&XA!%#)@
M4)#3W2UMN0JPU0UUPMBCA\D;N'D=KLGND @;1Z/KJF&=+Z.NK!YQ<]/O"HN$
MT++?,D%I!E#U7=G;=#_N_Y*6,3OU31J95//4[5;0T2;.+<AU$P'YQ>7$\:/G
M)A&/)]=P/#N_-E=<?]9-<)C&:7O2X%3$Y'#/0&;%CN3G'5<+F=*A(B5:C[O:
MY#RO%-3#T]PG"E4OK^HD=@7N]DW?G_AF/"45JVS7/=%N%CI9N%?[9^ M@R@K
M44(DE(_D&^J&2\;5@R>,)@UHHSCFOK,[=@H[?7$M?MC5UL2)8 OGWN6E1,6/
M;9.(]8TT#7Q<B2#L#VRU?9O\4EYVJ7X@Q)ACW),3G*V8;LF]0)L4-NIG\"!:
M[H&Y 7<-G,]WK.R%I]MB4O_#WLO>]'TYL![^PGU^ZY?=3.%[3_+Y%78ILNQ,
M16QM5-5,ZMBM"O:M1O]:AN]-=P?WZ&6ZJK91IKJBH!#9D!W)\6<6E8E7%P/M
MYI_8?ST<]B;_Z1Y?5&B(2C,>T]$:L?F<Z&C?\FPL1C:0MIMD1UA%TG1%N\%C
M<>6$'I6O+*^=^OTG;TX<%%H%M?+L2Y^^K*; _(0T+[_YBC<;>$88\4![WYAA
MQ-$2/VG9N,,#YT%U<NE$[BF@JU91W%T[=9\]-;FK&+.&.L?PL4FV:.((SEQ"
M51/3X'>$7-[<%EG7TTP#XP'NO=2\K(;B-\2"@=?N?,E*W#4).*&4!'[]7I>F
M]N;QB)"5Y+23,SQ8IO[VI\OHF\3$'CHQJ,7%BI5FRF*N#8+@3'_5,HX7BT/?
MXXE"7@=Q25'#-$U?EIB@P A\WN 9>F45">&CAS$&O?'C:KX93D_#Y\AZ=\8J
M8YUKW]I\_C+VVZ'"@W$F(SHB4K/GCI]/JO.'4=N8Z7WFT$-2B%5%&5ID.\9%
M+(#[BD3:#B-&7P.M&P,)8JG<#B8N2*%_&J2+AX)>@XB+'&=).7_"_#L*7OA-
M.B8P;[]G>#*];7;%P7@P9P5NY2R,=.[Y,3G96297^X5"#H N^'$*0*G2%T&J
M(/-.7^H^F=SY:?(MKU0Q_(!!91HUT+=FHNCZ_'!+&WZ2XN9E@U3JF5-D\3\*
MEV*&'*XN.]R%?IW". (DV"&%5R**@L[/DKK&#LA4(9AUWL @EIVW(OL--^-\
MB1IR;LDILDD4#()#4!$+12ZM\!75=$N2!<ZPL#+BJK)>)D;^0J5-<>*KHH?#
M$5OIJ5U"&>C;</RD1<N-%[M)6:.[J*$]9C<+RT!%0""79FJ#QWA13.(.O4A7
MZKVF4:Z;:?/?ZYRRWEQ,7556H<:S^J)[FYJU\6[BJYI,6[]!60J6LRG!C2VT
MB18EUIEV/04:9K#6;W(DY!S WW6AO1@2H4 ;(G&YQ*"$%;'?3I06),E5-^)T
MCR?K*^VCCKB4HDREI>D@YCR.R\32:@)=K,EV'HSF8&MCE,%<,X'5JQGK$^KA
MS1<_>)"/)?J4:M9M7]*E"DPYE3PL84(Y()B,$#EA-V:VI$8$/;2&M<'=6T_X
MLB@OUBC,HEJ,O<J,:RH5!??H;&PN9H2R$V-=%5.O>>/KP-930!"WZ8*1[;+*
M2'%_T?J !Q/U:.(COTDRU<^93%0,T,W1'8OP)G&ECVC#9F@E9K4;<G-XO2J,
M?"@K_O+2->(R@ 7>2SJ&O9?*/T/BZE(GYT"$/V<HX&AM&$F%_L1G[Z]DW]Z7
M?Z)+F5JF6C.2?[CH38<ZY U.I8W2BE)I&DISBU0RNG^=/+2M&&>5]!EG^9K:
MEGT1=ELN=G,_3@_ZT7#17E30R:WRND2PA]ZZN2)+=7#O:K8;1V8>LN0N@LU_
M<52<;;Z1HZW]L,K7KG"RRVS-PHS>XC&#HOG3H]A>TOZMT#V[&]:4B:J!>V+]
MDJ30V18;YFB#;<\N0@6*'0B:3:5J=I(=4>PR!M@!E48F)A&G[;3U3C:7](T+
M9?&:WA-8@9#^K#JA_;KN6"\E"TUFQ_.(5!E5PU?]J@TU=7U^LJ;YU?&H?LW4
MPDW\,G.IPS8?-6?_BS'S]-\4+ /)*PWH-?9;'QOW"SZ?U([(".5TX._MT+7Q
M]!IM ?$5T@X NA9(0VY4/4:EZ22H#)I%/3:ZIF2/?'7 *+ <$T_HL+U4-Q#"
MP#6.YJF3_NI(@*"K%C'6'$-T,W$D*<[6P._8CY7OSM*[SJJ-%A9M2@*5/NKU
M\(>%U0K=-2/+>44AI[BBSSG1#UO.EE?-(A"$_K6?/UQF*$I'FGBL14A='!/&
M:03!T)OFNO>[G>N4HAICO8VA!O-V_AIVUZPE>>H0#-D+G)W:P[=.OD)OG *>
M1]#%:ZGAKY<>M3NH(,;;%4]H41G((\W8;1OJW1\W;FA71=U._"E@J]%[F=A;
MC4!%F;<-$J*_'R&N.;:?"L3HI^[NS^\-D<@+81<'0:N+D,6+*A".80/# :6)
MO?S;&17G"V:,*QT?"H#WL[4A]4G]/)5<<L#N'U.X/^8YB9FT/'OTJ2+0;#OX
M>-7/M7AM7MYW'@X*U"<?L74*2UI)/%DZ0=Q7$HQ]$L\AN46UT!#4D09D&?;F
MMM9&^K<KV>5\R^?V6['CNOZ0^4F[CT!E^%/?$DN4PV)N$Z/K<VY];M$CI6>=
M][B=+M&P4P09XHZXTPPI3GP1KAT?_&W>=20624NK YQD\IBCGG$G?R[]X (C
M8-$DCI6,^SI&$ HEF@:VB68OI=@AZU$W,?/VFUH?9F+2[Q*W#7P7$H-:D[PT
M=I2:1\4M%A0WA9*<ABM7N#?:66>^)3ATW,1%^5 _IR^8WC5BG94>>E$Y*:4-
M&Z+PN]/^!BJ%FY9>\AXT+QYC(U>:1O.\=NP.\TFKZ+,75J3HTFWG+6HV._U#
M"^G:VI%*9=%5Y.2ZBP-V<D_;L]6\UNQ[HO6J*?!EU<<B<G6ULS4K18OGH^K*
MAB!Y/Z7Z1C'UV(/'JDV5U0)4SSG:N/@B:I@=C!9U+B,X.U)OP0L3@6BF$P8(
M6>/TL*R];6QPJ'QIRN3D#SK?\;%DE^L3<YZ\<+M'4$1951V"IS%_-5Z$LW"F
M<.4';%JE_;4WOJ2:Y&IJF] 6T98Q.!NUUGD86)8S:>@IF?"H/-:F6N35JEK/
MCX^DMW1B'4)WLU=4E!L[: VD1]1E%:6Q\3@BTT(_@%?%.5*%$;(S;W+ L* @
M)^I=>/60@3Z!XD886;4',<'WR"M20JL;^\IN;%%-C(;HNPBAX\T\ENG..)YD
M2N4R:*6;MD%Z%X>>]*T0CGN+>*-R^U_?Z\-"X"Z?1'G"F!-G$O*L#U^KMSK6
MZSII?(*UT;X*O?2%B'A3:"U-?[LD$./6[PW0H#+ 'OT$:H,;C,.+L9MB/PFY
M*!_LT-FA3>WN4:S6DC_<'V$"6W*3JVNH854D8E_9\V@!B+N2RCB\Y>2P(.'<
MUPJ3^\#=9R4\9DYO&U=N1$O[7J9JWC<2NDND\_F$%74@%-418<PIA !^6[>Y
M)C@<&,<<K7S;F5@%_WXT/IU6B_ NHP%#/WRMQ;GI,GS%#X;<4?>H3=P&]RV^
MSXXYX&JCLX_D@]6+?O>F1ZT"@R5I_;7#5)N&B?CDH2,W+;/EZ%TE*F;J?N2Y
M-&5S!_R>!);%G_*WS1MIZ/$4%UZ0^FS[0K-A<,Y)MHM+,FY.&'2A/Z(JQ,(%
M0=G!Y610RU.8.'/U@H#W#H\S.ES>,+668I<@7(AH@ZVUKG$S":OJW#,*3UO$
MWEV0ZH+D0#J;'#"S!6*^^F2B&C4N<5(6L9:>(B3<PX:&;_MM48-X2]R'4C8^
M)!=YJ>;L'KE *ZH#%5-_+$I%"+Z;^DYL*[E4HOT\R,W>*^N;H9$TTB#O@WPL
MW;+IU<LF;4(Y?_]&,!@@^F08..#3J7Y"_:HR"8^3)^5YTLAB#./87C30L=%[
MQWUV!<YS6C9?O3F]V'S-9%5?HL'84^12@9W@BSM7JV;?V:_%=+@TDS7H+9 2
M*V?R^,YW(9BFOPQBW.+@<$O*6]5I;XD/1TG8NHR%1H3":#V:@[:MG/D50S:_
MCV0D]!DZ$68R+U-8U>OV9_<[NVL,#>ML#N>?N2D78O*LBJ086! B\^L8_6EB
MUI6U6B0!WT]3BK"%S8P!IR[>2GAUCVKFE<.&O@F>)_T-_RL?\K^AD@S&BGB9
M+?NKBJC"F8,[]$:=PZ]'=28MEH10@D@\E0MF5I]OKRG'M_)EZQKHB_L9^!B\
MBE=3>/;0:9% R&*^I)W;H3/U=H/?CDSS4.&'TD#%H<-K?K09*C\'HV8-GRQ!
M]VL?)? *YQ3\^=C_V&!S. _[ZP_(;YU&+%?@MI!&V;-X"B"7S:X02A[K ;^7
MZ[ET.U^'FZJ[DZ!$:*/Y"IKCA 2>$O\.UH&LBHD8G+8F>>^<?#6'WF>OY#J"
M<@-'**C#YKF8((*LJ@RJ,*QRTALS%R_UG6_.[ (!,>?D"0-J 1C,0%T].E_:
M-(1NU=H0NO1((Q/7[XY[^#Y%86UAL06MX1J^E65&^?DTL(1^ 7-'Z6C9&+.S
M##\@ME!0JX_K$M,D?K-;'%M;0FM=?0A\[03>X)C<2 QHK!>_,Y?RF2!]+4KZ
M_O3E5*U"SWL5XU ;[@:E!7HE;1N-(; $#6O9I7BQQ9X8.&C,9I%[5F@=QA O
M:$2J.MQ>=*>R.A*'R<DKGY)M+6JLR=P.J @F17;D=(;L&9G0CDO;W!-^M RL
M);.9JA5WZO<2RYI2=<N>&' @_;;)$L"@"ZGID.9$T46U%EL5=4?4T0C^_C/Q
M7SGA-F$!O\&(5,U+2&L/!_<=11VU,#K]Y&Y)K"Y*7UGFZ.&6":+<4_KQ9U-5
M,33:ZVN3\73M*0"<[17=FO2#S9!XM-,PJV9ZJAM>"(O#+.UZA-[%<ZMO8)SF
MW6NF,0=CTR*6Y*OG$;"8YPK3 IY[-=([R>7CE%$'?<JNBTB9'J0H]2*!XQ/3
M5(5N^I?@ 1YQ^\5&TPX-\*%DDI?=O.[SJE*,PP:=9.EQ:1^G5?V<[T\E<5#B
M.KFB6#V6I\CS6G"2KK)274/W-SGSLW10Q<*] BIHT6/C04]F>/+43[(*@8$:
MS_+R/'-#QT]KZI[71QG6VBE?6NHW!PO-$A92>T1XT>X[V%+IOG\K<.'R%_EL
MC\S;=@T""KF4.12>,QO!/\86X^-#.8C.] +L!7/"=#/#/"ZN/"\FX?$06C;J
MU'S#.D$C@@?QE.1B@P:=G.>7X!C_9(:%>F! ]0QSXKCV,/IA$4MGDA/2TJZA
M,0VL'.KYV4MQ9<4(":.PU^K/QO:0FQ$:>Q;(7.ZIS/H!&+1W8TC=;&2,0+CW
MF/B=&$1_+(M)$ =1C=;HSX58@8+%7TC>NN+9O+ZSY)5)\)WHQ\9DJN2^]%A3
M&;QA?)^!?MALU%07RNI+TLHKA:(&IH#=3(OQO>R56D=[/=OEA+$!AF?WZ#*.
M7T<02CQ>=S=?2A/Z_E+/.+OCN_#='8L Z5[3FAYJW*_C=LKF_4*9-0Q79\00
M7\H6,DM61(WVJ@-B5X>5PU2:JB99NMTNI2[;S4CY^ BTM)0X9]I!)4/$UA]J
M8[@5(WUV1]1U1+U&?%_[C9=K=:G-&:[2&]L\XB#::SN;]_3T-,MSU?A\9QIA
MB:;:JP+*8GQ"CJXF+?0:X)*KQFT9UG4GC?/2MJ2P!JEP8H?-><;G:I]KOKRZ
M<X5S.L]/2-V'3S5#]?W4M?)2C.@#L?0()0C->[..-SR>]Z!WD"LO'Q6*NK'J
MHE)G<_B)YA*C,ZWB&RI-Z;2W^PQ[FR/3?LGF3X4<@E"FD(7+A7M*O&1YL6LJ
M#<*E,^^0M#6M[-=,I^(Q,NJ26.&K2E.L+\42@SWE /=Z1ZRU/<KNL1?U#64M
MFRE8P2*^<HXE&F'"#NE@/_YPG,G0O&B"TI5:[K,1WQ)8I"4\\'!>/BZ.0]Y3
MLVK2M_TRF):M:=ZK%/&YF;@G5SE]0K* IB.W\I(MF?MEX8BVG2)WJ9KL\\^Z
MV&?!^V97OHQ=MO'*SG0V-&)AP,WN&4Z\J]0]-;%(^0L-FT :UV5]A,/:H7>2
MA\V\"12V E^I'IMD>:^;)OJ]9$:MP12DOY_6J*"=][#OF?[%5=<.T6ABC9&W
MOZ-M74%=) ^53,CT.TK6&&Y^1;..S64=XCWR[-FG;[70XDH'U'Q:9LU",>6I
M.A69R&1:)R+KYP5?D[DL7)H05:U_'?)>AG_Q7O<GQL:N/I(6:H9=KJ?N]OH.
M'@U9K];L=]5EGY\-30V1:<%*[-_G,$.$:J#CM,G]LHI1)SNJ51T-(GJE;A([
M/)X#.7Y3PMS: U5[H]G68YEV$7?;3*N%NSWUI?5@W<W/'I*C-+XA]IL.0_5^
MZ6KXULG%(>H5-:N__QS6= D%+:Q ;Z,%\IJB/^S)5CO8YA LMW0Q0!L5-&D
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M2<[XL<9_1F#O%#G^ XN_O[^PO[BPI[>SB*BLK*S((S$1,3$@=@30)]##]WD
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MBK$R X";!12]0&C1?:B>@6WPX0PVPHK#H$^1@-,*(,=918*7U4<2;[(<"JR
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M\N5Q.+&?ZP+Y<"U$.I-I]SU!ZY@]9S:UR\!@?US =E+K=-GMX!W@B/A0^9_
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MU;?4DAR?4Q9$7N:]Z35S49]%34R6^H#2VN-X--/#DGK#*]52X<7J^U)ZV!T
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MB 6,@"]FXG[44\RJ\FO/R6.#>?:U+\W6815C;"SM_P1H]BR07 -+-]HY(N\
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MQ@%]KR?N1JGME$>K\K(B,&SGE9CA&A4@U<)S4)V6@3O"=KEQ(7)>^&#D[:V
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MK((FS'7L+-EJK-CMQI)L6C[\8-_,$W-[0!3EISHMI_]]2B]<"K<M4^GD<C6
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ML3,VGG$Y;MPO';B(TCWKOP.TV49[M+/VE^AG=BF?#%<Z88(_]NO7 M:CJ^X
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MB.X :E5'89WA!*L_%)0#Z1DN)!FQSNQH]>\LE!X2II;83G!.FO-T!.<.$$V
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M:!<YQH7U"ZN?(/20Q,G@M%)PVA>'1S"[5GZ^,I?8Z;V):9@&\O0*39X.5/J
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M$@%-*V;$H6FR^7ZU4IBK^APKX%UZ=BV&MTSX.AV^)E,?_OZ5$8G,TXJA!4V
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M<O\H[T62TZ^UUR.3DE1BN\M$HY_S++*'"_S'5ESL2H&W1/,V1KT\#1/R:6W
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M[;B#5WE*FUH\"T58/H1::TBJLP-6J&<R7^;O,).JMO/N L/D]YP@J>*,H<+
ME-R7DRA >R$N/<,P1+@SHT&%Q).C@/+85PHL>1&"2[YW@I=(5B&OF22 !LA(
MXDZ[B'I;Z7F-DQG.3V[:M^ECUD-<O>2K-K;U<X#_ ]*&Z,:8-XDH( W\GRT[
MY=I:O9,=+3^Y'ZKX@>NZ9^#'VJBGCK#*TVS-\+/]\6FQ/1[O :I#9[Y?D^;!
MKGD82+Y>Q ["<LXQK+  .DDT+,L]5B8VCSCVRDTOO/_H(4Q#9Z<6PXB\0B:_
MW>??A9&N#NO2%0LFL?9XS4>:GNX+IJ5AXCT\GK;\O-E^YP"-8<Y3QQJ>'IZD
M%R^?'22.@$M=C +3&.&RR7>FN@*>X5!8[M&J7VU(EY&4RRZ+ " ^<B@?%H_0
MU2-M6CQNB1PD0?HOT0XFU2C^B,^_)N>,O,E9_H1W-""XFKG("<*99[+;LA\]
M(D73AUC%CA>X6OV?KIMA6IJN]&\_:JOX\S)1H_IT;_>'*^IT\&RP8P=]#HC*
MDHMMK44&W!D<[1KPZ)^X&O72['U,=O:<X,[:,:N11)LJ[X_N7N0BWZ"7Q>M=
MU^WHQ[ZPB/U!D<TSLG[B;/MH-KWD0GUF4F54<DU8)O H_G=Z$?5+(X"!HT\K
M$, 5;08[OL-)%6/ZC.7UD]=YI,^CG?B:#DF:FY?VDD'@2<]UI#E2S&&7I&4^
MZE?@#;@'H/QG='M%10B7+5Q*;EH%7@^DKL?!H:TK.LDH?RU6)UD<3W>ZDF;/
M%Y,7 22[P?<MV7^U> L<U?35;"F]W;G*%)-(V_4QZP/G<!]:E1>XXO[(@M,M
M::#OX4:RS:8+JS!N"2?K8)C,^D;TV](3\VF9>IYB"A5F-H\.C_]$>2BK_1UE
MI:CS*;EK Z\00SD@@R>BY0K'#BIC#LB5Z&6S,VQ^[W3T*\>;P74.W=('2;N2
M_TX4/XWF6Y@HO#H'O&7TZ3E,Z<)(XDMVK6P,N6Z>L"3M+NO%P$&8)KLGZ@X]
MA R=XO_X2$"E\0J7\KXU658_DI!G,0S<15E9_Z^XJ-*ZU1U?<5"<4A";BW0<
M0.![#D*>88%[#/2:I&.\ O (1"!A,;+Q<&LH;TQAL1%66U>M]'_!C'6ER[!&
M!%*G:O(G2EKKMBL\"YM?6/.*>\<:^RWZ0YQ96VO<MR75XGZ])6VS IJJQ0*K
M!^T.[:9B;56[,@W\L.^X#;:A(XX:/>I^ZA?K-J1S/AA8B8@GU'Y#JN>K<WLF
M2),EX^=N(]CR4<MB*P.%'.B-:3GTQNV7^2XK\J4W6Q [8]IOBB9AIS$KXQO?
M:V+Y5,!'OQMT#SC")1>;(<W]?WHG1>W&.D?T#!A'%E]D^^!6).XEB2?;O(SK
M=J?%$9"8Y]LJ%ODK:BNR";)7-:KVCIL_5<VOJJ]1@&/KGTL'!W 14UNEMH3Q
M1Q:?Y>=<:U2MH[Y0;I-_4;ANJ;XMO1^XA0G'LK)IOS'$C9R9%H\'?;7.CKL5
M<;U=_IJG G#P'#!];\NYJ<#.H1&W(1Q\*]_OM2+Z;>P:_UOYQ;6FOT219\C]
M9ZM@C^=Q3[Y_(EM3W</P,/*SJK3CC[+:RTR4>*Y&Q<D']O\K$A83)Z/$XT;J
M\DNTLO)1:)U"P^+<GH,2@V+#@I-S %4>Y^S(9UWMMXZ.W!UNGM0B+?>LX_7C
M=U%,"P0'<E4WZ@3I>P8M;D2V?@*9.#Y2R^Q@%0Q[]0JWG'1TZ<E@H(FYL'%J
MO1%5J"D26@<RDO.27M@%$(]Q)9(H&7F9G*M<ON< M-EBJRB]=-@NU,5.MJUT
MBB)BHE\!<E&6&5LIP+\:T3 32]\R;:[8]S"CYQ"<ZFC%VM+/_Y0R;['4B['%
MQ^@IWL^FA$,3EB+WR=MVP> <8'"/,M*G:3D]?D=Z^[9@$-8HT$;;O.$D^B7S
MMJ:5U;1=:*KJ(,UR].SQ,R$OE$ /NO9TY,WIXBNS<T##NGG VAFC1(S/FMB/
M=L5^7#6<\QP 6R_0AL8"E^Q^S1U^(MC(-^[Q&"XI.RWKK3,*O=MC:%^D2">_
M7T@B]=\(PT\E5YAV4>EYGAV2:M=-8P2J]C>U2I]9:T_FH4P;E"<<U=9XID/6
M=PN0%E,:L"/&2AG#:1V8$Q G884BP<;5$/;J'=!SB2PSIZQ/F]HBMNS,]1S3
MTL3HV76N%GBKDMO]XY0K&\WU%6?9'\MG]U.VW7V".PP#F'&=VCPM2SQBN8?*
M2++8GZZ*_\&:OJ:W_,60$W$S!D>T$ZBJRDF9>Q2F7)LR>N< ,@P;CC"K^_T;
M7N1WP\0<^DGYA.9_B8>V3=(MJL=O/A99P(9:2E5K'DT<Y5=:?L_+W2_ = 6F
M%;BP*+.@4$PI36I.-5YNNU^@J*J]XA>R%WDX2')AV3@V&,  Q5R@@N7>S<D#
M773@'K@RNK&CCY7+%I$O*4AK-#!84?]+MFFX4T,Y68L)4F $,Y\H1ZPLORFT
M[Q:]+SR83:1<[)^VT''XI"K\$\PH$GXR!=IY5:0]G!ZTXL76UII]]>S6GZ6!
M:3]-]()IJ 7JF_<1-6U?O:\.]E_^G0W^A,GO:,Q'!: +)W%5%W_@@E5]:#I;
MV"8/THWVVF_S\1--J>=DG*F@VG-4L#WUU!SD*<&"!/ZI3L=$SLG+D< )SH>"
M%OB_$>. "*N"8<H5^",;A??*0.,58(+LS?LHIGR+"\<DI1Z(\1Y=#U3_YD$)
MXB8'U^1%3#9=]H85RC AXIURZ0%X)+,)\>DB<85!2NUK4!%U?? 2R#N^YD0(
M?+WR<Y$9CD*U+'Z4\<3 L>4(W\@\BMZ[_M,>OY9,N7U/\>$Y0'[;DJ[UC_6V
MOE5TBP,L!55>/>$W.!A6G"^M$TA=L[>AY"3@25!A12RB81K#VPNQG*EE!7N%
M[& \<W]X:B&8-R"ODMOI1_J!>&:[3.$MED^EYO#:PBK'3>X":1UGT5QYF8#U
MBQW":'4ED"3Z!2M[.J/.H8:E]U^)#T1K2ECW'#C@A\_8O+?U6>^M0CH&2*Q,
M!3'@.! /-U@!\J&,BHMY4RZ<M8"ELSW2V_"1A$*0N/'9GK8N6@-[-0:&($GB
MJD&U!*0.21!CE5"2#*(:@O?I>'4F2E(:<CK*6_XK"QW5_;!14ZNTH_*F4Z'$
M-Z*69!48_PM",;-Z M?E,FO"L%U"Y8L5=9;<:A]WT(&+X?RGKQ#M4X5NDW4B
MLC%*K!1?3I2FL:-,<AD. 5VEA.!]WYP&?[T.3_DV*Q^7=@OMAO[]D+K?!?FO
M&VKB;,HL"[=CM+3QG.->O6\',K]\W?=48/XJZ4@0Q'Q;+U%;Y>9BLC=B'F6*
M+#$-%SYX&]5'3HZT=E[^R1._"K7TP;00A,,;\9+KLD,X=I*@%!GG\ANUJRYJ
M$A>?3[4R]\6]XXW8\MT<"YNVR/#VOAIFF32F-5"?<@253?@^[_J6DL/QON78
MZD]Q;=%]U: 3MW+8CRSK RF"<?0KZ-2MZ=K9&D3'JCX:&1_0YQ];N,YP&"&O
M[=.T9O7ZR#+HB5M!O3:@8KNPY,NTFG;T?=>L?'XNL]$8QT"L:F23O0N3P]2M
M1O8E1%C07;Q("@XRBJ7)6V&PN=7,:,$\)S/^EO4 \Z5LS4,Q)(L!MYMA\_ /
MK"B9/LLZN?9KQ4;K7,IJRD)]O8&]?F5HM<CM)&^F?]-.HED"^BWL=/.=XX*)
M>'^03LEDIB^;^2,37#V8_0>=B?&+CONW?#8W+>^?X;.K^-NR_RS.\H>>"$QG
M"#,;;9T#/N::2/SQ%+1SR >.V49/F.:YCE4<J*'M9_+R>^ZZ.F2;J%>./!+J
MJU!I,.FCQ&TO$T<?3C'6,[-I],X(/KRG.W0RIB&P9.R%R:@*C ZD.^/7]LSW
M>;=$L!)-='.Y%=/_>?K]3UO ^N9FL#F['^>@;J"#A0,:9399.5:5XB4WN!]5
MR/KU&T!U0+^?78Z0?MS+*(<&:V_SK_-MC357I]L,3WW,21G3C0-=C?-;:EU,
M\!7M=G?\K_D<0%(!+>< IA/]FBV1+$E^O(CU'Y=BR9HCWJG[:^%D)PK?BY:S
MKXZT__)/U0DEX%')RE^4Q;)<>3JZW[3!19MERG/>];I19,6?[79@Z7C-@EK%
MHU"S3_2%;%SN'3_.@'T(L*THR;_F+F)^P_4&RY)\[;":TVS,OS^=]@29I% M
MBE5"L9G#/Q]W-3H;GQ27PR5O)IGC\:,$X/Q(&B)"4X<A^"!FL'_&,3%C:E&B
M.D5>%B07R]+52Z:&>7(.^-!A7AV'(90M7G<U5%-]XM&=!=_#M$86&(?TI3FO
MK4=OC[^%JUKM1 5XK@G92#N]=C^6$8XA9)NEG@CQVLJ]1H-/VUZ< ]A2N#C5
MQGKL$]6RF_=3X_K8MZG%P*NWSU[HS_]>>5#^RN5C2G4IZ[<A3WN3CBMK*QV[
MB(31&8I$US*;,-VO'5OCL!JN@[[ ST8UA6=#' 6_EQWV>A5;8V^U<9>E)HIL
MA*TES.Z,03NVK[2XBTR7J-#:V(]S]3C9E^#.; [2'O=4-%:M=,6VI4N$S==Z
M49Y]GC^+5%8 XC:D64;V@@Z.&4JS"XW2+0C9)J+U##:_?UL,\\LYQC82,ZQ>
M1H] 5'=>G%;.L#Q\U'\M,B!9*8!["AXQ]4)M?B(Y6DC8MC8U:N\5D^3Z9)[Q
MQ[7L%46[^]Z_NESH4NS4\BQ@ZNQ4E UO9 ]:!;451KTRK3)KNFO>W'G*_@2
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MJP@#][_AFXC1$&#>B("%BJT2"BR2_V?1*TC7L'!?_:I/\4"UGMVCO7+--IC
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MY&-#2_;-Z)3]'WXIB-=PA;)?4].65S+. 5@W)DKJ,Q:4YD*"VFK!QF!FW9^
MHFQ"^>^.(O@7++6BAWZI98[Z1+6[!P?IN+Z#H/ED%1N>?CI2*<C+N=WMSP/!
M/;\ I'AX!*_%,,?H4?51H$:\K[ZWY4JOEKH\^T_WZNSC1T3"PJ-P9TE:@28Z
MMG, ;*=!TFLL9PUP!:.QL<O1>RQ*C.50K X-R*XKY^S@U+ J%)Q^;"NX:KSL
MZ<DUGA)FR&./8"HN/ <P<K59>KCG]DPB+U@R,D\#@1-8)>04RF96$=QQRI$:
MV8B$S&00M\TJ1%@5(FS=Q>D+&00IB8T#K8^Q-%K97J50O=7_B[E -/DL+K/
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M(<HG3,6"UX_&?K9^#5D7F%7A\&_\84-)3@>?),^.BS[$>8=RN3 Q%B79<R
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MY+3C"&XG-RXHF=ZYZYO,$YW'[:X9\RH;.R=:)<=69=0A'6-C.EYTM:G,Y[\
M-*1M\ QP/;T=K0MRG'Q;DBM*/>6[P[RW^L(L*\""#[6ZNVF;XVB[A<Q^);YI
M::)#&QP$DB<&$V/!NVF5.R)B --50].^?>C.0Z__,9;2$+:-AC^4+MBBB<ZI
M 6;A1P5EE9", '//WU%TE3K\-BG& B[GUN&\RZ;SOFC [_W*OD Q&J&U,)$\
M_XU@JG:*A)V+<R4L(WCYO"2E7$ QC$=1SEZ/0&EZY;ZKOU AY_=<?O5IJ4..
M;)?%R];L<YW)]MZXW8M\-5=,27%@T6\O%OW3><A*];'8T(3RNIQN2^ZBLF!:
M8<)&=%)+DH%55J=8;!.WXUP"]?3RV.I1YH<#AV]3=^/-.F%WH-]=?*;LV^1W
M)O _]4]YM\A6!G<F$@XB?SE<WQCB;.J520K^, <_M#@#C'6\[>H8I)SJV;-E
M<G[#,['X"?DSM-YJ58]3YMKIUG>>8&X40WMTH0 _#DG2- MN'E4ZOO90O)D*
MW@:"*2\5K(!2*ZJ0D[;C^NDRZ;117&F2GXB:E,<[<@PPY=V_K=<5;:$S0: ^
M]8]^Z6TP\F-Y^O/O+#IZ-T.$>>]!=4)PQF_H]-QF?"J6M1<MV^]S-#I>_);\
M4_@+'@2K""-D T$^SAYTY\TW*%ZE^=S1*\MWDEICI08C6FCQQ[KE!GNNCX&A
MQ7"]NZ%#-'+SGU18Q^.^X&D0Q>.K(-?I[)*)C@ [O[NJ2DV]+#QQ'UFT=CH<
MA2:ZH3^'1S>EIE14(RP"2N:MNH>/R0.;C[[,&/IQO O160H$S\BV\%E6Y*)?
M_ $Y2Y3%Q(D2["_577EY@SW8A:;NBN<U[0JQF=:UR1GW\$.<?';X:2VJ&:X(
M"JI!E2AN67+?8HBZ31$6F_7IFF0_K%I\\&#WHL1FZE+-_BXE]K\XXN36/&_.
MYT8"Q4M>0#AND6I0SC*-7<40VBY!IOM_;\BCUAM+5FWL\I:#N6TC6:WC/W_5
MG.6[>Y(SU6.<3LNXO7]W/_I='?LV_.3FQZ=%7O&P.=G]RBLG*&5VXF-84&6L
MH@3KF/7H:ZMEIUH5B1</'P7]*+W,^2;UHQ!-/@<,BB/0N6L$#I*.-'&!0+N\
M0.@6^N?>-/?6^M*X=)_L#7-,D[%,O4W/?0KE>F7LWM*WS5B8;5=NA'Q(U,[)
MIVF)R-V;@&]8Q#=."=I?'(6_$G0.!E5)+5$54/CC^)U5?ZNG)'1*0TBLHFS[
M?I0P=+N;>\TT>WRGPNNO33XBN.</5J/Q;[8--,:5HL.75)-9HG=0^WGCIWZ1
MQU!B[EY9.K79< F<($SP,(YKY/0:)>1ZW(B+Y*9L73B,CH*NJ'!'^*%XY<"8
MPT_VJ(NPB@V.3M8/4<2^ @$:GFN.T34Q^Z<YXD]/)M3+>'SX-X$0D+/>18L(
MB6+70DIM=!8NC^=1C@:[3N/*)U6+NM2FWS&@;D-N2Z4 3,"@)!3C@]E"=Y"/
M^& O])FN/?-&R>=1(A.ZX ,WVX@1,*011,OUL,0*K<L'<9I9 8E\2 @_+TJH
MLA,!/)$[(YS>",3UR1CUO0@!LN<MG[+!O9CH_O"FG0%AU)V?$C:2978R?M-K
M0BK3CSQV)(@M$\NL)+O&>JP?=<QT_CDB2MHPY?\1P9?*#AILPW=4QBL[_VR%
M!^H%<?PS;M!O:E%5VU?_=A1'_H<=/#;<LC^6)&>7@OVY.F=:QIRG8EVTOQVR
M);2UBG>_/HG+?N4)R[VJ.7A;L\$F=K/\!,ML:H7F['L5IUP05\M_3 2=R)4I
M2"88%D0+T%T88C73O&OY8,S,=,G5_[Q ."@#PG^Z"S3^9H8RST<E2T6];/?$
MP=S0;V>L/4<MO[C6RFS<<W]M0PR*1)7*%=(4<6@BO&;?[%2E\$6@.9S[I4;7
M=J[WM.D8P0I'6H26S5NDMG9S$[P9C)]?GFX+XWFTFIM?*5Y51Z=Q76[3VJ+-
MG>,VQ:HQ>.+=MA2[U@>XS,H]CL<FP?S^5X\I*H)*AS(P"J.+JA*>93D>\.-5
MW@[3;I([3Z="NX6^0>G:'Y^A'6*'>43-^['2[0V[\UX8=$.Q@U/_?;D8[$3(
MLE%R4'\Y$>Q<4!1?N%P07>0<97\NR_&YQM^3_@LT/:^6$1Q-RS  R3-&@2\6
MD*B3Q""I,-.+E9,4NHLLP@)B"*.'O)R+6/$DQ[S C-YWD=J@>+QOZMFUQ0"R
M^%4$WVCA^);#O'6*F&WLF/@G$-UOV]HZJ[EBR_<C(_8+\T-4"%VA4?3&=.['
MQ1T!E&DUV;P\9M8-<1=B#F?/981!KO?&9T8P]/_(MQ@I4^-)3Z?[_=,/*,3D
MNR_MPC:FKYDN7$E!13UMWI3KN^N^Z60F&*!383N6AY4_&?ZO5DWC[A S(*P9
M4!D#HU5=(-+$\5EBR,=R/IU*=OU<;X(Q?=1Y[0I>%]%ZE@C4:2YE)JKGU;M8
M@F XZ+F<AHGW&2.GSHV0?NJUR$2(V5%!/B@5*O-05W-&2\$(6_R)*[::[3;:
M'E3D_'U OP<RKBWG',.XU!<//B69+'1M=+4NP+7&(*%DX]^RTY\>_'RSX$<3
MV[7Y>.Y$ /JC5Z 7J2Q36ITY[*/MG#[H!>L7>JH@-HB2^(^JL=F]2)4DUB0H
MGQB\A9):#CPB"7TCG#(0EJI2X6-M.5Q9NNZ>3:+)J(3Z^SN:IT6^#$3.Z\=>
M'K-QHJMZ! ;78X/"UG%I9LD^VGU'SK4O2ZN'.\H"6_T)L=[W^CF-8_HQ#< X
M(E+NEM+U^YQM+6]K&PG'3)72[1]S.W(8XNR:HV1/?XWX_\CS<V#>9V:9]UCH
M.TE#8H[H?(,-"FN=@J@9JZDX!FS9?+>M$U",V<^G.<>$CX&%XT1X8%N 0MV'
MX;JY,*(2[+W"':A&,Q]'Q&"OJ$@G2$HK50)GA(M1I2"D)8(AS'?%(#Z2([G/
MOS! 3,=YW-FB.628!:<$'TRG6KDR-E05*-.<E"AS0%6J;3NR'\\:1%S9)K,>
MVDOO!#P6"2=HNWZ[O>MY67,(/D'.GVFFW(LE:Q9..'MJNZ.>WC7=0DP/_GE2
M='K8G_ R8E%CHU7GL'%V/WRT*Y<J4'MFQ75DW1T=^^IQPL_OW>U7-S1MVYI>
M_WV\MCD+Y%O[1^[T%\:4*3B[NDH=R7 ]I[TDYZG\5[AK@>V?I V[BV*A25J6
M=T@H_@9/Q;C7G@EY?,X]<D0F=%:7L1'(.-C=-':U^EF")\+TX5R[C&26'\..
M/F!PQ>@Y:&)%1ORYY:0F&'JG39UNW6@@Y&XRH0BTNVR2S>_9^Z)+J@@A5*1]
ML?Q"^"&A$R21A3FW$;AS=P;/._<%@@6/B@Q@KF);A$@]&W0.;G.FJ* D$1>C
M926+.!6\TG4&H)94D1:AIQ.2F=.^R(<8XDRLT-<OPSN3IZ.'Z=LRU!D*>,+K
M9(NEM?FF2GZ10'G<*M+<?O08 N0KRTWODE+-5:-:T+#+=?+S ).5_^EUZH5>
M7TS'S' HTYR!,Z:]C\T&L5BX=E1_KK!S3!.@-'OI>7O)YHBDW*D2;WM5*H$#
M7&)E/<+M6!]E(,M,EW](6Q? 2M(NW*:/?Q,DU'"2%?R []VQATP82N(,\!+Z
MX\&V\KS7W$WRHP-@<$C'+]:6@33W#Q9EJM-3L_LV,';+YYT;*6.-8H/Y2Q/6
M_ZPG"U'=TD58),EKYCB7*OC!%$@C5@JZ^)C1V)=%SN&\ <XZO6*N)U:O"3NZ
MU?@( ;<3F%UN+$[>V<@ME$/>,$G^@*GBI3>R";T2LZ]._?1D6,V82'&N:%D*
MHY<N& 97[R=@+4M)>R@"XMT"BKND?MVX6(7U67?0@\6T: <&,9%GPU\FLT[-
M5O[<;#*QFZ.^Y@[PS]$31K(&3;(Q**43A09^!3/H;. S71+3M$T7GL/"B$*+
MV[]S6#J9THZQ]S=91$:M@A6R/\-&"A4JPS?B5.Z0O8RV.",?CDC+]F)>BP,3
MTDP';ZFT8X7=[EUA&ROV=[<</7U,MCVES89Y5Y-$X(N].UL.<^P!1PE;E6(X
M3+]:&PC?F5CV[&53Q.2"SUH?4:B[VZO^%<^_W]\]7SUH6.$=KM@G0FVBH_=2
M=F..%6-T=8$:M_*B?8)JRC3>))Q7ML)G6MC_9GFGW4K\O\SF+PC;9FU]&YRW
MR-T+-M_(O8L>'8G@J^)&^;DN)OP]AF"VZ=MBJ^^^*T0IATT7F\0^6.?[*OHP
M-V)'[OAYI17XDX,06__]TRN4BRI+. LUTCW;&$/<S-#.L6A&<4GL547)^-9T
M@P$,7(5L>GK'T<EDUM5._O;!R^PSP*7<P947#"D/I7FRD@>5@K9/ \:69 4]
M9V\-+S(P;8"MU:J#; _84U6\#!(#C?&GD<U4ZX;BT1D0:=2Y'9GT4]PI9Y (
MFOB(B-D8Q8W?1J7EH^Q1?"6'(5MP1_GW!=KL!IRP]\IXQ:!5%JIG,;K A&;Y
M(BZE -,8(Q$=#./>0]!%]C,M[Z<G#F4DHLVN6L#S/U9=_MI#Q1HF:>FF7,</
MOQF$-_\]O=3E(AF2"XHG_)[6XQ[ 47C5[IOZJ"P1LGU\]NI#]1\\893>X9Q;
MM15(*"&1P]\5[)A[!J6MP+)-6_TXP('O&28 [((0AQ#?7%L#*DB6*1?&RG(I
M4=A'1)U=%YC$P'4R8S0ZAM5&/K7=[@)MGP%B<FXV$41<%=7S*A0-"A:M?(S.
M )SBG+MIZT06KX2G6IOP':I$.>YC>$:G9!A2VK^9!4TUVHXSB5#[%DSG/S'8
M!L-G-U$O^#_^,2+Y2S@B3OXHE+?,%Y"3?>EO**$E_"3@#)#;V^)/1O_-5+D!
M9?+\+9;\=_"N3IG_\'O]S&"Y^)4@AH3I]?V(IT)#+;?)$]M658U;>TV_2!J1
MYO<*](-'63AYVW)F/DK _.:DEV86!+W\8?'K8C[[ULK.>U4X.YLL#ZF&8QN]
MG<@C7-E$04*SKDWH]H^H?52_424D2.VR&7*4,=?P,EJ,9"S"OZGJ;#WY%C%M
M^<_+: 1M+) D!O,<9<QJ7DG$)8+[@#M(D2<2.IZCX#Y5KHLD%BY-R%B:6O6H
MH)0WZ@*YF*9 #J?$RF0%F#VX^43*R*#D9D/JX2BXM4//G%U+\LFF=L,[^^IH
M,.2Q"0C.\]CXKK:ZX55I>#24E7#_L:^7(59;+QA;>DV\5 :25EH[+>WDPE*J
M&.W%@>L\ZL1H:;8+G0C@\*<IQ)W$@;9H?C3M!1DWVOYAP7GW=.T!2_FZO<&1
MZ2W*WF\.CP94V:_OLX=0C2"$FM_ 3" 2"3P? X)#?5R/= /9DS6:'1,Z872N
MSVD>*UP*_Q0@^_<,@!'Z5NZ0TSL+O=<-O]D'OF7<^9O![GMW60L+2?W<+X<P
M/2?'Z%^%,W;\N#GB/#AM^X-J]T_<],VOI,$(U^"'9&#P4-(/UM/K!KR:)KLF
MGZ#_ H61;7+5;;C1F]:UC'O C<SES%^;Z4?JHHZDKA#IW_]2.X?[18Q&-].(
M](YRE%F'1WCBB95/_]V!X?_8C"//XB",25E8]9@+7)NJ%@S79ZBV7^J#>BGR
M'PT*]*P[*9H_[UW19$/81%J8J;GS(J;AXP9!X_TB(YTFU^X5+YOV8BA(LRN;
MUSO;JV^TR0I27]-H<Z75H)*%O:RWJJ%,VVWKMZ8'!4:RTX\G\HTJ.W5@_-M/
M[5(ZS2R>YA^KDJ9/<KT'2AE.LF?QL_NVJ!#+X5TQ2B@=&-Y$??7'ZX_$"B75
M39TD2C:+PF5EB9%@8? 7,K33T57:OW-2Q$QCJC_^DM*EP]V*FQTMM_'!',3B
M09,$;^$0#^^LHL)?AT<<J4OS3:IRIF^#P1PZI*.B1N32+Y\W1*$)X\#A$-@N
M%PCTD:6]0K4?:/L6O39@NJ$D;XJ]%0(K1MG;GU?LN  30K63BP^],5HTO,#L
M"+-;C!8<X4^$/"LAI+\QU%YY:C%\IPMX/TY;,0&VJLRV7#/T]E2$T (4,[B:
M;]*3IO^+_>!O0*+EZ<VMK&D9PBV]?IIT]Z.^S/@P]C>W[4\9O&:9HM>/53U<
MB\ 4/4,8TE=IHU!N[ZF=U034;N7@=JRKWNB=KRYWL;M9Z>H3)^-3&E192FB#
M]$P)+-IMLZ-AH;/,/_BM/IUR@12GC^9J+LP;(CN;7VM=]4X\UA>53H:N;9%A
MEH)W\C5D8HVUQ;C3@+WZ>MG!FW,&((>@E56K#'27:>+)J!&N*FA"6EJ-:$D4
M3 TP_=0UBL(0]>H28@YQJX::$\B$3:K^Z&=1^W'R\.85_.7SFFE^WAL[2SOT
M&:.?-I<Z'^'HY(M \;F&4KI9IHGER3I5S\+GW1@LT$\:BS+LHW05V*X:]8-U
MYK1MJY^.-]H=C9N>#.ZI!VXX?M9/MH3=A!?56--M'%E.9$N3M)<;XNL27>UD
M?.<Y#];Y3V5V.-KRXWSCY4V-*@_8!1TKLJY=D^5_W@+6?:Y;YMZZK*Y=KW.B
MPJ6ULM.Q;E!I1M=CCX+P$\TNEM NTC__J2OH8GM\+W]-'V$=H/J5I!'SMHAX
MYV#/PH,9H3<7]IOC!X?JVI-*^&(MX?CN["6J9(_9/U0_G+")=:?C(S1>++L.
M+',U-!+F+8453+-+H6Z!1H@)8H/X'?]"S4]3X&W7(_)"OKOA-_M1V4&6"F$@
MD[&@H6^6]>B)\NO*=QW\VB.YWT4X47BRY@\"QZ.MD[3*XOZE\2G-16[[*QSA
M6FNJS,IS$S5EBYNA.;):I_>!Q<XUZ9+.#1A;E^8JRTE6I46M-]J<'M&GI;(=
M0=S'MDO'9X##LF*Z%%2G,5!.:'RCL3"=1?,7'JQ0^3/H(DF7V&C\FE9PE"A]
MA.5U^F:&X/0?$>' #+_"<@T!;YK&</P71P8GXOX#[RZ47#[76 N$G/-=QO-W
M/!&4E%H"HGUE=-Y  @JB!3_1**%4HI.B\]@41D9H=B:N=(WR%T&*M# FFC#;
MF6(*,*+$7D_$_-.CXF0-HL[P#0KOXI':J6*!;QW.'[G]2AX>X85@..ILY @F
M*NEW?+22<DK_]&[^ZW;=_Z>N1MWGZEIV0="2Z#%/NQ!7^MUU/11CYKT'=;7/
M4\*&QJRW-&<3R1:50"0Q'+'54J15]U1ROG[.G^/#&^CGT[MF[L(CBS+F@/?R
M'*ESB^/6M^9N"/,Z!NP2<S4:GZ?K%Y7T -U_;9X^#N0[ WRX:6A+YTRQSL'8
MPJ6V #"?2E#9[^E_XYO^:O:1%WQG,+25H6!DO(EV=LDJX?9T&'O3F.R/9PEU
M09=41KX$BP4^:"(#2V-6)<:"V1I>O<KPG%8]7>74]Y?>.N!PM17X41[S.+V9
M84.WT%IZPX=02/5I#U<34/%S"1=KC->U*H(_^K:T6Z9VK=7 PP^W;5X@?5/W
MV!3#2%^FK8.ACQ"#94 8-HV[C-N-=B\"=T5Z4<X%T3>LSIMRU7RN[7[%BDU8
M' 34[0@MH\_07H;-^S L*U.345?@_EN#\:].AX=_N\3O?EQZMW.0\,)[WKM"
M ,*RGJ9^?T=ZQFE<E$D.T0<2T1$E)?F"=_Q$X\##F2DV"?EC_I,SZOL?9E@K
MXL0)F!LMWCG"C+$^2^S-1V,/7 .31357K7)ND,/* Q7JA"#!X\5:(4%VC_DU
M@PK)_A4#J]\Y6,F5SH?(L(?68B  YE /_:[KE^^QT/S608U"Q&LV&:_-D0EI
MNM$>!9?C@3'];)]! VT?V_FW:Z_]I)6,FK&M6QMY>ZSHHC0+HRSF^1<.L+#?
M9I\=Z415^X.C-)J%S63Q^;S\S2;Z*UEB&K/X#+MS(;Z@U. E'UQL;F*X"G0P
MQ%=[^454]2O:C#H.E][*,GBU*[.WD&HP\*!HUQ>+X.CC*GY%>$R[\CU<H&LI
M.BV713R6!=G5<V<S>77=VCWRV,#Q[XGTL?C,\Q9/F3_$)X$#4WB#@ZXYV]M9
M2])\9HX9KYM!NA8C0HTA^<,:*:Z#)C.V"9]:9$CJQ0G%"93^CGOC[:E-36K;
M>ETE@R%>Z]&SZZ[F#!-- %GF3N6422N/RY^NJ=@2T"(!<LI&!@+YW;G2VE !
MI<GS)NP;%\("!#INBF)$F!B-CB("7"*J[.1-")^S!?#70 G(KA-PRLZ*:@'O
MQ:HYTT9TTG->^4S]O)+X<R'.5C"E/9DQJ31Z+MZ=JDQ"&M]N D-N1%Y$H!5P
M4:J53WU0QOG(,E<Y1#T/YADK^)E'H=;Z-S,BF.#K!;&X+.3]VX"W^EW+8H7B
M\(K"^AIB6_3ZCW3KYK8S0%S@@(+$ KS=SD):HT7;SV4Z6]D=!M-L]31//F*E
MI7-]O*'RENN?_9ZMFID=L.XD(#I:NM/ TXL8<M?\+M8U_2\C@WPJI]1"8]"1
M:,]=8WV0][/2BWQ9$*PSZ'\'YH#429HF8CH?Y5/!$NK(2HBCLG*  XZ5&[55
M^6'2!MO<Y"$T":H(+ M\^S5)\IT!Q1D ;5 [XIVM!FR%,S5B&ZLCZ[&?R]S:
M+WV:-"4MJZM\5Q9LV(IU]]P[ SB/(C]I/KQW119 VGPO/^95%F)/GFO?']MS
MK?G';%F]S19&H<#F1\DQ-S26;.X9!PSFY"JT[QZM)?HO%IVHL.ZP4QHD ,D!
M#PNOMCV??J'2[SL9I;KH.D'U_AN;+SO0'%<X?&PTV\_S_.?7D\(8=.+7:W8]
M1$JCQ!&L96702EZ]=_TW\*%USN>Q:R,C]TP\N(&/4T+UDL3[).V3M'?+5B<:
M!^_ZAQ\K5-BNC#P7&8!O:;*9UT]$RNQ24-:KI&,EVVM0"#*3,=[N#)"PSTOG
MJ"(A^E=6J9YG]+!]81%:.VNRGX.\J^^&GR!_)2A44BX?5M_>&6%P2'DS()-C
M@#I0]Y;_B)*NB)GI^?Z<#V[)@$A4HZT/?B4YE/-VOWSZP;B"W[.2Z:ZTRJDS
MP*IYUT?OU2 K\_<#\SJ,+B7.GR_+#KRE'&E0N0?^\MM_TB#"V:S!\D?=G(HX
MR[[LJ1G:PW\O6'YT9_D](JD-\$&LEX9Y_K8-X-#<^(?-#2O/>EB62I14G;<U
M)$#V^33_WM^>]_JF'-]@.)!(,W8Q_RJVK;\&S/AH6-;XQOW7GZ":7;G_I,_O
MXMOM4UEL;MX9H#O X Q0&7D&V'E@+>YFFGIT4[>Z"*<H5+0RL5Z1R9.>NT)%
M]?,KWY4D0.>@.ZB-)/,^4 $5]%DEX^[#'9>7ZP./@KJD)U;'9,Q;I$;C?M)I
MBZM;YOI/?*@"K'?9;UK:R& ;,20&=/^DR([GR\[H3%5#KVJV?:6 Q;KE@1>]
MF]XN:YY0JVG:X77LNNJZVRW4!]&$FU<[KS/?3X"M83CEMPWKHXE7:]];^0@A
MJ]-IWWEDV4.6AF"^%2$SQZ\XZ?7#"KJX$O*XCT^E"RN66,!.L>B"!\.!"J]+
M_-_O U.+:=LLN3M[KU/]^GX0G$6RG @O'8=8/'JHH\Y]WTF.CY)MS&HFY( 3
M*U;>>LB,V#K-I-Z/P8(1ZB'5W3]+VV/35@]9;88[@;7#3([H>'&8,=I71NBD
M><9:0W=1HN]F8]<#.<=OE!0']M.%U1_ +3?@AQ1?]YRZLIH8.)RN4RZK@$97
M65TK?GA6)X,D^WV"A6LU1KS10&5=%*W?UZV?ODM^];,-[,:'N@%H!D,AQ4%L
M]CL^2C>/W!<)O8@Q7_W)/UM,HN7;.MZ0G\121$8\@Z8Q-*#+D$?Y?E TDS>D
M/Q1W!L@RM:&NM4JX,TG)<K.^:N=:0Q!R Z_K39^:864^:J+][V^21M+^I2*S
MSN[OIYQ>F^O H;67.*R6JYOBMZ_9>9W?[@2]O8:&))ZT=B1U/#AP:*!-S@I$
MO#\#"*Z(5K .=DP$I3SA1::I>%*R\&PGV%!*?RC55A5%ORB#>,'3$J!(<J1E
M1K9K[<,5GN_<]]F6& Q U9@J'.L]H03L4_K@[?M[N^S0$-/$&7(H(\%1F"3P
MO=,3('4&N -TA\[I@D7?_6.@K[+[).MREXSKQ!3,;@[QI"'9L\PC]H17BUKR
M_G;=>5/"''2\?VBA.;NN'!"DK)UFY_=:N.Q^8CQ(?(#)SZ?/8\7XC\T+OM#U
MA]KSVI]+1-DVB/X\K*WEO48QT5-1FM.R85T<689%UZR_I0X^T+]Q(I0WO,%G
MS6ATM6'BP(U],R9U0]D8T <+EG:?96_0?/N:J\0B\;I7[-W8E[D#-981@SUN
ML[6-GNF132K0@BX[":E-MG'1\F^? &P4H:O/)VJ27,Q9YD+D1SP:!&0'CY!#
M\6> )7:^!)5Y3D1(7<@.0RFII(X<(/[RIIK,_&#%S!F@@[4S6UM#/#.@D1KQ
MT]-T!!?>&)*#"Z^K!(NX.<X_7(,+T&^\&,%?CT-YA1?7@J"L&$/)U_0IQH^G
MI$L?Q#G-EJ6A0/GN35#3*.9I++M2XZC@-[)/"$(>WCJ2;;V\9*=.;Y;WOP5$
M72T,AH+J(EVD"HI'BLBD.E\SQDGAFF++J,<KC<BZI (A!8J_?]A"?K2K9KTU
MM!YXC'E)PE;C0@2W.TO3TP1\6,R7U?U9"+H1@X\V4GW (O:\A0:%!D']_(14
MEFT1"_M:,FK+<W/F9U_I\@^B,G.=PER2!'-'SIN@YM68ZA;=#U?NJ/N> 6Z>
M2DT'JI@/[RYGFF_]_%:FR?=SF&*,HZ#V]'X@39CI%V5ALH\\4=ZEO3^IC>N&
MOH3O82Z$G%6KT#%O9I^VE*G$;5*XENODC2NDZL'G;ULWWY9"0 8P.$EN=4&,
MY(/VSKE;R*'HH5OW$,'(&QI%;V=JO=^(-(KO7&2OU-0NV-FLN)B)T"01N>"M
M_Z6P'C[#&*E?H;X8KT8X:LO6AC]8-<9I&X^P<(V,FF<;AQFAF5W"1LJZV Z#
M)FPL!WG1N-<"/'IFH<>"$Z.ED&%$9!@2)&@4@"RUCP%/*;#OI9.@0!(0[GS^
MK_9>WICK[,9JF=XP/,SR/A8L;MYR.YP8.S)HJ_4@QVC9U0GSL-AS?/ [%HI(
MFG*@Y*IPEE^L^GOTW:O05MO%="'_EI[[FBG)-N>5K!=3FFD:-S>J-Z>"9OWQ
MPL02#'VC*^UK*_PWDF%O_)9GF297%H/'1\K?')!CSVLOPN ;8[.4'T[O\XT?
MVQ<5IX;L6YA\O4*QX3%*ZC?!M]#8=KF)!8H',$5B]EA.1BL_MT9X'>+MR*7T
MBR5.N 4-@Y8J]YY*W("_!6^_]K:8R.E<*J54LU)I;#K=RCZU^]LK:=6H=DT)
M!KN#$>T2(8FN.Q*]2U21$MIK5X,Z%#4X$"K0&\A[-JMF;OMRIJ! -,0&&LJ:
MG$48"PN\&S07!;>>[=+\<'IZJ$]_Z>0/:')(F;'='EE1/V>57PSNVT;'L&F+
M5=OG?C-WCPM\RQ=#QRX)K)5W"G/_U^72*I \U=J.#105DJ_,-$NCY!\K*B;$
MC#8J%&I(%:X+!A:.+4+)A5UI,"?X-.O6FR/EG&N3V:H&@RHEYCLJT]*=SR?*
M[]_R.O4OJJVUQ-E'?VUZ5%G8^S56V038R92"*"_:==W%S:/-S7B#FAKI=F:3
MHB6C]V]$_1>X-I\RL&TV['7\O+++%N)OT@4+HZSGE9=W55;>N<<%"O3NA7FC
M[O(B3<"XRVRY,&0"U@*4#7WX(HJ0!L\-V$)RPL*DZ\J,Q?0AC3KT''A(NT$C
MG@W=Y%!PLG*;2JFGXH6&X$<:&I_B).O^@BQ,- ZJQW09*X+YJ&6^9)B\YML<
MRJF8TRNP^C S[XMSZZPC3"5RKD]M?=6T0DS41R V70(3EW-I6>G=NJV(L(W*
MX\#/6O],5A]BH3V2[J^I!/_Y!<7X@4+A*M43^375:Z7!?OM>OW&T)69SB/O6
M6-Z SXHM\30RQ5CB]/I^/8V;V_K%:>3=9UBNO8I%C:)>\*H1<B0'>U^G&74Q
M4&Q(0HMH5E*(,D_F <'. +<)&?J@]X?LC,FS6N7>S[W[XN05EGD_ZTUF?5RF
M[-54Z[()&)TC\9C+6^-S,ISWRGS"<\"OMZV3A^Q,+[WWBL>_:Q8@$3@ZJ:<B
MQ/%D]\[^@A7/E7US(R*CIT-DQEYB3G,"V^O5G?*C;(_^W>:.+.U7:3]9K]N_
M>OHRK$<QR:-'"?H HM-O\CXYM993\K5MF3^1'?PJR9J+(H1U1I3UZ=.C->Z<
M^6N*9NQ,/R* HVX[!S-'P/#N@V3_ITB*14K*T7SV<*_5_7 ]#)Z9_Q^&K7.C
M?A8L'6"E(!6Q5F->RO#@=GJWH80^I8KJ-+:BR</=YS722B;SOBZ39HSK&)\S
MX/5\Q=.4DV&3M0>.C#4T3M[!7"3-O;U\: !#(^C%4\ MWELT-*8[;//P1KZX
MPCJ\B+2 ]\G8I^).(7&JW[2CX"6^L?P*(_"JX7+;I(M"M:X-0:56FK+!F3LT
M\^/$CZ75Y.-WQ2N//ZTT?+ PL6I:Y*.)_!I^$-H]2!F=KPZ*KA7\)88C;C;9
MN9= AB!WP;';3_*X3I#SLCSO-7[..^R7RD?$B/J(O"*<6LYQ387&TV9G>WIM
MGEZN8LTT85/D+E6?^K5N3_[ C>=8]_[U/4G\WNG.AJPBVQS21OPYG"^*>W@W
M)F8&W(RX(@P5,'NBK^])8\!1N&))?Z@3+@77]9#Q!KE'<XWZQ*#57;)S7!+O
M&;1MR+W2GWY;LAX(Y(UOEBET9\1_3MJJ=IM*3AZX)K>W;EFFJ_DE?(])\G$1
MZ8ZU!%1(R,N5?L"Z3[LI!T9#F7=<JL >L';H,N'S0SFHZ,,CLV1[@6Y%-HZY
MD:_FB0WX &80X6ZR1@VZ0N8+8;C)QJR(BN&E^?RM6_.'?WUFL:)-CM3S:<9*
M813.DRDWXV_KMXI]J;")UH^3J?D5^!-/8L0T+,R^N,Y*.8D-_?1(<>^O*:MH
MWH0;RMW[VLR]P'8<;=@A:Q&.1MZLA)=#_\/T868.3QQZU[W6JL:NSDY*DD;#
M?W#V.FJ>].J%[?/I'KO,/I_)>L?[CVTF8?]"Y+]M9[_Z5UN;GCTIX9$+<B*F
MJFN+NL'IIXOQ79%IJR"@^OJUY8&G70^N1JXD>1U>,L I:J5/8/Q6P1\M>YG'
M][DO7U]:V)>. $Z9EZ@!988RJYU67U C6K)=*=1N:C>':;W(XHCIHN ^7BR*
MZ+BFQ.Y](,)=]^\@7D/1I[MW+@=*#2^<2C;_LK,.I5G[\Y7TI':H,VO/8Z L
MS<+IVVIC8H(MS#U244M1=<^(-R^V(_MGDL,GCT\*-#DG0G2)#89?<)L_$T7U
M?H\UZ<%WFVB#4O/]_37H-@=@\ZX<8<VZ93;48NTRA^8>/MQOJROWKWE>VN]4
M$5PRUXA+38S^^DE-[,K+1?C/$7$GWHQX70[DZNK3M@YI]W"*M *ONGEC:1%N
MBY!$"HL%A(B>&V8$7! :QRM*U!FFH+(?78G;-H_LC[W@<QQ4[:#N;;+&YF!+
M:6]R> #SZR! ? '%S,)I"O'B9'P%SNM+0;3@T%5Z8[1$#V,:'$.\%"Z?:0"B
MPIDA11Y/9V%NYA'Y"T)I^]V2!<P!8:L@CNLD0NM6K2D33'':L4S&J2KE=$/U
MS[)_:=E(DE88C?I;\AH-DT31UJ\Z 76T>^5@SX?7@IZ+Q;M*.4?Z6RKKM.Y[
M_?+.QW*S6[F*GG:!HYM$I=6N)K,9SCN!\CC62:NO2;+;D1M&VG%=)=*I(C%J
M$K^MM+;T(SQ[[KG>/X'B KF/GKQH?WT2-Q= /^8=<>_60&BV9@@ZV'WWUEPX
M8C"]UO;V<1PQ/9D(LQF)Y]8^JMZH49R>)CD9FH5R=):7N57JXUHHESGDJX)>
MS]14TV>Y!<F\_FZRK!#]K]E>E]#$[4]H6,Q6BBW5^KWL6UNGM+KZM87OFU/"
M^': ?(Q_GT;NH!>\F .AY&=-^//6#N)8*C.6^%/9F$:)^H7FN<O!2P>Y>$UY
M/SPW_ F^X%W WL.":/X';H^/^<\ 5"K1V:IYRT>F^%L^TEJW03[B 29$0T3=
M!38P[PE6HI+AQ9<ND$MZ%-5\3JI$NM@/LS4#W@:M1^H27:8M6^<>!#RRN5B5
M?C1<;W3 @0UI;V$8:W+D!_+IPRVWP]Y\*X)N6)*LOY(EVU1NISJ1; I/JDOM
MWXP*#QARJJW:4F<M91@;W.8/@"3HJO/M[\FCAM$D9&_CFN562()/;N3GJC%%
M7LY(5_H/KJKVM!C[,;[6D=HF/N2QRKE8]7@+H%MKF038_$;IOGSI;ELZM*"8
M-8AFK8QZ *669]Y1XMY -'^9Z/#X'2^4>-J7X,SK.7XTM;V::PL[/LR],N>E
MA2LE-DGQ0E5E""=FA[N:7AVC$8*Z&165:G6DL=#3^Y"&<OC',LZ]'VJ?3SN_
M=;$>7F57R?:\*?F\-E71X$I8J5:XUO&JKA9))3)0)=2N[(5&V3!+K=BJM7IK
MQVH,]E^@6K[EJI']O>,O7X.@Q$>FU6OOD_)9:<NNE)>OK37EFN0$]U8O+GJX
MMR ?,(P\)IFNWG\E-]N 3YY):T# A4XNA^QY]IU M$Z9P#!D?P&Y;2#HCZ_"
M>X96X<5F?@]?CFR":"P*VSP*W=0(,4MI840L[\I9XQE7W$2Y:VNB=6.B:'#1
MO,(_@P ,..MC3I)KB3U#<_-L?-RMPMQ@J/U,2QB:[.2JOSR)3:NJ[8Y"Q&;'
M_(Y8OG$&8%W-970X[<#%^02/51]EB+?A%A<\G!1#;AS[]\8K2OI2W'K7H7H<
MXW&\ROUB2'KS^D\4&FP!"MY($&1'GEX=:0XS(A5'V%]F-U[4%4A9?"[*DS(_
M=_2K"U([$\+&16YPOPD=,P(B^JF:".G(-Y:.G-P+$2S=B_5OC@W4:,MY630;
MH,?]KS]Z@'Z3%-X^BRZZ$YSZDE51'3'I;]O)2D@&/\X%@[V'VQ_^G4Q^C^1>
MC=WOT$@64(*NV1DST&79Q''8D^$.IRF[.R7X[YOZ%@!XF:1SFL P#GH?*1P*
MO'_QT8HAIN_W;.9>XA#;B1"+&9+AK<(5W?NS"'.DY7)#&N(,P+%GG'IZ1%UV
M &\^B0"_1!ZIF<0Y4IZHUV[>VZZ\2YOU=T79L@7LJUU+9J=*F:](_Y.O.W!S
MNO+Y\MAATF:TR*=]N 95(:D8O1M>H=SA8*,_8IW])WZX0]W'SZ=$]O%=R;F"
M':,=BE ;:(>3Y<)I_]7K9P!)_&$1E=0<J7>S[[A?K'H%Q#\E559J3?.I(S66
MTVNZL'%,=)?G3F -H;7=_3I5:P+Z-8\@5N(8.QS1D\\2\,)T2GL_0$R]RJT:
M,CQ\V[(M-#I'_M7)J+Y!H\V.?6\Y1JXA>70E9A\\G:JD4<L#2@TPU86?7\2_
M/EN]0+$]P_)J<:E?C)DF%!5_[$+J9$"N$WV*>ABS,!-F)5+/5D>R,/@CS$)>
MDAE*4!HE^,3L DN>X7Q9QV1?G5?@J  1RG,Q%AX7LZ_N],W6%DUO9!PQY&4"
MWB&@:2N?7 R?2<L0]E'.,,A3^RH +M//NPHRF$6<LCH?X6XD866B!0T?] &1
M(IP=H/NO1@4\P:G.B;@) 5848!U'*)K2!A7I4FD@BJ4?T6,?$ET9S 7;7DM-
M\!=?4J?''^&=/W9 XG/. +X%D&$Z:7B!$Q+G/E(328N5^;BJ#HE,W#J\P!!(
MG[ODAL3DBZP^P$A=<%0X$7QQ'\RF,4:CA/=8]O_F9#70G.OBG=V+F3!7JI#P
M:%WO1"V[T#_1J26@H@G\=:3]P_R9R9F@PNE^Y)3 ;XYK72O3S5::)T5\K5CK
MQUT@WAJLDP8A1_8T$#9W+-1?<Q@=]]><*+0D:</65_TAVYE7&I,6IV+J,_S#
M%%D]6D7\=RQ #B+1.=5MN4>I?!7[[/#KA>>'H]<(S^#[9+&YD)MNGU;^3/BV
MY\K_W#RYZD&-0'[FD+#WZ'9PX1QHR+UU#"1%O!\/_E[6)R5T!A#=MY7/A1PX
M+["II0@YDE/-;SKW0]UZS@ 90\2A,K36OY;5X]B;,3WE#_]5NBYBTH^J-4SQ
MD>Z%R5=DH+A7)P7HW<^G@[.MUR=LBY](/*7\)\U:^=V +GBK^0P0X79O\ZH(
MUD!)ME.@*]J+C;,^XZ\#_,@('WQI%^1%R'YVG!.1*_PWGEK)@;+9SW:K^%BR
M7%R9DQSA0.RZ0?WK7D0MZ.%)9J C!VAD7Z\UH5I3G.5$:!C9F:$W8>8P(SH@
MHM)AV47$INL>/L^2F=$@$HO(MTDT+#)Q@BS^ PO96B56?W-_,/Q=?KV5$=+9
M.-<A)ZT>4B[6\GT7U+?66K=D;S>-F*:W4+_]G9-3M@]\D_D,X.9P+F/-M[_9
MLF@GJ*PQOMM/^LNY\-P@^NNY3?_Y] !ZP, F8KOPFGLQ6J/!;-.ZF\S$FRN?
M&X,I>R3W\IX')UJ0K#E3$3^.:[*007']LZ\QP9RJ'8YEBTKUU=<_(F5K^QJ%
M9)=;M9GJ_-,6DTE023:*@WU!E;ON4K^RX\BU\_+M"EW0^!'L\Z<R7IE]6>_/
MK].[27MF1U^GV-X'?\RK(Z_/RD1K2?4)B3R<^HBWM+\7;G?2G#5G92E\-_H4
M+)5TX*9BKP$_F=^<_S 23$F./Q9N0/=7A+O\3JM+7N0,=^8ZEM\2_A J%KU[
M7KY;3TL>[; +#6*IU<S&G"2(\N$=HQPM#A&<J8PU8-8=BA7=(TKIG]A^<1'-
M@U?ES?>F$B:'D<>RT"FBS_1]<OVL"FW[GI4YD$E_660MU%@S7[IW\E=<1ZZ$
M'/&G-A\Q $?,#S#MFVC)I4C^ZUGW;P9<J;Q^T#R@@X>8^J54'ESN9,KK4.!H
M!CM7VEO4)[%WJ/1=\11(%1P.[FR^%I1AE5U0Z*JLN$$!9IOW.!S=<'?=(8,"
M4'.UX6_!/"Z7+#W\,XU(;)ZYU.!.XH38;D/S=E!.+Z?G.J&NBN'1EFTK-CUD
MU=S'L U?*3;U8[E\5W>YD.X7E$DP;CBO[E633Y<TD?,&-VYW750W$^UE]%&Z
M^1]OL@#7.],[^G]UQGK]? ]=X_,^.;<\:,(UZ9;87.(E9#)'&"0(^Y5,_<QB
MFW_I8;/Z]P\;U);&1Z-I!"Y7\.E5@&[J0P'-NK6@U27Q#)KG67:3>[3XY0GM
M1I]-)Q]"N,NML=: G;6@&R2%=@E_3K5TBQK\Z1_W*^H+M7!>83)[9(=_3CJI
MK7WV54NR5YZV],E(Y*LCGY:%X.N&/S@ ^Q6MYB>%Z"8@,A.H^WT5B^,^\+,5
MZ*IB%TJL(^V6RXQTY/D'3ZHG.?*/.<8FE>;DZ\OV!W(>JZV)2<2^_)O9",9@
M=AR[.'FP?L$?7W]P4Y1$(/ Y53/X*#O/3]C4=OE49I;OB@[OWPB%])%#?#V3
MB.9RIVQW3X0^?62PN<T@WU;/L.LU(^N\\NHU!P'F.IYUFW%^,H7IMXL!DNPC
MRB*RVU<<Z^V$Y5.)E-(L=D9$N?J\/P.,E;T^(/#NXEN2[3P"WG3<KU7C_HIZ
M!6#W7_I7(=,WBXU'5/Y:J:GQ_,X^]K,VG?Q>HFY@GC)M4'4S>@<\OXM255LU
MWO6MQTH+]O3>,;=!HDYBVH]"YL6\ER;&* Y&UK=V0GRM-69:Q\U43Z#BW)?\
MV7R1I;$[R),$8Y#I#^WCD>-X/Y-T_6>08D319.Z4,UJ\Z[CI-^/I4Z0!_8NG
MY<)K+BY^(?3BES5GH2*F,),4+S.VB)L!>,_T,O>MNE2PM^\!H^BNM9K)_2D;
MH*CL1/\[%:IH65/?(I1QLZ7=FQTZ4Q1B.2HE"YM<+U$A'FJ,,\)A*XI5#6R;
M+_"13I'9X%4CM)+SW8>@I$(0C*!W@['(!D_O(^W4:T^X()R@>!*#ER\JHD#!
M9]1^:1O>^PAO!Y90OSAR=%XV_P>7?J_]WQ@_U"7S8E XQ#&/,AZW.5-\<4&]
MU&I>63'J.A%\5O)2/IJ_1/U!_[ZZ3/:QU,0P8_C_JYIR8(RA*M=(SL5V?>$&
M_.8%-V+H<D+#?^>#<7&ZP-*G=EHX#*&,1^5C4C38%5_N=TT^L83R\N=^^%=-
M$7%X--3,,N]4\")%4'1>,GL+[C' ,[-(NKS2P: BK7+\758/B+U9'BO^KLE$
M@;W5CRM'N!3OV>BA*,F9W7,[]A_%Q[OP(;V1.@AP_LT$TK0P1'5$'K-)%\Q1
M_IU]6M9%Z;RHG)=P%SCT-%U:%&:Q>.ACQ+ Z@_J#_\TPQ%'\,J'ZLJ('9?Y3
M&K:+(N2J']3>W>:7B:-(J*O?FT74QN_U79XT;*RUU5JR.XZSML&M%]0+VCW"
MM\8 =?'W8W_;Q#X8:]*&T*O.B@#%1YE$3H"6R1VG0KFO6B.QUVZVG9+QOD63
M-HYZ"<+)BVD<(H?<SH32FDQ;&25L_[D)@R_F_7D^4>!>"_R9/J8?,I'1VIG3
MZN^$?.&[B[9+7=AIH1*WB1(;<D-HNS\\=11;&W[P,SSK#(#1+J-=(?$?81UA
M)FF- L.%!G_#FV\A^(*TDJ8L$'JE5^D7*G)>X[2O#9NH[T,$T^0YVCF-NXQ,
M$T]F++_P%!Z845N]^#+T=[NRPK[6=B_A9W 8ZEA(5/?DM=F7QT-=[C/9M\[K
MD;V5L@WI#*!7L)!U:"_=8<6D2Y..3;*8'!SV4_A2Q_HKKA"945]"3(,#ZW/^
M+2HX1R@4R9X!=N'="2_PNT>/&X;7YJI&+"+&?(K_B6@V."R< 6[KI\8AT5FU
M3^?41GE)ROEG #7**'IT*:>EZ_;[YLZUOWMHPE;AZF.C:7*Z4>X/)N@^HU?-
M]>8D\7\)W:^'+."KKT@PXP0>A>93K7WER@]M0OATJ4:1%B>&NM'*BMI?$[_]
MCTQ,S@ /J$WO!8E2$!-I;#D^;*]87\EA;"#=2@3.QND 3=5/2]MHY\?;EQEY
MOWT[#(+"F D,INJFZLQF1N\H\]A5!.&UA>FC2%%8>E9C<_!&%PVW!,K(TQC#
M/?^D0;W@),&QR>,DM;:-VS!??P3)_'^:>NNHJ-KO?7A\4%"I1Z53Z>Y.$8;N
M9D@%A)F1[E908J13AE)Z& 8D!J2DNX<!E&;H[GC('WS>]5WK_7^??>YUUGWV
MV==]KGU=.^&BKL4?#A*F$L#0\4FD3*P#JY]TJ+(@IL""R$TK-KL)K)KHA2AY
MA$BM#'[OXL;'FW@X8>ZGO%ZH'--=$J]PS3WH>0L@.L]3VQ_PIDEIRODJXOLW
M[9+F:"61_.''$:VL'K>P;LWC<IT?_A/DQ6U-<FI(Y/R@W/J)@&_OVQI_;YGI
M=I])[RH9.8KF-#U!QKES<ZNWQ%=6(SVN+ QAY;6B?WQ#ND'.3:ZG$0-C)XY#
M?SVWL(*:,1NA^"&DW>3BD3+,!;XEK)9OQD&JMX#QF5=_>4R7R=UZUG+:ZOC_
M=:1!H>L547_%8T6^O7YFR?EL<\+&DY-C^)N00NN0JY1)2G]46R!_-N'O&'\?
M6></?-*X,_9SX;'N6<:;TK'4QO;V[%?C3DY6EB3'Y_.JG]^;2Q*D(,V*-ZE)
M+X:+V6LU31P6RZG!<MPQ\+9E$41'#>:?)*4@:E)FQC71V8C.L0Y^M\U:+;/R
M))E&96L3DCUH=UV#?CDD[J'7"0+Z(Y/TG=*6 ;_ZEZ!-^\'W#EC.K:ET;1"Q
MGM!I4;D_Q >77?TDB5<2C#P#2D+9\,;V#)%Z[',(XUR@$'#'P% N152!^7]U
MLA#VKF@.26@TN6>XI98HE0+F*.9]@9($1V&RJPGUC1 4>: $R.M[VT=>]6K
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MBGM^,/L5;C@\F'U?M@ ]45>@9NOB.LV<-J#RJ"+3GFI'8IB  '!!HT-Z)7-
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MIZS ([-,Y=U5V$9U,W'Y%7,YHBEO?IC9"3;KL\ A[?[FZ,^X#K6CV[K_YW>
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MH2-6(?] 0J '(.(A(.$AP'L -    @K"7P?@[P,!$0D9!14-_1D&YI- W7,
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M?)IZ$@[ 1@7OZL(!/\.?;.7# 6%!]N!_KC=A,_(L0!/-38',=5<?99Z.68G
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M73$RR8S.#1U_K2JIG]6D(*.G9S6ZK&%/#N"5GLQ#E9>X/_NW,UA^Q>X"8$J
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M7(S((UT-^]2&JS4VL/W"9*7B81_=&@M+KGBL5(E9H5?RTE>BD;;3%L.?+[R
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MU,CTS5@O<Z];-E%4L# \S(#@1M(XOAPS0^V8E2P+/IXQR@"Y&0^0$JN#/%$
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M$ZQ53?YJR\8)(U"F>P L:6@7)DS)4X@M%CO1"0&<7"H+$P)@L_F6W$[T_#*
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M7$YD'03@(/4!QL)0S)7Y<K6N)CCYJCW-JT)1IM1B]\*JI?,,D"HP-S'^*^;
M=AL5'GA$48U)M\%B;./X<R9A_A0EPF% O5S%.LFD)+TJ1MQ7A^>6QD-&!*2L
M#IA/R6Q0'@326 HY$<3T0BF;$2/,K>CPOR>)DQ601)[S;VM;SD@I:!868Z_;
M-'3(2[-K]DJT'EYQAD9!;119:#+6(6$8(F\B0S:J6FGK"3R/YU1$4E$Z*K?E
M/L1OH6E4T67X2Y0R\G(246FEJ$S''<>,X51W$YB";8 !M,UA-&1=F"-&JQ1)
M8ZPN]P#36OJ2C"W['^ZDD)H0\J EO? ._04-$2LRIT' R:["/'L,\J6_PY99
M=;48\_)SKBQ]WP7PSZ^$Y>SR'X T7P!ZK@70N1?I\I%)[N-<MWQ6PY[W@/I!
ML2XLFI^.\AB?;]&XY4)R,$=2[<"7_5"WH((0!K72Z=[WU%",9,Y))QRQ3")+
M=2V'(=C<Q1^F4NT@67,7QC+35Q_(Y[L1OL%Q#&DD8)#K)I*"-"]Q.(3YW=8,
MP:]RB=TJ&;8J@)$66)OEXDG^@/!1S [!(FQEQ)3X#K-9GT$7*H+3TTPE7SR>
M+?K=(<*\D$D\*,6\;O,$[1'G',:M9M)$3%R 1?@&G:(UTX%FI;N1>T5]@G;G
M6)313+^HR-TV;Y3]G&UNQB#F*%[A_*RDJ=/[^BT%M:D"JE_F=4J$W=]&I;E'
MI6'TRP.205**[]._*HKE/<_B'GV7!I_V@4:B2\TV12FG_P?.S-SJMGK[YXH7
M.!PZ*#SG=*]MW?'>G)54LV'/A:[HK)0.:)?7ZE.J-&\V27S<0Y;=>'N)?Y(.
M3-MID7;HVI C21#FABHGT;Y:B<@B2?2369N2,E*PRH'I>,>\3Q[PLX,>%!&D
M^"Z#CA_<T\$> F008"7M,TEZ4? 2+ZHG5PTPIB5U;?VP\(=^^&OAAXG$_22E
MCV1$[,C1S#N]IU69;* _7K_%36=%Q]A19%2+P+'##Q^9FG9#4UCD(-8X4>2$
M4=I.5GI,&#QL-*6*@^0K(]N/1K'@P\E)F>'#Y$1+N?,&77+C%WU2>A?E-*(M
M'[_H\%@,GO?4PR&J]>$0Y</@#[_*>\M'W2 ,4&DTJ+Q4$)CCQ!L\)KL'I(3>
M SSQ0CM^[TQJ?)PN=UNI3 '"\K3[\4J@V_=R5?'S5K1K6GQ<:M"])FW'ZY/-
MZ;'8U-#1\JUG3&*V%*4H(=QUE7<(7CG=&XNEX9$YZ(^\/GB49UG%^TF6N2QN
M5?C#_I!/FA/9Y'-:;O$5#XM@:Q298XD9]?("%KGT,;1H,"+'_/9,6JAZ[ J@
M!/KN6K@A4E!7W2BHB,#P'&80D8*CBQV"_:8@YH?WQ^.]'.T7FT=<A!_;KU2J
M2+NRS4OFN2UJ)M@XX-@'#'8G-0*J5LP^,QGG::FU$#;-'!31+F+XSW\5YEBE
MB-P#26L*C3'/&\RJ_^Y(SARD#<XZ@[+%%"596IY3BXZ!1G\O^#!SO3G.>H,7
MW!=?3&?7'^+A7<L)(WON> ]P0_3JV4]-S9$Y/T)SV^KW($1KKYI)]CTD7*\_
M<U<ZH"W[.$#;I_?5Y5<UXF[XQ21P0_P)3%?!HJX-U6T&8P9>1GA[-G%R=]U=
M>SF."!O)'3#< QH7DS_&/6+O_:-49C +AH_ /)/D!M_Y[#%SKP; Y8DV^%@'
MYN%/O 3G\",T_T"S\3ZHV@"6R\%5/7;!?^#[1&$ E\<3M*]]<+MQLQU5_HC<
M;]QL/9 7_HOLUL3)]@CO9X_PH_XAQ/X9-:;]GW2TA<4'<O#>H[!'755/40'O
M?X(">T^B'Y%4UB@YV(,GV'3O']CT"8A_@F ?WXUY0E]%-NX.;[;_ [Y2FCSV
M'I&)_R-L*_G4LZ(%T#U*V'J:_AX3\ 38_@,,R_U!;6.?>C,/^JNO4@>#'U';
M*+EW+L2*ER/5?P!9[<<Q:]Z<XS\O]O EXX?F_3'*4W93B2699$@7FCWJA FT
MRNY<PLF#)_CR?$L RQT$K*Z#M-F'A&<"9U#"RJ!["A/(^Y3Q:U<1[@EY+LO:
M>/> =OK=6&=QEA.&KR)>JB%?BP5%9-#,IS/RE!*L55T,2J<L2[)^US.1]+S^
M4A3"6(@F)[!#O0/(3><'( .XE)\2PY20-?[^?P1P[/< $-^1C)/N/Z<QFZYU
M78G/$M^S+SSS11IDHT.OKZ*/D\*X15&S5'E4:@K=+RC%H?:5L:1!#D)YB,Q+
M5*OA?NI:>V*0$'/HU^D!P3X_,3CG=/^ ;A^&W$,%=+/GXFG.KY1>#2!"V+\@
MO$?(8J_II&;RDR&))(!2MZ8-B&$J.9'8CP7J!]6/LBY=*U<*=TI_LA/+^@3(
MR5?0,\DB0'I&-R(RPL^L%!.6"'R><Y;%0XDS(R\^$S2.KE%5$S$ARTA'#&^Z
MJ_(N6J^_%*6KR$)7>&2I!HKM(GTD34.AXX/4-V957].;J^<7] H*H2$-R(K*
MWAL>]E-49RA!&]@Q/_5?FS@W=(9FG9#\_) &R^_,Q09VFL'^-@E--USO1/,J
MCSO9<:E5[E>->6?;10K6CAC[BA2^+'KHDA\#U0!2A^,*AB1-G%A'"FR(-*<3
MFD/Z0Z@:5;,[66%?-^.P).;V8KW\BC@W$;4DZ2SW$XXPOPCRPL,IV,['K4._
MC*6TEL/-M#H(6Y#^!6E"6\K.CF2%4V_0D?GM=)),"64W2K>N1,-M./-(EEFB
MB$.DDG76BA8T9D49=L74^ Y=AD9%][U$<J&V>Z0<.*F2H7,MT+@+H/*EK#>'
MX6Q7?%^4:V[=9O!6"(Z4%,XVCV24A"Z/R"7%Q6BT.%W?JVCU94(#]IAQK"U1
MM#BJ0NEPA6D&[JH^#>O(,%Z!6T9S5D80LIV?1F5M*R<G3!*J;(,)EU9%6[>Z
M\UE/080V,JD"L"Y)!IS=4-_DLHXR.9$W!+"%*^[E@ ?M':0L.!ZM\6N.J="N
MR>6CI,?YSH"9)!<52>:Z"!#7AZ YTA%T=SF$-(S+VEJER9D\"+IE45@??F%Z
MG&?[;GU[5Q71^TOBC7G-&K'$PFA..1NO9A B*;PS;T5L?ITX4J$I.^ZVNMTN
M! ^94D4FR9XZLB0INOVP7*KQ781V"U09N8CO1TF1V:3X"NRD,W:LOT^G(=7V
M0DTV3[[.9KKPPG-@=H*&LO0F9K"(@B,+=Q@F;BX*K &1F?( 9MJAE"\^-(,'
MN#8JCMEC9$24F0MYB8NWA:-FC=/R+(]%?12'=F5MZ;6?;+JCT=@OI9JO+4PB
MHD)R"9.'\%[:Y[FD$,.$K!,&"!9>"*4$DZBYA%E+@"W0E5O1+%LL"\GJH_OS
M#D:U.04\>EESAAW*MVRO%D'60.!SS';/&F%,E:ZH?T&FJK@9]0RNX09*8V%U
M?;ZT5^*ON"./8,7V10E43;5T L(IOD_Y_Q272**MA[-3C&Q(-7M;0D#G#NNV
MRT\(QI3G1^]S(% 4?4'60^Z<N^L[=DM5.?ES/H*$[";=EQ0_*@*&:$Y96TA<
M<S>4S5:AFY0V-)Y^UE=QZAYPVD!UAN=61A,/]WP%O<LW-.HIJ)OVPN8>L#I[
M!T]#I"EI\=TPPL(U*^)#W/0P1OS24DKT"#J:AG3!%A\U<%:/@0I+,(@2\#H)
M9J&*M3CM)G>&!W%=#%F#QL+L!-.*Z(L/@QFD\"EA. U97]ARC^A+<.:PW#,6
M6LL'8A": #_.246Q[Q9E\PDF3+@$YT3EGXS69\I8!?^,Q@J;6_TS2YL6N/=G
M%FZ42LH_G,98.?]PQDMJJ/U#+E>)^8?LA)7Y#SE9V&S)'8F>!P%@J@ :_I-B
M#1C**'\8P7DPE&G;_)],:00DZO]JR4\4Z_V9I)#QT)+WW>;'-"N8(HK2<Y=#
MP-.H\=U^O#0D1^7^/Q?Y=RL#\J2/$A:,Y0 '#4*3@%?,*/I'QE9!W!\9G-0;
MB& <HB@8&="3,##@OYEVIJXS8N&@H&?_JK2]X?56K,255-[E+>71)6GHZ0^=
MMSW(+?:9&_NH L6F%PEVOX^5[@&5NE<L-)O5UD8^&ZS-^UQXJ\7XO5M7'PK0
M\Z!V$="-H"N)-[SBW:=8@I)4&13K% 3*6RQDR"^?B>RKAFO\7NBP![T/?B\_
M/@EQR'E?LRN1C)?0]?L>0!KM>(J%_LZUJ'95NBS9 =['-*/!5'IYNM4&O7)1
MSD*8%*V@JHP>QVBLQ*I#^GVY.(=/F36Q6Z PWT2!)'X+4^>BFPPJU3P3E6(4
M&[8<EY(0A(KL-"M;[)6XS Y5>0 M!^=&H@PQY=4PO2EYO,PY<Z>W!.QJ"VQL
MY(!0'7D6AIZ!SP81"CN+4&VL$PU6OV2"!9[U#M 2^M,!=8 <6).94M[A,,Q+
M3%S996?N1N]U*%JR-*817'K;*&QI+\/(J6+JP^((_:SX4L8.>:G]\GS[:F+H
M>ZQUU=O@GW6E/!T6]6B\7GNF&Z8"S]5+87#8!YSEM%A335_F?WF^YG(U26M(
M9L.9QW.\JRW56S;;&D=;4M/=8=)ZM:/<-,97SF\L:B00F<*D$8-7-CU#N:Y(
M')9OKR%)0$$IZ(P%SWH\GU&XE8'UBWV.9X?D*D$V1K('/X:QHJ,K$=^:8A(*
MV4']'+M)H"(3^\$9VH-72S=Z5$3MJ;"<,-Z-($!HEX"]P5AG0F:?WST;KTD1
MN5 [SX!A]LJ7&K C;7OF(?0,+?[%EH?JIX2L$N$U8>)!$3;G_)^;%>$UW.%9
M^84""G;R<W.TC;>! 3H,ZJ_>CUK'R-<<^K?LJ5BUB;\]AF&DW.3)=7XGTIWN
M1A*'%M^R\Z+PVB,>GJX+D0!@?@<I!2);12/5//L)"8VF0TZE<W<?I6,M*;"P
MC2DR#!>LP7UP\=\T"-&E3;[^]96PX04A#>_OAK6XMX7F(FJ_S6\$\<7"H\)
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M.0/7?.I'$37(N.7>X RD1,V-.H@G.+\KF=Z(35)4,H+V'(64JZFBC-7=[A!
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M!'BS(Z*<TA!NI(F_/VP"?*]%5\PR?-#:H9L+$3$^R-<CJ>Z4:7"\)Z8+($K
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MJRP?L45KK"4*MY\Y*V%<DV)HLI+6FIP,D?LJ./*<<2T^WQXG\\V,]:#01G!
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MTIF04JZ>J1 =Q:8R3IHAF(T>+<$:H?;EQX\?Y8[JD9(@W[2N3M6MO'KOED3
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MD/TQ[-U#N5,1')!>8<&%W($L7;O*D_M:\2@!.X2E2\P#J=%L&5]>RZJ&V&X
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MW4\XT$?X-V'H;\)^.("1V3E_C 8'NO/ YW58K9&DX*%_$"8A",4@8ET7&:!
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M[K2'LOD(1BRS>LGA1;&]J)]:W Y2/$S\F<;'X8#%\X>1+&6]PLNL8 !-41+
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MB%J*#_[@KL7,)?'KFI?-08A7Y61N>!4]]!>;$!PP;3XO*$_E&"4R;[.=*(?
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M,$GJB:#FS.V:F%+^M:&1/E.ZXE:X11(?E+9_IAFI/9KZZ_:]?D+"H;0NGER
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M9H3Z_9?3R?^GY9__T8O3T+Q<2]-RJ@,'TF/ &[4VHRR]32(I;B2]E,<XD7!
MLE=.GT3M?/AHYP5;=_X8\HPT)+9&DZH_E45;H2K&)K!'N'81^YY.TGILN6@H
MIU-26>V;HE?H1X7<01ITR=M*$:UG2 9MELV[7GO'+1L^-875EWR%2&S0KZX5
MB21:TT04"\YPH*GPJT2CLH=.J'TD\VA0Y];2&WW;9W0U7QS[H-B=HCH3LF\3
MC"B^IZF.YD;(^[HJ.II=?%G^$$DC^AW=1[9E,]AIZ2NI9!7G#UJGGLQ5_Q%2
MV1,+%+LE;IL/8U6STD:UNARO29^D,>.1JHE<8O7&QMASVV1@JXX>%KXBU[9,
MC?-AL+)NE[8!4T?6#>1EW2HX*-B%Y-T_K R9\:A<!)^J&["%%Y2S+^K+DKU]
MWH;M=#-F #N-_%;$N=FY,V\7XHC7>@Y.[2B1@ .3:,_A ,Z)H_+G;#UV\'JF
M,)B:$=;P+"GNGDVX4L\/%/QIKEXX,$\-V?5B6#CGM./+9__B<O\''APP'J^Q
M>>.\ 2&8MLE0O@Z;86I?1V^/?$) N:%G0O,-N_ON7Q(A!Y3M#]*X>Y6C/1<-
MP#LG<WJZ;B3WU!_%-WS9>SI_?:1]=B[N<)-L"@=\8J]9!A)\8F$IS30"O3#6
M138?QA9SS#PKPB<YCXWFC'E ^[B0B_%0<"ON4A]ULG&E[#6M.ZZ/P3N0XMBH
M6-I"[[>@D;>=X#I?,*NF[#7:PE=)&7T[IDBW51-PXJW&<CNO,13]'-Q"?3JU
ML<B7%HA*X,V^3&M^P;,_+][F[Y/N;1,XQBN\R]0GD%#^<OFJ=V+#@[*U$<:!
MMC4E%[G#YIT+4>W(21<911GB;&.\?)7L[L3+2>323Z"3 >6F!5O[7GW-M+_6
M/BB5"S+[4)K%8#&Y>>-#O18&D1[((EL(C>&?<C*"YIWCMEW.EM6,T,H\$,21
MH(KA]HB2+OU.0Q$/-;SF';<M-SUD!XC[',T0<_X.U_K(:%!@RB>QV[':7%SV
M)(V4N&Y*N4+7;]8D;AVS<<,4'4.^8)+7*8/(Y91QN-%I>@-ZF86/W)1V,ETH
M/PLC#1TR4_%HET3)^4O2T%2I;2H2CP>S_LSX&A9&8HDOJ*).I?+FXWL_H^Q%
MRH^G%*1#F65N(FM=CJ[<"[NJD77@>B/3B6)2&R'II(%5JS=)M;MI^[65>Q<'
M<*"K& ZTW_W6E:P$!](HKT/GKR7=OBGQ*'8R.8+N?DK&C$D[O 6O>=I=L]L*
MWWJ!#UG !WB9R^PIR@2@"^+F\] #5A5TWC]IT>E J]=PH.]TY."S,OE;\"$/
M@A;<NCK2O Z% S0"< #;B-8I224+M@+N@P-8AU@6RA=@T)$HY):0/(CG]#%H
MNP+Q!$(X7CAPL8^0KA\AG?8GYTA\[,QH.,!S#>KR&?A3'M=K=D/0G3QW;5"&
MU=EO(]0<G0P'/I8^6>>MKQA/H[FU. ='U3+! 8[U6PL(N'5EI&OPY_]A[:VC
MXOB:=M$!DI"@P9TA 8)K<!L(P=W==7!W& @2,K@GN+L$=PL.P=W=);@S7,CO
M?;_OO6=]ZZY[SCK_=/>NJN>IO7MZ>E=U]>SY=Z>V_K-3U %.%_E]'0J]_U2M
MB6,? 0EG3_Y&^9S7DYAP=LN[L'6ENI)1NVJ-"V [/8MEO&V#3&P!2J'N'F%S
M?90&S*C4O;<*5R)$=45PS(Y276PQ$M+T7!N$NDV&R=][V'Z\6%%\F\$/;C,I
M%Z^'+YD7?4WOJ8B,LT&$S2 $K>5^<:82G/N!;%_8.2\S/#?13@;>W*SZPYR]
M0.Q7MCY#S)?<QFU='YL_V$M'27 /$E"<24Q%_Z LXD9QU(?@ 2,L]JK&3$C5
M^^A?E_*CX6-,$![R\;^)WE61$U@L(@R^J+CA5P@L3*]M<C)I!PW]6#U?+#:&
M(&'=%RZ'O,W-^N(@V+.O<*W+/_VQ-=/O?B^I"B6_)XFP9&G;P(95\)Y.\RTV
MJ>5[K"" "WL>W(W]->&&0*KH%Z4>"ZC )*/'B.EHQ!8D=XCW%;N;P'NJXV*G
M&.^-PYE&H[,2_="1C?/L@=RJB<L]ZLQF_].U_UR &TJ=_MIF/5%+0G'.]KU#
MWD",N77)3*0'] P"?]VA/>WL;=MQNSFF:<GA&_Q9OG2T:C4<?:E]?CG2[:),
MMHSU),*7J1H(W-6<BB#7HAS2GS#]5E/Q80S96X,UM9-IJM&N-$DQ4(JN!&C:
M^KL_CR,,]=I^?5!*[P0M+]LR0?70WJ8Q_8[G9;@@&K[_Q"/@#6EG8IK6B6B)
MP<K49% U:HRN#O#GL*OQ48C-F_FZ[K @^Z 7X5_QAV143VP[OC$U66?L$0I:
M:HG)5>CA"^@Q4GYJ EYF_?999@#?JXZ674!>]N3L7&)JRVQGJ*\!7H@@%E#
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M0_9_8E0HCY78W+](@<_&C0Y!UY>TK_E I6"'2@T)3\O4W"51P(-+,N%..&W
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M>J"&EZ0%"8#^^,2ZGSP"/,_3WU#GWU\_ IIO%;;%'OZ,^5)D9IUEP:YVQ5*
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M=IFEJ8GQ6>-.$.2=$OCWM+2;/X:D@(K>EMU\CO:7S8:4$;2D..Z\Q-'V:5X
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M 65M_AUSEPGYUP'"UEE@5<*Z1 ,VS,[W#?Y!O+?H'UWP>&4%^6\GK:FZ75C
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M_"ZIK7X?ZD*5V::VE6E%+4Z,>45><@U*JD:&TVA78%:-50O,@3496>&KOA=
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MF0K3+M;U.0#N9MOPAUYSO6J>@DJ1V 8EJ]V3P!X!'>D/<5=6Q\,5UVO[:H^
M@%6G@0!S+4/SL4I$YH.Y&1('6=G7?7PKQZ@J(U[6!OGMZ^96I.N*#>[2ES(I
MH^1AY06ZV6AUAWZI =,MHS*FF%I"+C<NCP#_NN;_I[VW#(NKV<(%FV#!0W /
M$C2XNP5W=VV"NSL$ H'&70*-NX7@%MQ=@[N[$WR:?.<[WSGWWGGN/#/S8W[,
M\_3N[EWK[;?66K6J:E5W[=V@8W?.!S(!EM-J%(ZDQJ<3'?_V0FP\)MFN]/NJ
M,3ARAPUN_FX9*G]ON9P4;\&<JOX<RQ) 4Q,%-!)U5SW>" ',?0!VRP3(8)Z=
M)^_&9\5-^!X73(33^>B\;[<6+&'P.N]DP?OH&<!;SA56KL#G?#":)PK?>?)V
M_XSJ:XW?XAZ/M"P] U;53M/.H#&+N^X=,G+DU?&ETF..!F3)$;@R_;4R=/5D
MU0_'/;)')MT(?_E>ID;&AX,]FH3CHZ%,7)HC'(M#6N!\7D;',OV4OAWNXCR;
M+VGP-57=#XV-?GD\SXWM$9\VP>4*I^RH(\3TI ?4DO$K-.,F,"X?^?HCI3F?
MCHTU _OM=OJ)#6<X+5<'[ Z\G3Z:PR^X+ 'H,XW@&9QQC"-.[;PX[7V6ZK1.
M\MKUU;,V0C/PEQNL$S:(CBK%!J<\C&)C_.$*2$EK*R'.#>7>_+G^=Y0EUW[5
M2Y6W6>A1&>%7P%&B[[22OB0'%8512*,8C%]R6KVV,NP9]L(_>!/>.U\))!QC
MOA@\^(3FIWC-S$?[:^U7Z)5SF/@O38F\/7L%HO .(>\=ZT-C* JH]DTS:,SI
M4QP0GT+!HIZ5.?T5$H'Y$=OLW).R8L"(0\S(ZYL1+\0;3^JG\9)&F>.%UI4I
MB'+H&>W$M$VBZT5KHNM9/H1GVJ&8XC%4!*Q-A*>>ET2.<FSN.-WSTEJ_PV00
MJ$+S4]U^1GE^Z<KY'"N2WN);$/Y9?TV,\0BQ24MGLL!."*(@\T^"WSDBM4%\
M@CQ\C1$9<RX2KDA;51SK^U(C3*YGHS ;8,J,M?PZ,P^&P+P!P36\*5DT-];O
M%QB#)$R])<3N,,[P ,)[&TP_\YD#NZ9C/X;/A\;N>76=Z497GS.7V@([F RD
M? @06"9> 30KTSL)+R(/'=V+:TE0^,2*%M(9]9"P@I/L^+2MX%"V^S:C=V"B
MX>%AG ' ,J^R%\KS/V%SA0;$Z%A86P'5'#%8+5DT1^CWS!/X,+Q/D.QR?Y_R
MF9Q^!(%?B@J 6,D8P*?EBA9F&BGX6SKQEN'M<)J',<6J^&MKIU[?0+QAKT\0
M3K7#G\?I&CG[Q#U47S->_:X0?QH]0TU"U'./-$V_@O7 !'PB!%(P#L:-75UA
M86:@-2NL=8,F.V,0>@H*?)*4$C:A@-&U6CV2_*AP4*O$+%9+Y@60UBY6V+KQ
M68*>[3J]%2!V#Y2O_]:);T35F1H?/>CD+K1"W'W["P]^^QVA#YSGU,P*RE6*
M"_OIU>XS "0^?RXSJV<"N[D(T.P;$2;<W""LXP-=%]/XF:O7*?SF?Q2=[3I#
M,@C^23I-WUK%)P2\QTXR8^,!]E)ZSQ&%:KPC]&=J)K3'6<Y6 +CG=&F;W($K
M2>9<PGC=#2?)+K@??[U/#A#ZX/0[UAUWM%%)X5Z\0L9GQ>]/&&%^:_>E\_M=
MFE<7_CN/<695JR0@ %;OI^9F.)CW\B2UC"K(&[B64M:L D1.FM_:37%Y+81,
M9B&PS>2!:.\#92!](TWSH2-_F,XWO05Z-J=M^U0!U,Q(,EOMGM?XM%@MX[40
M!,]Q83?X5D)L7G+4.TZC=4WG0-TS%TQ0([2,^Q-,\"TL?87E=>]0,A6W:6_%
M:=JIU4)A_@5^17;KP?A=^4L4U21U$FG;Z)I[I@B>ALXKL$\W0!8HRJNPHB/"
M2G%IP!,_S_3\!ZJIBO74E:Z;#DUZ^HC\9%*^'DX3[E4?)J=H!5G$:T]:?2.]
MPZ-'N_T[R-BS.>_6L5"2SJKHAVX0>M442N[.6#87)KJ5/SLB";_/N^H4D]J$
MTU%"\T!.G%2H.W 7E7;#6"AV\_#K?LFS' #/[P"FFZ0N=)\_.=+1>0;HZ^M@
M%HE6=JQX<YQ>YV1;I.IU5_]4!S<9QW+,;[H8RG,C.RHT;& 5>:P1H3X#U*JF
MCMGJM<_' \5H PK("=R )T!HO!'F;N<I=886C>L,_9:;^X'-*"#R+K[6S*36
MT^@72\D\[$T& AC#G:F-<+!#M[ZFDHD%]GO4WXOM'M;._253ZK9RQ[TF*O-.
MZ<W@9N6U**#Z;A&> OS8+_@BJFN-'AO\/>&/TX>?:N+LSIK]F*A.9P41+T$7
M)R$A,T]4I^+Y7)HU"E55KX0?C^$$DE52]SL..(GW*CJ?H+ X&A8,[_#!Q!AG
M1=3ERAU_?KV&''\6R=K%%3<+!T((^GYG/DYK,JR/"Y=43[]C6U[5MX9^#WW@
MMD83:U9_B-FG]?YPT$ZW_J[Y&3!TZBN;]U4W+M6S;J1@Y2(O'9]LK;%RQ((T
M(C\=V#>4O'.?\PR8UH6?VP4YZ5+4,>A4=HN]GRA 4I@NE>5$!?8O_,)*+M:\
MT*%C\\#*WN!T=(O.2+[)-^.;U/,GL$@I -+%(2HST80J4)&#U&DWHW\$7BC+
M5%>294.#+0R@\^AP'&"Y*R-IU/D[N?,ON3(M8C\$:6!..%KD1^/#.WXB)[S*
M8W_#3F.(0[2/6)^<J02F@<IT(^9B.U\H_I#*J@H3OZ84* \7K1NM-#4!K6Y-
MCW]WS86YRB'#>:/JJ+#**IEX5,+QP&I90C1\.,!Q= X<=?2,N20929R?^%C/
MFYP _WF7MGJ0#X"9\E!Y\\;Y58WS;>(GQ7TW8%$9=LAZ7).U9*MK%S, NI_=
M=&: H.%C/2I"CZ,DEN^-D%>(6K0_0;3DZ)1:.@MC96]0J.;EXXHT"5# !BE1
M&U^!K%9 UH?FPB*FTXD"'>I[^)J"YW*UN_**M6V6?R?J%W632LZT&^:TR.3K
M/&?I!LJ,[)#UVW=0C1[A;H1>:EY+%%\=&@*9\.QDS5(7)QFGUSMBP.NYD>+U
M8+V]2E47JJ(B&Q0GO31:F7?IL<+-16W ;JFB'^\;U*%C%FI4IQY^NV S!S-+
MKGAAF1&;E&!P&4O824M]&P /M7]5!BV<L!)^[K6T;@S']Y]C/$TK=^^V6=EU
M&,6-YG,G I3K*$5RZ1"T"3JCCTU3.7)[)MI64,C"="([ER[H*6N*/FY9/_DF
M&"&]?LV/=H9/-?DEL8P,Z$Z2KJ@C(D,7;:*5:\$DK^E;DV#?MBC==JH9<SMU
M+9R;8*2/B@8_7] RL62=T_J5T;;7),VPZ^GK[#4[B]BD!2\K=:PGHKGV-]RB
M6G&C4<_ PNQ.N&A03*.J>R8031ND*+WI D^6QS9AD1VF?B[J]U;D_(-\"Q(Q
MBGI#7>RR2"P-7(D,.GT+*L%D9=%Z"TM%#"=_L&=4GEH3?A'-'GU?E=B'0J!C
M09WG)ZEO8[H3IB!I8VMEBY8B)_FY\^-AF$5#QX)WZ_$#"OH6P=]D@_OYVO>D
MM@.G5#].2A48$U!1$QR/5YGO*087J?4;:)LLQL[5[F/O/%;J.8,D#Z+I0&]M
M&D)'3[\+EKFN!BMZ.6BI[GII 9M-0%'8QSZT34)2993R@&//25DUA/0:4B>^
MGCZ6[))JV:Y8.MW.'J'U+*:KC0,-ITC5H17R LP(M!H+#_ZSMOQD]P)'_I@K
M6$PE_<^G>2\_JNQX"P.=O-P0XF2;&X/IEU5F#3S>,@B-K&KQ<W629):#&*^,
M&PP(+%EFI?)>7^&6AL>QVH&!F!_+"79HVRO;<=OAW;C6BWE##ZW,W^CI:(5\
MJHF=AQU-3,(1\.Y*I$BTCEGYG'@WT_+)W=&L?IPTY63MIYD9D \F>73$5XTB
M5N1Q,6Z^QH*_'1;SEP.A]28S(D)'>-PE=)ECZVG",DD-^J>Z?@M02<^^)IGX
M( G7[8+',^"G)W'U>WO;7JWYYI\':[9%I>^'GP$AWF(,.2422.496U%D7"04
M.40_[Q4 P (NK'U,]>J2D<3O3ZWEV?&8=7SY"D&I0XV.^P5=;F;=/W6E&;17
M2QV"R!VW-)Q0?K9([A05[ORV6B>"5JR=:F8M7^PO7M9EV==0+C7FCQ@43/2\
M&.'F.P-=%=-E 0]<:EIPEO8V)7Z$;FKX0IW]3"&PP%<(T;^1F<;L]:.?X132
M?#C.3#MG84*5E_="=QQ<[:Y&>Y]V]Y1'&;) \30:\5#C(:0W]! MO+#[NF\G
M/$,I.ZYWIB:N+EO[]N[KC]!N2*J ^$"5LZ0GW^C>S FSQB@R\#U\Y_7KC7U'
M]P.=1##6F+5SJ'.)#>7TASR]']U;.T,D1Y ,S=%)!U,=HT+=]CS.CV6*K%9<
MZG0DQ/F;''WU@EMEE8O[.Y?%PL$T8D^P@GX#=TD2CTW$UG3-]' :AH*EC#!%
M3+!Y:(]TW&3FWIYZ8>GMYMTS0,%A#A(PRDS_+_TE^__V*+7#<+?L[=;6GC60
M<GB;6\+FN%"O1>ZR*_SN+F:RQ7I<#8^+G;J)C3).W2Q:;LV.Q#RU[#AL;;"I
MB(V@.Y*]I;E)(W:*6"_:%E9>QEG?_63830!MPELXN]O#K&S_&3!O3U[X(^7K
MZ-9&](,9/T_<57DJ:+<$E"!Y7OWSR""]+X(M'3+WE:L(O:CR9]I3+RYYO+X;
M>Z7Q_@P]X+<KX>?A@4B_)<L#*]!O\+8@LE#GD^^O9X"0YTA%V\A#[2"._"-D
M]CM;DK&(!N=RPC7,56@C)9S?+MRT'(@J_T1DCJF_+/?I7Y3:X3^(1)]4V7.8
M_9)G;NO"M-Q>*%KK"AU8*^N(EH45XU/ ]Q9;;*."."$=LP+C6/S=,X!GNG:J
M*^R'$-1&A<)3C5J:*_>TN5K4AVI3V< TM\)NFWZ3)'(WJ)82'B^\[">BCB(I
M5KRQ-!?M;/;[GY<3#I((*H'M>49@RW!;4NOQ^LE$;*.V7),YL:\.ZR*PE![]
MA1?B'GG&#:$(ZW%L7RYSN/.,%CTG^PN%VXL0<L>.)1$W4M7(LN#9KHCVV)1-
MOH LV);FV!!%ZU>G3IV4UM.J>QV5)DKGEOJM/YW_O"S:VAE[BW99B/7+%L4E
ME3+)SB7K0S\^7TK,8LQ8 !/KY9/S>@U+&9V$"N7R$W5;I,U0EUGJ5,#-6_&/
MAMV/$U:(5JR$<Y\&=L)3]YSER(]*<U?%F2$+F7@.X]JI2SGJ]D*+RD+X<-<]
M=9-)($B!M1^1W\?G0&!!J7:<+_FC+9#/NWGF:NNJ:0X!6Q_7TRUK+B<]/R][
M/,4M%"\D4;;Q(N;712D"HUD0;O86B_NP\V$1)7A!BN#7RW=US<@WL^)P[^V2
MU:6^M=N"YFT>SY?K0T4"'*%1:Z:#@)8]4CHWZ:Z1!1.9M6/3Y<W;T?XX $9"
M];*\ZH?>F*UC7JG,.MX65!T5M=@K='&6>CS<;IY1V61I[R3&NG(QG6F;+K=!
M 6%5+JXC90GOVK#M'J3$=PZ+TV(PX%34YC%DBY9M;D,6S%7$=9=TTM7&Q0W[
M10$[RQ.[8_ >T"UN4*V=B\B*9:U[T5<S;,3@Q/AKSM@(:YQZS$Y=3+63FZ(\
MKJO E>]L[FH/E/[#3$]>?G.Q0C26@M-,)3!<L\_7:>OJ0#5Y;/8(-OTFC?QQ
MD(/)R^N7,)"H>M[EL=J64P:)H6=W)[TUQ#;X!V-XDCK=5D!.+*L6A_;2>%.$
M%+F54?WEGGI*6D5#FOO1,',H7)D^C,S>%Y/DSO3<.S-0Z0Y[Z'+Z.'H^?O24
M:4 ,@4L^<?7U@1*X>JRG1I3,MIV0:=?2*5S51A7F-.EGT&<\9R++<H^2.P[\
MA]Y?GM',!Z "GD.P&'\RB"=U5),&F3(VCBTX$+P1FN/0PRHWS)9J4DM35$>5
M$,!=?%M@JP>^?#N'QS<I-0Q?QLDN;A,6&!X9O^6-;Y?R&13%=BAC$AM-0-94
MJ,-$<Z5HY0],/3F*NJ/%>!P'#52(S@[H;0G&,.$]G"D@Q63HQT\3OO*A=?^U
M95!FZ.6HC=PV+\ZK(LN7AGIE+09F[B^*97 GLHPT#3^IN@AWSF>#?U4K,!HK
M3Q-EYP_'G?F-?'DW&W2%-B*#[E>"->0^LGZ^J%7S[8T#J4\=]FEZ)@T5*YT]
MD]/GJW+PRS1*0MRYTUO005:=L!TW\+$A80K;5"ZW.",=JOW=IIF-JAO&[*_3
MW#B9M4$+V_>16D2Y-GNTDJ\99F^C8:D("9%-U*=-W"WTV+@211NZ8N%LA:D\
M1H1-VZ_P-@IPNZTFO )FJ;-!HH@[8;4;%R0CC?A_+C]^'[FXLBR83O#MOO<B
M-[M4Y-CNA&0DR<G/_<EY7EN(VO3I[&'/C;/H82\[T1_G3['M"R(6),3[S]DW
M&2'4?VCR)\9>_:&)&-[WXY&FQCUZ>=5[>;*A!S!L7[W@IIZ<XY5QFUY>;>U4
M;B>4( S+!1<Y#A#I>TS 4>_4>/U=JC0UE!N)BOC&O@5U)KRM0'Y$[Q0$B021
MZ/UYA[KH(\>P <[_-I_4\@['X8H-@HD% 5PW]LTADO>8R'K_XJ$!'&;\BP<6
M(B&(*LK-]B>*VS?OOV*+5WRU>9>JFZ$BEY<)"SDW@>"U 9!S<7G/5&G>,>@?
M/A!8[A]A#M4,A%\W0QOR@) V"%2;W(V+ 1@4RO $JO\B8O$QS_9'_@M!#>7H
M8^GNN[.AJ/IR2;4_Q=\SV']/&QD/AO&BJ[\)TXRO!$EB#L;HA@4X8_FP+*+N
M7E/ZG2PF8&B$2<ACVV+EO)]\0EA5D;R0-G'JWSN20^E!0>:GP<';KN2GHER:
M;?+8R&-<TH8VG.Q7;AYC"MZ7]#UP>)SL*R/P4=*,8H(5^)K GK05;D+2D?,N
MDE97A:- W_E2A^C5@O826MH7BM/.&"6I;,DWS<@4"FK<I>YY[M^HNTB VF_V
ME3^RQO+_ H'5:WE\:G@RWE;B@=R#EQ*@>QD0J-WQ!!6T%Z)T4/#4SW7X-^7]
M>(K!T@92'A].DWVOQU8K-XXW5@KRJ;>!SC0M*@^RUN/B[KDE7%_!XN9P05MR
M4))\(%%B3+"% A5FH8*T%0>K9-8B8M*07G+Q7 &J.5'O1*!<'A:YK#MW'MP7
MW33E'T=<P]BTJW1CO@2->MH'^%Y,%WQ9;$(W/:)^AS4[TUDY^TX6^&D:T=BP
M\KC0-_%76$JN)E-A:?@2PGQ6;!7H!*YUVGML@TYP431/Y &L5^6<2BWGQQ_'
MN6+G51HD5Z. >NI!)?-2YB$[5 OEM)\P4K=2C&/BG">:>,!HF7"E>5,C^T:&
M,YUX5*UCZK=5U:W52ACO=AV;C[$RW#[QO>%,S>GOOXTKCIP&=S<F3:?^-'&8
M!_!\CJ5+"G"-/4I&"6L-[M8)4Q:OZ4T<Z?4WX;=B@5<ISF4.5N[EA2]CGR5+
M;>*EFK$Y*IMF;1G5:T[5=.'FBWO3FY*^Y*X=,*A0A]QKCY+V_43)T@W[FJ&B
MU?5UQT:L>6SEFZI/-CI#D61O;L/;$HFG8VS(V/!\^@K1WMU<%:RL*#C1Q')=
M1]3SJ6+;V]%OKR5EZ8Y9'B?FQ'I]V^USJL6]2(0_F4YAS/]1'XGK;]*C,^LU
M56);N8 GBESY+G+P2&TT!J4JEQMYT2-B9%VPO\")JH$CQ[M*AVG9=37<N9S6
MV>+8WU@DL.VJ+._+$EOI.3/W*MDI;=GVK%G(%30A"'OKO0T*JQW);$!1YRJ
M>0I,EX">7!YJ7XPMWUGF$K7U&';D5$2L-8"FS.-;,_R8?DSBL0C5_\X5*X=5
M(2O!U4VW;[9'WK*AZ%-T/SGW$YG<1RO6!FNF*=-<MI[,;(["",F>E-LQ)0(5
MA")<!R7\+)QJ>-69#;>>[G[N:_B[:9U^OH4&@WSMLMWO;'4?-'[$>ER7_EJ+
M\K6HTEI2D:F/CU?^8KHG/#0[*6%)4$[#@VC"'&YOT9#';U%0QD+PRDF.S31Z
M^DT7.5M\0S>Y"FF(1X5P'4E]%'\\XL6EWDC)OH/^ET!K2WAE.L0E-"=J[>$[
MC'>+POS[FU9I^,7I0B5C_O;\!VDW^MU-[J(":/)7UO-? '>3I K2C9D9W@[J
MD5(MDA_?F0 I,UN18,,O2%8COEV6O8_ZK"5 ^;C\V26P'\J/!?Z\S$("[!#E
M&JDK9O!)W.GPVP/>T:62F%O&*\V7W6R<W3=*RU;:K@DVF!HW-#^E2F<N=0;K
M .4DI%\%.<9_X?'#NBI!YIW1Y=\*1ZGQOTI*5Q;88D-%A,BA-*EU Q335CVG
MQ?M#4XF):^^)O]K!7YM/UMJ2F&)X- D 1YXVKQZLY(LM:ATU-?.:ZYST&A,I
M+2I;?G1=A*.R1G6437A%O)Y#E 2D.<2!MK?/B*802)E$:;/E6&30WYM&LHOZ
M\[[5]?<8Z?!$UR.%^@SS"@T&/Y2>/D>QR.YMH<TJ+8#3\]%<Q&3ZSQ:Y? ]F
MOU$VR,I-C.T01;<MN^XAN74GU6^%+(J2\78[XZ:O8(@.%[.F9;/[&< W^72+
M^6\\83L01GGF)([DX4+A?E-IL_=? "?8<%HZM_ZH)X^"QW/J\Y>-_!;/ &^0
M;CL0,;&.K_ 9\!<_K> ?_ISD#T83,RL)+S0#?PI;$R#4;T$+YSF0CUK=*FU)
M0)A_G><DNS);6)D-0(@KMB1>\ 8#D8:5$6+6MTK/  <_VA?J^M8$'&A\T/QY
MSM/ZDZK'7P(&.':LJJW>Q^Z'PO.-EW)=4WZLRO\J0/:D PY&W8=!:BNXP3G/
M7F>A+O.C%X30$6O[_:&0PRK[(\H95#AFW!)K&SB26:[AJ_Y3C06$J4C75 ^K
MZ+\@0]G5#W\ UO\^OZ:ZT3C/,?9S\:,%#&=7U_Z?GXYD5[LRWDALB7<_[3X4
M0O,D5G/\QZE 8L6AP7'40$38X_BM(BPB[_3CRSNE2K]&05HAI;R2!9S[' C5
M,\#95[4M1TQ_MG6))('@I3 7EI;V^ _+GS* 2G:Y]1^JDC]4/+3;TR_"^3]"
MU>RRH[^$NX*T@"(QG?F?@><YYI<0D=J?FY0(FE]B9D)-^/_9NO._V+[3VM.]
MM!KF[?I3]!D0*:4?HPO??7G!1X+HN<SXY'^%X1K&8Q^S78'U:#V:+D?)-<P?
M9_7&R]X"K<;8TQ6__D2>+Y+ZG7&X=[Z_I.'J5<'IBK8AX87"JG,N+S+=L&2K
M<Z#\7%.,:+@]-5%(R)'2!A8U'MM2;BJ\40*91/-Z=!%149]T&@C>6"S\8R??
MY);A$JRXE&UU(9.E]'?JWID<HV%!>%]SHSBA0R85_TQZ?HT6NJ#@]7B5RE1%
M6+)8@,62^:LT6-A<W (H(6U[ #YBI>VR3R*.#-EQ.'*4L7N^195L'!KC<6 L
MPI&<9O/L5H3">Q;X(L*IU#<8TD.+UKHS,;/KQ4>*E^G8=[AEG/(%@H>!M[\4
MV;TD_#M&RETO^?WP+P:E]"6A/[>M3L<XYT_/;G@6 :Y&Z&C$0G-'(L\GZ#+/
M1=00+ZI)MK3NU/(/]BB,:J8;P34:LF :CAAJ#1ABXM)^-OO%P%;ST>' FV(M
M!QO*B*9'<5XU6+]?3+WL<=>NICIAH=!IF\BGM#2E"XK1?=!'T-26UK) 5??7
M"4YIS@*/YK;K40W9!.Y=DD#U+C'WMJ<:&'3JB+E<ZZM1616]NJ[VSX2&)LYL
MT:@?]0T)3792A2F/BLB3-.OPD.!Z<<DK+LKH)+.#%S#09%&;IUTYH_CDC2.
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M^#=V_L]@T6VPS=?[A&GP7S+!-;'?P">_&K_[1TAX$%3(9T>JS>HO5UP06V;
M\+'CMK5,M^)!/+7A0N"-=-J9]NW(X.D9(/'BCLG"G 3XNJ+%"[3?2@(XO0]^
MEL^ FSO!)T[U4@%D=S=Y,W,[%]%FPY-$B((_( TN&FX@DA5:AN D+L<*(D&Z
MA$00H_;7QP>%)[)2T=,3R2\H=3@%Q.49#W(NU:KWU*Z<'HGTSX#!WD?O<&IO
M*B/ [:<&076#TQ)1D5J#6PO.QTO!CNK=XDW0+O"#GH<=I>DSP%C';U3*C_D)
MZVN9-^\$^T*A+4,YH]*:<M@6#T"8>X?6JCR['*5#=WP\>3JMN#<VIQ&1.CL&
M]L\_J K].%+DV#DK\'@&'#Y50]%CX60\C1Y(O#P)O1U7^JOX_Q?^_\+_%O[9
MCY(T^@PPNRH,[:>:\1=\GOL_ %!+ P04    " #G@W]65_.QMH#8 @#OYP(
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MNZE !=X85QASM@ ])Y:CD1LC\4U^$=>3/#O3Z7T+O'[+*4>-Y'8?O>:]H7!
MS2_.-@4^0S;@A9[)$SF*I8+*D6F]AGR0$B/>3(HWYA,:!V$-=VTX&-48=_;L
M7/**#D>R2-=RW@0*0REG$M<@S)K-;\@H4KT%G[S JQXI%]OJ%/SH:7#83KA6
M<42QX)NTU7-I-_#VP$90L4+=@=[\261Y99$/QCZQWVO4F*$<)7*^\%H4T1G?
M:G[TEF\YB-#PL^?#JCV.RV]J,@,L\7ZKT?/-R%KH.FD4W2WPZOJ!@VM0&3)X
MF;;!=&A>H]N5K:*34\'">-Y/]CW9;!%#':J-=$FJ'PE>HY4!B;]=Z*&31.#T
MJN!#M3XIGZ>SLN*8@-K>LL:23V1T$0;2=-(RH6WK&TTE.:9[M/*?GV7A-RP_
MT_13]M[BD.QS8\8/<=SN9!>/JU<=MYN4\5S]/=)9MG:1;I2D*#C(D$7+0(+?
M+SW[T?$6:.2(O3:&LQ^MNT3"!YFU)K9:4>,-[=-4DE0T;-PH XJCEUPRJ^[+
M\<;+LPO#\8X%NXST2I/MXL4])3MT0=5IUG=Z#1K=> 7OGS[7!JYQ' ^K?;[(
M"=4APU>#L/JD/#[/[5$]6OGZ.>B7^ET)O$4'RC&7,I_.H@I3Q87RB ;Q%.<W
M'XG/?* .>S.C?D7?:V-;KU?]U\.;A>7 9\K:I"[3%.*D(D-T#'5,0+7#U=.#
M[KV)JAW_WM0FC/%7KBI'!R:TBZ=D*8#NUG*YT0I[GLO#V"NA2[I:8[J$P<*E
MHZ=HI0UE;EN.6SX=CA;B1,/J]K_+A#V-!H*/_,4#)IW^+BVVU1W#:@H8;UM.
M3]14(%DZTLSQ3V!)$P&N,X2<T@O80YF354#"[+$90/"N^-^,LO6]J#"47QF0
M9HF;@G%BG.IQYN*-/\T/95862F/_0SC9TZ  ']K%7OKC=N]R8DH]1=/3]VAS
M"?H;_G70@_T%_U#V73L*@*K85>Z]CH%"6]Q#]EV77<!3UZ586&_]L2)'$: F
MIS_J#^KE+*YS*84]X\1\/$TOJKKYHL"I8QMC_W2IOX 7Q"IA41S*3N)X NSI
MF^Q]VM'Y/= !F)_<<'5Z^T]K226(=P"FPMY%QG+6L+**PS(34/. "99>WIO-
M1TYG%M--CTM@Q8.EO%"*Q0RA/UZ0C^YA+LX_W1<59;0D:,M.H>OR5Z[8'RFC
M@2"*[W\$Y_+XUQ9\?].-"G6->HS? _]+L*\10$[? @^;!IC/[[G>8("GY%^$
M_&9N5[X%+ AO@;PQO/GGNE0%T+_&)CP$KW?!Z ?HTM DB\ZGQY6@*[UDP0R2
M82>ISL[LM\#<0S,Z-?LI>&J%KFO-$"FS<VF6%ZA<7J",P?"!54;DP]F^+"HE
MY>KA-3E:=TA[.'HOVY\&*E:J,/!^K+_+I!^R[%*RI\ T +_XTNK:DX,_YTBG
M"VEL>$I+?Z1Q"_0>'&J)KEHV&O81+K'+RG?[F_>8BIZR;UZJ_: ?'-37*K@[
M?VDX!;8D0,T9'"LAOFBR)#+ ]%OB$I0BWI']O@6D@-F;R$!IL/O&Z#UGTGOU
ML*#W7.1D%X$S07/7K)1#J)ELYJ;)8'%+$.9O+3\(Y23%QE;_THIE:MO1G"5*
M18OA%IAM2$.%RWJ&-(I$K] <N'DV/8UEOCK8QIK[XQW$4&?+P;.6$RJ?NHA"
M:%.P#STFOZI^'UCTXN@(. ATO2)=&.*(D]'W"(V!?HX6>^EFZG??89;R_&]B
MR$E;HL?EEXOS+=>^?6O=<("4()"OZ4=%<)VE^&6'W%04A\VA\'&"9_1ORW75
M _7U(R;5AZD).<1.H'>!J4ON+)?4!\A@+XPSCMZ$! LRI UA<5YI4)T.UJ_)
M?7>VX2!2"<O>Z-^JZ^('LAL";RV@59FWP%?Q0G%,0E5V!\OSPHUCYBJ_I]YA
MPTYL?+R5'A-J/L+,NEHFGR@$G($:XFC55)E:25X_MJG]9KUH* 7&J=9^!8+U
M2Q?IJ>SC68-IPV>S H<^WR_(/B58T2@PTYQMB)ZYI%49@0WVW*W]</9YA=B:
MWDG<\)S<T_1*+L6M=&PMKEDS[6L=.S,=X89*$H,%=7*@VR%D"LRE7NF4"/G7
MM\!+5VK?D*&P7@,#U/U&,RR1D)8<9IWC9*3A6 AIB.,13N 3V]<K.G3V^?YS
MNS11)ZA!>9Y@/+DIC-VV,F?1'DZ[!Z^VE?D N6@[_K^9A2C K\PGZN3!^6],
M.[%,7/=_=T?T<0QS'#18^#]?<,7-6:N// 0"D]<U$Y"*M\!J?J)OFDG$>D]/
M1D*HS02DP?#52-M2S,"[OG9,+,A6CLEN(-Z:N9+934$GZ[7AIUK7_=2QJGI9
MKF(]>F?R)Q;J;$#L;ZOW^BZW@'A1$#6;D]!!(I7RJ16QC-@R'M9$_7E&,+;'
M4D[Z"H4,1*#?=:YF0 \9]G16-"=Z?%%-E%@.(F7F!&;<@3TP;],5)*@9[A+V
MV8H^MX0M],[X;^V?P&LK)XXMA7O]B6$#YY*!H^RT!4ZV/$T/]!79,JY8AQ*V
MF$RL41??Y5QKJF0.)' 4L4HH?NEE<(O--UTDY7T_# Q#N]RXTWQ'[3QPU_T8
M=[]?@0H3#<8X#>U)% WQDA?#"\_75,X&Y1H*KI[M7)9$!(L&TB![;,#NY;XV
M2@%5TL94G]IK(!"OLIAWT4*/WW=OY#&EG(&M6TOE=53651[=.:V<:IQ\L>@2
MV(0(4+1,R&'JQ!]=2WQXF+!FVI;EHS?#^OA3;QQ=X:,(UC3O09@4#MM&]#<D
MF&@%N 7 "=$[ZU[9C%@#$PM[='+UB#H%NR<+#^L>X8&YMNEI@1>=S7$&E MT
MW (7SZUT6 J'&M5F%+=[6!K.6TU@)BME#!DK9<>C7^5Q1URO'@<Z(X="B#(L
M(T0)-8,$M)+4YD1_NE7ON'C;>(M;4VRP<?7Y=7U94N<+6<VQD*]OCMXE[$?!
M%,%\E16"PNH/WF+S)#>3Q1)<]80,Q;KOJ/<+-BB<]C%-9D(7X"1:P@-H Q&
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M!T9IQ^B3[,8,H.[UP2.[N6Q8*R\;%H+R+Z';$S;A3-\E:IX52/Y]G"C!&[<
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M]O@Z>L4-)NJI'S4G<15(V%IYW)'+G3!=9AOJKJ# .,_9WT#,!6I/F&I.F[]
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MI2TY?/O^_&'K?-*]YQ"?HL6BI=:6V&]9XB3Y:19C^]?J1:,EEGU;)D_E?&_
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M<T+DO-;UGUI8;%\#R!+7<BN>%UE38[AH@-];WE98#)1AXJV"4E!4CS6-PN8
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MQEDW40XH1\3K&R0Z:@^E )[J*-G\_TL_Y):?^)[]P4S 74D7%N[%V)H>N.E
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M'BGJZ.H&,TX%YDOC\]X,RG"6N6=> ZQ\:*&G*C6? @(RE8*>27@4< D#%,=
MFX&JJR-*![+!(P6Q<D9G:[_6O#D 1*%AOU[J],EX'VQY7RY[(9.^F/?._*$;
M%=2^^T,/L-M41L^MZ.[HC,$3@P LR^H!S#R87;&G9Z/0U],;V!'Z+ Y5KJYR
M!CTZA=GB"_(A;L"J (]FZ1SU-#Z_?J5I=1>/$_0]43&>7\?"U%-3S'WY?L8-
M)5$6)^X;(=ZM>@:Q=]_QPK0$*MJNP@2"F18*,C=U7 "-*I21OZ?-2)<<97O>
M;[?=;X1;5"B=#TN,A,7PBL[I-3!?0O)3\&D:W F/?G76D$;='S>^+UA-D6,R
MK]S0JM?Z 8$&3>JJWU9*3?<B>$2!/%(AY;V/B(J3<X8!Q:)[7^++D?Q.)$?\
MP,)\@E"7OYGX+S<@VW<*;BS=KYE#9NQBV37 #EQKIU:3_E.A/EF%(9LCZO E
MK9\)W_M.#>XBES_V<1E)FQ.CGJQ3\34'U1/<X[!$6\1;IORF'43*6%<;,[P-
M'E?[A;%,&>I;VW+::U%9"J&.<V/?=BN<HTS?=%:??G+//U[NPN3N)&]^HN2(
M-\UL^B#/-ZUYU;4;Y%([T094@IO#R83NF/RHC4=='')7#X*!B_C?82]^"L.#
MZ*9>A=_] +WCX98B)[IC;5@6:Z030&]451NCMD;#>VN]5XXDY9.(0_6WX2=]
MK/%]SI09&@;N(T8U52Z&WCUIZ',V+Y,$I\//8Z2M!FW3PKO>S1 6Y(&DU\>L
M)%A_5,QR_3MEF ?R:KQL(9=WRF)GP_OM5;:N4$-;\]6MRO8Y2C7:WDD!,O,<
M\K.(R7IDPBZ&$2FNY)OL@(@BDV7N\9#A?#2U6[[VR<;KCG(RCR;U3!\Y><-I
M*66YF<7RZ"FGZ@-R31U[I<15]D[I+^^PA5NTQ:%):ZC&J?*:C6?] Q WY^4D
MVX_F]>_=I[AW7J4:F&=KQK_\TR!R1UV?^NDF9QM\X!K0:9'[7/A'O]BOM3!*
MYV!G?R/I*X7JLV'&>CU&%4>N.Q$!MX!;4X6Q4^D.5RX61PKG\"<239^G Q/^
M$_'T\=4L0XZP.X<1.R>6L7TJ;%/G2.<VV7'D,19T0*OR=]CLGN0,7]-.R)UM
MT&E70#3H@+"58D@5Z],H]F!LV/1OVD>P/EKL8QL'PNNX&?>U^8,M&"2B+AT[
M?'ISICG\I/+327RS F@P,>^,.WNWC16I "R68+Q0+U&_\=6FUF:R54PG8U"@
M S[!'67SR92OS9]@C::L"#]YQG8-H-(M:@DY0,Z',VSY7 ,XX90#"J5B%):%
M+2VFX(NT?=W[.^)+EJOW_ZI_WB+3KI?['#+4 K$4C5X=H\=,"<C)63S<FYZW
ML'329?W-0,I92U?\-."@';-:<CB_I'X; K4T3I\)+T=]@J0V7 /64QJR3 Z?
M[C- DN/F^L5JC1-MDHTJ&)#$($BNU=X4+#]">#WWG<^5\3Z8&TG+)B,C+3_#
MCK=6=DJAA8:#W\-#^RBK^M_^R1V'C-"&="*:FV*'/TTBA-AOWUK]O.6'KCFF
M87(Z%33[-<ZE"J(+?!Q_*W&;B=+CV89.X(QB[NQ0P$F1*U*S7,3:1N-!!VE5
M>82'QT3:]+O<DL=63J"P7IV71C;Q@)M(LO75YJ3%T:XB?B#"J0K6E*@VT >&
MCV@5C Y/4@W29,'@LM-1VS)>F!!0[,#0VSGR2?C#B;4$GAJ.5L_%O%@=/KWF
M,(X1>7$KYFT[J[IL_LPLF*;SL(.$A+])HC1W%G./^=>QT\\>:\8>"<,&,8/@
MVV#!R]:,J<%CAER.(DMWO62&:)_3PK=.IC'#RI0#5\:0W>S7[@9S&FM]GY%I
M8P>?YQ8_143;L=6OZ*R5E(L;[G$T(23$CT;XR S:=/:V"LHU!)SOO]8Z]6,W
MNI>PD43NT&.G7S32)!E3:S[,3$(,0J;;V_ ,A)F$F/0QO'5>KG_;9KRP\)8M
M=MM\4,MUQ(9))$[*CW/:#K6H,4#R[0J_?"<<J\/)R#RM//=CSX;@Q?"HW_9B
M;^P*OWI0O.'VWEHPMGO(X4%46GW*5=R!LE*2HVC^UJ_PRT6]S2N&Y\-W%$O,
MRLE$34YM-G16U/K-C6NF6_6 ;^VXM/-JQ/*UJX5\2N!U#/N-<E7;&8_Q7\?X
MN1=S3*A&M&&9^0"SL C<4U ->_H33V,TPUM35%;UX*"'HN"@M"G,T)A!V%D&
M<$MK2QY!XD>377J_37X:R]_I_S4O>Y:L3(.0MWQEC'2\NE]992SQV5O,)S@S
M22AGTI[+;6/4IX>M/XA!"Z831&Z8&N?<K[R=34G<@7]B7F:SB7[M+]"C,Z(G
M;EG(RQ7FEKJOH'7,<PT0K&YCRB24<Q-)RF,B3&W-F2E7_'Y>@>FXGNM< R@6
M.H]2),]FGJLQ47)G7G4T@6.BCZ3:_\Y$M C6$RE,+@4G/E2-A=A;59CI+7MJ
MK0VW^[.03^MZ>>E_J!K9F^NXR2J4*PB;5B4*Y*S8\%06 .5^^3GEJ$\QI_QT
M$4\.1<#XT/->V<%@N) 8*#K,)"]Z7K: D5YBBCG@-6!$7]I_LKZ>?I' %\K2
MZ']:E&=9K(BQ2GTE*,OT485Q\CDPA_.2HB2Z48?4P%QF\=GLV*-4[L#N^R,W
M&=9YPU1VGW@>%<]/R[:=,KP1.6&=_J"$M96TJZUG27X!J.JQ==U!A=Y/R?5A
M4Y>;3"YXLIV1"%CHPQ5<[J6A\WC(!H^*(FV2T)]NV[QKE?,N#4C1HE^]4=)9
M,LL"HX2>>YJ0#6D.^13;_39=V]=UC%]D)XUWBEGEB=K(JGF&>KFH(A[[ZUVK
MH-BQ4U#I8%D!W\D#6=Y*Q5($]AJ ^!_$#:\38WP2A%L?\;]HE_^W7U0@ZR9?
M?(0 ">+_S\H8AO[?-4;_:Q"WZ_^LS$E( 0$>*R76#@*"^# NHE/_#7*P_1\R
M:IDJMX]S79B/\[-(W;17E(2A"1:XD/ WTUZ0I_NTB^O@2V;:SCERO]=R]=I[
M&%ENK=SWWM2%G\HDJ)X.)6O!O?C*RV*E\+?RW5>Y2%'0BHYS(.STVQTA,PYM
MQ:@(O9&9N![?%,L9H5S44/'-K_L#)@UW@HV= ^?/[2HT[CQGUDRR4=LJ>4*^
M8K[(-V5MB;O*+>SA3Q*9;NZL#O&J_D&E9,N76]T <WFYQ 3MG.H*ID%X$T*F
M1+#O'$,FPG]9<'P@-[06WE*F<!-5>'T-8%&0"2AQRA!(9*RM0O*\=6,7^X0I
M"=[^4^%!D%R1#_G43GVD1PZ--(\X.=?BX(:$"]L+=Z]N[""KE.2AI:8$#7<;
M-&']>PN_DPE;J\33*S\>CQN5?2JRY><2)Y*)[_8#2H\@56/ X80@9=+A*['@
M43E^;/:*'_P,'NW:>[#(6*<KW!@S;YEU,:<'#IC1QS%UVETL6RY1P"EASS61
MM1:JCMY^=G=MM;8F6OVQ%3UNY-N'CG5,<ND9/XLP%/$]MMPW?40EGLA/9[)#
MLXFT*-LC?TM/QQDF,#@_T,J&\0>6?\2&^/S!W8#I(3K3) /'6?D*L4.R5TP;
M.PCB'DYQ;1(JA%:/P_-W,_EG=OXS3FA8(/:5UEW4IY<) M\ICA9J3:?^)6IM
M[-OM+, Q2FAF]SFL[3=NJ5-)O28?HS\OR,*#(J&S#Q6/'6V5N%A9ZN* Z,X0
MY=WRMZ[L(^/@E,W>JE=I:^]?=C7>),UT.HO5(4CR1^9-7MVPQB3H058@QTAO
M,Y3Z 9#2G#GQX]=@6^:+ML[FX,I2K1&PB%O!( J^\3YG>U;1[>SD2%'L^66B
MUSXU8:I'B0]W&I,_=<5%Z.TU#,EY]JQO0VM0UTW 65V69]DSY<QS930?31,6
M_!2I(!.4O95YKX4-$ECE4)_RSYC\Y.>%&QJ<B=> 7?\HTQEK%B4. ECO&YBZ
M>MH:-%5K,K4V^0!>W7JA]"OUVVRK?$,O4R:($+O*_\>\W5Y17P%('O'3G+6W
M_"?R_*5^[<;,:7:RECS_:P]_=*MPFU.U>[%\HPB=5=."=]78MQ9G=*U&.SAX
MDK7GOQDG]-9_G^<01,7(%JSFK C2F =+*-P]$])1:2$N%4]+WS^9G\YM@D>4
ME)!M@E ?BJ-H7Q/==TMJ$V\DX8DQVKTWM3U#+=G][5)7EKZ!%JOXOTG1,!"5
M)Q7<5R_?J=5,>CL\?,XP^$+KVTNFT*K+W0SX5OW2/:#89R:0;Z>5X,%3)0E"
M'7,Y+S)5SZ^V:._VYOT#A@_,_G<BJI+H5W3-ZS(N&?<N+K<^G&9*15T#PI2K
M$N7TB-R^<EP]%^FO0BBM+VL,)U;/1+03A>NP%"$+']1][6,0UX O[;6%D:YP
MO7O1RBL%D5G;*=19E2^139]@B3[E>[8-B[<6_GR,VS?+9&TA+PZ4Q.E%>0>9
MG&"&T";Y.105<%VRZ(+,XM%1)?=[:X/T-MQPO_U=/ P*Z?2WRWTK7?P!Y=/P
MMG:Z%O9J.DK2S;#S80>I[/QT\-@._;ILFPLLO]5GJ=]R, UA4'^<??1%[O0[
MT1S/W<D)G":*N$&*X,E%+L+"KCV=B\_OB9"ZL0=B/&/]C\1F"_\T&27[6M_;
M4[BA0(Z^_%"]]'=O@.05"5%E!/KO34!6+D8@W3,93YH;6E.$+.9@TD@6ANR:
MKSQ1>>\H8A?85%@X("BE>T1M?%]4BRU:F:#E!9-1Q\W+Z$$*F,N--WXGKJ9Q
M%DZVL/X_ 'A A[_0E3YXT]%I?6VG:W4ZXR4N64OZ\SPWQU\.?B#)\3IO#WB6
M\;Q-\/[R[DUBYE,2A(UC!*0$YR#DGGVKE-4^/T/[1U]8>!KWX90ZMIUG-Y,0
MCN6#0HIVA\^P KZ-UK]GM+?P_P")X;WQUJ5O!JE^M\9[B< 6ZC=F-2?X3G]*
MX?PCX[^$_A'XBW>A:%:1KJ\5NJM?6J$)(V "2Q."3UXKNIUJ<HWY>:45I;2W
MF82BXNU[)]]?D>>^#OASH7PA\6>)/$D'P]:T_P"$?9?L=TTYV7!)_I7T-XJ\
M::=\6OA7;:E9:%_PD4L<J/-8*Y7R),9Y/?%>6^);[XF^-M>U7PS)IEI;>$)I
M0!>CF7;P0<YKNK/P3)I/AJ72-+NI(F\DY\M]@D;;@%@.IKGK-2Y9S=Y>M]"H
M>ZG&*T/4OA[XT;6/!\%SK5I%HLRDQ&U9]V .!7&ZQJ>G^%O&6= T62^BU F6
M\FC.$! X^G6O//#<,OA7P3%H/B*YF.I7]PT<;1MN= 3P?:O1_ _PUD\&V]V]
MQJ<]XLRY6.0YQ7'*,:;;OH^G1FW,Y)(K>&?C)<;KW3AHL>FZA'ODBL!EC(.Q
MXQUJ#16UK5X[C7A9MHFJ7I*S?-@D ^E&@ZFL6M3ZAJ,%G:^2C?Z1(NQPH_'I
M5+Q!\7/#MK#;3-J37?FMD1VPQA0>_P"->9BLPPF&3<YQCZL[\/@<3B':$)/T
M16\2?"<:QJEMJ%]J9-^L>TR[03SZ9SBK.G_!WPUI<<=S<6QU>Z3YA)<+NP>W
M'2N=U;X[1S1K+8V< 4<9F.YE'KCIFN4U3QEXP\50FSEN;A49LHMB/*('4!B!
MP,=Z^:Q'%N$HKEI-R?DM/+4]S#\+8JL^>HE%>;U^X])\1-#:V<<$44-A;;MN
M[S%CQ[8'/Z5775-,L=1MM+24SWTRC$84J"".N\_X5Y!-:ZE8%9KN20)"_F('
MD#9X[OW/'>KZR7$<NGSVEM<W4SRYW8,BD,,E<CI]:\;_ %JJUG[E.R36]V[=
M3UX\,4J:O4J7;3[)7/1KCQS9Z%)!8RQI';ON\]O,,DJOV P " <"J4/BF^M+
MF[DF>.V,.TP2^45DD8C@>F,]N]-L/"^KZOH5Y;7&E+;7+3D03WCK'Y$3'<Q7
MG)((ZUT%C\)KBTL?M6IZAYMHT8;!!=S-C&_)Z<<8KMHXC,<5/F2?*]5=6MI:
MS.6I0P&%BXMKF6CL[WU6J.#77#'Y@OK=9+J\5U9YFW%7_DN>U4CJEQI6FK+;
MOY4<YV20XR WJ.X_^M7;Z7X0\&33 2+=73JXA:*XN-O/4=.1DY[UZ1#9Z%X9
MM88CIUG9P ,(F9/-8-UZOGWYK:.68^LI1JS45;2S;9E+,L'3M*E!R=];I)'S
MY)HUSJUTSPVEY?MLS&XC)7D=#Q_6K5C\-?$EP1_H(MXMF1Y\RH=OOFNSO/BY
M<7=U?0M"MOIL,ZQBW24!FXR7.,<9[# K:\/^*K+6-)N[M-/>[5PR2R,PVA1W
M*]!D\#%7#A:%U.K-W\M/O(_UFJ6<:4$EYZ_<>81^$;#@W7B"WM-R;U2WA:4D
M X."=H[&MK4O NE:)##Y=MJ&N-<J94F5UCC( SC R<GTSCWKN;RUTR'P[:F:
MPA^Q&'9/#&#M!'0''3KVKB=8^)[^%6M(%LK;^RPFV)XD)82!ON#.>V/SKUZ.
M0X*F^91N_-M_AL>55SS&5%:4[+RLOQ.=M/$.G6_ADZE9Z9;VE[$S)/HMU:/+
M>H=^U64D[6YQZ#J:YWP_XR\7>*/%4EO8Q36T;1>8_ELL*(ZD?NEW#K@'..,G
M@UL:_;7>J:U::BMY+97L\>^*"2504=S\S-P<J$W''3 &>:]$\-WFD2>%U9':
M3#)!>3Q6QA5V+99DP1QQGC ->K'#X:BK.*2]$>1+$5JCO[1M^;90O_!5V)KF
M3^WUD6^&/L;1_,AQRG7D<UG6?PEM=%MVO=4NV\N']VT5LXE;IWR,X]O>NDU+
M0;?4 U]HFF7J_;HA$;IYCY8ZCS%1SNSCO]*YQOAOK%L819W7VRY@5<?:9F,;
M'^)B#\O<_7BN>IF>7X5I2G&,GT;2?W&488B>J3E\CF-/M4M_$$>FQK)-;1-Y
MEJCRJ(]W.2$"X'/J15AM#2?6-0*7D+V@B,D:.VY$<.&V^_W>1COWKIM/\%W5
MBUTL]G:2D3F6*8KN."N&.?4'D9JA)\,;S7]:DU#4%@M5$+0Q)90A,Y/#-CJ0
M/7N:\7$<695AY<KJ*_E=_D=5/+\1)7Y?T,ZS\367AEKV[T^TM[FXDA5YHQNS
M+)D;@%R, #)_"G:A\0K;Q+:S*D;(D2L8E7 C;<1QN(X/7VY/-;$?P1-QJ5O<
MS7%Q(+>()&L;!%W8(+D@;BQSU)-1^*OV8U\2:%.FE7UQI6KKEX'9@\)?J Z$
M<C/H17G4^,L!6JJE3N[NU[.R\[G3_9]:,6Y67S,RXGT?3X;2"4O%;-*;>W\X
M&0@J2"#CL0,C-5=4\30ZA>+9:9'&5BGWHUO'E\%"""F.<#)'TZBO+-#A^(FL
M7&HP)!"FH6EX;.>-E0;=C;?,V/D$\<GOVQUKZZ^'>AZ9J6APZC;Z?:->PAK>
MXDCB!/F8VL%8C=CD]^AKZ#&YE]4A&HH.<7U73U1A3PKJ.W,DSQ%O#;03)#J%
MI=QH\*B".)?WBR$8W%SM![_**30_AN=2O;"UO1,^G-^\N2AVY=3Q&?7U_&OI
M=_ \&H+$+@&7:Q9?, .P]<#CI3]8\.QZ?IDAC2) @$@11SN]<]:\/_6.O44I
M*D^5+J='U."LE/7T*WB&+3+;P;%I[PHFGPJJB#'RC'2N,U#5-=O+[3H--L[:
MZTYALDWH,*!_]:MSQAYNJ>'8H\C=(RC ZFNE\/Z9#8::J(F#@$UXN7\05*U.
MI[5WDF[:6T]#LEAXQL^AA0?"_3+'4HM:M?.MI^/,@CE/E$_[M>@VMM;36Z/Y
M$8;')"BFQV_F6;C/&*GT^'RX=I;O7?1Q=:5:+;;C)7WT33Z&,H1Y=M430PI'
MT4#\*M+BH0J_WA3QCL:^BHUI=?S.9Q).*C95[BAF]ZK2L6'#8K2IBG!:*X*-
MROJ2PR1,C(KY_O"O.?$7P[GU,O+:W?V2+JR1KC/XUW\MJ\AX>I8[<^7L:OG*
M>98B==JUHKTU-_9P2/*OA[X,.B:U)>1R2.N/+=9>_O6OXC\'V.H7ER\:K'=L
M/S![&NO^PM;W#LB[4QQ7@'Q@^,4GPO\ B1HOV]&.D7Q\F2=?X&) &?SK"MG6
M,^L\E..RO:VC2WU*CA:=1-LH7N@M#.Z.A#JQ!&*S9M/\N/E<<UZ7XBM6N=1-
MS;1>9#,JN&!X.1UKF;O3)?F+0./PKZS#\08&I&+G4BF^C=FO+4\F>!JQVBV<
M*UOY=]Q\H85+!9[O,3HX/2M*?2YOMD0,+!0?O$<8J1K4+?H!P=ISFO9HYAAJ
MWP5(R]&G^1R2HSA\46C*6Q>.905W C)*CFK-M9AB>"!FMMH40ABP!(J&::%6
MV@9.,Y6NWF(L5-JQ8R:K7'S,HQ@8SFIIC+-(HCB9SZ!2:>^BWS*)9D$*?WIG
M""ES);L?*WLB+SE51D_2HKB825/#8)(Q"W/G-Z6\9D'Y]*FN+>TME EC^<?\
M_$P7_P =7FH=2/34T5*3WT,C[TWRY./2KT=C/(N3$8U_O2$*/UI1JJ0_ZN1(
M0.UK" 3_ ,"?)_*JDFH([[MF]^TD[F1OU./TJ.>;V1?)".[+:VEN,E[AI6Q]
MRW3=^IXI\<D-N=RP10GLTQ\U_P A@5FR7KS<.Y(].@_*H?M"_7%3RR?Q,I2B
MOA1KR7SW#?,7E [,=J_@!3O.&W!&T>B\"LN.^_*IQ-Y@Y--1C'83E*6Y;2YB
M5N"/SJPMW'_>&?8UGQPJW1<FK,<"KR0!3%H7%N%;OFIUF#<"JB1Q_C3AM#<<
M?C1J,T4E*]>14L<P["L]>/XZO6-I<7S!+>"2=S_<4FI*+<<@VFK$<@ XK1TW
MP#K=Y@&W$/\ OGG\JZC3?A+,V#=W>U?2,<U#:+46SC5F"XJW:P7.H2!;:"24
M_P"PN:].T_X<:)8A2\#73CO*YQ^0KH[>WALXQ';PI"@Z*B@"H<ET+4.YYWH_
MP[OKO#WTGV./^[]YS_A7:Z/X;T_1<>1#OE[RR<M6G14.39:BD/)S2445)04^
MF4^@ HHHH ?12+2T %"]:*%ZT .HHHH **** ,EA3"*>0:;5D"+3=M/(IFV@
M"-JB;C/&:F84S&>HJM0U*[ ^G%,9>]66C)Z5$RE<C%!)#MIKJ-OO4[8VCUH.
M&7I0!4:/<.#BHI$Z#UJTS;2!BH9.H.* *ZCR9 03P<TVXF^;('6GR*6)]:BG
MC*Q@L#]:L@ADD[U3E9FY'3TJPRDU"R[10 ZQ'^D9SP1BLR]C^SW4B9R,YJ];
ML=X(J/5HPLRR=F7- &>%]\U'(V#S4J\!B1QBHF_>$$<4 ,#=?[IYIJQ_-@9Q
MVJ5<9P>*D)1<<U9+)[>%57=5A7"\8YJG]H500#2*S,W6@6I8DN"RX7FG[=MN
M6/7TJK#&5WM(.,YSFK2@R@,>$[+0!+IGRS1DC!W #\Z]7M_^/=/I7E>G_/>1
M>@88KU6)2L*#VK&H;4QRTZF[33E4XK(U"BC:<T=.I _&@ HIC31+]Z6-?JPJ
MO-J]A;_ZR]@3_>D H N+2UCMXPT6'@ZA"3_L9;^0J%O'&E,,Q/),/]F,C^>*
MKE?87,NYO4C5R\WCR!<[80J_]-'&?R&:IS^-IY%)C,: G PI)I\K)YD=H%-5
MYM0M+?B2YC4^A89_*N"NM:O;P%7F;R_0G&?PK/V*K J&<M^54H$N?8]$?Q)I
MD;;3>1Y_&E_X2+3?^?I?R-< +22;;R(QGTQ3_P"RT4EY)F3^9HY4'.SOO[>T
M_P#Y^D_6C^WM._Y_(Q^-<!'%:%CN+-ZMDTLJ:=&@+@'\>:.5!SL[YM?TU?O7
MD0^IJ.3Q5HT2Y?4K=1ZEP*\QN%TIF;$#OGT)K+OM+TB15W6>YC_>YQ5*FB74
M9ZP_CSPY&"6UFT '4^:,"LVX^+G@ZU4E_$-D3_=23<Q^@%<'I_PK\.7RQ7,M
MFSN><<XKHU\*Z'IMN8X+.&,8Z",?SHY8>8<T_(L/\:-)=L65AJ%[Z,L!53[Y
M-:%K\3;690TMA<0 ^N#BN3D-HS&.V24A> 4X'YU6DT:*:,F>9^?X0W I\L2>
M:7<]*M?'&C73!3>+ Y_AF^6MF&:.XC$D,BRH>C(00?QKP2]T.QCCPNWC^\O]
M:R+?4+W1YFFTN=K5E[QO@'\#3]DGLP]LUNCZ7HKPW3?C=K>F^2VH64>HVN<2
M/"0'7WXXKT/P[\4O#OB;8EO?K!=-UMKG]VX/ISP?P)K*5.432-2,NIU]%+UY
M!R*.:S-1**** $W4G6C::=0 FV@"EHH **** "F\4NZC[U  M'OVIM*#0 ZD
MYH^[2T -R:.O-.HH 3\*%I:7^*@!**7Z4?=H 7I2?Q4E+]Z@!DC>6K-C.!TK
M"TGQ%]NN-DB;$<D(V#U!QM/;-1:IXPM]+\3:=HLEM<237RL5FCC)C7']X]JX
MK4/$UY9_&2/1YK$1Z']E\_[2$./,SW(XK2-.4ONN1*5C/^-WP_UCQ=\0OAYJ
M.G6WG6NEWWG7+YQL7UK.\70S^#=8NX/&"MXC\%:G<><\]V-RV;Y^1 O<9_E7
MJ^M>,+'PWH,FI7<@= I9(X<EI,=E'4U+'JVE:]X=MK^]C2*QN%60)> +@GID
M'O6D:DN5*4=%H1RJ[L]6>%_%2QCL_'VDZ^GPWL-<T:R@CF.O3$![:-><J,=A
M7?\ A'0],^(%GJVKS:R?$7AGQ JF'3;@ Q1*.H45K_$[Q-H&@^&X[/6F:.PU
M;_00\70!AC.>PYKE+'P7X;\'WG@C2],DU":UM2PM)+9BT1R/^6A'&*WYG4@M
MTUMZ(CEY9,KZ3\/_  A\!=4U;Q=JFKW=\;Z\$=HUZ1(NG(^%%O#@?*GM7COQ
MN\(W'A?]I+PI\0?"_BB83ZU>0:=J>F6S!AY0!(W@<CKWKUKX=QKX4\9>(_"?
MB21M7O;R:35K>-E,B)#DD#G@&LOP[X5\*^&_&#^/] \(:UJ%]XJU1+:]BV$K
M:LHV_:&5C\J@ <BMZ=5TW*4FVVK>33V7D3**E%)::_<<C^VA\/;CXI>*/!VE
MZC=ZSH/A?37_ +6FURR"M;Q3QMA$<'G<=QQ]*\S_ &IM4N_A_P"*(;_[';WV
MDZU]@DEUK265+[;"BG9<EL\2=!@#@U]/_'O1_%NJ:;93Z/<21:)I[B]O[>T"
MFXN@G/E 'C#=Z\H\03?!3XC:MI6I>(;*/1]?UB[MWEL]2D,;L8 -I(^Z N!]
M:Z<-6<5"ZNHWT7ZF-:.KMHWW/!_"7@L_&;6O$7C/P;I'B_PG:;HHXK70[F./
M?(3M?:Q'8<FO8_\ A9%MXH^%OC;X?Z*GB&]\:^#D6UCU-I$;4;H1R*#*)<<<
M]1Z9K U3QYX:U[Q]XC@O-=U31[^UE\RPOO"X+6DD8.%5<D+OQUYK&F\=Z-X-
MT?4?#FC65Y(WB9_-NM=U"7]^\O?<JYP3GUQ7=4JJI:ZVLTNVV[ZG+S1I_:WW
M/8_"O@>Y^,7[..E#XLWJV6NB1YK+4/.C2XMF'"%6)V[\ C\:Y/XB:OX'FN?"
MMEX\\)7.B#4+;[!#K#R)YT;*^%5MG4R8W9QWKYSCNM8\=6]A\/=8EN;SPCI$
MCR1S0DPGS2<D%E.2/QKT>Y\&O!?Z>UE>?9-*MHU8;CNW,#Q@'O7/\+;YNK:2
MTM?L+VW-HE\V>K^ ?B=I7@W4M8OH-(\0&/:+2UT74)%6"%(_E$B<?Q8R?K7G
M_C+Q(NH>/O#VG:'H\VA*;PW8_LE&"12N23)(QZ\G/%=4NEW?BC7(+QTFEABB
M"NP0A&]3QSTKN;?1;32Y-.C^V6]G]L^2)G<!V/ICKG\*\RMBJ-!\]1VOYG73
MP];$>[%-^A@:]\+_ !/J?BO3[[5O$\FHZ%'&5N[6\D+%B<8*CI6Q=?"/PIJ"
MVLALS&MO.K)) H4DCH">XK:;7+"&QBDC9]2N%D,,L[NJ1C&>HSN)Z8&,TR'Q
M)K%[)?FUM8 +6+Y+:S.9D;IN?/0 <UX=;.\/3DE&5WY*_3R/8HY/7E&[CRKS
M=NIUBP-:LGF.L,8"@>8P5<#W/MBL37O$5KI7B!;P:G]ICBCVR6%LA;!]2>@'
MO7GFL+>>)+/4);ZSN=0OXY +>U:5B)4(&YPO8>_TKE)-09;7S+2\F2YN(V@$
M,F6+HN,QMQC(_I7QN,XFK)N-&"M;=[VO;;N?68/AVFU>M/7LOOW['H&M>.K&
MZCO=4L="\O4K1@9%N068$$ =/K3Y/B)KTGB2WN&OX+O2C;@S6ZO@0LR]\8-<
M_9Z'K6N7UU:)$RR7,2E)KA0K2L0.H8CH!U]!7>:+\'Q?1V]MKUW']AMV4+'8
MH5=I,'YFDP,CVKR8ULVS"46N:RM9[+1]?)H]*5'+,#%I\MW?3=ZK\SRWQ-;O
MI-PLE_>R3"[!(;#,JJ1D!2>HYK$M_#T]U;NMK927DDD88P6Z;G]5( ' KZ1E
M^"^B:/L%M;FYNG3RR]W(9 JY].G3BO1M'T>TMX8<1K$L8PL?&%^GIQVK2/"^
M(Q4G/$S26MDM6K[ZLSEQ'2P\5'#P;>EV]%IY'R98_"SQ!<:=!;7%BFGN9@J7
M%UP3GD# S^M=?X;^'-JNJ/:W'B&XEN[B,Q$VX^5L'))R2.@( KV35H;6XNY)
MK1D>)&*S2%\*K#G<1G!Q7@_C[Q39^ [.[F83222?(+F/*HH)R !U!/L._P"-
M?1X'A+ T;.2<I)):NVWD>!C.)\96ORM1CY*_XLO6_P#PAWA77)]#733JEW$X
MF2._E WDG!*C[O\ ^JN@T/QLLU]/:Z=#%"(_D5DP@#*,LG'4<UX]I/B:Z\37
M6E76OV8MXHF#6]I@*6)'+DMP!@CJ>2:RM>UO5[_1[F:[ME6RM7^SSR0QI$J0
MOS@$=6-?78?*\+0C:%-+Y?J?*ULRQ-=WE4;]3Z5D\::4MS;VNIV.]HG5/.)V
MQO(5+;<]QQ6#\2OB]<6%O;_8H7$<L)=%91M(S@8]>>?RK@_A?XB\-3Z?+::G
MY,<RS,+6:1PK6JA<+RW&><'&>YKRMKH>'_'EY_9>IP7UCN;R)G7:@&0V5#="
M#GIZ5Z$:48O5'G3K.4=&=A9^*+R+QMYB^>NGK;>;*_E[9">"6P.G.?TKKE^*
MGAZ_TN>>9[O5;2S&/)N)&4R,2%Z#H 3CGTKAH]:DO+Z%H8_-GNQR+<[BV>[#
MMGKS7IGACX=Z7J6EI%KMG")&"JZ0KAF"\KN<=>@&.E?.YQG^7Y-!2Q%1)O:-
M]7Z(WPE&OBFXQC>W7H<1XP\076K^/M)73+.V2&^@B$2LP <J!N5O4YQ6):ZA
MK?A?5M5LH],NKE[IBDD*!O)C;<<]>H'&*^@]'^&,$,-L+:V6UBA^:+9_"2<U
MU-CX%@A^:6/S';JS#.?>OS6IQUBL4^7!8=VZ2;T:]#WXY92BKU9Z]D>;:-I>
MJWWAFVAB9M,NX82&/F;DE8Y].1QCZ8K,TOX2Z\UK#%<:OY4D4IDDE1,2/G!!
MY[C'7WKW.T\/PV?.V-/]XU:\NRA5@\BL3_=%>1+/,XK7E6JQA'7167IJ]3HC
MA</!^[%R/*+'X.Z9#>-)]BDN;@.S"620\D]3P>E=E:^"X88X1;VL=J8UVA?X
M>G0COS74MKMM;J%4;\=*JGQ0B?=11Z<5X=3'48R<L1C)2OJU=M+TMV-HTW]B
MFD-M=!\ZSBAECC8Q]U4@&H9/!\/7'?=\QZ&EF\52MPL0&:I7NL3S2,%<%.QY
MKQ,9G63J-_>G)65]F]--SHITZU][%U?#=M'C>T:X[=:E73["#JZ_\!6N?:ZG
M;K)4322-U=C7S4N)\'%_NZ"OYL[?J]1_%,ZI9K"'LS?D*FCUJQAQMC4?4UQ>
MT,>>:F6,*N[MTS6U'BZNG^YI1BEY7%+!P?Q2;/GOXX>(-.\*_&K4;=KRWM$U
M73A?K'-A5W*0CG/''3/UKKOV5_BI-JU]J^C3SP7!%NMXD=N0WE9)&UN>#C!_
M&OF3_@H9HLOB#XU?#Z#3IS%JD6CWDZ@H"C1JZF3<V?E.W.#@_A74_P#!/UKJ
MZ\5:Q<'48+JSAL/+>:R0^2S%D*JY9599 .JGUK^C*.*JXS(8XINTG&^G=.Q\
M]**C7]G;2Y]]+KP:,N5\L*VWICFLW7KZ:XLV8*IC8-G<V",#K5?^T%\N$J5'
MS$*K$#\N>M<IXP\27$>ER+!,IF0YDCW D+WR1G KY+"5\9B+*HVXV6RM=GH>
MRBGHB];SI<:+82,%E4$DGIR":UK'5EV[3QQ7G7PG\92>,?!<TI54^SW<\*(N
M"-JR,%/'J .O/-=(9EMRA8X8UY].C66+E&"V;3T*=G$Z^37!%I[G/4[1S40\
M0"VL48DY8YZUP.J>*(5FBLXY Q7[WUK'\0>/+>VD2)9,J@QQ7L5*>)YW[)-\
MJLOS9FHQLN;J>F-XP*] ?SIT?CC;U0G\:\1F^)$*]-Y^BFJC_$Y VT1R$^F*
MY8T\RB[QC+[F5RT>K7WGT$OCJ#;RC"HI/&T'\,9)]S7@'_"SCT$+'\*5?B8<
M\V[?A6\I9I:TH/[C-1H]&OO/>/\ A+D8_<P/K5F#Q-$>?,*GTS7@R_$RU5?W
MHDC^JU+!\0M,NV"_; C]@<BN&V.4KRB[^AM[.G+8]Z;7!<L1Y@QCUKYP_:&\
M-)\3/ VJ^2-UQ:RL\+#D_*.U=3)XJ-GX8U:[CF\V1(6$>TY)8\ ?G6?\+]-U
M1?#D=EK5N5>Y61MQY^_G@_G7T60T:E2=2K7;;5DK]V95HJG&RZ_DCLO@KJUM
MX@^%?AJ\O972Y:S5'!&>5RI_E79R:?ID@/[_ /-!7@DEYJG@WP[HNFV\:1QJ
MDFW+8R-YJBWC?6\$AHA_P(UX5;A_&U:U1JDG'F=GJM+Z!]:HI?'8]]N-%TW:
MQ\]&;LI3&:X3QU86EG:K/&%#*0>.*\[C\8:U,NXW,*CZG_"J&I>(+V^4)<W2
MLG=5[UK@^'<RIXJ%2*Y5%KKY[[BEC,/R.,I7^1V'VS3TPV('&,XV2-_457F\
M164<FU$?([0Q(G\P:\^O-?*MMW?A5?\ MC=_%7[E3I^[[SN?*^VET21W=QXR
M2/*QQ-*>WFS-_)<5DW7B:XF8,B0P^ZQ@D?B<URSZ@&;.>:C:\;L*KE@MD'M)
MOJ;\^L7<V?,NI&']W<<?E5)K[R@3NK+^T,>6/'M2+,TWW00/7%5ML+?<TX]2
M+]B*D^U,PXX-9\<;=AEO>KT-A/( 2"!^53J/0<)Y,'./J33XYFZ#D_[(JU#I
M:KC(R:LK;K'QC\J+!=%5-[?>;;[5=A;;CC=[TL<*KG"<U/;V\MU.L5NC3S,<
M".)=Q/Y46'</.=6'6@7#\Y?\*[OP_P#!GQ%K3(]U$NE6QZO<GY\>R#G\\5Z5
MH?P2\/Z3MDNUDU.8?\]N$_[Y%9N21K&#?0\+T?2]4UQ]EA9SWAS@F)"0/J>@
MKN]'^">NWA22]ECLD/5-V6KW6"..UA6*"-88E&%1!@ 4[FLG4?0U5-=3A='^
M$.E::H:9FNG'\3C-==9Z7::?&$AA51],5;HJ')LT44M@'R]!@>U+ZTE+_%4C
M%6EHHH **** '4444 %/IE/H **** 'T444 %*M)3J "BBB@ HHHH SOD;H.
M:8RCH>M1O)MQ4:R R!JL@D\MUY[>]#+MZU(LV[CM3]RMQ0!5559L;@#2;0IP
M>M+/#^!Z@TQ664;6X84 (S8[5"V:F;*G:?P-1,.M5J&I$PS[4T_+WJ1JC:@D
MC?)J-L]^E2MQUJ$N&H C;&ZI9HQ-8I@<C-1,.<]J;]H*PE2,#/%!!6\M6C1^
MF>M59U^]BI_,+0;1ZU4FDV\'BK 6UCS&V/O>]-UA"L<)/7%-AF$;<G Q1JDC
M21@X^7H* ,UN>*:/EHQCK44AYZT .D8!2<<U7\[/>B1OEQGBI+/2[B^8>6F(
M^[MP*L@C/[QADU;A@DN& B5F/^S6O::38V.TS/\ :9/[N<**O2:HD*[((T0?
MD!2YNP6[F='H5U,!YC*B?7FKJ:.BK\\K%?[JC%#:TB<OQCO4<NN0KDN0!ZDT
MM2M"PL,%JR/$C%T.5)/>I9_$&I2=;MHAVQ@5@W'BB'_EDA<>HZ5C7WB*:9]J
M1[O84^7N+F2.BN]<OQPU],<]]^*RI-4O(69UU.5EZD-*:IQ0W-Y&&>-@?0\"
MDDA2V!WIN^IP/RJK(B["/7-1NY3B]N-F>,.<5?BDGQEKB9_7=(<57AA>X0-%
M&@';+8'\J5H[AFV[!M[C/!IBU(=2NI_)(AEW/V"Y-58;>Z?'FR[SWW''Z5HS
M1&U7S9$0KZ!JFA\N9<@J#Z4!U(K-EA;! ![E1FK*Y\QF9_- Y"[L"HI[1>2#
MM^E58[6=),C _P!KUHU'L:'GQ;%>79&.R@$FK=J'N\#Y@N>I&,55MX4<'S3O
M;L.E7([PQ#8B[1CK4E(T;>.VC5B[>81V-2-<+P%0JOKZ5AR3,I)+!?;O4DEU
M(;?(X!'-*P[EJ35%W%?-554XW&D74;;<//N/-4>O%<7J8@;.VX)ES\RJ:S_)
MG5AL=94QTZ$5:BC/VC/0[O6--LH6"2KGJ-S 9_&N;NO$<.]BH0C.<F0"N:NA
MEMKKE3ZBLB[MU&0%R,<U:@B)39W<'B*TDSO:%!WS,*E;Q5H\?!N;<'W<<5Y#
M=1*P.%4BLJYARI5@OX57(B>=GT#'\5-&MX5A:^A&P8X<<UCWGQ+T>[N@AU..
M.WQECGD^U?/=Y:@-]P8S^-5ID#-@*NWV%1RHKG9]$W?Q(TF&UVV-U;RGH!YH
M'\ZY*^\;7]ZV$NH8AG[J.&->-20*@.U1GZ5!Y?S$J"I]F(JTDNA,FWU/5+SQ
M'J#,(R[2'KD]#5VSFFNK8/,TA)/W5KR6WU*[M&S'/,A]F)K6@^)6O:?'A9XY
ME[":)6_6JN9V[L]173[GR9/(_=9ZAFSGZBF:;IS6[LLS;F'.<<Y]C7F<'Q@U
M*"93-8P2\Y)C+*3^I%=!9_&K3=P:\TRZMLC):.02C/TP*6I1ZM'XNU31X%:#
M4KN-%'*ALC]16AH_Q@U^-BCSV]V%Y'G18)]LBO+8_B%H&J0NJZTL?F=8ID,>
M/J>?YUL:?]CF4O9W,%RWW?W,P<XQUZU/+'JBN:2V9[+I/Q>N[B-7NM'&P\$V
M\N3Q[$5UVC^/-(UA5VS-;.W1+A=A/TKY]MYW;*OOBE!S\SX!'?G'%*UPWF*W
MFR!5.X@,.GL>U9NE%FJK21]11R),NY'5AZJ<BG5\V6GBC4=%7_1+YDPV?+8$
MG'US75Z;\9-0AG,4JPS1)@;IOD)^E8NC+H;*M%[GM%%</IOQ8TVZW"YC:W*G
M:65@P^OTKIK/Q%IM]Q#>1LW7:6P:R<6MT;*2>S-*BA<,,J01[45)0RBBB@!6
MI**=_#0 -2TWZTZ@ HI/>CWH 6BBB@!?NTE(U+0 5R_CS4]1TS3;5M-M);N6
M6X6)UAZJISEOTKJ>32T1=G=B>JL8>DWC21Q?;(=LZCAF&6%:DEK!,VZ2%)#Z
MLH)K%US5#I^I6WG26L%A@F:::4(5].M9=]\6O"6GK,SZW:R^4,NL+>80,9[5
MIRM[$\RC\3+GB+P/8Z]<6US(F9;5MT2Y.T'Z5/J/ABTUS14TW4HO/MSM;8K;
M1D<X&*YVW^-7AW4--DOM-FDO+9" TFPH@_$CK[5Y;=?M':CKEU-:QZ-=:,D7
MFXO#'YHRN2HP#T(!/X?C6D:=25NASRKPC?6Y[?XH\ Z'XPTF'3M6M!<6D!!1
M2V-N.G-<SJ'C[PG\-;S3O#_VFVMXH\KF24$P8'?O7SUI?Q4\4:MX-U"V:^O&
M%VAC@W1 -YC/@!GSQ[8Q@=<U'X5^%YUB^A?Q)ITHCM6:9[B_N2\UU(?E(R%
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MC5)0VBBB@!5H]:%H_BH 2G>E(M+SF@!:*** "BBA>M #J*** '?PTM-'I3J
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MH=1J]O]_K78MC[Q"M6<R)&K/H:*)Z&)K0#Y(T401X$:B_A&GIB9*Z7\R[5
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M!'*5C%?52;R@\UC&$M>:Y+,0!BH-+<N;AGQ\(Y\[M[J:7F9J,4( _O1\YZ]
M3)54/B9EL.#Y,WM).-."F?J!3#=?7_2A_*B*UU41]Q$(V&]I*>[;"P>\1PR?
MNPF,P<:RP0KO, !JX[QJ+[3#G/-L/4=!/EW9RJI;&".V>AM+L_F<!%N$;S]D
M1D\Y=L^4,04KO'5TIA+DC!N QQ3MO[1) *UY;ISFFRY.3?JSHZMEHF6!T@&
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MZT/S*:AV[$6]"/(DDQ.OVA4:$-R&Z_H@^. F@M$*(5#[%8'3_@3 ^LXY!P_
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M'2G<:^VS/6OK4<E[?/>_4IKZ_S$<,8VQEO\[#/OBKB!+A@2@F9+Q?\7@7H!
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M?:11<VK"7CSSP<)"H$4"LXB;87Q(':L(+:<XC*+B\GO)M'-25M;2]=&<&[F
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M8(BH<:*;&W-9#+ KB1?8!?@@]P733'C8C1@M9POON<X2:*^"E/H.B#W;TS!
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M&4TJO&#?\G$#[5GN\K^66,'1;MR2?>1*!C!SG<(L^5$>F]X%8V^Y,G+;9M"
M[ )$377]"PAVP-V=G5&R(]U:C.<J=FF_:0PZ,83UCE*;H'45)NR(ECUJIC(&
MFM.G%1*8>YF=)AJ'-23LE14WM"8O<<G&4X9J!,^?U2A$A[-6E$O+H>/+NH#1
M_@QU$VZ>L((WGU@2O@9+:<Q#]Q##BOUS:9*I$AB=SL@%M.R 5KHE7-[#J\XD
MP/IXVJ[Y4P$T4S?@1W0'VY!]H5@$W/$)<%J5B]*-9#W=3N28?Q6^(E T5$9
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M_)2)H<C(,U$M0ZK-] (X6Q=NUS9?M-"5$C7KL&5,Z\MBP6RE;C U\2&OD2Y
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MXBD'OE+JX<G S$ :NS3![&W]Z-4F_=\=$!V,VEWYD5$,;U;1A/]_3'UG5!/
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M3KXV"ZH[C9'*Y'7)"[8./6?>8VFY0PRS.PM;KHH(F4,794O;CG2]V$:Q7GX
MRW<^6TYF!7("2L\C.;Q#8I4BMVQ-4KE4NI7RQR]#B+.C$9)T\IP-BWFC6_]N
MVD$[\]M5M.#L'/2O@DM<SZOB[-V9U4\T"0B1Q)72*R4'Z72QS'PU*RLP:\J,
MDNN:!%%,48\V8%ASO!'*#\KI 9*CYPP1;,>.Z92.CQ')N_<-"XX>8H<6IQ_N
MK^$@E:7%?KF@MHE"+2>KS\Y%"V6BI43GY\H\RE?E.[_/V<D?'M#YGJ V8J5M
M',N-C"?D204J6M_D;:&]AY+AQ22,*ZI-UTOUW_*L/;I6Z]_TR"@%+.\%T;L7
MS11E0-B@/<6V-T[I\HI:==>33M\$-:MD82@_N\YFLG*JID8Q'P/!N]]$"F^<
MDJ2=6U+ZT (M*0T,^FE-Q6R'=:+ZR:8C LF]"UU+UM_(,,7%[Q\]BOMIT'&W
MH% OJ9-]K2+AS@@\37VENDCM;I*Q<;=XII3_ [7 9*J,E9Y7QN([TU,Z97XN
M*'&OHAC.;-["1;Q_X2)PX;G20"^"I6E%9.K,_(^8I$NIG6]IUX3)D&/O'G,?
M62-<5.#GH1A#POS.J%,0(3BX8,#9V^YA/ZTZ@ZI/!GVIM)?$*50F/[9%:,U#
M7^GGF=4R:4V=9Q]#.OY4J"H-E;ST9X9UH[$GY-0\K2WE[PVI\\/EA:[7#4^2
M&\@^I*;G#2_T) .?^5G!)4-$'A14BR+\P^GYS@]@_B.H:I@FFD5E8KG9F5LS
M+3 <SC7WY9? 04)C%0M5EH5]_8:(]_AIJ/N.14VK@NY/YMT+-*)P=NN5X=^>
M9=U$8<%O&6S5$UM&=,/5X*+S'?^2MT6S#>:O/BWYBE>1HF3Y_=)[TDG6ML-4
MOI9:N1:7V#)[<TBO-QJ7]_)5Y1CM[W-0/LI@_VB<$,9Q4I7>A:,L2BD@*=K-
M\C%?#V8",J<J3AJA^_?83EV"B4N#/F(3PH#I1:"Y;<B4'X72;X(_Q)X^F,:J
M)T%N.-$2*'5*,>.S7MYF83+X7,KHRGAKN89W([A<&):\?Z,WXU+>F(IX;U5"
M"/$)</U\I00U,W*84/ L,IU[?9?25':PP2GAG,&KZL%*+4_ =\N?+CG1(%3P
MS"Z".'T)[>&H']@0DAW>BJ/.JWQK4;J=V=:]8GR](_''>2DQX].FIH: R<Z<
MFAWIJF@R2:R_H:N>579QJGK!1 Y10%UN;?!^%I@@$V\\4/IC8W>)J\<M\*1'
M!@>2+(K/O^*D>Q=J57]$H']$]361V\M29=-SO,7![8;_6>]VGT+=_OYLAZGT
ML)&=N!-W>DVB8'M,'S>35=&9ICZR4"V;;][K4B1<J\JUYG-N*1>YM!=4CN1*
M:HQ]LL+9FU$?@S'*74]#$5;7^!,EJA[+,06]GF@5*C>BJ:.I'J+LQPM^DM]G
M?,.XO9[B7;(->M^,BD+Y-+.JFFW_8;>.1]I$!#XQ?Q.^[,3$R*FOX0J93SYG
M4N20Z]8_=1A(]7>YL3U)A"_>N1*K;9PD^NFI=I]H+:FA84E*'SFZ2=<0Q?/,
MF?52?:C).KB069MXQ\QJN8W,'.A7TW\+T/6>J(L-:R;QY!CR;9B].J[<Z5E\
M)JQY=VN'MU MY&/Z;B<+RYKX5NZ?J3&MSO&_Z*<LKNH4R[I=&K7KY=SM!]I%
ML79@8#P[=JO%GG?W?LX+("G+DY] T#S.IF2*[_DX[+F35^ZK\[\&T[> W521
MU1!I7%IZ"9CI/PV^;#A1?.SZF0OLK'N,!!>HQ3VB%5XNA-H$6_/$] ZE/+OA
MFB4UFXQGPLG,K@TGHN5JV,PZ1;A5#]OQ>L)IM2%8__R44%BTNE?Y@U3,8;9=
M#UU:*6-]QG(4G_1;F>8Z;94@\<B$K0D& X/BLS"#9JQ9?-G6%&>IHQ@EMT2<
MRP-R[RLB?>P<VB"RG<-4\QX,3-3^BQP-9;58/_\:2@[SZMF2#09-]^NGH1D0
M7[UN =3!,!MC8T;!#P)^WY)^XID?;@F[WM]^O"/9F_#2N:(H%CST&-X:61GL
M<&&;M+Q'TT.W&,5SDOA* \.=/+XN[ )GC#?&T725RY'Z'2E@=U_5Y:*3SMO=
M7(@A[W\67D^.?DT&Y;ABH%(&V.!X)!K2A>EY];'F\ '_<Y:S?YZ:7!B9M>13
M[EYEJD;8:X0R['-(\D0P@I'>8"@(T35N9C[@P!^1S/"#_;61(7G;D!N^V17?
M$)-BB&T[Z<"K#ZSC.23BOP.;"R!@NI@/M2<=F]RL(WQCL,\X8_V)()9 5P9W
MPGK>-Q.GES1%GCMF21BU@WMGKA\2_X*ZZY*Y\M\-6CZG_T3 7HC3CT&GQW4O
M1#I09Y09<9T;\-R17VED.G'%("(/@H(AFZ@25-&AQ%/-EP"I1P#_JQT5#<KO
MKOE7/Z %$N3DF_5TZZ65AIU4]=G@/$LUDF^2GC\)#Q)1,/YV :/M7/(3[O*.
MNFFSNMR9+=Z:Y \YA(1GNB%\C6-!4M<I2YR\MH8G_-_F%6=-_;<1;0&**7EG
MLHM_QQQ&S6;G>4LI#A0H;1"G;3L2_:+:#N>A9A_3W_F[PEWO[IB35>9/'@29
MNY?.S"DE,4PL/3KJ"3PRJ0H/>>&7#L_A0#*1()!UY9?UT7Q\K'QZA\I:6TC]
MW&Y"R%E](/2)EG_=2;6V,W]<CHG+]-:LR-"5)"X]\IA4P,LNP];>18]J+FQ=
M"-C:/IEO$)MEX-H[X$RQ5;] /PXKH==I3UA4Q[W?D+,7)'S18)6Y>K+5*K9\
M"Q#EI_.S86])X63<537:N 4XK4"L@QRQ<9G\L2^FK!Q$GMJG#, ^1PD(F$18
M;)F&GT8]T1[UVH1Q!Q:W-->QMKXB%EW%M22=34+Z"UCW<Y<,DM260V/9JK&5
M$+M\^Q1-"$_\(W;%AVH2# SX9U2#]K> A]8IVE.N)]!@)Q[A@61;L##/%XU^
MFN/*EJXIT+O<1Q.JX]XV2&_#C'=E]]@]R'GD5Y(0:X:BZ:"-.!@IY93FY'[=
MM=1:0V.C#6!XI9PB#J@1S*W<=SD.,I$R@?W:SNSH&GGF4']!G0>&FE:P<[)T
MQ$%AS:7G[CGPL$30Z2V 9.N".-P:*6*JM<N,B\BYZSNE[SCP6&<4,*]"=;08
ML\^*U8S#8#O"3Q)A ^X^*9J??_=<V=#&N<]=@\$]F5^K@[0F7B!A&>SUS?$N
M'!/[4=2QOP%N 2E;F3%)^#25&9$CX;@FW[D5[Y$8NIM(G) VCBRK1,75*EA<
M:,:D83%:LU<&(%,^ZNT:0V,@J9&*D5%5IWOB*I2J-_ ^"[$_P7R].Y5\-C[P
M=LH[WNSF6D2=NE?(J3^12^OG/?/7XB+ SJ.E-R5&1HX!\-VZ5G"QOD3"!NV#
MQMQ0U7&MV)C4^D/!=5_8B.%9<*GCXF-I]P(EC*GQAQP,IZD++T:<@N7./<T\
M?)43]J"S;FQ?)- "7#1=B</S6OQ)4QP@3YILSEP+,LV;<SQT$)-\JI]6/Z[,
MUGHI@3XDZ%^.%,=7^O;0'22*+$:-VJ>E1VI@X<9[X+\_N];<- *FGJR77*/2
M(N4=I;:]S1BQ"P4V*[$E^ZWPHM?K<Y)5^X4L&ZR_E@@39%.1I@[-3]%,$._B
MS47P^$F@03)&P3FY)2R.Z-_%P!P'RZ[ )5&QR_-6II*P6HV)V3Z'YT>L;H5[
M+FON.3"SQ1Y\NBQ/C#&8?KWI4DM9>,?(Z.XC#S&QCQW%(I2Q;9@!]1<+T2]F
MM@+,/_,YK7S\#<,,X*?B&X0$WLW)_'X%?MOEVW#!N+J(GD $+_/7)'D6_R8;
M$UT8]&=/QZ":?*T'_ LVT\0"Z@#T61PL(]'NV1L.(VW^F&U?ZAORB7V8@Q%4
M9 ?60*'LP:SO)&M\KJ/2QVD<.IBVE[?@!]3[7%"/; 4Z>U-GO%!IT6R)VDL=
M\R!A@C/*@-L:L#*HW\T&T<(S-&I3''!3*84OEB,7K3Z5Y/!FOKPE\\CFRUN
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MZ7K%O')NZ[$N[14O]!":$I[ADEF O7O $M['D-G?CE@ !M052H7K-'V W_U
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M=!5LJ;JC+ ('/$>+'NWJ%CP0-N2NL$3:#US)[GA6*M?X=CB/5'[8(W5#+/[
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M(2#SZ>K#P-/Z\X8]MQ.'=0#-R']'2EZ)"PYD"WKDG?7>7$K-@-36*E.DMVR
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MO0_DH(;_C3&=IJT2/XL1G.L<AMS ZK=&>0_=X,S1S8:\\H4MFZ:S%),WU*.
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M7#^)%J)SY S(8_SG57TBAJJ5$T% MWZZ_9&GQ?&&HQ;\WF.JZB?<M:-,(UA
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M-K=0<<CQ99!)KJ=4'HA+;LY?7GH /9:%+#YN-D\Q-"1Q<FF>3TGPS<KW6&(
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MS#-6.E0RG^X["IT&BRR.L-M<2W=^FJHW+XP0U_/;MN[ O'%F&7S45?B8.E#
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MJ+/P.3#SH$&)M,K;H,&,M#MY?11\"CX'6Y;E8N+I9GKH--\;LYN0_]>NH-8
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M:D9]5>0T%& V6,X 3D7L3#X(F1GO44[=Q_6); J./>]O%Q/W'/2],):2"&"
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M[)?BPZ4*[LI3:NV?+_T/AMO;,UFMO_!Q7W\!0>$78Q*1<D3YOBXJTGM+=O8
M%8Y2CCS<F:#"M93_V6*[_![OO)A>"_>MW1.Z4PRZY=^?UO&N<J(1/G99X2G
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MYO)!!#XU]Y.E>3\/30*>HRE28SO,6.&-B&F[=5NPB?_9#[NKNZIW$O?@^D?
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M,\'X2??W0N66<,W8L[63V?>IS^%LT918#9>;LBK[4)*-K=D.=9[,5=)1IT>
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M5HJ3Z"&_7OXWA-G:;5 3YOI /?-;YE5RU0GWB9!#PZC+:QH;J>/=+GMDL5=
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M$]$U@)0I_]O6P7_K.?6>/IOH<"T9 1$K8TL#^%0Y?'BY+FE96Y9N+P_YH-U
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M=\K_GT_ZKUB/UIP$>*JJ-Z=^HOLO*HF?_ ? 4"YF]>A&RLLS[C?_.LBFZ1[
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M2W %;[L@:N=@W'L*F,PNVPI_)2%!*7MUSURW(F_4"$PF]QLF9TX^PF':_*
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M*__U C5J VO>=)%&*.W';A%^RNUU/HF<:+LL KJ"<TN$9'H-*I"60+"VD)<
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MP5]'46%<!'XQ\.$^ABLGZ\__%95R1W0,?/R!@"O?7@W@4/E@Q9T30!)O/AR
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MJYKB6"TA2((/WS>:A,D0&P=)#;[KPJX8&[\9,)\G&$.XGR75BZQ'P/*E#?Z
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M,5H=(%V^CIM+@O%EH[>G _84S;QY#EB^.6?VMD04DJU43;:LPQ?L6A>#=T*
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M%%T^4+^((26-I1\+=_&S70*<8#R2Z[/7R,^+R'?E:!]M\@EBK.L]S<\0RVH
ME;C\U<J?001^/W0N2,KL6U[!B>5)0&7ICZ24U*KCZE;BZ]8O0.ZF9RUWR'.D
M]Y5B1[4G;$G<YLXJ.#E!7%4<S57)T98:,O_IW;,GYYDVIHK"^+5+ "I-I@=N
MQ:],:'9=W?ZTEF/<,,%9(Q@SE^QM-/#$L/145D&EVLCJP]S*:_!O^<)2RBA;
M:VU=&Q=9SFOKHVFU>PA*BRA I<C?_@FQHJHQ%Y=Y=.*AH[4O$X:)HK]-\UK]
M;=N$CTEQD*5XC@"=<WC+W=<>.U0!PB,7?&8]V>0,GVB3N&U#3HX[M][?E$Q
MG1P<G-Z'"HV8X3?5HC^XZ@>*>\,2?N0M8[I7EN//F%:[@6RH)1+_O[H3E>24
MNJ61.*:I]CULZ$:29DC^7U4R]F\P1;"=5?A<S0"<X1K92]C_F-VVH;!'TN*/
M$EWL'[[VJ\WQ6?O&%LY#K)9\ [W#6TBK#^<OI!9Y]25@B'YWVT#,TENK]JB)
MAOC^R),X57LLH$\><A830=9E_5!3?J'U\0++FJ_?^]PJ:X[X%A8W>[MJF'#!
MX@/4'J\0FKASJE;OZP 5*#-+^EQ+ET_9<OU]%LN5,\,3YC>H<GTYAR^<S:]"
M(944D>%L2*=!GNF&0G_(<'J">VQ2%<G[C-GA4%<W]!)P<Y%4&>E,&21)HKOS
M*PWH:^?HJG\G(5FT779>P1@WUP5VFT*Q5'TOJ]L81>AMBK=Y:#SL-(B*NA$'
M\6CXLI#,IE&@7UXN<4WI>>F#"MW/-;O1A]V7@% '2 ,P4KS)@IC5A@ID(N'\
M*QG@#,H#@Z8Q<J>D[.WSY34)>87Y8$+A8F7()0"P'<3E-$?;I.>V0!#C%/4P
M*]GZ_B)WKV90OY[[^A\<MQ=@$1%4X7)0PC4J=#I<JERH!MEHQ5S'MK?3QX26
M<B#'FK,RY^;=%94*!VAL2)*'_QA/J,>9%GE@@5LAFWF]5IF!F-?3LKNGKY\J
M*:[_LT--B_EC_4]JS54.8-4<_07O&O!& 'LAV:#=Z^'[?/#/X\<OLO5-OQ_9
M"R;Z)T+*\,8LT J1,;D.^]A'Z<^AK+65&6*9'&-3;@_R-U5]U-K^*PN\W=JO
M$Q%*U_A(_V1Z4FZE0N_9]78ZQ@3M:XRN.0_V64X>4"B 4(T--9,.=U7%YKV?
M_NGRS3M5__16RPIU=>@*7:$.-5YWHD(, ?6>;#O\XGVE=JH>#J[/UV^',"8J
M/:H8?29<DN#UDT[IVI_R<_=VM/+=&C/(VLL$81< S[N)2X#>:+VF(!8IC(F:
MI1Z?3SOBY%E\IU3:J;!VP"RSHPBT"SP$REUG^\P1HO3$U(HQ//<2< W1OJZ7
MTD+IC,M!2PX*%\[L/@S^MIB@;01^:LF.B>PIRL#\&AGHP?\-,,5;*&--(_M<
M2RI^_;A%WH!DI)_T0]CY>+ B'5Y,)5'<G[)G^9^_)K$>'&1W/K!!)[YHM>OM
M3D*BZ24&;$CHPO<01-780:"\KJQUC' ,46['0B\6!=,^IQM2&4.:*=W7B'Y=
MJWHJ"*ZRL<D23@J^ZMC"&WJTE=(?[54H:.0>R@!:=G:16@NZV]M7;I6&,;K*
M^>'N4%&@<%$#<;MJ,?:A@7$RLO1]_1QG+7"3&>WD:ZZ,B1'WS),P4TEJ#V(8
MOT/LIV<=%5L2[K--KYVWBF0')7<E%2&*<05/K"]V.)[T)+65;IT!/?% -LZ%
M.@C<_^#OIE3(-?*6\$=B9THA?B[JZ_J1!K';VV.L5/V7G5R;,DKOE5OR@7]"
M.4B)N3N](Q7[NUNE]3K<Y.+"[$V]1/$1I*>R "L6H,U6"L5KBKH]2''\S:,Q
MN4FP3%J@17SH[K;TBB\T:6X*LTD\B)Q5=]5Q6NW4=L,H 9^'KV[5RG]Z7V@0
M"MB7,D@5S4O>EA.>B2$=A>\H0O$SRNMYRK::*[Q Q52E?P#Q"CF6=RB$,%"4
M5ER!*%,&[4[XT+BN 78V+1OG=VC)2<_UW&1Q,!QWN9KB@N'7.+-*Z=8*'W5M
MXO3P)I-"TZ@YS?=JWQCW,^5?1L/I1<?<#4)ZJ\;*]"36E@C/O)Y@&WQRRL4T
MH:F&<H5M?>!#RQ52869<KE(.RDQ;KE9CJR"%CBH0OQ@?ODL>TQW?#@#FFH#]
MX'],Q8E/@+SF-[F5#_8\CWZE*3) GDQ F10V:V%RB'#RF"(/X]BZ117BNC"P
M'U^JW;'D'!" '9X6RV!&9-"3.CGG?P+]-\VX&#J+ZC"<!TJL.YZT'.W_D)^K
M7S;"-SX2R5T9?H*41>_!IS2_LK@*'OPA1!6AO>4/"R$ECM@:0?^/R2J,GZ;]
M,;'J0>%^LVLG6A88J6!.",XK/YCR:_NAYYZYLLW-X+"P=SZ'#/3@A@(_*0P1
M9&;V45'?95#7DL9I=P"R0(6-.-#8$NU__PK^RIY?U!,7$>>!>%^>GZ%R\7=\
M%1>J:A!2'+.2]\3/BU_ZZ)%CEDC]> #,K9@[<DXS'"AM:GS;Z'Z4HBGE@&_Q
M9JK0^NM//8E_YG-6.<^%A\\LB,G(/E]/V(VNPZ,4$GS 6MG^NZT=9&"%; S\
MDI]RJ!6\A7CE-0UU=176:/!>65,QDE6D<;K@'!8K3-GE]H<7,4 5!W[0N9G*
M'[0DTX7Q[8*W#U[(]C"?-7EV+^IK,9P9.&A-[$^^:WYA@]2_:1JR:7ZO,VPV
M3O1FCFVXH_G/V+9^K:P#HT;H3Z5:37)PT2:7!2)JB&W-1&9R:N473[;?LJ<V
M0X>$3ZA6H#S$K/FASI;ZIU^;0R4(7HHWGYZ/BQ:D+"B!(.6\HS)C+-!NUM*%
M3.7NEV,I] KZ6LQ".R+W9^ET_ [*4=$_TXWVGK9R^WQZ2QR$%R^(RP^J'F.>
M) ;"JT<K!"80BSZ/ZYX-\'L.(7Q;PZ2C$4"3)A16G,MP\#U8;F9(T/BYIYMW
M$8+0]44D;#OM=6(87N#@Q+!N[@6TE#UF)52AT?1N;(&_-Z5\_%=^O^9<LK\9
M#.D3_[I^CU PA,N/K=7DX$F*FB8RA'E< C@<L1"W,L%:2XAL;Z.1+4]*-\+)
MUX\ZU@?-QS/.]=OH:7*[G9V@C0N#DUQYO5Y9Y,[-]2-ZW\--^)=[ZX=&,?N4
M'ZRPHS6>NJR:<"U/A^#"F7L%5-&:-]7[;U(S-*O,<Q:B)HKEP\LQ*>C7;5\!
MO6]_>+#"WI!^@"RBU[RQA4PKBP.A1,;ZA:'@T>+4V9]<#1:8Z#QP]]:H+K3D
M3_3=/M>P],=^[J_'%%6+_G8'X-!IRC4P;QE;NU/$3GI]/LX*!!Y1+[4PLP"S
M.[Y];2:VN9Z];B+A:,2E4] @?5CE^KXQ6)[;)$[/^.=)5*;8V*/#!P,+L=RR
M&*\12S.S1]4<A:D^2TM4^T^E5=1^7F"JH1*8ZU*;[#0#DOP'<U8J%LJEOOFX
M\ZPI'22ZH9:R>;PQR.=W?/,QEOE]!037V4F830 TH_84ZX;I&/=9M:!2DOZ9
MQI\]SM4UQI->GUH/%'>GFH'EA-=-@>\:,CK3,R"OCAY$SKZ,4@K^[&]@9I3=
M=H0+:,@,Z[7H8YP1^1/0.62S(5P[G-Z[YXQ5,Q6[)_=GT9%@(+18Z;JK./M@
M)W'AZ9VFB[[:=*4J,]E[9DI.L]G$2X#5J<5L_GNXVD@(G_W]T/P2UOL="#'8
MS0V<W4#'IAO/V*U89)BJ4O-Z0W&$> X*-8J,)J"-16S3K11$<@[Y\2 /;:7?
M[6/F(TW"N7/:UJV.S'W+YE";=CYZ4U(HV5B7N))1,O6TT>BNAHV:0M,TW:<W
M9/[V!A;YFW!NQ=25Z]&O:H38XW5!/;4DFC!1::WHH;O^D:QNO!FJNP)^44Q8
MK37E%(4!\6Z_YGXV]AZ:21?6I[5Z1W'R_.83&4K/SF!QVK3FQ%/P:'O]Z-[V
ML8X\UQZ]-:25U\G( *12 D9'_^ZY_G2Q!3+61%\142L.%MP]3T9K2V7[_MG0
M\</HQS]J %VH1$/<>\_<WI>1#??/&=XTFY4$'$:!;7@T<O;/X"7$K*^B'O64
MM:W@GZG"+,YU3TH763-)W+IHDDN%':145)2R7-02^+W1@1QA8P*?;_XP$9[&
M.].!ED@03#4]3N(-@S3INW0@/;F@$Q>?RH0B\-_MQG+BWG_ ^B[8S&C[MR 6
MXV^ _5Z8D/^4;4#X/N3O,#V]X=9V";AQO-=^TI6&OP3<4BZ\-XT+W3KEFD*[
M\61FU38]G]=6Z0!]VDAE"G;^(?S<1H&'[4@Y.2:?4WJ@RBU)O=")GP%E ?EU
M>+(:MD++NQ6JX-E\#!)! Y0BC^!ZZ_+AG_*KG=";2C-EA+I=M24'BJ>LX^7>
MZ"R.*M3X\BE=*=_*:,)0JK/Z;0;G#\(#07QGQID5T@_%[1)?(NL$Q0AM@]<&
M&8+]VF<3O28E'?K6)'^WLHA>W//Y+>PP4BEJP:FG9_QN,29.P;,H0)_L6TP.
M)M0J<[7\ _CQ_7V=/H5528F&K5R=Y&@2;NCM"$(G7L GN"/A=3_T=CS=\6)*
M-^7)V\?D3V\Q2&%A NA%K?[]E*$[QQ_Y+QJFDKMG0;Z,0@AH!\DJW+E),W=2
M:D6SL#K$?)HN['SC?+X%%0LI<_0+RX/$Y>$<SG%FL^^RGBK:I _&H@2DLKC1
MI*L#4GN^DU\]^2;7+=2RB47\S!:J9=.:A^$U"5=QX0">#QVG>AY(YVAN(/4*
M23TRP'#I[Y!01@'@W>Y?*-BTCBIXLK)<Q'G[3#B_*4O0S/]S?&0D[^.GW<T^
MP6W-$/,6<A,ZD>R6.TPP22@1"\C1.'Y6Z4%RB$*>5M[2QI_KL&IPT->@=3CV
M*^2G!U\]]% H%<QWSZ@B?PY0A<&?PX^_V'U<4N?O7<UZ#*D'+U^TC1&0FOFU
M379&UUV#/F0=?"P\DXW0'F\9\1D*YHK]4^"J$)?<,,L)-;.*-PZ?-[NVN-L1
M%,'#U:4?H>(95)15(?WQD-%!$!RJ>#[3C7)20GK3[I4(QN65KLE#!Y*_A!]N
M$JI=[O<?[I<6UJ:SB=*Z\"7WGW*EB,ZSD;8LD\6FHTK=2CIMZ& >LT9['P_@
M46W?&(?W#%8 <"2 ^F&BA2I+'W.=*7?>D?0]O0BU6!A]?[E=$E!L!Y]K5L(%
ML$Z)>@B806X\R*$4UOJ3EPH%T&IIHN,< 4/]0=^048TFV2 0X*%7^ALD\I_;
M_SM>]E^6$3_K@,O\[T1;"_V/B;OK#U-XC97\?U<*C_146;;^T0.]=\Q0;K!C
MWB\AG,SHB&J(-A):F/?U^C_.3D!"<Z@)A8536L@W5Z$LT&*]9W3_T3<B\8/Z
MP<Q_-9<4;&J]H@+<>S0Z\NP&ZNX86\%_[H1Z3U,W+X2+BOL_1&B]1@W6<JCU
M=*:TGM%52I-6"5?FA\);A$<"I!=H3^%*$)!7O#9:ZV&AK'/=M,"# B8)R?7T
M_8$)4BHA-_!FQJE>4.^1,54*QT&@2<TC-N#&;5Z 4-D/WT)KVZV*0&Y\:ZPE
M TD]IJ))  R/5#2$7JM+4FL)UX+D,PX*ODUXVT ,LONST+A!;EVDB3C0C<U&
MJ[<U&[3AM-?& EC&9C8M[R5>OUW+V/+$*:Y7$?.TA^*VPZ9ESX)XO-&1LC*)
M_9.'DK'6* S)80W9/#>7[%[M;1QEB=40W9VOL;5Q!3#_,"CV_W ):*=-G\J:
M5 WHG _&P4&DB%_!W#Z_@==5:*(4N8Y<Y\#N%M4@\^\4S"+,Q[9(%Y9D!?5B
M'8CN_"6@JS(JF%6LZ7YY/."OJ0\S:'B6A-)$ 9+4?1[K@4383*;NTU 2-2E"
M'"9[A/ZZ"ZQ]47XK;0"N3 YX>*I]9DC.)7IWS(H2ASXU*=@%_PN5$\P&5G^\
MT''9S+Y-P]2F3_)]B\,UFKZVGDX88Q F^]8*F2+_#$(\"D5Z$FV-W*R<T/)9
M.0L7&C5H=\#+!ZS<3\5^_338C9.T'-12TY4[*( TJ)Y,].X.16;S2&5?.0,.
MGVE6V2=U,.%PZUY'3+X/]LS?%7\G*S ^%^F_<OOAK_N XS,@<N+P$ZGO=PO5
M1$IWASPP*C=C*_WP<^*5]^X<-#UU,:LW3D-,*>@2CM0%Q4Q!RWO"?T]T4J$^
MP"\7XCXM4/<%T9:D K,U$.S3._6H4\LO'7[]1122(B+7;D0!+"X!3V:R4^-\
M=+_,(=F_!+B=WI@-,"(Z)_@XZ#>.@(Y3\*^':*@L;&Y_;+R-CU]^":XWVV:7
M4$XD141+70(HR;J&)+:"45Y);91_#VY64N#8L?"+(4_21UP.&4:BT"0CYI5H
M.T\8TY"Q]A/BHMH=:G)TSA(2Q;F5$L3L+XK:\U:3QEK8L*+LB@UY6+AH!1X%
MSIJ\%RNJ%^G]:-7K"J&G3 :(I&Z6W?*W(X5VMV-DTTN):UB[$1P!@;\A(+81
M7U4/X+E*[183AZRW[&O^E*%5L_:HORZ^+R&B.0"Q(([+7Y -OV ALR]DSGV6
MTCAC+PL,\]12:W$O*:E_U.+L5&9S@S.BUSQ1?IYDB2(M+AJ?/<(0+=.*US?+
M?.*[N*K!\N:2P-2K3(5+*49M"GI7GE*(N#[=X!>I2'5=,:I?3\BL?K@OC;"2
MK^R*Y_()/@P=:V%U.E&.*-$J!7<;(S$+C>D3EC-6ME7'RN;?$UPUCHEJ<JS[
M+QT\ CP[F:)C*\<%!+>%\(W<]11/=RS=\/QQ?,PD;$<K,YE=L[XAPXHXK:=9
MTBT-_UWEFX:K=Y70X)RWH;SE6\E+%EZ \4/F4-Y=O H@#/)TBIY7BGRG-HI&
M-8J:Z>E;[OB!(1&_[%<K9Y*^"V:PJ?S%S\K,8R*5TF:QW.J=7<6N[U&U'>HK
M24XU54JAE2X:"%;>L4 Q7>24RA9.^'<0Q=D'DGBG.(#<AK*@T$&2L)\/A#/O
MGNK6-L&J=!55'O4\?-$;=TVQ5$ Q;J(MX,IY<8M(@,_P&<V"MB1^\$<6^SC*
M;$K4:VM#P7+PZ4H"(]Z(HO_-+1<E+5LJBO2AR1[+\QLKZA@/XR]KP>Q-*B2;
M#DN9:B(+5P"75=AV:XT.'$Z3($U[8#':$?79.58BRE8PLP/_N%Z.C^J\2*SE
M3L =$J85EM^=2^YK^V !<CKA'4NSB5N@% ]S9:F6GX>_X^'[UORCM?+QBOJP
MAW'_R26 \'R!UNKOG X9:Y>WOG*A+2&JLZB19;S;6_,^V9;B]L<_?Y9BW#"-
ML*AL?B >=';O'P[]<@FH,;H$&),H3[RRWQ>GQ;AQ-W:I/MN%WM/36OK!_'$T
M520EOCFB/]ZZ4@$69\EJ%?/F3(+9(IM-T_;H0@NDD7#-F!/V),1H\TSPJ%*>
MY- -XSZ3)4_.PR) *4FYF_&++^OE7<I3)2;5Z5)(QXF==Z\MWU\^+;_6,_\1
M4_</G;#CFE,)R_/H$:F2 R5+72K+;B9=MZ6IKM>;>[UDD5O!U>731&$3_16O
MP S);^7([4 /M8=RE3?(-*3VCJRGI*,.(, 'JS56KF@Z?XS(TD3Z6FII94#"
M[,/&&\+I=Q_?CFO'-&.JOYE;I)5Y&S.3'4^12'T.=^U_U8@^+U-="H#[SX)6
M8#_UC/:UA)>EMM#8_?L?];0#J0HGFIMBOS@,ML75Y5Q;;$&G'R/H-ES>VG8P
MW#:D9^A\LRF/NLCF$>4V_2')%VN\..*\.)[]QB2D\3VR9XYERH)M2+NQKJ'V
ML^ 1C<3C'>/_P=A[1\/U?FWC0D($$=&[1.\1+5%&2+0(0M31HAMC3! ,1DD$
MT3L)0:*W(<H8770BVF P&)THPR 8_<WG^?Z>W_M]GO=9[WK_N-;YXYQUW^O<
MZ[[/OO8^>U^[(*SD*;"V&MD:=;D/6[ ,F[W0_RZ#M^GP =QOK&U*? $EH]",
MCYVW 9:5P921<Z[L90,Y#SND<JHYEM_LFGJW<.V^S.XNW\T8$O6YL6RSS)5J
M ?QEPTNUQ/0.7 Y:?E$;$&!EZ&RJ-BM-$N@:.X&IR<=I@[F^444'<*=-^"7#
M.,$Z/=9D#7L""% Q<)-TR,+[QZ/'IQ/B=@=:HX>4?$M;UN]GUI+/?MS"B)N+
M]P7,+LM$KNXY8+#A3<6EVJ^I9,RQQC7M@(D)&+2C9K!4_B,2_*$1=D6RW)VK
MY(;/^$5H_;:(\-(=AU;BTZ@BF>6E#OJ&&=$P;L-T"Y0CF,ZV8"8KK2N;3Q^(
MSDNK,[ELI&>(,4;_*4-X@MD'=,I<OD+KD&O[O *H<X/%.>;NM#KL_# <D@?E
M[7?GCJI<TK_CB@;3%'1_15RF"MT\"%\HV3++YANI5*):M+(+$%</*TME(@B>
M?[\1_J3$%-XX':_NI=@.7II3HUSX/H&X5Q?SL*#5<R_[QT1FH* -&%D'L<-M
MF3I?D>BCQ!-X\>^F)BJO$4VHS/\,TP%Q-]%:*L&0;*N3?EEHCPGT]E>)6E'9
MLZ""L\^5!B<Q_F,IR9E1YV&0VW%GNHU_3T^$>L6[NR=-]?1W-04SUIL=OYF#
M@IC!RE<DSLWC:R^=;-O V?7#SYO 2]KGM+?,8>^P%BXCUUMZED5]ETHL89GZ
MQ%@>'2&=*>#:TP">F94^!0_S;FW%EJ84?-4!!?X&H7&R7>Z(LE3=HV3:$F"0
M]S%E+GZ7MC$PUF\G?I&*DWPPC:40%;=0GNT0DA3ZG?$($W:T2V>I!Y6@N8@J
MCH7WM4>]&A:A\5"YT\HU-;CDLBW3 M#:=?\V4.[ TD=1;&-3X-M31K1>9_A]
M&+FG&:W$XQUK?;IH=;_:R"C.]-&LIH%5Y0< #RB(?5^\0AR+W11*@3AL4L G
M1Q0FMVL"940@CE7C\I#@FE\]\AH[4GW+6]:FR_K3@DM<1<OZ> -;I].7'S5&
MU'VR020^G%LNF"+^ 0'[[?4)KL EF\B,\.BE] F9LOYLJFD3X25W#5K'/PBA
MRP=F5K,ZSHQ-L>HPS<]OOJZ7R/;.6VP";NQY_?8%PJN?5+ZO+AJF#UA'5WMO
M12XVZJHYAX/E$A/M5<,I."8UQ1Q&*6J(WW*15NS6&'?[E@,.,4KP@9^G;S]C
MW[S(N4;S9#E/=8:\M;63H4_,>J@^(3LN"71$UUY:JDY/%6G[:>^]=))H6>,>
MPP'(KE<3R0SQ$UCT=E)I]+M^7'XZ3;7DG 57(?3$+M& ;ES\0NL7WJF:67<=
M0&$:E04UFR:5;$I V&:3.I]!AAQG;]N6VX]^R+XKF/Z[%^#/H_9QK/=K7PQ*
M.RO2!N)2[;MQ7&"\N[A[S]+:_MK1:WN71I[=1.# TJS_E^,H %ME^+3[>FOV
MT@U%UG''=\/[E4""VU$K#[(N635)=FQ[^[SI<)S^ NHF?%BA^1*%D<D"Z]76
MIU:*N;-+)WTF\3>%$+9A04.GZ\_'9)LL+(0='EIV>^H/_KY&%C6D6[])MVWG
M<HSMB87"!HJFL--YGR!KBWIC,_OEG/:=^RZGWVH:40[99VY5R)H=!VX<( L<
MT&M25N8Z_UI;? 'ME/5,7F[?G;W]K/X8$>BE&J^Q1S*V[2WDT!J;NO:0$_WA
MQS)GL2'JEVQ=T6<;D&\US7-1LVS%.G:@+-^N :[2[%RZ84))(MT0.PMT3;LB
M 0R$^#V13CU<JA,_-PCX!MN>'G)*0^_=$NVGT_/JF8W)3KE@[DZ$%?48;*1K
MP)S>#2?[\C*(AR:%!9Z:Q+W:V&3?,6]V@6L2&ME]:\&/;7U<4K2,FJY(Z+H%
MP_"0/\&WL9M!O&/9PA.L,AM\F6M8Q=1=@\Z2C5;AO?WN0'JS3F>?JH(OGP=*
M'MG=/-\*7A*HRB=B(3H=_F(/,R'2-*TL.M7%CQX!/LO>WIK;K?QF[2R\ -.,
M0BHVS"><Y:8^,+JNY+%K]<Q$>%'' L&L';UMAJ+'6G$Y2.^<99^;BB[X-,3K
M-J)&#XTL8E=?(W-6)517<C!-8(NRX#NJ][=HR),]:.]8UBR<9!%HE5V=]_PH
MF9H?5UK"MH(^+X%; )QZ]^TC<U82V@@Q 5<DP!4E6PG4(CL+6OT];D?Q?9(.
MESFI<^B?\D";SB*-O;_+[>T+3Z94&O/B8]7HY5GQ68["IW=A ("#M5D)6[A8
M%"Y%)G<\K5VRJU>7V73OPP, PIOF,NKUKP!R%HY#;H0CN)5V[,]'2'?88MWX
MG5V4N>5Y;PO(E0F;J[IB\6"T-H "YT23]5O1ON6I>#X ,!9<^Q5:8VU>]]MY
M]I96RX_C;_(M?YB*:(.78CTQ3FP.V;;)I([/^N9')I\NMN'GH)IAW\*'\5)#
M\-6D>^DVS[-[.HT(0ZF^9<"-,ZS&[%&+VG+96K$K6\B>&":=3?87UG% 0[>3
MY[Y47%LL.& []-73'VUW#A^=JP?GS0$C[E;%R<:23^DKNU[$958.( 8*<*Z8
M[QU=;<GN4@+2DU'#2!24FABT?SGTK'[<9]>O??C3A&>'UEL/R'*+VO$%_[?]
MV,2G!W(*3C4^3:LVA 6D@K*K,A>NNS96X>CGF/$&=[;_XTU=/P?<(\P?%;H"
MY(Z$^'*79[E.CE2+:D6E%IM\5&&TV808$]H"!3#*K!J>;+$]?TJX_$;>X@S.
M';R,*TE/?MP9D,$[P.S$)@41P(C+;DCH?;[.9A3E()7"NM%^BLGY />4Y33T
M6VD2EI88=?=DU%*R5]X<L*:SI_;2JO0I"=>=%HQ:1D+X8*EN:]7>5?N.!WP'
MFNE?O!ES'J;%W&W8P$D0X\G+BYYE+^&!&VKY5R1=WYYPY'0T4,I"B28'PX5B
MVG*9_J4 W!,_0S7%H+=_FKXW)EQ>"L!@3D,^$Y)4-DJM(H$4QBBV%!1)O_O/
M'R+4SE_.#*-]5K4J7V5.PAF]%@>VE)TL"MM@ZP>%IJQV+5[9A]^6Y[!U$;<;
MG,6[/-8OE4]8^O]4NJ#/59AC:S]$=:QLVCC$KU#22PUMLQ"NG5XR3N2$RS?&
MY11M".HENJ_8WXM:HKN;TW7X6T4AW7#0BZ%RE%N9J-EYG*S#A?(L1OUZ+VK&
MY\[7=^*U:V, E[I(6JD?<1YOMBK#6;AB4X);JFN2W=Z0]9'$$2O2=A?BDDMA
M4/W6^.TV5_0.8$*&Z8IDL[,TA&(QZI#VVB8VYV/SG(8Y ^B#6Q3MDN$CV4'#
M&H]FSKB,MZD7^W2YJ)!F9G >#*8IAODI5SZ8_N:QF-?X.!=5TDP/TZYOF?E,
MEIZPW+H[.UD+_VK6<+0L5709B\/8(;O</EH[OF\94WU%LLB.^<,)5'Y^;(1$
M.3VR3R*[O<Q2?E=7!M<6.3:I&PME!V>D1918=!?9IBUX<GA84.4/+TG2]M)T
MA?^T\Y56@\E*Y#E#*D!B3ZF*<Q+Y C64::0[&[>A]C*D6#.F<8B!H&FW8["W
MN6O45@E8M\KFUF\TI6#2*N] FKNN"^@X<=/$8[:+A7=?GIJMLWZ\\E!<2E+\
MVP,Q-_@4'ZN$L-M?%N;FV)IV?T_J8J(QAC%_"5?I,3M?CPS?4!MDZV-8(6>4
M&&&XALY%?IG]D<0H].NAT5$98Z2:^+]:R97]NXJU)WJ$S ?]3N?_S+[X/X-$
M675I_[6JZ#^!J#7XYY;[/^K:16]8U0%1$F1"1:/J/QP?@UQR%_Z.P//OV2KT
M+@4%,QI8DN?"XR__5:HD;)*451?"&/!JHTSOOX:L_D&R2T%N")LZW.+,UC56
M$*]\]M@:N-%8F.>\>&%R:05<&M#+@)6C71:UL!K&/*1/?7_3!)9HUQIK6%8L
M^9<QX)VBEC#"7]NCC&_G4SO0)7C8W"76]'!)7"0%@X;98-%&!.N:9=IP:P47
M"?3QDUIYKXWCQ!ZZU.67>C?)1MX\\(\Z2TH_,6#=QVUN1/:L#^7<4?(KABT?
MV>X--:F$(?5I9UP;Q7\!31*]7'H-,N%B=YJ%DV)68NZM4#M3O&LZ$R9&S;4Y
MS9-G9@8, JRDM:/89RRVM.]EX)[9?#9G]4J,FZZ$Y.8H>" ;HU-QQP">B]3=
M@I$VI^!H.6QV5LG4'* !8:4)\2H:2NIG&.IA>B:<1C/#.(R5G3Q7J-"GKDLM
M+?J8J9JCP_84-'91B2<WO:?4DMEPG6.91?;XP!DI];FTP/1S$V*N>_M\..%2
M$6;3C1.[R+AD(>8M'F4)():@-W0+MX3SAF+IYV[R&F>05ER;B^WD]%_^8@HB
M:!Y]:23BB\V!(&X:)9W%$O&._C)K6+3^F1A34%6/!8UHU0*$A8SO3_NIO#>_
M!+A,QE2T90=N2QN#O+!?%NRQN4V<Z03P3" =(W,)L<U,M *91_1N06_A-\\[
MKDC\OJ2MD\6)?B%(A%82,R\I8TMA)C.=P):Z%N=O<^;(L+E,=;'JO ;'6-I?
M%P]N<AP-!JX.(QBM9^9644:72X'9J(8#S7  CP4Q[TBJH2%>"U/.QGVK(@,"
MK=VPRZI0+X[,TZK;=5,9^/+Z:*D^APJG''].+_4V\BU>"VP $]#EK&W[KGOT
M#8;9?B\IZKZ]PULGNKV-AA8?I05X-UBB+(O:VUC8EHXO*3<68MDF7TQ((%/B
M-</^3+T]P:U:4]J!WL4(+-:2ZJG[<^-3RT&F;3277*Z(Q<$ \^@S)]S:))!P
M4?*7^VAXJW4XA,0.6;#?LO_F-CG1BX2U]0Q_:)7;,XU1DEZFO0;[R4V[E<$@
M/7-%XK3%I'&@VQQGZ8Z+^MTO8.QQO^[)=?N,>B/+@;XA _]L44+;T7LB9$DR
M%FC=ML2_]QXV_Q*E3PM"7?(0QD\AL8W-'\JUM$0J>1/3[/M_L&S8.&%1/TV:
M(SJ":(A92^0AY_H8)5'EK.:]6<U"HOV+;#J^Q.\.(+YL$.6U]U^$K+\D/:HT
MBZWKHQ&6.>*@U_S9=MM;9YCT<H:;24Q6G,S,<>\9FW?/YP"HW2[HOD9,-5,F
M.T.%I^KC0CCO^*W+N1PVZ,KW<<B?@3EIW?=C+[-['% -,+N+WW%J31:@1TJ'
MY*T-L^R).AG*%:?NY:;W]BFV*Q$"J65!(\R^1PJI!<C)* EO=N?ZL?5XO%P/
M@P'?DT++NS>7*H/;Y8#+.A>?WU;2NLJQA2>7;QQC0V?-79D\9_JBQ6>K-7XH
MQ+ROH&4\#)/8-"P9#)1'+=#%2T3TMM5LN>;4J'3%1P;=VBM K'!Q8Y -<-5%
MO#^[M@"JP;PAC=G!9.9^0K/<0^FH::(IP=DRN;.-Z_ $SS<&O>2UL;($80,Q
MC,LA%B</:MZ---RH&B=G76LMSDU'8HXFS]]I_)RC'5*,O[N)G3RG;S(D.CLN
MY-!K+W/3;O!JC;LYC?'':/)YIOYR,[T;3B9:\WC8]9@;R][??)%XKGR!7.2^
M8]7/?01$(CX\/=-_\?F6W9I0NV)^;/H]#:\-&R-\I1!QE=#;;7/G'F'UBB14
MR22;:?)<!0[]RIR6XUK=])-!:OB.(]_K+W=^A Z:UAJ"D!!W?5&MD_F.MEJ5
M3EWP4GI8L_[R)[B'1%-N?H9[<O$6CCZ[HZ>]")NDAW]?QAMRIX&'1)_L<<5P
M%S;]\Q7)#5)"[*Q/^CYH!*:WV6.EZE8@5_+F0)1/PZK)EY%URSIR,9CBW'KO
MX8#CGJ0E(<#%4&+:#2Z=/ZLI_J/OQ-I\/>&&THH(V>^.ENQ':)8)!ENCUX%"
M1U$29QNO#2!F)](+D-'XHSGB7H!XUCD36TMV_.T</]F4_AN=[1P##_/#U+(*
MPOUV;<S'-II<.1J0&A^?"^7F_Z>0'*D_^D"=@03+& CRB /Y?25S*<;B'O-I
M<S)F ;;H?EZ(/!<B^TOLA+U]Q\Y1!XR^T-X!(#M("3G7YC)WL>UE,&>E[LR:
MYDO7TV(V-O^:;\8\^WY;CLZHQ XB';Y78:PUI M2O__78$9X/NB3S428;S*_
M E[$>4?Q0^=%J7>X4I9;<P-8=<M=?;-IWA]),9BBXS_I[!>ODS>TT1)-.CJ[
MW[GSU3<V)W'NUCL! IR:XN^:3UFZ[#*>^<E-L_ L4R#?G';O%.1N2,U8X,2.
M9ZH+^0=N5OU ;&QFQ*7?MW9RCI&L90\$\>BP+H"=.A'-P7S9O9C& )4JN 9A
M.R,0A96I7^1QU!@CFIB&OPWT-:EJR%Z"G6\P'VL8L;[*+LS'-*N6PDRMT6[C
M5 FCM  A(UJI:C^$_+'=X;.3EMAX2MFV"&@!8=S0RO)GZ* \_>W'VS1.\.?(
M-BL^BY. /Q%NLXW4]>LQK\Z-L$,Y)9TEO<6]SLX\-G\\VQ3]$6_3<<)CXG_J
MN2YMW=Q?B23?!BL;I6#R-NS[*IHE)9(PH9W'*'E?:<WDZT77[AR>@Z&O"/G^
MY*&%EKK!\"UGR4];M/R?%A("2[T)/4C'KSA+X+S&V,"]-%8CAT\7-Q2VS# 2
M2LR,FUJ-;ZL4*>T_.0_^X(B9U)1.-G$PVSS<R.S&44I/3;%'"NK/]0IUWBHB
MS.LW5A'.,1G=874YO(#1NZ^9;4S6DTW^G.&?JY "YZ(_FFQ_]=RGEE"6L@SL
M*8 N#_I3UO97W+V<I'F8UN56-DE:%6,1':^&V\A0N6.HS+7U-$*_^4S):847
MV/.#I#"Y^U)DO%FQDBH,C6_MA=XAW=0XF=.W-+:RZ-Q8U@5B3<(5S:/J$_H%
M=QDCYGB,+KE'WUZ1<+':3=AGFZ+;ZQY*+W)S[@$KC)+3ZF:SH-_ZX/*9+\?/
MO8LWZVH&/$C+^A)^KH.&7=%[[@BY+A4L_4"IS'L_<<3*R6N#R>S#42)4UX;R
MHD:GQBS+'<4B<; ?<T5RK>*I%@%0X[Q4]J'9;#%R\CA,XUG((9FLY:B7Y[9N
MAHF2YE'AV-MYJBV@_,?EII2!)7:KB,'UXX\/:)'PN5+PPXVZNC1YGY&?^'3<
M^;Z^M>B6"E92&\H.4YBUG/F(5U)^ZQO[14QSE4*Y8<::% M(K+6QY'-/+!S9
M\92R>I,N8GK9Q&%\=\U9].AD)\V/[IF=8K!XMD!'5>\+4W4"JKLQ_D-1E(ZB
M>066_V*BH4]3L%CVA[['14&I[HT2%[?\P$Y?%@!RELC=G='V/@^L[9;V^V<3
M)-]QB'(W8^-,S@'86_F[,2BK'(0R5"?%#L"+\"(LTJ)<N0T:!!T7WW@_Q[*+
MO&V#RW6]@R=B_O:LY<.TKICL&S7UXU!)[N'Z=/'7>1)%9[W8+'#!!DYR[[K_
M..FI<"%DV?<6BY%G/:KB0W)1[.W*;YOVKQS')'C8:=/3A/0Q#<,4OYD /$T9
MHP@)<6\5H7Z.CV]J)  GW @0W*0Z&S?P,YSQ@Z6=-JOI&ISKSRX9<6B($^$O
MJ-,$#A87P)*FDNU,%.PT/!,#GTO7$P[Q8T0OR_=@H=IP^<B 9G)G,N([CIA3
M$[D"QU+7OY-,/DAK=%R\(HGOS\=VJ_Y8;_4P5P@J@"SI^KGO=/=L"$I)IGRE
MR2+?PS79,.M"*US:"+$L\.D_/32,L^(-/G&>\SG/ ]V51P>PFY,9:26.SB76
MJHS?'H5[%F0]@*T7#R/,,<@L??WZNG&[ %Y)K%9D7=#9XQZS4RZD1<>I>&%)
MB:YOP)M(V=9M'B72LE0>7XZW%7F6.A"PCDLE!,';5/^L0:?XU<\ITH,?F_I
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MP%\'TS'(K/8TM>E%3ZANNL[>![M 5TUI*6\DUB/^>:9EAN1=V/M \J4Y-;Z
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MO6UQ@MW68U61V,3XIA,#Q'F/0CFWL<<7IBS$%KHI&@.PG>;^4^0%KZ%%S3&
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M*4,I^STIA$L=)KOS)-J'<"Q&B7*GZNCUDO8(@N4K#P6MZIC-\E[O=@;<[-0
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MUNL+E7DZB-!S ]-?-]>=E,I,>HDW%"Y48% _[%['!:EK_*)MG-.9^>TN[F
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M^=2W]K?(#;B#+P/:=YZ0UQKV/95RTJ1'J'&^_?&KLW*R;%U(:*.D$(;#EAH
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MJ[6\<Y00500)4N3]H781>%"8U*/EAP EY;PB<XKOH"Q88(KB*XDH[).[H 5
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MC7LQSG6K9T*BT[OD<\39JIIX*553XKI]V4S<X3<("CC(R'C:"[IH1L&=S[F
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MF]DK]=2W [C X_.F))KR1@P[<!71=W(9T];XB]LD\FB#.TGTX2>#BF]\WM^
MH9P-_A\TE.@K OF4/<]'<O/56N7Y@M4:*H[$X[ $%[< IH' ^?U9V*[(R2V
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M=$9.P0S_[US6/VOA-AXCN=0C]>'A\" DIX9[:F")FW);[.%4\Y\/02[G K<
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MKF<NT:P9^-85)#@U5X4P7IV2?A%'G=<JU[EAO*JV/Z8S>C[6)?[P7M9&,C-
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M[KDL\W"M:!MINT],K]43&MUX,J%<I2PU7D2@>LZPF%X' S",%(2#WP%WZT?
M^Y[V_&PQ<85[OUCJH]FC?/>:_ 0I474PG_#UR=Z#I*>@C8TQ&Q C:7!S7H]Z
MJS.QR >*,DJV08(UV"+GJ+79EW"Y^D2PT%Q)*=X)$GG-=B61&\R=<6R>*-3S
M:=$-F5>'=X6/\3ANV3BV4EO]A26%W%A1K.Z#4I]^Y&2M++V(6KQQ6%<-$X0J
M_-0-Y#C\+6VQQ<#:,&QR,QO:VS$LU(4<OE$_NW=P6B8K0%O40H,E5=]H+&D(
M9'[HK233<?4\WWBSTC'1S9QZBO.ZRJ_5\/G8+_-![N7@JUU2G)I=!@6X"EO
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M<JE2H@A-W(5G??);;&_G>>K7-^\.=(,CGA*C(G^AQ\U*I]4Z7-4HL;ZQ[3I
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MQ%HQUL,;8_]Q^U[F&CF98)W@BJOP^@YP0@K-UGMX!XAZW+9YFT'A<_F2=?G
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M3S7]0.*)\)9^<EYU+_&&()/+3UW=[>,$>FM/F=J; ZK8,B ]1_Q'#2'-2)M
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MC)*DR8P,,L,E1N!CV:;+#Q0I6$#Y+H_B"U:_2XZEB6NI?[AW^F\+*,!ZE05
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M\/UMOGSDJ7:CC[?)?L;J?6*3&<I@7<Y968/[['CT1QH EBHG31G 6FN&D;>
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M-@!"*22M5[\]*&&(WN-RH\*WS)#0(RX7,7-+4"TVD2UD!:\+T;E6==)X\1V
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M+(KVL*PD$Y0K,1@.X?7B4S"&=PZQ>./KK NV<>L(-)\9PA*#AIR:DWKR)?4
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MU4G[=MZ2-/GB<F\&N<\.2A1@R2A:3-BD9N$ <9SLSWY.*/D$QO=X#G65W\C
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M-Q&]M)[7<Y(S$2S[GD@[+V+V><1J&?4N_)[$AQM9X8Q %X,I9(6R:,]K:RR
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MLGN^K92Q*$'3@:'JB5P*:>+REOOX/HQ^2&RCKM8X,ORZ4R[&=I,BYTNY5<&
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M-_3Z1P?/8Z?;)$HH=NI&)T48XRC 2=6?P]V?E.AM%SZ)PY53GVGP7C?)A\D
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M[QJ:6"6.>+L(*V:\/AS>KGL)I ]@_[Q">P#HKM8LO_;YW3+HO4=N94>:!2J
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MDU?M&#=N1_2!0JX<ZI)=W$W 3,4/I$RW?=?0=X@K[9W=R5W[UM;Q0';Z(/#
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M%13M+BC(()CZ?1D? /T2D=GBX[:JQ&L33LJ$.,M'DI2GRFS_H*!N-6[3;92
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M4JNYV4814I'$?$4R66:"Z+J'^Y8341X>&N]1=MH+B?[/0JFAS3J?#(GLA13
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M,=1P^H [S#Y[[D?8 ]^L.^K()(_O>XNTA 0XX*_08CY#X4W0$(,:[DHI0[)
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M7%^"3LMDWBD7&=] 6^.6XY-;)OM6Y=]]@XQ]K6M.6$=2TKL^<SX''D=@ ;_
M%&_)"GP+$0/ %=IE+."AU(.,[<*S3(+?C];TQA .6(#^:-#;^@I'O1B%5K"?
M]XA8LN !)F*R\(<EBLN^J^(@!U19#;92 E9L /6%2.R&,=))K0O@CNIA] LG
M: /D4V\PFI'/E^KG01[]<6 O9B>3J!9T\GP+DP0;:1Q&,UQD',(M#7N *Z#S
MM7Y2O]TWXMS6.^56>"V"0(0*;O6:?E^4SGM5<F9_C8R >^ (G4#<;#%Z4N0Q
M6C.SW7J.H 58>_1C@&= D @8ISV$$6Z!PY>M<18>@ZVK)EFX LPQ6EFKS%@
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MQP(,(>-[_4WL[1@R:1P(SP-.-<O\0[.(J(9DG. 6!7^HPB 2!WD9FC+.%["
M-.N_6P+?Z=%$USA(D'%%NHXST8_0@P#WOZ];25>62(?1VE-+TAC70X&5##(F
MHK50DW0'7)LDBG'X.I((>KW9VE<R:2N$$>?$ O:2<29[Y9L[4JZX=E9"ZZ!Q
MRA\6H'_/JN@WWM!9'G=CWO%"6W"H?[I0)Q[-@ZLX+..H]51@5_/O30N\K25*
M+&!=#X<2RF(QKF,>4IBW;$@H^V:+@.#2@[=#P#&-JVGY92S@ZK8LC@Q8_.MQ
M/!I:;)_KZ9J!CM/ "3C.IFZ643VW/2OCJL0QI 2ZMW0- YPK_%6MW0@=M/\&
M'-:%,.F*Y 0XTQ- UXF]<;8^-WIOA&/8[V'- 3,*TP*ZFL[ZQQ8G003:"M?%
M#BS %9KF%?'_M/?=44T_V[Y!5)2J/T&D1@&I(M([ 9&J]"I5$>E%.M*"(J!(
M$9 N!.E210B]2HE(KP%""[U#J %"\K[X\_S.N>?><^^Z[[WUWOOCK95969DU
MLV?/GCU[/GMFLB<(& ]CON/9QI]UM7-*N ".DP+<VI [^"^@FWGVFHL.M !Z
MJ/:2(Q#HB$\5 ?2R8&21 -(G@#:3=_B(.FH1;E$'R8'28;]>.]T*@^QP]N*W
M\1ZC2":,$EX!Z/X4N"<0O+V$EVU,V"FNJ0:'0G8NX!KC/(9^26@^X";0K7K
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M8U;/)>6% J$FR&$9 /:^?HP3:]@.>"<\\:+CQ4ATV8^1U<<=6IV,KC;$R[!
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M[H1#2\4@>X<D!!"M#F);H[UOCEYDRV2R^2P\Q/!'39+.EIG>\%* #R@N.90
M>I]-  4+SH&/B<_N'$!PIOYR"@:"@!SX"*#O29BH4Z*SRPG@LQ@5.C+\O1(0
MO)K\&:DA:JTNQJZCN  *;#UT$7 08N\!C+A' (PQE?L!<NDZHR6JH,+1N;'M
MW"[>>_"[Y@#T%]ESD%]4&])_9+(4)!9;^0$,DEJW0_8 QCORH&>Q-!YA$?A
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M[^G<^)\Y6_W_Z?]*(B*,_0]02P,$%     @ YX-_5BF)CF@L]0$ 4!<" !
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MX*K,S41JG-2(^]6L0[-W==%:V#NBQP_"F*L(-3FR@R?EGH2:S30L(!RXA+7
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M9FN0-KO"MS/Z)XM'=]%G#-_WI[H@_$-J:Q3&P[N,'I\D7U3R]\N!(>IYVNS
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MK#?^3]!E:"KUR2U-SEDP(M20R)$5I,V67I@FE#:D9IUD>PJO2)$<D]WF7"(
M] ?,[BSP.&U6EP2 $2Y#4F"A]^#<0GV3):?.+>:JCB/'&S8*TLO75'BM05ZO
M;R!KQN_/93?!@N75(Q[45+.($#/JF*3&+AN ;JW/2/>N"'G%EB66>^5=$Y$-
M\!KA9T:_QY>; '%U7>_NS4AZ2($IU\I/@R+X [BN^E>T&H:!9R^YK8A)S5K6
MF@C0X7I;Y&RO*68]PCY>O6S^LK;=TW:$VWLL=*AXS]ZQR/"(EA^GVHALJ73F
M+6N+6;:6ZX-RCJ+1*$4-6]T5H>!G5F4#'.TBAD!$.1!JI&K!J("S+-*L_>?B
M-4S ^.$K4YEZI@R!7!__8:J,9/'2CZZY8XSD5,UQ2A<X8*NY:D^(SIY-1G*=
M56J=6>CK0(\G.%5C%4Y#2:P?&)8+U<9V;V^9 )V\GJ9?8:Z_7\T2DZ,Y-4Y7
M57I!MCF(PF8&A8<P_2<XF?-/=]407?-<.,9V< SR$@&/ $>JRL2KE6!#;CVR
M*N*-JGTGP.4_0!2Q*KLKYG!(@>U](QJ"4A/C0S_9NV,3];-I#>9D6/&/!J3Z
MX]<U]S^R<?I*?AZ4A'ALI.4$@H(6>@2.#)VA'X1>U?6CXB0U"((1.$I'0I6.
M1EU&;&:,SQ0Q)*YQ[Q"^+*%@,(#U-,8I.:FR^139<%'+OZQ@X,M:D;Q(H&OE
MD"W9Q0^5RNUN5X23-'VT,KFEIG;=&KC0T:)IK"=M49;WX3(U5M5*'E"O[-<@
MH29POVX2:03233MU._57VN3B#%,J)_FX2*Q,%F-\%:-9 ;A>7W=,;.ENW2M=
M8#N:_-7]ZXW/-\UV:@("4/&G;KG(_?ORQDU>8O;70$,(X2A094Z0KF58F/@
M5"8=[[&^_G.*0<-V'Q9=+$"4#+L59^OIUR6T(/;8=U']/.T9^J?WJX!T4?4U
MZ4YROL?]P1\WD4W?=J1<&DY_H4GE[_4:JX&P=S9T#B@\/7O@9OMZDN2E-T@3
M48V2Z*>1W6K)FYU6"[*D&<Y8E&/^DPVU_5N5N47I-HSO.J5KC*:,TFSD M_!
MJ0DN-_*?H&Z6X!G&_.;KU0W-C;)B\GS^FEEY6FUP\"X8]7TM<&!L%_K9\E4X
M/KLK/QL!C]P2K!OC4;K&-ODAHX.LV\YSGV@0NT_B3[ID*@WSUSORE1$H7TP
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MP_O'Y+SK@+N;S3+49S)GTTV-":$*DO.0VRE\IMG 3V^0JVU7P-8*5U6Z1']
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M+1X&N2Q;O[UH[_V8SU7+\@PNAYJ6))EP>A B%D4YZ5QICK.&\Y.YJ"?/<\L
M,.O"0ZBZZA93[\&%ZVNK3RCT]E2C#K9:]_Y#TI^ \([VS04.G]YP^_.9/T<
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M#FY8AC96Z][-MTQ[P$L;5UC<G"(KJZ)X$;D:.I_O;C1K9S"[V)Q3G"V0ANF
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M2S\'R_:+TGB]@B"U6.[,GYTJ9!:1421VP>N!K&E8450L3LW<,L<(6J?)#?C
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M^8_/!5#SFOH2;DZ0E[WW' >%YZ?O1>]IDXQ\TDV$*B<Q&OS<HY"I@>J9=31
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M9O7X]%<ADT589XZE36#V*=?>7%)ITSYCU0H68";R!DW';:<(WV,1KQ5T;<#
MA J4*$O9O."*D(X$.\<P>53;GRT1S@^>'\@0I=_89P#O_%BR4]0H#&G9NH@L
MM>-5##F&JTKB#5Z7Q*N %RW_QUO$3VA\LE&LB7C=E2M>4;8<PW2W\8 CT%\
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M%+(MWI?SZIOQ#P)_ ;C2+?0G8$(_C8/C=TGN+LR^5(??JS&F /]XBAM)9%P
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M"OA*6U&ZZ-G^[&Y)!,' :(D'*5KI(W:R<6SEO^*Z7*KS-QWQA?_$7M>HG!T
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M=3>1F=*$OB/5,DB9^FZ%5<(>)8*&*/3@7]U;OWSHHHR/\(+,N]730M&.%+6
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M>MQ!]PIO\-=:JC9I*R%T+RU$4%K&TIU#VMAB</7S9Z-\L,I=W'CO7@<S:^^
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MR%^=!J$I8*P+=<BW1!]==0^N&]YC-O7*-A0O[]<:%=J'+"!R"_!HL*>D^N"
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M$;3@\.9TD6R+:%2-<QX[XT(WL_WI!?WNBR&IIX69PQ*C[A3/H',W:T !CX0
M)SI3XE]&*F=[U2NC2)1MFQ16I_Z310'.8[=L-='7X_,T66M^65[]S14W -/R
M))C;2QG\/FKD:]*?B75EE]]ZC*SR>?E'5R8)-?W*LJ9B$*?=,WL=D/WJ(^F<
MK,%<JM_][=PL*5UI^:G+K?SU)1&L>[))T@N$W8E(%>5"'3^M!I^/$A_.*G3
M#$1XD3J!ZRPA6:N.#,:,LTV;<^Z3"1Y!%%4<)G1!M<LM"X/8_#+4!H6 PFV]
M?$?#V09<\*E%G]Q%FCFQ2/Z&:3C'@YAJ]JG_'8JV_Y=^!)B;G7.,?PKX'8+M
M7V4&/Q:.?.Q=NI(4XT^;SKY=H:$=5!%<(IDZD_%,L6P6ILH6&<"KL]"O1V4T
M3[S&3]"&GK2<H!XKS'05<XG!N$PQ9J9(&_U@O,N?DQ8L+B5J6QL9W@27&&O<
MHH1AE%CN2,F]3^P)91P*7[T/C9/,>SR>WDIH 4;5#G1<@I,P''FACU=:&P@:
M=M?N_=JI@*BY\GFI9\\!5D//XH1'IRI7/K.Z8*[KM-8H=>"'<%.O6_6(8:]'
M-1&)9?9ED=S5:0?F# 'L=9\+C>=?2LG:=]-$,(C#8V+,]3:#Q[(WP# 74DV2
M30X<XOK=(%32/QS5@%634#"ORD8F3S#2.$G#R+64]<26YPG=?@P8]8+7@6Y!
M+9FCO%O5Q4ZB@8J@Q7]\]E/[VP]-@SVL M*P4-YM2;%TEB'X'IMO[2\3L'+^
M;:VX4!WF0VV3^0]\7).P1+4AK\SV@,J*)6O%,[U@\U CUH]K]R>ZMV3<*9Y;
MF5JOIB!&!*Z[5-QG&DV@$MVGSLAEU!T..+SQL8PBDI25GPLP:E*8Q$"H2N*H
M4,20B3D^?[DY(FMJ$C]#]#H8S!C/_MJQ%_#>IE+']<"VA-I.O\C7QUHMKB(7
MB9 BY[Y?%'8U3^=YPEK(6S?=<E%1>:;? ,%J7R&KZUY8 MZ3L+LO*=]6&*>V
M_\(:+Y)9J3BE:IY24U?Q>U6V)D3ZF&G0]H.!9QZ)+1MF&J\U$U'L5PKAI^6?
ML<C1B9D&+T,([1\P-0KVE1PON7NYR4>&V7!@\<[@*Y$+JV3-M#7?5QZH2%B(
MX)NG3/P'/)@6>-8_'+XZ:?\JU]-*P]T;] O!46P=^\20W 5YYW)5GZNG(M$V
M4'I</D=H-;E<68:R8O=#,:V*0\;OGT>0=.O5/O_Q]@S.-B QT3Y<ZF$MN/H'
M*HT7+AUTIN2HF4MC590OXQ(8MG"B6)JA+NNR3Q_K="29.6(L-:E(D47NN4Z/
M'L:9VQ.Y=2YYFDUTJOL<6!Q0_6U%H<'C\13^5JUJU1-^DL=$MD*D!C&Z6AD.
MO'[I\%E@++VGN.+#],5.S*%U7&RJZB^M-M+FI,R)E7YL+S,U/ A5V;^H)5!1
MG02#0BQSMMV+IA22WP.8#K638[?*Z'EG+1G9!>.YRO]7:5#9X"-*F+8!#,>"
M^W]T]VBH_F=J<N&ZE@U2_6>"_H>26!I<_W\. J7(:/Z?O3<:,&&%IZH<7(,X
M_U.MQ- ^\G\Y$58\_&^)Z5 ]%.?_K'_ZS^O_VS]KW$HD/R&2XHDG,!E@L^4E
M(**X#Y"APS-#E&\F,X%-V!W]#>-$N:P@Y-2@T4'CM/NE;: %M"'M*U)\XK[Q
M901T,E/=;S66J&KU"V \B51^-Z=?0\Z-2!\'2#\1Q;_RJ5Q=.+VBOJCUK)$%
M2@A^)[ZI;H!8@%EC?T#SN]KY@VLB7+V4.]X#3LV9>*IN:WS%J7LRG4;Q72IX
MY<W5WX0;%\+=KB#2>TI\KXE'>B2C&%?!B:LYG]U#361R!G[9>F[ 2HO51I"U
M!)^TX^O=L2_<6"*WF1:-Z$#+AM2BJ8A]3ZQZ/INMQR]]_^DE&.V]BHJ\CS&*
M>"SX"+(P_J+_E3[AYXJ(5(JLM=Y##&%9:9&KC^AW#SG>TGE'X2)]**>:4C:!
M@B1UK44&ZH=E"P&IC:H!,[V>Q40WWH18D[5\\##@R42<S_$L@J54 _#T SM$
M]-DS4Z1Y%IMNV!PN%1OX(X.)N77N*X+C26-#K89>9"+OUU?9#X6JML9S_E<T
M$(/);4F[2"CRRX7V<OACC])XL?STS[;@!EFXDGM@P6:#8V?.;JQ_:,0HX?@/
MWLDI^-F+3%NTW,6@AM=V8)O[".Y4$9)6,E-TCG+&L?UE>B\2C4JCU:]9XYVZ
M_@Y8^:Y"(8^5O82JA6T9,7]\@V1SDC0+K*Y)&?"LY[X(+#GCUMXAMV9 1G N
M>UON<K2?O!6YTWRNA(N*+X6%BLJ/B225AW!TR_1G-901:!B_.A*UDD^W5?KX
M7'$*>+C,UZIO1NAWA7NLLEULO%\M),@_],,NU$3C>A1XXDRK,SP&/X' K@9P
M)#(AN4SG/D8'9R%$[6A;O#'?X$.SI1-#YGG_L B!36JA2?CC4(E83JWVKF%W
M(7K>N.;/[5WH$':9C$<A-TCZEQJ;'?F>RS@;SCGE%%/J(JS6.,@E+&5=].:$
M[5U-X*NIVR_K;7+2"^,C9E:U:KTQ23>-+@62=(-_,QSD2SX+-/OXD1-HFQ:M
M+LM(.226HB 9GRVFGI;^KH^!^UAPTR6)R^(-(#B7ZI\JC\5@C%NC3@-YGB.#
M.DYS1OD:\E]$A* @WQSFOO7_N0S#7D^&EFA60VI8\8*H:Q8%7.PRD3(RRKZ;
MR0*8N>5.KY\*K[= ;:?&!%8WJ*61RWV.W#W4%* :3CX%+-C7Z7SZ*?3(R]U!
M _;"%_<1^MM)?+K;-H*=H6)^+S'YF5Z07U5YT\1?<*AII>XQ?=NW2,*=T=^U
M4[]IW01O89DXD6&+7E5#_W"\R."G_D__RYH9_CZ!S\3'_Z"+F5MN%7R[N/N$
MC;V4#@?2^JE,K^S1I>WIS5YSO:"XVP]CO&$?F]#57_C-0A^J^+PDI.Z)'M45
M:-*>['$0,F0FA+C\*2\+2?@D)BP+EH^[K:7-4L.OEMWK9$$E<4].'.RL".C?
M8*1I#>.\ 39J+-J%SRU:O-[VB?_^DFG*W2V=K38(/R\:R,&P8Y;XO-]:# G,
M:O7]KK6G59AY>S5;G.CI)WV:DDV6E[/Z@>[""E/1YN<D/V1O3.<+[>QZ;UOT
M6A"+7DE\1%VQ+AUPK/]MABI///2W'HYA*?\@5+Y@S\W+._D#&YE5GB51:]'P
M^&P+RY>"#4N/):,HHPG+R"GA;7:S?8HTW5D5DV!@O7ST]')"SI)(ZJ0NE%(I
M\M0F!FF8FE"1JT\UUCA24C55JLPC6O*L,+.<38-IY%B#;HB=.PHVH[U;0!%R
M6VP[/:DV 9L,\WT7!SAH>Z$J2C\F=5OW[3HXYV717FW.3@&IKH#DL@1MSXGK
M $O T(S1NEN:FI;#+L6*C.UJBA^BG/6YO5ESB[%'KW'3[PECD^881^;XFH,G
M.87?:@PIJF6HVZ22JZJR]-(ED;P_8^HU*U(>X;!\$DXO&S'T^H30RC4FN:,8
MSUGF&/.O26\2VBL>J9ISY.>5_8;$B#B0$]0=:PES$!$"Y\S=^,ZO4>:=A>54
M9KDM^,SY-\"\FM4G)Y* 8HX4%9<81&68HWVS%(",IW&ZO[E0*]"C5*9=?F%F
M10<*+(F$S>%:7?O\+JM?/[- L!T_'AHUC9,#U;H@9F8MZK*C*&THR*(LT\Q$
M!M.$>+/#FBIL>%564BX5]SJJZOGK3\!NYIE$!\](G<<^TAE8$(UPE==8THOI
ML4KIL\HZ-Z" EI:6GP18!I\C==RJ)?-"ZSZ(3A-_\.=PQ91%P(XGH\;]\HV6
MQS2^3P0RI<(-N]>^9[E<_I=J+9Y>:7EZ"4Z/$DP3VO-0+^@&LB6H%\ZRBH!"
M3:0,+:-5RBZ.P3IK]_]PU.VN_ ^UVV&'=KUO\A^,EPY-XG,MO@41_!<Z-S@?
M!TL($4-9:,/JF]L_L?L,<:7Y$?$H<S'&"ABU@+6/=F=WF1T5T3ZP2O'L9G4V
MQU/"5'/*0HYY5F7BR/$55F"Q4[W6"Y=<$3V]K,P$(Y5- :T+!D(_0R(!>*2
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M9'J*H3TV1'72  T8^6^>@JP,(-Z7-X 6Y&G7UB)4Y3DF7<-.]H6*'=7J5RH
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MW+A3P(GG["1C:L2),3X**P33H9F_@$$$WNG W36&MR>@X@Y9G?QV%JT^,&H
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M'B3^3]2;C!5@D*B(VR((0SV*ZW\?VO(1!XE*"H/P\$UB9L  #AE&*'$^ GX
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MG'0$!C7^2B,':E!R# P\ZVB4/SOBU$0FW%;.^W"<ORJMU9;N",Q?UY9?(!6
MX/2#2B9V;N_+BLGN"M N*HIS3%4$%\MOS2ZTVXW"\Q2J #I).1]CA6;(?#%!
M_,Q#>X26OS/4E4(.4^ TH'C<F>6[G_$L:@M&"BY)8\EL[<2ZHFS8-3C9;04<
M5N+>53E-=(2=9"V?U3O7$12598:#NVS9Q6D^M^XMOB[T6#U 3)5QJ%X6F,B
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M4,E"J401K5JZ&ZP"K!2 CV(LA?^O\L^U1311E-H0S>P$JE*6M-V8>X TB"2
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M#7K^EKEB/1A%T[$7.0_+W*3&%*Y4#%;I[F]&[Z25?D[&[V+#F$"_X"2>#*-
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M^Z,%7\ET(GX:9BJ!2,23>PSVLFVF"NI-DU$@NT<7C>""P=MN%D<@WS#[B\L
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M"99GGN?KOXG9G.IW1 8!7J0R?,\OU.ID@%@+4(9")+^L7I577WN../72$H#
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M4J9)[>11#>XQ__=%5"N;0"*WP;]&;@OI%&7/2<TQLU.9&U5%WDY6)]+^J%/
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M\5 )^6E9!KZ=[+NC)KSE)OEU[*Z?QUTB8MA;7(Z$I<,T9M@ =WP__5"N+:]
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M#2@1YIJ-]0W]LZA:L5?(W=]<61-$8R"VSTQKP;SM'[[+V;AOXZ2#J Z]E.2
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M9QB#\L,+=]U*QUH+Q]K12AXC-A_0+!76@I]#@A\#&V^/Z%^ W&J^YX:7_R]
M:-6$YR:4+'X&-9B5B),XHO#ZQ>J[TNS&1+0;Q+:I=2-9<4";;CDDTO9Q&#M"
MZEH?7Q"=XK2VMWD_OQ%JE;&__*S"N4!%H!IXM+4;O]OAN5E^8R29KN&1*MC1
M]Y#@,'Y^7H(X9X-(JVC%HE*LSIDR]:X;+=1#XY0I@KZ+S!Z)%7D9CH9>S1_M
M,U2JXP!  =9R1[X:Q@&I3-XO$. :Y\QARM0>LI4^[FU&%H<DUE7U*:_N]701
M/16P?1.FT/^HOKX1T^F-5^7*R/E+GB>WFX\I8+'QSJI+%GSXI5Q7^6[0<YOD
M54V'W2:Q-94Z=R3-56+HP3&YRN_GCY0H,6&I[[KA#QI%PAM2.,_N1N>);MVL
MH&EW_69C8GX7&P >HD:LW[.=ZA)<XQJ3(^P8M%SUWK=JA4^2#7TUKQ?_G966
MLJ&3?F?&HY'*L84#TJ('-/>+JXMIL$<UZ%CZPN0Z']X2"XHY'%L^8W<940S)
M0())79Z?(%A*/1E=DG4BQLYZJKLV>I6XYHA4$;HNC"MJR-$DHMQG>=081P5A
MA'S"H?^<^0B;;0H^:X ^?L'[XOK,8IM<J+*!MHK[>S<UIK(15D28@C <OH)6
M-8@;)K'] %5 =#H-7)Q:8O0,PP$Q+>('BXQ5-Q*=2EP,BS$GR)K6U_*?YIH\
M%]K)R1W:QC_'IE=;#P7ST0DD-.CCY][<[[X6G6O(22MWI_J"G2<^Y'@N^,:K
M81K*F?=(<^"QQQ-QF'OV8G\<6;5D*-E:R>?@-#,-W'!E%2,[%$^B9%3RACF:
MN7.\P&V<0?U9*H3.&O_G\J'9O/<C=9I?FX/?1?.<EB.B6?-TW^PS2.9%OB;-
MS"?/PK'!;JB1=L$+ X5U+$;M"2G#?:PYWG^I?C+CIX@;V"RSZC01I(=:#M:P
MCK68@G+4=N'4:VXVZ0*^]=N5=H)+C/E]'3H][=UP>\<5S9[7(\IFY\+D^U9L
MC35IS)[/XL]_W*._5\T/4L%XNQ?[-5T:IQU+Q[\B2,0F*"";->-J"/RR,?8V
M1+VC='."*^V&(D:85?ER&FK9UN248RK8#S 3I;R-WU(@W33/)^CL'_=FVC&V
M.<46(1P'_%OJ&^LQ8YP!N10-TK0X7S+\.#8D?R+[Y8@+W$M,-Q.WU$7CA]#0
ML)\W3QUVU'',TLA7)Y=(7ZG=.<ZB?:FA?<:.+]6(:$=D88"O7,CGXJ4Q]A^]
MSA1#2IK K4P5Y0H=F7M\'VHQ-D>]46QU;&=C6%2@4,:UK[GKY67K.. >2AFD
MYP__3,'3:#+V^-9$<+G5E0S#X$KE8.!X%=,83'))W/U6G+EP?]SWEA<%RXH[
MBY.X_C@)-#S66W,U0TB<8/N=/)Y]55./UJWTF:J>4Z7@) (VDY-8HM%/EI?7
M?Y_@?<]*T]UB2A:WRD=;I&Z6",ZI!P0_B%(FZ)I$Z 2;,3;@L/[J'1'Z,UQ=
M/\A"FS40P%8;#[>1=\^D+R#J)D$%4;]0]X]VRL/,ES9.QCKO&OF>[JP>X*GC
M^JQ336VC;J-Q$],(&22(W_,_.1W=,&A(6]\11+<\& V,!^!=+ Y=X/D.QI=R
M)J9C?"F"G5@OSZM3;Y3AF(\T-;4)./>T'^1>&U/0]H?>V\M.FKNE6_A26_]A
MF]5+X%G \\%/F^,>!T=OT.I5S*=LHY6.3W&\"G PZ8B*;M*]FAR<QZOW&=)7
MXGNG;\%=W86P;]9.V5%/+7@^CE$-\%YY6F[$WW Y((+9*K=[W%KB4E#Y9DC!
M#G)D.S'=3U:T8O,/!".-,N^=TK8'A=7/%,PH/=!P=@[F^F%D,<)_K!CPIBM-
M7[Q=,6 QRSR(0X><2J/2W*),-]XV<2LS9!<MN3_:_EY**G*. 7C^_$UOCYX9
M*H7>O\T8AI$D+EYQXA\LZY^SJPJL9<QZ[Y,\'XY((7"XY:E?<@L;SAWX?5T%
M8<R<+;H8DQ-Y[?[>TXH/K99EA.[*?VGWJ<0X;L7N.S \J;W/AG)-_GD$:\R/
MJT(T)SHGF;%K4C?#0[%*8KV6DU9'W,M;V':&<, V$.HN]I4J:'_.7H+H"CY>
M(483@LH^WW4]K4Z!M5'=.9U'ZY^ION5Y!:IPR)0IT,-'@H0+$_C>F.HQW=E?
MKU!E!7)'^^ !;"7WW_K?(4#0P)5/\8N@.JPQ??R8(/77*8BN?,Y6(D,1\K=;
MQBWJ6M%D*FP:JA;&*0K8"OKO5TV_9UZBVU+Y29#4-OT,M/$-8S%RU8VDJ[8
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M,4I2+3NO>O,&H*:*3%97N2P@A"#_0T@KC,S!_K_8H*,?Y\8ZTOFO-;5_\'L
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MGIC:#DZM?ZS^"ZAH'IW)VSO/B3P:Y!^^Y>][.AC@?-0.EO\>1Z8HQ@OJPB1
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M>K[A(%F(1XV'</#7D<5E'UD0VR4VN3@'\^%GS*Z_)XF9A5N:[W?U[RB_ N*
MMW^!>QV&]0=2#+ERP>5O^ZE06QDWI+H%?K-&LQT0+V'*YAR97M.PY4H]%8,]
M)3;T45>L'7-I=-5.G T6TZBZVBLG!N&D&PU$(*GZ"23^NX88/3TGSS85UFJ0
M+IJ[%'Y"-A)8JLV>_I(U-==8LLAI70Q=T)REWJ&#8]*3L9/B]N98G=0:,YN/
M><1).CLF.1NDV!@QVY?YE0L4Y/A$Z0/6 *9TP$H4%75EVC''GDW(O2)?Y,?H
M;E5:;%5=6+RR/KA95-ZNU#@>]'C:9CZ(S;O%Q=Y&H,.WVA>N$4=]P^&+^ST?
MC<"Q46P9!S20Y$Q.-%TR33,2G\+4^3I]=B,7.@W)16U4^/%"MHP3@F0:7"G]
MEJ_-VE(\^/RF\B],$)W=U2*\6 0VW(%8,QT;@UTR78T++Z:\4M8V'L.E4]]_
MVM.$:N&734IN@2F"V"J@[]C1+%%)[F[)#"8C/42\(*N%C:$VKN^^9GFE9,6N
M-_HJ%"2AXI;)I54EGPH95]*WW^<T-5L@9:#RJ.Y!NNIJKMD.5:"F+2Z"CUZ^
M6RX+J7C3C8I='GLK9OO)?5+?'4+AL%R:W.$@L)BM>!;P.L4$-F#>3/Z*5.@S
MDC2PWXHC11,MT><NPF5GM-R5OU#NIVR)GF^./A(\^PN0]"K6"8_P?8B8_XRH
M @_E"<X+E+:B;IZ/$0MI:^H!D1"61H0>A3DF]&'@KL*'[TYY6E"%&6Y,'"+'
M7Y)?T(J87TO)KS"3\HE2:Y5RO%SP0!YYO<W,#Y=TGFDU5PS^\_H6E%',$H6/
MRC /2P/6]BTS6CGEW)I.*L'S6S\(EF:*@']@6;V$/D$W0<LQ@;W-QFX3W6^3
MV1_E^$W.=)RHIE^[(LX6G\LG&@P:?"03(Y=<O3$E";H?'-[S;B=,MIL$4P_+
MDYQ^Z'!RH5/<X_3I*5]^L6'^D!(?2N.=6G,<C^5#0I&RE[J%RDD^UD2LR6""
M1QSZQ7WI*<4>^72;<>>"K#77BQ!]O.E.=&S\SK55@D_VZSJ/"H7 CMZC^-C>
M$.EY]7;AV"#(RDFXG6EMHW:*XTD# 3)6M>D1B. C-5)NA0HS@D7R5)1,8R%,
M,70@^P\TYFS)]?C92/3H(!EQ(-&O/T*N[T+XDH/5^XUB]1K>K)&(JV:NG..5
MW7ATML<O:B3CKE:QT4VN_W92?8@&I[R8^HFL1WUNJ*F$\'_2'"[ ]W,=S![/
M>I>C@F;ZLD,WL.)385=3E1*WSC&G(%\PXETRRNZWR,$A7Q$W=P9FQ"3 ?,PR
M=J*9TS38,T5'\G!=@^Q-\:.TQ; ?V64#D6IH\L0.AQ(UH2R1V4\0LE]#+=+E
M=Z8H1!A-'AUDEFT=ST/;=/F6/<8^W;'\0&O<>X,4:=+!Y8)O6/C;F!H=_= Q
MFSAT=N16/4P>2FUZ&!"=_(?<(&:=@UZ 6<?EROC=C>S,C9%GU08I^'G$@K?=
M^JFZ"<L3ISU2A4Q4@T;IE>PN2G)K Q^+16">5M9R)G1//4S1NM\G8+RQ@&'^
MS-@3>3+8KN[DX#?.348 LC^G2HC9TV(/8VMK<0K4XC99UC#X7#&W2.BV+HXF
M[=<JMA3*3 TJ=N%8ZUY]L?A%E(!09LC3H@F*!O5G"PZE^P8,(\L>K4&8<-;Y
MT7:1-[JXS7%"N.>5W\OJ!G*>W3^'&L]!F^Q/U\QE.(6,AK11?X%X%K&9#@V6
M?)8<^6'$-AF1S4SG\]Z/-\HJO+]OJNU!$T&*:$:8'&SMXA-#0WW<Z)!<Z6C"
MGI.>60?Z+Q!-0ZK]%S"*N1@Q]WH/HZ$37I34V5P6OICXMG%V>KX7>J^O.>*<
M9DC3+$PB2![:BU"D)%6GV*Z,:ZE@RJ@&#^;)=J:;)/1W,<ATC[9;8+5"3F#R
M<#IE5&R]J^!UC4_>JK$X:B3S$B%4J(!.D0R"T9_A3.$=_5E,[A!*M79<C/MF
M=NY7A5B&W.AZ_@4(A,F^((X>[AM\-7WC(]IL<&2U6,;I::;@"]KB2#VT4D1U
MB>1)SM-P$E3(A^$' !?3D^.)X(#OBRYV]3-V+=%]PX4/W&<:%GDRZ90R$A#>
MG@5K86)2: B+*3PEKNVBKEG.<?"7(XOG ^V*/B$W0I;Y+Q6K-P]1WV#EU@?O
M-Y;8U@3<^B-H#[.+4>KK:R[>A*:T1TI!A;Y!MHNE?EU<+:B0KTFG,>\B?T]A
MP3M#-JRF%Z[ 'S)P3ST;KHP9$<(,!Y=M>U,=DJDRK)V#:Z,%"\I]Q%F1_6TW
MKOPR6IJ08*GLK1M0I5\V.84C+<.3=)8OXC2&G!XBT@S D7=""ACS!'S$K&$4
M<[NN9,KV+C)E8#'XBU\,^3U[\/(]V[82QKRD>+CDF@:"N[EP\B5/U-'T:SH!
M;EGJ"M2DZGP#.;&52H7Y[_OR\CCX_U +&2D(O7=#B=ZDS""+:NP^&[US.T5=
MQX-]-*W>K+F1I1E^U+WQMS6?,3>'H-[A4D1UB=ZWOX#<194]WHP+_A]QUVT(
MW3H!^JV5P S-)E_R:VYI=84M-UU;/^1@^KXA=T+AHU/'9E.3+:M'=JO&HJC7
M?2-E]P9>F9(I;ZJWCGW6,]5+]!5W6- )%+,(.>9YBP5A3KP(O2\HD'FKZ[/\
MR&@=]8[L)YGFH24X*LABG7_ZM>;DTCFN(9VRC%)+95R0!IK&A"L*H_ZC,JQ<
MR1VI8"0<DT>/QDM",*M?/Z^C0:^R4A2\#?/,!N"WW ZWW)&P  ]'N5Q:LH/'
MN!P<+R95K<KAXQR#"T?.0L75RZNFOYW>I;$3T)V/>X!IQT+[;+ZZ0)1]_/\"
MX<9U#OVW7)D]?X%)ZMN'80K-0R$*\T'BB$->F^"+-$V51#+-BFPQOVO3#XX<
M1C$+PRWLA.SR\7\\+4Z2"Y*1B) DG%%FDBUGR2.:^-IE58:4C&> (B\H>_'<
MTI*+AN%U984G*_'%5['X8'>+Y'8GM+SJ3-&<<O.12Y3M?1(WYH$0[WV&P>;7
M7\TE86=],CU;R9HW_/'S(?P8]5WM3+J38J%GX=>%XX"3'P]L"-:&Y?64=.:-
M],8?>*_R9W\]V!@YY?)!0*"5H]LXJ/640C\2O-!TB_]]1BN0/7?@E_88IK9"
MF?%42$**X_-1*H8!6$(U)2&+FFKSD-8-:6-C=-$O69&'V=;O0AXL*"B7.XC^
M6'W ^>O=-JYG:OQ1 Z 76TF^QJ)]!A7!= ]"OR0&=3LQW5)A[=,N)PV$T$C7
MUMS_.<QIG(ZQ1H#C.U0N/BN)C'MP>YN_SV>U>(_'/^O-7-ASPY3"?^,T&4(P
M4+DX^1?0H_P+W.E,GH5S818_@?YR1[,BZ07(<2;OU]ZAN>RS<5JS!),I^-RK
MWT93\M@!S_%AD-B>Y721,0&>N^"M=RNKYY3/8EM$_$P"ZW.UWYC%PLU#+SUB
MK2VZFAF+NN.'Y*XSK9,,A\H4-RPU].<5_O /MFT/(=9022?X5JH#F*)1QVFI
M27Y0) H]QC"/F2PS#WT5:L=F6MH";E^96 \N WU#2=]P4N[7KA[*)4KK/#BV
MC$NT=;>,3Q3T[")K=%(F62JJ_O[8Z;+=W1+K;$(<0C[NH:2,9MC+YN TQ/)V
M_XBT^GUDJ3#S6T1^\UY8>C;:P"LH%$V:IOZLH6Z%/6F5!B?RI@S$88H:V_\+
MD E+FL,FO@32^1.3J4"-,=[-MQ1.+XD^,-*R_DJ/W[T5D>#H%8=1E;=P2Y4S
M+5SVE\]W\+VE*D%]$VW/^X#U S25UVAV=<JLM*#3.FRDDJ=KRN'&"LYN28FO
M'W'=Y"_G>,4D%WDUA2^.'Z]@@$QZ97^CZ-8DY6Y+^%IWU(2))0/Z8EUJZKS=
M_CRP<:ZJQ/5308J]RDGZ<Z5[RS!P)(>7?G'Q*W=+9+GKAS/7F3"%$T1L0J,>
MR=[4^OXIP4@&B,TBC7"G?/^J.^'.%*MZ%TY(],[EO+NT.RU3DJH+?656KK^Q
M+TH6NDZ][O>0.K+?)XXAK.7V ]:.F>] IVO_\MI@ N*9TUC:EJJ$4Z,FRWRC
MQ[K2@B#7O,21-C_Q"T)SAZ]CN;X3@8NRR'?LZ8CJ=,9!@M<V5_$759'7?) ]
M=M!9 1DC?#>Y9*%C#?Q,75=[EIBC&6NR!JJ*53L")4 E()%X9=UGJ\8==O%
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MU&G39_L:>I/VC&,],Y=R>#"':7O$SNWXFVR\#48P7 ++YLE;!]$PF24K64<
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M#6OG2I*738J(XP@LT">6O@."I IZ<+MK_D\D=M\MJW*1V>UE0=*HDM* 2]^
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M+'=UWG'&&#&_ NRT++<>Q4X'$-^>)P3KLFBXF#/ (/6]Z$+8??9X*UZ!PDZ
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M8?4\*(_1 0UK2_+G_6CQ??0+*6_B[24!//EW/B^K19Z6NV"++?&I&1(]"G)
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M.F+9!I@GS%T UT8O@"K\!:"VJ5 Q74UX=E*LT4>/^4V]=JX4T5^KM=T2,=R
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MG66K5N&F(V^M(!]BTN+I4C>A=(7K43/O@OC#%=L)L/:&)JVD(,G[L)?SXAD
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M<S#+_FE'E@-C0PY7XLM5>HA]4:E"@<8^'_$ZQ/)G>B)%*=!]IV$1I+IIW[N
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MI<[;>:F7-Y4*CMDE\M]@T??_O7(Q]S]02P,$%     @ YX-_5EUA9E\Z@P
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MQ P35SZ#8*OXJ.')_/;S^ ^-E-A/\Q"*N',:X\--$)"FT7BKTKI><'_;1]5
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MH4K96A>!><S&?^DKS51DWN1*^5C7E^=:>MW/[:'^1Z4F=F8+X<U*#8P/<HE
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MM!+!@=?(Z5<0D-7CK*UN?$2,D$JDE:A_KFL?;VQ;\#([F;\EC]=,3$M\8$)
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MX6?HYJMJXOEN9'YFD[@/=#^^Y2L#FXH]WS-;@,^^'F"UI2YT !:F#F0@>AJ
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MEQ=&5*2_PQ"N=1M^,F3@49)^=NAI@AG*K1"^D:,]5HI<7+ E+ WZ&%&#*&0
M\0I<OEA7AR(&?R4#(;QQR<Z4Q@^\04)R\.F[\1769  U.+T[*1L%P,>D@JP/
MD=+,:FI12K+@05HY>99 TKH29&M+Z0#G3-#O)!)_8;BS QL5$W#4E^G=T0+)
M=G"YYT_JAA76X#IR=PCB7//[_'>.[ !HIS^6I<>DH(NSOW@LNLAVD W?PZ>2
M]N5#_IQTGZ%8F/UC_HNRWB%E1_%OU AG! GF2 ::8B%_S12C +\QT3_D-+BY
M0 8R-O_!^'$X*N"76D[_N?Y*$[B  C>?.MRL[(0@!77]8OQU!87H;SK0C7?J
M?5 B\7#=]$PFW2&'>TFD_;RM_$,B<)!VP3?*O7Y0<;]HOY$F[A[R"EKHR8 #
MC&1(6!H@+B,7*Q"[0YH&F71[ W"4"TA4]8\U4-,)=U^2@9X Z$:.WJ(^&5#[
M 3)3&*UWD?G/(ZX'@)M ^#M0SSLIMGOKH@?;+L%=OPCTY9=( M*OE(@XD"GY
M@*1?U'-T- $UAU12$/07(G2QG'3W944%L"%KN+=&!E[E?$D"80LN%2"3B8L'
M;H>J2/5!; V1 15']5"F?CC*@K@T*4K<@?=&G:%8%?D% C6Z)0)R5+8WP)D2
M*K"@ _)JNW5(*Q"Y"/H=?YDH<1M.6(G=/-R^#.(P_9HM3?])"/T:%%3[4#P_
MI=WI+?FAO$R:B>EI^)>^6F03R%=N=BBDE@PLYH RIR-(@=6+>IK :=#G,TKV
M^B."R4 QB J:[ $<I47\RI=."E1:<,X.90*=4(UO2W[^+HD NYNN6P$<?#V8
MVP.)-L!5=,\ /? 0I(K9Y &.N"QF#IYPN*RDM!N_"*I):H&$)2Z;I4,"D"KN
MXM\HYY$-SCUP?_ 4'L\-WOM)*RX511>9%X?C0L"#F$.6+=3S$Y.=*7K>S*5]
M,",#3T-<V_]%4/ZO&P'%T]@=\)+>XMOK-P%EA5A =OJ0;TX!ZG_D%[K#<&Y2
M<DK\&]7;PW\H8'[(XN#A[B(=4!L5?\U6#E.+62YX&WP/ Y%XOTD)('DX4W:I
MF ?S YAF"@;$MG^E!]/"BI5?.?%^?[_D[]2B[.+"^3L_<?PU8PB11?P*:<R6
MEIJ_4QK-7S,Z24FA_F^'&8%JZ8\,^X^#50ZY3W8!32)PF#9T*UX4_4Y&OV;,
MA\SD6>J:9=*537&H743Z7]_^[ZZ**!;*X9U#G0<^GHLZ>DK$$&OXB!;)YP6P
M_\>7CP+_'G=_Z9ZR[__="O/Y RE@F@<%1UPK^*48"H/\@;>'"9ZB1^]JQ>_L
M/)^7:VGY2UMF?\W$MKM#_J41^"LJP(!Q: 66/\J%OQW\+XW^3U80!%6\0WF
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MK;_XH<5I2H+LW(00]Y&_V<F6 Y6'(@,A\)VW5+"H3^!2QB\.5^+Q.K.@$IQ
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MVLXM,K$%<ZB=&V:S#GWST%-'!'W2YIW_>_]-/Y^\X'_B%5E1F[&1WE"OL61
MS:&IU6V>K<K>N7+TJ_<I^=BBYT]9@H"E9@5 ,F#5<8HY"\,&1M/1ETMG YN+
M16E)L%!SI1Q-A0'@>8:O325I?!>5A6BB<;,@L(MEY ]+&%,EK#_U+ @9&"(5
M8>TB!.QYDVFJ=FC"&B1ZP#QXDPU-8?:6%SY<8)[^#QFXT"*M8)EJ*W3PR4<?
M%*3YD@1K&A$662-,%!D_B.VALX'RNW3IA/P[%_\S#YCX?\._=13+.OFX,8%1
MX;?M+VTCY]@ -AU+'R35A$6ZT.AY\,P.90Y)<TTOOI:?.;[^&%B>GPSQ-T3!
M45YDJO63Y1?ZJ?[ 8$& C-5/-OS!\?6'SXE6/$DL10L2>C,]TJ%B<,8TZ]4I
M1C6:'W.,#82]ZLZBS[&!%C/"CIZ)V?5T*' 8PP6Q 10,<"4<@.O\<X!;F9SB
M,^)"GT!"-V3[C)O4J0NZY$$ATG4VX!&8=F 7LB0*CSJ\=V)N61M'7S0]E^Y
MFN1_.8]V:1_ $R<)_LC#()((;0^$==6&*QQ-]6=4_N,K^,$'.RPC&J.!2'B@
M!4^ILX( 7>8^9W=)H[^1E*PU&ZIED,OH]]O^?Y1C&8/V=.K*"D)/FJN:PBHD
MBB%+;'_FTY<54/S=%(^Z-,L(\0$/4=6!;VT%9/#/M:!OQ_=RZC#2:U%A6;EH
M*_@=VUE=CTL0=6?Z.Q-&HMF [ O3[#\&GO!T)ZD$FX#"<LP$AP83@H8.O/G/
M0AS,'C=&Q_Q]K4Z=-!%]EO,#//LZS0]MJ9;0VPCL-C@A4WSY><#&1QOXVQZ#
MLG )TX!^F=FYRW*CSAG9_M=5D%Y1-6)!<$_VW)GFDA?BBQ(H2RQ8BC;;CXS]
M->/5Y460^B'&PT@23#*8/XW^C^#@"AM8H^KS""-/]GW4C5O[.89_[6N9O+SE
M->97>(X#*F$HY;R#IJ(AII]>?HSED2765,^OI09(4P=R(2X]-E#6P 9*WQ3#
M(UXW2*+Q*+"!=;;),T>5(!^]<<E6G5?3ID)364S5/9T(UFIG-N 'PP-E+UA:
MRJ&1NO[%&CJ+%1 .$@/U)NEHY1\+&*!ITNZON=C 'E@*ZQ0D,/61+?M)<U2%
M/+5$;]SA!KN.8I@+! ;ZPI+K] '"PI,1#_1,P-7>P**C-@E:@Q9U0+5!CCS0
MY^>OA#ML?4]=W3'V*=73=A=8G>I3,B;93L]\F$,.] ,[\7L^>P2UTXBVY*,1
M7;WY9WZW:.O(>4_FF3L7+)?+YXT\9 N_!<1J&H#JOW+^*DR[,6S@=DIRY&E9
MN3?W<6]]&^2N^HAH86"B1*RAP0]]*.;+0Y,I"#_DUP=L)BQTXE5PZR'X1:D7
M7X;[<&NA#]^\W3("+'/3Q<78  !SSVX'\$P/8:"IN'/F[KB/""R/80;@&ZWE
M^ \&75V82Z+@AX'+!=Z>;TA9:;$AJ*H"5@!2?=ZK):K@M-T%AR=K;Z"R!TJQ
M6.67CY(]Y(X[FTT8W+P@I9WK\0:_"[C^VET\O6GD>H;H_:U5II:1T9&I,(Y:
MA/PLP <ITF%%<^J.8D:0A$ B$7J7,[M%Y]ZB"&#U%1\B*8OXH(" E91D"/EQ
M_5XC+5 55[?IS_BC"151!%.-30],"S>/IWD%=G!@G@+W]& !&3VQAJJS%5Q
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MP#F#)4ASE[*L6QH[K@X93B.G/Q+>$ Q?M?MJ,T-]3[.!$C&P-P5SF T\=29
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M2FJ:HCLL?MLHU('*0,N7-7QW:0\H*J6DY4QQL!L41(>J:#_7G])_]A![@O=
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ML(% -,39Q5+.A@UT5KA LEB:VRQ,AO XY) @/EA=ZTYA [9/T5/C:#_P;.9
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M$IP'Q,1DI&2,Y.2,HIRLG*+_C\==!X#J 7[  W,\'"X +A4.'A7.70^  P#
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MMRDY<K,S)B2? G?'+7BJ>:*4!.(&53WW3=_DR[A-*.EL3.G;QSCW/Z0&XY4
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MY55[ WPG][B%:-8DH;AU%_H;VSN42A/PW_S.#,9HG80<35:SE#.)XT>"GU4
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MCI+X$Y' =TQ1-\EL8C8;]VQ<)G\OA!K\F9+<X8^3W],^J7Y&*^^T3?$[P-<
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MSCEGD"!1PL7G?=Z3SUIWW?6M=;Y[?E1/3^^NZNK>W575NZN[B;\)R;.\34:
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M:;VLLM3F-0E^@UIV=(L=$DXSF'1232TVT/H2/5W$S)1KC5:UJR/[]IEZ$?A
MP'_4F2.=*?696(KH>J*/\'U;M;:LK[F:--G([!/3'\6*&T)F=&HO/?10PK>
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MVI]+ ?U/S@?_$?YE[?\_U?'_#!SR0?%SJ.JO XI/*@7)IZZT90^-_O&/2WB
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M>[><F" F5(E5ZLC\& @.QKW+!(;E1[HS*CS.3QC%+LRE$=1R :AB"R4F: &
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M57S'_=^PMSFQ^E%M]0PW<2SYK5"9&I;?J10JX3V&=7TH(;#?F#:_<%OE2M#
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MI[OH[=>Y34D[!^&Z:AV5N5:A;.^CR>^[R=$,WM,P9O=]3ZSI-T'7$-F2/[L
MC%]MIZDP,=X33/1@1"/'/C H=?&W,#56% R2G?&&*;RX_W%NC2W.H?:Y5SZ8
MC$*(4)Q-="?G#KWR>,^8>%E;31-K>6VC\=ZW%VEZ6TS,^Y09+]]O/*9FH^5R
M*:LD/DZ%'#_T>X[::@9_J"]SOZU 6 D[I1)/D#$$*?A\I2EH1=\3_D3L>'&P
M.E5)[;G;.CUB*,77E>9?N'()>!EWG+:,V7G"XCAZ$I+0<M$R5=E+<L_+:MSC
M+?N'J5UJ[AMLQ8//*93C?:M+BC;KE %O<M52*7B%#ME8QHQ[APJ2$TCU.LX(
M<TP=%F],[W[#0_^\F<0O&<K:Q$R(\,EZNYQY7^5M] <QZ-O@?A?A2\!697$*
M]PH]Q,#H5XD03ZD#KOC3",IPEQP[4.6/%VF)N^H1[*K5+$H ;L;BVJI;,EXG
MB"^-?7BXP<J :Z[;YL_$&AST-)A%OL"R*I?:&;<>E->G2D^0]QD^RLO-:ASV
MY_TZ37T)H)1A@9DJ%@XZVMEO]0XR1.??SNYO"_LE2L/6K\G4"%%RP9!_<"T:
M_JE/].UT)_N!^5Z3]LWE]K!4@ST];Q;OJ0 I4S^14Z+O=U_ /'HCSDQ(SB\!
M'])LY'H&YS=HSAUF6WP\<);X,.,"J*8FCX_5RDVGTQ)[SIW368Q[9X-%)FAJ
MD;;S&"&Y=\MUA2\A7>IWW4QUU"!!R/UOL2Y:@O%PJ^ALDCY(AKMY+Q*INI(:
M04X_S@;:&"W9?*]3;=K,Q)Q_9HL<5Z@=VT%+RU=8!5F3!:&K:"X\[)8N 2^.
MRJTQ8\>UW4+>=QM;(/'8Q:4FW8\[CYT*SQ68CP'%]8$ (@"C\%A]UAWV>;92
M4KV-2P#SL?V*TOZ<PSA\NP11*W-BS1<GW=:BQS+5(E+:8MC,U?7.20,PR*]1
M%P [O9&G1L# ]YP\S7Y.(3HI]-9I"7+NEWP_T?XDHK4=UUN'Z[AX2?)<IZO9
M8#W3H=Z!PQ#.QD!*R!S&&Q:[[[:WF3*K),/<FJ@G5YWP[@E38>54:U%NG#P@
M9!MRTYB\X;HN^2=X&=M+[<P2OJ3X95G*E*T \B_W-/#X&_&#*URG6JV-L,O@
M>BDN5ZNWSTQ-GER+>8&<@5MYXB\K-A0H:\G2F L?3PPU/ CWBNG] (,B+FXV
M-=7L&[T(0.,V'3PF#]99]T]>]*(S(;'N5G-'>=V3%AOAN02H>KU[+"XMY#!M
M4Q_QD3KL_C"TGX2W.SZ*%9\)*6RB03U([5'Z_?S&FHSS]+(9X;(,ZOFR(Y.?
M8?]##;G&:_=ECIC#XTQ]#<:^"1RJC#\]*3 ,$WK5N=$F_=U"#7M3X=]3J%#1
M+!+/-X$GD50K$QW>4:$L<VW;N'M7PQSK2=VR("OMM'.(6=14<N6QDY;"8*#8
M+O*ZD_1P<9ELJ(_TH9WY!!A=#_,=:8K!%8X/ZUW#/$_O /;^K&9+[.4ED5)Z
M^1:"&_21M&ZHFE=HM<IX;SADI+\Y]>7K^)XOL?S"68A+ .&;9"GG<NJ';*;D
MXX #OGDJ&CT.*Z5A4V[: C %&Y7JBN'F =F& ?_CD\PVCD?5R_Z\2-OC:=2#
M7C;6/B'7=ZN&A-V_7K8OV?:!7CDY\:=0=GOF.Q$ZFSM\Z0WC=+R 43/2Q("]
MPMJ7ABGA3-*)W72><:#'<8[D@<:/D%\ZIR,3UK]D6TQ E9T#ZS[AP9OG;1"I
M/WZ2^FM$+A?2'F+\;MSL%=5@QR[1;,@76RA^R>W'=C-"!^M(\$4=GC_$\QM[
MVRZ+>MZ:W(BN1>*OLBY7];B)H1C/G40?K%.E3"X;$GT03CN9[I1A:SI^OERN
M/70)4&_.K*BX8<%-NOI]>*HMKHAI<6$^)>Q>=XQZU)1HZ0&X9RZF-_A,$2%X
MP0Z?5KA!R6&<?LW.R76:\J.OG7)B1Q6@K/?#9^YAE(_%S)+GHJ565U0R8_$P
M\1/40\H@B2[BR1;M:H><,J_=TB63REMG#&,Y=>'GG-?/WKU::]XW]8^O]')0
MJ39A?/;.T;6HLM^,S2+].^@PH:=(C+6DZ N^DB.+H%K#RU\[M*5AO/WC9LZM
MP;TW]\8X$OC>HO9685+W5@8,Y&B",NP(WI8F,5MG''&*T1XM%X -3I2%O^"+
M;S12#D*=H$V&4LQ+2A1D+V<W$SB5A)/I4]N63 -BI>[[%7KM+O<,,EJU.8D5
M=Q#2#OHI5W71U_92\#6P!R&9KF<.M-@/2> G&>F[QMQ;]RO3X5ECOO74ZS [
M)-[81%G>,!3)O9IUI*(3IG.L^_UN2D<DD_"P_0\[I7C/!WQD"O=XB(5/_"U2
M0@.:52ACI\R2?\U+Z-#N446(U>UY7@*T#6S2H J[-,.*YWPW._PE6XX#',0B
M2^#/:OMLSC\E$>)]XFP+B6&/]LSEK;1(>J3OB'!:K56D9UHM&G3@-SO) ^4]
MN\FDMT)BI#=]06EJOKCYS9D]4;#/V"9THT*6:+.-DO,38!:##M3 S;>FG!6%
MU%R#=UAHNFJK3@E1&ABHR!'P94X[2=6/Y'N1EE-=(6C&H<;FIZET'N,)B\8[
M[\^V2 (>3EP(V$^)T7FFNCH\OAG"-D38[Z<MZ6XAKT'LML]+R!@$6$X0MXJZ
MV&&#/DC6%3&[2>]9(OYKJN&+#D^7U\\N'H^]61,.K6&'6T\!'KR21E''G--Z
M^_>1Z+?TQZL'96Y;C#HT'1?)1[=9+/OZI,AGTP0^1_]D5RV_Z _4XC7>N"XZ
M5;'4[\W5L\"GVUPUGE\?IN9X)_'I:&$AY?KISD5B&5P8D^L%+K<+]#]=RZ-U
M+N#;LE5R@22K'K*!;J'#KY5!8A^% #>MO2DB0W>F5JK7Q6 +&V%MU AJ"*)@
MEZ6Q*=HHLTEBV]S9Q='7<D5+S)D$+K+99AI403J"QQ"2)4MW:M<OERY5=YUP
MH1<X&7P]=@"HEI6N3P3!N-7O/ ]1"?=5'0%E,G?_D.&L13KD1UL_?+E:9&KW
M?;U9FGFY?","Q.<@?5>^6<GV_# 1)U"ZJ1)B0R'8 [8YM%1-V5.>48W7J0F"
M[I.[HE>>C4,^[@4PSEEX62P[5D:0)-7.I'QGS&-&67M]-Y_TM6.,*4G3PK1E
MT[]0Y'[/GNV,\F/?5^%=5IT\?V7[>K73^&XR5<>9)-B!P6JT<2LY KY_-]*E
M_X)R;_?CPDO5#H!=S;@,&\(G^5/7-]+!:V2B5%L%7A-N!*-3K?VJ>8_>Y$4'
M7NQMJELKI!/AAD19Y8JWZ2?7/[O)S+]-W6Q8OG3\>>3L#D?+'O&PRWZ,RI)Y
M-:+0U#X +Q353)59;GRMEWUUWSRA?NJ7"^O+D-X%AHDV6(FC+FZL_!BZ- :J
MYO;UUSR_EUUG-ETF$_>9L#MJH:XC+E8(0.F](7$ZY=DXO8A[7'(Z,>O[4RP!
M5[='YH?[!>@04!\HMD]L^59L-,U]#L/F%$\92(,SP:#O9R\UI"X9SO/=(M)#
MRP3SX$=JF4RJ=%U2+?X+H9/T=F?[+9F[[-&E7@%$7PV, O-7$LUG?L")0@_R
M>%L)1C%270RO[M+5/W#2==5:H4HQN9G4US8^I[^7_A&7<AW]462$HN[[5#)C
M:G#=S;<ZMX\UMX2^R9@N&@M,G&8E'^XNNDD^+<JBL9& CUX"/K-,Z3L<2'OZ
M>_).2T5VW*=SJEQ6%40[7^LMG 4/S]()T5!<_QQBWI>=J<* H%MCTV?JHN1=
M*9(R]+#;X7B.V'91[RK*17ZP_+_Q3_@+7R/9?5C#^?/><X?P0:QAH;K.)/;'
M<WZR>&,-]PG4'JON1,PG 5$0&T,45/2.0-3DS8X#NI;.XH78A30T5_6PVD75
MY#DK*&V#;%S*T+=]FT1&8I:SGX$N+T7%<7F!=6Q:*6Q9^NV02(BY[Z?GLY6?
MMJF?[?/?D^!N+0G7MH]_E9O!TT20*FJ</W =A[9H[4EF0;SQ#]&8+J9#8T'E
MB:#^*.AM51W1/F ; IT'M JL"B1%+R$!RQE4B0)WC(!+6GC )3UW^)L)*R0/
M?7F@7C$/XE[<TAB24)U7"S<E(260>#EZ A(OAR,ZOZ\(-;A1+:+:B[Q1]'%<
M&<3^G#KL$K"Z>!7Q=O?3H$//X'/FWP6@?Q;HC2R;5'W3D,M-[OFHBR"Y(Z6G
MOEH/=%J/][=&T@A)D\!S5.ZQDT#9\^F"W*&!8(;0DM#&2LTG?$[#^OU%%5ZD
M]\"PAHB/3N;X@@H+2J,?YSZMNAJQI0YM.2379BZ+VX^:I$*2\S^KH!^H>H:5
MCJHB[WE7"'C<F#7+ U7;L0_Y6[GJ+EN@!2TL4F6,2YMMY($26_8EL++HQJ/2
M'P?L 7<8N6LI*YZ  ^_'U"%L^U?3!C1B3I:33*E\29-VH='1SN),AVV/2EP2
M)JT!Q'K:*\X*%M)@18[.G\ 71)8O)0:AXB7:'RK9=[(>Z*:GY0L7/=$O#13"
MATH\YHNC=(95BCPX!/F6&V:0J:/MW%K+*H:GZO.&1A]ZCE+Z+J-#XH-FTT4;
M3V[%IY4IXAG^M-$3"P.E,_:]$OP0/VAC*D'Q6(6RT:H/HY_UX2GF^C.^.9VW
M@,GZ62/D^WCSA>]#O-W4^.&@7%9-M1SB!=[2N:!9M%D-K\#;:!%V.V_.W)3Y
M^+$ZL2"#-3::?#CRAA/.IF$*"#=],3L>"K.NWH2T>.L9LD9DHR3['A.ZY(_F
MQB>?IPEF(QC2-#Z%-1@)^^7>.5@!^5+': U,T&VCVZGXJ;*4^LEHRF;YLGJ#
MMQ^PI[FCM0M9JZU3C-MVO2H#)O@/';5FU@T&C-*/TY5JZZU_2$%7!4&DZ@(P
MX]AO9)3^ @^9KS$8.LR*X-(\+<FR2%*EE/DPJ;G%UA[]Z[OZA_(AAV2*YOO7
M)I/:XJPY8_0T,AF>$,)\^O!L#LM4G=^+@]X <S7=^#B#-Q"?'^+L5\01GIT1
MG2JWV>[1]L8\M;P$Z-RTT)RJ@M%,S'/G(FN%_O$C,H837P (2%=!<8YJYR8G
M[^(Z JR"<\9&-:_-2G//_KX&OJ/[+F0Q$PRX#^_A\8RR9H".JO==77Z'RLT,
MU,J+M1>+58=QXX@AQ9"_3T(\<-3CJAMH:Z C4Q):#P=[^:KHT:TB:3BV3>35
M</3*[AI@H5M%HH^@HW+7@438ICP/A6[#\^ 8 > [K=PH,G48#WO<#30$#1T%
M8\^Z0)RQ%.0C3GP:(!I:@R-T-?JK&T'*HYL:8  G/CU8 %B&ZP@$$-K#>#[B
M 5\!T;JXV.&O*(!B:?&!H)DFL+3@!HKGP:6+X3G79O]@;R$0ND.0@@1HY8U%
MYTE@!P<$R>THCVJ ^9Y><83EC"<P'4POC\J-%:*OLA-'$6%'X,815A[-6,8V
MTR3Z@^F@V2@B[%F(>Y8'GON.D\#]=Q<"[_ZX7M.*3> &9?M<=89E7@Z5FQRH
MD!/,380EX9U3QS C_'I>W0.DP".L!'"QW0JKH7VP@L'RAX/*#;P%N.(V42WP
M%= 1]TH(A*C?_ 9JY?Q#/'_*VOY78+I\#O<5\X\@?W2!IKN2K?&U6?&5/Z5^
M)>4>8:S86'2OR$4];KP2,[8R=M)%,J# :X_&BW((OII: QNQ?6+%2+NI/*(J
M<Y5\Y ,)RAB[ZO5W _5IG+<$[AJ!) + K__78H@$^\(N ?$+EX#M1=EM4[F*
ME>6^X>BYB]:5B[JNY:J4C5*-SXJA!'%T9.K*+YZ(EU"SQX'A0B<.,BOB('B8
M^T]F_K"<9]>.2A.4V=,=59Y;KBFS7[,J6H\WQIN6TO4N>,/!(S\(2:?.*4A4
M1X05I<<H8XC=5;DY R?4N5' 2%4 "H.;B3025044DB8EY2:*JL+P@41A\+('
MR >C\@JC:FDP6C52K#>9A2D'KT>-052-%-;CTA00:#)'%:H"$3WC<6W[,8D-
M=OPB+J1Z-<(!=#3A.;5?.W"G,\@P?IB'J6&I+< NX%; ]._WHOA^7#EGTI,"
M%[>VF)@35%-VCZ)*,Y;<0T*^8;RH:G,^P6$9]??C@2EBLUZ?Q^TW[@NGX/.\
MH^2.J/'7P[#'4W:P%LMI@]W?H\BI=O3*?&-XYUUQ6PRK@P25GROKDK2JP-IM
M(US>ZBP6:%%]R+"324I!CJHR>$I4O'K7 Q54>],7XL6@1S7">B!1WCU)I?$H
M2LAO*[*Y21Q#RNG[=? C\5M7F+!R48Z!"I2C3\](X?9UIR.&(ND\AE'!^WA0
ML!#>M2FO%+-N=R3\V7<)\?QE04\GDV;OC*E54B*2NO=YR8 0PYTC+D,B$=W/
M\ */*BJN1!TK11<'?!"MR&*EB2DZ?!V4&#%*U_<QXA@#4VQ(*\9=W0!).O7B
MUJS=G3,=0[\B1Z)50?%PC$G:*-E<^0V*=:FT&ZQ12"^\5L@PARO6'^*_R^?'
MR?-4 >[:KE@^R("*2JRC(NYY%V>Z\,:3LJO=,D\J(^71?NX.41.;#YEZ91I:
MX/%$OUK".E$WU7 ]FSX&+9S:09.?>$V?"=X+<W$!L^,CWE#86-6NA>;Y!@7!
M,),$]JANY HE/,4(:=#[P;LPH:FOY-X;PQ,$9(ZF@#V2]*2(B,*^LU+;WIF?
M',/ZU:ZY0GH3][Y]R]3;,+"$HPT;T8N)ZFATZOM?DVYJUO&\M0_["6R@>8NA
M9GG .Y+)^3;$RKQ1&UQKY3P"-3?Z2D04D:6L'MRJC]G"WY65#MBEEMHV^$:_
MFR"S=Q_1J^$5[+WC#K_%Q$>Q/)T@5[%^,.(HY6ZZ-B])LP^=!47:/=A$?]<$
M,"7[+S,N5.M_ .LP/D@;S.2)WWTL99#^O$!!Q.!CU'+,9+IBTY< THHI'49X
M:996__1$W0%AE[+S\4,ZP#"S@\6VA<6XTE5\.9L_]L^"WD8"8#SWB>X3X;O"
MKR)JT$"4X8/_C#=Q%<+B=^B*_ZQ0\ZJ+>]Q]5_MK8.?OGYG_G?U:?A=>[="1
MWFB;ZO*OG3K&J#MZ2  /D/:-$CL:\=M7 3=4RFF9T  TU,9G]/^DX"H/I@7B
M8_Y.[/][1AK>=W25_1W/_G^O@#71"_44KZ@@;-C>0^AJDQ>B?XI\GGL0Q_4J
MQ$E0Z/^#9$=PL2;I=Y@1;,'OH"C_G(5$T2N&(/_@YU\9A/N_/7/_++SSB'N>
M^_<&)5AR_Q7)!*_C@C^@[^L?7_$ TW8N!,2DG+HN,O,NZCI2RCB:K@(^<0%)
M252:4Y\!HPFKL7;Z<Q1=,SU+R,.?UM>6RVG[,(T<G'U%&\V(O!D-SPT/ \*,
MJ9?KK\8/B$14+P'"ZPFO$QG3$*AM91Y3-2)\@B0HG2!,#E^0&YBW& :/RX&.
M<!<+X'/GHX!  2!$'NL8@N1ST+@9/+D9O#<UN5'YVVF/.6DQC-X%/U'Y*?G]
M Q!E^I"Q5X-ALQGCR3#;&1J)\L@ LO?7F.'IA:9TXW&=!M_>('6+WC-,*&7\
M,IB;>SE0P])#RB=%80)28SC(C! VL^MZ/J#!S&"L]3R6B]U]G OE5H*SK:-@
M4),?+!EBF/N!0V3G>%6-C>PVGY+W/(D7&<8X=Y\P>J5N?-H=0ZZF'E.>O5<I
M6[=?T(Y?,ZM2I,Z*YW2?867;_,U>R>*0UO2S!.=79YC\)PD!=*-Z=E+Y;CZI
MP8*BK1).'*8D31(5,B[I]2NHYRK=.YZTCFV#>!6$**_0+M^O[K">:^ZWWN)+
MZ3NXZ(]KF[0JWUJO@S .<G.H6&2%B,*[29/EQ(9X_(_@\0(IBP:6'1AVMQUI
M^RH%>W L_'UQ7!FB;#]^D&TA=X^,,F,P"&.8HIAUF*0T6KE1::HOJ%B_I$^U
M5+\"7&N4YCE(M(;=( 1,93 9B@2E;2S/JW:4<^N',H.P]A;M0*!Y6+R4BEBN
M41H*QTO+L#AQ^'YG>*S&%6CR0%QP3VX!5O6!UKW1".!QW_V IW2JX:=B'#VS
M>CCP2;JD8X?W(*R^R=3-(:5APB:1:&;080[,]CEJN<85;);NP"(PC427Y-O4
MV7&TO/$92\Y\0#>8\U90DD6<DO^.ED$H;9BQS60WSG.Z^'*USJ)-U54B \N8
MI)GKTB6)P'AR7P!U4^FI%JIUZ\-C+8QJ66WP"F.TT[$W6:J,\ !1:5S\(P05
MRR6@B/EU831G7\  SDE:&RM&/ KB#KXM^XNS]\(K]L/H^6O;]H-N?]N*>+7Z
MR-BDPO-DFP5+YM<%F53OLH_POH.>T^1Q1H;SR*,%Q(\:"/=!U&=LITX!*Y^.
M0,7-,6A3"<W1/&.\BQQ_VT(MUBZ:6\3G6@_G>EMAM?5VKFGI2;E&=2,"S!?&
MQ'Y:#AUO9KJ"[T",+".L-:TRV8-%V4<_&/'$%F_^>/)*.,@X7*UZ^#3^9*IN
M83AM%0\#&18U3:5XNRE&LXZE.P@M+=&^-G<$\LY>C)-M%7V_)C(45)!]XLD<
M21=Z)EMP"1BNN01\4JZ+1$:\@KBL":_N+:8L.%)?G(*45SH?\*W2@S;.\\QH
M,4;I<0@2ML3TCC3JYW<N 7YT11=$(RX!R^:%6QMG#D5)[KI"@P2I4K\PB[1C
MHCNX#I$:EO3%D(F?H'6O=QV5-OM?AD,%_69D,[WF\-+X18<*ERK/DC+Q+MJF
M3Z>GC[ ^!W()H&:6ESW\T3[5UD:02("]@55_?TJCZ3^?W9FMY31Q(\MHGW Y
M<R/$5R[-HRT=O[\%UVQ,U:A8)EM]M7<'KX3L) @6\&G]$D T>+S3&_WY$E )
MOK!MZ5YNVH 4VCQ_Y2L@,:Z5]U%V*<=#\Q+01SI]<=%P#+T$=,EO91_BUET"
MVLLO*%>2&D%,DVGGVMG6']N7<HYT3G&P /33%+97V;]G]^?IA. _HF0*=4YT
MK"X!82&3LE_P'2X! 29GW'_/\O6ZP#OR9H5.,V77I",OZ,CT+P$YE)7GY\Y[
M>7_+53)VY!'$PKNVGEX"DG[</89+ZUT$&K;_/&KOC/UKIN49012==!Y9\?B%
MWG]#*F?A&T_^K:J>:6)I$JO,>H5GA=4!?YUF8,#?)_VM%KT6P\&_1>E"071!
MC#?AQ.8E@.>KQ=Z(3^$YH#S@VW9 */-?,UZ[)#2BSY7_C;$;11^-[M#X:6<?
M9&$N 22$)0$C1+]5$_*WG%',Y]$0%;3ET8. _N?49Z),Q9< .3Z+7Z>?EE3^
MEC.7#%$F81H-_R]-(?/L37TVYH^&V3]/?BM:$EZ:=![S[PX/+;J^(9^UW=N_
MC4BE>T+57R7Z-B^N04':OVX+Z;#^*2C[0%KC$F >>X;QXT N4KA)^9J!M%%Q
M6SPDW.6DC[[PA1Q75MC3$8;070*T,KK$&Z-QWGUQ-UOSSNYEDF%JO 04%K67
M\SQ!J+EKL?7*+MD?#U^$D%P"?.]>2>.F44_ (4W KZ6 SL8/^VII:VZIBHO&
M]H:3C(5G A:TEX 1RTO M]#?:O6[)=GOED;4:2(JHN%'/M(QXQ=4E5&7@"]"
MEX"?G9< K$#J?.TN ?+AEX VZC.^R$':O#3Y_PX56_[GBO9F5Q4;_D\K_FWH
MW!@$X62QIZ3.,:Q-!&O:NK#W]TVLYG=.[F>?$S!?'%OL50@B3<?(2L>^>F;_
MK3'6S(26KLB>$LN>[[4OF9H!W55E*C6J9__:-N\_,.3Z%#+(<MHJV(OXFY+$
M_FUT2LSH;RWX7[.9^@_JLT5?[!V^O=(JYRNM>OQ/K7+PPFK5W3^U"LPP1CVY
M^9\S>5?4-@9!MG7X_-]1T9#_"O5,QZ$)\S+E:H>2LL>PQ2NY#/PA?FOMX[SE
MDR,-U<>3#U<2; SIJ=]8[IARF([)KMY_)+NY+'M^73=_3J0X[(75K,HL) L@
MP36%*N"B*9R&?):^"K].U)!((U"01((A?X77XR)B?NL3\Q'(BB <+B>M.9B]
M9KZ)M8%]8M\NFF0/0/NFV=O9YRL/]1,COCPJ5BZ?B+7 NJ_@OW@S9C15D>PZ
MX3^<630+;9E?J31A2$%FV7/F_\H.H-*1:'C_]95=1^0A,$1N]!U_^F4/X4N
M$+WBX>N_(HTK![#=Y=+E\I/J((??VC';U)!_E&;=:UC_"9WOSJVJI-/NHTO
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M "&>DBP801XTQ)..%$-3, K^")<$OLI'Y7X5)88@N:].4*L4I&#W5ZS$:/*
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M^:07[!O2F_>\?GS39@VES5TC:AG_$>.UK4I 0A (#$)&U?-HB2)37@L$7MM
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M*?/@E*O%\E>5 2R T"1J3CT+$<0R%'D)8+, :EPTZ_R,]JLL#NB[]^VBL?T
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M^!&YUULWSZCZ2N9<Q >U2#\K@PTB!$T$;? HQS9_O,%Z.\I:'!9V(PT[KZ)
MJT1/H=1X/_XEO.3U7#]IM3Z:8OS9(W;]8)>5$.C,]6CFKUV)4(7.I0,2,0/H
MBZ.2J52%&WOZ*R *VPA&4-H.I!=4?4-\U= @<Y7T39C[83E'$VPM(WJ)POT@
M2PO,7IIAE6:G>:!%&Z,XC>Q]]2F9S!2DFN,SP1&O<FWB^<<L823]3;H;L3!7
M'OV\5W8$^1+.S6";07*VOAQ]LOLYA5]7TIP >FIWD@>G!Z/TMY92R_7C\)W
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M<8H!F@;W/&M6($$XI3ONJ.",7AO(]256*_B&^H1<;4\IEC?JATL]8UB?K]7
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M5J]+6;Y"A?#MJ=Q03BON^JS]V!H8\ J"6C!>P^UG%^##"CR9P$I1HKPE$E-
M\_Q1<,FZ2?@$" 6%( =J8D*D,+D>KH* _:S4>7]>">K41-10_@9IY)-R[8UP
M7W'%MNI^G)&G:)D\VCD\0^J?K&1[4VZ]^H7U:7FME!"'EAK=#X$A:3!P9K=S
MY7W?C&8JO_PT$C#Z$6C_(;(NA U+W<R@SA8 '/&1]/?+&46;GKUJP0.IGZ51
M^6$S+X^OYWCE5J P:8*3ZGCQ-V3U!<F5KDR>)SDD1 8..2M!-<JL)Z*&/+\!
MIW]7*ZC_3^=\QQ_5?MV16U>(*Q4\'\\4\[=U4T=QL=\ Z[\*3Q5";OZI7K!3
M?A)W_W?U@ME_5"]4EG@U^:F*!@?2/Q$Q)5][?66A94&A>;;/_"PC%%8&%!:J
MP"0X+<L[8EVRWM-9M[ANO&ZRV03ML[W!\LE1YTH0XY$K>;IG89<@O.'&[7!^
MI0EI%\O+9Y XIO57OZ1^'2#/29C6V-S OS&:K:JLKE7]#5K'X#I\<2'4PI0Y
M6,$%@)V+[*W%88=P53QM(ZUB-^B*'%3*3IY2P7_VEN(,..D<OG,V6"'31LYL
M1_C+LYR\WTU$8Z:^&'W8J4CS#X('ME^ZF^J2:ZU5K(?;@?GY)7'SG$<#@>F(
MIW24"^@2*Z,0L"NQ$?Z@%9,L?=$T&#I3^J[BX["!#>J^7Q)<KRF3'=;9F$D!
MW>LH[7$8WQ=:%1A:^/!+X]6=)CP.#V=/.WJ;A74!Z2;-,S,9+H\4VWK*!ZQQ
M2RPLRN3&FD^-5,)W!:8* D=.86CHU,CV]L$P,@/P<"#=(E&&MD:8'3LH8E3'
M&XZC%O%0!K<-<W08ND 3S7<D*H/T5RSIYE">SR=@\B&V(=IHFR3S)IW[U>@G
MA?6\35)D-G;D1%G.\)IC7O?426]ZP[\^*<YM89 ?YC/_A*OZ8:&GNK9/B4^P
MF(6E>_^5#8T_=63>N15KF;9G3"DA1$3'MQ2E:;UO:0\_5[,E_(ZS3#7XQXN^
M?;_$M[Q48MF-HD<:-JD:K_.',=]RN@5D%+;)4H&8K5YQ,DGQ(F74U0AC*W*S
M==JSFOUD]I?0VI+4:8B1F<,,5OFNT[5161Q.?UW@:<&L/!1>IR]!FT'#]55'
MH(J;BJ&[2+AVS\4#Z[68/-F2QL?7-+0F\2D&[1@I&W&>$9OFX;$M;=X8,13!
MZDQD2[WG.TNN\#<")&4!&PQ66P,3*0A+61B78Q@*K(],&%S%B2($I@>&>EYA
M]IH>6]BW#TU'AB&G^Z?Z>PUG36*=W0@B"3,AG\\2I-+L>=45N##=-^> [)0I
M$M!#H&6U=M% N?29@<XWO@II< IU:B.MO2,57E-A2M+(^8R#\-XYYK+/208G
MBJ:5I&"@B/'DMQ;;UU[OZI#Q]O B#P*98HX,PD6_UR=R_5Z:HZ3H9K\T81(8
MN-<OUXI('H9 )HDZKI)5H0S>:C16>?G<*Y=XO?_F&<7+?W?M>!Z)^M?(+?G3
M%QM=9;7A8:WCB66+.,?\(\7RW!Z:_[H_2H<(F_BVQZ_%?[9$V8EXH7M%#K4D
M[K/+O/N[ 2+F=<=UN=N5L( ?(CO&-%:W9NOL/!IT&/96<T^1,[DW?W_:'W<V
MK15F&W->;EHV&(=:^[.FHR2NW'I=X9HQ9U,]G0%A<39Z$[9LZS#FN.M@[=?*
M6 &DXB"UCN.JHD<#<A91Y:*YR@7!W%_ /[742=)644/;,Q-S-2R$&;)Y+.+-
MUI,[8G25/\7%:1@@C.B@,+L5:WB,T 2A)IM10Q'B'%"CV"V2T])@":;(EUGN
MK[?NU0AE#K0 J'P%K9[[#/.L$M20=*OO*J18,N.-)"Z%O?;#3C;JH4UX4C\+
M9<^?$"L(:!8[2J:DAK!_+=36!PKSKDDBK1M(/K6./7UA^C);AS4WQ_$'84KK
MR:(E*H#\G&N?PF\LY>]\Y_F])&O?'?P$:[\ ?A'AT9O/=K[(8*3/);@I)N;O
M92>-@N[;!O0@M .EB@@;B\U0^M![=6KK53BMQ;190@'4/:_5UZ4,7VSGQ!\?
MR,8YA4<%K]<R+P&((SX*9'*6+_8Y,$KK.LD*VHAL2ZM!I]3I\V##C91Y6>CQ
M>"G<\VDAQ2^8'=  UH(?DMP8.'*T/96LW[MS&J.\3U8_!.0:8YH%>TD-1,X.
M60TP8WW2V3MX1U<FOO6LE)F:J -T%%/T'>G9<X*5N%1\.C:A*:_X]G2P-^G8
M6[>3S8T\Z.#)\JXD:KI32%314TS'T>&3*09@J@R:>4>HQ.*#BDJH$UA5R:I[
M2DK_G%$<8UQCH*&2^P^"T 8<YZV7.MNK]3C);>;\SO< <W2OX0AR-R:)A?>(
M!3U+?O'BN9Z2\M0"&2C 3)+*$BCI#_2U<ZLC@9)3ZZ E_T: 3H$%7^D\J*_U
M[ELA<V?SK%?N&U@2,@;"Y)NO)\IZK6D6E7DQ_<XR25@9=5A8,KN&3EIP\>UC
M>^LOO,21KS0*$KD5-BT*YKC#IJM[):Y*X!3+LS7E=>Q\J#61.3]'+3>YFR;1
M#+?3IBA(;3+#5#A?ORAE<SS_R-TDNPU4*)V?PNS0I&SK-JK3B738@$NR$*&$
MP-4:XP@+N.=/U(]9.7& J6!U*AZ=*MA8AL%TW BTI,R@2J>FG(-9_&6BN(%T
MIETM&VDIKWS]#R3H/G,V<16TS[8AA^VGM%R GN8I"284.KIH'02=%,.U2538
M3IU.Y/,'&$L+:)C;>P*M>0B*I.TW2@CCU3>QZPQ-.POTY<I:I_P["N)&^&5Z
M)7EEG,Z445.4\"FJ\G-Q;E/U_)Z!I/R5]!^$:'C#PWK+PF5EYBN^*E$\#/J<
M%FRC?S_4VZO_#GR4/HYX!EX]P\G)6.2_8:73:XY4<2RO\P\"-@5]#G1X/[*+
MZ)_^?85N!9.3!"KT^?CX@64ZBM?> ^:DFF(S*/0D0?)9LI:^;'9,B@6ZP_RK
M>)F3N98K8,A$U%#Q+>3D*.--51Q_Q\^[%WJ,O@<)NZ-\0W-4,%%.*O\C6T?M
MRF M#[-?+9HW/E=E1])3HP:[;HW'C/=$4XF%6.L/G[ADTJN&;;$\CTI=^F?;
M!'7D@ZN;@J4&Z)7 E16L#7P^UR1$OCA:6"Q*#>#H8,"R+L^!HZ%GOFP(8'7O
MI/G%99F9W3>I.&PFQB./1Y"M'%_98CXRR33+\"[G5FY:=C]!*:]:WIR#;@IB
MKM,\,-26%0;4,,(G4[+QZI?S+[K@Y0ZYO9BLEP8>9A0LM]6B9_6%U;H7;X<+
M&+D 8SZ)7NO#,0]]*GZ9CACJD!FW^G:/0^L]N9P@4Z;O>GG87']Y_W#E7^#]
M7+<6TKB/ [PTN,"IU%_,NJ")P?)Y</S(K17;53G@,/]+M@3ZO5_QI4%U/FF)
MFIU )HSPW7Z>N@<P!ZQKDQ5?ZYZ/\ 00!N]RGXT@G*F)90T#6BX+% EE,69'
MTW.=4;@7%2SX\K6'4Z'7N6AD,_;(KW5J^X^K.O*5>,UF,EF_?"=KYB&CJ&S^
M@Y !"09>;O6/V9&$W(Z33W[7B(#*$7^WV?O-N69X:]WG!!YYW7FOI4CKJ4-&
M9]$V/YC<,( NY,24TJHB3Z*Y-=*M6-+<YRZ%^I*L+L8GF>6JO(F)C,;5B^#H
M9O\JU_BK:EQP*<_(A2_((GA4:QV?QEIU% TS]UZ+V##D#!'QWKRVPW<J6#3"
M<]5ZH_2,7#4H88_R&6<HRR+K$:'T!?+_E*K([JTB^FUZ_RO$HO3=]O;-,S0O
MM5_M_M,#U75&WG3G;+7/%&<E:^)1/8]HL;AS!D- *]7G;TZ5QS, WKR[JI %
M;*^21#WJ_8MMI/Z3;=83(Z=-&J.*_G9PK:4X4,)/SL</_MN5DC,P\A*R'B.C
MNM+F]XMT,$ZZK5Y8\KA_C6D K<U+N8LIO;EWJ_[SI0[2&8!+2QHXU^Q54K*3
M]5@\?P1VEM>6=$X7QG ?)XS&[W39T_\]O>-Q$8>) YP>:$D*"'<O8U%BG_@N
M1E=\1SSI1<91S-A9ND3_]&1]G/8'H14U?7T>U/Z-QIR<^IRQ+<PX(/O0V\/]
M>/[2 ' >6$\>HW\=?*=J\,9W8<<[;88[)M,AJ_@W8T);?_0Y$\/[>B9IXVF3
MHD5'KP$QP6!IZQP7L';26N2&VGSAC2-V0A5FPUL\9K5*2P$F#6\\D6./2_C'
M %9X:\'&^&Q_PC<W-SK/CJZHE(<8!3QR;BZ>^7[]67U9[\*ARI)021<+[D$V
M"]@F2 @$4%(2G/[AG/JS/"3&XQCW'=3>3/GJ4Y#^Q+Y-ZVTVIDV9W@@> *RT
M,:^%Z@FLGC_)+Y-Z_D=A\UB\^/OTM-G/$XBQ$7?C0-8X>B^-G.&%\,DOX&KF
MKW<-^Z9NHD,-G]2"]-DZ;6IJ5.O?IV<%W,YEK19M1E[M3LV^']@P_:&1EG!_
M5?[9M;,<]MMK3M")W4;R6^2;0,;1*O(%'WXWCD<A#9FH82:-=Z-5,-;A@OC$
MX'CS'ZI<O=_Z\8,+FI19C[7_(#3WJ--HI=V(U*>VLG)/NA<2*:@1_RV^E[RU
MGOW;WNW'O_N]:3T/1(NN>QH_,S+NLUB2*!%,4?_;\*UT7*WX^2BML_U?N44]
M\Y^&.7,+S4F/@<?_;JT#D'UJ^H.P AQ3OW)ZRO'#PF^\LV)*NV[^^MY+ET-L
M/"<> H$J9'&K@I D)L#6JH-YNH(XP7.(BWTJ#$("[(^]WBXQV3$-V-O?W4^7
M)VK/ /&Y42LE._MB%;FT?Q!TE2N $>J.TY.F&AJ?=XN.3=^([45ZJS?=Y!G'
MS!$40VF%E>RWE>G>8 XY",X!X4*T,W2"93LJ>=<23'73U#KXQTCGY6R&7T %
M*;%4(^V8 OY<G;U:7*&N.]:*N4F94BU3K!N)S".V_1S-%_UMKE6C*[J;)$>[
M-B*+*AFK2J$2G_AWM2A8W.X5$KTB_.,7$<4Z^P%;IHRE!C6]Q5 [!I:885'8
M6?3KG<9B[@H<95>V!=8_"*X8I-W"9P9YI59VN.8-R)$)J8Y<"@C. 3]1I-_@
MY9(2OB)TSTYRZRWOKKBO:&;TL!?3#'XM*\IJS100 A'9/3K19+XN\_^*D*'H
MKI8D4G:/R6+O9=_WM3"]0.I5Q$-SS$)];HHA)=5:-JEU&860A]#.;+$BR;UW
ML'XM\FENAJ(+"V[:#;>NW08ZIPWLK.QM[**>/-O]YI;_D>Z<0$/B#[RNH6$^
M08^R*+Q>M$?J_!6)*2[C5$#\%1B;,Q-('5EC29?QJ=;I6-0-#-!TW!QBV>"/
M3TL<4]U3:[6T#3NB+SXOK:"+M33":*2I)/<3/H@JOIC]O5\E89G+Q6?138_R
M1NAC&_"E.6V.Q'"_XYA<HEXV54TWT;%X [- )ER37>BBW[8&P5S,C/I6T07D
M+DS?NPC1@:_5UY&WL@6=QTSF+B-'3AW3QOOGDK9,V]C5;7Q;*EYXD(N3ZV,P
MP*/T;Y,AM;IB4-M:BN072Y1)E_WFLYJNJ\"G7O\-=R94U*OD'7/YP O;(^IQ
MC;H&GHFRU%3,K%(VTY5@1F@W:RPW%7?X7?%%W+RWEMKI@B19-F4,ON>N\H>N
MIMP=_47/JB+BR$F]0!OOKOH_"&9GP)+$Q;=B2)\]X/1#D]).L:IUH^U:$9*O
ME2NH&EM^+VK;#93?Z(1A=^#$:^$4!1)6==QKU5YI"=TQI2W/]HE524DU/>SD
MJ\1R8'6%?G83[K4R[*20&%@+&)W043IAHJ>V<1N16/IF:35?O]T/=^;=VUH=
M^GXU_C,Q$J2Y+[!>=37PV":5J0ISK0,W)0Z-]OU%G(0A[T,[%H*<P/^#K;>.
M:_K]_O^G$M(B3&FD8S2,[@;I,08CE! $!(31($BJHTME=#-&"-(((MW=)=(A
MW4C\X!7OS_OS^7W_V.VVZVQ[[K9=S^MZGOOSG/,X\K$?X\@[+>@2_BX39SW_
MMTP\]?]8X,,S!PCZ7UDU4ASQ!QJM;JE4+#?;U;\2C'<6OI,U7@."?T1=\FEO
MFCP'C#OL\7MX5OP]?&E"M11WDK@..26]-QU*"Q)8:?DH"FP@UROG;,X3J@D3
MG2RB-<Y16(Z7'(<XV]9)&FB.9IC,0SGN]XC2C&@&081>B8(IM>P-XYCU/NW\
M@8QQKR?D:=Q%#0R-4G-.K!NSNFA24C!4HKR/6@V_O^OZUG18<#;]!%.3$,9_
MB(Y#!G"Z F$,F5"3 P-& NBHIM9W7J%A,@56W2 C!%DJ2 L2K03E<]PT^"!H
M/(?Y<H;1,O:%ND-Q*7(9V?>07]Y:9/(OHCY*>J3C+32EVHVUNJU#+0!5\,$(
MG)G1]!<>.N2$^L>5$0P=M)QL;@=\]LIX0T+S8S%\KT(MEUXKV9AVT&IA/ZLC
M$NL IPB]D.NU?4.@<:@=P'3%6?3TZEO4#0_U@H7;,A#7 -.T6RW(];2[_1=0
M[T^77O27]V&?[1R),UQQGXG=SH!)J=\?\!HTPJ,3&3-_?QZ%O/>N5U/0ZJCX
M70VC%G14_@CSH*6)IT+#J@J(?B6K99NI&OOS]"MT)?K=-&2FDW'U^4(^Z&*I
M"J+ S*>P-)92^/9.C#Y@;@9Z^NXC4C7[F;Q]8FASI&BANV\-:^'<T[KM4:&(
MQ%*]B3#WW_6:)@=O3?#32\6=D8D*9!WHZD=,2I;5R"^Q6\\?99@])E^S9/FJ
MU&G=6YY':[?1VVK3F*$$QV6Z6Y88X\!,TFKT/O^)@1T:-PBV%9]L7?K\&910
M7*<CVR*!>#!(U?LH_U6Y@;V.EFV#K-:HZP-L_ETEO)"NKL=#63%O.*VU$+H)
MK7!S%SZJY <HV8N1]&3(*P7&X)UUV"@^KSH2NQOZDY=)+/_5"X<L,7,=DRVF
M'&U1*<ZOK-ZH[+88Q?8:-!5W7HZQ%;Z@!O>6_D3'<)XZ@H$Q&W="IU]]7C\&
M1ZP@EGW+8'D)2FGXUA;9PBL3-S#"Z_=;'&45]FV$L,XSSV+XRR0+CQ>8SG-3
MSNRE*/EO:?/=SN7O\-2G.W&4!3R>"YG6;$6/L+2&OM).8HX_4</B#%OK-Y0^
M!XR5QHJ;DUD_3?,N/%B"^HMX[VE8R!8R>Y-GD@G;/54]Z9"N,$EIJG#-]Q!E
M&_L2,UHF3BM,A"1RK76E3G8V',.$WS$UB\,%C$M.AD^B"25TG#53*O$;'GBY
M)7FUV:=\3:Q7QJO?Z$%<5,2S_OB!P6-O)P\KS61C=LM_$3\_^DR0=KV(Q[.7
M/UNF1PP-W?B2M]VJ(,RU@R:MA4)]1_:JU+%>O;P&[ -OMB=?F(\)<;C_@KW#
MU6GQ>3T7?5,?ETI+()*]N/GS7R*$)' XT6WA^O25RF?_OPK7^;4JUG_2?O]7
MN^@ N&FB=QJ5>PL^#%.QR+\+UY$F.O ;=R$[F]<;FR*G%?M)WIUXI@9;_J?K
MLK]]_)M!41(_?N!U*X'\Q3=;O7XV<82C'#-P7S"\6]#TIDK]]@:4FCER<#5,
MJZ,EK:!EY.\)/16*-8^30A]R@&A6,DGZ[G=8@<Z0>]/!^VZ4BY+8+ORGX^7/
MV _DI 3-Y(K3PUI$[",)/M*GZ$EQ27Q5V@)?.9L%Y$BOR1Z7B TG$8(&A*PO
MARY!'"D3$;I%3SH*_R1T40TYM^I44^*4&B<?FF7#G:\!*KY'O:X&*LL MV*[
MQNU814F H/$Q;F1%&=/#\AJT5#G,&2M1__RAQ)B%H48$\U,WSJK=B!F#%I6E
M GCJ'K/3O1CV3>1XQK(\S/V%L5+J;/ KK+*'+LY!X3#L_.\QQ2;3V%,*B(#^
M5;-8W"GWCPYE)7O>J(-K (7QCT=5G-WH)*_LI8*TJPH'Y3:'_"J'5E.!C84G
M V9&/=> @SY]MO.Q-]O)C(LZ V42G:^@*D<%UX#=*&#0UCUCTCR,R(VSDU/V
M<67 ;Z<ENMPO).K4 (W9T+#4]>E:L4(]BA#E)AJ>^G[R0L\_.I\D^$4\_=>Y
M9O8C7/J^VL0C$/7[C]08C)KA$0B5(/2=0'TPV.$KWQ7^NJLY^RS-)C4GXF2R
M7>D7MP%UO'6P:D./3%M&W>[1_BQ-T[/+J<.?ITKIR ?K/I)VXBX@>0IN!X#5
M)Y_%E9\0"I]BKJY*\==VMB_[J1T$7KXWJ(I;4S*IJG@:IA*2^6)*C096U.N6
M77UY.$!O,LIJBIN(5?D+5X]#'I^SU:!-/]YB"[VXA1_?J)N:C#RA)^D;]GS8
M=#_MWK8@\21KZ37@JR__:[*5@ ]K2FYPUC1"[V<3A?$4"<T/Q9'#)'1&@H3-
MP"W;' NQ5XOEP=EX!Z2Q;36;1V=OM!&F"0L/^&9#07&C#UC=_:!U)XG+2J*8
MY)D)/81VU5(@)RC!BYZ03PI]? T L=,6Y)!'HRNGR5JC+[.:!80%=$.\H#[$
M.91)S>,O<>3T?D:#%U<#[?L*"]_PF(*&O\3'EUM\D6+(1<+5G[=N:>X\5<*B
M^S<(-7H;A,K&K/S\-PA5<MNET#3^BFS5^0;4_)$IFE><;G:O0[SRVNG_)SFN
M]D [4N:?Y+@*DE\B&1?ZOL,3>D@)?%#P>71FY*&.WJ, )5YU2CDE\FHT.\?+
M5G+R(.#DA6#-ON^S!WV2/[X>%0NY%5T#L#6/_2G6A\@"5@D'C@4+ZH?7<#L0
MF@>D6B1PGR]<_5.8OCMA/??8IFJ8]FAB%'N3J=I']+T<(BN\YQ9[XMOK1$U&
M[7]][FQ_A1JE:C5*A2UV!)H9=> 2D?:/@]]938!,85%,L^9.'#19#E=N'49Q
M,9J_?2C</6K)D_$W#O:1BT*/UDUC#RC O=P=Q?4+Y8NH/KV'Y\)'"^4K.T8N
MA-J4A\[R0KG;$=W2S.WU3L:'Q=Z346G&8^TY#F0]+26>L7L4TXF/=]@8"[@"
MMW^Z-]*$1Q69HD1BU(/>ON&L@]<"!H]P<QZ*,?Z.DC[-(?"WF=1DM,2EO%#R
MLD&8#>_1S:[N(KO9S[+\-\UX(W&'RHUIJ[U,\91XV%L%"Q74U)58.6)O>[S)
M4W%H G0'#$8.M8-.<'C)._$DU=,6S9KS<RE#/&6:D^(<%D$*:?7[5PD[M;&_
M/GO#WN!NIW$G*H_RN, VQVKJ2L=JPXXV3687CHKZN3+HYXI\R/83C@N=FPUR
M@BR43A;BJ&;VB]SIF8QK-5R]^\'?%RE\OY.:B)Q,@P/,?,MCCJIMO!4TR;/U
M], /D43DDUR0D[_!J^Z_P>M_"6V/K;A)T\<<IV]IY4:.;&P9T[/^5>EBY[]/
M\&^E"Y3M?/QO[DK[W]Q5<<M=O<:(L>Z& ?_[V4([O\B'#;].;9"7!WZ,'M ;
MO*7]>%UU;,:@BGM%M&ODP)&O5E>F1U_]W:%.'>-#!OMG8\)?W7X^3+X"'@C$
M%N<-C ].867Z$ZZ7),?@!YT9(":6B^N7GO7-:4J$4I(W9<HJ>WM#S7D_0O%V
MD)V"0J&SD40(V/18VVXZ,9_HA7U^+3W#N0'9G=6GE%.9BDRXZ^HY9XXV'[0G
MU%J6?R_S37Y\]6!5[&K+55SSPIT/&)6RR'P^+L),]*I,?HGO">!Q'GQ=J$B<
M;<K*XBXOP=0WN[(@@\2]S\BO(3S0T:OLL:ESLZ[G;AQQC6!'G3M_:A:2>*+L
MK-1@#''5.WI\B\@VP=R$3&>]EFH1NK87:ZS@>T&I=B^5.Q_XZ)D2-;*W;9 G
M3)# #[^4O?IC4E QSHM(KW2*A[8MJTHN/<?O+Y=A+R)VWQO!/]16+EZ^OZQF
M5)1#_RU\UZXXRXG,]O%>+^ YF8O( N?JI-7,BRO.6*#7EF-6+&VC2@AN_0MP
M1J_QZ:M]SY88A2<&K *3/];>%!!\/3968=5@^L+B,Q:D52*H(% =*EDY\ANA
MO^/7[[H7E2"[]$$\QL1^0=J1]R346[G[CHKSI[-H'ZH"*D/J)P"\9M()@_#2
MMB^2%^K=36SIA:<.-JF&@6SQ9:\]/,"UI1O#7X->44U-<?@._-FON3=7SA0Q
M-U'UB4;V<CS;L+#0FH/S [,9R8D2-'9(-Y2D]@D!]M9AYI)Z9CQX33DG(ZE+
M$7MZAQX^$*A &2NF]J2DX\Z:;5E3&];G:4D7]@ZI4OERLHFSC#LIQ*I7%=PS
M?>45<@Y8^^$"PHA&G/+#-4M3B\DAZRX^7%3H2/)E>F>%%47CED:9VX=%J]=J
M<6(Y)!]H($Z)J1D8]I<C2Y>#%YAW(_%?$[9,9Q>]IGP%GB>PBVT-5?<JN7\4
MI1D?D/L3*F##XD?HDO^A3 +550M[+#'Y0W< ?_(;W=,OD]5\?6] 1*-&2<[3
MD?%*#RNXX1?%Q=H0J*1B3:J8E-)3NQX_R*"WWF9WDBK]0::]LG<U'MR6YH@A
M1\BM6' ].#LG._UND(HW1VS+_R\X]%?Z6S#]?PQ5F5Y>4;OCZ!F4@^BP/9J.
MBOF_66F)GC1.FL/R&J !.1^G@>#4.;VW3R,7N72^0:4P%1/(:>+:L-\&@SX:
MRB^;%VDO045:SO I1Z>Z8H8$6(Q+WA;&B):XOU3\2G4-Q.EII.E>]6B2%D2U
MWT,76!G>N)2'ZR%T"E<\BQX+Z0U[G@P%ZX7+ <NMS$5C5'<8N&:5%(/YF8\Q
MQ&]1 0W/XO%':7KB9< 6PKTZ?43:-!6**((GZP: KI6O@_M*+YN[((IEC(E"
M;7H5YG$H9]-N@T3"[H3]^P4:P0UV1RT:U$*EK=_I*F"D.NAIW57;E:KOI3S!
M9L_#XR57@4E2B4;N,4@+AE H3M$;3$0F)DF7)@DQ5@*? /$1>H)?$AY;VR)0
MWZG-Q0_S9@W?-VS)523PAX^%.MQWDO$JA_"P$>9F3"DF3FM\#B3V'G6E7/>_
M>[9GENV_WG%[B^E;V9GV<='D-2"W_U;$[(C^;6,:T,[H&I#&=)O]>V \CY/C
M]B]4]=*'#V=H$-(,K J=\:D J5T!XVJ/Z?$%#XN20"(O.@N[E>_/C=8[<'HI
MKE( %6<RO+M)NI2L-"GCL.VUCEKVGT,A9)PQ$&?"2D8>>';JD@P!M(6PO5Y2
M+ER/<S%8:5QJ_7BW[.9/?((_OZ<M1L/]],X\QQ.+A&A>T8(Y",:1>3@[_O</
M])W?\ZB*^XV]UHH>:O OM(WX,)PP_!;\4CSF UWRI@,-H\ J>!\\T7 2R2>[
M4L2QWX8+;S.>X^-\64R1G#QBR&7/G)UJ^V<#J8V*[HP9R\F,Y?J MY!*A<Y@
M0L5Y]6J^LW!!Z/*QYH:M@&VZ.M;5CT'1O?SS>WJ,5&E=W?J;CSSSG/<C/@B'
MCTSWR\F:.&OI8#^UL&OU D; GHR>M,(8\#8U^50+E;U''-.A5?>SQ H$.G#L
MBJ&AVZWL+Z3LXJON('IE>>\+8<>XZ]UIU:N^9YMC'VH^E&$!+V;NEH]/[ <2
MV-2;NM)NX,C!!1XM*XQE64(ZJM>A2S0C,X.D<;HUF;(^5,\-A)+ X3QMR</*
M=N:D4K8:\E_BQ!>IB4..W="TS?K:0UFXJ,Z4U\RXR?AK0CE,P*#'S+"GN22U
M_";#UD4IP-B/SJ:5G^B8Z-67#I?.VH&3ZYC&8B.: ^O0YBI@DC_I?4W'MK=%
M^M^"7*W+^+0A$2X&"JA2P@3B+,J(3B"<.OR!H%;;.BI\!B*7'Y[Q-@.>$J:1
M#!:MD*LC/WJ%"GWG\L*N@G)=OQW^];&=@O"APC6 S/[92:LWD=<*TG_!V?;F
M;,+VIO4VU Y)-HSZ@$VN:_J.[Z\E/864N"V%OP$BC_\ D5G*+2]Y_BWTQ6]6
MT2I%>3@A\ZM%76XL14EMF#8P7@\?GH1BD!A&<]B21^.[L=P-C'WTJ8*%AT0;
MKB#%](NE/RY_KE&;A$*FKUY9A;U@?L],;+=!,Y7COK>74UK'>,EEP2,*N8_;
M1)80U]<5._Q5W"M/$G 6I#BX:7H=.MJ(\,@'^:?NX6[IM#)7[M?V?5880)(J
M<2MZNX.7Z?BCNO8H[YUF&EP<F%7EL[-K%WGY1RZT%1'.HL FEYPQXTH;X=TX
M9R$>Y]0O'J^;>5CXF9L>A_I!SPT@4IPEL^(&Z_HV0,_+02CKFCW9QZ2O[$:^
M5;$DQ_;N/ZH+[_N9RLMXSY;)?"N*@1Y]J,>C%LOA8Q)]A= (VAZ-&:I8\XP=
MG 2R?(5PUI922"(/HCX$SK4;5=5XBM2UIXV,Y\GHQ@5LFHBTF(K^3!$;^]E+
M[9PR_<9V>! I8*>Z;Q]64\)R-AF5.=:0^(O;4K^9BU4T:J]2!9CE@?,I2X5@
MJHUY1.Z7VHR@WJ8TXZA5>>388RCSW29)0C_H&/KE;"_((J^WDV*Z9[AT5SKF
MN2(J-). ET4.)^)IB[A4=LR/W.GMU^X?[A>+LFS*P[7!7\>Y-*6G&'^3:#:,
MJF>IC_&G/DR ]K*Y.V[ ([/'PZWJWB3^(O?1=_<HRPY68XKW$[#=FV5I\6$-
M$[WB.>*H5+K7N;JIM'3,[^S?G/RJ]H&)8?R;)GEH39^=_<L#)^976C_A7Y=Q
M=(J]#O/N5_H&/P?;9; 6V_0D+6^-=$7.9*-+^^XLH@ZO >^&ZV;F6GZW.'1<
M8((,@?042Z[%);^6VR>/C*/$90L:CS#!\)'E%A=-X8_MEOE;46+@[F<,L1J+
MR\4HY3_0W['I/;*6J(X1)FH\&H/.B;V5F<(=*Y?'>^2OD&C29NL*I\=BP,@>
M"T0[95[7TLL<"C8'32B$-<WY\4F6T[*9A$L2SPOM[5+@YI0S2N_'J08LP0[]
MU:!6=[CGE9];^_N(0I]$_1U7W?2AU/B$#I\(0W7;/)3Z\X%X724LP\.=6[AY
M^B_</!.^P+L&Q&P_.S^Z[23 ^3MO-TTBZDJ0^D)_P\G[AG6P_Y^LD_87ZSP<
MI!ZXXI2VVU*BS2\FVPC>4>=XF9X=0D[%GN-2>/=CP%/5#!\]715O?%4=05AY
MHF9#J3V/W^^WHPQZT\+3'9^/&6/ PM()83C,4G*RVLO0$P%U==^]U,R"4"/L
MDD\,9XO4H6]"[)3#*"A^ %R+';)=9-Q,^@\8 W=%31P74KSOR-_Y,P.=M(Q4
M9->W"@]"]E :IE"LVF)JG&V_ANQ]\SDD/"&[=T[UBUN+ I;MF2LC*'_C;UN1
MG<-04VF?H5)13TFXM?KE')7<]ZX!!<"FES8QIJ/?^9"KL3P-2R[(KMHSK\.5
MBI6%,B=E:(&NOJ:Q8VE509#Q<?LRL&^ZBO0:4 OR&YC'GZ6A2.G%[MBPI<Y%
M#(5?3)(_R'ZA3;O>Z28Y7B:V0]V\ZBF^Z_8#RZ]B7NK=4$/XN*5Q%/&S]*7W
MG9=$OAOS[YZ<C[;.L;F3VK4-/E63FR./+X>0W;8MNJ^@SH$+AVAGB,PFT0&3
M.O:DPFO^E.&?&^LVQRYF(9YQK[N<B1=A_(>5KMR.[E4EYC7>H$(XU69S/4E2
MKZ4MV\Q*R7@1 H:YP9U?8S68P;$Z+L]<M5\%1XEG 8=@M89+HPH94?1L0,?I
MU0/4-^[+TX/S<2;3]A;FR^7"M-^6,A&O+S&A!2=1F!]U0P]C/R)[:;ELT_6&
MH ]:KZ@J_CL=#OI_QJ(;/1N^,DQ;<E,IFF:!*:;Y9[=2B0$0R-^=#9W_Z6PH
M\Z>M863D&K!$Z?9/:7^Q]E'_U5ZQ=WO1IS?I5U3F>?Y$P-#5BI%;A1+&:/=T
M7=EL/?DAI-Q350PV>R92B9G7W.QH7LW,_SZ\2J<0MG_W&[4E\,P;5N$KPZJ-
MPUE8!Q<S3/5+ $H_0L!&-IGIC+<A.CVEG65ZKQOW.5M(/^'W(5IEN@PVL"W)
M4I<>EI6_"%CXX@CXH[ WJH6WU>J@3L7!)[U>:+\U/6%38N>X9>BX'QS3DZG!
M,KV2M;37ZTI'\]&+AUEM+Z"Q\.GKP!4GWN6/(FPK:_;/Y")?.LW9ICBSR9D1
M<W+D9>R!J1S5#L4I7]\I>*5*@U\^LPHVK74V,;1WD]1R775)GO:S:6?\',X<
M8D*,T.N-8E]"0']UE%T# JX!ZL>O]T_*I<?9\G/8D]S9GAB@Z$",+<O8]NT=
M)5#!-1!&(FJ#'V6,^'-D]EJM?UF3:<!W1''.M..(+<=&)*,;8FBX7[>VE5Y7
M_?/;<M<\?A&XOF($::0U\]QRJ/Q"B:J]8#:VAE$[4247Q&#)_"D![[Y G3'E
M<?'C+&FGA(+P_H\XE<'!?4U+/-Y'F,JQH7XAYS9O7LJC5HW[+ \*/I#TW!%K
M1-^/59Z+99_NVEI$F2RF>-@S,8+ C[E8WR%"SR*U.(<F6Y_ JED?X>(_3D;6
M"&@Z9DQ)XVWUJA"%I]G85W5WD'0%#Q^'(HH\L\/_Y-L(MJ_R\P6%1ZF7/Z](
M04DH<Z;[]C53'N=)?>O3G8/J]ZFGC7WJ9H41YW_\+4 A+):;TILC4:Y?$4"\
M->2+Z2HI8IH)$F]BPD>^5D4_=+6A,^R@><TIFDJIN+%ZTKI+++H.(Z)M9\'8
M%,H]Y EZ11KFFRA6; R1[6C<M4\??/&8CB8BR'%R/]F .%_:_6Y]%\^N6 ZZ
M\QG3>_=MRC[[^U[2"*]F<!TZ@Q#'RY'?$$8'[V",46WWGO0@=Z>^9UZ]AH!L
M;!BK&<@TV=V_BW=W=;D=7N$MLD[<$-$J9O_(8_YR*N9(#"&;1Q<_/%9M=!0&
M=29BR-/3>>OD#8>K6Y4SK#^#7#RY!L0Z_=. :O_'_[74T_:#!*ZHCB3B-&^.
M,K6A$OKA9AW(_BMCZB73<K,I 17\Q\FO*KJ Q54+@/X/TU?5>4?%^LB%M):^
M<Z=913F.7\Y:K:+<<D4_E$3STPDA=0-O0U6#\'M29U9S7B7DS[$PQ4!?BTTZ
M!& Y%-8<_HYU'X=R/7$%FFXUWVN%1V=',OH8R'L6.-&)M;K##/#U+RK>>5CI
MTW [429OXS!Q<]Y!?32D]-&G04ZJKP@HQ3^G0, ?J (V#3=FCC#.JF_L!L.$
M)G]D<LC-C\H(1I:'.M1S?F"K7A4%&EE-9'S*%VIV\4#HU(4X?J.R#=B<(VOX
M\FT(3AU15SH#(UTP=D6>0XB%@]I =/UZJ.E+_>![!G3+*PY]'C9%>A8<G(^;
M14P@8UY,HNU#R3JX'6AAQS8E/0L6,LJL'YNZ9Z_(D_5*.NQ@\?=[7WXN?#'3
M\\#G$L1J^S1V$C,>51-AHRH-V8&^P?)N;U03.<W2I3]<\C]D,'/.5XG06J,_
M^_V7WH+**5:2KR;:?SSFK[RXX^SO>T(U,H=_A>),]OS.G"S>?0KD5&,@U-=[
M1"LQ[#M^ +B7XRIL;1;8O8Q1N\<934+^I4/RK;8)0N,@TA;Q4-8<CU63"<@=
MH)6R+YJ?*2.L"0IXP1U@LE!@RO%^%Z1D;?H9"%]@XI:(()],B0>BM\+(@CHQ
M[F/([J"QA,Q'JSE/+9GBMN='. L6B5K53<06XJR]]:J)#!]*THS&Q^@0E8]6
M\6!+&@/$P$0AK3Z9S>2E;<R2J$>S"$A.@W.0SB163%L^I]L3_*A.-QI(H(BS
M*MXC#:KRB!C]0%0%B9:MP!"W"@1;;%V1?PF:K4&7D/0B_P-^K K02ZY=W0*;
MMN!Y,S#.NH!9XRW5A\EWZKY]<KF.7:.YK*'+I6.)#7(:L::Y[U?DQ3"EP<$Q
M.8?YC<Z]1H(<%*W"RJ;?+%"*,SF@JB*H'P*%LKT/!DCDOZ3IVE<F\2ZTF$(@
MOUFN)/*,PK-#^J '?&+DN%CZ9&H_6N7+2.>*V1-5O[*!H:=2MKT\2K([J,K0
M]TN?@'>BZ0Y5U81:0J;*XL1MY7_;WVU'NK2M5AB'3D2J8D#$$@8/8]:',Q"B
M;8L5RM,8S<7C@AW*?O4FB(0!O7S0"HI(D]DZBT"I#3WQ\5XL"#-$YCZUS$#!
M6-O[8)4>OIJ8/!I9VRK\I;A$2PJ44"%J;BJ</(._&M,IZ,?4RMR=P)A$  W,
M^/A5; ?=M3&692Y:K/M#S?[["/=)1GN.\U0$.CP66T\XC)(P_02#W28*CB(3
M2*VPTMS1:HMYL7MDP137:I.=B!E;C=$;A'$7)(^^;^/D$U!2Q^%\]1CL>DL\
M2=KG:Z!!4)^0X,T \]=@<[#)EVNI^.BO.IV^O[8 ]\S(D3L'3NU.9[3S_R2_
MM7J/Y_G^TSCZ5B:@!U;DK#]S_HI^=^'F(ZRN[<]O;R1FH)[D9-^6ZR#9TS-L
M9=?5M&C1Q&R0W>,E8\_B1TP%7V02?(C"=[7]Q0M^!:R;L<Q/2GXGGTR#M?I$
M9IDOFZFYV0;'TWRAW>1,(1:/'"KUI[%,E5$/W()NO7^N1KM!X*#)AFV%S4(K
MAW%@%'IA%$I2KZ&J&^MA+33A8Q*4[#V><GK,Q_W;:MOTW:\ T[E,RZJ91\Y5
M9; TSRZCU8K*F6#%R-?^^-D>$&/!M#*GSS"?#!&"P^*[_8&@V@'MV7-]C4.;
M0JVZ4R7H9VBT2R:F1V(,E\M#\/ZT#^6AY-AHJF+R&+"9/,5XKJ)UQ. @KIG_
M-\@0!8NJC8R=B<C,C7WYRZ3NCN& W9Y\=;* U6M-@M<G(LI+C<Q!% N5:UYD
MN=MV4CU/0V>3#X%M%]JV3+M'X;MU+1Z+G!._[;,BSP=?-,GZ_I@8XVT1]2_W
M!3UL$63L3O9VAI!/"YS:@5)ULW//4O<M?C-2E[6C"_9FNEDVN[)_];U^4S#[
MA]J8O/2M(^AD DK-I]9%=K56'*8EGG*2P[IMKY#?5X5O&/@NL+K(IBQ4AS70
M37;F2[N"X=-[H43,*A.H@0#*)<!=+0F#&)>XD46T?.IN3/;'0):NJL3-2,X9
MW>COG$NCGG<,\!N#8% *5HT,*5!E,E>4>/D&?,CCP99SE;F1BCK,B(Z]6B+@
M$#WP_I?(8PJ';R3>!6""=NS,J!.%'&_]E^K. _L8"UOSP_RC-YU C[Z+W:SD
ML?&@,3SPP%="Y9\M6B!:*^3QD#*G?E0#KI[=#1!E&<_:3>'H?5Q$V[6YUE!K
M5#"O5=%&J5?["!E$4I+J^(Q+O%Z!.4<E>-/#?U8/E0]?Y3*+'A9BRE7+D'4J
M.5:#*R#1R>2BA5^]5CWI?**]#G8$H<P&BI?B(V;*<WTHN,!R@,1!*HG=_C7@
MH<KR9ERXY0KS%7C](TUU1Z_7:O@BZ2G2Q)4SMP;#YJ!MPQ6[8DMSR2)ZDCM.
M>JAW3TT)J%AZ<ZF\%4'0_EL$ 7,K@J &Z_W^7R((ZG4<%VQ]EM> \+:3/(C/
M,$;Y7_CI_W_!#]G$W+L]W0.8'?N6DC.]?D@FDIT+CDV.'Y.AQ/TD)ST]JY[<
M(QM.P]'A7IMZB<:,Q1]!UF75S-@:X%/?:H73WCBV]Y#N2]F;]1U+O&^G-GG=
M]-57^H2MJ?;5E\5MTB@S.PDTD.4LIFCUR.RHYXHI5/I/Z8!-M'.RLY'(!V9!
MP;:ZH./# HM- RXL4DP)!C_5_HVZZ@>45113= U&*%S?J/LT<ETYSI\F+'#P
M 7\_>,6]!>=N/43_2X30=(7Y2DUX,FJ_.I35//PYRB9/Y>,YK6/H#'+'0<L<
MN#K%<!;B<6QS<K<L>C/RLX'I?%<#2$\K(='K1-/ZG8K+;"*)$[5-:D*5/>*1
MO!-U".)13"=WMJ7?1'?:JO& H;S%_AGWY<84FS3C.._/N6S\@J(#D3RAY7 L
MR'&T@HNR/9]1?VX72_S9FG?05'%]0OV(/9<HKM@32-S O+.!4J(NM>K(@P<M
MC:?7@ 9-WU_B":FRWJ&,#4%*DTX(ND4Z"_/Q$N \//#W",_C5&:FM")]^EJG
MD""]%W".E[G>CV[EDC0?MJ$X-(6&&=YY0W:4.#:U,[A?MO]H'6$;NF4EHOA
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M:1.2O3CKP>UZ2Q^42R=)^@^'\-YP",%8O<QBWD74+:G\U>SS^7?O:IL]>NW
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MW&$X6$$HH\!^<5H<$H&W.##2?6-2EE4SEQ=8421GZ'P/((BYH\*](64$GZ#
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M/11(FI76*?&AHX$/(T>,R+-O<AHP"!YYWJ.CR>FIH?&!G470K#*M&C 9T)H
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MUL4N?V74*AORK260Z7(G?W?!0\B;8@F7%+SI&$5(HZ7XB#SK=?*;20<".9S
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MRKE8D9G7KZB>##0.WR_J*</"K>IL#+R_Y@^,5N,(0@YN_<AK&"V<O2P4H[H
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MZL  0?^_U1'-!W.M%DR_CV<=_<F7R?GER[R=N'K6&PJK6<I )6H\!&TYE?7
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M2A_*.[YT'+4Z3/@N>$R3M!N5$ZFLY#4D)IP%I";GF\#3OT@<R^C-^CNAMB=
MN_(3 /NOI36$)>"4#I]'H;_D9%;_J3"#27K1Q0PN1#C]CD 1Z(>[F\$XE7RO
M%+]EH@;W4@'0]D"'\HAA$/P$V"F[_OF3>$T_.X"[K9L:M&Z+4/.VCK_>!_ZD
M[N&R]0G0FOM LW*2X\/P!! X?@(</PM]A(L'Y>J[J3/&/%^C\G,BP^<K9!VM
MY_-/@,?'F)/<1PS)8/^=FB? G^Z;67TW_OSI1[WKMM_F[_S#HN0#=<RS_S?Z
M;(G?WPEU- M97N8^?^))+X$K0YZA?UR-N5$F>F9:QNP3X/K"/]C+;_) 8O)
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M/YCO$4,QN'6G^3?^UQ%R/S.U:$M/_F>S>D[<OUZO_R:OU[]8_"\6_SL6QS[
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MC^46;;W_)B[CZOTRBA"< W?0H./^TFN6(GOO:E:0:5K?])SS8[!CW-3$3>
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MJE36<F=L<X^PA7#G+^S7<BGQ7UVS#&+X^TYM,LTT"*'-Y\T"V3U B\;DII*
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M]B73]<S@9L]RL]=VQ*M1,>B8%!*BY41D)Q1CX$:-T)L5H1!Z5WS4'.M(G]
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M8MGQGLOWR4)1E1UZ&^\]8M3[?+9MR9$I=\^Z,=H7B,#\OE&?W!2V*#5\7T3
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M-;5T^P@$%!4$$IH(2A%B!*6((""@AJ:  :1)4S F(B4@72E&4"/2!"2A2A+
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M0H9!*(\C*  K4J\I((+6:J&D4@"-#!L"PJ7B=GOQ*?#HZNBOWGB\$:_?@L@
MUDML1=:S*.M($100,1<6+GPFC5PME8IE79F-_K_B;\]&4JE!'W-KI25 ZRRE
M0&@=+UZLGM3:<! A$W4^##69;;;=DG#0BUMRG;D=[=;[T;ESN\MC>1VW6 AH
MN"<5.SY=D$"X/-!V%+ *G!4M5,?N+G=R5CGB$@MNUR[VB8O;EA^W?]9#+O;.
M"UW)L,62G.ABG6E0S.#SHX+D0*,FN)'*%9@$B*[945CV?+KF:\0S&@>7-2%B
M&:29$B .^HL 8^FPW*^+EV*M(*:&0:ZYIF)T#VD@/WW2]H7&FOGDC1]P],TL
MC\[?&+%6*.%Y2 W@ZY<&P2T3MORN5(<5_(W4D+-+@.]C\="V)0!2?7FVW<"G
MZ+QASP&Z:F"R@[_CEP72U0Q@T_(@"*_GZ0UZ0T&HM$V*!!?Z?S#PHPF8$YZ<
M&XYYJS;S? 'F@T[ ;*GP6@1K$A;4BUMTVT>).P9MCJC@)+TD;];[1$L;\^PI
MSOF@:YDM#U,,I9'..:/0+8CXUE C%A4%1#Q6%A;R^?=\WSTM5#X!9,Z&"&U&
M:TEE<=0+I#5JK*6K]FK+_3"0.3->JEZ"Z7@3'";W(UM[>G+'M^:YQ.9/%CSM
M>KFWTMBG[UV-+_SV;TQ7\$N  *4WIW F_TF%_42^9787RM1+YMF+6;,@15?G
MPYX,7H0-W\=&"FXZ1=2Z"]DYW%L57IE:87@2/7VP*KW2<U-Y2"9.6CBY3]E8
M=UPM%E]@8:UY+-23(C5(M>Q\RW<Y<P&VW64G0$LQ@RDK.PP:OQ[6F(YRG@(=
MP2CD$TGU9W@!QV.O*>!2O#;I,GB;!0@,/F.Z3Y0:F%^0&G5- 4CEPA^B^TH-
M?,PP 6(*L)Z^4 "Z?G+%?LA4O3XI^/MH7&WW\EV(B[EGFMX;LFU:L(W(@<-.
MN?ZWN!56\/NPF43\H38_K>Q>YXB?OD>J):&N\Z&ISC4CW/V0S@9:[!*@O/!M
M^(>U#&:XT8*T9'FU#FF=6W #;5G8F27 >.8#>[KZCRP!/LP3%L&TT(#7U@PF
M)P_>DX:Y%R?$<*F%+N_-;&3I3H[G_.('NG_#/ERI/BG3'=!=*"WS:#IKT<%=
MP4Q_^67U'FMOZF+P\['Y&1BI3>V..DZH'MP<\%F*[IG1\.45HCPY'3E?:LO#
MSG1_D67FJR@E=%'.6%ICVA_-1M8U6N]>@%+XZ9-2T;DE@/_K)4"P1Y_(')]+
MZ5@G[W6[G\E"W/&Q(3PT;?F-(LM:36WZ95F:_,'-?XSLG_LD\O.Q*_^9O,D_
M[=&7$LG!RY[DGR6^.')LH>JE.KLZ^^ 2X.OMVM\,9DX1&T/FN 5( /M@Z4]*
M_8<]^Q6M^(41?/BQ7\C,^.7=75;CE8-9?N8!<LK_]HF_$6X5J0M#1!4&_+"A
M)0"]I2T?J\%"T_^H9@FPK![&NY-:Q^C2QH!OC>S9J?'DAUUBC0M^3CX9KV=,
M6VM!@=6B=DQFV#G>0DA7>Y*BHFY+H5<#?0V8HW3^?W/=LH+_4; H1!,1H8>W
M2)$J^%-8^IK"U"!TKY,_P1=.)<E(50 DA:/1@PPFJ#54DI"O46_H82;TH+9P
M--U%!?Q#"WW\!T8OR+3!(]UHU4&-\G_ .*]@!2M8P0K^/3B7GOT74$L#!!0
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M&>ANTM#1T_T&P2.XZD-XC>3:-1(Z"C(*NO_E[?(3@)J8D(N0F "/"X!/C4=
MC7?9 ^"XDO4:WA_;7T7&P[^2\3H1,0DIV=4%=3< ^'@$!/B$!+^EOCH;<'4>
M0$A]C>:6F/)U6ETK(BYW.O'@A%SBVP^J.^GUQC#<$M8O0DA(&1AO,C'S\/+Q
M"]R1E)*6D;TG]_"1BJJ:NH:FOL$S0R-C$U.;*U<Y.(*=/#R]O'U@OGZA+\/"
M(R*CHA.3WB2GI*:E9^3E%Q06%9>4OO]84UM7W]#8U-S5W=/;U_]Y8'!\8G)J
M&OEM9G8%A5[]OK:^L;F%W=O_=7!XA#L^^:T7'H  [Z_;_U0OZBN]\ D)"0B)
M?NN%A^_S^P)JPFNWQ*[3*.L26;G3<HD'$],]2,BM[B2Y+:&'H;=^,4;*P"VY
MPH/]K=H?FOW?4RSD_Y%F?U/L?^@U"R GP+MR'@$U  @XU\^+Y@?\=_M_K>&]
MU9-I$X:GGB)@W2C&SJ67S?$]0$+XP\E6H+N5<$6-XR5@9II1.C&*AQ@D/E?[
M_A(@"X17#07E<T^G^8GW&!CDC;O,@*S-FYZ-5O!7,9]G."N W#$3W8NWL*GQ
M=:),6WYKR6 X9M[XV^R<:6T""7&DV:>XP OQGS.SQ&3#_L(.>DHCKHQ/9BU<
M<%M/?];6)@>C16F5EZN(MP,YFPT3E[0^OCMYIM,Z0.>\2@47*+S9)$7?0@ -
M+UPO-L4E=2LQXF).GP9^:6?'9:[L1L[VOPSD<Z(9+C5M-7V+V=ADGE>/ ?/D
M_8SLN:V\7^OZ/=SX [?1V!+@0E -&[HRS[S*R' T1#_5EW$25GK>^R-E[Z9M
M8Z1W[ +3&X^]A&&H/L4=\. 1N!;I<$PJWK1Y"0@34R^GNNGH%Q_I*1\C+-%C
M&A&VRUJJK:,=/:N1WSF"/Z\B9,L>(?"6G5@!V9M='1'7+@9WQB5@Q4=[@8P'
M&K55A-N"1?TN-GF;;E*'/&FT@BR&=PH>X)&$'\?=?,[<+&MBF"\WJ,%ONKEX
MTB)H8IRNE5PX?[H8S5]IW14M(,Z/QY"J5#N[?PEX9<H7Z04E7.P(AULAEH<-
MQYE<K5MKZFL;39ALK$OOF#_D%'A+6P-Q/WH/[L_0%-0Z(OC*7Q7280.BAD/.
MB]O)+'$-3W%S[\','[?TC97)F2F3>3[LC4N3;[F$2FOM$8@2A%H@?WB<ZL"&
M4*(]5!QG?+ADB#T<NGQL+EU:I&H3?D*?.B3R%%/,<_,&P,Y]+X0R@+F1],WQ
M#O>\C.:)[U;"'8VY+R<GT9JFR_P.DF^]2D0(:EUO(X0'7Y>KNOFS^E2]1C@L
M,<!F=>9"T3JA<"VTL%8OLV5$$7C7CGZPX$;WNAK=DI 8WDVKM>2EV![^ :FZ
M.Y3E=I+CWXT:O#P[].Q$#%,]?ECZ>!56B5;CC% LP'C3['A;[&&9^TI+FX 0
M%\:F])2^=5!9AM0'[=ZY$736+Z0*.*#H$/88O"/]W:>Y(__'T[; -[6?YCPV
M!(-Q_E@/55PZ"LJ\Z2=?CL49Z5O<6=NZ1\"=RJZIP14G^PUDM;XKZ*?_RHZ_
MB2=OZ3/E:=8"&#)4'DB/"Q]%3Q>C9Y0XG1K865K&$[M$KS5G5YM]*:!U*PZ4
M866/I/KRHN<YE6XA?\GLR!'R*]&8"L]3,A6ZIWC_/V@$5(7P^$O -<U+0)(\
M%G@>:(S8U#1"DD/0()R :FX)K&S9L!1S">A>I,>"HLXT A2SND1B5N;F6F!H
MC= :Q:Y'UB,W8G-C;%^5$$G-I0ZHT9-H;&0XI\.%3O@. RX!B;28[8O>'> E
M0"._-% &_CAB>:D+Q  ;-_/P/8\IUO).R4$/>X$22'Z0T1,>$F9@1T.S:^VS
M5K)?ME..'4#QX9JU4Y(+S"/C:TL7-UQT#[58B5_EIN 7)RN$/F9HWMU!+(.B
M3P)+\V&AGRS9.CY> EXB'M9AZ=_4^U!Q/A1<:FL)\F9BIP<=6KF_-@EZDG$X
MHH^#5A6>$&G+**3V6O),*^ABN&'QVEBCWC[<EUG85$71^)D\BEBROX6?FT'#
MJ;[#QA'X/;&EE"_"02'C@.V!M@,ZXH<&,"KPUJ8E)Z8JYA9FK5!J,9/M^V'<
M)< Q6B!?6)):@PFVNM<3<N^A")+U.3(%SH@[P%X"5JX'VV :>CGP%911YQ"5
M6,\=><MQ6[%O%CVAMKQFX0^9@W(1OHVL+P:)[QV!7LGU1\*I3D6V3^R;',IQ
M0_W,TPDE#X3A]_(7E@0MS0O*;X$$. 9#I-^H5MSBX+8I<[>HL]X8%)OP+\IP
M71).+4DI[;C]&6$+"E%BPCK\4,FSW/* )>J7.")+/5PXHJ74*Y@>[</+G%.Y
MN(D</QLP70L>61L>Q?%T!/_Z?IYY)H6R<B]'@*5ZSU0)*JZ4ZW#T^ERS'SC"
M0K!+O/_.(REC"V&56=:!L]NA7?E9MK)+@_/H97;-\J(8KF_+L?S6(Z/#.VVR
M&JEZ3",P6V[&= R3BK@$$.Z F&!$*P&IW1S49_)8JHA=2?GMZ;:I.MD4,@:U
MA"RED=4D>8;G'9RS^#70T_=SAJ7#JJT&[>-@7TA)7EU,@\Z>TA#TP.575>@E
M8#D#L:?? 0:=LB .ZQ8"<E&[C"8XF0>-4Z(N7O)I7)PW:[/$T4\;K9\ C%W&
M5A4.;KG))1))83A^/$1KFRWOQK6+.RD)XURP+%HU6,-&*<5[J9W-+[^,I8O<
M+(M$N9031NT,K$>O=VD$Z% 3M;YQ67?PIL'E!<;]K'I=%Q^;LD2C) ^_CQEI
M"$"[ #L7J1TEOSF?,18Z[0T%^&%W,\ _:S<RU%_Z&JAWET#3TV0 WG)+.]?>
MGSW"&H7#F9:O+ ';?Z)M>"%1"HLWQ'Q?2P47S_2>SD1DB@OL<QM_T7KU?.#M
M*@ .13%D8R&'3\X+6D%8LDY+X@Y<^M5$[!>FZ"LMV-3<LYRQ4,W5NI-7XR6B
M3&H0/NMF(&43GE<XS#">9&I16($,D&[\+M)&67.HA47V0$"QEDH8Z6HH6MMG
MI:*<0!<S&JT RE^<'6'T5-YAAY3D)QJR@PE@0O (SM<>)HB:N,+RP&^&0#J%
M9R@H'2Z_>]0&)9A%ICHNR6:-?JPM<M,Z-M%0W0*^J?'FYWYHY=.@'#?%FN7X
M5^V<<.,I.ZQ/5"M? &:[^\.LU+O,E07-I\C4%_+Y&EYN052"T)3;L<0+$<GQ
MY'58T)DHE Q&A*KJM=#2_8C+Q73K34D=[T"=SUB*30>L/!/@I8)U7>K7OF2W
M)KP3SH8_?\OH^M[-BQ655YDX.^IR<0FX)3.8O!C1<@GH5(0'8%E0]0FH-JU^
M)<4IA0<7;-,B<#DAVP\?HZ>APM9VV5_BKJ5]%O\4_D+I^1,-]#85,^)S;ODE
M /EFZ42X;/T2\&T4M=X93PVSAQ*<W3FU3Q=YE0UI&?=RY(D[;NTB,U<?IUUC
ML&=)$^LS<".-/LB.99<+_=1.,+F>JH&4*JUT60M9'%4>^UE'4OBZ;\Z@G+K]
MDP[+DM-J'"2Q9JU7.G^PLKP\)9LKO_X(*(VP \9ETRCA773['44K""]G\?68
M2A6UN/%U9.JFC3J:RAI\/HPAIJ+)2K>2!8H-!I$9(1$?ECZ-4L%LND^R>R$(
M>IEXN YZ%Y=FN3T,"):NJ:D5ZTVJH6$@)]D*LO)&M:Y?D&07+>)\EHNJ,,B^
M"U*L:@S"M\1B7K&];:7ELW.EBUVXE)U$JZ61O(FF/+[')ZET3'U_?_:'B+X=
M_\Z[L(>][^1Q?)4=ARFIOCF;'EOB&WMBG:K4H9\Z#2W+Z=E4M00.Q:1NF<UU
M9>HF[W;TM("&$!*RBW>$=X[9M[%=HWW,$7T65*=0$((83CQ1"Q;U"C"=L&!^
M7+/%JVH0HI'X*-V&I#J\*RAQQOH^_3KBHTPOA=;3\T*ENSA\9*_<:/0944&G
M7<E&$F1\5'$2WW@LB\&D/P.[]H"N23Z9/OA6E'-'Y.Q13.TE8(ZVFUUI*I =
MUXTBZI:/IWH/"T1JCWWWE0Q0'DS)@)AXW[3_Y"7,_X!!-W3O!E58?0=-+<?<
M!$HF$AK("&%H-GKU:T=2)7 OW^1;+YW;[6,DP%G\99S.@JKY<; 1#U6&;.E$
M="&//(2EPO (%%OY[*#YI]<2$5P7<6J%FT#QMOF@V'PT<+XK"Z8ZE!NS3T+?
M:Q?5359SU38DZ;AN"M*VD?)B<MB5[U4*'AIA%G:OXA9T=Y9 HWVZ2N&A5'M6
MT<ZDU'4J^:ZOG[[F?R#PX'9.^*E0_^5MHK;=&5/UU8+Q0P:KW]=.WXSS14'9
MX%)8I9+9^O@RF-Y E5U-PH5%4A_QW%[D5 Q]YROJ1G8Y4+ T\ ;R$(6K1EL8
MK41$2H*H<"E#3QKB]K:TW-D:4EU<\;S%\6[-4JY0I5=W/GPK06&;#'0J'7@A
M6^926;8>B%I*.9V?QGFAH(S?KF:32JO%\HY9WPDRLO4>=+EJA\5"Z0 ==Y/'
M/_.^>C2=^@"3&VOE<J6R3:*."I9TM"<5Q*)@40+7P3Y#ABI1?ILQG<4Y;[[C
M#N Y(!N@?OQE;=8@:]5H_OW+H$"+]S.\K=N=@=P=21>D$I6PX59&= R"9*N=
M.;X[97:J_^7!S8K8I6S73TV.RG&B"Q_V6:^Q:9#M&S0K%:*K(CKJ(WHL0'T<
M% HFZ.T 0WF8 E,%F$'+'5PT!WC\FH3;*V[.5Z M_<W/EXG$SDB%?'9(WQ+I
MN2A4O*KXR]QY1*M[Q9DQ9K2/@PB6VF.*C/R%H,(E;FM,2 ENKM=.,0\)W= 0
M3ULSZG+@+BNU)KD)<%_"/.$(:^:6B^B-R?3URM3/A6WMC0\NSEEV1".'[N-'
M/3=YZ?%:=N%.DRP3'WW;*<-5H76CE0K;@;9,1G%$^+U+ E?!BM;-7%PU@"C+
M:G5[+W4>.WVWWG><I/PL6BG\!K<U3CF-<<BK1:%7-":0?.JJ! H.KT.39=DC
M>WBIV=\X%]B<CM;2[DM/$:H&IZ7BU5M%'SY[<YL4$Z.Y)<P]W0)R4=2(GX%^
M&</Y_-5Q<-#RCM%?'3>ZP^+RA^.X_XWCGBQ&8 F>GA< P:.12H2AII.2(#P<
M/K'PSYPQJ.W'YLG=->'&MI[''PO<CU^(?)MYT2VD@]\H>@T7?0+%\?]L0=]>
MKF(UP^D;8B8#V>JG*Q7X2GJ=7<].[:\-/2!W#]R)2%OFWU('9=0!5T"PLD.K
M\ZI6$RRC-F:M%!4?'J@4]J3$DT6FM6U\ERY\GWGQKFVB^*+5H""KIG_)PB#Z
MR:[M\;,VSXY1]X6S2F%DO(+^J<3%=#LC#AJ RC+K 5*T!KAP;;I4++ ,[7#]
MLO,N[&EY9R#\/8A;^*+6ZXZ/1S89+<JG1V<6@JX*$@D4@<51T*J=XHODA. %
MT(F47UA\,.ZY(>]ZJ] XQHH.+RGY5ZS'ROGZSK53;1@+2JB9MRP?Q[ARGMQS
M.+$U+6&RX)0Z_LMXQU97O/^&@<M(M$G[,[U[E52'+EBVG]FGUG PEKWPRA9@
M/ZH8BHQ-YJRC,"GBW-3/#RI:TSQN*"J[M>-DZ<OM=&8T"IK>/#M<O 1DA9H5
MCE\"<L<#/[=S8J&A0,>E5QW7O99N0MBEQ\ZD4V1.+ M19$GN_LRC-.HVOCK"
M/26*> ^#\'H#$I?,C;HZ\%N52P9._>%&V&?](6<N13AH;TH*0X9A10G,Z&E#
M0Z(Z9XCT/M,*NV82R^OQ:S=9=[A)3RM;OSC%*YAN)7GOV@6T#L5U;^1%HV_J
MJM !_K_>,M4*A:]J&0TM%0#?BM;5 7WO>$TO.D!VV-7AZQQ1Y= #4<JM^@R[
MW4/[0G>(D&%#"\'Y.\,'--K%E=.<Z';!U8[0HZ5:GT^7 -(9&(L!3J;H['[]
M1U]\6+X:5KNM>#;F\\B$-MOG?695!WN'3]RKRTD@^PF67:J,^F+03&=GP01X
M.^#$J?PD$5VQ:S.@Q 83[9GMCZ5%<<1YGDL\PA)/<*A_'*M-CQV?,1VXH\V9
MLIK'5. 0+=K\/O(&VMUZ:OL4+(!(MA&X)U]G'7;&?R;@F(,?S?\/C7!64< Q
M+X@F-G\\)1J@TY7R7WEWJ<S"XJ$#F;9"*:'6D,;M:[H'O.]%HR6]3YLK$D[,
M^7!?KQ?29UX"2!B2+P'*\L#3BPZTVAFWJ=$YX8]+P.[))2 6 -8UZ< D@$&_
M:&LN 1W;%Y*(+I5"Q-<GHU?Y6]450/+_*H"48L5!VZ] NU;L/*][,Q\Y4!/0
MH*+"'45NMY!,[2O4#W@FBM.0K#HAF;D$+!U< I@!XWDUB!6N\8X-/H=+  )Y
M=A6G7\9<U;PY6=GGEP 0-H?BCJ#,!8VPX$6(-^+H'-$7CU.O_2> CI5;5P \
MX#\ P,!_@"/0C![^)\C\OX<+DBPI7_I'R/\P@,_A81J=S&%LY<37X^WX]?O,
M=(;0?S2<'-JPNNZ9Q*)9UTT[^("!*WL^;Y D_W^Z(/\-\'\HP'>DY,QMD8;#
M\IBIET/!)^/_T7G]'PX,_PWP7P%@:-\:LC@_*H3MIP*)O;UVMH$_3)_UQR4-
MP%G#M$M Y1\@#Z] -"?^!(G]WT\-K2N2\C<IJ/.;O,\L^<_QD^,?\/ *5>PO
M 7\/.O:/@/>9#?YW1. [XYZ]O_W>Y*]+V43>QTO "N\X<$/P:JX'DUQ(=F 2
MP<!?='_E4?S//*Z2U7_'F^J+O..,E:7VP)WF/WPQ9B#DI26L83Z[T.U)&[YG
M2Q5?R9]#=?V\0Z2XYCPA\/:HBV3*?K]UH6U4],=L,3EJ4! 9EJ '>[YT8ROT
M8G'U2LSS*U8AH8B!=V=7?OH NP2,18%&KP$\09CJUF>7@(?LI5>R)R)BY2\8
MU*(O 1NV4PB,N ZVTC4:L E<L855781K&UT""+C_B&S_2*]MY% F_6.__/\)
M#!H7C"KE?G05!5,-+'K(,P?N2N"08Q>TY^_;^0('Y HK8_-PBTN]<BK+X1>P
MGO#G39V.1[2=56\#.> R6,9>89AC.]-$P>3!;1:-U7ZDXQ:$PW0,JJ!89@%N
M?DGAX@^Y%>UH]O[#%G_=IU/(8>25NAFP"33=^,:[&]Z8RJA2,YZV.?6EUD7W
MQG .3Z-!N:(VM##00NY9552=\)- Z4S! 58E?W)V2&B%*!4NY,I%)W7MQ44C
M+E4N<YXOJIZ"^4LV(CR<]OO9Q2=<+1>W+::%BQ^&QYF5TD=,TEY9\)]LTE:(
M&Z=XV$]@B?4J@VS>XH6E[2RZ]T+ <ASA@3RPO<U;31&=LP]Y-Z9M&@DV'ZO)
M7 +(;O<B?HD[=>"8^'Z/PK\GI]NK,>V^"KI*"2MEA5@:U997F.>DW[UBKY_>
MGV0?/%G(:=)IC<@ 3%X"PF)1'2=,4J S\J3?.=4_RK0N\VS;@G=MCS&%/SU/
M.1&'WKSOTE3V+SE/IOBQ)[NO9,;TM5J5])!(GRLE([H#Z2?JM)7DTU]6?I,/
M:;S9:QHOIO#YRQ7SA/_!W/$?2?#AH=^CHQI5J\8X.NO<HZ-?%1L7+/T^Y![W
M/_HZ!SHW*&^KB=0W0?3?_4L4B(TQSE/8RE?8Y/NL;+D6@GBAHL=ZC<\XW6/O
MX$3OC>^S;U' %9O?.EOH_]4/?#VBM B[+G2O:9GVVMV[YY4ZR6YW_:;X%<1=
ME6R@DL3QX0LCWP\+L RI-NN/F@WT!?JXXQXF'92_02U$?X.>"4'I.8[3_V3_
M'INZ0XTEZM?=&(.P\T[RQ&C6F<D2&I%'#.G/APX<50IXBH^;]LPT@)5.!R8P
M9=[OJ#+UVF$N?''J2>7%P;_*&(I-4/&1--O,A]E$85YM/D]J,V3S,G=.0NMY
M^<AG1LF2=+!HV%"GTAUFND")9J0($WV*MOB)!G4,^<Y-14CR&)S!2_L!:MH,
M)VQZ0T/(;[HR>\5L@1(U83!>%TF93YZ9-QOX7,U=]TNJ+M/1HB2V,LES^BAC
ML0XB=Q '2:>/6-8V_"=[%E9/UEG8]"= VH7'B['<;K*GCQ45/A$11&]( O$W
MLNF5;IG+UE]-V-O=<QKX^F\YGH#W^QO9O?[ED$%J5<!96C+[D'X<8<7,9T]C
MEQSC 3:+C<,>W::I$5X:DJ>G)K=:XLMA T4%[[Z0+6$^*EP-T(>\97\)0!S_
M1'M\J6"A?_XLXJF*#-@U*..Y)^+?Z^#YE$CC7T\GPX2\14AJ#,2&P/Q)]RV&
MLGFS 8@[MWBIAHUU>7$)5Y ,XC\GXOTG!<[_AOE+OX*KT1N/JOK;Z'V;%Z14
MBA-$4=% 0#7QO?ZAE4XZ'M!5R1>9Q3R U>7UZ&/T!8-,=,>&S13P=_^JX@[[
M%K:EC\6])L%]*Z/+@NB3]LA_7]8@.1V<\87@)2 W]2K.?QH ]KWMH%8P_@+
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MVB]'Y_7#B6<4ZN,AX+%WVI+9?!33:I2[U< @C&HYS2=SV7_>_CH_@-(I!OX
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M8N)6MX=Q<T3GC,O%A#OK+GF)#* X3&H,IM4E]SVV%[TX*C2M^SU?<+RN]A)
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MG3)9YJ6CI3%&\=S5'Z#DW=9?/BG,J:U;)+P=GXQ9V( OY9VIQO0973.T<OR
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MZ*1O6JFB1=BI3N_1C '-#ZO* H&!(QA8%$A_+,$F2]6'?_F4&;=O."Y2:_'
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M(WA@=-\;YVZ^$E%] ?E!!OPV/BB?RWW:[##(%UU=?#%RP<&<6^LO>3_+C+Z
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M3@=M3%[XA+BSZNN0_PX7=L:+1=;55L'>EL+<)PKH@""#H9\RQWVOC@Q8<7V
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M?KR#';A<Q$[[$=.QPQ,H))Q7V]!8K[:7^S2'>A+5KA^*&X&K1";?TUO54&I
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MVS'XW%Q$!1;?B7B)F#G)SN9*$KC_ K)U*JDMHZ9^N'QG_^$WXEW[E)76?'[
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M' N-''OC+?&4D)2,59G7W3=C]!K^+\K>PZD)-@KW1%%0JH+T*EVJ=&E!1;J
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MR2(<X5G6<FT#U6\3^Y(=KP3,F7O%JVB8RB3#5U>>F3ZF0N,,Q*0B]D&J&/T
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MJ-Y#ZY?%I?/B6@!P6^=@%J>QL [L*[M1*C95ITG^:FWPR;/?Y'POEDDJ+-*
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M<S)T_J<M_[!1_"/H4J]TLN!IT>,RIDPSG48W64;1Z8(R*4MX@A>>WW^4B4\
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MH=VWUZH(R3KIT!!?HLN&FWEVZ""R55I"?%&=EI7O#R^-\)M1ZC/[-<68R"@
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M)9SA\LWH)U1]\ B =.+&'I.C0>YQOCSV:'\I;?')O5> ^GO <RCN_"N.&O/
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M@O AJGF]U!(\;U-4*!E@3$*R"N0NX1=9CY+H>V<(JVLD-6:K#X0?+L70"G<
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M-..,VTE59C_@VYCMC]6>$=JLQ0G''9N.7V@4\VW87(N?D&*DVH@B<3S^L.?
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M4W8BNXX^'\NRB#%UE7PW?9FVY]=!A<.OD[34;^M]H.!!6XDE30.49<K\+'>
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MK.AF<+9 5A.$KN0OH-5^_OCK,+B*,3[OY?!LV5\ RV&E<R.5F=3+>[>=T5F
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MR;2BJ9CMCKCX!P>@HPSI^[6_IV84/,I:!>Y*G-UPZO)Y9KIU+^G-J"RSK"S
MF*$9A304TBO0Y&:[K9_LPN//FY@AM*<;@CCB^QS"/DTB7\JY!L1+1BW7CLWS
M,CX;D$N6 02,1H_SDB]< _"JYP]W0EA)IY0I_\"-(OVYV.]3IV@!Y 6MXY;%
M/MF%1GTFLE>DA+(I(#D\FN])_QZ4 KX7K/K_M?[$P#1?^SXY;Q/P-@G8,7V<
M6P!U3M^Q&S'ISW*0X3^JDFO675KHZ+Z@7&RAW=SAB_-VCN;>E;<A_ 1*H)JR
MSK8T]WA<G))J=C#)H&9^^2C>Y,]RHC<V,08$R2R[3Q5NDD>K">$&VMMF<*03
M"'\-^.I3<*X5F*XS\_%&9S#?4O:&6]4+>VZ.L1N3?B(R'\SL,[Y".YT7K,TU
M8>H\R;=8_4XJ [U5'#R_F@AW@D7#H7%01,<!7=\??7MR?>XGG;^@O[<OC&!+
M,.JZ+*5Q^=.F!L!8 .S;>H)*-$2QH<M/\K_&JHHBE_7=(($A\E=5W4]6OM#Z
ME!4A1XV[))^_M_<PS7**8C*)??J^I!A4U>SO"2K/<S9V6Y DT_26DMRGM=@,
M@+1;JM6K_@4M[83P6&R9@P<B>+G#B!7(>;6*$BABML%I,79"&9= ;N&,9<02
M)RFE>8K = X4FF:_E*.FNXHJ-K% YR*T T] [$3Q!O%*'*L@Z=PH7-/.4CHK
M'C_^QP(NB4 9/J7]>>_NE7>@ :&X9(D96GED]=*%\>5SLH^"[X97QTH>',D!
M:<$<3ZM-:[>SB^OJ%1S\RY78(3::*/MQ=_,MYH2S-<Y/"*^9\^S>4C?O!TR&
M',&@^*9@Y4P/2HM:=^Z0';E%H]DPM>S936]E*K]/ [,@<H-SUS[E<9;.[%=U
MSN8X2O='S]:=S^?'H44D2D/T4%CG4+B$?M/CALY_OF?3+)Q5MR4^FW4IG['/
M)*0QZ"OLO"D;-=8XA#(9#*.DRZSZ_0MCFEL..AN@[LP;655EA9C2C9![T>V:
MJ>Y9!(O; B6=PC1^WJ<(*._<GE?#9QG5?E-\7A3J \Q/5!^?D4-T1ZPNN=!(
M_=RUDHY+R$[3JLG65YC?8B(P14J42M2'#!D8:?(.GA4/FA\O1$X'H>G/J6A)
M4WO>9@P>;J'?H@\H+7IS1,V1M<B96XSP4U]#S-AOA21SY?M!*@[7@+LFTT<D
M>U3ZO*2'Q-9'S*@D6]]F 1.QH&PN2 %;>\FX8)G1,7(- ,T[W>.U=#LSUHU#
MB4K%%%8AG):^5R[7>P@,,J^[%QD1T$50\#SYJ,A^[8RP<C^@8N:WB'H9M/_Y
M27M QM=E^$B0:B 4K/?4%YX9(_#LBBW Y+7"0) :@Y;P?"<I2*5HBX5*6MT4
MPKOEUR&VN2.VIB08/7SU"+P #'J=)1KMFE8;-1/S;3"YI%F?<!(GJ1N9RUK-
MO[0=+'> 77S)<N-09%[:Q&ZI)9SX&^..@ST$]?NZV_XR>YQY4 784 ^8FR0T
M^%M!/77;P$7:T"TEWE$1"]/P\;J.CV]O;'=ZF:]_LQ8L15F N28Q GNYNBJS
M)IP>A/,7)+M2;<]%'0%VN]?8[$LI-JJ9W$RC4I1.<*G?J%'M[[K&W!EUM K/
M[P.I]3K^PSGF7HHK[BQ2$N%>CT6KPQ+KQPS#BV30YNP)P^J\"$LEUJ6$MW Z
MO 1RV,L:2AT ZP "-M/KB%D<*=*)^/HL%W@LS<791%20,6&\)6)WW]7+SUHS
M3:HWI/UV4_#><:O1PJNM3XV6_:H5;)@OM=O*47D,E4?7@/O/OF*QXFOV>%,3
MW\"?9AMG_3LLKETXF17^AP,?!;O0K)M(9><4(_\?VH]/3=E2MK.(P8QSC\>Y
M4NE6JBP4^_VGO95&)TL<@A-42(%+IU6F=&(2H6(VYL=/'V?KO3.Y'"D!=>$5
MFU@Y=V];5:E1$*&\8T_&UI*G.9,BYKFA:N$'J;:UPI;@NYZLIER[,ZU*B)2R
MEQ*U=$_;<Z4-7MT]U_LOITA7* ";"_5W\5=@K'D/ ,P'&.W%+D?ZU";U+5A1
M>#6P9XLL0\7;E&Y/(!09#SL:Y3.%O(:LUW/'I> %"&P#=3+GD<^?Y\ FLQ.Y
MA.B@6]Y@RB<Y$OSJ^S[?JCL]!N<#D@3&0($UQLR_+GP:(2!!^6:9+3FJ;R?#
MOP>5CGWU"*'AQT#:%\/.^JU%?UO?:,GT^^_&$<*/M&_7\S]=N7$0.[Y/Y1+Z
M?OR)J>5LAONSPHC'2FESZJ_]OU?6>'.MJSD-74G@.<+<%Y^,"0ES#:^G*7\R
M!*1C&!+P)7].K+GP%Y%EQ(K4A[EJ.^ !E I.6-NZVDH.MXL5%$<_;OJJ#MI6
M8")H&^&[_O/ZSD4K>8;3#EN$-7O-_S N&1AM6RX=:TJ/B J9O )B@Y@*,0RS
MIF;VQIII#4;]01GEK[S]G^7UUJ<_BU; QAY^L;$GM9_S=7#((=TYP2?T)+>9
MDXB^H(O%%1%%P?QL8BY^(@YQ&V_R+>AV<;_K)M$;G<[P*CZ[T42BB'(C\,AC
MW+FUL[7)S1^XLUW2Z?2K>:WLSG9&MUGA5@$B(&A4<JXCMJ _0<$D-/^"%K_^
MV>M[Z)+<V,C @.,<I86R@7]KIV?+ Z%::G8(-SZSJ3'>@,%^TN?2T\A>3A:I
M!#>6[0U^<5F*63]]*I>G56F^);]F)Y9+-M\D;+CD5O"+9,QNECMOG'A';.]V
MB\!RYM[>'@NE,U4E4VJL?73$@P ]S$C*.-M)M&AQO*S41['.H/WEWBAS?'9A
MGST>/!WD[QE<6% YA)+=7(LU^4**T9-++Z2*IWAU*.)7Y<\-M>7OM6?T"(L+
ML4F-C4ZC.&UG X@W5LST3;#!*%#O)NBX2F,]MPVJ$"S)*4,E0A[:8(D1*@&O
M?_&LF9QH@W^;O0R+TBS:JJK^0]S;;LK'H4;UZL^UGZ 4'IUW->7=(+F;C5YP
M!^(N'_9D2-F7_&CX8WV$?@(S='OGJ7R_%H%OB3^&2C&+4Z/V67X0^S]!L A)
M^<WCXCR]II2^!M_3O":67J@=(O)_A,3_LY3Z_S'B*S%17.94+E Y+,CUM[R7
M0>B]<TZB2]:\\I0T+EICY\E[G]+-$7B0?/ZVN?(WKX(2DHWVV*VZP)S"K@L[
MJ)/!KZA^N=EX3#=5$RA0N]O5S3:7R7DU[IL@?^LMXX@HCTN$S^N7]&MU&Q._
M?AS<MC/JG+/<B%G3S -? ]I:D:0&_.TJM_O!31H1]K&SR2]@/R3B/"J/F$6K
MU-0NRX,K1M W9A"8UE#FA$59SB(_3]!=FMRSX.[!_H,PA7N?S(L%P9^H06#V
MESCM[RM/]P=F?6$_KP&V+5'F3F%!VIY%6R<OGU9%'AB_.M@CPNA'CRZ9A8,J
MDHU-V.# 55/?Y'_90NTGEU&-UT(/-8>^ D'WE*V7QA[/\'RUPNZ),W.D1<B;
M;^EU"X&>W/AMW@"<@G692W<,WIF2GQ-+?MCA5ND_2RX+4R$PIF<IY4BB\Q#?
MV&=*R:@1D0J";DX'OE#S44<D*8+CLNV)=4764MSN7AFZS13)Q^UKOGBA6?G/
M?G*'%*-VG6+1?B[U;K+-%YP:.D_28YR(\N]O_;3[6 E5-DQS[SH6W0LTH<:'
MXK!1A(ILV7&^V"]<2"KJ )\&;Y>?"?#3#RO<-ZI?/#Q;@WJYW]*SCUA,,CTK
MZF#1XIV8^307O.VK.;H>Q]O<2-;=I0[UW!%&J91+Y+/:\WV+K[W1>Z&9\,Z&
M;"M9*J@$\>EYZ)3D<AY>:R%"S&^9F,ID0O;,)1W&_W"0AW!1,:DD",JXXAEV
M&JXTL=,(IR7%FHPHXW5"IZ06%O,BW"X,O7:EJLOYTO?F4CD^^SRX<<*BQFVD
M/ZQV6RG1B8V@X=D)$%U6G]]P:4)#:L\ +STFBH359I#4]8+SA3^!')?E*.4/
M.-VO2EQU+4;\1"<!7;O: \'>EL6L$ &()]%I&,K7 ,YNXN>)RAQX2Y8H6'")
M1'FX++7\%Q 6FZ$_T^\5IN)(]E7,-!2ORWEO<YZ6Q.?DXB26J_9D^J7GCQ_7
M '/ 6<ZRV8.*IPX*]U7]3# )S$%2)-:2'$_S^*Y>_11A1CR9DN \&)]]=2^*
MT'B"<]J]X9T?97(N_8+3*>[^-8#SDS/9,>>B\FX[?F+YP9V147-$+3IR]\"J
M;IWC\T2!7SLQF01>E.G(6H^IW69PRUYEFS@<Q+<L)<0$.3Q&XS>3IV5F[&8Q
MCPW0S;*P6B7F"[)A$04!O%_TE?M]Z]^S_2&K1.2Y[+\'4"056L?7!C&8';3#
MS<C_S:A06_QBD4M]6:C$1CI_9R7]DJ"8<WD8VOMPEA'6JSWXM=$]7'^IME8;
MS SLXRJ]X+Y,PS-9)NCCQ_]+\.0_Y,FXE1A2>^-<@"6TCA81,HA\W+2&*L%A
M=HWP@XN(H5J";A3$512H<;<W)(T G=BM7K;R5?&KG23.0J:Z6SF.EWP7@.J=
M[%HZOABQHJO23^\/XS\&/R7;K_O'"5*";JE:D@;H K^P>IP9VT2V+)9PDM7F
M\ 9FB])5Y7^,UGH1^:?Z:-,FAT/J,O4(8M@N%]>5^;XNJ_SKQ@<^-_"RL(5F
MP[#WW1TWG'/5AT^QA;X_@<&7\!;0=MYT"D9_2]")R/Y\5/ 6Y"3[-Q\>AKP&
M+"8J/T!)EKD$9(2)T+$&AXR3O7Y(];=A2_ @&C=F/K.;$6#EMO9<9B8>L15:
M ^ODQOLN3_RGH"G<:S[9&A#CTZ-QA^OCU/%/X"876N[?^1/\:-@]E^*SJ\0Z
MLHSS;P^H_Y*1N13<U@&:(0B,,0YE4\J9+KYT_?0!9<P,!R47#PQQR' %4;R)
MR9"W\,NGDMI_H[XR*N3*&[Y21U\ "6'(>*6'&P$Y989LZ5LM_$< DU";I 6\
MCNCT^;L1NU!R,%)/*N?N7=>1OPPMYI<?1HZU@\V[6",=XE63?*EC*0JY2/T>
M+729UX":707XX#23<HZ/MF5)!Y5(CNMZ;8^RN:ZM$Q[^$WX-2/ +G>/LJ81,
M=YR-!RI(B#'(LJH?E-6E.?+E:>DS*$; ^KLM62[6_AD("^DMP&119W2PT]SE
M)=PN%B[\*G;5J$Q@...IT9@R>':*@U_H+YW;T#LC&4W$A,I[M,*93ZL[#46U
MMT*?L=2E^/_<HC?=8CPPMVKSZ:;Z1E6,QE^F7S%/3Y(X=1?\^[=.JYJC)+NN
M)CGAZ'PG MRHH3$)PIU68R!SH#%(,JF\X$54#U^P.[#1O>' /OOVL;40(>"Q
MZB/O6QNCBP*;\LZ6=0F8NE49186+2E=7;LL(MR!>'W0_/F3B8V@H<:ES[1/>
M^T'G1^62;!)7DA6,E'H!-:N/>(MT$&9*#A98Q82[.TX'759<[HXGX$3O;^22
MCZYD&*'"VF*3^Z@!7A5/BL(2IKF\&7\Z9*&D<>2=.LJ6$] CJYL$1U0247.U
MS@=H:$U.J" 6MQ 8.LZDPWB<:T]IV@6^-43M(#:4:ZX!K:>U%D83B'>.3:C3
MS$+.YT/D0]9,^(0+;J*MC?)@TQ];3!6X MZ$KD>Z5*7Z:\YB/[7EAF:0=3==
MEA^$)N2Q9"S-APFWY$1]AU"4)#N3L1)C+PN7\(X)(BFV;58O+<-F9K9M*!86
M;/P*C'//5A"='1&!>9LF0:HP:])Y1X+WIX7FU"45V3]5":UR00'^R92%-L]^
MI!?N0P"=PQ=*2--&RU:NT%XY'0,K]5=.?O8+5#^DF5NAG"SYU>C/9@/<9C(R
M,E5J#ZL0E!L[6&-_WD2U.SM?-3L-)H'@R\PKLI8.&'UPD\D<I&CZZ@*.YV2[
M,C(A%I*B@%$*'RZ_%6F5O!I1]F;!G)AA;DW _;:D2<!SZ6DSE8#?I*]' GO&
MIT2D.:E-D\.%>2X&SMZ'*>-KUM6''V.N*#*N 3S[.*;+_]Y? X:H'_P?FIOO
M">7_QU^&S3#P?[>"+07 _$EEN'Z@,0FX")7K>LH])CRX'UU*X[=OK;HXQROL
MV2GGF">_$X[S5G=WQ>YW >]-^TEW9;!8Q6;OVNF9D#]R_"P#>EK25:S)H&XL
M\Q/X*X1B4]#]9V%5-'.X+L-V(U72S*P]5U[ X4*$#Q2\]#V#7.!K$XP*EL,6
MCV'5 00 IZZ&BZ3&F!W9!8L3VKN)\G8?-54!!#,LH:@XY8;=UW:N6J^YEU;Z
MV%FIU9N?Y62\-W;S[W>Q%Y ]E'S5P>DT+O3R>[8+&ZY0ZL!\)N=W.E>&*BJP
M(?:316+#WE.RL/K1141LT:_&:H8(\%)@)B\XILS!8<"?M]FD@\7UV>I2+/?$
MCVWSXC*PQRJ&-IWM /#SC?$5)GX^N,U0 GRP>%)"<GJ%(MQR5^SLL9@NF1-G
MJ? &B4 -WKG#Y0ZYD $^4/:!AJ6)&D2\JH%8@TP_A"RW\(>=IZ[Q<$@OE\Z3
M-EW7$I>#.*]&Z[RE!_!$"3KA=E[?;E,;8! W)Y%R:LOW&N"4&6)OILO'4.$D
M(1>04JI"K/=U-;;&U=4H1(VE.%A)&UO1$>E+TG*^X6']7B&\+6,*5MYV[/V_
MS&*#+^O[/9FRXK,D;T[[_-@8]FP:0?(&6W2<V<ZV?ZH18O?YE_-@R_\.9OF(
M;F?I#'QQ8M$L3:&DT5-\OG!%&VA%HR+7+=R;D)H_**E]S@/*<CX/7CME&AM=
M;ACUFI-R_H4X+*0\T-Q7W:D57@I&N8\Y),0@!H$;\%9W![9J#3':S$^W/5E@
M$=Z4_5PZ)H;C[\/.3GTJ&3X?09D1,TW-[,)N(HR\KI\+/2VK\DN@(]F2X?J\
MTOY3\BZ"LR.YC+D<TJ6.H(E<EFO ?SHC W=_HM1FK6UP2H@!$%H&19#^#R)D
M/T)LI;PXT>>5X2ANS&&9G]8]BM-1*[IS#8!'%K!OUPX'<3$@!)VB7(\0,7Y(
MC^X[R(8U6[%4N[T1$Z>X+1;%<Q<BO6FW9ZA=(LLS[5OLV[-!?(N7P*7^O1S8
MYDM^K@9DYZ*,O.GQ8+,G)8%,"Q^'\MB4DE^,$!1Z9(_P'\^+%GW<- [%[G07
M@MQ&(8-G7T/#:PTV_,?PX]5TZ[F11]2>F'EJ?$A#F87JR3YMH=G#B^S!#_O6
M1GR154J/S!)H>I_TO+&"<]&O_LH-:ZY0FO@COFVNU._ HNU>NU?7X+:N<.]X
M3KY]VKW=AD:R\Z 2:9Y\Z@XDT,;S]Z@;O1&^!U;W>7\UH$P-R3#%TCK&'QJ-
M.LQ0??MN&BPX?"7DUSBC@]T1.A(4#ZQZ2-0E?DA-F)#9M/ZPR&[+&1$Z34QG
M>MFS;)CBQ3KPYM'91."2,@TLPEJW>HLP*#DIS20W]MW!>"^UH5;&057+<M S
M@5#4W(E.MAT7&8N))]3QJ"FAQY=8B,6\!,:TI5U'F3V4K-MYE=M[3C$;8B3L
M!:G,@YU8$5S1&APC<[\R:3U*;"P!ZJ^6%QRX= T SH&FX\/$AB3%:^9]UB6[
M#=1;OAI,Z]?(0?DTAX^@VOI7&(-I^3K("=NB2>B2,I#Z)8Y?C\W>L2&4?#-)
M,2RY\,FC)-^G1)@^'ITG6;7,/!DS77_L>L*5AG *E&S;J*O#MWZ&A7$5#+L6
M7<U+TU;8*MF,P)<3MQB7"D^MZ9MX:R_X<-^R"?" WUT>&EWO9JW^NE=+5<ND
M[IC1J+ 94R_[9^@46=8)9Z_1\Z\?0J$O-?;3YBQO-@=7L.K<WTJQ--=:[+F?
M!AIWM70(%E(/Q47:P5F>%%L)HQWKMQ9R O8[1%E4RX(8A[UV&1_R);^F]#SX
MQDUSC$,#1Q8S.ACE=#H"6;9"A5?=EB6;EG=IK@%_E)[[>?F_P::WRWLF"D;M
M"9! GN;RXO?F!P8V(:Z54E,"HOO8Y?!!A M?Q =4YGJ->EW6D_:_%X(W-LWF
MF1%(PNW5G>GJSIW_&I\M,TA'7.C[@I\L$%OVA3[81CU\*'3;9_0M)G$3]VR/
MD#8,MRO99,'^2.^TEO^QV!/@F%GA%[*L>[ [C"4\\(Y(%G"LAV,?U]0CO4>A
M4]> ,>3M<J;Z#,W&ED#!+Q1D!8=92)U>0^GH,N$S3JZK(9:BXX1X*,YWX0&(
M^8.B>"ZN&;QT)\8G*R@@MP%"#4]* QM-^Q W3=%<YY3@41":#U_45<*9C7!;
M9J/Q@[F/>,T(.[5C#Z;EILOT(UE+S;M'/7SETKG2G$M[R 5QE*]P4YF\3?7!
M2DJ0SO9D:>.XD\[]^\YR5E5A=U+</>BJ!N7?_^5 >%KC=XG98+:)^^FCF&>-
M9UA+3V;AV%*RQK/X-+:!Q\<L1HJK^7SADA:JC8$YCE=+<U^4G41\@#\KKM@)
MG0EAWKTYZFJ(0QZ']4%F\Y4JI:X:UICOFBG*.2][SE(T5[2$A>L.@$6BSOW\
MBTMD&:3Q97 >AWJH4BEQJ!.YJAUTA^&OZ18G^1H>I.[QH-WF7=M?S]CS,0X9
M_ 8J2UN88PZV_^2O$+33_S8Q]HPJP]@\IS9Q041*6%=R4.O!SSK'KW]K0.+J
MMM)F]A=C,:7F[>(%[)B'_?JC*^D+NBD[@X><Z.:MI_9PQD_PV%E:##9/*KS[
MZ4:$9,?;T5<)HGT*\EXP5?Q^%\2S]1I ?<QY\TDEI]U8_.'']D3%.'\O7[(!
MI'C"<YE)-QNC0:YF##&6P/150>4G28*D_=;4,7R"*4S^!PT-OWE762ZM]-Y8
M%\TBD,>K%&06/UM^.3J@*"!0R/M 7U7L?Z2UG$XA?=45(=TM#V*>RI"3XV%D
M$<N.%84++IZ3.EQ%T%*DG^4%M(LZ<'^GEPNVDT+0U+7D7+5AO@;(#;Q+S9GJ
MW['CE^9VZIC -J8=SIE71H_2'9!OUA]WVB*UWKH(X!J,XB.KC.PV=*>D.Z8#
MP29H1NP36E.0EH;01_'XM+8@5Y*[Z.<+JZ#JQQ ELY@7BQYUJ*N! XC2EGR,
M/PM_ :2GYZ,*K!+%ZF]W_B)(-JOKF.G<>D!!G*.>#&K4%31A5V:Q;8PE^GZQ
M>_:C0/1VN2B]G]?F-K%^\N&/RP4M21T.=LYWB:V-SL(E8BT-Y$40<"Y?W;@$
M AFAG2@ER^.A07-(M"<U<WX^ANW,-% 93SRGAN;>4(P+/GV_@$^>ZN3YE!ZN
M2OY1\O3Q@W#F)$+/;YDSDTWRG29"H [!Z=NNZV2,?\$-9LO#I$Y P(>AY:&]
MF\7WI(U!*Q<N)9C*TRQ0:IHCJ[:R@& UP:'=TI+2PB[-'<>^S;7<+EBR62-1
M@U-;YRO]"8RZ<%K,8[CJNQ+@X/[=: +/,M#J^EC/]UDU,.%/RS1<E_2E3#@O
M*@VR;OTEP>8CV&8YX[_=$!X_"9>DN;+Z.+7Y%=IY-#W!)'P_B!P6G%;,Y76:
MKC% #0BIVC:'UI7=Y(WZ"'5;GI"TGN]9UAFU?_R+.L%UHLL&/KC+DR[-&, !
MHV=F7;7X.D5]#(,6H=WIA73>4T7Z0XH_R^91FFV%\)!@#K8,.O#[%F3S+88*
ME/FPB M1.\<*I.O[))))*P?%6*TN#0FN]7GZ-" U^>DA$-OR:F<2$5?-MLIT
MJG?[6U;<]_)<\4V#L4#3[KREG[?^S*W1?[[]WM)O^S6\T<]M/Q^A>".M[9MZ
MM)N(Q RGF,,I,SXXS/-LHHV3DG0PPBS)&HHX@O2L>)+TR!U*M@*"<>ZUJ&@O
MA>1XBJK0KE!ZB6L A7E3C:;G,TXA#ZJ5\3S@A?)P$#?HT>\Z[X1B2GK#5XMS
MRKM #V^Z 6TWJPO<9V7Z?P2WT(9#07=Y/W)X(P-K$J"4[88&J4N9# R^.H+!
M0Q>3Y2:B86B&6?-M8Q/:S:%J"^VHL00Q^?>YB*-K0!=P2G0I Z-CBWE'\/G"
MF._KV/3!^_2CHLRV=<H2)_EF"/D0I#:88UI>F]+[+IM^*>#&"Q:YHC$?N>"^
M0YGXI\N.CHJ?&2YF@P(R41[G*GX-M;]/XOS+>ZHA*\C^Z,O!2YC28YL-]&T4
MGACN40G2J_7X?46G&J(8Q$Y2QK7<N3 -=N\P-X0V5PY8.S'3] 5$ \[(B?YX
MFFP\4K<NCK9O@O9./1U;7(>G]3><SU?6E7.VYT(\*ZD,4>6O2N?>A'?=><WM
M[^K%D.^$>Y<[-@FOL%QF[@1897FGZ/(^M?:,S_&P'!L!B5L)*=O'3B$79O.>
M014Y#5#XR[$HB=;D5\-AX$$[CV"WP^DW4+&51S]IY$Y:Q:<UD.:F!\4*B7,"
M(RZB7'<1Z6YR%/%B6HW%#>#@55 2HE:YS=2[XBRL8R*&I4.!U!+C7@2P&3XN
MW<6DL.#Z8AF3T527%4)'VS91R=HE<F*9TMJ_CQX1;%X&O2'X1M)4@W]NU'VB
M*):W?B^C8DG3?,X_!YY8@#2C,W8-J]X&.Y.M:MI+W[-/5O/WC _F%YY4]Z!'
MJK[77;=.(G N J/0["73?'7@"JZ/3Z(TN;<$^^I^++,-D1\EG0N0EK4))W_R
M*+98WOW2,.YZ.NF4^'(YZW3PZI[1.=L6)R=*VAT72B/>"]O4>#F]'F52CX'Z
M(2_H$Y81"VUS%FTVE,=%2783T/F]NZO* G:)B+.?4G\;'CJX=[  +GPN(T,7
M?_C.2UUAQY6XS.:=:U0/S%^R=2U> _R6Y]&#>. ?Y>AKP%UOIWA,1TPIZ=/L
M%["[F# 7+%]Q>]MY.5Q:D$5 VK#6ME*/_,<,*:5C(L ]4=C'QHZ52,A:4]!T
M6";&\8PY(I,Q?GT>"=]-$+OW9,@.8%(D H&E?:GEZ^H8S%'CZOU/L;+LH1Y8
MVQ1T4=%KP;W:9XY'X*[DQ!)2C"]^'"_:WC+SZN7(%?_4Y)Q5H6:Y!I>J'19]
M $=]TX='KS'1O>(*-V8_-!M-3AZ*51@KR(=\*LC5A8KB1WU]KE@"C3$JI[!S
M6RO6T&FZK2=QK/U?;D;=40,G#Z]H^QD],4V]!M"5PCY<%J/$2TC?ECMG,^@$
M=![PP_FF4=F=H\Y*MQ-V?4_$TMCJ+(JT!'3?0:8V#:X!F(X0TUL?'YK(XJX!
MS,ZY%'#_8_#?7][KJ^\%6Y6X0T8SY@4:K[KQ5'26L\"4094#OF4;B8MW$5W8
MD[]!%L)]L1<%&F][?NFZD3+/':W[/9[D170GS]K[]WF<F@R$/"5@D;CS;KXQ
M]_7OLKCGZ\[$3D>S#1,D=E?A67I4:'0A8GAO>4R86VIGE_MFN>R@Q(TCWQT,
M7FKF7>,W\_&;J&_4;&]D;*Z:@_N+-[,AMJ8X#86D1+'/8(RRDPUY-V?$!W2S
MLE.\)#G8PVR!M044Q]DF3;_IXQG>&*:DS\F3!3@&1ELK(/&Y$4_Z/K43=TMH
MRYAA_0NQN<_'40XXQ\8Q_665)!;DJWWK-/PU0'\B1,0O:]\&*SKGM?$]#,FW
M6D6/,T;<02R[[YR;IBTA/Q5^&1LBOU%0.3RXUO;?WP+NZ)%L:Y2:,(_C<[\Y
M*QXYU^&9V@3RY#^+;#Z5[G0?O"Y13HHN^04WSY9$I35Y=D9$528D-_+@+>U8
MPGX'I8:913?R [_;U)TZ-.55?T!&1W'TP6Y_<<9)YB4:L<NT0*=PXUQQ<M:%
M1<)C%DS+;_.<X^V^IX;Z]Y"ID8<A7*93T%X=-L;H)FE[?H[QI7E.B+!["\XM
M1;%X].KG$GRZA! 1#4.YX"B;+?32BG)]^-:4O7P8PEYX59]=7@-NF1RT+-TD
MQ7Z@J@YU:?\M;>DJT\_ ]+^ZMS[]_R-(F<3O)92#)G1YTZB2=4!H#^=KP#?V
MK2IHF=76Q*!'L*#.1S_'$)1)X04E*:DD2!D2>J[&ONWO;!L7O;[6BD.AMSYX
M>$O\?"^?3K;E?//>,/ZR9=H[YMU,O3LY0XY57MO,+13ASLD*UQ#Y, =M?;RB
MI.V&%JY)&/@F<::G-.1$"W<A;<<V\?+YI.H1S AOG:TXOEW*W9U0!(!,;>E(
M_M"SPE3;6MX$<[>'/'*^,..YG[(ZOL#(C\J$"+_E86-'B(8=:7@U_>V+RDPP
MWG_!D5U2B[;>I%D%Q8/!WVT&OX2H='>Z3[DD]=NQJGD:>>]J_=LXI<FN"."!
M?D1XQZ3_4-HU1TTPO#H+=_AN2B@V)E=FV\0^<6NZ1CDMS"ZETRLK8G*BV]26
MP_D/WP.@FIV. SOQ9Z+,#,LE$:-O?M;?,!+2RY'7]T:VTW2L^"NN2Z;@!3R^
MD$;'OMV#Q\E^-TW_RY; ?E&2TF#V)^ NV$I+G>[I^3M+"#1.<">@L^E5L >1
M)V)-?]O2.JZ@)TA?&*.DTKV&V,N:W_C+'LW9I#\PG)+/FN5SQ8T<GCX5%C8F
M/9M!EV]^LFR'B,'KI0YFV;+UA[ ZT/\: _Z^ER]P-T?:#D@*?EP'I\EK0!\4
M]A#?$?D@AG\;&7WY7"N?O]C,TQJOS;I3-R/XO<3:^)'2L1.&[>/TK$4GO;5-
M;78O;?*OYGOM;X:]+LETQP?/5"<3[]HI+!I7MQ@.0J-+PIH'I>I'O(552M#A
MF+X#N?QEA@UK=KQ.<3;,A5N_ 4A]"=?:"GB,T4JP(1A8F6U3%G-UP1]13J,:
MES$!$9.VT4O?YU](/296Q=O[C7@?DH,"V=VC4!:+^V0DXS,S[FC!&##.R*/W
M_7&5O"DI5<%^@J76DU70[/%=1+"8)6=DK?^%)EM5]UK_"5%YKE][J>G=6.V7
M]]6GYN$^-<_:WFU[EL>;4,FO5S1\J;+1+M1TQ);LWI^K6Q#?MDJ^X$IH#:',
MZV )&]4,]<)IU.(_55&KXI3)9DPWZS:+_CIA3?9;'Y_>N 8X-FH'&[O?O1#+
MTR#<;@-Q\#:>0L?C7[ML[D;+QG38/EK>V:S@"(;Z[=86_X;7ZQ[Y]?3])E+_
MHW;BA/!\7!G,6Y89RQ-SOT-6[+[<%[/<YQ,2@?O<[<1X)['?61;?3L:;8"/-
ME&TLDG41); HT321E3A/!UO4:1^Y&D-0KUU?^Y(#O^>[@(?*%"&<\WY+[Y,-
MG^Q5+3^[>X,UHJ7(*V B9RE[^1<JCKW0P+VQSC)-!,@MN=$(3/#.!@)GYUT:
MA1'%^:54?Z,!@38.E:MQ*\,B0GL?H@//OZUW>XK:A(!^I,59/>S2*5@;C,M:
M38A7@!1.FY/EF\\^J\O"*BG9[+-T$. @#A;"[81O*>\@-NW8#PX:%CF992BK
M"F<3&UJ$8+^E)G4.BL,(E50V[< 1@6W0#9<+*<(-LO--L>[>47\\[9F"5##A
M:5X+'&/ I9ASJI*4VMAM=B 07CJ)\]RTK1:@T(=Q!+B"H2.!A;'3\PP8GOT2
M^4R%Y3+?+[B@R,>&YJAS*$C5T^?N @\?]P*#Q/B,FDQ1[]-/<!;BUO2\;$$:
MJHPR54"IME%QC,7@;^3G"F#JV7B@S-^QJI+&2"T.X\781<?LP)*9VE%+;;%P
MK%BB9W3FM$C??JI)32.S'3'8LSU@;J8/(BGH[\%0<PWH53$= >E/0E'$S>R:
M?"OY\W%W<E);>WM6VNKX"/-CIQD.0KM3LV:%A>6F]3/I$VK*363BGFKLUW=9
M!I;E.[AVG"PGREON;42%WR]L(%1@6&<@%^V7R/'I#O@>NYWA.)F5S5_5L1+7
M+5VM,5)HQ18:4(T5F7SKNC]4SDA.)AFPT%;'@@R;,!C=B\T0S*B/4)9>% Q7
M.AS:[#",;5[I<ZIVD2"&=TN#:#[]Y]VIX[$TZ00_%S(\G6ZL6D,J\@<IXZ3P
MVY([0PZI._?:U^X%CJ$%X!H0XVN ZO>:M[Z]4B$?=?6/8,8YOQ"RCW>%W<*%
MJEECY.T;N2@KG/[&<B#@. OY?2#)RV;+N*?N!)R:(<M5X:>K/:2@HD#8FAAY
M52[3F2=#=77<=Z&.QDHDU\G5CEA2&G[^]KWG/(2AL @2Z5%,5,]L7^;+PV #
M@LQAQ/"81WW8]1SHI,D0UECN;9%;"ZCQZJ_IJ-B_FV;>$6R]D%_*HR3%X(C)
M:.H?.NC9[E+NX/%0]ZYF&^/?Y^P==<GT3WJ.#$]4E1QX7MM1*,;MT\^"LD0R
MBA<69!N&QZ\!WC=C3]-R6Z;FA=!6$>>\TQZ9=\1J?N%/8B2I>9=US^W!H>Q-
MJ\)KJX(O]]95"48MD2(B+4.2W8-GDBB%1Y4V_(4-1?A,<^1G=Q[\Y4"^<XQG
M\8S2Z$==/H;5*QZT^TZ#F^T<E=:]HR[=(E\=ST#P/W3\'>JL%?G0/<*W!S-?
MX[U//UV)933?K90BJOZQN\\6W5V:I2:N]&E"P=OC%Z*H*TWV*S[9TK?<FI-P
MY-.(Z"J 35(;XVP:UNYM*(E;D$)".1ZB!.O4$F_4J1Q$+XID]]8[-'(2Q,/J
M*D%*AJ:?B/*/F2!O8UY5_[-(03/0H\PZ],/,\XQXR66^D9IEO,Y^I @"N/.7
MH7*GU5U^7#V@1+(RU#5^&D]QD.OTO:6G $&0*LK'^-2)HXR16K8*Q^;AA3E)
MEE#VA)UU?/K"LG0GE*_-),.Q9W[GMS^&U6/_7]:%NMER]TK +Z*M;@+B<2='
M-HIWP#>6+&N"I%KJUZN*OVHI][-0#_SFEETTMFR3-6F73&VOB/V"4Z;::NQJ
M*K>R)-69/;_U7\[5L?F"P7'#>B6%PG%A5?'$'^F)>:9@"&]$MV&"$++?5+MX
MKMMMA(+M-2H=P^#RJR?;14"GNY;LQTDQI-SGQM/_D<GT7&:9^.[D$#2N 36A
M:4&071O'J[[Z:T"X-JDH[]5%Q;(HKJ2,TN?) WV-W["B%OL<R5W(<8YA'S_S
MRX@#6!9X<W"*R1*)1F(5I!]3*E1+)*VW/+BQB)9!'2H8E5=R-D;L"OGP+\MN
MZV\TCA]]>F@;LRLT2S4VKS DBI+&0;4&]>(*?KSIDP:B"G_0OL4'GYG^W>6*
M=0HOJ:<:0\F7N52Z9SUZM1K9Y9'5C%_'9*#)"4^@LR9 =N1WA17RK^+=G<J=
M\[SU8P46?G</SM,JJ>\,8)=-ZV+TA:GA=<S5T4+D6S9MT( %S-D3:'\*M/T!
MN0\8K(_\@B!'UF=[Q5P#A)K!*S;A+;2B2@Q;6&.L<)P I*P^]W:P;^&@0Y49
MIO3UML0AP-=)II \&Y2>Z'RVDL##2@M/* K*/-<CV0XLO$LP0>1Y-DP.$SN#
MAY>%66[_]A?Q:&$S&9Q_CM<)+RNPLK3J7!=P^,PM<0-_]!Q%)Y14K6Z8YB#S
M:&)X :Z[RUQ&<NH8VFS<R\\14;EJ-/Q:Z,.+XEW6SNO@X,D=U8*[L!<*LHG%
M?Z01MU*=^*/[<&ISUY<WJQ4P,']TXXS,#J=Q8;4,83(;MK>8T:BB[TL73[SC
M#QM;H-FZ#S(73L4>")7:ZJ<IM;7DY4UA<!&1:,IM&\=QB=Z,81'[Z;Z_&E&#
M@$M!X@+1@N!0$G7U<$J3:MY^P7\L5RU C_QW.8.C[/;;M:34.MD2/?(_+4C?
MW2CHQ6-27#Y)N_W,;-Q\C]??6.HTX^&NB;*#,NFI;_C%!YCRUR!]2F>62HO7
M!I:$=;$=1?!:*(G?J/,:T+HP/:I""/PS$:#3'S^NMD(_L*AX9BS=RH@'=MTE
MC[HHK)N KIQR_P&R^OP$3F4'1N[E:_[Z2*B?K92C-6"@HE#X9L,3Q$Y:K22Y
M:7CM>FN.DDP+/0<$MX*9K. $ZN19LQZ>N @0('?KC%IIMO?C-A7((WU3VRF8
MX2C$2P@&=+FQ.,% ^#IP^ Z_68.8#1O0AMJ3;DLJBOYI+&3JZTELZY*]NUX$
M",(0MM:-)M!"6Y_49;6UQ<XS!F]-1+N D(-ES7NE$T(U=.\EM\Z^:N.RHY:9
MF#,\;P<=+)B?KK<AIR,BT((@.<FYELP'51H^;'KDE<Y7ST;W:Z7EC<G)>P!7
M1F'>%-6)W>#B*'O#^NYM72R*-VD.$GDJ*T^,OPU1]><C*D_UE'T4:P@8N@/"
M2$=":[""E+"@\4 SD2-F%6X*Y1A%@;J,<E6[0!ZF! \6L3_3U. Y/S=JE=?$
MD^?9[C@:_Y_4S$=-H8R;5YY6P;\<UGNKC"D57VFT.#S;0=HA&49,^S\4ODDG
MUG!*''?CH" =MD*,X+KO2WD]\F=>8.U^+5EV1E[#DVT+/>>E^GC5A,&X.W.3
MFZ;(].WUAP5I,?R+:]!)$E;QB4(4Y**;_.$'[&?A!?-6J-F\F>5TT1C]:R,S
MS!R/R;ITUV#8+GX"HVE?<YI^XF8?N]OUQZ)DV^97.F[=](=UYWED%"9C!.UR
M68>2.PNNBJJZ;37T%OCFVXXSF<ER\3?O1<Z;)*;.,X>9SC*7@Q?55GRW&2)O
M!5.'8"Z4"1(F_S,(2-CRS1.3ZJCY-^M\SOTASB\;E3&Z4Q-O1]VX9IYTEM<D
MRAJ3?57<WFF9+!XT&&MQJC^*,U=S@12"[7V4VV3N?%9<T"2D9U=!I#R%4E(0
MJ=X,PQ.9%XHD\RMJPNWCPS[[>/T#?@4RJX08!6WRL*-,M[7W]Q)2Z;&?!?Q&
M,7+N7XXR]T4=]?X6I2L<@ ^;<"<=W2'2I'+MP)BNJ_[XMT+=IV^I T/C)9FO
M>.<LA0YK_DQU 4$D#+'T ]ZW=6U?.SAC]V-IE>(E6*!BKD:VFO937-)J'H*A
MN2YFV9VBL\@"BBYA'WEPH-M_$A8R$40OKHE'MH=O<"KO1+7X6N)::)3M6LBV
M6VHQN\(_ZTH\GLPRB@O/S<;]I6A^0#-UE7:^76+:7C39ZG+S5O@#BG)%0-%;
M$8$^+]M-3%HZ9@Z77__=8J9;T$M5*/2&KK$#E>7G&XOG)K0$;4QZ[D-\SLYP
M7_* 7GDY6VY:]? 829 82P"!%N@D@XV'IZHH#L8?!,]Z6'/:X9%&I)^'G/??
MMG4G4.CJ6Q,\B'%:N*W+VHV)W3>?1D7$^CWFGQ%.PA2 )0CH7G$UR-/C@9@T
MS_D]64O?NV">/AWI-C0=B=9^P*O>U&YEND%HKF)]/\$8+4W*+\A&X&%3T* 1
MNP^]KCNJP<SXF3?9'3UG\;4MSJ.]CLJU-+DYX!'OQ^! 4*/]??YOU1@0X"(S
MQ7@<I?R@\7729<[8KH/#:9AOR\T+V<!*ORK*WL'<@85OJ+7&O.GSI7*2<M?=
MTC\OXK=7'=@30$MHSH4M(HMN1J%,4HEL:O5YZHVC_:[]^/0K<KS&Z)%9FMN*
MC1!7'A;]"C_XW_%@-,<CKD>'@QY\@_(KL5G'E+IA*7ZXPUV6'P<:?UN\=9EA
MOZYN72B,HH!+#9*R!1KS$R)-S:5D@U=\)#G.KRT47G-*=QD7WC7JQ W0+,^C
M+88F]/*,G847Z2W#^VIR=1OZ SAW60E\^J2B99<YGH$\YX]?+%;)L?^0^,X6
MG;.8Y9M%!L\K>,-/:BO=SJ'F"G.X[99H:I7\!%,Y6+O<HA+"F<&%7 2K[<G8
MH;)(<8=BHL@9;,-V$3@*M6)YUR*,H_;&B73X\12*_UQDB\XL!VDP3> Z?BMO
MTG;"1&?UYE!KEZ?*5[RZFP^+[FC*"KUWU0?A*#CH]H6$41_!8C< OZ*?DAVO
M_]_E'.O_NYSCQ_]3SO%9J?3_;61OZ&MEO)[NJ7A+5 N1AO-,3/!T'8Y(/]MB
M]3,)&I7KBMGJ6+P'(%J!V^=9$HB0$<13$<@U )EU>)+$S_$/A:RYK9PZ@!$!
MZ^WLMHK<5M]V3D3OS5(<)B$B[C3( 01'KQYLKKKNB0Q[<DM-']XCMOP')@:S
M2XN\B7BD1UX=)#NTFCQBMG8:Q6923=)M9_HX>?F+K]5MJHC$B2?J& Q;KTIU
M+<=&[TCJ"&RW!\!GVGQ?H%-O#+HHT3<FF)Z_&X8#BR#=2YD\S8=I-/(>YCYH
MGF1'B^!LW2K!E]K=4$BN,?<]\6A /WS<O;8,E:Y&"X-I=1(X"J?[,1E-WRQ"
M\1EF<YMPQ9&J8S83]I+YF2VZ?CDJ@?4L0+STU4"]7K;FIH%T[D3N!P$F]FU!
MC7@K78.<ZN]I]:#-_*SI%W:)]O%/R;@&(%EPA61!T:(WV.U@R8Z?NWI^#&XZ
M- ,:<P60Y&.&+P^;$:B[8EQLHQ99O.(&V!1=5+3$HMV=<K_,JV'JEDD2Y$_U
M@\M05:98WC DPU%9K=_KQ+_)HOAEWOQ,S<U\6ZSFA_@YJ5.T$S.[ #&BN&<Z
M]0SZMQ-:-FU[Q7MFY&,,AT>^G+*7[50OVD*.J'L+00]@KX^AOW8^=K]=_U \
M;T$R=@E2N66K[?]%+2S<E,SLDU^O=DV#':2IIU'YN?0+G?_IQUJ^Q0FBOV,1
M](-FC"1Q+NMU*%1S)\DTKPCLF2NC#!$<FZPNM=8X08;:I?1$B^5]QX.5L/-"
MP<7[(#B;2.!8>IUHF:6ZN^V"JXN?@\W2+\U?X0?OQB#=\7T[4QMS9;/3EM\E
MSVM6IH7.@I(R4WKC]=,,9+G@TW-O6R".V%V&:M?::#'D;-;8\#%EA86_I"BM
ME?"*ZXRP'I6_]G2IWWE']^77.F.ALF"^N89K0"XZ^NF:S&IT.O>K3$)&%'T[
M!Z]+NW^%TS6 XT#T59[Y@2B#%;BQN(PORA8UY=3[IH9C/L:*+YK1(EAI!+N_
MWIAQ:>]4/IY X2=RTI&^>_E3(8'ZA:?0[BAW==GL?.YMU4"S'Z'_&;Z9V+/'
M+M7Y):GQ/*=RQWA8%RWEO-+&6S7YQ:_.;VDG9.@B[=*B+CN-XQ5%.W(?/7,Q
M+M =JJ1?#_K@R#U29EJ7L;S/J.K@_G34JYX3[+91Z O]%1]PG'+BD@M;DMG_
M&1YZ?^N3D.]$NV_:!?GHS8;!J.GF@8Q%BVUFH77D^'[>,YU8!]U\V$O\V^R2
M[5$K/W?#,8:EB"L%!.>2GB F1,BOP+B)8#=M8X/Q*-D4L(M^+^/J)5'"33&2
MFO2/H#V0C)/6) 5^6$JO]COV6SDLS%)=64>#3G::?ME(57N7J9-I@W[>[)T\
MF\@*4B.$K<=)AJ,;7M!J1C&KW[IWED*4=#Y:B#C;__Y94RXYMOW41,[7J>)A
MX[O40#A6HOF-RV&>6%#[LYZSZ!G\CY%V3X]@GV<T1G;[T1U#.QPX7 ^=0C?/
MNF^1+X?0T'S/P+Q?//86/UFSD?0^;>2WU =-;)!E<=!(N]LOF36%C)-*FRA=
M)Z?\]A)-JAK:DY6$(N_&HAB1_'NS(1MIY+SUH3$L!9,;R#MSZ:_C0OV";^O8
M1+$_] _4,%T)<N':]MBX[QS@FC+YXGMC#M-_9WGF(_56C(/J<:F6K(@/"1+)
M-TJ#Z'D14#^-:9*;?73/JN^@E'@_F&3</I"\H#NV>S6CG,LMNMTO,'CB=%O&
MT^B?;V @N/7%@Y'"KS)NQ?,*?POT3(7]0R,<K_X2;@54Y5J+,_?5#8087P@V
M$QAS/!9;Z*Q<ZAYUWDI?2A?_>RNZK7[$1K<:V9@^&U6XFGT^C@D;SSDN[7G6
MX-M5/-BAPP@M-I>@^Q<Z-;]DL Z6,K0B=JJ;**VZR8(J$R8GG);F/AP+%L\O
MO7%Z[]:[:XGLH.27R-$/&? )/^VS(S5OCR6ORCRUE77+S+P&4%3X93HRCEYF
M'?SQ;QB@/&D;#TQ@DQGMLWZ">&[6%J:UV_<=$]"?8M@RLF^H_SE/[$K_X170
M\RTILUP%MT"A[5V\F_"N-O:R$'CJZC%2O?:@:& FJBMD4(DY"J592<K320G^
M-3#<ZA:Q3OEC90+QJD(%$NPK4A4.V0A"Z** S7X9.WF5YAN$K9K@,N,K30^B
MU/:I2?V<^0R(93@R+'Y-)5'NP*5S _(4#=$*R ASFVDGGJ7ZWN7+76B*TNW+
M,^]"SH%F'-]/@+L(T[!.]I,(A/#+!;UZJ<3=/H<SSB*WF>*X"E67ARHT2^>]
ML?BN3)004E8Z5JI0M2TCKH /=#P@-Y'L=X#C&=U[$!%8_[TF?4=PXD*S>,'9
MY.T4GX*JM'X-.IA45,HJ59\LF"^3J96RH>/9+>5S^()POFN..]37[O[N'QU0
MPB[X4I-U]Z:7@_C;YTUGV)M= ^?JYA/P@_T'\A<);C+,VP;#YEY"EI9O?I]F
MK+[)_$-6)<BMUZ =19Y<],$Z&C37KO1[4"'"5NT9.=0)Y39;DVKID?3%9%2?
M XI'$I,)?&VA %)&6]8[J1'3[5(#W\SG/12MK; G26:F^P_YLL[H<5U%^&T#
MDOR2MBYPL[H=9Z2'9.)O]8SWM'Y<9:I:TNZ6^S%K,2&/O;G<[OU3Z&K'QU-!
MB1A&3[A'5TA: U\\K$HB=;10XVH 15<1SM4 :^Z6@)0[TV"WMML\G:M5(>Y<
M()[W?^?$]4"<P.G1M_%K\B3'I*[76OY5ZO.5PBM)FJQ=.\S/U-[ZER'?\Z*&
M]H]('4C&&E7FC3Z4T;V%<91+V78Z869>"W;3;I4R%I==!3+76<MS88B+JLM1
MQFKHSA>38SGA_+HD>UBT13PK.6=:D(.-RU7_F2LG_J\RO1MUSVG+LP/,"%JH
M8N/STU_1G^]M7) O"[;<)&6-&M=^@M)3;RE'!4:O\YMIX9W)MG5CYX%(4BM^
M;Q!C;GZKX=WI9[9$\D<3?70@6N'(.HT>+13]OHU&2,_9ZC4@"B6* U+I\&[+
M6_ADBL]P%P4M5)K%A-)9S90]M CGA )<2"9:Z4NQE=N_?4"CA.=3=<G:I8=V
M[JDE4-V"U^GEME3/VGG6&F!TUD!9:,&*H!MO^J^QDX6(*W;W&)M[3@AD2D\+
MXE7X8'_2T,3/JUY.QI*1*CY\7B1[AA[<73BH?3R0A0";<NH<=4$_2WE#0R??
M"1 %^>XR%X.4@2%/U2O,FEX<4O=RX>^RQXGE^8%TW'&"_FE53&0EDOUSSE+8
M7(HQ)Z_#5$$:V5W+DIW>*I7E:P"UNG>PB)/816\N"?:BN6>3:=J<P.H&&"+O
MMZEQ:CM!$>H0N+N0UL]:;0\<-J3I;<S\V@9F.LTU1_,U( YD;AHWZT6_!+CF
M4C>.&<UJWGA2';WMK7)9YG>2^(V%_V*#+,^&;/-,)\MTZUFGA-\ GMR<")QJ
MP;U>  ;I$_V@JWEO\VC3]!,+L"AX9PC/2+8N8P8]I<NX^)K8$2S;*W2&6X]D
M1N"Z&A\]?Z6N.[>GVWS\X,9Y7@$I16>"V[BV*5KMSQ,RJH0VQ#9AO_4:4+>6
M40&>'$:$CXCR;CCRW 1O#4:$UMW&1.RD'5^J*5H+?1K^W0\(4-]M/I?>Y*QE
M:F-_R[R;AJB@R J4_7.:]IF':@*G_B>47A=?LJR:4_>K*E($W>W!S .8J4Y6
M'C2_;$1>UB@PX^(XB(*^G:UA$>E]BH($^N6PH7%E9QWC@[8[46Z2#%Z40SGM
M/'KD6[GYGHS-''D(<<BCV_9OTS9";I(20UBWT].12"7';+Z>CR%[P>".*]9@
M]/(?<^M3L1K)Q>--B[.Z"(8.?86#=64QRR'R^?O]X"I3C !#UMUWSW^O&.G>
M=U[7PP_DEUB$[!9_*7BUI^IW#=A9)W"Q:XDOK06/O&RPS 7/EY(=>"[E(F&D
MT.7UZ"!6G/,3#:_-&(O!KV1E"B8Q5^-YC C=L&L LY"(5X=N35)SNZB(^*#D
MB?HN]6+2KPOG8%MC"Z\6@"!MW/AIQKF[#G>0VE?QC_"N4I\O,UF L^TV&\9:
MT<@L=L2*H="$,,5L4NXKNWSH O :\(M6(3^-N=Y,?J*#$RYW#7#:.$,74).0
MC6]VX[*'/#H#==LXXZ9;(H5%,5&5T[?@C@=%"N08CQ><*G[1./FP0[NL:7;4
M!:G_O0OZ^:B]4ST*ZXJ5]ZQ.LF<X=(I&Z>-$F;9-/KGL\IC[RQB3?Q4HB0BA
MV=2;59Q;7:FIS4,ECQ?).&[_</RL5 -Q;YN.#7'U?9IST3\':LY%%'<',Z#H
M+LND[9YZVO#Q=0ES !DX:90RGO_*$_;? I</!ZEX?ZCH9RBO^[ZC_(E'V6^(
M?(QI6A+Q?U'VED%M1N_:;R@MM,4*%+<6;='B4*Q <7=(@)3B!"T6O :T:('B
M5HI+"!;<);A;<8(6"21H\+?_O<^9<\Z>,_/.^V%]6U_6L^ZYGNMWSUK7REAQ
MC""TE4XPJP,2.27P32 K7Y.*/UZ5YL(J@BIM*V=&T\Q7B;WA6HWVT^CW8G4#
M$5T9+$WH-[2[7)#/R%W1]O9H;9ZA$$@I5?KJ_@18V?SW070+0R7<HAZS3^V,
MGP-)8M1(6VOEPMDV>Z/FO+0L3ZUKC%:9A=_0W0&J#[_S\MV2XGR>FFN=V1J[
M^=\PWB2AA]NZ3/N_==O\K&.#MP0[!3)-O@N%77,X.BT;ZI>HR#G;M8&NR7)[
M?N%,-*N_*WQ;-5^??8I7Y^&>--9<Q524RYYVX;M.T_U2%*T>8)3@DF%/%'.Z
MN\+8[,82'BC'42;TR?=9_QN_GL!$^Q*U-<[&X_ZHXH&#6VZ":#2+H=AJWA>;
MMR%E,@\"A:\^0(]Z=:<3NBS=LD#GOY4D'WU9;H5CQ;\=B$3+K&4)C5DSFFS/
MHA^A6D! 7#3';7:!CJ?SV-G]<\FR76=KD,M^P!W@FF*E>YZK2^Y[6O[FS2(G
MZ,\, )^X)"KC%G$)61>87V]OI4A=#3C-0JDL&5/A!#&C7;<""*R73A[(?&X
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M0;UMS&I6EB_B6%(%1R TQ?D'OBPUVUU-X- 0JD),:\KNF8]3@>33;<E=2)]
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M)@K@@4ESHX0D>CY<UD;:'HMXHKT9LX%U1:*+%/F(QEB!'#?UH<8&ZDEGCP;
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MBWD>I_E3:B(G LN@'O<"1?'%#4\]T"[U#H2C(8%T>Q:F9Z'^'"):]!71L6J
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M?TV)DX+\JTLKE[(E9%[)Z;P*9ZN,O9"@G:2=).='!J6GNGC_!N'>Z/\$UCO
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MI2:H*1]S&%PK3K1(*>$\42ND?Q8BB:R(,.Q*YKJ$:JBD"HQV+-WDFLG$;UT
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M"*:'DJG5I;=G4Z*O'8M4421ISPQ.J2HQA_)0F-=6HZS+V@MFU5OZ$6_JKRU
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M6F"UOEF EXU2-5T^X0@N;&&O":+-N1TRX+[9>;1G3$!%-78'<'(4?GL'^*O
MU4L5[2%B(-#/C'R*MW)-CE4)O>9:@T3"J4QE3A,6JEA_C3#&D'@ 3WL06X@
MT9_*#&J<=A'"U]PZ][)15WLNXN:532VU-$D50W"^AAW6+P.S.=>FV,)0V9?0
M*XULA7%K3,Q/ZYAE;UW!C*BVIW@#>]$/9K^<)")X>']L#%=\R/ M5S.%/UN=
M;7!B>7R2LI6@C+&K:KS-]:,%\T'ZKY50,@8=EQMIEJ5V8\L]YSE[UT7WM&B0
M:5D1>YM#ME$A^!FSQ7_;*-';D^_CMO4^]!)0^,');+F[R;_\=1RK+ON4.W*Z
M\3ZS_;)+!3OE8O-MOYYMR_(T>/F"OY#L?A.-C#"8_^_MJ\;) Z(!I*WLZ=]&
MFNB<1INC P7);3LG1E@]0J;Q>!3TE56^C@JXAO+)/'AT6BXV"FYLJ4/>H#,>
M\^>UZ-<_2&R,57\RZ2$B4#/'OT7S<-U!+E1^#4:F,2ZBNZ5'M=_EGQ(CY 31
MTN.UXK1.^1FXU@"FT&QEB^[O2PV9>GE2(O3S*4+06?1+T-//T*A93(S8'< G
ME;0HK>Q!?E3N-H._L=%T>4Z^68*S1U!V]I+C/,>?II]90FT!>_)Y(I;8":BW
MSQ*@@1&K$ET;5*T5XW$4E$\;Y&DB0DEI^1)?%-)C7.%D,L/SC#;"R*U71,,H
MQU<V8T+<B9ZJ.O'Y>F@(KXF1?;E.L:.Q3S+7JY>=+F5@TK65SMI9_#C6AW<
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M)'E.DA>@ZO7\=]<?</;>F,.>44\WRJ#/?U-_OVOC_C+?W#FS"^+Y5A@:H<%
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M2PR!&2<G<IG!L1JBM9&HCK-OYT#NP/H;GN.NU2C_@@2XCM^#LHA[#Q8'5#S
M[K@F_:P]E!9L>=_JA]S.&R:NSZC;B>K;B4_224N?LM8:X]A4Q%.Z>*]%C3 D
M93RH*T-B@#>A6RN/SU&?(FL.W2\"AWT7H'XJ>1V7KVAT*338Y<.5U[MUN2X0
MY;+:^YS@T58Y^66$S\6,K#,%7S%26POPX0/4]B2/>!^*!LY(>>%DQZ*W1/ZA
M6<-2P#HX-)#*G15+FNM*ZBY> 2? ?;KR@ 8HSO##3C2HI][_9685N_4B80$"
M^7(0 0UN5A\_Q;.S-A.NJZ Y4#IX9=B%X;-,79L7H=4)8#;<WED&-K;[4=:L
MIAGOLP2)&.+JN!N>;(Q<9U  LK%+K7C!O$RS*<W,LSXM(JFVP(AWO2B;7%82
M"E^K04X<^(B5KW#46"?L:^FLRGULA']/+&PCL7JX0<"8=DHBA_H'&:WTR%E?
M6_;Z*)M44BU[:,(ZK+4P?QB2^UY<[U-M271>C9+5A2WF]VGMEU^X1_IFUW50
M$U<EC]O7N ;9ED<5$URJ!.ZT)BE.]%O5Q>;6^EGRE%D:7J4SLBR?UY0"S(1C
M/I!HW6"2D;SQEJ J)F.?EOX+&LF.\X([0*<L:_U5 (51S"$'1'M'*Z:#U6]?
M+G("!EQ2Z;+W<"W= 0WO0]AD)4CS.M9EWX!1TH9H;V]2-G,94/RR9)W8(?N,
MN6^L4\><+].?WCJ8G3Q'3Z<0.I,L%:VGPE$1!4]A_7&RZ,3G?ZWPVP?<+%'N
M?PR,..K)^6>X6D8I[/,!&D7FYG_Z6=7O;Y<,M#QP@+)TOH9WZSPQVS'N9X\X
M DP\Z)/?2VOX=<V'M?^.^NKH\V&I0TS6JIWN<G9RF00S'+X_B;D]UIO)4YK>
M_I8RM>YS[1$!@*VYT4-]SVPQ_>,BWXS=*/N9F94ZMIFT B/AD-E6]NER43X%
MN[1=U& 32XAZ>H\E9S/6I\6[!#PT::Z]6;44;F5: ]!3'S IROMU+^+%?PVR
MV>S_<8E5[PYP7^,.$.^));KM?!7RER "<)E\^_A)3IMUV_=W4;'[_XULV4VQ
MY.!=DR2#75]AI\]CK"I,4Z&S@P;GDG^E3$[(_O]#RT^B%7N A-T"3* 5)Q_J
M6XI)8ZKH]8FQ'V;*PJ>B*U 6)'WB2L1(ZBJ*.:=0,6H)W#J[L'@,EIYNDE'8
MUOK14G,$:J#E8Z"2*/+0)*NO:9NW[F1F:$A;,,C:03 8S['*4[ZF7(FSC"NX
M?H\YCZE1?3?AQAJVID)6N[K_+%@4P_(YF!N,8QXY(@J0 E5[^8K4/6KX=#FQ
M<\L[>:VUCE^$JS)#U;RL<\T28WY-RIU[4(IWA;<JM<>331;I/;4_5%F@1LD/
M&;KEWYTY%V37D$@8E)-43 "GIY&TEL(@]'E9Y+/ESKRPL),KB[GH/_ZD3D$T
M:[W=$-H#?MC! ?S7QS7'O*B!+\P%*2P.$#SZ$>I/;]XWVQ?#I;!?)SFB?OR8
M8\L/7/>^4H*.'%U*A;=$/;Q4KL0JS:))UB+[H^)%[E,MU+EH_W*&+O3$0T/4
MJ#%U&4?Q]<'3Z_JJ-G&9,68Q6@Z0M-.5;P(D/0L'GF-X'WE$/>KM\_7_X&E/
M3HK\751>J(R7HH=8^S*]?''O0]]0%9K)3WLJF8)WTM6(/%9>=_P-$7+%7_VE
MF<]ZQM@_//_D7>S%\M1T626(,[/R%O+MLJC\O*.-]C=&'/FHV:3(K##RMT4?
MQ?&/]A@RT8W(Z"[IJ&,+@0C8_FU7H99-LQ_TP^^/,OCMY\SXN%2LM?E4L]L+
MS'*T#WL6+6R$BJ4*:YZ9W36Y3D;O!/0-Y0)%TMJX<3JFN_XO=MX[JJFNVQ<.
MHN"C(A:*=!20#B*]!D1 0*3WIM*[2 LU* (2FH" % &EEQ!1:BBA%VG2(?30
M2R"A!A+"C<][WGO.>]X[[CGG&_>>[_[Q_+$RLO=<>\ZYYIQ[KM]<:^RE+V?\
MA['WF=Z^^J=>!R_!LG?/*Y\:_*+(:ER8-6Y#=G1^EO^A*0<,[+XT<5!FLIPR
MX/;33)H><Z\>04ZP'Y>[?=3Z0:FH<6(NL*(N<LF<]>:8'&6Y^>9I9'1NLKC3
MIP87RLL*;U.+F(U2EZ#*FK%O$9\"W<5'UL&T7(L>DZ%=N\+BPF%$JMXE*)O>
MN.NAK+DL#PNAJ/ 5)_OM./X/%1AB9:GWD='MF4=I:NE2T4)D6^EWW /&8%%E
M0L @+N-0'[V \;A\_S6Q6UT>C'5L\.D-:WD5417VZP/TP(=AD W7$'9+T[;E
M#U;BP+O<'_A\% /<*VC+',V,7@0_F+SAO=JPQ\*ZWQ9PG"!Z\]K,SNF$,EO,
ME]&R19%>ZJ,/&ZNL(J8A#^ 91G$,0\FP>W<SU38,TAQ>Y/>PIGDRI@Q^ MVO
M$>_F&%7H708.L*C?J^N]0[>O7IEE-/W ZI*):5:_;M;36VT,8MT*+1@!C+,5
M_?<JN9/GC&BQ0'Z0<)[4P&*8E24FSJYV^+F![.?(.S"?H2 9-_2P2T+,GA;
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M#RNFWS7.*PH!K*?PVE>1V9Y80RWH+X^_G+NTERX283-75RRN5(SL3- Z<OD
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M9X/7!I4NGHWR>TF/;=,V.>X\6YW>U@J,[5]K@R%?(PVK3 Z@+FS ['>RC2J
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M];NBG96[8K#6?&H<[2T)D ?+M%)0O/5[QMD&*V,DDI3"8=HZXH<2:;!,>+8
M6^/3L;NQ LKDO=?Y'PK3BDV9Y[%A6 ]?+NF9]P)G"Q8H64=W*,1CWM@ZA(AT
M.C'N:4IS(5L:QIKO;!BJW]R1K?'J+DK7ZIKX=5S0O!-R'1?6ED6-B\W?5'@P
M;&[Z"SV9$7TW#!''QQ8]QT[*WI"F>RZ,V>&5(WF.DK=VJGZP4PN^DFH^+N]:
MF \ELH%*FXE"HPVF*(GAJF@>TTJ\]<GV9/>92Z<Y4YR,@6"SQK]LJ_S;IM!_
MED;*H2,*O,'4>[!8IMW?)T@KG -PMO,0$S:AD<%%:Z9 OW[S*=HA*M> D7%5
M(ZHLE4!@"R+4CU5F[%ZJR;Q= >V<[<[8!I &8>LFJ3DRAV\SB[9X8!'M]6LB
M5:Z-^EE(?Z]^5Y9;>*[QE$9 MO Z\6[C+Q_.IA^I/VNMR UD.JO\8-;RL]L%
M3AFX6*'\_!DGR<1IB\Z7*1+(GX&,N?6K1S"-AZOF6362#^%^3"HTO]=3>?ZI
ME1KYD6;]5FT7V>F^PKM++R^75.I0UN,HC\JQE)%N(2WEW$?C&3%NKI2$K1'O
M$P7:(.<16W^K>:4&>9M4LA_6+*38D[X8AE9DT\9%'XDWI*JGG /:_*B*.BF6
MD4H4#6P=6;18X7 3,Q<C/[KN3*K>9,+65XQUURX3CE7J><6X?2#/.6 %J9_,
M,3+>V-6&J*(,5V W^RS:"9>CRX^@&K)L_D79>W.>B2XVZ!Q0J:C6%VJ#@3I5
MH060[R(H8@<ID4TI8PA[X&6"THA]/<8HEZE/=>5*,QD:<C+?:7TY2&O!?!6"
M?Y;XV*@YD5:@X//V11FSJDHJ@=)J"7P,&)*3N!C3U0ODE1L77X7ZWY^\ST6G
M<!'4R3LN\RVV.1ET6/A*)MS ,6*QG\.TJV7+%(C4V"-'7#63@'_R2-"1.LQ_
M)08>:R_)HS;KJKU2TW.=()JY0VN%-W!<#LHDVS N>X[WXER56_#)?YG/Q)AJ
M]AKZM5*-*K[1P&R.06"&54@D=,P&[5HTE+07;U9*6]K/G4'@'^ U^?@)+?Y.
MHLEB6ZYEYKCH"[R.WEP7\?J9B.'NY/Q3ZM,*%J#6>$ZBDGO8<5KGDP)](_'5
MZKAQ'9U+G+;C=JCV'PR GF(Y)=&IDNYM?^*NN-Z\J)EHUA+D#Q:J84WOXL\%
MA;4)7)R4)Y&TD:]:AQ\GQZ]HPT<%@Q /N>\_4MCAE0^M/CXV>E"14,.^8>#N
MXU*/CKXV=?%U6-7]C,+-+)Y:<W/'O.PLWV)VXU_ Z^< 6_^=RK$).?WB\M3"
M^YQD3RZ%;CL:4X <WA(H2W'[%I':WZH3C7W;NNG#6>M@97*R&.&6^8L'J>-!
MQOY4_=WQKZH_Q+94='A9"9Q]E1/$'&NEJF!\,VB.?\4+.%\&+'MF3@PTL6,[
MJY:@ZCL^]1NP//8/9?,\IU?T'C^3ZSY$1+%5151 -V!?<<$4:047]/L [G9'
M!S#RNH:L4_M$E$.ZZN:PR/W2PZ_I1LPOOY:]):$AG=_K/O^;1G:Z_T\[L,!_
M/-15D4T/W**(6!X,X3H'3,K]WGIM0X3"']-;\4BF\L.9? Z('+\F=BA)0(D?
MST)X2L)8 >< 4J].[:G-JZ8<R?=?P-VUY45&Q)?LQRSEF)%;7_9/T YJ9+KE
M)4C_;(MU"=\4(FT<D3_<GZ'ZQ-6_X[DS<IENBX-WF@=?[^3-PN(N5J=A^?5R
MYZ.4<OIVL]$'I9VO]]>N[EJ'O\#LY/N;SLX0G5L7+5T?9YJ[B0XHR+O<L *Y
MJ]1%A4QQQ MB!\U.2GV]K!JQ2V8N6UMW)"]@.R(,T8<P]E6$3\_&SZQ;<K/:
M&T\CHG/?O@WV(64-X^_!E_\#FP&,.K*CQ3\K=)1!J_C?NYF7:2P+V@PILD;Y
M8P-<=B_&4[/<_T5G"?.K><CFN6L6PC="9 :WTA?$7EE=M;ZE4?*=W\'QM?]@
M#HPG_YKA=RDQLFU6!9P7ZO>G(-3>ZU5,T90C0IF:C(].4KFK_+4ZL[T<OQ34
MI-.ZQW+:*1&VE'6P7$?Y8K>T_.2B/2K;$[LM[MY9IQZNEK/#*EM@QV+SRPLP
MG]R:NY+OZ'EV:G%Y<WH.E6_0:GM!\%<7%"(]6#/<7=TOQP(<C.2W5N?IG:UH
M1\L.GC1(%U@XU7BVTIVZ1/D))#H4'=!NCRO(#(7<VC@5CBQ;M;YA/9?W>C#8
MA;N7P>LXN/^ZNXR)PT2Z O1ZA3WQJ1;#>[>9W%JHB^P@O^8+NJ774TR#&GM1
M32*.Q$NCZ$IYC1U!OM5-6GOS-S$4S(R[WAE3PFX7S&8Z_ MJ^_QN?% :;+0O
M8>*9975;HGID"33:+[>Y!<]NH'")P]XOM&NO4?GB%#%Z629IN(A@@DMV6SA[
MO?ISS^XAW<_KA;0KQVP,E>< -%I&<[U_-N]9.4KDE_W7O,^)D-'>CX?R7JAW
M6!P=&]DF3T]5P^3G+IT XVA<J=4YX)W5P!/"?*7V@V8]+X@?^B;611OW!H5W
M@5&7FD].M^9(/-"T2=_C[W^TI)/15YN<#S82%]OX2>C+N*G)H<7QI$N@ZWZ:
M"NWH@]\S"K0HZ 5T>MTC5Z5XIBM?UMU%Y</[GE,C01JR#0S!O39RL02GC+_5
MW$EF74USMDI]6.SCPA;1MMC8D&)LK-;!1;$^+>L'#O>WI"%;9[V'$RT#.;14
MSW'6P7\$JA\EQTF_)AR@:J<JI^M-C)R@]G%T^.]RMKRGMWAMQX3M:^+F-(NS
M+@_H2;PV]%SG+\.J=5+Y=;(RC1P(JGR1H+/S7.FDS68M2,GQ='O5?^&Q8FNB
M4I<8/OB1B[G_EYC0Q!A)V@G<DA'&_LO7C9L@#W7XR.&=B3,)TY69<L]I;$G(
M \P#S.>XV-?PQI0"'WY/8++S"<B+("#O].8GH3YPIU]4O+#$T2PBDI.WR+3?
M?E^5*];^4?Z'@Q=HTY_YGP /M9446>.7A$.)/!CAML^4G>F9O*P)4&9S6FEY
MT7[_J@!PG((<J*9S_OH!-;GS7N&1:H1V FL_;(3<;[BA]9\ R)\@I.LL?9<.
M. 5$?7R\\ &<')2<BZQ:+?:XS""P8(.%Y2,<ZM=SS])"!,O*.?;&Y>OD_:Y@
MLB,DG/Q1I;8)[6 )U<!LC4%:TT=AJ7L%+Z*AVYB][+V"X%C,G&2\2M4;!<N*
M<&"R#V-R0THU#-_)P0SYB2ESLO%@W+V(1EM2;0]9F'V3][0>P&4:&D>M:2'7
M]K(D&<Q,NL2Y7;(9B$.:Y*!TI F[27R*WS?FBD%]*^7^P#4T;T$'U4K#EX]
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M9(+GO0=QKUESSP$J,J24<*GP'! -&Y?A(=_S(C)'_D,0KY\#(N]N @_TH><
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MK*C"O5A6W9S+<O&>:@D[?&">OTC_G21+@-)R((1$U3_Q]E<-92=YAU6MMI@
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M5E[/GG]FN;'=@)*F0;W;R]RWK?K1=M7'\%P!5G>'$SCOH0*-%74NBPN]]$%
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MYG-@Q'[Z?+O.=W_YWW9N%-Q9E\V2"JGS%VQ=J.FR <FIO'P)Z!F:- XY@JX
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M!CZ;F#A]CW-2#&0+>K@%H*&IS_CYR(>(9?K-#A;<.=OMSK"9?F25SRGYK3+
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MIKF=(+'VKS+77EV7#G$/Z\]MELL&Y?+2^[3*M?W*;,99@E2VN8_$]DU#>5+
M+>GU*1J:ZC.#)_##O9.CW+;Z.JMN#W =%[U,KT5S5C&$V?.X^_QE-T<I+WIV
M%?U/A4_)=M88PH;PKMW!TPX0#O=?\5$W3'R:]$-I(AMP6E)(>0L'_,3L>=7(
M<Z6_[HID1(SYQ_6@/R#G)[Z=$7T)E@9X89O!G@P_J>&_4[N6A!!LH3Y^)JT9
MBP+PS*%DUL\+!$OG(M*9MEF/L2)M0\2*L3Z+C5CL7H2"2- K6<&1$"1 N%5H
M99A.6Z6A+LHUBH<?D/DD<M6"H4'J84WU8G+$(VMGVQ".\-)1P,(>S7<>?J'^
MTVIU$V&&Y\)K,<(;1A??@[*":\TJN*O:_#%3[>"<ZEA%SNT\J?&4.>,7Q->S
M_V5C+.:H^E_OCOO;B#"[+H2Z*H?R>8)S\R,3W#O*[2RNR=FT /?440\C-P@-
MAW]Y2OCGP'LSVK5R@\^2F<A3!8Y@6]Y&$STC.<*PF0J=R7[B2Z*TQ4)Y+BIJ
M,Z&&=Z[QN/ZDH ^=O<^IZCCZ$S?WX-MO$VFOZ::K%L!3X2*Y=<Y>"U5$:;:D
MM834] U?N2R@81<?^:%AJ$E$=HH75L^.E7A:&PF15G5>:WK#E;,_"LCVP^NB
M-"BEC@)2![NEWQA#7\#_4-1S[@VX<;$K3STR44%BS-\U&<F7)Z;K;!S%!M:Y
MX!<W +& CR\;!7"UR.<'YV_U;6RHHMZM&1LX0_Y0/."Y_[59M>=CSO$'W4+3
MK6-EUTP^#=0Z1@84#/_)S>A>BU)_IGSFZ,7_U[]P"Q!KG%+=&X6N@8FDA<(P
M*C=G7([O^NL$QX1[0DPC0FD$<I9"7Z;PZ4A1 ]VSZUF_3M"$6$/TR7.U[V6U
M-P62(*7( ZKAT=G":.A"'DO[6U("@4Z/D%'\@H^HBN%V5>-\[3$_7=VK&W]W
M5]>*!@U3\__W6!(Z&6C\74V\]K/ZK2:"OH?F\ROSDO3["PTY'5P^%_ZW8YTA
M\/YRX\#/KTN=^\L_[*@Z] ,Z6?1=-L<FT1.EO#J7V30BXWH2;H<:8 _*Y-\\
MS#:*H)A/EI&9PG'I;O8^"$'8@=/'AU^=X_@PX1;"\-Q$1$DWV*[(Y:.;;^A?
M:!=?.XT^S=]S1];:!NKJW/%-29_ON0)[]R>V0\W>Q1?HL!D_6]::R^4TRECD
MKJDC3Y4*KT]7E)OCM)^JDY=:%81V?N; WEJ,D_=S54V"79>;E89.K6[OT J8
M-6X*B&TS*X!G6@7@O0'_/99MJ2.S;25+$NTZK]DQJ^)UKFS1HE$T.:\./1K)
M@-NNOWY?6MZ_6.>N/[;1C<\W:#ZRK/%F]V?4/M(@)A_BVN34XF=(?9TXHS3S
M/-N]GZVR0IL)*:O.XJKNQMC%EC#*A?Z 2E.75'/Q;%_69%W LLVS?B.%T8K2
M>Z"XM"")K21F?[>YP5BGU3\4VJ]FEB9J;5M3%G=&A'[S:!C^2\%,/S6WI()/
MD!+ A^5)+AP"7^R'U5?#%WUN#R8)AF@'Y@UK@CAI]DLUY5,7+-=2+5_4!0BS
M4E;YT1H5-,;BMW"JK^]+TYD&1B5&G?7VQGSR?3[;04\Y\&)6Y =00N/7+5B_
MU$7@PR>"GJ6\X#TMN$7OVA)Y\:,@HW,%Q_UF( ;(FU-7+:>Q;=K.B.1X.H5D
M<GOR_(-$;,<*G'([</J'X<V&/(1>Z#N2:U=0KU10%P]T#(#672D%Q[1>^E1)
MZT__:"%$YI8(?:P>T6\!LT9O1DIPT#!Q3S1M!?-#P*MWI]8$B?M=0<#J+ VS
MII7Q-%N!ID-'J$%S$C3CARU3GU!.QO93;-8#SDCS,ACDU)KC!P&!2_%LJM+5
M34:*LEFTIKQ4;V1M-M8&#6B8^LB4K2RLK2.K_/PX+ ML7SS@0]L),OE4RXVW
M*K8S3AQBAA>!;WM;<K+VF8'3:Q(:2+-"("0Q4:2HX].<M_"Q6V7IU8@11"='
M_CK>OKIY[P\%G9S6F'$/G8HGW4N_T< =D4(I7P)HKC?%Q#I$0%Z4TM>7[WZV
MG!F])Q$JLL-E+#S14*KS,BG?()_6TL?%\\2,32E.,G-2WKI4P@M*&6"_GV6A
MOZBT?UM0LY^XZ@37VM?H6.'*D#$RHO>W-3I](.RZO]YB4[2_:VXD8UY4B!S5
MC"^E__O*^?AE05W;E @<G7&GTM,Q0'YZ3=;E(M+TVW[\1N.^ 9[;F>7.PG4E
ME=)LI_7C^%3+X XFP!*]V=#9-)UIS_CGX-[.8<>']=N'37L&O_!B5&7%3'!J
M%)X_FF=*TL)F8F)%^YBJIBH 1+@/=2,/0J26H1U1AS6[EM='@]U2QM-AN//Q
M"LOFW*L6[+TR?Q4D3;1QYO@+=S-T:EO('<=7S1G9,Z<U)M'6Q?*R5C16$O\2
M,I+" AP0\^]@SN<Q"N O39A]:'W+>G0 PWC!7>4^,";8HUH#K\'2K0-T^GAA
M_\W;9;E5NZ@HE#'OWM=>NEMF4-"IN_<^SZ@<:W3Z.XQCU,W <=A'ESQ>XII#
M@]D%$X/\Z7 0NJ^:DX:-+#I9Z5HT4FC[P'\V,)80]D7VB:QE<=DC9V8X3W(,
M?]5_:K>!0A*^X" MDKNPT%VL,_V>46I\FTY\R<O0T^J!@^"<9AW80_CP>L0O
M5>C_*#CKJ";8[X'CU]<$1$2ZE)06I%-%6D!J@P%#&3T&TJ-?E9*4EE$2HS<D
M1H?D:*0V&"6C>R-'^GM__S[GW/.<<\^]]W,__]SCV$@:KVWP#)EA.77]\HGB
M[?!\E_/LV/[;@[,*!<_*L>PZE:_(1:T_X%I6=>.71OP]K=%Q8V>2ZWP L?;8
M-D[X(2#7L.F5YR&=^#TT+^$=))8;=.9O<B+N$;LS<^%S_UNO,5*0:=)G<Y/"
MQ4TZ-4_7)]]J.>C//NOKW<7^QIU^K>5T[$6$K^Y//Z5]])>J//9?,RV,C\TC
M56H"'-BU608/<19(8YJ;6T]P.92?[7Y'&"Z;'?1YU#XH&JT]BFO(SY9O&)';
MSCM.*3,IW=<"I&*D/N P<0\+?4%Q4PVQ>_38IS<,?Z++=2C#Y)NODE3>;-7O
M,@25X5F?+<SAZG_-!_REZKH6#7X#!Z@]_HI-71WE^L-RVD]LYDY@@"\L=_V<
MV093QZB/QRX$T;IFO_C-860@M>+#LQ Y"LQ2K2VYD$YIJL,<669=)>Q*EFOY
M<^#3$@<4^VN_F9_C?4CU)VTYH^]:([N3^QECO%RKA)X&QP7MYL-MWN$J>3^)
M%;Y<YX((W1>Q-*>XEVS6ZS^,'(W3?#L6_ZP8T-[#:=!TYLO-R&6A(=&1F[?
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MQ*HM@:AGPS!;@:O@NKVQ_3LZ>,5/CI9:3^B"!99W;U,O6^*%F@-QS@YFI?\
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M<4O)_8DP';K-OLI1FWLZ,KTU'*>'M75.GK/-^ VU75HW?.B=(/U'0HY0-\:
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MP9L] :D)D=[NM\^,%]\*-FQ]<-BF *G)7X@ U!\!2XD',Z_)*:-9D2F5 I2
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M1(^M#1"0;V)!YP_V'>>)JZ$D-@<5:3>I(S+;QW,G=>Y7U4)7[H;E?^/RIW0
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MCT=*VI84*=&K62ODBU%B"4IH;Y_VT=NGXF'9AAN[?N4FCF\[T4#^WCIR%[W
MV_M5S';UFO9+?)VZ!(&V &@%Y*JC.;JA>[ SWE!VLE.>RK=\"1P.3!A$HRK[
M;M%REIJ=RJMMK$/WQT!!>M+Y49UE/\JATTJ<DRI>Y;)&'5+D+:>=+9068Z9#
MS=_US5!0#D@86GR=:8W\QR.16L]!NTMY_$+;LF#DX30PLZ@V1I5B7B+ B*;0
M]QR4\*&]3#19BV)(D 70&H.UP5]C]/07A35GAT\$*>?4_:Q.>-YTR.DJCD\
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ML \49>F\3\5IA7WA=A<?_!@%^;U?+XT=S:N92F]"+@*4LJ\ <U#ZOKF2]8S
M3\OR]D::VB;XJ]_(K)WS%OB4:<&+OA1#KR%R!PBZPYC@@/L]N]"41+(UHYTD
M*A9CJQO=,+\HMI[[>G3/<U[+%PN.3:B6/RG--W@I>B0KTTFJ6ZB_)?#IXO&V
M!=F7B,CNMX>OAF@V&L-3'$]'9]OXHNXU:9/AZ""L4%%@OE!SW(&($0L6%! Y
M#K?[9 U'1]Z&^1]E.P%Z3-G8HCO'.S5Y8R=?:A:WH*U&NO=^4B"1H)5!'5<^
M:MUZ5_:A\)7O)HS\.>.3]W7,5L8-%Z#+H7ZH_J!)/K>J(,?QSD, [*]KA91[
MC3_]>4\,XPK:2"I<N$HXA&K?W#XJT,"J:+,\8!T\KG-*HK( 5]?!LU85_\G?
M94"YBX^)FI;@6UMLO4H=U[$OV#Q,-5[1^QLEO>X3-*?4S=%*&\E=++A4&;WF
M!)(+K*A*T.W4/XQ)#L+E3LC;FZNI2[<HCS^-<>]@=I<MA^+9$B[)/Q^:;WV[
M(;'Q34\A^7A+2+9L-?<583+J*"YS[[GI5*&=]<>-,//<F>Q?!7K[*IR?D;_F
MMDS*=X9R:V7]3]OEGL6>#]S?VXW1Y61@V'N9RTE0VH\5P^4 =[\TU8,';)8\
MN^31/J2&$]Q-R?)<A8'5*T7^I%^"R6:(O;^XC[$J77[-_?G3._;>?JU)KFZE
M9N_YUSSK#03RC==:RI@2M,XR"B<E[D;U]?WU/4%4U\I/A6A$@/?3S2 ,=.L7
MOXT>$&Z?F(X=91:!^-54U_C4A219CW\E3^79B_QNYCC9WU5*^VO"D2R?F:FZ
MM6^14CA;;R,3GL;#72-Z0T**B#Q^^3$VI-;;CJVO\<_N9=-G(4NN3.N&HC]U
M*OMS#,G-LFRN!D!MRP-!XZOBK?#/[T:KV+R4G2KDZ)(NK.R2E>MR)1[96(69
M+M",%X]Y 1QA7(F2$U'G8Q$<H[!+,U#:>+K^?[?__FQ 792!!CH7LG15-J<+
M'3$%O;*>C4&9\R YTN'6YPYUVIS7[ZI"6[76JVK_G>^MI;9H1EKH<E-D,N;)
MW04F>7XE?$V7X7E7F&-CY)3Y#8DWV^M>6<"PJ+1TV^WR&;(0)$=OGI16L)X%
MS%10.:D7H.RYUG?.>@;"@M03*/2XJ@>9R/M6/8NNAU 3M0YB+"*GE$Q67V](
M:#X,'P-8%!6NAXQI>;S^@G[B,5FRN2E"2+(UQ=/4ILF,&Y)49[^:0%3K>CBM
M>+5C-YT"X$^;*!AG'$S3JDVY/>IPWH&LH'YB_>V8M Z@J(V11R:KEU+W-R(O
M1G(E]%D!>):-+MF[7ED!D75M-?+/-H5E'=5DJM:5W5*:XD^DVRBW=9P\Y*)@
M/%E/2VA/*2\5D8Z.^_*A7E!1T%6/1D;PVI=-P-]FTL]<R,1^M 0_^16BGSEN
M3 ZY!32$4<; NR*N.OK%$.<-,1<=/WR&L>5T;(K:G=?"Z>IM>>H.UR.@YQUT
M1Q4PNXT/^(7F/X\'B\T?52/>#<I_R*5'W@.7%8N<&B$PC7>:HHS'-(=YM^.J
M5F1]]X%:PC]T&\)M^\NV_3;B IG<O,1:!G\$&)P96J2J&T5JLJ+)D ZKW4^<
M/]HU!JA;4FN2]=NU@L-=- (:;48+"=Q%8"P_KZSTAU!KNS.MA;(@4"^,-J5J
M7MDG>1P78M.BN_&AEO#63',C V[S<&%6D\;T1&+X;YC72EQ(;= O>21:IR:;
MO"06L.NN??HBCS)K%I>"2E_U;^OI]VHD:F-?Y]0!3)=0=<N63(XW)-/^0?&T
M$*^&^M0OC_H .ZXS9*Z7O(+4KN#R$Q=M+ "[_\#IL_%,?IBC6="AI4BN:%5E
MF^OX>2[+#8D7%'?.8:.+7\]AJ<S]-"L@;,2\WN!HN,WE]XT^W[)1%E18/\YF
MV#QU0\(7I"K&+,<^1F>8I FYY[75Q&QTV]\A@) R]1L?G.+EY^7FPVFE5_Z^
M ]:YYENNG]S'-PM40J=(D$RJ2D3S'_6RCFG7'?XG+[0;6U("2]S*8V>?2]U\
M4)#J):6_O\V[59?^N;?$8>0NU2-U+YZCBMG[*Z.(KN+TN!PM193_81)P""-6
M-+I.>W+Z7U%FI77TR2FL[5;/#<G]O<J9PN$;DL+Z,T6*NV*<"V&IR>/[+C(D
M=8V\+1=W(%8-T\''?N:38> ;DN5G[+^EE;+%K]U!(Y>:!$8,_:/T@TIO>@;Y
M%PB19N+6,H)BTS\<LWL2-TZZ?ONUF+N:5D>!,M(PV102\KC67%T%S[(CI3%(
M<_0]IV[I:@^P1AD! RW+/W:28'W6@ R8?AKSZWOH"^F-A<()>4=76DOM@&>\
MSS.$.4=O'[P\.D5(-X]Z[I)J@WUT&P-P%P6M &^9)M;=78M$QNQ@#MS+9:>/
M6Z^'E 1:M'\>Y4ATL@) F7R%'^A9*>=[D/;F1$'UEJYXB/_".]A!#=S-;*.C
M+EUS;&6R65%&7&?@S=<)Y079+G],%90+GL8]4F"RGFT_T$-F_L21HQNMIY,Z
MJ?<+KY54M.G/-KV+C:5B]/AR#Y"1=Z'>-3/14OM*5.J3X,4T?1 !\F<$0>4J
MTU1>(B)QCM;K"J!(PH(%%48Z_-X_8/.+\.B6VAYB+?2S'4C=\\0$\U?BKR-8
M,XNFNPX0G*4XG 4'(4L7E""N76M1:$0=AM2_3M7KL:3ADY$/XDSRC/^T]92]
M.;V'46DRD5TS^(;$0)S1J_3P'4.GN"2\T0W*D[]ND"H%6I"$RM%NRTE$\DO1
M)F,5N;?HY 5D<2$]WXA&2T.1UB.B.,\L-!U9#"UKW#&<6I5X0P+K=.-DY"KK
M=$V.D_X\( NBQ0V-'S] ,IT].DUAKJD:6C8WJ*+Z"9NLVEQCH. 0A>Y^:OC8
M>'HD.:\^V/Q]/6]?PE6MP,:.(X4C'S:H<Z^[RWYKQR11I8_\<W=AF=*?B[(,
M1GW>CF139P7/ZA*.U\SKK:BKW&LN1S::9AJ>SB&:C(%^JM@9DX!X-TRK1]4(
MM6'B<N#Q%Q4&MZ8V%D#2F)=Z#IVN:9.J!5FT*8"=F1E3J:73T FQ2A7/Y_%B
M#YFYO11<A _I-A*/3^ /3P0N?'[]+#=5HC,D?G>)GV)%(T\K<4\R\5U4V60#
MT;);G3"K%$2''JFH[LBRJ7=IV %MW)!$6U+:X7.A'B5_,QZBN[CE#DX0:FF
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M0? +L<'<GS<D4XW&(GU_%P669YH7>ZZYY)\>3XR+IC(YMS_4*[=N9E9RY +
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ML7B1A]W)@45[X5W/K]K-:HEO+A40]O\HC6U6OIK3_*N#T;[/DB<BHY7M4H)
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M?#(";/^W:E1P:4'L)44[.,.<1:,]<;Z/ :]T&@8]E &E:K5G")J&3=B%F>@
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MO;V%#!#Q87IYOZ *"G_.:FH_VA!S%((4.5EO><2OQ#1'O%Q(,.X3_H7@US;
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M:93_-*8V "198.S*^$E&0A:@J(V7 ;;F@\FST<HK_)QA)(:Z%3\:GKKXBQY
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M8,5<5SW.82+&L%068&ZT_Z](291]62#3*"10WR:A0_,"W;PAYH/1'3XSGV=
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M5%1->D;9MG\#@DC3Q[*3I1D0KN9^WR'*>K%-_.85>0UIP__T]S/:N<Y*S9Z
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M5ZK2\WIU*H_O@\6MRXT+MI"OICXC7IQ;%Q:T.IL9O_7YU161<=62) H,RRV
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M1U4M+-T/F*\6\]&1U[DW#UK_\\JYP,&23%OVH2J1/_C6(/M.]AE0)QOUV!*
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M ?)O"S#V3K_EN^%Z![N7^1$\UH%.3\!((<U?6X,/(*$CU*/PCP"^,L=7VV,
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M2")QVG<W#^<6M*N RB!*(3V0SUFUO18A(^G7DI9"O X0^$'Z_G@\%+TH$F>
MR-3(F-&X'IF1:Z.<@F7I)[VIU_>.XQKQCC,#&+;6C4L^35FJE<@A#S(<3D"S
M;/O-NB!:OVW7A1ZVD:#X^ENR?]J73\R<6/+8-LZMEXZ>!#&?Y$@XE8%<0OR:
M7+(HUC<=@S22QS Y#EYFXNL'CQPO;LDZC^ZU1?_X5$L7CES%8%M;<&Z)WCF,
MG?QVB3*H%699#I<N0UBW\(/MD$<2W[X;*7/RM_$G^I_ %4; PK:X.2:\0PXJ
M8R#ZELP;(O!AZ".7EN:BO25>LT*80<V+3GD=4LT0K9X;@)=<FZ7=3<[W]]/D
M!L[$S:,/1-A_  JWS=D;B9[M0;\&G[MW-?DHIPA('1E-U.\4A:ES_30(F)5]
M6@3(]/;#X;FH]-)1B9IO26:.>:10YT\E7MX)9WZT:1 M/SK@+5D'J\^:9+/3
MH[:[]J\JS!8<*_(+SZ:\3 8%8%#1WLK[8$,LB&>F4#/.^Y8L(U/M6?F9'W\V
MOWXZ5&[029/52U.3)3JXP[*S9R0W:N>SR>9IL%A=RER76'?04X$:YH\,_S8Y
MV+1,29PU1]Z,Z5WIO#N?%7@UW%FW-5NP,.NDN]C_8M[E*(U=XZ=Z58+!F[3%
MQ)[JLDN>*[E)Y[5+R1ID2^IW8K;U(DJSA[U6\!0ZSGI'GW'@)_>S1HY9=$XB
M:5N1/0P4 !U;ISV)X2%O,J/M!C"\F1R&V4KTV*^8E;@*0'5*!#F3K"E^6OT^
M4%\(@-'Y9_U1?$DH$-N&.H_FGR0S>B9U :0I"R#C%D5(*1/7 BK!7D2SL:KY
MPN]/ NTW',&#S8QQS"MG'1^;S59#@FF2:ZKY?WBCR2'!M-$<ADZ2>#?Q507=
MX:$H2EF*5^C#ZY@;;N4J?T?OG(]\#B%^))I(M"!1+=(GA'R;UK[2Z.\_=T.Y
MQVM:VP_,,R_YKS[4$(03[Z%+(NK07\)T/1 M.JJZ42T<SG.T:L]4#?B<]L[9
M\RXV(DQPA4&&UUAI(8&$B9=-X[C+#TIB!.*9Y(R94_*T$<8#%'!:H9[)/YJ=
M7GVGRX*N7HO:^&2+88C,'4G=D7KPOLKK<'J\#$(_%/>N&5@AL73&4KV?7[WH
M./*NK<4R<@M:@ALO)J6J,*.S?%,P"7]49PS9)DY1H6GBKL\/J^:VC/>MSINJ
M0$PFB!:SLG&?4N2L>H=ZH@#3CN\-O?<(JHU__,:X:=GKP#RNPG'CDB>(M_EK
M?.@"*)K($QF">S$R0*?2(L_9/PF"UJ9H50TZ:DFE*ER>&M=I0I0LTBT&Q#]^
M:PB\*H[-NWQ)T@80JA.J54J'A 17H>+.,W_GD-FC%L#T)HBA= SA)P*-%%!<
M2MZ\)6.7N(1HXGBB]ZJ_.G B.^^,'U">TW9<:!6E9[L;O[FK\[7" A@\2@E<
M/HBI:;E1:(N"+](3D\(D7-ZMSXG4:)6_.8'G#G& ]26V+F!FG;=D^W5^.Q<<
MK68OA7(8;'357GI@,\UOAD:_/#'-[[R>9-UY@M<F<EJ:RZ;RS<<.)JDU$R5'
M4G4;C^PBT$835XB!\5J%3.NBT57$)">U)]I4.9VG%43ZZ0)6RU,O:1%L;61:
M1-'I%X\)">X:+'*Y%%!6F%9-HN%!ES_V;'0Q9)3:'U*II'*&97[X@SJ1*6I\
M ;H+=4WGK*#)8%;2#_\4''>=*O2OZD+%.#U]4H>"TN>7DA]0^?-H'+95K_WF
M,>&@,XO./57M7H;BC@>T+X?/HG>_RA#&=>*\S$V0'/=?UG)!+X[M1.H*&+*P
MTN)NFN09?F.XKMK$/ZH-FB<NOAY'4/FAZA[W?8__*IIJ3ETJ.!R+@G 7EV)'
MRSHZ;LFZ3?KXE+S[XHMTKV8%6"[B_Q:9:P6 7JH+TPX!B\ YE\:.,=:%23_5
MH5\&U+#H+%)$D%#JK[]^\M;]2=DTDX0E##PV8^D1O*K2^SCY2X-L\NHV<$2O
MI'!_=-_VV-8PWV,ST"+TN!_(3NZX'6K.QW''\Q0N1$JPEX3%Y&)M!][_&Z]F
M#52Z'_S"<=8<QI94]N$\^;1">N$S:,)'^!]'-.>"FWC,^ASZV<31KL#FTYL:
M*C7E@]]\."<EQSI%GREY <4P[)0S ]!89"[UNT("9(, Z#'AB9-G*=DZU>MI
MX=!W.!2[ORVP1JU!3T"-;U[L%;;-'++&B#ZC.C V_+U]2_;0YSYBF-I<X:3!
MCSR:@2Q0A+Z?5UY!%4=H^W,L.FUD5=8BYZ.==U;="B(/IRM"R2;WW/E'?]=-
MXI;LWTVO[8O5&N RP^OINY> 2!+/:=^(#S6#\HH#=$H/R>ZCMH0I E\3L_#K
M!41E4[$'G%'JWU98S.;9/?D77XD 3&#L:E1O4E;+!-0J_F,J;# ?V'Q*43#@
M-'*M'O90X#&3<E1V2 1X"?)<"JFKQ@*._7#WK-1-WJQL4?E)[X#56P3%__C3
ML5EE+L;KR/3'%U+CX>8^ 4%VD(@WT\Y<DI^^A5#1:96JL;.45W6OUO+R4N;=
M<(PACF'_S&]K<&=+/+J [@AZ:_$9"O 5:;]BTPR$;NCC6?UD!:S+AXB!PAS)
MHV"64A!E'=JZ03ZS.E>8=L8AMA8#.ITR_[%Q5+6@J1][H'W3.Q;)&MF=3'%G
ML8@P'(J)<-'<!G@.*5Y5 D/WS"1*;+W6=_0K>.SL_U8Y94(_+IK#:F4"7H?_
MJF2G(:5,PKD:L4),RD_V/^R=>^V"QE$>Y5(URSP-!!256)_((.,2)A!_2V8_
M%V0[ 9=H:6':=UN'Y-F:IM$O42;'FXVN7IMI'&;[RE0,<E@0>XKD,QXML,BR
MG'E\")@S2T_:':X:=$7J_!EX%T; A^Y8Z/K;=[Z1_F8/*GULW\0.%CEGG*8L
M6'%+$"@DA<VICM?_-3ZY\[N/<<V$N /(:OZ(I<\O;'J)]&+$P3I+;LF^&>+V
MN?\%V6+2C_<L),!6HVZO$67[N?U_PPS/C0'5 OL5$'X(8X=XC*")[+ZB7292
MLHM4/MSI0>*VG8CW-!7['A&EL59$_TQU?8*8@LH"-!W!=BN0G4N/)5I5[1UL
MTZ<L]^*GYD,:_BT\#10J81\Z</Z%Q%GD9EQ\:Z;MOB6C+D(UUM%5/V*[S]VF
MJ@2RDX;= \N6SJC>[6>FX/2(ISP#J01)0I*BNO4SI\H&JX;CT ^T3Y5B,U,&
M+R?M_DD#S#[N%UR#_GVJ\O).+&D'M]#%P/YXKSA1A O&@O2&^Q)YNN_@0IX
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M#;-GG([3;DAW4I0H:4[E9^5KZ[;(1?D 7?AP-J"WX9:L;K_-%0D G*::J$9
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M13J;?&9G^T]7-\$I;ZK(HR8>T;ROG]//'RD9G^,B5;TA*F7#F.1X%[3<4W#
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M7=$:IFFZO%"?5J\](B184SJV< !0S-!O@ZKP 8V0@4<UMM?;#J7G)B$1G9H
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M9SLGN^<%+BCK3.L]/<L @SWKN)J&%EK+_F*KJL<CYF+ZLZ<=@1E+.?%PDTB
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MR[G&3R5T3QH/DQ;-[QT&3/2>N32D6Q,OJ*8/X)GFJ+[FLO$ WZ53.$'VELD
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MY&UDQYC4D/]+NS0ZS)4WHZY8V'R)G!%?6?2@-NRWI5$;N5D@E1:E(X#V&!!
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M/'Q0#K7M :$B>4T:5.P_P7]O3'2C-:NX' 9IK7O4,.]HW 9]Y"A_=W4+IS:
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M543UV XC=-GP 0=5,T0?<BJ??]^@/M[W=E9A%?1,V0VS^]\_(]N$G@(9=B?
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M?OJ@KLO[Q%6,MB\B<6#XFK1'%_.WJ?65@B0HMH9@[O^T>GEZLF*"YZGA9[W
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M%:3R],74<ZUB/4Q(+VVT7!&>1":5[W_R6)'6!-VFAB:?)+IIQN#QM9O-[-W
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M[P!.N32$DO,+T-7*9\K/#(NV^43\;TL?->)]8A>&=L 6MU;EZGO0,+* )O8
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MM:34:G&.3FD-(9=!,=SRJMV#-,<NZFM(.%K W[@KTYKPHD16\G9R#P!H6IM
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M[[3@1,[>/.%)+?HR!,28L#OA#3W97>5D_%9^6>$^,XB>?B^3SSF%[8E17$K
M'Z92\R<Z"YZD52CI7?=RTD\52F_6MX]><]/\%]V^Z$)*Z=)\AY[#9@MG=3)]
M0QAS_<N&!=9E7\8_@R9Z<S],?,>N;9O&]KNYC.1X6I!_^J598L7DU5+GM)-
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MR>S.%-@+PP'JD)-948VFL6SK7"?@2*%V435?SP >W9X,X=]^Q%WV^RO?W/I
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M=C,ERO*$F]T4-J73\N$%*$K7TWW[Q-BCKR8JH8WE_N@JV>I>AT860:M6K,X
M54L=-G YB9Q.3@^?F8%;=563V)"Y;4D'/RF8TC#S:AU'BV"OTX61<[37?T3
MQ?@UA=G?P\7K^KIXL_4^:L_,OWAUH/#JO8L7+MUL#)8NLBO,]C+!UL#A=ZMW
M@O0R*;>IH%$:SV*H9AW!_SW!?^_*3[2,(2A[L!ZF5-ES?[ JH.IEY6CX;9D\
MR*^DY10R-U5(B^'%+&O]-8=F$U_O<7[1A?54[^=_O^7/,RS%:[(^S3Z*!0LT
MK'A4%$[5+^PO33A\)6+>H:OA'?NQ=B()^8BD3E\'=PTM*8:H)+?2Q1G;NV7O
M"^W;%?1L&$6#+'ZI_932<J5(4)7(D<LMG!U.8F.'GI#.635G-Q?_%6V3--<8
MAN'90"-KM<<WGL4=5$ZNM.34VTF'M=@4IF77-$[^620)9[ITA1I2;E 5B-'A
M?ON7MNV<L"4(F)EZW;A7LTEILW'?+)\@^J,\X\C,+P5>?F68S6D:30@1C1^*
M?GTHK&K31(B,T3'-E(CQ!X/@@V]]2;EC-W<<OZZ5NJRSI#H-DL<>DPXM*R0*
MSIU13B*35SF1_;@K\CI\F,X2I0K;9FZAQ5>;<BO:9H- 21&G_=J]@RBZ:VZ#
M5S)8&E+-'U!$J7>B\3_RZ)(>3J6V_Z3,Z4,XMSYSW-8;)A\/9[PR3-*\W,G=
MQ]A2'ZM6_'_ <)'2<NXETV4-/"O1T7KQ-.T,\/P,<.U/-BARWY6042$6[$ *
MY#UJC*S,RV2UW#/JEZEUSP+5W6Q"N_=)>!-W0:07I\DO1G;]PQ17+7MRG>$<
M[T<0 Y>,5!W2?%J$UD(;F(JY3X ^L"O_%!XHP60YI/0- =(#>I>N'UZTOE9(
M&SX#L/HY0OT3P/CIR)?*3^>Z#ROC/(7PU6RAW?$JKYB0D]-F_)+WNE5R CVU
M3T/[?9IFA-QVXO +]AWG_&Q_I_)PU[<KF)U4.X0?>M#U7>-MMG,B2';P?47$
M]8_YKA8N=W)+;S-N=+//H/!)/4D<F[-'\:'B\'*81O"EBOWFXT^I@Q??)S[S
M_\O% T\_T''IO=4">]WL+35OS8O-SOEH;W)H^B/ JD8K=ICD2+9W(3*S"\Z0
M%<VJB=HMGVW:_Z_6KC0:"K8-CWU/*I1MQ)2E)JELS5A:;(D)1=%8FB390C(8
M)I5MT)"E-_N^,\*0?1TQ7F1G;&.0)<90F)CXYMV^\Y[W.]\YWX_OQ_7O?I[[
MW,^YE^O^<9TGP$U*V?V(_D)>O%B9P;@YK^1M=0 _I9P!W ,RE&B"4>>@UNG+
M8H30,&J$RDC& 8!'-7]SRC%VT;U&YA9,';7)LG)FTF\KF]E4X.:Q%193:V,:
MEHCV>MD]:>9Q8#O71D=$]I.1:<68"%A!-P5NXNOF%1E>WYUP5*&9V'E<XI"Z
ML#,E=#6-EC4GAP&C#"DS7%8K5EMEMQ)?6QXE$5L"EV(RGGT#2 !^S+V)7WUF
MMKWE&U>3,L!L*6[3+Q>B2A!$J,*>,N,,33L2M&$12H:+PC;8N&/<CXQ=U)$-
MEX&!5*^K7[^%*JN93WYKN&6_;J3KH$#,,HMU+5%Q ,5\T5+]F;POB=QKYZ%(
M(MI,L8<S7XN-)'FHI@54/N.D3,U%!U&'TP17JVG]WD6N%GMMWY!8TZH VGUD
MEGG="$FD&9 W<>J=T_'C'<J1HSB/6@S>(A.?_7W0IZQ2 P9$06@S!"7^2;H/
MP4^EM"$+CNBIJ#/NCO8L%KQCY\O/+?NA5(FY[:[B:-5DJ0QO?S*,VVK)9\=P
MP0CID/C%\WW7%5#O:J$!>V'T(4X_WJU=A4(\0I2[*[]A>"JM4^,.%1GU:?45
MK7&.<@VY;7S&2NO"!=^FB3.4@-LFVF/L]S>DM&S/"B0%WD=@W,.T$4W!C8KT
M%],:0\]*W-Q%W1]A+;$$L4K+PVYGGU_M>@:-$Q]CQS[)!P&XA*F0X-/4H9\-
M<,W%S"KF,Z=>87(_N3FE<:Y9=+N@I/X<V-]PN)1ARA<.WI)G&!:TG"K@DNW<
MI-Z^RC+/W1J4&E^RX;_M2'?:(/82!261)A/MX =)8&IVPMU2Q/W%QZEJ]\[#
M0"(MT,0M[VQ*(N[.I:&4$=+:\F]Y$TJ#M0*Y4:HT(SJLU0^D)?5Y'"XF )[F
MX;''I_5:'/']Y0"0D%0=R2_%X:E]"/UP)L26A^'J16&N=X])J2D4\=SGM?6Q
M[6)1GTC=(9..AFXG3B]$!-)4Q?G/-PNM#GDLFZ\5^A/7X5M^NSL"@HHC38^P
M(:D@>HY@.QS6*N(3J!R%,"TPV$3MV\R 4Z6GK<M7;UY4D'U IBE?ZP"6PUIA
M4HRK4FJC#"%$/O+]R^)JE\W"^QP P<O"'A+UBMCI,T_3GPNOQIG?65EV4G%P
MG9YJ8(M_#FUK.0!4X-K2 (RK(_5>Z4B+/MB&1>4]G#=HNG<B#%QV43A,&5 6
M>6ZNJ\?!V9;I)<6'(-HH[<XK +%L[*K_V.].K>SW26WTM#82ZTY.7N?2T.@U
M]C_%MZ9?7=3S:_:ZLPUU6_@=(K$?Q9%.=VQUF@T0-0Z]]AD15))9,>#U6$:/
M'0C.5.R<C&TP<$E>A(ZF,+1_QNR?0($W@A<Q]1>S5A)MFE"@/8=%!L@J+O<K
MTJ[#X>UL@GG"6;Z7U^Q#CK-JYF+"AA*-3P_X?VW*_P[59H;#7*M;UP'T ;3H
M8S&]#_842&:/=SZZU;@0^N[>_(\)JD'<T5X@](4?!OT:_5 P>)^-_F)?O?]9
MBM4,P4S9":^!,BKH _=ZQ*B]]VQU4#]QCXTMZ!-K0QW&U;I]Q&<GJ;9B>*7.
MCTMQ%>G>#ANK)E<38*+:X0Q3,D3R&IQ)-[PE!B=^K )8<NYFWXDFL[SCRO';
MQF:.(9T-*P:^UZE?^GFY]]1+TLB(LL2MCBS>L'1['38 []!"P/(3!XL2@QP-
MU82NNIPEGE/EZKAP6VX&<"-"%WMCXTV0<^GX->E$(,2SB_U5%D'F\$9U;9F*
M98LV.^,D6?(>WE7)I";-<E.+6)M:DC^YXA/.Z;4 VC$SE-%/EL2T("4\;%X1
MY([%&^:/J[E-L1)WH.:?;,NUVX#A-I<C.@)E^K>L9XY.E..K,H!A>'FI(1Q,
M6O]I$7>?>J1\EUS!Z8R-ZE4TK9JB'U$,-:1HRMX;PG=+IB$:8MM)F0VYO[J>
M7ZMAO1@O$-<"3M  )6X? #H2*O](-(?2[O)-YD37TM24'9RKX$3PMI_D'X08
M5O(_[#39'-N7\4KU2J1U-=FGO:I MD M3X>6=%&>V7TM:8KP?H4J%GTLX^53
M?[C>45,=E[YCMJ\B5'#99][5UA]B.V2B-DD)E$;)T:H)2JQ]Y'41)Z,2>N##
M*%!5;:K96MG+J"\A1[@XKDR+^]CXJA"0Z.UK=-/?5%/3?!6TR0$Z[/9UHQ21
M X!E0SW^Q]W:2J=+O3)VGYXO;5?I:) M*W^2X*V%*H5ZT ^Q-W;*W4;75R0*
M5OK)W7M"*"%;UC0N=.O?2=2E&.IFU\<+OF.WJ*SK'9(AYXU]M$!T.3),% 7!
M-M<V!5=.-'&UB>ERQLZ_#N&X\EIYK24R*/E"M!X,.IH>6!EW><O:N*LJ902G
M/S/$[#7-Q=KVZ""_YQ%.V?JTW8X K9$U)<0;JB_U>&>$3+[C6SU'G5.Q.RXW
M'"JJI87J-LYLF]/M-WQN#'S''J&[&:6(&NF^Z3,H'UH_ZR+-]IQWPKI;PCKD
MBW@5M:7#@^ OR%\)5@LKGL^>IU;Y^%Q=L+Z[B3L6V(,61'G0>MMF#P!AE3PJ
M,WQ.5! ^U'S(K=0Q.,A%N,;W)OG%:M;BK$E_,,!")&-/E"$Z?$E 4*^6QIGF
MD;M4;>SO> RKH.7%8>%D&[B\PZYS/:>%NX:+M:%[X:O>NI\ISD*1:/QD.FIK
M9AVHN.J;1X"-K\_N=!3!1?HZ D]4C<CTYWRK7"LW=!LIV9R7O4YL,6DG+CJ1
M:B1X.^DQ>PJH\W1\UM*N?C@#HDD-SVZ/'EM6K<6OI<3QI@?+3/.\O="L+$Y,
M8,9G0]"5'RT2MS*V=E;+V6/6J0?)O4U;8+F1!<81$+REQ%\LX+PM^>"+JSX*
M%+M0-PFIR^\%/(+H .SDV:)I,\R!U]?JBI!*2[^OF9"B7OMAT!WO/%''9QA$
M[!(H'H0JE\F=C&?ARO'G8!83X5*2Y6A@!A$K3:_9 Z/4Z M%=U=L5/O=\45)
MASD*#P"N,Q-M+%R0M_*.URVWGM:]X33\[?/X,.#O/0ICL:N)B[A4XMPN0KKY
M **.8Y);@P\(;2V!OAXY]0L2-0!6 S:I*0+XMO/P_<9O%A.6>7EV"W#37]O(
M4:J#+5]G?\D=YDP$]^3'[MFL3K-KO7MD"U7+^I$4BK"!(/8X&:*#J"M>I20D
M^BY^]%R$>-0-H/"392]5"I]['-S-)9JG:QZS*XN1#WY2N=YU&M>0@ELYI$#%
M"AP 0E3I%J0O447PQZ3&/-]L&UWT U)>^);1V&RJ*C]VH<>S\ZD.^:7@5>[2
M44I>"YJ=X4*C]4/=9R?@@:T:T+&LCY.XHW/B63'<S]35B3'P=2MM?M.UE6\*
M7I"2E*G1=,^28M^\5L'Q T S$/!]KP[(0G\PVO9Y:LWYO:S3J437&I+4O1,I
M+[J:P4&Q;W(;13ZC+NY!]@=FA!JEZ=A/4J#8V;2H<RKO7:WU NR<U/CX3YH^
M]%#K!I6[.+HFG_.(?+FVZU#[$2N"$J:CY[XN-&SH!S$T*! "BVY'2?;$E &
M+#!P4KTT\7C-H&=<]H_$*<W  (+\=.</?S*P59L/R347&CI!7FR?$4*VM6TO
M>XMB7'*'!\T&,L*:]W6.R+RV3H-V7%4 ?W@(DN]=KT+'.RP% @<8%W,)>4N[
MWJ7Q]J*[==;R%L=C-9]B ,#X)Z,J5N4X%05G!^>&3\+$8BV,?''',5-=P/\1
MTKSRF;_\H;7\#QBP8N1S_R8/-@-D8GY7C+V0S\38_>."OXS_;03X+_C+V\W_
M1<_%GO.G9O)/Z# ]GO]OLNI_0OM@_%]02P,$%     @ YX-_5C=UJ!+@-0$
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M13Y8+P5M+1^*"N*%C=O(FBX^4WYG? +N<K!]#D-239W,)Q\<^S5#GPH<=")
M=:96=0QFW88*Q _-ZVI4/-V%SDWNCE3@V4]6I&T$0<RR6>[DM#$WK&T$FF5Y
M/VQ@O!P6106<,>Q(R;+NK7AC*^-#'M>3H'6,]8AC-M>='.412G,:X1@[&_[V
M$-(89,]R)(8#X^K2!1L.RH?\V,KRQ=TVRV+[$P7'!FN0:9TV;,R)VRF=RMM9
MN=!9J!"1IY'&NUNY:[8T]Z7[WWL/AX;C@DC)70#DS+)0>-?."Z&#:M]8S$Q)
M, /EG0=L5U:2MOO?"V__1KB#8O'1DU,2Y" HQ_?Z[H6["7#G>!8[?*DNE?(H
MYG\MVK$7MJUA9M0+( '[,;O\:.>_Q2HW 7%K:^V\Y\^S8Y#N[U[1//92GK6$
M5:*;[."7:LK>X102%@<MPB\3N>8\"Z2:SZHVTJ=2!#8F&<BL\)VC<"K ;H>X
MC":A5T]GGKIG]S1U#'5YV TMD8K'$. "24A3$$L/4D3K&!HIBCWU1X+]1NRQ
MY/&1BL+PIN.D*L,1?88H8(N;^\266XE'HJ^]>\[%X!CE9P4?]7>4.D,D\TP>
M60F+X[OYK9C741'PBNBH^M/("X3X25:>4P9H^K%8G6>Y!ZIC.VKOGV!DD3H3
MM)].=:?T##QN[&0M5K[Y?<'-^Y_'Q 9>QNKV3,%:;]T8L[T.?OLMC0]_V6D8
MHZXT?J":Q+E-8::=7-*N?2O"B!,WL=$/N!'$]/QM4_T/,?Z$27.R9IL14Z%)
MS3O9Q=!6HB42V0^_!HO"$GK'FTR"WS1Z]PZO2@QHM'0S3 J# <=(U?M]$]B4
M?T G3HQWL=:D3T-6-(PKA^ E4IA-J >Z:#WK+Z2<Y)8IHP+M[V_%:/IDS"[T
MI0] KEEPOI HO)3P5HRHTQ)^ED+V_)$UPFX!)QPS;A "0R"7OZ!_\?CI[VGZ
M^2[DZV&QP4&718YAZU'%+(&5 O&YEN?IO=K4YP6];T\K'ZLK=K=GPZ[FH)=2
MNQ=JC+)H;6U';4]<CN=R3C+4Q?XX%,9/T&3;I8..TO-YZ#B,QUJ""$"H>T$R
MQV863X?*Z_628 ZAKN[/.P-F[3P%9GQ+3<W">\X3F.$)FL87^%^U7D16OX$I
MY_B/@U":'%;LPS_'&E5/><'/IVJ5E0VX]$U<*=F/5O/@3C&+M+L7Q6]T [R_
MA;:UB@U$QX(3#RFBO?(:=(2,<S$4WL'B@,":S!:5-0X)[<M^ZDP6_'CEQ:QJ
MUY4CK\(^8QB+ UCW,3KCCKV[1<YR4FY:C1F9D5E/_'XW[F":VF:K=MW2D7&H
MUH.]J<Z3MJ[>-IZU9\H+9IO>C@Y3"0X;9N/MG,J*#'EYG[ZPP /A'+/8AFW[
MED2GUT^>Y+^D)?^E89.^UGABO-WX 8P5].HTFX2UP87M/6I^2^D[EACHM;(R
M]2SMPL,.HA/#DX%V!IJV$[>%ZI[X!^E^Q[CZ7$P_JWK%QI$>*?RZ'<AL>.J+
M$$+:$W:F?;ZYXITRVM(SZWRGQCD)[RU3Y ^VOV[G3<W_6A94'<2>[>.[+^<$
MO(TP+]VK=F02'.9LP@AHP$8;IUQP0\VR9A?C2>?DBF0=DGHGV@S4I 7$)JJ:
MGOL(E9[F.[(^O'TUSU]L ERY^QII0<ZN-<'>ML;NU^ ?(,%]_&4[MZJJ?'*"
MHJRFI9Z/M#=N* JJU_BW]R9=>5/&I[RS13SK8;'+1N(6Q-_I7R54EO96WBY0
M(/=G#J#FI;Y$$,V1.H1*++P-JO\VX;RV7PDIS39Z-^5I%M+U:L(-@H?5>PR)
M54GGE^2F.I;BGSKE,:N-L*2WC\-<P-4^:]&ZPBGTL""^#8>X2]+&^I@,%FVM
M[4>>Q1V[G[I;]R/9D[\V 7_A2/&'-#[YI, R6_JK[7T,\_!OEBT"7?'U0HMG
M!HNG#>"P;]\]MAGT!XNF$]3QFH?CG>.Y _480SMTSG5=-_G0[^.[X>GT%C<4
MO\D623G87VLV%7]>75Z[;TK14.V9<?:KQ2_M=W*2]/;5PJ>&5A#3L$B0X3I%
M0KYQQUM-WE<JXF!^27'*BP.FBD4<:ON8%#!!HZ/O@C_,W)T%L9<PAVR#'TT/
M-;!%)MD:\-PM\DQ)%8ACOO%H[7T,UVC"^W./4/CR!81U6'>;/$&7=&1_6=%#
M3)S2Z>%30 '][I%P=:D<[KS="(S6 W(R%?! L5$&QFCJ!Y3.2E:@N=V)*1O-
MJ;P9PQS^L]7IAWCBR[:;;O@I))J1> EET^,/,F5P]JE3L.A3&AREV)6EA6K>
M;D+T2J=LM]X,BY#CF-J+!'.OF83G3JKMK5#FKVY$<(*-&O6GH7PIH,&ILS1A
M\PUOM["H'_/U'=V*"Q\5,)/ PB8=$DZ\VV69]&GSDIZ*;L#$9+%7^!SR'&,I
M':BU%%JZG>N.\*FO\BFSRFD[S$BL=W$1IVU7%79_=2SC-]NN:Z$V>)VNB],:
M2B1K[-HR%< .F>&J8PP;^V1BGD<-GM@PEGXJ[L9$*[[[D$$\?<<:'O-A?.,&
MG!N:.*I"!8X,9,7P9M(2'A E2;K5N+TG*KP>-9=/6NM[O@J.;I8P3AE>]E$0
M9[^EP+_]4.O 4YJ!D%Z\SZN=Q/EM6!5]W@01.@+/M<"B/2=]&(*G+D0;#!0%
M5/8?NSM#D\U[XK[951?5#K4G\YZ]16$*5UIQ'C[1&D=[9[%=]U<Y#(KY\QX;
M>!4.OYB=?$CS )C-OLJX\M8?\213$*<;&R9 R)AH;UX;/FLX<(S@X.3/4_ZB
M4-%9/(:'HS<\2$MDPOIPX^-#9QR,O\&Q%O0";$U9T92S?;_Y>F;"<$J\IU1>
MYWP&<DYUD\^G7'!DL,OI??K8Q]/JWBBJ*+?212(F^I/R!&2>?@2,Y/""I#1
M81JUOF)CKY-ZIM]/B7G$6>\;V]JY#@!Q),Q;EZ&Z^U(3T?%*55I5_&R(=_MI
M?*=+60%78!&9'K*J [B:U5$/([_24$1>)MPF>B'5">#$N)!^OMO8<0-^@=[=
M#L'88!&;!T>NT@_XO8T3\F$07S^>R42HQ$&%\@!.I<$ =7]PM[)PI#H1[2&@
MIA%0NL[AHWAZ>C@/VZIY'0U,3-/W"]H.'>WXTOZ=U6.:8#RKC[>DK"#MB%*4
M 1&E2IS*"F<NZ>(0%9B4[:,(-@<%T2U9M_O(Q'K)E)6V>#!TS18T?F$J,3:
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MFSU;-_(<%YLG3[$#W:[F#$^<@<!;4UU3%4?,J9OCL; *#(ES]2S(2J "YZG
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M,EG])[=AZ<?08M1?N)5M_LDM[Z-<X^>$DIA9^*33GW1T23*A?S*>2;WZ0]<
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M? 98\!O[[PBMOC !LBU^LQCS1%NC])U>D(AH0V5BA?9O?G=NQ[#HQ 9GK-%
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M"1GO'<;5OZ((D0A<XW\HQSX<KK\S>_I@R("/#6=K\9G]@:#F.L 5ZOMA]G8
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M3AU\#25B%;EU:<3@OUUXY] ]+!]T%DM/@'9Z%&#SRYI'%+& !A*G"M) 95%
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MVTW2(DO7X5=+PC5:2KF,7X_W[%YU6[\=Q9)[CZ$N[WSKB4[Q9]F*5[U]($<
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MA/)'M'?,E''!\Q.=X^6V1U$(5E)9Q8>;5N#9TD@J/_%9]</6<;ZLLAW[=H8
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M(%DCIUQA20_-RJR]TI/]WD _95O[P:,Z*9%^K+0+0!-Z,/F=!K7\%^<M7TR
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M9&6J-N.%6F+]$N\F^]WIY3G_33@[PZM=51,AL=*A@0.$B' V1CB6 5'S@=B
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M./PC<^(?H)SIZ-(TH*Y8>&IG&QM#-A5'75(=>512T6L(!T87&TXG,H,9Q*Z
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MEC&/"G6'P<@M*VWW'AX9@:]@QP5^^'_WO!J+K+" D:(+G.JO4TE(318(6Y:
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M'O3\/OT2ZZ [IB=GTASJ+V>_*J3;RYXP>X6 _E;%$\_&+*QV("]G7M5E\<0
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M1<B%BV,DF'QL&>MU/6Q(,G;QWSZ PG\P0#@4BIU2 =*V4Q6+8]YUS9>LUWU
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M/=(! 5["Y?6A?+\2X;?\IZ.0I$^!I9&V&@T&"Y71V+W\S<@G8NF.:]LF!>Y
M!BN012910O3_]AWS+\DCM@/)E88S!K;S4CF '7XQFC*T34S_&M:-[3BEQJ_]
MKR\EIC(]9[.]-Q>0.#-="I/Y^B6.V1'V#\ZR;6<S0S&C/&VLT-<;BS)Q?/-^
MHJB/_AWP_P=FJA-A5<0+4?_ON)P09X9?6@AO7@V#2&\(3<0WI/^MR^;,96#%
M[WY?XM&[3IA1D?FW&16__CW&7TTN3J>(W.)G:6$_GZH6I(X7 [SJU^+!$V\
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M/B'BPB+Q#/V  +?^*.;NVS_<D_2/W38C8793$Z/\;GQ8P==(EKR8\D?WQ;Z
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M7.V!H+$C+"@P T:OT<Z3AS^_%4"FQ;[XJ2.G!="7>_Y_ K6RB-RMJF+O_^D
M^/OL\;\<.!2T+O8_R+761U@O!% DD9TH@/9]'<$NN.(;ZRAH[!8R/\2#.K24
MXLE/IWZIQU3!Y/ \ "\8GJN'3=400,KAAP#\F_W\J6ZUH;QSU&+N@@%LL<%[
M3 ZE 2DU(:7AC"RLP);*55_+7_%W=P?OH\Y-O8$APC "::'R)MOA:TOZE1=R
MPB%7>KJ%-G8OXH7<.Z+4E-[@I+M)\?CY.!)+F?LQ4U*8 .J5Q3/]&[*&8([8
M!Z0^%^%.>2@93AC8[&^+QR&X/T\%44"I8B&6UR8\;G#WOW+>R#DV&*B+/\<
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ML!8!$70]<81#?7UOK^GFJUJ91+!8#0/I>3#O\JP%$* ;"(0%Z(Z-=(=,6!&
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MD* $TU$,27=\:R:\1<U<#KS7X5>M0XH:B@9*,+\TKTA3W39>EP1,7_T6W22
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M@=1]A%9,Q=9CTN3Q;60=2U+(N9:YOD JB]:&HJB]: B)FK<+Y2\3<_M%1"W
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MQ-OH*!G00Q;28R$4LPCY%P!PN?&"TF^=Z5+?X98)130&@LQ,O!*Z:MT+C7.
M_[<[</X'@'+8FS,MA)I509UQ]GJ<$YW3E3"IF1:\RPA= G4&K0NW8U\(0C+7
MS/-4*)8I0@H< 9$G)86,$!C1KDC365R5)AH*[SZ'M<(MRVL$4(X$GX$C,,^$
MO[T2\1 5_.OC:&Q.A07OD1#3E[V>SQ*RR6QS+_C;QE$KF-,$Z #4X8_WM9NX
M&QTC,JZ[$D?1H4MCHT?V"'53^:;$\VFC@^09:2#"M^P0O_GXNPWK&J93@GU4
M*-[:@1KBE?H6D?<I.+@I:\O2QX=32GYKN^1R_-'SGA.V\D"4-HG\4@2W S)
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M3\*^E%S0XB_Z+F93(:)(3.?Y3@5'F3?(CQOC?@)>7VA< \BNCB)3$8Z)<5<
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MM_HQ?Q"R ;/3[B8U_/&N ?[8TWK:WN<L)7A8E["P6W-IL3]/ $VZ1D-7G>G
MSF91WZ@WYWJ!0&52= EUEK]ERT=T1AV]@>M81V:=]R+HF+0757Y3>N/0=O)8
M[+ 66SF"S-+J;3HFO>B/Y3D^ADJU^U;W[67.+MKSI4VC.X<50+M<_N23S?8+
M$3-VN*LIUZ5TYLD;%"4\KZ_7DKDT5TNX1FCS @=Y0AMRNUZB5E7I0&<-=XSL
M%]HL&!$>NY&3HH8+UZ[5N(5]SAVS83A+"\XAX&9X.ZBS,]V;=WRP"A:V)#1&
MQUT1#81'"C(R[P30D=V^)J(%A^<ZUFJN6$+"\_Z^5.HFL-3B \R]"2P@8\_N
M)#P70.,?.G)%$.Y*;##R%$"-MH&C*+"&G"$2OC9N?7E"VA;F9WIW":DB_>@=
M5,Q^J=W2I#466=2>HA3Q__ C27:].G,L]4.66%6+)"73:\"UWJQH@K!SD&[G
M0\F^\#$ R\> !NEU/B3TA5.XAT;9<>H990?RL-P)-\I^I^K#*%6&\C4VDJSB
M>K[VZ#20^2U/"N,(H)[WD[_*A/(I7F/DVE/^%#89N]])'@%#8O>O#U+Q![@"
MK&O3+0Z,/FB2">>G>&(E_$$!5)_(L^K@DW@=("(PE-]AH\)**N'!480&/4)O
MX(Y9KYMD+O 3CV$E7TU8$24\0M2$_4?"2K":["&+TJH(*^1/E,1^KQ3[R[$K
M#N+5,08KG9?[WIXUF,P_>2:'^_,K4 V'I_DU.C??NJ_E\59Q=\8LREUQ(3=:
M*?3#IIFD/]QLPB &\K&>Y2S\4EBRBZ&<TKI+W_M.MZVL=JY=\+FC:-9\[=>-
MII_3=Y$J^*UK;;Q/"Z #"GH%W(YS2VKU;5/9B87Y4Z^:^JNU\(U__W/M?MT_
MM-?>/]6P9)W2\D!#B>T5 5)&!H>.G]KV<WG&NJ2?JS<N)JW/G\_V:Z;P),"*
MD6#UM,TR*\GYUWJ-]W+4T"D=Y**2P]+J,PO#O*;792QT3(A(K+H>MFE2PWK5
MAO5JSO<F]LK[6GXEF7G)B$=,4SL99J<Z03=,%_P##10OK]R:$"2?8?EH^_WX
MR7CZ:+?JA!RC-3OVA5G'BSD//:1(J0[H"/>_<NHR?]X-FZ098_FI_J T?9GO
MCH@M]S:!?X5@)C6H-J@YQS_.,6XIAO=QK;9WK=K9%-YE7-FU->'R(KS>ZMJP
M:0!EQCB4)X7TC)%E/3_973I\:_RD:1I2MGB1VK&-LC99-H^&/3CRN>NQOA+L
MC/K!1VW/L[NUMS2H]=?=W/R'N_2#A+#CU3B8ZC'8Z@"559]TQK:)^&7&MDTW
M 0&:TM+*E<:5YD:0O)&J99C9\?<3 #U6E8931?],E[M8-SDH<5S.84_\K\5#
M\)VNUYPBG9/QS;13,ZP +K6@ID0==VEJD8LK]$<"_LA5_>612HL&-;6:F2+0
MIA$7A/]: 3I@YWO5W5<V;4F(R,C8]EI$T*91"N;\87 DBN8C@[1N!]/UWG44
MOIQ;0LCS_HE(J<HV ?0HJAZ+T/$2\P_;DI%6%P9MR7#'TT6 ]PO^$9]X.\-*
M4W/&I$;C!ERHE<^NXRTPM0SN9I%R[DX$HK#<,>G!F[>9E8[(B\+%L2\";QT/
M+)3D\XB,>]NO#:=\O?A"SCC-6>,/&P4^^1Y8W8*S^%QI\L=8#Y2-.]Q@C9FF
M;>RZ9M$'JCL1"X1S2YG%E\@29X8_SBUH<CS\%>XN&;'(=/G0]<*EVEWR@V;9
MP'9LE^0WDNO?[EV/%NY=MRR;]6HX3 "]PP8L>OO68?[ .::Z@77Y4!=]L,U#
MN+RIK7*QN;3II.PS"MK?_[L NE2G>Y(ZP6!QA4S&RB<^OORSZA.JFGI>@\4S
M=F1R#\OM^>61>CSC:DKJQWP8*<O#$W4>>P(15GE3\(K1!PK>\E:63^G@'0<1
M5]L5VZ29*Z[BM7)(ZG>[=[S>4-'S!BR(72D2%5M2YQ@VOMCN'S*4+I8;<CMC
M1]Q&7RO.S$[7;;/=I=U3P'V=_(V^UA,DI=UE]"Y_OG9J9I?A;WW2S9/5+1;E
MJ15,+C&#PIWO[MU^:F:GRXR9G<X3KNT [:U.:5D%70J++/.U//(YRM#(4$;O
M(YV7$7 [3QWZ:K $*9U<B!4\(W+7NZ7>\"_I<2@INO^F4W<^87"T9M=FN@_?
M)7Y1@]K<ZU><\;V\FX2OMLF;DX6OIO&]W&)[S3*N?8V_,OJA0UC$%?^JM8'V
M:VG<YN4_%P8Q_&!I)#WE+Y^0?JU/A6X?7Y\J2)_[Z_9[5)W?@4;2Q070Z"98
M.(=M>Q ^O6"0';-4F'S@;-BMFG 52@A3"^*J)L0_&MLN/S3^/76JJ5D&E!G]
MO3@4?]I_6YW9U)V^XPLTR61GAJ9^3SR?O5TS5*&BOF=+,FSGOE)\C4O&UWL3
M1:_K9<3'=O<O :*9)GQ=A^<_&(XF\VP3:^MSP,X"]Q.Y  8-"'PKK=^;_%K_
M[G^\VMW8]FU\=SA.@K4P-ZIJ#YXG,1F^1/UB7"_Z.CFI+HV$G@$CI><,TKGX
M">[^+=:EBCZ@*&<>1K[(CNT8DGX1NF$H=21%S;9_N]@U]O 27>I3>E',-P<3
M#T)HYN0KI9T)365PE+\:3QNK4M1FFS#NNAC\QE#RJ=ZL=_5=0_#3S=U+#FZI
MC)1;40HI/F_/;^3?E\56VK=V\,-BD[&KIL3;]$>A?4JM_>=@L?X36Z:_K%=<
M\B3 R2\R8-ZU!SE&4U:BYXT-M_D*(!E?RS3SZ6=OVSUN-S.UWYU:&K;&0$6O
MV/CW70,5*CFF]K49)-](U@@[]Z$A>Y$:NEP L6OU,/G!-DG^;Q\1#2JVVJ:1
MU<F.RB$%UT\?-J6RF\#3Y%8B?PYPC/H_T=$CN>2^<@F4B^X:HG?//26 8."1
MGC9!W] 9=,(\N#/4E.,HRC7.-UB!5,Z*',C!LZ@/8?*IK1[\.3P2;T1/ ,DG
MXM>'A->M'IB>.<]/"[CQQ' M_@8:TM&+,%2!IV^+R??@A'7!.&$FJ![]M21W
MT7'D"QT$)*E$1A-1"NZ\_@FA2R',%Q;L(]0+Y"'S=!@GTXC0^$&2,\Q^C-P_
MU8_R2=@D:CD8LS,'F>'8^</D*.""S0<T=+3) KYA#1JF;4-M>1&HC%1JD3%^
MA0!ZW2F 0KK8,0+HSWQDE&:>YP00/E'GPL.2^H!:X%"^C.9$(2U4@Y5(Y8S(
M@5Q1^B^=/@_IQ%,R(Q'4Z2%2Z.6/?V';#_-YT0+H?*)($E+S<7E2<4)O" D5
M0/=CZ"A*PL0)@QI((8)_)4R8KX6!OLQ8"[9'_T7BT!_ 62JC EJ1EA<&RF!X
MK0!^ M4384KC6#:##GN!!QX(6K6"&/?(5P$TV,$$GNC]71VX# !D=0%4^#(0
MD#LM<A!7C Y2^!*G?BH@31G/.G8 ;'>SHP#;!6T8^R;PGT&,-+.6J8%=""[A
M,T5R\,:5!8<3N*%Q"*T4K#[FZ!N$P9#$23PH(M$$U1?#A1N##(!!?[&6QCY"
MP=7S#>Z_ *R*(%)>]*CRR'V]5"P@<!E<HS^(!8)X8B*QW0HX7D'^@/H$63UL
M*\*,C8,;V]JD@4;"Y1>VP0,C0$FN):B>21&5NW2$,%(D@- CMPE]E<REB7OH
MTXXH+YD]H@)8]$K2[]=*62ICPG2RSE9:ERAA67.)_)G8?I(.M.F29L&ZP4C/
M:,@*31N:?EMV9[6AO5M(S-)=2]\=?_F;<2&GOD96XYFQXC##HW>:--N[Y.+O
M3:G.(*R@UU/R/. ZO;J<QX^"_U=[7QX/=??^/5+<D2614*9%D;5";NM0MR1)
MR!+5))$EII)(&$LH0A%"&C7V)4D2R61+R4Z$&$,99)FQC&$6S_F(BN[OK[ZO
MY_6\GN>/YX^IZ%SG7-?[7,O[,S/7.2HCQJ;!SS%BGMX<+@D"(QHRZ#W94+O(
MA;SB_Q.W2"[_^/&_OPE]_C=FWW^#D%F\"+WAE?T>"?9^@8>L ]BMMZ">TCT2
M;U-8!Y+>8EVUSC3J%D7[<$@D=6GR&>H6W0J&6>P$_YVXZE'D5N@'DY3/QG?!
MWTOZQBRBHGJM?SY*)EY?/]E:_VW*P6=&9PV+?-8''P9K2%MXR:L%7]'>H0?]
MK&2T4H8_EO_LT:/0F#N@ONS0%N*'S4J\Q6X%ZX,_!.Q;*K<I# ?#+BUK+G/R
M-X^K^OGVP=CS?X\ZXRR<I(R,>8VC8^\<,=KI,P34[OHVJ\"J'Y,_\ML'-BCQ
MI];!A?JIH?)SQVDVE4G*XF)E'L OEK2AQ9(6N34=".G>.<Q*#951HJ9?DH29
MCFBOG$QZF\EBWU(3[,6JI<UO9&VES7\L JK5Z?Q^P1(/;P&7N U5T^W+.*]B
MP_X3T[ZXS^O2T!\/?9V#'8A3\6U0LI  I8T%:"TSKYPD<#29-=\_YP=DJ FZ
MA1RZQSYM193]3K-7.Z"/ZS2MJ?_I4E4IJ2H=I@3T7\F_W!"^XI )K>5NYG0:
M:P C'?&YA2F+_IB:@1X4BYH(HJ_]:E,U7)!S]4;.%VK&('K<M&$.9C&K1$D$
MN<^8"O++F>CT.5A2A%DMAJ0#GU'$\Z,_=H(JFG3%I,N 4:='>QMFFY+E]5(\
M(@O="':K1!*Q!S[3@YD>?11;8FW8AGDO<MZQWG@F1.,L8F(,SB#KQ/+0:=!]
M5B87[%L*K3]Z-Z5.K+MZ!UU?C)ZN17A^&V22AHU6#QB11.\^5Q/"=*\$&7%@
M8BMTX14:7Y2MO3%W6,X>T2_M',3TZ@5KVG<^A+I%R""F!4SO/[M4]61F"(A>
M1DZ,@,D.G('>7@*YNLLLR<$S\\D,D0X2#?1=T;5@MA.EH"#DHO$";/I"Z8;A
MIXF9](IV?Z8[].;40 U\HDR.-GVT_U;C.]'2>7W.PR<J$6.^1C.[O*+//*EZ
M:6W-.7+,Q0P[!PM7!O$:C]YF\E?FH^TJ]W.Z$>JXG@2WT*L$##R7R-PQBV"&
M1>"T<A!MB%:<*KHGWJF@#,V+&-X-9 <&I28/33!<&([-->ANY/MQG02?X+!-
MVXDS4>F *3O6G'OT'[CR?#^EV$*_Y7S?.#M@1[PN;4N:51^O6-K&-LD%)2R_
MG[Y=PJ$4<]N\X_W%BY):*R7/1AS?(/G(-Z+B@0_W5-^#58RL8I&^4)?RYT?;
MOPJ;! 6+?E%3SG*(SN1Z\+1A[T;-SO<KRF7]M/6'5I_X$-[)5V78@K-!AJSO
M,-*7&2X1+C'DWQSC.F[IX:/R16D-=V'.?>]=)V1S2>(45?_RMEWOO1 W/?=2
MT.=.5V+#6F(/]3U][#+8G;%[>]Z81S79C!ZB@F-<K84NMOF0U>50.R6SGMFT
M9V7,^O%_DHM65&O6$XT,B9'FW4A/==+IO.<1GQ]C6% R>M;3.X^9Z;2N@$+D
M*Y,AW$ "M44Z@7U_\[/*1C55R79+G?-B*DFO7VAS<*L]D ]N9K9 )7/?=!":
MY*@$O5NZS:32HN)00M>H"_[C+([!ZHP;:TP^N<VT"]#6]SFT2<>'0 34W'W0
MUV2_R6!IQH!G<3(WS<%*L_!TV\Q.C3**MRT[10,0%\U.#(UBQZP"67U !*KQ
MM2BT/1U4_(?H<AQ5$=3I6XV,5+(\,V .Q@T*<BL*E.#G7O[M,_<0WQ1 C[5C
M:7 S (53/8.F^.J7T11,1?VL(%UU#N9_'$>M%6VG\)SKMT*?'<)/<D'':]G&
MT,3GQ:N >.$?B,/S)G:S16;V,;4*$-/#37,P&P?P:,H-41;;Y[AGS!WH!AP!
M3Q>&V)8=LQGB6C_#T:E1.DRO00YG(YF^;?#IX49&5"9(3RI]3$9<QZ_#:0:
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MV=H+F&;@_VU/_-T+/=?^OP!02P,$%     @ YX-_5KI\NFA1, $ .Y ! !
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MJID <C(*"G)*"I+6X.Q=<!Z@9*9B.2ZC2<UJ;$LCX,4F&YJ4?4CP;$4;N\D
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MG[LC"Q*3&BRT5>]*O)5_?+RZ,N;0S;4TT6&!XLH']RD^E1O-GUD+[,.)\/.
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M%GHBT)M_APC8W@6MU<\KWZV#A!&!KV+3\(\P,# &BR5:GGO>RHD193+68@/
M@VSOX$ ?_GH;2T.H_PA?OO#M^WL4+JB+L+F##"4"+D9[&IX O!XT.Y]U; 9L
M@K8V.0Y0@TU-2ELO]I&]!U8'^#X* N-PI1:;>5'P)9+0Z?:FCMTL=U1E=)>
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MHHUD(1$H86.+/="29+MTZM^Z@/@_>Y =>J^7"\9W6R%\S(=P(]<U!3QM/"2
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M0]!O_?!XX$I.:95H#ZT ]*"4X>Q ZG-J8RT>0X#-9%W>71YX9%PUE*KWG'K
M5+R[K'HQG@>4Q!T\BN:E<3#Y)&H7AQ<EKV;;C2LN6 =I099,D/-R_V35,RJ:
MUV833O>5"K802V>8!LS>Q^X[YB:?GG-'GG2>F7($^BG9+I=!K)B\OKC8A=\2
MPM"8.)-SBZ/']V(?3]GSO_#66SA?>J7PP57?P[/,^X-U[*+%$T(W]VX+W?/]
MV(J." _3H\LM%@%,R>G$.TX* D:L,K/ ;,K^\,G(BZ)D5;_K/E#5_Z]V"-)!
MKO!C^X$;@5D2\7]B_XF(I,RB B39>P.<T-'A32XE,)<0R)9C9-E*&M>!==J3
MXG->"BV<V=O,G*_F0FW.+#";6 ?K8IXA8H]CFGMBY"WAK!>RYP8<AH];CK,M
M4=E*-H57UU-4[.1>4FD0S;EW^F]G_G*:610N1@FQRS$,WWFAOUG$\^F/N10"
M#QF$?PU&@47:ZK-$PJ,^6- DO*<)#MJCCQ7<?03N+)^Q8!):K<%W"@(/T&,$
M]?E]N/[7EZCNDA64X+KWS'<U#BS4Y#V;L4WQEB9H(Z6)^9.08<A7=Q@[=.W*
M"'0GV6)G7.(=RI5Q3Q$9@]@57T'LZTFZZ&"3OITW0&9OHW LT@1#!?B:^J\Z
M8*P+@M&=V9/? BN:R1D\M?B!38,7ZF<1D+T#%@'</[(,I.Z![(GX([Y]<P&A
MEAE[;H[ >1&!9']P!@;6!:9\%);/\)+"DN2DFS.82[;]"?0@I1!BK@<?!18,
M@]ZP/$-8)@IC:;0G1 2.0->4H(24C-'$+::LGB^>D? %RT'XZ@<('C"KML>:
M$[2:10A-X!;?3^5F)NT'GAS%[OVJI_YVF".P*((^\AYJ"D4$!@QL0FW@:"*P
M)]Y"3@3\2%>0M20I=)Z#E(?^U9[XMSTR&NM)!(XG\L$_@IO13A;=QM]&@(U_
M5QCI"%LEJ#L2 7"'%M]RA^*O(ET:B$#B-=0GZ)LF2S#:S43%N-EO\"BE/R\2
M[)[+2OTZLVX]"Y\P[YQAJCI A ?N-'A&C5T\G\7YC1,\50Q2U-M5[T'%;.Z6
ME-!'7XUYFIR<F.EW_HW5B]WZ;XF[5EF(?!J#E*$=Y(=03/KN]CIZ%8'CM^@/
M82%,W\59>Q.!\+<6WZ"O0/?T8?$+03JX4CQSQGOTBGAS</.!"!:RFX+IZY34
M7YJ7:CY1.%<SE*4:8#]L6P>>,&6/F]$]37P$U?CVC??Q5->=@%*5CLL+IB;;
M%[_4O7UB,WI4HWJ>7WJT10W+V)T1E9L?X'8.FS2KG,=X!&'GM<MG\T&#0G0;
MZJ^H+"C$.B2(JNP9;8)U9VSVH#BQC2:8I;"=9HY6?JXPF 2!5=+".,A7UIVR
MN?H%[OE"TL'TZ0^JYBIB&2BP%W%%1L.8%7*?&_G?F>T[*C4US;_E4.(R9E\+
M'$NA%X%^LAL.C%F$NB/C0HYCI#L@[%]@C/T(UDGGKZXJ6467]RP,TZ>FFKR6
M7O?&!V+>#[AYMT-?,49(XC0+L9D]^S5E6Y;=1SU>M;W 9LPVF973(3Y92@G$
M>5SJ"//^A&YQQV>W4.."L-X8\_DC2/\MG8Y]1,2W)T[#WPS5J_K'TF4JKM N
M506%7FT7B)NE JY?Z=)\>Y8G62<?WJ:"T\P)H-EEK][2>: @ZE/&_>;@4EU]
M4]U-<=''B9U9]X[HG68?=H/4CG5(<FAAII%>>0%-RS9"R;H[EG4[)N:7[&]%
MG&_\SG(UCIQ,>=;\'0+ 42C%HV8?:RC&=D^?KL" CJ7:GEJ6N_NX<OPUV[A]
M.L!%F3PK'I?4F- :R(MX!8LG0(.%\0BUX\AG@NT3-.&SV\AJ ^MK(G4-<2_N
MW*#4[&#73.YT%XE#(\3=:SJ>K"5>Q2.KE[9JVV8HL4KZ4?O=F^BT$KO\4B5F
MGJ#&("4)]=<!XWK:S&)F9A"I[:S4YOG$B8XYIU;X_0PH6(@QG2C.GN%TGWN5
MY(,?=3Q!)BC>&[*A/=/81E.K8#%&D-)9?W^;DVL'&DG@3YBF#I[S59U+N[ES
M4O(>_W-=>#-,B3 Z49,,GRU$4,:O[99YNN$S*A\\T>_^_/EL9F7_0C'7KH*8
M^U'5:K^[8G.H2>\YZ0<*?4Q?<KY?'?S6?!0J:RAB.B@2]G7^(7D'&4SFTX;5
MB:F94^C:D".$801]B[)+B$C=P#=E23O,[$R)I5M:]\AZ+D^+/V-WOW%E'Z5W
MS-ZYCL#\<'B;4_7>^\X3%#S=0M.*F]R7[;B^]0KRY[PD M>YY)]Y[W;BG\LW
M:ZOR&1F,\!B?^+!L<K7\H2LE?K37MR,HP<5"\:-4WW5\)D$Z6!;[^L T -6]
M[W^_91(]=?MUU7NE\[55C^^F&U9+--Q9$&4-+J< :-M3>9^.#1$!UJ8[A3@1
MK!<:QN4:?C<KUDYR7JM)[-&+Y(JPH(KV1&]#T-D=4,H R.4,\(T& _@Q&ODY
M\77RJO[@;$WJ?*\JO4"8^3%>_M-(02(0%AK@?VG+?,U__L!05EH#?6A],^_2
M&8T+'#)OQ;ZW"_+Z=[$LWC;[Z-60T/@$]BJQH]$S$7'80T,<9UI=O>58.:_U
MN*-P1OJ94X$+VH1E8EJQ]\P%VR<-R6PI7<&LLXVP^]"7+66S\+A]63 UL:Q=
M=,O^GG2I#Q[JMY4)KU:W6O?B[!-O,'XA FOG2J^YP"M@'9F3;^M.KA\;S)/]
M9*7+(D_N(GOM02O.C7'7O#_X^-;0KLA , 1Y-]UJ8&-]P]UC-N&2C>#N$[^7
MQQ8Y;[T)W!&H^OS=(61U0_"%+@\89X=0+HP/9F@U1%RX^1/+3Q0[%5D9^&$D
M]!UB3I,+S3<EL70PO$&TUTBCW,K(NW>#3#&K:)\"+FYU#%9C.>FE5^KI!:\V
MY!.X/31<0QK_&.J>B8B>*,-/;49 ]%N&?=RB^L8WSMT1MZ=X_@AX,>M/4<&U
MGWRPZ[-%-?*M<W5K&^W>\%;P=!3/VV,/4IZ59'J$/R]Z5AH3_PTRESCA9+CU
MN8(C>@=%%7"@/;PYJ%N&K.ZCMYH<[SC1+3[8J\U^6Q4OL= 7.X,QA$:A: @T
M 94](6);T?<5#-T,*]*V)OI>A]&69T9H:>L<X^(\8GE:89<F@D"]&L*QI8TH
ML<+98T/1G)*PH.7 ZI'<2:M;VN/DEB7,'P($'TKTH=S6-36$@\]CH9AK5PV=
MT.KV;MQ3]9?>2B$<#Q<H4=JY-22>^VK7?,'_Y6)%3X#_KEWZ'..:4LYJ!NOK
M')PQYD.JR(/<D>/"0K(O#\Z/5AY1ZKQTQX&3^6MX7-Q86; "OJ1) MTW[C@V
MKW2_T%KP8NV]@A)>5\LW#3K,5<[->DZ"SIO-;H,$Q9ESA3A&;*A$:L*A8-40
MKZ< 5>4L7!_KORLXHJ:.01!HE^8]V8)U!O)'<5QW7_2)#;&0R5F?/W_JNMBQ
MP[UY]@^IY9)&BX/>K,'H-0:P1ENF'0B>)GH'] Q=GT)W8L"@=A1:D"VFM^O:
M-:.SATJ-$F:J.")0CC-'EAN6XM!@'_5J<\/PJ??R;DO -;]TNIE3W6=KH%,*
M-&NU\XQDV/E9C_ 7N-,87-913%Z\K&:^P:'X;-^D\"7*\+374RE/QT+!KLP2
M>2QQUPV#8Q!XD+\EQ,.$>(R>OJW+/S-:(*9O]@T7XSZQ5&85,@6AN?EMAL%E
MS**@T,4=+3H7Q'=CWC!973TNIM#E*:[>>H4S+E*$,H[7S1E:W=,!80ZVJL1Z
M>P853ZS6ML5'C$WXU.S6/B?7C-*A"*P9G6AU=R^D'.LB AAC=S>M)GP:$7 4
MO5F^MG1E*/D<>]/]F6-5M8=O,1J.TTS7H-S[F"TF04TU6RBFK]E,[AF7)[9<
MG=)_H3!.(_*<2@\GH77HS91T-D).XP,V\N!L@-+<9FQYD_B\Z1;-_;52H1'/
MJO?DK\L77U5KIJ7=9&*RXS3QYXVC2#(KASI[1C7 VQZW2!BB@_PPYY.B#1;-
M3KZ[J);-KW0GL\7D<>^Q!?..:;XM-B@=$9A]#N.NZKMO<WJ8P#6.?7GQ9'4N
M>VV2%T6=<VI^?8S6Y:^OR:( T<M9(WTA'Q'D.W R0@\! HLD'!]M<L'L]W3Y
M<WPW'^M6OJ3V<,_MI!&O<P'37/?L(4FQ-L&<!3,M;QGX;)&-.*:PTUUZ3KL^
MWYFC0:/VQ8-%.=<,EYKZ^DJ'Z-<WP#T^)5+D]@)&SF;K(/@<9F)[WJF='LZ#
M+>S*8A_VV1.L'TK7'PH9< FP<":L9?:D"[PJ.LGVD--KL,F(0.=P<":  CT6
M&D*'..168U$ZFK_IX5[Z4??F2&[$H;S)]CIQS7/;AV^KF&L1 :HS6VG1:.E8
M6&5W;L%*C?^NJN'8,T^5ACN27C>O?&6<4K6DP:<L6_B952CM(6[ASF&'YJ!
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MRR_WGGP/'N#\&&X\\G:7X7B7:6GLOWH*A_F%(81P;A^.#Q;99N>YG '%1>^
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M+YVAN.C/E!?:*!B^-=H,-A7K@P48AGJ,0W27!)2O-RGOTFJM&;/+;O)6?7Y
MM]\1^$@E_V-JE&[RV>8CXN=\\$I7M*V::1=1ICRM&A X=8"T]I!'7M2F153W
M-)^!23QY\WJGE[C:AZFKR<V6)_*:,/ H!75MP[,''2H*Z[@(N2FK9<QK"2:
MLM[D(D"!M+4XO%A<KR#,3A,1+%[;C0V :7'DQ^(+#U0@<EXK_NX?[BZG:3!C
M1A,#I7UF&+[L^ZZ$4;W/CS#6E1O[?(4FHSE%"U!^6I'C+%DMP9/)TVOR^</*
MB2AG!Y[D\]?/B?&U4<:X<W4! 3UML%#_&:I)2XS N4)LRAS?PB!L.:WAP;:4
M?#U7N$*E8/&U&Y)I9A\6E2EY%P)'8^>>,;:_5]H]$5OH3/!3FUD[T)V=2<BL
M(7MJ_ZUD,EY8M;8N^>5><'%AS!V!^*6(4PEFEZS)NL^H:]^22]0_'#$DFB<S
M;5L$K;S)<]G0L-0]TT07E]IT"OFT(B4Y=.MA_1)7EP'H*?@Z[2R,(]@>\P5S
M-,7?+3O \NJEC-VJP:.-1]NB5H,"*N(WJ _'W<J%BHDD:F*6(N0A-%C(14S(
MDX+6++Z*:LO3I0Z:0H['9*)H-IV*^TP,G3WD/>1]7C9U7YN8<#'SNO;1HLW.
MZ= D7W.5&Z^S.GD1$,).7?S\2XO 5?-K SMX:UNA3NEUNZ<GO)XUMG7?4@F\
MDB'*A1 )4X/(>^F(1%1Q"4;J=Y<5G#E+?OL,3P#74DSP- ,FM3/IK72DO+)P
M_!7C&<.(5/KO9U0#*&KSK5_GGH@_X]B8\R5$- !Q=4!^ZAJ:,QY9.O_X^0[5
M(W39Z>I,(T46"\O7UTW?*")9'L?8\?C9<?;<O,PE;]]/I8L3F7-V1]<:'78N
MIKQHGR \-$<7YY5&X4%VFC=1T^!%@'D']V)[7W& F\ZPR&7FTEHSIC=M.EI4
MCYXRZE>G:!L"@L[[/-.3-HK1!=6++T[Z?:?^("<DVB2>Z_XF]"-= A]%QVY)
M\,LOW%9B(713I7[&HG4T12GTVPE!G_-!O>_)<;2&'-:=5L#X1X] HHSS6RFN
M+S@M?"YW"=1(G5OUKQV4;Y0\,:VSS2_!XQ/*]9(:S09<!)8F"E_GW!-)6$#R
MZ02V9;9J,#4TN#UI$LDVN/V^N2#%,/1I;;'P;:-FMP&=YT>%DI7++$;FXM>O
M'7:G/R9Z.8Y=8HAS_:I_" TF_R#W$];R?+W/I9@AE_Z**WR <  %1<QPKCR9
M^*MS=.=83E[JSC8Y/2Q>Q =0/"]=-^]08;R?'V/H='9(X<YQ*KN@@]-+HHR7
MZ(M[YLQ%G]-9>$;@%+)MZ)LE.C*TT_W8BNHJ7\9P*6;EWBXZK>"ZTOUF?V-T
MY?.':?3*2.QDG[Q^'SUSF/']-\FGT8@,43(%'@-UUP\&ZMH?9BY5IN =FH<-
M3GI^N&-&R1WU77- 05**079;:ZA\YZ/,PGB?"T\'/S7UL"!%HJ;IP!FFY<"+
MZ7,'WM0I!==<;M5>72L;9(>&A9K9?]T02.;*U<M.TE>[+>K@*TC)%!BF:BKZ
M_/ DE )[MEO9C)'6^=+)WAN/= I:&_L?ZM=P)#T\K1&6E46+B?#[VIK%TI],
MJRM[OL&>S"KA"<\M+_.OSJ]S+['T& SL/)-U5^S1&5JK6GX@.SXYT<,KI=MV
M\AYP&UA1O>(NTM' $>V8["YX=DB^.(_'QH#G])PC?\2+N)%2T-(/B_&*_P\W
MEG'G#1"!!6@A$1AKA\L85__I/H][*GT1J*_"740 Y@_?-Q;V4^@)%@9[%BGI
M_8-&L!MX(%'Q_-Z_D$S1B].0P_2 I=/+]TN$U&;34.T!\R95(B#T8ZSKQUCM
M04Y#<3#U%0T!PYQXU*E"8TO.V"KC*I,!/2!32X\EOOV)B=;W2)-/*A#!X& B
MD/(!"Q9 5C>A.SFN^X1E>(#;?-^$^/[D!?S+)BI??WF_W9>35YN2==N8@;K,
M9"/ ?%@6=QEC<#L8ELOX'4EZ7*VDK6TD_V*S@W)1S7Y5 R3/BYJ'&486FLKM
MH:>3XUFRYOYBH';BI3DZ,72,X,3 ^-MSG- YEP .0C3?;P,EP_M=C'O8EIU@
MHUT_54+PVPU'PHRKXH$9(TY2F@+>/Y_S\\D@$9PD%/PX!_+\^"Q=:DL$EM '
M7?C,!"* D#U [/$!%DLMTM*X:P@^^$>6;2)POEH:)VD$<LUD_^*R#;Z$C9_%
MF\Y)QZW?##;-G;(VS)WJ83LUW;FQ=N,Z^YF;R4:N$PD"T54QII;E19^[KLL\
MS%;6?Y2LMW,W@7Z7!H;MV3M-!!YW]1'"^8)61=[#5 C=(5*8S7 ";7-:)7*Y
MP7I@1$J(:<I:AR=5@I,AZMA\>%]UD$'P9<R)S3U>']!=GEND>Z%KI)G/*BQR
M&9[(7$D(KJ6(*8F,*QY,,920SX0E];OOYGI67X>WCV*D\0S[T@2:KE_/-UNV
MHG:4OJ"P$-+SS5:(JZ!54([I1(,#)3XBH)'_70[N64UVMP0!]MTELT;[O/)0
M'"/I9FBPQHC,G_7<Y_4Q^CF0N\H&!;$;@(W7S>QM2]<_HQZXQB\+PQ8Z@EU*
M$OQ+UXL93'43V*R<"PG_]2"6T=6MOB@UO;RW+OD!L8;#'D_F;:F:AST6:*R>
MO>@<W-T1JK\\Y/F>]1NO-33D<E[R5-4@+J'KD:E?3++6Y(7RZ/K6$P/: P9:
MQR#DN/864/^P+OAK"=(-)[9!"#R+Q$91" 89!9VMN JE"^%AW(_]1 2^I):O
MH:PNW(4MM,/H-9:'S EB[JR$INM@#^!FG+I;+J*#S]-@@+<KY6N)=,$I\Y+&
MVQ/BT3QG+D=<TN1WHL[SG)";[<&SHRB(P-PY)R+0(Y%U><4;ZHM_%^BO"I&>
M2)2J(P)89V38S(X9#HS'2'80.=X"(M"A%7R4".14S\)QHC=!DD6=RF(<<H-!
M]5D6*33-(42 @1T#(\3,@%T )KN2",P_@H-,H%DYM;\S23N9[L$^<>C8UDZD
M.%5[S6 &$-30+V58$2) )P$E*.O@Y)W:$O<E0FC!*CVFCP@D&*^MP 7I<U]]
MQ1=-KEO!2?.>X#P-.!]%FC>!=V@'L_]I$?X/R*^H.JF$/L]JGKLE\40@*@XK
M0P2TW%K!6>-K8*R]@<[E:AR&#UA@H 0V,SCN=J*3:>5!V)>UW2 3]]UR*(%;
M:18%HD0)_PD26*5'Q6.E01F>;1#LI7&2"/5G1HOP6QN-SV*0ZF*3=TOB_@D-
M#.L,>A7U1RASQ_M("%A_>"=2?<,--)/=*;HE';(/E"*PSGV_P\Y HBU]9K ;
MA542>2!_;0S=$V9Q.F+R4T!4?^2;>[+!'\143.$.^'<N)1N!YWKZ]#UF7.<S
M=Q.P4C/;?Y"0!RJ5B)7\DU(VW84@//(;?I9WB]\T^91+$[A59VM)UOX6$R1S
M'_XPQ0WD^HD8R@$*FEO>^*Q\QM4P:Z0;C B=7\Y-_(4[PP$XTH-+_1%<6B1!
MXG?!!CP5W]&@*EGESGXD&NG<<FH@9P2G6GK5;>)"5X3YA,,;JS,+O$SE$<5M
ME+S<3[>NR:/71O-IJXQKTF+.2$TH#@YH'@>W;&,M*FHP5[38 '>V1>,8=V5G
M8$+,[\!8"_B90H"*PN>7.'$HVA8-/3A42XC5GTIXB0/M/L[(3 0^:J%V+"Z_
M5.QE<V>K,CWSD^44-YO]X#K;D9WJ7S*NTE:9[L:XJX0]S'3QBQ'-:XLBK<@N
M%#5P<4*L:C_/A-6=Q\4Y.^ZB*#HMYB&K<VZ,A2@9%C]$!!K@J5Z[>(F71"!-
MFK!<KC&3?WZ?X:AH3GS>\",VDW6-1^X:CTBW08*GKL)2AT83;=F1[;%UX0.M
M8!W,D6+?G&!AK*=(@B^?5-_Z_OL=3._NJ+.F&/<+V2<.QXY^+*L[?,O;4$22
M*;-B1T+;O$R@6&%[;,WHP ;><37 SMK05"?Z_-;%<*$;NSR&W=.Z"U.+#1Y"
MX8^N7TZ)<U(;:PE =AX%RZ.H>K3A^?67@R<+6C*?!E=DWX#J6TRW#2[.",V?
M+GJ3!.-V@?-!W8V8%"K'<2R8*D4EJ48/H8=U"8J"AS\VT]R['<"GXH>L23&L
M^WICNSTS/OS=US;Z1MYY]<J+!NE^M)_Z)ES\,IKQ&?BN.TK1!#%7@CB^0,T(
M0P0,JRI2.FPX!\HV% R&FCZ5X3N.1C%ON],O2LC,(I[<84MKI.C?>2&3,> N
M9;21H34D1%B7B"OA:X1J9M@G/5JU.7[@$$!6S1@1(KPEE"6Y=31<(RE?#Y_N
M]'S&P.TS3(Y1]&5<U),G-=U,"\$]%$+,DSBJ09QE/HX>8UV;X)@VWU6Q7$$$
MG/54/5+NO";K\Z.[S+K"H)%>ARQ+&(WQ,M6KZI<1FV30.TRM#=#M^>\^QM<(
M8*%;L6WPPTTB#H6K(<>&JWF<%1Y(TU?YG7HK('J&.7I3U_W34U&*8QL%Z7*O
MV-=+-)Z):PF[&N4WU !%1*#2GD_+L.=&U)">C;O=EJK%&-1E76?N0Z:#XS1_
M/PYZ-+\$UJ#\S*,P*8(IFZ%:N\M1F3(KT YAX2YU\8U+,V6UW(NK<]+]CF5$
MP+$7U>[6B7)#DD^N( ZI&2)7-&2V:"++J@Q/H-$#/CQCU9)W:K]?Z#KDHN=>
M)"A"<V?>[Q!'TQJCH9%MLD!TEEBH'E(1G[:#X%E&5?:%S6%C_14V8PVS@PH;
M/CMH^SF;G(M+OQHCP?I!\X.1 GR^L+N,8U8IPOV;M3Z7@J2Y2;TA5&>@3'?[
M&WWM:=TA=6K=MWZ0>\+/UC@&EP)?IDR$T_*5?.Z;L)M7ZH'<@]('*Z'?2D+:
MN3\4!MVJ2=\_?%0IG>6<A([0DYCS3X*[M.+"](^LMZ)K4?;0B1=]NU58;_BN
MSM .]'Z&*W-0H;R1$'.R;H*]X5R67,*9X/ VM3#+6(O83$O^SW8"F3;6!Z>Q
MN6BC3@:ESL#$!$2'!%5:V9T\"\WG'S^=71L=:I*6J*KL/=5UFPTXLV*D_XT(
MK'W?R3%(_5I1=F5 S]Q7.LTU/;[)."=8!A-2C$YDG>DI< Z\><(M\TD063_9
M<,5IX(C>,;JMS7#4T1810K^)14!AQS37 $X0\\8EM*9IBRGMKH'I/0TN=(S2
ME8A3-&XRGE;,9PU+POWZ=P?S3,P?8=WF([L16RV;<TJ)[FOR"%:K-GSV<YMQ
M57IKBS')]FBAO-<5M2<NGEW@O:4>9J!X<3BC9K9:?,#H:\+:E:*=/2&KR.<.
MXN)[0\*0=E?%H073[RY6=(^R]4I@MBD'U?*!5MM:QR)*O=F/<VN=S*YH.\:<
ME#7.UIJ_@-!WT]8*[CH0)HSP*V''#S2#=;&>Z&=*'5N36$,/,XGW A,!-OXQ
M7S336 R/ >%/CV15?PKI@[.UB ?K;GWOM!;I@1W);.<^^N#.@O-^N*8\[*;A
M1K.]D$'J%?>MN9";IM7E$ED]6C!W%:.-+4-K#6VH7\&\F+&Y_=!"G'V9#D-Q
M\AD9K=90NQ/IKQ6V8?%0MW4#&/YY&8$>=VR@"N_?Q=08;VDY>@$QOA_X_!WB
MI+U\9"#DB3::0UGD*,I9>H("K;.6RQ^-AG(Y[W/$!],$W:[QK[7AJ\QZ\[7[
M;#UE7J5^0N$1ZFMW !8Y\S==WE\0)P?WM)LL=\/PI?+2$42 .EAX/O%(AR>:
M$7M!ZGK5 /=G4X8BV?)-17\@];R-+H5ZW8H =F >&3=#W<3LA"Y::SH^'R^9
M7QNSY]-H4')-TNS:%;6%=X,/['BB0I:!C2\,=)+ASKOO"QYI&UY+YGMUH^42
M_A7*79J%\ YJ6SW4PE?=CTK6+?,MLUFDRGL72CO.>]/>=AM^],-3QWQ7QG,K
MGB>'FG*7K1"=GC$33NWP4'\8BYIV3,UNAKUYLF7[9/!XWA5:%J=&U4B(!8;/
M=+=UR^E>L 0FMJ=%?D#>#"/2R764PUI2V. ]W\)>]J>^X]?&' V8BN,+ 8Q8
M48V4_5VCJJ&(\R-$H"+*5_R<X&U.GV-C;XZBJGMB6D2#M;'5<ZC(C(OQ7C0=
M>$7+M)2K42[V(QYVMY&';84T.=^\BE)]=>9T%_-%2X9&B)%L:AY2 I\&=WXO
MLIN#M<@2J:@DO!M>=SPX45CH.;-P 8"*;<0=T50C7%FM&*^*;WTO;9Q:5,:X
M5@]O<(DOZ$5UG&$K*H&3(O-PVCK$. :((3WZ]>>[];5'3H#5]'$\E-#"NA<#
MK&JP@!U?.@?^[A016#Z?^G&,#Y-..%^'6MW8) +Z0N7=8>2_GOWYZ\$HC-G$
MI?#I$#HX$/MFWR[.;,34S\WLG5!)Q$=)0W?*5IZAIMA'#&9EB[=8C;78*^ZO
MB.8D X42[@4#%Y34>M ]:V-ST'CN;P45I7U%%C#+R5B34=D<ZCBY4Y2R2F?7
MAT;K4-CK,]&H'?8Q%$8 0E" G17+_^3VH3A]SLWP@]=%([^[DD<$WM\:SM9.
M=<QEMT\9D.KIDSB@PJD3@>?E]40 #O8:\SXH3!N<$?Y%HAP^@T5AI^X>X8X?
M0>PZLNZ9HST)54O0[3V$&KSC#UQH$M??1GQW-%:43 EOVXF ...W0F6P?WNW
MMT3@E)[;Q%/YSAP0 ;#8XBGMXP[ITJ# )(8&ZR#'9U9EIUPR?+L6Z$\./))*
MJA2]SF1O'S@V9)M8YHWBL*>8G4EX<!KR,1VQ+UP2J.QW5,%6M,M:8>]IP ?!
M]R6V2Q=]+>-2#.\H. 97'J@1WH4P8Q<Q_0&)%HW#99MV36GOS3Y<OOPQ^^JM
MWD^+?8$[BOBP$/X-T-,%S;^I''G CW/$B'3,A)?E8Z,[:S*N;+N:7CS^6%F5
MRZ[C5F$=-#6()V08>BC<>[Y,Z6L*$7A0WF1S1;_ZCN%0HWOC>):?>1<G[@@+
MFZUUE[!]BID>/]CZ'&;$?">$[7_'$Z*)0/S 7P?&<L'"TSA8@ AD;QKB\G[^
MHE]4#E8+[,NF,_?TB$#GF/2NL/3>=ZP<R&RU#=FG50-AA,Q]QU-5;X(P@K4Q
M3RZ!DX,TX+MY@"=]1FK_5<A@XD3L'!,1>/)K%1<B<&.0](MCX9#]Y<=$H-\(
M?6<!_E*ZH]MSC\XM$K5:!<-Y-$$[9AC7-#@)8P^Q3@9W'"LKCW4/G78Y<G!]
M20A0J5B'64T2P'*1EBMJAL^E$$,"!)D&GK(X T)6=UL1W4PKHX,!UG'VKL<)
M-I)7&-]^;\$(YM\)>(<8_ZH?>0(AVYSR<;\T.E;X08)XFNU]D]CP5^[7FB7=
MOFDLU\,>XUT9"NI4D1-!<RP5C/-E"D:#1H03)3_0.O8/M-R60Y"68 /2]S:D
M-AK5W;(3>&)(>\C&%^S>M#!P0G3S3S_E$KAC9XD GC'0<U&$]!N)*Z":2?AW
M<(L.(J!R,/!E.14IA\]!.<+H0H:G^09\X.RPE7T?"\.W4YHG$N6-ZQVM\Y2>
M\(3))(PHX10XVHC /L1GY@VHT5-4M4@[%0CL]D^%7(L'RB[JWXHUO".#=SLR
M\G1L.A%!^NT^:K#7==U"$:C![N.K))3 QXAQ(D0A>>&S#N!.(S"& BV[''P<
MM.S[[Q["C, .0;_<'8*+0;$9*[O8S4W6;W'0;60S1 .DSB8<!OTV,@_''0:[
MTP4+(ZR/3AMBG[O)'6SG:^"X6)@F2'7E!UK?_Q%;!5CM=_=;U(:4E"?D/I,A
MBBUL9GCP<_@;T=O2H%PX*)8!#DKUQ#'\0RIRGQM'DII&DNHHGYEJ;7G[Y:=#
M&PPZ2Q"+GM6/B,].1N)KP6"X'[F/50"C#A:/PLB"[6P2Z?<ISP=S@RH@NV>P
M7& 3U5N]"WTZ777G_:K!ZL?$)8?;Y3T],,P7>#AT1R%@D@A0G"0">T<S05&1
M6#E0E'D\Z6ESDBRWM<33^P/@BAJ-#PB.1B>#(+PD&$)^PN#Y"P;H7#^*&@5B
M74N@'B=A?3=I28'?VW1_5W#OL85Z8CSIURKA8)?NMH7\10'!?(&&0W84L&/@
M\C=)R[?T;F<DJDZGCWE!W_6\YN\!VT.0)HP(_%''1*P/I W^"_ ?T-B7]JB[
M3'L1OOTOVMX[K*FNV1N.HH B(+T3E2;2D2)%8KD!$3&""@I"1#H(2&^!*$@O
M$5!00"(" M*EUTB7+KV7! 2D)I002'LWWL]SSG.>\Y[K>K_O>[\_PD5VUIJ9
M-;/VS/S6WFN-7!$6\3$T<YPX@9A_@P"F!\"MXQ^V-ZH',+0^7*AR5*E;&Z\;
M>\;GAL'B[.-%YWLZD('\#;?+_J/BQ9<1S8\QFP%/$"O'D\?PD@XJIQ4:.[J8
M:: 3KXZP_W\JV &!^0GYYVC^T ]\NZ/B/P1?H*QJ-412O07CU^& @"ROC@#P
MOVCSR#+7CG:O9N0#HR,*_&T::!JBX>[C5"'[PTV1@_$C=1W1/XE>>7ZDSS_T
M7]! Y0QD]F6,73/J%549_R4>"^$Q=_07_B"S4:]:95S(5!M'%UIEI#L0&A0L
MW;MF84.R5'"=X,%645ZZ0++-I6W/C[Y^\C$5]EY9X"HK,)A@BW8()G979XN2
MAZ"!,IU^1VKABU,0\\FH;5M_"4HH(/>N<Z",Q*QRF 0%&U20^SP,P+$_[@'Q
M,?@&$%@_':VAYLBHI)6#RO^Q0TU+O05717ZM"41R2VX::,#!+'X4'(I>//]/
M.)U$_XO3T.!HWY7\69_L+*'?CM<N?HXJ.>VE\O'Z+>"_.[Q "!8-U?H _:I]
M#J!O=?KBYZRC*,Y  W4#2O,< [L.UK$>/*.!-E,6-@X?0#]A'\%2ZI$+)AO7
M/\$9\?0?LU8G5;+S# )<7-CU181'CE7.;S[UL*AY6%Q^5>31.[%ASU2A&P\$
M'FX6)N@8KC#118V^SFO_[&75*]PYA5<LYD_X,B+IWEUGHN4.(UZ$!O>3NR;W
MEP'N/#<133?@W)E4;>> G1 :*+KX<T<H7 FR9#Z(P-'+4<5#,#!F\$&R)XI\
M+/K((^NN\<H=$*@[78>-&M2@XNKMK6!4!?TK_$(K?]*[K)7)I%29V.IJ/[D[
M 8^XIUY51/;ZKP6NYEME_.;7+);]F/WH]_:5R7ZGY_%)PJ]S^?(E4G;R;Z=]
M5=71+%V?Z3=Z[:B3\M"F5_;W(T^$_[<@4?CM,J+NO ;%'SNKO];>UA"6ZIA1
MI,Q4=? L6(PJ8=OQ\S@4-%KN'%;\ >& '!]K0Y4GQY5O. <I3/OJWQ[\B;!U
M4/&_J5;Y)D:ST7$ZP\[%[_OW>1\)+J=5EZV?J^AGZ(G6H'ZM4VC7LYVVZ+-P
ML\N.AVGR\;6<?<8G-[OYWBSN3B_CM]#VR! ?"%B+=4V8L0QO0KX0[QC+_F35
M\/IR(GNU;<RQ"R^F;J3[G8@1'(N',U BEHFZ=@O9>-;67K/VE/#(\LPLW3P]
MNJEI!]S'J?H<AVPUL;=[X!?&T% ::#[=7SP: '#A&.W]N(J W1%E[9',D0O1
MG=R#.8<EYV>;DF-*9':$=0;I)2?WC23,3#MZ9C4I'X/4$$WJMF5$)$9. -&L
MAY$*>+\P?*%JA_UJ3-.-:;/+7)>F97^IG0QC['.:#I+WG6I+5P3NBI=P)9Q=
M3/$>F(5\:5@Z]->[AL+%)./#UU\&%B_H&89MBY]./37OO+#424"=I/9I :$C
MU/6++QV +8T! 6.UL*<2N >UT_9/,>6W<;5^<3@3P?> ( %BU^7"H,J78[2D
M'<&5YX:T^%>$P<1\^GA,JS$NO?BTOFMV>5SVEWAKW['>IQQ.]!(.EJ\Z55(D
MC%#K EFSYF078C\V%FJ"9RF>AS*NFKRQ-VU8JO"1R?SK6U]!'5^/QS%&G6ZZ
M\OD]$>$\D@;1F6Q(4H(;$4/SZW_GPO]*?8 _KNFAQ_G3[)*F=U21@/M&G+)E
ML#POR\BRUBEB!3YZ@;L&BYCHP.H&>Z)"Q_B7P[/2)TDME98)7=.58S+\/3]N
MQOY@M&GQ8E#>&\V9=W/%A;D>\W4_O,HN!B1'I1NR7ZI4I4X$F;SE_;(G ]C+
M/M!^Z5<%N1$SN5]ZD$]270D2)6:3N,E.^"_%>)%VO3RB>5;MD-&<Z4<VT:AQ
M_22-*OFGWAL2=+E\3:<6#)S:3??)'"W-<UQ;C2+$&O)CFP)F\9E/(UG!YY\7
M_:#[^O0'F6Y)3:;#HN;0%0-;%RDF2Q)Y\*R8I%2\\:BS1ONCQYN_<&/]+MF:
M-3>0%1XU("&=:;N48C_ B=- (YMH&Y)<< XVN_8W=^V08\L]84'*@N2)B"A*
M?EG"5-D0G5"WD;&/9=>A2! )@XRC@1RW0B#T\/M?R,:H)K#-P/J>&K?0>1>;
M:K1\J,-,SU<6Q2D3UQ.)8[SK2G-@1(L&$7$'YQ.Q03T/OS/&KEI7AQ=/QJ3F
MKVQ:Z)G7V.]?.BNO0O>=;K0.^@I((;<:F<EBN.5@N8IQLLZA#'KBPK#(-Y(X
M\2U*FI?<L2A[3*.FW;=H:D/4I\!LI"A4;"QO 8P;J96@<!1'(8@W84?GG*!Q
M(RG !504ZN\+7!M@1U=3K>'9\D9ML"+<GE*CA Q'L&QY"4 9B5/7A\5]-V0J
M6-E\C3<'1V<6GS8Z*471O37O$SG!/16WAX-U ,DQ[+2R:^P<_5[_"4?^I+Q,
M7[>-(N69N]3>S+JZ:IXO?LLO7IB/L_LN?.(%G::\C2/F+<>O."VC)WD(U\,)
M(<01')#Q,/G6KS!C[A]3]QW2[IA\[2/\@K*<4G>YBS*Z1R@4$<.MWXR>WH%,
M:G0<[L="G)'!%MR-(Q7F D"N&"&=@8ZT3#>_*K=D_2Y*[X)BJ<B^B*6FBZ#'
M(W0I(GQ3N7BR94$X0[P,RPS#T$"OBS>M!O:D"ATWS2Y:LY?(PP>?OY5^'H1[
M=CRC7TT=4<D3JR4Y&S0VRS,0)&A?*]$:7HKK24;CPM?8I),(O[+']XVDD?S<
MYSYG3-\Z:%=;0KT.4H:_P/='R:'M4!%!QP:#.'JQ&Z=W'0ZKPIR#S-7^<FTT
M_NMC_*OV/B%&.YCA0X+17U-FZ84D:2 1X, @VEPC4UKOR%(O./KLGWVBTRX9
ME@IR"E!ZS''F>('-VQ"R]JN#_ 7H!,P K]KF.J&[@(JH0$<TRI-@8?,DB[0W
M3AX7LG[35?LX3[U_03\S%5CV@W)YB,RI*85+FOL^R]\0?9O;],9O8Y-ODY%)
M,J5^3B)_\=T$8T5$)!K@8[AP M.8%@OY//'=/+,J-KN H*5<:>;G\@4WP.K4
M])A/=Y+J/)#PB5W^A5_3B6B3.@2NQ<U;RZ^Q%H^(@LRG$&@@K@IHQ*Q4<NOA
MW<_2GCNN7_6.ZS+6GHT7;S[3<[WO@(GM5;!:_X"%$ Z"1#OU3R#G.R)D@BY-
M$U56^T9<Y<3##7C8YRQN;+!WGU?,/7^;>_)!<*OJ/05!2$D0VI4D/4UF 1QE
MH>,D9^VG86X2E:W@=AZZ1\%JX\G2-0%O7S[>8E=*.I5SFGR2J)KA2Q_HI:E3
MJYL2#\M.GE 5Z1H$W>\)NNY^N0YU_;:!^\H>?]R7XB;4\348BR87-Q(+X;7P
M77NLRO'DB9//@!]4TOO'O=3W%Q\VSPNZI5^&B5('^*-]<ZBGW7"J+>KOJJL'
ME;IMZH+Y% <^O#<0Q[$*A-SD$2%%_X:]*$"I./VB@:8$,!9UKG@F#) A,YIJ
M97\E\O_2*?S2(GS@HH0]B,^T6(\:Q ^'_R!5*_#D_BK=0 @7<6E"<<&J]SHE
M8C[K&/.="(S:.A=%A!$:B718R'C'PDED!_HU6T5QN/!R4&9.^ZG@/EW7=-5[
M?E5OTZR(9KP=W<A"JKBO/HR2*? ]79X8B(?J#9#5LF?$*W*^V4,F+V#G=44#
M4FZZ@;N_F0BH!+/>?Z.P=AB6ZHQU/=7_B9C"9.XR2!A;GWP-I1^7]9$%[UM7
M<NXT20CG%&HYB89V!Z DR1KX$S !B'4 A+UI'L7IE&F*U\G,%1)IKAT?VBSL
MGN[1<ZC_475.@K>S[WH'GV KXDP?<'-Q0Q9,J(+':*#.=WL,WQ&OU>W62;@E
MN9,K/HDSOXWWDU55VN?A^*QOY<&*B&B7=;N\-A\L?F<T;]C'M?J=LC6R!S;E
M3C+"H;[#&'Q56$_YHIO\==!8!W%T=)OZ&"%MQ\_PK[/2Z<_K[GTXQ12_<^.N
M!LJ1V(3G:$=\0VWHX52;9@7Q#PGYN/W6GX]^NV(H^M9Y(,7L4OOIBY8MF:PO
M @1-!N; 6O1$*T("T4?N=;V1>!37VR>3,-,W$N4?KS-=8&=<:66;9I<*Q<VM
M)^S/L=6S+<A%4)5=A>:(XNT:,J<9/2N&,!$97;WR[+=LDC-^7*JYYWV8UEGX
MR+U\5S.1>CHO3W\>Q0$_B7?Y((!X_MM_O9?NAI8/WZNH@,5/O/M:%>M'&?GZ
M\@(R<DY "^S;#6!:]B)-N0Q[9Z8Y>P?I7%G"'5'X)7GC6?3Y65;AS*B=XEA^
M1DHIQ%'NN(.I7MP.H.$6O[E[HWL14YZJ/#T_C'L%>&UADCY/<4*OFNBN[G=
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MWKBG6U%01Z*H+U,I*9"R/<@APQ. 29G%1V"F"@_]4(,J\+ODH(BX/]T^4E!
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M8&ZB+8<ARWT(0-T_<W-ZFCM0 O_1-G']2/[^(^+^7)P>\J7+_]'88<X*#2A
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MFQ#LY9 (81&\2_3GBK:VCM M'NBPN'UE"R'X59<(@NV>3B"SK\EZ-,G4%[7
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MJ&9P3\-!1M92-!9?^\XR?B@$)D;M@9P($J&V4:_@+5Y9?>I> ++YE/5N+X?
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M//AIOIG1;E;=QH'>IU<@!2"2U6IJG**ER]TC[*@=>OXM2)G4@0.SHQ0!O--
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M3 5+RO@W7O\"-],JUGEI=%KGU1_=(A'!Q;B^3S,VB#F1>%:(8:25PY):!=>
M\AMT,PD,CL>-]<X2H2WA"3+3<$8_G @$(' %0#^IEV?(&)]AW(*Y0+%.\ZX8
M!Z)$ G>H;HL@\&32'R#'UFJNU131<++Q3$8JSI-/8[:<]>- .?5O79?V=YG7
MGL6VFBS.O6&W[<;GMI"NG77?,UAZ/^&A,%CRV-,%P*"QP&EF'.) $V)FYO,
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MM0^,-)70^%&TKSWBKD<".A?EBF0;6]T7; "#O/6DIM#1^T+3=NK)0O[ R$.
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MOEB)H6KW['FVPE6[-_=UXK5"=BE#1H%\O&/IFJ139'_73YY2.SB0:PZ.=;'
M/R2J?7548\N63?5C9TLLO-TBE6*CQ[4) E\2?]S$=1\"3IGW'(SN%P"","_P
MT#IS+5=$NG3"+'TOYHSC"H(')^!PWP]4#D0_!?MC)C9I<J!K+=S/)X)SW(1D
M&3CGTB-(A42IY^(9Q/;205"EA_M6W(%+!7T$.- S<2P+_<8.NF'"GPWAP]&A
M4EU#VBWR\ [F5[Q9 BOUIZH;LCKRAQ_<K8WR@W[04 593?CAP5Y4!_]PJ>%
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M;XB?^-";YTHWVP'7'H')1.0CX;?C+-J]G_:?%"M4>C/2I!^J.8/0=L->F;V
MC\T *6$RW'$,.-)].%8 !_IJW!MXOB?2-GJ<+TW\Q&1Z&"+\ O@2(>!Q<.QP
M#"4-I.@QB<@^M-]XZ5N&W9<^,Z,A[2@UY]@9I/,YT)@ 8$^;);^'U"\-\DZ8
M*6==^U/=_$O?=?_(*N$ZN"0[$O'',_B TXT#Z$D3JV:P*WI.+3=S*SP1]W\#
M6E?W<]WK/>2MWO6,N.8\#-WL-4C_]4 I &;J41(E'03$&'2/* "J[N"!D=]#
M5O*NZUTZF4Y A*O($ZLP4WW /X)YMZ07/[U8@ D*N*]&->(='S]?J1+R\L_#
MTLU!D*X]/*O$WTXBE:X$ G1;C5_XHW3'P(5#W L/?/8\@*MFCN\X3(G*@YQT
MJQDN)![=_6_F#G-=L$T-2_X1W+\)-UH#M&-=\3Z#KS*>KM[Y@\S'K\1/P&*\
M3^/QWH]T=WE'KGX7VW!(MO!$^NU"\8]PKP1NM(4#'7\$6*9Q69X$+)OT$2YZ
M';N&[B8*X@HEO0>(?8LKMC>NPP9DG/M6<B _>'J"T=6V9P;.AH\EGPOW2\X,
MR2P4ACOH0 %=F8!KI=-NAH(+U)P]$.%ATL3*&8UC6?)?9[J1IB=RN]H,%":V
M:?:J-+[\OJHKJ@F,^A4L>[XV>YH##35T4=:]>@-GS>- ;_!L;UTGYJ.\B_9E
M^+7QWYGG/1=QH 9^''N-FJ^7QX9VO^PQ[0I^0<Q(]0\9G\]W+8D[7./#J"%,
MOVQ:@*>$3I,UO@OY"D\.E1;IRJ\\1KY,J-T=UEYRPJ4>D[IG%-WDE Q(P[](
MUP'U(/CI1014/2T9;E%J-=<SMZH6:S^4AQ%A%I &,S7$W5A*G@'WS^H4C!;_
M#@%TW'-('?. P?$B[)D=K!8"5%Q-M\1%J954%8\O$#^1-DK70,T+W4@/C^KY
MKQZ]A(LOJE9NJ%:I$L[E0(N6DB96S) #EKEH'6D<^8W>TD/R@A87N+>,_="T
M)OV'YW(\F(@S':QS;ODHTA!U2OBK_/EM_*1H>_U7 4,FLO(\!F",MYY#TQU@
M6)\*I7 3XX";!*,6X'(I 97O<*XS&/![T>@[_*V4]!H;G"'65;VBS;$[].W0
ME273S)8SRW5-?T1>NMCY3+;NL=G(CD1V>!M<JD3G18K!O-!2\]8&_N$S;&NS
M.7OTJWE'T\<VQBF7'9Z,'<W:ZMG#&(I_)0?"=:$R#UY8992FQ"15O5"U=BC!
MQN+OW>9:(Y%R[1<,JLGEAG_)QJK[Z7+F),.?L-6LC[7A(EQ#GU,E;Q@"5W '
MLK%=[6-CZ?@"+&#$%5FQ!]?'@LD9Z&99&U[#-929#CYU/]4.XU$K0+?9$_N+
MA/;O4-:?WKZHXD)]0Z'POT.AV^[-4K?^<$;ZH<SX A<.5+(,W2QK=N"1%5ZX
M/CI,)B$%ZSXLM>E\<&B;%1YH&DA'9@C,#NYAXC@+-PIL\3AQ.Z\H:DIO2!V+
M@33:;.;LAFD 9'H&Y,[IA5@N);A$4)J%$)A3,W0>X?HFN'043XMLE[P054I)
M%1@16 E\TS9N?6Z30E?4Y$"1M? ($:#))<ZGN_S,QHIDM!:-N9\A_'1G5VFW
ML%,,#EU6'!5Z>B(M@WX %)C$&E;@#/Y<7!^%BU_TX*"M5T!S6)4PJ!H761/'
MZ3.,$>C[0;)%+ 8^ ]3;$XR[0&VGZWJ7H%OW*1HRV)BIT5EY_^H37FM1OGV)
MX5:S%M9&H',PUB08'4I^(#P?5_B&WGVV0"6H-R2Q-H+A_C$#@Z<?. VHU<U2
M<]L8AZD2<A4&J?ZBL[]T1?@3*/W:H[5E4E0K#.4F.@!Q")L#<>UKUR_V-&M?
MG'85&NG,ACN6_1H ,,XE&&D6>T;7B55!VWV*-4Y:DBF!*!I;+IH![>NG>1'<
M#-/U>;R2YQ/:Y*V0%8RY8<&R)+;_XE[Q:L5WO;= (K2-C.R9V8QN#:X/\+ .
M'?)+"Q6Z!(:9&=/=Y _-^&L/X1+AN>7BPHU.XJ*>$]\R:3$7^#D0'U.Z_97Z
M6KKO:"&&?OF"6Y:.+7_7&>\D]:ST] 75G:&=V:2.53"#B6ZPC*IV)?>X C<]
M83,O+-_HK5D.2P(+Q(#I?5R-'<0C0%G4&C#0&J=_"IT3S@ JC0:6WC+')IA.
MP]RMZ3PT[.27* <!_WT=5$ZSC;@.09@Q/4,A6L/.%0Q*ZM\Q*(-!R6"Y<?6]
MQJIL;9D3T# HM,;!G+DS,^51A$-SREBP6C'D[-8+9J3L30@UV;PD?;E?"Q=R
M@$P))K'8<!>1[1UY F.?K/)QWMF6WI:1==](/]* .S>O7Z_,J,''T_+XK3ZL
M;CM7P031C=7"CI/$4:8,;_ 3"UR?YW2?PY6\>VEL])CL2?KPZ"RA7N%DX&/G
M'>?3AD:$,S9MD?Y*I+FQG8@L"3 ZN /<??):5GD+G7%-E%\6FT7J$ $"8[C;
M$H;[*'9<H,V(=L!AZ?>2!UO3L'0MH%(2JE$,)62.6XT+[5M/TDA@ +]8XMBB
MFR\9O_QN@>RMLVP?+SE0\YGM!-SBQ$>3H1$;/;K+E[X1''=X0J&/;3+?+>&_
M\/P?]KX$'JJV;?Q(\I3D*:02TVJ7%I(LTZ8)(102)JF01XK*$DZ[4IKLI9BR
MA,0DI(@)2279]S*$[ P&LY[YWV>&UN=]O_?]_M]_^_V_W\\RYS[WN;;[NJ[[
MNL_<UWUAVQ?###H?^[D-^UXD'9>\K[.^ [''\8XX1(^?!#ZINYLORIK*N8-%
MP459<+LTS&#P!XE,#2:S@<="H47.\G@"(/AY__ ,ZG[ 2%14(& 1T/!P5D"?
M71'0B2(P18RAFVU1Y8?;9;#?+LX3GYL]!RL2.@[P#8]04+YO\E&0.;[0@^<6
M.7/R 5 63R6TIZCTYV.4 1@KA42+PDY\4MZ.S <&1R2RO?CA%GI<3T4I[XD$
M(94@XZ(L;#L&.S;"QXMJC=_W#N<J/BEZ*'$A]LIN) #+IX) 9(#!*X69XUOV
M?#;9N3B5_+V)UE6Y'^[JX%-0*U":*D:W ?'BU F 'S98&SW,8:NF.(S!7V<&
MWX-KBJWVGEJ(':7P'ZC9XI0Y!\A%1N@N8L_'U@A4&(NA YVQOR7Q5%$32&0
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M\ !^%^G=C>2Y4)AV0F<.PJTN3-*'CP<V9' NPIV5Z)<*C:MAFB;)CS0#;:E
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M^]6>6?F289S\[W?A7VZ& #J%.=I\Y+B)X>F/6Y;0+$W!Y5HL7ZB#%<R#O+&
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MV3Y<Z!IRI+2=$">C+V&E]2^=H_&?.M<C8>!DB>IRQE9U@3'<P%B'Z>)CE*S
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MRH# 2V>.8[L2\,QU+H;WS/]*?O=9%BQ]9]=' #2K430&*-*PZ2M;AQR\H1-
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M/:=!8O$!-!/^^XERD2A6;U0D2D#]T+@ZN'NXN(3DEG.T(MO5RO^IRY4<[OY
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M>OG2GZ9'5&S?ZGYAP*4QJ?4Q*D]A$X(ZDB!,>&+'O:F%*&N+A:\?\^T&!39
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M-M;^)&P\@OZ<C(,TMOM?\&VJ9>A:T\XMEKFR;!S:'F>L=]@L82Y;[#$+2WQ
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MA.!#DW.OZ18'AG<*B;_"ER66*1G(!+M=D__J8V\?[:#M'A,H=T5(T=:W)'1
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M%4<#$J!N^[$;P9/=/5;2TO_<A!(&G^J"^K'-02'#"<4K1[\@+<K(I7/J5VF
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MP00HZ1]M0YR$'EY+YE,\#24:@LZ]!YWK@> ?N_QJ<9KZ4>-X*#@GS,3498Z
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MJ<+NL'D+T.+;V91MV&HXO;4_FLCC7-1-H<?-]P78/V^,J.NHK>9\*M?*:=(
M<G)W'5PL^-++^/7B[N@_!,B@ !CTB$KCG[+EUJ %>RR>'O?)S38FBV?]-D+B
MIXZ9GSJH%\"DTE$SG3W_90F&E1FD 8T2%#RX_DB#AQCPT.TA&%:I%HWC:WF)
MQ52N1AAI#=2=1-1?IP'T7D (S*DG_[+SC#\$_] 2&6Q,FAI ME@4@UT$'HXH
MSL0:BP6;_O-M^B,FL^A?UO@*7<COXMZ^) @CBYM#)NBQZ23K#,M\+T<(F3W9
M#E[G@J2M<W;#RJPL(Z\3NX4]U!5I@%T@9IWON;<Y8__CMF$I[SK0EG!P$HAX
MT?HK-(LBA^NOA%X 8W-W$8F5>OE'Z$HX5O5^VMSPA\U^D_BT?QBE_8=1MA<Z
M]=63=:48Z>',^]4JZ+0,C!X>MZPU[=-=W#XY:K _+CG_0ZRN5S+89)9#W_R,
M'_)?MOWTTGI^-WUH"$+(XKP_75;*;QN6(*) WWNVM0:>/$AT\;G7CVPQM*</
M8W!0B W#?D:F-PA, ].7@AS@%?@$\E?#RAE;J#_N708]@N%3KR*#Z"$QH-]-
M^GGW(YA D@[>V@\$^<ABZ?!))&DNB:@G@VD"\53/=7I5$P>6,TW"E?9W>\$(
M9?WHY;N0(23Y.D7QH=23:4B+=%&B_&L+61QS1YT*J80<J?79S:>>,N8O,M!W
MZ<\GK2^^*SW4>.'Q8"\P&RJ!,,+/-_?N%42VU1KOXY :MQI[&V40-Q[U\=W1
ML^_?=>90SS5X3M>N%$HLSQ<1D9<) 2WH ]8N5E_TA[?8@FY9J=9\=Q8_TWDK
M5FU-]]K!<%MW EN;!9P+-O4<Q=' 'SIGS!&HV87.JW@P=[+.3>7Q1T9(H*)6
M_+P0_!!XE08XHQF)2%QT&T=D*#=!)YNW.&_I\E)?#],+#AO-BPI//R@^:'UP
M1ME%W&$GN:0QLVP*$R^ ;.\-\P(95TA1%RZIRCJHPCEO3E*.J75U_(V\9,KQ
M=S/3I^99E#/Q++BY8L)@,QIGC6*&!VH9I9]+1WK6QUK4FXE??6MT93<3XJMW
M<@<[@@.;[=:.Q.O3@#']::UAP^%J?'Y;O,/5 TX]=T_R.@HR$78Q/B.U"I4D
M%8/)%,-)M-@T(UY]O@CCD:4>LEKB?$>PM2&Z5-\+X)?I?FHIW*%SMA=KGO,$
M\5W.W5^S@"1M<9 PB)M+(*F3I3\U!*#'>X,<K_?KU*07GJ_L$HVX8M.VORQU
M@4&C9$Z<DJ,,V3G=>(0&?)7-H &)9JOQ3SF)HR0MA"A>?*0%%:/FF7"SO_IJ
MM36*LS"W;S9E3D:&L]VCNW6OP,7T4ZJ"E0:C:]\D<GPE"@PYPB!X4PX.1"CQ
M82%1NA7#X3\[!$W7533TWOTN^4#%S?EB(.0"&DFT)]A?(!8>0Q>WN_GG$/.U
M,[H^-9Q^P6S]_AC,.\;4+-_[A_1SJ;=4GK7BY5J2+<(-[]F9<'AJI+.'R[/6
MC3_.>,C#?3H1Z]#*(XZC?.FOV?O=-OI(UA?*B^H8ZE[Z)R1->XB5AJ^S^AO,
M6/O]'^7#WM1']W *.PH:W;R<^M1$0\K*</3H-[<O)-8IZ>'\M6TT-V%C:X7=
MG63FG"ZP/ZGH/=YN6/1.B'!T</GP#Q^#H-PMABI)Z>[Y)HWO$U_4WUZY%2=5
M5OERRI3RD"*-,P:AG6"3&N(BI8PJCC@\@+#+'[-<.#'1Y?G"U4K,M,OSR.66
M6)*HI!AR@KE9&-%>)\S8B^"AE#>ID6\2C0D^<R _K+^)QJ]-V.B[VZPG2T\*
MZ^E;RZCNR3S1Y'#Z]?636R67?/H5CJ18.$W"G9#ZZE'KZ#AUD*,Q[QJ1 2<[
MBC$NZ?YRJ3^4O[FT)MSIB/RAG-?9:6KJL1@_*5ZQ?4XW=[.6:?!MEA*2(A!!
M>#5!"]L:8F1.X _#&#?OQ6 _YS'EF2*->(&C+8R2IN5Z+:J]KOI<KM-SNB-9
M*1.C"UNUYKPLEQNBCJ4<EI=JNWE=X> =K[H-91SR%0U8"<JA#IH0/WPFNIGB
M240ST3O5]<G'H)@/V)/^HMV>Y3K26<2#!%(G#:@:Z4R*$["(\B^#M6JRXJ^Z
M'9:D 94#.+=O"=_CQ$H[111N/%@Q+-[7$,:J"7K&E!E]:0WI[/EJDAUFEB![
M,2#YW*L]L[N7O^^9"E-0$U"]5<WV+7<#N?R>9!B(W'R&_UY70KRC-Z3TJ.KQ
MM,-B*)^"HY;T<U-=X34.T0VTG9N%8,DT\G/ 9BSQ'N'P)I)8A]/*<0D>B2'#
MI)LR"YSKKYD;!,!2W^Q+9FB,L_\RS=.,T*'4-1U'0"N)IY\O\=7XNHZ1MTP"
MBULLQA#RAW<G6I[+>Q6ZIM#?\YI%/(H[^2.;=\!M9G&'T##9DEI7/=E1M=CM
MT]2]Q\$$TJ<\]N^-3@D\:%554TLX^I2UU+.*6*P=^,'R^HP'_P\OG3O>5VV%
M* 5-,D3HYL*@)EO@_-7^ALL%2^GOA1\;#[1GC$X8F+^V02DJ,DM=GI,0G@]O
MUX]SG:YO3*J8JE5XS8/3/$$I:] H(E\QC@IE[5.&W@]5/;,29)_78-)\_4#"
M!&+MA)EHP*F/'"Q,=T.B<3R;N=C5Z":9H:H8\HI5KW[]Z\IX.=R@F,P[^4D9
M%I[M'V#H72IJ/C6<)=QIXROWJ/YDJ"GOK_@]K0#MM99B+.&K$_%T5OO4V)</
M0HL0DZ^APUDJ]ZABEH$2N.@H?TC4R$ZQP,WB$"4+-??%+WQLWOS;1A=(2Z_?
M?520KB=^(J2>)THU0:KJ*AI'R+HX \S+A:S]CPY\@1MT>'TTXSPCG'X#Z$&
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MU+W@F])D; $1#*KK9-.^$?(ARNY<U**K5[AI#PTT@77XC,#FJ',@OJ/!5 9
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M.S(^>%I5JOTUS:].Y!$+0V8>LKZ6H\=7B&AD@/L9XA08G9$1[2@X]2-6AN]
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M*&;E,AE* ]V-SZ<<Z<O'0C8YUY!;J_1R_PA[2N%_\]'C_^D?@S_>AAR-!-%
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M>74I7^I%_0SG;/7+GY5TK=% H6[+ 6"< 8(3%GJ[5[)$2D$#O]YKQ%7J)9V
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M@F5OO&:_5#_K"\<138G6H ?.U;OX/[%,'G!8-1U/3ZK(]FV %"%"71L?^Z3
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M>L/],0LR?!N\2F*F2_C7$&NFN5-(0A^23#U/UP1X^#9D=9-Y6_1MZI;T1J0
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M.W$8JQ)N7*V5]<7'<_Q2RHB+.NQ 2GG<'O#I:]K=EUKO$3(6RMZ3SSJS$8N
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MW%C61W4X=7!QZ(>@#NGS37^HK^ LS3DVDNR2QA=^2S>XJ4%N<\\S'=%#?S[
M]'\FN>VL>6+AJG.;5U_EM]VF]9JL3C-[NT:X !9H8SA>I#2OW!.B=*1OJ?Y5
M:8I#YJI;)S[?UK@]].[NA7>-3ZMU/F$T&?P3AR66TG6OJ2QP+,[*)%PD\S>7
M.;8:2O4M;[U;=(+X853Z9%?7B8 M,8%/#I%"-Z1,+0FT3<=8&+XY*RB-)I^
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MC^:U]G_]M/\_\]GE^^\"_*].;:_V CUQW[:MDB5@#?<\379[1QV!9I(+-3Q
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M=]]_65/WY,D^;"NFU@,,/=Y+!O9;4[9"Z[;D'/D8@XEG9MX/%*K<[CCB>+0
MPX>>^CWS[1;"_X'RL04&PIWA SP[[+(6M-]OUDY?5#[7BWCRV45D[#H.1%$*
M1!DF<'OQVDH+W#:TB;_7-NG::<M?(?H< 'P%"B"ER&1'C(C"!4O1)J#",R\<
M%4R:M;-2!;B-<P_A1YF@2P#@9D4F"P"Z2-Y65#;JFK_0T0U9])K2/02$!N"L
M\*.3:AVR+I+[%96-7US-Q+8*HWW/]L/0_% &77QVW3TQ1S%<5N-MOR6)=@,M
MNX  IG=/]]\Z7)CH<>:UAJ"/$M&9<*L($?&)!8JC(\U>EP)7UI$"$[+XEWX4
M];B:P85:%Z%/4=0W@39CC7UV)?;,USEO;K/U_ 1Q/A?Z9*'($>A_(R%R&RX#
M-9-Q;<O\USPNN:[;M$'K5/9L;T'W#FQ-T.G\TZ5K6SR>>ES-M"PXK\;.*64*
M.;/7 86HHP3&A/'=RO&LSO%LH/XH0A8Q*-U]^/?&6?SB[K&C DY@%E@OSF:7
M,86PK8L#>"P=KEH>>32>>37C1\D.9/$V2G<7[KUQE_9QYE7B'Z:-;,GS<.5'
M$L#X_9$A7T"7D,9;2SSM%BJ8K6AO[D$'3!AVG4Z5:%JCA.?H5XI&WF;X@RV"
M@1L?4Y![+68]XQ1_V\S /R+WEM105+%G*OW@U<JDYLO[&<]HV?F9D>M7GGU\
M6N$LVR^\N7QQZ:J8S>/2G2XMKLD?-[2O*%5S+"+GW#KC$WS:E+@AC%\RM?PZ
MY0NYHI@30W%^VDOS? >WK*$PI<(I:7:#]+0@6@#NH'KW/N#JGY6S]0L>B,VC
M=8U@=\?YQO1M.2@^*^\@%[KJXM,@L9WSPO^=>8[+PN#9D1+;X<\'PDY78:B<
M>/=S%9]+ E_WUC5^&FQU#TN=N"7X37[EO6#UU[B+QFYF>[$/9=5NWW6T0Q:;
M<Z'N-AQ/J5[ HZ/2'?([GH39'!T'$G>$"^0Q;+8>*G QH ,;V'XK^<)6W:DO
M91"TLSI:)O =\E6AA5O([!P TYHT9L[6:R<M-=<[OT'X:<#1%P\WLM^7K>ZN
M%=MD_W&I8I+$!<]&,(*$LIK!5(Z=_ #LNC1;KAF>=B#V)2W$5> L-#K&DU,1
M,2?*#Z_@^V5<@OT%GPN>U=W22:XDVG.@#C->#^;7FY4W_*4!!$KK"*"50?WI
MJORX_O\1^<N"65:CM=_:F2V_RKZ.-+CJFB\IB])JKB5 R['90HLDO=!S4Q:Y
ML/QA.^3K?W)X[*D"&.CJ8"8"7B*5<;B!.K;H#; 79FQ9;*MI,_"\=J'>I."3
M4F9IO^ZC2-3!3?KN(J?]>IV^X-]T<\S!J@YV!_ U<1;]O^+^]5KE_THD9X(V
MUY:[@BGFEZY:Q[ \"W>MYUUOL;]P_J6CICQF[ \P:%7)I\CR=-T;[;1<8)8(
M'ILUN-"BSTM.0+8"N?+U,DM_1(^)M9/$\C1U:8[%X2>TY*L4%;SXX+.^.0Y\
MHTX76:GK90ETZ.-BL2WWMGSH?*A:]08[!_FT3&U[9DGY)2[T+AQ;K+BD^;0P
M/P.LK5O'F];(''D89!>:H<ID%W2^\M@@<?VP3(8\*3'-[#%[7CI](Q%XSH)O
MV[ISG!>7/'VG"*>=T-M\K=U7*4JH1B#_N."F>>0]SU9\9/3G3XF_(\WM ZM,
MK;"%*4].!ZKD?@G.WW%B=\]. 7/7^;%B:Q?MA!H4"RE7?408IEF^-"14TJI/
M>+6;6Y9?Q^2D27% QK;PR_X>\^WG-45D)!^ 2LG:T0&Y5T:&^9 *RD)D.>-F
MO\TJ6M\G*E/1Z4R--4[CTA_9H>Y.Z^]]5K ]I2X[5V?;ZG/R=?;15]1%_L7Y
M*F+WZ)<1/7P %QI8RGM;E<Z6YD*2>?>XD,TY]&V1[YCJ/[TT_KO?.9M-6/HE
MC=G8WID]SDW?<M##;&W1PVR->(?9#OZETD:E4OR08J>QD;98\GJ<%"[8T].L
M #^W G:N7!Y)M0OTV27$*FA'-#NFS-Y2YV([$/9)+F2U 3EH%G ;V:A(Q[@5
M.G$LUP"6J5W$W&<.LHY-6HM^?ZGWC;T$;NOPVOUS ^U?XNK^HQ;R0M,JV-I<
MZ)[(.\K$_#=H"**UF ME$:5C)UV1<PT]J?+@; 2LB>XI JB7WA0DP*+Y!98?
M+#F"6[D02Q",BY[TI __\?M(^6N,."Z$\0$H4^Y2P:K?T+KS'%Z4TMZ?SX4F
MMJ#HGB7PY_ZK2+R$9&Q=Z1CV0]SWB_ 6D3(B0U(X-*C=<DMI14 0%_(=GPK#
MAV!INZFY=#)G4)P+.?>/JSAZ&5Q(DF)3)&U?IAGIN/!RLXIU?YT/NEEKG;<R
M%^(LJ>]1Z<Y#0Q)3Z"((:.'4Q@3^JH3_P@O7N\[C3F,J!5[SU!E&3^ WBL@=
MSR'@YIM2=UMA\F'FQI7BK/MP3V.4MXCV/YPQ]'<_O@+V(2YDUJK(6OZ",B:5
MW/<:3R#UL3=R(5NQ4.1Z_9>?KVP_4M(:!S>V8_V13>DTP4+<#24O0_K)BH<J
MCBR/Y&6K' VD@UMW?>9"YM;1#YQF']U\P,7&D;8Q!XYA&!RA8PN&YZG=.*O\
M?"*5+O[6Z3C=\+;9JB67@@RRC&Y*[ G#')LC69'OMUYE@ NE90XXTE@3T<O$
M;60#C&O3<[66968T7+0D279**KPNOO B^4TIWX-O*<5;'5,8JVB8 GPJR;>-
M%G_MS-.,VOW#KLJ9)LJU+?OSY]S7U=03BGD)00+&]_<]/NLJ,8^N30_U&_MB
MQU(\6&W8LLNT=MQ^CYII>56)Y"SMHSM7+]&<EWR?(*?__47^_VZK@&K'-\Q4
M=P*H'IL\\?JWJ-N_Q "COT4M<&(0IXF!;15DD[IO4_J_XCH%O%O/(XFX2<=O
MZ.G7(W#D5C"@/; /Q-K:L0$&;-TOYZBLC!U(+J4<XUE38]R8YB7SNUJ\92@B
M^KKOL%.,5URHYF3RR&NL !<JW<< 3<<OPT_M3__ZEY?Z__BSFGRGR%R4 ]9J
M1\M(0(Y5C9IT862/XE+XT]9N] 4=9/#;KG%S'T%@&N3!8G="!'@-U8Z6#_[C
M-ZEF?'1=!*NQ%*CP&@I"",F>^J8%UE(EW5?A 5L4F7&5LMO8OXI^)K1S]I-V
MLQ,M9BZ>)>6ST=,D)#C#=_#6TV-^B^-()3+W\F2>BO=%/(="KBM*2L&\@Q7?
M/QQ0$#4R%YTV 7\>\<^KGE=ZB:.6O@W# 6T;,S@H^.2_\)*8;S6UK[G'\1I#
MA MMB-G%A2[@."O'OQHB27DW7F.O<*$1?67%R0V@B63M*0G?_\J98'Z,9PBY
M #^QY0C<8VA=?XXBAJUG&"#%\HJ<><^S?L9VWX8=G6^1TJ7]D:WF]EA^C?5.
M9/=+FG.$^YN?9^_[(/QL\^9%42%'C/3FB=H=?W3GL\9BFUU4,>RW:$,,9OZ8
M:/NPW.<3/G.&*/KAE%5>1B_<\YRDVHL\J8-WDAP&99P'LS4EBJ<<G80/A>T/
M--_WLNS!WL_G?.O_>#HKVWNS6LA["U>L,=;.VZ H*_,M=NY7!EW*OWCI9_F^
M%*L]ZR^^WN3VS"C_[3?;V\=SM^:X3>AE9>9PPGR6ESLF?G$\E^=KK\,9"0ZW
M[;P=,CLH\,+VR,>&E\4,6H[IB!KS!!#X;R+FCV#$*1W!# KR5@W]^(LO@$?D
M>S'CW2+(%1G,[N/_\)WK[WZ" FV53'D)/BZ4[$E$"/K#CG\YD"WM;WM?K&0J
M3"N8Y@:\*R:V<@7<. \,Z<GK7*CO!)CT@<O%A3JXD,9O\[Y+(3ST:7AJ@@LI
M#5M8Z%M,$&_\);S_+V/;3/ ;A2F+6<2%^MO*N)!>2#8Z$]^_LNS_LOAYWBCE
MR=6?>2A]YL+$TA<-C)FMR:*NS,M21*B-?<<;.TGL19/#7J>G>B@L&/\LP-(,
M6<_TV5-R#*#.Y\4*D#6!KQ0,?*5)T)AJ!1L_F\M B/*H$(<P@ ^+*YI"_^D1
M!. W]V\F]^01GA/PE@VZ^C[J!4@#+T"P:NR?#HGXVX,C%(MPXSY+@)M$ #V[
MZ_30\]_&_@_!K#<KF(I_1^;S6D';84]*(_FR!6/+VW?/G\J(:U6^.]%X^'7A
M/JFLS,4O^M>J.V\Q/=3R[A:?RECW+2VLNS!0QV4Y6%JM66-(97'X>&93VJ#*
MDT!F=6?=FM9+LE*RT.RKE\+9V1S2('RLTF_*^_$D,<<1^XXLMG=GB %G);N7
M'NB^;Y#]8OM\N,SP\QC4EB@[L11[)&\E%RJ0YT)S%_J!/SM?:BU:=OZ.(FO3
MLPS6-HQTZ%W5MJRL5I^%C,J=C%NTRL+(];1<\B>V>D+3IB9OROUU\^;LTUYT
M+@;RRDVUKM]7J<J)TMKB0($0$49\27AB;%5/AI.R*EDQ>.)99=G\=2_/V>QZ
M_FBUW;9M9"V&,SV[^ ^V"EWP'?YF)BSRE': ]%0UQNGR-VOC-O8',8/7IX(7
M[VR^ FVXW]*^>DJWJ/+65T&&7>O#=)&;X@U-L/_P6>/\<N\SM9;,N_.,I,2N
M/FOR.57 &L5C\%Z+7]*[_%F[I//',_$W\N1H+XR.?.Y-$#?,:5S<N775QN4'
M-=+OK CJW/SMQ$!!C9GEDL\#><*<IQK'LT(+(BAK&"XZ58"OK5+6F]N*P62P
MO;?=8= I6?C*!J5=<U;,:MN?+#*;HXDG+7AA3TW;2V3),/@+/,.M&=<*LNZ&
MMBDN:BZ.B]@;8)@NN\GLJ,O\)%7)0UZJ!\[[XJ/&XJ*JWWM9+V?\Z5#*3+9Q
MD]K,*2-EC/11+P7ZN>]?TCYFT0^7W/!2:RVZVK2#J%6NE'NSN Z'2UI\X,![
MI]CDBDFIV^&C]^A*!X]Q(8E%,-4)QX7\[B7 55H8UN!SG)VD9BQNS_L8R9Q>
MGXVGYY^?F(L=SH@''?X^CPN1EL/#&7$#':OIFH+AZF0MM*8W%]+Z@PM1G739
MFP*&F71_A'5:\]&UICUCV^4K**TG@.-6>1L[V0S65,*27 CQ G3SFHAV:[MT
MHZMMW$#IRA^EC\'=DC_#/#&RN?SG4H9Y*!<:;1?A3-1Q'ET+D_#3\1AF;S(
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MH6#F$+6R=L=:W4J*F66PHHI=DG-&IM-VN_-L+O0^-$IDRG_Z/<]'PK<<I;:
M 'B^P^*D%R<V/I+3LOV\+ W;NC4+90KE5%=>K+JAP^B>%9$M988?[<< <P+X
M^M"/>-NB?&F9BNOB=2Y@:6'6<.4+P%T,LE2>PN-#^8VY57]"LN[/ KC@)%BS
M:Z5,"U!\>Y_\O5]Q*?XDT7G,)2GZC2)C_V9*=\.,</T:V5,S?5N100 ^=ZOB
M3S;9&R>_5SW^IL'(BO2S )#(^TYB]0N[(SH72+20+W!E&H_;)<UDY@3*'--\
MC;58&5QP!&6Q&CF%GN/@VLAFZ3+#K5XL3"9T4EHWH?0 /B5 +A0_.HCILN\\
MZJI2X&6\(INFR[EM"OQJN=,U$C_@K"C$]-*A9 TIB]D2-IGSK\V>T!,<CPGV
M[5,VV_I5[K5IR>=V=KD2LJ2,!'@85;[P<GNX? C@]U4WXAW#!C8Z!/0S8#0,
MU*FKMJ*P-YIA1X<Q70YPJ]R;[[S(\\='OR$R])/A[B;L1U12ARMY;*N;K]$4
M^P@7'':9;M$/F)K4?ZKB]6)A)*$+^Q.[?I[,&V>F&V#N17YOXBKB^%8X"PX^
M"L8"[CS 2D=.)3?U&=OL7FL?K&52Q3*Y^\WG!/Q6!.Y*YTPOT.O)91B&I,$J
MF&&]S8H>D]DY,4PGU_3FZ&B<U?;=-Q7>5U1[[OF&*<N1/3N_K%D@5OX+YB!D
M20"1.4D<52G[4+;=0AY-UA;>CGC7C@)-,D2!>IGAID<ONG9_G8]!W_EAG+!<
M:$_ZQ7EM>I]&SY+"DG<73*6]9.O2<PK$I':>+,;9AP?P]8F:;?^ZX35F9(@4
M%OL3XQ'?ZFJK;O:&1LPH>! GL>$U%H6(SK]XR$P3"&AC"9N&XXEJYNJ4X&X=
M(%C:?>!.:2Q%6=(Y/WUUI4<F&4:6R!.9WTAA0,-D@86XZG/J,2A_(<+89P>,
M[SQF.+9U'0EQE^ZR?[EJS%20O4$)]/1L=KD,?78W8AZ/%M>9BD^, =>D"*ND
MQZ%@V71 ]:A:P@O,(!-@)/B<"F5YPLPVT(PY@V)^G-QIB)G_M2]7I?VLK_O]
M8M^"6Y1Z"NOI:V=?#2_I*K@%N%9[<R]>LPC1.7K,Z.V0XUV&VC,]1UJESNT]
ML7*E+8 ILR@1@^B77"@3+"4C]9CAN,%>"DK]BIK]"^Q@*:7[OL\IXF OW$U
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M63(3"&8^%_H*RM=X!T^7K^)'1O'U/KH]&KNYD.3^[!I\^+IH@OQGK!8P9W'
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MT),(,!/GOZ<P$G$,'.HC[58-Y4*^]V#ZX3:8-HB= U>5D(%(/V$9Y1C:($X
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MF=DJS:'9-P-T00A#I:%:)[^C07T&3=Q(-Q>*7 )3YV1ER?)]\'!!.<"B3,Z
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M0AP?* S-,A:+C^D2LS+:<%C@^%_%+AYVV\QSV[;C&!:^>K5@'1CV%$Q/A)4
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M[L@SG7JJR#EXX%_@0PFL 1Z'MKW(>]@)4FSW-F^NX8G"'I;L0G[@E8(F<+]
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M.)<RXUSJHK\T\K@<5/3' N.-(;5>8;FL_JT8<X!B3.OLQ=9:9 W4S$43GDD
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M!$L;:8/&(\SJ19</_(,8*^!/B@8 W^NU&N''",;9?8P#EO.Z>_EC/M@'$/4
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M TWOQ@,C!94UI?L\PEF/K=>MQW2W@YX-L?%@CU75CAEM \O_\0+K3(5;$1<
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M+J/PQ(*E9B)BB0;6"4@,QS ?@JH-(1X7AZIDR1]7XQ?.,[TQRQW0A\"SA]F
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MNWM;@T.OSI(4=[EG&@T:#&+)QU6N;PG++R+V;(]1/+PQ__^; %!+ P04
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M6AK>CC?43,[J_J( OVF*_,+B[^\OZW]"ULO;64Y>5555[KB"G(*"#$@A<R?
MT\<>)N-YY\@O!F>=[CAXN][R<?7R/$3[;G_=R]='4\37U]51[8;]#:7KCHY*
M,M?M3SC*R,L[VLO8.YZ0EW$\<<)114G^I,(-^>LBO\0[.OPA_9:O]\T?LAT=
MY)QN.GDX>?K< :TA3\/LZ*#F[>KLXG/GIW3MFS[_.?@W76GKU6[:>SIKBL!D
M')UNV/O>] $GY7[._KH!Y8!6969FUI#[&P1R?S' KQ'0IN#='QZ@N>,/+SIY
M@J[S!WU$Q0(B.C#7&P!@: A( 0# !-"%/P%V@7=TP*\/=0PX ]#OVD7[#WYV
M@_\9F!@8=N]F8&%DW,.TEV7O7E865E8V]OW[V-@YV5E9]_'NX^3BYN'AV<O!
M=X"7^\!^;AYN&A,Z>G#-;@9F!@9F;C96-N[_\(?Z'N!DVM7$D$Q/)P+LXJ2C
MYZ2C-@,0$"L#W8_/;\ATNT",>QB9F%E808+*?< N.GKZ7;OI::C!V1!P'MC-
MR;#_L+SV'BYC>T:1V]P*8?$OF(Z<+FO@,>G!B9ZX[AW.S,++=X!?X*B8N(2D
ME**2LLI)5;4S9W5T]<[IGS>];&9N<<72R@%TE;.+J]L='U\_?UA 8,2]R*CH
M^S&(A,3'2<DI3YZF9F9EY^3FY1<4OBZOJ*RJ?E/SMK&IN:6UK?W#Q]Z^_H'!
MH>&14>S4]->9V;GYA6_XM>_K&YM;A.T=FEYT #W=[\\_U(L3U&O7[MWTNQEI
M>M'M\J<1<.YF."R_9[^V,:/];2X1A3 F[M/Q+\H:F(^<,,'Q7/?N8>$55<0>
MQ=-4^Z'9/Z=8^/^69G\H]J=>H\!>>CK0>?2< !0@FV8B)("?UW;6E-EF639E
M%,/@L1RL770F:U' O*HZ56'B9%G2BS !E>,1%:]D U3GY1' CK5+EDMILERI
M$C0.4]GV,)BU8%%M,!'+L8<0V#-9V>WK'J=FD-;Q_I.G:,(>O>OWE3-71MFM
M=T\+&^,PT]5Q6BHNZ/*ML TAO[510_?+0QYUAD4+*7*N_D'LR$KCLS%19]3U
M6<]=*GA_C:G3).[#K!85R*QW(J>0;A?*M:P^M&.ME+G^W;(2YUGFJIRDE74L
M\8N.<X#7W#$9Z83/1ZZ]YSWZ*G#ZP(Y;SOPE8TNUZAC%8@:S2LWS71?W[^=:
MOI-MC1\2O-]I1@4B([%V._P^<!+' RJ R/S$'HZ8@V/M8=:4*!L(%:#/I )3
M!7QM$P=NT 7K9)?+O]^U<RQQ82M_)N3N_/Q+97Q>=!9V8UD^M#H>24Y-HP+,
M0]'0^6N]5 "G+$>1NJN2_Q)"N%BG2@7.[$FA F%E</QE>*,OMFOG@"*:Q$:3
MF<'V39J1PE7*#N]NR*$"DS?M2&80W'/8'4H4FQR(X#J(()\^$-% !>XM-J'6
MC[O""8)\5(!'CR1N>Y *O(@PH +OA]&$0F B\Q4<JX:;(^\5L*/L::$"+<;_
MER)"XY[!;JWC]R3#ES>A-!J7EU""89WF;YIX*H"_C/GK*KIW.M>HP-\KD_47
M10 OXRO0ORKS5T5."?:;<_Q5&>C?*W)ISP9/Q%^50?Z/AV0'NNF'N+]QG=P?
M8] ?8XG_?S; _Z60GH,#U='HGP,*/QPG 3KNHH;*'SAI9P[U/STR_7^.B.:3
MDX&P" /H)A',4#P&_\AQ__U@_T]'--0Z(>292DD.3?F1NZ@ X8(BQPZ[*YK
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M3[S_GZ\2_RD54B(5V$\%AA7FP-VLY&/VF:3[HPVS^]V&L6JQ@7'" &S.2@]
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M C+B%N:J?7)J5*"+EPJPC*:8JCUGI2OP-X6^WH#O[+&!8Y+!X;_[@DD5$\W
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M=BHN:NS(.0:OD$]4\J.*5<=?%RU[(GOP&Z[3LRUW>6,LZ7E>1<3U3%SN8**
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MPHPQJ0R3N4DM2Q L2[CU4S,T]1WJXL#!#W@6^K2S^F!(#T ?9<Y%;-M9V$:
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M,E$B[)!(K$0C F>VR7"N'?!0(!L17C"Y9N*:O=>M0#YE<+]V7]OL,01F'P]
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MA-,P8,NMZ1CNV-9L?4M1H"XL%)[3YMUM0QJ*^&&:7[4G=F8;X<+-%H(,U)E
M_(!]Y(SIHN*]6F).8_FM]',#0NXDW%@=K_KQW;TGT[W[/XN@[VX6/I@XPAL1
M(ZXQNB-O_,I=<]<@BT-I,4_DLC75M+(?SVAE/35+STJ_0:X27!4OQ;U\RX/E
M";+ZXS9?9&%-]RXMNN<A"/:+=FJV5=_>IO(O+JU=VXF?%<KY.WGUSN2]/[Y&
M-H3BS;JVEK!P;2W?KRDSL4MJ?]G%SW?\9CC^/&[^MW28).4D##F=]B+)G3C5
M 0Z0ZC7L:F'_R7J3>D*Q9Z"V$H6@S]> *.3XVEO7DL;@8WF+(7+B[.E_:G7
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M(XE3R* S[''G7N7HQ'-;[-H>$9SE7?AL];_-*SH70N49J5IP?9.6I--._Y0
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MOJ^$R;4L*<C2I+Y@!K?-]TC@O:O.*:E0U*WG9ES59>/UP9YP2'J0@=+#S9K
M4V0]VMIT=;B!(M;3NG[6A')?5_!F0]O>4&#7HEU&R5:PNHT7-+(:G+4BA//8
M&:@'!RGQ*G4P%V6(>+KEVDX9K2?GM';T?Q=Q>=RV17"5<H%DD5)90[9Y4W!1
MD\=0/;?4*_3=BLX5VR^Y=G#24QBHX0:H,!?L3#BFG,]]\NT>Y2]>I[[A5?QG
MRSVE>[?I&VU_][#)38POW="PT<<K[XPMAI0$-KHP''P4"!<I=757#)$$/XMY
MA+4#>(H>F"9JP/)!B!YS_> 'F%DP2U(2VSP4HQ[Z;SY/009Q,O7S-P@@3./L
M$V N<)^Q)9#N50#=\M >,FNK\-'PDVN ,+%TIY'8R%#E2I_#,!_P\NJ.(4BF
M@/0><3!0 \CR!(_#R1$^CH".6LH1-/P S40= ^;?$@9J I[7@AN+5 :*<@0+
M0V5,4N+%2CIX[F*6#]\4K"L\O DO_'^X^Q)X*->^X5N22IH65)2I5!32*9+"
MJ(YL(;*3:;=5BD3"W:Y(TR:M1B1*3+:49,I:46,7JFG(3@9CC%GN^:Y[9BSI
MG/<]S_>^S_=[W^_W/#GW<OWW:YW[O]BMN?!^@$DR3/%OG-GP'3N+R#XO<,"*
MNQUA.#<:2_?Z$@";7>]^X%]?\+GO];83U50!-CZ$JL/UN:X@*]8%N%WH?&&D
M>_I=$YDF!@-:V,%.<(04Y.P@HCS5HK)/56F]\M+J'9PGJ0R& ($S()!]A@ZN
ME0M32<AK/X8596&ST2(T9<@(%(%E0$5@LH!B-AM@Z+J\&9FA#;9?/=QS  $X
MO9X%H[B5(U3-LUB"Q\(T'2QK(V TE,<&70!-00(V@Y1!U*2=M8[/(S)>WGII
M]0'. T>N?O8P&13 2 !0ZVPXO_28CL:81\,X@"7(P$B=[G&WSUTV0V9XX%I9
M MXUN O[8 I=]%H%?6V)S/ ';-+ 4".CF6^F VI<(;7L#RHMN_:@^::6 M89
M,)6,O,;2SY*Y"($S"(1*20G3N>70;'3:!2Y!2<*\P&;=[;3G6;W%9Q9J&]QN
MSIY75SGC>J=KDHMDQ%UDI5$^H&*.YETO+RVZFO)-^A@?BGH+"(/- (-(/P<0
MPS]P0,,*A@I -CLC#2"/,Y"G!]DLDF[TKM8J _RO-.]=,YDF!0_QL(,](EN.
M:;,=H%'SH0I0@XD1A_(_>NVG">"+U7\!07/3R L53D55$*;2LD?'F[4)6!?N
M SW)-0J9 71#+!>R/5!E9;1&/ I-VS-&1>='510+5/34AP^->18O:DT7M#[*
ML"HM\A7"8(3O\9(O1A4S4(E2N(-F+2)P<V&A#!=P(E4=!2IXTT*FS82'N$(-
M&'$7 [7ASB \/C30&1][>;_DNMS9^P!",C<4Y<CYK2O6*\*YL)-Y13?9(>$+
MFN0*BV<F5:I>8!V#&X\/Y\J-6B.^E65(X+X>5MR%+"Y/>'WTAM4Q2="Y)X?#
M%.J(;49N:DT,Y^ST):( "#P"*V+XZ/86]-U%\C R+/WB*.*CUJ_$[P%9#<FM
M8"H$8TPPJXS>=<;%AC_3H;#^=$9@G, >A#'7V>M5QH.W4^EA@)10LRGGPU:^
M:2739.$A]HBV2$!;FX7:>A ;?HH"YZT ]F<([4]@&>*1D% >FDVK=C,JUEA\
M\7BIM%8>&''ST=<;P>N=<-Y*(30!E2Q<T+0)S9_  "I;\S@@.*ZB!U._D0=6
M?4F.\K?4W/EMR7[TP7P?J9.O&"P%!;UM6*<N/]*0.!46.%0Z8*=\ZCD?,N)/
MN8/PX 0R$W0X(HGK*Q2@1R  "[!0PY-QV2(Y]@G:G5=3^X$R+H-I)Q"(#[K5
MV7WDUE8ATZC=*F$*!=$!XB1WJ+R8BZ='$(>&L(+<5U'(S.> $E% R?F&M3AF
M[ ,CKM)!0$A)2+I9YN<DK/ )CM4J4-V6!B0$[J4@KP]9&;X!6X^S!T?HHGRM
MI_;W"ODZ%+9RDC)7"6SA<%@1K)$S$H)#80^6&T_#LXP(7"[<1.0%XFB*N&$P
MSS"H$& - (.W6"! '#*3"=@C"/FUV39)FZO4/19I@PCI@7(#Q>--$6KYR0'J
M05T_:];RJ&S_6VR.O4.]@C8WJY@+S@HD!^P,\@_<=SQ'&N[.&&@08&M%3O A
ME(]))_,1UV%<<\') DPC>GRHEPK,_AG' 'UG :J50ADQ @^LGN;_Z2L-YCP^
M% U60F \U\RVF&F$KC5C4+H)")-Y@;6Q)U?CGE&XH/\5PV#"WD4< A"7T>[K
M&@:]1PJ\A^_;X53G8:AJ $5&;V'T#C=R-?(<PVE%3<I4A2G@L!2$HK,+@SX@
MA=Y#7;@>(LH?ZC)#%6@R4R5F&J4+S-[1^<)>EG(-]&=U,LJJAY7!?,PI"M<%
MOK 9B3X@^)*8FS+>9Y[QMX[?A5[$/KN<Y> <T"T,;ZYY,2Y5]3^O]H%&H?]6
MED1V?'+TD5_9]P3<W1Q:\ U;Q;A8UQ2Z[?G-"B."6.3>30\O#;XEG8Y")J?3
M4^TEB[ZMVH7PP*PQCU36X:V8F;P^/8'^:LK#09P*[OLMUQG/6?Z<0T$>]/MG
M^UT^M]G=.1\UK;*I].K"JKB+CG3HRZ8?W_VUV/GX*#+=DCQDW-JM!%B3IR#W
M:\C;GO3.:KG_.>Z9E:'LI[\L?&._H5<!04L/PEWS0!^/O9.]XM>(DFT2Q$E@
MAQ8?"]=>PK+5O?:GYBB [<]-L%EV725("OJ/G:=5A3FKE4=R5KN><@UN(J#%
M4N#A8BD;8_^58BGC/$M5L\:[J6^3]/X73"NQX.^]28_*_P<>ZY)EG8FQ81/_
MJ=/M83XT$P<F DOA1/#%'M,[&]F,3 1RU"(-EF,ZT#_"IBB)>O "%+G"P4'^
MWS$XT'\AKGSH+0YN5B)F1/&"O'!L?R>>@1,WA'<'T0^8S3S.RR&[Z_D69Y>X
M!QYD)CQU=/ZB_K!V0SQ21<TZ8%P0],3"N%B6F0J.2[$A'\-K&Z<164I5.%9A
MH"Q]8-]*]\+,?<D7+D42GKQ@Q(E7Y((#8&@L\A''V/8#4)6+XT-%RZETAF5=
M$HFKMAQ'-TJ$>\-:V*_QS? 1EY*7 VZ:1PB>/W(5N,9E^FH!&EM[_<_VU-K1
MD4<12^,;BWJ'PE+>455/OCEO-W?AT91T5E*4<T;UG;D=*K%/?PEW>$F]0.VS
MY(*-Y,X2(D^FNORW,7=2C?5+G(?6_W4UHG'CB2'?WS,??F_* I/V#G2;7*89
M*/TOQ#E->$$(A?L6]-;RSE.0ZQMWO/XO52-2Z<3W28+-7\HLN&W92[#.@DZZ
M%4V:LA-U_U&-J2'_P !&79:@/[@"Q:"_/-QBV2-O;X*NI+9-/W3'OQ"Q(AZ*
M^EZ##=L$^+.7P(&[\<6O'M[_/'@'17?R-^>6WX;=[T5 WL4MSL$WX;N5'W%G
M.0^MS%G42)GMZ'$3KI?/1,XDJ#UG'R3C=-,VQ"R1V+_B[FV;23O%)G8&Y#>U
MGN<JTXB3O686)GI=#\AU6%2FF;QZ1JU_CUJ(>WW*AR=)BCMNU]D:_&#$EMKK
M683U4\Z2YV98AM\,+*]<E/NL*L/<U%S5ML)/I7KE@93M$^.Z]]M-G/'VZFUC
M7<7)BJ%;ZJ?]=\1<_JKK\1&-C4&S<(W/>]OY4(+PB><O*\%04A&6;@F#2;LX
M6J4ZQRB9B[O<Z5!]R/5G7Z.>-7NFVB?_#5V7_;:9++DG]GY9.H[VF9QNQ8?N
M@.4C\B,82->\.@Y6W4[.3;5574Y^'1YY3-\1C.W=Z-@V#T4P6AJ("2D:YPU_
M)GPGO=6H(Q2$J-/QIXLB&J7,PM?1<I"JU\3=[X_(KZM3*TU84>"SH;;=N_>$
M_3LBW=9R:#4%'+EK6^[SH?@C=BP70[R7S(_ZW-K JRI)!X[BZ.;XH=7X\\2!
M/+ #-DM1;7\R%(5,2>)#R\SHE<@+5[C=KS!8R\$>47N-;[$YMKDM-JS@ERHU
M*2<:E=% L-GP<!R8%B5H\SRZY$4CWF;A@DL8O^ *?V_ M?\WA&R>1(,["&."
M.^#_<A08F'YG4X;#/63$&LK_X>J-+C]&_V%4YHY)8V,_Q']?=-W_*XON[%XI
ML.A*#"^ZF?_V15>,!F<6Y^'D@@ZQM%-8^#Q7;;S$UZ].I5&N!R;3J9O*5]\]
M?N]T^9:Z_/5[3T5/?J<_SZMQ3Q/A(C85<TG+?+'>"E7>' >;TS6KG]=D;?>H
M*5(IPV9/-5I;=F*:?86K"N]>R )699%][O(:39V4@;LLZ_J!\_%^\^<<CH$,
M-:54POY\,V^+->:PUX/>K#P^),4UH/.>AY+:G@_>V7<OE>(ALR_FA(G2W,O&
M2RXE%72L%E]D+::T3LOJVFQ[W3E,Y\LG2/7IS(1J]6;,@Y)D#[FK!RRO?-V\
MUZY)^LMIFU5=AL$[7$@G$2P+IA%"F\J#M.*+'[:7*)66%SE^<YS;_./:EJ4/
MC^E&^3@,:E5;'^J:6=0)!O&<[7FME99D-*BSXQK7>AI8(K$('\(@RTB=N#X;
M72VP,'!0OY?O!QLE=?V3/0Q-!Q?'>=: [1[+"3L@#7.X.-8=/,M)$CD%#GIP
M*.B'+F_.!:OT&<5[=]$^4^[L^)2 R.V!R_X@]]#Y4*,'3-N/94\B\Q LU]Q7
MT?A-(V%)H$W?YF>^9B\KP?&Q%,<0(<7]VI 1]UXQTO73@C, (Q&1<^-M%C%*
M8#D2!Z8)85KL9K:;[G)=]_A'Z.Z7MZO@O%(^E+@'IO8@1=<1.3![Q7BA-YF^
MBQ=%W\AU8,B\OG="<LUZ2Y:CD9!_,EJ$X /@P9O#XT,U*=XEBJ<CHJN&E#Z[
M4%ZBQ]L/WNQ)63P>EF:!UKS@0]N*^! YGZMZ>P;!=*)2Q67C8]/=OK3#M'U\
MJ$J++"I(X @/ (0< <+WS(= -_.O=.GO/TJFI^$ZY*F#+/B<!E<-K+8&+<+R
M""W<U#:5ON*8N&MZ%UNB?!\"6I?AMOE403D+M'J$$O) H&Z6O4XS8:/!!;?X
ME<;,Z1[^Z_$L1RQ*C(W+NT>>F067 B;:^-#4EIRK%L;G._3NG9 M+:13+DF0
M+N8XXCX[YE;Z2365ME^8&:R7%(>;">:152@/<5S5<^5*V :G06Q?/0[,>*3F
MJ;>*UGX^M+6-3-L#HZ+1!7GB1Z];=:\:75L!%"IU^[XR5VTCD*9&@ FM#G()
MAW+/@,_YAAC'O9<YL8ZYH*X"SBO",J8+>(U"Y)1YF^\B"(&>XO6>F3#97CQ,
M3V ;',N!."!L1!B]?$E5KK_^7O'&RSV?74K;YS1.:B)T,86Z&X*1J<=38(^0
M(OT5^/2,C3U'>Z^!12XJD9*0>8*]1?LH:2*:.2# VZ[7O^MNH[G&I@J2UGW#
MGUT[#C XQZ+WV[[85+#XM 5$F9!]^ BA9E%P"GG5]:"G7P'0L8Z/"4@A3KK,
M.>/5KIQYTH2AD!=,TH.[19?)_1BA@4D?B*=PF0G%I)-\:#(#(]9.%LLTMZ.8
MF-AM*$E6WN:XI'_9<8M-C]:MGLFR!_;?1JA?E!WR*2H4H:V/ F-GQT!:^X>,
M9@7-!B_;]$ _&<\EUW!;%(JGO3XJDBX<D9/DK=,6%@XIPJ52NU\WPO7.C=]>
M?X=GL=;FY_MZ9+O4?CKXS6J%B4SOG^7K3<I:MD>?E2U2[=QP88+.7-+J7-DR
M8OJ==.J1QSJ>$126@SARJEM8<8-,?X;K4!1V,I>^HN5!#QQ]"OS=@"6EQ)$'
MW<,U.L 4FW@"1NN!^"+;XC[(ZJ9VV=:!*40*@LOTA%T>_6&<Q8<H9V!J.2+[
MZ?BF^S_"=/9\7ODI%)G=PP[- H.:YJBXJC>T01>;G,^4PZ\M.DJY7?G',\;@
MDV_;GKC^FF'X>MBSE)_>++AH4VU^M@M^U_XZKUE\Z"EC8[<]F0;6U81)HE&C
M>:N8J16*[1.XI,)JMBI%^:_68UB6Y/:W0KY.-77QH5+ )%CUG<!N2\7ZZ>XH
MM1,2=65P'EBH+:2!C#A4QM&;ZE,_PG2O6D9*H").:45UC]8ML 9SP9A&E O%
M\8K&\24S.XYBZ=%P)1"<@F0J<Y6)C.]403T*!T6TX_L4V._G0USE,TB0LZ F
M!Y5^'S/4ZRTHEO$4JV+53##5V;;C[MC'<<ALM-2]NI#2F>:IN@_,(J=] RIN
M@RGA D+8O\*B,!9) IP'U&DA0G)22:H^<H_,$-KF+F$,H2.CA,ZEUQ/4 J>Z
M)&IIPS1M;'\C=;BN1I.(^20IMTP%O<1F V\8#?*Q,!<"OF<E%9QN*M:7(G8]
M/#[KZWSOSEO&C*3.N4\7H/%94]S.@9YQ$^PUVN),"J47= :4:7!?BI0*YWF,
MXHE8LD>3HK:]^<^O=XGT.X2AOA$N+=D^(EEQ:#YHG6T#VCB:%K;_QPB+<4C0
M70&+F))Y,@<4(^4,#L%YGKC6]T+3$UCFN';1]3-N:MA:C&FNS:16[C(B8Q3'
MR+7#"<EXG3USVXU6R*\ETS1!AULV7"YES$VA>W&\QLWE/@_NXNFW^5#E=5$7
M&(/GFT-<B>(-G]A#8+LR1M*J'M96\C [J;JI%GV%^C968',W)8JG(](,Z=(:
M,!KVP@V62.;N+F;\9)VX2+&T;ZL:P%.WD1(2,$^'**CAX- @H2"ANG M3%L%
M.%PKJN( Y^T"1 \*BSXD*1Q4, 1ZT0CWATOB!$4JFH-F-V+2.KZM@M.NMW04
M@O75\LN?>KBZ9)7?LEG?7;@!SS(CMW\<5NCH==K:J99J5GLG%7.74ADMP^H<
MO79 T&3=CF*H@/Z\]=K"*B'(K![V46\A\QQ#!4/;*PHX^DVX,DY4/D,-R+%%
M5-'C\I/E0:DF#R>1N4OCD&"%$?'=AK$]):#]PLX ],H\<"JQB!BM<Y&.W!<"
MV!G=5.DKE!.T<<&UEI-%A31(;#^<H-!(:DZJY6>5-''G,<\(+%-R>Y6PD,;[
MSRHCKT6< S'QC Y!&8Z]73('@)!@E9YB/\S6@R#;>WPH5L0C4<TZ=GI [#MI
M/,L4UUY-%A;ZN %7)@E$+JU7J5<ID\J.NI#S<24]^!;A"[F7#Z4%)\VAY;YD
MXD-S%<*[FG->ZTMPOEV0C'<D6_&B_,'!'8]NXB._VV+I9X9=1-TE@0ZF&/'6
M9PVKFL#V$S+L>-=0P:-M4@)W*5;$MP9W"971);C<=V">#"_VYDG04_- 3[5(
M&%&T-F\#=@3>_9D\3+\&5X*]0RX9746N"43  Q&FKC%[?DW<#)EEB1+L%&AH
M"5&$?G]WC$K"3C"":$NP_3W"FBNHA:XC]U%)T08R!V4<I#58)KAVT,^QHFG7
M$+ "MI_H!VFG]+5AQ\H-3Y8#L' $'!<%<,K<);"(AENWS*4,%(4QN9TJ1('R
M/X>W@0\U\2&>YR<TC?I"39BV&/0OF L+6<0S1/PD;7"/<P=,PK1%X/T>T(W
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MO'G\3"[Q"=E]0Z 5>&TC\<2'\01VU[_1_&)=NT&Y$,B,>0858,^^.RNRZC%
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MM4VG_QZ^U#2E6F>=4ACO"%>UB7J12C<GG@I9^*+7.SQ3>HX-4IWK]=JZT7C
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M>X9'YGPO%[U\*-&Q@L#,P#(J$98F[+61#YGC>LYLE:JRQ7:[X]H3 %(X,T:
M5%/L6%@\+UD %H]4A:)HRB0^K" R'^+ !$"=1.@V1L]+N=*02^QC/N2Y&:'R
MZ.Y_W5)%V'+A2BL;/I3Q0$@ ]A" >)SR"4O@Q6.$S)MBP8FKYXS!'-'*3UD
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MUH5\1R6][I'B.\RF[ B;8*GO8.W@0X:S\\BL]9E\J"E2-QVQ'YS>1A6):B2
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M./H(*@L):L:P]^EXK';(L!JM*O3W]4!&8XX\"1?(/W:,J0=B^7L]D$G_W?5
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M1O='0G'#-&KK6_8//.PG)!O5_H$KY4,3@N]T!8&Q-OTP:P/8[Q(C</3%E<!
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M&_IE>A[Z59D/ 'H%H%$^Y#2*/E>!#U$&1O OGG\ICGFUTZC>*!D/.D\$G8K
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M5AX@W[/A&V'#MT0PEPE9<Q[MT-XBK,.]R=.U_W6[W:Z/5J#S)-$YR.GG8S1
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M2W0^]K/*6-/(GZ.USH$[771$R#M$U>57=UZ)Y+QN]FJPJ&C;KO584(]G[L$
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MT27NR6]R &K?X=4I.AF-ZT^#3$!XT]W#D1P%0'M1%@'H) "N$YY,QZS,]")
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MUU)B?_KGC^.OZO>F=.]KR%ZY#J*:@<-//I0PA/N6-&C#"-NV^S+S41F:YJS
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M,O::(7Y4A"FA@38G;K)H9/\.P+&N_/$F:L1DP6#VY I*>:88K=BO3>&Y9XW
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M5YUZ8N.P>[Q%:TQ]4FS,3*S!__A)\U\O?<T&[G%7#O 53_#OO?L@@%N5XJ-
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M^S(VF\HXI(+M>8=E#?+,AYP4=JR;+SXE0$0:F)A5@$Q9(YNI-S-@%I91>$^
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M9TGFB3-DGGCN+<G%7[OP>=V'L_:OZC9VOK[1O3/CG<TS:)&$N?1 H&SX8;O
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M&,B )RX6MOWHJ]!]NK+U;Z/W5M)1C%1>EV3.SD 6V!&VQS5[2;SST@:"G7B
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M+*3$HJ W8%0FJMXG3J#!G%']\C&+[99-@\B/@38H([FGY07OE9+&:LC#8?N
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MIK(KD?4G4+ *UA^WGW_<K^5;KO,Z.R,#?U>-)TV'\(,^F<- M 4SL0;BX$E
M/&MO)\HE$:.U9*U67!Z\JVE6+CCY518>6UE^.T?G.;(0V^ ESGN&B7&5:S3<
MFE5(:[^TUVUZ73.](V]%I27MTJU(_6<:"C&M-UWN+K#N(#J"(;S1R[49?Q7_
MG'AIJ'26O6PVEKQT.'D'&KOS6(BN_OT9ZAN_/0N;%NH>@4F Q6VY#D,=RSJ
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MBV?I$"N\]*,BHR?EE/?.=J_6'K?RP(ZYN(LD9[V]*W4MC6P])-OBO)](L7L
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M[+*V%</! XENQ?)WSEJ5G]ND\FO-NYH*<M<#/AKTJ;01'I(;B1^SAJY81:F
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MX^F[^ LZF7VF?45-$4$CZEI^#61';\E-WU([K:)$?84?.1@%6OE5/+UD:S6
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MR9FD2$:>YMHO\9VAC,U_475S2LO3E^@:_62--+_L^O"&T/SHSP3#S&\2,3<
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M\!\!&  0$!,<OH ?+P)""!$Q">D1,G(*$*'D*$!( ($0$D&(B8F(P+N>X'V
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M[+\,U9)W5XRE9S-MQ*UE\8JA0K&3,G1:\E#@  Q.C]OM4EDEKB"_-50T3V'
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M0M,6W((=W^T@[ 2%#LUQC5/KF-+MH5RSVP\Z<5=_CU9+($C(S(&-KIV_J(E
MH[AZS9_T-1E]JX<>. 7SB^(J$.OTB@V,?;%M$:F6 ]84+3T48:2MQ?<@EIRC
MNYJDF9KJ)!HJ$UMVM"9HQ)4N_NE2_[$/!.RQE\C?^B06&'84KG%O)^>IW:JX
M\EQVBOEFPKWQQEL*8J0;253\?";=SJEB;]YM7*$JP6F?7VG7,M1K<(7IEZ#B
M=*X*Y5C3\/LI=11>;-.XOCFOOX2Y)I)JF35JV1?VR=PLX?9]EGN4\>^8V-P[
M2+7D[TO$!#_B8"WIR^6?C.6YO9X@?C6'\\9:8U>BV<3B^R55-1\A-_F\"?,E
MKE>0H%*Q.1IF*0M(3BY6PZB[V$G'TRF,<?]I;]P<J? #R\OGE'F8:9-O2=E?
M,+$>NS6 !YX)E%CC@9$6.ML@T1-D8DQ[U)$$ P6!0GG)&='6>C>CK#,YN.V2
M;P:J)D+G'[A$EQ9]$FQQHDW&=A\=KV##"6>X65)A7Y66P;G\]7B;%?/<^H,U
MK[G&U(5ENA'1?DPBV!#IAVR()=&HII1;PQBNJTY$=VQ1"1FJ5+]HBD'>\W[H
MM)DU^+'+V'1!?^!.L>/91&;+M*AF_YL8/I]O;DG4@8$S&6NW4(^H46:$38P$
MXU%/CL\2W7X8=NV^ZXJF&OFH/@LO]N7H[9"[U6T:Y.<CN@OR !<A ^8L],Q$
MPT"W9JC2W6[;(Q1GPFUN.40\QNQ*.1C:3-QYUY_<N3D7?BU!0$*9ZQ:#<(-,
M]52"XJP,.S%]JY%KP9+(7O&M8<X>H8[Z\;O<; +V[I.ATU?!LOZHG6UQS'L_
M.<NT$)FW1[Y$RDL).KQ*<$VBW@ZL^;!V<G!A[T%DZ92Q29+'I_C"*2>QJ5=K
M>IMVC-S8F71+-\+!EAO,\9UEG+ROCK4+$;Q'>E+'FW,/5T=\"KK3?.)6:C^D
MY#8-RQSBCO_4\-MZ(7\A_F.$2@VNC9"PUCM#:-]9XU7_O(=4X>G/%9_>WPWS
M%[_GM-*]>-TK/EON-=JV:=A2)&:N_S[3YUPY3J!\?C =>'C\>%"(?V!=OZ0B
MPY-2WHZB%M?Q8_F]\^$.6W.\)66!I^R@U^<8&0HI(K5OA;%]<PP:F[KM54S0
MN?MT9O=A_^>&I?)9CG>;N?O\#]5ZG%GC*(R"=T2^;C!:LE-3TWBP3& $LA8-
M8YZ5*!=:<S6GB-)=Y%7P67M4+8YQ,#1A[KU1ON:5=;="+:^D=D5PZ-+'ET=N
M2'"\7)1A3Z=O&T1'&VOH]/ +Y;BFJ=+O3D<U40]A<L#1%M;"6!6Y:AM;-7]E
M3@K3?NAVU3?MN1CG A7@7&Q (1I:8+.9PZ]N#*40_Y**B&]3<"PV>TVJ,RH\
M6'^RE5PE@'>!V>O176^8//0KU]44-[9Q+558THSW\8H>_B6N$!ZFE^GM,70\
MYO><J]DK%\\.-K (][T6FDZXNOP,^O7,F431#*E%@>I^.FNZA=CI1L%VT2@.
MI*\P\P#B_#6.TZMU"Q195MLGJK[:N>[W:ISUYFG:@1(,6QF65$6P?'**V+U7
M(Z=(:T\F!DSVY=6?CJ-KHNVV;^N_?FXOI+=VGH/'V*7.=V"Z&N5K(8H'NN4W
M=&; ='S.3D!2C7WJDWGJM59;5MJFG8>J--KGZP%; RG/24]2]<K8MHD962'^
MDMK:CY MJ"\>J/^*!YX3!^!(\,!6]J<.)R.ETQ7EW4M3CA66:2\AX6ZGP^%
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M#IE?E%YJ1E<N2S2] M?@ED #%]KHNWIMJ>[7-=7AI96G'M>*K?I?&K%'U9F
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M^Y9M]%>BMO,$C\M\Z2M7/QYK<&/;KK#"*JYHRR&@!KM>U,S'[M#-O+9>$\V
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MBRRYZEWJ<X,2C]4J8+75&1_^(>,M_;;BVJA0<# "#+D6!2MU3V%9E0F:YA0
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MMI*!R#'\X;KKG]>UDH0B[7#S^ZRL;'!NCW&$%^!DN_9D SCY@38T-J9:PDC
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M].91WF6FU?^'&LVYI)542.XK1==LE:-!]T#WM&P@V-C4PFGB_]<!#RB* 2E
M3% ]YA02P$& -RVR_Z4E8T(_M/P(@[S66$37(?FD;4B \%Y[8A]ZZ/Z%B@M_
M2?HB7-$]IP_F+*6"_R7E@&KJ#:\+]$3K\Z&?_8(-#$]R7P=45ULG!0CX,*7.
MT4B7*Z"?U?0H3.WN3*O*Z%"PS'"YH(YPF@I6#G@]8D&3&O/,LB5U!&63.2:S
MK8:K-'JNM%JDZI_'9K8%U8,6O&;P9#] 8$L"MH\4TR:C>" O.MN#P%>%DD^V
M6"IZ%!RT>^K7!@I$!3?)&#1JY%EH([K_6MJ2\)<4J0-$'D0)K')VNKM7;>7
M2D R^';F2U7^;6";L/NNJY9$.4-=0?F4\E%U:M#>H\ A)J7-@;H4BLOU==@(
M%K)V._*G#HSK T&GIO5&&QB&W'^Q*-,K0X&"(B7W&0K*X!L0#6@@8[QHD,,G
M_A,@DVHK^]> 3(I]0D6#+SAHE>P_C<<DJP7JX.!Q!V.":E?[V9+E,N(7.8K[
ML6AZZ/&@/H+>7P]=5JZ/?M6])*B;UO)UZDE@%W9!PU^BX#GJJVG_:O.VW@U"
M@?_GE^6K6\;C\B;G8NU^JPS6RTG\<D2Z!M59+,?FTDJEJV91.FO$V#>37)Y6
M<SOC0U3<H4%KI8$_L[/##)?;I;(1/H!"CXJ26-[>>+W*S?>---_,"3_RS$P%
M6WV.2NK>SEXQW6OV;4EHTS)H'7)QLTXH.]5#P@,2 "V\!KV'M6JB:UJ()SEP
M\H 9"5CCTB"$"Z\0T/W\J+/J='9S^E@RMP^LU>%OYS99Y99<O[*H0^XL; TF
MW\N.-E/:6/$(RJT*Z\R6&LB=W6O,6,K%*:A$\_4[-0@1DI0"#ZK379LS*5RK
M7AH)(-<OELRMLL;]\-O<P5]Q5WR3^_)_D/WW<W>O<I, <U60'0VQ1QU>(8!-
M'C^*79T./>?4/3-/X6] D]F?_$_8=;1+?/!8O=OJRPZ!8BSAY8-^R\LM*O*F
M.GXB<?%9EBMU+T0:XMJ].Z6GS3;*FEF3964"":M:*QO[5=GNJ_R2ZU>&,5YP
M]+^SZPY%;R$!8XN%@Q,D@)\1D3Y  K"%*[=$3V* &F+-0Z(G"9C^#;=^]6Q6
MG99E;)$$4/CEWB+6Y3#"C+ 4IM@QME6%>F* )W,,_S>YI39R[USG+MK 3?WN
M"J)O9HU,1*_*N(@EHA'@LR^#"II9A'0(P<H(ONC%%7 2<#+P90>Z9A"4[+HF
MF2S"< ,Y=HX[\-^98__%+%<$3NX0V,7-9-39QV3$-\FVWR:O<[__/OGV1ULI
M;!;X9"ISHJM52M% LGNN\>C83\X.HKANMY^V]W/1GRU)%O6$*KK&&YBJOZ'Z
MWZ8>PZY1.T"5KY)QZ^20L6N(=2WN]0@8)"LW=IUJ\'=0X0^/!6\^_ BV9++7
ML\1Q]?&ADX0_?D:O:N4K<JO$&KGLGR87;B#/?XM<N)&\*@2[@>R\REV^D7S"
MW($!<7F4!/Q!5@HA>)2(1D-*"3><68:4HO\5-?O[U+#_/=2X0^'"._.''(F)
M%%W8KNFBXBM=?(M,<^->#[X1S2HX93>7P_LI4'AL9?JAZR ,=]70- =LX;I7
M;HG@.7#*:4FVMICNW6<U/R;,6:<L$L@&G&Z KID [=<!4QF#;4U>$U_U5:G?
M)5_[$3+8$/PPG2HUOK3)\=$6\^:H'Y^IDF>KJ GU])>,MI^-;[N\F[B\?8DQ
M<F?L*Q]37_G@PSMUM8(44I-U3X9FLG OW!RP]2S#M[UCF904[!LY;>DN*G6B
M%[;-$NS)^2;UQ5+A0P\_*/*U1C.G_< VV"9!N. CJC*A='%9I9CN3O$7\0G6
MLN-1J26[!/M>\.W**"RL2\ALP/G*X-^%A1]I[[ ?.;)BS89LW)J52;C_='C[
MU:-A[VI5;3@9#@3DJJE[)-*D_,!,AYKI6;N>((NS/;N((E#ZQN3QNX1D1"_/
M-M[=U<:L.^5G=\EHO-K:*:7C[N$F'>XCO'U,X[.@XF'FZ/UO"7 :VV[MAL^#
M^_2Z3HG%(D2."/8E'[?"VW<=]'<*W'*N$P4/4#UZW6^/&TN.0FU YD<!>OF+
MM7ZU7Z' OQ7\RC'G[S#*"#ZFE;>Y9N>V+:SY^H#??LVZEQ?O-YIH#?CN[=U?
MQ:5X^^FK4H2/0S<SDH\=V$+E"*<ATB*YVWS3XX>%]B<:GKAL4OU6U*<SX%72
MN*3XQ'CP0+U))/UR&G\IXI2^;[;=BX]6X:ZYPVV>2<9>LL&OPXZT++_F_"*4
M$R7TN9X$*&?EI*IGU4=;-$ITQC;0Q,.IQ[^W7VRND&+)VNV!.:[<E)P>"%=F
M,F\8U94P6E;->+G#B76O9ND5I%QHV?62DPWA174G3$W9=1\[69I=0C[G>?E9
M9CC8,R*:.:MW@$F1R_JN)CS\V>LW[.UZ[=9#?F'I)0=H;JH/TM<NZ4HFYF7S
MR=9FM+:[J^OE-S#7[*(]@?C#?"JA9G_J0H0UC\*VD>VJ@_"AREOC=LE'?L#J
MD@Q'N6S#U V[]=IW+,?H,JH:/!^L<QI\/- [T+6W'SN15\[-2$?M-POK0^YX
M$BEZ1]/"Y+R ?:B3S"8WKBIL<<Z>%^THM:>HDBLO,HKKM[Y9,FY.D]UA?CSE
M=HIGZ=4B\<H:HSW5V^4P:JD"T@_-][3X3MB(YYW"?:S8-&VCJLQ>QLKVJ."T
M@YHK,)'X77=+@YBV'9$NK/ @TZAJ@&\@[FE+6%;+_J0</R4>U0&;BT&*O"6N
M@*GOLX01S/A%%]K24[[3CP[)98Q6G2E_DYB;@V%]$\K\49 Y85C_L8]]7-?"
MW-+ V^;.^H^_&TU7FAD_"F]#?KIRW*K&1]!&06^*=_:3U+V4M'B7=BX3([=K
MT<PO>$WDG8Q*B_@?]&\[DZSV9N:EJN&9LOWGNI5X=I$ 1K8@.>_(T>^];*>Y
M'_C=O^^' :*=.^%6,*.C_MEM,]EE,W1CH.)2E':?8JL0?7K:*UV*!Z#7M/:9
MP@RIZ[4.T[+6FST^(/&'X&8O&3%#GI O(R[)]XJOHGQQ<2\*(L1?BHW4#/8_
MOR/37F+\P2.1^GW@'2>/,WUC<T=#,XL_BJ<=WF(_BM(N7[#6I-=Z53\Q^] #
MH7WW,!LU$** S4MH./[LZ??WZ)]DY67G*;A9]D5H5%[62*-ACAT]*RV#?QUU
M\)F"J)BWTW3*N4O@S.#Z+.SNN'Z6CT.;@I=SZ_CI!AM'9SP)2/>^L:A.;R)M
M(]OE$73AU)Q_NWM^W[%\N8(FAU=)8L9J/DAF0;T3#H)$R<,3GVN2W5I4GG3)
MQ49_O* T/W"#MR#.$<GUW2]!F#K;2Z[QQM9POKJO(BA?8$:31!WAX<;A$]NA
M$DS/>&\^*I!*X;6L+O_6YY,KOS>8Y5[N[#A?(1C-<VOP%M\;^XFR"22O,Q%G
MC'LC5)B#:1.R>8(SBL8JBTD?$]?<'OEN1/1.:%:X?QK5;+);<1A7?V2D86O;
M\'SSR]^U;22HQ)1D+ATS]T(0G)-Z7BC7:-<U]U9_1'F]W^,%-Y0XT?@;G.;"
M3WCY8D9QN\@B>E\H3_5$JO#*ZZA.?JA)T_YT$Q!^U,^%+3IJ,MEI%9G9:,/>
MYK?<++Q<QMES8GXN&?-C>P<U3<YJ8XD]0:T&';$%S8?J)N#'%7GZAL_F>3^W
M#N.Z<_/<B[&PDRDB[)8[WW RN@ L%[[D_MA7R X7$-V'0JWMMK!5P7,QFJDG
M:WRTRCYIDP VR]O%GCO#N"_]GG#YI1VMIZD,X%U:H]P5XW6$<-%\ZDR4<;PX
MKEBL/BX\_ASFN7+>R[*>N[)@EYU+]>;]]SWX;'*L#)N43;/]&"ML%88(ZF^1
MG%R1Y:)!U6R:K$POQ>_Q";EY73; ^GF,UWZ!*8:HY%U<9V*RX>^WR^SB-YD]
M1OR,X,I\8IF@6"?^7(7.HC%,M$$P[,A<F73L]Q]8WOE*6%C]F5$!$0GE#SX?
MEP$9H5>C:#;13MZ3\_+-J)X3YW;K"8FR+O.-N6&+1MLUD#S).&LGZ1?<Q=;6
M_-.]^PV07NDQ^TIW,><J]3,&MU4;Z'X0T+.(P]0WMY=FS_P6JUBI9/:V'V"6
M&360_OZ@15<XV?KM1+NJQ[&SP67HEC([B_$![&>:DHH1M]GD- SP+K.ES49N
M9& K%X$_4YN!K2A-Z?C)I#$Z$:9!OKTO?:NY51)C7325'O>RP<(XO(WH1DHX
M^P*LXWX Q?(D:>0>KH0]T/+:E8!EI:P[I5H=-ZI%".Q450_W/[O^M$C7MTOQ
M4L;=(A4Q4R[-(BJD["<'!ZNM<CLFFS.?W35Z%5P]9YCQ9K*XWKUD@I_F28V
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M1?6.P\XVMJMEO4)G>"GJ^H=?YXO@F:IRK.E3,I\J/X=[T=N&BKU]E]]8T#^
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M08F%8I%MAI4,\ 6#R-#$GPPH6@L2XU##]B ,G6H"0:*M$N!!78I:W2<-)=Z
MXKET/8S8-CS*4[%H_2WMUE17W4P4LHS=W$G10#UR^A<$2+&M]=S[:Q_*I6YV
M(0X JKP=<V=?O_;7R IN[W&NNGW_V:-)C6*].!]:P6_2H(P'J:"16$4*[4(S
M#?5AV^&S1Y=B&>JZ2+*F9, >'GI:RQ!>G0:=%5](L03B @7_E6E31I),6*=V
M]_P#_F V1_[+ES<IN2:B*NS83E\+1K_)-XW!K;!.X]$$GSEP&'LUB)O1#6$P
MS!C;6ESQLX)G C122K(Z)/^8>\\>/U2O/D\&Z.@J48MKX!SZ#")P>B9B9""F
M"T:@9FW4,HEYE4BX-RLEFT &GA+'%'^KK,JGHHQ6T%&X&SAW9648.P()G/W^
M8[&$$YAKT*%E-!F@J'1H]4_D+0M?$,_[7&FVIUQ[SC9X6;U7BBKBAD4(W1Y;
M=FK*P,E4?QQH:>PY 4>W]N%975@7GR0GHR-.U8VE*^6JBRV#TY0?=")0,';3
M?T!B?(*R1*YR.Y(!_!+(EUHJWW,UY<>_"ZOTE_Q=H$4P+O /)9$03+%O!4;!
MB=DN<%?9&2>CE>I$I]8[F[;NVNY^6YZ=!$&+80V5E%8%[LJ[UA)5DM,C!IWZ
M&!L3N^'65GL?[^ZN*3[?[8ZP[FJ2463(W*I2X6(M=WFZ=]#GR/@?).#/2O'I
M\!H&,D J!HVIIK.>$^9D@-<>7B R7FQ#DG<A ]@Y =(MF['3XKC%>\0/)J.Z
M!"EW9,VB?0RW%\>EP&O8GJ!RN<>36/4#<8&'P.4_<5K579,ZW5. #(3LADY-
MVA%I"P,'2#O(0,V#&"SV*,G7N-*SZA!QT#MM61!.*W=3B457Z-6WQN*_,?W)
MLO!W$K76;:-KJ(%:L2NDEF87ON>]F"2M6=2 <>CYUIS3QL)]#06/+ 5HXQ]6
M?]3< O/W5.--9<_-VRW.<D.:>@4R8$SE5EF<0.)K[_40]*YFSKL2 @4I?BTY
M_O8BQ;.UIG71_B\;-A4#,O" APP0/6K)0&S$O#@=#GX!(UW.$,5D>/W$66<R
M< -JY!YC"CO1TZ7B82&95EB4_Z"J2YUA:VD&3!>SQ7]^32VG929]H=2YU&++
M4;.UZB;W1R9AC$S"]HX350MV&GG#R%,'K<\[J_I-#43?(4%V[IQ_,AMR(SQF
MH165RMN/UWU@&T$SFI-O'+Y=*EA)-@"I.'\T&$M'!I@;DZ;./"DQVYMB$O(
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M\!KW>E)Q%U@4R0AJ?&?OU$79M"3BB#NT9C0Y+G#U]N2MS^Q$5P AW.^T(+I
MZHIO%"% J!42>88,9 RMZF;HHL#ER^"->K[XM!&S>P+O"UIO'P;_D;CVGY4@
M$AO1'^*?VX5.H;YV-K?5X&-W7$%7W5YM\\T[@9NE^+80>OF+RC[P I%0W.U!
M*X) ?*?U T,UIS<S?#:NC>\%+RI3H^!E^<\QP>>V>+(.TH-UYH-6'+"4,BTZ
MJ_700W6O,KLPQF^SMV3]^,YZT*3DL.9D365*TKB6^V8>3D_MC-9>VOS OC,_
M"5?I.9UBTW_669_+AW-/_&*E(R]-"[8K77FMHI??U]9.7.M2[NOS,5DGI$KE
M$A8L*7-^2]!^LP2,B[_Q>0/37WW;.:Q_6QG_<O^NX _Y'B_^:][O7W,4^">*
M[9Z0Y\W9"*&^WX[TC6> ZCNA'[=!)[BZ):UE86%/9\RA<R(?2"J22BRZ[R 7
MO@@9XR9PG5UI@4[ED;2G0H?=OUD=Q808G .6R/BL 7Z74:,5E*#+B.W_ROTY
M7]*?8AM%7;.Q4<HI*KX?:>/FDGT[1K#?I\+= :?S[)"2/6T]_5W^JP<S@AZH
MM#^KXSGUBDJU=/-UFSMM)(Y*T4=&KBZ&K8X<(\>?BIG+J4%G'2%^@I1%R1G[
M+V;G>MQ[^E!0\YJ%\UO*;G2D^*V2/7&KBH.;GF!6@J(-5]M?/)IOWYH4.%7!
M6?4<::3LLJ>G=BW43O/V;=RHCW2QR#E2>ZY-<IQYSA5B>>X6)=+R<<93*%5
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MI9GV$OGA7OX<#-*A#YRJ!W]E+(K%Z4=N6R^VWST<]>F4K"#RPM GAE)L#GL
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M(Z+#GW=9XDMB!1;3YHYVN=FST:^I"O<^Y2C%LE \(0-LUQ0?1&_![!"_9!M
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MB/_\1J82H/LY&_&Y^,M*%HHO%5*%)DMM_S1#C%$Y%ZGOYH12 B:JP$NLV2]
M >Q4AW"QUQUOUG$4OZN&RR09.! 7*!3P27/DXC18'*P+:D)8?8+WQT\9*6W
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M-#&K<;#E;L_#(\(5#^>3L*4H? -S Y[AU:J1)<<3!=[]T,X5EQ?-K0]W?)D
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MR()?QVXG\8P4EJ_W?078)RYP,WQ<BQXF7"?2*""PY)K2;798XG1_+'AN2C&
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MJW5OR29-C=W"<C-<?$D;XWDMMW.@C,+ZF9LJ\"BYM(O'/4BF@Z4!*U'0\*\
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M":LFIN/4PHF]G)33^D,!GP):R=9>>TG8-.)51RK@(!Z9EM7VR)C.U+]P0KN
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MBA6BS:O),K.I+FR2F_%V?G:2;R=U^R8ZRH;*4.\4'P?*V><[%S^NJ$Q9><K
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MJ:MX_1KWH29.&_Q);SH.>2/FLXD,0?;G+0IOFUWS^,A#;4;B,7"NVAT['*@
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MLXP\01I;)\I$+2LMP_3[E*K]?4K+4YS8OU[]_G!."&VU!J.Z\0XY,N-,+5G
M%Y D$YW85X:V)2E]C.)-1.C0;&2P.%*]6Y*LV^Q^^'F9RJ,CW4-Y1SZLO(EK
M3E,38>=J2JTF"5%2J,-D,:(=YJW?\+A$SCB"=T3[O'Z!P=F[H4G<1X^&;CWE
MWCQ>YT-U]59M0E#E$+$%I5)"+_SN-;BZPLYJ[34_JFVBN==9/&RACZV0S-N,
M*%?]@MO70>:TJB-AHTO2=@M9%40YW/]$:MBK& M<9;]PVI!3 S^ *N9<YLX*
M[L5P;F#$G4BE:38/'E.:ASVM1MZKMF9,/K^\LA>K2Y9(.5 ^P3 RK(R[5UY=
MFKQ/\O;S]J]FZ*_X62R=KX5&NZA+;9[PEI]RKMHIV1MP^OF<+E.MA&U'%2$5
M/ 0ITZDD.3:-B5$=2%U7T,TP@5^S8!+)1?1NJV-?X=X<#^Y<5I/B.25%K"O'
M=BH^.8WCPXUC<7S>\I>#>S3.V\O7%I"$==K$/4Y)O.1A >D @IHT"1E&C_,^
MF::&%Q"H\&8KA0R+2;/N)3<MI3,K8H4E["4\TXGI61F/Z[XQ7C%A3BR@!%?/
M$&H-4%)T2@G-K"Q^/IU?<' Y7F,+V-"LWU--$'0^N\@4Z/=J2_@606EW=31:
ME<TZ!7F![7*G2DJ\H]0=H.9/C'Z[]1F??/5%T14'KH.PU8$W7%C:]>!^G"#T
M(M*"E-,0".,:G8?R]I\H&OYPZ465]HQZ"_?%N-F]GG;9))0YH_P=]=7$%#7T
MG9\*;(_R5]&LFS57;A\X<,WMD>=K'VP&<R_SIX00 _0=%\30-7<!9ZM-H@M3
M,F%I^=V TKC_HXYJCZ^M!&%L23!', '"B7)R\YN#BN.G"\EL;H7. =_V]#M_
M%8%:2D6TJ#M"^]B6,]3(+6$D?$,5.@II]-%ZKDHPX[%^WF+64Z))O4[PIW;.
MW.,X)9Q3%U56-5:>V?&!?H(4:.TG9\=]FX@Z.%C7>>5RO G_UZ%JC[835239
M#5Q+QKX?=<>I]]8;QZ1[EC?S#ZT[#LD]Z/4R6?+V'KDXD60$QC0$7=#S:N$/
MZ'ZZ?&])AYH2C3O(SFFBM#165]SEF/CIT)"3[!L)5VO<M/2*JKRYUK_$%V$O
MW;S<NH@XR>Q.35D.=2>KK\">B"*>S)(N/58L;LO5" [4*]]**Z^0G!GWB&5#
MF/HY,K5K99BUQT%DV.W\@W/6$#?I/LP"&G8DWGYRJ4*%W"_IA([IYZ6]L@,*
M=:)OOF2NOP'P'U'U*BBGU2A"R6PC0< /0^2Q<A_(+Q5>*JF.@Q*^KHO<*)E(
MD5$;%>2EZ?94&E%EA5KRL/OI)[N#^?T"OZ<T(PXJ]/_0XHHGW(7?F)2LKM9Y
MV7H4EQT$HRG114JH;"18@QUGV54D0Z53>^DSCQS^NJJ!3)U-V;ZEW4" -U(
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M0W@F@**8H?[SQ2NJ<K, >00]L6<PTH\I[4M7!14S=M45064# =WX]Q689[$
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M/P\+/*V$.7KJ&6!RQM-N-ZFQ!78X6&2 @1Y?#7.@YI*F;R>+:;HNYSF(1;*
MFT>C*G<?"/2TFZ0=;7RCAR78CBP0%XD<R47<BQ>.2SN-CZD<EKER]MEYVSY)
M8>8*5]]/V1(FU&ORWNJJT^O$U"V%GYN%S^3++^CA H=H9<.#0W:+9:^'G1@,
MR*O-7WL,1JR"WFW!>:?KN93BH="%T'C4:2)NPM]/C!E&1A%R8=34::6S3"E4
MFPT5%).(PZBYX[4%=7YDSF=*,!&D%37 RW6S3G#K4)1/GL((]LBE#>4-S?^*
M8>PQA;"<[%E?[9@F)KWD*"+<::3-;OA]CIHQR]S7I=G<U ,YHALEY3CD]6U2
MZC7J$\B")X;743\VA9A<+(#F$%2I_8AAD6*_A,+SS#LO@_3-$JR(#*%?#';?
MD<@$%3R"!=S/8A[!J3)XC5'C6!90!A].--ZTTHQD5CC^6M,'20%Z&\('$N[R
M&3 <+2C2!4!>V [[8ST0\ZP!&)YGE8EB 5.%+$!RW9&BTZ,32;MA[4QK>M_]
M8'Q]U_)HB;W:<@].+V\]A^+( A)J*D 6C"=\QVGG:<A\81AIQ;V;1F?+5.=
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MUA5UP"YVNY&YKQ14VP0Q%-[:G;%[<=F*FO>G2UM4+%-7F8G8N::V1MBR1+*
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MD_-!?/!@\O_^5&#GO#8$GK+^F058G<%L*.1L*:[!+N FD,'=B/4.T'CU:BR
M"_:'<X9()CJO8WL E2]LM"-D2DO9AJ1:I2P;D(LOUST>-O]YK_?]\UP^6^=Y
M,0$9$>!9THY6EHV>=]9 UZE1N><Z2V/O/DC7[6/@HL#';YY8I7'F,..P-36@
MDQQGO@*C1"%J;E<L[-QKXN@2XG"070'[[I@L':51;>D^$]LXL/>KT=\;_LX)
MT;].LL15?BJ<DI'6-%22:E'HDVIO>]7-S/8+$.,Q= :N>?:F66Y;-TYKH.,1
M=>90HH,5_S)]!;\![<ZL R'ZB2ZE (3DG[/,/6"OD\$.E:3!43]<0)7%#KHI
M-;IUD7=;!(3$/"\6,*>._MN[,;3X:*H[DP\R5,T,@V.H(N[_]^LT>]'+MF X
MS^NB\Y2S .+)G4:F#F1A%+9S((L%A**^0*?^OBJAH/U>1.Z4&S'#0/$XCB#Q
M5I[$1H RDH^1AYM3]@<+2P:Q6#L LS3[AOZ@5\/#5[$I2(>XJJ4B5RA5W#1N
M5'OF833OZ*BYZ'?#D7SQBD\1PB[G/A4F9CL4)0UO_-B$Q&X1^.20%T#"M]]K
M5-6TWVK>PF]3KZ:B?W]^,J>D?/4MN@&R=U(1S0)*C$+H\ GT 5<)<5*-.C9*
M1F7'RZ.SUK;>..+6@)VE-[8T;YIW*(]I:$H)!"-0-6INP'6Q*"!QP6RG]MK9
M^)+T(=\>^8(ZW4:BI%3EI'09_7OO1$8Y[?((M:=%4<S/L]$G0_06<290['.O
M3+M/DLB%68'5Z_4>\9P/7+^S *?JRJ5@#NH:L=_?[8%D]XKHA;>/GL4>'(\0
M#UN1G>$-0;'1]6E:=.5NI.XD5M@U632H%#>H=-%-97/R7IQ-<L6KXA2?^\_\
M&Z+#(W/B,LE)-LXZBLG=1K:*I9NH-]O3U^R^GVJK]89.O?\4O3U47XC?4Z?-
M>*-Q.]</-RD37K=W'BJ;TE!U>B FW=7\)KWR71S\:<VWV+/F7<;Q#96H6,+^
MC:Y!0N-9^B7J;3*G<8)YSSV=JE[O_>[+N8'[;HGX""YVY4QKBV>;F4VJOR[.
M_62>9C57L(.8G3G49+4LFUVY=4+I:G9TQ.[(^^MV-XF=DI;431)*FUE/5F+R
M,0>BQV86UII]]:>*9JX^I\BH=94B9\EY% \2O@$7J=X5I:%*EFTZ0\W3CEPV
M_K0S\?S;@FZ[O7P&2G2F8=P)'Y]C@I4;+JVT7ONY@>^K2G(0^);EO1!4[N]!
MN7AA=@C1'H=Q6GAX/GK=?9 %3"(A$AJG@O*MYTV=N5V#Y*.BG=E73M$OH?,?
M#@6G>-(,F1U0D=J?W@Q][3[I$OWAM$YI+>XV*9?ZQ/'8/+ZO<ZZSA(%%BF<D
M$1[QH'0;:4^4%W?>Z=6E'%%9SHRX+<:>#*Q9BY-M-QXMG6O )Q]'%C^)'ZQV
MWQHCR(I<*V&\XQ?HU9TS5PU8D7U1X2TR4Z?"^%BZ*F+)[$/P**$X%\_-XW<B
MTD[4Z"MU46ZM2N8F7ZUO3+)Y\=Q_UV<H%+FK'^:(XQA&7B41T#7:042#<PNG
M%*?Z%$6(E2,/.XO5V&&-7^NA2>GBF0("$@'MYS[6_KRW66U%L7*G.ID5[O>T
M4C4>H;U--Q5[J1!PMS=OR@U"\2$K+@M,J&FX3V+%79)%^_-<I'N5&((3;XM[
MB;>KSICQU4Q-S69XI,[#;N.BK%9CF$*+5JBHU=2=Q4:KL/G%H/,/?,/-^&JK
M7WQM6]KM:=%A;_ADH??CN_&>^.(>!L;6Z[1R6GQ,'+9P(^N,><=!SMRWEF>^
M7I#(K),@J<50:L@IT4B]29B8G9/=_E[WC$;=;CEEV.=B@.W<!8[#+6.U>FHM
MLM8-ONO,[[ 2]PCZB4QJ&8K?C[OY8W=V_C*U.KE]_.%>9 +>O>_L1D'477I-
M7VW.ZIV"24<W@:&9E92D*INDI[79[MZ;+" DZ)7!6'79U(/%V'6$1'#?T%9L
M/LJ9$#%D]$2Y4BF/<:5=WRFVZ&Q97+9C;#LY+/)TCN31M=V>+. ("[B7#A_'
M-;YB'IN#'*S1\R762EBNK+ROKO4\4J_P]NGUB8>&/FM[B=$7#"Y\A/84Q?Q;
MK]NA(D+EM&SZX[9]H9WDR*?P!CO^?N7RT )3PY+DN8;(W0VG[K#195]21<CW
M('&8 V#0%;R<HY_=ZK4F,_C^X?2ULO,O^N#Q=%/2-N,MZIXFI#G%JC_W[<BP
MTVINAV#:V3B%NP>?SQ_E<.!FKU]R_8:RAPSV0_C])!N8Z@DMT./%*EN=JA3-
M[&%=IS%K4C9;/2=.O#]QC7[NBUF>%;)44O;^:$F >__PQN%\F$NB>:_NR(:Q
M-K)^Z+]INS_JRT!Y/WP,;&I* Z1TM_QQ&^<O2;S2U]/_NS<M2MS\X^NLQ#^*
MA;^[K(-CJ-9W+&!%=0W['3= 8!IFW6 !!;ZX'3YLMWX7=0/#:&&:;^-I( 2U
M];E -K]O@31,>>LU#$3JI58Z]Z8&TIT\%P!BSXXRR-7K,[[\/>)F>YN&0K7=
M(;$ 1E@O"]#!CP7_VO*)N@XVP!*WP8;8$TP@K%G6@+7<VF !W:5;F$C4%*(7
MMMBOR #@ A!B'^Q2%VI*/WE'?T/IU_(>#/8/?_-R6XOR$;1;(B,#5$L*A!T5
MT9VZ2D5!I"P)'T<WF.A$67ZF6>1-;,>UI$/7ZDSC#SQ47\O"9@?<#)86MF+V
M!UKIK\8@<N.<U)]/VR%>A='T46TX^B40[Y2[F"&NO!20?"<XD(08_C#FL_A:
MHV8)L<]D=*3W$5[SR&71!V_9K4>TXU4E>?A>]$:'U=OM[ZF3H%H;D58BW2D&
MI^MY?$C)\J7Z@@L!:P:0FY%]=F++GNO^5IV<DI0:AKP]$?4L@X-4'#P\9$77
MBA!!'B/*JW$$9IK -,TR'X]^K@?I@$MM_#I%BX%1ZC"OJNSV2M/WL?FTAKAO
MHJDEB$50TT@)#3AA)<@21L#YK(O%1U^=SK6VPP%9SRYC3Q4RPIB'ACJY;>:K
M,O(YI 1*^DHOY(1)I.UKT<P;?>;*E>BL8[Y@^M F7]=LN9B:A/%,&5!K-]"^
MN(BEG^U@#HX=K:1ZD +K,\1)<>M.HH)Y'[2R.WSO3@F[J4RY(4E[5S."7)]3
M&30EI#@53I*UPM_(QC^U^[9?U;Q/,;9WU$;\UMNN;T8RSRY@/]$=2;A&R$$-
M4:1\@?.9,:= 0:6R%HTW65PWGIF%]@K,V@DPXIC"5(N);%N%=7@3KSM/0/-&
MBL>P),^9*)OGKP.X7DLXZ_->2YU-M+D[7%K+,(7[VJ5?R=YWS>BWE:H-V>"V
MCSW![5 A\]VO2MHNL5=VX#-0]5 -[6Q+NC)9,_M[EJN;MV"M"O7>*^,(H@K)
M*&#']PMS7P_TB)]%8V.50&5)SR?3CL>'FLL*/&,S:EW;-A4'<B8L<B>%R))S
M^#-VFNVC;>[N?N1AC=#RJ98#>T>_RZ;;?RZM*^7*_] 7'^\L4_R@T]9W!5'T
MVE_<]UKK*^8/PAH2P0%;',5M7'#]@7O0M:V".8RJY63&"LS7':5>GG#G]UN\
M1([(RO'?H3P)EU- MDA8O2;'CC,F^TN00>-'#A-]PU?HFD0Q1-D\W/KZYTC9
M]!S)%RNR:C/\23;B2\O7\-MZM5 MRKGI#[@T>BPJ%+6F@SP,#L) !$.P=!V_
M)'3/FW<?W:QT_^>N@D[!)4>QK!:4U4[CY6XYNG+FP+PZTDX[+E&6@V_VHK$.
MT/4##B.M3NA&! LT?M2>R(<M\2W ==:FW.7KKIPQTH0F=8G?E=0_S'VQSQF;
MX&["2)L)6_:<6!V$C6,:5D5LJ(T-!#ZOO LUSN]<BG0*1PWM[T6&AHN(?9[
MK;Y%&/@941RI)\:Q(LXI 2H)[ZVH$4,(]9X3-=^J^PY72"^]!HP,?Y:3M2@W
MJ;YD3ROTS?Z-J*/]0F$?G,OWNYV??#]CB+,KA32Z#^I/X!NZ#FD3CTA>JZC
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M\/<N!_YI::\+@?R-5/#*7SE[-JHD4/^#]=WG1JA#ZJI9I^Z';19$U%V@9M.
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M(FZ^W)+*V)R$%*H78,CZDP_2[N?M3PS ORP\.2[^F9A9 .$TB4/9[TF7+GU
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M5E%M@F743Q)ME2P@ K&T0%J@ST$(P;^8YX-GTM9 \0C8KS4@)3'ZD=4]XE_
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MSK,L@+8)XN7[-1EGXQOPZWP0G"5O@X%BU9TL( 1.@ZC[Q5S$*J@/GL#0;%G
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MF#;79<Y-H$E7?<7!X%T<D,R^90$4673M&[(^<Z< +\AQ'1)X9';*$S,JK+\
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MR+'CHN7WS1=XNA'']"[;.IX[E;-F>DLH362F]NO;L/LZ[ZSZ2]%G5SY/UI_
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MP#)3\/9TXEWY!.?([[C=N0.113$2=?SG$_5.N?OA>HC!+&!1ER$-V8E!-/-
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MFD+TG9 \EWCBFM-^YM>KF2F!X$*'6@&%_1[6DD(,5;E8>H.GV[AW\%E+C'<
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MXZ77F*U@Q5ZUN"IQ&VJ8*9W*L+#1G!*X].[832\OE1##[?!'F:9Q06WS+."
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M[Y\!066FSP")DF= /Z2G>2/SM_KH=21YSK8HU1-1;?0C?$7;RV? "W$8NV?
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M VUTF($LXT&6=-WI:!*%.+S,4]2?CO8T6.V_1H9I:?KG1TQV P1@/C,P PD
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M9JWK ([J(VDWI,CQ[,X*JG%#3[E)]Z-S!EOF^>E.;O1K,1ICWC&BBS66?XZ
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MPW7"/]+"9BU]XU3;?NI")*X29UU:3Y*^._6#FI\.F46UU2T\68]/OYGA+FV
M)>RRSR(B\5:YZR+WY(I7Z*:DYO#["IPNALUU;XEKXWOQ+9.NL-"KI5LZ@-L4
MB7N;>#\Q9)ZXDF5ZI W"K9QCKI6"H*ZV_3UIO)-V8[4"-DSVHGV@0<A=ULIA
M[^ITGK9QNH3B$66D1WWRB#P#8S^P&%ZJ,H$[X"(9O7+[;-)LTL:@MH%ME/BM
MI''&Q<X]Z;ADR#FI'+?N%S$_SJB&\HST,[!R(9ERL5Z=VJ_WM(FC0HB5[F>4
M1$/)# \ LV:U>4JDU!5!T.H#P+^_NVG/4D,+K+#IZ,\- E],A/".KKHKU4!P
M 0>,=T90>AIW]+I&/[@^ED4FJ.;U?(3X94"57^?3EK0_EUZQ&\*&T_"(UP+2
MI._1/49P%;AL;CPF"T)+I;68F:,I3F ="W)O;TA;Q:X.7W[ZCO>.25CKN$5C
M+0'Q(>2'S)EG'4_G>4?O-VWV,9PQ=8CS-B_CAY)G9'C=QR%6JZFV.KIA+7 ^
M5';=WJ$\[<]T_4F*1S?&:2FL//3415;JL _NXL.M>25RU 3*RW"(8Z(,6-E@
M_/0=F,6F -&Z^3.=\YE.8@3N.O?%]\!O">.>W,8&>12?#7P>-ZJ2:WC^-QG1
MX#=3=;(_W*B#Y0ZRR>H\NB#3:%$\4$FV'HE<I8"FMZ &;"UV"1XH'8A&U#P7
MG(,.5!+Y_[P\!?_C?-7"_^)L+'E/_^_0,9^"<?W!,B!C+A9@@B);GL ZL#8A
M)70SD&=5#2NFQVW88E*3X 8<@@\QS;\U<%!PYOST%*$\:!:?2* ]Z#KB!F^T
MFFCZ4*C<:U';+_TI-AV*4*Q7S._B?0%M-<<B]S7=P).)N8M:-3)W],#O=> 3
M&-_4SG H=6&KM=>R=4:7]824Q&]):7%AT$1,+7_DLOYQ"O96M.2JR50YDZ[R
M"G)2R6'XF3I1D@^ND4*D6Q-?ECP 3-/N7<?1F!BO2W/J)ZE^&H*&=&Y(JC6E
M^6FP!8-!)8F$Y+^9-!IB2OIRW_"H[2OC'!+ORRFB2^5Q+Y?;X+X]&GRANL-$
M1T3 @5TK2Y&7EH!K 697+M>BBD;-1TVI8P "5AE75<2E<E-Z43/1WP!/&%!$
M_FDN2&(7*401 9[4!F.WJ%3)8  /:P&^*HGFC_5B>I[)1BB/BV"!=52J)!B>
M/>\E*CS,LT$Q3,D#'B@KOB913U//Y\WOS,8,A<2JO&#_3!V/2LU8QD,I$S,I
MM:LV1M<86>Y?3'P!;WS^V0>BS2#@%CX*!T$16'/F9)<&H*BIDU\VU.^)9!IO
M>]V(H.N?KMA\NLP\&T]A0@D3C C/,0DO545Q]]WE[>#I_(%0"+YRFB%$%!_8
M1\ ([!9YD18QU:-JC8L%7.ZR//@% _S!&J5D*WF=?9MJLVC/=-0V.XE8C%7E
MNA !_OQN/-.BXWA5X<7Z5+BA/;4*,)^3CG-)D//*[A#\R\_D#/@JDV\FWU*#
M?-C-T9U$W7N7+\)!F@; X8YMSR^OP-5O>VL\D<;N;Y-P)(]() BWI]?TAZ!8
M3C?%I#L%E0T*J1OII]^V[K*,JD=82^R_%K57N/(M*:?%>[^:+\'!KDPLEC%'
M%R+/]*Q82A& \@.C@*%<-*9*?=F$-YRHEY":YS!0"9UG1T$]/U&)9>2<@],I
MB%M=UNTS8C5!Q#'U'G]7-:DP2TDS9N#W&&JU0SJ/X#Z1SF=;' <J5=Y!@G(N
M%*,D[IC:,F^5,35SP_?C3V.[I>;6"::?$;W.T9P<U!!174_;Q>S#^(R;.-*'
MGXEV=AWX!][T>N1(P?+B1/@9CQ-&OAB8 2IJ/4I?^D_WRGP(U7]SMV)P@6;0
M_BN^0L"_XBMH2LU0CXL3H ?]FR'I&'=[):0/9^)1KO.X?F\+^(DPBUQQ)=[X
MWOP-HI71\?&B%RT@8BL"6XL514Y8!]L9V&'^ /#@JJU-J$"1!$;8\T\ZS@+O
M %[ L:6&VYTG\3,Q>+E@1H"2.($(,+5  'O #G]G]YO-#Y5:S<Z%S=HA4N'/
MXT/+G4YZ8*,&P\YAOL0RU'\81+F4/RQQ 93D1EQW^YS4-MOK_)7(ZO%!]>*F
M@*FY>A..:6#':A'OJ&?4>>.1/,,T/Z8S<+B?AX<@U0G.0CWA0^TE/\,;@DZB
MAG$ZS/-G5(0[B(7C/6Y.@C^>&/_DCE;VXQ"E_&^E$]W3>&X.%Q3S_%$H4?Z3
MJSY!\];$6;SL">57\S]0+!@_X&=BU'/]\!5T.F"0OD#IBYK^X5:QF_;-'S0L
M-H_%=YBD6$@9J5/?& 6GB^/%'V]45Q^@CE+/8M-)5YZ47.;:>_'8R&?4?[F^
M_=?R=&+:XEVYH7W<HD24A,ACAW<6@BTT\PG)91@9R!FBNE^#&2!O<L$,*'B[
MTC&NPZR<LGXBSVG 2L-$!?\W6O^CI'A?"$4HHF%@Q \6CON) X!*_\$2G!3G
MBS;1YMGT (@9*7\ Z$\\ /AN,,^A6;8I[^M*C8^?S?EDJ.KE#^KBY,:018FS
M6/_.VWJLB>;^3,H\-P:=*!=,D8N2F1#TD1&'T:(KI(@%<P)=8O !H!%E61]?
ME^YWFIGHBH.8#U94K+87=T.F<43HP(=W?ZE&S$BH#6UX60P=^V5.FV+)+7#(
MMW];)4F8\\?40S<+5$YPR]>5UE)GRN_.&+Y1W>7$GS)*FV%MY2VZ_[UZ7M%,
M7.\X9GU1C-]8DJ,KN52L^(%L4NE9<@)".:?$7(%LVM>UI#)<9"M?JR)2.2*^
M5YD@; 9"\!+-+RU#W0\;72HW!ML5J&/L6^@GAYJ/!F;%5&1<54910(WI55)&
MD7N4YU11CW]<CP\%$_TS5AD@I0 U'? HUY\_7KHP.HCTQ4J#O1G919XO2"EG
M@=FE, <@< A7'Q"%T%V,Z;.*U-]3K)C7EN[&V 87; **[0@&,P% 1]H&-X&_
M-M$2T:9+VI&G*&%&KD[AGZ<-+X&[/Q11[24W]=39M?(UCPRX(2,/ (486<@"
MSS') X I)<KJ73<GUCF#<"OQ0C0$I'JJV6HU&>*]':TE4$<F]4]17H[#_$E<
M0EP:; %$P2? ?Y+3*R_^29)%X9LP)UX/_15['P\MN!#[(,*LPM+NY8?C5:+1
MNO?$'_C"7D4XZ+T6TKN++NP"&<)2"UXEHF$4Z 8K\Y);L=)9T-$4"E!:CJDI
MOH]NW]=S/HA\6Q$NIJA ;A'?P.2VE:N\L$!FH*(9\);][&9L*028JYH>S)3*
MG>&>WX"?F4XV?9U2UD!O<$$@(0UPH;OY=E5 6+PD??$BGDB-RNF\I+H[[$IJ
MCKQ*Y:6.6TB,:PD,T"/P<_T[DZ2EQ5SJU'A,\_UY(C/J"2Y3C<Y1G7U'QJCO
M0E4 N+E%A.##=>/%10E'AZF+RT\JX(;?V'0>.*]*$7.I /,PKD'9@R3LX_50
M/$X)CHG']'YI(%NU]AS:P" 1O,1-3ZUIX*A/?> -169B-0]I,W/?JS\21#,J
M0>N)W&/UR_05"EI=-4HL&X &.DF? ENR51P<[,M*T)5G_VO! W\P0\5=[%8K
MD9+(_B/[-.070*@9_[L]5V.D^@'PW\1]&<3J']ZU7?_3NW:PHU_&PVM2,VWJ
M;&'G*EX;8";UI9#\Q$%,(PYM]-8-\<556%^7Y=L9R,V*RK[#WNF>8,G5ZHO^
M"U?W7QI2\]Q-H5+ >IEKREX2"+34BM)R)J9\+ +7_7";8 X)ZEUFJ[-Y)U\K
MK:^@0VWO\+,5C*20D9'.53T:+4P^FMAPA\7=:B*2H&L_2/$J><*V1(;WT]:X
M[2+2#H]B;<R,L)>-.66)>-<AH*A,W *I,Q:_H9'^B52*VD:*NBUA' &5HCVA
M%PVM,ZEA?NFI9"]Z\,KM;T9[AWWT9IY'!QT^ %SD9T^$C)%;D,R7^9L,Y<E*
M]<8[UM%:'*"M>F3 ^C'6,.'E=(L_A[O<B'<ZK-Z5O_?],O-8[A05*2E1'(>;
MBDP;R;?<_(/C6>D,[K>2Y7]=%NA=XUB\;6C$J]_TV>L4T]YA5J@?][;CGP<1
M)F=92*78_LI*OIZIZABQL*P[PP!1RKW:L4I"K(2_ZFQ"F9I_FO4M_(7B[,;V
M+2@3J8L@N/V*<UD?&N[U8M$E K6M;JN=\&+)Q4OK3*XQ^IZ.?0C"6;O.\P"X
MF.A>,]G_P_@-UX;5O;\;&DK3C[_T.)VD+C\[> V<TA\ 0=_=!C J0.LKF,B
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MTD*^B-O]H7N&*LJ7ME6=KPQ\5M3.DP-KIR<\WQF:E]:6,>GXU/FE7=?#PQX
MX=&/ND4WY*R"C'D1P1GO19R'5(#4NL;)/1V0 J]^PJ-I]<S*?W>K\T/<@,V9
M#2!\,=%6,_8 V, P>P#HB'O&F9#0]U *K9)IK[B59\E=E[/AZDS'W=>_U:8Y
MX KFXH\ED#XG.(WN2=! QKI&WJJ@7-=Y$:P=D^VTT31H>Q!?#=<XZ'>G7:_
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MW$6\J:HW) G8A/Y^7*4%"&K"6N2C9-M3T]L8''5(N\'K>IQL+A8+YH/#[0>
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M)&X;)5_V* 1D1=#I6-[^_3J]?^"S?XGW%V)YE6Y+2Q[_E\O_-4;O/_+[]K(
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M5R6UV>.DEWY=/1\@;45<)ZF2C2^)O\7F;^,!1A^*>/LF-; (:Y*,_@%/VU2
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M]:YOFK6(;Y$N2D/"2:<4OR)R@ZVBJ@IDMRTT@H4@._'\W5XMOVQ!..SL/:>
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M_ILTEM<.4W<GQE;<6];-Z>Q,2[7?'?NZG[*P6?4)UJE2I5\M%E@C54/M/B"
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M6 >Y_42:/ 3<IOJ=AS7\\:9RA54_0C-D1>V[.SV/TYR+9O$%_X/"@%WQ\LH
MZ>+5)QW;W-Y)E"RAV(Z^9?A4TYF9 %W5//%&14;5DT*Y"M[Y1$Y01 B\=:2B
MH>'K$*-RL"\$4"OE%K]9\"KFMH/C<!'%)-\'_40L&]OVI03:5?0+8RC$1O=<
M.YB7J<K5B>AUD*_[4C+H#T"<U*CYZ4K_TE9[2O>Y=D<KPM&+#) #TB;)T1&G
M"U7Z"/+!.FD=0U@.;SE:PR-U?TSD2_? Q"%_E3U\XB@@0C'WXW7B'\#K:W)I
M[F6O PER:(*OA5<)\Q9)/^NWB\ 2KY*#. ?HGL-/?+9/ ,&["HAQO1OO=[ML
MH5W"3Q.9M(;B,RC!_$Q5MO-](_Y=#CQ'WS)]M-%E1B8TQFQLR;8],8AH?2R3
M"^5B9Q$JI,Q J[0&2_5VHI6-;ENL% LC 9SJG^V<'%RV#1;&O(_N>G5_!PD!
MYLQ#L7BEA3'A6N'MD*]>U/O3/2ZH6!B);;P3O[R_J/\!?(T^P,[TX=J022ER
M[7RV06JF1&:W6+-+7.C"(#':20Y!W_(,8&$7[U7P\;DUB)&K+ :R)..F/Y@%
M\Y47C7]WLG/#Q&ND4O5\(511GR^H^<:^$:K05KPW%$%>>S3FYO60;RM&/]WS
M\UR)Q.1";LY5I@C@97(W05!0)#U@E@S>JJE\%M>/487LTL>F0A<JD%:#>9DC
MOK354,"-TGX@GU:+9=6V#KT>8OQ>0FG&78G%/VS.T#TP'<Q0/^O@Q)C&1,].
M+[-+E6J#WYPD;-9RI*0\JA3TG%O<TARY^2%CA,HV(@)V(JWGB&?$=ZFV5S/$
M>HD3:(-4:O#HU>G'Z[3&<DH'!3_<57&>Y====/1$CB;!.O'>/HY[>9X8D 5%
M)NW>ZRTO*ED+OLH?E1D5K?W;C#0D&6<(8_PV:1V\;@T,2,^LJ'U,@3L/NW\+
MK3(2-G:+OSP"8L-Y/?+I?N5!*YM?0TE%*>Z6WE(.14+4!O&&,+GD"%0J*9+8
M^[-;EN:N3[7QPM6X5D$8[932L.(K<&?@;Y=4E%\#H\;K*1JR;7HCB_G</)QE
M#<E5@;]METFR(X4"E;T4I4E\P:HH,,(QA<WU?#G3&8YB&/C*.<PSU_@W5&9N
MW8CU4>*]3>/I5A,,8#.CNT5AU=*UN<&&X?*W)2TO)::E<?%55[EI.][\$/[(
MG_9&0<"E"PRN_L&#4(-&0X7 "*GV\4/^B@):*+= WQ/AA*ZM_/I0#YIW2-NU
M8@V9@%=Y#UKWG.7^WF] :,,LXU%@X63IH2NNM'':F'$G!^TZOE((H]3=*M*D
M8OY&^+9YJIHFY,=.1>I/ZFR >XH6,TS8S@_?^Q('Z+C>TV'9LPFB=V<O7'G;
M5J.5E;H89#B)^E'*<NU(W-*4LJ.R*1DWEX7-FCI6JM@[A!<CO3$-;J 0!OBM
MGMAVG8>A=L@WO:H$(M]UIWY?81'2KVR7.BWQMS*O:8K>_@&H&:&4N+ 7Q8Q@
MXBGN-7@/WNT&LULX4FQ1:.EZL/HXO6T []H$LXG!1N_-C6:KH'I6,]5O1RM%
MX*QAI ^SVJVA"_=-ZD[,Q=GY2K7O5D4@@),! 4:H4,WUVAN9 '=XLH&"M2N*
M?TMMDCAZNMI\4K]%.*L/1Y%I(L4GZYL\+%]6H,*\AEJ:K#$JK%FY9B1VX6:S
M7&5SP6R6H29NW*?*'/#U ]<?@#Q@O[2RIR+CF&C73\_,<_W#PDJN? %.-,ZB
M6?254DL]7N.LC_SZBW2P$!DKJ^:\P_5WM%QA"QH40MG[ZI$$\EB.0PPK$Z*-
MX1/!@S4>A"DU/7ZA)Z+%,&C%IVW#^"2UV YN==O6.I!V*(B@Q1RFY0<!3)?>
M45P*>93&SF!HO(^*6DK(/HJ?>9(LS;:]$:^OVC,,V2DSK*;TG41U%#A8S=:]
M>]CV]97N_)1L)%O@T(K;]L0,\8J4VKG2,]17 #D3.^NY##XQ(3D6>&EJ6^VW
MP[5+JF4LG=,FEX:\7'TNS?J#].WUFV[#8*,.(/:&PQ)..7".:"GB3=IWK"<Q
MAY;A<); O,TJ3.OH#1'>2G)V.MF32JOV1$=ZCIHMX*X8;.8 ,DJ673^"5R=B
M$1'5>9GK"Y@KKNUS.]H<++E2GYZV*\L/B"?X5[+0 ]]EH9J$UZMHFP))Q(\C
MQRX21/8WK :[J0Z%JU-\U'&IOC4\!AU"/M5$XRLF3'\ '29".: D[P)NH5\'
M3<2JTDOZWH.+A1Z';GT =TUML6^;Y [:!F%-F)]$.$M ^HNV,T;T:G6_\>SI
M[[9X$*!25@9'G,NV]: C<C0ZBMJ#Z0KC^RB':OWIU7&[H5G+)#RN@HN_>,;Z
M3@&^,;N9<&QC&9E(KW*73M5<[K!I]=_8>^NP*+MN<7CH!E% &I0<2HF13@7I
MDBX)$08DA@Z1$M2A&X9FZ$9F:$4ZI+M%:9#N_@9]GN=]WO.[?M<Y?YSOO-_U
M?N>/#3O77FOM=:^]UCWW7MO*]^-:@N"M>TVI^)M7GAG$ = R6Y=JMPT!7]=W
M5 5-O0#N_^S2^O_NA U]+$7P1Y22L9LH)1]OKFK'^>>O"S1F/I >D6D.&B1]
MD,J" D06IBI*2_76$TGCIVHPW4 (;.%2&P6I47MW5L\OPNV<(93;!/3!Z(*I
M?8G33^Q^A/9'8AM.C OZW#:::WNUPBRQ=(9A3!O)%9]O\<J1']I6:242/*G^
MXC9:FX>'Q]5>SR$O#;^9ACJF=!!9_=,2G#+5 ]T1?>9H"8CHC(&&2@[9U$BL
M&+4Z."L%J&?1E!>H 7440&,4F <'I!"Q8OH--]T<RI-^DH'*^.<%2C'710>J
MX9#C"NR 209B:8?'RQ[?G.<+.::8OAT8NTC2'AQ Q5\G(+RN(D#M 2(F]<X:
MF9J JDAT>QPI :;$967JL!,N=(HVQ\HP5 EMC-G=0-K+=;$Q,L/N) =F-5Y:
M(7!P)YX>P**KR,8S+U!IHJ4\QP"N4ZOJ0Z":*N7M(C3O->8R1S@T81=D\-!S
M8:RZ*:?W@1F&WH]"%ML4V6_^/!8L/[?<&>1 <>)593GL^L4?H6].L#\)4>/>
M1J?2?N?8 HK=&5QU&^I9ESV?2M,E1G0]8$.K@TXB:QF7B-'#55S&KVB&05BB
M/_:F1^4X;S_',YXL\@DP_3JI-XYEQ%GU+K<2M]?07.@P"'<P>*9U7^?[YW S
M_[':I$VDCX@.V(Y$_$O_04%)69:[GJIY8EAK-7J-I8Q29ETJ%1W?G)PY%09;
MH,&C_E<64U+"I5QS<7$_8@G3%YY-E8141=\G#>]QI4=20 PQ5V6+9C9@7]5<
MY@:!RY7V!T7:<="L^:/BV)%K@ NT>.[TJ(!&R[3YOK1);2^I.RO9RZH7O;G3
MQ<E?"(%?\QZ+P9<P:'>UTDXG(^(8&5.TWS;&YI(!YK>8SS0UP9.P.B?95<1B
M".0)S3O:D0K<^5@JP'.(/D%1STS[UY3Y '",\0>+*;U\S)3S0<X#5JW%L7H:
M=X.W!(SJ<N(VL<>;C;VJ,Z3Z+^7"LKB1XU2+QX5V+O.IT\+B@NJQB0NX'6ZV
M/B5)+1C->^T%(8UI3W0[+6!!#UZ'==7C>H4UCF6!M3@Q%QO%V9<2M'21V=4\
M\(8G_+Q-JV"Y+&T9/$%Y-7+8U => 9KR=4 3N<;5<(.G8BZMS\]]K8+J@0Y8
MC+L(KS.G* 8O-U1LR^).2B@]\OVXNI1_U**+Q4B)GHJB< JODQ8A0">!"93[
M8W3+]E2]@BOSJ2KX:W:2]M1]A6O RT*9:7BKK[?X^H%["8:EJ&/+7(K52W"1
MZK+FFM/$:0R7/DZ^N,WG'*P>B)PIMK[Z%J,K1HG;!Q^L[CB/=MZN-EF()4US
M.R&6/0&#8I!^NZZ83=>W^ YA;V =$A')HP:(>-QN,]HPG<O;BY0B-]0=[HEJ
M(R/L+'QC+CIZ)U<-U&,=K!9#Q28VAF3>L'$=7 X3U:O.M\UBM+-+H=*S,]($
MC^5V4U%;)'^0,P39J+!2EDH,^Q6K 48Y)U]$R^W5O+*<1E(LZ0BHKW>RI/>?
MOJ!BG,=_Q;[;J1Z666>%U/4/;9K-!KA0ECQQB_["KESG\DJS",3@XLJV[027
M^=H=/R6_FP*!K8!4^*3Z<(PN\H:0Q1<;3AE1%1&@>F9.9K-(;*&-\!'@WOT\
M<DQ3,/_[DHAT1C8:B":HP9W0J!L_8C[7AEI]MJ%"\\TJ/3+R>%A:,,XQ6VB>
M=$:'@[M^9OFM)5NF^>8@A:Q\=;[0F0Y73!TBRA-+2IC<<^MJ8,4*T[505U2F
M"_E1[9FQN@[9_% E7RE!UBVM #6B-5VN;D_F\KF)#>WL:T#:ZTW[['TEFR&I
MWEO"8>]R7+X]3M8I=CU3AAX1A&>,SBR^ 45E=&:QA?K8FJ*V_:/5S]:K'A.)
M0GT][' DH_"93IY8C+(!D&1-45Q6]$[1)!89+UZ79=<A2&9# P@,F&*-MZ1:
M:[/BB(+6OSQ8[5,=X_ZG&#9EBJ?!<V-7WM/ ;6EED\=!#-O0,XA4L84.Z-&C
MU =6(QYKLHQK2EHO_OK*H)FOAH[$RX<,;=&$92>M\&QF:-JP2\SYT6/V/N%M
MX^T@EP)$&-V]]$LS*LXU8RPRM)Z3P1<B'"*$Q9H?*,_08#,5<6S#\ZX.L>V-
MW>D03'=2!%^^=:)9?'G6P .[Q]S!!2P-S(M,<C0HD\]FW7UG+?Z!\\/N<,"A
M>%'"J#VR?INX;]OR1=60' G/=$745+5J$&W=Z_ACOH;VQ_&1N_WYY$I7I,E)
MQ9\[G O%XA?>C\AAXXRX9A!NRDK^\)-2)7C:1>L_5FTB]"Y8^>4]Q+05F++_
MJX)S1DY[@$"Z<,#;*1J[Y[;B4V#$@XZ$I:V.*G8,_F9-WH&!\G9:/_@P4G>W
M'$>.)E@ZTM'+E;PL>PVN5$'QE2T1XT[,ML:&B*+MH^<OW=GK/T*DB!J@)#^%
M;Z$M>AKSMG-&QI7Z?L?_*,F)74M0T8?-YW6N<[HSLB?#C5WP8$)J:B!V\1KP
MI1(VDJR(3%>YZG_1*O0%(_\X@] PQ/?6'#A@9&JMZ XC?K-<YP)T9J@D%S$T
M7UW#,9059$Y"J^/B19\1]5ZRBO:+T-Y%18J/U]@(+]=#9AO5T?GX=6L,2:/1
M&.4JF<'3&%%ST&:ZU_*%$FOEHW32S]6(\ <@?4)[!5I=E:+5W?4=#M'$Q<>Q
MKBO8E?9BO,ZOHW*N<O=?,>8R =[$HBGI0BZ164_Y>4,S&-W80G5-9#[N3T]5
MNM+=II,;8G_A5"D;%HW6V?88.\(C&FYBXR &/E:7N[M_WX_]Y%7!.,C22;D(
MB"$YVVM]DM)@0ML8?0=Y\5&:'O&U%RV[\=PR;-J@9U:/9]ZF+3>R,YI@.K[.
M4XZR?$J2 ] T+/=Y2@ R/04NN5-*(! 6 ZNP^OX5_GVM^(&E=M02'_!Q)+$3
MEGY$R[%;:)=E0</#^*['E/9O<DLE(DMR+Q/5&.W.+WI2MOJ<#WH!YC27ABT[
MTVWYADT0JT:S.#RNP&JDR9A+2-%&HBNWA$\"*>']1GSPBYW+V9$HT%7^<&M8
M^H-N?)(EG3*7@J5$)4NOL2$+.D&2S@$L<4'#NIAG,<HCW)HT2"-XKF+-EC0H
MZGN7:W2UD_[TY*.7INVZIAZL=72B,N<L&R9&1LC>04J>K]419AI*&6+N#I \
MDT^9K[>-_?W9-J3(B@\V5>?V-4=XWO)^F)]B>AN-!MCO'\O=,8_XJ5RN>7K:
MN6ZKVJ%J:[<I_G5&?@'K_9>+0K^=GV/CQ$<B@88MG'>8O3'0?2J'_(#6-O V
MKW)EK =[^:L>Y+7%ZQIK\=CZSWJ$T;0(]Z<*U^CI0N3K81[+8&H3(Z31J$ -
MTI#? <C9I_W.0HJVXSW;6*F+S#'%&-BFC=+.R; 4?+9%TW3TRD/SUJ;]#/33
M@V">,NX@Y%;^7FO-!*89)"+'Z/- ]+%"<&OWE\>AM*YM %8DH56+.^E'.XV[
M&.7%-"M1#306T6Z(0EKB9"?;DD^(\Y>IH&1AFG%[B':,[-O5%N6DK^PXD2+J
M:.ZT3"W10%G@D3/">_-'X<D3WS9)'-'W;!*S'$S?BY+L8'T+VE&;%7L94K@,
M!J-#+HM#/^-':9P>R'@-8#N$^BX:UTAZ$#I*9)5&A6'0/8T9RAMY%7W5M?F"
M&8?!@_!'P218T*VJU^%1UG!;M4T@)98L0'WG"20WM.T6-I^$_,;(* W\S6L[
MMDEX@*Y>;.$,K[J0.*\Q14@.$7W_SQ_/6/43Z3[Q.2N/',@VIMK?3RW9TO5G
M-[J*18MC32Z9VZ!P=]>8>L+HU-JZ&,T;?OC2^.7>@A;LJT)55=R\4%2>.5QB
MHL@-IM+CS@G:RCC69)L5=4,[(482SC%$VCAX6[P>*[T&O/8T\[]8Q6"0O?NX
M/4'%E5:C3WU+?B)N5=QF.2%HUSX;>\>MW=VB#+MT+8W.6%+3=M@19<X]KG3/
M6I&)5E'_-OD-5%_>8H;A<C: _2C#(2(<MTK>TC)(L?BG%)V7>8E*GJW[&3*N
MM\<M*L13\,Z=:$C@AH'[%&7CK1X>F"@"X/G=4S*(I2K&E:ZYUSO_TW!']RU_
MWA-B!%IRSFGZ3I(-S3E)I+>IINUZ^D[,VA/&KMGT'IUX> 9-$?(3HLY6*?/"
MS-UJ!X1_8DHG1W.ZE6;XEH&?'NU"5!WG\3!T<3'.)9W"R/Z':**3Y%P7:(PX
MB7:,M3J#!V'F+"JU\_EG4)\U!NLD4?&4?2;KZZ\Q'Q\?LEUPK+Q;.-?)\RT0
M?=$Y;7X$0.UZ'(WYJP7YX \O7EKWO"Z&-HR<R<$$2L2Y==3X[=\X/;3&2-OI
MZLLK1I>FB1@O*)(@;0<1DIQZOFDT:,RQ+LHUGE5D!4L,3+_G#'52>]Z>$2&5
M-JX1O]6AP<O<FQ#R%9/>QQH]M<%F3B3]GF/\Z7-U=\V-0*L/B(([0"9'^74Y
M6QTZVL>E"@6>V0DJ]9#AE*%O8 *?_*E9*N@IK7]UF0!:[N24VYDN\+OF1QN1
ME+">9LV\<<"NL=E\J$LQ33J)R+=/R^D>8]%=QYU27ZZP_7AL<54C/!X")D=<
M"]^02>XJ3?'?.2;9!]GWJU@SQ5G5V"8D;-<3DG17PG=FQKZ7_!A9-&2[!L2C
MX:QZ#6 ])[@&=/)K,,=?+KB<P9YCMGXP<UKW-RYE8/%*AR$1GXBY.?ILK7.X
MHIW[-=0&$?[P:3$EGODA_I2(9S! \RX7F.W]04X4QM7.[@GUV"YOM"31<X$G
M[VZE?L[*'A%X,@(B,&R/+9*:I'7]@5@)$/YAG6W<V8*IC@/,)8(@K.$!PVH/
MR=K%VE<VGA[9S27-G]?P*)MK&E\]CD3K:GN.4L/Q_C\0H_0T.BA\3?1>O6$M
M5<HNKC/43TK<HN3Q646OBJ'."[*+9<687IR'I'[:$&V12B>:S<"\SXLF:D$^
M,#7IDZ!LR+CX-N+EGGB%-J+DGLLT:]4^80B3Y0?*#/RT6RO287Z=7:<^P@)I
M#Z\!46[2?GB0H>QA!&<JS[/%=>XCX^F&&,HK5V>=85]D,1$B8BF@R9]^!*UW
MW5? "UV1)/*+PYD?[]FX4K'<._E:70QK5=XI>-T@8\/0C\K$>%ZTB@Y,4BVU
M=V6EY/<;1N<,7=<H0X&2[S.(WX MKP%O=9_NTU512;V42!GWQG\P::$Q;,VX
M,%5H#*9(,'@^ ;4+>_IU<UM_UUJP:ZF-IX1IJJ S5 [MXFP _=O&'9Y"@4N^
M.:!]G+MP;"3@#-H9N-G1/M#E@X5PBMW B(GJ+[$SL>9^E)4PYBXW-L_3[IAY
M#. =&.9N$%Y<_Y#?Y;'7)Q)=<\F.GA9U#6#Z7'"U<D@^8A0Z+714/*U";H=,
M#I-2UL]=YS4(Q0#BY'D!EB\HI8=R&5W2U!*N,&V([@EZM#QCT>6D)N]X%:/[
MLT%2(M5MV^[-UU<_C;Y8T'D=%E' 9*9LJD7\8FM3M147<DFN 29^?*Z$>6$E
M8N5\G1B";P[E!I$/3I1 _&!R1&F9_U$PH[__,/G0C/4/'R>Z)SV^+A+S#"MC
M68T#;X8]C^J5<A$UXD8\/U'"SFZP!FOX?"]$HR%\$EVN^XF]JG,X\KG\A^?M
M!J%!V(>R+>XFR%JS7!4'R%%(?75="E'F^PG> UI-_=7F?MVZSW>L^@%V'3D
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M<JSM']&*K].JR,Y=/RQEAH1-0R*^J&.[!PSX6M3/HP]_K8E0:<\<P+E0!;D
M</?4Z/I4[%:G](:XB>HZC?CKMY@HNWJ?YJU^M?)TARPG"%(M4+8!+$]4R'H+
MY7$DP>*UJT+9PQ+/J;^Q8UHZ.7_S-Z16C19HKYOFN0:(/&/E#84H8(>7;_#;
MW'^%"*3L4 0L'Z@T3YM,O'%(W#T9:PP"7#6'13#'U*"-C*8*/@E1C5YK:/XQ
M']U"WWA5EY]&DS:E()N6NS/=Z33P$Z?,Q%L=RX&$@Z>BA,O4M^15Q$[NR4.^
MKF+.:%[G:\!'J!J^84Y569%,4K.\;GR_KT'M@W>E%%>V103+5?P,<QWE#RT.
M!=!,6@,75)Z@M3?U7V!7'E"!WM5^]N;TEFLM)DE;Y*622"WR5=[Y:6!W40WI
MZ1GRV>P0/LQ.EW)M\"YY=%A"=W5UZZ&D?P9^W<N8@M(25U<O[A]W.BKB*=@P
MTCP+ SH,=D:<07[0HQZB9F$%0@D_G<VTQ%T\@^7O6SPLQB7W3N7F9HCYM=*E
M/EL;S-@,^41]UK@;SQ^A,FN-H23?&/&L'+K.PIF&RT0IOB&-@Y,R:LLI])/[
M-FX=/N)__HS1/Y\G,OQ]GNC6VG-)8]].VYOP8).^J5H*471DQ '0D4Y%]BP_
M,GK/-2-[!/6T/I?S1U4IG!(W8RQ3C^BV;.1=#9*YMO[O1B?OG9]L-HVJIX8G
M/R9]#MZL7GH%B=G4<\_H*&IM"L@051!S5C_QU=9;?&+A'UI1-'4 %$]/OTU%
M6\X8/C,>1/YSW3@M=FO+V-QY$Z988B:8:D'E\)F8TDL;=B;BM!+63YRUY(:O
MH2*0E>\_/[2<I$H&V%7%3B3B :,Q"NQJ!*IBQU S8Z<0R1&)43_^'6]#B!H0
M2^WQ*]P&%;O SN@M@9]#Z*;-*3<QO7:E[JN#FPH9P5^&;]IL;OT5YBL'VX\%
M.T'BD![LK/DH\B+^O#TU4ARRJ1&H!/,B\>$1]X,$3[4,!ML$]7W(G75F*2?T
M^K@+K2.BRH\U/Z,6^1C<L\S3<!<S*%20,.E4SLFC^-N)W*$AKIN,CC8;&VM]
M:LLG*OOV\GAJ/A&+B (Z$K'XKSJR[';EXE+%>8$:3^]MYIBM\YM4+M,G%V07
M; 2>Z$AJ0D6!R^&B:<](IDG]'^V5$GM1CSUPYLLW]'Q([!S ;[RKMQL6<JJ.
MC4W&?L%A8ZJ5DU&X'!TSL$\P[2.MD6LH&'8G7KAXVD[]8XV;$QXE59EQ;1@/
MMV6 LIWK_88L)=R2!\RAO!Q&BV?.^F.9U!"1 HO+;$_]%PU#O60:0G/7 !<+
ML7$-\'?+^!GQW?M.SGNT6B94 S^"'WLVU!T:C>O"AH*IQ-4D24/B?H9V(@AP
M/3B&7KB#&(>*HYKTGI*[I '?CCN4!PK1><[T)<B4)WU%Z#EH:*WLC-9GM4>+
ML O/CWT7:!XE?OMXNI<V=(XJ#<1!*9^X0*NC;&"\"3]5;:QC8SZC'UV5K1R"
M6Q+BNFJ*MUER,1L,K ;S*-!R?!-[AE#^3NZ5,A:7VKZ=N!?1*8'T5M]9"EI/
MF+"(W8TR.FR/*P"K/NI\&22'@W0<;1):C[ E" N%?V6"0R&TQ03FC^ALI#WO
M+40&^J4ANZ=MG)1X>BX5-@W59ZH$ZP-$=)-%^)0/X+@*QG=7XA6&.0"+)#D"
M7<SW] V]782$VK2\@YY,T<0+YYZ&U/KYM!(.>CY1[;(A$=N:IKQ]TDY5I^,^
MC<D"9X.(?[)1JF^KK0J]G$Q8^K)Q6-R5^R&)?^\>E?N6S7",$"_(YYM+I4T7
M[=M$_Q6A&<XWHHE,'Z@@^[N5Y$TJ3N8UV(]8'SI'V(P-@PPA3 0?)$Y.<8ZM
M4_$4G&G+"ZS<7"'M#!^P<4R07IPQN'C-;<?5%L+%U@[:)<V;YHN.(P>>]F84
MN]7V"IM&#1]%M495>HL*F&JG'//*BT4_@>P'/_)]67!5#>SFH5:.:P?J[-\&
MM)B*7]KJB=(\0[@)%X7A+]UWIG^#3'PRV&KJ0=(_6#3$/<=V/L%XG&=D/6:_
MFP)DU%7,CPI3V+?W-(N4*R:F2?N1:K/(SX\E$5#O749HV,66:"Y,2^A2W'\B
MJS/UTE.OW!X:2 [/#P<R2<I&ENS;SS^<UU6\&YD=>FE+S8VNMP*^YXE#BS&5
M$Z$TPOP^AO\=6^CX&QJ*#*3PKI"53B^__,? KVB'(-KJAS+)D^U-(^$V,1Y>
M1R\)8^K+UTN&2F2_%[B11^T5.W7;Y(4;PH4L-XNZHGS!335872;"]V&5L[W\
M6"&DV%]L)D.4JN0?*5&7TY'D<IAQQRJ2.TJ5*B:N@3('":D_]"ED&LTHLD1_
M?^OCB%=B2V")=%PA?(JY *NRUV'/]GG;KHHM,JI42_LX+HY)=S,"5F-EXFR0
M&ON=QL:PL2:L-U*3P.<C/>_P"OE62T99<N_8Z<_[\GVRBZ*):8U"9? 1M,,R
M0RP&MY][O#9#]"*:0\0!\9_NO/^/*EJ9-N94TR)E.#\#^]6*>"^[ICAP1!U#
M7MQ[$+% MLZ.EF$>6?IT.!=XH([AEN9#Q#I<+\P0)P$%V,])=X@#\=]\1IRA
M.MWR<MM0J!9B8Z(K0'5\%#67 +X&4+N2 69,3?%5:F@)%W)NQI"LC 4(S3NK
M9OE1(=+@@6>:FT<78-1T4N+] @#// TI0@+_+Y=@R $J2]3BWI2!3@DYN4'-
MKK\*".E71 $<JLWI<,0&6V=@1WI;2"!,SY^AFOVD!8(, 80DS]2R_&@"O,TC
M@5^N;O#*YA4SU0B%C*7* @3!_0[=D<#-MAL\AJ'XT3XW= +L9WS ;BOYJ/EP
ML;%QR/S5)']U=A!>V8<[//="33A;RYBRNZV .*8CH<P;E")J5T,"L>-O& >1
MESZ[00[+/F\XAX;DE=4X&6K.9.%-J"9_N] --8!H)RQ1,@2*(RFT;Q"O;D+I
MT52G&PU6L^4A15!XS-"+N/<RFDAL2QR@1@9YK/4C>4078#=\8[ !F.+VHCJ%
M%O0K7P+=JE4E;BBJ81K>@U.*\]^PL!KC\QL$EM#*.!)%$]B$-_R3-;['T0WK
MIA3$@8_2';K390$"@3"IO)/:F\'H>';P9+#'8)*JM&4?AU0>9<<2"J'['H'Y
MA'PBM[R'VO ?4\H/:C^5@I.SH#"@31^* 3-5@5$+BKX;#CG,F?;W'T(QAY^0
M1HQT3:DZ#>=&/NJ]]T\'=-.E?G%3&(<,ZTN'@Z(/&:"W!H F-_P-YD.&AC\M
M2U.?+5^\PJ7M:+BAQJZXB8-QB&(EH;9X!WTL)ENI>(7:C40LJI,MI'T>05')
MZ[\M]?M^H__9) \&$P$P<EY?WM@K)2A[Q1)EK^#^'_8*Y2I[A@N93JZ,ABP9
MUD\<&!V%7L\KOKQ 6?8#<2#(!Q.1P"=4(M-GQZ^IC&[*7;-PJFN68Q/92S,=
M\> K!R[GQ)D6=5C9%-=SRMMNK.6OW@QBM@,"K1FWGYV.AX3FV:G9AYEX3,+B
MM\;.$)V^HPHS+MC(]U.M]*E%- ;Z: K^S4$XG#-C04'=)I/9?HME!NM?=!H\
M]7NAV6D%%"+^LC@EY*M,?7<%:G.'"_R^*P)1UD8&#M3C=SQ1_%__-;_XB%%'
M",R#R111UDLH]:]?.7><-3!4L?VC ]6(U%%FCA\KD2IV)LK 861YIH:=B4J)
M76AY+S-G58FD[F HP=Y3&PV5%RL24>5BR'EF-9DK#]8EP?BE.K9Z435*,!PW
M20B=4/:<#S@)+H#K]E.C/N7,)?>."G,D9"P(CE,5&&)&>5ODMK.)CRO-C I'
MH5^P# 9Q'FS35?AUR2-/@&B<YT51XG!VL'>(QSN:\.WV&LBC&/FMEA(>5QW2
M2UCS'.E>9.!N025,1@IGU(-L9MP2]!4CW'Z/#"D DP%GCY*Z"<',!-X.XV7P
M=-Q1-L==Q)!7N2?P1:8#TRIT&;; [AQ HF[-"E.S& HQLC&J@Z>/OI9@[JGR
MK6<K+'NL5]G"DEU$Y3X=&FU;(^8S50*QPVKF4Z 4\UE?+ I>GCAP/ W]#K>B
MK2[$KR!A8W$$4E^QXV+6U5K4>.$/Q;3L3<I;5L<I[CEZZPC4OUYCC2%N<R/T
M%=FWDFV:>EI8 <U?XR$,W6O'C:3%H8_]6@VU?7T_/M81;TW+G/61M67,(GT<
MP2Q64-;*2Q(0;UY!FZ;]D8SRC[OS 9 N4&*/@7E7$WV<0'UVA#,MFL;[)'4^
MI\_(B:P2"[RN9"^33V+JIW<ZY>0PW,D'I N?</T@[6[7.?7I_^38?KMISU&6
M^8Z*'4?T-_=(VS0/CT]A!=I5H0=/4B(G30VIK@&'(^UK;*0E7_:^'93*C6OK
MQD:?>Y-N&%1\2X[O&=J!XP/(6T2(7KG+E,2_>^RXV[+T-G%S"XO+JV>(4YZI
M?3C4O<V<(!UH3MQZ&N8?I5DR-6U4R?3.R/1<B\.GERR!>W*02#X6JPN#27B=
M8\;D7A4346 XFLUBFGO=[7*'SW*X6>T>FJSA#JDCRX7-#=R%HKS%38C8(#4G
M&RK05TT^*8UI\O:9V>[!91;<G,[%HP)N'CMXTI#+#.]>I',O:ZFRF0+GQ'JR
MGDZ8(F':PE2^KW7W^9(V,^'AIE[T+)=SUT,=T@5K<K01RV#Q4%RYA;P2Q4#<
M/E)=4-MT+Y4D)-@)1P88:608RTPV\^GNA2W]4J+!4YYEO<C+[><V'TJIX+9!
MHA8XRYC:A:_H7 ?&O6O;.V,#ZY>E1"]M,NHX*"Q[@HPX"];Y]:O'E>Z]#:A@
MVF'F'O :Q7@3:9@:S=]5OXR3-X8(N\/VZ/ 1//K)V,^]4Q)//(#;:9N// GY
M'GWD4*JA:M3DNR1O"OZKD[(RW1RO$VLG^-<VB9="+CD9+EEU?5+_ZLO;_EU3
MM@ BV ]MZ/.;?_Y(!=.E++WT'P=LF#M#7<C41? YG]W[938Q,0Y*T6YE6K>>
MD\X(&8+I:M @>M0^PT]MF6V"W(5?U2VF^:SWO[?OT?DLPY"2%I 1#(1KF;=[
M*A+*";7+>E*NE418D2C%T[97:/C /]#2$N.B5QXP1/]8OA=%*2[.T9?N<60S
M.'.1WWKQ]@!D0*73?J7@\5#9 ]0?:/2Q=ESD]4BRW#>S/EFRU_6/'\R*#0BO
MF5P#^+S@*Z^V7Y)IR*)[$9.MF^:@=+ZC0!/*?=T!SX_(I!&Q8J 4_XW_&HE2
MX[\R*/\S]I?RAZ+\6!)RW+Q J=NHZBR4=\O(@OISX]F:*A+QV#""F_*I& 7F
M41EGJ=O!.;U/B'BLT96'EK-N8E+'"+R$S\I]ER+I904GY\]*D<S*JY'36\\X
M">?48R/NCV!O2CA>%)@$KAF91 C8>=Z-Q-5RHD2Z;16N6DBZUL&^Y^H+T)R_
M]5"2!G9WBNK2W^<6&%PURZ$HGIQ+ZV "+WH/*^E*YMAB:RQU/I:#+R6 D/61
M_&-U]P1&ZU*09N!'\BH/88]A8%!FGQ ,+# $QLLP51$4R$WT>H:FD!LCKR(
MXW9$!V</Q:BPIA40R(A&G!PGI+S..]6EL CICI9['=@$<"D=_?*"<8_7Z&U4
M2<-0&O$*8ZZ(;FJH6D+BX4.1(J9[WR=2N^G?AJO(Q4/UT!4>?*$L\81Z0EI_
M9MR)ZK!QC:OO^A!0H#?-%#ZZPA$FLV*L-3S13ZU<>(X>ZI_R\,?[31W7*'R[
MZ29&B#'C'25^^XCH!E+E^-D?R G&]OU]6FBOMD-!2VUGERT9/[EZ;UIN_LQ3
M9+^I*/4Z_;BM76AH6@:TYU,5L<26(27Y,%[ !VA][2O7HOB$;U::-6PS(\Y,
M'901E*YBT'<T'GW.O0YP@=#BWO=(JV@F/\&(&CTK<K,']&RW%,KM50T!8W?%
M".?QHQ28)5GJ7J2,V<-$ANM$@-MAQ;L]V9@:$18G6AI],>Q=+)-7YA(F>,5@
MND5+KLGIC8'1H)&[X)<AQ^\PEN9U5!,7/PV#67E[(?9D"L1- ;V!L *[D)SP
MA\%B/D?<G<7)R;4O73B:9&"UF-6"? $5KV?)V "7-G'WA5FZC<)_" :\Y(MB
M-@TB]!"8=F>?B#M6"KB;XI^6E/<XJU]\P#M17HH?J<IG,VS-W\M)N8\O\KV:
M=F$(J>=V4-'5%W?(KWFE9QI_&_,#2J?6]CNT9]741[,3:M[K"=SR'ZJVNWCT
MX?93KIPD&D<S PL5Y+Y8UWWBN<,&Q[=B,H:T07')WV;:AYO/T5\\$"HA_1X?
MUUW*)'=8FJG]+%;[N136 XW :-M<H1?5O/' Q+$S6C=W T>P>VS#.X;CB;(\
MJ;;7FXSHWL222[]C+@@)8R,@2Q.](TZT#?DW2CKR)A8.^O^F__X4.31$#<!1
M/#W;N'IL4'WYYNO%QBK]Z/[F^-]N#R6DPR)+%8*#*A)O3H0\,Y'_$9:3\%8Z
M9=CO:QQ#D//9X<_HQHF2*U/),?SV[!GSZ4<MPZYL5N4GIE<3C<$NH8A7CFIY
MH KGE_$?T7";R^0.06S!?A\_NKW&[>RDCWW^358@M.7CSJ?/R'U08:U6I43P
M+8UC$=K2?!;O8M&KTSXI\E?3( 28:.IN%9/H)Z#+5V?O_$^+@8MJ<<YSU:F/
M@7)4:ENPP]7OWUC?<;_6S..13XJO_%3=>0T0KR=L]\$"!Q,7W2>)A!;;/:3,
M[,27*5CEB+(M\HA:9-$2G*6/TR@2$5&PAFCEX,/:UFV/?D#SC@[E7T_B=*5E
M%6</*@6$/XJ*2D-.X@\4%+H)+2EF2S!+"F0,603U/QL+)8UJ?ZIA^+PB6G?&
M$67O^PU7RJ:K#[P!2^=B_-H:OHR8#OMG__%&DNB7_H=C)X!8;@<J$LGAYF G
M_KDC !2)V$&4*+CHRL.5&B]38=AB()YU4X':7H 82 @D"S,:P$1I?XWEL.9(
MHQA7JOQCXI':#!Y)@9<W7H&1IT!2+D4VJB^LS-V6Z"<K,)8O?2B'6V%+DEI5
MK$5SR5WHO.2^"JEQ7,C4G311G?:8X@X/ZMN.7X>0+&&L'[)<L6@J2J4,0?'%
M%B$G),\-%B%'KL+A$XVV=SYR.?*KL":6&C!;C(0'!-A^Y%E?H5WH_@D4F)(!
M2U*_"!<8OMD#S-'!_-("0]8RYJA](!*U4;0"A;:A*_23R1II"@\M^FPS9YXJ
MKFS%)6MYC$KLX(!:0AM9(I[Q)'!-JD\0%)6\ISS#'PZ^1WUJ*%8Q ZV@=6I?
M?VP12B_R;/,[MI75Z]=?WI#O?RS<[/9*Z<O9,JI\3_EZX+&GC\\ZWJ"]7G>+
M37A ;@!(WHA) F\E'%$:]([!/1S8IK=\1,&7@YAEYE^@V]6'E;P%)U7N'6L8
M<Z_RD,K=0@L=T]JE"0PR;A/97"3=-B@ %806( N%T:CA\D,IA9=-ZS:!M+=E
M#C<-CRG>A[;5]CFG?R_NNF?!$?0\\AI NFT<NPBKB54T=*=- UIT"XISM%9L
MVM6L"(R\IV"\;:MJFSQ$1C1SE.THBI\F] 6'-7&MG\R8KA 8UWQ4\HFNVT@V
MZ@LH;NE6\H[-5=I$E*J: 22AP1*G3O1U@#1&/IR-,K==.OS148ZXBO>M409A
M#8/LR$3AG"SHQYL'5LT)*/FW,UL4HKI]T;X=;1&7;QY? S*A9UQNQ;FVI-99
MT(#_59G_KZG,02F\/R^(+/OC@L@SO!KR_<T=F+B5=B^RG7Y/!C?H/9.XE_:3
M#Z1I",W;W]]35#\_7HHXR)ZY!NQONEX#WM!<<"I%F8V@P>S7)%>F5JXN!$\T
M*6*N?$H;MUM\@^YB)P^4%,PF&[).09C?X=KRRP_3<UX>DWS*/;]J3WAN&/+!
M_ FB_AZQA_\UH+E$_ZG@UF1&O8F3,\;*J6Y4>-S3K=;#G92HB*1")CT[>V*\
M]X0\XK9I$-!,$:85X')AE6//:/9]*7?:W ;AY/,#]VL _CMYJ-[K%I:2N1\=
M,1C[9[J/:(C</5-=;?);GA848 (=;H5AHX>BGCI%,SY:\ZF-&W0UZM1.CVJO
M 8U$5^3;.9:9^\/+3O4,_=(JT:!8NS>RK*<X%_7&OM^"4= %NZX!$B@.?&]L
M_N!]IF0:]N,T?LESTUUZ2:Z&:EL=%VX815O8K>UA-J 3?$IB:%MVOO/MNXIY
MAVB)O=IE??6)+NU.Q1PU':1-"6RC2>",J\YSJ]X%$QK>??7#-A?JJK[N"-&!
MC>H?(Y%SWF^^UUP"JXZ4,'O9J^M9ZI9Q4/-#(05WBP1B"Y!9#TC[R3 TMIT4
M*,9_H1,KNG E_IOG7GAK!2O(;6MYE&W^SOL:T(\<OSQQV,G99[X&I/]&2;:Y
M=3(/0]TS D7.[_$I+ ZG1W6_F$!FQ*5,)*;M -J_!M#_T<KZRK?C-YAL"BX,
M57(C5=^5W]S33+H&K/V1I7IAG@#24[L&J/X>EKIR#1@F2+_ <=C)(  ,^Q=^
MLY;<;T95HDU? &51O$R[*WE"_.V[%(5_#G810?J9F?,UP&_SBJP1? W(%?S=
M]E4X[V7A9;9O/PT*D.\.?//QE<>L[[SH-2 (8("="BLZRKP&B-G[[M U-D<@
M47+$]3OOQ_TREKKHJ G5R/.K(M8XU+< M<Y?W%"<1&]+&5HNO"S^#=8!!=;V
M+RB1Q?J]5(7?;)^?+OR)S]_R6"%4<)#AIM+?)B7YJ[&Y+1K,K_UY1'(EK/\*
MH_I$XV_(^4^4JU#]*+K,_W/.;$$4*:@':5[4-PC-_/4X+]?WP_KW?MMCU28;
MQW;O[9W#)0>G+SA#JVU/07@OXH?6G&:?H&2TZ[VJ@BR=ATK2U%0TM[::Q.$]
MD Y-6 7'Z5TCDM/Y;]_5SI]>/OR3SM7@*/F5@EV^5\,*^:&GDNN_61'3_Q=_
M=:2! DGYH=> @S\7)MCY+Y;YWT%MA9DH.5@+&K_":#Q1M[(?.WYZ-2%X\DR&
MF16F\N2E[U]2DV;[EZCE4K#T<=X_DT/6A[\B288.@)_33O_Q!.44<"J121G,
MT@I>[#CLE+Z2:2!N8*YE<Q.A8HMKZL,(%RJRN\-=)__B?,8EWSSF9XU#I3'%
M*D[DS)O8^>%ZL\S:"2^2RFJ&G-<M<![OB>-[0H;.,M\@'(+HJ>L;A;2>2B<P
M.'ESJ]2Y>+ODQFQC<RE-S='K\AF,M:,;7N3@'=T;#0%^@R?N:#'DO/!,TS.C
MY)!OT=F?>;H89VVOQ'#F[K!37)#$;(D]ME'*QXWBO26>H1:;)@5OME\-%\"Q
M(SW/J\ WKX.ND,*\F#(2)\>N3Z6>K\/*Y<NOE>) 5'R(HBIQT//S>"A\%0O'
MF_D1F_ H=#G]*V>\'*'7;2#W=T ]]2"I,3;'*_LD)=J7LZ@G/ QKZFN4A6N$
M6B5*/:CD3$PJ<A:H6$SEO-\8>A<!;,!OX-[JXGIE7R[JDXJ2S";(_?0#SHK-
M7_0(6TX,3_,L85EJX[<ZJ\KM;0'H.!PJ^CQ%?+XS726BU@@>O-@I"!XW];I$
MC2V0,QHO7QL-V^HK[ V<RCPJ*$SUC[(KM[/O&,-& ?M(KTQR8)M^HQU,9MFV
MTAZQ]L&M?<AZ]WS_6%3XZ_1_:/R4A=7<[;^T/$WVC6;Y-5:VE4_MY*3B&E#6
MZ7O ^UPV?'0?SK5G-(F[R:-P;L2\3$%)T^ZM.\@A)[HP5QF?6\$@RRA,E9//
M_J^.:OKOG&3X@,F.O.&?()J:&A ]*:"O"'O;7;JW';49X2(P(PVHKMD+P1VX
ME=A!GH:23Y.UG.XTVUC*7;)U(NU(XP_A,X,1SDI34,IB5O'>!RNRE#GY/]E6
MGJXH08$S7&P"I!U>!D !7.47Q&#KK-3FIJ<K<BC@!(P7JQVU<#+SD*#(Q+.A
MA0TY]JSO-[?@$F"+KV9!T9MN?DB1 Z+<L%A-E!4B![3.P&PC0\0"-'K)$(!8
M\YN?SC2@!NQH[#D9 ^@H=\U/6GGOZM7\80&07U'^SA*I] QX(L,UI]!<QCP4
M!:$5!1JP,A;J/2B+9OIKXE -QX^W(DH$ A&[L#?L.1 ],Y/+5::Q= 6H*B_-
M*RE$O1,0(DMA'*A1[[T XTU#K -7#^CACA Y(A%HFAZTQYHNC =H7?21Z$E3
M?P:<#*'YD4@NW$>6#FS=1B&U/2!%Q'X!MB8STB'TL>X8BX?R-+= #G-^Y2@H
MOT;-G&L@XE;*2B2B$]OH_M7+_V^?VL@TR['(-)1OS%K,-LJ<++\[9#59?XC0
MGZ]QT7B54,T8?YU#^2-1PLDTI+!1(-31H+PH>40)SG^U,H8,H8[^2_SPPL&0
M_]#M#]R O$JR %;V-N[?82A^C?F/,/&@-YTHL_[VRAG^/WT.\_^7Z3:@2XBL
MB>O%"Y$K%\ 9,.W5"RNO*Y?/YKX^OB( 5[)OO)*?&U/I_U9L^.?BY__9HN>O
MXNS:Y=+%ZESZW/,^/SI9P1ZU[0<K3Q/_8_';7\6R_V\4_U,DDQF.Q_<S<#0T
MDA9,/CY843G7$NJ'-:9REKQ[V96?BP=GNB\K&?;@UZ#$=QHJ^W?.-TX'E]E^
M#_K/BK=\J:]<.FJ#)3]Q1+3[*9[?'E3W*<48TKI8^V8=@NHZ4BMKW]%]4WV9
M^^!TM3&5O>;]@>O%ZDJ$XY+/!^O\SX.DUX#XD-/!H_<5J2C(_?3?N[NL\]^,
MDEP</.^+-7KB)9+>'FY]3*P[$0]].RN#K1P24<)8__8@RE=$&#XC_-S<BX,!
M*2.YE'7E0I"ORLMA>C[84_^.\Z>*+']?R)77@Q6%H_?.$2#)F]Y<7>RYGH.^
M_;(7:[G+ $=+Y4OK9>/FGGBHU2\>Y:"(^WHZBNM*UL)!7/HY%3Q)CP @_H-:
M^]_TWYN>C<JYA/1K$$1= U[#=AX@C; Q^X$O%]#ZR;>G\ONB4%ZV$<,U0!JT
M_V,'&YBE+SC%<S<"H=1Q_C(":>3;W]IX/)GOFTINSGJNW7%Q@7(=?6 2HY!K
M@.3M:\"WEYE9?JSG*O^WAO_KB/\"J.'_ZHC^B^.$JW,!G]R5*^^O-SW>"2#0
M'DS9^ZXTH'"';PHR[.\^N#RRH1V$*>-]_@?8F$V4L_B;ODH%^2??;&I0GL '
MW^W*IU/VDBL_GI__'!%X!N1S0*K].2+B']G,K!"LKL^CDG_,7>A[NGTS![7R
MP%VV<ZUKP/X<:OR03Z[OZ0FJ XC8NA?0]7E8\B_B_LR]$WB9^.$&SI_$24@N
M_)I:&"Z (J+T-R*#1T7IOP%1H  I_5D2R%I?N7K#<@WXW/L8QB]UQR=WX8\B
M _A/8M0U!S"__552.DK^ Q 6CT\^N@-BY@\6_(U-RU! \I\EZW\LR#LR\[^O
MCX8KBI'B2S>32<L"U&Y0VOXU0/OW>H"PP<X*_H)3I?_',@P-H3^_D2S/7ZQ&
M47C3GE_ /D#?0CC^S"9^-48IVO.TUV9CJ)\^G6=R5OE-J"W/'$6"SOL\+#FO
M!:1:J<K]M1(F+&WGP$#83H5S?E$1@UI@5NK]^#AGR!'(&<+/X YRW]05[I]B
M.7, *;8IZF70<70\2SO<[+!8*7K]>Z73]GZM*&*&X=3AMW3HCG3%_(V#MG]U
MRLSIY;U]6;CPAWA)_+5:(<)9,1.:$Y&SJO+8-]3HGP4M?4G54N.1_ 9ZM8,M
MLEQ@5/AICZEJP'N,?#;+:](.Q+&*-/L,]O45@SLV5^VWV74<O4478O5\7;'_
M:%]//?M>TDL>#7E.QH6#$DXKZQ="NE0MZ,Z=H/VX#87.,X-8Z^J=A)*M7/"$
M0>>\+Z4;*,].K#,',S2G;BE,P]LE:<PACGFK<*($ZYZ%%/;VT?O\HTHO*E6R
MJB4*74NTX./I<4)P(S@JKI()T.)?LZL6UYUR[[PEET.XM1B@;;2 =&!C#OI9
M<,3>Q17E%TW%0"=E$:/!<CDB*@73>MR'ES]W]_;#J,Y8EP.!B42XN:FRGRGA
M"QW^HF>9PS_!0A?W/\X8R<T9MW:+5%@HFL^$5)W)LA-O)Y=:"T;0JM"0M[Y#
MDUHN2H0]M;1J]5? H'7D9#/(Y(EC87C;]ZFQ)LP8LW3=@T&X<(UH7Z:7KB7;
MTNEIHC/T];[ X*LZ,RH3I]N%%8GMM(]&+=$4A);K+'14:./86V(--XK"Q'_$
M@W/TKG;O]2OV16WE>/)0_'A^[U1GGV1)ARV,?EU)J6%KKU_T(Z?$PSG-;,7N
M^^8*;/=J#TJ^LWUU\]R*O?VJVC7?1%H<$:!O]H&,_H6D<)N>L=S6VM60@9:N
M&-%R(7]5ON:=^U<_HY4 O)N:[1]N>VHFW,:91XN4!5.G[1&*W7?!<X542-4D
MY!WWBOXEXEA? (1^3W.XO2&C3,TP10-J$>.>%1T$D5B.<C?NC(^L=R>6+L!4
MM__,2J0D\1J0NW8-R,0_(W!@/AN\1WSC<SW^EP=E_;=-N?M2Y$BU4TR3:\ X
MSC5@0.7UB0C^\:;EI(OH,IUL0_H97EGJ3P>*M4>\4PO[.3TQ%8K)L9Y1UH-2
MS.%R[*"BP8E.U/KHHCP= U.67U[_W^^*![)G8 G$:@ZA?/]L 3UIV7L"2;F\
MDW"!*78TA>PL?Y3=CA@>\Z. *AH V#.&U-$';P8JR *XR335T91@BF[L:&@Y
MO2QD@)^#,#LRP#JP-N<FL T^.^!7;6U6= J'2> W&14)8>91"[P^:<H+X!QC
ME4MY])0L@-B)2%2-Z.B0HY46 HTPB7^*C/53>!;@8]O4#O1V&3RH 0HJKA;8
MQ55)/WMF)KFZIB;I]6F"F^?UDO$+%"5Q\N]J4#1\ 8+9LYL-LH.*IQLN"XR<
MH4.TB]KR<2]JXPCRO\S#%MJZ!\6+,P4-+L-L;<'9>\NII,\"*\,#BN7U[0WT
M#8^?F&D1^[D4XC'W(V)J2!(@185NU3'",Q.=Q^3[*H),:\_<Z[GU[L4I3SMU
M!,88=D)W_.!IHQ%Y^3/,UMU%.HLLLI]W<*>_8".\!)S'DC^_M<,O HJ#6=]O
M$L.Q2\ETIB,)'FZLR9MRR,DOQ&@;E$3+28SI5O2;/*U-_7"YRL .@N8NXG@R
MGR9O7=J^V5(/N^?(W'6J\U$F^$-@9X8%Q[N*?)4V&R^7Q=-7G5C($9NW^>8S
M#@>]AJ1MF$\$ZI=4C=+FC[)#7#+-P(2*E%9S13/95Z\RY$(# ;QTMFRB43H&
M>H&:<0^RM*&8/!.4"WZ<(K; G/J'<$Y608 J^B6';00/0?Y\!&0.S>D3EN:(
M=,"J-%?Q[C4 +?2 O/A9Q8J*M<AZ'^=')KE["4DON/N_ZQ-A#O#+]751"6MZ
M17(L?&>YW?[YA7[[[E3AG)%B*'."H'1=\(IU:2'$VVA_L1C&]>1^LH;\%%_4
M*\SR!4B;P5R+$\+#]$3FJ;3^V-!,7ZA[^Z"CKK6PLDM)7+U^B7EW<&1ZTCG2
M2+?1-(=>ULVP#[W@5:B5@.;.7:JUJ>A/)S\CL)_?X0;[[E%47@-*?VL@$N3K
M\YQK0*=!_U5]WM5;SE6>$7FL+"B0\%_^FN3?- $1ZW9T3[I%JB0_;E4.=[^Z
MDOOL-8+0K8)PL1U_3!U<R*2S736VD)R\&R2G%GW"L'/'Y%:,PI(_A'$?[_1I
M7GG9 RKM9L6.(O\E]Q#^^;K;M>%J\99"EN+..JH/Q<\TC<!C^YTO6MK8U_R_
MS16TN QTVY4*Q60X"97LG'1V=\6$-.]U(2O<R3098EU[V5=@!_9I>7&V6-PH
M38.(_?O+AMC?7X\KP/#@ H"7H8,*J#K-9;_;4'YY+W7TY1B!6-1?J"([&I@?
MI=#N*,"(4+H*CJI%4V3O!0R@*<F!V=&L?VFPG-RA990"5!X*_ 4;GXC[$13@
M2I:4]]+OMK\L^8.,'\<L55'P.AD2$RQ)0Z7WB#62>*<.MJE"Q79^VL 3@]+U
MZ@A(7I=_I$[#*R>DE@^%49EL;(9PU6/-X\*Q!Y][;;HVH(<%C2X[MISR0/8L
MA"%5.4J W[-GQ4=*^*$M5\+D#).T[Q.V0K8-&&_/$,)RJ":]Z_@PTS==2L4L
M:]6<6:^XPCB]E;H4L=!^8# _L*F]JKCX"(BKP:DA-Q",Q\/8FC$LG0LH:Z'D
M>N[!4CN[:KL\?1R155MB0>G'["2Q(YD*#@OFTTV3V+1HZD[@CL>A/"Z1!7P?
M(&=V8A]/7"RHY;O]C2\M<"_'DP'S(083!HBZ@U$=;_Y,<U,SB#*%V&>M?X[?
MNK/^G>684F$<%=6VELEPCS:,61-GCFY#;K.E$N?9:G"E?FY(3Y@>$ST>:VQQ
MWXE-,'\'W4GT4EPLS^V'-L"R!;!B75@BD_6&NF>--D%G/U=SXE:4LDS8ZM,>
ME1<9T!32Q^HZ*7"#4XL3*9R8\-K\S9+-TO>!2\%ZX<:)EPN;J@UOFVS"J6!4
MS$*,3D@3O;YEBBW%5F%SD7'5#BP[4N(<VJ[[!G*K]R.6[=X5'.?S,$;Q=/28
M0[7QGQ: N'ORN1+M.1E/ P]G?#@J^*FT:"W+M2K=2S)1*HPYF8* N2IJ2(&:
M?6'I_=4#:9W-G'!=[0C_>D;W-FT?A1[^)E:QMG9YJEZ5W+!QWFH?.&A4AJC[
M9PWKJC"-D;V-(MZ5BV[UQ Y]Z=(GSBN9,=_#6<F#>[]BQ;N4G1+HH_9S%]1^
M'N2#-17K9\">%=G\K_Y*X=\U1<='1Y(AG<.HCZNW&-)/\,K2S>.LICHP90?.
MQP=$NN,''?PZ'NVY7@-<QGM(?%D"Q:P#P>T*](?+%F#A=1>SE:^<J2RI"UDS
M"IQR/_N[(_G>I,5.CT+/Z(H+DX2_4#'M%D^PG)N<#@%D=B =H#?  #61+N(Q
M"!+G,V=7J$_RIT/QQ+$P-3=9DBH"VPA6;3-*6F%:ZH;P4O]1?YR!Y?CEV9QA
M"CRWGN\??:1Z-6O?3C67F;\5PEB2+/$FXVVT3$'N*&R@[^(@R16'-:$.LXU=
M@J]'O[52'\ UN?:LY" H*[',)W186CHK4 X^H#P(8\]EO'FMG<T: /[U<AL&
MX)6ERNX%8(<.4;/?0L3&OO2C"("@=&.&&8P?9<OQW"BZ5AYG61:J[)O["J@R
M,& FL4D"5@*_="+B1H'*WL,BPT?9@+UD*,49.J2A;)&?C1WOAV\TI"%% #.P
M8Q>H>P]=I:AV)&%\F9J3M.7216HQ!PD]TPK-C Q>M1YDBY_IMVG 7C-Y:49P
M_M5YE:^NP+O,/.>]Q_&7!=M[%^LKZD0ZM7RL^4,US0_;]##=5FWA1,_2$I)6
MELEJ.<#E" U9-[O,%NX#%+'^*'W/K>QO3[G2.&^331J2_.&9$"Y_BG;%MS5U
M_?Y%HVY_:2OREO!&EL&?2]R%,.J*9HN/T=:#:5*/_+R?E2RR8ID0E K2!\"5
M:K,)GWD 3$MM1GA;\RN?DOK,/&36[7^FLMZ? ZTMPP0NH7SIAG8I=$02H=FC
M [-^<<Y'6#BF#\JK:76R5=,,Y>8K7;!SG2!1;9H77_A2<'IEG6MSL%3'.G)4
MOR*U=21L@*D60AA<OHHYS&-O.:L+%!^_GW2BT)@)#=1K9RQBDE^:9@ >E]!D
M_6RM;0[/=BM>EE.PO-S9B[5G,.B/J]5//8 7 &ID58K],+Z^<,\U$C$.EH?C
MW6/@4>5X@.!\HFNOY-P0'CL=P0.^GR0_2WE>TPZ>9#5^@C+_YRAJP18CM,40
M1W]5['7#$)\ZNVY.+%,^SZ4@WD2CK_SME!;QA!XX4P4S"DN&3R$-\L7G\AU,
MT,D+!:: AN>"43$L(^$6B"#IEM?UP9Y%YNU+]L(NL;EXBT39YUIW>6[/>S)U
M;D5[P;P3 GR^\<=$\#9M&)?)9K8\GS594SVWZ;X_]20[NH_DN>+HX(+'4H]?
M*/=C\H^=90];2PT9Z;]0CR*MW+ED0L,#D2[?4Q>5TWG(LPTPE@[[!33\I,2%
MLCXYK\2W_6?J,B<VZ.]&'@DZ?%^H3[A7; _X=IY0TR'#A7_K0CIG0I6Q]E,
M4+)N"&!SX4[:>RO^D6YH:/"S2-LEWY!:A_?/'+UX^'QZ?4CFU4YO'V1)4553
ME<[(T4P,AT[/)-97NBU?S75CB/<4D%F<I/HQE$A;E.C9& :ECCPC7R=MZE@R
M>M .OP:0$6:3G+Z"'X":7@,6=!H!.V2^3+)B@N(XVN(!9^DRVW36<[QIH\\V
MCY)WCQ*=B'D;K$ 2;HO[1H(^4.99J=>A_MHY#<B@@"[([9H5PGEJYYF6V]LH
M:56[E^2'7:15BA4V$K0[ M'NG?W8LIP$1TGDIQKSC'<ZY:G-'9X$=P9PR$9>
MG*'YNM)\V53&%&1-YBJ@WO8DOSL:SL%S)*7(((Z%]45H6__;M(%3UU+RAL]<
M'\>4"NU&G2!AXYQ.KQ:<';HXO>-)YD#9JQ-_-(6#Q]UJW9%AA0&->Z% QB?R
M,>VM<Y2BP;UH>S+[%<K\G-K@F9?ZFJ##E^C1PO XP0Y&EZN]\OMAFN/J;+TT
MA6'M)1:VK>/J!0<\_$^H<\*Z6@75:P]TJ0HA"=P_L68O#N!NP)2T#G*BMAF*
MHJ05Z+VKR39E"TYW;/W9-;GOH6,NU'VIHC^#][ E_(-5GM/N"5TA%F&#JU_<
M=N6N 39EH!F*C3I/^'OZOB]:#VVJ!+ET:/+UPIO:P=GG1'J?&J?"YD8Q*UOP
M@Y,&[XY.H"F1MPKB&@ U9>D&EC.=G6:,%0)7D/=>$Z>72(-:U1G!N>$@<<$4
MS38!YTR/105LB3U::&[:O.=6WFZ,TK"8PF7X433_:0#?Z?QMR)I)&.$/CWA9
M!D["T/$N":Z5'\YT+5<2PZ&^U<]U)UY,?%$5DC:>@)&^-1_7O./.?;>-YO\A
M[B^?XGJBME%X@"!!D^#N[NX6W)V!P1((P=V=0'#W,+B[N[L'U^!.< ;+  .\
M_,Y[GSKW^0?.4[7[0U=W[=I[=?=:U[6ZU^K6<J!044BU[U.KV0@R"R/%8B6;
M_(>-ST?-)-];M>F62NOO7P1Q\$<$=M,[2+9O+M6;SLL5#G@'/TO":(>M9/_5
M&C;T9)K&/$.&+";+_QB,4X%/& X<=KX3XCH1RJ-W!L]G,X[Q5!-]LC]Z!=0H
M]"QH.[?GI]KELM-FY-8 H&5[YR[*D(+58Z'8"=Y0/A/65A8Y469K'GJ0;GA&
MW2W9"Z/'W7VU1=_CW(DQ[EPU6_57GS*[Q2+B80\S\$;J(0$'+5A@PCTAL+*(
M4*80GR5L[%CVPEM;8X*D'%VULB1/*]XJR; /CNQ-P9\1]DXJ=<U)F0=NSW:L
MYBMHRJS'$I Y5R5H/-?_R9E0V+5XV78"N_\WP.>3Q$]FX#R7\A4#TJ2-(4+1
MJ.@%B!KZ*!DA[O+3^)\\^D7$63-W'\V+W88MO?F]I'&?4:G8W-8*)Q62L6YZ
MH.H@R<R\XJ4$[<:QO &IE4"?X)!6AG9="_UD1RB7T,&P9<Q!/?S]!2-_=(YU
MF4.IOM$KH*PM4OE>]]UBD.?1._5+\@C =2\J_U'V9I.>\5JZ;U/KSXD-*?0%
M>IU:?C*)]O!153X'PDG>]Z(ASB\OWAH=L2GH#3*H]JDR.J\ RVT=SFJK8A-6
MAZI_W@XXB1G>5#$4?PB+,!(TJ,.,1B5)?Y%AR&/*B5J[K7]^,XW?-%1J\7F^
M)Q6Q,@=F=,D@0K>U"+:3@JP9J\]WS!4L(DAN,7O5JP^^L-@7<J'OD2QZV9_G
M1?/,RT8MX'U!Y%K3;.A\MV8XQ(PIIDM8KK"67@7_MU4/E5]'*>;ST@R"DXA3
MTI\55+>N@Z85NO=[R0'UO;/?%_O_-G1D)W>4I8_4+RK<*:%I2B^KYY%5<TMK
MI?:S7>Z5\#B,O0).%PG<#(@K_;(O"-]O WK!C;D(@0(C("(G:&BL%!!:M%-%
MK$=D-#GAE_N!&$6>\'C2;6E98V--SNGC!DDDH?P%\S!,[2H2PV3(P;=]J))3
MOB^;$6LRN^G46P=L]6A456B7'$KQ(\R1V;K\8]#!NL)IF:< -0_>D&[J"9HO
MRXULUO49(C *-&_AG+#9JT?RI;52FW[6"//O[";W#]DKH4C36@K2 >0\7)QE
M1X-,%1&-1X<OW$IC")9U':0R;"<%?"46MC\.6V-PIQ%_.3-YLE&U19A'+,EO
M%3!.BBG8X]/>(#D%&[)'O]"O> H],NN?9UL$R Z+*UXHB,;X;D'V$797PIZY
MR,<[.+0+-,NC[Z3'_I!+_ 4M"%TD.)1*%&F:H\.=@PPJPJ%>'H@E ^>,Q6"!
M5X!C&\O*N9%.=Y&%.U^?"T[8K!ZVGD[Q'J/!-Y[;-@^/ WE#.+"]LR"LO&BX
MR,HRP,\-W?CW &^TWRO@)UI'Z=:-&3*O+(:9:IM=G;'$Y-ENU94WY_UA9E+L
M7NOS@L-1"2Y(:<WREQS++'/.C@4 '.FG.CX/[_-KEW56?PB5RQTM__Y$C<,"
M0+* =((8+3]/-2PKU8!.9':"%^%PQ/O[,]MTJVE*ACM:HK&)U%=SUHV^/SA*
M;=.YU092T*R=Z0_6Y\7ZAFVMI B4@-VF)H$SF.3.Z1IO6_0 CSGI8D/DC<D[
M&&.8)(1C@1C8U&H^IK<GSL=MQ+.#J>_2I= AFL:3T24T+X!<PZNYIU7?;*OD
MAFI6RL)M>,QW3JK('GJ8%-"DT]+=TDX8=,B(G,_!RRTV1!N*[)N=#+9\S^\$
MYK?(+2_SL:.D9#,U[8ROQ$24P:OYRML7Q-P*,KD(/:Q(!$4>!MJ"05^>>BT2
MEG(T:^QD<31D./Z/^5@EE104?@"U7P'Q*D?/C@'/[Y:GEOGJC(::I=_=TW5'
M+ ;L8_\_FX[;?QF<--=Q*EV6X[=6?EYG=4^1L\F5%%FJE0^X48O6DIE^;(I3
M=P+1,(Z*<U#G'>M[K+( E7[]&CS*26VM^$IQ9Y#%<TIC-?@*L$AN*$N5-4R%
M,8W);U +.G!"=4R\CRH/%G@6^>IW%E\!!WEG3 <AKX T85#'!3WM-V,G8Q5%
M7HI;42&W]8@[!_1:SQRO=:PI8)7&MP66;W[!4RW&/^^J#&RNI3H41R:VCZ O
M*3YV7?M.*<]K7-?=P9OE*5:2)Z[MG&781//JH><HGQ&"IWQT\H9]%I5BF!@.
M=0,O/OO[9=ZH!!TOZ<9J?T-UY$=W6NWRUFL2Q:+KQD[2-CSBT4SDS!Z.CW:K
M?MHPO*GZCH.*Q%#X(P2YB,[J/Y=%/!@ 4E2>FX%3D+5ZGXO TU8\*Q'T1L 0
M"PLGW\UP6G$K@ 5S$2?I+ \C3=%G97!"W\@)MP22Y1NK@ ,;SFG.P('=^"(_
MDRJ %4$ $".C)9QE\6&R%D%C01$M#N $9&\Y"6#,CYY5""RHENPK7V:EP63;
MH3422M#EP-J1*G4*_F=06GG2ITJWXCWUB:Y=W&$./3[/XX2\M=Q=BV7&6^C*
M177N$C1TT&3VU"Q(>%MZ^9'%C=>5AF9 0)3;6);(/L5>U@^3+K%**0NOC7HS
M-3@:7G@.4VBYM0DH]M7*]7_RM6NQ!AK&OR>Y']*A-%M(^6E_)@?025C>S ?+
M1NI9Z X@'44>#<F!T[=2%P]*K?0[JTB2A%(D4R@[O+5GJ1H*+9V&]=C5JF33
MS'?,S<<Y$2-VJZMJ?\J)6+B(&SH#:L!1=7?E(*+4V=X$9CE.5U'NE<7\WS\9
MGQY&>14^O'M FA%[!109CZ0#'H)"1!_GV@\7CK(K?XV.]ZVUCI"6OW_Y]TMU
M=C[VCF*',!EOM+?4WK'N1^<W]&VPO<*9M&[QMSHEX?K!7LRGCB6[,U;\B[&8
M6"[Y24N5MFXW"FR8X*G^1<9U=$Z763S<$6[VG"@JB O-ZC='.5<%W]GY'8[1
M5(MC\X*,[PZ6DP97AE),J72P5=^TU+%R*YDV9U9'B?N8SA$"#V_I2>&?SP9?
M62H "3%3LOND8DT\J9#&N<%Z:A9#6X==7MS;V8A$'KL0+R[,SOOR:THVD40:
M1ZX5D:6)MB.=#FY'(]J@7664C'V$I:(8XC,N$45J]#Z0[IF/%MN2>$-!.=^5
M2[S8'3!6X7M$TJ04X?[P9*Q--1ND[6@ARJE-),C $YMR@20TQ9O7ZM@VAGR\
M=:^F2KW%W=52BN0#')  #;I4!+;5##1S(+RKSF0?--=X!334;_%H'D5K FL]
M;4PWTUX!E#;BCQ<YCQ]J<BN.-MC_%Q71KH]_8Z*4(?_C9X0[5B[)3OX=ZU7X
MB"QUH!:USSY('$J?7_:LXBY&!OU38OF(D9K]Z#?0R!FRGNORN$P*\7E1)#GQ
MQE4/X#;.VG$((2-8%.'^ZN-DTZYOAJZZ]\)[FY*%^%ELD:!B?:_3 V(_,=1-
MXL='+/C5A>*+ =G+G7@O[519*:;\JI ?AB5,">JP<XGIJ7>"AW= BXDO2%_M
M=Y+6B^EF)/4NH3& 6F$\LG=L;@7H(4A.MFKL:;++,_=0#S#'?S]MZA+YJ#4@
M-&=CC-NPR._"0R5+%D;*_+M;!.IK>-S\^-O2H]]]M-=]&[7OBCWF33[=1"?W
M,11/*NUXX=A3F$C(IX;5:4L<D.2/P+IQS]27TV%R[&^12Q9KK*.1)&19S-W0
M19+4;.+9\Y9:G6BDOA-99C"4.3\+.*Q6.EHXXI"&$1L7;U,)?0'4UU*8$9)7
M\>6>]N=("_]U%/H ,8GA@3:JB.GKCJ-?V%ZYS(NG?#]](5Z&P95]7OY4WV9;
M6)<4_+!<#T.-00[6CRQUX0YRFN(>TH4^D5@,@'P^(!1.QODSFU3*F(HFQ@8)
M.822L3G@>.JI.;LXV?J6$7>06/#NYWSH]"N')@TZ6S[*3$1)O(!0IK=$;Z!+
MEWW<0E 34"*MH)P PC)\*SM\H8NO?",VH.?8O/6(WD-1NU0S!I1H)+X=,KEW
M!1P<47YR[ CV4CG\--D* 0?WB@DN^C+N,MQVR7J!9G/&+3.O8C*!\[\ GR1N
MX;N5(.UR6(-1"<A:SIA^F"=Z@I5 4<&\AF;H78D27IE9^0AU^#<3EB^0CB2C
MZ;ZJ@">#O@G;,Y#2)^KO]*G3XDMI(^W$-@'HOT9#JJMV;M3-,F]K>*"4U=7I
MNV@5:!'PDEQX^Z^ #[VEZC&^Q)&@0>!""V3+R*NIPXZ-48]%7CFRI$R JD,<
MY1C4G705-5'+U77641A'[H,1;"SN/0<=V0WVK>R[^/QQ&163^P$XY]U=8;%]
MB>Y7?!3.FJ]M5%"& -#>-?T[G,5+7%_M6572SX[G&2K>8OWO1;EFZD\$%JS.
ML"7"5[ :)KA$]<>[MV<J<5B-&E(]\H+7$BVBYL/CC?3K<^DK(%6B#F$K\FUB
M\T?1)ZXZX-@+$D;R$?3>_F6N_FG=GEJ>4M7\L]D/?]OA(U_7=H:HYA&\9IB[
M:*QXD>]SC8U03URG$VVP$8^ZUR&-,BR7<=CFCS\&W2L@K+DWFI%UQ+ZX\VA$
M')4W2U@O0WMF]NC'^L1/>N\Z00&$S3;'S6&!B"%8Z%I=[M:[NQ@^/;;;#7W?
M_2^JAZ*BK35?VA:0?NS$M9AT7S;(I!-XU,#-B+% DP9:K,PJD< \E(J_^>KC
MQKN4=MG*P27]416G7*#-78P_KX#O#36*%14$"TTYZIHBII<Z$/S!'IP,O>_Q
M%3T7,SF)O'=5$2_8T)$!.]*#E-'69 X:@T]Z6,.5,$1YM8AJTL ;WU14M1+<
M6P-V@>W@95[/2JD"K3_#3%N4!8,O'%VK4"SIF]\5@NJTZXX*O5/6KX!>1E(8
MOROA!!SGL)IJ\G1<60Z6WCM2&H=CN5X\!(FN=]$1<;?YLY[XS&[/TCF=<D\2
M2C3>1N%RYN@K J+>;VCBQR>1;.QVS*$Z"@3Z$M#4<V[;/ OG\RL 4O$*@ O8
MU^YX!50'/\YI+R]XP5X!ZMTE\=":N(C)X_LWJ#)S>ERE7Y/6[QS#^\UFX,/U
MO=ND[\1N)WG$])3XW/PK0*JF^/*N(@ +^N4$G_6IU!0YN[B"&";D?A8((0[X
MF<T.H;29!,%DJ /0!X/$*0U[(CO9JWR%%L[W#?;:9>@$J<Q.+XU\8/H0BPBW
M]ZR=HB5<Y3D/W]%(O+,%JN5&THS9V_5H(<P<,6$7.O'P@H] &0)=9XVLJFML
MBQEQ#)@,?X0(H8V?(U;F^YB($T<G\!46F3403_P3VP6U!SM.ND:.BW'?%3]]
M;T3FT:1OP)9LI\U(9!6$SLT^QCGW";:8BI>I2V>3K\QF&-R?S0FIW%JK(HFF
M<QQ7]?8!SH-X.YO;91JQ RJEX;J;R.+L2(N3[-!1/PG, '!T(X_(0CO7=2E5
M?2/T&J-K/A[/6X,1[U(Z$%,MT[4?28"CFXQ7=T>AO*GS3<A8 C+.LMYD*??N
M!-?:_F[7_X;OQ:_J[?G^-8>;7?'^2=5UK)B8ZP?SB&!?]9AD^S&#E)+Q8M_E
MPKLT/NJ6C(S1*DV*\28$5>I1D)70=9GMW",'NHHXR^2CYQ1YR9V_0UEP/1P9
M-SN%@O6\RZL9&?.:\C9@1 D'5Q@5PGB"(DD7-M/=XA-4I[KRU7V*^X%^(1Y;
MB'KD  .2V)('\,U6W)'0>=I3SHQN,B6AF:%="8R3?4>NP)?=(R#T[S6GQ<J>
MTVE@)S"0KJO,\H6CK:W1PB;DU]E1E\]E_WI ?X/&ELTKX"]5)[-DM/B0DK8C
MH<H1Q>U?&T,6J@.=IJ97@(;"F>7))CS$[R*)KZLTG<"."Y?F"#=GIX8$&J?0
MDJ-4F[#/+T[%YB4U'S?5G;V<9P*5=?CPHW8MH:5%\:%BI[\ IARACP"XC([S
MGD<S6>LWG#6^6$,,68+![5:(,G9*EN*;2K 19,'^56]M!T0YE'3DR':F'X90
M(]&9_?/ZR[P <T!Q0#E!U='WS7?T<3)&OE*IV^,]O6' !9>1J!)IEA'SKK";
M+;RP>5XXH!T[K5I=UM]O?^,XJ1B=]*(/\T78=2 K.'%P_Z@'H=G?>04PS4'/
MYA3VT'3B.;0#?XXXM7?%[20[L0>Z[F##_Z*G/M7W:>0H+]2M++SP?:ZPRJ:!
M6E0-^L_3F,?N)W)?]Y0>=@=?>42,1'82L-\\[1"S]%S"33J)D\_QSYZ1!F*2
MG(L^:?DCIYOT/89N2^O[E6R1S )3JW%U;32]*L^\6,!W+RF[3Q,="M^L)E*T
MLN\6/ -ZC5E[EFUY.W[&(V5]^VY[1'AJ^)*&[B&.P[H3CT"\^26NO[LIB#<6
M91'I P, #K3'U!\BP%"U_#<T93I+C,6S1JL=(N)/'K2SUQRA@:(UT "W#*EP
M?P4@W+T!Y!K6)FV#5(D3PMBM X,<G!?\K5.B*!N0A#[=%Y&5L;Z]8DY#I+2]
M''PHT:ZPP5#:F-0K@.PF^IL/R?<L-NMD.]GEAT^;)3/=Z/-NK.P#?/?>A9MV
MOR60S"^-".TYHTD\JEWZ_)F#A]K?>4=3V^2DRKR<>@-EN8>=DHQQ=<3\//@,
MR(P@4KJ0K)CG9&/B4/>8A.@8E,N$R&WQ'2IHPRM A)=\%%CE.;]+E[*]EN')
MOINR^44/5V6#^0W#A4!VIA]N<U[>5-G=Z<+ 3>GQNY== X$#"/E0'*=DL/K^
M/P3<BQ>\M@5[&+>Y6'%T6A7>-ZUEP1H!A]A-8ENL!D/,@*.X5X!QE[CT(N72
MK8V1[ )NT*[H7Y2^D;G:H1:?UA4-;S#UL0D_S+DME9U@+<4=#E</X!?B1R7L
MO3PI3OH*V'>(>VF+VV<\..&J*CVHTYQ6A,0-&@CLZR;84AB%%V85QIW.M96R
MW]7 0U-FOR6PV>781F03KRS/DV.:2E_Q_=+X?$BABJSUPQ@-8J<C1JER'9TZ
M!GO[E>7[)G.9(?V/IK-7_V*ZJ;W C4-S>(<<#VMQUH-7J5T54+FA^+6':RJO
M748S^FI5YN-I5.F*'3\1IA"-#]NH#SG#G.'=]*/P@6(S87%5%F'E%8+SR3J)
MV#./6H/<UMR>("_7F.$+^3Z)+J_;FD]-4,G=22__/Y4F#]RUH]B?B,6@N.?X
MJ\\UH;[D9$7N_MH_'$55!6HHQ'%A7W=]FJ,&'EVH:LC;$2$7SLQA6$2=TW^*
M;EB[,,4'-\F6_4EL=*]ICS?WO!7>"YQ&NYC(0)&-TP:S,1H6OI-WN5'^N$,F
MG^MVA9QMLF9M)PT.A>[\2J[F$&>ZOPQ&5QM8<_0."DBOSK2CO_.<<N]Z#.BE
MP](:%J.9YO953..JA2OXZW?Z5V<I;U8$T:',D.^=>[FS3Z:3B3!,#N$%3[O[
MDORF1A<:/E?2MZ(AJ]T?F+!6)")#T#IG=(:_<)W.BX4-4X5\;-+?IUQC)O.7
M3WM8W/KHRP2A#W$=*/>K9DQE3_^IO):V!?[;#9 A7'1[3^#_;[SW\1NPWK-:
M8*O?^U>*[ ""/:Q,9[ <MRN&]R)(+@U&!+D[+'%T%=7T2%4IRO<0V7:O%(^]
MF2"/J'+O 'Q\FRL5Z5!#(W\:B;IOVZ-(HMQ&6"._7P']2@ZG!S7B(7:J,0*[
MKB#]EV ?DO/JC-V><,Y!N\$:.]L?V((CY"_MCP@[W7%^^9Z*F],:B!8F)L/E
MO@S-D>QPQY61N)L4OR5.G(Q61&6%@!G1E9F9GV:<)#S?+4]ND4F^ G[6PPL^
MKT*@P#EDT<?E*7(R08BAP(D9^7@%\_*GI!M8D(T4_N>KK:A.MY(A="X1D"L*
MGN@#BOSMT#?5;DIHP"Z-7*J\141]Y]5N=RST>P3^#YZ-<CC+'P*DJD++J;[^
ML3A+C?\(;CJSU7R_W1@U5I2G'"@J*24YN-X]DQMG#(J]-U(=4ENE#3PCJQ9X
M<=N+N!H8SF;J2#W5[;1$_K6B/X9,N$=P;C32WR7)4Q.R^WBSWQ2BM$^2">]B
MF/(*&&;_< K.T/=T45[G_LF8N.^]ASNABON5\8FFL@O5=K_3:%O4II=,YF\7
M9O4*,"96$O<\ ,57Q677!.6BTX7F?OK 0=0 X!P@!*DA,?+<O%2.-/F(K"0Z
M2"6T';Q^^PC,\P6\ N(1K\96Z03( ZL[=81W<(I38!%1'0)J4<O.:]#G?7T"
ME+5 +-4465'DH4WQ5T!$XGOS& EIUFP.SF<FAQCR:[%US*V7\D?BON;:-4_-
MOJ\2D:::$J2J3#;:,4(?ZA=8R]Z0^J<J=M><4+!,UN]H.F-RY!5@]O$G:-(0
MD:\8^7SG4A![)]P>I,80>LVY4Z$IA"\^5P&#:PI[PKSXF\O56.02NZY5H/MA
M0*B:W\,L #<<1KQC9]:_B;:\K,%*:,Y2L/QCTO$5@&*1TDU+=TQP0'/B-^2'
ML?L*>,#AE=P:%5F>>FL4WR\L:70VN\'-)GVRYF72#Y OL_11>P-ZA/P_7>%G
M^!_-1R8^D'9@/R['>9KU@E\!@[A)VET+^J:F<K_V]\'KS[G99J7'EJ^ D_OF
MK='O=;[4KP T DNG&*2#@EIT]W,)+UB%(DX!.CT/:P 7F\5)JC\%U&B705-X
MA//(N]$BS,1WN><58$?7<W5HI_E)6\5ZD+]'"E8QR+N%XBL#84GHKOB0M>"H
M]J;>*RV)>)?"KA*5B&>;OS4[:CUU@L?;2VB1BRYJH)A'TR#5GO)C[ZI5JVMY
MB[;O4<'3@KA;4.(W*QUQ!M,Q+S>N"%\[=':9QIV$<08)YT1HL)02<E,"8K>7
M%[]^CBM11NWTDU&TYC2"8XY5=WY_JE:,N?!X=>DBD1_)&/B_STG^?US@M/[S
M1<I<_O]]D=-9(7[(Y0&C5/]>6L5?@FR.IOK!M"$X&BKV=-3Y/1,4HY5C/,U!
M9X:KW2AGLK+,ZH?)V&NX68J*BL,S%>/1Q!6_$%);TPM&-G0,78!GU8D[4E*,
M#]@L!M$YBHDW:BU=<?\2XCA<J>K/S]-46=B^4>K7HR!UMJ\H,1?\Z=]-8TV?
M.U[V]RY4^Z#&78/K;D<S_:X*_B"P;]K[D'(17CF&P:&3KW0[P2@[I8)9OFZX
MMP(]7DY<\3J'A\:;*S+35:#UHK"NS4:I\8N?_#E(B@#]/<5M=?"@D*$'1]>@
M8MO7Z&PGPZP&!1ONU?7:[R]X),"6GT.*_J<BAL;X:9LR\PKR<!JC!;PGH)&D
M$QP-!3  @_;=K$10]"S8*A>!Y[]PD2R&7# 2FQ6WG+64!)J\%>/[_%ZA)+#R
MK$R@L16W#$$Q')A;WK-PDA+SORNM _%Y<N<MBQ$:E)0G!<@8T4$@>\O_0I:*
M<A$G&7A6N27^Z]4(V $S"A;P !H;UV<E,(MP-I/;<A%Y-#)G)7 NOVXY.5!E
ME5<BY%@O+NQ&;I-3A.E(AIX&1Y9"*L,UNH\/2_6-QDH:#!2=8V&"Y\9B7%'.
M]Z7_KF&?[WVC&QR<2[L-0C61^/FK](TZ\(\0ZZ9YK;$M1/^V> ;+:M%&D#HI
M8(:0CB78T0T@"; X,\Z-B#>KV':I;88>^/M$@MANC<Q44 8K_Z[#@HN B4=G
M%Y]V^:)S-(QJA[32C[3[%GZ81EH+C7;,!'4WGOSM-!ZAC@(J:^A<BB^ ,SU*
MV<47GJV9?>J$',M\+/5F&HD;;P@QFNIN3!M9#Q*,OK*@2Z";ENMOC:=""B.C
M0D8V3D&ZCNS)1'3 9,[O!.<FS#[-?F%2.A__P-NK5W+Y-];+A:U6=8B JTD+
M)\@ ML_(18;JX^.R?!Q3)PH^P^S.:B+AS2D(9"GO8K#-)@FB7P'XOO/O3LJ'
MG-?W!/*=VG&P,9%4G:0B.&.+;9M[.LW9GRH/],A25"\8%R=7]] Y<MW@B[^[
MIZ12-^EE5GCK./#)K.?>/3BK2E1F^*Z2SCIWATICUW>/O!N<'!L1S])/W'LF
M'Y>_Q[4G[=B?/XB(:5@KD,5Q-B YFM%2-MA^WHNCP>3R>J=;D[J:HKFT4.:$
M#K_,TLO,N:EF.,]J]KTY41LU?N^2C&"^Y'K<U&VLEW&%J$*DA:V?"G__*;P+
MP]!-+@/$#V0T8FD.1VQXC]MM3C E6E[H*,.ZM. \I8='['Y>X<S2OZ!D0]68
M,(K 0% NT8F/28VXGW'Y9;O*;=[X5.1A4TE*\I.+^W6G(FNR7>_)2L72I_=F
MW]4_'P7:\&WJY[.BX3FD16?N-C8N,-KV9F;>56<2_?MM?<.$>3#PK[2 !)73
MN$=K2+?.0>E-,33E/'NH/:, 9W1N+M*&JRQ> 49O'/PS[BTN(PXKCH;\U__)
MG@OPUM8;P:7\:]V9)&,?<IAB9G(I_ 5KJECWA!0K]86-!";]Z]I3X]__=01"
MY\]V##WUB]&P5_ZEVE5V@;-%1YQ2MOW%P?LJ!@?7*!NW(.()@5V-$)T4"82;
M&BGLB/N%/90*O5\5W.'0A4(HDJ%[NIJ)F2%^+T"\J:95@"* VGC'AR^D=.T!
MOT%O73H@2 $W[*;\T9>,8,XH1XW(KH'?A#'!Y4$#7;I <N9@784Y:K>+2M1B
MP*/9F6T;DEBP[LR\UU%JSS,Q$47(+WOB+B]J<[96Y: :.:?OOV:[AALKLGB$
M<&K"8.U2$M%-H<*$$\N<D>]O'P@L2)IRU(SZ@UH4YP9ESN5+V8:XCR-L<B31
M5PL%*/8^Y[Y_P@@DV-^[J]&8JW;M$E9N:HR\_Z/) X#C@CPN)\&\VIM;&^JN
MV2B3HY]',&+]*H(QV*VBNZI*U_ZI(O1E\RWYXF*M4OXXG-\(9P(RJ3UME'7S
M0J;R]M9:3?&JB"@?**,O]R&K7>S;MT2\ES] RSI/U&7I+PKCCX]$ESRO $PH
MOW+&5'.<LKXPW_YH]<DOL&MYRY@76V%5=$U(-[8?0E^WT7@"[]8EJ4NT4R0$
M"\_31^M*+6KS J7PNB!C*M*QQ*$:PT^:EY57%E^]Z?[Y&O*XZ+,TXT;@FS%V
MQD8M/L 2.2"NO(Q$CB_D1G-$7(8Y$I43-\^7<H#!P+LTV0'[C;Y'>&Q8$^3+
M7@:='T90[XQ96IN\V4])WLX\ CS;;"SW^R/IPV8=BO;OC,;BQEM8:6;.6)?0
ME*((3+7B$T9S X06=\OFH[1-Y[^:WE[1+"4:U"(:H>Z1 $?%:!K;KWJB+JMV
MO\N%:C6&; =/FPQW]\7*'\AX_C$2*M.*EUMJ<!#ASC_A9Q4]3+/A*;R^EGW/
M._USB$78WD96*V8Q#@U*F-?T"@B_X$V'8P8P>6 6]3SK' ?@WW9D 7MOJO*Y
M.VTKU3$+>/]8/<J$)H>*BLT1?[/7D_WA\J S$O'-J&K\MN^OE<ZPC^'G*M+X
M!=M*WZ:KTY%:*&-U?F<CZR&FYP"FMVOI"R6T^V;8 ?'?RB:IJ+A[K/9V=I>3
MR><-3X0!(%#,MUVG+;Y9[R?)2XH?C#._*_(/*=?,&N/XH"FBY"/0X#>CT'BE
M68VFEZV3.(I1/M0!>_B].;HV]H5-3MA>1&-':^,2S[UN)%#&;9KB$S)!C6G]
MO)WK"F)74:=ZOQ"-32 SO>85?Y@;D-VE6,(P,TT;D'17K6,<73ZN91 [,IG-
MN1P6)Z*%TRZ;;<8"_]7L],*SQJ/QRK?!ES%N(.U=!&A^W'W*T24[9>8X&VN6
MQTLZ%>3[L>??/<96EEW(,$"4J6)WH8"@SS+$;)^56WWQA<2S9-J2\)NF=D$T
MDN&RDQ]D6F]A3\F.71EOF4V"]:4V)W?()[9DIXI<C[;F]LEKBV 3$B2WIV/K
MB[_S+.; MZ74_"FN_9!#OLH\>F",W0JM]L "%X(EVPU!'B"V O/QUTDG<L&-
MT1/6D%^)Q]7 L)Q8;.SI8E6)\!Z\'I>7D' 9@ COOKQ-X]ZV*_+0BVKI:RO=
MM8:D\%ZD HR8:#,F-VK/V@,Q.XA]QRX6H;1;QBB1,$KL@N$73)CW<A4,>1I&
ME6:([A7<L]1%"1,M[ JOMQ/Z4R4GKVQF*:X('E"HF]NUK&2E;);=KY3'T:J*
MU2PX2[9M1V:\+HGB$J-K%0DH*A9X!=AWK>VRI;F5P?C!Q-(LNQQ#R%JCU>4.
MJ)9 ?!/K#(6&1-_@0QZ)9CG?I9Q$D:Y?[\S>F46.%_/R(Z7VC?O67=T,0SRI
M+G8<[*(J_,[0N7*.H%HOE)[C-\-U1:OZ/$1N;2LD;[/A-/(1\[*7C*@K9S)#
ML64C,ZL4R;]3YQ4 E>71,F4):& 5&T=Q8!CDV_<8<IT@55C4$73#U J&$G%N
M?Z-^\>X)<#$6W:L6H_N-*<NF?3L-65ZX!^FDIB,GF-GA=NI/C28SE*>1X<ZR
M5;\L\J59T>SOCT+@_SPN?1@N FDJN>*Q'O]ZF0XC18W&!LHIF@Z6 HP!?Y$E
MU30BMY-KA%-9?3<@6]*M48-CY2B_^D2L,\),D5\!QMT)0QH]<[9-\LK\][.&
M,G^^&>ZV,^AJE_R^QP:*X/?FX%U4VMU.8S5GT^K T\2+"SR:MIO$>N,\AD;8
ME/97#Y,1ZKC\&*N1K+N2"[-E2SW<4FQ2T#XPF" D5UP#KS+N<8Y'0EK0H[E0
MJDHB2LYU%*U',\C9/+EW4_.VG]Y7XBU:Q#Q(^!N%75<ZX&Z>MC\8>6B%) JJ
M+FST]N[],%$5#_3EI5U>Q4RPZYD9YE";QRURVGFFN]X4]LD26M4S>TKH_!+R
MB'KZ,E= V)X0NS/NU(/6\ I G10X>UEYD/'T"'N UED*/S>4;-N<G!J)S8VO
M&(#61M 17O3SM_UU9$18<X<\V?;F6.:V^7:8!A$03L$'1='W]BKLD6_:1X]W
MRI??ZQ5@B'5= Q8CJO:G&RYYNK:XJ2G?Q$E M\^+C\851:GL<$#[FPH,L&Z>
MJZ+*R=FDD> _TI#"/MNC7:_ %;%LNTK-R]R6=GH !OI^FH;1Y>[16]X/^0GR
M=@(_-&I1)/(1F'^-M^$;&1#B2Q?,'E%I;$F.MH^EP&0HBC@H8/(;G#T4)X91
MNY09K)[BJ7?6&Y2D_@U,E%4X-U0+>F$Q\I13)I+9^)$M$,%X8\>\?G_8_<NS
M[QV9RP)9RK0Q%&L >.V59*7[=),X'FAQ6Q'**V0\7-[^^4#,!6(2Q>L0X3W4
MR7=O_Q%S94]"GO!$#?>2#.FJ[JKGQU &B>K?.7FAG<AKYKSY3NZ"8U6R$=7F
M( G.-FH >/$;>H<\@:AE373T;IX*B/I 3&&F[4W,' %[_Q)B,X%+BN+.@=ZH
MDR:H?YTVHP;GSO'>A$L1;C]=;6-BCX^ FTW_\=R,G/(Z6[(:9M1ZM1QIWS@I
MI<8%*IY+Q.1\=#$.@."/W!OSQJXNJ]52Z=BF7;]\G[9/K\F[,T&S7)VE>U(+
M HH:Q>/!3E+" GT%2Y3KUXYK'Z)FTR5?4IK058CLM#7^Q1=6N^0@W1)/8O>]
M HXC#M(/N'Z*.DK4R")$N^=121N5<W1G)^^^)_4!8EA7-\GQ%S"MDMQW;9_C
M#R;)T178FUOV:4P)+<G!F-107@'3P:^ K0&C41P=IL7\*D*TY)VP_H#WC*.U
M#D-CU2UJ\]OS+%\:FU3B/_.53DL"40I'"/9PV:H48/;;*;^"XWW #S5[M2-1
M!?;#G)<KP+F5XUAFME?  %BLA"/U2:6YU6E3;X!H#4U?/8=CO_J;KQ# $U^)
MNI,Y9Q3X V9L FWE"B$?VCHU43< 25F@]CD0#:%&,U'TXN;X[<3@:[3RXWN;
M5\[G/%C12+0<@32&G'5<+I@_0O7BH+*V :?Q-6!?:WEH'@.I]/$P\\E*;BS*
MDD""!LX7IF@X_22HB51;![^6E7NBH868C32:Q:D,.K ^.<?OW>(4\:YJFENY
M+U<,JTZA6RP?4P$]PKOE9)@@Y%8,)7&7>>+SKLDN6BBY1N3C3TFBD8,SHU]K
MC9B<AN?+;T/BX6R1I-RRZ24@.7T,E"-42YD#SQB63+T"/HI\]=B3C7PZB\/X
M*3<NR^1OMES-_.<%S6D;S3>:).?0IO9M+<69-K,6K1*["?_\3ME(;NB]Y-Y1
M>4P&F/EY^,>T^08>9=<0/7.^+#(&Y#\.;LZ=O6D9# K8,5=VR<D6/S)^",B-
M^PCCCE*90ELM0U[XD7-L(F0#RH'1=@OCZ\8+Z)?(H"W'K$SZF149$*O0S2U"
M.0=Q7N#;Z^:C&34UH/'Y<2F-& Y J-VN!]@'J#L\1OWE\RCWRBL =.(+A&3?
M#!+QM)NG9MM-]I^[8[0F'$<#NZS]B>=X<Z"O@/GSHR\<A#.?Q(GRK+;%,?YT
M0V\K3%\!FY9]XN-UGJNXY(UEY)XX:FQ0QNV,"I^!FJW/LZ1%7^6VX[VS;8CW
MCF#1S4<)3TVDW*O=D7H?/U !RI$ )*:E6YX!BHLT^NRW3S9I"'!%T9S/-JB>
MQTQ31>UZQ8V"/2$EY%B-]9($/[RJU[7QFOGN=4\=[#X-?8IF8N@E#]&K5JP_
M2HJ?63HV$?#UT-QD:B'UESE>+O*C\,)-]]MYIM?*5/$K,3"41T(8(Z#1_>4-
M*=#*RNM2RX1Q0\B-KDC!^IOZO$,9U5#<%TWN+8%J'Z.E)I-P?]I8R?<6#HD"
M"Q;61TO=Q=U7V5%E$K4;Q_?7Y6P+ZX$I9$$919YR4K-ZHK%9[YS9Y5#XL8:[
M$&-+"'UD2)7754&7_9K'KX#W6[)-NE:)Z_'<"_&JXB (.;QGR<L']@\3M'=E
M9D'518[:M]N[W77,IZ.WU3[J5^)A34IQ0J?*/PKI:9LQ_3N!HNBVFLE,K..6
M5W'AXA_L.QV**]U!O@E_#+*F&:6"LX7V(L_% ,'/P;Y"<6_6G](X"RODUL:'
MOD%%:,6@9S-N@EAM0:=*7+YV;H=33W_ ]N=_X,$_1:>NUK7K)VX"D]#Z0]H>
M/YEPYMW&"GF1'^&.F AGR5-_EW]04==5=T3I])&QE7O2V/._<.R'I4QU.70E
M',LR(@"NMAENBJ]:8PG!/=M(HJ_/-(S:O8T^ DORMA@&3PY1WB )F' _/1[R
M+LXK7#FI0ZFI^MHJX:F/PU$XW^B#04>-&U+)]U=5<3@7E3J\"5FIM:IJG(SM
M#0"!2L2O>_<B']9VWK\"HE(#@W^09/ZX8#YAK-IKC=A+QY-?^5*!'L3,-3%
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MA=%52HC-3'R2UI$<L!>$6:]32-Q(_^$\WYDVW&W62O1&+:1FG5)IQ&[GMXE
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M.&4LOW@>,@Q8L^DAO0IE&YFLD 5LR=G(VNN)NREIZMCV-7M4"YA_^]P/[OP
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MQC0M93ZP]!QBR)U5]FGO&BB&07C 6[XN1M !D9 ^.8/%*Z[(A".!,X0B2Y.
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M66:Q+8OSI##2^_(H-VL29I50OI '=\H$ID@DR>W#6&I]%2MW<'K;(G.;'-J
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MO<'R!<"']T>5HDN<(93M7(].'7/77Z/YN6E%].O%%YI,B F+@?2[69&ACI;
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MWTJZB2ROPPL\'^%LXA,/3&T))KP?<5G6\8QI5$(7EPH[G%BARGCW/+H:CZM
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M92(XHG.""S=@^Y7L J4K4YE="TN:V3(Q_@\ 6'MOTJM:,"BLRI\E,D84;WO
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M(CIUB\.O"TIQCFOPB?%A.N>Z@"*+ Q48EU>?YN]HD:A*DE5X9B10Y'V@,ZI
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MO%SE-^I6 1GT^&3,E9AV"!,5+8O43;:69<6]%1#1B1UC9 [J,'6KN/PU^7X
MB1FB*CV9U,# ]WY+1./TC3.ZD(RIM^I IMQHYO1OV^T@?9'.]B7RW5K8.)-9
M1C?AOG<%+7H@!H3%(+![+W.\^(XWKF:@,])N=$<&]G88$,<,5"9_QMF9J% U
M?#=Y_HC":_8MMO*%^<<IL*E4A66WFDTSUPCI<!4^074L&!MG6#Q6T8T1R!$D
M45I.W:Q;2W: I.)OYV2!$ ]KTISJ$,4E[B]J3P.Y$-&+G/?\3$= (*K-NQX+
ML-/?-GWXCRK';]#>@0D'33L',5+493C^LS2_H\*)2DE>+2X 7^!$-D!H&Q)
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M^(% K@Y@[$L1F \%5>AY+5;O(CDQ_]M*27RM20>S[-5'@D>?I>5EX9$0+N5
M(OE]%_VK^X_&W3LFASA&#DQ#8X"E>#! [4*5&"E33L"=8@0BHDE,@;I2PMDD
M$C^F':O4>W$HY,87R\S4)ZF!#-:?=0//NC77)<EJN</T,*P1!*>1@XNU"5'A
M-G\X\F.^ 88N$YR@MI-GM2^8PLQS6*OX<T+Y',_4EO:=I<%DHL-IV)BK6]4
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M_E/$INB!)^GZ^;\/\;^2SK, (6.Y'Y+Z4I^$^KM(O/\EX=ME.%K)NHB-!GD
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M1"=W8<=9*/GL ;IT7_3)B%'#H"P46C(?V#Q&,H.79U>TO'+OJ^FAHU^KUU9
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MA%W4(E38TXZHJ!;@16)*6# &QH?US,U6+70-S3B#%:1/0J.,-<R%[*F@B5#
M5]+TYK>$*Y^5BK-0X;-B?=N1#!?*R"IM,8F,@7)IM8(PR">)VT\@F?L#5S45
M\+-!>ZPV[V^]M *.RE:1\WP)B5SJR-N;A$6%66AF=9%VWM]Z'@'' &?9"CMB
M97K# 51VU3'PLUNT86JS=^R22"9Y[3VXLNX@!.W9A:1%H[ Z%^7G_J]BLG6>
MY4'+0ROPGRZ=#G,66+R=0'219#*$QGQ>P\/T"*];VD<-=ZBWH 4@10IO9&-
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M,XJO#$]G5(5F/6P? 7BD%1#@-/0R"IW@HNH1\.)_3">;M$9@?ZT2"CY4526
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M\K#_TB[T F*02YJ4+\S$I##ZT%ZX]),K7\:!^+OQKNZ"WM;3KXR15_&P;8L
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M4?ZVQP/=A;Y?"-AP0K5N]T\' .$N5U=U2#U52UQT ^P!Q"?<DRMI5WF,KCW
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M*?GWG2WOEP4(8JZ\B)8#W8].=L@H<4]@/R>"\;:$YHPXI.#&<2S;B4T3C(\
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MU/3,[-S\[S\+ZPCDQN;6]L[N'OKOR>G9^07F\NI?7C@ 7)S_-OZ7O"CO>3W
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MX 31E^#B8DLB^V--Q/]EH!0O/RS4Z#(J(?)*(&]X!Y\O5P9_+5VM)PV2^)/
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M+<OMKT*416:AOC3[!\O9R&2Q?P3=5C^VS]XK>5VCKHOBO,_?#K(RG].+NCO
M6D1,37?]D91"==!F@5G?L4&/",&+V>-$98JI"M2^:X/*/^,>0T?SGD=89*U?
MF /YUZ_6>6)N#J.WA._O.P:11;Y;F\T[P(3;=TP_(H4J*'#@"8OR_H]OJ0_[
M&YF;Y6XS!K$4(/2[PUZ&T<[*.P +U 8S?*^$AX6$DI,5CHT*\\G!<!?D6V!=
M]:'7";,TU;IH8EVG<8EV^X<5CP.R$Y;B(.14NRBKVU _C+*K2V/QR3-.T*$#
M!,46'8*> CNQE,*XN@?X"G#V"Z<Z1%-RCQ9#R5B8/H+ OY4_0+8SR<*"50_J
MC29S0&187\0X!>8GB<!QBXKIYZQ7.V)VSY,S[A\%1Y(BT]SRU\<3!?>/\=O,
MT9 +G*G6AI]B7Y&/2I8_.'QPV!':\J+'ZJ#5XA+/2-QT[DV)GG>1\0-!LM!N
M#F@6-#$_Q*IPK^TGIN>MR+\TTUE3B9=US=1_SF(_ASY>88G=706/ AQE]WSL
M0)98,S1992*?V\B:.R)C9J@Q;$)S,'0NZ0[ Z0\CP':D;-IQ+2_6SD,JWZ<,
M"^]S#'4@6GJ,*@7&<V5:L)328Q<#(+I.K1J;7[DZ4EU%.U]S?IR-"5;&PD2#
M$K1@:EV%A](Y."7>!/MS7<A^5M+)Q@A@KWNSP0_MS8+GI ,WNF TVDJ[90KL
MY<OR#4]+R_OK$P+EC%JB]7U?(P/>0S9CEY /EG6%^ >DI$9%4CYA5_.4J%RS
M]'7X)ZOTS0+]:WA'I++[?+29=!YDQ_WS!&LL3 %]?P!/2*A%%Y[.'Q_;O3Z7
M0L^G_%7F=/O@D# $J@T)-FO*_<M9,32] F!#/]NEW]]X!YR93P:'14VQA.H%
M/0@^ILI1N4IT_';:G;C0G%JRN-N,5J<E/(\5) ^N>^V#8&/9'Y50%1[\U<7D
M0EQZ2;Q?_.'SX^=??YH][S)2TEDCR&&!-8CR+@E^&H?*U8S38BW0W%>'\*P2
MCKCA?XKY\X;ON[8J+ B5&$Z%6C+[Y>O#ORQPH8BHZ- G"O*T@(ID_I3[G  [
M+#\YW;>6@ )KM*T[AS,\@("L@4(*CV@[;2G\IR>2*9[/D'_KAM97!T?5C\VB
MM><V'ET>-G#WT$O-N]K18"F%2__HOAM+*V;"PX-<;JM]$DWP<$IA4I[]-,2"
MJ5OP-MT=R:75S#P(\T*X7?K= <A6EJU@PPXQ.4P,&[@0%(@$_'K.W8LWRZ)=
MHO\[QP-R?<^,PULA!2QNP%!5(]\=@!F:V<E2.@3%E(SH9<1K66UMUV_5C^Q,
M^CDN=,5)G\I[." *$_RSTJR"&9FDY$S5=C&(%C !.M24<; IN<EW>U&[5R:#
MV/COONVTU[HN[;3F-6D [99DB@LO1_IQOOEP..=W&]&!B\SZ1X\8]%9==\IV
M7G-P%S?(!"I/0-0RI5+U?^ZGVBJ@Z1 ;[5+[N[DB<ZUZC,98WJX'6S>URFQ2
M>VD\D'[OH2_:EU8:,9U/$1T^8H\OZ'#R%-$=O*TH20Z!X6'GA$^-\J(8/7 H
M6/FWB">+^>==X$\0AVT5JA!!7HGX6.?N;U#+37ET0H#W5\&\],].KG]&E*6:
M$T%F=91B0[3I@:)$F8OYB>T?RQKQGT\6U7&JJA.*C40H8[(M"MB0P/@5SFEE
M=FO+P8C-A:><,;K11VN/A"0&[6C/:E]O<D[S.0M//O3NS,1-OYP'H;D=AMH+
M+UI2-H06PQG H*G3.P!P,#C8@^;7!0!T3"V-L]T]U[%YP&]HG"^B[7DNC.69
M]_)/P;^!FN3]2G7T.P%>J,O/,R#'$V4:]CS*,?[-C2(F2_C+K=?D9SNWLIFK
M_;:X,SS?HA3\AY8_/DML&'*]K.S-3?Y<@<F=N@.\Q$?$ZOXB7"[L:ZOWXXA_
M5S520J3 (A24A5"K<3+V[WS.O-$[-%\>&$&N++SD1H?>9=R:]+X#O+.'ZQ?7
M"MQ*8)2=&8E4&X/@TY1<E^91O?[4MH^3CX9_J 9V/1&+M)*MRS4Q#=+2HR4I
MM'?-BNI_T=I^!R@P_'[C+6$GN\=& W9",.70Z6AQQ2ERBWG)8JMWJI_DQB80
M?5:MF4A:NTYVRR\T03E%EU**-<9#[81-\]!#4IOK;ZJ:V^1R=+_WV@T6@":I
M=;TO,K\.'>L""4Z@+S$V:'%]ZI\+CE\ ,+6EFBYF\K(K,Z>4<&Z,@@VJHM@!
M[Y@'V6=&-L'6=79HZX5*<TP8.B_68C B5R[IXB&<Z__IFY3+H:0WCP1^5-1Q
M0S!U"<[\:#=^EJ@23\,-541T)JAWSTB.ZJU<O)#M3/P<HXZ<GH)]Q:1XD6#$
MK\P^DN;)OBY54G+;!L5,EG53G#:FTGSZ_O;E&[9/<]F,__BQ=33?.F1N?\4^
M1D<DG$$I]#UJ&],LX[_A/J,C*RQ_BDZ!AQR]KUVP=,G2P=.E= 3@IN>>QPM[
M%%T61_$/,W\R$-K63\D/JABY;6TYJ5/DWC4=7,W2<3>YI9J%T;C-W[*C$@-#
M$E?<%__X-I+'5F,U,$ETT:]TG %I5R_6(OP"I(S7HCU0U$XW+: J*"EZI53Z
M.S+T#B"6'9/?UZ;T9,#4L _>+.U22]'6-6UZWPGO6SJFD>24 6Y^V.,!!XCW
ME5FQNFB\%>Z627_OMQ9+ZAWPJ3:LT'0X6U# B#;*/YYV4G*<PNEU-/?UW"\8
M]13/;/%,3+[ATO-W-?%TA;9"\K]S&:<3-<BWVDE)?8VFZ;B:08QAP<++F<&K
M<-T0&ZK>P5?OTI:I&%,QC"C1.$L FB[A4+ALB\;[Q.FZ:1_4J'Y\P,+D(GNM
MLWU[62>QIJ,.DVH%)C;!Z)0[8L)H&4(5J?(#9W[:49[&9)2990[CB=4XEP)P
MU):3:@_4A;(?F7!A/C%^@S6V03]OY<U7E:B_W4C=:>?^]I3BCQ>#X&>"!["
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ME:U\.WI<&')1&!^R\N&6$$9ELZAMJ_B\H?T[5>IOOSH()(/A&66EWX6]+_P
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M,5B3N,(.?+<ZID+R&18\?2^]YVO?-Y\_%PB5CX.+PD :"+F[%]3BQ"ZFXY^
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M/F^QWJ39B!1D85^[8:*X-1#QP0GC!*QA0F,:WOZXNST2QLV+(>G3]F-Y1G\
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M3OQKV]P=7MG2ZL#T%"V3,4UE';+9&I$V:PUVS#-G$FD:/EU?ZI)Z/A4'TGX
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M8TM(PCOMU-P]ARH"JI(L5GP'!4JHD^8+Z3VGVXN*67NP.NL16R5)]AMJ@7Y
MXFO.01&M%(TK*J*?Q]>N L.FBY85T?.>E+=Z:<':_/Z5X=RC$J5G2;GI%F,%
M8*ZY(T'!/K+A&--*JLLAZ5F[<IV=!4 L)3"7Z!4GO6@2N27N+8GF!-UOE_(O
MQ&RU@BD&K!;%(3J^3GZ5<MJ:IPHOEKW17@(TI?UT05_.KPW/*F;4C9W"F5YY
M3.*4+>\K\$K]M%1XBU!BO)DQ/1#6F<4U@/U]^[JE@6ELD+I J[AT6-)#LW3_
MC3FP4*#09J34ASF5!JYX6RGZPJ'BQ_5/F^=D&B2O$U\)JAJR8!4,Y'+ 185
MMXQ,?T2D!F]4VHBZF^Q*'08_*I$=F+B<8[L.,7BB79!%H&U?TG'.:QWUQ=1M
M>IP/QU]J:QK- P"4M-:Y[DJSX;/33['G7[X.#GA5L4&8EG]1BE18_DR7F!<H
MY1-VW+%"_9;_2UWDC>"O=LKZL(T7(=L_UYSFF(Q971I3).OEOAL&5-_)(':_
M58[Z!SA,?=SCZ1\AGW;T<ZE/M\OXG(Q=%&?U"J(.9[D,LB'*DNY8:4_T,^&
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M7%F*<&A#&53-[.OX3835LD?-L.F7*%B;!%-_IM/JU5!C+)&A_7[*Z7NH2JA
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M18W GO1]:KLZYQIC)5][KG&\N- *D0.M*LVM-^I"E^1DJ:7*YC^Y*D=9-]"
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MZ1=?G@WY0H88HEN!./[BO+RSQJYD;6O*&[2?(:HLS#W^?XN"J4_ FA;?1A\
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M6\,4OHRE)&1LZ?N*UMPN2T*]*-K%:4G7>,?2_7$KNPA&[>#V"9T&Q.?$\JD
MT>9V4@OTO93O)U/-7G-#DJ 3F: ?ZO28Y6;F/CDJR.?MWN>QIL*DSW\3RD.
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M0=[7, N2XK2Z[B=@>JV1HE0J4=4S7NH&1]\3[^N461LN)YWC43$/ );=Q@>
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M7W]H3ZQ.5'64H*75[=0.B3.<%"L658J^,T4%V5G-2VNQN34IR[\?A:(_ .J
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MYA\S/3"0#]C#&=LSOX.8SD'?&P\18'JM=+#4:LQT0+.\M.,<5@[C1?$AW4M
MJ:-FVD;QM0IG+%::A8BLWLEV#I0HI%6BB*VL4.B3"R&+"Q^Z;6##% ,(1<FL
M.:FJ&=5R1X76L8?&P GVC-/: <B8TOGK;,3/DBB)N:,;N=="YB&?&E?IBZ3X
M^NWM/)9O^"F)]!4M)4C57+ (R]>#UK'6M!J.'OLMS/_-?;7431M/O5EL: &M
M? _C#Q2I(G&8-'<0N) O S!>4.8A)FI@-P_?'R -[I931^N&C>2GCQ\QA2V1
MUB.RJSU>NW.K?/F-Y::_FX4BDJFS/H"HH2EV1C]IS'6]6O9#U</KG$$,(*1
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MWSK];]*HS#L&43V?4NQ'I1ZWQ0G LS/X(U!.-^YZ#<IE;E6Z>M%>BJV*A7?
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M?)0<GW1^W-#WDM5&OA^(\X@^/<8 <JL^M;)T@BRTF4[ZP/&?&;1A!F%U,2K
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M(6C@)=W0GW-7A)\^N,2^'J+J4-XVY;^*IX?D(4(]J]$E@U$T$5S/G2\RPS"
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MY_T#IHLT2C\0S/;:,FCOZ/G9(50^^L)F:UOH/E3:)C[K&7R)<M\Q8PI"B3U
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MGY8Z"*:.O ]Z)+5W&E39/RM.3N(V0DZ>RW&[E D?SW)<2C2[^S5U?6)<?3P
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M,/! 7E3W"'A^TPW]\N1\*B<PUIE-OZ9L_>DW&Z(_L=C-&V$WF<NIO:80,39
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MQ)W0<U_&DF5;OZGOGT[(^:.9[ K0.XSRBE[UMUP26466]B^"$1&GAB<X#5>
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M''U,45HG[P0'S&&UHIA3X@K0 D'R^K2G[\E<WL"\O+3;+ZVTHK %PI!3R"O
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M 5%VM[!2\YCA 6"Q+09D7S\&.LQKLQ-#)5R6I77D*DPL#U8CWJZF 1 V:9G
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ML\L]J<GN$ZF.=0!(5$>R$OU\\#W-050]T@$@51WI(%;]\P>$&;B?7 80QT>
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M#IF>=^OINS9ZES87MGV'&B01.@K33<;4&# +#%66?A!0=]0"<Q<(?HL7G)H
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MO[^?F?0C4@-F2^U*%G@@0XC 62!DA3MC&J:FD<Y>'3UZ9*6Z)#!L@=-%=E0
MZ=Z=4W_39_66W)O[C2;C]2@'QSY\KEZ6$<241".$D#;B\NL#@#2JX6R,/\$A
M+<-6!]UK53[VOCKKI"">\BAE.\CL 8"<R"Z"J3*;2/5'Q/#_O83@+8T$],7T
M>D89=#TT&#;K"DQ#@L>T)[B/8N\)_QPN4@ C0KB9.@Y(!7/)P8@0K'C+#H?8
M1#PC*LUORP:*/E^$E2VCDG>UO\@K"SO3!XJGHR=Z(7+.3%8DYQ0AB1!>WID*
M4&9QI/;5O2?'](H'+A#WQWW5>*P6IVM//NK3D@BA#( S.<AA94=F @<HT,7S
M(A0HQGF3F9B*2-79S]R'P]F.3,N"YXNIFSAY/?0 @-';%V$I>+P'SB)*B--C
MRANO49*1C<<>I3/^/&[9[5KQO,)V:E;,QG*-4$:<<!N1>Z/N_5;NU^A@J5B%
MJ5KJY4[6. <_X1]KHC@OQZOCUSP/EG2X-;1D3;D&GOB^$8X/.=NIQWB,L-NJ
M6[AI9K.;<'=TZ$(;N62.)D^S5=;5$YS,J 8R*.S:7 @=N+'\C:(43%4R\#3A
M_]51S__K25R&FCT4>"" D@K^<"* ]*_/0S-]UI7\0B.R7)\&>8PMG6V6\5J)
M\!2&;YM]%'_SL6/$[L//A3VU3'Y^(6^9S3Y4[TVY(*Z=LB#H^EOGA_RS\[L8
MJD[^V2U2TH'_2F25YO%;;\IW+7V&<HUT)/ R=E5Y/-[NI0IOPQOE_9BIP&PX
ML3HZDBVI/W#AB[P<[) $,#(QBZBTX$FI$O;86WFKDK*]RCB.X]Y<?/X/HSUV
M+VO$"+*',]FI],*3@#*]2)B*&E6+=Z81?01HL3$BP0CSQN8PEX,%C8F?.TG3
MU."R:69\<)_(1U84NJK#--_*5M"EJ<T]CN>AH.R!14VC'V7("-J1[;*%6ZY*
M?BFF=I;%/@Z,6ND8MD^1714/V^QP)99#5$\N" 6?#$N\80N'[2-X5TC\#A'>
M F\VMQ.5]8CXT]D# .O*R@8^,]$BY:Y9:*GC>R)SXW*!&1'1$<'$-$4.,K1T
MPM'ZV\? ]<G*-W;Q;BHIM!^EJ%^@SK6]MJCJ.'(Z9;FKP0IAECR<S[%8GE-1
M2M /X>YQ'L+5L1%%%%S9!H42H]Q*4 88U%2",8JU>%)7Y[&9J#?9['6:ZZ*=
M<?B#"3W3,E@#(YR0B&SK7XSQ%]7*FNA[2^5HOJIH6358VW:S9TTHN.49W:@<
M.="M"#D6I^ME:IP018^P"VN!G'G>ZL( I6U>?$A52Y/NA?73K>*;+_4P4JEK
M[@B^C!5.>G_HF/3"U9PMUBI;:%YH%E<QX=:]O4+_L"+PC%?F :!8'S+>KE*N
M"EWYI'43\ 1#YBG71-J A84]INP+._C7L:Z?/W'AQ7&LA!YF'C$A$0DN\?M/
MK\=",\YVT9N?\&GH[V7.NES]<'784ED^3 KT6D(9<^<EAR:#Q:=TO\GV&(\:
M@,]>V'>0##6N\"=0!D3"]>_7LB\C\RN.L%I03$^O+\^/SO0\&3'7MNDT)_I6
ML-\Y^U7U?LK'NA'[>7?.Z8!K44<6?S1W2'14YEIEH\/&23K+MK"<7P6F?8'4
M,L,M6/X!,*%X[S >$MWE+O( ")?4N=Y.ZJ\N2FKWSV7,NV5SGL,$ZMB&8OX;
M]_/Y?2(@N&C#=")6]T 8M27K[L$KN)*X4E1JV+60-69C1ZBB8 )DF20=XY?R
MGXZ)[6C[NUL] )8XP1R]>:9KL"T)"?PT1\4<.0I)-%RF(_592:;3Y//9)P'H
M*IVXUAKAETI/GV#@?&I<KA/[P-;1.EWY65>6<F-F)*? Q5Z+4GZ887]7/P(_
M@#GBV!+AEI;+^3SCX$D.@<GI@8A]M99?+/4GW-W]@D31EBZB5?3[^/'P0]]O
M1\:3W[NGOU7DQJP>Q1O5://Q]+'^J.)KBQ<AY#:JIM/Y4"P575%:7ED>VS?Y
MX;MN"P<.%%2(O 7YN%;FVQ8\>RR>W,5CZ9ASK9^QLASA./\ \';#MK[D)(B0
M%<'B5IU+">(M_;I^URAXE7M?E_$ ,-B&6N9_T#+@6/60=O1\ V/%PP%H>LWE
MH9Q9SC0+=7@ T ;+5VW8:6BJ=ZT.O!2F8/[$K=Q\Z<"_1'@_&N&D3(F>N5"G
M7L_MW;/<F0)WIY]ZI'"9^_$'GE$XL;A03,>:FNQ+ZO:$1*BF&;9KO'L,.W"
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M?56D+MZDCX!?W&>G[M_"+37NDS:ZO_?%^AN^KLY\3KM=^)Z6C&^:2/(64%5
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M^TA$=3_6<N%E[:&>LKH03!SL.G!+<T=V[VGI]>X>TZNY<)A_8WWCA'A)[+R
MN.;F\_88*L7MSVI_J2KM'LLS_ ' S\[_[0& R%]F?;<P2ZR<[<*^(K:B7?+X
MJ$'\ 9 4E]3KY4M\F'<:>G55==MQ";S+\]^_7[PN$^YJP./'.TOZ1:3?B;JG
MR>]T@3"62R1].70YD?\ ^$6H7V4U6[IIJ.2#RAU;M8>VUQG_7JA?I+U109V[
M:SHS\X_T9/%DW>'_1:3?RSI=Z7FPC_HG?G_B]S_#S^]7_%1-_QF_K+_AE\_R
MG^ W^8C?J]]7C'I;._NW-YW_5X8M/Q7Q^JE(X:,BLK\J\AC4_J()TB.$Y+]!
MV/ +CT<((_\%A P_(2S[*9;$KQ F_0<(_SLU_\10ZJ<JT)_MZO4/""G_ X0Z
M/R$$_5ZH?];XIPE&W/^$4.<7D7XOZ]]-,/:G":K_7JA?I/V'#3;\M,&)7X7Z
M1=:_V^"? /[1 *;_9)WA-=#V%W75"1=F^?-D<Q[[!(1,@29"P;^\*(57ES^%
ME/_)T^>)-)_;:HA)C(5_A9RJBMW +?_23;#KGL'[C_YYQ:>%QL/V>1840R05
M(G)IZ^:VIH]AVM-P<Y)RA5+7B[Q5QYGX"=^O[5S'%_9B%EPTSX [XF*<&0"?
M/@;6C5N*FZ\BF$K_MK]1*L!T9HWJVH2Z2E.<P04>3;2J\J!8C(-P+7L[3- K
MY7FO"M0\N6<^U3OY,RP%)24:6T5[2?9<[F_'7K_W+??]9GBC7WA9TT&$47?I
MQOL%S[=N[C3,7'P%P=JJ525'QI=/G$]CP1:?E[OE_G7Q$44TX7T2HW/<(=F.
M>DV("R??I]JL)=[X>]Q#NOF,G'9Y-B+;G&U,.,B&>5D#OKM074V2^+B">(EO
M=WM;P#R35W-5AI_F\=H4RD;-/GG  ,[6EJ0_C." S'JM5^/]N_'\6_5[S"/X
MZ;F^<<ZN_I.!2^6DP.2C^4*HIL96Q=$6&Y!XKE?BJ>"E(@]OAE'S1M;G=M.,
MT,$)OTNK-FWJ0??_A[VW#HNKZ?)%.WC0! L0-+@&MZ AN+M[\."N3="D@[M[
MXQ+<W1T:#4[C[FZ7O.]G<YYSYMP[=[Z9.??.'VL_O7O_:EG5+MM5JSS?!#N7
M".TJ#KA\UZR<(02-70>N$=G(8[6OAJ/K\#</KO2S$JL0 D,%"P>3VH><TK&:
M# O=Y.4JDZ7-161IQ5ESC^324YU;2%J3E8X?4M<W9"8^X=>$H-XAWQSU7@J\
MAQ07,_()NW$@H39&K:ROG/1R;#>TAK2NOKJV!TMCWL0[?BP "-25%!J6X/U:
M6AWR *7QGHAY;EV4(>&28+UG9X-^.H'MQA=Y/QN3DFZYW?1FK>CH];6XVAO-
M<,7RCRAA.2MGUT85;JY6&?6[\[Y'PMS\[F44USQ0-&UM:^T[I4>K2)15N- 4
M!P]5%$%,JPDOPV1):SE'L_I8(\;3,D0<#/2;I/TW_$Q/@!XMIN02[9TWZCZZ
MYT^ W;4Y.2#!XG+LXGQ^62*?;M9UD.#W&A>'W;LR&WW.*T!*]W0SHN9DD^SQ
M$Z!-6;K ,EBI.4Y48L-(KDWXV18![+2U^CW-M2-[.>*6:B@Q%K% /6Y2DP^Y
MKMB<YAOO B,I6K['C\TUG)3NZU>E%A"GU&246&=^8?9F)L]?+^B1;=XUI0KP
MB]!&&AX/WZ^BXZ]%O!*4.@?BIU_G.#.E=  3RO"O1:$EB)US8B6XY?DB-J<Z
MAQ+I@LR]D(9\I9 =*5F]:2RSW&L1J%PT])<,[NK!X;&DGW(4R[4Z?X:7\/3%
M^^_Q!'"/XK/93 BSQPMF+=Y%/X[AQ+6NB^P++.(.B'PQXGL'TY93M8^CG@#=
M1TW"*:8BD=?3IYF2>HN!CLOM:R2QI*;<_8 KO#*F$Z+:\.IF2R@*FA@C\0BN
M@$Q.Y"9&QT\O2F@KUO8CGSR:57ROPAG)(%;E9V\K$+?+FI. \0(L>B]WSI+C
MQ0-]Q[TM=!E[UDN2P"?:G3VR/U!:YSZ1^T#52[C@7NA8+=NPP-*C<V%>AWO9
M)F _G,).^':*@;VXJ6.K]7"-] SBU\EO!^\NV'6$M>OB\PI2S<AZ:*5I@WYJ
MQ(WH:V>5$F7[7:LU\$T7;=%;FJQP8#0^&9BX)8;A/;M[,KKQ4B?AJ>C;"COZ
M$:^7:_&33:\%\@I-P!,]5"Z[GIMU@XS&O22O2DL/JTJLG3RY";\]&G&%^;3$
MLG0.ZI-N\J\FA(G8T2SW[0()3DE@W 8U:T\^7.MWO3':],*5[!\YS+M5Q<!Q
MR^M:(C]I/YX)LM7K$YHW26/SQ>#W+BAF:_;;DCRA[KGM#>)(99V7->=+_GHW
MRL)%G)<Y[$&94\*1PUJK^5JSI:XLZ=["%JI-!)2L.,$N<B(G%7=PC,?G. ]*
M'4FV3L.(:?+!<0/184-G%.H=JVERP$16H=L_<$$TN:3==@0-7R9SB5[PE#[6
ME;VF&I8XF805PGM,EZ(1]#S^O9@*W-X-H,1&]U#@P<^  ?&&3,1Q 1MR)J16
M[>MZI5AZ+(;*NX<J"KUEU:*5?P9^^V@&%"U2R6,*J*>0X]F7AZ2],Q[A#/?(
M?@![\G0W_PPA.4*VKYYD<HO;&/<L="I9"[)U(!RT(?MF$^5$/J:"J%2M7(.4
MD]@2:SKSJ5*Q0:AX<="Y1,.:<57Q)X#>Y"/+>.0!?E"%I2OUE4*.E =,$RB)
M$7?797AJ<.4)@$2-,Y813N)D-I?3I\ ":M$H_3KLR#3_L2;X6K@$NQ;$<IJ/
M?; 4% ULQJ4 )K#4$JI^**(Y?+%BFLM$"SX9FZ(TTN:Q:J;;[5@[P U1[>71
M8],E]H=>I)3D9M[5WR+PH_$?KZ5982A#WB7*?&->BQ"W_ Y1$HM,#1?#B(P0
M)LY*>=OB5L8Y?J_LF"-54WL3A=% >%EZ.7>(TJ?F::&:3<Z#T\YKP_!+DO5X
M1UJAZ)A-"897S03]/SKD)C]M'IAV1X*6WS]C>I=7U6JP[\L:ZX),>0;IYZ0:
M<9PAM_VU3E9"QTW2T35UJ?3J KP*,_I/$&+*\9,G !F2X%&AX"KE^!-@FQSQ
MX4*/F1N[O@QX]_:N%W$Z<7_Y.&K["7#^VO_Q-OL14Y?DT8\9N*RZQI/-_@0H
M!S:]+ZG\U?KWQ.+W% V"#W &3X"6HAY',?/'[L=C;^NTX2? 2Z;P)X PWO\@
MBRV)3?SR_97_WI=+VVM))^ M4OL3P%OQ'^$G*>-)@L^22+3-*H$=TME/@#$Q
MC+O=\+_#U4,V0\8??CRLW,[S)_]-1Y5_ #>9L9N&[^L?(4[_^E<, AH] =P$
M:D9-GP !\>)/@(P0DJLIDK_#R_"'\;/OWMRU7]1X<OW=T/Q_A+N-F ^3S+8N
M8?RW7_Y/\TMP5]*S*J1_J%(I.8-_\%=)PE!&&CY[\#FJQA/ HWHR"!!BS>>O
MAY23N9"'BBY\7GK7X4.__./#],TM E6]O:9.?F\2TV;5"=_(T)$#KU*(,BRB
M@LHZ@8N]'M-CGDU<W48/-SBW3,J9P]/RQ3_YL_:_.^6B9R![LQ$:L^?L(P9Z
MN;THJXHQ0,;W96_ANG;,M7A\%:XU=J VO3L%5RK^X?IJV".W=:7Y;=<HK&4$
M>XNTC0R/#DE'=<Y$";CB[FT/ 4PR<BV?NI.]#3*M$V51FO5JB7.3Q7'-)=XL
MQZG06%_!KG!;&=EQ7O Y_8Z-M7/K*QV+-Z]X= ,"T?HO;M4A B3'<C]6$_/B
M9;Y"V5)'4*)>WJHRFJV6!3G?^=OG:QS&I&EQTMX7[D"SB8$L&F>"2-=F'6H^
MW%767%U<O*ES)K$J]-0B"XZ: N23%"?47;KBDC/.B>Q%2#I9$6T&/AR'O!C^
M3O)HF;JLP\_%W_Q^^";-,K?U^*@SC:KN#0$X/E& 61<O4U!'#:@!<CU%(7Z9
M,;=S*8A3M6?-I13UN&BFN"4AIITGM<TG:]="< U)"CQ<M:;+QV1>L:.?.A @
MN#8:.)T^1,&,?A[1%1ELA3F.EICO/;X>OY>'Z2R<?ZGH\<HE?<A1F^^SKMA]
M,2Z?)_0HQ,G:84:N8L(F"OHIWMY\1&B$=OFUT^"/\&!BHL8 MEX;G(WY4;PR
M&1)4+P;V]KPG@%DX*>?J&=&O)X!GB1.Y>(4NH],RI=:4LH$8/K3B=D@)I O3
MFZ;I)76\(  GJ7=+QF<'[&T1@WJSZ/1VE##MKG7ZD+>^KHUUT>F,G"%K4/=^
M'I<&M_<<ZQ+Q-[6Y DN^F.U &M_R"RSUS&K/?XKL:()3;<O>>QWR.5X=V,4C
M#W\M"Y6E[ZQ-FM0"SVES.W;EO?TICZ/=<1O:4G12K*]MUA<G]OE]+QS!Q;#T
M*C#065?&DHO7QX8+8:!>0>*24'4>"&O.V;#NT<1I^)Y<MW# #G#K=*1V8E^U
MK E,V'>7[]+./V_]D41T,?^E-@3FU ,UZ9SDE=N/#H_XH/:6>M">?.+TNUV'
MPB[[Z)OIT6]-;[.N"XQUM6:&7X[Y5ST:9=0>(P9;.]&RFQ>'SZ:L9_-0"]3?
M6_&HA\3P16@<>XY;K KB6H2N"K[BW]49@NT*05+0\&J5L]>7GHN/@E#'PMFH
M,V17.]QR=9*@F'-E[?9T?FFIX %NZ;K)H,)JJA?F1E 8N/4]=Y_)"ARKW,7Q
M;T$GH_Z/K\:\9',M*RUOG=0=1!VK=?OQ=,S*RSR;?_HK5$7-K=A\G['"T!H\
M/@JH"D>97Q &"XV+?SB*>,,8'>):F/?-+F>5N(8VCCV51&[\( Z-=_J#F[@)
MR723=$>P6<\>%$<208G9_9'N%M:\YX/Z![,5:_1>?6^;I5]Q-V?Q2Q);\R<%
M>9J4E$Q9Y:L-U7?7V;U):>EE>Q4[:@H\G^S:[#":E8Y+2E--3BQ[T+@4XQ7\
M>-JT@]O?'[+H'93<<QV/?K/I7LHVTO/9#U,6U%'ZY<5SO)2>/Z<_]\O=%;=U
M=Y9E;6]/%ZCM)TL)Z7+8=9?_#EROU\ $;E1@^$R->SF/7C)^[R4VW[O 65R\
M?BO2? +GL7 Y-%,>H7H5\>+6!\>XBQ@+TB0+9[<;437XUD;G=SU1H9$LA[FO
M&TYU'?L$H.CLK,=_^R;Z<;MTH%W^GO:;Z_D=TLY%Z0_58[T?Q3MJ#=8'C?S5
M-7S5Z&*"(W3G'O !6C00)4Y<0[Z?R>'R)2)=U$BEPZW/Q1+WVM.$*?.XM^NG
M$#@OIB)#[UX=9Y415F@RSIRC#%,^1QXE0H49<.IMM6,-VY&D'I09Q<B*^YW"
M>@0%M__>BDWSVF+5V\.1XS -)3IZHUSF4;6BFW)XDQIKN.GM:OI++;=I6/ U
M:$VE"6EV5<H8L8!PVB:R8-Y->@VWT%GLU*@NYB!)CGO$4>]7QK7(I^-)3_9&
MBA^"73ZF]Z,<^ET"<&-\"B<M!6:;O$#,J)S'=Y5AU$ZW@>'XU^G05/HN 3I(
M]L0A?$?7QTK8TPM^I#*?"=_'H>HY5C[PH^HH5Z<\*G_3JU0^ZX -"2-TG^JI
M7N1NS)ZF=[Z%_(#BO2DE/]#V2XP#*=YQ44>;W\.$819XAS2:'V_HJ?-A&HI!
M6TT*C9DA*^O$';X\\M!-WQ=\:71N)=1U7N)8CKMT#ZW!3!N;0EC;CJ*^_0N\
M,/#(7(3PC.>E%<N="C0(:@O>]$I$G!#"+]\=)="IB'AW5T\C7[$HZUH8RY9[
M-MYPBOE3J-O!D%+ DPBK<+R5YC<:/J V\=X+02@*N_U>.22X2AUFI-8#(\''
M<J2FZFSU!$A,^93WL_A 7K+^>/$F[-,0JD, .LM%22KO X7HG-4,6"XF=GR0
MEH7\^+1\D2&<W$.)SVY6[M5\B-,(?4;H%4T/;;Q:O_-K?>B^10VTVS-RYW*'
MEM7ZK<=4SR?$P.(BW*0!$<*2TZT2*_>O\78["LEUK_FDUM+H(INU:6ND%H@3
MB^[*1RQC'ZI<68@&X_8M<_RVZ]$F'0S(_25=W2\_,4;8L8$VG@ 0]@B(-2OM
M-IO2?/%<Q%EJ(N*5K&DT2AQX<F/R4<(A]$!+37@U@")$VI6JL"/B5ZX=VY[2
M0P&^0QZ'?6XW+>Z<EF%< <=H]2<;.0^U^Q\%L3/*(B-7X+/8&']-TVW%RZ][
M<GT\?=7T-)LBW4:SN[6/;QLQL-CCUD^#JVT2O^ZZ%=_EJRGT^M'>T0QK8.^?
M?SA Z8K3VFA(6%=-)LRSU_;/@T5HPEFKG[!IF3 A%Z?A(:]4SW#3[AW3IYNS
MA!.UX^[?MAKL,M0A&O^%'/]ACA:T.X"O\<H39&=CK\.;;45F84$K^C\>%?EO
MH)P,^*PHD*1OE>)O;CDY,..2H@!&[!CE%^8YV4D +9JL"'ALI>>[+!! !!*A
ME&214_M"7FOCWOT)\*XK_8^-]##UX<3 OC+J!V?Y+5UN^;7VFT15GS6S6$51
MG*N7Y-TNSY)^D/Z./TXH(O3<2[&'K&8HBF)3_A&2W)*&P0]$ _Z,^_M4R"O/
MP(CG)Q9C+L]WRAN?MK$51054^&% -#D0M.=K5M]O<":]WT]%,?.\O@^D62 Z
M[W&-9S;\2ZL&SS?U"N;/22@B?E_I22N>!:?^\?OE'^(9_(7 RB/'4FN91!;/
M'"T[Y>:)E@/Y-)894\_6*LI+;SDQ\.@<,$AG_#_[(>VBB_X.ZV8#J8D/\\:.
MUO^08'*?WI3K.E8VGA;43&M)D\(;I 9'+$9[P[&B7[^4VJLHF43W.VS&/W&/
MU;\S6?.&*$4UO*"EG<V*5O^)!@9W8\^]H$7C#5$T^!U)1,E>B#/L?%]1Y!O:
MD3#[ON)7T6J\<>$\11#F*S^0%NTL7%;<,Q(3I$7S\Z4H([8&PHFT]%<Q>%PA
M2NPJ!1A%:1"+:,2?#R 0*(C!5XI-6HPV1,KB"\'+?-UO1Q]?DTN"#!.0"\]>
M+Q5*VKEO^KZO[B/:?1/%,_ =8.,YK5+K1F29M2L53>/2X3\=0608R)=5GE5&
M^(J><WK3RK,39]!.?E#-NC1V2I\G]!HA7J'J#0M"" :SDPVTY(4=^EK*M&D)
MT-ZD.J.6%?TZ;WXQ04J89S#M(KN'97;LG+I@)%0/36M.VN  OD=@]4;.BN!7
M*?NO@/6(PCICLA'WDF9/V8IX]-;&IB= W)<F3BM\GXE"C>; 7>SZ;S;A#PUS
M+]DQ1#*:RJM.$"(WI$1P2>A=$9HZ#B%'G4G?_0P3*D]K\TLW?^5!(&].%['L
M,.I"C*JK=:E&]29 W/#E,3XK4QT^_3>OV<'E/1:W$2:(+L(E"1N8-*1K..VZ
M(NZKBY_F%@KFTV,;C6H9G(5V$?8?.?9$Z2*5>$PRFWE?*FR566833<SW;_1?
M68K6PSNJ'&V\15#G.5+:F4TS5C] 7B,]46Q:<9PK)VU6^<"U-N$LR]$O2!?Q
M:R]L,FMBC, SCCKY *U:B-1CHC,@A*:M%ZPJAI2!,1+1KXN,-)H81V%(VDE,
MQV$B_!62P6HORQKB7*3X4;;")1Z2\'F-JBBQF:YYJ&PC-25IH.G&8#UV7X=\
MF)YU<$$,@T+%]+--J&8D170**^%FZ7,7=Q#;]&,>SMFKD7+T,O*P])G$?>F7
M&&:>X1;W+1KWN6D:-S[/0TLU2_^&)A,-,Z("QL,PKR#CRI\'^F*Y$*7R=>Z<
M?6EN]#S750W7N(0/,=;V?29[6D._*&CS<Y36T+IMB35+)!N_@U>!1+H[87&N
M3X"FVFV\"YS=2Z[+VP 4CB;0KKBQ'@9'_F**G<=T6&*AI0#).T].T^#K+,00
M]<1OG8SCO^3R'!?RB>A3CX] ^Q=W!L81E&UWX]&Z2!3A4J=S]@O+]I-*Q*GF
M&4;C$KR0L7_K*@V !:TL&7O#+"QYK@57?B]Y6NSPK@\KI&KTM?9VK8!=8XHI
M?T'L_9DN!A^F S^+;'<&1=\%>%A,X*2'93F)>T$6%T;&7T)BF"TZ"ET<3$J1
MYI_$:$ Q#-@"BS6A8KH10CX4^D>/.7C3TO^LIWD7S[%UV]N]C+S=$#P+KH^S
MP%X-H<&#/1IVYJ5JSKO^(:=]P ODQ)38\D/3SH5,HGTY$Q-E3@EC"=>9D.=N
M'TAC48A&B3H1Q^[6>1T6\SDMNYG ]Y:5US2Y?=<1A)>/3PT3*N0BBD]<C7^Q
M<\A/*P;@?C#_B4'AE)N$**AW3F#P>[N^<6_Z*7W_GUM2Y'C56=9&;W#6GP"E
M!?=[>2_OS3VR"5H[_VP=$$.P%<7'",<] 74\O3Y5_BEKU<Y)WD&I) %A>?;F
M5(F?Z?VZ7+LI'Z--;T5KLLV00")^"IABWFPZ)',HZ9&E-;SD4ML;S&Y7V82F
MC6^K4YM$P-XUTTBJ;0 Q!PR])E4BH'S443>KMK;HV<\7'\-C4-$M:8W=DS</
M@%WIGT<<FW'*J8-L(?@4F)TTW^X?I0]-[NFU>CMKSJXMM:/7'XK3\/I]$5O!
M5LHDLI1F4R^5S,C3[)=+$ ,7/(@O3+[D<@%-OT<N<S/DT=],W?!Q>1(5QR-=
M0D3Q!@/B[7%*9#Z13BVMG[*19#X;IE9=%GQ4NJ]V@&KUEO!SK8R2KOE,@VQW
MY0!Y% _>%[+*:*43E4L9RVC6<%C[%<5'_-)TS8FCHXM\Z[DYI#P:Y*S: 7%^
MM\*B54;)Q1DGRC&3&,'A&Y7BS^XVZS6M4"[9<^;RF;FO_:0N)=^]./+%;2EZ
M^TS"CP*B&:_#IO0F1.N;0SY(PKESB\;)UM]Z3(>_D1M>-N)/*34+LP\[)WZ)
MF+^GBY ('C:&2GM:5>G4<N]BX"AW@<KW9B1?H03WL'2;R./CC\82\+J(J2*&
M59=@!)>95KQYNPKB6O7J;;<%6[H!.\<6M?3>YGQ/5 EXV/KX8GVBX$?>V[WJ
MP/W$@?3X,FQG[A+GXX,%B X?FLT@9NAL/ =\S0]7=T..24.^NMO[1;HU$+C(
MMD!@./$AG\^8_U:MN2RXS,9:=,P\ZIV//DM-M"Y5:[:D/5IL<Y5=<2,/PVP_
MM#XOQ"])HEIR=I6FA.:<?H<#MURAQ<-/@Z6M=SI_U.98QL#+/7_>1R3"JD0=
M+)!KD_S))^V!]@4B-S\ZVI<G0 >;5W[I$0P;:J %\^RMBLL<_,5BY0(&';?P
M+.IP)?6D"I\LSF500>5[_'M:1'+2$ZUX7IR+XN.N@70> /:7@M%FK2= @+2R
M9A+1-%0N4R8%FCZ]\[[*/TH,@[BJ;K-FIJ/AJYH)"Z8_0_*CX;6J%1KRG:*?
M)F.7Y^N:<I=VA/096B KNB0;%SE^5O5[=OIY>N<Z 9UR6#\CZUF.<BB>JA,C
MFQ&-"TD'#S5,_59(,&NMTA2U<?0>)"RV*@V_-1)KR-,I<I)5#&+PJ.K:Z8&Y
ML*LLXI7_2;IZ*AGM1BVJ5TFQ^9)2R8Q%C-5^J=K&25(LA]'ZOAZE'&5#X"";
M_X'V:+5H,DQ,DW&=!49#G&KM&F3?#3D4_#QD?X:)2.%\F56U[_2A:$_9KD5%
MH> F)#S,*GOZBVB>_\%XG" ;85^3__6D/#X.)<Z"7G^*+#9QC#_81?^,K A%
M%%OU]_':[S^SDTBQ.B!Q&[BQ*TH-V%=]Y0S;ZEAB.*V9TZN%6]4-==W=W<:7
M4PGQHV\_5=F00W-)PSE1CQ@T<UGO<5/C+]H\0VVY2F5W'7_N:87OR.%@-@P2
MU-W$G'?S>1_&KMX0^[F*;&>!X/Y9\;W^JQ(9#BQ8(Y<9ZLN6*U>=S!N9-!?+
M2A=P8B]$>#&RFM330.&'X;'#E+G7;:3;'G(BA'&\U&"]=8<V$1IB%]BH[FG+
MQ/PVY/RJ[%W#U]C:/'0>A$82Y+U6V]H[RDZC38'$([D5)ZW8 N@F0YS>E%'/
M^C#@3$"=*%0:V^]SYXMTJ=$IQCG6RBZ)^4GDJ@DUK#=JU8P47(H1E")M_+NA
M4+X6TI^&IX8.WA[3U2F12T*5SFMX M6IA9K!T\6'^-]"PM_#SO#DI@;6<U:B
M-5UV55E1^!K0%KJ\=+0\"4 OCSRSO<O>4=*OJU+T.Z&W0])M>Y#<D<X3)83@
M^."[P[&05:JUO&Y$_,;^UO:5Q7X.+ T)/7I]&44:?0FLHA5]4Y"RK_R)YTQC
MUI<U5]@:^O03]<"#>V&CE7SI6/S07BU($%G[KWT3;EU"RM0G0(+O%JA%H^D3
M#+I5Z!- &L*!4-D(3R3'<TB?7=Z 2;K9G# 9DNT8VIU+,0TI6,#1)MQ,1]MG
MX,O&[6_VMEQ/.#U;KC;5R0 F^SZ4:TBA0$D^S-:,J!R0(T(23-;#S@<UMIJ5
M2:+N)D+62NAW;OTV0J-7/<^T/C;AKM?U64E]C)[+U.0;2CFFNU@*=DJRG5M3
MHS@=W-%DYHX#9 <K]^7N]G@B0SYMRBA_\K?KI9C4L)XMNE1+SH$/E-4:#^14
M(5T?O-48#.U#L[0\'K@%'BKGZ:BE?37&(DF$=[*V?BV"'V+]KL6;.Q=L/.YJ
M7PZ]]QWHW"3*U[A:S(3UY1&(G;Z.[A3CLC@(QE]'WGJG2&@BOWRD!RTN%"5D
MS84.;>DGK)PE80H):+ZXI,JM4PBQ5S4AM_&F5TL*"_I<(1Z&(=>36YEHZ%WA
MD.>')IIZ&5GCWBT:O:!(X@V_(-HR85K1I"LMGE*$+D6VIUL;V$(F[KKQRS*[
MKVXG_I$."A%3[7GDI^=]I/S"?*/A@.=<*C6)Q4O.MBWJ;(!$ZM_'?A]BVB3?
MT?HJ#W*H+#\IGV@;4?AK4+VRDU7V52RKROFPNS,I=-\ISTF*U@*>45CXW[Q:
M-N9U-VW.@;(G,Y]^3R()/KL7:H2__SG']A+KE(V3+>*N5FAR?IT?8Y_4(6#=
MI4SP.G)U&7O1;6!&X_C"M\[\M1"3V,+*)85:6*KUFBW6-D%-/-1*VI,C#:T\
M81)&3CR38Y&[NX.15=LT+!6:*K>U^F'OM.'MR1>(C48;G)^G&KL [_1HA]/)
MZS@L[\T8XXT08WLB0>0MAG.2[W;F;X@)M"6P9%7,(1^S'6&/TCWF?G00S-T3
M$[RN&LFB9*PDCZQ+F1Z(I3SA:%VAKZ0ZZM5_33:^>@+;;H4;&[N 7+JY,\)[
MIOL>Y/-N>=Y-6;P) @UENE#@9,^Q#@\Y2Z/K:5P=5CM;E='BX\R5%38.E?D<
MQA)RIB,?\L5G</4)@&SND2*:\UTHZ1<A0[K3N7%;01Z!4I2>H8ON6)/9"<Q6
M#R>OZ,%T*JN$2!]CEPV,T]V@7O3:8/V^%W[^* I.PD=ADX-N.V(4(,JULEYM
MM2ZKIU51&RXM99WFM\L;\6J/EO+<SF*+-[BL3X"B5.2X\[[BO?R."L79'/?1
M#D&4';9K#EN;DHS&^OHH$8JH#,>9Y3UM/?+:22_Z;,K6 -*J($VPJ4N=LXK,
M6GHR",I^@ *5]R.V%A3R>SN/Z] W@H"-E;95HCW3]'XM5;QS.EKRW:)^\1%#
M3>@59P1S'36AH]8I[61C5.495MT1VKW0B0PQ4^4XGPACX( N(;EF!>=RMT^L
M<9</YXF. '?=&+O;2K+#:R0ZA(E>BD<._V?GP%Z7>)EE6[V9(P*G<$)"=RQ!
M"7A\*<3R'+^TKZW4PJ%#<X-:1NU9I%)(ZR>/V!L$+-+6C1=UU;377#V/% *,
MT9T^=!(^D^\LA ,  %C^(H&CWD?6F7L1;ZO5#^9J2]V@/E,%5X,(^W3PE]I
M9]/K3JJJ+Z.75G,)]RN=I+&P>SK[:6].C@*=[W:\>.!<U6;"-!I?G*Y'CTA<
M%$]:\(L7U$,%O\W5^*]:\V]6?9HZG!\D^XDCQY9R7NQ- L4 53T!7FMHN07I
M\NY.7PKY[U>(]3![IM:7D."X8>B>O FHNJ&*I)BR3AYR6S#1#S'&+P:BF1.S
M!'>IZ=L>QT7")PWP_8I:%'FQES)U.BY=9VGIEMZSQ!#>4Y)EC@*7O#;P\A6J
M'4__[4SFM=UNK]B/.T?;>;8S=[?>'1W@/3E![3UCUW1+W_*O+ 1Y-KN55?O>
M%2O() PZND_UH')\QEAKCT\, 2+Q5C-"_;BTO;C4)M_O>:6F/^:5G-; CL1\
M3X!(/?E_&>G+715;4=_.K5W\H^0(RQQ($!.Q/'O,RK%VPB1($% []XXU+\G!
M]X ZJ;?EY$5ST'3/$L:[.4X DX/\Y#1W4SUN[@NV&XHM&TNT94Z1"$_U>%1D
M9\*-YD.;PNJL#XN:K="<\7(_9MZS/36C),J3P-V4EUKO(](S2N&/2DW,ER1G
M&^QRB$7)]72J>^>:MLX\$$<Y1B^00;?GM;L<6KVZJWVFE9/.M*6PXJ_0Y1YA
ML=+UJO;,N'RP6C5\6=F+A>3J^O;IHY,56^KDZ:P24^6OTM]EU[345S*NRYR8
MA9#U6#3!U7HN^L!>;K=F6'2<J6J[$V4"-H)<TL'.#4ZX/RV2BNWF!I$4A%G+
MK1><\4OA=.6HWR"88OFGWJP_6'9:SH6 ^JZB&K@4\$ -U[S1KCX?58V<9E"5
MVU[^C+45Q$-$A ^5+HR80X_B82#R'K5<TSK=* DL3[S/<#5FK]#7E23HF>BO
M=I?S4!%_0;\\'#JC3?S5J?<12QL3@UAAZRS?J8:ZE^"KZ0=QPK0/ZNC.;VOJ
MI/V=J1/\ >L0QHL%QZH]>^JD)X![K7/N,>M&[97U69WG9Q<"%+90JR&;QH9;
M@TG.6Y-B%Y<93!'&^:I6&G52*C2'\J6%#I*!Q'9@<_1T*CK8TQ:][SVE*EP4
M+*'C]'>#O,)P_5.2:IE#9[3L[EOW??49[I49:JA1KVX#M2TK41V'<-EAXK1I
MO='@>)BC0C_Y*%F4&)/&YVCUH':IE/J<3X54K@1?2KRMS?*6?^%^<X@6F^T5
MF&P@9)F7+OHE0A.!8YW.Q8]F/[;K^I,T[$-B%(>R;QDH[&W]P?I99FQ$RL;7
MF^^WTTIM4DKQZ3<Q144:>WPL6!0$J56@P??Q;>31,V<%Y]KNC%Z4'E1J8C9V
M8AB*<_48!RC==5C)]:Z1(44&D)8BKSO_)9F[H(DXO@=+LZ\%KIOOK;&*IM<\
M6]%F'[YQ#;@C>3CO@=*[HJMCM%3N6LS;J#?W('5]'"B#)K1H"R ,5;BO,G&[
MT'4, 9=(]1"6/NS6RARMPG#).MPQK<%2!/B< )I>(S'!$O?#]'<"9831D7XW
M%-,C!87S).CM>?,#GVU0"D_"8@?+$5^'94<F+;\,C HIE94L*B)R_5YB8\.1
M *Y=4C85"0DD@>1-94<==<25SQ<XA'$QF FTQ X2*5V+O>-R1&IK5_J%E]L)
M]+3DJRNE"L&J]ZIMN[<D1L[]\9,VNSI--6Q4JBKE\0G@42LGU+<GNE=^LD["
M,O_3,04]J,["UH8RU88B32V&F+!6RE-O4=*.VNH[L0*W]2(=L')S<?:A08NH
M)>7@"?"R)O.,\)4;=5C5,!67-;66QM?EIA4,L+V5MQ,3WWF:,.W=<&.)S79#
MEYH'Y:[DAY*N8-*M%GJ"!()(+7?L(BKSSK>SUZR?F^!UTS?@5B[8'Z0DLBK&
M">0282D^NY0*>-X5E7\_S$DF]%V/H(W2'>63)ISH,Y9O %>&@ZT(X>8FB51<
M'DG3EHCTWF;FRCL,(/2311S<^^8[Z<KH7R=IZF%45HI?O2W@*57CUU<(8W[7
MF"+&W>9%$'R@3F+!1?PEUV:T,<E^,#5UZ*$T3W-UBC.-HNY.ZHLKJCHY8-(B
M7QR\N'C#R]'GSG7HL#_@<:?.QOBP7M%+$<\:+Q=0(RLQUY/]#MMJYQL/WH)Y
M&(SZ$R"8?BZ[R/3.S&]^/Q_V)J#*TJ$3S*6N27ZLFJ*44G%\?Z=._CQDS7LE
M=WQT-YQ65;&\N$!>/-&W]J'&9B6I;L7L@"^Z+E5E7&,, 1Y;O2+;I&"8VN5Y
M%,$"CZTHMX*=",YP,+< YU]@2(V/GWNFJIV+ \CDEZ)_YED0\(^4.+S[ZJ._
M9L0-TZPL#K$^3U;U@^N]2KB@:O)RX65?ZT<;*<2V+6*TN-0WJ@HCVN]608U6
MZSA+@8POM2A=14?N@$T,S;- QO_I\]O_T80TC*T 9].DJJG\KC0R4I'W1 BO
M]M6Z&O]B*\[$X*MW%8<&HY: ]?>,#=,?V*>YZ-U?D$V>A5W,Z,Z?NA5_*+)I
M\JIZ,;>=5.P1FR2+WU7(#*V-G#:O:'L-:0J6;4T6G50S'SV4["SQL [=U1&*
M[FK/MK'?-A?J6"?B:%I_ JC)TRKSEF:;OA7D6M(!OBQB[26:_(#WF012<4"6
M+M_DS&,N+V]9P5'O]I')VJM>Q;ZM;UC8-JL3-4O-U8R(N0MCH*R33@8\42W9
M"!L%+QU3(\KNC[<G&7*1;])<Z^MSJGJ_1[?7S6F'BW+V>D=6N,7/0=HA_4<3
M)7JSZ><0^$;A&#N6I--!'JJ),@+(CN9GY3"W80_^WA#I^WQ.LV83*U[O6I#U
M_>RDJ"O>C080QP7B3%H]NQ6;3%HM GPET7(EM>-TA/;K5P]5L[/9WJ ZHR&0
M).@ 3IW;JF?MN&!S4E_Y6UQ,R"5"372J+-:8&FC;I:# _'*=CH^<.*'(7F]V
MD61Q$,OSLWJTO/DX2<-02WV!T\TPN*,/%BV/>UBD0S^?+J^479'=E/]'=3 Y
M3OOUCXY0N-S=/M^\(T:&-(86^F\JQDM%TF5ZBV**R_A[FDIYW'+= Q8)$OCZ
MZ"F@^9](&@[P9GTP!13K28SI5G:31LK-H-S13^.3\"N@&7RBZU+DGE.WDQJI
M7](["6B0&6KZN9Y:L9:,L6)4/#^),H8Z@X:0+1(F-YQ9/;U/+\XH^_?9=#B&
M.ZJ[<I@)9VQPM!V12S=X/B^28UK")LHA ISS#TU#-<JC&;?IXCC>5M9 7J*[
M]>$L[3$V$ XDF\;41HK7<)"C'*D<<K#KA0C$>@RV$6Q<8]CMH7K/MYZ5YLE?
M>X.U::RR9ACX3T;7-/EDR(^3/#FO^'9L;9@H?UFC5K"<*VM[  .J%^513VYH
M@"WVM^JYVAJ:FC3:VA+&O=XIC\Z&*>4WJ96[:([2N$L]X[D-*4&QQY<= RLZ
MBT-FB7(NYS"-L[:$@1)M*D2%D1\77@$N"@[4O=+?&^I$YV_45TA^L2UU&]51
M+G@#9OS,_&]=RL0>4Q4#"$"')E>[M>W(=U,+Q+Y/#/3'MMZ, S'@OGJN5M=(
M@N?40YIRFQBQQ\_C^&Q@&NZ57EEFW.A"T8C=5\L"/!"#JBDFC=P/MT)KQ4S;
MY[Q%/?!@B7@A $_TF*..8%K913\LF&B#\SQ%:=VVCR^@T;"05#%:3>:?"5OL
MQBD0:(CB9Q86Z9"+;&P%,F9^6@G$$FSE%RP2%I,3,KC0L-@AM[-'47?!WX&6
M=GK_9;]U53 40\5$_?K+:2%-5LO*B1^()N-YR*I8B *@<,K.Z+6D*92!Q<<[
M$,56T?TY1L.WQI^?E3I+C^@UQIW=C#V!6.?2C:TH8IBAX+XGBNW[8=-_5(LF
M]P)=X1##'A*6QZXH;8 A;ZF3YKXW'04R("J?\^]KSP+!#/%[WX[/8RM*#7&\
MZ)620=:BF0*@\_[!HV-UTK@:SA1$8[G6@#Y[()Y7*T53H/X1]7Z^\7;,O;<:
M6WF2 3&MRN59L]RI@ C%O2-1[&H4R^?V@K#,X0_MQ1SG0,HSL"7$!E3TTF+C
M>=-,GQ1AR)7CH\>4SV4QO8UVE%ZYP)ZU&M!/G2\RH;&.D_DQ9Z#+\5 U?>ED
M7M<I7]C/%$^V9_>F6I:JU# 4)1IT-=ZU$H>%1#J&62S,# XH)6^:Y61E%3_+
MRC;\\4_>,_M?EF0-DYRQ7^B.>:C20HEC<P>32AC<AP$&B\(1;L72S^V#NCH?
M#T*%3<GMB1"A\^)/TA#5,M0]V5Q=[ZB5=+(1 #^\3D,M'I^CAKI:SKH3>80Y
M[-1*JCJB8(--\'2)5%\YB^/IBRBK@./<.E/%/-W:H>SU48]]?X8(=M:0 KS<
MM*SR?GVWI;D!2;+R $YT=%[3<J8FS4(=,8U&,0S9W,+K/)%TL0;W6$<KLI'5
MN9^R,X<U?A('>F!D.\LM(G$*2^D2>;YO8>O1D]%JU4BYM7X\1O"=(2LNI;J+
M=88I,])YEB9.YR/X4W:P:I52O+,*3;4LI38FY)@(2MY6ZL)3BY1D_339S0)[
M4@V31G<BUB*3&%KM B8UZP8BL)\L)PH.<X/6:/:,\Z88BN]EW_+7S!Y!^_4O
M'XH2*EN21E9+ME"CQ>P&+,;U9%'[V1FKV_NZ;9<T.J%69)[6U1QXP4?80!R9
MK!7N87[$^46&%81-L!4)\V&X_X'.9:+=^)!!!$XD.A*_J/,T>G']*/:4&!>V
MBK:F>CZ8LV0JKN;^SGR&:5#SBF C1I.$-O\R?I('=3[B.[H&-/OSUS41U$R-
MBVZUUM:@1T0-#9MSG' X-K&VRI^])>8Q^ETB\ID0^";A4\E(>?5F%LPK>"!!
MIR9X\2M+-P<X@M ]9ZM:O=*W><UP(PB;55;@LO>CY5L,9!TK)J:DK8&OX<)+
M%6D]T$/9?#P_^M;C@Z*Y'99.:@IU?I=,(C0RW"6PE2#"CEH >X8\Z:YV9LDL
MYEO5>2N8+L%9[)4Z_&W^6\48XS"-2R0V'?1LRRUID)"D8QR/P*3QI('JM^+#
M#3[2$,^IOJI 1%8)C5L5GH5L!F-NG:2T#]J)]A5\[TN^]%IABVP()R6@\PO$
MDCG2LH?.6N10W*I>%Z\&;+S" ,N'7&28^N(^UPTP_V0"G.=>Y2G+PAA8Q9]L
MW?_ !/Z. CY)G/633]M8 )S1W%QH&]&7@YZ*9AT<%>HF&:VH1QVIJ/T$. ZR
M I[M"AZ5B]^3)2W?WX;?[:M//WB$GQ$K9RIMPN.T/@&03&N?  +9CW?8P [\
MDB? :/X3H*6;1"_SON,2!Q69'OCX:MCVT5O\X?+W.:%LSTS3%9\ WB"!9I&;
MP'TZ/&RU)\#?F"O^(S]OC^ SQ)_Y!O\+110O=DF&B#LROXK:/@'^4?3?L3/Y
M0&9/Y*#_C9[M_Z^U0 X4@0$M_POS!%=1IY\ 6Y/ 9:/P,H5'P[O_ #7^%\Y(
M/]O^PQG;SA&IR*DR?V:)(_X=S?\(.'X"//,P_8N>]<^2_?_4LQ0XFO$'6+_S
M"<#L^3+A+WINW=]B_$7/OZ*]@1C/EE#]5<^_L/X[]N)>\-F.Q+_H^3?&_TE:
MB+GW_.F-1V_$/POH!VV2T]^NE=^[MEF[Q&)V0T2H9N='7]-H0 )]TKQ9JK+F
MPRKL=\"%OB8@@2Z@>8@E@]MSYXI?T2 C"N3,H+.Q^@46.'-F"R\K-JC%(\1_
M^=GA:^#@;24630B9&9*R<6CDIRDBQ:Y"I@WY#XNQ_U^4Z#CQAR4E1 %*40+5
MZ?;HCMU?*C8+95^U9Z!;;BZ7X7QWM9X![962(50PE=R.(9+P.8CP#KZ>VW9,
MUSKB$RP.U9N$/5T08U:Y*C7=G<5TX"Z^\_Q^WCC5$'"*KBEN+T2<[FZ!4/+Y
M<H*4-,0;S>VP/E/'O,'_TTI"0E3>7+.97&O8Y1S/BH'X2;B(DN6<"L%PHKCB
MYHM.#W51@I;AV0&P@+?\*Y->:K T7(MNU^?T:+[IL.J<44,'P\^DM*OETY6!
M19(]$)XRH\?I9,D4B[J^0T83R6GF4IBU,,O<YIPY:=M-AH&*L+:+8@VCAC &
M<F)$PDF@24/LU<!0;RT'U/ G9K;BR):WCG2*N\P1:1E:VT5)* *P8HEH2(4X
M[8+.PE7=36/5E+P,KR19$%'G T,T;Y=_/CE5LV4L^:#I!?>:'*0>H2R3L]Q\
M9AH)?@&X!_,$>%VJ)GV@-B+/N)_7AW>CDG1QP$FO^VZA%Y])7CFM2M(ABICT
MAXM'A;^>:ZWDMK.VR,#!ER;AHM<;\[$B]W(NTP=YOM_?R8H=U]ZAS#6^.]C/
M'A>CK>L?U2^1V9,66A_KL\:0+R\WJ?9W-"Y2Y[]T-J7;";.JJH?KZ Y?MX++
M<2B']=^U&NPV!LN5YGDS<+%+1>RXC/ 23FV,[4/XNQTL</2P3AMJ5Y7Q-U#\
MA, /99])%"8_^>'%N-NOW$V/Q%OP'4<QPQL6-4;A?R7ZR:*K'WQ3:9@6C!/
M]D:OC-:9N3!6P,CM' S'7BIY7E0^WXUW0ZX5C]TH7*:>V98Z^T(N"R3R[S\=
MD<,.J%)R%&>/?F&><R#.K@.?%<UNFH BBJU4!X^M* ,#DJ+5@?^]+XV1+',?
M5612F6A*G=*7B-521.<)$"*I"R.;$Y[JX6V9B:AD#Z*R&>?L.GDQ6.I3U>*E
MOZP_TN0Z!#RJW1)/> (LVXXTV^[7 UD&+V)G+]\+O#\JVQ)/?W,U<U9&=$9R
M=W SOBEX-7^6?<>D/_2^N+2WW/T$Z UD^1."L]9B_-SBM/+R]3[>^3@!309O
M_/?HR_?U?DL94MSJ?KBX[W8[^E-,.,MS#;J<2O++X='@=F#?\\T?++#_Y*?W
MX4\Q?^IUJ=.:(%#12-S])P?B/]BIA]V$/US>;_^IU4/\^TV,?YH^O"?+?SXE
M_I.?8,7&??O_WD&"?U.(E^^ZM:4U]5^7E3WZXV[O9N9?L>M/-E=3_SJ?O"UR
M\J23ZCA1 ]795PX\I?.=:11GOM6-7MS;O<V.TVV3.:6I@X'.Y*6]U>^)8WS7
M49TNLM.ES@Z/C+.%@<B"R K<X&Y^,:[C[.,\HQ"E281';)_?1\]QO&@-) G\
M@&T4*F2[*KXJUXV7K?#V6O'Z]SET?P-Y^"Y@2/$Z[\AE8\,'$8OCL1].&IC&
MQ?I*T9IGM3WW_W+_TX=E_P4(5B(_1P:4%NG[SI>-ZD=8;+(](A&]BPHT?QA7
M%.#(Q?G@5IS\0T\>9VI!^$!3'?=77S?@\_;5:/92X/I\GUTGI/&:2@<Q](K>
M8%T=C2-M16QA.NU[_EOU.XKU $%'_GQ85YWQM:D25QIB@QV=& &\>LQ7)\9+
MC6+U5FY7+^J(@PK[W=F> +C\11*3,1)V,KW^G739K'6J1P?JT(GS.\-(O(3;
M)#53XSACR9#+T>GOD[:F7/!C/YE<2F>S59X[=A:I82C1!S)&V&A#B)!(C?IY
M@CB.9.NP/I\Y*];\#V%T75K.0RGU-&B:CWTAJ*TC2^<40<;):?8$N 58!Y@/
M^W13B6NG OMN.!^UH]C\A]%J#=EO<9>0X%"E-\IU[LMK$V;;\(LJ=+@BR1"S
M-LOCSA.1^&9"$U8M5;W&^1DHW7HE<=WUZO,*"W9E.2C-"%4RB.I]Z#OCB&NF
M^56U8LOLVH@0Z N/K^X])!^OSDLMN<_\)]6E,U"U^]AZCG;TTG3]4WD<A\Y.
M8M>X3[MFJ;'K,U OP-W>K]>;BQG_W0[2^@<B ^?R\*S!8@/JH?$<G3N/?%Q+
MW,W'J^4TUJT;-?=;>;8]N2>"H;U!U0_TTE;D/)-X[_HH>I:$=JZG!E*J)-U!
M6R:1>Y*1>QIO6N@FV _TYJ4;$@,7VP9H1,)':C$(_3@GI1AM@AUD0LS8533X
M66EA ?7K9I.3VV^H1KES^BY*E;L>&>K&G!DYIXF8K*J:(NBEB>U?]>'S><[(
M-KWR-)LKH8*;_(R>FPT+2Y**ZK9RZF&:>>:$3R5>@H/'0[J9D\DU*2PI+2E:
M#+!*.TF__W$*G/GTZ#R6EE5_A/\$Z(.1O]U.'VE@7N[YGJH?< :BR6II)Q_X
MO3_@=]P/C=]+_-NP%45Q?\\ _GQVAZCO[V7[SV^ HL'_!)1'7M%ROQHLHVR>
M \TI;N>L_@!$NXZ1*+)RF34<#W7>%5XG]-=CQX\($@DB0G-I>7O"=*&M71FT
MC3?S-:2=N\4\=;+(R<RTF=:2N3WFE0.&O=R*-WU_=5CYY'^!U5[_)Q%+_+L,
MMPJZ*?92<U@Z#;:Y_&&KM*F6<7^%*L"F+T\_0_\VBP+_UVA?YL[,TMB20+;]
M.IYN@(G60B)C:-4"JQ-U,WRD1RU')E52)>'#A#1Q+.9*.8,Y+)LG2Y=].7\8
M=\':S_J$^RWSDF\'XP@X0@4?%1"<>&607%E,.7RX8\5PL%4R+=H48#_>)NEX
M_&Y:8&@9(8IG+S3C>5EY*-U*DFA@(QL@>GA4W-3KT'J8D&AF4O^TBSTL&O,$
M'(3ZO53<I8WOL%9IYQ-6ANQI6VSF>-#J[&]2=89*9<%ZU#>?H27BV2-YB4+8
M5LW!;K%=* 0O(D&SX^]8NFGYYT&?/8SRJ<27M=0&"HC':%P\?HRE*(W1Y/R;
M)[W_-<I?'_VB$OOVX63^=K+_UXLU8A(3^7#>7Q2E^U^C9PXG6[&)N:XC5RG%
M$.39;6#S;[JMKGM7IQZ+2D(=.V_C+UURQ!G'L&Y4]=&\6*>4NU[O$5-/ :ML
M,NX2>-KOFXLF+ZO*\,^LWUIO&'T9H>YI>3L3#X4OJ9_!2+4;FCZ]__7-PR>K
MP99H;VXY@(\'O(-2B/^>Z@-E8R?6F..>+F+X_<M"MVC%RDDG75%K)NMK^-;@
M//)P2YO6XSNEDS=!^Z2-DXG5GN3--J-B7U[L',@:D4YB54>A$%('\XF4[1 S
M3JP2D\9KU31$,*QTDL[R/%Y86%WY4$T]4NB8:\F54V:X]=_TT_F'=>YIZY$<
MNX;O<PQ^*%'N.M&=[;H#!YAMZLO%UB/ZOS>Z#G__[7'BS:\DUC2%$3'[1QRF
M*JZ*9K]>2NC.Q1':TK6R7+1FFB:QE]SV^DN$B[T#N9.1/"C)M09GDEYX?K^-
MC2$L7)1_F 1,0QFA&]-=U^U2N*<5WTNB@,QU]1$-&\1;Y6I!^"6]>Z'R&8CY
M]-P2/YAG,<48-,)!9M4RQ#!"(MYR(AX@0*ZY[=%3=1O"9>P"E4/40_")38:&
MO['B70XIJ^J[V!PO^;*,U!?6%8+>Z%.]/3?C][Y:\-N<_K?L))**7Z7X;WGX
M2$Z*Y5]YL4PO=ZD3C 9>!/Z,V]]46)X(M\Q7R:WVG.6@OI8OVYWS6]*T9&N>
M:UL1<=H>;'),:YHI1(_MOB81.:'Z8>N41C&EK.CJS/+Z'H#NB7SP09U2#4R?
M%:&D=)53G,#,+^JX]-R>1\"E7XP+ICI1YY=Z]@!/ =&/#=1G)<?_6#<3*_P;
MPC>5E'2L2N$%H:*S3&#'*$=MJAE4S1[P<4#UXFJM1X_+2_N8:9!7_/O*\-_6
MPC2][N.8O;;MFC6T<%D(@R4X9DF@2DYYO2A5*TG4<B*=9B^CWM?7C@A)0>2W
MZJO43E5OZ<S/ B'\9]=X_R<1%<T<K7D&PCYV$(M\EB]^Y2GX5UA"GJ+0RRI%
MD!;-"Q;I?\B]?FX1E3:XJ9D--)73'N\=ELR/9]U\U#_S+YFW99GPKL N+/L
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M_XX4,BY*BDR3D_GS#;MI%(@)9EP46P?F?_+9"X8X)F;7FMZ7&,WP&@R$2MT
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MTJE XEL3'8,#[,P@J6UC?S!P"L,=PONEV]D:[8_ YW0G ;B:G_6Z<+9)G#3
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M^U[Z\XX(F4D<$#:<849"GV8+S7Y]F8O4CEH(1*@4)9H3AI24O73O X$V$7N
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MXST0Q3#T84!"]'DO)'N__O/O?P/LWZ=_# ;@ J/ _P#.B#<8AU/R$5S!.?H
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M^V#DJJ0>@O_'=W2S;_X+4$L#!!0    ( .>#?U;/WMX8920  *I' @ 5
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MPZ1!Y($!.O7M*/>=35\]&>NJ5U$*6^/R1 136?L 1)"L#6CIPJ7(XEFVT($
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MVAJZ0:><NQ=\M\!)9 <N&:WO7@@GJ^INFCL#R1/0%=8E["*XLS1@'^LZ]+5
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M!OVUN9OFV9^JS#S55-4=;[SHMXL0H6+FJF&7 AP.=M-4AU+<2(X854H_Z"*
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M(T-MX-F$XU.R<O;@.TNT EC^_H/YZN8S#QY):)LV:MLD>)HD0J,H]AQXV.I
M3%<FK.X+NJY"&A<YU$(0-G30#31AQ%>"?XGB3AM!75+CUHXMI%$"_D[C;>9#
M-34!UM-3B?D+'"+OD;,R;4=G!X 6RV=<L C@$(1!!2J,#SV>(,:%@ZR7E?_
MON?:JS,4.:'WQ _LX50:'UPB822",_2<M= 3J"3.<J2>V)'GT)S$GI_$R+U"
M,55$'IC =<-_XATT%!JA'UDS[*0A:\@B+5FT*8NT9;'&ACUXN,8QS?-D^_YJ
M2OYE;'G/:'.,RI7],T_V FF+TK9RXM:&NNYG3BA?;DWF\U?'3X@V+T@W*9G)
MN4UVA<'CVC!JG:/A4JVR%G2G!]U2$ND<H6K:,>;80;6)@>E"5>)C_%'&EL*>
MK)H)""[(]]FH =?ME5H0'DYUQFW&FYF5N4<MKJGI9OT ^,E8C-EW[OO#W>13
M(_-LP]"L;^MK,#2J=<;V2*+,;V 536EDI7LE< &H28R1#-_2!CU=XH1W^58)
M>5U9;'M>SJK3C<19S9".!Y99B@:UAO'J+K2#R'98HBFY +DOU8WV9+)O920M
M1M,J$C4G7@X06V+C+*ZI>T,,07JR*OTBN^]M1<Z8[:TLP."VM8,6C=^=RLG$
MWVRVH6' WK$+C-6GX=HJS: E0Y%%T5J_J:R>75T'E<.8F;LMVPX<D[=>/0 X
M:/C>63A]M!?<4+)B$4V;'HZ58YA1X\8HFDQK-B_<MN)/0$#QG9AKN*HP*.2C
MF"AM&KA7.+ WWQ1%%_D16A/2,R'Q<<';B63>Q*0+7I.GM!Y-8-"I[90T2_3@
M!8_3QQ QCO@ATU!Y79Z^CMT+2XIDW%B[4Z\8;3]%MGZQ2%]BI;<7B]Y>+-(_
M<;V]6 2+E\^_XWZRB)NQ<V)88CF)K!KI05PQ5T::1H4#J^JF[B>:[M]U]5OW
MHP")PRHUU_BBA2#Y8'H!KEQL-"#!S!OGC+D.\1Q%=.*Q_0N$> ]?5TJ.!@TN
M_ZJ7_Y"#T8N<$%$V[7!U@H.D2=',>U<K.!H]\]B76*P/>0J>QX%DMSIH7G^Y
M$_#C][43\,-]*R>W3D_$"#:>?O<72U]>*TB*,ZF)<[1O;4A9*2USSO$K4M9L
M4;@"_*;]W+ZR!A0<RS>6-N;4702'8+,QJL/T7?#+\/2_I=O%I%>_W]PN;VZ7
M-[>+<6Z7,3M=3-R[C?T@77XV>CLG?SLG-V N>SLGW]US\K-,G<5X_^LD=!9V
MA.1.SEM0Z '0H0[3VTH)'U28\"R&X(@A*Z4K.5_;[7659=7N?#6J9X]M"!3/
MRHQ)[1N&C5LFMGRH(,]AGQ7D+"BW)#P2>%5(:=Q"]3K$#D)N1&^RY:^2KF7D
M'P)QZHT$40DAMCBOR+ZG_WD@<R+YYC]02P,$%     @ YX-_5K<]5V4G8
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M6=[3Q>!E-2@"R7=?;T%*834O0?8^!B>*"I'H@>A#H#\W4KXK^BQ?LMB--*:
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M 5%'CU#!('K;NJ\5DDCT"GBQS3O''4[S'7& SZ=YK!ZA&+3\DLK*A#ZUM"J
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M$4 *JZGZWD<0E2Y#)#3^7ET'<OGG3\L'&N-;<2%!+N;;]<M #MU_5P8$!33
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MLNGVA8)<O.L!E%ZQ8Q)@^DHI+/6UN9^96/C;<2VBCZ2CIQ'=5%LM,L$@Q!"
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M?2GQU>J\K)(-F7:K8E8/A7SZ*CG KD_J2P1GBA;6D!9?^!,SK5AP/ISF[-P
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M8.*,= [P9%424Z!DS+8_*W;^M$QW,8XO")TZ]HF%YW!D:[*, AWMFKB@%$?
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M>O0]LE" L_?);8[!&[)7,VT[9*('O#MF",-VQ@X0CJPK=B[<B3MBZ_R#M]Z
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M43RO\H*=4%$4@E,*/MDVPK0N QW4P?3 [IB%<_:X0GFCA%*BA99=-7B$;0?
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MC^:*,MX..ZO@M8>;AP+!B:=#)095*1_Z7*&KAIL\J\+'5KDN\A4N:1S8*+W
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MDN")7,>)EHWF(PU/P5D<,5E*@\>0W+)I$DJ)?Y_&WN]L&N+/11SZ;*<Z)[/
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MYND@IKT^,#2]Y\6#(/MNKF*QR93:1A=EV6R\H:GY$E'BQ>P*\F\Q@X*%YE3
MQAG\#FZZM@!=!]=_V8+-4K%>IS.N<'L,X/,@S%+BUR[BYCIPY[&'IO*6J8-L
MNW+#<#UA?XHY,*;VN$2:CCBNE=U4T$S'&<\*;WS\&(PQCI7>W)8"ZZ^:[8J2
MA/452^F:_6"G"WEAHN@3OQR(SQKJ#Y4&*6]<N*@=.^^X/UO&;R+LKWG+8B+E
M5,+8V_EZR/V^XIJ#5>E#)[R[$N(=S>.G]SX)WG/.\+\(%@GVL'_\)CXT>4Q2
MRN2P'"ET'TDHQO^-M:DU>;^'696<>& CMD]JMT5]3E70)M1S8NH3RGA=CN52
M;P>JICM<T>+]2OBOO/,60;A!>4;CI8P[!2=BR42KC&*?V \W)^S[/I_#9>C.
MV]E9:P+DYS$&0UNIP>+H.4D\&H@KGH:Q.RV!_#U!Y6\+;7MF<[EV[L@\X//E
M4]DX<*GW!4D7(.,_8.X42FJ1$)A$4>:&=V054PWC=UL"^?T#)K_;:$-B\__)
MF%I(:+B&<+K1&,CL'S&9+:$0B=]" 0\X?R ,;[8&<OPG5,5#0B,2R^\7) SY
M]=2-0%+>UA[(]I\QV2ZGTP+&B^O0.3M:X+RO= &R_Q=;V-^@%@F!6T*#V&='
M.@7POM$8R/6/F%R74(C*[XO(AW)[TQ1\_\%G=HT\)%9?!HGGAOF,+MG/$C6[
M6YI#68YRY]22B<KV?Q&7@IE>:0QE.<HU5$/BGAE^EE&Z,QGEKB)O#64YR@54
M1^2>>7X1I4&ZYI'&-]GR<6LXW>5ULQ64QRB73AE1*+PM+0U1R@.H5?RMMX3R
M&.6NJ2(.A<]GC![JAE>13U[^BZQ5C&XTA7(:Y8ZI) ^%U;<TX.Y0]X&GWS2:
M;:',1KE9J@E$X?:#^W+E\\=8[J?,F:1GNK0+E/<HUTH0N2@0<,<%NHHKYN(S
M[BM.UV>QK]S2-1VA<*#<-PU(1P%EXON41R7D?UP'$3E60=':'/Q&A > @DQ+
MV'YBQO83.-M1[J%:,BUA^P<SMG^ LQWE+JHE$Y/M9^RO4_H0/TM>H*6-H2Q'
MN8MJ2,1DN#AIIO26QD]!GHE)Q_5&#RCK$:^H:F)1!3X_Y"'27K:$\AOQNMI.
M'":?;^,D=</_&ZQTFF1[>RC/$2^N*D+W;6#,<>=&"YDK4:T)E+\H=]56<O;-
M4HXP):Y<?'=;0!F*<@%M(V;/_+R.^=O'(HZ4]MAF*RA?46Z2,J+VO?%R1^)$
MNO0KOP9[L*%LJW4R]LS&KS1(V0QXT%,6%38:R:N8I"F4O2C7/R5Y>V;UO<A$
MP*-E/S,-D0;;['Z[?&YK!V4RRF5/3MB>.7Q+"4>:,+5;^''Q2 ,ZG<UD.Z^J
M/93C*'<]/:&XG+]*DHQ04_ZW](*B@'+M@Q*][WTF#^M:'Y\\/O"(&<DNTV@%
MY37*E4]&U)YY>Q,_4)=G"+]?+Q_C4!X>TMH0RF&4"YZ"M#TS>6<>[>RM-8$R
M%N5FUTH.TIYP\>*)7"]R[X7VEE &H]ST5,2A[;UST-X[-]Q[46Y\,J*0>)O[
MAK,5-7T,@[DKCR13=@#'V6!R7$'JON/W1,@/KQU!EV(>E^PO[6R7-(4R'"=$
M4D7>OEF=^4%*_'Q*ET'D1AZ[4FW3L$NXKNT%!0 GAA)(-(IY_RL)P_^*XN?H
MGKA)'!$_5_55%GYI%R@*B&^(&G)1(/AG'&:,2U0X@E+)&I TA;(<\>U00AZ.
M[V7NU+PY>_(B02J.RWI &8_XB*@F%LD_+25\SL$3.7=3MYBABO^R'E#^(SXH
MJHE%\Y^G9^S@F<?J-_-:0RBW$5UA6TE#8?+]T@W#,A>QBLFUAE F(_J\MI*&
MPN2+):%SMJE]HO%SNBAB.U7,EG2 ,AW1LU5)*@[S7[9QY'G\FY+S+:W!V0D0
MV2XE$BOMQB;Q][VHVT@E7%>UA_(=-;!23NB>.3]-%X16]2<QF2MV;U,Y/>A[
M05% N:Y"B<8Y6RN1_,JC=:<=E-^(%],VPG!BIK+',/ NP]A5ZN4[S:#\1;R%
MMI"%PMY3-_J=9JO46]_2V".$/Y\DF]4&N! !!X!"@G@_-6(%CKE@FR]99$=-
MIEDJ:B:S^2F-!LI^4&@P@S@!A"-I0<DVT(OXI^L[GA>9NRD\D)?TE'WH=[52
M!.@.Q0<UHQ"8#7N&Z<J;46'PCNDD34F2LTWN3*!J#P4"Y4*L)Q3C;26FEP%=
M7DEN!K4F4/ZBW'U;R<%AJ=RC8*<!./\;(CL1_0>*&5P7]>F5#-TV@C(5YVFU
MG:06QO[M?6/VU^P'HR67;J]COY-D^L1YYVP>(=G?BRY.T:>W1,S<Y%'P/$O>
MS5UWE8L%"=.D_,E6/HH?_+:9SW2V>2B]C7,;C"(O==$=UKN_K'>AK"C:H*6A
MW@XKF;412W<7AH22$3:=[D 4MPLH'HWF:#FQU<QM0T!"*CH09VZRX#5IV!^\
MELV3&W*U=I*>N92NV3U#U$V2 P/LCI9<&X1!W(4D2_!K*]HHMU\4O92=T/)Q
M=\ *0#TZ0K>4K-S WU9#$J;='2KE2($ZHV7T[H"8 3?0D0-BU V-X4U^'=#0
M\9W-/2]X=9U3+9VAF%X:IVXH6F(A=DW<A"SBT+]:KBB[-@@;S2<:MWH %)U4
M?="2B9LH&'JB+5E)NB6$F$7<7*%[#:ME6[F.;<3"SLS%B- D+VNHU\OA(Z E
M*.]_A3)E$_IJJTP8?,-2]4%+<]X5 "E^MM[""E^+Y-9=<V56KW)(VN,E28?S
M.@918@\PO,!\DRPE-K(N> G5>\"CIA\=H<K40+L;9H[UP?>S5Z"$**J]*\Q.
MJDYX"=V'P1? $?15UT59'$ ]'"%!_#"8'8!6>%MN#&*N&KMN:V.\#/-P+C>L
M33*:T?&H>/?HC.R-EG@9Z+LB(:,6'8:)[XM+(+L.NH%_%9VYJX"=B97Y*E0]
M0%^\_/5=H8)S!!\\S\N6F:C>+>S(W'67D@5/>/9$\OKQO*[Z#6'7_@?W1:FT
MFPV$EQJ_,ZS=>(6.\1VO$!X1_\*E$?=-K=!Q3F8\+Y@<5DA?O*SZ79&$<P0=
MO"9M)OHA9L;]KN#(*3[@2YI..^YN(<;,[C_X=5S)FT'A1_5DNQ5<79 T\"J9
M&'?<VCXHW=J<O^P,\1]O;FXC4?; ;:H &HIVNJ78$&3;GFKJ!%7MW<A0L!5(
M>/B>PJK5UM8R2'8$2L;\RO2KYS,R &>AFR33F=B@)R\!!(=FET.$HTE%Q2\2
MR?91F=)YO&3:K,+ZT=+6,AADHE6W@;10LO4<QK)"14^$I@&3HUUCV6<BB:W>
M&'0T';&=<^4RUC!-@5B ?I?:G1S3H*942* O#&JWA(H@0:A-5][?%F?WQHFI
M-.[J^&$9?'E YR1+%S$-_KW5PW6P-?MAK[..>,D88"5.(C^=(49E'VS?]U[X
M[!)N)3;J:' %;5W"P4=[,^Z%TMAQX3V?M\R/*E!G;+=W,&0&K+ )-O@1I>R$
M[0_?!29K#Z?&''4GD[0#MFM[=U@L.Y,,TY/(J.IR&HWX9MP5'-A1M&_S]3;-
M\W0V79&\/'7N755Y!+VNADSLF+-_J)FSM^,Y\<S9CN@PRIV=,1TQ*(I@YF^Z
MFZGJ3=K2#C@+JV!K-"^"Q0!QVXHNR+=:#1BU9:4E'7W7NV/<8Y_GD;+GY(F$
M\8J354Q7]2"O[(9]E]7SO?X2#^ ".E:?2,3("MDD)_XRB ).$L^'K$5+VQ'[
M;FN*%Y 3Z(@UZ#+8\O#OLJ:H2*D]8(^)#4U;SRH AM7&V-?;CB=6D]X#1E$D
MCR=)FA-5B.=-',4EM3=$J4]!>F/?C\UP-N$(_C;*_1RKD]N9M6(]:OIAWYT-
MER:("^A@?7*#*.'[!KM$1A<O?*)9D"QR1Y!S\JA8:("NV#=J,\C O$!'K</J
MZK^P1G.J-D/)9$T=VLG'MG&(YE)KAATI;HA?&XT'C%F+1W_IS:\WG8 ZH\>7
MFP%LP!#TC505DR%*8#!13"X9/_Y!0O\A_NRFHH#C0SQY<H.0^X%=QO3>K6;"
MTH>]C/I1]&AW$_A;5*9QP4 7. 5W.NT2%@36=P<<P(P#/AC*0*'RM?G430)/
M#K*D.7I<O=GFKR0:??5])<%\P>N1/C$%<D[RHB[36>,130.5X3#H8?9F$'9B
MDF7/C5+OTEJP4!&Y5XL9VGF%_%'Y"EGYD+/YDB,^(9XEJQ_[L[N*D[\Z?RD^
M^A].\5GL.)QN:25 W=\B<7I%XG2(@WP+Q1D5DP,.Q<D%B.M<<<2W+V X3GNW
M0X2EG1+TL)S:M'21.9+FE@&B$K:ZRMA.4,6<;X/;LRXRQ\YPG"YX6!V.4W%]
MT\=*-9IB>TYT@4-*,3H6DI0U.EPTW;#]*+I@!.($.E[U#"8ZH&3ML7TDNB"D
MIAT=&D":(.VR@@^![?S0:8F9<@@=T[<8>&D,_,E;#+PM,?!X^O7K#8(WAN=
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M4,8D0Z%[Y0^B:2KY9"O"N60. [%R+ MJYPVQANT&&7(3%G0\NFS:W&^#1(F
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MVCFJ7:X=O]<EI%]6*P0A;7SU5=V;]RJE$@!?EY3F/H#36>7=NGAOW9/ JB:
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M"Z0=LMLE^EY%\E@Y%0#?M//)=BC9'!4H.V1QJ.5W%R2_7U+"@]\)DX%T_PJ
M<@9VOJG:MH<"0/P&I':O9[]R!G8^D1Z$U-IX[@^MZIP'3X%/(I\3O&=5=??3
M=KYAVB:G*MA:!!3O-5&\[C6HYM./$J)Z2_SA>]5;8OYH*,9UJ@,[Q<AO[XAV
MOB->+%=AO";DGM"GP".2-1&*:;"_36=WQ(OG$7_)SPL<"0K!;XJ#?LZ.UX21
MWQ<'Y1C^6^,PY  >'@?_D!W2-NK*K0GAX"S$3]QR%;$CD=PSU,0)?UU,79V
M1=GIVQ,+)3O0\Z!(9J?+:*+I9@?* .F%8350MI#>8-TQ+C(.+":1?TZ>2!BO
M^"P+E5'Z0%CT!G7&MJ^#Q+$&F@%7T.^^GTA$J!NRJ4[\91 %7*M)@R<"Q!#8
M'=O"UP5%(\Z@X]A^3I@:'M"?8D=2+T&6 RNO^U]=;L]()QX3O2!=*R_XQZH+
M?C&04X[T=J&WZD+?U99UPQ:!L&!=_)$Q5*\B1D<F2-I'>1"CKR-O+79EKNZ
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M\AY67,)T;\RMK:V\%VN?CEM)P7\9KLVK<5YK0;FV[B58(6)J4*YM>N!]=1;
MSK T#'QXS[!O!KXW ]_(1H/79=][54^[\!WL[>7V[>5V**L0OXD%N][$MQGU
M%FY"8&^Y1B-@F^H&>-WMP#'T?3(/A;]*DDQE?=AMA6QDT-T<VEX=:A3:P?9;
M&JC*MU7;6*8<@'B^0QXZQ\]"-TFFLZ]B5:=3>L<S0VP20FS6ZYD;AL0_71?M
MDJ*A0G7H/3#VSF>([4",1!>(6QI[A/@)CXSANP.O&[@A2_W*I.R'_2!B"">,
M#4:6UN(W_#^/[.AC/_G_4$L#!!0    ( .>#?U91L(B)VNP  ";V   -
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M'58A[[" O-#].$6ZT>' ]\-2>SD,U!B?T"?I892=5=(03D*;G/V(& @#HZR
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M'?;[-_8%FOCRL/>/HTS0GXG#V; .^R]U[:_@\KCKJ\MC6!'ZC[^PV0/%E6W
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M ZME-:)CI*Y*S&\!9V[JB"B:Z:7>QY\9* 49(M![)N.GPH&3V8LH^1EF(@=
M-7\-I]CZS(LDFABNM8N@"7+&-;M):)8"14. "3/]Q;+.L8H.H(R.@H"EB+P=
M:QL##=6..&,3!?<I"VBAVE,A^MYUEH2);!N]5?'D!*P56+I:T)-5A<#8,&%T
M#<<A[3V,L%54L5+Q;\?W-"1CR+_E4$',EN%$\BG?(>VI:JM;'SILGN3)[$DR
M2;1NEA-L+H$.?]NNWCJN7235>R65Y-32UOYAHE4G<IY;@'K.G+_K4<0[3R#'
M;', K%-91LSPL?4+YX/QKCK\Q3/VQ:V.>U)3B#0**9XM1Z"#W1N'0#JE+.^A
MS3>C84)@]W?C/LRF&L\U<6C)7P6_)FSP=%0\>6.#T.6^,.I>(Q>365J=.**X
MN._7M'ER_\4-D>1V(+,02A<G.GLKTR8>WV\7"[#UN5WF3H#1GOM;P; (+]V2
M=^,Z*-FI ,@Q9?H]<$,#UMYT6-M#QM&4/=HP^LG0 !4 BP]OB4C5";(G[N8E
MP>;ZS;K<8<E!7/R'F$M_C:TOTAG-,\=IMMV8I&U[(;<U<AF&VO; YNUR05E^
M.61EQZ5QXEBWR8D7<39[-DC)>,+XS&F4%"1-$.M!9 /9 _:\B!E[2;?56$&G
M_![G75Q<#@%-73\'/D)^UDH_O%'YACRYXNSH[DUZT$C.>)O#[$U W2D4$?$(
MO+0*%,4KN#B,0N;T/XZMMVJ4KC0UK=".4QV1%L-PA8>K-OWFO[WH&NFP&2A,
M9JTIO\OMQ_/9@,:6\#%\ODL/5[.@$EE>-9[,%ZVFY=-KZW0>*B2CYC4=%Q<&
MD4<X"X)3H\!Q6[ACS*A-0D2^84"K1P"2[]6JG#E.L3P@YNX*W%=SQM6KGP<0
M$U^RZGZOK72E928G.J!JQ1V?6UQ=&I@GWAOB4[%"3FC0:Y1FZ%W,D6?DAX]<
M#0G2U*IYVE=;V_>IZ(2\C_YUK?3=D)',(A+5:M.M@!<-I>R+6 S>OU7?4#<4
MU@:V>H\?J:&,-.Q!C76'CQM!HX4,9_>!]N\39435[P=Q "%^!TM;5;]F0-T?
MB=[4,$43<_Z\Q+ _J%;J]#)+V%ZQ)1R #5:MKM:H&_AK;1NXZQ5@Q0&LXU%;
MHU_0Q(YNX'[SGW0.X/,Z L7N3[O! 8RE2<:D%[77H98/MAN ?T5[ SF ^CNC
M'=MWNB$^JK :R"X 5]B'2B-R  PG/^ N.KO8V:O=EP/P\;1GY^2+#UV5W"HO
M^Z\#H _8JHHB=.%\+-.Q^X:_82:ZQFUZQ7 \HVK:K4$OW.569P@4'J26>#/[
M-#]0[52PL^67:SP3N8$0_G9>J"[7"N./K#DSI H:\R7(3<0.V<"H=/+IEO/2
M;K2><JPWHC;&PXV65U'@_;)I1G0,!VO5NOC^D<FSSLNUH0ZT_NDE B:MI2F>
MI3(W[4<%LE2XINLDK;LW.:SH")S]#24.<7>SC0C%GG.W:_S(6@["U<[5-R-\
M\"^&#5[D$T$6L20:IELN/V'C]DC[::9>;P3PB".!O-2%BG<Q3$II5V%F0D3,
MYOIY'=ZX!Q8K- ]A[9/#IJ$W1EMUHE2;!J<\FL>&A]?^:DLD4=ZW?DVK3^\0
M?'&[@H:7D]D,<DX .06?*3Y9K"CSDB"<ZW;;W_Q)X(=;M\^JR#U=J%81J+TY
MBT_MNLL\;^NIXOZ'N'9[/SW0KNAHR:2UO4A2S9A)U$ X3/),+2K6.C5TIP'B
MANH2H3V8_AP51A(R_GM&B2Z=>G>VUH[6CT,T$=3G9H_-? [<61R;<*1];<Q2
M*;QR_T23T7K0K>:#MS'E2"TFL'3E?<#%E2BAC1<A<V=,I/N#L,R2&_2CCDB3
MQM91C1K662WH;D_9KY7PT-6FZKNUZSI%]=T^4&U=W;SP<19?MU H@0,0]*/=
M>\S7A4J:T1Z'8_@0' !QMW1_D,8!Q&WU!;7+^K,51G46'_53U@-%(VIZJX$_
MJV45AP>F7YFA*DQ]Y7<>_$FLI,]3QA9QBEESF_$S$F/4<:0(U=CC\D3PEBMV
MO0&CL (60%&"5>.0/C .@!_#@.=2$<%+U]C#:7_1%3]4!.SHA3-V&H\UI#/V
M&?.H'Q3!B%V29 QC%\\!_+W4;L6:7&*+_^A@=2SM[ )M_,$BL4+,P#VK,>WJ
M(.U LNY'%!6J#G6D)^)Q4%AMH(E,3J>+7.;KFK66Q=+*-2W5)S\X@">Q_?!"
M[!4%/1M7;-@WK!0_LH.;-D]*S#B 5^-97(5V0LWNY>^=??0/Z)P#'4V8 =(Z
M$G4X $FD/*T12S6.GNOM LIBA)F:A,NCK5J15&#J[+'7M--/&[7TGJ H2H\5
MH_=LS6Z^*+S16#\RN.+NC*D)?-<;4?43P@H8W*J[0R;]["]9UG)#^%C2\],;
M]N$-ZD8>@PTQ]M3NI:Z^TL&&)5K)Y]II+RO_XG/#)\;NT=Y.1)VB3<W4YE>W
M3#H$ZZ%\GH!IY:GY[+78]BNH;QVDH@YK60T.0,-DGAM&X55N& ,Y(^!?H@TK
M:SN[T<.H+H<WJ$&H)0?0F5O. 4A#A-U8%OEVM%ZBB#@B:2ZB:VU:JPNC$*N,
M!*4Y#\^++L](TU3C+N@TFF@QXQGV/&LM [F'V]KSA8JZQ]$E@0PKW4KAU]6V
ME/W3!CC'G\>!/"SP:-#YS:!6X%Q:M<>>3?04M#!(\.H'?',<5:5 8+WV39VH
MY]1GB:P&\1Y=T%5Y8-'#EXC)F,QCL<^+U3B Q5M<U/9+)##-W/IC!&Z)"5:.
M83F^?F3/V'CZ]NCC_7*?]*C&E7Q_526IXXBY)27D]IX9TH*FFT+QX,>CI?W#
MQ0+)1?C:Y^B'3;R,I?5&VS/IKFDI8F>Z\O*H#D?/\(D%?U*<X3JFUJ.$!9I+
M_-.M+\Q0RQ[-AY<8Q^P0)-!<6"\8%#L$Y#61@WK+C@1O _G\H?"W@=?[?4-+
MITZC-?,_UF?Z!V<^5X^=@)X34YQ9^SL]^ZWF2Y<$X@UZH*SY.4^5!!JU$25+
M:2\]R@'(]DIH?KA*I:$\\D[7"B=8MXZ^4[N(0%S)R?"\]FZPH#X'79EC$3?C
MF\2>P7:/OL?,[#\L\TBBK#9/@53@IK>7;U9ME&3N-E3U@P-^2GH[J?IWB"C%
MF78J%3^Y>"HTS@60?=$.P!?'RZ?VZ#)?5ORGGHNSB+ ?HKT&\V5G/P!N7P8\
M )!?G7M4(6E*?NWD=)E'Z4 V4>SF11Z@=T(,:@8W1)U*A\ET_NIN-B,/G+N1
M<-:VIQ0R\_!*4U.IM20*N7+.Z9S;1XT7P[OJ\LK!OA<0S2U9@0]OW+R[JF)7
M?W/%=.19N:W>H:=SI87^SA'A!RPN;"K72P!D)9^WUIA+Y,UT3BT(%?,0(.(L
MGGD%%-%$EM:;&N8%<Z<U#)E6D5U7=1T_-T(%U1H_OO^E6F!3;:3:D60_"LN6
M\ BZ^;5L(.W,':/AT.+O/E4[?2 QEXUL ^>YEX I+ZW[6T4:=FWC.L>/"]IX
M;![SG)R!NEQ_Y097JQ8RG+"J+YX7KI 3TNT9&-"?<RT1O=+C:$12YM4B35'-
MT&F-8&&[Q'7*7O7QF'-KO<! ]<,XXMK^Z<WN AAAI&S_9<^.(Q(\4LNRU7W-
M:'MGPU#32W^A^Q+(BWPP!#*]R]7U60$MN$2\<@3]CHWQ[H5W2 -<P*Q JVGM
MMS4LI3_JU\QQ+GN]HS$R=; >M@<-AMW*X_HW\LAPFW4:^!.ZVI[J%\>PE^VG
M2TU1 YE#BTTP48\U9_?2HNGB_*.)P)^S/P5CI+J ?&G2(ZX=B6\_X",T!WS=
MQR&'M&VNW"KL5CPWJIUF TG-8D;_]3'HH)J&D#?K3I _XJMCPX?Z(<HHWB@>
M6CN[0I8W'%M8KTT)"-'.,@L-4:X'!.KUH'@SE+O:E5K>TQN+*"39[P&7_-G*
M8TCQVI6"Z[8HQW?#VFKKMK@WF;]M&B8N;*N#5H8]OWT]-;X3,C/;Z^.KG>-Q
M?Y)E0VLLQ:T52]<%!7.98.9X/-&1&7^ED<; 7B@M(5#6DH/N[7D*!IWLO="F
M/O:V_9BE]T*KQVWMD>5!4D#P;[,N1#P#24,G!V_9I&&AD%0%:8+) =H;CQ@,
MP3V^OYRE/ZXTWB"8IF[A.H17L"!$[$PX#Z(E/!&!\]=RB-??7O36S_SR?3RO
MCF9!($_/$M7V.L287[@5(S7*#ON:25X=<<*G[5G8?B@^B]0[W* 1<$KW$O/@
MX>9AI)IDRYE"\]'MK^!C)K6[VUNK!Q[.SKO$!:_7N(^+R'BM1K OMM .*4HU
MTF)Q<&H?ZW8 Y0_+<Q=$OMKJF"S+,CY4\+?TXM*>.I:4!WO=?%H4$[EW!7FZ
M[MT@W@@CZM5[&[<\7JP275(2>$9;Z" 'X%5(D&HI3WV=?6:CP2.<+H2=R=6&
M^+6U)FY\8434Z>H^],9CCK"D:9L).AEJD,;1[>-M]M;T_5[B(VE[VD!"Z7?H
M!%!$E7EOO/(U$VH^'-9F9&XO,A LUFO7E, !X)7W;/K/?3UYM%!C<J]+SHF4
MN!F&-?]UG"2R8O7J.ZEZ69&/[L=83!-)Q<-DR%.VTJE(@ZK>UZM<P?6QVH-0
MBW@04)!>8+LU+AWT\)#FE0.;=OP^QY<>_GB_\?U#GUJF=1, 25"J."+\]\%'
M/L96!@:G<DC>[6U6J_:JJ@4!]U\^.ICSY8<BK^YAE93Y=GNEH]D!$2*_7+@/
MX=6A;=6GD8#?G_GD_<JXY'*@.WKI4YMY5]=O-[W\<=TIRA?LV$+;1XG; ?A<
ME:=&:C)]P@=N.#TRD&?*G/+C4PA)O.X2IZ_^E'\N4T1YH;-3D4)S)+0#QS>W
M_<;#A*1=L_F/F.E6EKH&BIE)[RI^FR]>%5AP.M^=FO+@1[9TICY]E@QTR6?
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M1]'#_B?ONX%IM2!!#N"*7CR8]G(8_.?@_P/_U>8I=@P-S98(@7  6DFLDQR
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M%Q,VCU[2/V)Y_&%XOE,5S+]OCWHKJ<+IAFF/80__H9?%3L\RRQ_(X : :1S
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M"\2,H,;X7!UC67"5BR-3@] .I)4GO!X9Y@"\Z.BTAM<H18P_>;RR/*# &Q,
M@U6NMF2P*ZL[@\K\&=(YGU6(6;T2<T!P(*8>G()TH$LB?;$KWH TT]%8?98<
ML[P"86YU=WS]O#8FB0,X""<E&9:E\-B_(G^;G79EYCN.+ Y:O:O'YU_#Z\4Z
M%X4Y2_QNLV'8,;%E"#T'&BGA)#.DPIZ*CD<U-'46+N.%0ET'PSJ.!'1(M9^'
M0HXA12I7!B<1H3?E^A-S2@(=E@O02?--0\X#5'U4_:9WI_>I+7O!V''INI4(
M$R4Z(PLWI:!EN5_%LJI@&G6Q1>K'\&BF1>PAEN=0J^AM/YT%7%KP$V^UNF%\
MM.LF-JP/;R\2.*R+J_Y<ZU\0FXF#?T,T,8C,F+D. 0202&8D5!I/H!LV9:$%
MO EOF1T4W3I&AS!"^J<%T7TL/S6H_0209W6H>4Q[S4O:>AAI$5$++<!ON=LV
M/E=)W,8^TD_F /QPJ>Z87A0O8I-H.P=%\S/5NKLX -O6NN;ZNM%:%@^<YG&3
M&1DZM[;.._$I*S"*\:;X9+O'WGXH,18TVO!Q_XB1C;$1@7R'[-$MHO4Z]C/J
MF#1EAP $V( ?MXJJ$F!)LXJQLGII(%4X*B2Z1I4( ZP4B])ZB<^UF=H0X<^E
M:XG4H5KX_I&@*]3HFPV/IA!Y&Z9'\SB *YZQ(^V'\/0) N:P;7E@&3 U+Q:8
MT]6R/,J2J]WQ5J7UE%/[I2:<:<J(&J3M\*W6X:W"ZI"J6<0Y=5WU0!LO]25-
MVR5A]Q%&'S-&CY"&2YEH!])YT24V\^K 3W)"B;@:EA%^' Z1@/[JRVLQ;X)Q
M  +5!-J$P\BP0'"K8RG2_@,ML912[?K#L.@-2?SR*T5'OSU59I-;GM$TM O,
M#Y(MM:*B)I&K0.%6=>W=B2<Z7JISX!0X%D8T46V5]I8:_+DPWFH#K>E\O4QV
M7,X<=[=/VII=-_;>"'">M=\MGT,1,LPHJ$2DRZN9TVBAQG(ZA(K+:# R%KUF
M&%Q(F95CSKK0%=-N-?;PGWA?,/QE7_EC0_T3#S.#9Y^&+6W:)< -Z+C@6!XH
MI.&4H7U*&2WO<0".5.&?QVBYQE;-7B*X;[$5QFK"A@LZ6,KN]3:5DS;[.94K
M,R<Q?XUCY8;9!.?L8<I=_8@.O'#^;62Q'(8202RA2]FG&$((DLQH:9;2+^BE
MU?83-),/=''"+HO<1W].ZV"=E,M/;#6NZ(?7>$ CI U]MXL6,?"RPFJK X E
M5N0>F/FQVUMH_QW+."B:LFG$B!O=VD,?$5P)+AC_,@!,5#Q,\R(JGN(EFZ=_
MK4!$W#BI9@H7=+,)RG6[^\(>P_IK_QG2OI)9V%VP$T^AX=%)%TPT$4;4\#0:
MMT..YG<9QGX(>,L2 1[!0V.L5\'\S+2K@_AHA7MPNATZ1",19.%7@;I+=O<J
M.OUK=?;Z2%LBD%S?*1 3MC,C0Q\OI$A_9):6(5"][U<*C'<261XU2.GW$W@-
M8$"!2F8.=A;Q(E@="U*CIC2H9=A<?M= /T/;J-+^/!OTJ&V>6Q_O[Q]DJ,-G
M*1;=9RYL)3%/Y47Y8GL)MO>XWAU&W_,<#0,GY>UZ+,^8= RO:[S%V!6L$9T+
M>DI*33+\M#4_8-9U,R[RJ0;MG4=@"+J[XZ6TW]=HIQ-JIV+_5A1E&M"VD;[A
MLZ(;2#6J$+B'6U1LJ+8FMA%$$YELHWZ^ZR-("+34=;;_M6= EXWKX<V$"V'1
M,F'1:)VT.0TB&+ &/C+?S RAB"A,0X$-."(N)8MILN<!W>1;EG.NV[L8&"OY
M"V1/G4(EAN^:Y,> 4^Y?6,1_Q-.$R@KAJ$HWMZZKW9,%[<^2&)^8X5P[=HH)
M.XVFPM8_*K@XT,HJQF\@_#P_U-$'4N;*Z3-8BB,%*PYIIQ>1)P-HGLN7$%43
MA/<(&P=Z')<O]-P_M(^>5RE^$_LM5@R6&"O'+ 9)4I.WT+*(QHE.MGQ3/A%S
MA)IR86/+"!ME ()0]>A_:$F$SSZ973%2FW_1>Y.U8V)%I#]#*0YE5A734VH
MY/9K=G^[$FT6W>&'25BDJD.M('P!9-RZQ+B<(D[ZR>P5IA6=YR:SD&9$*##'
M59A))HPEILW/BDXS;6R&@GUS7 H_[9XZ':-F-[).%-C-?C&5,YH='7$J\\GC
M+)+CYS6(VBJFX5X1A0.00XQT3<BYI.+W [_L<>UV4JO:G"W0C+9E6%Q"A:60
MI5.VIV)T2<0)$\T8<4>;( U"2R:.:K-OL2=N01MX43+SW7W51%E:M.^%8?YZ
M#*702"):)'%6?+O?^6O7K!32@XH3"6#,".''0+(!-#"Q!9S0?BJ@Y4<+*7UK
M77?^Y@AL^Z/>T*M!N)"[B"@9I&?H]#WO]ZF?![;+7G, BJ'[XN60[92?J-R'
M[0JP:?%1M8ND+WPS?(?RE/55E>-XA8TDDQQ&6+<I@L8WNA;_A.'$E\/EL G?
MQ:=7\F<G"_IKI!LC1&TDZJ8#=LS)%/G(X.S+2X)*<!6$E^HG=UOJI1@8]1R+
MR/O/&O[S4D:FG_C8IZO[@)$IL8CO#P"_M.2]X5=*]1?<+@"URZC3@;F_6PS^
MJB!9R'05(0LON29_UIVV1B2?\7"U7JFM40<)N3\LU@""3E<Z,A!RW[XYI;DL
M.IVE/J@2"O#_HOYQ!:I%+C_4$[[]O:U^\ <]:T KT\)X-6/L[W Z:.19HH39
MJ>$OJUF?XI5:,T[P5QGEA7D_D%F27"+1.OXZ@J)&TX7^ -60EO1&PTS4CPN&
M\+4_6[6J5-5/ZH*],T?'0:H::2!4V=5JPM$[&Q!99II;YEGU8.RFLMM6OZ-C
M 7F7;-[T:T-]07#1? E:"4 7#&@5@PB^D9FJ9^>039K]_K<N/4]O4JOL11R5
M^SMD],P7Q'WI<16"6*)4\3F<RCG\XK,;V78/PK.WWB'L@-BTKJ'N$&%E@2?5
MJ821[COS3ZEU&B*)198]>*<$-XR.G:6!506AP!D_78,Z":$YR_I@&+O,=>W@
M]U=/=8@42U\#A5Y5[9KE:>FK 8?[G., 5/,&3@$DE*$'?HET::04V'?!Q%?:
M=6!)42[IK6Z4HH@K='"<SKI93ZP)[1E;;+Q!$-?D8;6 4/48*IEHP%Y9#Q+&
MOET3?C=MYI_W.3H(%A(I1!H"TQQ(/.XLW?TZMCKB'.G&&-P_C!\IXL_MO \G
MI//M]0BS_+,?'S:G'LI;H<1-G;^5R'_=H+=_ 57?GE >*$@G$(>8'A;TI<Q8
M>:18![V< #X,)9^A>^=4,!^#(N8@(HCX;A?%HR<M68&SPJU"M4QT-XWY</6K
MPTC:I%"$2UWS<(-1'V0_:.[H/0W1N7* #P)]-H]'JQ<![U0SZGOPXF6@XZ=[
M!NV.A.?RSK9'YP5=^"Q$XSOOR99Z=@ +AG+ES].:D;9^UF]5SNETI#3G9<@A
M8XBCFB_#ZO3=/1V(:GR9V"?%BJZM4H*R:5!)"[YDIZJ>6LT,V1:9N^7)Y0XZ
MLMX@^CBM8]T)MRS.54QRF$=(02HZ&2,(,J4+$KF<#XI!A5"#Y& \JR@QEFTE
M8LI+#.%(<&\LI-A+NZYX7QK7 8LSK4F>[Z5V)1>&ZG/V();_B[CW#&NJ:]=%
MHZ@@" &17J+2I(O26U1>NH#T3E142HR\] "!*$AO2E5*$!%"1Z2$&CH("$B7
M("4)()T$*1%"LGG7]YUUUMK7OLZUS_ZS?R09F6/.9(PYGO$\]SWGF/=S]Z%:
M/!(GTF,SSS^&$/(O7&U*CMRC UX*BYZ@_(6X#WY9&<NSKV:-)"%TR-(FY%SJ
MW\X]YZN2J->(0YZ#W6%"DXJ3X;PO$.!"W!S.R6/7DQN39WC*^>M?E5/ER71
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M!U<7-P9_3+8;F1?$I$&'.B0[+:HD+%&VJ505)5(\Z-VS]TENIZ/%JNMZ6R9
M.5<LDY"S6FXU4=RKY/&X]9,0KQE[6LD-W6'$EJ34"U!':%M\BZL'09^<BXYO
M>0HEJLF)M2#Y9BFI+A&]EUU&.#"H;:\KNHBLS4-.7*J'8@VD7[0^>C-I9=I/
MUL&, YX$>[S1;0F/Z/X-3_FSO=Q*%LU:J9&(J1)MJTOI_%.YOR:W8-,4,GOQ
MR>>6E)!^T9;J@+K&6UVO0?-]U-O1'2-'(DBF-E D[<P(D0ZXLKJ23'$#1K3M
MZ=$XD/@J$I .N%VW 2Y4OO-K"SPA^#BO.@F$4J5&W3ZJ%<)'K=B;T"H87]Q7
M.GE]Y1&O18)'YTU"&-NSY# Q='GCPK'P\RJ-1M_FQ]:_AB0-38X'3/H59[TH
MLJ.:M@0ZX-*/#7ZWJ!;[TR*K!_9Z';?VM7&$"D$+>6<<<?=)=9"T1Z7'D<E)
M(:KBN8@<2B___+<P>[O.5_QO9I,YX1]_WQFGB@41S*[,4W3T4<:Y/)T\60<U
MOG@3?H*.)#11HLO763N^R/3^V#-C 8& ,\D9KH^'%^;1__1XX3]Z3)JF,-(!
M[W%@?(XV&QTP*D#1I0.BVMK!U.'OM+09AN)U[)E>]2]5@O=+3T*B3\JKV0LW
MN3RL[&^52&%[!N)+U(;+"BP*Y:'\UA*&>63&V\:G_*(\+<V5T43WX6]XS]UA
M:[4@&UF]^3&?W$;8T#.B!&\#'7 NL9+RJLYF>KB9($+@$UK*[M:WG01C5C(<
M[9^C,V#0+1#.9] ;*HTS$\6\V)TQ]'9?+LA)FV@D+R17(52@BX,+0A3:<4>&
MH8=07H1\BS/!<8=Q1A>M?*(L &:96[_M'D!:^\(IERL8<$UFY:*HE/(6>![\
MO]7G4?E"91T5DY&7Y'VM9(DOUKZ"2:6?2@9\PC^5+BMI9<K79B5_\<N*6+)(
MX)$665QQ8S3OBRG6QPU9%6<P*!H5&M1.K!3$A:?5.@T[K0><+$F!X;3S#Z\]
MPXC>*FZ(R?GTSOIRY4WE:J88/<. 9=.;3-:G2!YX9FDU#&3YJKE+FY^/;Q4K
M/,ZIF63ZM\$FFR$Q3S/YX&^*6H/;XJ_.AV?6\RY1F1N&;^^BH^M1+W.6W@ 6
MV:%SM:VR,L0D5>*LH,';'OZ798+>'W7YKU\Z9W"Z<=3Z[YBX@I>W*3L)PG(/
MJ0_0;\8ZE^PVWR_5U1C5/4WHP5=[=[=T\O+VS6AJ7AO(EQ'%-1E*B@WR%N<%
MMN>P.D:@LZRJWC\BC]R,8E.<Y%=:,TK)ETI)R2I?EFZ#:LQ;0-]#OR3?!<V)
MC"9O_$8Z6:7%Y>LQ$H*?'((39<-$PV+^)3QJXAKI.L[LO=]WY4QFD."W1,$G
M+W O2<Q$M?Z?S#E'-WG7;]U1&C0N\@SI=XE^&[/8>ROX;_ (TA0G_^[-3_PG
M@#!<0"'/Z0E1[>2\43^;WE*R1-&R$^H.443+ &2AY<XPPI9>=MF4&A+$W;??
M:S:Q&YQEMIGK>'Q*"<[.4J6_4QO@)S^=4AB_YKS->=4G^G#)GU<[*D*0(>7M
MF?Y^*\$S*4%"+T6/+WUG1"&?K"\LT %?N1?P^@>F%2=T /45C,:U&N;$)_+$
M7I"C[A;3F1A-[\BK)TQ:K,).@K1MN=MYZ:I]3N1>C?^OPZW4^C*YX:H_WG<,
MLRDL, HW_,?_ _K8)53/6^;X>/>I E+7_GED^?]M]@U:_V1;VVFHEVWK; 4.
M1*,SN9$_S9R"@\G[!0/1M* >.@ A412JI7;D>T<XZ"2U#(FD ZXZ(B-!,^J8
M0SI@]SR&8IO_YP'J;3=R\2)-N&^W8/"?PT9$EDQS?<>_1U"^,^95OB]]%6YX
M&NM0-AM]BVK:OW#E'>CAI,3 </;ZT2^*HD)5_8EAKBLW.ES;S^UZ.[?'<8ZI
M)H_RC&NC7H/RRV4=\+![-QZHI#,P W O1""FK^PBUIK5!-E1(U7-IS#5Q&Q/
M"G1Y'U*R.S3P^J3!3U>(Y^#)Q(1W4A['8R'IS7-;^_'_+*(E;XZLA,WB..F
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M3)9$';U>6GYJ/FZDBK6NS'H^1Z!)MIV\ \,@%%L4$R4=!NZ=W9(F 'NJ+B.
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M<Z1HV$W)4VT]W-P(DO)*)[<41T]]CT>MY:!/!@SF$:@(<J.*4?I+$!<I2++
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MUW:OT[:$_X+,E11_8'I]0QVX3+NRK^L203T*N?1[.PC]C_K5OU^WS!K"RNB
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MWV>=?WA,?:W'A>9V6SC.W(EG+??6R[_#^.LP-DP47K]#.'C[$>[;ZR),$LP
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M1KH6V#0A17#A+>K-0YXP04HF8=",=>U _2\P*0><6 ?F\9CB@9 R/16&2'2
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MSL(F=CW]!C5&"/-?L0G5L_RC)H&\H@7;6WBI82B3QO93'[OWXUB@X 3FY03
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MQOT<9KK/6*#_<1^0_%VHC$454L!$P*]#*2U57[^=/Q5$F2C#M%FX!.HM,H_
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M(%Q+<J0^GBE"I*?7L4J*EH"!ZM7I:;A(ZI-I9?U&FT'!6P[V]H:V-[T<Q_<
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M,%)+>/ZT\F>C_-F8,@O3#)/X/TM*'LA],\:=ZG]:S,4J>?*VI:M&>H5(,_B
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M &5X,3 M,RYH=&U02P$"% ,4    " #G@W]6J@9%\, #  "K$   "@
M        @ 'BU $ 97@R,RTQ+FAT;5!+ 0(4 Q0    ( .>#?U9[B!GC:P@
M  !"   *              "  <K8 0!E>#,Q+3$N:'1M4$L! A0#%     @
MYX-_5O\GLE=-"   34,   H              ( !7>$! &5X,S$M,BYH=&U0
M2P$"% ,4    " #G@W]6%+!$6E\$  #Q%P  "@              @ '2Z0$
M97@S,BTQ+FAT;5!+ 0(4 Q0    ( .>#?U87:0Z@3 0  "L6   *
M      "  5GN 0!E>#,R+3(N:'1M4$L! A0#%     @ YX-_5DL.9!859@,
ML3<=  P              ( !S?(! &9O<FTQ,"UK+FAT;5!+ 0(4 Q0    (
M .>#?U92&^):L1(! 'I4 0 0              "  0Q9!0!F;W)M,3 M:U\P
M,#,N:G!G4$L! A0#%     @ YX-_5O 0@>)Z[@  )O(  !
M ( !ZVL& &9O<FTQ,"UK7S P-"YJ<&=02P$"% ,4    " #G@W]6%4T $6!#
M 0"=9 $ $               @ &36@< 9F]R;3$P+6M?,# V+FIP9U!+ 0(4
M Q0    ( .>#?U97\[&V@-@" ._G @ 0              "  2&>" !F;W)M
M,3 M:U\P,#<N:G!G4$L! A0#%     @ YX-_5DU".C,BN0$ !=<! !
M         ( !SW8+ &9O<FTQ,"UK7S P."YJ<&=02P$"% ,4    " #G@W]6
M*8F.:"SU 0!0%P( $               @ $?, T 9F]R;3$P+6M?,# Y+FIP
M9U!+ 0(4 Q0    ( .>#?U9=869?.H,  /RW   0              "  7DE
M#P!F;W)M,3 M:U\P,3 N:G!G4$L! A0#%     @ YX-_5N%])1CB( ( .(H"
M !               ( !X:@/ &9O<FTQ,"UK7S Q,2YJ<&=02P$"% ,4
M" #G@W]6>[8VU0G3 P"G_ , $               @ 'QR1$ 9F]R;3$P+6M?
M,#$R+FIP9U!+ 0(4 Q0    ( .>#?U8W=:@2X#4! #>5 0 0
M  "  2B=%0!F;W)M,3 M:U\P,3,N:G!G4$L! A0#%     @ YX-_5KI\NFA1
M, $ .Y ! !               ( !-M,6 &9O<FTQ,"UK7S Q-"YJ<&=02P$"
M% ,4    " #G@W]6J*NJ>#<; 0"3>@$ $               @ &U Q@ 9F]R
M;3$P+6M?,#$U+FIP9U!+ 0(4 Q0    ( .>#?U;C]D8$7^0  #E% 0 0
M          "  1H?&0!F;W)M,3 M:U\P,38N:G!G4$L! A0#%     @ YX-_
M5LA%0W6;WP  <$ ! !               ( !IP,: &9O<FTQ,"UK7S Q-RYJ
M<&=02P$"% ,4    " #G@W]6=C_IJL.H  #2%@$ $               @ %P
MXQH 9F]R;3$P+6M?,#$X+FIP9U!+ 0(4 Q0    ( .>#?U9KO"\_)I\  'PL
M 0 0              "  6&,&P!F;W)M,3 M:U\P,C$N:G!G4$L! A0#%
M  @ YX-_5HWW@K2(C   )M<   T              ( !M2L< &=R87!H7S P
M,2YJ<&=02P$"% ,4    " #G@W]6:.V;2.,( @"=5P( #0
M@ %HN!P :'EP97)?,# Q+FIP9U!+ 0(4 Q0    ( .>#?U9XZQFINI4! 'LL
M @ 0              "  7;!'@!R97-E87)C:%\P,#$N:G!G4$L! A0#%
M  @ YX-_5J",SQ!2#P  =9X  !$              ( !7E<@ ')N>'0M,C R
M,C$R,S$N>'-D4$L! A0#%     @ YX-_5N,S9_-5$0  UL\  !4
M     ( !WV8@ ')N>'0M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( .>#
M?U;/WMX8920  *I' @ 5              "  6=X( !R;GAT+3(P,C(Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    " #G@W]6MSU792=@  !OL 4 %0
M    @ '_G"  <FYX="TR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ YX-_
M5E?42JA"0   K2X$ !4              ( !6?T@ ')N>'0M,C R,C$R,S%?
M<')E+GAM;%!+ 0(4 Q0    ( .>#?U91L(B)VNP  ";V   -
K  "  <X](0!T:6=E<E\P,#$N:G!G4$L%!@     A "$ W@<  -,J(@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
